PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Kessler, D; Gase, K; Baldwin, IT				Kessler, Danny; Gase, Klaus; Baldwin, Ian T.			Field experiments with transformed plants reveal the sense of floral scents	SCIENCE			English	Article							NICOTIANA-ATTENUATA; POLLINATION; CHEMISTRY; ECOLOGY; SHIFT	Plants use many means to attract pollinators, including visual cues and odor. We investigated how nonpigment floral chemistry influences nectar removal, floral visitation, florivory, rates of outcrossing, and fitness through both male and female functions. We blocked expression of biosynthetic genes of the dominant floral attractant [ benzyl acetone (Nachal1)] and nectar repellent [ nicotine (Napmt1/2)] in all combinations in the native tobacco Nicotiana attenuata and measured their effects on plants in their native habitat. Both repellent and attractant were required to maximize capsule production and seed siring in emasculated flowers and flower visitation by native pollinators, whereas nicotine reduced florivory and nectar robbing.	[Kessler, Danny; Gase, Klaus; Baldwin, Ian T.] Max Planck Inst Chem Ecol, Dept Mol Ecol, DE-07745 Jena, Germany	Max Planck Society	Baldwin, IT (corresponding author), Max Planck Inst Chem Ecol, Dept Mol Ecol, Hans Knoll Str 8, DE-07745 Jena, Germany.	baldwin@ice.mpg.de	Baldwin, Ian T/K-1809-2013	Baldwin, Ian/0000-0001-5371-2974	Max-Planck-Gesellschaft	Max-Planck-Gesellschaft(Max Planck Society)	Supported by the Max-Planck-Gesellschaft. We thank M. Baldwin, A. Kessler, and E. Wheeler for critically reading the manuscript; Brigham Young University for the use of the Lytle Ranch Preserve field station; and U. S. Department of Agriculture-Animal and Plant Health Inspection Service for constructive regulatory oversight of the genetically modified organism releases. Gene sequences have been deposited in GenBank with accession numbers EU503226 and EU503227.	Abe I, 2001, EUR J BIOCHEM, V268, P3354, DOI 10.1046/j.1432-1327.2001.02255.x; Bradshaw HD, 2003, NATURE, V426, P176, DOI 10.1038/nature02106; Dobson HEM, 2006, BIOLOGY OF FLORAL SCENT, P147; Euler M, 1996, OECOLOGIA, V107, P102, DOI 10.1007/BF00582240; Hartmann T, 2008, P NATL ACAD SCI USA, V105, P4541, DOI 10.1073/pnas.0709231105; Hoballah ME, 2007, PLANT CELL, V19, P779, DOI 10.1105/tpc.106.048694; Kessler D, 2007, PLANT J, V49, P840, DOI 10.1111/j.1365-313X.2006.02995.x; McCall AC, 2006, ECOL LETT, V9, P1351, DOI 10.1111/j.1461-0248.2006.00975.x; Raguso RA, 2008, ENTOMOL EXP APPL, V128, P196, DOI 10.1111/j.1570-7458.2008.00683.x; Sime Karen R, 2003, BMC Ecol, V3, P6, DOI 10.1186/1472-6785-3-6; Steppuhn A, 2004, PLOS BIOL, V2, P1074, DOI 10.1371/journal.pbio.0020217; Strauss SY, 2007, ECOLOGY EVOLUTION FL, P120; VONMARILAUN AK, 1879, SCHUTZMITTEL BLUTHEN	13	265	274	2	231	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 29	2008	321	5893					1200	1202		10.1126/science.1160072	http://dx.doi.org/10.1126/science.1160072			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341ZM	18755975				2022-12-28	WOS:000258754400042
J	Psaty, BM; Vandenbroucke, JP				Psaty, Bruce M.; Vandenbroucke, Jan P.			Opportunities for enhancing the FDA guidance on pharmacovigilance	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ROSIGLITAZONE; GLUCOSE		[Psaty, Bruce M.] Univ Washington, Cardiovasc Hlth Res Unit, Dept Med, Seattle, WA 98101 USA; [Psaty, Bruce M.] Univ Washington, Cardiovasc Hlth Res Unit, Dept Epidemiol, Seattle, WA 98101 USA; [Psaty, Bruce M.] Univ Washington, Cardiovasc Hlth Res Unit, Dept Hlth Serv, Seattle, WA 98101 USA; [Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; [Vandenbroucke, Jan P.] Leiden Univ, Med Ctr, Dept Epidemiol, Leiden, Netherlands	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Group Health Cooperative; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Psaty, BM (corresponding author), Univ Washington, Cardiovasc Hlth Res Unit, Dept Med, 1730 Minor Ave,Suite 1360, Seattle, WA 98101 USA.	psaty@u.washington.edu	Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080295, R01HL085251, R01HL074745, U01HL080295, R01HL087652] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2998, DOI DOI 10.1016/S1062-1458(03)00049-7; *FOOD DRUG ADM, SENT IN NAT STRAT MO; *FOOD DRUG ADM, 2008, FED REGISTER, V73, P21963; Gerstein HC, 2006, LANCET, V368, P1096, DOI 10.1016/S0140-6736(06)69420-8; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; Home PD, 2007, NEW ENGL J MED, V357, P28, DOI 10.1056/NEJMoa073394; Joffe HV, 2007, NEW ENGL J MED, V357, P1775; Kahn SE, 2006, NEW ENGL J MED, V355, P2427, DOI 10.1056/NEJMoa066224; MISBIN RI, MED OFFICE REV AVAND; Nissen SE, 2007, NEW ENGL J MED, V356, P2457, DOI 10.1056/NEJMoa072761; Psaty BM, 2008, JAMA-J AM MED ASSOC, V299, P1949, DOI 10.1001/jama.299.16.1949; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Vandenbroucke JP, 2008, PLOS MED, V5, P339, DOI 10.1371/journal.pmed.0050067; von Elm E, 2007, ANN INTERN MED, V147, P573, DOI 10.7326/0003-4819-147-8-200710160-00010	14	14	14	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2008	300	8					952	954		10.1001/jama.300.8.952	http://dx.doi.org/10.1001/jama.300.8.952			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	341AR	18728269				2022-12-28	WOS:000258687100030
J	Arntzen, CJ				Arntzen, Charles J.			Plant science - Using tobacco to treat cancer	SCIENCE			English	Editorial Material							NON-HODGKINS-LYMPHOMA; TRANSGENIC PLANTS		Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA; Arizona State Univ, Arizona Biodesign Inst, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	Arntzen, CJ (corresponding author), Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA.	charles.arntzen@asu.edu						CARROLL WL, 1986, J EXP MED, V164, P1566, DOI 10.1084/jem.164.5.1566; CHASE M, 2008, WALL STREET J   0223, pA3; HIATT A, 1989, NATURE, V342, P76, DOI 10.1038/342076a0; MASON HS, 1992, P NATL ACAD SCI USA, V89, P11745, DOI 10.1073/pnas.89.24.11745; McCormick AA, 2008, P NATL ACAD SCI USA, V105, P10131, DOI 10.1073/pnas.0803636105; Ries L., 2005, SEER CANC STAT REV 1; Ruffini PA, 2005, CURR GENE THER, V5, P511, DOI 10.2174/156652305774329221; Travis J, 2008, SCIENCE, V320, P473, DOI 10.1126/science.320.5875.473; TUSE D, COMMUNICATION	9	20	22	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 22	2008	321	5892					1052	1053		10.1126/science.1163420	http://dx.doi.org/10.1126/science.1163420			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339RL	18719274				2022-12-28	WOS:000258594900028
J	Lazar, MA				Lazar, Mitchell A.			Developmental biology - How now, brown fat?	SCIENCE			English	Editorial Material							ADIPOCYTES; OBESITY; WHITE		Univ Penn, Inst Diabet Obes & Metab, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Lazar, MA (corresponding author), Univ Penn, Inst Diabet Obes & Metab, Dept Med, 415 Curie Blvd, Philadelphia, PA 19104 USA.	lazar@mail.med.upenn.edu	Lazar, Mitchell A/AAF-3738-2019					CRISAN M, 2008, STEM CELLS; Farmer SR, 2008, GENE DEV, V22, P1269, DOI 10.1101/gad.1681308; Finck BN, 2006, J CLIN INVEST, V116, P615, DOI 10.1172/JCI27794; Gesta S, 2007, CELL, V131, P242, DOI 10.1016/j.cell.2007.10.004; KISSEBAH AH, 1994, PHYSIOL REV, V74, P761, DOI 10.1152/physrev.1994.74.4.761; Lazar MA, 2005, SCIENCE, V307, P373, DOI 10.1126/science.1104342; Lehrke M, 2005, CELL, V123, P993, DOI 10.1016/j.cell.2005.11.026; Nedergaard J, 2007, AM J PHYSIOL-ENDOC M, V293, pE444, DOI 10.1152/ajpendo.00691.2006; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Seale P, 2008, NATURE, V454, P961, DOI 10.1038/nature07182; Seale P, 2007, CELL METAB, V6, P38, DOI 10.1016/j.cmet.2007.06.001; Timmons JA, 2007, P NATL ACAD SCI USA, V104, P4401, DOI 10.1073/pnas.0610615104; Tiraby C, 2003, TRENDS ENDOCRIN MET, V14, P439, DOI 10.1016/j.tem.2003.10.001	13	36	52	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	2008	321	5892					1048	1049		10.1126/science.1164094	http://dx.doi.org/10.1126/science.1164094			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339RL	18719271				2022-12-28	WOS:000258594900025
J	Vernazza, P; Binzel, RP; Thomas, CA; DeMeo, FE; Bus, SJ; Rivkin, AS; Tokunaga, AT				Vernazza, P.; Binzel, R. P.; Thomas, C. A.; DeMeo, F. E.; Bus, S. J.; Rivkin, A. S.; Tokunaga, A. T.			Compositional differences between meteorites and near-Earth asteroids	NATURE			English	Article							S-TYPE ASTEROIDS; SPECTRAL PROPERTIES; ORDINARY CHONDRITES; SURFACES; POPULATION; EVOLUTION; OBJECTS; BODIES; FLORA; MODEL	Understanding the nature and origin of the asteroid population in Earth's vicinity (near-Earth asteroids, and its subset of potentially hazardous asteroids) is a matter of both scientific interest and practical importance(1). It is generally expected that the compositions of the asteroids that are most likely to hit Earth should reflect those of the most common meteorites. Here we report that most near-Earth asteroids (including the potentially hazardous subset) have spectral properties quantitatively similar to the class of meteorites known as LL chondrites. The prominent Flora family in the inner part of the asteroid belt shares the same spectral properties, suggesting that it is a dominant source of near-Earth asteroids. The observed similarity of near-Earth asteroids to LL chondrites is, however, surprising, as this meteorite class is relatively rare (similar to 8 per cent of all meteorite falls). One possible explanation is the role of a size-dependent process, such as the Yarkovsky effect, in transporting material from the main belt.	[Vernazza, P.] European Space Agcy, Res & Sci Support Dept, NL-2201 AZ Noordwijk, Netherlands; [Binzel, R. P.; Thomas, C. A.] MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA; [DeMeo, F. E.] Observ Paris, Lab Etud Spatiales & Instrumentat Astrophys, F-92195 Meudon, France; [Bus, S. J.] Univ Hawaii, Inst Astron, Hilo, HI 96720 USA; [Rivkin, A. S.] Johns Hopkins Univ, Appl Phys Lab, Laurel, MD 20723 USA; [Tokunaga, A. T.] Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA	European Space Agency; Massachusetts Institute of Technology (MIT); UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Sorbonne Universite; University of Hawaii System; University Hawaii Hilo; Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory; University of Hawaii System	Vernazza, P (corresponding author), European Space Agcy, Res & Sci Support Dept, Keplerlaan 1, NL-2201 AZ Noordwijk, Netherlands.	pierre.vernazza@esa.int	Rivkin, Andrew S/B-7744-2016	Rivkin, Andrew S/0000-0002-9939-9976; Tokunaga, Alan/0000-0001-8136-9704; Thomas, Cristina/0000-0003-3091-5757				Binzel RP, 2004, ICARUS, V170, P259, DOI 10.1016/j.icarus.2004.04.004; Binzel RP, 1996, SCIENCE, V273, P946, DOI 10.1126/science.273.5277.946; Bottke W. F., 2002, ASTEROIDS, P395; Bottke WF, 2000, ICARUS, V145, P301, DOI 10.1006/icar.2000.6361; Brunetto R, 2006, ICARUS, V184, P327, DOI 10.1016/j.icarus.2006.05.019; BUS SJ, 1999, COMPOSITIONAL STRUCT; Chapman CR, 2004, ANNU REV EARTH PL SC, V32, P539, DOI 10.1146/annurev.earth.32.101802.120453; Chapman CR, 1996, METEORIT PLANET SCI, V31, P699, DOI 10.1111/j.1945-5100.1996.tb02107.x; Clark BE, 2002, ASTEROIDS, P585, DOI DOI 10.1016/0273-1177(91)90551-T; GAFFEY MJ, 1993, ICARUS, V106, P573, DOI 10.1006/icar.1993.1194; GAFFEY MJ, 1984, ICARUS, V60, P83, DOI 10.1016/0019-1035(84)90140-4; GEHRELS T, 1994, HAZARDS DUE COMETS A; Hutchison R., 2004, METEORITES PETROLOGI; Lucey PG, 1998, J GEOPHYS RES-PLANET, V103, P1703, DOI 10.1029/97JE03145; Maier WD, 2006, NATURE, V441, P203, DOI 10.1038/nature04751; MCFADDEN LA, 1985, SCIENCE, V229, P160, DOI 10.1126/science.229.4709.160; Nesvorny D, 2002, ICARUS, V157, P155, DOI 10.1006/icar.2002.6830; Nesvorny D, 2007, ICARUS, V188, P400, DOI 10.1016/j.icarus.2006.11.021; Pieters CM, 2000, METEORIT PLANET SCI, V35, P1101, DOI 10.1111/j.1945-5100.2000.tb01496.x; Rayner JT, 2003, PUBL ASTRON SOC PAC, V115, P362, DOI 10.1086/367745; RUBINCAM DP, 1995, J GEOPHYS RES-PLANET, V100, P1585, DOI 10.1029/94JE02411; Shkuratov Y, 1999, ICARUS, V137, P235, DOI 10.1006/icar.1998.6035; Stuart JS, 2004, ICARUS, V170, P295, DOI 10.1016/j.icarus.2004.03.018; SUNSHINE JM, 1990, J GEOPHYS RES-SOLID, V95, P6955, DOI 10.1029/JB095iB05p06955; Tagle R, 2006, METEORIT PLANET SCI, V41, P1721, DOI 10.1111/j.1945-5100.2006.tb00448.x	25	115	117	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 14	2008	454	7206					858	860		10.1038/nature07154	http://dx.doi.org/10.1038/nature07154			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	336XH	18704080				2022-12-28	WOS:000258398600029
J	Clark, AG				Clark, Andrew G.			Genome sequences from extinct relatives	CELL			English	Editorial Material							NEANDERTHAL DNA		Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Cornell University	Clark, AG (corresponding author), Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA.	ac347@cornell.edu		Clark, Andrew/0000-0001-7159-8511				Fagundes NJR, 2007, P NATL ACAD SCI USA, V104, P17614, DOI 10.1073/pnas.0708280104; Garrigan D, 2006, NAT REV GENET, V7, P669, DOI 10.1038/nrg1941; Green RE, 2006, NATURE, V444, P330, DOI 10.1038/nature05336; Krings M, 1997, CELL, V90, P19, DOI 10.1016/S0092-8674(00)80310-4; Noonan JP, 2006, SCIENCE, V314, P1113, DOI 10.1126/science.1131412; Nordborg M, 1998, AM J HUM GENET, V63, P1237, DOI 10.1086/302052; Plagnol V, 2006, PLOS GENET, V2, P972, DOI 10.1371/journal.pgen.0020105; Smith FH, 1999, P NATL ACAD SCI USA, V96, P12281, DOI 10.1073/pnas.96.22.12281; Wall JD, 2007, PLOS GENET, V3, P1862, DOI 10.1371/journal.pgen.0030175	9	6	6	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 8	2008	134	3					388	389		10.1016/j.cell.2008.07.026	http://dx.doi.org/10.1016/j.cell.2008.07.026			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SO	18692462	Bronze			2022-12-28	WOS:000258665500011
J	de Lusignan, S; Buxton, N; Kent, A				de Lusignan, Simon; Buxton, Nicola; Kent, Andy			10-MINUTE CONSULTATION New patient asking for a benzodiazepine prescription	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[de Lusignan, Simon; Buxton, Nicola] Univ London St Georges Hosp, Div Community Hlth Sci, London SW17 0RE, England; [Kent, Andy] Univ London St Georges Hosp, Div Mental Hlth, London SW17 0RE, England	St Georges University London; St Georges University London	de Lusignan, S (corresponding author), Univ London St Georges Hosp, Div Community Hlth Sci, London SW17 0RE, England.	slusigna@sgul.ac.uk	de Lusignan, Simon/A-6609-2011; de Lusignan, Simon/A-4125-2009; de Lusignan, Smion/S-7838-2019	de Lusignan, Simon/0000-0002-8553-2641; de Lusignan, Smion/0000-0002-8553-2641					0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 1	2008	337								a658	10.1136/bmj.a658	http://dx.doi.org/10.1136/bmj.a658			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	368AM	18755766	Green Submitted			2022-12-28	WOS:000260593700035
J	Keshavjee, S; Gelmanova, IY; Farmer, PE; Mishustin, SP; Strelis, AK; Andreev, YG; Pasechnikov, AD; Atwood, S; Mukherjee, JS; Rich, ML; Furin, JJ; Nardell, EA; Kim, JY; Shin, SS				Keshavjee, Salmaan; Gelmanova, Irina Y.; Farmer, Paul E.; Mishustin, Sergey P.; Strelis, Aivar K.; Andreev, Yevgeny G.; Pasechnikov, Alexander D.; Atwood, Sidney; Mukherjee, Joia S.; Rich, Michael L.; Furin, Jennifer J.; Nardell, Edward A.; Kim, Jim Y.; Shin, Sonya S.			Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study	LANCET			English	Article							SHORT-COURSE CHEMOTHERAPY; TREATMENT OUTCOMES; MANAGEMENT; SURGERY; THERAPY; PRISON; LIMA	Background Mycobacterium tuberculosis strains that cause untreatable drug-resistant disease are a threat worldwide. We describe the treatment, management, and outcomes of patients with extensively drug-resistant tuberculosis in Tomsk, Russia. Methods We undertook a retrospective cohort study of 608 patients with multidrug resistant tuberculosis who had treatment in civilian or prison services, between Sept 10, 2000, and Nov 1, 2004, according to the treatment strategy recommended by WHO. Clinical characteristics, management practices, and treatment outcomes of patients with extensively drug-resistant (XDR) tuberculosis and non-extensively drug-resistant (non-XDR) tuberculosis are described. The main outcome was the frequency of poor and favourable outcomes at the end of treatment. Findings Of 608 patients with multidrug resistant tuberculosis, 29 (4.8%) patients had baseline XDR tuberculosis. Treatment failure was more common in patients with XDR tuberculosis than in those with non-XDR tuberculosis (31% vs 8.5%, p=0.0008). 48.3% of patients with XDR tuberculosis and 66.7% of patients with non-XDR tuberculosis had treatment cure or completion (p=0.04). The frequency and management of adverse events did not differ between patients with XDR and non-XDR tuberculosis. Interpretation The chronic features of tuberculosis in these patients suggest that extensively drug-resistant tuberculosis may be acquired through previous treatments that include second-line drugs. Aggressive management of this infectious disease is feasible and can prevent high mortality rates and further transmission of drug-resistant strains of Mycobacterium tuberculosis. Funding Bill & Melinda Gates Foundation, Eli Lilly Foundation, The Open Society Institute, Frank Hatch Fellowships in Global Health Equity at the Brigham & Women's Hospital, Infectious Disease Society of America, the Heiser Foundation, the United States National Institutes of Health, and the John D and Catherine T MacArthur Foundation.	[Keshavjee, Salmaan; Farmer, Paul E.; Nardell, Edward A.; Kim, Jim Y.] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA 02115 USA; [Keshavjee, Salmaan; Farmer, Paul E.; Atwood, Sidney; Mukherjee, Joia S.; Rich, Michael L.; Furin, Jennifer J.; Nardell, Edward A.; Kim, Jim Y.; Shin, Sonya S.] Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA 02115 USA; [Keshavjee, Salmaan; Gelmanova, Irina Y.; Farmer, Paul E.; Mukherjee, Joia S.; Rich, Michael L.; Furin, Jennifer J.; Nardell, Edward A.; Kim, Jim Y.; Shin, Sonya S.] Partners Hlth, Boston, MA USA; [Gelmanova, Irina Y.; Pasechnikov, Alexander D.] Partners Hlth, Moscow, Russia; [Mishustin, Sergey P.] Tomsk Oblast TB Serv, Tomsk, Russia; [Strelis, Aivar K.] Siberia State Med Univ, Tomsk, Russia; [Strelis, Aivar K.] Tomsk Oblast TB Hosp, Tomsk, Russia; [Andreev, Yevgeny G.] Minist Justice, Tomsk Penitentiary Serv, Tomsk, Russia; [Nardell, Edward A.; Kim, Jim Y.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Partners Healthcare System; Siberian State Medical University; Harvard University; Harvard T.H. Chan School of Public Health	Keshavjee, S (corresponding author), Harvard Univ, Sch Med, Dept Global Hlth & Social Med, 641 Huntington Ave, Boston, MA 02115 USA.	skeshavjee@partners.org	Mishustin, Sergey/AAI-4202-2020	Keshavjee, Salmaan/0000-0002-6967-3305; Atwood, Sidney/0000-0001-8865-6300; Mishustin, Sergey/0000-0002-4414-460X	Bill & Melinda Gates Foundation; Eli Lilly Foundation; Frank Hatch Fellowships in Global Health Equity at the Brigham & Women's Hospital; Infectious Disease Society of America; Heiser Foundation; US National Institutes of Health; John D and Catherine T MacArthur Foundation	Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation); Eli Lilly Foundation(Eli Lilly); Frank Hatch Fellowships in Global Health Equity at the Brigham & Women's Hospital; Infectious Disease Society of America; Heiser Foundation; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); John D and Catherine T MacArthur Foundation	JJF, IYG, SK, EAN, SSS, ADP, and MLR received partial salary and/or travel support from the Bill & Melinda Gates Foundation and Eli Lilly Foundation. JJF, SK, MLR, and SSS received salary support also from the Frank Hatch Fellowships in Global Health Equity at the Brigham & Women's Hospital. S S S received additional salary support from the Infectious Disease Society of America, the Heiser Foundation, and the US National Institutes of Health. SK received travel and research funding from the John D and Catherine T MacArthur Foundation.	Bender D. A., 1997, NUTR REFERENCE HDB; Braden CR, 2001, CLIN INFECT DIS, V33, pE42, DOI 10.1086/322635; Chan ED, 2004, AM J RESP CRIT CARE, V169, P1103, DOI 10.1164/rccm.200308-1159OC; Cox H, 2006, PLOS MED, V3, P1836, DOI 10.1371/journal.pmed.0030384; Espinal MA, 2000, JAMA-J AM MED ASSOC, V283, P2537, DOI 10.1001/jama.283.19.2537; Farmer P, 1999, INT J TUBERC LUNG D, V3, P365; FARMER PE, 2000, J RESP DIS, V21, P53; Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1; Gelmanova IY, 2007, B WORLD HEALTH ORGAN, V85, P703, DOI 10.2471/BLT.06.038331; Gupta R, 2002, TROP MED INT HEALTH, V7, P970, DOI 10.1046/j.1365-3156.2002.00960.x; Keshavjee S., 2007, Innovations: Technology / Governance / Globalisation, V2, P87, DOI 10.1162/itgg.2007.2.4.87; KESHAVJEE S, 2007, ANN NY ACAD SCI, V1136, P1; Kim HR, 2007, CLIN INFECT DIS, V45, P1290, DOI 10.1086/522537; Kim JY, 2003, TUBERCULOSIS, V83, P59, DOI 10.1016/S1472-9792(02)00078-1; Kimerling ME, 1999, INT J TUBERC LUNG D, V3, P451; Kir A, 1997, EUR J CARDIO-THORAC, V12, P531, DOI 10.1016/S1010-7940(97)00230-3; Laserson KF, 2005, INT J TUBERC LUNG D, V9, P640; Li X, 2007, J INFECT DIS, V195, P864, DOI 10.1086/511985; Masjedi MR, 2006, CLIN INFECT DIS, V43, P841, DOI 10.1086/507542; Mawer C, 2001, LANCET, V358, P445, DOI 10.1016/S0140-6736(01)05621-5; Migliori GB, 2007, EUR RESPIR J, V30, P623, DOI 10.1183/09031936.00077307; Migliori GB, 2002, INT J TUBERC LUNG D, V6, P858; MIGLIORI GB, 2008, EUR RESPIR J, V31, P1; Migliori GB, 2008, CLIN INFECT DIS, V46, P958, DOI 10.1086/528875; Migliori GB, 2007, EMERG INFECT DIS, V13, P780, DOI 10.3201/eid1305.070200; Mitnick C, 2003, NEW ENGL J MED, V348, P119, DOI 10.1056/NEJMoa022928; Mukherjee JS, 2004, LANCET, V363, P474, DOI 10.1016/S0140-6736(04)15496-2; Pomerantz BJ, 2001, J THORAC CARDIOV SUR, V121, P448, DOI 10.1067/mtc.2001.112339; POMERANTZ M, 1991, ANN THORAC SURG, V52, P1108, DOI 10.1016/0003-4975(91)91289-8; Saravia JC, 2005, INT J TUBERC LUNG D, V9, P421; Seung KJ, 2004, CLIN INFECT DIS, V39, P1321, DOI 10.1086/425005; Shah NS, 2007, EMERG INFECT DIS, V13, P380, DOI 10.3201/eid1303.061400; Shin SS, 2006, INT J TUBERC LUNG D, V10, P402; Somocurcio JG, 2007, THORAX, V62, P416, DOI 10.1136/thx.2005.051961; *WHO, WHOHTMTB2007387; *WHO, 2006, WHOHTMTB2007374; *WHO, GREEN LIGHT COMM GLC; *WHO INT UN TUB LU, 2008, 4 WHO INT UN TUB LUN; World Health Organization, 2006, WHOHTMTB2006362; Wright A., 2006, Morbidity and Mortality Weekly Report, V55, P301; 2006, MMWR MORB MORTAL WKL, V56, P250	41	137	144	0	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 18	2008	372	9647					1403	1409		10.1016/S0140-6736(08)61204-0	http://dx.doi.org/10.1016/S0140-6736(08)61204-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	362WP	18723218				2022-12-28	WOS:000260228200026
J	Mosse, YP; Laudenslager, M; Longo, L; Cole, KA; Wood, A; Attiyeh, EF; Laquaglia, MJ; Sennett, R; Lynch, JE; Perri, P; Laureys, G; Speleman, F; Kim, C; Hou, CP; Hakonarson, H; Torkamani, A; Schork, NJ; Brodeur, GM; Tonini, GP; Rappaport, E; Devoto, M; Maris, JM				Mosse, Yael P.; Laudenslager, Marci; Longo, Luca; Cole, Kristina A.; Wood, Andrew; Attiyeh, Edward F.; Laquaglia, Michael J.; Sennett, Rachel; Lynch, Jill E.; Perri, Patrizia; Laureys, Genevieve; Speleman, Frank; Kim, Cecilia; Hou, Cuiping; Hakonarson, Hakon; Torkamani, Ali; Schork, Nicholas J.; Brodeur, Garrett M.; Tonini, Gian P.; Rappaport, Eric; Devoto, Marcella; Maris, John M.			Identification of ALK as a major familial neuroblastoma predisposition gene	NATURE			English	Article							ANAPLASTIC LYMPHOMA KINASE; FUNCTIONAL-ANALYSIS; HOMEOBOX GENE; B-RAF; MUTATIONS; EXPRESSION; PHOX2B; RECEPTOR; CANCER; ACTIVATION	Neuroblastoma is a childhood cancer that can be inherited, but the genetic aetiology is largely unknown. Here we show that germline mutations in the anaplastic lymphoma kinase (ALK) gene explain most hereditary neuroblastomas, and that activating mutations can also be somatically acquired. We first identified a significant linkage signal at chromosome bands 2p23-24 using a whole- genome scan in neuroblastoma pedigrees. Resequencing of regional candidate genes identified three separate germline missense mutations in the tyrosine kinase domain of ALK that segregated with the disease in eight separate families. Resequencing in 194 high- risk neuroblastoma samples showed somatically acquired mutations in the tyrosine kinase domain in 12.4% of samples. Nine of the ten mutations map to critical regions of the kinase domain and were predicted, with high probability, to be oncogenic drivers. Mutations resulted in constitutive phosphorylation, and targeted knockdown of ALK messenger RNA resulted in profound inhibition of growth in all cell lines harbouring mutant or amplified ALK, as well as in two out of six wild- type cell lines for ALK. Our results demonstrate that heritable mutations of ALK are the main cause of familial neuroblastoma, and that germline or acquired activation of this cell- surface kinase is a tractable therapeutic target for this lethal paediatric malignancy.	[Mosse, Yael P.; Laudenslager, Marci; Cole, Kristina A.; Wood, Andrew; Attiyeh, Edward F.; Laquaglia, Michael J.; Sennett, Rachel; Lynch, Jill E.; Hou, Cuiping; Brodeur, Garrett M.; Rappaport, Eric; Maris, John M.] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Pediat,Div Oncol, Philadelphia, PA 19104 USA; [Mosse, Yael P.; Laudenslager, Marci; Cole, Kristina A.; Wood, Andrew; Attiyeh, Edward F.; Laquaglia, Michael J.; Sennett, Rachel; Lynch, Jill E.; Hou, Cuiping; Brodeur, Garrett M.; Rappaport, Eric; Maris, John M.] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Pediat,Ctr Childhood Canc Res, Philadelphia, PA 19104 USA; [Longo, Luca; Perri, Patrizia; Tonini, Gian P.] Natl Inst Canc Res, Italian Neuroblastoma Fdn, I-16132 Genoa, Italy; [Perri, Patrizia] Adv Biotechnol Ctr, I-16132 Genoa, Italy; [Laureys, Genevieve; Speleman, Frank] Ghent Univ Hosp, Ctr Med Genet, B-9000 Ghent, Belgium; [Kim, Cecilia; Hou, Cuiping; Hakonarson, Hakon] Childrens Hosp Philadelphia, Ctr Appl Genom, Philadelphia, PA 19104 USA; [Torkamani, Ali; Schork, Nicholas J.] Scripps Genom Med, La Jolla, CA 92037 USA; [Torkamani, Ali; Schork, Nicholas J.] Scripps Res Inst, La Jolla, CA 92037 USA; [Hakonarson, Hakon; Devoto, Marcella] Univ Penn, Sch Med, Div Genet, Childrens Hosp Philadelphia,Dept Pediat, Philadelphia, PA 19104 USA; [Hakonarson, Hakon; Devoto, Marcella] Univ Penn, Sch Med, CCEB, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Devoto, Marcella] Univ Roma La Sapienza, Dept Expt Med, I-00161 Rome, Italy; [Maris, John M.] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Genoa; IRCCS AOU San Martino IST; Ghent University; Ghent University Hospital; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Scripps Research Institute; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Sapienza University Rome; University of Pennsylvania; Pennsylvania Medicine	Maris, JM (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Pediat,Div Oncol, Philadelphia, PA 19104 USA.	maris@chop.edu	laureys, genevieve/AAG-2390-2021; Rappaport, Eric/GRO-4051-2022; Devoto, Marcella/AAP-7595-2021; Cole, Kristina/M-3922-2015; Perri, Patrizia/I-8124-2018; Perri, Patrizia/AFV-5794-2022; Longo, Luca/K-6156-2018; speleman, frank/AAR-5184-2020	Perri, Patrizia/0000-0003-2538-8278; Perri, Patrizia/0000-0003-2538-8278; Longo, Luca/0000-0002-5153-4243; speleman, frank/0000-0002-6628-8559; DEVOTO, MARCELLA/0000-0002-4431-5114; Schork, Nicholas/0000-0003-0920-5013	National Institutes of Health [K08-111733, R01-CA78454, R01-CA87847]; American Society of Clinical Oncology Career Development Award; Foerderer-Murray Fund; Carly Hillman Fund; Alex's Lemonade Stand Foundation; Andrew's Army Foundation; Giulio D'Angio Endowed Chair; Italian Neuroblastoma Foundation; Center for Applied Genomics at the Joseph Stokes Research Institute; Scripps Genomic Medicine; Scripps Dickinson Scholarship; Abramson Family Cancer Research Institute; NATIONAL CANCER INSTITUTE [U10CA098543, R01CA078545, R01CA087847, R01CA124709, K08CA111733] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025774] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Society of Clinical Oncology Career Development Award; Foerderer-Murray Fund; Carly Hillman Fund; Alex's Lemonade Stand Foundation; Andrew's Army Foundation; Giulio D'Angio Endowed Chair; Italian Neuroblastoma Foundation; Center for Applied Genomics at the Joseph Stokes Research Institute; Scripps Genomic Medicine; Scripps Dickinson Scholarship; Abramson Family Cancer Research Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We acknowledge the families and children that participated in this research study, and the Children's Oncology Group for providing specimens. We thank W. London for providing statistical analyses related to the Children's Oncology Group tumour set, H. Rydbeck for his assistance with the linkage analysis, M. Wasik for technical assistance, and J. Felgenhauer, N. Van Roy and C. McConville for providing neuroblastoma pedigrees. This work was supported in part by National Institutes of Health grants K08-111733 (Y.P.M.), R01-CA78454 (J.M.M.), R01-CA87847 (J.M.M.), an American Society of Clinical Oncology Career Development Award (Y.P.M.), the Foerderer-Murray Fund (Y.P.M.), the Carly Hillman Fund (Y.P.M.), the Alex's Lemonade Stand Foundation (J.M.M.), the Andrew's Army Foundation (J.M.M.), the Giulio D'Angio Endowed Chair (J.M.M.), the Italian Neuroblastoma Foundation (L.L.), the Center for Applied Genomics at the Joseph Stokes Research Institute (H.H.), Scripps Genomic Medicine (A.T., N.J.S.), the Scripps Dickinson Scholarship (A.T.), and the Abramson Family Cancer Research Institute ( J. M. M.).	Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786; Amiel J, 2003, NAT GENET, V33, P459, DOI 10.1038/ng1130; Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; Balak MN, 2006, CLIN CANCER RES, V12, P6494, DOI 10.1158/1078-0432.CCR-06-1570; Chiarle R, 2008, NAT REV CANCER, V8, P11, DOI 10.1038/nrc2291; Cole KA, 2008, MOL CANCER RES, V6, P735, DOI 10.1158/1541-7786.MCR-07-2102; Dirks WG, 2002, INT J CANCER, V100, P49, DOI 10.1002/ijc.10435; Friedman DL, 2005, CANCER EPIDEM BIOMAR, V14, P1922, DOI 10.1158/1055-9965.EPI-05-0066; George RE, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000255; Griffin CA, 1999, CANCER RES, V59, P2776; Ikenoue T, 2004, CANCER RES, V64, P3428, DOI 10.1158/0008-5472.CAN-03-3591; Ikenoue T, 2003, CANCER RES, V63, P8132; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Jazii FR, 2006, WORLD J GASTROENTERO, V12, P7104, DOI 10.3748/wjg.v12.i44.7104; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Kannan N, 2005, J MOL BIOL, V351, P956, DOI 10.1016/j.jmb.2005.06.057; KNUDSON AG, 1972, AM J HUM GENET, V24, P514; KUSHNER BH, 1986, CANCER-AM CANCER SOC, V57, P1887, DOI 10.1002/1097-0142(19860501)57:9<1887::AID-CNCR2820570931>3.0.CO;2-7; Lamant L, 2000, AM J PATHOL, V156, P1711, DOI 10.1016/S0002-9440(10)65042-0; Lee JW, 2006, CANCER LETT, V237, P89, DOI 10.1016/j.canlet.2005.05.026; Lee JW, 2006, CLIN CANCER RES, V12, P57, DOI 10.1158/1078-0432.CCR-05-0976; Li MY, 2005, AM J HUM GENET, V76, P934, DOI 10.1086/430277; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Longo L, 2007, HUM HERED, V63, P205, DOI 10.1159/000099997; Maris JM, 1997, EUR J CANCER, V33, P1923, DOI 10.1016/S0959-8049(97)00265-7; Maris JM, 2005, PEDIAT ONCOL, P21; Maris JM, 2002, CANCER RES, V62, P6651; Maris JM, 2008, NEW ENGL J MED, V358, P2585, DOI 10.1056/NEJMoa0708698; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; McDermott U, 2008, CANCER RES, V68, P3389, DOI 10.1158/0008-5472.CAN-07-6186; Miyake I, 2002, ONCOGENE, V21, P5823, DOI 10.1038/sj.onc.1205735; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Mosse YP, 2004, AM J HUM GENET, V75, P727, DOI 10.1086/424530; Motegi A, 2004, J CELL SCI, V117, P3319, DOI 10.1242/jcs.01183; Osajima-Hakomori Y, 2005, AM J PATHOL, V167, P213, DOI 10.1016/S0002-9440(10)62966-5; Perri P, 2002, ONCOGENE, V21, P8356, DOI 10.1038/sj.onc.1206009; Raabe EH, 2008, ONCOGENE, V27, P469, DOI 10.1038/sj.onc.1210659; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; SCHWAB M, 1984, NATURE, V308, P288, DOI 10.1038/308288a0; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Torkamani A, 2008, CANCER RES, V68, P1675, DOI 10.1158/0008-5472.CAN-07-5283; Torkamani A, 2007, BIOINFORMATICS, V23, P2918, DOI 10.1093/bioinformatics/btm437; Trochet D, 2004, AM J HUM GENET, V74, P761, DOI 10.1086/383253; van Limpt V, 2004, ONCOGENE, V23, P9280, DOI 10.1038/sj.onc.1208157; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Wigginton JE, 2005, BIOINFORMATICS, V21, P3445, DOI 10.1093/bioinformatics/bti529; Yu NC, 2006, ANAL CHEM, V78, P35, DOI 10.1021/ac051695v	50	914	976	4	84	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 16	2008	455	7215					930	U22		10.1038/nature07261	http://dx.doi.org/10.1038/nature07261			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	360DW	18724359	Green Accepted			2022-12-28	WOS:000260038300042
J	Barrett, RDH; Rogers, SM; Schluter, D				Barrett, Rowan D. H.; Rogers, Sean M.; Schluter, Dolph			Natural selection on a major armor gene in threespine stickleback	SCIENCE			English	Article							GASTEROSTEUS-ACULEATUS; PARALLEL EVOLUTION; MORPHOLOGICAL-CHANGES; PELVIC REDUCTION; FRESH-WATER; POPULATION; FITNESS; SIZE; REPRODUCTION; SPECIATION	Experimental estimates of the effects of selection on genes determining adaptive traits add to our understanding of the mechanisms of evolution. We measured selection on genotypes of the Ectodysplasin locus, which underlie differences in lateral plates in threespine stickleback fish. A derived allele (low) causing reduced plate number has been fixed repeatedly after marine stickleback colonized freshwater from the sea, where the ancestral allele (complete) predominates. We transplanted marine sticklebacks carrying both alleles to freshwater ponds and tracked genotype frequencies over a generation. The low allele increased in frequency once lateral plates developed, most likely via a growth advantage. Opposing selection at the larval stage and changing dominance for fitness throughout life suggest either that the gene affects additional traits undergoing selection or that linked loci also are affecting fitness.	[Barrett, Rowan D. H.; Rogers, Sean M.; Schluter, Dolph] Univ British Columbia, Dept Zool, Vancouver, BC V6T 1Z4, Canada; [Barrett, Rowan D. H.; Rogers, Sean M.; Schluter, Dolph] Univ British Columbia, Biodivers Res Ctr, Vancouver, BC V6T 1Z4, Canada	University of British Columbia; University of British Columbia	Barrett, RDH (corresponding author), Univ British Columbia, Dept Zool, 6270 Univ Blvd, Vancouver, BC V6T 1Z4, Canada.	rbarrett@zoology.ubc.ca	barrett, rowan/G-3906-2010	Barrett, Rowan/0000-0003-3044-2531; Schluter, Dolph/0000-0003-1683-7836	Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery and Special Research Opportunity; Canada Foundation for Innovation; NSERC postdoctoral	Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery and Special Research Opportunity(Natural Sciences and Engineering Research Council of Canada (NSERC)); Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR); NSERC postdoctoral(Natural Sciences and Engineering Research Council of Canada (NSERC))	We thank K. Marchinko, A. Paccard, M. Dosani, K. Dhahan, J.-B. Oboni, E. Sciampe, C. Verchere, J. Courchesne, E. J. Davis, F. Guillaume, J. Hill, C. Jordan, C. Spencer, M. Barrueto, M. Dionne, and S. Rogers for field and genotyping assistance and S. Otto, R. Grant, S. Barrett, and the Schluter lab group for comments on the manuscript. Supported by Natural Sciences and Engineering Research Council of Canada (NSERC) Discovery and Special Research Opportunity grants (D.S.), grants from the Canada Foundation for Innovation (D.S.), and NSERC postdoctoral (S.M.R.) and graduate scholarships (R.D.H.B.). Microsatellite sequences were deposited in GenBank by the Stanford Genome Research Center with the accessions BV678144, BV678119, BV678140, and BV67814.	Abzhanov A, 2004, SCIENCE, V305, P1462, DOI 10.1126/science.1098095; Aebischer A, 1996, J AVIAN BIOL, V27, P143, DOI 10.2307/3677143; Akey JM, 2004, PLOS BIOL, V2, P1591, DOI 10.1371/journal.pbio.0020286; Albertson RC, 2005, P NATL ACAD SCI USA, V102, P16287, DOI 10.1073/pnas.0506649102; Bell M.A., 1994, EVOLUTIONARY BIOL TH; BELL MA, 1977, COPEIA, P277; BELL MA, 1993, EVOLUTION, V47, P906, DOI 10.1111/j.1558-5646.1993.tb01243.x; Bell MA, 2001, GENETICA, V112, P445; Bell MA, 2004, EVOLUTION, V58, P814; BELL MA, 1981, EVOLUTION INT J ORG, V38, P665; Bradshaw HD, 1998, GENETICS, V149, P367; Candolin U, 2003, EVOLUTION, V57, P862, DOI 10.1111/j.0014-3820.2003.tb00297.x; Colosimo PF, 2005, SCIENCE, V307, P1928, DOI 10.1126/science.1107239; Curry RA, 2005, ENVIRON BIOL FISH, V72, P111, DOI 10.1007/s10641-004-6582-2; Einum S, 2000, EVOLUTION, V54, P628, DOI 10.1111/j.0014-3820.2000.tb00064.x; Ellegren H, 2008, NATURE, V452, P169, DOI 10.1038/nature06737; FOSTER SA, 1988, OECOLOGIA, V74, P577, DOI 10.1007/BF00380056; GILES N, 1983, J ZOOL, V199, P535; HAGEN DW, 1973, HEREDITY, V30, P273, DOI 10.1038/hdy.1973.38; Hasselquist D, 1998, ECOLOGY, V79, P2376, DOI 10.2307/176829; Hoekstra HE, 2006, SCIENCE, V313, P101, DOI 10.1126/science.1126121; KLEPAKER T, 1993, CAN J ZOOL, V71, P1251, DOI 10.1139/z93-171; Kristjansson BK, 2005, ENVIRON BIOL FISH, V74, P357, DOI 10.1007/s10641-005-1487-2; Kristjansson BK, 2002, EVOL ECOL RES, V4, P659; LANDA K, 1992, EVOLUTION, V46, P121, DOI [10.1111/j.1558-5646.1992.tb01989.x, 10.2307/2409809]; Marchinko KB, 2007, EVOLUTION, V61, P1084, DOI 10.1111/j.1558-5646.2007.00103.x; MOLLER AP, 1994, BEHAV ECOL SOCIOBIOL, V35, P115, DOI 10.1007/BF00171501; Nielsen R, 2005, PLOS BIOL, V3, P976, DOI 10.1371/journal.pbio.0030170; Reimchen TE, 2000, BEHAVIOUR, V137, P1081, DOI 10.1163/156853900502448; Rogers SM, 2007, MOL BIOL EVOL, V24, P1423, DOI 10.1093/molbev/msm066; ROWE L, 1994, AM NAT, V143, P698, DOI 10.1086/285627; Rundle HD, 2000, SCIENCE, V287, P306, DOI 10.1126/science.287.5451.306; Schluter D, 2004, AM NAT, V163, P809, DOI 10.1086/383621; SCHULTZ ET, 1991, AM NAT, V138, P1408, DOI 10.1086/285294; Shapiro JA, 2007, P NATL ACAD SCI USA, V104, P2271, DOI 10.1073/pnas.0610385104; Shapiro MD, 2004, NATURE, V428, P717, DOI 10.1038/nature02415; Simpson G. G., 1953, MAJOR FEATURES EVOLU, DOI DOI 10.7312/SIMP93764; VERHULST S, 1991, J ANIM ECOL, V60, P269, DOI 10.2307/5459; Wootton JC, 2002, NATURE, V418, P320, DOI 10.1038/nature00813; Wright SI, 2005, SCIENCE, V308, P1310, DOI 10.1126/science.1107891	40	285	291	3	230	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 10	2008	322	5899					255	257		10.1126/science.1159978	http://dx.doi.org/10.1126/science.1159978			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	358FK	18755942				2022-12-28	WOS:000259902300047
J	Tavazzi, L; Maggioni, AP; Marchioli, R; Barlera, S; Franzosi, MG; Latini, R; Lucci, D; Nicolosi, GL; Porcu, M; Tognoni, G				Tavazzi, Luigi; Maggioni, Aldo P.; Marchioli, Roberto; Barlera, Simona; Franzosi, Maria Grazia; Latini, Roberto; Lucci, Donata; Nicolosi, Gian Luigi; Porcu, Maurizio; Tognoni, Gianni		GISSI HF Investigators	Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial	LANCET			English	Article							STATIN THERAPY; SYSTOLIC FUNCTION; LOWER MORTALITY; ATORVASTATIN; METAANALYSIS; RISK	Background Large observational studies, small prospective studies and post-hoc analyses of randomised clinical trials have suggested that statins could be beneficial in patients with chronic heart failure. However, previous studies have been methodologically weak. We investigated the efficacy and safety of the statin rosuvastatin in patients with heart failure. Methods We undertook a randomised, double-blind, placebo-controlled trial in 326 cardiology and 31 internal medicine centres in Italy. We enrolled patients aged 18 years or older with chronic heart failure of New York Heart Association class II-IV, irrespective of cause and left ventricular ejection fraction, and randomly assigned them to rosuvastatin 10 mg daily (n=2285) or placebo (n=2289) by a concealed, computerised telephone randomisation system. Patients were followed up for a median of 3 - 9 years (IQR 3.0-4.4). Primary endpoints were time to death, and time to death or admission to hospital for cardiovascular reasons. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00336336. Findings We analysed all randomised patients. 657 (29%) patients died from any cause in the rosuvastatin group and 644 (28%) in the placebo group (adjusted hazard ratio [HR] 1.00 [95-5% CI 0.898-1.122], p=0.943). 1305 (57%) patients in the rosuvastatin group and 1283 (56%) in the placebo group died or were admitted to hospital for cardiovascular reasons (adjustedHR1.01 [99% CI 0.908-1.112], p=0.903). Inbothgroups, gastrointestinal disorders were the most frequent adverse reaction (34 [1%] rosuvastatin group vs 44 [2%] placebo group). Interpretation Rosuvastatin 10 mg daily did not affect clinical outcomes in patients with chronic heart failure of any cause, in whom the drug was safe. Funding SocietA Prodotti Antibiotici (SPA; Italy), Pfizer, Sigma Tau, and AstraZeneca.	[Tavazzi, Luigi] GVM Hosp Care & Res, Cotignola, Italy; [Maggioni, Aldo P.; Lucci, Donata] ANMCO Res Ctr, Florence, Italy; [Marchioli, Roberto; Tognoni, Gianni] Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy; [Barlera, Simona; Franzosi, Maria Grazia; Latini, Roberto] Ist Ric Farmacol Mario Negri, Milan, Italy; [Nicolosi, Gian Luigi] AO S Maria Angeli, Pordenone, Italy; [Porcu, Maurizio] AO Brotzu S Michele, Cagliari, Italy	Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO); Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Tavazzi, L (corresponding author), GVM Hosp Care & Res, Cotignola, Italy.		Milani, Valentina/AAB-5367-2019; Danzi, Gian Battista/P-2244-2016; Cosentino, Nicola/K-2853-2016; Banzato, Alberto/AAF-2622-2021; Porcu, Maurizio/AAO-6175-2020; raimondo, rosa/N-5351-2019; Latini, Roberto/AAB-1410-2020; Turazza, Fabio/AAB-8736-2020; Nicolosi, Gian Luigi/AAT-9893-2020; sinagra, gianfranco gs/P-7643-2014; Maggioni, Aldo Pietro/AAL-5334-2020; Tavazzi, Luigi/ABD-5119-2020; Ghio, Stefano/ABH-1151-2021	Milani, Valentina/0000-0002-2989-981X; Danzi, Gian Battista/0000-0003-0897-8006; Cosentino, Nicola/0000-0002-8628-3106; Banzato, Alberto/0000-0001-5315-5135; raimondo, rosa/0000-0002-7428-7564; Latini, Roberto/0000-0002-3729-4650; Turazza, Fabio/0000-0002-2348-5309; Nicolosi, Gian Luigi/0000-0002-2218-2808; Maggioni, Aldo Pietro/0000-0003-2764-6779; Tavazzi, Luigi/0000-0003-0336-8356; Yusuf, Salim/0000-0003-4776-5601; COLIZZI, CHRISTIAN/0000-0003-1378-3019; tarantini, luigi/0000-0003-2580-0963; Ghio, Stefano/0000-0002-1858-1152	Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO), Florence, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy; SPA; Pfizer; Sigma Tau; AstraZeneca	Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO), Florence, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy; SPA; Pfizer(Pfizer); Sigma Tau; AstraZeneca(AstraZeneca)	GISSI is endorsed by Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO), Florence, Italy; by Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; and by Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy. SPA, Pfizer, Sigma Tau, and AstraZeneca concurred to fund the study. AstraZeneca provided the experimental treatment. We thank the participants in the study, and the doctors, nurses, ethics committees, and administrative staffin hospitals who assisted with its conduct.	Cannon CP, 2006, J AM COLL CARDIOL, V48, P438, DOI 10.1016/j.jacc.2006.04.070; de Lemos JA, 2004, JAMA-J AM MED ASSOC, V292, P1307, DOI 10.1001/jama.292.11.1307; Dilaveris P, 2007, CURR VASC PHARMACOL, V5, P227; Fukuta H, 2005, CIRCULATION, V112, P357, DOI 10.1161/CIRCULATIONAHA.104.519876; *GISSI HF INV, 2008, LANCET          0831, DOI DOI 10.1016/S0140-6736(08)61239-8; Jain MK, 2005, NAT REV DRUG DISCOV, V4, P977, DOI 10.1038/nrd1901; Kastelein JJP, 2008, CIRCULATION, V117, P3002, DOI 10.1161/CIRCULATIONAHA.107.713438; Khush KK, 2007, CIRCULATION, V115, P576, DOI 10.1161/CIRCULATIONAHA.106.625574; Kjekshus J, 1997, J Card Fail, V3, P249, DOI 10.1016/S1071-9164(97)90022-1; Kjekshus J, 2007, NEW ENGL J MED, V357, P2248, DOI 10.1056/NEJMoa0706201; Krum Henry, 2008, Heart Fail Clin, V4, P177, DOI 10.1016/j.hfc.2008.01.002; Krum H, 2007, INT J CARDIOL, V119, P48, DOI 10.1016/j.ijcard.2006.07.106; Krum H, 2007, J CARD FAIL, V13, P1, DOI 10.1016/j.cardfail.2006.09.008; Kumar Amit, 2008, Heart Fail Clin, V4, P129, DOI 10.1016/j.hfc.2008.01.010; Laufs U, 1998, CIRCULATION, V97, P1129, DOI 10.1161/01.CIR.97.12.1129; Levantesi G, 2007, AM J CARDIOL, V100, P1644, DOI 10.1016/j.amjcard.2007.07.015; Levy Wayne C, 2008, Heart Fail Clin, V4, P201, DOI 10.1016/j.hfc.2008.01.006; Mann DL, 2004, CIRCULATION, V109, P1594, DOI 10.1161/01.CIR.0000124490.27666.B2; Marchioli R, 1996, ARCH INTERN MED, V156, P1158, DOI 10.1001/archinte.156.11.1158; Mathur Nitin, 2008, Heart Fail Clin, V4, P153, DOI 10.1016/j.hfc.2008.01.007; Mozaffarian D, 2004, AM J CARDIOL, V93, P1124, DOI 10.1016/j.amjcard.2004.01.039; Node K, 2003, CIRCULATION, V108, P839, DOI 10.1161/01.CIR.0000084539.58092.DE; Ramasubbu K, 2008, J AM COLL CARDIOL, V51, P415, DOI 10.1016/j.jacc.2007.10.009; Sandek A, 2007, J AM COLL CARDIOL, V50, P1561, DOI 10.1016/j.jacc.2007.07.016; Sander S, 2006, J CARD FAIL, V12, P464, DOI 10.1016/j.cardfail.2006.03.007; Scirica BM, 2006, J AM COLL CARDIOL, V47, P2326, DOI 10.1016/j.jacc.2006.03.034; Serebruany VL, 2008, AM J CARDIOL, V101, P1808, DOI 10.1016/j.amjcard.2008.02.084; Sola S, 2006, J AM COLL CARDIOL, V47, P332, DOI 10.1016/j.jacc.2005.06.088; Tavazzi L, 2004, EUR J HEART FAIL, V6, P635, DOI 10.1016/j.ejheart.2004.03.001; von Haehling Stephan, 2008, Heart Fail Clin, V4, P141, DOI 10.1016/j.hfc.2008.01.009; Wojnicz R, 2006, AM J CARDIOL, V97, P899, DOI 10.1016/j.amjcard.2005.09.142; Yamada T, 2007, AM HEART J, V153, DOI 10.1016/j.ahj.2007.03.027	32	777	813	2	27	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 4	2008	372	9645					1231	1239		10.1016/S0140-6736(08)61240-4	http://dx.doi.org/10.1016/S0140-6736(08)61240-4			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	357YB	18757089				2022-12-28	WOS:000259882000029
J	Gubbels, SP; Woessner, DW; Mitchell, JC; Ricci, AJ; Brigande, JV				Gubbels, Samuel P.; Woessner, David W.; Mitchell, John C.; Ricci, Anthony J.; Brigande, John V.			Functional auditory hair cells produced in the mammalian cochlea by in utero gene transfer	NATURE			English	Article							INNER-EAR DEVELOPMENT; HEARING-LOSS; MYOSIN VIIA; MATH1; MOUSE; THERAPY; MECHANOTRANSDUCTION; REPLACEMENT; EXPRESSION; GENERATION	Sensory hair cells in the mammalian cochlea convert mechanical stimuli into electrical impulses that subserve audition(1,2). Loss of hair cells and their innervating neurons is the most frequent cause of hearing impairment(3). Atonal homologue 1 ( encoded by Atoh1, also known as Math1) is a basic helix - loop - helix transcription factor required for hair- cell development(4-6), and its misexpression in vitro(7,8) and in vivo(9,10) generates hair- cell- like cells. Atoh1- based gene therapy to ameliorate auditory(10) and vestibular(11) dysfunction has been proposed. However, the biophysical properties of putative hair cells induced by Atoh1 misexpression have not been characterized. Here we show that in utero gene transfer of Atoh1 produces functional supernumerary hair cells in the mouse cochlea. The induced hair cells display stereociliary bundles, attract neuronal processes and express the ribbon synapse marker carboxyterminal binding protein 2 ( refs 12,13). Moreover, the hair cells are capable of mechanoelectrical transduction(1,2) and show basolateral conductances with age- appropriate specializations. Our results demonstrate that manipulation of cell fate by transcription factor misexpression produces functional sensory cells in the postnatal mammalian cochlea. We expect that our in utero gene transfer paradigm will enable the design and validation of gene therapies to ameliorate hearing loss in mouse models of human deafness(14,15).	[Gubbels, Samuel P.; Woessner, David W.; Brigande, John V.] Oregon Hlth & Sci Univ, Oregon Hearing Res Ctr, Dept Otolaryngol, Portland, OR 97239 USA; [Mitchell, John C.] Oregon Hlth & Sci Univ, Dept Restorat Dent, Div Biomat & Biomech, Sch Dent, Portland, OR 97239 USA; [Ricci, Anthony J.] Stanford Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Stanford, CA 94305 USA	Oregon Health & Science University; Oregon Health & Science University; Stanford University	Brigande, JV (corresponding author), Oregon Hlth & Sci Univ, Oregon Hearing Res Ctr, Dept Otolaryngol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	brigande@ohsu.edu		ricci, anthony/0000-0002-1706-8904	National Institute on Deafness and Other Communication Disorders; McKnight Endowment Fund for Neuroscience; American Otological Society; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC008595, R01DC003896] Funding Source: NIH RePORTER	National Institute on Deafness and Other Communication Disorders(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); McKnight Endowment Fund for Neuroscience; American Otological Society; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	We thank C. Bresee and J. Jungwirth for expert technical support; C. Cepko and G. Nolan for plasmids EF1 alpha-GFP and BMN-IRES-GFP, respectively; A. Kiernan, D. Fekete, S. Heller, A. Nguyen-Huynh, C. Bresee and J. Jungwirth for critical comments that improved the manuscript; D. Trune, B. Fritzsch and N. Segil for helpful discussions; S. Griest for statistical analyses; and M. Campbell and S. Nigra for exceptional animal care. This study was supported by grants from the National Institute on Deafness and Other Communication Disorders (J.V.B. and A.J.R.), the McKnight Endowment Fund for Neuroscience (J.J.B.) and the American Otological Society (Research Training Fellowship to S.P.G.).	Bermingham NA, 1999, SCIENCE, V284, P1837, DOI 10.1126/science.284.5421.1837; Brown SDM, 2008, NAT REV GENET, V9, P277, DOI 10.1038/nrg2309; Chen P, 2002, DEVELOPMENT, V129, P2495; Chen P, 1999, DEVELOPMENT, V126, P1581; DAVIS A, 1993, HEARING SCI HEARING; Friedman LM, 2007, INT J DEV BIOL, V51, P609, DOI 10.1387/ijdb.072365lf; Fritzsch B, 2005, BRAIN RES BULL, V66, P249, DOI 10.1016/j.brainresbull.2005.05.016; Grant L, 2007, PFLUG ARCH EUR J PHY, V454, P793, DOI 10.1007/s00424-007-0253-z; GUBBELS S, 2007, 30 ANN MIDWINTER RES, V30, P330; HASSON T, 1995, P NATL ACAD SCI USA, V92, P9815, DOI 10.1073/pnas.92.21.9815; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; Hu ZQ, 2006, STEM CELLS DEV, V15, P449, DOI 10.1089/scd.2006.15.449; Izumikawa M, 2005, NAT MED, V11, P271, DOI 10.1038/nm1193; Jones JM, 2006, J NEUROSCI, V26, P550, DOI 10.1523/JNEUROSCI.3859-05.2006; Kawamoto K, 2003, J NEUROSCI, V23, P4395; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; Knirsch M, 2007, J NEUROSCI, V27, P6442, DOI 10.1523/JNEUROSCI.5364-06.2007; Li HW, 2004, TRENDS MOL MED, V10, P309, DOI 10.1016/j.molmed.2004.05.008; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; Maklad A, 2003, DEV BRAIN RES, V140, P223, DOI 10.1016/S0165-3806(02)00609-0; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; Self T, 1998, DEVELOPMENT, V125, P557; SHER AE, 1971, ACTA OTO-LARYNGOL, P1; Staecker H, 2007, OTOL NEUROTOL, V28, P223, DOI 10.1097/MAO.0b013e31802b3225; Vollrath MA, 2007, ANNU REV NEUROSCI, V30, P339, DOI 10.1146/annurev.neuro.29.051605.112917; Waguespack J, 2007, J NEUROSCI, V27, P13890, DOI 10.1523/JNEUROSCI.2159-07.2007; Wan L, 2005, J NEUROSCI, V25, P941, DOI 10.1523/JNEUROSCI.4657-04.2005; Woods C, 2004, NAT NEUROSCI, V7, P1310, DOI 10.1038/nn1349; Wu YC, 1999, J NEUROPHYSIOL, V82, P2171, DOI 10.1152/jn.1999.82.5.2171; Zheng JL, 2000, NAT NEUROSCI, V3, P580, DOI 10.1038/75753	30	192	223	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 25	2008	455	7212					537	U47		10.1038/nature07265	http://dx.doi.org/10.1038/nature07265			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	351TU	18754012	Green Accepted			2022-12-28	WOS:000259449600047
J	Yauch, RL; Gould, SE; Scales, SJ; Tang, T; Tian, H; Ahn, CP; Marshall, D; Fu, L; Januario, T; Kallop, D; Nannini-Pepe, M; Kotkow, K; Marsters, JC; Rubin, LL; de Sauvage, FJ				Yauch, Robert L.; Gould, Stephen E.; Scales, Suzie J.; Tang, Tracy; Tian, Hua; Ahn, Christina P.; Marshall, Derek; Fu, Ling; Januario, Thomas; Kallop, Dara; Nannini-Pepe, Michelle; Kotkow, Karen; Marsters, James C., Jr.; Rubin, Lee L.; de Sauvage, Frederic J.			A paracrine requirement for hedgehog signalling in cancer	NATURE			English	Article							SONIC HEDGEHOG; PANCREATIC-CANCER; GROWTH-FACTOR; STROMAL FIBROBLASTS; MESENCHYMAL CELLS; PATHWAY; MEDULLOBLASTOMA; RENEWAL; TRACT	Ligand- dependent activation of the hedgehog (Hh) signalling pathway has been associated with tumorigenesis in a number of human tissues(1-7). Here we show that, although previous reports have described a cell- autonomous role for Hh signalling in these tumours(1-7), Hh ligands fail to activate signalling in tumour epithelial cells. In contrast, our data support ligand- dependent activation of the Hh pathway in the stromal microenvironment. Specific inhibition of Hh signalling using small molecule inhibitors, a neutralizing anti- Hh antibody or genetic deletion of smoothened ( Smo) in the mouse stroma results in growth inhibition in xenograft tumour models. Taken together, these studies demonstrate a paracrine requirement for Hh ligand signalling in the tumorigenesis of Hh- expressing cancers and have important implications for the development of Hh pathway antagonists in cancer.	[Yauch, Robert L.; Gould, Stephen E.; Scales, Suzie J.; Tang, Tracy; Tian, Hua; Ahn, Christina P.; Marshall, Derek; Fu, Ling; Januario, Thomas; Kallop, Dara; Nannini-Pepe, Michelle; Marsters, James C., Jr.; de Sauvage, Frederic J.] Genentech Inc, San Francisco, CA 94080 USA; [Kotkow, Karen; Rubin, Lee L.] Curis Inc, Cambridge, MA 02138 USA	Roche Holding; Genentech	de Sauvage, FJ (corresponding author), Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.	sauvage@gene.com	de Sauvage, Frederic/ABE-8400-2020; Scales, Suzie J./H-4507-2019	de Sauvage, Frederic/0000-0002-5275-2584; Scales, Suzie J./0000-0003-2544-0283; Rubin, Lee/0000-0002-8658-841X	National Cancer Institute; National Center for Research Resources; National Institutes of Health	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank A. McMahon and M. Scott for providing transgenic mice; T. Holcomb, K. Wagner, D. Lee and P. Wen for their assistance in cell line screening; J. Ernst for rSHH, M. Cole for assistance with imaging; S. Louie for assistance with graphics; P. Haverty for assistance with gene expression data; and M. Evangelista, C. Callahan and V. Dixit for comments and discussions. Tissue samples were provided by the Cooperative Human Tissue Network, which is funded by the National Cancer Institute, and the National Center for Research Resources, which is supported by the National Institutes of Health. Other investigators may have received samples from these same tissues.	Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; BERGMANN U, 1995, CANCER RES, V55, P2007; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; di Magliano MP, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001155; Duda DG, 2004, CANCER RES, V64, P5920, DOI 10.1158/0008-5472.CAN-04-1268; Durai R, 2005, INT J COLORECTAL DIS, V20, P203, DOI 10.1007/s00384-004-0675-4; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; Fan L, 2004, ENDOCRINOLOGY, V145, P3961, DOI 10.1210/en.2004-0079; Frank-Kamenetsky Maria, 2002, J Biol, V1, P10, DOI 10.1186/1475-4924-1-10; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Ingram WJ, 2002, ONCOGENE, V21, P8196, DOI 10.1038/sj.onc.1205975; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kayed H, 2004, INT J CANCER, V110, P668, DOI 10.1002/ijc.20194; Long FX, 2001, DEVELOPMENT, V128, P5099; Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112; Pola R, 2001, NAT MED, V7, P706, DOI 10.1038/89083; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; Sasai K, 2006, CANCER RES, V66, P4215, DOI 10.1158/0008-5472.CAN-05-4505; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; van den Brink GR, 2007, PHYSIOL REV, V87, P1343, DOI 10.1152/physrev.00054.2006; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; YONEDA T, 1981, SCIENCE, V213, P563, DOI 10.1126/science.7017936; Yuan Z, 2007, ONCOGENE, V26, P1046, DOI 10.1038/sj.onc.1209860; Zeng G, 2006, NEOPLASIA, V8, P279, DOI 10.1593/neo.05607	30	762	803	1	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	2008	455	7211					406	U61		10.1038/nature07275	http://dx.doi.org/10.1038/nature07275			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349EX	18754008				2022-12-28	WOS:000259265200048
J	Kesselheim, AS; Studdert, DM				Kesselheim, Aaron S.; Studdert, David M.			Whistleblower-initiated enforcement actions against health care fraud and abuse in the United States, 1996 to 2005	ANNALS OF INTERNAL MEDICINE			English	Article							MEDICARE	Federal regulators have aggressively prosecuted health care fraud since the early 1990s, leading to billions of dollars in financial recoveries. Nearly all major cases today are qui tam actions, involving whistleblowers with inside knowledge of the allegedly illegal schemes. This article documents the outcomes of major enforcement actions and describe the schemes, defendants, and whistleblowers involved. The authors obtained an inventory of unsealed federal qui tam litigation targeting health care fraud that was resolved between 1996 and 2005 from the U. S. Department of Justice and gathered further information from publicly available sources. Among 379 cases, $9.3 billion was recovered, with more than $1.0 billion paid to whistleblowers. Case frequency peaked in 2001, but annual recoveries increased sharply from 2002 to 2005. Whistleblowers were frequently executives or physicians, and 75% were employees of defendant organizations. The 13 (4%) cases against pharmaceutical companies accounted for $3.6 billion (39%) of total recoveries. This study illuminates the scope and characteristics of qui tam fraud litigation and the whistleblowers who animate this important tool for addressing waste in the health care sector.	Univ Melbourne, Melbourne, Vic, Australia; Brigham & Womens Hosp, Boston, MA 02115 USA	University of Melbourne; Harvard University; Brigham & Women's Hospital	Kesselheim, AS (corresponding author), Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA.	akesselheim@partners.org	Studdert, David/AAF-3116-2021; Kesselheim, Aaron/R-6793-2017	Studdert, David/0000-0003-0585-5537; Kesselheim, Aaron/0000-0002-8867-2666	Harvard School of Public Health	Harvard School of Public Health	By an Agency for Healthcare Research and Quality Post-Doctoral Fellowship in Health Services Research at the Harvard School of Public Health (Dr. Kesselheim).	ALBERT T, 2003, AM MED NEW      0127, P12; Avorn J, 2005, POWERFUL MED BENEFIT; BARGER JF, 2005, TUL L REV, V80, P465; Becker D, 2005, J HEALTH ECON, V24, P189, DOI 10.1016/j.jhealeco.2004.07.002; BOESE JT, 2006, CIVIL FALSE CLAIMS Q; Bucy PH, 2002, SOUTH CALIF LAW REV, V76, P1; Davies C, 1997, PROGRAM-ELECTRON LIB, V31, P373; *DHHS OFF INSP GEN, 2006, PROT PUBL HLTH HUM S; Garber A, 2007, HEALTH AFFAIR, V26, P1545, DOI 10.1377/hlthaff.26.6.1545; Iglehart JK, 2007, NEW ENGL J MED, V356, P734, DOI 10.1056/NEJMhpr066650; HENNESSYFISKE M, 2008, LOS ANGELES TIM 0108, pB1; Hyman David A., 2002, CATO J, V22, P151; Johnson Carrie, 2008, WASH POST, pA1; JOST TS, 1999, ALA L REV, V51, P239; Kalb PE, 1999, JAMA-J AM MED ASSOC, V282, P1163, DOI 10.1001/jama.282.12.1163; Klein RD, 2006, ARCH PATHOL LAB MED, V130, P1169; KRAUSE JH, 2002, CARDOZO LAW REV, V23, P1363; Krause Joan H., 2003, J LAW POLICY, V12, P55; Lubalin JS, 1999, SCI ENG ETHICS, V5, P229, DOI 10.1007/s11948-999-0014-9; Matthew Dayna Bowen, 2007, U MICH J L REFORM, V40, P281; McKoy JM, 2005, J CLIN ONCOL, V23, P8894, DOI 10.1200/JCO.2005.01.4605; Meyer J. A, 2006, FIGHTING MEDICARE FR; Rabecs RN, 2006, J CRIM LAW CRIM, V96, P727; Sage WM, 1999, JAMA-J AM MED ASSOC, V282, P1179, DOI 10.1001/jama.282.12.1179; Satiani B, 2005, SURGERY, V137, P472, DOI 10.1016/j.surg.2004.12.005; SILVERMAN E, 2001, 8133 NBER; Smith JJ, 2003, AM J ROENTGENOL, V180, P591, DOI 10.2214/ajr.180.3.1800591; Sparrow M., 2000, LICENSE STEAL FRAUD; Stanton TH, 2001, HEALTH AFFAIR, V20, P28, DOI 10.1377/hlthaff.20.4.28; *US DEP JUST CIV D, 2006, FRAUD STAT; *US DEP JUST CIV D, EL READ ROOM; US Department of Labor. Bureau of Labor Statistics, CONS PRIC IND; *US GEN ACC OFF, 1998, PUBL GAO HEHS; *US GEN ACC OFF, 2006, PUBL GAO; *US GEN ACC OFF, 1992, PUBL GAO HRD, V9269; WEINBERG N, 2005, FORBES          0314, P90	36	27	27	0	22	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2008	149	5					342	W71		10.7326/0003-4819-149-5-200809020-00009	http://dx.doi.org/10.7326/0003-4819-149-5-200809020-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	348SD	18765704				2022-12-28	WOS:000259229300007
J	Fletcher, S				Fletcher, Suzanne			Pharma and CME: View from the US	BRITISH MEDICAL JOURNAL			English	Editorial Material							CONTINUING MEDICAL-EDUCATION		[Fletcher, Suzanne] Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; [Fletcher, Suzanne] Harvard Pilgrim Hlth Care, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care	Fletcher, S (corresponding author), Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA.	suzanne_fletcher@hms.harvard.edu						*ACCR COUNC CONT M, ESS AR THEIR EL; *AG HEALTHC RES QU, 2007, EFF CONT MED ED, P149; *ASS AM MED COLL, REP AAMC TASK FORC I; Cabot RC, 1905, BOSTON MED SURG J, V153, P461, DOI 10.1056/NEJM190510261531701; Davis D, 1999, JAMA-J AM MED ASSOC, V282, P867, DOI 10.1001/jama.282.9.867; Steinbrook R, 2008, JAMA-J AM MED ASSOC, V299, P1060, DOI 10.1001/jama.299.9.1060	6	8	8	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 30	2008	337	7668							a1023	10.1136/bmj.a1023	http://dx.doi.org/10.1136/bmj.a1023			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350OM	18703647				2022-12-28	WOS:000259362100022
J	Moynihan, R				Moynihan, Ray			Is the relationship between pharma and medical education on the rocks?	BRITISH MEDICAL JOURNAL			English	Editorial Material							INDUSTRY		[Moynihan, Ray] Univ Newcastle, Callaghan, NSW 2308, Australia	University of Newcastle		Ray.moynihan@newcastle.edu.au	Moynihan, Ray/ABC-3010-2020					*AM ASS MED COLL T, 2008, IND FUND MED ED; FLETCHER S, 2008, C J MAC FDN; MOYNIHAN R, BMJ UNPUB; Moynihan R, 2005, SELLING SICKNESS DRU; Sorrell WH., PHARM MARKETING DISC; Steinman MA, 2006, ANN INTERN MED, V145, P284, DOI 10.7326/0003-4819-145-4-200608150-00008; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373	7	8	8	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 30	2008	337	7668							a925	10.1136/bmj.a925	http://dx.doi.org/10.1136/bmj.a925			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350OM	18703653				2022-12-28	WOS:000259362100021
J	Pisacane, A				Pisacane, Alfredo			Rethinking continuing medical education	BRITISH MEDICAL JOURNAL			English	Editorial Material							PHARMACEUTICAL-INDUSTRY; PHYSICIANS; HEALTH		[Pisacane, Alfredo] Univ Naples Federico 2, I-80131 Naples, Italy	University of Naples Federico II	Pisacane, A (corresponding author), Univ Naples Federico 2, I-80131 Naples, Italy.	pisacane@unina.it						Armson H, 2007, CAN FAM PHYSICIAN, V53, P1477; Cattaneo A, 2001, BMJ-BRIT MED J, V323, P1358, DOI 10.1136/bmj.323.7325.1358; Davis D, 1999, JAMA-J AM MED ASSOC, V282, P867, DOI 10.1001/jama.282.9.867; GRIMSHAW JM, 2001, MED CARE S, V39, P112; Hebert PC, 2008, CAN MED ASSOC J, V178, P805, DOI 10.1503/cmaj.080317; *IT MIN HLTH, ED CONT MED; JAMTVEDT G, 2006, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000259.PUB2; Knowles MS, 1998, ADULT LEARNER DEFINI; LEXCHIN J, 1993, CAN MED ASSOC J, V149, P1401; Mansouri M, 2007, J CONTIN EDUC HEALTH, V27, P6, DOI 10.1002/chp.88; Moynihan R, 2003, BRIT MED J, V326, P1163, DOI 10.1136/bmj.326.7400.1163; Moynihan R, 2008, BRIT MED J, V336, P416, DOI 10.1136/bmj.39496.430336.DB; OBRIEN MAT, 2000, COCHRANE DB SYST REV, V2; PISARCANE A, 2007, COME FARE ED CONTINU; RENNAN TA, 2006, JAMA-J AM MED ASSOC, V295, P429; Sandars J, 2006, E LEARNING GP ED; Steinbrook R, 2008, JAMA-J AM MED ASSOC, V299, P1060, DOI 10.1001/jama.299.9.1060; Studdert DM, 2004, NEW ENGL J MED, V351, P1891, DOI 10.1056/NEJMlim042229; Topol EJ, 2004, NEW ENGL J MED, V351, P1707, DOI 10.1056/NEJMp048286; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373	20	7	8	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 30	2008	337	7668							a973	10.1136/bmj.a973	http://dx.doi.org/10.1136/bmj.a973			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350OM	18703654				2022-12-28	WOS:000259362100025
J	Raguso, RA				Raguso, Robert A.			Plant science - The "invisible hand" of floral chemistry	SCIENCE			English	Editorial Material							NECTAR; POLLINATION; VISITORS; SCENTS		[Raguso, Robert A.] Cornell Univ, Dept Neurobiol & Behav, Ithaca, NY 14853 USA	Cornell University	Raguso, RA (corresponding author), Cornell Univ, Dept Neurobiol & Behav, Ithaca, NY 14853 USA.	rar229@cornell.edu						Adler LS, 2005, ECOLOGY, V86, P2968, DOI 10.1890/05-0118; Ashman TL, 2005, ECOLOGY, V86, P2099, DOI 10.1890/04-1161; Clauss MJ, 2000, AM NAT, V155, P168, DOI 10.1086/303314; Cozzolino S, 2005, TRENDS ECOL EVOL, V20, P487, DOI 10.1016/j.tree.2005.06.004; Frank R, 2007, EC NATURALIST; Johnson SD, 2004, P ROY SOC B-BIOL SCI, V271, P803, DOI 10.1098/rspb.2003.2659; Johnson SD, 2006, ECOLOGY, V87, P2709, DOI 10.1890/0012-9658(2006)87[2709:DBNFAA]2.0.CO;2; Kessler D, 2008, SCIENCE, V321, P1200, DOI 10.1126/science.1160072; Kessler D, 2007, PLANT J, V49, P840, DOI 10.1111/j.1365-313X.2006.02995.x; Knight TM, 2005, ANNU REV ECOL EVOL S, V36, P467, DOI 10.1146/annurev.ecolsys.36.102403.115320; Lara C, 2002, OIKOS, V96, P470, DOI 10.1034/j.1600-0706.2002.960309.x; Raguso RA, 2005, ANIM BEHAV, V69, P407, DOI 10.1016/j.anbehav.2004.04.015; Raguso RA, 2008, ENTOMOL EXP APPL, V128, P196, DOI 10.1111/j.1570-7458.2008.00683.x; Riffell JA, 2008, P NATL ACAD SCI USA, V105, P3404, DOI 10.1073/pnas.0709811105; Terry I, 2007, SCIENCE, V318, P70, DOI 10.1126/science.1145147	15	20	21	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2008	321	5893					1163	1164		10.1126/science.1163570	http://dx.doi.org/10.1126/science.1163570			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341ZM	18755960				2022-12-28	WOS:000258754400026
J	Bartlett, JG; Branson, BM; Fenton, K; Hauschild, BC; Miller, V; Mayer, KH				Bartlett, John G.; Branson, Bernard M.; Fenton, Kevin; Hauschild, Benjamin C.; Miller, Veronica; Mayer, Kenneth H.			Opt-out testing for human immunodeficiency virus in the United States - Progress and challenges	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOR-DISEASE-CONTROL; HIV-INFECTION; RISK; HEALTH; CARE; DIAGNOSIS; IMPROVE	The Centers for Disease Control and Prevention ( CDC) has recommended human immunodeficiency virus ( HIV) testing for all persons aged 13 to 64 years in all health care settings. Signed consent would not be required and counseling with referral would be managed as it is for other serious conditions. The goal of the recommendations is to promote earlier entry into care to reduce unnecessary mortality and facilitate prevention by behavioral changes that accompany knowledge of serostatus. Concerns about the change include laws in some states that mandate signed consent and counseling, a perception that counseling is an effective prevention strategy, variability in payment coverage for the test, concerns about the stigma and discrimination that may accompany the HIV diagnosis, and the possibility that other testing policies would be more effective. Eleven of 16 states have changed legislation to reduce barriers to testing, 35 of 74 national professional societies have endorsed the new recommendations, and multiple demonstration projects have shown feasibility. Metrics to evaluate the health outcomes of the CDC's recommendations for HIV testing have been defined, but the data necessary to determine the effects on early entry into care, the actual reduction in disease incidence, and the unanticipated consequences are not yet available.	[Bartlett, John G.] Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA; [Branson, Bernard M.; Fenton, Kevin] Ctr Dis Control & Prevent, Atlanta, GA USA; [Hauschild, Benjamin C.; Miller, Veronica] Forum Collaborat HIV Res, Washington, DC USA; [Hauschild, Benjamin C.; Miller, Veronica] George Washington Univ, Washington, DC USA; [Mayer, Kenneth H.] Brown Univ, Dept Med, Providence, RI 02912 USA; [Mayer, Kenneth H.] Miriam Hosp, Providence, RI 02906 USA	Johns Hopkins University; Centers for Disease Control & Prevention - USA; George Washington University; Brown University; Lifespan Health Rhode Island; Miriam Hospital	Bartlett, JG (corresponding author), Johns Hopkins Univ, Sch Med, 1830 E Monument St,Room 447, Baltimore, MD 21205 USA.	jb@jhmi.edu						Smith Nicole M., 2006, Morbidity and Mortality Weekly Report, V55, P1; Anonymous, 2008, Morbidity and Mortality Weekly Report, V57, P681; Bartlett JG, 2007, CLIN INFECT DIS, V45, pS203, DOI 10.1086/522539; Bayer R, 2006, NEW ENGL J MED, V355, P647, DOI 10.1056/NEJMp068153; Branson BM, 2007, CLIN INFECT DIS, V45, pS221, DOI 10.1086/522541; Burke RC, 2007, AIDS, V21, P1617, DOI 10.1097/QAD.0b013e32823f91ff; Calderon Y, 2006, ANN EMERG MED, V48, P21, DOI 10.1016/j.annemergmed.2006.01.003; Centers for Disease Control and Prevention, 2003, MMWR MORB MORTAL WKL, V52, P581; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P1110; *DEP HHS, HIV AIDS SURV REP 20; Duffus W., 2006, Morbidity and Mortality Weekly Report, V55, P1269; Durant T., 2007, Morbidity and Mortality Weekly Report, V56, P189; Ehrenkranz PD, 2008, ACAD EMERG MED, V15, P144, DOI 10.1111/j.1553-2712.2008.00028.x; Fenton KA, 2007, CLIN INFECT DIS, V45, pS213, DOI 10.1086/522615; Gostin LO, 2006, JAMA-J AM MED ASSOC, V296, P2023, DOI 10.1001/jama.296.16.2023; Gruskin S, 2008, DEV WORLD BIOETH, V8, P23, DOI 10.1111/j.1471-8847.2007.00222.x; Hanssens C, 2007, CLIN INFECT DIS, V45, pS232, DOI 10.1086/522543; Haukoos JS, 2007, ACAD EMERG MED, V14, P1149, DOI 10.1111/j.1553-2712.2007.tb02335.x; Holtgrave DR, 2007, PLOS MED, V4, P1011, DOI 10.1371/journal.pmed.0040194; Kamb ML, 1998, JAMA-J AM MED ASSOC, V280, P1161, DOI 10.1001/jama.280.13.1161; Kates J, 2007, CLIN INFECT DIS, V45, pS255, DOI 10.1086/522547; Kelen GD, 1999, ANN EMERG MED, V33, P147, DOI 10.1016/S0196-0644(99)70387-2; Keruly JC, 2007, CLIN INFECT DIS, V45, P1369, DOI 10.1086/522759; Lee LM, 2007, PUBLIC HEALTH REP, V122, P72, DOI 10.1177/00333549071220S111; Lifson AR, 2007, LANCET, V369, P539, DOI 10.1016/S0140-6736(07)60249-9; Marks G, 2006, AIDS, V20, P1447, DOI 10.1097/01.aids.0000233579.79714.8d; McCaig LF, ADV DATA VITAL HLTH; McQuillan GM, 2006, JAIDS-J ACQ IMM DEF, V41, P651, DOI 10.1097/01.qai.0000194235.31078.f6; Mollen C, 2008, AIDS PATIENT CARE ST, V22, P505, DOI 10.1089/apc.2007.0098; MOORE R, 2008, 15 C RETR OPP INF FE; *NAT HIV AIDS CLIN, 2008, STAT HIV TEST LAWS; Ostermann J, 2007, ARCH INTERN MED, V167, P2128, DOI 10.1001/archinte.167.19.2128; Palella FJ, 2003, ANN INTERN MED, V138, P620, DOI 10.7326/0003-4819-138-8-200304150-00007; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Paltiel AD, 2005, NEW ENGL J MED, V352, P586, DOI 10.1056/NEJMsa042088; Rothman RE, 2004, ANN EMERG MED, V44, P31, DOI 10.1016/j.annemergmed.2004.01.016; Sanders GD, 2005, NEW ENGL J MED, V352, P570, DOI 10.1056/NEJMsa042657; Sullivan PS, 2004, JAIDS-J ACQ IMM DEF, V35, P511, DOI 10.1097/00126334-200404150-00009; Swamy Madhavi, 2007, HIV AIDS Policy Law Rev, V12, P39; Telzak E. E., 2007, Morbidity and Mortality Weekly Report, V56, P597; Torian LV, 2008, ARCH INTERN MED, V168, P1181, DOI 10.1001/archinte.168.11.1181; VALDISERRI RO, 1993, PUBLIC HEALTH REP, V108, P12; Valdiserri RO, 2007, PLOS MED, V4, P975, DOI 10.1371/journal.pmed.0040200; Walensky RP, 2006, J INFECT DIS, V194, P11, DOI 10.1086/505147; Watensky RP, 2005, AM J MED, V118, P292, DOI 10.1016/j.amjmed.2004.07.055; Weinhardt LS, 1999, AM J PUBLIC HEALTH, V89, P1397, DOI 10.2105/AJPH.89.9.1397; Wynia MK, 2006, AM J BIOETHICS, V6, P5, DOI 10.1080/15265160600843536	47	90	90	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2008	300	8					945	951		10.1001/jama.300.8.945	http://dx.doi.org/10.1001/jama.300.8.945			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	341AR	18728268				2022-12-28	WOS:000258687100029
J	Dubernard, JM; Devauchelle, B				Dubernard, Jean-Michel; Devauchelle, Bernard			Face transplantation	LANCET			English	Editorial Material							ALLOGRAFT; SKIN; HAND		[Dubernard, Jean-Michel] E Herriot Univ, Lyon Hosp 1, F-69437 Lyon, France; [Devauchelle, Bernard] Amiens Nord Univ Hosp, Amiens, France	CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens	Dubernard, JM (corresponding author), E Herriot Univ, Lyon Hosp 1, F-69437 Lyon, France.	jean-michel.dubernard@chu-lyon.fr						Brennan DC, 2006, NEW ENGL J MED, V355, P1967, DOI 10.1056/NEJMoa060068; Devauchelle B, 2006, LANCET, V368, P203, DOI 10.1016/S0140-6736(06)68935-6; Dubernard JM, 2007, NEW ENGL J MED, V357, P2451, DOI 10.1056/NEJMoa072828; Eljaafari A, 2006, TRANSPLANTATION, V82, P1764, DOI 10.1097/01.tp.0000250937.46187.ca; Fehr T, 2004, TRANSPL IMMUNOL, V13, P117, DOI 10.1016/j.trim.2004.05.009; Guo SZ, 2008, LANCET, V372, P631, DOI 10.1016/S0140-6736(08)61276-3; Kanitakis J, 2006, TRANSPLANTATION, V82, P1610, DOI 10.1097/01.tp.0000248780.55263.33; Lantieri L, 2008, LANCET, V372, P639, DOI 10.1016/S0140-6736(08)61277-5; Siemionow M, 2008, ANN PLAS SURG, V60, P455, DOI 10.1097/SAP.0b013e3180db2765; Thaunat O, 2006, AM J TRANSPLANT, V6, P2238, DOI 10.1111/j.1600-6143.2006.01486.x	10	22	24	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 23	2008	372	9639					603	604		10.1016/S0140-6736(08)61252-0	http://dx.doi.org/10.1016/S0140-6736(08)61252-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	340BX	18722848				2022-12-28	WOS:000258622200004
J	Torti, C; Frank, I				Torti, Carlo; Frank, Ian			A king in the CASTLE? Optimum initial HIV protease inhibitor	LANCET			English	Editorial Material							NAIVE HIV-1-INFECTED PATIENTS; EFFICACY; SAFETY; LOPINAVIR/RITONAVIR; COMBINATION; NELFINAVIR; MANAGEMENT; INFECTION; THERAPY		[Torti, Carlo] Univ Brescia, Inst Infect & Trop Dis, I-25123 Brescia, Italy; [Frank, Ian] Univ Penn, Div Infect Dis, Philadelphia, PA 19104 USA	University of Brescia; University of Pennsylvania	Torti, C (corresponding author), Univ Brescia, Inst Infect & Trop Dis, I-25123 Brescia, Italy.	torti@med.unibs.it						[Anonymous], 2008, GUID US ANT AG HIV I; Clumeck N, 2008, HIV MED, V9, P65, DOI 10.1111/j.1468-1293.2007.00533.x; Joseph E, 2006, LANCET, V368, P476, DOI 10.1016/S0140-6736(06)69155-1; Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993, DOI 10.1056/NEJMoa030218; GATHE J, 2008, 15 C RETR OPP INF BO, P775; Gathe JC, 2004, AIDS, V18, P1529, DOI 10.1097/01.aids.0000131332.30548.92; Hammer SM, 2006, JAMA-J AM MED ASSOC, V296, P827, DOI 10.1001/jama.296.7.827; MALAN N, 2006, 13 C RETR OPP INF DE; Markowitz M, 2007, JAIDS-J ACQ IMM DEF, V46, P125, DOI 10.1097/QAI.0b013e318157131c; Molina JM, 2008, LANCET, V372, P646, DOI 10.1016/S0140-6736(08)61081-8; Ortiz R, 2008, AIDS, V22, P1389, DOI 10.1097/QAD.0b013e32830285fb; POZNIAK A, 2007, 14 C RETR OPP INF CR; Riddler SA, 2008, NEW ENGL J MED, V358, P2095, DOI 10.1056/NEJMoa074609; Rodriguez-Novoa S, 2007, AIDS, V21, P41, DOI 10.1097/QAD.0b013e328011d7c1; Rotger M, 2005, J INFECT DIS, V192, P1381, DOI 10.1086/466531; SAAG M, 2007, 4 IAS C HIV PATH TRE; Walmsley S, 2002, NEW ENGL J MED, V346, P2039, DOI 10.1056/NEJMoa012354; WALMSLEY S, 2007, 11 EUR AIDS C EACS M	18	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	2008	372	9639					604	606		10.1016/S0140-6736(08)61253-2	http://dx.doi.org/10.1016/S0140-6736(08)61253-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	340BX	18722849				2022-12-28	WOS:000258622200005
J	Bonnell, IA; Rice, WKM				Bonnell, I. A.; Rice, W. K. M.			Star formation around supermassive black holes	SCIENCE			English	Article							SGR-A-ASTERISK; GALACTIC-CENTER; ACCRETION DISK; CENTRAL PARSEC; MASS FUNCTION; MILKY-WAY; SIMULATIONS; DYNAMICS; GALAXY	The presence of young massive stars orbiting on eccentric rings within a few tenths of a parsec of the supermassive black hole in the galactic center is challenging for theories of star formation. The high tidal shear from the black hole should tear apart the molecular clouds that form stars elsewhere in the Galaxy, and transport of stars to the galactic center also appears unlikely during their lifetimes. We conducted numerical simulations of the infall of a giant molecular cloud that interacts with the black hole. The transfer of energy during closest approach allows part of the cloud to become bound to the black hole, forming an eccentric disk that quickly fragments to form stars. Compressional heating due to the black hole raises the temperature of the gas up to several hundred to several thousand kelvin, ensuring that the fragmentation produces relatively high stellar masses. These stars retain the eccentricity of the disk and, for a sufficiently massive initial cloud, produce an extremely top- heavy distribution of stellar masses. This potentially repetitive process may explain the presence of multiple eccentric rings of young stars in the presence of a supermassive black hole.	[Bonnell, I. A.] Univ St Andrews, Scottish Univ Phys Alliance, Sch Phys & Astron, St Andrews KY16 9SS, Fife, Scotland; [Rice, W. K. M.] Univ Edinburgh, Scottish Univ Phys Alliance, Inst Astron, Edinburgh EH9 3HJ, Midlothian, Scotland	University of St Andrews; University of Edinburgh	Bonnell, IA (corresponding author), Univ St Andrews, Scottish Univ Phys Alliance, Sch Phys & Astron, St Andrews KY16 9SS, Fife, Scotland.	iab1@st-andrews.ac.uk	Rice, Ken/H-5084-2011	Rice, Ken/0000-0002-6379-9185	STFC [PP/D000890/1, PP/F000065/1] Funding Source: UKRI; Science and Technology Facilities Council [PP/D000890/1, PP/F000065/1] Funding Source: researchfish	STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))		Alexander RD, 2008, ASTROPHYS J, V674, P927, DOI 10.1086/525519; Alexander RD, 2007, ASTROPHYS J, V654, P907, DOI 10.1086/509709; BATE MR, 1995, MON NOT R ASTRON SOC, V277, P362, DOI 10.1093/mnras/277.2.362; Elmegreen BG, 2006, ASTROPHYS J, V648, P572, DOI 10.1086/505785; Gammie CF, 2001, ASTROPHYS J, V553, P174, DOI 10.1086/320631; Genzel R, 1997, MON NOT R ASTRON SOC, V291, P219, DOI 10.1093/mnras/291.1.219; Gurkan MA, 2005, ASTROPHYS J, V628, P236, DOI 10.1086/430694; MONAGHAN JJ, 1992, ANNU REV ASTRON ASTR, V30, P543, DOI 10.1146/annurev.aa.30.090192.002551; Nayakshin S, 2005, MON NOT R ASTRON SOC, V364, pL23, DOI 10.1111/j.1745-3933.2005.00097.x; Nayakshin S, 2005, ASTRON ASTROPHYS, V437, P437, DOI 10.1051/0004-6361:20042052; Nayakshin S, 2007, MON NOT R ASTRON SOC, V379, P21, DOI 10.1111/j.1365-2966.2007.11938.x; Paumard T, 2006, ASTROPHYS J, V643, P1011, DOI 10.1086/503273; PHINNEY ES, 1989, IAU SYMP, V136, P543; Rice WKM, 2003, MON NOT R ASTRON SOC, V339, P1025, DOI 10.1046/j.1365-8711.2003.06253.x; Schodel R, 2002, NATURE, V419, P694, DOI 10.1038/nature01121; Stamatellos D, 2007, ASTRON ASTROPHYS, V475, P37, DOI 10.1051/0004-6361:20077373; Wardle M, 2008, ASTROPHYS J LETT, V683, pL37, DOI 10.1086/591471	19	136	136	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 22	2008	321	5892					1060	1062		10.1126/science.1160653	http://dx.doi.org/10.1126/science.1160653			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339RL	18719276	Green Submitted			2022-12-28	WOS:000258594900031
J	Brechbuhl, J; Klaey, M; Broillet, MC				Brechbuehl, Julien; Klaey, Magali; Broillet, Marie-Christine			Grueneberg ganglion cells mediate alarm pheromone detection in mice	SCIENCE			English	Article							STRESS-INDUCED HYPERTHERMIA; OLFACTORY-BULB; PRIMARY CILIUM; RATS; RECEPTORS; MOUSE; CUES; CONSPECIFICS; COMPONENTS; GLOMERULI	Alarm pheromones ( APs) are widely used throughout the plant and animal kingdoms. Species such as fish, insects, and mammals signal danger to conspecifics by releasing volatile alarm molecules. Thus far, neither the chemicals, their bodily source, nor the sensory system involved in their detection have been isolated or identified in mammals. We found that APs are recognized by the Grueneberg ganglion ( GG), a recently discovered olfactory subsystem. We showed with electron microscopy that GG neurons bear primary cilia, with cell bodies ensheathed by glial cells. APs evoked calcium responses in GG neurons in vitro and induced freezing behavior in vivo, which completely disappeared when the GG degenerated after axotomy. We conclude that mice detect APs through the activation of olfactory GG neurons.	[Brechbuehl, Julien; Klaey, Magali; Broillet, Marie-Christine] Univ Lausanne, Dept Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Lausanne	Broillet, MC (corresponding author), Univ Lausanne, Dept Pharmacol & Toxicol, Bugnon 27, CH-1005 Lausanne, Switzerland.	mbroille@unil.ch	Brechbühl, Julien/AAF-7815-2020	Brechbühl, Julien/0000-0002-2335-3058; Broillet, Marie-Christine/0000-0002-0487-6638	Department of Pharmacology and Toxicology; Swiss National Science Foundation; Leenaards Foundation	Department of Pharmacology and Toxicology; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Leenaards Foundation	We thank I. Rodriguez for the OMP-GFP mice; J. and S. Fakan for their enthusiastic help with EM techniques and for analyzing EM micrographs; G. Knott, A. Mucciolo, and S. Rosset for preparing EM tissue samples; the Cellular Imaging Facility of the University of Lausanne and its coordinator J.-Y. Chatton for valuable advice; C. Lebrand for providing antibodies; N. Rosenblatt-Velin for help with animal handling; and K. Geering and R. Stoop for fruitful discussions on the manuscript. Supported by the Department of Pharmacology and Toxicology, the Swiss National Science Foundation, and the Leenaards Foundation.	ABEL EL, 1991, PHYSIOL BEHAV, V50, P723, DOI 10.1016/0031-9384(91)90009-D; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; Beale MH, 2006, P NATL ACAD SCI USA, V103, P10509, DOI 10.1073/pnas.0603998103; Boissy A, 1998, PHYSIOL BEHAV, V63, P489, DOI 10.1016/S0031-9384(97)00466-6; Brennan PA, 2006, NATURE, V444, P308, DOI 10.1038/nature05404; Fleischer J, 2006, HISTOCHEM CELL BIOL, V125, P337, DOI 10.1007/s00418-005-0077-x; Fleischer J, 2007, CHEM SENSES, V32, P623, DOI 10.1093/chemse/bjm032; Fleischer J, 2006, J NEUROCHEM, V98, P543, DOI 10.1111/j.1471-4159.2006.03894.x; Fuss SH, 2005, EUR J NEUROSCI, V22, P2649, DOI 10.1111/j.1460-9568.2005.04468.x; GRUENEBERG H, 1973, Zeitschrift fuer Anatomie und Entwicklungsgeschichte, V140, P39; Gutierrez-Garcia AG, 2007, PHYSIOL BEHAV, V91, P166, DOI 10.1016/j.physbeh.2007.02.006; Hauser R, 2005, FORENSIC SCI INT, V155, P226, DOI 10.1016/j.forsciint.2005.08.005; Hu J, 2007, SCIENCE, V317, P953, DOI 10.1126/science.1144233; Kikusui T, 2001, PHYSIOL BEHAV, V72, P45, DOI 10.1016/S0031-9384(00)00370-X; Kiyokawa Y, 2005, CHEM SENSES, V30, P513, DOI 10.1093/chemse/bji044; Koos DS, 2005, NEUROREPORT, V16, P1929, DOI 10.1097/01.wnr.0000186597.72081.10; Leach MC, 2002, COMPARATIVE MED, V52, P249; Leinders-Zufall T, 2000, NATURE, V405, P792, DOI 10.1038/35015572; MATHES C, 1995, J GEN PHYSIOL, V106, P975, DOI 10.1085/jgp.106.5.975; Mirza RS, 2001, J CHEM ECOL, V27, P1641, DOI 10.1023/A:1010414426082; Mondor EB, 2004, P ROY SOC B-BIOL SCI, V271, pS341, DOI 10.1098/rsbl.2004.0179; Ono M, 2003, NATURE, V424, P637, DOI 10.1038/424637a; Praetorius HA, 2005, ANNU REV PHYSIOL, V67, P515, DOI 10.1146/annurev.physiol.67.040403.101353; Roppolo D, 2006, EUR J NEUROSCI, V23, P2887, DOI 10.1111/j.1460-9568.2006.04818.x; SHINODA K, 1989, J COMP NEUROL, V284, P362, DOI 10.1002/cne.902840304; Singla V, 2006, SCIENCE, V313, P629, DOI 10.1126/science.1124534; Storan MJ, 2006, J COMP NEUROL, V494, P834, DOI 10.1002/cne.20858; STOWE MK, 1995, P NATL ACAD SCI USA, V92, P23, DOI 10.1073/pnas.92.1.23; TACHIBANA T, 1990, ARCH HISTOL CYTOL, V53, P147, DOI 10.1679/aohc.53.147; Wisenden BD, 2001, ANIM BEHAV, V62, P761, DOI 10.1006/anbe.2001.1797; ZALAQUETT C, 1991, PHYSIOL BEHAV, V50, P221, DOI 10.1016/0031-9384(91)90524-R	31	147	150	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	2008	321	5892					1092	1095		10.1126/science.1160770	http://dx.doi.org/10.1126/science.1160770			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339RL	18719286				2022-12-28	WOS:000258594900042
J	Krizhanovsky, V; Yon, M; Dickins, RA; Hearn, S; Simon, J; Miething, C; Yee, H; Zender, L; Lowe, SW				Krizhanovsky, Valery; Yon, Monica; Dickins, Ross A.; Hearn, Stephen; Simon, Janelle; Miething, Cornelius; Yee, Herman; Zender, Lars; Lowe, Scott W.			Senescence of activated stellate cells limits liver fibrosis	CELL			English	Article							ONCOGENE-INDUCED SENESCENCE; NATURAL-KILLER-CELLS; HEPATITIS-B-VIRUS; CELLULAR SENESCENCE; HETEROCHROMATIN FORMATION; TRANSGENIC MICE; P53; PATHWAY; TUMORIGENESIS; CANCER	Cellular senescence acts as a potent mechanism of tumor suppression; however, its functional contribution to noncancer pathologies has not been examined. Here we show that senescent cells accumulate in murine livers treated to produce fibrosis, a precursor pathology to cirrhosis. The senescent cells are derived primarily from activated hepatic stellate cells, which initially proliferate in response to liver damage and produce the extracellular matrix deposited in the fibrotic scar. In mice lacking key senescence regulators, stellate cells continue to proliferate, leading to excessive liver fibrosis. Furthermore, senescent activated stellate cells exhibit gene expression profile consistent with cell-cycle exit, reduced secretion of extracellular matrix components, enhanced secretion of extracellular matrix-degrading enzymes, and enhanced immune surveillance. Accordingly natural killer cells preferentially kill senescent activated stellate cells in vitro and in vivo, thereby facilitating the resolution of fibrosis. Therefore, the senescence program limits the fibrogenic response to acute tissue damage.	[Krizhanovsky, Valery; Yon, Monica; Dickins, Ross A.; Hearn, Stephen; Simon, Janelle; Miething, Cornelius; Zender, Lars; Lowe, Scott W.] Cold Spring Harbor Lab, Howard Hughes Med Inst, Cold Spring Harbor, NY 11724 USA; [Yon, Monica] Univ Sao Paulo, Inst Ciencias Biomed, Dept Imunol, BR-05508 Sao Paulo, Brazil; [Yee, Herman] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; Universidade de Sao Paulo; New York University	Lowe, SW (corresponding author), Cold Spring Harbor Lab, Howard Hughes Med Inst, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	lowe@cshl.edu	Miething, Cornelius/F-9498-2014; Dickins, Ross A/K-2852-2012; Krizhanovsky, Valery/D-1336-2010	Miething, Cornelius/0000-0003-4699-3805; Dickins, Ross A/0000-0003-4112-5304; Hearn, Stephen/0000-0002-2489-2424; Krizhanovsky, Valery/0000-0002-3977-5482	Leukemia and Lymphoma Society; National Institutes of Health [AG16379]; National Council for Scientific and Technological Development (CNPq); German Research Foundation [ZE-545/2-1]; NATIONAL CANCER INSTITUTE [P30CA008748, P01CA013106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R56AG016379, R01AG016379] Funding Source: NIH RePORTER	Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Council for Scientific and Technological Development (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); German Research Foundation(German Research Foundation (DFG)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We gratefully acknowledge M. Spector for insightful suggestions and critical reading and editing of the manuscript; G. P. Amarante-Mendes for reagents and advice; M. J. Bahr for reading the manuscript; M. McCurrach for editorial advice; members of the Lowe laboratory for stimulating discussions; E. Hernando and L. Chiriboga for IHC; K. Diggins, L. Bianco, and the CSHL animal facility for help with animals; P. Moody and the CSHL Flow Cytometry facility for help with laser scanning cytometry. This work was supported by a postdoctoral fellowship from the Leukemia and Lymphoma Society (V. K.) and grant AG16379 from the National Institutes of Health (S. W. L.). M. Y. is supported by a doctoral fellowship from the National Council for Scientific and Technological Development (CNPq). L. Z. is a Seligson Clinical Fellow and supported by the German Research Foundation (Emmy Noether Programme, ZE-545/2-1 and the Excellence Cluster "Rebirth''). S. W. L. is a Howard Hughes Medical Institute investigator.	Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282; Berenguer M, 2000, J HEPATOL, V32, P673, DOI 10.1016/S0168-8278(00)80231-7; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Dickins RA, 2007, NAT GENET, V39, P914, DOI 10.1038/ng2045; Drexler HG, 2000, LEUKEMIA, V14, P777, DOI 10.1038/sj.leu.2401778; Gasser S, 2005, NATURE, V436, P1186, DOI 10.1038/nature03884; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; He L, 2007, NAT REV CANCER, V7, P819, DOI 10.1038/nrc2232; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Muhanna N, 2007, CLIN EXP IMMUNOL, V148, P338, DOI 10.1111/j.1365-2249.2007.03353.x; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Narita M, 2006, CELL, V126, P503, DOI 10.1016/j.cell.2006.05.052; *NCHS, 2004, NAT VITT STAT REP; Passino MA, 2007, SCIENCE, V315, P1853, DOI 10.1126/science.1137603; Radaeva S, 2006, GASTROENTEROLOGY, V130, P435, DOI 10.1053/j.gastro.2005.10.055; Raulet DH, 2006, NAT REV IMMUNOL, V6, P520, DOI 10.1038/nri1863; Rehermann B, 2005, NAT REV IMMUNOL, V5, P215, DOI 10.1038/nri1573; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schnabl B, 2003, HEPATOLOGY, V37, P653, DOI 10.1053/jhep.2003.50097; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shimizu I, 2007, WORLD J GASTROENTERO, V13, P4295, DOI 10.3748/wjg.v13.i32.4295; Wang HP, 2004, MOL CELL NEUROSCI, V27, P489, DOI 10.1016/j.mcn.2004.08.004; Wiemann SU, 2002, FASEB J, V16, P935, DOI 10.1096/fj.01-0977com; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Zhuo L, 2001, GENESIS, V31, P85, DOI 10.1002/gene.10008	35	1228	1280	4	155	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 22	2008	134	4					657	667		10.1016/j.cell.2008.06.049	http://dx.doi.org/10.1016/j.cell.2008.06.049			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SR	18724938	Green Accepted, Bronze			2022-12-28	WOS:000258665800018
J	Baker, CD; Caplan, A; Davis, K; Dentzer, S; Epstein, AM; Frist, B; Galvin, RS; King-Shaw, RJ; Lee, TH; Oberlander, JB; Rosenbaum, S; Schroeder, SA; Tuckson, RV				Baker, Charles D.; Caplan, Arthur; Davis, Karen; Dentzer, Susan; Epstein, Arnold M.; Frist, Bill; Galvin, Robert S.; King-Shaw, Ruben J., Jr.; Lee, Thomas H.; Oberlander, Jonathan B.; Rosenbaum, Sara; Schroeder, Steven A.; Tuckson, Reed V.			Health of the nation - Coverage for all Americans	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Baker, Charles D.] Harvard Pilgrim Hlth Care Inc, Wellesley, MA 02481 USA; [Caplan, Arthur] Univ Penn, Philadelphia, PA 19104 USA; [Davis, Karen] Commonwealth Fund, New York, NY USA; [Epstein, Arnold M.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Galvin, Robert S.] Gen Elect, Global Hlth Care, Fairfield, CT USA; [King-Shaw, Ruben J., Jr.] Mansa Equity Partners, Tallahassee, FL USA; [King-Shaw, Ruben J., Jr.] Mansa Equity Partners, Carlisle, MA USA; [Lee, Thomas H.] Partners HealthCare Syst, Boston, MA USA; [Oberlander, Jonathan B.] Univ N Carolina, Chapel Hill, NC USA; [Rosenbaum, Sara] George Washington Univ, Washington, DC USA; [Schroeder, Steven A.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Tuckson, Reed V.] UnitedHlth Grp, Med Affairs, Minneapolis, MN USA	Harvard Pilgrim Health Care; University of Pennsylvania; Commonwealth Fund; Harvard University; Harvard T.H. Chan School of Public Health; General Electric; Partners Healthcare System; University of North Carolina; University of North Carolina Chapel Hill; George Washington University; University of California System; University of California San Francisco	Baker, CD (corresponding author), Harvard Pilgrim Hlth Care Inc, Wellesley, MA 02481 USA.								0	7	7	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 21	2008	359	8					777	780		10.1056/NEJMp0805637	http://dx.doi.org/10.1056/NEJMp0805637			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	339HL	18716294				2022-12-28	WOS:000258568600001
J	Yao, J; Liu, ZW; Liu, YM; Wang, Y; Sun, C; Bartal, G; Stacy, AM; Zhang, X				Yao, Jie; Liu, Zhaowei; Liu, Yongmin; Wang, Yuan; Sun, Cheng; Bartal, Guy; Stacy, Angelica M.; Zhang, Xiang			Optical negative refraction in bulk metamaterials of nanowires	SCIENCE			English	Article							PHOTONIC CRYSTALS; INDEX; LENS		[Yao, Jie; Liu, Zhaowei; Liu, Yongmin; Wang, Yuan; Sun, Cheng; Bartal, Guy; Zhang, Xiang] Univ Calif Berkeley, Natl Sci Fdn, NSEC, Berkeley, CA 94720 USA; [Stacy, Angelica M.] Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; [Zhang, Xiang] Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA	National Science Foundation (NSF); University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Zhang, X (corresponding author), Univ Calif Berkeley, Natl Sci Fdn, NSEC, 5130 Etcheverry Hall, Berkeley, CA 94720 USA.	xiang@berkeley.edu	Sun, Cheng/B-7609-2009; Wang, Yuan/F-7211-2011; Zhang, Xiang/F-6905-2011; Liu, Yongmin/F-5322-2010; Sun, Cheng/A-8111-2010; Liu, Zhaowei/A-8521-2010; Liu, Zhaowei/N-9936-2019	Wang, Yuan/0000-0001-7892-2812; Sun, Cheng/0000-0002-2744-0896; Liu, Zhaowei/0000-0002-5732-8109; Liu, Yongmin/0000-0003-1084-6651; Zhang, Xiang/0000-0002-3272-894X; Yao, Jie/0000-0003-0557-759X				Berrier A, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.073902; Cubukcu E, 2003, NATURE, V423, P604, DOI 10.1038/423604b; Dolling G, 2007, OPT LETT, V32, P53, DOI 10.1364/OL.32.000053; Hoffman AJ, 2007, NAT MATER, V6, P946, DOI 10.1038/nmat2033; Lezec HJ, 2007, SCIENCE, V316, P430, DOI 10.1126/science.1139266; MASUDA H, 1995, SCIENCE, V268, P1466, DOI 10.1126/science.268.5216.1466; Parimi PV, 2003, NATURE, V426, P404, DOI 10.1038/426404a; Pendry JB, 2006, SCIENCE, V312, P1780, DOI 10.1126/science.1125907; Pendry JB, 2000, PHYS REV LETT, V85, P3966, DOI 10.1103/PhysRevLett.85.3966; Schonbrun E, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2435344; Shelby RA, 2001, SCIENCE, V292, P77, DOI 10.1126/science.1058847; Silveirinha MG, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.035108; Smith DR, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.077405; VESELAGO VG, 1968, SOV PHYS USPEKHI, V10, P509, DOI 10.1070/PU1968v010n04ABEH003699; Wangberg R, 2006, J OPT SOC AM B, V23, P498, DOI 10.1364/JOSAB.23.000498	15	751	780	16	372	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 15	2008	321	5891					930	930		10.1126/science.1157566	http://dx.doi.org/10.1126/science.1157566			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	337LD	18703734	Green Submitted			2022-12-28	WOS:000258436700029
J	Salart, D; Baas, A; Branciard, C; Gisin, N; Zbinden, H				Salart, Daniel; Baas, Augustin; Branciard, Cyril; Gisin, Nicolas; Zbinden, Hugo			Testing the speed of 'spooky action at a distance'	NATURE			English	Article							BELL INEQUALITIES; VIOLATION	Correlations are generally described by one of two mechanisms: either a first event influences a second one by sending information encoded in bosons or other physical carriers, or the correlated events have some common causes in their shared history. Quantum physics predicts an entirely different kind of cause for some correlations, named entanglement. This reveals itself in correlations that violate Bell inequalities (implying that they cannot be described by common causes) between space-like separated events (implying that they cannot be described by classical communication). Many Bell tests have been performed(1), and loopholes related to locality(2-4) and detection(5,6) have been closed in several independent experiments. It is still possible that a first event could influence a second, but the speed of this hypothetical influence (Einstein's 'spooky action at a distance') would need to be defined in some universal privileged reference frame and be greater than the speed of light. Here we put stringent experimental bounds on the speed of all such hypothetical influences. We performed a Bell test over more than 24 hours between two villages separated by 18 km and approximately east-west oriented, with the source located precisely in the middle. We continuously observed two-photon interferences well above the Bell inequality threshold. Taking advantage of the Earth's rotation, the configuration of our experiment allowed us to determine, for any hypothetically privileged frame, a lower bound for the speed of the influence. For example, if such a privileged reference frame exists and is such that the Earth's speed in this frame is less than 10(-3) times that of the speed of light, then the speed of the influence would have to exceed that of light by at least four orders of magnitude.	[Salart, Daniel; Baas, Augustin; Branciard, Cyril; Gisin, Nicolas; Zbinden, Hugo] Univ Geneva, Appl Phys Grp, CH-1211 Geneva 4, Switzerland	University of Geneva	Salart, D (corresponding author), Univ Geneva, Appl Phys Grp, 20 Rue Ecole Med, CH-1211 Geneva 4, Switzerland.	daniel.salart@physics.unige.ch	Zbinden, Hugo/AAE-7258-2019; Branciard, Cyril/A-6964-2012	Branciard, Cyril/0000-0001-9460-825X				ASPECT A, 1982, PHYS REV LETT, V49, P91, DOI 10.1103/PhysRevLett.49.91; Aspect A, 1999, NATURE, V398, P189, DOI 10.1038/18296; BOHM D, 1952, PHYS REV, V85, P166, DOI 10.1103/PhysRev.85.166; BOHM D, 1952, PHYS REV, V85, P180, DOI 10.1103/PhysRev.85.180; BOHM D, 1993, UNDIVIDED UNIVERSE, P293; BRENDEL J, 1999, P 5 OPT FIB MEAS C U, P12; Eberhard P.H., 1989, QUANTUM THEORY PICTU, P169; FEINBERG G, 1967, PHYS REV, V159, P1089, DOI 10.1103/PhysRev.159.1089; FRANSON JD, 1989, PHYS REV LETT, V62, P2205, DOI 10.1103/PhysRevLett.62.2205; GARISTO R, 2002, WHAT IS SPEED QUANTU; Gisin N, 2000, ANN PHYS-BERLIN, V9, P831, DOI 10.1002/1521-3889(200011)9:11/12<831::AID-ANDP831>3.0.CO;2-7; Matsukevich DN, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.150404; PASSY R, 1994, J LIGHTWAVE TECHNOL, V12, P1622, DOI 10.1109/50.320946; Rowe MA, 2001, NATURE, V409, P791, DOI 10.1038/35057215; Scarani V, 2000, PHYS LETT A, V276, P1, DOI 10.1016/S0375-9601(00)00609-5; Scholder F, 2002, OPT COMMUN, V213, P57, DOI 10.1016/S0030-4018(02)02053-9; Tanzilli S, 2002, EUR PHYS J D, V18, P155, DOI 10.1140/epjd/e20020019; Thew RT, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.062304; Tittel W, 1998, PHYS REV LETT, V81, P3563, DOI 10.1103/PhysRevLett.81.3563; Weihs G, 1998, PHYS REV LETT, V81, P5039, DOI 10.1103/PhysRevLett.81.5039; Zbinden H, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.022111	22	141	150	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 14	2008	454	7206					861	864		10.1038/nature07121	http://dx.doi.org/10.1038/nature07121			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	336XH	18704081	Green Submitted			2022-12-28	WOS:000258398600030
J	Peto, R; Emberson, J; Landray, M; Baigent, C; Collins, R; Clare, R; Califf, R				Peto, Richard; Emberson, Jonathan; Landray, Martin; Baigent, Colin; Collins, Rory; Clare, Robert; Califf, Robert			Analyses of cancer data from three Ezetimibe trials	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REQUIRING PROLONGED OBSERVATION; TIME RELATIONSHIPS; PRAVASTATIN; PATIENT; PROSPER; DESIGN; RISK	Background: Five years of statin therapy lowers low-density lipoprotein (LDL) cholesterol substantially and, over a 5-year period, results in reductions in the incidence of cardiovascular events. The Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial (ClinicalTrials.gov number, NCT00092677) has raised the hypothesis that adding ezetimibe to statin therapy for larger LDL cholesterol reductions might increase the incidence of cancer. Methods: We compared the results of a hypothesis-generating analysis of the incidence of cancer in the SEAS trial of ezetimibe plus simvastatin in 1873 patients (mean follow-up after ezetimibe or matching placebo was begun, 4.1 years) with a hypothesis-testing analysis of cancer data from the two large ongoing trials of this regimen: the Study of Heart and Renal Protection (SHARP) (NCT00125593) with 9264 patients (mean follow-up, 2.7 years) and the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) (NCT00202878), currently with 11,353 patients (mean follow-up, 1.0 year). Results: In the SEAS trial, assignment to ezetimibe was associated with an increase in any new onset of cancer (101 patients in the active-treatment group vs. 65 in the control group) from several cancer sites. In SHARP and IMPROVE-IT combined, there was no overall excess of cancer (313 active-treatment vs. 326 control; risk ratio, 0.96; 95% confidence interval, 0.82 to 1.12; P=0.61) and no significant excess at any particular site. Among patients assigned to ezetimibe, there were more, albeit not significantly more, deaths from cancer (97, vs. 72 in the control group; P=0.07), but there were also fewer, although not significantly fewer, other cases of cancer (216, vs. 254 in the control group; P=0.08). There was no evidence of a trend in the risk ratio for incidence of or death from cancer with increasing duration of follow-up. Conclusions: The available results from these three trials do not provide credible evidence of any adverse effect of ezetimibe on rates of cancer. Follow-up of longer duration will permit the balance of risks and benefits to be determined more reliably.	[Peto, Richard; Emberson, Jonathan; Landray, Martin; Baigent, Colin; Collins, Rory] Univ Oxford, CTSU, Oxford OX3 7LF, England; [Clare, Robert; Califf, Robert] Duke Univ, Duke Clin Res Inst, Durham, NC USA	University of Oxford; Duke University	Peto, R (corresponding author), Univ Oxford, CTSU, Richard Doll Bldg,Old Road Campus, Oxford OX3 7LF, England.	secretary@ctsu.ox.ac.uk		Emberson, Jonathan/0000-0001-7792-9422; Landray, Martin/0000-0001-6646-827X	Merck; Schering-Plough; MRC [MC_U137686853] Funding Source: UKRI; Medical Research Council [MC_U137686853] Funding Source: researchfish	Merck(Merck & Company); Schering-Plough(Merck & CompanySchering Plough Corporation); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	These analyses were initiated, conducted, interpreted, and reported (here and, in preliminary form, to the Food and Drug Administration in July) by the authors, independently of any pharmaceutical company. Although the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU) are conducting SHARP and the Duke Clinical Research Institute is conducting IMPROVE-IT ( in collaboration with the Thrombolysis in Myocardial Infarction Study Group), they are doing so independently of the study funders (Merck and Schering-Plough). The CTSU has a policy of not accepting any honoraria or consultancy fees that directly or indirectly come from industry, although costs of taking part in scientific meetings can be paid. Oxford University is applying for a patent on a genetic test to predict statin-induced myopathy. Dr. Clare reports having a salaried role as statistician in the IMPROVE-IT trial and Dr. Califf reports receiving consulting fees from Merck and Schering-Plough that are donated to his university and to not-for-profit charities. No other potential conflict of interest relevant to this article was reported. We thank the patients who have agreed to take part in these trials, the collaborating institutions and investigators, and the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) investigators for unpublished cancer-incidence data.	Baigent C, 2003, KIDNEY INT, V63, pS207, DOI 10.1046/j.1523-1755.63.s84.4.x; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Califf RM, 2007, HEALTH AFFAIR, V26, P62, DOI 10.1377/hlthaff.26.1.62; CANNON CP, IN PRESS AM HEART J; Collins R, 2002, LANCET, V360, P1618, DOI 10.1016/S0140-6736(02)11650-3; Collins R, 2001, LANCET, V357, P373, DOI 10.1016/S0140-6736(00)03651-5; *CTT COLL, 2008, LANCET, V371, P2084; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; DOLL R, 1978, J EPIDEMIOL COMMUN H, V32, P303, DOI 10.1136/jech.32.4.303; Drazen JM, 2008, NEW ENGL J MED, V358, P1507, DOI 10.1056/NEJMe0801842; Ellenberg SS., 2002, DATA MONITORING COMM; Grant AM, 2005, LANCET, V365, P711; Hochberg Y., 1987, MULTIPLE COMP PROCED; MANTEL N, 1959, J NATL CANCER I, V22, P719; PETO R, 1991, CANCER RES, V51, P6452; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Peto R, 1980, IARC Monogr Eval Carcinog Risk Chem Hum Suppl, P311; Rossebo AB, 2008, NEW ENGL J MED, V359, P1343, DOI 10.1056/NEJMoa0804602; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; TOMATIS L, 1990, IARC SCI PUBLICATION, V100	22	171	182	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 25	2008	359	13					1357	1366		10.1056/NEJMsa0806603	http://dx.doi.org/10.1056/NEJMsa0806603			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	351QZ	18765432	Bronze			2022-12-28	WOS:000259440900006
J	Sprake, C; Cantillon, P; Metcalf, J; Spencer, J				Sprake, Caroline; Cantillon, Peter; Metcalf, Jane; Spencer, John			Teaching rounds - Teaching in an ambulatory care setting	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							12 TIPS; EDUCATION	Four third- year medical students are coming to the clinic for half a day a week. They have just finished their basic clinical skills training and the aim of their attendance is to further develop their history taking and examination skills in the maelstrom of clinical practice. What organisational issues do you need to consider?	[Sprake, Caroline; Metcalf, Jane; Spencer, John] Univ Newcastle, Sch Med Sci Educ Dev, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Cantillon, Peter] Natl Univ Ireland Univ Coll Galway, Dept Gen Practice, Galway, Ireland	Newcastle University - UK; Ollscoil na Gaillimhe-University of Galway	Spencer, J (corresponding author), Univ Newcastle, Sch Med Sci Educ Dev, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	j.a.spencer@ncl.ac.uk						*CAN I HLTH INF, 1998, NAT AMB CAR REP SYST; Dent JA, 2001, MED TEACH, V23, P345, DOI 10.1080/01421590120057012; Howe A, 2003, BRIT MED J, V327, P326, DOI 10.1136/bmj.327.7410.326; Irby DM, 2008, BRIT MED J, V336, P384, DOI 10.1136/bmj.39456.727199.AD; IRBY DM, 1995, ACAD MED, V70, P898, DOI 10.1097/00001888-199510000-00014; Ker JS, 2002, MED TEACH, V24, P437, DOI 10.1080/01421590220145842; Lipsky MS, 1999, MED TEACH, V21, P469; Sackett D., 2000, EVIDENCE BASED MED P, DOI DOI 10.1136/BMJ.H3089; Schuwirth LWT, 2006, BMJ-BRIT MED J, V333, P544, DOI 10.1136/bmj.38952.701875.94; Smail S, 2006, EDUC PRIM CARE, V17, P171, DOI 10.1080/14739879.2006.11864055; Spencer J, 2000, MED EDUC, V34, P851, DOI 10.1046/j.1365-2923.2000.00779.x; Spencer J, 2003, BMJ-BRIT MED J, V326, P591, DOI 10.1136/bmj.326.7389.591; WOOLLISCROFT JO, 1989, ACAD MED, V64, P644, DOI 10.1097/00001888-198911000-00002	13	7	7	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 20	2008	337	7671							a1156	10.1136/bmj.a1156	http://dx.doi.org/10.1136/bmj.a1156			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354EP	18768554				2022-12-28	WOS:000259622000036
J	Simonetti, A; Marzi, S; Myasnikov, AG; Fabbretti, A; Yusupov, M; Gualerzi, CO; Klaholz, BP				Simonetti, Angelita; Marzi, Stefano; Myasnikov, Alexander G.; Fabbretti, Attilio; Yusupov, Marat; Gualerzi, Claudio O.; Klaholz, Bruno P.			Structure of the 30S translation initiation complex	NATURE			English	Article							MESSENGER-RNA TRANSLATION; RIBOSOMAL-SUBUNIT; CRYSTAL-STRUCTURE; BINDING; FMET-TRNA(FMET); TERMINATION; BOOTSTRAP; MOVEMENT; REVEALS; EVENTS	Translation initiation, the rate- limiting step of the universal process of protein synthesis, proceeds through sequential, tightly regulated steps. In bacteria, the correct messenger RNA start site and the reading frame are selected when, with the help of initiation factors IF1, IF2 and IF3, the initiation codon is decoded in the peptidyl site of the 30S ribosomal subunit by the fMet-tRNA(fMet) anticodon. This yields a 30S initiation complex (30SIC) that is an intermediate in the formation of the 70S initiation complex (70SIC) that occurs on joining of the 50S ribosomal subunit to the 30SIC and release of the initiation factors(1-3). The localization of IF2 in the 30SIC has proved to be difficult so far using biochemical approaches, but could now be addressed using cryo- electron microscopy and advanced particle separation techniques on the basis of three- dimensional statistical analysis. Here we report the direct visualization of a 30SIC containing mRNA, fMet-tRNA(fMet) and initiation factors IF1 and GTP-bound IF2. We demonstrate that the fMet-tRNA(fMet) is held in a characteristic and precise position and conformation by two interactions that contribute to the formation of a stable complex: one involves the transfer RNA decoding stem which is buried in the 30S peptidyl site, and the other occurs between the carboxy- terminal domain of IF2 and the tRNA acceptor end. The structure provides insights into the mechanism of 70SIC assembly and rationalizes the rapid activation of GTP hydrolysis triggered on 30SIC-50S joining(2,3) by showing that the GTP- binding domain of IF2 would directly face the GTPase-activated centre of the 50S subunit.	[Simonetti, Angelita; Marzi, Stefano; Myasnikov, Alexander G.; Yusupov, Marat; Klaholz, Bruno P.] Inst Genet & Mol & Cellular Biol, Dept Struct Biol & Genom, F-67404 Illkirch Graffenstaden, France; [Simonetti, Angelita; Marzi, Stefano; Myasnikov, Alexander G.; Yusupov, Marat; Klaholz, Bruno P.] INSERM, U596, F-67404 Illkirch Graffenstaden, France; [Simonetti, Angelita; Marzi, Stefano; Myasnikov, Alexander G.; Yusupov, Marat; Klaholz, Bruno P.] CNRS, UMR7104, F-67404 Illkirch Graffenstaden, France; [Simonetti, Angelita; Marzi, Stefano; Myasnikov, Alexander G.; Yusupov, Marat; Klaholz, Bruno P.] Univ Strasbourg, F-67070 Strasbourg, France; [Marzi, Stefano] CNRS, Inst Biol Mol & Cellulaire, Architecture & React ARN, UPR 9002, F-67084 Strasbourg, France; [Fabbretti, Attilio; Gualerzi, Claudio O.] Univ Camerino, Dept Biol, Genet Lab, MCA, I-62032 Camerino, MC, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Camerino	Klaholz, BP (corresponding author), Inst Genet & Mol & Cellular Biol, Dept Struct Biol & Genom, F-67404 Illkirch Graffenstaden, France.	klaholz@igbmc.u-strasbg.fr	Fabbretti, Attilio/L-2524-2013; Yusupov, Marat/I-6126-2013; Marzi, Stefano/A-1810-2012; Myasnikov, Alexander/T-4654-2018	Fabbretti, Attilio/0000-0003-3928-2781; Yusupov, Marat/0000-0001-5544-0597; Marzi, Stefano/0000-0003-0399-4613; Simonetti, Angelita/0000-0001-7983-4945	Centre National pour la Recherche Scientifique; Ministere de la Recherche et de la Technologie; European Molecular Biology Organization Young Investigator Programme; Institut du Developpement et des Ressources en Informatique Scientifique; European Commission [LSHG-CT-2006-031220]; SPINE2; Institut National de la Sante et de la Recherche Medicale; Fondation de la Recherche Medicale; ULP,; CNRS; FRM; Alsace Regio; Association pour la Recherche sur le Cancer	Centre National pour la Recherche Scientifique; Ministere de la Recherche et de la Technologie; European Molecular Biology Organization Young Investigator Programme(European Molecular Biology Organization (EMBO)); Institut du Developpement et des Ressources en Informatique Scientifique; European Commission(European CommissionEuropean Commission Joint Research Centre); SPINE2; Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Fondation de la Recherche Medicale(Fondation pour la Recherche Medicale); ULP,; CNRS(Centre National de la Recherche Scientifique (CNRS)); FRM(Fondation pour la Recherche Medicale); Alsace Regio; Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council)	We thank J. Thompson for providing IF2 strains, M. Argentini for mass spectroscopy analysis of IF1 and IF2, and P. Schultz, D. Moras, J.- C. Thierry, V. Mallouh, G. Yusupova and I. Orlov for their constant support and interest. This work was supported by grants from the Centre National pour la Recherche Scientifique (CNRS), the Ministere de la Recherche et de la Technologie, the European Molecular Biology Organization Young Investigator Programme, the Institut du Developpement et des Ressources en Informatique Scientifique, and the European Commission as SPINE2-complexes (contract n<SUP>o</SUP> LSHG-CT-2006-031220). A. S. is a PhD student in a co-tutorial between the Universite Louis Pasteur (ULP) and the Universita di Camerino, and was supported by SPINE2- complexes, by the Institut National de la Sante et de la Recherche Medicale (INSERM) and by the Fondation de la Recherche Medicale (FRM). S. M. was supported by postdoctoral fellowships from the ULP, the CNRS and from the FRM, and A. G. M. was a recipient of postdoctoral fellowships from the CNRS and the FRM. The electron microscope facility is supported by the Alsace Region, the INSERM, the CNRS and the Association pour la Recherche sur le Cancer.	Ali IK, 2006, MOL CELL, V23, P865, DOI 10.1016/j.molcel.2006.08.011; Allen GS, 2005, CELL, V121, P703, DOI 10.1016/j.cell.2005.03.023; Antoun Ayman, 2004, Biol Proced Online, V6, P35, DOI 10.1251/bpo71; Carter AP, 2001, SCIENCE, V291, P498, DOI 10.1126/science.1057766; Caserta E, 2006, J MOL BIOL, V362, P787, DOI 10.1016/j.jmb.2006.07.043; EFRON B, 1981, BIOMETRIKA, V68, P589, DOI 10.1093/biomet/68.3.589; FECHTER P, IN PRESS METHODS MOL; Giuliodori AM, 2007, RNA, V13, P1355, DOI 10.1261/rna.455607; Grigoriadou C, 2007, J MOL BIOL, V373, P562, DOI 10.1016/j.jmb.2007.07.032; Gualerzi CO, 2001, COLD SPRING HARB SYM, V66, P363, DOI 10.1101/sqb.2001.66.363; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; Guenneugues M, 2000, EMBO J, V19, P5233, DOI 10.1093/emboj/19.19.5233; HAYNOR DR, 1989, IEEE T MED IMAGING, V8, P337, DOI 10.1109/42.41486; Klaholz BP, 2003, NATURE, V421, P90, DOI 10.1038/nature01225; Klaholz BP, 2004, NATURE, V427, P862, DOI 10.1038/nature02332; Korostelev A, 2006, CELL, V126, P1065, DOI 10.1016/j.cell.2006.08.032; Marzi S, 2007, CELL, V130, P1019, DOI 10.1016/j.cell.2007.07.008; Milon P, 2008, MOL CELL, V30, P712, DOI 10.1016/j.molcel.2008.04.014; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; Myasnikov AG, 2005, NAT STRUCT MOL BIOL, V12, P1145, DOI 10.1038/nsmb1012; Orlov IM, 2006, J STRUCT BIOL, V154, P287, DOI 10.1016/j.jsb.2006.03.007; Penczek PA, 2006, J STRUCT BIOL, V154, P168, DOI 10.1016/j.jsb.2006.01.003; RODNINA MV, 1994, ANAL BIOCHEM, V219, P380, DOI 10.1006/abio.1994.1282; Roll-Mecak A, 2000, CELL, V103, P781, DOI 10.1016/S0092-8674(00)00181-1; Rosenthal PB, 2003, J MOL BIOL, V333, P721, DOI 10.1016/j.jmb.2003.07.013; Schluenzen F, 2000, CELL, V102, P615, DOI 10.1016/S0092-8674(00)00084-2; Selmer M, 2006, SCIENCE, V313, P1935, DOI 10.1126/science.1131127; SIMONETTI A, 2008, NATURE PROTCOLS, DOI DOI 10.1038/NPROT.2008.130; Szkaradkiewicz K, 2000, EUR J BIOCHEM, V267, P4290, DOI 10.1046/j.1432-1327.2000.01480.x; Thompson J, 2004, NUCLEIC ACIDS RES, V32, P5954, DOI 10.1093/nar/gkh925; Tomsic J, 2000, EMBO J, V19, P2127, DOI 10.1093/emboj/19.9.2127; Valle M, 2002, EMBO J, V21, P3557, DOI 10.1093/emboj/cdf326; van Heel M, 2005, J STRUCT BIOL, V151, P250, DOI 10.1016/j.jsb.2005.05.009; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Yusupova G, 2006, NATURE, V444, P391, DOI 10.1038/nature05281; Yusupova GZ, 2001, CELL, V106, P233, DOI 10.1016/S0092-8674(01)00435-4	37	159	159	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	2008	455	7211					416	U73		10.1038/nature07192	http://dx.doi.org/10.1038/nature07192			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349EX	18758445				2022-12-28	WOS:000259265200050
J	Davis, A				Davis, Amy			Outsourced radiology: Will doctors be deskilled?	BRITISH MEDICAL JOURNAL			English	Editorial Material							TELERADIOLOGY					adavis@bmj.com						Dixon Adrian K, 2008, J Am Coll Radiol, V5, P12, DOI 10.1016/j.jacr.2007.09.010; *FAC CLIN RAD, 2004, TEL GUID DOC CLIN RA; Larson DB, 2005, AM J ROENTGENOL, V185, P24, DOI 10.2214/ajr.185.1.01850024; *PEN RAD AC, HIST RITI PROJ; Thrall JH, 2007, RADIOLOGY, V244, P325, DOI 10.1148/radiol.2442070676; Thrall JH, 2007, RADIOLOGY, V243, P613, DOI 10.1148/radiol.2433070350	6	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 6	2008	337	7669							a785	10.1136/bmj.a785	http://dx.doi.org/10.1136/bmj.a785			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	351JP	18694883				2022-12-28	WOS:000259420900028
J	Fox, K; Ford, I; Steg, PG; Tendera, M; Ferrari, R				Fox, Kim; Ford, Ian; Steg, P. Gabriel; Tendera, Michal; Ferrari, Roberto		BEAUTIFUL Investigators	Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial	LANCET			English	Article							I-F INHIBITOR; ELEVATED HEART-RATE; MYOCARDIAL-INFARCTION; MORTALITY; CARVEDILOL; SURVIVAL; EFFICACY; FAILURE; ANGINA; DESIGN	Background Ivabradine specifically inhibits the I-f current in the sinoatrial node to lower heart rate, without affecting other aspects of cardiac function. We aimed to test whether lowering the heart rate with ivabradine reduces cardiovascular death and morbidity in patients with coronary artery disease and left-ventricular systolic dysfunction. Methods Between December, 2004, and December, 2006, we screened 12473 patients at 781 centres in 33 countries. We enrolled 10 917 eligible patients who had coronary artery disease and a left-ventricular ejection fraction of less than 40% in a randomised, double-blind, placebo-controlled, parallel-group trial. 5479 patients received 5 mg ivabradine, with the intention of increasing to the target dose of 7.5 mg twice a day, and 5438 received matched placebo in addition to appropriate cardiovascular medication. The primary endpoint was a composite of cardiovascular death admission to hospital for acute myocardial infarction, and admission to hospital for new onset or worsening heart failure. We analysed patients by intention to treat. The study is registered with ClinicalTrials.gov, number NCT00143507. Findings Mean heart rate at baseline was 71.6 (SD 9.9) beats per minute (bpm). Median follow-tip was 19 months (IQR 16-24). Ivabradine reduced heart rate by 6 bpm (S E 0.2) at 12 months, corrected for placebo. Most (87%) patients were receiving beta blockers in addition to study drugs, and no safety concerns were identified. Ivabradine did not affect the primary composite endpoint (hazard ratio 1. 00, 95% CI 0 . 91-1. 1, p=0 . 94). 1233 (22 . 5%) patients in the ivabradine group had serious adverse events, compared with 1239 (22.8%) controls (p=0.70). In a prespecified subgroup of patients with heart rate of 70 bpm or greater, ivabradine treatment did not affect the primary composite outcome (hazard ratio 0 . 91, 95% CI 0 . 81-1.04, p=0.17), cardiovascular death, or admission to hospital for new-onset or worsening heart failure. However, it did reduce secondary endpoints: admission to hospital for fatal and non-fatal myocardial infarction (0 . 64, 95% CI 0 . 49-0 . 84, p=0 . 001) and coronary revascularisation (0. 70, 95% CI 0 . 52-0.93, p=0 .016). Interpretation Reduction in heart rate with ivabradine does not improve cardiac outcomes in all patients with stable coronary artery disease and left-ventricular systolic dysfunction, but could be used to reduce the incidence of coronary artery disease outcomes in a subgroup of patients who have heart rates of 70 bprn or greater. Funding Servier, France.	[Fox, Kim] Royal Brompton Hosp, London SW3 6NP, England; [Ford, Ian] Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland; [Steg, P. Gabriel] Hop Bichat Claude Bernard, F-75877 Paris 18, France; [Tendera, Michal] Med Univ Silesia, Katowice, Poland; [Ferrari, Roberto] Univ Ferrara, S Maugeri Fdn, I-44100 Ferrara, Italy	Royal Brompton Hospital; University of Glasgow; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Medical University Silesia; Istituti Clinici Scientifici Maugeri IRCCS; University of Ferrara	Fox, K (corresponding author), Royal Brompton Hosp, Sydney St, London SW3 6NP, England.	k.fox@rbht.nhs.uk	Ford, Ian/ABE-6145-2020; Tendera, Michal/AAA-1875-2022; Perna, Eduardo Roque/AAT-6497-2021; Kubica, Jacek/D-6906-2014; Georgescu, Catalina Arsenescu/R-5709-2017; Belenkov, Yury N/B-4159-2018; Atherton, John J/B-9994-2011; cornel, jan hein/Y-7065-2019; Arnolda, Leonard F/B-7986-2008; Böhm, Michael/C-3638-2011; Tomescu, Cleopatra M/F-5197-2011; Grabauskiene, Virginija/H-2848-2018; Golukhova, Elena/Q-1768-2015; Svistov, Aleksandr S/G-8291-2018; Bazylevych, Andriy/G-2834-2019; Shpektor, Alexander V/B-1083-2016; FERRARI, ROBERTO/ABD-5169-2020; Zhilyaev, Evgeny/E-3774-2016; Freedman, Saul B/C-1625-2013; Korzh, Oleksii/E-4291-2016; Khomazyuk, Tetyana Anastasievna/AAZ-8588-2021; Ponikowski, Piotr/O-6454-2015; Zateyshchikov, Dmitry/AGN-8590-2022; Hradec, Jaromir/S-2388-2016; Nedogoda, Sergey V/O-4656-2014; Zateyshchikov, Dmitry A/D-6575-2012; Colquhoun, David M/F-9078-2013; Manolis, Antonis/F-5003-2014; Zadionchenko, Vladimir/A-7445-2016; Sinkiewicz, Wladyslaw/G-5169-2014; STEG, Philippe Gabriel/Z-1567-2019; Sinescu, Crina Julieta/AAA-8793-2021; Maas, A.H.E.M./H-8070-2014; Lopatin, Yuri/N-9262-2015; Yakushin, Sergey/N-4165-2013; Mareev, Vyacheslav Yurievich/Q-1375-2017; Vasyuk, Yury/G-1772-2013; Seredyuk, Nestor/W-6794-2018; Moiseeva, Olga/A-4580-2014; Tashchuk, Viktor/D-4901-2017	Perna, Eduardo Roque/0000-0002-9977-7623; Kubica, Jacek/0000-0001-8250-754X; Georgescu, Catalina Arsenescu/0000-0001-5142-7598; Atherton, John J/0000-0003-2271-578X; cornel, jan hein/0000-0002-1006-2112; Grabauskiene, Virginija/0000-0002-3671-1993; Golukhova, Elena/0000-0002-6252-0322; Svistov, Aleksandr S/0000-0003-0246-5680; Bazylevych, Andriy/0000-0001-5053-2548; Zhilyaev, Evgeny/0000-0002-9443-1164; Freedman, Saul B/0000-0002-3809-2911; Korzh, Oleksii/0000-0001-6838-4360; Khomazyuk, Tetyana Anastasievna/0000-0002-2368-5116; Ponikowski, Piotr/0000-0002-3391-7064; Zateyshchikov, Dmitry/0000-0001-7065-2045; Hradec, Jaromir/0000-0001-7597-8239; Nedogoda, Sergey V/0000-0001-5981-1754; Zateyshchikov, Dmitry A/0000-0001-7065-2045; Manolis, Antonis/0000-0002-0336-4745; Zadionchenko, Vladimir/0000-0003-2377-5266; Sinescu, Crina Julieta/0000-0001-5933-8549; Maas, A.H.E.M./0000-0001-5782-9926; GALINIER, Michel/0000-0003-1735-3390; Erglis, Andrejs/0000-0002-3999-0182; Ferrari, Roberto/0000-0003-2046-9175; Murray, Gordon/0000-0001-9866-4734; Lopatin, Yuri/0000-0001-8744-7144; Yakushin, Sergey/0000-0001-7202-742X; STEG, Philippe Gabriel/0000-0001-6896-2941; Bulaeva, Naida/0000-0002-5091-0518; Viigimaa, Margus/0000-0001-5575-5978; Kolomiets, Sergiy/0000-0002-3095-7386; Perez-Villa, Felix/0000-0001-9244-938X; Kaye, David/0000-0003-4058-0372; Mareev, Vyacheslav Yurievich/0000-0002-7285-2048; URAL, DILEK/0000-0003-0224-1433; Kober, Lars/0000-0002-6635-1466; Vasyuk, Yury/0000-0003-2913-9797; Freitas, Joao/0000-0001-7478-3042; Nikita, Perepech/0000-0003-4057-5813; Rudyk, Iurii/0000-0002-3363-868X; Seredyuk, Nestor/0000-0002-3616-2445; Kovalenko, Volodymyr/0000-0003-3802-9207; Moiseeva, Olga/0000-0002-7817-3847; Janion, Marianna/0000-0002-8811-4568; Kmec, Jan/0000-0002-3036-891X; Tashchuk, Viktor/0000-0002-7988-5256; Mostovoy, Yuriy/0000-0002-7041-1230; Cameron, James/0000-0003-0589-0367; Vojacek, Jan F/0000-0001-7724-9734; Varoneckas, Giedrius/0000-0001-8073-4335; Tendera, Michal/0000-0002-0812-6113; Rynkiewicz, Andrzej/0000-0002-5284-9511; Pella, Daniel/0000-0001-9999-6271; Weir, Christopher/0000-0002-6494-4903	Servier; Sanofi-Aventis; Astelias; Astra Zeneca; Bayer; Boehringer-Ingelheim; BMS; Endotis; GSK; Medtronic; MSID Nycomed; The Medicines Company	Servier(Servier); Sanofi-Aventis(Sanofi-Aventis); Astelias; Astra Zeneca(AstraZeneca); Bayer(Bayer AG); Boehringer-Ingelheim(Boehringer Ingelheim); BMS(Bristol-Myers Squibb); Endotis; GSK(GlaxoSmithKline); Medtronic(Medtronic); MSID Nycomed; The Medicines Company	All authors have received fees, research grants, or both from Servier. PGS has also received a research grant from Sanofi-Aventis, and has received fees for speaking or consulting from Astelias, Astra Zeneca, Bayer, Boehringer-Ingelheim, BMS, Endotis, GSK, Medtronic, MSID Nycomed, Sanofi-Aventis, and The Medicines Company	Boden WE, 2007, NEW ENGL J MED, V356, P1503, DOI 10.1056/NEJMoa070829; Borer JS, 2003, CIRCULATION, V107, P817, DOI 10.1161/01.CIR.0000048143.25023.87; Burns RJ, 2002, J AM COLL CARDIOL, V39, P30, DOI 10.1016/S0735-1097(01)01711-9; Camm A John, 2003, Drugs R D, V4, P83, DOI 10.2165/00126839-200304020-00001; Daly CA, 2006, BMJ-BRIT MED J, V332, P262, DOI 10.1136/bmj.38695.605440.AE; Dargie HJ, 2002, LANCET, V359, P1269, DOI 10.1016/s0140-6736(02)08265-x; Dargie HJ, 1999, LANCET, V353, P1360, DOI 10.1016/S0140-6736(05)74355-5; Diaz A, 2005, EUR HEART J, V26, P967, DOI 10.1093/eurheartj/ehi190; DiFrancesco D, 2004, DRUGS, V64, P1757, DOI 10.2165/00003495-200464160-00003; Fox K, 2008, CARDIOLOGY, V110, P271, DOI 10.1159/000112412; Fox K, 2007, J AM COLL CARDIOL, V50, P823, DOI 10.1016/j.jacc.2007.04.079; Fox K, 2006, AM HEART J, V152, P860, DOI 10.1016/j.ahj.2006.01.013; Fox KM, 2003, LANCET, V362, P782; Giannoglou GD, 2008, INT J CARDIOL, V126, P302, DOI 10.1016/j.ijcard.2007.08.077; Graham I, 2007, EUR HEART J, V28, P2375, DOI 10.1093/eurheartj/ehm316; Heidland UE, 2001, CIRCULATION, V104, P1477, DOI 10.1161/hc3801.096325; Hjalmarson A, 1999, LANCET, V353, P2001; Joannides R, 2006, BRIT J CLIN PHARMACO, V61, P127, DOI 10.1111/j.1365-2125.2005.02544.x; KANNEL WB, 1987, AM HEART J, V113, P1489, DOI 10.1016/0002-8703(87)90666-1; Kolloch R, 2008, EUR HEART J, V29, P1327, DOI 10.1093/eurheartj/ehn123; Komajda M, 2003, EUR HEART J, V24, P464, DOI 10.1016/S0195-668X(02)00700-5; Manz M, 2003, CARDIOLOGY, V100, P149, DOI 10.1159/000073933; McMurray J, 2005, J AM COLL CARDIOL, V45, P525, DOI 10.1016/j.jacc.2004.09.076; Packer M, 2001, NEW ENGL J MED, V344, P1651, DOI 10.1056/NEJM200105313442201; Palatini P, 2004, CLIN EXP HYPERTENS, V26, P637, DOI 10.1081/CEH-200031959; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Steg PG, 2007, JAMA-J AM MED ASSOC, V297, P1197, DOI 10.1001/jama.297.11.1197; Tardif JC, 2005, EUR HEART J, V26, P2529, DOI 10.1093/eurheartj/ehi586; Wang TJ, 2003, CIRCULATION, V108, P977, DOI 10.1161/01.CIR.0000085166.44904.79	29	786	829	0	83	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 6	2008	372	9641					807	816		10.1016/S0140-6736(08)61170-8	http://dx.doi.org/10.1016/S0140-6736(08)61170-8			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	347FB	18757088				2022-12-28	WOS:000259124900023
J	Heng, JIT; Nguyen, L; Castro, DS; Zimmer, C; Wildner, H; Armant, O; Skowronska-Krawczyk, D; Bedogni, F; Matter, JM; Hevner, R; Guillemot, F				Heng, Julian Ik-Tsen; Nguyen, Laurent; Castro, Diogo S.; Zimmer, Celine; Wildner, Hendrik; Armant, Olivier; Skowronska-Krawczyk, Dorota; Bedogni, Francesco; Matter, Jean-Marc; Hevner, Robert; Guillemot, Francois			Neurogenin 2 controls cortical neuron migration through regulation of Rnd2	NATURE			English	Article							CEREBRAL-CORTEX; PYRAMIDAL NEURONS; CELL-MIGRATION; PRONEURAL BHLH; RHO FAMILY; DIFFERENTIATION; NEOCORTEX; PROTEINS; SPECIFICATION; HIPPOCAMPUS	Motility is a universal property of newly generated neurons. How cell migration is coordinately regulated with other aspects of neuron production is not well understood. Here we show that the proneural protein neurogenin 2 ( Neurog2), which controls neurogenesis in the embryonic cerebral cortex(1,2), directly induces the expression of the small GTP- binding protein Rnd2 ( ref. 3) in newly generated mouse cortical neurons before they initiate migration. Rnd2 silencing leads to a defect in radial migration of cortical neurons similar to that observed when the Neurog2 gene is deleted. Remarkably, restoring Rnd2 expression in Neurog2- mutant neurons is sufficient to rescue their ability to migrate. Our results identify Rnd2 as a novel essential regulator of neuronal migration in the cerebral cortex and demonstrate that Rnd2 is a major effector of Neurog2 function in the promotion of migration. Thus, a proneural protein controls the complex cellular behaviour of cell migration through a remarkably direct pathway involving the transcriptional activation of a small GTP- binding protein.	[Heng, Julian Ik-Tsen; Nguyen, Laurent; Castro, Diogo S.; Zimmer, Celine; Wildner, Hendrik; Armant, Olivier; Guillemot, Francois] Natl Inst Med Res, Div Mol Neurobiol, London NW7 1AA, England; [Skowronska-Krawczyk, Dorota; Matter, Jean-Marc] Univ Geneva, Dept Biochem, CH-1211 Geneva 4, Switzerland; [Bedogni, Francesco; Hevner, Robert] Univ Washington, Harborview Med Ctr, Sch Med, Dept Pathol, Seattle, WA 98104 USA	MRC National Institute for Medical Research; University of Geneva; Harborview Medical Center; University of Washington; University of Washington Seattle	Guillemot, F (corresponding author), Natl Inst Med Res, Div Mol Neurobiol, Mill Hill, London NW7 1AA, England.	fguille@nimr.mrc.ac.uk	Castro, Diogo S/I-6217-2016; Guillemot, Francois/AAV-1482-2021	Castro, Diogo S/0000-0001-8178-9565; Nguyen, Laurent/0000-0002-8560-3008; armant, olivier/0000-0001-7101-9209; bedogni, francesco/0000-0002-6651-0041; Heng, Julian Ik-Tsen/0000-0002-0378-7078	Australian CJ Martin Fellowship [310616]; Medical Research Council career development fellowship; European Molecular Biology Organization; Medical Research Council career development fellowships; European Commission 6th Framework Programme for Research and Technological Development; Medical Research Council; MRC [MC_U117570528] Funding Source: UKRI; Medical Research Council [MC_U117570528] Funding Source: researchfish	Australian CJ Martin Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Medical Research Council career development fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Molecular Biology Organization(European Molecular Biology Organization (EMBO)); Medical Research Council career development fellowships(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Commission 6th Framework Programme for Research and Technological Development(European Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We are grateful to S. Wood for technical assistance in generating transgenic embryos. Wethank members of the Guillemot laboratory for suggestions on the manuscript, and F. Polleux (University of North Carolina) for the pNeuroD1 plasmid and D. Anderson (California Institute of Technology) for the anti- Neurog2 antibody. J.I.-T.H. is supported by an Australian CJ Martin Fellowship (grant number 310616) and a Medical Research Council career development fellowship (UK), L.N. and H.W. by postdoctoral fellowships awarded by the European Molecular Biology Organization, and D.S.C. and C.Z. by Medical Research Council career development fellowships ( UK). This work was supported by grants from the European Commission 6th Framework Programme for Research and Technological Development to F.G. and by institutional funds from the Medical Research Council ( UK).	Ayala R, 2007, CELL, V128, P29, DOI 10.1016/j.cell.2006.12.021; Bertrand N, 2002, NAT REV NEUROSCI, V3, P517, DOI 10.1038/nrn874; Bron R, 2007, NEURAL DEV, V2, DOI 10.1186/1749-8104-2-21; Castro DS, 2006, DEV CELL, V11, P831, DOI 10.1016/j.devcel.2006.10.006; Chardin P, 2006, NAT REV MOL CELL BIO, V7, P54, DOI 10.1038/nrm1788; Chardin P, 2003, CURR BIOL, V13, pR702, DOI 10.1016/j.cub.2003.08.042; Englund C, 2005, J NEUROSCI, V25, P247, DOI 10.1523/JNEUROSCI.2899-04.2005; Fode C, 2000, GENE DEV, V14, P67; Ge WH, 2006, P NATL ACAD SCI USA, V103, P1319, DOI 10.1073/pnas.0510419103; Goebbels S, 2006, GENESIS, V44, P611, DOI 10.1002/dvg.20256; Gohlke JM, 2008, BMC BIOL, V6, DOI 10.1186/1741-7007-6-15; Hand R, 2005, NEURON, V48, P45, DOI 10.1016/j.neuron.2005.08.032; Huang HP, 2000, MOL CELL BIOL, V20, P3292, DOI 10.1128/MCB.20.9.3292-3307.2000; Ince-Dunn G, 2006, NEURON, V49, P683, DOI 10.1016/j.neuron.2006.01.031; Kakimoto T, 2004, J BIOL CHEM, V279, P14104, DOI 10.1074/jbc.M312763200; LoTurco JJ, 2006, TRENDS NEUROSCI, V29, P407, DOI 10.1016/j.tins.2006.05.006; Marin O, 2003, ANNU REV NEUROSCI, V26, P441, DOI 10.1146/annurev.neuro.26.041002.131058; Mattar P, 2004, DEV BIOL, V273, P373, DOI 10.1016/j.ydbio.2004.06.013; McManus MF, 2005, J CHILD NEUROL, V20, P280, DOI 10.1177/08830738050200040301; Nakamura K, 2006, NEUROSCI RES, V54, P149, DOI 10.1016/j.neures.2005.10.008; Negishi M, 2005, NEUROSCIENTIST, V11, P187, DOI 10.1177/1073858404268768; Nguyen L, 2006, GENE DEV, V20, P1511, DOI 10.1101/gad.377106; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; Ross SE, 2003, NEURON, V39, P13, DOI 10.1016/S0896-6273(03)00365-9; Schuurmans C, 2004, EMBO J, V23, P2892, DOI 10.1038/sj.emboj.7600278; Schwab MH, 2000, J NEUROSCI, V20, P3714, DOI 10.1523/JNEUROSCI.20-10-03714.2000; SEO S, 2007, EMBO J; Tabata H, 2003, J NEUROSCI, V23, P9996; Tanaka H, 2006, J BIOL CHEM, V281, P10355, DOI 10.1074/jbc.M511314200; Yokota Y, 2007, NEURON, V54, P429, DOI 10.1016/j.neuron.2007.04.016	30	208	209	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	2008	455	7209					114	U82		10.1038/nature07198	http://dx.doi.org/10.1038/nature07198			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	343XS	18690213				2022-12-28	WOS:000258890200048
J	Lines, J; Schapira, A; Smith, T				Lines, Jo; Schapira, Allan; Smith, Tom			Tackling malaria today	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							VECTOR CONTROL; IMMUNIZATION; MORTALITY; IMPACT		[Lines, Jo] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; [Schapira, Allan; Smith, Tom] Swiss Trop Inst, CH-4051 Basel, Switzerland	University of London; London School of Hygiene & Tropical Medicine; University of Basel; Swiss Tropical & Public Health Institute	Lines, J (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.	jo.lines@lshtm.ac.uk	Smith, Thomas/B-5569-2015	Smith, Thomas/0000-0002-3650-9381; Lines, Jo/0000-0001-5380-4916				*AFR UN, 2007, 3 ORD SESS AFR UN C; [Anonymous], CONT MAL MULT RES CA; Biai S, 2007, BRIT MED J, V335, P862, DOI 10.1136/bmj.39345.467813.80; Bill & Melinda Gates Foundation, 2007, MAL FOR COLL INN IMP; Bradley DJ., 1991, DIS MORTALITY SUBSAH, P248; Casman EA, 2002, CONTEXTUAL DETERMINA; de Savigny Don, 2008, FIXING HLTH SYSTEMS; Feachem R, 2008, LANCET, V371, P1633, DOI 10.1016/S0140-6736(08)60424-9; GRAMICCIA G, 1988, PRINCIPLES PRACTICE, P1335; Hastings IM, 2004, TRENDS PARASITOL, V20, P512, DOI 10.1016/j.pt.2004.08.006; Maire N, 2006, AM J TROP MED HYG, V75, P111, DOI 10.4269/ajtmh.2006.75.111; Molineaux L, 2020, GARKI PROJECT RES EP, V8; MOUCHET J, 1953, CAHIERS ORSTOM EMP, V1, P39; Najera JA., 1998, MALARIA EPIDEMICS DE; Ottesen EA, 1997, ERADICATION INFECT D, P47; PAYNE D, 1988, PARASITOL TODAY, V4, P112, DOI 10.1016/0169-4758(88)90042-7; PAYNE D, 1976, B WORLD HEALTH ORGAN, V54, P369; Smith DL, 2007, PLOS BIOL, V5, P531, DOI 10.1371/journal.pbio.0050042; Sochantha T, 2006, TROP MED INT HEALTH, V11, P1166, DOI 10.1111/j.1365-3156.2006.01673.x; TATEM AJ, 2007, PLOS 1, V12, pE1298; *UN, SECR GEN ANN ROLL BA; Webster J, 2005, LANCET INFECT DIS, V5, P709, DOI 10.1016/S1473-3099(05)70269-3; *WHO, 1968, WHO TECH REP SER, P382; World Health Organization, 2007, MAL EL FIELD MAN LOW; WRIGHT JW, 1972, ANNU REV ENTOMOL, V17, P75, DOI 10.1146/annurev.en.17.010172.000451; ZAHAR AR, 1984, B WORLD HEALTH ORGAN, V62, P89	26	11	12	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 23	2008	337	7667							a869	10.1136/bmj.a869	http://dx.doi.org/10.1136/bmj.a869			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	346FD	18713802	Green Accepted			2022-12-28	WOS:000259053100024
J	Parnes, O				Parnes, Ohad			Historical keyword - Inflammation	LANCET			English	Editorial Material												ucgaosp@ucl.ac.uk							0	4	4	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	2008	372	9639					621	621		10.1016/S0140-6736(08)61262-3	http://dx.doi.org/10.1016/S0140-6736(08)61262-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	340BX	18722856				2022-12-28	WOS:000258622200012
J	Sebire, NJ; Seckl, MJ				Sebire, N. J.; Seckl, M. J.			Gestational trophoblastic disease: current management of hydatidiform mole	BMJ-BRITISH MEDICAL JOURNAL			English	Review							AGENT METHOTREXATE CHEMOTHERAPY; PREGNANCY; EVACUATION; TUMORS; RISK; NEOPLASIA; DIAGNOSIS; PROTOCOL; MODE		[Sebire, N. J.; Seckl, M. J.] Charing Cross Hosp, Dept Med Oncol, Trophoblast Dis Ctr, London W6 8RF, England	Imperial College London	Seckl, MJ (corresponding author), Charing Cross Hosp, Dept Med Oncol, Trophoblast Dis Ctr, London W6 8RF, England.	m.seckl@imperial.ac.uk	sebire, neil J/C-4960-2008	Sebire, Neil/0000-0001-5348-9063				Blagden SP, 2002, BRIT J CANCER, V86, P26, DOI 10.1038/sj.bjc.6600041; Bower M, 1998, EUR J CANCER, V34, P1204, DOI 10.1016/S0959-8049(98)00059-8; Castrillon DH, 2001, AM J SURG PATHOL, V25, P1225, DOI 10.1097/00000478-200110000-00001; Costa HLFF, 2006, GYNECOL ONCOL, V100, P579, DOI 10.1016/j.ygyno.2005.09.031; Fisher RA, 1998, J REPROD MED, V43, P87; Fisher RA, 2000, HUM REPROD, V15, P594, DOI 10.1093/humrep/15.3.594; Foulmann K, 2006, GYNECOL ONCOL, V102, P103, DOI 10.1016/j.ygyno.2006.02.038; Fowler DJ, 2006, ULTRASOUND OBST GYN, V27, P56, DOI 10.1002/uog.2592; Gemer O, 2000, ARCH GYNECOL OBSTET, V264, P33, DOI 10.1007/PL00007481; Johns J, 2005, ULTRASOUND OBST GYN, V25, P493, DOI 10.1002/uog.1888; McNeish IA, 2002, J CLIN ONCOL, V20, P1838, DOI 10.1200/JCO.2002.07.166; Mitchell H, 2007, MOL CELL ENDOCRINOL, V260, P310, DOI 10.1016/j.mce.2006.09.003; Murdoch S, 2006, NAT GENET, V38, P300, DOI 10.1038/ng1740; NGAN H, 2003, GESTATIONAL TROPHOBL, P156; Powles T, 2007, BRIT J CANCER, V96, P732, DOI 10.1038/sj.bjc.6603608; *ROYAL COLL OBST G, 2000, MAN EARL PREGN LOSS; Rustin GJS, 1996, J CLIN ONCOL, V14, P2769, DOI 10.1200/JCO.1996.14.10.2769; Savage P, 2005, GYNECOL ONCOL, V99, P251, DOI 10.1016/j.ygyno.2005.07.025; Sebire N, 2002, CURR DIAGN PATHOL, V8, P430; Sebire NJ, 2007, BJOG-INT J OBSTET GY, V114, P760, DOI 10.1111/j.1471-0528.2007.01320.x; Sebire NJ, 2003, PEDIATR DEVEL PATHOL, V6, P69, DOI 10.1007/s10024-002-0079-9; Sebire NJ, 2003, BJOG-INT J OBSTET GY, V110, P22, DOI 10.1016/S1470-0328(02)02988-9; Sebire NJ, 2002, LANCET, V359, P2165, DOI 10.1016/S0140-6736(02)09085-2; Sebire NJ, 2002, BJOG-INT J OBSTET GY, V109, P99, DOI 10.1111/j.1471-0528.2002.t01-1-01037.x; Seckl MJ, 2000, LANCET, V356, P36, DOI 10.1016/S0140-6736(00)02432-6; Seckl MJ, 2004, LANCET, V364, P705, DOI 10.1016/S0140-6736(04)16898-0; Seckl MJ, 2004, J REPROD MED, V49, P527; SECKL MJ, IN PRESS GESTATIONAL; SMITH HO, 2003, GESTATIONAL TROPHOBL, P39; STONE M, 1976, BRIT J OBSTET GYNAEC, V83, P913, DOI 10.1111/j.1471-0528.1976.tb00774.x; SZULMAN AE, 1978, AM J OBSTET GYNECOL, V131, P665, DOI 10.1016/0002-9378(78)90829-3; Tidy JA, 2000, GYNECOL ONCOL, V78, P309, DOI 10.1006/gyno.2000.5839; TIDY JA, 2004, MANAGEMENT GESTATION; Wiesma S, 2006, AUST NZ J OBSTET GYN, V46, P119, DOI 10.1111/j.1479-828X.2006.00539.x	34	23	24	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 23	2008	337	7667							a1193	10.1136/bmj.a1193	http://dx.doi.org/10.1136/bmj.a1193			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	346FD	18708429				2022-12-28	WOS:000259053100029
J	Sang, LY; Coller, HA; Roberts, JM				Sang, Liyun; Coller, Hilary A.; Roberts, James M.			Control of the reversibility of cellular quiescence by the transcriptional repressor HES1	SCIENCE			English	Article							NOTCH PATHWAY; SENESCENCE; EXPRESSION; P21; ENHANCER; CELLS; MODEL; HAIRY; P53	The mechanisms by which quiescent cells, including adult stem cells, preserve their ability to resume proliferation after weeks or even years of cell cycle arrest are not known. We report that reversibility is not a passive property of nondividing cells, because enforced cell cycle arrest for a period as brief as 4 days initiates spontaneous, premature, and irreversible senescence. Increased expression of the gene encoding the basic helix- loop- helix protein HES1 was required for quiescence to be reversible, because HES1 prevented both premature senescence and inappropriate differentiation in quiescent fibroblasts. In some human tumors, the HES1 pathway was activated, which allowed these cells to evade differentiation and irreversible cell cycle arrest. We conclude that HES1 safeguards against irreversible cell cycle exit both during normal cellular quiescence and pathologically in the setting of tumorigenesis.	[Sang, Liyun; Roberts, James M.] Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; [Sang, Liyun] Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA; [Coller, Hilary A.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; [Roberts, James M.] Univ Washington, Dept Biochem, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Princeton University; University of Washington; University of Washington Seattle	Roberts, JM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA.	jroberts@fhcrc.org	Roberts, James/AAI-3283-2020	Roberts, James/0000-0002-2671-3207	Howard Hughes Medical Institute; NIH; New Jersey Commission on Cancer Research; Pharmaceutical Research and Manufacturers of America Foundation; National Institute of General Medical Sciences Center of Excellence [P50 GM071508]; NATIONAL CANCER INSTITUTE [R01CA118043] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM071508] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); New Jersey Commission on Cancer Research; Pharmaceutical Research and Manufacturers of America Foundation; National Institute of General Medical Sciences Center of Excellence(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We acknowledge expert advice and materials from S. Tapscott and members of the Tapscott laboratory, J. Olson and members of the Olson laboratory, members of the Galloway laboratory, S. Parkhurst, V. Vasioukhin, X. Yu, C. Civin, K. Fitzgerald, W. Chien, K. Loeb, M. Mehaffey, R. Eisenman, M. Groudine, D. Gottschling, R. Zhang, P. Adams, and members of the Roberts laboratory. L. S. acknowledges support from the Howard Hughes Medical Institute. J. M. R. was supported by grants from NIH. H. A. C. is the Milton E. Cassel scholar of the Rita Allen Foundation and acknowledges support from the New Jersey Commission on Cancer Research and the Pharmaceutical Research and Manufacturers of America Foundation. H. A. C. is supported by National Institute of General Medical Sciences Center of Excellence grant P50 GM071508.	Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Coller HA, 2006, PLOS BIOL, V4, P329, DOI 10.1371/journal.pbio.0040083; Cuevas IC, 2005, CANCER RES, V65, P5070, DOI 10.1158/0008-5472.CAN-05-0240; Curry CL, 2006, LAB INVEST, V86, P842, DOI 10.1038/labinvest.3700442; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; Farnie G, 2007, JNCI-J NATL CANCER I, V99, P616, DOI 10.1093/jnci/djk133; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Geling A, 2002, EMBO REP, V3, P688, DOI 10.1093/embo-reports/kvf124; Grbavec D, 1996, BIOCHEM BIOPH RES CO, V223, P701, DOI 10.1006/bbrc.1996.0959; Grigoryev SA, 2006, CHROMOSOME RES, V14, P53, DOI 10.1007/s10577-005-1021-6; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hallahan AR, 2004, CANCER RES, V64, P7794, DOI 10.1158/0008-5472.CAN-04-1813; Hopfer O, 2005, BRIT J CANCER, V93, P709, DOI 10.1038/sj.bjc.6602719; Ingram WJ, 2008, ONCOGENE, V27, P1489, DOI 10.1038/sj.onc.1210767; JENNINGS B, 1994, DEVELOPMENT, V120, P3537; Konishi J, 2007, CANCER RES, V67, P8051, DOI 10.1158/0008-5472.CAN-07-1022; Kwon YH, 2002, J BIOL CHEM, V277, P41417, DOI 10.1074/jbc.M203388200; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; Yu XB, 2006, STEM CELLS, V24, P876, DOI 10.1634/stemcells.2005-0598	28	227	243	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 22	2008	321	5892					1095	1100		10.1126/science.1155998	http://dx.doi.org/10.1126/science.1155998			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339RL	18719287	Green Accepted			2022-12-28	WOS:000258594900043
J	Jones, LM; Bradshaw, DA				Jones, Lisa M.; Bradshaw, David A.			Benign mediastinal teratoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Jones, Lisa M.; Bradshaw, David A.] Naval Med Ctr San Diego, San Diego, CA 92134 USA	United States Department of Defense; United States Navy; Naval Medical Center San Diego	Jones, LM (corresponding author), Naval Med Ctr San Diego, San Diego, CA 92134 USA.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 21	2008	359	8					841	841		10.1056/NEJMicm054552	http://dx.doi.org/10.1056/NEJMicm054552			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339HL	18716301				2022-12-28	WOS:000258568600009
J	Podolsky, SH; Greene, JA				Podolsky, Scott H.; Greene, Jeremy A.			A historical perspective of pharmaceutical promotion and physician education	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CONTINUING MEDICAL-EDUCATION		[Podolsky, Scott H.] Harvard Univ, Sch Med, Countway Med Lib, Ctr Hist Med, Boston, MA 02115 USA; [Podolsky, Scott H.] Harvard Univ, Sch Med, Dept Social Med, Boston, MA 02115 USA; [Greene, Jeremy A.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA; [Greene, Jeremy A.] Harvard Univ, Dept Hist Sci, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University	Podolsky, SH (corresponding author), Harvard Univ, Sch Med, Countway Med Lib, Ctr Hist Med, 10 Shattuck St, Boston, MA 02115 USA.	scott_podolsky@hms.harvard.edu						DEHAEN P, 1962, DRUG COSMET IND, V90, P228; DEHAEN P, 1962, DRUG COSMET IND, V90, P230; DEHAEN P, 1962, DRUG COSMET IND, V90, P240; DEHAEN P, 1962, DRUG COSMET IND, V90, P141; DEHAEN P, 1962, DRUG COSMET IND, V90, P222; DEHAEN P, 1962, DRUG COSMET IND, V90, P234; DICHTER E, 1955, RES STUDY PHARM ADVE, P39; DOWLING HF, 1957, JAMA-J AM MED ASSOC, V165, P657, DOI 10.1001/jama.1957.02980240015004; DOWLING HF, 1970, MED MAN DEV REGULATI; FERRER JM, 1975, B NEW YORK ACAD MED, V51, P785; Gagnon MA, 2008, PLOS MED, V5, P29, DOI 10.1371/journal.pmed.0050001; GARAI PR, 1964, DRUGS OUR SOC, P189; MAY CD, 1961, J MED EDUC, V36, P1; OODMAN L, 1960, PHARM BASIS THERAPEU; Relman AS, 2003, JAMA-J AM MED ASSOC, V289, P2418, DOI 10.1001/jama.289.18.2418; SACKLER A, FREEDOM INQUIRY FREE; Steinbrook R, 2008, JAMA-J AM MED ASSOC, V299, P1060, DOI 10.1001/jama.299.9.1060; Todd J S, 1992, J Okla State Med Assoc, V85, P227; 1963, JAMA, V185, P533	19	25	24	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	2008	300	7					831	833		10.1001/jama.300.7.831	http://dx.doi.org/10.1001/jama.300.7.831			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	338VM	18714063				2022-12-28	WOS:000258537500023
J	Sarafidis, PA; Bakris, GL				Sarafidis, Pantelis A.; Bakris, George L.			Renin-angiotensin blockade and kidney disease	LANCET			English	Editorial Material							RENAL OUTCOMES; INHIBITORS; THERAPY; SYSTEM		[Bakris, George L.] Univ Chicago, Pritzker Sch Med, Dept Med, Hypertens Dis Unit, Chicago, IL 60637 USA; [Sarafidis, Pantelis A.] Aristotle Univ Thessaloniki, Amer Hellen Educ Progress Assoc Hosp, Dept Med, Sect Nephrol & Hypertens, GR-54006 Thessaloniki, Greece	University of Chicago; Aristotle University of Thessaloniki	Bakris, GL (corresponding author), Univ Chicago, Pritzker Sch Med, Dept Med, Hypertens Dis Unit, Chicago, IL 60637 USA.	gbakris@gmail.com	Sarafidis, Pantelis/AFO-2131-2022	Sarafidis, Pantelis/0000-0002-9174-4018				Alonso A, 2004, AM J KIDNEY DIS, V43, P1, DOI 10.1053/j.ajkd.2003.09.009; BROWN SA, 1993, KIDNEY INT, V43, P1210, DOI 10.1038/ki.1993.171; Casas JP, 2005, LANCET, V366, P2026, DOI 10.1016/S0140-6736(05)67814-2; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; EIDANI A, 2006, AM J NEPHROL, V26, P629; Kunz R, 2008, ANN INTERN MED, V148, P30, DOI 10.7326/0003-4819-148-1-200801010-00190; LINDEMAN RD, 1985, J AM GERIATR SOC, V33, P278, DOI 10.1111/j.1532-5415.1985.tb07117.x; Mancia G., 2007, REV ESP CARDIOL, V60, p968., DOI [10.1097/HJH.0b013e3282f857e7, DOI 10.1097/HJH.0B013E3282F857E7]; Mann JFE, 2008, LANCET, V372, P547, DOI 10.1016/S0140-6736(08)61236-2; ROWE JW, 1976, J GERONTOL, V31, P155, DOI 10.1093/geronj/31.2.155; Sarafidis PA, 2007, AM J KIDNEY DIS, V49, P12, DOI 10.1053/j.ajkd.2006.10.014	11	43	47	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 16	2008	372	9638					511	512		10.1016/S0140-6736(08)61212-X	http://dx.doi.org/10.1016/S0140-6736(08)61212-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339MS	18707969				2022-12-28	WOS:000258582300005
J	Morita, H; Wu, JS; Zipes, DP				Morita, Hiroshi; Wu, Jiashin; Zipes, Douglas P.			The QT syndromes: long and short	LANCET			English	Article							INFANT-DEATH-SYNDROME; SUDDEN CARDIAC DEATH; LIFE-THREATENING ARRHYTHMIAS; ANDERSEN-TAWIL-SYNDROME; POTASSIUM CHANNEL GENE; LANGE-NIELSEN-SYNDROME; LATE SODIUM CURRENT; T-WAVE ALTERNANS; RISK STRATIFICATION; CLINICAL-COURSE	This Seminar presents the most recent information about the congenital long and short QT syndromes, emphasising the varied genotype-phenotype association in the ten different long QT syndromes and the five different short QT syndromes. Although uncommon, these syndromes serve as a Rosetta stone for the understanding of inherited ion-channel disorders leading to life-threatening cardiac arrhythmias. Ionic abnormal changes mainly affecting K(+), Na(+), or Ca(2+) currents, which either prolong or shorten ventricular repolarisation, can create a substrate of electrophysiological heterogeneity that predisposes to the development of ventricular tachyarrhythmias and sudden death. The understanding of the genetic basis of the syndromes is hoped to lead to genetic therapy that can restore repolarisation. Presently, symptomatic individuals are generally best treated with an implantable cardioverter defibrillator. Clinicians should be aware of these syndromes and realise that drugs, ischaemia, exercise, and emotions can precipitate sudden death in susceptible individuals.	[Morita, Hiroshi; Wu, Jiashin; Zipes, Douglas P.] Indiana Univ, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA; [Morita, Hiroshi; Wu, Jiashin; Zipes, Douglas P.] Indiana Univ, Sch Med, Div Cardiol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Zipes, DP (corresponding author), Indiana Univ, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA.	dzipes@iupui.edu	Wu, Jiashin/A-5654-2012	Zipes, Douglas/0000-0001-7141-6829; Wu, Jiashin/0000-0002-8003-6235				Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Andelfinger G, 2002, AM J HUM GENET, V71, P663, DOI 10.1086/342360; Antzelevitch C, 2007, CIRCULATION, V115, P442, DOI 10.1161/CIRCULATIONAHA.106.668392; Arnestad M, 2007, CIRCULATION, V115, P361, DOI 10.1161/CIRCULATIONAHA.106.658021; Bellocq C, 2004, CIRCULATION, V109, P2394, DOI 10.1161/01.CIR.0000130409.72142.FE; Benhorin J, 2000, CIRCULATION, V101, P1698; Brink PA, 2005, CIRCULATION, V112, P2602, DOI 10.1161/CIRCULATIONAHA.105.572453; BROWNE KF, 1982, AM J CARDIOL, V50, P1099, DOI 10.1016/0002-9149(82)90425-8; Brugada R, 2004, CIRCULATION, V109, P30, DOI 10.1161/01.CIR.0000109482.92774.3A; Chinushi M, 1998, CIRC RES, V83, P614, DOI 10.1161/01.RES.83.6.614; Cronk LB, 2007, HEART RHYTHM, V4, P161, DOI 10.1016/j.hrthm.2006.11.030; Crotti L, 2007, CIRCULATION, V116, P2366, DOI 10.1161/CIRCULATIONAHA.107.726950; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Donger C, 1997, CIRCULATION, V96, P2778, DOI 10.1161/01.CIR.96.9.2778; ELSHERIF N, 1994, CARDIAC ELECTROPHYSI, P687; Emori T, 2001, J CARDIOVASC ELECTR, V12, P1369, DOI 10.1046/j.1540-8167.2001.01369.x; ERTHERIDGE SP, 2003, J AM COLL CARDIOL, V42, P1777; Etheridge SP, 2007, J AM COLL CARDIOL, V50, P1335, DOI 10.1016/j.jacc.2007.05.042; Gaita F, 2003, CIRCULATION, V108, P965, DOI 10.1161/01.CIR.0000085071.28695.C4; Giustetto C, 2006, EUR HEART J, V27, P2440, DOI 10.1093/eurheartj/ehl185; Goldenberg I, 2006, J CARDIOVASC ELECTR, V17, P1161, DOI 10.1111/j.1540-8167.2006.00587.x; Goldenberg I, 2006, J AM COLL CARDIOL, V48, P1047, DOI 10.1016/j.jacc.2006.06.033; Goldman D S, 2000, Circulation, V102, pE46; Hobbs JB, 2006, JAMA-J AM MED ASSOC, V296, P1249, DOI 10.1001/jama.296.10.1249; Hofman N, 2007, EUR HEART J, V28, P1399, DOI 10.1093/eurheartj/ehm118; Hofman N, 2007, EUR HEART J, V28, P575, DOI 10.1093/eurheartj/ehl355; Hong K, 2005, CARDIOVASC RES, V68, P433, DOI 10.1016/j.cardiores.2005.06.023; Hong K, 2005, J CARDIOVASC ELECTR, V16, P394, DOI 10.1046/j.1540-8167.2005.40621.x; Hunt DPJ, 2005, EMERG MED J, V22, P600, DOI 10.1136/emj.2003.007997; Kaufman ES, 2001, J CARDIOVASC ELECTR, V12, P455, DOI 10.1046/j.1540-8167.2001.00455.x; Lupoglazoff JM, 2004, J AM COLL CARDIOL, V43, P826, DOI 10.1016/j.jacc.2003.09.049; Medeiros-Domingo A, 2007, CIRCULATION, V116, P134, DOI 10.1161/CIRCULATIONAHA.106.659086; Mohler PJ, 2007, CIRCULATION, V115, P432, DOI 10.1161/CIRCULATIONAHA.106.656512; Mohler PJ, 2003, NATURE, V421, P634, DOI 10.1038/nature01335; Morita H, 2007, CARDIOVASC RES, V75, P510, DOI 10.1016/j.cardiores.2007.04.028; Moss AJ, 2002, CIRCULATION, V105, P794, DOI 10.1161/hc0702.105124; Moss AJ, 2007, CIRCULATION, V115, P2481, DOI 10.1161/CIRCULATIONAHA.106.665406; Nakamura K, 2007, J AM COLL CARDIOL, V50, P1808, DOI 10.1016/j.jacc.2007.07.037; Napolitano C, 2006, PHARMACOL THERAPEUT, V110, P1, DOI 10.1016/j.pharmthera.2005.08.003; Napolitano C, 2005, JAMA-J AM MED ASSOC, V294, P2975, DOI 10.1001/jama.294.23.2975; Napolitano C, 2000, PROG CARDIOVASC DIS, V42, P345, DOI 10.1053/pcad.2000.0420345; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; Noda T, 2002, EUR HEART J, V23, P975, DOI 10.1053/euhj.2001.3079; Nuyens D, 2001, NAT MED, V7, P1021, DOI 10.1038/nm0901-1021; Paulussen ADC, 2004, J MOL MED, V82, P182, DOI 10.1007/s00109-003-0522-z; Plaster NM, 2001, CELL, V105, P511, DOI 10.1016/S0092-8674(01)00342-7; Priori SG, 2000, CIRCULATION, V102, P945, DOI 10.1161/01.CIR.102.9.945; Priori SG, 2005, CIRC RES, V96, P800, DOI 10.1161/01.RES.0000162101.76263.8c; Priori SG, 2004, JAMA-J AM MED ASSOC, V292, P1341, DOI 10.1001/jama.292.11.1341; Priori SG, 2003, NEW ENGL J MED, V348, P1866, DOI 10.1056/NEJMoa022147; PRIORI SG, 1996, CIRC RES, V78, P1008; RUBART M, 1993, CIRCULATION, V88, P1832, DOI 10.1161/01.CIR.88.4.1832; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Sauer AJ, 2007, J AM COLL CARDIOL, V49, P329, DOI 10.1016/j.jacc.2006.08.057; Schimpf R, 2005, CARDIOVASC RES, V67, P357, DOI 10.1016/j.cardiores.2005.03.026; SCHULZEBAHR, 1997, NAT GENET, V15, P267; Schwartz PJ, 2006, CIRCULATION, V113, P783, DOI 10.1161/CIRCULATIONAHA.105.592899; Schwartz PJ, 2001, CIRCULATION, V103, P89; Schwartz PJ, 2003, J CARDIOVASC ELECTR, V14, P1120, DOI 10.1046/j.1540-8167.2003.03339.x; Schwartz PJ, 2004, CIRCULATION, V109, P1826, DOI 10.1161/01.CIR.0000125523.14403.1E; SCHWARTZ PJ, 1993, CIRCULATION, V88, P782, DOI 10.1161/01.CIR.88.2.782; Schwartz PJ, 1998, NEW ENGL J MED, V338, P1709, DOI 10.1056/NEJM199806113382401; Schwartz PJ, 1995, CARDIAC ELECTROPHYSI, P788; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Seth R, 2007, J AM COLL CARDIOL, V49, P1092, DOI 10.1016/j.jacc.2006.09.054; Sherman J, 2005, HEART RHYTHM, V2, P1218, DOI 10.1016/j.hrthm.2005.07.026; Shimizu W, 2004, HEART RHYTHM, V1, P276, DOI 10.1016/j.hrthm.2004.04.021; Shimizu W, 2000, J AM COLL CARDIOL, V35, P778, DOI 10.1016/S0735-1097(99)00582-3; Shimizu W, 1998, CIRCULATION, V97, P1581, DOI 10.1161/01.CIR.97.16.1581; Shimizu W, 1999, CIRCULATION, V99, P1499, DOI 10.1161/01.CIR.99.11.1499; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Splawski I, 2004, CELL, V119, P19, DOI 10.1016/j.cell.2004.09.011; Swan H, 1999, J AM COLL CARDIOL, V34, P823, DOI 10.1016/S0735-1097(99)00255-7; Swan H, 1998, J AM COLL CARDIOL, V32, P486, DOI 10.1016/S0735-1097(98)00248-4; Tan HNL, 2006, CIRCULATION, V114, P2096, DOI 10.1161/CIRCULATIONAHA.106.642694; Tester DJ, 2007, J AM COLL CARDIOL, V49, P240, DOI 10.1016/j.jacc.2006.10.010; Tester DJ, 2005, HEART RHYTHM, V2, P507, DOI 10.1016/j.hrthm.2005.01.020; Ueda N, 2004, CARDIOVASC RES, V63, P69, DOI 10.1016/j.cardiores.2004.02.014; Vatta M, 2006, CIRCULATION, V114, P2104, DOI 10.1161/CIRCULATIONAHA.106.635268; Veldkamp MW, 2003, CIRC RES, V92, P976, DOI 10.1161/01.RES.0000069689.09869.A8; Viskin S, 2004, HEART RHYTHM, V1, P587, DOI 10.1016/j.hrthm.2004.07.010; Viskin S, 1996, J AM COLL CARDIOL, V28, P1262, DOI 10.1016/S0735-1097(96)00311-7; Vyas H, 2006, CIRCULATION, V113, P1385, DOI 10.1161/CIRCULATIONAHA.105.600445; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; ZAREBA W, 1994, J AM COLL CARDIOL, V23, P1541, DOI 10.1016/0735-1097(94)90653-X; Zareba W, 2003, J AM COLL CARDIOL, V42, P103, DOI 10.1016/S0735-1097(03)00554-0; Zareba W, 1998, NEW ENGL J MED, V339, P960, DOI 10.1056/NEJM199810013391404; Zareba W, 2003, J CARDIOVASC ELECTR, V14, P337, DOI 10.1046/j.1540-8167.2003.02545.x; Zhang L, 2000, CIRCULATION, V102, P2849; Zhang L, 2005, CIRCULATION, V111, P2720, DOI 10.1161/CIRCULATIONAHA.104.472498; ZIPES DP, 1991, CIRCULATION, V84, P1414, DOI 10.1161/01.CIR.84.3.1414	93	223	243	0	32	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG-SEP	2008	372	9640					750	763		10.1016/S0140-6736(08)61307-0	http://dx.doi.org/10.1016/S0140-6736(08)61307-0			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	344YZ	18761222				2022-12-28	WOS:000258964500032
J	Pendry, JB				Pendry, J. B.			Time reversal and negative refraction	SCIENCE			English	Article							PHASE-CONJUGATION	Time reversal and negative refraction have been shown to be intimately linked processes. We propose a scheme that exploits transitions between positive and negative frequencies to mimic negative refraction at an interface and hence to make a negatively refracting lens. The theory applies equally to electromagnetic and acoustic waves. We also propose an experimental realization, and under ideal circumstances this lens can exhibit subwavelength resolution, limited only by the strength of the time- reversed signal.	[Pendry, J. B.] Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Dept Phys, London SW7 2AZ, England	Imperial College London	Pendry, JB (corresponding author), Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Dept Phys, Prince Consort Rd, London SW7 2AZ, England.	j.pendry@imperial.ac.uk	刘, 奇/AAF-2601-2021	Pendry, John/0000-0001-5145-5441				Allen CA, 2003, IEEE MTT S INT MICR, P1875, DOI 10.1109/MWSYM.2003.1210522; Cheianov VV, 2007, SCIENCE, V315, P1252, DOI 10.1126/science.1138020; Kobayashi K, 2006, J PHYS-CONDENS MAT, V18, P3703, DOI 10.1088/0953-8984/18/15/016; Malyuskin O, 2006, IEEE T ANTENN PROPAG, V54, P1399, DOI 10.1109/TAP.2006.874352; Maslovski S, 2003, J APPL PHYS, V94, P4241, DOI 10.1063/1.1604935; Merlin R, 2007, SCIENCE, V317, P927, DOI 10.1126/science.1143884; NIETOVESPERINAS M, 1985, J OPT SOC AM A, V2, P1429, DOI 10.1364/JOSAA.2.001429; Pendry JB, 2004, CONTEMP PHYS, V45, P191, DOI 10.1080/00107510410001667434; Pendry JB, 2004, SCIENCE, V306, P1353, DOI 10.1126/science.1104467; Pendry JB, 2003, J PHYS-CONDENS MAT, V15, P6345, DOI 10.1088/0953-8984/15/37/004; Pendry JB, 2000, PHYS REV LETT, V85, P3966, DOI 10.1103/PhysRevLett.85.3966; Pendry JB, 1999, IEEE T MICROW THEORY, V47, P2075, DOI 10.1109/22.798002; VESELAGO VG, 1968, SOV PHYS USPEKHI, V10, P509, DOI 10.1070/PU1968v010n04ABEH003699; Woerdman J. P., 1970, Optics Communications, V2, P212, DOI 10.1016/0030-4018(70)90140-9; Wubs M, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.046612; Yeh P., 1993, INTRO PHOTOREFRACTIV; Yon S, 2003, J ACOUST SOC AM, V113, P1533, DOI 10.1121/1.1543587	17	165	171	6	116	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	2008	322	5898					71	73		10.1126/science.1162087	http://dx.doi.org/10.1126/science.1162087			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	355AE	18755940				2022-12-28	WOS:000259680200038
J	Muller, FJ; Laurent, LC; Kostka, D; Ulitsky, I; Williams, R; Lu, C; Park, IH; Rao, MS; Shamir, R; Schwartz, PH; Schmidt, NO; Loring, JF				Mueller, Franz-Josef; Laurent, Louise C.; Kostka, Dennis; Ulitsky, Igor; Williams, Roy; Lu, Christina; Park, In-Hyun; Rao, Mahendra S.; Shamir, Ron; Schwartz, Philip H.; Schmidt, Nils O.; Loring, Jeanne F.			Regulatory networks define phenotypic classes of human stem cell lines	NATURE			English	Article							GENE-EXPRESSION PROFILES; CLASS DISCOVERY; BIOLOGICAL NETWORKS; PROGENITOR CELLS; GENOME-WIDE; PLURIPOTENCY; DIFFERENTIATION; CANCER	Stem cells are defined as self- renewing cell populations that can differentiate into multiple distinct cell types. However, hundreds of different human cell lines from embryonic, fetal and adult sources have been called stem cells, even though they range from pluripotent cells - typified by embryonic stem cells, which are capable of virtually unlimited proliferation and differentiation - to adult stem cell lines, which can generate a far more limited repertoire of differentiated cell types. The rapid increase in reports of new sources of stem cells and their anticipated value to regenerative medicine(1,2) has highlighted the need for a general, reproducible method for classification of these cells(3). We report here the creation and analysis of a database of global gene expression profiles ( which we call the 'stem cell matrix') that enables the classification of cultured human stem cells in the context of a wide variety of pluripotent, multipotent and differentiated cell types. Using an unsupervised clustering method(4,5) to categorize a collection of similar to 150 cell samples, we discovered that pluripotent stem cell lines group together, whereas other cell types, including brain-derived neural stem cell lines, are very diverse. Using further bioinformatic analysis(6) we uncovered a protein - protein network (PluriNet) that is shared by the pluripotent cells ( embryonic stem cells, embryonal carcinomas and induced pluripotent cells). Analysis of published data showed that the PluriNet seems to be a common characteristic of pluripotent cells, including mouse embryonic stem and induced pluripotent cells and human oocytes. Our results offer a new strategy for classifying stem cells and support the idea that pluripotency and self- renewal are under tight control by specific molecular networks.	[Mueller, Franz-Josef; Laurent, Louise C.; Lu, Christina; Loring, Jeanne F.] Scripps Res Inst, Ctr Regenerat Med, La Jolla, CA 92037 USA; [Mueller, Franz-Josef] Univ Hosp Schleswig Holstein, Ctr Psychiat, ZIP Kiel, D-24105 Kiel, Germany; [Laurent, Louise C.] Univ Calif San Diego, Dept Reprod Med, San Diego, CA 92035 USA; [Kostka, Dennis] Max Planck Inst Mol Genet, Dept Computat Mol Biol, D-14195 Berlin, Germany; [Ulitsky, Igor; Shamir, Ron] Tel Aviv Univ, Sch Comp Sci, IL-69978 Tel Aviv, Israel; [Williams, Roy; Loring, Jeanne F.] Burnham Inst, La Jolla, CA 92037 USA; [Park, In-Hyun] Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02115 USA; [Park, In-Hyun] Dana Farber Canc Inst, Boston, MA 02115 USA; [Rao, Mahendra S.] Invitrogen Co, Frederick, MD 21704 USA; [Rao, Mahendra S.] Buck Inst Aging, Ctr Stem Cell Biol, Novato, CA 94945 USA; [Schwartz, Philip H.] Childrens Hosp Orange Cty, Res Inst, Ctr Res Neurosci, Orange, CA 92868 USA; [Schwartz, Philip H.] Univ Calif Irvine, Ctr Dev Biol, Irvine, CA 92697 USA; [Schmidt, Nils O.] Univ Med Ctr Hamburg Eppendorf, Dept Neurosurg, D-20246 Hamburg, Germany	Scripps Research Institute; University of Kiel; Schleswig Holstein University Hospital; University of California System; University of California San Diego; Max Planck Society; Tel Aviv University; Sanford Burnham Prebys Medical Discovery Institute; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Thermo Fisher Scientific; Buck Institute for Research on Aging; Childrens Hospital of Orange County; University of California System; University of California Irvine; University of Hamburg; University Medical Center Hamburg-Eppendorf	Muller, FJ (corresponding author), Scripps Res Inst, Ctr Regenerat Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	fj.mueller@zip-kiel.de; jloring@scripps.edu	Müller, Franz-Josef/E-3336-2010; Ulitsky, Igor/D-4828-2009; Schmidt, Nils Ole/D-5696-2014; Loring, Jeanne F/A-1620-2011; Shamir, Ron/E-6514-2011	Müller, Franz-Josef/0000-0001-9478-8430; Schmidt, Nils Ole/0000-0001-6910-8843; Loring, Jeanne F/0000-0001-6226-9767; Shamir, Ron/0000-0003-1889-9870; Ulitsky, Igor/0000-0003-0555-6561; Williams, Roy/0000-0002-5442-9166; Laurent, Louise/0000-0002-2095-7534	Christian- Abrechts University Young Investigator Award; Hamburger Krebsgesellschaft Grant; Edmond J. Safra Bioinformatics program fellowship at Tel- Aviv University (I.U.); Converging Technologies Program of The Israel Science Foundation [1767.07]; Raymond and Beverly Sackler Chair in Bioinformatics; Reproductive Scientist Development Program Scholar Award [K12 5K12HD000849-20]; California Institute for Regenerative Medicine Clinical Scholar Award [NIH P20 GM075059-01]; Alzheimer's Association;  [SFB-654/C5]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD000849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM075059] Funding Source: NIH RePORTER	Christian- Abrechts University Young Investigator Award; Hamburger Krebsgesellschaft Grant; Edmond J. Safra Bioinformatics program fellowship at Tel- Aviv University (I.U.); Converging Technologies Program of The Israel Science Foundation(Israel Science Foundation); Raymond and Beverly Sackler Chair in Bioinformatics; Reproductive Scientist Development Program Scholar Award; California Institute for Regenerative Medicine Clinical Scholar Award; Alzheimer's Association(Alzheimer's Association); ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank C. Stubban, H. Dittmer, S. Zapf and H. Meissner for their work with various cell cultures. We are grateful to D. Wakeman, R. Gonzalez, S. McKercher, J. P. Lee, H.- S. Park and S. Y. Moon for sharing their cell preparations for the type collection. We are also grateful to R. Wesselschmidt and M. Pera for their unique GCT lines and G. Daley for providing human iPSCs. A. M. Kocabas and J. Cibelli shared their human oocyte expression data with us. A. Barsky let us use the Cerebral 2.0 plug- in before its publication. M. Rosentraeger helped to compile the cell culture metadata. We thank J. Aldenhoff, D. Hinze- Selch, M. Westphal, K. Lamszus, U. Kehler, D. Barker and A. Fritz for their support and discussions of this project. This study has been supported by the following grants and awards: Christian- Abrechts University Young Investigator Award (F.- J.M.), SFB-654/C5 Sleep and Plasticity (F.- J. M. and D. Hinze- Selch), Hamburger Krebsgesellschaft Grant (N.O.S.), Edmond J. Safra Bioinformatics program fellowship at Tel- Aviv University (I.U.), Converging Technologies Program of The Israel Science Foundation Grant No 1767.07 (R.S.), Raymond and Beverly Sackler Chair in Bioinformatics (R.S.), Reproductive Scientist Development Program Scholar Award K12 5K12HD000849-20 (L.C.L.), California Institute for Regenerative Medicine Clinical Scholar Award (L.C.L.), NIH P20 GM075059-01 (J.F.L.), the Alzheimer's Association (J.F.L.), and anonymous donations in support of stem cell research.	Adewumi O, 2007, NAT BIOTECHNOL, V25, P803, DOI 10.1038/nbt1318; Barnes M, 2005, NUCLEIC ACIDS RES, V33, P5914, DOI 10.1093/nar/gki890; Barsky A, 2007, BIOINFORMATICS, V23, P1040, DOI 10.1093/bioinformatics/btm057; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Brunet JP, 2004, P NATL ACAD SCI USA, V101, P4164, DOI 10.1073/pnas.0308531101; Caraux G, 2005, BIOINFORMATICS, V21, P1280, DOI 10.1093/bioinformatics/bti141; Carpenter MK, 2003, CLONING STEM CELLS, V5, P79, DOI 10.1089/153623003321512193; Chambers I, 2007, NATURE, V450, P1230, DOI 10.1038/nature06403; Cline MS, 2007, NAT PROTOC, V2, P2366, DOI 10.1038/nprot.2007.324; Cowan CA, 2004, NEW ENGL J MED, V350, P1353, DOI 10.1056/NEJMsr040330; Donoho D., 2003, P NIPS; Efron B, 2007, ANN APPL STAT, V1, P107, DOI 10.1214/07-AOAS101; Ewing RM, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100134; Gao Y, 2005, BIOINFORMATICS, V21, P3970, DOI 10.1093/bioinformatics/bti653; Goldman B, 2008, NATURE REPORTS STEM, DOI [10.1038/stemcells.2008.26, DOI 10.1038/STEMCELLS.2008.26]; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Ideker Trey, 2002, Bioinformatics, V18 Suppl 1, pS233; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Kocabas AM, 2006, P NATL ACAD SCI USA, V103, P14027, DOI 10.1073/pnas.0603227103; Kornblum HI, 2001, NAT REV NEUROSCI, V2, P843, DOI 10.1038/35097597; Lacayo NJ, 2004, BLOOD, V104, P2646, DOI 10.1182/blood-2003-12-4449; Mishra GR, 2006, NUCLEIC ACIDS RES, V34, pD411, DOI 10.1093/nar/gkj141; Monti S, 2003, MACH LEARN, V52, P91, DOI 10.1023/A:1023949509487; Muller FJ, 2006, NAT REV NEUROSCI, V7, P75, DOI 10.1038/nrn1829; Murry CE, 2008, CELL, V132, P661, DOI 10.1016/j.cell.2008.02.008; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Palmer TD, 2001, NATURE, V411, P42, DOI 10.1038/35075141; Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]; Ploner A, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-80; R Development Core Team, 2007, R LANG ENV STAT COMP; Schwartz PH, 2003, J NEUROSCI RES, V74, P838, DOI 10.1002/jnr.10854; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tesar PJ, 2007, NATURE, V448, P196, DOI 10.1038/nature05972; Troyanskaya OG, 2002, BIOINFORMATICS, V18, P1454, DOI 10.1093/bioinformatics/18.11.1454; Ulitsky I, 2007, BMC SYST BIOL, V1, DOI 10.1186/1752-0509-1-8; Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284; Wang QT, 2004, DEV CELL, V6, P133, DOI 10.1016/S1534-5807(03)00404-0; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zeng XM, 2004, RESTOR NEUROL NEUROS, V22, P421	41	263	265	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	2008	455	7211					401	U55		10.1038/nature07213	http://dx.doi.org/10.1038/nature07213			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349EX	18724358	Green Accepted			2022-12-28	WOS:000259265200047
J	Sacco, RL; Diener, H; Yusuf, S; Cotton, D; Ounpuu, S; Lawton, WA; Palesch, Y; Martin, RH; Albers, GW; Bath, P; Bornstein, N; Chan, BPL; Chen, ST; Cunha, L; Dahlof, B; De Keyser, J; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lu, CZ; Machnig, T; Pais, P; Roberts, R; Skvortsova, V; Teal, P; Toni, D; VanderMaelen, C; Voigt, T; Weber, M; Yoon, BW				Sacco, Ralph L.; Diener, Hans-Christoph; Yusuf, Salim; Cotton, Daniel; Ounpuu, Stephanie; Lawton, William A.; Palesch, Yuko; Martin, Renee H.; Albers, Gregory W.; Bath, Philip; Bornstein, Natan; Chan, Bernard P. L.; Chen, Sien-Tsong; Cunha, Luis; Dahlof, Bjorn; De Keyser, Jacques; Donnan, Geoffrey A.; Estol, Conrado; Gorelick, Philip; Gu, Vivian; Hermansson, Karin; Hilbrich, Lutz; Kaste, Markku; Lu, Chuanzhen; Machnig, Thomas; Pais, Prem; Roberts, Robin; Skvortsova, Veronika; Teal, Philip; Toni, Danilo; VanderMaelen, Cam; Voigt, Thor; Weber, Michael; Yoon, Byung-Woo		PRoFESS Study Grp	Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSIENT ISCHEMIC ATTACK; NON-INFERIORITY TRIALS; DOUBLE-BLIND; PREVENTION; TICLOPIDINE; PLACEBO; REGIMENS; WARFARIN; DESIGN; ISSUES	Background: Recurrent stroke is a frequent, disabling event after ischemic stroke. This study compared the efficacy and safety of two antiplatelet regimens - aspirin plus extended-release dipyridamole (ASA-ERDP) versus clopidogrel. Methods: In this double-blind, 2-by-2 factorial trial, we randomly assigned patients to receive 25 mg of aspirin plus 200 mg of extended-release dipyridamole twice daily or to receive 75 mg of clopidogrel daily. The primary outcome was first recurrence of stroke. The secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes. Sequential statistical testing of noninferiority (margin of 1.075), followed by superiority testing, was planned. Results: A total of 20,332 patients were followed for a mean of 2.5 years. Recurrent stroke occurred in 916 patients (9.0%) receiving ASA-ERDP and in 898 patients (8.8%) receiving clopidogrel (hazard ratio, 1.01; 95% confidence interval [CI], 0.92 to 1.11). The secondary outcome occurred in 1333 patients (13.1%) in each group (hazard ratio for ASA-ERDP, 0.99; 95% CI, 0.92 to 1.07). There were more major hemorrhagic events among ASA-ERDP recipients (419 [4.1%]) than among clopidogrel recipients (365 [3.6%]) (hazard ratio, 1.15; 95% CI, 1.00 to 1.32), including intracranial hemorrhage (hazard ratio, 1.42; 95% CI, 1.11 to 1.83). The net risk of recurrent stroke or major hemorrhagic event was similar in the two groups (1194 ASA-ERDP recipients [11.7%], vs. 1156 clopidogrel recipients [11.4%]; hazard ratio, 1.03; 95% CI, 0.95 to 1.11). Conclusions: The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel. There is no evidence that either of the two treatments was superior to the other in the prevention of recurrent stroke. (ClinicalTrials.gov number, NCT00153062.).	[Sacco, Ralph L.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA; [Diener, Hans-Christoph] Univ Duisberg Essen, Essen, Germany; [Machnig, Thomas] Boehringer Ingelheim KG, D-6507 Ingelheim, Germany; [Yusuf, Salim; Roberts, Robin] McMaster Univ, Hamilton, ON, Canada; [Yusuf, Salim] Hamilton Hlth Sci, Hamilton, ON, Canada; [Ounpuu, Stephanie] Boehringer Ingelheim GmbH & Co KG, Burlington, ON, Canada; [Teal, Philip] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Cotton, Daniel; Hilbrich, Lutz; VanderMaelen, Cam; Voigt, Thor] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA; [Lawton, William A.] Boehringer Ingelheim GmbH & Co KG, Bracknell, Berks, England; [Bath, Philip] Univ Nottingham, Nottingham NG7 2RD, England; [Palesch, Yuko; Martin, Renee H.] Med Univ S Carolina, Charleston, SC 29425 USA; [Albers, Gregory W.] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA; [Bornstein, Natan] Ichilov Hosp, Tel Aviv, Israel; [Chan, Bernard P. L.] Natl Univ Singapore Hosp, Singapore 117548, Singapore; [Chen, Sien-Tsong] Chang Gung Mem Hosp, Taipei 10591, Taiwan; [Cunha, Luis] Hosp Univ Coimbra, Coimbra, Portugal; [Dahlof, Bjorn] Sahlgrens Univ Hosp, Gothenburg, Sweden; [De Keyser, Jacques] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands; [Donnan, Geoffrey A.] Univ Melbourne, Heidelberg West, Australia; [Estol, Conrado] Neurol Ctr Treatment & Res, Buenos Aires, DF, Argentina; [Gorelick, Philip] Univ Illinois, Chicago, IL USA; [Gu, Vivian] Boehringer Ingelheim Shanghai Pharmaceut, Shanghai, Peoples R China; [Lu, Chuanzhen] Huashan Hosp, Shanghai, Peoples R China; [Hermansson, Karin] Boehringer Ingelheim GmbH & Co KG, Stockholm, Sweden; [Kaste, Markku] Univ Helsinki, Cent Hosp, Helsinki, Finland; [Pais, Prem] St Johns Med Coll, Bangalore, Karnataka, India; [Skvortsova, Veronika] Russian State Med Univ, Moscow 117437, Russia; [Toni, Danilo] Univ Roma La Sapienza, Rome, Italy; [Weber, Michael] SUNY Downstate Coll Med, New York, NY USA; [Yoon, Byung-Woo] Seoul Natl Univ Hosp, Seoul 110744, South Korea	University of Miami; University of Duisburg Essen; Boehringer Ingelheim; McMaster University; McMaster University; Boehringer Ingelheim; University of British Columbia; Boehringer Ingelheim; Boehringer Ingelheim; University of Nottingham; Medical University of South Carolina; Stanford University; Tel Aviv University; National University of Singapore; Chang Gung Memorial Hospital; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); Sahlgrenska University Hospital; University of Groningen; University of Melbourne; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Boehringer Ingelheim; Fudan University; Boehringer Ingelheim; University of Helsinki; Helsinki University Central Hospital; St. John's National Academy of Health Sciences; St. John's Medical College; Pirogov Russian National Research Medical University; Sapienza University Rome; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Seoul National University (SNU); Seoul National University Hospital	Sacco, RL (corresponding author), Univ Miami, Miller Sch Med, Clin Res Bldg,1120 NW 14th St,Suite 1353, Miami, FL 33136 USA.	rsacco@med.miami.edu	Vanhooren, Geert/H-4433-2011; Witte, Otto/P-4127-2018; Sacco, Ralph/Y-9278-2019; Forsting, Michael/C-6925-2013; Leung, Thomas W/AAU-6475-2021; De Keyser, Jacques/AAA-8721-2021; Chen, Christopher/E-7023-2013; Varakin, Yuriy Ya/C-8634-2012; Moskovko, Gennadii/AAE-8505-2019; Kasner, Scott/C-6109-2011; Egido, Jose A/E-3837-2015; Kovrazhkina, Elena/AAR-2425-2021; Hamann, Gerhard F./J-6300-2014; Yoon, Byung Woo/J-5557-2012; Tanne, David/F-2560-2010; amintaeva, asya/B-4416-2012; LEYS, Didier/G-2955-2016; Timerbaeva, Sofia L/C-9051-2012; Iversen, Helle Klingenberg/B-9154-2009; Toni, Danilo/K-3151-2016; bladin, chris/B-9136-2013; Parsons, Mark W./G-3750-2014; Luisa, Sacchetti/F-2644-2011; Kotov, Sergey V./E-4451-2017; passmore, anthony/C-9824-2009; De Keyser, Jacques/D-3725-2013; Skogar, Orjan/A-4084-2013; Bath, Philip/F-9020-2011	Vanhooren, Geert/0000-0001-6818-9346; Witte, Otto/0000-0003-2101-4105; Leung, Thomas W/0000-0001-8193-0709; De Keyser, Jacques/0000-0002-3394-7757; Chen, Christopher/0000-0002-1047-9225; Moskovko, Gennadii/0000-0002-8349-8865; Egido, Jose A/0000-0003-1698-9127; Tanne, David/0000-0002-6699-2220; LEYS, Didier/0000-0003-4408-4392; Toni, Danilo/0000-0003-2735-8427; Luisa, Sacchetti/0000-0002-2318-9868; Kotov, Sergey V./0000-0002-8706-7317; De Keyser, Jacques/0000-0002-3394-7757; Wieneke, Heinrich/0000-0002-6709-0982; Molto Jorda, Jose Manuel/0000-0002-3861-6295; Wuttig, Helge/0000-0003-1877-8905; Andersen, Grethe/0000-0001-6807-2500; Kaste, Markku/0000-0001-6557-6412; Iversen, Helle Klingenberg/0000-0002-5880-6352; Dalkara, Turgay/0000-0003-3943-7819; Skogar, Orjan/0000-0001-8260-5967; Albers, Gregory/0000-0003-0263-4632; Milo, Ron/0000-0001-8556-2579; corea, francesco/0000-0002-5864-9991; Donnan, Geoffrey/0000-0001-6324-3403; Yusuf, Salim/0000-0003-4776-5601; Consoli, Domenico/0000-0002-2050-5538; Fiebach, Jochen B./0000-0002-7936-6958; Dichgans, Martin/0000-0002-0654-387X; De Falco, Fabrizio/0000-0001-5065-1678; Skogar, Orjan/0000-0002-7527-7229; Teitelbaum, Jeanne/0000-0002-9834-3882; Cunha, Luis/0000-0002-0828-3485; Sobesky, Jan/0000-0001-5459-3655; Bath, Philip/0000-0003-2734-5132; Poppert, Holger/0000-0003-2189-7681; Papamitsakis, Nikolaos/0000-0001-9003-3399	Boehringer Ingelheim; GlaxoSmithKline; Sanofi-Aventis; Abbott; AstraZeneca; Bayer Vital; Bristol-Myers Squibb; D-Pharm; Fresenius; Janssen Cilag; Merck Sharp Dohme; Novartis; Novo Nordisk; Paion; Parke-Davis; Pfizer; Sankyo; Servier; Solvay; Thrombogenics; Wyeth; Yamaguchi; NMT Medical; Parexel International; Forest Research Institute; Daiichi-Sankyo; Bayer; TAP Pharmaceutical Products; Myriad; Takeda; Daiichi Sankyo; Merck; Brainsgate; diaDexus; Forest Laboratories; Gilead; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K23NS054084] Funding Source: NIH RePORTER	Boehringer Ingelheim(Boehringer Ingelheim); GlaxoSmithKline(GlaxoSmithKline); Sanofi-Aventis(Sanofi-Aventis); Abbott(Abbott Laboratories); AstraZeneca(AstraZeneca); Bayer Vital(Bayer AG); Bristol-Myers Squibb(Bristol-Myers Squibb); D-Pharm; Fresenius; Janssen Cilag(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Merck Sharp Dohme(Merck & Company); Novartis(Novartis); Novo Nordisk(Novo Nordisk); Paion; Parke-Davis; Pfizer(Pfizer); Sankyo; Servier(Servier); Solvay(Solvay SA); Thrombogenics; Wyeth(Wyeth); Yamaguchi; NMT Medical; Parexel International; Forest Research Institute; Daiichi-Sankyo(Daiichi Sankyo Company Limited); Bayer(Bayer AG); TAP Pharmaceutical Products; Myriad; Takeda(Takeda Pharmaceutical Company Ltd); Daiichi Sankyo(Daiichi Sankyo Company Limited); Merck(Merck & Company); Brainsgate; diaDexus; Forest Laboratories; Gilead(Gilead Sciences); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Dr. Sacco reports receiving consulting fees from Boehringer Ingelheim, GlaxoSmithKline, and Sanofi-Aventis and lecture fees from Boehringer Ingelheim; Dr. Diener, honoraria and consulting and lecture fees from Abbott, AstraZeneca, Bayer Vital, Bristol-Myers Squibb, Boehringer Ingelheim, D-Pharm, Fresenius, GlaxoSmithKline, Janssen Cilag, Merck Sharp & Dohme, Novartis, Novo Nordisk, Paion, Parke-Davis, Pfizer, Sanofi-Aventis, Sankyo, Servier, Solvay, Thrombogenics, Wyeth, and Yamaguchi and grant support from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Novartis, Janssen-Cilag, and Sanofi-Aventis; and Dr. Yusuf, consulting and lecture fees from Boehringer Ingelheim, Sanofi-Aventis, Bristol- Myers Squibb, AstraZeneca, and GlaxoSmithKline and grant support from Sanofi-Aventis, Bristol-Myers Squibb, and GlaxoSmithKline. Mr. Cotton, Dr. Ounpuu, Mr. Lawton, Dr. Gu, Dr. Hermansson, Dr. Hilbrich, Dr. Machnig, Dr. VanderMaelen, and Dr. Voigt report being employees of Boehringer Ingelheim. Drs. Palesch, Martin, Bath, Chen, De Keyser, and Estol report receiving consulting fees from Boehringer Ingelheim; Dr. Albers, consulting and lecture fees from Boehringer Ingelheim and grant support from Boehringer Ingelheim, NMT Medical, Parexel International, AstraZeneca, and Forest Research Institute; Dr. Dahlof, consulting fees from Boehringer Ingelheim, Daiichi-Sankyo, and Novartis and lecture fees from Boehringer Ingelheim, Novartis, and Pfizer; Dr. Donnan, Mr. Roberts, and Dr. Kaste, consulting and lecture fees from Boehringer Ingelheim; Dr. Gorelick, consulting fees from Boehringer Ingelheim, Bayer, TAP Pharmaceutical Products, Myriad, Pfizer, Takeda, Daiichi Sankyo, Novartis, Merck, Brainsgate, and D-Pharm and lecture fees from Boehringer Ingelheim and diaDexus; Dr. Pais, consulting fees and grant support from Boehringer Ingelheim; Dr. Teal, consulting fees from Sanofi-Aventis, Bristol-Myers Squibb, Boehringer Ingelheim, and Bayer and lecture fees from Sanofi-Aventis, Bristol-Myers Squibb, and Boehringer Ingelheim; Dr. Toni, consulting fees from Boehringer Ingelheim and lecture fees from Boehringer Ingelheim, Sanofi-Aventis, and Novo Nordisk; and Dr. Weber, consulting fees and speakers' fees or honoraria from Novartis, Bristol-Myers Squibb, Daiichi-Sankyo, Boehringer Ingelheim, GlaxoSmithKline, and Forest Laboratories, consulting fees from Gilead and Takeda, and speakers' fees or honoraria from Sanofi-Aventis. No other potential conflict of interest relevant to this article was reported.; We thank Vicky Hinstridge for technical assistance and Karuna Bellamkonda and Michael Pannucci for programming support.	ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Akhtar Mateen, 2007, Congest Heart Fail, V13, P130, DOI 10.1111/j.1527-5299.2007.06047.x; Antithrombotic Trialists' Collaboration, 2002, BMJ-BRIT MED J, V324, P141, DOI DOI 10.1136/BMJ.324.7330.141; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Bhatt DL, 2006, NEW ENGL J MED, V354, P1706, DOI 10.1056/NEJMoa060989; Chimowitz MI, 2005, NEW ENGL J MED, V352, P1305, DOI 10.1056/NEJMoa043033; D'Agostino RB, 2003, STAT MED, V22, P169, DOI 10.1002/sim.1425; Dhamoon MS, 2006, NEUROLOGY, V66, P641, DOI 10.1212/01.wnl.0000201253.93811.f6; Diener HC, 2007, CEREBROVASC DIS, V23, P368, DOI 10.1159/000100105; Diener HC, 2004, LANCET, V364, P331, DOI 10.1016/S0140-6736(04)16721-4; Diener HC, 1996, J NEUROL SCI, V143, P1, DOI 10.1016/S0022-510X(96)00308-5; Fisher LD, 2001, AM HEART J, V141, P26, DOI 10.1067/mhj.2001.111262; Flerning TR, 2008, STAT MED, V27, P317, DOI 10.1002/sim.2855; GENT M, 1989, LANCET, V1, P1215, DOI 10.1016/S0140-6736(89)92327-1; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Gorelick PB, 2003, JAMA-J AM MED ASSOC, V289, P2947, DOI 10.1001/jama.289.22.2947; Hacke W, 2008, CEREBROVASC DIS, V25, P457, DOI 10.1159/000131083; Halkes PHA, 2007, LANCET NEUROL, V6, P115, DOI 10.1016/S1474-4422(06)70685-8; Halkes PHA, 2006, LANCET, V367, P1665; HASS WK, 1989, NEW ENGL J MED, V321, P501, DOI 10.1056/NEJM198908243210804; HAYBITTLE JL, 1971, BRIT J RADIOL, V44, P793, DOI 10.1259/0007-1285-44-526-793; Hirsh J, 2004, CHEST, V126, p172S, DOI 10.1378/chest.126.3_suppl.172S; Hung HMJ, 2003, STAT MED, V22, P213, DOI 10.1002/sim.1315; Laster LL, 2003, STAT MED, V22, P187, DOI 10.1002/sim.1137; MAHONEY F I, 1965, Md State Med J, V14, P61; Mohr JP, 2001, NEW ENGL J MED, V345, P1444, DOI 10.1056/NEJMoa011258; Sacco RL, 2006, STROKE, V37, P577, DOI 10.1161/01.STR.0000199147.30016.74; Thijs V, 2008, EUR HEART J, V29, P1086, DOI 10.1093/eurheartj/ehn106; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Wang SJ, 2003, STAT MED, V22, P227, DOI 10.1002/sim.1316; Yusuf S, 2001, NEW ENGL J MED, V345, P494	31	640	667	1	83	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 18	2008	359	12					1238	1251		10.1056/NEJMoa0805002	http://dx.doi.org/10.1056/NEJMoa0805002			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	349DV	18753638	Green Accepted, Green Published			2022-12-28	WOS:000259259900007
J	Douglas, IJ; Smeeth, L				Douglas, Ian J.; Smeeth, Liam			Exposure to antipsychotics and risk of stroke: self controlled case series study	BRITISH MEDICAL JOURNAL			English	Article							PRACTICE RESEARCH DATABASE; SEVERE MENTAL-ILLNESS; PRIMARY-CARE; ISCHEMIC-STROKE; PEOPLE; SIMULATION; MORTALITY; DEMENTIA; TRIAL; DRUGS	Objectives To investigate the association between use of typical and atypical antipsychotic drugs and incidence of stroke in patients with and without dementia. Design Self controlled case series. Setting UK based electronic primary care records in the general practice research database ( GPRD). Participants All patients registered in the database with a recorded incident stroke and at least one prescription for any antipsychotic drug before the end of 2002: 6790 eligible participants were identified and included in the final analysis. Main outcome measures Rate ratio for stroke in periods of time exposed to antipsychotics compared with unexposed periods. Results Use of any antipsychotic drug was associated with a rate ratio for stroke of 1.73 ( 95% confidence interval 1.60 to 1.87): 1.69 ( 1.55 to 1.84) for typical antipsychotics and 2.32 ( 1.73 to 3.10) for atypical antipsychotics. In patients receiving any antipsychotic drug, the rate ratios were 3.50 ( 2.97 to 4.12) for those with dementia and 1.41 ( 1.29 to 1.55) for those without dementia. Conclusions All antipsychotics are associated with an increased risk of stroke, and the risk might be higher in patients receiving atypical antipsychotics than those receiving typical antipsychotics. People with dementia seem to be at a higher risk of an associated stroke than people without dementia and use of antipsychotics should, when possible, be avoided in these patients.	[Douglas, Ian J.; Smeeth, Liam] Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Douglas, IJ (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.	ian.douglas@lshtm.ac.uk	Smeeth, Liam/X-5862-2018	Smeeth, Liam/0000-0002-9168-6022	Wellcome Trust [082178] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Andersohn F, 2006, STROKE, V37, P1725, DOI 10.1161/01.STR.0000226642.55207.94; *COMM SAF MED, 2006, AT ANT DRUGS STROK M; *EUR PHARM WORK PA, 2006, PUBL ASS REP ANT CER; Gibbs RGJ, 2001, STROKE, V32, P1085, DOI 10.1161/01.STR.32.5.1085; Gill SS, 2005, BMJ-BRIT MED J, V330, P445, DOI 10.1136/bmj.38330.470486.8F; Health Canada, 2002, IMP DRUG SAF INF RIS; Herrmann N, 2004, AM J PSYCHIAT, V161, P1113, DOI 10.1176/appi.ajp.161.6.1113; Jick SS, 2003, PHARMACOTHERAPY, V23, P686, DOI 10.1592/phco.23.5.686.32205; Lawson DH, 1998, QJM-MON J ASSOC PHYS, V91, P445, DOI 10.1093/qjmed/91.6.445; Liebetrau M, 2003, STROKE, V34, P2617, DOI 10.1161/01.STR.0000094420.80781.A9; *MED HEALTHC PROD, 2004, SUMM CLIN TRIAL DAT; Mowat D, 2004, BRIT MED J, V328, P1262, DOI 10.1136/bmj.328.7450.1262-b; Mulnier HE, 2006, DIABETOLOGIA, V49, P2859, DOI 10.1007/s00125-006-0493-z; *OFF NAT STAT, 2000, KEY HLTH STAT GE MB6, V2, P149; Osborn DPJ, 2007, ARCH GEN PSYCHIAT, V64, P242, DOI 10.1001/archpsyc.64.2.242; Osborn DPJ, 2006, BRIT J PSYCHIAT, V188, P271, DOI 10.1192/bjp.bp.104.008060; Smeeth L, 2004, NEW ENGL J MED, V351, P2611, DOI 10.1056/NEJMoa041747; Tannen RL, 2007, J CLIN EPIDEMIOL, V60, P686, DOI 10.1016/j.jclinepi.2006.10.012; Tannen RL, 2006, J CLIN EPIDEMIOL, V59, P254, DOI 10.1016/j.jclinepi.2005.08.008; Whitaker HJ, 2006, STAT MED, V25, P1768, DOI 10.1002/sim.2302	20	190	192	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2008	337	7670							a1227	10.1136/bmj.a1227	http://dx.doi.org/10.1136/bmj.a1227			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354DT	18755769	Green Accepted, Green Published, hybrid			2022-12-28	WOS:000259619800038
J	Woolf, K; Cave, J; Greenhalgh, T; Dacre, J				Woolf, Katherine; Cave, Judith; Greenhalgh, Trisha; Dacre, Jane			Ethnic stereotypes and the underachievement of UK medical students from ethnic minorities: qualitative study	BRITISH MEDICAL JOURNAL			English	Article							PERFORMANCE; SCHOOL; PHYSICIANS; SUCCESS; THREAT; GENDER	Objective To explore ethnic stereotypes of UK medical students in the context of academic underachievement of medical students from ethnic minorities. Design Qualitative study using semistructured one to one interviews and focus groups. Setting A London medical school. Participants 27 year 3 medical students and 25 clinical teachers, purposively sampled for ethnicity and sex. Methods Data were analysed using the theory of stereotype threat ( a psychological phenomenon thought to negatively affect the performance of people from ethnic minorities in educational contexts) and the constant comparative method. Results Participants believed the student- teacher relationship was vital for clinical learning. Teachers had strong perceptions about "good" clinical students ( interactive, keen, respectful), and some described being aggressive towards students whom they perceived as quiet, unmotivated, and unwilling. Students had equally strong perceptions about "good" clinical teachers ( encouraging, interested, interactive, non- aggressive). Students and teachers had concordant and well developed perceptions of the "typical" Asian clinical medical student who was considered over- reliant on books, poor at communicating with patients, too quiet during clinical teaching sessions, and unmotivated owing to being pushed into studying medicine by ambitious parents. Stereotypes of the "typical" white student were less well developed: autonomous, confident, and outgoing team player. Direct discrimination was not reported. Conclusions Asian clinical medical students may be more likely than white students to be perceived stereotypically and negatively, which may reduce their learning by jeopardising their relationships with teachers. The existence of a negative stereotype about their group also raises the possibility that underperformance of medical students from ethnic minorities may be partly due to stereotype threat. It is recommended that clinical teachers be given opportunities and training to encourage them to get to know their students as individuals and thus foster positive educational relationships with them.	[Woolf, Katherine; Cave, Judith; Dacre, Jane] UCL, Acad Ctr Med Educ, Div Med Educ, London N19 5NF, England; [Greenhalgh, Trisha] UCL, Open Learning Unit, Dept Primary Care & Populat Sci, London N19 5NF, England	University of London; University College London; University of London; University College London	Woolf, K (corresponding author), UCL, Acad Ctr Med Educ, Div Med Educ, London N19 5NF, England.	k.woolf@medsch.ucl.ac.uk	Woolf, Katherine/AAD-8043-2021; Greiver, Michelle/N-8764-2015; Greenhalgh, Trisha/B-1825-2015	Woolf, Katherine/0000-0003-4915-0715; Greiver, Michelle/0000-0001-8957-0285; Greenhalgh, Trisha/0000-0003-2369-8088	General Medical Council; Cancer Research UK; Higher Education Funding Council	General Medical Council; Cancer Research UK(Cancer Research UK); Higher Education Funding Council(UK Research & Innovation (UKRI)Higher Education Funding Council for England (HEFCE))	We thank Sara Belle for comoderating the focus groups, the participants for taking time to answer our questions, and thosewhomade useful comments on earlier drafts of the paper and during oral presentations of the data. KW's salary is supported by the General Medical Council. JC's salary is supported by Cancer Research UK. The other authors are funded by the Higher Education Funding Council.	Beagan BL, 2003, MED EDUC, V37, P852, DOI 10.1046/j.1365-2923.2003.01622.x; Bessant R, 2006, POSTGRAD MED J, V82, P145, DOI 10.1136/pmj.2005.035998; Carter Y, 1999, INTRO QUALITATIVE ME; Cohen GL, 2006, SCIENCE, V313, P1307, DOI 10.1126/science.1128317; Dewhurst NG, 2007, BMC MED, V5, DOI 10.1186/1741-7015-5-8; DILLNER L, 1995, BRIT MED J, V310, P209, DOI 10.1136/bmj.310.6974.209; Eysenck M. W., 2000, COGNITIVE PSYCHOL ST, V4; Ferguson E, 2002, BMJ-BRIT MED J, V324, P952, DOI 10.1136/bmj.324.7343.952; Green AR, 2007, J GEN INTERN MED, V22, P1231, DOI 10.1007/s11606-007-0258-5; Haidet P, 2006, J GEN INTERN MED, V21, pS16, DOI 10.1111/j.1525-1497.2006.00304.x; Haq I, 2005, MED EDUC, V39, P1126, DOI 10.1111/j.1365-2929.2005.02319.x; Howe A, 2001, MED EDUC, V35, P666, DOI 10.1046/j.1365-2923.2001.00925.x; Kay-Lambkin F, 2002, MED EDUC, V36, P154, DOI 10.1046/j.1365-2923.2002.01071.x; Krueger R.A., 2015, FOCUS GROUPS PRACTIC; Lempp Heidi, 2006, BMC Med Educ, V6, P17, DOI 10.1186/1472-6920-6-17; Lumb AB, 2004, MED EDUC, V38, P1002, DOI 10.1111/j.1365-2929.2004.01912.x; McConnell AR, 2001, J EXP SOC PSYCHOL, V37, P435, DOI 10.1006/jesp.2000.1470; McManus IC, 2008, BMC MED EDUC, V8, DOI 10.1186/1472-6920-8-21; McManus IC, 1996, MED EDUC, V30, P195, DOI 10.1111/j.1365-2923.1996.tb00742.x; Roberts JH, 2008, MED EDUC, V42, P45, DOI 10.1111/j.1365-2923.2007.02902.x; SINCLAIR S., 1997, MAKING DOCTORS I APP; Steele CM, 1997, AM PSYCHOL, V52, P613, DOI 10.1037/0003-066X.52.6.613; STEELE CM, 1995, J PERS SOC PSYCHOL, V69, P797, DOI 10.1037/0022-3514.69.5.797; Wass V, 2003, BRIT MED J, V326, P800, DOI 10.1136/bmj.326.7393.800; WILSON V, BR ED RES J, V4, P23; WOOLF K, 2007, ADV HLTH SCI ED 0509; XU G, 1993, ACAD MED, V68, P82, DOI 10.1097/00001888-199301000-00013	27	53	53	0	14	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2008	337	7670							a1220	10.1136/bmj.a1220	http://dx.doi.org/10.1136/bmj.a1220			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	354DT	18710846	Green Submitted, Green Published, hybrid			2022-12-28	WOS:000259619800036
J	Crawford, F				Crawford, Fay			Uncertainties page - How can we best prevent new foot ulcers in people with diabetes?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Crawford, Fay] Univ Edinburgh, Div Community Hlth Sci, GP Sect, Edinburgh EH3 8DE, Midlothian, Scotland	University of Edinburgh	Crawford, F (corresponding author), Univ Edinburgh, Div Community Hlth Sci, GP Sect, Edinburgh EH3 8DE, Midlothian, Scotland.	fay.crawford@ed.ac.uk		Crawford, Fay/0000-0002-0473-9959				BOULTON AJ, EFFICACY PADDED HOSI; Boyko EJ, 2006, DIABETES CARE, V29, P2563, DOI 10.2337/dc06-1661; Crawford F, 2007, QJM-INT J MED, V100, P65; International Working Group on the Diabetic Foot, 1999, INT CONS DIAB FOOT; Mason J, 1999, DIABETIC MED, V16, P801, DOI 10.1046/j.1464-5491.1999.00133.x; McCabe CJ, 1998, DIABETIC MED, V15, P80, DOI 10.1002/(SICI)1096-9136(199801)15:1<80::AID-DIA517>3.0.CO;2-K; McIntosh AP, 2003, PREVENTION MANAGEMEN; Plank J, 2003, DIABETES CARE, V26, P1691, DOI 10.2337/diacare.26.6.1691; *SCOTT INT GUID NE, 2001, MAN DIAB SIGN 55; Singh N, 2005, JAMA-J AM MED ASSOC, V293, P217, DOI 10.1001/jama.293.2.217; *SPENCER S, 2000, COCHRANE DB SYST REV; VALK GD, 2001, COCHRANE DB SYST REV	12	3	3	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 6	2008	337	7669							a1234	10.1136/bmj.a1234	http://dx.doi.org/10.1136/bmj.a1234			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	351JP	18768555				2022-12-28	WOS:000259420900039
J	Hong, JW; Hendrix, DA; Levine, MS				Hong, Joung-Woo; Hendrix, David A.; Levine, Michael S.			Shadow enhancers as a source of evolutionary novelty	SCIENCE			English	Article							DROSOPHILA-EMBRYO; GENE-REGULATION; DORSAL; ELEMENTS		[Hong, Joung-Woo; Hendrix, David A.; Levine, Michael S.] Univ Calif Berkeley, Dept Mol & Cell Biol, Div Genet Genom & Dev, Ctr Integrat Genom, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Levine, MS (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Genet Genom & Dev, Ctr Integrat Genom, 229 Stanley Hall, Berkeley, CA 94720 USA.	mlevine@berkeley.edu	Hong, Joung-Woo/AAG-1173-2021	Hong, Joung-Woo/0000-0001-6511-7881; Levine, Michael/0000-0001-7629-0081	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046638, R01GM046638] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM046638, GM46638] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Biemar F, 2006, P NATL ACAD SCI USA, V103, P12763, DOI 10.1073/pnas.0604484103; Jeong S, 2008, CELL, V132, P783, DOI 10.1016/j.cell.2008.01.014; Jeong YS, 2006, DEVELOPMENT, V133, P761, DOI 10.1242/dev.02239; Markstein M, 2002, P NATL ACAD SCI USA, V99, P763, DOI 10.1073/pnas.012591199; Stathopoulos A, 2002, CELL, V111, P687, DOI 10.1016/S0092-8674(02)01087-5; Xiong N, 2002, IMMUNITY, V16, P453, DOI 10.1016/S1074-7613(02)00285-6; Zeitlinger J, 2007, GENE DEV, V21, P385, DOI 10.1101/gad.1509607	7	309	313	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	2008	321	5894					1314	1314		10.1126/science.1160631	http://dx.doi.org/10.1126/science.1160631			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	344GG	18772429	Green Accepted			2022-12-28	WOS:000258914300039
J	Lu, DH; Yi, M; Mo, SK; Erickson, AS; Analytis, J; Chu, JH; Singh, DJ; Hussain, Z; Geballe, TH; Fisher, IR; Shen, ZX				Lu, D. H.; Yi, M.; Mo, S. -K.; Erickson, A. S.; Analytis, J.; Chu, J. -H.; Singh, D. J.; Hussain, Z.; Geballe, T. H.; Fisher, I. R.; Shen, Z. -X.			Electronic structure of the iron-based superconductor LaOFeP	NATURE			English	Article							43 K; LAO1-XFXFEAS; COMPOUND	The recent discovery of superconductivity in the iron oxypnictide family of compounds(1-9) has generated intense interest. The layered crystal structure with transition- metal ions in planar square- lattice form and the discovery of spin- density- wave order near 130 K ( refs 10, 11) seem to hint at a strong similarity with the copper oxide superconductors. An important current issue is the nature of the ground state of the parent compounds. Two distinct classes of theories, distinguished by the underlying band structure, have been put forward: a local- moment antiferromagnetic ground state in the strong- coupling approach(12-17), and an itinerant ground state in the weak- coupling approach(18-22). The first approach stresses on-site correlations, proximity to a Mott- insulating state and, thus, the resemblance to the high- transition- temperature copper oxides, whereas the second approach emphasizes the itinerant- electron physics and the interplay between the competing ferromagnetic and antiferromagnetic fluctuations. The debate over the two approaches is partly due to the lack of conclusive experimental information on the electronic structures. Here we report angle- resolved photoemission spectroscopy ( ARPES) of LaOFeP ( superconducting transition temperature, T-c = 5.9 K), the first- reported iron- based superconductor(2). Our results favour the itinerant ground state, albeit with band renormalization. In addition, our data reveal important differences between these and copper- based superconductors.	[Lu, D. H.; Yi, M.; Mo, S. -K.; Shen, Z. -X.] Stanford Univ, Dept Phys, Stanford, CA 94305 USA; [Lu, D. H.; Yi, M.; Mo, S. -K.; Shen, Z. -X.] Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA; [Lu, D. H.; Yi, M.; Mo, S. -K.; Shen, Z. -X.] Stanford Univ, Stanford Synchrotron Radiat Lab, Stanford, CA 94305 USA; [Mo, S. -K.; Hussain, Z.] Univ Calif Berkeley, Lawrence Berkeley Lab, Adv Light Source, Berkeley, CA 94720 USA; [Erickson, A. S.; Analytis, J.; Chu, J. -H.; Geballe, T. H.; Fisher, I. R.] Stanford Univ, Geballe Lab Adv Mat, Stanford, CA 94305 USA; [Erickson, A. S.; Analytis, J.; Chu, J. -H.; Geballe, T. H.; Fisher, I. R.] Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA; [Singh, D. J.] Oak Ridge Natl Lab, Mat Sci & Technol Div, Oak Ridge, TN 37831 USA	Stanford University; Stanford University; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Stanford University; Stanford University; United States Department of Energy (DOE); Oak Ridge National Laboratory	Shen, ZX (corresponding author), Stanford Univ, Dept Phys, Stanford, CA 94305 USA.	dhlu@slac.stanford.edu; zxshen@stanford.edu	Yi, Ming/E-3145-2010; analytis, james/ABE-6100-2020; Mo, Sung-Kwan/F-3489-2013; Singh, David J/I-2416-2012; Chu, Jiun-Haw/B-1613-2012	analytis, james/0000-0002-7657-7688; Mo, Sung-Kwan/0000-0003-0711-8514; Fisher, Ian/0000-0002-1278-7862; Chu, Jiun-Haw/0000-0001-6222-1210	Office of Basic Energy Science, Division of Materials Science and Engineering	Office of Basic Energy Science, Division of Materials Science and Engineering(United States Department of Energy (DOE))	We thank C. Cox, S. M. Kauzlarich and H. Hope for single-crystal X-ray diffraction measurements, and H. Yao, S. A. Kivelson, R. M. Martin, S. C. Zhang and X. L. Qi for discussions. ARPES experiments were performed at the Advanced Light Source, which is operated by the US Department of Energy Office of Basic Energy Science. Work at Stanford and Oak Ridge National Laboratory was supported by the Office of Basic Energy Science, Division of Materials Science and Engineering.	ARKO AJ, 1989, PHYS REV B, V40, P2268, DOI 10.1103/PhysRevB.40.2268; Cao C, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.220506; Chen GF, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.247002; Chen XH, 2008, NATURE, V453, P761, DOI 10.1038/nature07045; Day C, 2008, PHYS TODAY, V61, P11, DOI 10.1063/1.2930719; de la Cruz C, 2008, NATURE, V453, P899, DOI 10.1038/nature07057; Fang C, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.224509; Haule K, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.226402; ISHIDA Y, 2008, EVIDENCE PSEUDOGAP E; Kamihara Y, 2008, J AM CHEM SOC, V130, P3296, DOI 10.1021/ja800073m; Kamihara Y, 2006, J AM CHEM SOC, V128, P10012, DOI 10.1021/ja063355c; Lanzara A, 2001, NATURE, V412, P510, DOI 10.1038/35087518; Lebegue S, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.035110; LEE PA, 2008, SPIN TRIPLET P WAVE; MA F, 2008, ANTIFERROMAGNETIC SU; Mackenzie AP, 2003, REV MOD PHYS, V75, P657, DOI 10.1103/RevModPhys.75.657; MAZIN II, 2008, IN PRESS PHYS REV LE; Ou HW, 2008, CHINESE PHYS LETT, V25, P2225, DOI 10.1088/0256-307X/25/6/083; QIU Y, 2008, NEUTRON SCATTERING S; Raghu S, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.220503; REN ZA, 2008, SUPERCONDUCTIVITY 52; Ren ZA, 2008, CHINESE PHYS LETT, V25, P2215, DOI 10.1088/0256-307X/25/6/080; Sato T, 2008, J PHYS SOC JPN, V77, DOI 10.1143/JPSJ.77.063708; Singh DJ, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.237003; Wen HH, 2008, EPL-EUROPHYS LETT, V82, DOI 10.1209/0295-5075/82/17009; Xu C, 2008, PHYS REV B, V78, DOI 10.1103/PhysRevB.78.020501; Yin ZP, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.047001; ZHANG HJ, 2008, ENHANCED ORBITAL DEG	29	241	243	5	136	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	2008	455	7209					81	84		10.1038/nature07263	http://dx.doi.org/10.1038/nature07263			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	343XS	18769435	Green Submitted			2022-12-28	WOS:000258890200040
J	Miller, M; Hemenway, D				Miller, Matthew; Hemenway, David			Guns and suicide in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Miller, Matthew; Hemenway, David] Harvard Univ, Sch Publ Hlth, Harvard Injury Control Res Ctr, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Miller, M (corresponding author), Harvard Univ, Sch Publ Hlth, Harvard Injury Control Res Ctr, 665 Huntington Ave, Boston, MA 02115 USA.		miller, matthew/GQH-4858-2022; miller, matthew/H-4624-2011	miller, matthew/0000-0002-3267-6510				Hemenway D., 2004, PRIVATE GUNS PUBLIC; Mann JJ, 2005, JAMA-J AM MED ASSOC, V294, P2064, DOI 10.1001/jama.294.16.2064; Miller M, 1999, AGGRESS VIOLENT BEH, V4, P59, DOI 10.1016/S1359-1789(97)00057-8; Miller M, 2007, J TRAUMA, V62, P1029, DOI 10.1097/01.ta.0000198214.24056.40; Simon TR, 2001, SUICIDE LIFE-THREAT, V32, P49, DOI 10.1521/suli.32.1.5.49.24212	5	119	121	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2008	359	10					989	991		10.1056/NEJMp0805923	http://dx.doi.org/10.1056/NEJMp0805923			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	343KN	18768940				2022-12-28	WOS:000258852500001
J	[Anonymous]				[Anonymous]			Community cleverness required	NATURE			English	Editorial Material																			0	97	108	0	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 4	2008	455	7209					1	1		10.1038/455001a	http://dx.doi.org/10.1038/455001a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	343XS	18769385	Bronze			2022-12-28	WOS:000258890200001
J	Douvris, C; Ozerov, OV				Douvris, Christos; Ozerov, Oleg V.			Hydrodefluorination of perfluoroalkyl groups using silylium-carborane catalysts	SCIENCE			English	Article							FLUORINE BONDS; ACTIVATION; CATIONS; ANION	Carbon-fluorine bonds are among the most unreactive functionalities in chemistry. Interest in their activation arises in part from the high global warming potentials of anthropogenic polyfluoroorganic compounds. Conversion to carbon- hydrogen bonds (hydrodefluorination) is the simplest modification of carbon- fluorine bonds, but efficient catalytic hydrodefluorination of perfluoroalkyl groups has been an unmet challenge. We report a class of carborane- supported, highly electrophilic silylium compounds that act as long- lived catalysts for hydrodefluorination of trifluoromethyl and nonafluorobutyl groups by widely accessible silanes under mild conditions. The reactions are completely selective for aliphatic carbon- fluorine bonds in preference to aromatic carbon- fluorine bonds.	[Douvris, Christos; Ozerov, Oleg V.] Brandeis Univ, Dept Chem, Waltham, MA 02454 USA	Brandeis University	Ozerov, OV (corresponding author), Brandeis Univ, Dept Chem, MS 015,415 South St, Waltham, MA 02454 USA.	ozerov@brandeis.edu	Ozerov, Oleg V/D-4175-2015; Douvris, Christos/AAP-5712-2021	Douvris, Christos/0000-0002-4983-9275	U. S. Department of Energy's Office of Basic Energy Sciences [DE-FG02-06ER15815]; Research Corporation Research Innovation Award; Alfred P. Sloan Foundation Sloan Research Fellowship; Brandeis University	U. S. Department of Energy's Office of Basic Energy Sciences(United States Department of Energy (DOE)); Research Corporation Research Innovation Award(Research Corporation for Science Advancement); Alfred P. Sloan Foundation Sloan Research Fellowship(Alfred P. Sloan Foundation); Brandeis University	We are thankful to the U. S. Department of Energy's Office of Basic Energy Sciences (DE-FG02-06ER15815), Research Corporation ( Research Innovation Award to O.V.O.), Alfred P. Sloan Foundation ( Sloan Research Fellowship to O.V.O.), and Brandeis University for support of this research. We are indebted to S. Kunz and A. G. Redfield for their assistance with <SUP>11</SUP>B NMR experiments.	AIZENBERG M, 1994, SCIENCE, V265, P359, DOI 10.1126/science.265.5170.359; [Anonymous], 2008, PROTEOMICS; BRAUN T, 2007, COMPREHENSIVE ORG 3, V1, pCH26; Burdeniuc J, 1997, CHEM BER-RECL, V130, P145, DOI 10.1002/cber.19971300203; CHAKRABARTI N, 1988, MACROMOLECULES, V21, P3011, DOI 10.1021/ma00188a020; COTTON FA, 1972, ADV INORG CHEM, P113; Fuchibe K, 2006, J AM CHEM SOC, V128, P1434, DOI 10.1021/ja0565323; Hiyama T., 2000, ORGANOFLUORINE COMPO; Juhasz M, 2004, ANGEW CHEM INT EDIT, V43, P5352, DOI 10.1002/anie.200460005; KIPLINGER JL, 1994, CHEM REV, V94, P373, DOI 10.1021/cr00026a005; Klahn M, 2007, TETRAHEDRON LETT, V48, P8900, DOI 10.1016/j.tetlet.2007.10.056; Korbe S, 2006, CHEM REV, V106, P5208, DOI 10.1021/cr050548u; KRAUSE JR, 1977, J PHYS CHEM-US, V81, P281, DOI 10.1021/j100519a001; LAMBERT JB, 1993, J CHEM SOC CHEM COMM, P383, DOI 10.1039/c39930000383; LEFAVE GM, 1949, J AM CHEM SOC, V71, P4148; Mazurek U, 2003, CHEM COMMUN, P1321, DOI 10.1039/b211850e; Ochoa-Herrera V, 2008, ENVIRON SCI TECHNOL, V42, P3260, DOI 10.1021/es702842q; Panisch R, 2006, J AM CHEM SOC, V128, P9676, DOI 10.1021/ja061800y; Reed CA, 2005, CHEM COMMUN, P1669, DOI 10.1039/b415425h; Reed CA, 1998, ACCOUNTS CHEM RES, V31, P133, DOI 10.1021/ar970230r; Reed CA, 2003, J AM CHEM SOC, V125, P1796, DOI 10.1021/ja027336o; Reed CA, 1998, ACCOUNTS CHEM RES, V31, P325, DOI 10.1021/ar960132q; RICHMOND TG, 1999, TOPICS ORGANOMETALLI, V3, P243; Scott VJ, 2005, J AM CHEM SOC, V127, P2852, DOI 10.1021/ja0426138; Shine KP, 2007, SCIENCE, V315, P1804, DOI 10.1126/science.1141677; STEVENSON DP, 1948, J AM CHEM SOC, V70, P2773, DOI 10.1021/ja01188a041; Terao J, 2007, CHEM COMMUN, P855, DOI 10.1039/b613641a; WHITE L, 1947, J AM CHEM SOC, V69, P267, DOI 10.1021/ja01194a030; Zhang Y, 2008, CHEM COMMUN, P494, DOI 10.1039/b713933k	29	416	417	7	154	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2008	321	5893					1188	1190		10.1126/science.1159979	http://dx.doi.org/10.1126/science.1159979			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	341ZM	18755971				2022-12-28	WOS:000258754400038
J	Lunt, DJ; Foster, GL; Haywood, AM; Stone, EJ				Lunt, Daniel J.; Foster, Gavin L.; Haywood, Alan M.; Stone, Emma J.			Late Pliocene Greenland glaciation controlled by a decline in atmospheric CO2 levels	NATURE			English	Article							CARBON-DIOXIDE CONCENTRATIONS; NORTH-ATLANTIC; LATE NEOGENE; CLIMATE; PANAMA; EOCENE; UPLIFT; ICE; CLOSURE; WARMTH	It is thought(1,2) that the Northern Hemisphere experienced only ephemeral glaciations from the Late Eocene to the Early Pliocene epochs ( about 38 to 4 million years ago), and that the onset of extensive glaciations did not occur until about 3 million years ago(3,4). Several hypotheses have been proposed to explain this increase in Northern Hemisphere glaciation during the Late Pliocene(5-11). Here we use a fully coupled atmosphere - ocean general circulation model and an ice- sheet model to assess the impact of the proposed driving mechanisms for glaciation and the influence of orbital variations on the development of the Greenland ice sheet in particular. We find that Greenland glaciation is mainly controlled by a decrease in atmospheric carbon dioxide during the Late Pliocene. By contrast, our model results suggest that climatic shifts associated with the tectonically driven closure of the Panama seaway(5,6), with the termination of a permanent El Nino state(7-9) or with tectonic uplift(10) are not large enough to contribute significantly to the growth of the Greenland ice sheet; moreover, we find that none of these processes acted as a priming mechanism for glacial inception triggered by variations in the Earth's orbit.	[Lunt, Daniel J.; Stone, Emma J.] Univ Bristol, BRIDGE, Sch Geog Sci, Bristol BS8 1SS, Avon, England; [Lunt, Daniel J.] British Antarctic Survey, Geol Sci Div, Cambridge CB3 0ET, England; [Foster, Gavin L.] Univ Bristol, Dept Earth Sci, Bristol Isotope Grp, Bristol BS8 1RJ, Avon, England; [Haywood, Alan M.] Univ Leeds, Sch Earth & Environm, Leeds LS2 9JT, W Yorkshire, England	University of Bristol; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Antarctic Survey; University of Bristol; University of Leeds	Lunt, DJ (corresponding author), Univ Bristol, BRIDGE, Sch Geog Sci, Univ Rd, Bristol BS8 1SS, Avon, England.	d.j.lunt@bristol.ac.uk	Stone, Emma/H-9549-2012; Foster, Gavin/W-5968-2019; Lunt, Daniel J/G-9451-2011; Foster, Gavin/CAF-4654-2022	Stone, Emma/0000-0002-8633-8074; Lunt, Daniel J/0000-0003-3585-6928; Foster, Gavin/0000-0003-3688-9668	GEACEP (Greenhouse to ice-house: Evolution of the Antarctic Cryosphere and Palaeoenvironment) programme; BAS fellowship; RCUK fellowship; NERC research fellowship; NERC [bas010019] Funding Source: UKRI; Natural Environment Research Council [NER/I/S/2002/00720, bas010019] Funding Source: researchfish	GEACEP (Greenhouse to ice-house: Evolution of the Antarctic Cryosphere and Palaeoenvironment) programme; BAS fellowship; RCUK fellowship(UK Research & Innovation (UKRI)); NERC research fellowship(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	This work was carried out in the framework of the British Antarctic Survey GEACEP (Greenhouse to ice-house: Evolution of the Antarctic Cryosphere and Palaeoenvironment) programme. D. J. L. is funded by BAS and RCUK fellowships. G. L. F. is funded by a NERC research fellowship. E. J. S. is funded by a NERC studentship.	Bartoli G, 2005, EARTH PLANET SC LETT, V237, P33, DOI 10.1016/j.epsl.2005.06.020; BERGER A, 1991, QUATERNARY SCI REV, V10, P297, DOI 10.1016/0277-3791(91)90033-Q; Edgar KM, 2007, NATURE, V448, P908, DOI 10.1038/nature06053; Eldrett JS, 2007, NATURE, V446, P176, DOI 10.1038/nature05591; Gordon C, 2000, CLIM DYNAM, V16, P147, DOI 10.1007/s003820050010; GREENWOOD DR, 1995, GEOLOGY, V23, P1044, DOI 10.1130/0091-7613(1995)023<1044:ECCALT>2.3.CO;2; Haug GH, 1998, NATURE, V393, P673, DOI 10.1038/31447; Haywood AM, 2007, PALEOCEANOGRAPHY, V22, DOI 10.1029/2006PA001323; Haywood AM, 2005, GEOCHEM GEOPHY GEOSY, V6, DOI 10.1029/2004GC000799; Haywood AM, 2004, EARTH PLANET SC LETT, V218, P363, DOI 10.1016/S0012-821X(03)00685-X; HILL DJ, 2007, MICROPALAEONTOL SOC, V2, P517; Japsen P, 2000, GLOBAL PLANET CHANGE, V24, P165, DOI 10.1016/S0921-8181(00)00006-0; KEIGWIN L, 1982, SCIENCE, V217, P350, DOI 10.1126/science.217.4557.350; Kurschner WM, 1996, MAR MICROPALEONTOL, V27, P299, DOI 10.1016/0377-8398(95)00067-4; LISIECKI LE, 2005, PALEOCEANOGRAPHY, V0020; Lunt DJ, 2008, CLIM DYNAM, V30, P1, DOI 10.1007/s00382-007-0265-6; Maslin MA, 1998, QUATERNARY SCI REV, V17, P411, DOI 10.1016/S0277-3791(97)00047-4; Pagani M, 1999, SCIENCE, V285, P876, DOI 10.1126/science.285.5429.876; Pagani M, 2005, SCIENCE, V309, P600, DOI 10.1126/science.1110063; Payne AJ, 1999, CLIM DYNAM, V15, P115, DOI 10.1007/s003820050271; Pearson PN, 2000, NATURE, V406, P695, DOI 10.1038/35021000; Philander SG, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000837; RAYMO ME, 1992, NATURE, V359, P117, DOI 10.1038/359117a0; Raymo ME, 1996, MAR MICROPALEONTOL, V27, P313, DOI 10.1016/0377-8398(95)00048-8; RUDDIMAN WF, 1989, J GEOPHYS RES-ATMOS, V94, P18409, DOI 10.1029/JD094iD15p18409; SCHMIDT DN, 2007, MICROPALAEONTOL SOC, V2, P427; Siegenthaler U, 2005, SCIENCE, V310, P1313, DOI 10.1126/science.1120130; Soloman S., 2007, CLIMATE CHANGE 2007; Thiede J, 1998, QUATERNARY SCI REV, V17, P185, DOI 10.1016/S0277-3791(97)00076-0; Wara MW, 2005, SCIENCE, V309, P758, DOI 10.1126/science.1112596	30	186	198	1	89	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	2008	454	7208					1102	U41		10.1038/nature07223	http://dx.doi.org/10.1038/nature07223			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341MW	18756254				2022-12-28	WOS:000258719600034
J	Possover, M				Possover, Marc			Gossypiboma in the pouch of Douglas	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Hirslanden Clin, CH-8032 Zurich, Switzerland		Possover, M (corresponding author), Hirslanden Clin, CH-8032 Zurich, Switzerland.								0	6	7	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 21	2008	359	8					E9	E9		10.1056/NEJMicm075197	http://dx.doi.org/10.1056/NEJMicm075197			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339HL	18716293				2022-12-28	WOS:000258568600010
J	White, HD; Chew, DP				White, Harvey D.; Chew, Derek P.			Acute myocardial infarction	LANCET			English	Review							ST-SEGMENT-ELEVATION; ACUTE CORONARY SYNDROMES; GLYCOPROTEIN-IIB/IIIA INHIBITORS; EARLY INVASIVE MANAGEMENT; HIGH-RISK PATIENTS; HEALTH-CARE PROFESSIONALS; HEART-ASSOCIATION COUNCIL; WEIGHT HEPARIN ENOXAPARIN; CASE-FATALITY RATES; LONG-TERM SURVIVAL	Modern management of acute myocardial infarction is built on a clinical evidence base drawn from many studies undertaken over the past three decades. The evolution in clinical practice has substantially reduced mortality and morbidity associated with the condition. Key to this success is the effective integration of antithrombotic therapy combined with timely reperfusion, either primary percutaneous coronary intervention or fibrinolysis for ST-elevation myocardial infarction, and invasive investigation and revascularisation for non-ST-elevation myocardial infarction, underpinned by risk stratification and optimised systems of care. After the development of troponin assays for the detection of myonecrosis, the universal definition and classification of myocardial infarction now indicates the underlying pathophysiology. Additionally, an increasing appreciation of the importance of adverse events, such as bleeding, has emerged. Remaining challenges include the effective translation of this evidence to all patients with myocardial infarction, especially to those not well represented in clinical trials who remain at increased risk of adverse events, such as elderly patients and those with renal failure. On a global level, the epidemic of diabetes and obesity in the developed world and the transition from infectious diseases to cardiovascular disease in the developing world will place an increasing demand on health-care infrastructures required to deliver time-dependent and resource-intensive care. This Seminar discusses the underlying pathophysiology, evolving perspectives on diagnosis, risk stratification, and the invasive and pharmacological management of myocardial infarction.	[White, Harvey D.] Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland 1030, New Zealand; [Chew, Derek P.] Flinders Univ S Australia, Dept Cardiovasc Med, Adelaide, SA, Australia	Auckland City Hospital; Flinders University South Australia	White, HD (corresponding author), Auckland City Hosp, Green Lane Cardiovasc Serv, Private Bag 92024, Auckland 1030, New Zealand.	harveyw@adhb.govt.nz		Chew, Derek/0000-0003-3593-296X				Alexander KP, 2007, CIRCULATION, V115, P2549, DOI 10.1161/CIRCULATIONAHA.107.182615; Alexander KP, 2007, CIRCULATION, V115, P2570, DOI 10.1161/CIRCULATIONAHA.107.182616; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Anavekar NS, 2004, NEW ENGL J MED, V351, P1285, DOI 10.1056/NEJMoa041365; Andersen HR, 2003, NEW ENGL J MED, V349, P733, DOI 10.1056/NEJMoa025142; Anderson JL, 2007, CIRCULATION, V116, pE148, DOI 10.1161/CIRCULATIONAHA.107.181940; Andreotti F, 2005, CIRCULATION, V111, P1855, DOI 10.1161/01.CIR.0000160361.73423.23; [Anonymous], 1988, LANCET, V2, P349; Antman Elliott M, 2004, J Am Coll Cardiol, V44, P671, DOI 10.1016/j.jacc.2004.07.002; Antman EM, 2000, JAMA-J AM MED ASSOC, V284, P835, DOI 10.1001/jama.284.7.835; Antman EM, 2006, NEW ENGL J MED, V354, P1477, DOI 10.1056/NEJMoa060898; Antoniucci D, 2004, CIRCULATION, V109, P1704, DOI 10.1161/01.CIR.0000126284.40075.98; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Armstrong PW, 2007, JAMA-J AM MED ASSOC, V297, P43; *ASS SAF EFF NEW T, 2002, LANCET, V367, P569; Bach RG, 2004, ANN INTERN MED, V141, P186, DOI 10.7326/0003-4819-141-3-200408030-00007; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Bassand JP, 2007, EUR HEART J, V28, P1598, DOI 10.1093/eurheartj/ehm161; Bavry AA, 2006, J AM COLL CARDIOL, V48, P1319, DOI 10.1016/j.jacc.2006.06.050; Bhatt DL, 2004, JAMA-J AM MED ASSOC, V292, P2096, DOI 10.1001/jama.292.17.2096; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; Boersma E, 2006, EUR HEART J, V27, P779, DOI 10.1093/eurheartj/ehi810; Boersma E, 2000, CIRCULATION, V101, P2557, DOI 10.1161/01.CIR.101.22.2557; Boersma E, 2002, LANCET, V359, P189, DOI 10.1016/S0140-6736(02)07442-1; Boyle AJ, 2006, CIRCULATION, V114, P339, DOI 10.1161/CIRCULATIONAHA.105.590653; Bradley EH, 2006, NEW ENGL J MED, V355, P2308, DOI 10.1056/NEJMsa063117; Briel M, 2006, JAMA-J AM MED ASSOC, V295, P2046, DOI 10.1001/jama.295.17.2046; Buffon A, 2002, NEW ENGL J MED, V347, P5, DOI 10.1056/NEJMoa012295; Buxton AE, 1999, NEW ENGL J MED, V341, P1882, DOI 10.1056/NEJM199912163412503; Cannon CP, 2001, NEW ENGL J MED, V344, P1879, DOI 10.1056/NEJM200106213442501; Casscells W, 2003, CIRCULATION, V107, P2072, DOI 10.1161/01.CIR.0000069329.70061.68; Chen ZM, 2005, LANCET, V366, P1622; Chen ZM, 2005, LANCET, V366, P1607, DOI 10.1016/s0140-6736(05)67660-x; Clark AM, 2005, ANN INTERN MED, V143, P659, DOI 10.7326/0003-4819-143-9-200511010-00010; Collet JP, 2006, J AM COLL CARDIOL, V48, P1326, DOI 10.1016/j.jacc.2006.03.064; Collins R, 1997, NEW ENGL J MED, V336, P847, DOI 10.1056/NEJM199703203361207; COLLINS R, 1995, LANCET, V345, P669; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Davi G, 2007, NEW ENGL J MED, V357, P2482, DOI 10.1056/NEJMra071014; De Luca G, 2005, AM HEART J, V150, P827, DOI 10.1016/j.ahj.2004.12.030; De Luca G, 2005, AM HEART J, V150, P557, DOI 10.1016/j.ahj.2004.10.044; De Luca G, 2007, AM HEART J, V153, P343, DOI 10.1016/j.ahj.2006.11.020; DEVITA C, 1994, LANCET, V343, P1115; Di Mario C, 2008, LANCET, V371, P559, DOI 10.1016/S0140-6736(08)60268-8; Dixon SR, 2002, J AM COLL CARDIOL, V40, P1928, DOI 10.1016/S0735-1097(02)02567-6; Dokainish H, 2005, J AM COLL CARDIOL, V45, P19, DOI 10.1016/j.jacc.2004.09.056; Donahoe SM, 2007, JAMA-J AM MED ASSOC, V298, P765, DOI 10.1001/jama.298.7.765; Eagle KA, 2006, NAT CLIN PRACT CARD, V3, P163, DOI 10.1038/ncpcardio0499; Eagle KA, 2005, J AM COLL CARDIOL, V46, P1242, DOI 10.1016/j.jacc.2004.12.083; Eagle KA, 2002, LANCET, V359, P373, DOI 10.1016/S0140-6736(02)07595-5; Eikelboom JW, 2006, CIRCULATION, V114, P774, DOI 10.1161/CIRCULATIONAHA.106.612812; Ellis SG, 2008, NEW ENGL J MED, V358, P2205, DOI 10.1056/NEJMoa0706816; FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657; Ferguson JJ, 2004, JAMA-J AM MED ASSOC, V292, P45; Fernandez-Aviles F, 2004, LANCET, V364, P1045, DOI 10.1016/S0140-6736(04)17059-1; Fox KAA, 2004, CIRCULATION, V110, P1202, DOI 10.1161/01.CIR.0000140675.85342.1B; Fox KAA, 2002, LANCET, V360, P743, DOI 10.1016/S0140-6736(02)09894-X; Fox KAA, 2007, JAMA-J AM MED ASSOC, V297, P1892, DOI 10.1001/jama.297.17.1892; Furman MI, 2001, J AM COLL CARDIOL, V37, P1571, DOI 10.1016/S0735-1097(01)01203-7; Gersh BJ, 2005, JAMA-J AM MED ASSOC, V293, P979, DOI 10.1001/jama.293.8.979; Gershlick AH, 2005, NEW ENGL J MED, V353, P2758, DOI 10.1056/NEJMoa050849; Gibson CM, 2006, AM HEART J, V152, P668, DOI 10.1016/j.ahj.2006.06.003; Gibson CM, 2000, CIRCULATION, V101, P125, DOI 10.1161/01.CIR.101.2.125; Gibson CM, 2004, EUR HEART J, V25, P1998, DOI 10.1016/j.ehj.2004.08.016; Goncalves PDA, 2005, EUR HEART J, V26, P865, DOI 10.1093/eurheartj/ehi187; Granger CB, 2003, ARCH INTERN MED, V163, P2345, DOI 10.1001/archinte.163.19.2345; Heeschen C, 2004, CIRCULATION, V110, P3206, DOI 10.1161/01.CIR.0000147611.92021.2B; Henry TD, 2007, CIRCULATION, V116, P721, DOI 10.1161/CIRCULATIONAHA.107.694141; Herzog CA, 1998, NEW ENGL J MED, V339, P799, DOI 10.1056/NEJM199809173391203; Hirsch A, 2007, LANCET, V369, P827, DOI 10.1016/S0140-6736(07)60410-3; Ho PM, 2006, ARCH INTERN MED, V166, P1842, DOI 10.1001/archinte.166.17.1842; Hochman JS, 1999, NEW ENGL J MED, V341, P625, DOI 10.1056/NEJM199908263410901; Hochman JS, 2006, NEW ENGL J MED, V355, P2395, DOI 10.1056/NEJMoa066139; Jaffe AS, 2006, J AM COLL CARDIOL, V48, P1, DOI 10.1016/j.jacc.2006.02.056; Kastrati A, 2006, JAMA-J AM MED ASSOC, V295, P1531, DOI 10.1001/jama.295.13.joc60034; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; Keeley EC, 2006, LANCET, V367, P579, DOI 10.1016/S0140-6736(06)68148-8; Kindermann M, 2007, CLIN RES CARDIOL, V96, P767, DOI 10.1007/s00392-0591-z; Le May MR, 2008, NEW ENGL J MED, V358, P231, DOI 10.1056/NEJMoa073102; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; LEIZOROVICZ A, 1993, NEW ENGL J MED, V329, P383; Libby P, 2001, CIRCULATION, V104, P365, DOI 10.1161/01.CIR.104.3.365; Liew R, 2006, HEART, V92, P1030, DOI 10.1136/hrt.2005.078634; Mandelzweig L, 2006, EUR HEART J, V27, P2285, DOI 10.1093/eurheartj/ehl196; Manoukian SV, 2007, J AM COLL CARDIOL, V49, P1362, DOI 10.1016/j.jacc.2007.02.027; Martinez MW, 2007, CLIN CHEM, V53, P995, DOI 10.1373/clinchem.2007.086199; Mehta SR, 2005, JAMA-J AM MED ASSOC, V293, P437; Mehta SR, 2005, JAMA-J AM MED ASSOC, V293, P2908, DOI 10.1001/jama.293.23.2908; Montalescot G, 2001, NEW ENGL J MED, V344, P1895, DOI 10.1056/NEJM200106213442503; Montalescot G, 2007, EUR HEART J, V28, P443, DOI 10.1093/eurheartj/ehl472; Morrow DA, 2000, CIRCULATION, V102, P2031, DOI 10.1161/01.CIR.102.17.2031; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; Mukherjee D, 2004, CIRCULATION, V109, P745, DOI 10.1161/01.CIR.0000112577.69066.CB; Murphy SA, 2007, EUR HEART J, V28, P2077, DOI 10.1093/eurheartj/ehm224; Nallamothu BK, 2003, AM J CARDIOL, V92, P824, DOI 10.1016/S0002-9149(03)00891-9; Nallamothu BK, 2006, CIRCULATION, V113, P1189, DOI 10.1161/CIRCULATIONAHA.105.596346; Neumann FJ, 2003, JAMA-J AM MED ASSOC, V290, P1593, DOI 10.1001/jama.290.12.1593; Oler A, 1996, JAMA-J AM MED ASSOC, V276, P811, DOI 10.1001/jama.276.10.811; Orlandini A, 2006, EUR HEART J, V27, P527, DOI 10.1093/eurheartj/ehi701; Patti G, 2005, CIRCULATION, V111, P2099, DOI 10.1161/01.CIR.0000161383.06692.D4; Petersen JL, 2004, JAMA-J AM MED ASSOC, V292, P89, DOI 10.1001/jama.292.1.89; Peterson ED, 2006, JAMA-J AM MED ASSOC, V295, P1912, DOI 10.1001/jama.295.16.1912; Pfeffer MA, 2003, NEW ENGL J MED, V349, P1893, DOI 10.1056/NEJMoa032292; Pinto DS, 2006, CIRCULATION, V114, P2019, DOI 10.1161/CIRCULATIONAHA.106.638353; Pitt B, 2005, J AM COLL CARDIOL, V46, P425, DOI 10.1016/j.jacc.2005.04.038; Poirier P, 2006, CIRCULATION, V113, P898, DOI 10.1161/CIRCULATIONAHA.106.171016; Rao SV, 2004, JAMA-J AM MED ASSOC, V292, P1555, DOI 10.1001/jama.292.13.1555; Rioufol G, 2002, CIRCULATION, V106, P804, DOI 10.1161/01.CIR.0000025609.13806.31; Ryan J, 2007, J THROMB THROMBOLYS, V24, P293, DOI 10.1007/s11239-007-0038-4; Ryan JW, 2005, CIRCULATION, V112, P3049, DOI 10.1161/CIRCULATIONAHA.105.582346; Sabatine MS, 2005, NEW ENGL J MED, V352, P1179, DOI 10.1056/NEJMoa050522; Sanders GD, 2007, AM HEART J, V153, P951, DOI 10.1016/j.ahj.2007.03.002; Scott IA, 2002, MED J AUSTRALIA, V177, P26, DOI 10.5694/j.1326-5377.2002.tb04627.x; Silva JC, 2005, EUR HEART J, V26, P36, DOI 10.1093/eurheartj/ehi011; Spacek R, 2002, EUR HEART J, V23, P230, DOI 10.1053/euhj.2001.2735; Spertus JA, 2006, CIRCULATION, V113, P2803, DOI 10.1161/CIRCULATIONAHA.106.618066; Steg PG, 2003, CIRCULATION, V108, P2851, DOI 10.1161/01.CIR.0000103122.10021.F2; Stone GW, 2008, NEW ENGL J MED, V358, P2218, DOI 10.1056/NEJMoa0708191; Stone GW, 2007, JAMA-J AM MED ASSOC, V298, P2497, DOI 10.1001/jama.298.21.2497; Stone GW, 2007, JAMA-J AM MED ASSOC, V297, P591, DOI 10.1001/jama.297.6.591; Stone GW, 2006, NEW ENGL J MED, V355, P2203, DOI 10.1056/NEJMoa062437; Taher T, 2004, J AM COLL CARDIOL, V44, P38, DOI 10.1016/j.jacc.2004.03.041; Thygesen K, 2007, CIRCULATION, V116, P2634, DOI 10.1161/CIRCULATIONAHA.107.187397; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Topol EJ, 2000, CIRCULATION, V102, P1761; Topol EJ, 2005, J AM COLL CARDIOL, V46, P1456, DOI 10.1016/j.jacc.2005.06.064; Valgimigli M, 2005, JAMA-J AM MED ASSOC, V293, P2109, DOI 10.1001/jama.293.17.2109; Van de Werf F, 1999, LANCET, V354, P716, DOI 10.1016/S0140-6736(99)07403-6; Van de Werf F, 2003, EUR HEART J, V24, P28, DOI 10.1016/S0195-668X(02)00618-8; Wallentin L, 1999, LANCET, V354, P708; Wallentin L, 2000, LANCET, V356, P9, DOI 10.1016/S0140-6736(00)02427-2; Wallentin L, 2003, CIRCULATION, V108, P135, DOI 10.1161/01.CIR.0000081659.72985.A8; WHITE H, 1988, LANCET, V2, P914; White HD, 2008, HEART, V94, P679, DOI 10.1136/hrt.2007.130955; White HD, 2007, EUR HEART J, V28, P1066, DOI 10.1093/eurheartj/ehm081; White HD, 2006, AM HEART J, V152, P1042, DOI 10.1016/j.ahj.2006.08.002; White HD, 1998, EUR HEART J, V19, P1132, DOI 10.1053/euhj.1998.1017; White HD, 2001, LANCET, V358, P1855; Widimsky P, 2003, EUR HEART J, V24, P94, DOI 10.1016/S0195-668X(02)00468-2; Wijeysundera HC, 2007, J AM COLL CARDIOL, V49, P422, DOI 10.1016/j.jacc.2006.09.033; Wiviott SD, 2007, NEW ENGL J MED, V357, P2001, DOI 10.1056/NEJMoa0706482; Yusuf S, 2001, CIRCULATION, V104, P2746, DOI 10.1161/hc4601.099487; Yusuf S, 2006, JAMA-J AM MED ASSOC, V295, P1519; Yusuf S, 2006, NEW ENGL J MED, V354, P1464; Yusuf S, 2001, NEW ENGL J MED, V345, P494; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9; Yusuf S, 2001, CIRCULATION, V104, P2855, DOI 10.1161/hc4701.099488; Zarich SW, 2007, CIRCULATION, V115, pE436, DOI 10.1161/CIRCULATIONAHA.105.535732	149	519	545	2	63	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 16	2008	372	9638					570	584		10.1016/S0140-6736(08)61237-4	http://dx.doi.org/10.1016/S0140-6736(08)61237-4			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339MS	18707987				2022-12-28	WOS:000258582300031
J	Deng, WH; Guo, J; Hu, JA; Zhang, HG				Deng, Weihong; Guo, Jun; Hu, Jiani; Zhang, Honggang			Comment on "100% accuracy in automatic face recognition"	SCIENCE			English	Editorial Material									[Deng, Weihong; Guo, Jun; Hu, Jiani; Zhang, Honggang] Beijing Univ Posts & Telecommun, Sch Informat Engn, Beijing 100876, Peoples R China	Beijing University of Posts & Telecommunications	Deng, WH (corresponding author), Beijing Univ Posts & Telecommun, Sch Informat Engn, Beijing 100876, Peoples R China.	whdeng@bupt.edu.cn	Deng, Wei/GWC-9207-2022	Deng, Weihong/0000-0001-5952-6996				Craw I, 1999, IEEE T PATTERN ANAL, V21, P725, DOI 10.1109/34.784286; Jenkins R, 2008, SCIENCE, V319, P435, DOI 10.1126/science.1149656; Shan SG, 2004, SIXTH IEEE INTERNATIONAL CONFERENCE ON AUTOMATIC FACE AND GESTURE RECOGNITION, PROCEEDINGS, P314; Sinha P, 2002, NAT NEUROSCI, V5, P1093, DOI 10.1038/nn949; Zhao W, 2003, ACM COMPUT SURV, V35, P399, DOI 10.1145/954339.954342	5	10	10	2	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 15	2008	321	5891								10.1126/science.1157523	http://dx.doi.org/10.1126/science.1157523			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	337LD	18703725				2022-12-28	WOS:000258436700016
J	Budanov, AV; Karin, M				Budanov, Andrei V.; Karin, Michael			p53 target genes Sestrin1 and Sestrin2 connect genotoxic stress and mTOR signaling	CELL			English	Article							ACTIVATED PROTEIN-KINASE; S6 KINASE; TUBEROUS-SCLEROSIS; TUMOR-SUPPRESSOR; CELL-GROWTH; MAMMALIAN TARGET; RAPAMYCIN; TRANSLATION; PATHWAY; TSC2	The tumor suppressor p53 is activated upon genotoxic and oxidative stress and in turn inhibits cell proliferation and growth through induction of specific target genes. Cell growth is positively regulated by mTOR, whose activity is inhibited by the TSC1: TSC2 complex. Although genotoxic stress has been suggested to inhibit mTOR via p53-mediated activation of mTOR inhibitors, the precise mechanism of this link was unknown. We now demonstrate that the products of two p53 target genes, Sestrin1 and Sestrin2, activate the AMP-responsive protein kinase ( AMPK) and target it to phosphorylate TSC2 and stimulate its GAP activity, thereby inhibiting mTOR. Correspondingly, Sestrin2-deficient mice fail to inhibit mTOR signaling upon genotoxic challenge. Sestrin1 and Sestrin2 therefore provide an important link between genotoxic stress, p53 and the mTOR signaling pathway.	[Budanov, Andrei V.; Karin, Michael] Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Karin, M (corresponding author), Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, 9500 Gilman Dr, La Jolla, CA 92093 USA.	karinoffice@ucsd.edu	Budanov, Andrei V/HGD-5487-2022	Budanov, Andrei V/0000-0002-7943-1000	Tobacco Related Disease Research Program TRDRPW [15RT-0197]; National Institute of Environmental Health Science [5RO1 ES06376, 5R37 ES04151]; Superfund Basic Research Program [5P42 ES010337]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010337, R37ES004151, R01ES006376] Funding Source: NIH RePORTER	Tobacco Related Disease Research Program TRDRPW(University of California System); National Institute of Environmental Health Science(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Superfund Basic Research Program; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank D.J. Kwiatkowski (Department of Medicine, Brigham and Women's Hospital, Harvard Medical School) for Tsc2<SUP>-/-</SUP> and Tsc2<SUP>+/+</SUP> fibroblasts, E. Feinstein (Quark Biotech) for Sesn2 antibodies, N. Sonenberg (McGill University), K. L. Guan (UCSD), P. M. Chumakov (Lerner Research Institute, The Cleveland Clinic Foundation), J. Blenis (Department of Cell Biology, Harvard Medical School), G. Thomas (Genome Research Institute, University of Cincinnati), N. Hay (Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago), M. J. Birnbaum (Howard Hughes Medical Institute and Department of Medicine, University of Pennsylvania School of Medicine), S. W. Lowe ( Cold Spring Harbor Laboratory), and R. J. Shaw for gifts of plasmids and antibodies. We also thank W. E. Naugler for protein and cDNA samples from DEN-treated mice, J. Wang for p53 knockout mice, P. H. Tseng for help with gel filtration experiments, and V. Temkin for help with fluorescent-activated cell sorter analysis. Work was supported by grants from the Tobacco Related Disease Research Program (TRDRPW; 15RT-0197), the National Institute of Environmental Health Science (5RO1 ES06376 and 5R37 ES04151), and the Superfund Basic Research Program (5P42 ES010337). A. B. was supported by a postdoctoral fellowship from the Tobacco-Related Disease Research Program.	Astrinidis A, 2002, ONCOGENE, V21, P8470, DOI 10.1038/sj.onc.1205962; Averous J, 2008, ONCOGENE, V27, P1106, DOI 10.1038/sj.onc.1210715; Averous J, 2006, ONCOGENE, V25, P6423, DOI 10.1038/sj.onc.1209887; Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; Budanov AV, 2002, ONCOGENE, V21, P6017, DOI 10.1038/sj.onc.1205877; BUHLER R, 1992, EUR J BIOCHEM, V204, P407, DOI 10.1111/j.1432-1033.1992.tb16650.x; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Corradetti MN, 2006, ONCOGENE, V25, P6347, DOI 10.1038/sj.onc.1209885; Dames SA, 2005, J BIOL CHEM, V280, P20558, DOI 10.1074/jbc.M501116200; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Feng ZH, 2007, CANCER RES, V67, P3043, DOI 10.1158/0008-5472.CAN-06-4149; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Guan LJ, 2007, J BIOL CHEM, V282, P14213, DOI 10.1074/jbc.M610513200; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Horton LE, 2002, ONCOGENE, V21, P5325, DOI 10.1038/sj.onc.1205662; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kwiatkowski DJ, 2005, HUM MOL GENET, V14, pR251, DOI 10.1093/hmg/ddi260; Levine AJ, 2006, GENE DEV, V20, P267, DOI 10.1101/gad.1363206; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Motoshima H, 2006, J PHYSIOL-LONDON, V574, P63, DOI 10.1113/jphysiol.2006.108324; Peeters H, 2003, HUM GENET, V112, P573, DOI 10.1007/s00439-003-0917-5; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Ragnarsson G, 1999, BRIT J CANCER, V79, P1468, DOI 10.1038/sj.bjc.6690234; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, J BIOL CHEM, V280, P39505, DOI 10.1074/jbc.M506096200; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; Soliman GA, 2005, CURR OPIN LIPIDOL, V16, P317, DOI 10.1097/01.mol.0000169352.35642.06; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Thomas GV, 2006, CURR OPIN GENET DEV, V16, P78, DOI 10.1016/j.gde.2005.12.003; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Velasco-Miguel S, 1999, ONCOGENE, V18, P127, DOI 10.1038/sj.onc.1202274; Verna L, 1996, PHARMACOL THERAPEUT, V71, P57, DOI 10.1016/0163-7258(96)00062-9; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yang Q, 2007, CELL RES, V17, P666, DOI 10.1038/cr.2007.64; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	50	953	1004	2	73	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 8	2008	134	3					451	460		10.1016/j.cell.2008.06.028	http://dx.doi.org/10.1016/j.cell.2008.06.028			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SO	18692468	Green Submitted, Green Accepted, Bronze			2022-12-28	WOS:000258665500018
J	Swem, LR; Swem, DL; Wingreen, NS; Bassler, BL				Swem, Lee R.; Swem, Danielle L.; Wingreen, Ned S.; Bassler, Bonnie L.			Deducing receptor signaling parameters from in vivo analysis: LuxN/AI-1 quorum sensing in Vibrio harveyi	CELL			English	Article							LOCUS CONTROLLING EXPRESSION; TO-CELL COMMUNICATION; LUXR-LUXI FAMILY; ESCHERICHIA-COLI; BACTERIAL CHEMOTAXIS; TRANSCRIPTIONAL REGULATORS; STRUCTURAL IDENTIFICATION; NUCLEOTIDE-SEQUENCE; HISTIDINE KINASE; GENETIC-ANALYSIS	Quorum sensing, a process of bacterial cell-cell communication, relies on production, detection, and response to autoinducer signaling molecules. LuxN, a nine-transmembrane domain protein from Vibrio harveyi, is the founding example of membrane-bound receptors for acyl-homoserine lactone (AHL) autoinducers. We used mutagenesis and suppressor analyses to identify the AHL-binding domain of LuxN and discovered LuxN mutants that confer both decreased and increased AHL sensitivity. Our analysis of dose-response curves of multiple LuxN mutants pins these inverse phenotypes on quantifiable opposing shifts in the free-energy bias of LuxN for occupying its kinase and phosphatase states. To understand receptor activation and to characterize the pathway signaling parameters, we exploited a strong LuxN antagonist, one of fifteen small-molecule antagonists we identified. We find that quorum-sensing-mediated communication can be manipulated positively and negatively to control bacterial behavior and, more broadly, that signaling parameters can be deduced from in vivo data.	[Swem, Lee R.; Swem, Danielle L.; Wingreen, Ned S.; Bassler, Bonnie L.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; [Swem, Danielle L.; Bassler, Bonnie L.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	Princeton University; Howard Hughes Medical Institute	Bassler, BL (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	bbassler@princeton.edu		Bassler, Bonnie/0000-0002-0043-746X	Howard Hughes Medical Institute, National Institutes of Health (NIH) [5R01GM065859]; National Science Foundation [MCB-0343821]; NIH [5R01 AI 054442, GM787552]; National Cancer Institute's Initiative for Chemical Genetics, NIH, [N01-CO-12400]; Broad Institute of Harvard; MIT; Department of Health and Human Service; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054442] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065859] Funding Source: NIH RePORTER	Howard Hughes Medical Institute, National Institutes of Health (NIH)(Howard Hughes Medical InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute's Initiative for Chemical Genetics, NIH,(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Broad Institute of Harvard; MIT; Department of Health and Human Service; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the Howard Hughes Medical Institute, National Institutes of Health (NIH) grant 5R01GM065859, NIH grant 5R01 AI 054442, National Science Foundation grant MCB-0343821 to B. L. B., and NIH postdoctoral fellowship GM787552 to L. R. S. The antagonist screen has been funded in whole or in part with Federal funds from the National Cancer Institute's Initiative for Chemical Genetics, NIH, under contract number N01-CO-12400 and has been performed with the assistance of the Chemical Biology Platform of the Broad Institute of Harvard and MIT. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Service, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.	Ames P, 2002, P NATL ACAD SCI USA, V99, P7060, DOI 10.1073/pnas.092071899; BASSLER BL, 1993, MOL MICROBIOL, V9, P773, DOI 10.1111/j.1365-2958.1993.tb01737.x; Bray D, 1998, NATURE, V393, P85, DOI 10.1038/30018; CAO JG, 1989, J BIOL CHEM, V264, P21670; Chen X, 2002, NATURE, V415, P545, DOI 10.1038/415545a; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; Endres RG, 2007, PLOS COMPUT BIOL, V3, P1385, DOI 10.1371/journal.pcbi.0030150; ENGEBRECHT J, 1987, NUCLEIC ACIDS RES, V15, P10455, DOI 10.1093/nar/15.24.10455; ENGEBRECHT J, 1984, P NATL ACAD SCI-BIOL, V81, P4154, DOI 10.1073/pnas.81.13.4154; Freeman JA, 1999, J BACTERIOL, V181, P899, DOI 10.1128/JB.181.3.899-906.1999; Freeman JA, 1999, MOL MICROBIOL, V31, P665, DOI 10.1046/j.1365-2958.1999.01208.x; Freeman JA, 2000, MOL MICROBIOL, V35, P139, DOI 10.1046/j.1365-2958.2000.01684.x; Fuqua C, 2001, ANNU REV GENET, V35, P439, DOI 10.1146/annurev.genet.35.102401.090913; Fuqua C, 1996, ANNU REV MICROBIOL, V50, P727, DOI 10.1146/annurev.micro.50.1.727; FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; GOY MF, 1977, P NATL ACAD SCI USA, V74, P4964, DOI 10.1073/pnas.74.11.4964; Hammer BK, 2003, MOL MICROBIOL, V50, P101, DOI 10.1046/j.1365-2958.2003.03688.x; Henke JM, 2004, J BACTERIOL, V186, P6902, DOI 10.1128/JB.186.20.6902-6914.2004; Henke JM, 2004, J BACTERIOL, V186, P3794, DOI 10.1128/JB.186.12.3794-3805.2004; Higgins DA, 2007, NATURE, V450, P883, DOI 10.1038/nature06284; Jung K, 2007, J BACTERIOL, V189, P2945, DOI 10.1128/JB.01723-06; KEHRY MR, 1982, CELL, V29, P761, DOI 10.1016/0092-8674(82)90438-X; KEHRY MR, 1982, J BIOL CHEM, V257, P378; Keymer JE, 2006, P NATL ACAD SCI USA, V103, P1786, DOI 10.1073/pnas.0507438103; Kim KK, 1999, NATURE, V400, P787, DOI 10.1038/23512; Lenz DH, 2004, CELL, V118, P69, DOI 10.1016/j.cell.2004.06.009; MADDOCK JR, 1993, SCIENCE, V259, P1717; MARTIN M, 1989, J BACTERIOL, V171, P2406, DOI 10.1128/jb.171.5.2406-2414.1989; McFall-Ngai MJ, 2000, CURR OPIN MICROBIOL, V3, P603, DOI 10.1016/S1369-5274(00)00147-8; Miller MB, 2001, ANNU REV MICROBIOL, V55, P165, DOI 10.1146/annurev.micro.55.1.165; Neiditch MB, 2006, CELL, V126, P1095, DOI 10.1016/j.cell.2006.07.032; Neiditch MB, 2005, MOL CELL, V18, P507, DOI 10.1016/j.molcel.2005.04.020; Park H, 1998, P NATL ACAD SCI USA, V95, P6728, DOI 10.1073/pnas.95.12.6728; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHOWALTER RE, 1990, J BACTERIOL, V172, P2946, DOI 10.1128/jb.172.6.2946-2954.1990; Sourjik V, 2004, TRENDS MICROBIOL, V12, P569, DOI 10.1016/j.tim.2004.10.003; Sourjik V, 2004, NATURE, V428, P437, DOI 10.1038/nature02406; Sourjik V, 2002, P NATL ACAD SCI USA, V99, P123, DOI 10.1073/pnas.011589998; SPRINGER WR, 1977, P NATL ACAD SCI USA, V74, P533, DOI 10.1073/pnas.74.2.533; STOCK JB, 1978, P NATL ACAD SCI USA, V75, P3659, DOI 10.1073/pnas.75.8.3659; Surette MG, 1999, P NATL ACAD SCI USA, V96, P1639, DOI 10.1073/pnas.96.4.1639; Svenningsen SL, 2008, GENE DEV, V22, P226, DOI 10.1101/gad.1629908; TERWILLIGER TC, 1984, J BIOL CHEM, V259, P7719; Timmen M, 2006, J BIOL CHEM, V281, P24398, DOI 10.1074/jbc.M604108200; Tu KC, 2007, GENE DEV, V21, P221, DOI 10.1101/gad.1502407; Waters CM, 2005, ANNU REV CELL DEV BI, V21, P319, DOI 10.1146/annurev.cellbio.21.012704.131001; Zhu J, 1999, P NATL ACAD SCI USA, V96, P4832, DOI 10.1073/pnas.96.9.4832; Zhu J, 2001, P NATL ACAD SCI USA, V98, P1507, DOI 10.1073/pnas.98.4.1507	48	70	75	2	30	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 8	2008	134	3					461	473		10.1016/j.cell.2008.06.023	http://dx.doi.org/10.1016/j.cell.2008.06.023			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SO	18692469	Green Accepted, Bronze			2022-12-28	WOS:000258665500019
J	Kushner, HI				Kushner, Howard I.			The art of medicine - Medical historians and the history of medicine	LANCET			English	Editorial Material							LIFE		[Kushner, Howard I.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; [Kushner, Howard I.] Emory Univ, Grad Inst Liberal Arts, Atlanta, GA 30322 USA	Emory University; Rollins School Public Health; Emory University	Kushner, HI (corresponding author), Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.	hkushne@emory.edu						Cooter R, 2007, SOC HIST MED, V20, P441, DOI 10.1093/shm/hkm074; Kushner HI, 2006, B HIST MED, V80, P115, DOI 10.1353/bhm.2006.0025; Kushner HI, 2008, LANCET, V371, P552, DOI 10.1016/S0140-6736(08)60259-7; Osler W, 1892, PRINCIPLES PRACTICE; Pickstone JV, 2005, SOC HIST MED, V18, P307, DOI 10.1093/sochis/hki034	5	17	17	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG-SEP	2008	372	9640					710	711		10.1016/S0140-6736(08)61293-3	http://dx.doi.org/10.1016/S0140-6736(08)61293-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	344YZ	18767211	Bronze			2022-12-28	WOS:000258964500014
J	Caputo, A; Caci, E; Ferrera, L; Pedemonte, N; Barsanti, C; Sondo, E; Pfeffer, U; Ravazzolo, R; Zegarra-Moran, O; Galietta, LJV				Caputo, Antonella; Caci, Emanuela; Ferrera, Loretta; Pedemonte, Nicoletta; Barsanti, Cristina; Sondo, Elvira; Pfeffer, Ulrich; Ravazzolo, Roberto; Zegarra-Moran, Olga; Galietta, Luis J. V.			TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity	SCIENCE			English	Article							CA2+-ACTIVATED CL-CURRENTS; CELL-LINE; TRANSPORT; LUNG	Calcium-dependent chloride channels are required for normal electrolyte and fluid secretion, olfactory perception, and neuronal and smooth muscle excitability. The molecular identity of these membrane proteins is still unclear. Treatment of bronchial epithelial cells with interleukin-4 (IL-4) causes increased calcium-dependent chloride channel activity, presumably by regulating expression of the corresponding genes. We performed a global gene expression analysis to identify membrane proteins that are regulated by IL-4. Transfection of epithelial cells with specific small interfering RNA against each of these proteins shows that TMEM16A, a member of a family of putative plasma membrane proteins with unknown function, is associated with calcium-dependent chloride current, as measured with halide-sensitive fluorescent proteins, short-circuit current, and patch-clamp techniques. Our results indicate that TMEM16A is an intrinsic constituent of the calcium-dependent chloride channel. Identification of a previously unknown family of membrane proteins associated with chloride channel function will improve our understanding of chloride transport physiopathology and allow for the development of pharmacological tools useful for basic research and drug development.	[Caputo, Antonella; Caci, Emanuela; Ferrera, Loretta; Barsanti, Cristina; Sondo, Elvira; Ravazzolo, Roberto; Zegarra-Moran, Olga; Galietta, Luis J. V.] Ist Giannina Gaslini, Genet Mol Lab, I-16148 Genoa, Italy; [Pedemonte, Nicoletta; Galietta, Luis J. V.] Ctr Biotecnol Avanzate, I-16132 Genoa, Italy; [Pfeffer, Ulrich] Natl Inst Canc Res, I-16132 Genoa, Italy	University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; IRCCS AOU San Martino IST	Galietta, LJV (corresponding author), Ist Giannina Gaslini, Genet Mol Lab, I-16148 Genoa, Italy.	galietta@unige.it	Pedemonte, Nicoletta/B-3607-2010; Ferrera, Loretta/AAA-7641-2020; Pfeffer, Ulrich/J-7064-2016; Sondo, Elvira/K-3789-2018; Galietta, Luis JV/HCG-8692-2022; yang, xiao-jun/B-1927-2009; Ferrera, Loretta/AGJ-3063-2022	Pedemonte, Nicoletta/0000-0002-5161-1720; Ferrera, Loretta/0000-0003-0528-1158; Pfeffer, Ulrich/0000-0003-0872-4671; Sondo, Elvira/0000-0003-0971-2082; Galietta, Luis/0000-0001-8686-3461	Telethon Foundation [GGP05103]; Cystic Fibrosis Foundation Therapeutics; Connitato Interministeriale per la Programmazione Economica-Regione Liguria 2007 (Drug Discovery and Delivery); Italian Cystic Fibrosis Foundation	Telethon Foundation(Fondazione Telethon); Cystic Fibrosis Foundation Therapeutics(Italian Cystic Fibrosis Research Foundation); Connitato Interministeriale per la Programmazione Economica-Regione Liguria 2007 (Drug Discovery and Delivery); Italian Cystic Fibrosis Foundation(Ministry of Health, ItalyItalian Cystic Fibrosis Research Foundation)	This study was supported by grants from the Telethon Foundation (GGP05103), Cystic Fibrosis Foundation Therapeutics, Connitato Interministeriale per la Programmazione Economica-Regione Liguria 2007 (Drug Discovery and Delivery), and the Italian Cystic Fibrosis Foundation.	Carew MA, 2000, J BIOL CHEM, V275, P26906; Frings S, 2000, PROG NEUROBIOL, V60, P247, DOI 10.1016/S0301-0082(99)00027-1; Galietta LJV, 2002, J IMMUNOL, V168, P839, DOI 10.4049/jimmunol.168.2.839; GALIETTA LJV, 1994, PFLUG ARCH EUR J PHY, V426, P534, DOI 10.1007/BF00378531; Galietta LJV, 2001, J BIOL CHEM, V276, P19723, DOI 10.1074/jbc.M101892200; Gandhi R, 1998, J BIOL CHEM, V273, P32096, DOI 10.1074/jbc.273.48.32096; Gibson A, 2005, J BIOL CHEM, V280, P27205, DOI 10.1074/jbc.M504654200; Gruber AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1261; Hartzell C, 2005, ANNU REV PHYSIOL, V67, P719, DOI 10.1146/annurev.physiol.67.032003.154341; Huang P, 2001, J BIOL CHEM, V276, P20093, DOI 10.1074/jbc.M009376200; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; KUNZELMANN K, 1993, AM J RESP CELL MOL, V8, P522, DOI 10.1165/ajrcmb/8.5.522; Nilius B, 1997, J PHYSIOL-LONDON, V498, P381, DOI 10.1113/jphysiol.1997.sp021865; Pedemonte N, 2007, J IMMUNOL, V178, P5144, DOI 10.4049/jimmunol.178.8.5144; Qu ZQ, 2003, J BIOL CHEM, V278, P49563, DOI 10.1074/jbc.M308414200; Qu ZQ, 2003, AM J PHYSIOL-RENAL, V285, pF326, DOI 10.1152/ajprenal.00034.2003; Sun H, 2002, P NATL ACAD SCI USA, V99, P4008, DOI 10.1073/pnas.052692999	17	952	1014	1	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	2008	322	5901					590	594		10.1126/science.1163518	http://dx.doi.org/10.1126/science.1163518			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	363WV	18772398				2022-12-28	WOS:000260299100044
J	Evershed, RP; Payne, S; Sherratt, AG; Copley, MS; Coolidge, J; Urem-Kotsu, D; Kotsakis, K; Ozdogan, M; Ozdogan, AE; Nieuwenhuyse, O; Akkermans, PMMG; Bailey, D; Andeescu, RR; Campbell, S; Farid, S; Hodder, I; Yalman, N; Ozbasaran, M; Bicakci, E; Garfinkel, Y; Levy, T; Burton, MM				Evershed, Richard P.; Payne, Sebastian; Sherratt, Andrew G.; Copley, Mark S.; Coolidge, Jennifer; Urem-Kotsu, Duska; Kotsakis, Kostas; Ozdogan, Mehmet; Ozdogan, Asly E.; Nieuwenhuyse, Olivier; Akkermans, Peter M. M. G.; Bailey, Douglass; Andeescu, Radian-Romus; Campbell, Stuart; Farid, Shahina; Hodder, Ian; Yalman, Nurcan; Ozbasaran, Mihriban; Bicakci, Erhan; Garfinkel, Yossef; Levy, Thomas; Burton, Margie M.			Earliest date for milk use in the Near East and southeastern Europe linked to cattle herding	NATURE			English	Article							POTTERY VESSELS; POTSHERDS; PRODUCTS	The domestication of cattle, sheep and goats had already taken place in the Near East by the eighth millennium BC(1-3). Although there would have been considerable economic and nutritional gains from using these animals for their milk and other products from living animals - that is, traction and wool - the first clear evidence for these appears much later, from the late fifth and fourth millennia BC(4,5). Hence, the timing and region in which milking was first practised remain unknown. Organic residues preserved in archaeological pottery(6,7) have provided direct evidence for the use of milk in the fourth millennium in Britain(7-9), and in the sixth millennium in eastern Europe(10), based on the delta(13)C values of the major fatty acids of milk fat(6,7). Here we apply this approach to more than 2,200 pottery vessels from sites in the Near East and southeastern Europe dating from the fifth to the seventh millennia BC. We show that milk was in use by the seventh millennium; this is the earliest direct evidence to date. Milking was particularly important in northwestern Anatolia, pointing to regional differences linked with conditions more favourable to cattle compared to other regions, where sheep and goats were relatively common and milk use less important. The latter is supported by correlations between the fat type and animal bone evidence.	[Evershed, Richard P.; Copley, Mark S.] Univ Bristol, Sch Chem, Organ Geochem Unit, Bristol Biogeochem Res Ctr, Bristol BS8 1TS, Avon, England; [Payne, Sebastian] English Heritage, London EC1N 2ST, England; [Sherratt, Andrew G.] Univ Sheffield, Dept Archaeol, Sheffield S10 2TN, S Yorkshire, England; [Coolidge, Jennifer] Univ Oxford, Archaeol & Hist Art Res Lab, Oxford OX1 3QJ, England; [Urem-Kotsu, Duska; Kotsakis, Kostas] Aristotle Univ Thessaloniki, Dept Archaeol, Thessaloniki 54124, Greece; [Ozdogan, Mehmet; Ozbasaran, Mihriban; Bicakci, Erhan] Istanbul Univ, Prehist Dept, TR-34134 Istanbul, Turkey; [Ozdogan, Asly E.] Canakkale Onsekiz Mart Univ, Dept Archaeol, TR-17020 Canakkale, Turkey; [Nieuwenhuyse, Olivier; Akkermans, Peter M. M. G.] Netherlands Natl Museum Antiqu, NL-2301 EC Leiden, Netherlands; [Nieuwenhuyse, Olivier; Akkermans, Peter M. M. G.] Leiden Univ, NL-2301 EC Leiden, Netherlands; [Bailey, Douglass] Cardiff Univ, Sch Hist & Archaeol, Cardiff CF10 3EU, Wales; [Andeescu, Radian-Romus] Romanian Natl Museum Hist, Bucharest 030026, Romania; [Campbell, Stuart] Univ Manchester, Sch Arts Hist & Cultures, Manchester M13 9PL, Lancs, England; [Farid, Shahina] UCL, Inst Archaeol, London WC1H 0PY, England; [Hodder, Ian] Stanford Univ, Archaeol Ctr, Stanford, CA 94305 USA; [Yalman, Nurcan; Garfinkel, Yossef] Hebrew Univ Jerusalem, Inst Archaeol, IL-91905 Jerusalem, Israel; [Levy, Thomas; Burton, Margie M.] Univ Calif San Diego, Dept Anthropol, La Jolla, CA 92093 USA	University of Bristol; English Heritage; University of Sheffield; University of Oxford; Aristotle University of Thessaloniki; Istanbul University; Canakkale Onsekiz Mart University; Leiden University; Leiden University - Excl LUMC; Cardiff University; University of Manchester; University of London; University College London; Stanford University; Hebrew University of Jerusalem; University of California System; University of California San Diego	Evershed, RP (corresponding author), Univ Bristol, Sch Chem, Organ Geochem Unit, Bristol Biogeochem Res Ctr, Cantocks Close, Bristol BS8 1TS, Avon, England.	r.p.evershed@bristol.ac.uk	Ozbasaran, Mihriban/A-2421-2019; Garfinkel, Yosef/AAE-6626-2021; Bıçakçı, Erhan/AAC-5942-2020; Bailey, Doug/AAI-9709-2021; İriz, Erkan/AAF-2026-2019	Bailey, Doug/0000-0002-1304-8762	Leverhulme Trust [F/00182/T]; UK Natural Environment Research Council	Leverhulme Trust(Leverhulme Trust); UK Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	We thank the Leverhulme Trust for their support (F/00182/T), and the UK Natural Environment Research Council for mass spectromtry facilities.	AILLAUD S, 2000, THESIS U BRISTOL; BOESSNECK J, 1979, TIERKNOCKENFUNDE NEO; Bogucki, 1984, OXFORD J ARCHAEOL, V3, P15, DOI [10.1111/j.1468-0092.1984.tb00113.x, DOI 10.1111/J.1468-0092.1984.TB00113.X]; CHARTERS S, 1993, ARCHAEOMETRY, V35, P211, DOI 10.1111/j.1475-4754.1993.tb01036.x; CHRISTIE WW, 1981, LIPID METABOLISM RUM, P203; Clutton-Brock J., 1999, NATURAL HIST DOMESTI; Colledge S., 1996, ORIGINS SPREAD AGR P, P204; Copley MS, 2005, ANTIQUITY, V79, P895, DOI 10.1017/S0003598X00115029; Copley MS, 2005, J ARCHAEOL SCI, V32, P523, DOI 10.1016/j.jas.2004.08.006; Copley MS, 2003, P NATL ACAD SCI USA, V100, P1524, DOI 10.1073/pnas.0335955100; Craig OE, 2005, ANTIQUITY, V79, P882, DOI 10.1017/S0003598X00115017; Ducos P, 1993, PALEORIENT, V19, P153; Dudd SN, 1998, ORG GEOCHEM, V29, P1345, DOI 10.1016/S0146-6380(98)00093-X; Dudd SN, 1998, SCIENCE, V282, P1478, DOI 10.1126/science.282.5393.1478; EVERSHED RP, 1995, TETRAHEDRON LETT, V36, P8875, DOI 10.1016/0040-4039(95)01844-8; Evershed RP, 1997, ANTIQUITY, V71, P979, DOI 10.1017/S0003598X00085860; FAQUHAR GD, 1989, ANNU REV PLANT PHYS, V40, P503; Grigson C., 1995, ARCHAEOLOGY SOC HOLY; Hansel FA, 2004, TETRAHEDRON LETT, V45, P2999, DOI 10.1016/j.tetlet.2004.01.111; Kohler-Rollefson I., 1992, PASTORALISM LEVANT A, P11; Legge A.J., 1981, FARMING PRACTICE BRI, P169; LEVY TE, 1983, WORLD ARCHAEOL, V15, P15, DOI 10.1080/00438243.1983.9979882; MACDONALD P, 1988, ANIMAL NUTR; Martin L., 2005, MCDONALD I MONOGRAPH, P33; Mukherjee AJ., 2005, ZOOARCHAEOLOGY FATS, P77; Mukherjee AJ, 2007, ANTIQUITY, V81, P743, DOI 10.1017/S0003598X00095703; Payne S., 1973, ANATOL STUD, V23, P281, DOI [10.2307/3642547, DOI 10.2307/3642547]; Richards MP, 2003, J ARCHAEOL SCI, V30, P67, DOI 10.1006/jasc.2001.0825; SHERRATT A, 1983, WORLD ARCHAEOL, V15, P90, DOI 10.1080/00438243.1983.9979887; Sherratt A. G., 1981, PATTERN OF THE PAST, P261	30	366	377	6	123	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 25	2008	455	7212					528	531		10.1038/nature07180	http://dx.doi.org/10.1038/nature07180			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	351TU	18690215				2022-12-28	WOS:000259449600045
J	von Ahn, L; Maurer, B; McMillen, C; Abraham, D; Blum, M				von Ahn, Luis; Maurer, Benjamin; McMillen, Colin; Abraham, David; Blum, Manuel			reCAPTCHA: Human-based character recognition via web security measures	SCIENCE			English	Article								CAPTCHAs ( Completely Automated Public Turing test to tell Computers and Humans Apart) are widespread security measures on the World Wide Web that prevent automated programs from abusing online services. They do so by asking humans to perform a task that computers cannot yet perform, such as deciphering distorted characters. Our research explored whether such human effort can be channeled into a useful purpose: helping to digitize old printed material by asking users to decipher scanned words from books that computerized optical character recognition failed to recognize. We showed that this method can transcribe text with a word accuracy exceeding 99%, matching the guarantee of professional human transcribers. Our apparatus is deployed in more than 40,000 Web sites and has transcribed over 440 million words.	[von Ahn, Luis; Maurer, Benjamin; McMillen, Colin; Abraham, David; Blum, Manuel] Carnegie Mellon Univ, Dept Comp Sci, Pittsburgh, PA 15213 USA	Carnegie Mellon University	von Ahn, L (corresponding author), Carnegie Mellon Univ, Dept Comp Sci, 5000 Forbes Ave, Pittsburgh, PA 15213 USA.	biglou@cs.cmu.edu			Heinz Endowment and the Fine Foundation; Intel Corporation; New York Times Company; Army Research Office [DAAD19-02-1-0389]; Microsoft Research New Faculty Fellowship; MacArthur Fellowship	Heinz Endowment and the Fine Foundation; Intel Corporation(Intel Corporation); New York Times Company; Army Research Office; Microsoft Research New Faculty Fellowship(Microsoft); MacArthur Fellowship	This work was partially supported by gifts from the Heinz Endowment and the Fine Foundation, by an equipment grant from Intel Corporation and a research grant from the New York Times Company, and by the Army Research Office through grant number DAAD19-02-1-0389 to CyLab at Carnegie Mellon University. L.v.A. was partially supported by a Microsoft Research New Faculty Fellowship and a MacArthur Fellowship. L.v.A. is cofounder, president, and chief executive officer of reCAPTCHA, a free CAPTCHA service that helps to digitize books. B.M., C.M., D.A., and M.B. are also cofounders of reCAPTCHA. L.v.A., B.M., and M B. have filed a patent related to the technology described in this paper.	*ADV RES INC, DAT COLL SERV QUAL C; CHELLAPILLA K, 2005, P SIGCHI C HUM FACT, P711; CHELLAPILLA K, 2005, ADV NEURAL INFORM PR, V17, P265; Elson J, 2007, CCS'07: PROCEEDINGS OF THE 14TH ACM CONFERENCE ON COMPUTER AND COMMUNICATIONS SECURITY, P366; Kanungo T, 2004, IEEE T PATTERN ANAL, V26, P520, DOI 10.1109/TPAMI.2004.1265867; LONG FA, 1993, AM J ECON SOCIOL, V52, P223, DOI 10.1111/j.1536-7150.1993.tb02536.x; Mori G, 2003, PROC CVPR IEEE, P134; Thayananthan A, 2003, PROC CVPR IEEE, P127; von Ahn L, 2004, COMMUN ACM, V47, P57, DOI 10.1145/966389.966390; von Ahn L, 2003, LECT NOTES COMPUT SC, V2656, P294; von Ahn L, 2006, COMPUTER, V39, P92, DOI 10.1109/MC.2006.196; Von Ahn Luis, 2004, P SIGCHI C HUM FACT, P319, DOI DOI 10.1145/985692.985733; VONAHN L, 2004, P SIGCHI C HUM FACT, P55; 2008, ECONOMIST, V387, P105	14	527	557	4	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 12	2008	321	5895					1465	1468		10.1126/science.1160379	http://dx.doi.org/10.1126/science.1160379			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347DW	18703711	Green Submitted			2022-12-28	WOS:000259121800033
J	Kepecs, A; Uchida, N; Zariwala, HA; Mainen, ZF				Kepecs, Adam; Uchida, Naoshige; Zariwala, Hatim A.; Mainen, Zachary F.			Neural correlates, computation and behavioural impact of decision confidence	NATURE			English	Article							ORBITOFRONTAL CORTEX; PREFRONTAL CORTEX; MATCHING BEHAVIOR; REWARD PREFERENCE; NEURONAL-ACTIVITY; UNCERTAINTY; REPRESENTATION; MODELS; PERFORMANCE; AMYGDALA	Humans and other animals must often make decisions on the basis of imperfect evidence(1,2). Statisticians use measures such as P values to assign degrees of confidence to propositions, but little is known about how the brain computes confidence estimates about decisions. We explored this issue using behavioural analysis and neural recordings in rats in combination with computational modelling. Subjects were trained to perform an odour categorization task that allowed decision confidence to be manipulated by varying the distance of the test stimulus to the category boundary. To understand how confidence could be computed along with the choice itself, using standard models of decision-making(3-6), we defined a simple measure that quantified the quality of the evidence contributing to a particular decision. Here we show that the firing rates of many single neurons in the orbitofrontal cortex match closely to the predictions of confidence models and cannot be readily explained by alternative mechanisms, such as learning stimulus - outcome associations(7-10). Moreover, when tested using a delayed reward version of the task, we found that rats' willingness to wait for rewards increased with confidence, as predicted by the theoretical model. These results indicate that confidence estimates, previously suggested to require 'metacognition'(11,12) and conscious awareness(13,14), are available even in the rodent brain, can be computed with relatively simple operations, and can drive adaptive behaviour. We suggest that confidence estimation may be a fundamental and ubiquitous component of decision- making.	[Kepecs, Adam; Uchida, Naoshige; Zariwala, Hatim A.; Mainen, Zachary F.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Uchida, Naoshige] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; [Uchida, Naoshige] Harvard Univ, Ctr Brain Sci, Cambridge, MA 02138 USA; [Zariwala, Hatim A.] Allen Inst Brain Sci, Seattle, WA 98103 USA; [Mainen, Zachary F.] Gulbenkian Inst Sci, Champalimaud Neurosci Programme, P-2780901 Oeiras, Portugal	Cold Spring Harbor Laboratory; Harvard University; Harvard University; Allen Institute for Brain Science; Fundacao Champalimaud	Kepecs, A (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	kepecs@cshl.edu; zmainen@igc.gulbenkian.pt		Uchida, Naoshige/0000-0002-5755-9409; Kepecs, Adam/0000-0003-0049-8120; Mainen, Zachary/0000-0001-7913-9109	National Institutes of Health (NIDCD); Center for the Neural Mechanisms of Cognition at Cold Spring Harbor Laboratory; Swartz Foundation	National Institutes of Health (NIDCD)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); Center for the Neural Mechanisms of Cognition at Cold Spring Harbor Laboratory; Swartz Foundation	We thank J. Paton, A. Pouget, S. Raghavachari, G. Turner and members of the Mainen laboratory for comments on the manuscript. Support was provided by the National Institutes of Health (NIDCD) (Z.F.M.), the Center for the Neural Mechanisms of Cognition at Cold Spring Harbor Laboratory (Z.F.M.), and the Swartz Foundation (A.K., N.U., Z.F.M).	[Anonymous], 1982, JUDGMENT UNCERTAINTY; Barraclough DJ, 2004, NAT NEUROSCI, V7, P404, DOI 10.1038/nn1209; Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293; Behrens TEJ, 2007, NAT NEUROSCI, V10, P1214, DOI 10.1038/nn1954; Bogacz R, 2006, PSYCHOL REV, V113, P700, DOI 10.1037/0033-295X.113.4.700; Critchley HD, 2001, NEURON, V29, P537, DOI 10.1016/S0896-6273(01)00225-2; Davidson A.C., 1997, BOOTSTRAP METHODS TH; Daw ND, 2006, NATURE, V441, P876, DOI 10.1038/nature04766; Dayan P, 2000, NAT NEUROSCI, V3, P1218, DOI 10.1038/81504; Efron B., 1994, MONOGRAPHS STAT APPL; Feierstein CE, 2006, NEURON, V51, P495, DOI 10.1016/j.neuron.2006.06.032; Foote AL, 2007, CURR BIOL, V17, P551, DOI 10.1016/j.cub.2007.01.061; Glimcher PW, 2003, BRADFORD BOOKS, P1; Gottfried JA, 2003, SCIENCE, V301, P1104, DOI 10.1126/science.1087919; Grinband J, 2006, NEURON, V49, P757, DOI 10.1016/j.neuron.2006.01.032; Hampton RR, 2001, P NATL ACAD SCI USA, V98, P5359, DOI 10.1073/pnas.071600998; Hansen P.C., 1998, RANK DEFICIENT DISCR; Hikosaka K, 2000, CEREB CORTEX, V10, P263, DOI 10.1093/cercor/10.3.263; Hsu M, 2005, SCIENCE, V310, P1680, DOI 10.1126/science.1115327; Keren G, 1997, J BEHAV DECIS MAKING, V10, P269, DOI 10.1002/(SICI)1099-0771(199709)10:3<269::AID-BDM281>3.0.CO;2-L; Kim JN, 1999, NAT NEUROSCI, V2, P176, DOI 10.1038/5739; Knill DC, 2004, TRENDS NEUROSCI, V27, P712, DOI 10.1016/j.tins.2004.10.007; Koch C, 2007, NAT NEUROSCI, V10, P140, DOI 10.1038/nn0207-140; Lau B, 2005, J EXP ANAL BEHAV, V84, P555, DOI 10.1901/jeab.2005.110-04; Laubach M, 2000, NATURE, V405, P567, DOI 10.1038/35014604; Luck SJ, 1996, J EXP PSYCHOL HUMAN, V22, P725, DOI 10.1037/0096-1523.22.3.725; Mazurek ME, 2003, CEREB CORTEX, V13, P1257, DOI 10.1093/cercor/bhg097; Padoa-Schioppa C, 2006, NATURE, V441, P223, DOI 10.1038/nature04676; Persaud N, 2007, NAT NEUROSCI, V10, P257, DOI 10.1038/nn1840; Ratcliff R, 2004, PSYCHOL REV, V111, P333, DOI 10.1037/0033-295X.111.2.333; Roesch MR, 2006, NEURON, V51, P509, DOI 10.1016/j.neuron.2006.06.027; Schoenbaum G, 1998, NAT NEUROSCI, V1, P155, DOI 10.1038/407; Simmons JM, 2007, ANN NY ACAD SCI, V1121, P376, DOI 10.1196/annals.1401.028; Smith J.D., 2003, BEHAV BRAIN SCI, V26, P340; Smith JD, 2003, BEHAV BRAIN SCI, V26, P317; Stephens D.W., 1986, pi; Sugrue LP, 2004, SCIENCE, V304, P1782, DOI 10.1126/science.1094765; Tobler PN, 2007, J NEUROPHYSIOL, V97, P1621, DOI 10.1152/jn.00745.2006; Tremblay L, 1999, NATURE, V398, P704, DOI 10.1038/19525; Uchida N, 2003, NAT NEUROSCI, V6, P1224, DOI 10.1038/nn1142; Wallis JD, 2003, EUR J NEUROSCI, V18, P2069, DOI 10.1046/j.1460-9568.2003.02922.x; Wallis JD, 2007, ANNU REV NEUROSCI, V30, P31, DOI 10.1146/annurev.neuro.30.051606.094334; Yu AJ, 2005, NEURON, V46, P681, DOI 10.1016/j.neuron.2005.04.026	43	509	513	4	106	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 11	2008	455	7210					227	U55		10.1038/nature07200	http://dx.doi.org/10.1038/nature07200			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	346SZ	18690210				2022-12-28	WOS:000259090800048
J	Schuster, MA; Chung, PJ; Elliott, MN; Garfield, CF; Vestal, KD; Klein, DJ				Schuster, Mark A.; Chung, Paul J.; Elliott, Marc N.; Garfield, Craig F.; Vestal, Katherine D.; Klein, David J.			Awareness and use of california's paid family leave insurance among parents of chronically ill children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE; PROFILE; NEEDS; CLASSIFICATION; EXPENDITURES; PATTERNS	Context In 2004, California's Paid Family Leave Insurance Program ( PFLI) became the first state program to provide paid leave to care for an ill family member. Objective To assess awareness and use of the program by employed parents of children with special health care needs, a population likely to need leave. Design, Setting, and Participants Telephone interviews with successive cohorts of employed parents before ( November 21, 2003- January 31, 2004; n= 754) and after ( November 18, 2005- January 31, 2006; n= 766) PFLI began, randomly sampled from 2 children's hospitals, one in California ( with PFLI) and the other in Illinois ( without PFLI). Response rates were 82% before and 81% after ( California), and 80% before and 74% after ( Illinois). Main Outcome Measures Taking leave, length of leave, unmet need for leave, and awareness and use of PFLI. Results Similar percentages of parents at the California site reported taking at least 1 day of leave to care for their ill child before ( 295 [ 81%]) and after ( 327 [ 79%]) PFLI, taking at least 4 weeks before ( 64 [ 21%]) and after ( 74 [ 19%]) PFLI, and at least once in the past year not missing work despite believing their child's illness necessitated it before ( 152 [ 41%]) and after ( 156 [ 41%]) PFLI. Relative to Illinois, parents at the California site reported no change from before to after PFLI in taking at least 1 day of leave ( difference of differences, - 3%; 95% confidence interval [ CI], - 13% to 7%); taking at least 4 weeks of leave ( 1%; 95% CI, - 9% to 10%); or not missing work, despite believing their child's illness necessitated it (- 1%; 95% CI, - 13% to 10%). Only 77 parents ( 18%) had heard of PFLI approximately 18 months after the program began, and only 20 ( 5%) had used it. Even among parents without other access to paid leave, awareness and use of PFLI were minimal. Conclusions Parents of children with special health care needs receiving care at a California hospital were generally unaware of PFLI and rarely used it. Among parents of children with special health care needs, taking leave in California did not increase after PFLI implementation compared with Illinois.	[Schuster, Mark A.; Chung, Paul J.; Elliott, Marc N.; Klein, David J.] RAND Corp, Santa Monica, CA USA; [Schuster, Mark A.; Chung, Paul J.; Vestal, Katherine D.] Univ Calif Los Angeles, Dept Pediat, Mattel Childrens Hosp, David Geffen Sch Med, Los Angeles, CA 90024 USA; [Schuster, Mark A.] Univ Calif Los Angeles, Dept Hlth Serv, Sch Publ Hlth, Los Angeles, CA 90024 USA; [Garfield, Craig F.] Northwestern Univ, Feinberg Sch Med, Dept Pediat, Evanston Northwestern Healthcare, Evanston, IL USA	RAND Corporation; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; NorthShore University Health System; Northwestern University; Feinberg School of Medicine	Schuster, MA (corresponding author), Childrens Hosp, Dept Med, 300 Longwood Ave, Boston, MA 02115 USA.	mark.schuster@childrens.harvard.edu	Garfield, Craig/AAE-2525-2020	Garfield, Craig/0000-0002-6512-6005	National Institutes of Health [R21 HD052586]; Centers for Disease Control and Prevention [U48/DP000056]; RAND Health; RAND Institute for Civil Justice, and the California Endowment; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R21HD052586] Funding Source: NIH RePORTER; NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMO [U48DP000056] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); RAND Health; RAND Institute for Civil Justice, and the California Endowment; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMO(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	This study was supported in part by grants R21 HD052586 from the National Institutes of Health and U48/DP000056 from the Centers for Disease Control and Prevention, RAND Health, RAND Institute for Civil Justice, and the California Endowment.	*AM ASS PUBL OP RE, AAPOR OUTC RAT CALC; *CAL EMPL DEV DEP, DIS INS DI PROGR; CANTOR D, 2001, BALANCING NEEDS FAMI; Chan KS, 2005, MED CARE, V43, P256, DOI 10.1097/00005650-200503000-00008; Chen GY, 2008, ELECTRON J PROBAB, V13, P26, DOI 10.1214/EJP.v13-474; Chung PJ, 2007, PEDIATRICS, V119, pE1047, DOI 10.1542/peds.2006-2337; Coleman WL, 2004, PEDIATRICS, V113, P1406, DOI 10.1542/peds.113.5.1406; *COMM FAMMED LEAV, 1996, WORK BAL REP C FAM M; Currie J, 2002, J HEALTH ECON, V21, P313, DOI 10.1016/S0167-6296(01)00125-4; Daponte BO, 1999, J HUM RESOUR, V34, P612, DOI 10.2307/146382; Davidoff AJ, 2004, PEDIATRICS, V114, P394, DOI 10.1542/peds.114.2.394; Ferris TGG, 2001, PEDIATRICS, V108, P283, DOI 10.1542/peds.108.2.283; Gay JC, 1997, PEDIATR ANN, V26, P655, DOI 10.3928/0090-4481-19971101-07; Han WJ, 2003, DEMOGRAPHY, V40, P191, DOI 10.1353/dem.2003.0003; HEALY P, CLINTON PROPOSES BIG; Heymann SJ, 1996, PEDIATRICS, V98, P226; Hwang W, 2001, AMBUL PEDIATR, V1, P217, DOI 10.1367/1539-4409(2001)001<0217:CORAFM>2.0.CO;2; Kuhlthau KA, 2002, AMBUL PEDIATR, V2, P58, DOI 10.1367/1539-4409(2002)002<0058:CADLWA>2.0.CO;2; Little R. J. A., 1987, STAT ANAL MISSING DA; Muldoon J H, 1997, J Ambul Care Manage, V20, P1; *NAT ASS CHILDR HO, 2007, ALL CHILDR NEED CHIL; *NAT PARTN WOM FAM, 1921, STAT LOC ACT PAID FA; Neff JM, 2004, HEALTH SERV RES, V39, P73, DOI 10.1111/j.1475-6773.2004.00216.x; Neff JM, 2003, PEDIATRICS, V112, P691; Neff JM, 2002, AMBUL PEDIATR, V2, P71, DOI 10.1367/1539-4409(2002)002<0071:IACCWC>2.0.CO;2; Newacheck PW, 1998, PEDIATRICS, V102, P117, DOI 10.1542/peds.102.1.117; Newacheck PW, 2005, ARCH PEDIAT ADOL MED, V159, P10, DOI 10.1001/archpedi.159.1.10; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Perrin JM, 2007, HEALTH AFFAIR, V26, P1096, DOI 10.1377/hlthaff.26.4.1096; Perrin JM, 1999, ARCH PEDIAT ADOL MED, V153, P80; Royston P, 2004, STATA J, V4, P227, DOI 10.1177/1536867X0400400301; SCHUSTER MA, IN PRESS AM J PUBLIC; Shone LP, 2005, CURR OPIN PEDIATR, V17, P764, DOI 10.1097/01.mop.0000187192.74295.4c; Stein REK, 2002, AMBUL PEDIATR, V2, P63, DOI 10.1367/1539-4409(2002)002<0063:CDDOCC>2.0.CO;2; Stein REK, 2001, AMBUL PEDIATR, V1, P280, DOI 10.1367/1539-4409(2001)001<0280:CILTHC>2.0.CO;2; Sun GW, 1996, J CLIN EPIDEMIOL, V49, P907, DOI 10.1016/0895-4356(96)00025-X; *US BUR CENS, BEARFACTS ILL 1996 2; *US BUR CENS, BEARFACTS CAL 1996 2; *US BUR LAB STAT, ILL GLANC; *US BUR LAB STAT, 2007, NAT COMP SURV EMPL B; *US BUR LAB STAT, CAL GLANC; *US BUR LAB STAT, EMPL NONF PAYR STAT; *US DEP HHS, 2004, NAT SURV CHILDR SPEC; van Dyck PC, 2004, ARCH PEDIAT ADOL MED, V158, P884, DOI 10.1001/archpedi.158.9.884; Varni JW, 2003, AMBUL PEDIATR, V3, P329, DOI 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2	45	22	22	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	2008	300	9					1047	1055		10.1001/jama.300.9.1047	http://dx.doi.org/10.1001/jama.300.9.1047			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	342YN	18768416	Bronze, Green Accepted			2022-12-28	WOS:000258819600021
J	Ripley, TL; Harrison, D				Ripley, Toni L.; Harrison, Donald			The power to TRANSCEND	LANCET			English	Editorial Material							CORONARY-ARTERY-DISEASE; CHRONIC HEART-FAILURE; CARDIOVASCULAR EVENTS; HIGH-RISK; TRIAL; HYPERTENSION; CANDESARTAN; INHIBITORS; REDUCTION; MORBIDITY		[Ripley, Toni L.; Harrison, Donald] Univ Oklahoma, Coll Pharm, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Ripley, TL (corresponding author), Univ Oklahoma, Coll Pharm, Oklahoma City, OK 73190 USA.	toni-ripley@ouhsc.edu						Braunwald E, 2004, NEW ENGL J MED, V351, P2058; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Fox KM, 2003, LANCET, V362, P782; Granger CB, 2003, LANCET, V362, P772, DOI 10.1016/S0140-6736(03)14284-5; Jorde UP, 2000, CIRCULATION, V101, P844, DOI 10.1161/01.CIR.101.8.844; KAHN N, 2006, CMAJ, V174, P1737; McKelvie RS, 1999, CIRCULATION, V100, P1056, DOI 10.1161/01.CIR.100.10.1056; Mochizuki S, 2007, LANCET, V369, P1431, DOI 10.1016/S0140-6736(07)60669-2; *TRANSCEND INV, 2008, LANCET          0831; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Yusuf S, 2008, NEW ENGL J MED, V358, P1547, DOI 10.1056/NEJMoa0801317	11	7	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP-OCT	2008	372	9644					1128	1130		10.1016/S0140-6736(08)61243-X	http://dx.doi.org/10.1016/S0140-6736(08)61243-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	355UN	18757086				2022-12-28	WOS:000259734700007
J	Curatolo, P; Bombardieri, R; Jozwiak, S				Curatolo, Paolo; Bombardieri, Roberta; Jozwiak, Sergiusz			Tuberous sclerosis	LANCET			English	Review							GIANT-CELL ASTROCYTOMA; POLYCYSTIC KIDNEY-DISEASE; VISUAL-EVOKED POTENTIALS; GAP-RELATED DOMAIN; RENAL ANGIOMYOLIPOMA; MUTATIONAL ANALYSIS; EPILEPSY SURGERY; CARDIAC RHABDOMYOMAS; CONSENSUS CONFERENCE; EPILEPTOGENIC TUBER	Tuberous sclerosis is a genetic multisystern disorder characterised by widespread hamartomas in several organs, including the brain, heart, skin, eyes, kidney, lung, and liver. The affected genes are TSC1 and TSC2, encoding hamartin and tuberin respectively. The hamartin-tuberin complex inhibits the mammalian-target-of-rapamycin pathway, which controls cell growth and proliferation. Variations in the distribution, number, size, and location of lesions cause the clinical syndrome to vary, even between relatives. Most features of tuberous sclerosis become evident only in childhood after 3 years of age, limiting their usefulness for early diagnosis. Identification of patients at risk for severe manifestations is crucial. Increasing understanding of the molecular abnormalities caused by tuberous sclerosis may enable improved management of this disease.	[Curatolo, Paolo; Bombardieri, Roberta] Univ Roma Tor Vergata, Pediat Neurol Unit, Dept Neurosci, I-00133 Rome, Italy; [Jozwiak, Sergiusz] Childrens Mem Hlth Inst, Dept Neurol & Epileptol, Warsaw, Poland	University of Rome Tor Vergata; Children's Memorial Health Institute	Curatolo, P (corresponding author), Univ Roma Tor Vergata, Pediat Neurol Unit, Dept Neurosci, Via Montpellier 1, I-00133 Rome, Italy.	curatolo@uniroma2.it		Jozwiak, Sergiusz/0000-0003-3350-6326				An KS, 2007, GENET MED, V9, P88, DOI 10.1097/GIM.0b013e31803068c7; Astrinidis A, 2005, ONCOGENE, V24, P7475, DOI 10.1038/sj.onc.1209090; Astrinidis A, 2002, ONCOGENE, V21, P8470, DOI 10.1038/sj.onc.1205962; Aubry MC, 2000, AM J RESP CRIT CARE, V162, P749, DOI 10.1164/ajrccm.162.2.9911006; Avila NA, 2007, RADIOLOGY, V242, P277, DOI 10.1148/radiol.2421051767; Bader RS, 2003, J PEDIATR-US, V143, P620, DOI 10.1067/S0022-3476(03)00494-3; Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564; Bjornsson J, 1996, AM J PATHOL, V149, P1201; Bourneville D., 1880, ARCH NEUROL-CHICAGO, V1, P81; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; BRUNI O, 1995, BRAIN DEV-JPN, V17, P52, DOI 10.1016/0387-7604(94)00118-H; Calcagnotto ME, 2005, J NEUROSCI, V25, P9649, DOI 10.1523/JNEUROSCI.2687-05.2005; Carbonara C, 1996, GENE CHROMOSOME CANC, V15, P18, DOI 10.1002/(SICI)1098-2264(199601)15:1<18::AID-GCC3>3.0.CO;2-7; Carsillo T, 2000, P NATL ACAD SCI USA, V97, P6085, DOI 10.1073/pnas.97.11.6085; Chan JA, 2004, J NEUROPATH EXP NEUR, V63, P1236, DOI 10.1093/jnen/63.12.1236; CHIRON C, 1990, LANCET, V335, P363, DOI 10.1016/0140-6736(90)90660-W; Choi JE, 2006, BRAIN DEV-JPN, V28, P440, DOI 10.1016/j.braindev.2006.01.006; Chugani DC, 1998, ANN NEUROL, V44, P858, DOI 10.1002/ana.410440603; CONNOR JM, 1986, LANCET, V2, P1275; Crino PB, 2006, NEW ENGL J MED, V355, P1345, DOI 10.1056/NEJMra055323; Curatolo P, 2006, CURR OPIN NEUROL, V19, P119, DOI 10.1097/01.wco.0000218225.50807.12; Curatolo P, 2005, J CHILD NEUROL, V20, P318, DOI 10.1177/08830738050200040901; Curatolo P, 2004, EUR J PAEDIATR NEURO, V8, P327, DOI 10.1016/j.ejpn.2004.08.005; Curatolo P, 2001, BRAIN DEV-JPN, V23, P649, DOI 10.1016/S0387-7604(01)00290-X; Curatolo P, 2001, BRAIN DEV-JPN, V23, P502, DOI 10.1016/S0387-7604(01)00300-X; CURATOLO P, 1993, LANCET, V341, P176; CURATOLO P, 2003, TUBEROUS SCLEROSIS C; CURATOLO P, 1991, ANN NY ACAD SCI, V615, P8; Curatolo Paolo, 2002, Eur J Paediatr Neurol, V6, P15, DOI 10.1053/ejpn.2001.0538; CUSMAI R, 1990, EPILEPSIA, V31, P747, DOI 10.1111/j.1528-1157.1990.tb05516.x; Dabora SL, 2002, AM J HUM GENET, V71, P750, DOI 10.1086/342718; Dabora SL, 2001, AM J HUM GENET, V68, P64, DOI 10.1086/316951; de Ribaupierre S, 2007, NEUROSURGERY, V60, P83, DOI 10.1227/01.NEU.0000249216.19591.5D; de Vries P, 2005, EUR CHILD ADOLES PSY, V14, P183, DOI 10.1007/s00787-005-0443-1; de Vries PJ, 2007, EUR CHILD ADOLES PSY, V16, P16, DOI 10.1007/s00787-006-0570-3; Deonna T, 2007, DEV MED CHILD NEUROL, V49, P320; Devlin LA, 2006, DEV MED CHILD NEUROL, V48, P495, DOI 10.1017/S0012162206001058; DiMario FJ, 2004, J CHILD NEUROL, V19, P650, DOI 10.1177/08830738040190090401; DiMario FJ, 1996, CLIN PEDIATR, V35, P615, DOI 10.1177/000992289603501202; Ellisen LW, 2005, CELL CYCLE, V4, P1500, DOI 10.4161/cc.4.11.2139; Ewalt DH, 2005, J UROLOGY, V174, P1764, DOI 10.1097/01.ju.0000177497.31986.64; Ewalt DH, 1998, J UROLOGY, V160, P141, DOI 10.1016/S0022-5347(01)63072-6; Finlay GA, 2004, J BIOL CHEM, V279, P23114, DOI 10.1074/jbc.M401912200; Flanagan N, 1997, J MED GENET, V34, P637, DOI 10.1136/jmg.34.8.637; FLEURY P, 1987, FORTSCHR RONTG NEUEN, V146, P694, DOI 10.1055/s-2008-1048567; Franz DN, 2006, ANN NEUROL, V59, P490, DOI 10.1002/ana.20784; FRYER AE, 1987, LANCET, V1, P659; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Goh S, 2004, NEUROLOGY, V63, P1457, DOI 10.1212/01.wnl.0000142039.14522.1a; Gomez M. R., 1999, TUBEROUS SCLEROSIS C; Goncharova EA, 2006, AM J RESP CELL MOL, V34, P473, DOI 10.1165/rcmb.2005-0374OC; Hall MR, 2007, CUTIS, V80, P284; Hancock E, 1999, J CHILD NEUROL, V14, P71, DOI 10.1177/088307389901400201; Hancock E, 2002, RESP MED, V96, P1, DOI 10.1053/rmed.2001.1207; Harding GFA, 2000, NEUROLOGY, V55, P347, DOI 10.1212/WNL.55.3.347; Harding GFA, 2002, NEUROLOGY, V58, P1261, DOI 10.1212/WNL.58.8.1261; Harding GFA, 2000, EPILEPSIA, V41, P1420, DOI 10.1111/j.1528-1157.2000.tb00117.x; Harrison JE, 1999, AM J MED GENET, V88, P642, DOI 10.1002/(SICI)1096-8628(19991215)88:6<642::AID-AJMG12>3.0.CO;2-O; Henske EP, 1997, AM J PATHOL, V151, P1639; Herry I, 2007, EUR J INTERN MED, V18, P76, DOI 10.1016/j.ejim.2006.07.017; Humphrey A, 2004, NEUROLOGY, V62, P795, DOI 10.1212/01.WNL.0000113745.58425.EF; Humphrey A, 2006, DEV MED CHILD NEUROL, V48, P609, DOI 10.1017/S0012162206001277; Hung CC, 2006, BMC MED GENET, V7, DOI 10.1186/1471-2350-7-72; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; JAMBAQUE I, 1991, DEV MED CHILD NEUROL, V33, P698; Jambaque I, 2000, EPILEPSY RES, V38, P151, DOI 10.1016/S0920-1211(99)00082-0; Jansen AC, 2006, ANN NEUROL, V60, P528, DOI 10.1002/ana.21037; Jansen FE, 2006, EPILEPSIA, V47, P108, DOI 10.1111/j.1528-1167.2006.00373.x; Jansen FE, 2005, EPILEPSIA, V46, P415, DOI 10.1111/j.0013-9580.2005.31704.x; Jansen FE, 2003, ARCH NEUROL-CHICAGO, V60, P1580, DOI 10.1001/archneur.60.11.1580; Jansen FE, 2007, EPILEPSIA, V48, P1477, DOI 10.1111/j.1528-1167.2007.01117.x; Jansen LA, 2005, EPILEPSIA, V46, P1871, DOI 10.1111/j.1528-1167.2005.00289.x; Joinson C, 2003, PSYCHOL MED, V33, P335, DOI 10.1017/S0033291702007092; Jones AC, 1999, AM J HUM GENET, V64, P1305, DOI 10.1086/302381; Jozwiak J, 2005, NEUROMOL MED, V7, P287, DOI 10.1385/NMM:7:4:287; Jozwiak J, 2006, MED RES REV, V26, P160, DOI 10.1002/med.20049; JOZWIAK S, 1994, EUR J PEDIATR, V153, P155, DOI 10.1007/s004310050110; Jozwiak S, 2000, J CHILD NEUROL, V15, P652, DOI 10.1177/088307380001501003; Jozwiak S, 2005, J CHILD NEUROL, V20, P988, DOI 10.1177/08830738050200121101; Jozwiak S, 1998, INT J DERMATOL, V37, P911; JOZWIAK S, 1992, LANCET, V339, P180; JOZWIAK S, 1992, ARCH DIS CHILD, V67, P1363, DOI 10.1136/adc.67.11.1363; Jozwiak S, 2006, PEDIATRICS, V118, pE1146, DOI 10.1542/peds.2006-0504; Jurkiewicz E, 2006, PEDIATR RADIOL, V36, P463, DOI 10.1007/s00247-005-0092-z; KANDT RS, 1992, NAT GENET, V2, P37, DOI 10.1038/ng0992-37; Karbowniczek M, 2003, AM J RESP CRIT CARE, V167, P976, DOI 10.1164/rccm.200208-969OC; Kaur S, 2007, J BIOL CHEM, V282, P1757, DOI 10.1074/jbc.M607365200; Khanna PC, 2005, NEUROL INDIA, V53, P349, DOI 10.4103/0028-3886.16942; Khare L, 2001, J MED GENET, V38, P347, DOI 10.1136/jmg.38.5.347; Kothary N, 2005, J VASC INTERV RADIOL, V16, P45, DOI 10.1079/01.RVI.0000143769.79774.70; Kozlowski P, 2007, HUM GENET, V121, P389, DOI 10.1007/s00439-006-0308-9; Kwiatkowska J, 1999, NEW ENGL J MED, V340, P703, DOI 10.1056/NEJM199903043400905; Kwiatkowski DJ, 2005, HUM MOL GENET, V14, pR251, DOI 10.1093/hmg/ddi260; LAGOS JC, 1967, MAYO CLIN PROC, V42, P26; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Langkau N, 2002, EUR J PEDIATR, V161, P393, DOI 10.1007/s00431-001-0903-7; Lee L, 2006, GENE CHROMOSOME CANC, V45, P933, DOI 10.1002/gcc.20357; Lendvay TS, 2003, J UROLOGY, V169, P1635, DOI 10.1097/01.ju.0000058253.40352.60; Lortie A, 2002, EPILEPSY RES, V51, P133, DOI 10.1016/S0920-1211(02)00102-X; Luat AF, 2007, CURR OPIN NEUROL, V20, P142, DOI 10.1097/WCO.0b013e3280895d93; Maheshwar MM, 1997, HUM MOL GENET, V6, P1991, DOI 10.1093/hmg/6.11.1991; Marcotte L, 2006, NEUROMOL MED, V8, P531, DOI 10.1385/NMM:8:4:531; Mayer K, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.010835; McCormack FX, 2007, AM J RESP CRIT CARE, V176, P3, DOI 10.1164/rccm.200703-514ED; Mennel S, 2007, ACTA OPHTHALMOL SCAN, V85, P127, DOI 10.1111/j.1600-0420.2006.00781.x; Miyake Mototaka, 2005, Radiat Med, V23, P525; Moolten SE, 1942, ARCH INTERN MED, V69, P589, DOI 10.1001/archinte.1942.00200160040005; Nabbout R, 1999, J NEUROL NEUROSUR PS, V66, P370, DOI 10.1136/jnnp.66.3.370; NELLIST M, 1993, CELL, V75, P1305; O'Callaghan FJ, 2004, BJU INT, V94, P853, DOI 10.1111/j.1464-410X.2004.05046.x; O'Callaghan FJK, 1998, LANCET, V351, P1490, DOI 10.1016/S0140-6736(05)78872-3; OCALLAGHAN FJ, 2001, J CHILD NEUROL, V16, P678; OSBORNE JP, 1991, ANN NY ACAD SCI, V615, P125; Parisi P, 2007, EUR J PAEDIATR NEURO, V11, P331, DOI 10.1016/j.ejpn.2007.03.010; Peresson M, 1998, BRAIN DEV-JPN, V20, P512, DOI 10.1016/S0387-7604(98)00034-5; Prather P, 2004, J CHILD NEUROL, V19, P666, DOI 10.1177/08830738040190090601; Raju GP, 2007, PEDIATR NEUROL, V36, P128, DOI 10.1016/j.pediatrneurol.2006.08.009; Rakowski SK, 2006, KIDNEY INT, V70, P1777, DOI 10.1038/sj.ki.5001853; Rauktys A, 2008, BMC DERMATOL, V8, DOI 10.1186/1471-5945-8-1; Raznahan A, 2007, PSYCHOL MED, V37, P1293, DOI 10.1017/S0033291707000177; Ridler K, 2001, PSYCHOL MED, V31, P1437, DOI 10.1017/S0033291701004561; Roach ES, 1999, J CHILD NEUROL, V14, P401, DOI 10.1177/088307389901400610; Roach ES, 1998, J CHILD NEUROL, V13, P624, DOI 10.1177/088307389801301206; Robb VA, 2007, J UROLOGY, V177, P346, DOI 10.1016/j.juro.2006.08.076; Robertson DM, 1991, ANN N Y ACAD SCI, V615, P17; Robertson FM, 1996, J PEDIATR SURG, V31, P729, DOI 10.1016/S0022-3468(96)90689-2; Rok P, 2005, MED SCI MONITOR, V11, pCR230; Rowley SA, 2001, BRIT J OPHTHALMOL, V85, P420, DOI 10.1136/bjo.85.4.420; SAMPSON JR, 1989, J MED GENET, V26, P28, DOI 10.1136/jmg.26.1.28; Sampson JR, 1997, AM J HUM GENET, V61, P843, DOI 10.1086/514888; Sancak O, 2005, EUR J HUM GENET, V13, P731, DOI 10.1038/sj.ejhg.5201402; Sato T, 2002, J HUM GENET, V47, P20, DOI 10.1007/s10038-002-8651-8; Seri S, 1998, J CHILD NEUROL, V13, P33, DOI 10.1177/088307389801300106; SHATNI MJ, 1993, AM J OPHTHALMOL, V115, P539; SHEPHERD CW, 1991, MAYO CLIN PROC, V66, P792, DOI 10.1016/S0025-6196(12)61196-3; SHEPHERD CW, 1991, ARCH NEUROL-CHICAGO, V48, P400, DOI 10.1001/archneur.1991.00530160068015; Simmons JL, 2003, ONCOL REP, V10, P237; Smolarek TA, 1998, AM J HUM GENET, V62, P810, DOI 10.1086/301804; SMYTHE JF, 1990, AM J CARDIOL, V66, P1247, DOI 10.1016/0002-9149(90)91109-J; Sparagana SP, 2003, ARCH NEUROL-CHICAGO, V60, P1286, DOI 10.1001/archneur.60.9.1286; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Torres OA, 1998, J CHILD NEUROL, V13, P173, DOI 10.1177/088307389801300405; Valencia I, 2006, J CHILD NEUROL, V21, P1058, DOI 10.1177/7010.2006.00242; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Wang YL, 2007, ANN NEUROL, V61, P139, DOI 10.1002/ana.21058; WASHECKA R, 1991, UROLOGY, V37, P340, DOI 10.1016/0090-4295(91)80261-5; WEBB DW, 1993, ARCH DIS CHILD, V68, P367, DOI 10.1136/adc.68.3.367; Webb DW, 1996, BRIT J DERMATOL, V135, P1; Webb DW, 1996, DEV MED CHILD NEUROL, V38, P146; Weimbs T, 2006, CELL CYCLE, V5, P2425, DOI 10.4161/cc.5.21.3408; Weiner HL, 2004, J CHILD NEUROL, V19, P687, DOI 10.1177/08830738040190090901; White R, 2001, ANN NEUROL, V49, P67, DOI 10.1002/1531-8249(200101)49:1<67::AID-ANA10>3.0.CO;2-L; Wienecke R, 2006, AM J KIDNEY DIS, V48, pE27, DOI 10.1053/j.ajkd.2006.05.018; Wild JM, 2006, INVEST OPHTH VIS SCI, V47, P917, DOI 10.1167/iovs.05-0854; Williams JM, 2006, AM J KIDNEY DIS, V47, P95, DOI 10.1053/j.ajkd.2005.09.028; Winterkorn EB, 2006, PEDIATR NEPHROL, V21, P1189, DOI 10.1007/s00467-006-0133-3; Wu JY, 2006, NEUROLOGY, V66, P1270, DOI 10.1212/01.wnl.0000208412.59491.9b; Yates JRW, 2006, EUR J HUM GENET, V14, P1065, DOI 10.1038/sj.ejhg.5201625; Zaroff CM, 2005, EPILEPTIC DISORD, V7, P321	159	744	792	0	79	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	2008	372	9639					657	668		10.1016/S0140-6736(08)61279-9	http://dx.doi.org/10.1016/S0140-6736(08)61279-9			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	340BX	18722871				2022-12-28	WOS:000258622200030
J	Meltzer, MI				Meltzer, Martin I.			Health economics and prioritising health care	LANCET			English	Editorial Material							COST-EFFECTIVENESS; INFORMATION		Ctr Dis Control & Prevent, Div Emerging Dis & Surveillance Syst, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Meltzer, MI (corresponding author), Ctr Dis Control & Prevent, Div Emerging Dis & Surveillance Syst, Atlanta, GA 30333 USA.	qzm4@cdc.gov	Meltzer, Martin/AAT-3235-2021	Meltzer, Martin/0000-0002-7250-0472				[Anonymous], REC GUID ADV COMM IM; Blumstein JF, 1997, SOC SCI MED, V45, P545, DOI 10.1016/S0277-9536(96)00395-4; Culyer Anthony, 2007, J Health Serv Res Policy, V12, P56, DOI 10.1258/135581907779497567; Grosse Scott D, 2008, Expert Rev Pharmacoecon Outcomes Res, V8, P165, DOI 10.1586/14737167.8.2.165; Grosse SD, 2007, ANNU REV PUBL HEALTH, V28, P365, DOI 10.1146/annurev.publhealth.28.021406.144046; Kirschner N, 2008, ANN INTERN MED, V148, P956, DOI 10.7326/0003-4819-148-12-200806170-00222; LIEU T, 2008, ADV COMM IMM PRACT F; Meltzer MI, 2001, LANCET, V358, P993, DOI 10.1016/S0140-6736(01)06107-4; Neumann PJ, 2005, VALUE HEALTH, V8, P3, DOI 10.1111/j.1524-4733.2005.04010.x; Wilensky GR, 2008, ANN INTERN MED, V148, P967, DOI 10.7326/0003-4819-148-12-200806170-00224; Williams I, 2008, HEALTH TECHNOL ASSES, V12, P1	11	10	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	2008	372	9639					612	613		10.1016/S0140-6736(08)61257-X	http://dx.doi.org/10.1016/S0140-6736(08)61257-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	340BX	18722853				2022-12-28	WOS:000258622200009
J	Green, JL; Inoue, T; Sternberg, PW				Green, Jennifer L.; Inoue, Takao; Sternberg, Paul W.			Opposing wnt pathways orient cell polarity during organogenesis	CELL			English	Article							ELEGANS VULVAL DEVELOPMENT; RECEPTOR TYROSINE KINASE; CAENORHABDITIS-ELEGANS; C-ELEGANS; BETA-CATENIN; RECIPROCAL ASYMMETRY; SIGNALING PATHWAY; DIVISIONS; TRANSCRIPTION; PROTEIN	The orientation of asymmetric cell division contributes to the organization of cells within a tissue or organ. For example, mirror-image symmetry of the C. elegans vulva is achieved by the opposite division orientation of the vulval precursor cells (VPCs) flanking the axis of symmetry. We characterized the molecular mechanisms contributing to this division pattern. Wnts MOM-2 and LIN-44 are expressed at the axis of symmetry and orient the VPCs toward the center. These Wnts act via Fz/LIN-17 and Ryk/LIN-18, which control beta-catenin localization and activate gene transcription. In addition, VPCs on both sides of the axis of symmetry possess a uniform underlying "ground'' polarity, established by the instructive activity of Wnt/EGL-20. EGL-20 establishes ground polarity via a novel type of signaling involving the Ror receptor tyrosine kinase CAM-1 and the planar cell polarity component Van Gogh/VANG-1. Thus, tissue polarity is determined by the integration of multiple Wnt pathways.	[Green, Jennifer L.; Inoue, Takao; Sternberg, Paul W.] CALTECH, Howard Hughes Med Inst, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute	Sternberg, PW (corresponding author), CALTECH, Howard Hughes Med Inst, Div Biol, Mail Code 156-29, Pasadena, CA 91125 USA.	pws@caltech.edu		Sternberg, Paul/0000-0002-7699-0173	National Institutes of Health, National Center for Research Resources; Howard Hughes Medical Institute; California Institute of Technology; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023690] Funding Source: NIH RePORTER	National Institutes of Health, National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); California Institute of Technology; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	We thank Gladys Medina, Barbara Perry, and Shahla Gharib for technical assistance, members of our lab for helpful discussions, Andrea Choe for artistic input, and Marianne Bronner-Fraser, Scott Fraser, Cheryl Van Buskirk, Mihoko Kato, Elissa Hallem, and Adeline Seah for critically reading the manuscript. Many strains used in this study were provided by the Caenorhabditis Genetics Center, funded by the National Institutes of Health, National Center for Research Resources. Weare grateful to the late Peter Snow for his valuable assistance in making our CAM-1 antibody. P. W. S. is an investigator with the Howard Hughes Medical Institute, who supported this work, and J. L. G. was supported by the Moore Foundation Fellowship for graduate study toward the Doctor of Philosophy degree in Biology at the California Institute of Technology.	Baena-Lopez LA, 2005, CURR BIOL, V15, P1640, DOI 10.1016/j.cub.2005.07.062; BRENNER S, 1974, GENETICS, V77, P71; Coudreuse DYM, 2006, SCIENCE, V312, P921, DOI 10.1126/science.1124856; Deans MR, 2007, J NEUROSCI, V27, P3139, DOI 10.1523/JNEUROSCI.5151-06.2007; Deshpande R, 2005, DEV BIOL, V278, P118, DOI 10.1016/j.ydbio.2004.10.020; Eisenmann DM, 1998, DEVELOPMENT, V125, P3667; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; Gleason JE, 2006, DEV BIOL, V298, P442, DOI 10.1016/j.ydbio.2006.06.050; Gordon MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200; Green JL, 2007, DEVELOPMENT, V134, P4053, DOI 10.1242/dev.005363; HERMAN MA, 1995, CELL, V83, P101, DOI 10.1016/0092-8674(95)90238-4; Hikasa H, 2002, DEVELOPMENT, V129, P5227; Huang SY, 2007, DEVELOPMENT, V134, P2685, DOI 10.1242/dev.008268; Inoue T, 2004, CELL, V118, P795, DOI 10.1016/j.cell.2004.09.001; Inoue T, 2002, MECH DEVELOP, V119, pS203, DOI 10.1016/S0925-4773(03)00117-5; Jones C, 2007, BIOESSAYS, V29, P120, DOI 10.1002/bies.20526; Kidd AR, 2005, CELL, V121, P761, DOI 10.1016/j.cell.2005.03.029; Korswagen HC, 2000, NATURE, V406, P527, DOI 10.1038/35020099; Lo MC, 2004, CELL, V117, P95, DOI 10.1016/S0092-8674(04)00203-X; Maduro MF, 2002, DEV BIOL, V248, P128, DOI 10.1006/dbio.2002.0721; McNally K, 2006, J CELL BIOL, V175, P881, DOI 10.1083/jcb.200608117; Mizumoto K, 2007, TRENDS CELL BIOL, V17, P465, DOI 10.1016/j.tcb.2007.08.004; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Oishi I, 2003, GENES CELLS, V8, P645, DOI 10.1046/j.1365-2443.2003.00662.x; Pan CL, 2006, DEV CELL, V10, P367, DOI 10.1016/j.devcel.2006.02.010; Park FD, 2004, CURR BIOL, V14, P2252, DOI 10.1016/j.cub.2004.12.019; Phillips BT, 2007, P NATL ACAD SCI USA, V104, P3231, DOI 10.1073/pnas.0611507104; Rocheleau CE, 1999, CELL, V97, P717, DOI 10.1016/S0092-8674(00)80784-9; Sawa H, 1996, GENE DEV, V10, P2189, DOI 10.1101/gad.10.17.2189; Schambony A, 2007, DEV CELL, V12, P779, DOI 10.1016/j.devcel.2007.02.016; Schlesinger A, 1999, GENE DEV, V13, P2028, DOI 10.1101/gad.13.15.2028; Seifert JRK, 2007, NAT REV GENET, V8, P126, DOI 10.1038/nrg2042; Sherwood DR, 2005, CELL, V121, P951, DOI 10.1016/j.cell.2005.03.031; Shetty P, 2005, DEV BIOL, V285, P584, DOI 10.1016/j.ydbio.2005.07.008; STERNBERG PW, 1988, DEV BIOL, V130, P67, DOI 10.1016/0012-1606(88)90414-9; Sternberg PW., 2005, C ELEGANS RES COMMUN; Strutt D, 2005, CURR BIOL, V15, pR758, DOI 10.1016/j.cub.2005.08.053; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; Takeshita H, 2005, GENE DEV, V19, P1743, DOI 10.1101/gad.1322805; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960-9822(03)00240-9; Wang YS, 2007, DEVELOPMENT, V134, P647, DOI 10.1242/dev.02772; Whangbo J, 1999, MOL CELL, V4, P851, DOI 10.1016/S1097-2765(00)80394-9; Wodarz A, 2007, NAT CELL BIOL, V9, P1016, DOI 10.1038/ncb433; Zallen JA, 2007, CELL, V129, P1051, DOI 10.1016/j.cell.2007.05.050	46	129	148	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	2008	134	4					646	656		10.1016/j.cell.2008.06.026	http://dx.doi.org/10.1016/j.cell.2008.06.026			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SR	18724937	Bronze, Green Accepted			2022-12-28	WOS:000258665800017
J	Li, L; Weidner, DJ				Li, Li; Weidner, Donald J.			Effect of phase transitions on compressional-wave velocities in the Earth's mantle	NATURE			English	Article							HIGH-PRESSURES; TRANSFORMATION; DISCONTINUITY; TEMPERATURES; PEROVSKITE; DIFFUSION; KINETICS; OLIVINE; SPINEL	The velocities of seismic waves in the Earth are governed by the response of the constituent mineral assemblage to perturbations in pressure and stress. The effective bulk modulus is significantly lowered if the pressure of the seismic wave drives a volume- reducing phase transformation(1,2). A comparison between the amount of time required by phase transitions to reach equilibrium and the sampling period thus becomes crucial in defining the softening and attenuation of compressional waves within such a two- phase zone(3). These phenomena are difficult to assess experimentally, however, because data at conditions appropriate to the Earth's deep interior are required. Here we present synchrotron- based experimental data that demonstrate softening of the bulk modulus within the two- phase loop of olivine - ringwoodite on a timescale of 100 s. If the amplitude of the pressure perturbation and the grain size are scaled to those expected in the Earth, the compressional-wave velocities within the discontinuities at 410, 520 and, possibly, 660 km are likely to be significantly lower than otherwise expected. The generalization of these observations to aluminium- controlled phase transitions raises the possibility of large velocity perturbations throughout the upper 1,000 km of the mantle.	[Li, Li; Weidner, Donald J.] SUNY Stony Brook, Inst Mineral Phys, Dept Geosci, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Li, L (corresponding author), SUNY Stony Brook, Inst Mineral Phys, Dept Geosci, Stony Brook, NY 11794 USA.	lilli@ic.sunysb.edu			National Synchrotron Light Source; Consortium for Materials Properties in Earth Sciences; US Department of Energy [DE-AC02_ 98CH10886]; US National Science Foundation [EAR-0711365, EAR652887, EAR 01-35554]	National Synchrotron Light Source; Consortium for Materials Properties in Earth Sciences; US Department of Energy(United States Department of Energy (DOE)); US National Science Foundation(National Science Foundation (NSF))	We thank L. Wang and D. Lindsley for support for this project. We acknowledge support from the National Synchrotron Light Source and the Consortium for Materials Properties in Earth Sciences, and financial support from the US Department of Energy ( contract number DE-AC02_ 98CH10886) and the US National Science Foundation ( awards EAR-0711365, EAR652887 and EAR 01-35554). This is MPI publication number 466.	Akaogi M, 2002, PHYS EARTH PLANET IN, V132, P303, DOI 10.1016/S0031-9201(02)00075-4; ANDERSON DL, 1989, THEORY EARTH, P279; BINA CR, 1994, J GEOPHYS RES-SOL EA, V99, P15853, DOI 10.1029/94JB00462; BROWN JM, 1981, GEOPHYS J ROY ASTR S, V66, P579, DOI 10.1111/j.1365-246X.1981.tb04891.x; Chakraborty S, 1999, SCIENCE, V283, P362, DOI 10.1126/science.283.5400.362; Cherniak DJ, 1998, PHYS CHEM MINER, V26, P156, DOI 10.1007/s002690050172; Durham WB, 2002, REV MINERAL GEOCHEM, V51, P21, DOI 10.2138/gsrmg.51.1.21; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; Holzapfel C, 2005, SCIENCE, V309, P1707, DOI 10.1126/science.1111895; Irifune T., 1993, ISL ARC, V2, P55, DOI [10.1111/j.1440-1738.1993.tb00074.x, DOI 10.1111/J.1440-1738.1993.TB00074.X]; Jackson I., 2007, TREATISE GEOPHYS, V2, P493; KATSURA T, 1989, J GEOPHYS RES-SOLID, V94, P15663, DOI 10.1029/JB094iB11p15663; Li L, 2007, REV SCI INSTRUM, V78, DOI 10.1063/1.2735587; Morris SJS, 2002, J MECH PHYS SOLIDS, V50, P1363, DOI 10.1016/S0022-5096(01)00122-3; Ringwood A. E., 1970, PHYS EARTH PLANET IN, V3, P109, DOI DOI 10.1016/0031-9201(70)90047-6; RUBIE DC, 1994, PHYS EARTH PLANET IN, V86, P223, DOI 10.1016/0031-9201(94)05070-8; Tamisiea ME, 2002, EARTH PLANET SC LETT, V198, P459, DOI 10.1016/S0012-821X(02)00486-7; Vaisnys J. R., 1968, Journal of Geophysical Research, V73, P7675, DOI 10.1029/JB073i024p07675; Weidner DJ, 1998, J GEOPHYS RES-SOL EA, V103, P7431, DOI 10.1029/97JB03511; Weidner DJ., 2000, EARTHS DEEP INTERIOR, P215, DOI [10.1029/gm117p0215, DOI 10.1029/GM117P0215]	20	43	45	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 21	2008	454	7207					984	986		10.1038/nature07230	http://dx.doi.org/10.1038/nature07230			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339QB	18719587				2022-12-28	WOS:000258591000036
J	Lyons, TW				Lyons, Timothy W.			Ocean science - Ironing out ocean chemistry at the dawn of animal life	SCIENCE			English	Editorial Material							PROTEROZOIC OCEAN; OXYGENATION; SULFATE; EVOLUTION; ISOTOPE; ANOXIA; EARTH; RISE		Univ Calif Riverside, Dept Earth Sci, Riverside, CA 92521 USA	University of California System; University of California Riverside	Lyons, TW (corresponding author), Univ Calif Riverside, Dept Earth Sci, Riverside, CA 92521 USA.	timothy.lyons@ucr.edu						Anbar AD, 2002, SCIENCE, V297, P1137, DOI 10.1126/science.1069651; Arnold GL, 2004, SCIENCE, V304, P87, DOI 10.1126/science.1091785; Brocks JJ, 2005, NATURE, V437, P866, DOI 10.1038/nature04068; Canfield DE, 2004, AM J SCI, V304, P839, DOI 10.2475/ajs.304.10.839; Canfield DE, 1998, NATURE, V396, P450, DOI 10.1038/24839; Canfield DE, 1996, NATURE, V382, P127, DOI 10.1038/382127a0; Canfield DE, 2007, SCIENCE, V315, P92, DOI 10.1126/science.1135013; Canfield DE, 2008, SCIENCE, V321, P949, DOI 10.1126/science.1154499; Fike DA, 2008, GEOCHIM COSMOCHIM AC, V72, P2636, DOI 10.1016/j.gca.2008.03.021; Fike DA, 2006, NATURE, V444, P744, DOI 10.1038/nature05345; Holland HD, 2006, PHILOS T R SOC B, V361, P903, DOI 10.1098/rstb.2006.1838; Hurtgen MT, 2002, EARTH PLANET SC LETT, V203, P413, DOI 10.1016/S0012-821X(02)00804-X; Kah LC, 2004, NATURE, V431, P834, DOI 10.1038/nature02974; Poulton SW, 2004, NATURE, V431, P173, DOI 10.1038/nature02912; Scott C, 2008, NATURE, V452, P456, DOI 10.1038/nature06811; Shen Y, 2003, NATURE, V423, P632, DOI 10.1038/nature01651	16	6	6	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2008	321	5891					923	924		10.1126/science.1162870	http://dx.doi.org/10.1126/science.1162870			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	337LD	18703731				2022-12-28	WOS:000258436700026
J	Premenko-Lanier, M; Moseley, NB; Pruett, ST; Romagnoli, PA; Altman, JD				Premenko-Lanier, Mary; Moseley, Nelson B.; Pruett, Sarah T.; Romagnoli, Pablo A.; Altman, John D.			RETRACTED: Transient FTY720 treatment promotes immune-mediated clearance of a chronic viral infection (Retracted article. See vol. 464, pg. 942, 2010)	NATURE			English	Article; Retracted Publication							SPHINGOSINE 1-PHOSPHATE RECEPTORS; T-CELL RESPONSES; LYMPHOCYTE EGRESS; VIRUS-INFECTION; PERSISTENCE; IMMUNOMODULATOR; SPECIFICITY; IMPAIRMENT; EXHAUSTION; MICE	For a wide variety of microbial pathogens, the outcome of the infection is indeterminate. In some individuals the microbe is cleared, but in others it establishes a chronic infection, and the factors that tip this balance are often unknown. In a widely used model of chronic viral infection, C57BL/6 mice clear the Armstrong strain of lymphocytic choriomeningitis virus (LCMV), but the clone 13 strain persists(1,2). Here we show that the Armstrong strain induces a profound lymphopenia at days 1-3 after infection, but the clone 13 strain does not. If we transiently augment lymphopenia by treating the clone-13-infected mice with the drug FTY720 at days 0-2 after infection, the mice successfully clear the infection by day 30. Clearance does not occur when CD4 T cells are absent at the time of treatment, indicating that the drug is not exerting direct antiviral effects. Notably, FTY720 treatment of an already established persistent infection also leads to viral clearance. In both models, FTY720 treatment preserves or augments LCMV-specific CD4 and CD8 T-cell responses, a result that is counter-intuitive because FTY720 is generally regarded as a new immunosuppressive agent(3). Because FTY720 targets host pathways that are completely evolutionarily conserved, our results may be translatable into new immunotherapies for the treatment of chronic microbial infections in humans.	[Premenko-Lanier, Mary; Moseley, Nelson B.; Romagnoli, Pablo A.; Altman, John D.] Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30329 USA; [Premenko-Lanier, Mary; Moseley, Nelson B.; Romagnoli, Pablo A.; Altman, John D.] Emory Univ, Dept Microbiol & Immunol, Atlanta, GA 30329 USA; [Premenko-Lanier, Mary; Moseley, Nelson B.; Romagnoli, Pablo A.; Altman, John D.] Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA; [Premenko-Lanier, Mary; Moseley, Nelson B.; Romagnoli, Pablo A.; Altman, John D.] Emory Univ, Sch Med, Atlanta, GA 30329 USA; [Pruett, Sarah T.] Yerkes Natl Primate Res Ctr, Div Psychobiol, Atlanta, GA 30329 USA	Emory University; Emory University; Emory University; Emory University	Altman, JD (corresponding author), Emory Univ, Emory Vaccine Ctr, 954 Gatewood Rd, Atlanta, GA 30329 USA.	mflanie@emory.edu; jaltman@rmy.emory.edu	Romagnoli, Pablo Alberto/AAF-4719-2019; Pruett, Sarah/C-7433-2009	Romagnoli, Pablo Alberto/0000-0002-6328-9070; 	NIAID NIH HHS [AI042373, 5F32AI062002] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI062002] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHMED R, 1984, J VIROL, V51, P34, DOI 10.1128/JVI.51.1.34-41.1984; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Brooks DG, 2008, J EXP MED, V205, P533, DOI 10.1084/jem.20071948; Brooks DG, 2006, NAT MED, V12, P1301, DOI 10.1038/nm1492; Budde K, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341073; CEMBRZYNSKANOWAK M, 1989, ARCH IMMUNOL THER EX, V37, P499; Chiba K, 2005, PHARMACOL THERAPEUT, V108, P308, DOI 10.1016/j.pharmthera.2005.05.002; CHISARI FV, 1995, SPRINGER SEMIN IMMUN, V17, P261, DOI 10.1007/BF00196169; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; Folgori A, 2006, GUT, V55, P1012, DOI 10.1136/gut.2005.080077; Ha SJ, 2008, J EXP MED, V205, P543, DOI 10.1084/jem.20071949; Kappos L, 2006, NEW ENGL J MED, V355, P1124, DOI 10.1056/NEJMoa052643; Kunzendorf U, 2004, NEPHROL DIAL TRANSPL, V19, P1677, DOI 10.1093/ndt/gfh295; MAMALAKI C, 1993, DEV IMMUNOL, V3, P159, DOI 10.1155/1993/98015; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; Matter M, 2006, J EXP MED, V203, P2145, DOI 10.1084/jem.20060651; Merrill AH, 2005, METHODS, V36, P207, DOI 10.1016/j.ymeth.2005.01.009; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; Muller S, 2002, J VIROL, V76, P2375, DOI 10.1128/JVI.76.5.2375-2383.2002; Pinschewer DD, 2000, J IMMUNOL, V164, P5761, DOI 10.4049/jimmunol.164.11.5761; Shiow LR, 2006, NATURE, V440, P540, DOI 10.1038/nature04606; Wherry EJ, 2003, J VIROL, V77, P4911, DOI 10.1128/JVI.77.8.4911-4927.2003; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205	25	21	28	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 14	2008	454	7206					894	U52		10.1038/nature07199	http://dx.doi.org/10.1038/nature07199			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	336XH	18704087				2022-12-28	WOS:000258398600038
J	Hughson, FM				Hughson, Frederick M.			Both layers of the COPII coat come into view	CELL			English	Editorial Material							VESICLE COAT; CAGE; INSIGHTS		Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Hughson, FM (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	hughson@princeton.edu						Bi XP, 2007, DEV CELL, V13, P635, DOI 10.1016/j.devcel.2007.10.006; Bi XP, 2002, NATURE, V419, P271, DOI 10.1038/nature01040; Fath S, 2007, CELL, V129, P1325, DOI 10.1016/j.cell.2007.05.036; Fotin A, 2004, NATURE, V432, P573, DOI 10.1038/nature03079; Fromme JC, 2007, DEV CELL, V13, P623, DOI 10.1016/j.devcel.2007.10.005; Gurkan C, 2006, NAT REV MOL CELL BIO, V7, P727, DOI 10.1038/nrm2025; Stagg SM, 2006, NATURE, V439, P234, DOI 10.1038/nature04339; Young A, 2007, SEMIN CELL DEV BIOL, V18, P448, DOI 10.1016/j.semcdb.2007.07.006	8	1	1	0	0	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 8	2008	134	3					384	385		10.1016/j.cell.2008.07.027	http://dx.doi.org/10.1016/j.cell.2008.07.027			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SO	18692460	Bronze			2022-12-28	WOS:000258665500009
J	Kandun, IN; Tresnaningsih, E; Purba, WH; Lee, V; Samaan, G; Harun, S; Soni, E; Septiawati, C; Setiawati, T; Sariwati, E; Wandra, T				Kandun, I. Nyoman; Tresnaningsih, Erna; Purba, Wilfried H.; Lee, Vernon; Samaan, Gina; Harun, Syahrial; Soni, Eka; Septiawati, Chita; Setiawati, Tetty; Sariwati, Elvieda; Wandra, Toni			Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series	LANCET			English	Article							INFLUENZA-A H5N1; FLU	Background Indonesia has had the most human cases of highly pathogenic avian influenza A (H5N1) and one of the highest case-fatality rates worldwide. We described the factors associated with H5N1 case-fatality in Indonesia. Methods Between June, 2005, and February, 2008, there were 127 confirmed H5N1 infections. Investigation teams were deployed to investigate and manage each confirmed case; they obtained epidemiological and clinical data from case-investigation reports when possible and through interviews with patients, family members, and key individuals. Findings Of the 127 patients with confirmed H5N1 infections, 103 (81%) died. Median time to hospitalisation was 6 days (range 1-16). Of the 122 hospitalised patients for whom data were available, 121 (99%) had fever, 107 (88%) cough, and 103 (84%) dyspnoea on reaching hospital. However, for the first 2 days after onset, most had non-specific symptoms; only 31 had both fever and cough, and nine had fever and dyspnoea. Median time from onset to oseltamivir treatment was 7 days (range 0-21 days); treatment started within 2 days for one patient who survived, four (36.4%) of 11 receiving treatment within 2-4 days survived, six (37.5%) of 16 receiving treatment within 5-6 days survived, and ten (18 . 5%) of 44 receiving treatment at 7 days or later survived (p=0 . 03). Initiation of treatment within 2 days was associated with significantly lower mortality than was initiation at 5-6 days or later than 7 days (p<0 . 0001). Mortality was lower in clustered than unclustered cases (odds ratio 33.3, 95% CI 3.13-273). Treatment started at a median of 5 days (range 0-13 days) from onset in secondary cases in clusters compared with 8 days (range 4-16) for primary cases (p=0 . 04). Interpretation Development of better diagnostic methods and improved case management might improve identification of patients with H5N1 influenza, which could decrease mortality by allowing for earlier treatment with oseltamivir. Funding None.	[Kandun, I. Nyoman; Tresnaningsih, Erna; Purba, Wilfried H.; Soni, Eka; Septiawati, Chita; Setiawati, Tetty; Sariwati, Elvieda; Wandra, Toni] Minist Hlth, Directorate Gen Dis Control & Environm Hlth, Jakarta 10560, Indonesia; [Harun, Syahrial] Minist Hlth, Natl Inst Hlth Res & Dev, Jakarta 10560, Indonesia; [Lee, Vernon; Samaan, Gina] WHO, Indonesia Country Off, Jakarta, Indonesia	Ministry of Health - Indonesia; Ministry of Health - Indonesia; National Institute of Health Research & Development - Indonesia; World Health Organization	Wandra, T (corresponding author), Minist Hlth, Directorate Gen Dis Control & Environm Hlth, Jl Percetakan Negara 29,Katak Pos 223, Jakarta 10560, Indonesia.	twandra@yahoo.com	WANDRA, TONI/AAD-5736-2021	Wandra, Toni/0000-0002-4606-5411				[Anonymous], WHO CAS DEF HUM INF; Chua TH, 2007, AVIAN DIS, V51, P96, DOI 10.1637/0005-2086(2007)051[0096:PEOFDT]2.0.CO;2; de Jong MD, 2006, J CLIN VIROL, V35, P2, DOI 10.1016/j.jcv.2005.09.002; Dinh PN, 2006, EMERG INFECT DIS, V12, P1841; Hien TT, 2004, NEW ENGL J MED, V350, P1179, DOI 10.1056/NEJMoa040419; Kandun IN, 2006, NEW ENGL J MED, V355, P2186, DOI 10.1056/NEJMoa060930; Moscona A, 2005, NEW ENGL J MED, V353, P1363, DOI 10.1056/NEJMra050740; Oner AF, 2006, NEW ENGL J MED, V355, P2179, DOI 10.1056/NEJMoa060601; Pipper J, 2007, NAT MED, V13, P1259, DOI 10.1038/nm1634; Sedyaningsih ER, 2007, J INFECT DIS, V196, P522, DOI 10.1086/519692; Shinya K, 2006, NATURE, V440, P435, DOI 10.1038/440435a; Suarez DL, 2007, AVIAN DIS, V51, P201, DOI 10.1637/7732-101006-REGR.1; Thorson A, 2006, ARCH INTERN MED, V166, P119, DOI 10.1001/archinte.166.1.119; Ungchusak K, 2005, NEW ENGL J MED, V352, P333, DOI 10.1056/NEJMoa044021; Webster RG, 2006, NEW ENGL J MED, V355, P2174, DOI 10.1056/NEJMp068205; World Health Organization, CUM NUMB CONF HUM CA	16	113	119	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG-SEP	2008	372	9640					744	749		10.1016/S0140-6736(08)61125-3	http://dx.doi.org/10.1016/S0140-6736(08)61125-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	344YZ	18706688				2022-12-28	WOS:000258964500031
J	Wang, YL; Sheng, G; Juranek, S; Tuschl, T; Patel, DJ				Wang, Yanli; Sheng, Gang; Juranek, Stefan; Tuschl, Thomas; Patel, Dinshaw J.			Structure of the guide-strand-containing argonaute silencing complex	NATURE			English	Article							A-AEOLICUS ARGONAUTE; CRYSTAL-STRUCTURE; RNA RECOGNITION; RISC; SLICER; SPECIFICITY; CLEAVAGE; INSIGHTS; DISEASE	The slicer activity of the RNA- induced silencing complex is associated with argonaute, the RNase H- like PIWI domain of which catalyses guide- strand- mediated sequence- specific cleavage of target messenger RNA. Here we report on the crystal structure of Thermus thermophilus argonaute bound to a 5 '- phosphorylated 21- base DNA guide strand, thereby identifying the nucleic- acid- binding channel positioned between the PAZ- and PIWI- containing lobes, as well as the pivot- like conformational changes associated with complex formation. The bound guide strand is anchored at both of its ends, with the solvent- exposed Watson - Crick edges of stacked bases 2 to 6 positioned for nucleation with the mRNA target, whereas two critically positioned arginines lock bases 10 and 11 at the cleavage site into an unanticipated orthogonal alignment. Biochemical studies indicate that key amino acid residues at the active site and those lining the 5 '- phosphate- binding pocket made up of the Mid domain are critical for cleavage activity, whereas alterations of residues lining the 2- nucleotide 39- end- binding pocket made up of the PAZ domain show little effect.	[Wang, Yanli; Sheng, Gang; Patel, Dinshaw J.] Mem Sloan Kettering Canc Ctr, Struct Biol Program, New York, NY 10065 USA; [Juranek, Stefan; Tuschl, Thomas] Rockefeller Univ, Howard Hughes Med Inst, Lab RNA Mol Biol, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Rockefeller University	Patel, DJ (corresponding author), Mem Sloan Kettering Canc Ctr, Struct Biol Program, New York, NY 10065 USA.	pateld@mskcc.org	wang, yanli/G-3306-2010	Wang, Yanli/0000-0002-5969-1745	NIH; US Department of Energy; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI068776] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Energy(United States Department of Energy (DOE)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The research was supported by funds from the NIH to D.J.P. and T.T. We thank the staff of NE-CAT beam line at the Advanced Photon Source, Argonne National Laboratory, supported by the US Department of Energy, for assistance with data collection.	BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baulcombe D, 2004, NATURE, V431, P356, DOI 10.1038/nature02874; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chiu YL, 2002, MOL CELL, V10, P549, DOI 10.1016/S1097-2765(02)00652-4; de Fougerolles A, 2007, NAT REV DRUG DISCOV, V6, P443, DOI 10.1038/nrd2310; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Filipowicz W, 2005, CELL, V122, P17, DOI 10.1016/j.cell.2005.06.023; Haley B, 2004, NAT STRUCT MOL BIOL, V11, P599, DOI 10.1038/nsmb780; Hall TMT, 2005, STRUCTURE, V13, P1403, DOI 10.1016/j.str.2005.08.005; Hutvagner G, 2008, NAT REV MOL CELL BIO, V9, P22, DOI 10.1038/nrm2321; Kim DH, 2007, NAT REV GENET, V8, P173, DOI 10.1038/nrg2006; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lingel A, 2004, NAT STRUCT MOL BIOL, V11, P576, DOI 10.1038/nsmb777; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Ma JB, 2005, NATURE, V434, P666, DOI 10.1038/nature03514; Ma JB, 2004, NATURE, V429, P318, DOI 10.1038/nature02519; Martinez J, 2004, GENE DEV, V18, P975, DOI 10.1101/gad.1187904; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Nowotny M, 2005, CELL, V121, P1005, DOI 10.1016/j.cell.2005.04.024; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parker JS, 2006, TRENDS BIOCHEM SCI, V31, P622, DOI 10.1016/j.tibs.2006.09.010; Parker JS, 2005, NATURE, V434, P663, DOI 10.1038/nature03462; Parker JS, 2004, EMBO J, V23, P4727, DOI 10.1038/sj.emboj.7600488; Patel DJ, 2006, COLD SPRING HARB SYM, V71, P81, DOI 10.1101/sqb.2006.71.053; Rana TM, 2007, NAT REV MOL CELL BIO, V8, P23, DOI 10.1038/nrm2085; Rivas FV, 2005, NAT STRUCT MOL BIOL, V12, P340, DOI 10.1038/nsmb918; Song JJ, 2004, SCIENCE, V305, P1434, DOI 10.1126/science.1102514; Stark A, 2003, PLOS BIOL, V1, P397, DOI 10.1371/journal.pbio.0000060; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Tolia NH, 2007, NAT CHEM BIOL, V3, P36, DOI 10.1038/nchembio848; Tomari Y, 2005, GENE DEV, V19, P517, DOI 10.1101/gad.1284105; Yuan YR, 2005, MOL CELL, V19, P405, DOI 10.1016/j.molcel.2005.07.011; Yuan YR, 2006, STRUCTURE, V14, P1557, DOI 10.1016/j.str.2006.08.009	39	353	371	5	75	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 13	2008	456	7219					209	U34		10.1038/nature07315	http://dx.doi.org/10.1038/nature07315			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	374JJ	18754009	Green Accepted			2022-12-28	WOS:000261039300033
J	Rossebo, AB; Pedersen, TR; Boman, K; Brudi, P; Chambers, JB; Egstrup, K; Gerdts, E; Gohlke-Barwolf, C; Holme, I; Kesaniemi, YA; Malbecq, W; Nienaber, CA; Ray, S; Skjaerpe, T; Wachtell, K; Willenheimer, R				Rossebo, Anne B.; Pedersen, Terje R.; Boman, Kurt; Brudi, Philippe; Chambers, John B.; Egstrup, Kenneth; Gerdts, Eva; Gohlke-Barwolf, Christa; Holme, Ingar; Kesaniemi, Y. Antero; Malbecq, William; Nienaber, Christoph A.; Ray, Simon; Skjaerpe, Terje; Wachtell, Kristian; Willenheimer, Ronnie		SEAS Investigators	Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK-FACTORS; VALVE CALCIFICATION; CARDIOVASCULAR RISK; EUROPEAN-SOCIETY; EARLY LESION; PROGRESSION; ASSOCIATION; EXPRESSION; DISEASE; HYPERCHOLESTEROLEMIA	Background: Hyperlipidemia has been suggested as a risk factor for stenosis of the aortic valve, but lipid-lowering studies have had conflicting results. Methods: We conducted a randomized, double-blind trial involving 1873 patients with mild-to-moderate, asymptomatic aortic stenosis. The patients received either 40 mg of simvastatin plus 10 mg of ezetimibe or placebo daily. The primary outcome was a composite of major cardiovascular events, including death from cardiovascular causes, aortic-valve replacement, nonfatal myocardial infarction, hospitalization for unstable angina pectoris, heart failure, coronary-artery bypass grafting, percutaneous coronary intervention, and nonhemorrhagic stroke. Secondary outcomes were events related to aortic-valve stenosis and ischemic cardiovascular events. Results: During a median follow-up of 52.2 months, the primary outcome occurred in 333 patients (35.3%) in the simvastatin-ezetimibe group and in 355 patients (38.2%) in the placebo group (hazard ratio in the simvastatin-ezetimibe group, 0.96; 95% confidence interval [CI], 0.83 to 1.12; P=0.59). Aortic-valve replacement was performed in 267 patients (28.3%) in the simvastatin-ezetimibe group and in 278 patients (29.9%) in the placebo group (hazard ratio, 1.00; 95% CI, 0.84 to 1.18; P=0.97). Fewer patients had ischemic cardiovascular events in the simvastatin-ezetimibe group (148 patients) than in the placebo group (187 patients) (hazard ratio, 0.78; 95% CI, 0.63 to 0.97; P=0.02), mainly because of the smaller number of patients who underwent coronary-artery bypass grafting. Cancer occurred more frequently in the simvastatin-ezetimibe group (105 vs. 70, P=0.01). Conclusions: Simvastatin and ezetimibe did not reduce the composite outcome of combined aortic-valve events and ischemic events in patients with aortic stenosis. Such therapy reduced the incidence of ischemic cardiovascular events but not events related to aortic-valve stenosis. (ClinicalTrials.gov number, NCT00092677.).	[Rossebo, Anne B.] Aker Univ Hosp, Div Cardiol, N-0514 Oslo, Norway; [Pedersen, Terje R.; Holme, Ingar] Ullevaal Univ Hosp, Ctr Prevent Med, Oslo, Norway; [Pedersen, Terje R.] Univ Oslo, Fac Med, Oslo, Norway; [Boman, Kurt] Skelleftea Hosp, Skelleftea, Sweden; [Boman, Kurt] Umea Univ, Inst Publ Hlth & Clin Med, Umea, Sweden; [Brudi, Philippe] Merck Schering Plough, Whitehouse Stn, NJ USA; [Chambers, John B.] Guys & St Thomas Hosp, London SE1 9RT, England; [Egstrup, Kenneth] Svendborg Hosp, Svendborg, Denmark; [Gerdts, Eva] Univ Bergen, Bergen, Norway; [Gerdts, Eva] Haukeland Hosp, N-5021 Bergen, Norway; [Gohlke-Barwolf, Christa] Herz Zentrum Bad Krozingen, Bad Krozingen, Germany; [Kesaniemi, Y. Antero] Univ Oulu, Bioctr, Oulu, Finland; [Malbecq, William] MSD Europe, Brussels, Belgium; [Nienaber, Christoph A.] Univ Klinikum Rostock, Rostock, Germany; [Ray, Simon] Univ S Manchester Hosp, Manchester M20 8LR, Lancs, England; [Skjaerpe, Terje] St Olavs Hosp, Trondheim, Norway; [Wachtell, Kristian] Rigshosp, Ctr Heart, DK-2100 Copenhagen, Denmark; [Willenheimer, Ronnie] Lund Univ, Malmo, Sweden; [Willenheimer, Ronnie] Heart Hlth Grp, Malmo, Sweden	University of Oslo; University of Oslo; University of Oslo; Umea University; Merck & Company; Guy's & St Thomas' NHS Foundation Trust; University of Bergen; University of Oulu; Merck & Company; University of Rostock; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Norwegian University of Science & Technology (NTNU); Rigshospitalet; University of Copenhagen; Lund University	Rossebo, AB (corresponding author), Aker Univ Hosp, Div Cardiol, Trondheimsveien 235, N-0514 Oslo, Norway.	anne@rossebo.net	Munzel, Thomas/A-2912-2014	Munzel, Thomas/0000-0001-5503-4150; Schmidt, Erik Berg/0000-0002-0623-5666; Lloyd, Guy/0000-0003-1958-6606; Klemsdal, Tor Ole/0000-0001-5442-9134; Kjaergaard, Jesper/0000-0001-5244-0399; Andersen, Grethe/0000-0001-6807-2500; Naslund, Ulf/0000-0003-4100-8298; Boman, Kurt/0000-0002-0350-2132	Merck; Schering-Plough Pharmaceuticals; Pfizer; Astra-Zeneca; St. Jude Medical; Novartis; Orion Pharma; Essex	Merck(Merck & Company); Schering-Plough Pharmaceuticals(Merck & CompanySchering Plough Corporation); Pfizer(Pfizer); Astra-Zeneca(AstraZeneca); St. Jude Medical(St. Jude Medical); Novartis(Novartis); Orion Pharma; Essex	Supported by Merck and Schering-Plough Pharmaceuticals. Drs. Rossebo and Wachtell report receiving consulting fees from Merck and research support from Merck and Schering-Plough; Dr. Pedersen, receiving consulting fees from Merck and Schering-Plough and lecture fees from Pfizer and Astra-Zeneca; Dr. Boman, receiving lecture fees from AstraZeneca, Merck, and Schering- Plough and consulting fees from Merck; Drs. Brudi and Malbecq, being employees of Merck and having an equity interest in the company; Dr. Chambers, receiving consulting and lecture fees from St. Jude Medical; Dr. Egstrup, receiving consulting and lecture fees from Merck and Pfizer and lecture fees from AstraZeneca; Dr. Gerdts, receiving grant support and consulting fees from Merck; Dr. Gohlke-Barwolf, receiving consulting and lecture fees from Merck; Dr. Holme, receiving consulting fees from Merck and lecture fees from Merck and Pfizer; Dr. Kesaniemi, receiving consulting fees from AstraZeneca, Merck, Pfizer, and Schering-Plough, lecture fees from AstraZeneca, Merck, and Schering-Plough, and research support from Merck, Novartis, and Schering-Plough and having an equity interest in Orion Pharma; Dr. Nienaber, receiving lecture fees from Merck, Pfizer, and Essex; Dr. Skjaerpe, receiving consulting fees from Merck; Dr. Ray, receiving lecture fees from Merck; and Dr. Willenheimer, receiving lecture fees from Merck and Schering-Plough and consulting fees from Merck. No other potential conflict of interest relevant to this article was reported.	Agmon Y, 2001, J AM COLL CARDIOL, V38, P827, DOI 10.1016/S0735-1097(01)01422-X; ARONOW WS, 1987, AM J CARDIOL, V59, P998, DOI 10.1016/0002-9149(87)91144-1; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Bax JJ, 2006, J AM COLL CARDIOL, V48, P754, DOI 10.1016/j.jacc.2006.04.077; Bonow RO, 2007, J AM COLL CARDIOL, V49, P1014; Bosse Y, 2008, J AM COLL CARDIOL, V51, P1327, DOI 10.1016/j.jacc.2007.12.031; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Cosmi JE, 2002, ARCH INTERN MED, V162, P2345, DOI 10.1001/archinte.162.20.2345; Cowell SJ, 2005, NEW ENGL J MED, V352, P2389, DOI 10.1056/NEJMoa043876; Cramariuc D, 2008, AM J CARDIOL, V101, P510, DOI 10.1016/j.amjcard.2007.09.100; *CTT COLL, 2008, LANCET, V371, P2084; DEUTSCHER S, 1984, J CHRON DIS, V37, P407, DOI 10.1016/0021-9681(84)90108-5; Garg V, 2005, NATURE, V437, P270, DOI 10.1038/nature03940; HOAGLAND PM, 1985, AM J CARDIOL, V55, P744, DOI 10.1016/0002-9149(85)90149-3; Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005; LINDROOS M, 1993, J AM COLL CARDIOL, V21, P1220, DOI 10.1016/0735-1097(93)90249-Z; LINDROOS M, 1994, EUR HEART J, V15, P865; MAUTNER GC, 1993, AM J CARDIOL, V72, P194, DOI 10.1016/0002-9149(93)90159-A; MOHLER ER, 1991, CLIN CARDIOL, V14, P995, DOI 10.1002/clc.4960141210; Moura LM, 2007, J AM COLL CARDIOL, V49, P554, DOI 10.1016/j.jacc.2006.07.072; Novaro GM, 2001, CIRCULATION, V104, P2205, DOI 10.1161/hc4301.098249; Novaro GM, 2003, CIRCULATION, V108, P1804, DOI 10.1161/01.CIR.0000097560.96431.3E; Novaro GM, 2001, J HEART VALVE DIS, V10, P19; OBRIEN KD, 1995, CIRCULATION, V92, P2163, DOI 10.1161/01.CIR.92.8.2163; OBrien KD, 1996, ARTERIOSCL THROM VAS, V16, P523, DOI 10.1161/01.ATV.16.4.523; OLSSON M, 1994, J AM COLL CARDIOL, V23, P1162, DOI 10.1016/0735-1097(94)90606-8; OLSSON M, 1994, J AM COLL CARDIOL, V24, P1664, DOI 10.1016/0735-1097(94)90172-4; Olsson M, 1999, ARTERIOSCL THROM VAS, V19, P1218, DOI 10.1161/01.ATV.19.5.1218; OTTO CM, 1994, CIRCULATION, V90, P844, DOI 10.1161/01.CIR.90.2.844; Otto CM, 1999, NEW ENGL J MED, V341, P142, DOI 10.1056/NEJM199907153410302; OTTO CM, 1989, J AM COLL CARDIOL, V13, P545, DOI 10.1016/0735-1097(89)90590-1; Otto CM, 2004, EUR HEART J, V25, P185, DOI 10.1016/j.ehj.2003.12.010; Palta S, 2000, CIRCULATION, V101, P2497, DOI 10.1161/01.CIR.101.21.2497; Peto R, 2008, NEW ENGL J MED, V359, P1357, DOI 10.1056/NEJMsa0806603; Pohle K, 2004, MAYO CLIN PROC, V79, P1242, DOI 10.4065/79.10.1242; Rajamannan NM, 2007, NAT CLIN PRACT CARD, V4, P254, DOI 10.1038/ncpcardio0827; Rajamannan NM, 2005, CIRCULATION, V111, P3296, DOI 10.1161/CIRCULATIONAHA.104.473165; Rajamannan NM, 2003, CIRCULATION, V107, P2181, DOI 10.1161/01.CIR.0000070591.21548.69; Rajamannan NM, 2002, CIRCULATION, V105, P2660, DOI 10.1161/01.CIR.0000017435.87463.72; Rosenhek R, 2004, CIRCULATION, V110, P1291, DOI 10.1161/01.CIR.0000140723.15274.53; Rossebo AB, 2007, AM J CARDIOL, V99, P970, DOI 10.1016/j.amjcard.2006.10.064; Shavelle DM, 2002, LANCET, V359, P1125, DOI 10.1016/S0140-6736(02)08161-8; Stewart BF, 1997, J AM COLL CARDIOL, V29, P630, DOI 10.1016/S0735-1097(96)00563-3; Vahanian A, 2007, EUR HEART J, V28, P230, DOI 10.1093/eurheartj/ehl428	44	1106	1151	1	50	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 25	2008	359	13					1343	1356		10.1056/NEJMoa0804602	http://dx.doi.org/10.1056/NEJMoa0804602			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	351QZ	18765433				2022-12-28	WOS:000259440900005
J	Sato, Y; Yoshikawa, A; Yamagata, A; Mimura, H; Yamashita, M; Ookata, K; Nureki, O; Iwai, K; Komada, M; Fukai, S				Sato, Yusuke; Yoshikawa, Azusa; Yamagata, Atsushi; Mimura, Hisatoshi; Yamashita, Masami; Ookata, Kayoko; Nureki, Osamu; Iwai, Kazuhiro; Komada, Masayuki; Fukai, Shuya			Structural basis for specific cleavage of Lys 63-linked polyubiquitin chains	NATURE			English	Article							SPLICING FACTOR PRP8; CRYSTAL-STRUCTURE; UBIQUITIN; DOMAIN; DEUBIQUITINATION; RECOGNITION; PROTEIN; DEGRADATION; BINDING; REFINEMENT	Deubiquitinating enzymes ( DUBs) remove ubiquitin from conjugated substrates to regulate various cellular processes. The Zn2+-dependent DUBs AMSH and AMSH- LP regulate receptor trafficking by specifically cleaving Lys 63- linked polyubiquitin chains from internalized receptors. Here we report the crystal structures of the human AMSH- LP DUB domain alone and in complex with a Lys 63- linked di- ubiquitin at 1.2 angstrom and 1.6 angstrom resolutions, respectively. The AMSH- LP DUB domain consists of a Zn2+-coordinating catalytic core and two characteristic insertions, Ins- 1 and Ins- 2. The distal ubiquitin interacts with Ins- 1 and the core, whereas the proximal ubiquitin interacts with Ins- 2 and the core. The core and Ins- 1 form a catalytic groove that accommodates the Lys 63 side chain of the proximal ubiquitin and the isopeptide- linked carboxy- terminal tail of the distal ubiquitin. This is the first reported structure of a DUB in complex with an isopeptide- linked ubiquitin chain, which reveals the mechanism for Lys 63- linkage- specific deubiquitination by AMSH family members.	[Sato, Yusuke; Yoshikawa, Azusa; Yamagata, Atsushi; Mimura, Hisatoshi; Yamashita, Masami; Fukai, Shuya] Univ Tokyo, Struct Biol Lab, Div Life Sci, Synchrotron Radiat Res Org, Tokyo 1130032, Japan; [Sato, Yusuke; Yoshikawa, Azusa; Yamagata, Atsushi; Mimura, Hisatoshi; Yamashita, Masami; Fukai, Shuya] Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan; [Sato, Yusuke; Yoshikawa, Azusa; Ookata, Kayoko; Nureki, Osamu] Tokyo Inst Technol, Dept Biol Informat, Yokohama, Kanagawa 2268501, Japan; [Komada, Masayuki] Tokyo Inst Technol, Dept Biol Sci, Grad Sch Biosci & Biotechnol, Yokohama, Kanagawa 2268501, Japan; [Yamashita, Masami; Fukai, Shuya] Univ Tokyo, Dept Med Genome Sci, Grad Sch Frontier Sci, Chiba 2778501, Japan; [Iwai, Kazuhiro] Osaka Univ, Dept Biophys & Biochem, Grad Sch Med, Suita, Osaka 5650871, Japan	University of Tokyo; University of Tokyo; Tokyo Institute of Technology; Tokyo Institute of Technology; University of Tokyo; Osaka University	Fukai, S (corresponding author), Univ Tokyo, Struct Biol Lab, Div Life Sci, Synchrotron Radiat Res Org, Tokyo 1130032, Japan.	fukai@iam.u-tokyo.ac.jp	NUREKI, OSAMU/G-4960-2014; IWAI, KAZUHIRO/GSN-7385-2022; Fukai, Shuya/X-4838-2018; Sato, Yusuke/GPW-9280-2022	Fukai, Shuya/0000-0002-1241-1443; Sato, Yusuke/0000-0001-8495-8950; Iwai, Kazuhiro/0000-0001-5620-5951	MEXT; JSPS research fellowships	MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); JSPS research fellowships(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	We thank C. Toyoshima for support of this research. We thank M. Shirakawa and T. Tenno for advice about the K63-Ub<INF>2</INF> preparation. We thank S. Kaiser for critical reading and improvement of this manuscript. We thank the beam-line staffs at NW12A of PF-AR (Tsukuba, Japan) for technical help during data collection. This work was supported by grants from MEXT to S. F. and O.N. Y.S. is supported by JSPS research fellowships for young scientists.	Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Ambroggio XI, 2004, PLOS BIOL, V2, P113, DOI 10.1371/journal.pbio.0020002; Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Clague MJ, 2006, TRENDS CELL BIOL, V16, P551, DOI 10.1016/j.tcb.2006.09.002; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Eddins MJ, 2006, NAT STRUCT MOL BIOL, V13, P915, DOI 10.1038/nsmb1148; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gupta SP, 2007, CHEM REV, V107, P3042, DOI 10.1021/cr030448t; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; HOLDEN HM, 1987, BIOCHEMISTRY-US, V26, P8542, DOI 10.1021/bi00400a008; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; Huang FT, 2006, MOL CELL, V21, P737, DOI 10.1016/j.molcel.2006.02.018; Hurley JH, 2006, BIOCHEM J, V399, P361, DOI 10.1042/BJ20061138; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Kim MS, 2006, BIOCHEM BIOPH RES CO, V351, P612, DOI 10.1016/j.bbrc.2006.10.068; Komada Masayuki, 2008, Curr Drug Discov Technol, V5, P78, DOI 10.2174/157016308783769469; Lipscomb WN, 1996, CHEM REV, V96, P2375, DOI 10.1021/cr950042j; Maytal-Kivity V, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-28; McCullough J, 2004, J CELL BIOL, V166, P487, DOI 10.1083/jcb.200401141; Messick TE, 2008, J BIOL CHEM, V283, P11038, DOI 10.1074/jbc.M704398200; Miranda M, 2007, MOL INTERV, V7, P157, DOI 10.1124/mi.7.3.7; Misaghi S, 2005, J BIOL CHEM, V280, P1512, DOI 10.1074/jbc.M410770200; Mizuno E, 2005, MOL BIOL CELL, V16, P5163, DOI 10.1091/mbc.E05-06-0560; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pena V, 2007, MOL CELL, V25, P615, DOI 10.1016/j.molcel.2007.01.023; Pickart CM, 2005, METHOD ENZYMOL, V399, P21, DOI 10.1016/S0076-6879(05)99002-2; Reyes-Turcu FE, 2006, CELL, V124, P1197, DOI 10.1016/j.cell.2006.02.038; Saksena S, 2007, TRENDS BIOCHEM SCI, V32, P561, DOI 10.1016/j.tibs.2007.09.010; Sanches M, 2007, J MOL BIOL, V370, P846, DOI 10.1016/j.jmb.2007.04.084; Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930; Sobhian B, 2007, SCIENCE, V316, P1198, DOI 10.1126/science.1139516; Tenno T, 2004, GENES CELLS, V9, P865, DOI 10.1111/j.1365-2443.2004.00780.x; Tran HJTT, 2003, BIOCHEMISTRY-US, V42, P11460, DOI 10.1021/bi035033g; Trempe JF, 2005, EMBO J, V24, P3178, DOI 10.1038/sj.emboj.7600797; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Varadan R, 2004, J BIOL CHEM, V279, P7055, DOI 10.1074/jbc.M309184200; Varadan R, 2005, MOL CELL, V18, P687, DOI 10.1016/j.molcel.2005.05.013; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Vonrhein Clemens, 2007, Methods Mol Biol, V364, P215, DOI 10.1385/1-59745-266-1:215; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071; Zhang LD, 2007, PROTEIN SCI, V16, P1024, DOI 10.1110/ps.072872007; Zhu P, 2007, MOL CELL, V27, P609, DOI 10.1016/j.molcel.2007.07.024	49	253	258	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	2008	455	7211					358	U19		10.1038/nature07254	http://dx.doi.org/10.1038/nature07254			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349EX	18758443				2022-12-28	WOS:000259265200037
J	Ip, H				Ip, Hugh			Commentary: An "ethnic minority" medical student	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Ip, Hugh] Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England	Imperial College London	Ip, H (corresponding author), Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England.	hughip@gmail.com		Ip, Hugh/0000-0001-7423-5054				DAWES M, 2007, STUDENT BMJ, V15, P298; IP H, 2008, STUDENT BMJ, V16, P178; Ip H, 2008, BRIT MED J, V336, P1082, DOI 10.1136/bmj.39569.609641.80; MENTZER A, 2008, STUDENT BMJ, V16, P272	4	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2008	337	7670							a1240	10.1136/bmj.a1240	http://dx.doi.org/10.1136/bmj.a1240			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	354DT	18710847	hybrid			2022-12-28	WOS:000259619800037
J	Gerber, SH; Rah, JC; Min, SW; Liu, XR; de Wit, H; Dulubova, I; Meyer, AC; Rizo, J; Arancillo, M; Hammer, RE; Verhage, M; Rosenmund, C; Sudhof, TC				Gerber, Stefan H.; Rah, Jong-Cheol; Min, Sang-Won; Liu, Xinran; de Wit, Heidi; Dulubova, Irina; Meyer, Alexander C.; Rizo, Josep; Arancillo, Marife; Hammer, Robert E.; Verhage, Matthijs; Rosenmund, Christian; Sudhof, Thomas C.			Conformational switch of syntaxin-1 controls synaptic vesicle fusion	SCIENCE			English	Article							CALCIUM-CHANNELS; SNARE COMPLEX; N-TYPE; 1A; EXOCYTOSIS; MUNC18	During synaptic vesicle fusion, the soluble N- ethylmaleimide- sensitive factor- attachment protein receptor ( SNARE) protein syntaxin- 1 exhibits two conformations that both bind to Munc18- 1: a "closed" conformation outside the SNARE complex and an "open" conformation in the SNARE complex. Although SNARE complexes containing open syntaxin- 1 and Munc18- 1 are essential for exocytosis, the function of closed syntaxin- 1 is unknown. We generated knockin/knockout mice that expressed only open syntaxin- 1B. Syntaxin- 1B(Open) mice were viable but succumbed to generalized seizures at 2 to 3 months of age. Binding of Munc18- 1 to syntaxin- 1 was impaired in syntaxin- 1B(Open) synapses, and the size of the readily releasable vesicle pool was decreased; however, the rate of synaptic vesicle fusion was dramatically enhanced. Thus, the closed conformation of syntaxin- 1 gates the initiation of the synaptic vesicle fusion reaction, which is then mediated by SNARE- complex/ Munc18- 1 assemblies.	[Rah, Jong-Cheol; Arancillo, Marife; Rosenmund, Christian] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Rah, Jong-Cheol; Arancillo, Marife; Rosenmund, Christian] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA; [Gerber, Stefan H.; Min, Sang-Won; Liu, Xinran; Sudhof, Thomas C.] Univ Texas SW Med Ctr Dallas, Dept Neurosci, Dallas, TX 75390 USA; [Rah, Jong-Cheol; Meyer, Alexander C.; Rosenmund, Christian] Max Planck Inst Biophys Chem, Dept Membrane Biophys, D-37077 Gottingen, Germany; [Liu, Xinran; Sudhof, Thomas C.] Univ Texas SW Med Ctr Dallas, Dept Mol Genet, Dallas, TX 75390 USA; [de Wit, Heidi; Verhage, Matthijs] Vrije Univ Amsterdam, Dept Funct Genom, NL-1081 BT Amsterdam, Netherlands; [Rizo, Josep; Hammer, Robert E.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA; [Sudhof, Thomas C.] Univ Texas SW Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; University of Texas Southwestern Medical Center Dallas; Max Planck Society; University of Texas System; University of Texas Southwestern Medical Center Dallas; Vrije Universiteit Amsterdam; University of Texas System; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas	Rosenmund, C (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.	rosenmun@bcm.tmc.edu; tcs1@stanford.edu	Rosenmund, Christian/AAC-3596-2020; Meyer, Alexander/F-2479-2010	Rosenmund, Christian/0000-0002-3905-2444; verhage, matthijs/0000-0002-6085-7503; Hammer, Robert E./0000-0001-5487-7551; Rah, Jong-Cheol/0000-0003-3780-0522	Deutsche Forschungsgemeinschaft [GE1042/1-1, GE1042/3-1, GE1042/3-2, Ro1296/5-3]; NIH [NS051262, NS37200]; Netherlands Organization for Scientific Research [GpD970-10-036, GpD900-01-001, GpD916-36-043]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS051262, R01NS037200] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank N. Hamlin, I. Kornblum, A. Roth, I. Herfort, and E. Borowicz for technical assistance. This work was supported by grants from Deutsche Forschungsgemeinschaft (GE1042/1-1, GE1042/3-1, and GE1042/3-2 to S.H.G. and Ro1296/5-3 to C.R.), NIH (NS051262 to C.R. and NS37200 to J.R.), and Netherlands Organization for Scientific Research (GpD970-10-036 and 900-01-001 to M.V. and 916-36-043 to H.d.W.).	BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; Bruno N, 2005, TRENDS COGN SCI, V9, P1, DOI 10.1016/j.tics.2004.11.001; Condliffe SB, 2004, J BIOL CHEM, V279, P10085, DOI 10.1074/jbc.M313592200; de Wit H, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000126; Deken SL, 2000, NAT NEUROSCI, V3, P998, DOI 10.1038/79939; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Dulubova I, 2007, P NATL ACAD SCI USA, V104, P2697, DOI 10.1073/pnas.0611318104; Foletti DL, 2000, J NEUROSCI, V20, P4535, DOI 10.1523/JNEUROSCI.20-12-04535.2000; Jahn R, 2006, NAT REV MOL CELL BIO, V7, P631, DOI 10.1038/nrm2002; Khvotchev M, 2007, J NEUROSCI, V27, P12147, DOI 10.1523/JNEUROSCI.3655-07.2007; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; Pang ZP, 2006, EMBO J, V25, P2039, DOI 10.1038/sj.emboj.7601103; Richmond JE, 2001, NATURE, V412, P338, DOI 10.1038/35085583; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; Shen JS, 2007, CELL, V128, P183, DOI 10.1016/j.cell.2006.12.016; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Voets T, 2001, NEURON, V31, P581, DOI 10.1016/S0896-6273(01)00391-9; Weimer RM, 2003, NAT NEUROSCI, V6, P1023, DOI 10.1038/nn1118	21	205	213	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 12	2008	321	5895					1507	1510		10.1126/science.1163174	http://dx.doi.org/10.1126/science.1163174			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	347DW	18703708	Green Accepted			2022-12-28	WOS:000259121800046
J	Bhatnagar, D; Soran, H; Durrington, PN				Bhatnagar, Deepak; Soran, Handrean; Durrington, Paul N.			Hypercholesterolaemia and its management	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CORONARY-HEART-DISEASE; SERUM-CHOLESTEROL; RISK; THERAPY; STATINS; SAFETY		[Bhatnagar, Deepak] Royal Oldham Hosp, Ctr Diabet, Oldham OL1 2JH, England; [Bhatnagar, Deepak; Soran, Handrean; Durrington, Paul N.] Univ Manchester, Cardiovasc Res Grp, Core Technol Facil, Manchester M13 9NT, Lancs, England	University of Manchester	Bhatnagar, D (corresponding author), Royal Oldham Hosp, Ctr Diabet, Oldham OL1 2JH, England.	d.bhatnagar@man.ac.uk						Armitage J, 2007, LANCET, V370, P1781, DOI 10.1016/S0140-6736(07)60716-8; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Ballantyne CM, 2003, ARCH INTERN MED, V163, P553, DOI 10.1001/archinte.163.5.553; BETTERIDGE DJ, 1999, LIPOPROTEINS HLTH DI; Bhatnagar D, 2000, BRIT MED J, V321, P1497, DOI 10.1136/bmj.321.7275.1497; Charlton-Menys V, 2008, EXP PHYSIOL, V93, P27, DOI 10.1113/expphysiol.2007.035147; CHAUDHURY M, 2004, HLTH SURVEY ENGLAND, V2, P241; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; *DEP HLTH, 2000, NAT SERV FRAM COR HE; Durrington P, 2003, LANCET, V362, P717, DOI 10.1016/S0140-6736(03)14234-1; Durrington P.N., 2007, HYPERLIPIDAEMIA DIAG, V3rd; Durrington PN, 1999, LANCET, V353, P278, DOI 10.1016/S0140-6736(98)04027-6; Goldstein JL, 2001, METABOLIC MOL BASES, V8th, P2863; HAFFNER SM, 1990, JAMA-J AM MED ASSOC, V263, P2893, DOI 10.1001/jama.263.21.2893; Kane J, 2001, METAB MOL BASES INHE, P2717; Katan MB, 2003, MAYO CLIN PROC, V78, P965, DOI 10.4065/78.8.965; LAROSA JC, 1990, CIRCULATION, V81, P1721, DOI 10.1161/01.CIR.81.5.1721; Law MR, 2003, BRIT MED J, V326, P1423, DOI 10.1136/bmj.326.7404.1423; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Mahley RW., 2001, METABOLIC MOL BASES, V8th ed, P2835; National Institute for Health and Clinical Excellence, 2008, LIP MOD CARD RISK AS; Rioufol G, 2004, CIRCULATION, V110, P2875, DOI 10.1161/01.CIR.0000146337.05073.22; Sarwar N, 2007, CIRCULATION, V115, P450, DOI 10.1161/CIRCULATIONAHA.106.637793; Scriver C.R., 2001, METABOLIC MOL BASES; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; STONE NJ, 1974, CIRCULATION, V49, P476, DOI 10.1161/01.CIR.49.3.476; Tang JL, 1998, BMJ-BRIT MED J, V316, P1213, DOI 10.1136/bmj.316.7139.1213; Wood D, 2005, HEART, V91, P1, DOI 10.1136/hrt.2005.079988	28	81	84	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 30	2008	337	7668							a993	10.1136/bmj.a993	http://dx.doi.org/10.1136/bmj.a993			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350OM	18719012				2022-12-28	WOS:000259362100029
J	Kohsaka, Y; Taylor, C; Wahl, P; Schmidt, A; Lee, J; Fujita, K; Alldredge, JW; McElroy, K; Lee, J; Eisaki, H; Uchida, S; Lee, DH; Davis, JC				Kohsaka, Y.; Taylor, C.; Wahl, P.; Schmidt, A.; Lee, Jhinhwan; Fujita, K.; Alldredge, J. W.; McElroy, K.; Lee, Jinho; Eisaki, H.; Uchida, S.; Lee, D. -H.; Davis, J. C.			How cooper pairs vanish approaching the Mott insulator in Bi2Sr2CaCu2O8+delta	NATURE			English	Article							QUASI-PARTICLES; PHYSICS; PSEUDOGAP; EVOLUTION	The antiferromagnetic ground state of copper oxide Mott insulators is achieved by localizing an electron at each copper atom in real space (r-space). Removing a small fraction of these electrons ( hole doping) transforms this system into a superconducting fluid of delocalized Cooper pairs in momentum space ( k- space). During this transformation, two distinctive classes of electronic excitations appear. At high energies, the mysterious 'pseudogap' excitations are found, whereas, at lower energies, Bogoliubov quasi- particles - the excitations resulting from the breaking of Cooper pairs should exist. To explore this transformation, and to identify the two excitation types, we have imaged the electronic structure of Bi2Sr2CaCu2O8+delta in r- space and k- space simultaneously. We find that although the low- energy excitations are indeed Bogoliubov quasi- particles, they occupy only a restricted region of k- space that shrinks rapidly with diminishing hole density. Concomitantly, spectral weight is transferred to higher energy r- space states that lack the characteristics of excitations from delocalized Cooper pairs. Instead, these states break translational and rotational symmetries locally at the atomic scale in an energy- independent way. We demonstrate that these unusual r- space excitations are, in fact, the pseudogap states. Thus, as the Mott insulating state is approached by decreasing the hole density, the delocalized Cooper pairs vanish from k- space, to be replaced by locally translational- and rotational- symmetry- breaking pseudogap states in r- space.	[Kohsaka, Y.; Taylor, C.; Wahl, P.; Schmidt, A.; Lee, Jhinhwan; Fujita, K.; Alldredge, J. W.; Lee, Jinho; Davis, J. C.] Cornell Univ, Dept Phys, LASSP, Ithaca, NY 14853 USA; [Kohsaka, Y.] RIKEN, Wako, Saitama 3510198, Japan; [Fujita, K.] Univ Tokyo, Dept Phys, Bunkyo Ku, Tokyo 1130033, Japan; [Alldredge, J. W.; McElroy, K.] Univ Colorado, Dept Phys, Boulder, CO 80309 USA; [Lee, Jinho] Univ St Andrews, Sch Phys & Astron, St Andrews KY16 9SS, Fife, Scotland; [Lee, Jinho; Davis, J. C.] Brookhaven Natl Lab, CMPMS Dept, Upton, NY 11973 USA; [Eisaki, H.] Natl Inst Adv Ind Sci & Technol, Tsukuba, Ibaraki 3058568, Japan; [Lee, D. -H.] Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA	Cornell University; RIKEN; University of Tokyo; University of Colorado System; University of Colorado Boulder; University of St Andrews; United States Department of Energy (DOE); Brookhaven National Laboratory; National Institute of Advanced Industrial Science & Technology (AIST); University of California System; University of California Berkeley	Davis, JC (corresponding author), Cornell Univ, Dept Phys, LASSP, Ithaca, NY 14853 USA.	jcdavis@ccmr.cornell.edu	Lee, Jhinhwan/I-3727-2012; Kohsaka, Yuhki/A-4428-2009; Eisaki, Hiroshi/F-6317-2018; Wahl, Peter/F-9337-2014; Lee, Jhinhwan/C-2074-2011; mcelroy, kyle/D-1816-2013	Lee, Jhinhwan/0000-0001-7159-6305; Kohsaka, Yuhki/0000-0002-6459-2661; Eisaki, Hiroshi/0000-0002-8299-6416; Wahl, Peter/0000-0002-8635-1519; McElroy, Kyle/0000-0003-4799-2820	US National Science Foundation through the Cornell Center for Material Research; Brookhaven National Laboratory; US Department of Energy; US Office of Naval Research; Ministry of Science and Education (Japan); 21st Century COE Program of the Japan Society for the Promotion of Science.; Humboldt Foundation; US Army Research Office	US National Science Foundation through the Cornell Center for Material Research(National Science Foundation (NSF)); Brookhaven National Laboratory(United States Department of Energy (DOE)); US Department of Energy(United States Department of Energy (DOE)); US Office of Naval Research(Office of Naval Research); Ministry of Science and Education (Japan); 21st Century COE Program of the Japan Society for the Promotion of Science.(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Humboldt Foundation(Alexander von Humboldt Foundation); US Army Research Office	We acknowledge and thank A. V. Balatsky, J. C. Campuzano, E. Fradkin, A. Georges, T. Hanaguri, P. J. Hirschfeld, S. Kivelson, E.-A. Kim, G. Kotliar, P. A. Lee, M. Norman, P. Phillips, M. Randeria, T. M. Rice, S. Sachdev, K. Shen, Z. X. Shen, A. Tsvelik, M. Vojta and F. C. Zhang for discussions. This work was supported by the US National Science Foundation through the Cornell Center for Material Research, by Brookhaven National Laboratory, by the US Department of Energy, by the US Office of Naval Research, by a Grant-in-Aid for Scientific Research from the Ministry of Science and Education (Japan), and by the 21st Century COE Program of the Japan Society for the Promotion of Science. P. W. acknowledges support from the Humboldt Foundation and A. S. acknowledges support from the US Army Research Office.	Alldredge JW, 2008, NAT PHYS, V4, P319, DOI 10.1038/nphys917; Altman E, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.104508; Anderson PW, 2004, J PHYS-CONDENS MAT, V16, pR755, DOI 10.1088/0953-8984/16/24/R02; Balents L, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.144509; Berthod C, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.136401; Capriotti L, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.014508; Chakravarty S, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.094503; Chatterjee U, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.012504; Chatterjee U, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.107006; Civelli M, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.046402; Civelli M, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.106402; CROMMIE MF, 1993, NATURE, V363, P524, DOI 10.1038/363524a0; Fischer O, 2007, REV MOD PHYS, V79, P353, DOI 10.1103/RevModPhys.79.353; Gedik N, 2003, SCIENCE, V300, P1410, DOI 10.1126/science.1083038; Granath M, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.165128; Graser S, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.184504; Hanaguri T, 2007, NAT PHYS, V3, P865, DOI 10.1038/nphys753; Honerkamp C, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.035109; Hufner S, 2008, REP PROG PHYS, V71, DOI 10.1088/0034-4885/71/6/062501; Kanigel A, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.157001; Kanigel A, 2006, NAT PHYS, V2, P447, DOI 10.1038/nphys334; Kim EA, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.184514; Kohsaka Y, 2007, SCIENCE, V315, P1380, DOI 10.1126/science.1138584; Konik RM, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.086407; Lang KM, 2002, NATURE, V415, P412, DOI 10.1038/415412a; Le Tacon M, 2006, NAT PHYS, V2, P537, DOI 10.1038/nphys362; Lee PA, 2006, REV MOD PHYS, V78, P17, DOI 10.1103/RevModPhys.78.17; Lee WC, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.214518; McElroy K, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.067005; McElroy K, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.197005; McElroy K, 2003, NATURE, V422, P592, DOI 10.1038/nature01496; Norman MR, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.174501; Norman MR, 1998, NATURE, V392, P157, DOI 10.1038/32366; Nunner TS, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.104511; Orenstein J, 2000, SCIENCE, V288, P468, DOI 10.1126/science.288.5465.468; Paramekanti A, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.217002; Pelissetto A, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.027005; Senechal D, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.126401; Shen KM, 2005, SCIENCE, V307, P901, DOI 10.1126/science.1103627; Stanescu TD, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.104503; Stanescu TD, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.125110; Tanaka K, 2006, SCIENCE, V314, P1910, DOI 10.1126/science.1133411; Tesanovic Z, 2008, NAT PHYS, V4, P408, DOI 10.1038/nphys910; VOJTA M, 2008, ELECT PROPERTIES DIS; Vojta M, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.094504; Wang QH, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.020511; Yang KY, 2006, PHYS REV B, V73, DOI 10.1103/PhysRevB.73.174501	50	285	288	0	86	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	2008	454	7208					1072	1078		10.1038/nature07243	http://dx.doi.org/10.1038/nature07243			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341MW	18756248	Green Submitted			2022-12-28	WOS:000258719600028
J	Rousseau, P				Rousseau, Paul			Seventy-two hours	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												palliativedoctor@aol.com							0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2008	300	8					882	883		10.1001/jama.300.8.882	http://dx.doi.org/10.1001/jama.300.8.882			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	341AR	18728250				2022-12-28	WOS:000258687100001
J	Heath, I				Heath, Iona			Dare to use your own intelligence	BRITISH MEDICAL JOURNAL			English	Editorial Material												iona.heath@dsl.pipex.com						2008, BMJ, V337, pA1262; 1919, J CLIN EPIDEMOLOGY, V51, P297	2	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 23	2008	337	7667							a1319	10.1136/bmj.a1319	http://dx.doi.org/10.1136/bmj.a1319			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	346FD	18713804				2022-12-28	WOS:000259053100023
J	Horton, R				Horton, Richard			The art of medicine - The diplomatic library	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Horton, R (corresponding author), The Lancet, 32 Jamestown Rd, London NW1 7BY, England.								0	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 23	2008	372	9639					622	623		10.1016/S0140-6736(08)61264-7	http://dx.doi.org/10.1016/S0140-6736(08)61264-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	340BX	18727179	Bronze			2022-12-28	WOS:000258622200014
J	Molina, JM; Andrade-Villanueva, J; Echevarria, J; Chetchotisakd, P; Corral, J; David, N; Moyle, G; Mancini, M; Percival, L; Yang, R; Thiry, A; McGrath, D				Molina, Jean-Michel; Andrade-Villanueva, Jaime; Echevarria, Juan; Chetchotisakd, Ploenchan; Corral, Jorge; David, Neal; Moyle, Graeme; Mancini, Marco; Percival, Lisa; Yang, Rong; Thiry, Alexandra; McGrath, Donnie		CASTLE Study Team	Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and erntricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEASE INHIBITOR; THERAPY; EFAVIRENZ; ADHERENCE; REGIMENS; EMTRICITABINE; MEDICATIONS; DIDANOSINE; ADULTS	Background Atazanavir/ritonavir is as effective as lopinavir/ritonavir, with a more favourable lipid profile and less gastrointestinal toxicity, in treatment-experienced HIV-1-infected patients. We compared these two combinations directly in treatment-naive patients. Methods In this open-label, international non-inferiority study, 883 antiretroviral-naive, HIV-1-infected patients were randomly assigned to receive atazanavir/ritonavir 300/100 mg once daily (n=440) or lopinavir/ritonavir 400/100 mg twice daily (n=443), in combination with fixed-dose tenofovir/emtricitabine 300/200 mg once daily. Randomisation was done with a computer-generated centralised randomisation schedule and was stratified by baseline levels of HIV RNA (viral load) and geographic region. The primary endpoint was the proportion of patients with viral load less than 50 copies per mL at week 48. The main efficacy analysis was done by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00272779. Findings At week 48, 343 (78%) of 440 patients receiving atazanavir/ritonavir and 338 (76%) of 443 patients receiving lopinavir/ritonavir had achieved a viral load of less than 50 copies per mL (difference 1.7%, 95% CI -3.8 to 7.1). Mean increases from baseline in CD4 cell count were similar (203 cells per pL in the atazanavir/ritonavir group vs 219 cells per pL in the lopinavir/ritonavir group). 25 (6%) patients in the atazanavir/ritonavir group and 26 (6%) in the lopinavir/ ritonavir group were virological failures by week 48. Only two patients, both in the atazanavir/ritonavir group, had non-polymorphic protease inhibitor resistance mutations emerge oil treatment, which conferred phenotypic resistance to atazanavir in one patient. Serious adverse events were noted in 51 (12%) of 441 patients in the atazanavir/ritonavir group and in 42 (10%) of 437 patients in the lopinavir/ritonavir group. Fewer patients in the atazanavir/ritonavir group than in the lopinavir/ritonavir group experienced grade 2-4 treatment-related diarrhoea (10 [2%] vs 50 [11%]) and nausea (17 [4%] vs 33 [8%]). Grade 2-4 jaundice was seen in 16 (458) of 441 patients in the atazanavir/ritonavir group versus none of 437 patients in the lopinavir/ritonavir group; grade 3-4 increases in total bilirubin were seen in 146 (34%) of 435 patients on atazanavir/ritonavir and in one (<1%) of 431 patients on lopinavir/ritonavir. Interpretation In treatment-naive patients, atazanavir/ritonavir once-daily demonstrated similar antiviral efficacy to lopinavir/ritonavir twice-daily, with less gastrointestinal toxicity but with a higher rate of hyperbilirubinaemia. Funding Bristol-Myers Squibb.	[Molina, Jean-Michel] Hop St Louis, Dept Infect Dis, AP HP, Paris, France; [Molina, Jean-Michel] Univ Paris 07, F-75221 Paris 05, France; [Andrade-Villanueva, Jaime] Hosp Civil Guadalajara, Guadalajara, Jalisco, Mexico; [Echevarria, Juan] Hosp Nacl Cayetano Heredia, Lima, Peru; [Chetchotisakd, Ploenchan] Khon Kaen Univ, Dept Med, Khon Kaen, Thailand; [Corral, Jorge] Hosp Int Gral De Agudos Oscar Alende, Buenos Aires, DF, Argentina; [David, Neal] Brooklyn Med Ctr, Western Cape, South Africa; [Moyle, Graeme] Chelsea & Westminster Hosp, London, England; [Mancini, Marco; Percival, Lisa; Yang, Rong; Thiry, Alexandra; McGrath, Donnie] Bristol Myers Squibb Co, Wallingford, CT 06492 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Khon Kaen University; Imperial College London; Bristol-Myers Squibb	Molina, JM (corresponding author), Hop St Louis 1, Dept Infect Dis, Av C Vellefaux, F-75475 Paris 10, France.	jean-michel.molina@sls.aphp.fr	da Eira, Margareth/A-1965-2013; Pulido, Federico/B-8417-2009; Bergmann, Jean-Francois/L-6044-2017; Arribas, Jose/A-1595-2015; Andrade-Villanueva, Jaime Federico/GPK-6845-2022	Pulido, Federico/0000-0002-7414-8812; Bergmann, Jean-Francois/0000-0001-6861-9748; Eira, Margareth/0000-0002-6203-9600; Arribas, Jose/0000-0002-7410-9450; Andrade-Villanueva, Jaime Federico/0000-0003-1948-655X	Bristol-Myers Squibb	Bristol-Myers Squibb(Bristol-Myers Squibb)	We thank the investigators, study coordinators, site and data managers, and patients for their contributions. We also thank the Bristol-Myers Squibb team members: A Rightmire, C Day, M Ricciuti, M Mathew, R Bertz, M Child, C Tasker, A Gadoury, P Mrowiec, "DeGrosky, A Gopinathan, and I Absalon. Editorial support was provided by Cheryl Jenkins (Parexel, Worthing, UK) and was funded by Bristol-Myers Squibb.	Beusterien KM, 2007, AIDS CARE, V19, P982, DOI 10.1080/09540120701294278; CARR A, 2008, 15 C RETR OPP INF BO; Chesney MA, 2000, AIDS CARE, V12, P255, DOI 10.1080/09540120050042891; Conway B, 2007, JAIDS-J ACQ IMM DEF, V45, pS14, DOI 10.1097/QAI.0b013e3180600766; Crum NF, 2006, JAIDS-J ACQ IMM DEF, V41, P194, DOI 10.1097/01.qai.0000179459.31562.16; *DEP HHS, GUID US ANT AG HIV I; Dube Michael P, 2008, Circulation, V118, pe36, DOI 10.1161/CIRCULATIONAHA.107.189625; Joseph E, 2006, LANCET, V368, P476, DOI 10.1016/S0140-6736(06)69155-1; European AIDS Clinical Society, EACS GUID; Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993, DOI 10.1056/NEJMoa030218; Friis-Moller N, 2007, NEW ENGL J MED, V356, P1723, DOI 10.1056/NEJMoa062744; Gathe J, 2008, 15 C RETR OPP INF BO; Gazzard B, 2006, HIV MED, V7, P487, DOI 10.1111/j.1468-1293.2006.00424.x; Hammer SM, 2006, JAMA-J AM MED ASSOC, V296, P827, DOI 10.1001/jama.296.7.827; Hariri S, 2007, CLIN MICROBIOL REV, V20, P478, DOI 10.1128/CMR.00006-07; Harrison TS, 2005, DRUGS, V65, P2309, DOI 10.2165/00003495-200565160-00010; Jemsek JG, 2006, CLIN INFECT DIS, V42, P273, DOI 10.1086/498505; Johnson M, 2006, AIDS, V20, P711, DOI 10.1097/01.aids.0000216371.76689.63; Johnson Victoria A, 2007, Top HIV Med, V15, P119; King MS, 2004, J INFECT DIS, V190, P280, DOI 10.1086/422037; Kleeberger CA, 2001, J ACQ IMMUN DEF SYND, V26, P82, DOI 10.1097/00126334-200101010-00012; Law MG, 2006, HIV MED, V7, P218, DOI 10.1111/j.1468-1293.2006.00362.x; Lodwick RK, 2008, AIDS, V22, P1039, DOI 10.1097/QAD.0b013e3282fec415; Molina JM, 2007, ANTIVIR THER, V12, P417; Molina JM, 2005, J INFECT DIS, V191, P830, DOI 10.1086/428091; Malan DR, 2008, JAIDS-J ACQ IMM DEF, V47, P161, DOI 10.1097/QAI.0b013e31815ace6a; Ortiz R, 2008, AIDS, V22, P1389, DOI 10.1097/QAD.0b013e32830285fb; Perez-Elias MJ, 2007, EXPERT OPIN PHARMACO, V8, P689, DOI 10.1517/14656566.8.5.689; Robinson BS, 2000, ANTIMICROB AGENTS CH, V44, P2093, DOI 10.1128/AAC.44.8.2093-2099.2000; SMITH KY, 2008, 15 C RETR OPP INF BO; Vo TTN, 2008, J INFECT DIS, V197, P1685, DOI 10.1086/588141; Walmsley S, 2007, JAIDS-J ACQ IMM DEF, V45, pS5, DOI 10.1097/QAI.0b013e3180600709; World Health Organization, 2006, ANT THER HIV INF AD	33	326	336	0	35	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	2008	372	9639					646	655		10.1016/S0140-6736(08)61081-8	http://dx.doi.org/10.1016/S0140-6736(08)61081-8			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	340BX	18722869				2022-12-28	WOS:000258622200028
J	Schmidt, D				Schmidt, Dieter			Antiepileptic drug withdrawal in seizure-free patients	LANCET			English	Editorial Material							EPILEPSY		Epilepsy Res Grp Berlin, D-14163 Berlin, Germany	Epilepsy Research Group	Schmidt, D (corresponding author), Epilepsy Res Grp Berlin, D-14163 Berlin, Germany.	dbschmidt@t-online.de						CALLAGHAN N, 1988, NEW ENGL J MED, V318, P942, DOI 10.1056/NEJM198804143181502; CHADWICK D, 1991, LANCET, V337, P1175; Duncan JS, 2006, LANCET, V367, P1087, DOI 10.1016/S0140-6736(06)68477-8; Gowers WR, 1885, EPILEPSY OTHER CHRON, P210; JACOBY A, 1992, EPILEPSIA, V33, P1123, DOI 10.1111/j.1528-1157.1992.tb01769.x; Kwan P, 2000, NEW ENGL J MED, V342, P314, DOI 10.1056/NEJM200002033420503; Lossius MI, 2008, EPILEPSIA, V49, P455, DOI 10.1111/j.1528-1167.2007.01323.x; OVERWEG J, 1987, EPILEPSY RES, V1, P272, DOI 10.1016/0920-1211(87)90002-7; Sieveking E.H, 1857, LANCET, Vi, P527; Specchio LM, 2002, J NEUROL NEUROSUR PS, V72, P22, DOI 10.1136/jnnp.72.1.22	10	2	2	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 23	2008	372	9639					610	612		10.1016/S0140-6736(08)61256-8	http://dx.doi.org/10.1016/S0140-6736(08)61256-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	340BX	18722852				2022-12-28	WOS:000258622200008
J	Wang, YZ; Xie, YM; Wei, PR; King, RB; Schaefer, HF; Schleyer, PV; Robinson, GH				Wang, Yuzhong; Xie, Yaoming; Wei, Pingrong; King, R. Bruce; Schaefer, Henry F., III; Schleyer, Paul von R.; Robinson, Gregory H.			A stable silicon(0) compound with a Si=Si double bond	SCIENCE			English	Article							CHLOROSILYLENE; COMPLEXES; MOLECULES; SILYLENE; PLANAR; SI-2; BENT	Dative, or nonoxidative, ligand coordination is common in transition metal complexes; however, this bonding motif is rare in compounds of main group elements in the formal oxidation state of zero. Here, we report that the potassium graphite reduction of the neutral hypervalent silicon- carbene complex L:SiCl4 {where L: is : C[N(2,6-Pr-2(i)-C6H3)CH](2) and Pr-i is isopropyl} produces L:(Cl)Si-Si(Cl):L, a carbene- stabilized bis- silylene, and L:Si= Si:L, a carbene- stabilized diatomic silicon molecule with the Si atoms in the formal oxidation state of zero. The Si-Si bond distance of 2.2294 +/- 0.0011 ( standard deviation) angstroms in L:Si= Si:L is consistent with a Si=Si double bond. Complementary computational studies confirm the nature of the bonding in L:(Cl)Si-Si(Cl):L and L:Si=Si:L.	[Wang, Yuzhong; Xie, Yaoming; Wei, Pingrong; King, R. Bruce; Schaefer, Henry F., III; Schleyer, Paul von R.; Robinson, Gregory H.] Univ Georgia, Dept Chem, Athens, GA 30602 USA; [Wang, Yuzhong; Xie, Yaoming; Wei, Pingrong; King, R. Bruce; Schaefer, Henry F., III; Schleyer, Paul von R.; Robinson, Gregory H.] Univ Georgia, Ctr Computat Chem, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Schleyer, PV (corresponding author), Univ Georgia, Dept Chem, Athens, GA 30602 USA.	schleyer@chem.uga.edu; robinson@chem.uga.edu	Wang, Yuzhong/G-8842-2012	Wang, Yuzhong/0000-0003-3557-5085	NSF [CHE-0608142, CHE-0716718]	NSF(National Science Foundation (NSF))	We thank NSF for support of this work through grants CHE-0608142 ( G. H. R.) and CHE- 0716718 ( P. v. R. S. and R. B. K.). Coordinates and other crystallographic information for compounds 1, 2, and 3 have been deposited in the Cambridge Crystallographic Database Center with deposition numbers 686707, 686708, and 687305, respectively.	AKIBA KY, 1999, CHEM HYPERVALENT COM; Bourissou D, 2000, CHEM REV, V100, P39, DOI 10.1021/cr940472u; COLEGROVE BT, 1990, J PHYS CHEM-US, V94, P5593, DOI 10.1021/j100377a036; Corey J. Y., 1989, CHEM ORGANIC SILICON, V1; CORRIU R, 1994, J ORGANOMET CHEM, V466, P55, DOI 10.1016/0022-328X(94)88029-8; COWLEY AH, 1969, J AM CHEM SOC, V91, P1922, DOI 10.1021/ja01036a009; DENK M, 1994, J AM CHEM SOC, V116, P2691, DOI 10.1021/ja00085a088; Dyker CA, 2008, ANGEW CHEM INT EDIT, V47, P3206, DOI 10.1002/anie.200705620; Frisch M.J., 2016, GAUSSIAN16 REV B01; GASPAR PP, 1998, CHEM ORGANIC SILIC 3, V2, pCH43; Jutzi P., 2003, SILICON CHEM ATOM EX; Krapp A, 2006, CHEM-EUR J, V12, P9196, DOI 10.1002/chem.200600564; KUHN N, 1995, CHEM BER, V128, P245, DOI 10.1002/cber.19951280307; MACDONALD CLB, 2005, ENCY INORGANIC CHEM, V5, P2718; Molev G, 2006, J AM CHEM SOC, V128, P2784, DOI 10.1021/ja0575880; NESPER R, 1996, ORGANOSILICON CHEM, V2, P469; NIMLOS MR, 1987, J CHEM PHYS, V87, P5116, DOI 10.1063/1.453679; Ottosson H, 2006, CHEM-EUR J, V12, P1576, DOI 10.1002/chem.200500429; Pak C, 2000, J PHYS CHEM A, V104, P11232, DOI 10.1021/jp003029y; Power PP, 1999, CHEM REV, V99, P3463, DOI 10.1021/cr9408989; Schlegel HB., 2009, GAUSSIAN 09 REVISION; Sekiguchi A, 2004, SCIENCE, V305, P1755, DOI 10.1126/science.1102209; So CW, 2006, ANGEW CHEM INT EDIT, V45, P3948, DOI 10.1002/anie.200600647; Takahashi M, 2005, ORGANOMETALLICS, V24, P2433, DOI 10.1021/om050025c; Takeda N, 1997, J AM CHEM SOC, V119, P1456, DOI 10.1021/ja963092u; VANZEE RJ, 1985, J CHEM PHYS, V83, P6181, DOI 10.1063/1.449614; Wang YZ, 2008, J AM CHEM SOC, V130, P3298, DOI 10.1021/ja800257j; Wang Y, 2007, J AM CHEM SOC, V129, P12412, DOI 10.1021/ja075932i; Weidenbruch M, 2006, ANGEW CHEM INT EDIT, V45, P4241, DOI 10.1002/anie.200601414; Weidenbruch M., 2001, CHEM ORGANIC SILICON, V3; WEST R, 1981, SCIENCE, V214, P1343, DOI 10.1126/science.214.4527.1343; Zhou MF, 2004, J CHEM PHYS, V121, P10474, DOI 10.1063/1.1811078	32	550	554	2	188	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	2008	321	5892					1069	1071		10.1126/science.1160768	http://dx.doi.org/10.1126/science.1160768			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339RL	18719279				2022-12-28	WOS:000258594900034
J	Wilson, TD; Bar-Anan, Y				Wilson, Timothy D.; Bar-Anan, Yoav			Psychology - The unseen mind	SCIENCE			English	Editorial Material							SOCIAL COGNITION; IMPLICIT; RATIONALIZATION		[Wilson, Timothy D.; Bar-Anan, Yoav] Univ Virginia, Charlottesville, VA 22904 USA	University of Virginia	Wilson, TD (corresponding author), Univ Virginia, Charlottesville, VA 22904 USA.	twilson@virginia.edu	Bar-Anan, Yoav/AAM-7229-2021; Bar-Anan, Yoav/F-1679-2012					Bargh J. A., 1997, ADV SOC COG, VX, P1; Dijksterhuis A, 2006, PERSPECT PSYCHOL SCI, V1, P95, DOI 10.1111/j.1745-6916.2006.00007.x; EVANS JSBT, 1976, BRIT J PSYCHOL, V67, P479, DOI 10.1111/j.2044-8295.1976.tb01536.x; Fazio RH, 2003, ANNU REV PSYCHOL, V54, P297, DOI 10.1146/annurev.psych.54.101601.145225; Galdi S, 2008, SCIENCE, V321, P1100, DOI 10.1126/science.1160769; Gazzaniga M, 1978, THE INTEGRATED MIND; GREENWALD AG, 1995, PSYCHOL REV, V102, P4, DOI 10.1037/0033-295X.102.1.4; Hassin Ran R., 2005, NEW UNCONSCIOUS; Johansson P, 2005, SCIENCE, V310, P116, DOI 10.1126/science.1111709; NISBETT RE, 1977, PSYCHOL REV, V84, P231, DOI 10.1037/0033-295X.84.3.231; Nosek BA, 2007, CURR DIR PSYCHOL SCI, V16, P65, DOI 10.1111/j.1467-8721.2007.00477.x; RAHN WM, 1994, AM J POLIT SCI, V38, P582, DOI 10.2307/2111598; Wegner D.M., 2003, ILLUSION CONSCIOUS W; Wilson T. D., 2002, STRANGERS OURSELVES; Wilson TD, 2000, PSYCHOL REV, V107, P101, DOI 10.1037/0033-295X.107.1.101	15	32	32	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 22	2008	321	5892					1046	1047		10.1126/science.1163029	http://dx.doi.org/10.1126/science.1163029			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	339RL	18719269				2022-12-28	WOS:000258594900023
J	Peters, NC; Egen, JG; Secundino, N; Debrabant, A; Kimblin, N; Kamhawi, S; Lawyer, P; Fay, MP; Germain, RN; Sacks, D				Peters, Nathan C.; Egen, Jackson G.; Secundino, Nagila; Debrabant, Alain; Kimblin, Nicola; Kamhawi, Shaden; Lawyer, Phillip; Fay, Michael P.; Germain, Ronald N.; Sacks, David			In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies	SCIENCE			English	Article							MAJOR INFECTION; MICE; CELLS; MACROPHAGE; APOPTOSIS; SKIN; GRANULOCYTES; RECRUITMENT; MODULATION; CLEARANCE	Infection with the obligate intracellular protozoan Leishmania is thought to be initiated by direct parasitization of macrophages, but the early events following transmission to the skin by vector sand flies have been difficult to examine directly. Using dynamic intravital microscopy and flow cytometry, we observed a rapid and sustained neutrophilic infiltrate at localized sand fly bite sites. Invading neutrophils efficiently captured Leishmania major ( L. m.) parasites early after sand fly transmission or needle inoculation, but phagocytosed L. m. remained viable and infected neutrophils efficiently initiated infection. Furthermore, neutrophil depletion reduced, rather than enhanced, the ability of parasites to establish productive infections. Thus, L. m. appears to have evolved to both evade and exploit the innate host response to sand fly bite in order to establish and promote disease.	[Egen, Jackson G.; Germain, Ronald N.] NIAID, Immunol Lab, Bethesda, MD 20892 USA; [Peters, Nathan C.; Secundino, Nagila; Kimblin, Nicola; Kamhawi, Shaden; Lawyer, Phillip; Sacks, David] NIAID, Parasit Dis Lab, Bethesda, MD 20892 USA; [Debrabant, Alain] US FDA, Lab Bacterial Parasit & Unconvent Agents, Div Emerging & Transfus Transmitted Dis, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; [Fay, Michael P.] NIAID, Biostat Res Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Egen, JG (corresponding author), NIAID, Immunol Lab, Bldg 10, Bethesda, MD 20892 USA.	jegen@niaid.nih.gov; dsacks@nih.gov	Okpebholo, Love/A-8163-2010; Germain, Ronald N./Z-1945-2019; Secundino, Nagila/AAM-4553-2020; Germain, Ronald/ABE-7090-2020; Peters, Nathan/AAW-8289-2020; Fay, Michael P/A-2974-2008	Peters, Nathan/0000-0002-2548-9581; Fay, Michael P/0000-0002-8643-9625; Egen, Jackson/0000-0003-2053-0837	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000494, ZIAAI000256, ZIAAI001034] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 AI000256-26, Z01 AI000494-21] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Aga E, 2002, J IMMUNOL, V169, P898, DOI 10.4049/jimmunol.169.2.898; Amino R, 2006, NAT MED, V12, P220, DOI 10.1038/nm1350; Belkaid Y, 2000, P NATL ACAD SCI USA, V97, P6704, DOI 10.1073/pnas.97.12.6704; Belkaid Y, 2000, J IMMUNOL, V165, P969, DOI 10.4049/jimmunol.165.2.969; Boes M, 2002, NATURE, V418, P983, DOI 10.1038/nature01004; Burnett SH, 2004, J LEUKOCYTE BIOL, V75, P612, DOI 10.1189/jlb.0903442; Charmoy M, 2007, J LEUKOCYTE BIOL, V82, P288, DOI 10.1189/jlb.0706440; Chen L, 2005, PARASITOL INT, V54, P109, DOI 10.1016/j.parint.2005.02.001; Faust N, 2000, BLOOD, V96, P719; Gregory CD, 2004, IMMUNOLOGY, V113, P1, DOI 10.1111/j.1365-2567.2004.01959.x; Kamhawi S, 2000, SCIENCE, V290, P1351, DOI 10.1126/science.290.5495.1351; Kim JV, 2006, J IMMUNOL, V177, P5269, DOI 10.4049/jimmunol.177.8.5269; Kimblin N, 2008, P NATL ACAD SCI USA, V105, P10125, DOI 10.1073/pnas.0802331105; Krysko DV, 2006, APOPTOSIS, V11, P1709, DOI 10.1007/s10495-006-9527-8; Martin P, 2005, TRENDS CELL BIOL, V15, P599, DOI 10.1016/j.tcb.2005.09.002; Matte C, 2002, J INFECT DIS, V185, P673, DOI 10.1086/339260; Nauseef WM, 2007, IMMUNOL REV, V219, P88, DOI 10.1111/j.1600-065X.2007.00550.x; Peters N, 2006, IMMUNOL REV, V213, P159, DOI 10.1111/j.1600-065X.2006.00432.x; Ribeiro-Gomes FL, 2006, PARASITOLOGY, V132, pS61, DOI 10.1017/S0031182006000862; Segal AW, 2005, ANNU REV IMMUNOL, V23, P197, DOI 10.1146/annurev.immunol.23.021704.115653; Soong L, 2008, J IMMUNOL, V180, P4355, DOI 10.4049/jimmunol.180.7.4355; Tacchini-Cottier F, 2000, J IMMUNOL, V165, P2628, DOI 10.4049/jimmunol.165.5.2628; Teixeira CR, 2005, J IMMUNOL, V175, P8346, DOI 10.4049/jimmunol.175.12.8346; Van Zandbergen G, 2007, AUTOIMMUNITY, V40, P349, DOI 10.1080/08916930701356960; van Zandbergen G, 2004, J IMMUNOL, V173, P6521, DOI 10.4049/jimmunol.173.11.6521; Vanderberg JP, 2004, INT J PARASITOL, V34, P991, DOI 10.1016/j.ijpara.2004.05.005	26	571	581	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2008	321	5891					970	974		10.1126/science.1159194	http://dx.doi.org/10.1126/science.1159194			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	337LD	18703742	Green Accepted			2022-12-28	WOS:000258436700041
J	Boucek, MM; Mashburn, C; Dunn, SM; Frizell, R; Edwards, L; Pietra, B; Campbell, D				Boucek, Mark M.; Mashburn, Christine; Dunn, Susan M.; Frizell, Rebecca; Edwards, Leah; Pietra, Biagio; Campbell, David		Denver Childrens Pediat Heart	Pediatric heart transplantation after declaration of cardiocirculatory death	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIAC TRANSPLANTATION	In three infants awaiting orthotopic cardiac transplantation, transplantation was successfully performed with the use of organs from donors who had died from cardiocirculatory causes. The three recipients had blood group O and were in the highest-risk waiting-list category. The mean age of donors was 3.7 days, and the mean time to death after withdrawal from life support was 18.3 minutes. The 6-month survival rate was 100% for the 3 transplant recipients and 84% for 17 control infants who received transplants procured through standard organ donation. The mean number of rejection episodes among the three infants during the first 6 months after surgery was 0.3 per patient, as compared with 0.4 per patient among the controls. Echocardiographic measures of ventricular size and function at 6 months were similar among the three infants and the controls (left ventricular shortening fraction, 43.6% and 44.9%, respectively; P=0.73). No late deaths (within 3.5 years) have occurred in the three infants, and they have had functional and immunologic outcomes similar to those of controls. Mortality while awaiting a transplant is an order of magnitude higher in infants than in adults, and donors who died from cardiocirculatory causes offer an opportunity to decrease this waiting-list mortality.	[Boucek, Mark M.; Mashburn, Christine] Joe DiMaggio Childrens Hosp, Dept Pediat, Hollywood, FL 33021 USA; [Dunn, Susan M.; Frizell, Rebecca] Donor Alliance, Denver, CO USA; [Edwards, Leah] United Network Organ Sharing, Richmond, VA USA; [Pietra, Biagio; Campbell, David] Univ Colorado, Hlth Sci Ctr, Div Pediat & Cardiothorac Surg, Denver, CO USA	United Network for Organ Sharing; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Boucek, MM (corresponding author), Joe DiMaggio Childrens Hosp, Dept Pediat, 1150 North Ave,Suite 575, Hollywood, FL 33021 USA.	mboucek@mhs.net						BAILEY LL, 1986, NEW ENGL J MED, V315, P949, DOI 10.1056/NEJM198610093151507; BARNARD C N, 1967, South African Medical Journal, V41, P1271; Bernat JL, 2006, AM J TRANSPLANT, V6, P281, DOI 10.1111/j.1600-6143.2005.01194.x; Boucek MM, 2007, J HEART LUNG TRANSPL, V26, P796, DOI 10.1016/j.healun.2007.06.006; BOUCEK MM, 1990, J PEDIATR-US, V116, P171, DOI 10.1016/S0022-3476(05)82870-7; Chrisant MRK, 2005, J HEART LUNG TRANSPL, V24, P576, DOI 10.1016/j.healun.2004.01.019; Ethics Committee American College of Critical Care Medicine, 2001, Crit Care Med, V29, P1826; Feudtner C, 2002, PEDIATRICS, V109, P887, DOI 10.1542/peds.109.5.887; GUNDRY SR, 1995, J THORAC CARDIOV SUR, V109, P1097, DOI 10.1016/S0022-5223(95)70193-1; Ikle L, 2003, J PEDIATR-US, V142, P20, DOI 10.1067/mpd.2003.mpd0340; Koogler T, 1998, PEDIATRICS, V101, P1049, DOI 10.1542/peds.101.6.1049; Magee JC, 2004, AM J TRANSPLANT, V4, P54, DOI 10.1111/j.1600-6143.2004.00398.x; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Scheule AM, 2004, TRANSPLANTATION, V77, P1166, DOI 10.1097/01.TP.0000122229.79612.DE; Trulock EP, 2005, J HEART LUNG TRANSPL, V24, P956, DOI 10.1016/j.healun.2005.05.019	15	304	306	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 14	2008	359	7					709	714		10.1056/NEJMoa0800660	http://dx.doi.org/10.1056/NEJMoa0800660			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336XE	18703473	Bronze			2022-12-28	WOS:000258397900007
J	Beardsall, K; Brocklehurst, P; Ahluwalia, J				Beardsall, Kathryn; Brocklehurst, Peter; Ahluwalia, Jag			Should newborn infants be excluded from multiple research studies?	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED-TRIALS; PARENTS		[Beardsall, Kathryn] Univ Cambridge, Dept Paediat, Cambridge, England; [Brocklehurst, Peter] Univ Oxford, Natl Perinatal Epidemiol Unit, Oxford, England; [Beardsall, Kathryn; Ahluwalia, Jag] Cambridge Univ Hosp NHS Fdn Trust, Neonatol Unit, Rosie Hosp, Cambridge, England	University of Cambridge; University of Oxford; University of Cambridge	Beardsall, K (corresponding author), Univ Cambridge, Addenbrookes Hosp NHS Fdn Trust, Dept Paediat, Box 116, Cambridge CB2 2QQ, England.	kb274@cam.ac.uk	Brocklehurst, Peter/B-5804-2011					*ASS BRIT PHARM IN, 2007, GUID PHAS 1 CLIN TRI; *BRIT ASS PER MED, CLIN TRIALS DAT; Brocklehurst P, 1997, BRIT J OBSTET GYNAEC, V104, P765, DOI 10.1111/j.1471-0528.1997.tb12016.x; GUNN EV, 2005, BRIT MED J, V330, P1175; Halliday HL, 2003, COCHRANE DB SYST REV, V1; Mason SA, 2000, LANCET, V356, P2045, DOI 10.1016/S0140-6736(00)03401-2; Morley CJ, 2005, ARCH DIS CHILD-FETAL, V90, P225, DOI 10.1136/adc.2004.061986	7	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 9	2008	372	9637					503	505		10.1016/S0140-6736(08)61200-3	http://dx.doi.org/10.1016/S0140-6736(08)61200-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	335OD	18692716				2022-12-28	WOS:000258299000033
J	Hansen, G; Hercus, TR; McClure, BJ; Stomski, FC; Dottore, M; Powell, J; Ramshaw, H; Woodcock, JM; Xu, YB; Guthridge, M; McKinstry, WJ; Lopez, AF; Parker, MW				Hansen, Guido; Hercus, Timothy R.; McClure, Barbara J.; Stomski, Frank C.; Dottore, Mara; Powell, Jason; Ramshaw, Hayley; Woodcock, Joanna M.; Xu, Yibin; Guthridge, Mark; McKinstry, William J.; Lopez, Angel F.; Parker, Michael W.			The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation	CELL			English	Article							COLONY-STIMULATING FACTOR; COMMON BETA-CHAIN; HIGH-AFFINITY BINDING; IL-5 RECEPTORS; ALPHA-CHAIN; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAINS; HUMAN INTERLEUKIN-3; CRYSTAL-STRUCTURE; GROWTH-FACTOR	Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a pleiotropic cytokine that controls the production and function of blood cells, is deregulated in clinical conditions such as rheumatoid arthritis and leukemia, yet offers therapeutic value for other diseases. Its receptors are heterodimers consisting of a ligand-specific a subunit and a beta c subunit that is shared with the interleukin (IL)-3 and IL-5 receptors. How signaling is initiated remains an enigma. We report here the crystal structure of the human GM-CSF/GM-CSF receptor ternary complex and its assembly into an unexpected dodecamer or higher-order complex. Importantly, mutagenesis of the GM-CSF receptor at the dodecamer interface and functional studies reveal that dodecamer formation is required for receptor activation and signaling. This unusual form of receptor assembly likely applies also to IL-3 and IL-5 receptors, providing a structural basis for understanding their mechanism of activation and for the development of therapeutics.	[Hercus, Timothy R.; McClure, Barbara J.; Stomski, Frank C.; Dottore, Mara; Powell, Jason; Ramshaw, Hayley; Woodcock, Joanna M.; Guthridge, Mark; Lopez, Angel F.] Hanson Inst, Inst Med & Vet Sci, Div Human Immunol, Adelaide, SA 5000, Australia; [Hansen, Guido; Xu, Yibin; McKinstry, William J.; Parker, Michael W.] St Vincents Inst Med Res, Biota Struct Biol Lab, Fitzroy, Vic 3065, Australia; [Parker, Michael W.] Univ Melbourne, Mol Sci & Biotechnol Inst Bio21, Dept Biochem & Mol Biol, Melbourne, Vic 3010, Australia	Hanson Institute; Institute Medical & Veterinary Science Australia; St. Vincent's Institute of Medical Research; University of Melbourne	Lopez, AF (corresponding author), Hanson Inst, Inst Med & Vet Sci, Div Human Immunol, Adelaide, SA 5000, Australia.	angel.lopez@imvs.sa.gov.au; mparker@svi.edu.au	Parker, Michael W/F-9069-2013; Hansen, Guido/B-8859-2013; guthridge, mark a/I-1889-2014; McKinstry, William J/D-2612-2013; Ramshaw, Hayley/F-3828-2013; Lopez, Angel F/E-2260-2011	Parker, Michael W/0000-0002-3101-1138; Hansen, Guido/0000-0003-3737-5749; guthridge, mark a/0000-0002-0536-3471; McKinstry, William J/0000-0001-9668-9364; McClure, Barbara/0000-0002-5201-4127; Lopez, Angel F/0000-0001-7430-0135; Powell, jason/0000-0001-8493-9178; Woodcock, Joanna/0000-0001-5127-9687; Ramshaw, Hayley/0000-0001-9909-282X	Commonwealth of Australia; U.S. National Institutes of Health; National Center for Research Resources; U.S. Department of Energy; National Health and Medical Research Council of Australia (NHMRC); National Institutes of Health [RO1-AI50744-02]; Australian Cancer Research Foundation; Australian Research Council Federation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050744] Funding Source: NIH RePORTER	Commonwealth of Australia(Australian Government); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); U.S. Department of Energy(United States Department of Energy (DOE)); National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Australian Cancer Research Foundation; Australian Research Council Federation(Australian Research Council); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Jamie Rossjohn for his contributions during the early stages of this work, Richard D'Andrea for the pEQEco plasmid, Chris Bagley for helpful discussions, and Rebecca Krake and Anna Sapa for technical assistance. We thank Harry Tong and other staff at BioCARS for their help during our visit to the Advanced Photon Source (APS). Access to BioCARS was provided by the Australian Synchrotron Research Program funded by the Commonwealth of Australia. BioCARS is supported by the U.S. National Institutes of Health, National Center for Research Resources. APS is supported by the U.S. Department of Energy. This work was supported by grants from the National Health and Medical Research Council of Australia (NHMRC), the National Institutes of Health (RO1-AI50744-02), and the Australian Cancer Research Foundation. H. R. is a Peter Nelson Leukaemia Research Fund Senior Research Fellow. M. W. P. is an Australian Research Council Federation Fellow and an NHMRC Honorary Fellow.	Bagley CJ, 1997, BLOOD, V89, P1471, DOI 10.1182/blood.V89.5.1471.1471_1471_1482; Barouch DH, 2002, J IMMUNOL, V168, P562, DOI 10.4049/jimmunol.168.2.562; BARRY SC, 1994, J BIOL CHEM, V269, P8488; Birnbaum RA, 2000, MOL CELL, V5, P189, DOI 10.1016/S1097-2765(00)80415-3; Boulanger MJ, 2003, SCIENCE, V300, P2101, DOI 10.1126/science.1083901; BRIZZI MF, 1994, J BIOL CHEM, V269, P31680; Carr PD, 2006, ACTA CRYSTALLOGR F, V62, P509, DOI 10.1107/S1744309106016812; Carr PD, 2001, CELL, V104, P291, DOI 10.1016/S0092-8674(01)00213-6; Cook AD, 2001, ARTHRITIS RES, V3, P293, DOI 10.1186/ar318; DeLano W.L, PYMOL MOL GRAPHICS S; Dirksen U, 1998, BLOOD, V92, P1097; Fagerholm SC, 2006, BLOOD, V108, P3379, DOI 10.1182/blood-2006-03-013557; Fleetwood AJ, 2005, CRIT REV IMMUNOL, V25, P405, DOI 10.1615/CritRevImmunol.v25.i5.50; Guthridge MA, 2006, EMBO J, V25, P479, DOI 10.1038/sj.emboj.7600948; Guthridge MA, 1998, STEM CELLS, V16, P301, DOI 10.1002/stem.160301; Haman A, 1999, J BIOL CHEM, V274, P34155, DOI 10.1074/jbc.274.48.34155; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HERCUS TR, 1994, P NATL ACAD SCI USA, V91, P5838, DOI 10.1073/pnas.91.13.5838; HERCUS TR, 1994, BLOOD, V83, P3500; James C, 2005, NATURE, V434, P1144, DOI 10.1038/nature03546; Jenkins BJ, 1999, J BIOL CHEM, V274, P8669, DOI 10.1074/jbc.274.13.8669; Korzenik JR, 2005, NEW ENGL J MED, V352, P2193, DOI 10.1056/NEJMoa041109; Lia F, 1996, J BIOL CHEM, V271, P28287, DOI 10.1074/jbc.271.45.28287; Lilly MB, 2001, BLOOD, V97, P1662, DOI 10.1182/blood.V97.6.1662; LOCK P, 1994, P NATL ACAD SCI USA, V91, P252, DOI 10.1073/pnas.91.1.252; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; McClure BJ, 2003, BLOOD, V101, P1308, DOI 10.1182/blood-2002-06-1903; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Murphy JM, 2003, J BIOL CHEM, V278, P10572, DOI 10.1074/jbc.M211664200; Muto A, 1995, J ALLERGY CLIN IMMUN, V96, P1100, DOI 10.1016/S0091-6749(95)70195-8; Muto A, 1996, J EXP MED, V183, P1911, DOI 10.1084/jem.183.4.1911; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; Rajotte D, 1997, J EXP MED, V185, P1939, DOI 10.1084/jem.185.11.1939; Ramshaw HS, 2002, EXP HEMATOL, V30, P1124, DOI 10.1016/S0301-472X(02)00903-7; Rawlings JS, 2004, J CELL SCI, V117, P1281, DOI 10.1242/jcs.00963; Rossjohn J, 2000, BLOOD, V95, P2491; Rozwarski DA, 1996, PROTEINS, V26, P304, DOI 10.1002/(SICI)1097-0134(199611)26:3<304::AID-PROT6>3.0.CO;2-D; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Soldi R, 1997, BLOOD, V89, P863, DOI 10.1182/blood.V89.3.863; Stauber DJ, 2006, P NATL ACAD SCI USA, V103, P2788, DOI 10.1073/pnas.0511161103; Stomski FC, 1998, J BIOL CHEM, V273, P1192, DOI 10.1074/jbc.273.2.1192; Stomski FC, 1996, MOL CELL BIOL, V16, P3035; Sun XL, 2002, VACCINE, V20, P1466, DOI 10.1016/S0264-410X(01)00476-5; TAVERNIER J, 1995, P NATL ACAD SCI USA, V92, P5194, DOI 10.1073/pnas.92.11.5194; Wang XQ, 2005, SCIENCE, V310, P1159, DOI 10.1126/science.1117893; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; WilsonRawls J, 1996, CANCER RES, V56, P3426; WOODCOCK JM, 1994, EMBO J, V13, P5176, DOI 10.1002/j.1460-2075.1994.tb06848.x; Woodcock JM, 1997, BLOOD, V90, P3005, DOI 10.1182/blood.V90.8.3005; Woodcock JM, 1996, J BIOL CHEM, V271, P25999, DOI 10.1074/jbc.271.42.25999	53	223	235	0	25	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 8	2008	134	3					496	507		10.1016/j.cell.2008.05.053	http://dx.doi.org/10.1016/j.cell.2008.05.053			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SO	18692472	Bronze			2022-12-28	WOS:000258665500022
J	Westerhaus, M; Panjabi, R; Mukherjee, J				Westerhaus, Michael; Panjabi, Rajesh; Mukherjee, Joia			Violence and the role of illness narratives	LANCET			English	Editorial Material							MEDICINE		[Westerhaus, Michael; Mukherjee, Joia] Brigham & Womens Hosp, Div Social Med & Hlth Inequal, Boston, MA 02115 USA; [Panjabi, Rajesh] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital	Westerhaus, M (corresponding author), Brigham & Womens Hosp, Div Social Med & Hlth Inequal, 75 Francis St, Boston, MA 02115 USA.	mwesterhaus@partners.org						BEYRER C, 2007, PUBLIC HLTH HUMAN RI, P268; Burnham G, 2006, LANCET, V368, P1421, DOI 10.1016/S0140-6736(06)69491-9; Charon R., 2006, NARRATIVE MED HONORI; Charon R, 2008, LANCET, V371, P296, DOI 10.1016/S0140-6736(08)60156-7; Coghlan B, 2006, LANCET, V367, P44, DOI 10.1016/S0140-6736(06)67923-3; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; Kleinman A., 1988, ILLNESS NARRATIVES; LYON E, 2004, YALE J HLTH POLICY L, V1, P439; McLellan MF, 1997, LANCET, V349, P1618, DOI 10.1016/S0140-6736(97)04429-2; Nordstrom Carolyn, 2004, SHADOWS WAR VIOLENCE; PANJABI R, 2008, 17 INT AIDS C MEX CI; Ranson K, 2007, CONFLICT AFFECTED FR; Westerhaus MJ, 2007, AM J PUBLIC HEALTH, V97, P1184, DOI 10.2105/AJPH.2005.072777	13	1	1	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG-SEP	2008	372	9640					699	701		10.1016/S0140-6736(08)61286-6	http://dx.doi.org/10.1016/S0140-6736(08)61286-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	344YZ	18761209				2022-12-28	WOS:000258964500009
J	Cantin, AM				Cantin, Andre M.			Childhood pneumonia and oxygen treatment	LANCET			English	Editorial Material							PAPUA-NEW-GUINEA; CHILDREN; HYPOXEMIA; MORTALITY; WORLD		[Cantin, Andre M.] Univ Sherbrooke, Dept Med, Div Pulm, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Cantin, AM (corresponding author), Univ Sherbrooke, Dept Med, Div Pulm, Sherbrooke, PQ J1H 5N4, Canada.	andre.cantin@usherbrooke.ca						Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8; Dowell SF, 2000, NEW ENGL J MED, V342, P1399, DOI 10.1056/NEJM200005113421904; Duke T, 2001, INT J TUBERC LUNG D, V5, P511; DUKE T, 2008, LANCET          0818; Enarson P, 2008, B WORLD HEALTH ORGAN, V86, P344, DOI 10.2471/BLT.07.048017; Fu LY, 2006, PEDIATRICS, V118, pE1822, DOI 10.1542/peds.2005-2673; Matai S, 2008, ANN TROP PAEDIATR, V28, P71, DOI 10.1179/146532808X270716; ONYANGO FE, 1993, BRIT MED J, V306, P612, DOI 10.1136/bmj.306.6878.612; Scott JAG, 2008, J CLIN INVEST, V118, P1291, DOI 10.1172/JCI33947; Smyth A, 1998, ANN TROP PAEDIATR, V18, P31, DOI 10.1080/02724936.1998.11747923; Steinhoff M, 2007, LANCET, V369, P1409, DOI 10.1016/S0140-6736(07)60644-8; Williams BG, 2002, LANCET INFECT DIS, V2, P25, DOI 10.1016/S1473-3099(01)00170-0	12	1	1	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 11	2008	372	9646					1278	1280		10.1016/S0140-6736(08)61165-4	http://dx.doi.org/10.1016/S0140-6736(08)61165-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	360MB	18708249				2022-12-28	WOS:000260060500006
J	Huo, FW; Zheng, ZJ; Zheng, GF; Giam, LR; Zhang, H; Mirkin, CA				Huo, Fengwei; Zheng, Zijian; Zheng, Gengfeng; Giam, Louise R.; Zhang, Hua; Mirkin, Chad A.			Polymer pen lithography	SCIENCE			English	Article							SELF-ASSEMBLED MONOLAYERS; SOFT LITHOGRAPHY; NANOLITHOGRAPHY; PARALLEL; RESOLUTION; PATTERNS; STAMP	We report a low- cost, high- throughput scanning probe lithography method that uses a soft elastomeric tip array, rather than tips mounted on individual cantilevers, to deliver inks to a surface in a "direct write" manner. Polymer pen lithography merges the feature size control of dip- pen nanolithography with the large- area capability of contact printing. Because ink delivery is time and force dependent, features on the nanometer, micrometer, and macroscopic length scales can be formed with the same tip array. Arrays with as many as about 11 million pyramid- shaped pens can be brought into contact with substrates and readily leveled optically to ensure uniform pattern development.	[Huo, Fengwei; Zheng, Zijian; Zheng, Gengfeng; Zhang, Hua; Mirkin, Chad A.] Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; [Huo, Fengwei; Zheng, Zijian; Zheng, Gengfeng; Giam, Louise R.; Zhang, Hua; Mirkin, Chad A.] Northwestern Univ, Int Inst Nanotechnol, Evanston, IL 60208 USA; [Giam, Louise R.; Mirkin, Chad A.] Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA	Northwestern University; Northwestern University; Northwestern University	Mirkin, CA (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.	chadnano@northwestern.edu	Zhang, Hua/A-1302-2009; Zheng, Gengfeng/G-7023-2011; ZHENG, ZIJIAN/B-4012-2009; Mirkin, Chad A/E-3911-2010; Huo, Fengwei/A-2243-2011; huo, fengwei/A-2243-2011	Zhang, Hua/0000-0001-9518-740X; Zheng, Gengfeng/0000-0002-1803-6955; ZHENG, ZIJIAN/0000-0002-6653-7594; Huo, Fengwei/0000-0003-0904-6008; huo, fengwei/0000-0001-8990-6973; Mirkin, Chad/0000-0002-6634-7627	U. S. Air Force Office of Scientific Research (AFOSR); Defense Advanced Research Projects Agency (DARPA); NSF (Nanoscale Science and Engineering Center program); NIH Director's Pioneer Award; National Security Science and Engineering Faculty Fellowship; NSF for a Graduate Research Fellowship	U. S. Air Force Office of Scientific Research (AFOSR)(United States Department of DefenseAir Force Office of Scientific Research (AFOSR)); Defense Advanced Research Projects Agency (DARPA)(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); NSF (Nanoscale Science and Engineering Center program)(National Science Foundation (NSF)); NIH Director's Pioneer Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Security Science and Engineering Faculty Fellowship; NSF for a Graduate Research Fellowship(National Science Foundation (NSF))	C. A. M. acknowledges the U. S. Air Force Office of Scientific Research (AFOSR), the Defense Advanced Research Projects Agency (DARPA), and NSF (Nanoscale Science and Engineering Center program) for support of this research. C. A. M. is grateful for a NIH Director's Pioneer Award and a National Security Science and Engineering Faculty Fellowship from the U. S. Department of Defense. L. R. G. acknowledges the NSF for a Graduate Research Fellowship.	Chou SY, 1996, SCIENCE, V272, P85, DOI 10.1126/science.272.5258.85; Demers LM, 2002, SCIENCE, V296, P1836, DOI 10.1126/science.1071480; Gates BD, 2005, CHEM REV, V105, P1171, DOI 10.1021/cr030076o; Geissler M, 2004, ADV MATER, V16, P1249, DOI 10.1002/adma.200400835; Ginger DS, 2004, ANGEW CHEM INT EDIT, V43, P30, DOI 10.1002/anie.200300608; Hong SH, 2000, SCIENCE, V288, P1808, DOI 10.1126/science.288.5472.1808; Ito T, 2000, NATURE, V406, P1027, DOI 10.1038/35023233; Kramer S, 2003, CHEM REV, V103, P4367, DOI 10.1021/cr020704m; KUMAR A, 1993, APPL PHYS LETT, V63, P2002, DOI 10.1063/1.110628; Lee KB, 2002, SCIENCE, V295, P1702, DOI 10.1126/science.1067172; Lenhert S, 2007, SMALL, V3, P71, DOI 10.1002/smll.200600431; Loo YL, 2002, J AM CHEM SOC, V124, P7654, DOI 10.1021/ja026355v; Maoz R, 1999, ADV MATER, V11, P55, DOI 10.1002/(SICI)1521-4095(199901)11:1<55::AID-ADMA55>3.0.CO;2-8; Mirkin CA, 2007, ACS NANO, V1, P79, DOI 10.1021/nn700228m; Odom TW, 2002, LANGMUIR, V18, P5314, DOI 10.1021/la020169l; Piner RD, 1999, SCIENCE, V283, P661, DOI 10.1126/science.283.5402.661; Qi MH, 2004, NATURE, V429, P538, DOI 10.1038/nature02575; Salaita K, 2007, NAT NANOTECHNOL, V2, P145, DOI 10.1038/nnano.2007.39; Salaita K, 2006, ANGEW CHEM INT EDIT, V45, P7220, DOI 10.1002/anie.200603142; Schmid H, 2000, MACROMOLECULES, V33, P3042, DOI 10.1021/ma982034l; Wang XF, 2003, LANGMUIR, V19, P8951, DOI 10.1021/la034858o; Xia YN, 1998, ANNU REV MATER SCI, V28, P153, DOI 10.1146/annurev.matsci.28.1.153; Xia YN, 1998, ANGEW CHEM INT EDIT, V37, P550, DOI 10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.0.CO;2-G; Xu S, 1999, LANGMUIR, V15, P7244, DOI 10.1021/la9906727; Yousaf MN, 2001, P NATL ACAD SCI USA, V98, P5992, DOI 10.1073/pnas.101112898; Zhang H, 2004, NANO LETT, V4, P1649, DOI 10.1021/nl049185o; Zheng ZJ, 2006, J AM CHEM SOC, V128, P7730, DOI 10.1021/ja061636e	27	426	450	8	401	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2008	321	5896					1658	1660		10.1126/science.1162193	http://dx.doi.org/10.1126/science.1162193			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349RG	18703709	Green Accepted			2022-12-28	WOS:000259300400029
J	Lee, DS; Nioche, P; Hamberg, M; Raman, CS				Lee, Dong-Sun; Nioche, Pierre; Hamberg, Mats; Raman, C. S.			Structural insights into the evolutionary paths of oxylipin biosynthetic enzymes	NATURE			English	Article							ALLENE OXIDE SYNTHASE; LIPOXYGENASE FUSION PROTEIN; HYDROPEROXIDE LYASE; FATTY-ACID; METHYLOBACTERIUM-NODULANS; SIGNAL-TRANSDUCTION; CYTOCHROME-P450; IDENTIFICATION; ARABIDOPSIS; PURIFICATION	The oxylipin pathway generates not only prostaglandin- like jasmonates but also green leaf volatiles ( GLVs), which confer characteristic aromas to fruits and vegetables. Although allene oxide synthase ( AOS) and hydroperoxide lyase are atypical cytochrome P450 family members involved in the synthesis of jasmonates and GLVs, respectively, it is unknown how these enzymes rearrange their hydroperoxide substrates into different products. Here we present the crystal structures of Arabidopsis thaliana AOS, free and in complex with substrate or intermediate analogues. The structures reveal an unusual active site poised to control the reactivity of an epoxyallylic radical and its cation by means of interactions with an aromatic pi- system. Replacing the amino acid involved in these steps by a non- polar residue markedly reduces AOS activity and, unexpectedly, is both necessary and sufficient for converting AOS into a GLV biosynthetic enzyme. Furthermore, by combining our structural data with bioinformatic and biochemical analyses, we have discovered previously unknown hydroperoxide lyase in plant growth- promoting rhizobacteria, AOS in coral, and epoxyalcohol synthase in amphioxus. These results indicate that oxylipin biosynthetic genes were present in the last common ancestor of plants and animals, but were subsequently lost in all metazoan lineages except Placozoa, Cnidaria and Cephalochordata.	[Lee, Dong-Sun; Raman, C. S.] Univ Texas Houston, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Nioche, Pierre] Univ Paris 05, INSERM, UMR S 747, F-75270 Paris 06, France; [Hamberg, Mats] Karolinska Inst, Div Physiol Chem 2, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	University of Texas System; University of Texas Health Science Center Houston; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Karolinska Institutet	Raman, CS (corresponding author), Univ Texas Houston, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA.	ramancs@gmail.com	Lee, Dong Sun/HGV-2436-2022	Hamberg, Mats/0000-0002-8910-7810; Raman, C. S./0000-0002-1036-3193	Pew Charitable Trusts; Pew Scholar Award; The Robert A. Welch Foundation; The National Institutes of Health; American Heart Association; INSERM Avenir Grant; La Fondation pour la Recherche Medicale; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054444] Funding Source: NIH RePORTER	Pew Charitable Trusts; Pew Scholar Award; The Robert A. Welch Foundation(The Welch Foundation); The National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); INSERM Avenir Grant(Institut National de la Sante et de la Recherche Medicale (Inserm)); La Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	C. S. R. is grateful to the late N. Natarajaratnam and the late T. Traylor for encouragement; R. Cudney for nonanoyl-N- hydroxyethylglucamide (HEGA-9); K. Matsui for tomato HPL complementary DNA; K. Back and D. Park for Arabidopsis and rice cDNA libraries; L. Holland and J. Langeland for the amphioxus cDNA library; M. Medina for A. palmata expressed sequence tags; C. Marx and L. Moulin for M. nodulans cells; R. Muller for S. aurantiaca genomic DNA; L. Roman and B. Masters for the pCWori<SUP>+</SUP> vector; J. Navarro for the single crystal microspectrophotometer; T. Doukov, S. Soltis, A. Cohen and J. Charles for help with acquiring electronic absorption spectra of single crystals; S. Veeraraghavan for generating Fig. 5; R. Bach, T. Bach, A. Beckwith, W. Bernhard, D. Curran, A. Davies, T. Dibble, J. Finnerty, D. Fleischman, J. Froehlich, J. Groves, L. Holland, P. Holland, J. Howieson, H. Kaplan, D. Nelson, M. Newcomb, P. Ortiz de Montellano, N. Porter, T. Poulos, M. Sibi, S. Veeraraghavan and D. Whalen for discussions; Joint Genome Institute for access to sequence data; Stanford Synchrotron Radiation Laboratories (beam lines 9-2 and 11-1, T. Doukov and L. Dunn) and the Advanced Light Source (beam line 8.3.1, J. Holton, G. Meigs and J. Tanamachi; beam lines 8.2.1 and 8.2.2, C. Ralston) for beam time and assistance. This work is supported by Pew Charitable Trusts through a Pew Scholar Award (C.S.R.), The Robert A. Welch Foundation (C.S.R.), The National Institutes of Health (C.S.R.), a Beginning Grant in Aid from the American Heart Association (D.-S.L.), and an INSERM Avenir Grant sponsored by La Fondation pour la Recherche Medicale (P.N.).	Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baldwin IT, 2006, SCIENCE, V311, P812, DOI 10.1126/science.1118446; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; Beckers GJ, 2007, CURR OPIN PLANT BIOL, V10, P425, DOI 10.1016/j.pbi.2007.06.002; Beitlich T, 2007, J SYNCHROTRON RADIAT, V14, P11, DOI 10.1107/S0909049506049806; Bell CD, 2005, EVOLUTION, V59, P1245, DOI 10.1111/j.0014-3820.2005.tb01775.x; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; Brash AR, 2007, FEBS J, V274, P3494, DOI 10.1111/j.1742-4658.2007.05909.x; Brash AR, 1996, METHOD ENZYMOL, V272, P250, DOI 10.1016/S0076-6879(96)72030-X; BRASH AR, 1988, P NATL ACAD SCI USA, V85, P3382, DOI 10.1073/pnas.85.10.3382; Cartwright P, 2007, INTEGR COMP BIOL, V47, P744, DOI 10.1093/icb/icm071; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DeLano W.L, PYMOL MOL GRAPHICS S; Denisov IG, 2005, CHEM REV, V105, P2253, DOI 10.1021/cr0307143; Flescher E, 2007, CANCER LETT, V245, P1, DOI 10.1016/j.canlet.2006.03.001; Froehlich JE, 2001, PLANT PHYSIOL, V125, P306, DOI 10.1104/pp.125.1.306; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gershenzon J, 2007, P NATL ACAD SCI USA, V104, P5257, DOI 10.1073/pnas.0700906104; Grechkin AN, 2004, BBA-MOL CELL BIOL L, V1636, P47, DOI 10.1016/j.bbalip.2003.12.003; Grechkin AN, 2002, PROSTAG OTH LIPID M, V68-9, P457, DOI 10.1016/S0090-6980(02)00048-5; GRECHKIN AN, 1995, FEBS LETT, V371, P159, DOI 10.1016/0014-5793(95)00895-G; Green MT, 2004, SCIENCE, V304, P1653, DOI 10.1126/science.1096897; Groves JT, 2003, P NATL ACAD SCI USA, V100, P3569, DOI 10.1073/pnas.0830019100; Guengerich FP, 2002, NAT REV DRUG DISCOV, V1, P359, DOI 10.1038/nrd792; HAMBERG M, 1990, ARCH BIOCHEM BIOPHYS, V276, P518, DOI 10.1016/0003-9861(90)90753-L; HAMBERG M, 1987, BIOCHIM BIOPHYS ACTA, V920, P76, DOI 10.1016/0005-2760(87)90313-4; Hofmann E, 2006, PLANT CELL, V18, P3201, DOI 10.1105/tpc.106.043984; Hughes RK, 2006, FEBS LETT, V580, P4188, DOI 10.1016/j.febslet.2006.06.075; Itoh A, 2001, J BIOL CHEM, V276, P3620, DOI 10.1074/jbc.M008964200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joo H, 1999, NATURE, V399, P670, DOI 10.1038/21395; Jourand P, 2005, MOL PLANT MICROBE IN, V18, P1061, DOI 10.1094/MPMI-18-1061; Keirse MJNC, 2006, CLIN OBSTET GYNECOL, V49, P609, DOI 10.1097/00003081-200609000-00020; Kessler A, 2004, SCIENCE, V305, P665, DOI 10.1126/science.1096931; Koljak R, 1997, SCIENCE, V277, P1994, DOI 10.1126/science.277.5334.1994; Lancaster CRD, 1999, NATURE, V402, P377, DOI 10.1038/46483; Langeland JA, 1998, DEV GENES EVOL, V208, P569, DOI 10.1007/s004270050216; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB; Li L, 2004, PLANT CELL, V16, P126, DOI 10.1105/tpc.017954; LIECHTI R, 2006, SCI STKE, pCM3; LIECHTI R, 2006, SCI STKE, pCM2; Lohelaid H, 2008, BBA-GEN SUBJECTS, V1780, P315, DOI 10.1016/j.bbagen.2007.10.010; Matsui K, 2006, CURR OPIN PLANT BIOL, V9, P274, DOI 10.1016/j.pbi.2006.03.002; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nelson David R., 2006, Phytochemistry Reviews, V5, P193, DOI 10.1007/s11101-006-9015-3; Ogliaro F, 2002, J INORG BIOCHEM, V91, P554, DOI 10.1016/S0162-0134(02)00437-3; Oldham ML, 2005, P NATL ACAD SCI USA, V102, P297, DOI 10.1073/pnas.0406352102; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park JH, 2002, PLANT J, V31, P1, DOI 10.1046/j.1365-313X.2002.01328.x; Poulos T. L., 2005, CYTOCHROME P450 STRU, P87; Renier A, 2008, SOIL BIOL BIOCHEM, V40, P1404, DOI 10.1016/j.soilbio.2007.12.020; Rensing SA, 2008, SCIENCE, V319, P64, DOI 10.1126/science.1150646; RICHARDSON TH, 1993, ARCH BIOCHEM BIOPHYS, V300, P510, DOI 10.1006/abbi.1993.1069; Schlichting I, 2000, ACCOUNTS CHEM RES, V33, P532, DOI 10.1021/ar9900459; Schneider C, 2007, P NATL ACAD SCI USA, V104, P18941, DOI 10.1073/pnas.0707148104; Sheldrick GM, 1997, METHOD ENZYMOL, V276, P628, DOI 10.1016/S0076-6879(97)76083-X; Smith DM, 1998, J AM CHEM SOC, V120, P10223, DOI 10.1021/ja980635m; SONG WC, 1993, J BIOL CHEM, V268, P6293; SONG WC, 1991, SCIENCE, V253, P781, DOI 10.1126/science.1876834; Stumpe Michael, 2006, Phytochemistry Reviews, V5, P347, DOI 10.1007/s11101-006-9038-9; Tijet N, 2002, PROSTAG OTH LIPID M, V68-9, P423, DOI 10.1016/S0090-6980(02)00046-1; Van Loon LC, 2006, PLANT-ASSOCIATED BACTERIA, P269; VICK BA, 1976, PLANT PHYSIOL, V57, P780, DOI 10.1104/pp.57.5.780; Vidi PA, 2006, J BIOL CHEM, V281, P11225, DOI 10.1074/jbc.M511939200; vonWachenfeldt C, 1997, ARCH BIOCHEM BIOPHYS, V339, P107, DOI 10.1006/abbi.1996.9859; Wasternack C, 2007, ANN BOT-LONDON, V100, P681, DOI 10.1093/aob/mcm079; Wester MR, 2002, METHOD ENZYMOL, V357, P73; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531; Williams D, 2000, PERFORM RES, V5, P131; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Xie DX, 1998, SCIENCE, V280, P1091, DOI 10.1126/science.280.5366.1091; Zabetakis I, 1997, PLANT CELL TISS ORG, V50, P179, DOI 10.1023/A:1005968913237; ZIMMERMAN DC, 1966, BIOCHEM BIOPH RES CO, V23, P398, DOI 10.1016/0006-291X(66)90740-6	74	208	226	3	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	2008	455	7211					363	U27		10.1038/nature07307	http://dx.doi.org/10.1038/nature07307			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349EX	18716621				2022-12-28	WOS:000259265200038
J	Gomez-Roldan, V; Fermas, S; Brewer, PB; Puech-Pages, V; Dun, EA; Pillot, JP; Letisse, F; Matusova, R; Danoun, S; Portais, JC; Bouwmeester, H; Becard, G; Beveridge, CA; Rameau, C; Rochange, SF				Gomez-Roldan, Victoria; Fermas, Soraya; Brewer, Philip B.; Puech-Pages, Virginie; Dun, Elizabeth A.; Pillot, Jean-Paul; Letisse, Fabien; Matusova, Radoslava; Danoun, Saida; Portais, Jean-Charles; Bouwmeester, Harro; Becard, Guillaume; Beveridge, Christine A.; Rameau, Catherine; Rochange, Soizic F.			Strigolactone inhibition of shoot branching	NATURE			English	Article							ARBUSCULAR-MYCORRHIZAL FUNGI; ROOT PARASITIC PLANTS; GERMINATION STIMULANTS; PHOSPHORUS DEFICIENCY; SEED-GERMINATION; APICAL DOMINANCE; RMS1 MUTANT; ARABIDOPSIS; PEA; SIGNAL	A carotenoid- derived hormonal signal that inhibits shoot branching in plants has long escaped identification. Strigolactones are compounds thought to be derived from carotenoids and are known to trigger the germination of parasitic plant seeds and stimulate symbiotic fungi. Here we present evidence that carotenoid cleavage dioxygenase 8 shoot branching mutants of pea are strigolactone deficient and that strigolactone application restores the wild- type branching phenotype to ccd8 mutants. Moreover, we show that other branching mutants previously characterized as lacking a response to the branching inhibition signal also lack strigolactone response, and are not deficient in strigolactones. These responses are conserved in Arabidopsis. In agreement with the expected properties of the hormonal signal, exogenous strigolactone can be transported in shoots and act at low concentrations. We suggest that endogenous strigolactones or related compounds inhibit shoot branching in plants. Furthermore, ccd8 mutants demonstrate the diverse effects of strigolactones in shoot branching, mycorrhizal symbiosis and parasitic weed interaction.	[Fermas, Soraya; Pillot, Jean-Paul; Rameau, Catherine] Inst JP Bourgin, Genet & Ameliorat Plantes Stn, INRA, UR254, F-78000 Versailles, France; [Gomez-Roldan, Victoria; Puech-Pages, Virginie; Danoun, Saida; Becard, Guillaume; Rochange, Soizic F.] Univ Toulouse 1, F-31326 Castanet Tolosan, France; [Gomez-Roldan, Victoria; Puech-Pages, Virginie; Danoun, Saida; Becard, Guillaume; Rochange, Soizic F.] UPS, F-31326 Castanet Tolosan, France; [Gomez-Roldan, Victoria; Puech-Pages, Virginie; Danoun, Saida; Becard, Guillaume; Rochange, Soizic F.] CNRS, F-31326 Castanet Tolosan, France; [Brewer, Philip B.; Dun, Elizabeth A.; Beveridge, Christine A.] Univ Queensland, ARC Ctr Excellence Integrat Legume Res, Brisbane, Qld 4072, Australia; [Letisse, Fabien; Portais, Jean-Charles] INSA Toulouse, CNRS, UMR5504, UMR792,INRA, F-31400 Toulouse, France; [Matusova, Radoslava; Bouwmeester, Harro] Plant Res Int, NL-6700 AA Wageningen, Netherlands; [Bouwmeester, Harro] Univ Wageningen & Res Ctr, Lab Plant Physiol, NL-6703 BD Wageningen, Netherlands; [Beveridge, Christine A.] Univ Queensland, Sch Integrat Biol, Brisbane, Qld 4072, Australia	INRAE; UDICE-French Research Universities; Universite Paris Saclay; Universite de Toulouse; Universite Toulouse 1 Capitole; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); University of Queensland; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); INRAE; Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Institut National des Sciences Appliquees de Toulouse; Wageningen University & Research; University of Queensland	Rameau, C (corresponding author), Inst JP Bourgin, Genet & Ameliorat Plantes Stn, INRA, UR254, F-78000 Versailles, France.	becard@scsv.ups-tlse.fr; rameau@versailles.inra.fr	Beveridge, Christine Anne/B-3514-2009; Dun, Elizabeth/A-1283-2010; Bouwmeester, Harro J/C-1414-2008; Brewer, Philip B/C-6562-2008; Matusova, Radoslava/A-1886-2017; Gomez, Maria M/H-5391-2018	Beveridge, Christine Anne/0000-0003-0878-3110; Dun, Elizabeth/0000-0003-4068-0349; Brewer, Philip B/0000-0003-4871-9260; Matusova, Radoslava/0000-0001-9181-295X; Gomez, Maria M/0000-0002-8428-1588; Bouwmeester, Harro/0000-0003-0907-2732; Fabien, Letisse/0000-0002-1490-0152; Portais, Jean-Charles/0000-0002-3480-0933	French Ministry of Research and Higher Education; ANR; The Netherlands Organisation for Scientific Research (NWO; VICI-grant)	French Ministry of Research and Higher Education; ANR(French National Research Agency (ANR)); The Netherlands Organisation for Scientific Research (NWO; VICI-grant)(Netherlands Organization for Scientific Research (NWO))	V.G.-R. was supported by the French Ministry of Research and Higher Education. S. F. was supported by a grant from ANR. H.B. and R.M. were supported by a grant from The Netherlands Organisation for Scientific Research (NWO; VICI-grant). The authors are grateful to A. Marion-Poll for discussions, H.M.O. Leyser for supply of the Arabidopsis max4 seed, K. Yoneyama for the gift of orobanchyl acetate, and D. M. Joel for providing O. crenata seeds. The UPLC/QTOF mass spectrometer was made available to us by the Institut des Technologies Avancees du Vivant (Toulouse, France). We thank K. Condon for plant husbandry, the ARC Centre of Excellence for Integrative Legume Research and the European Union FP6 Grain Legumes Integrated Project for financial support.	Akiyama K, 2005, NATURE, V435, P824, DOI 10.1038/nature03608; Arumingtyas EL, 1992, PISUM GENET, V24, P17; Auldridge ME, 2006, PLANT J, V45, P982, DOI 10.1111/j.1365-313X.2006.02666.x; Berleth T, 2004, CURR OPIN PLANT BIOL, V7, P553, DOI 10.1016/j.pbi.2004.07.016; Besserer A, 2006, PLOS BIOL, V4, P1239, DOI 10.1371/journal.pbio.0040226; Beveridge CA, 2006, CURR OPIN PLANT BIOL, V9, P35, DOI 10.1016/j.pbi.2005.11.006; Beveridge CA, 1997, PLANT PHYSIOL, V115, P1251, DOI 10.1104/pp.115.3.1251; Beveridge CA, 1996, PLANT PHYSIOL, V110, P859, DOI 10.1104/pp.110.3.859; Beveridge CA, 2000, PLANT PHYSIOL, V123, P689, DOI 10.1104/pp.123.2.689; Booker J, 2005, DEV CELL, V8, P443, DOI 10.1016/j.devcel.2005.01.009; Booker J, 2004, CURR BIOL, V14, P1232, DOI 10.1016/j.cub.2004.06.061; Booker J, 2003, PLANT CELL, V15, P495, DOI 10.1105/tpc.007542; Bouvier F, 2005, TRENDS PLANT SCI, V10, P187, DOI 10.1016/j.tplants.2005.02.007; Bouwmeester HJ, 2007, TRENDS PLANT SCI, V12, P224, DOI 10.1016/j.tplants.2007.03.009; Brachmann A, 2006, PLOS BIOL, V4, P1111, DOI 10.1371/journal.pbio.0040239; COOK CE, 1972, J AM CHEM SOC, V94, P6198, DOI 10.1021/ja00772a048; Cowling RJ, 1998, PLANT PHYSIOL, V117, P1195, DOI 10.1104/pp.117.4.1195; Dodd IC, 2008, PLANT CELL PHYSIOL, V49, P791, DOI 10.1093/pcp/pcn052; Doust AN, 2007, CURR OPIN PLANT BIOL, V10, P21, DOI 10.1016/j.pbi.2006.11.015; Dun EA, 2006, PLANT PHYSIOL, V142, P812, DOI 10.1104/pp.106.086868; Foo E, 2005, PLANT CELL, V17, P464, DOI 10.1105/tpc.104.026716; Foo E, 2001, PLANT PHYSIOL, V126, P203, DOI 10.1104/pp.126.1.203; Giovannetti M., 1980, New Phytologist, V84, P489, DOI 10.1111/j.1469-8137.1980.tb04556.x; Goldwasser Y, 2008, PLANT GROWTH REGUL, V55, P21, DOI 10.1007/s10725-008-9253-z; Hewitt E., 1966, SAND WATER CULTURE M, V187-237, P430; Ishikawa S, 2005, PLANT CELL PHYSIOL, V46, P79, DOI 10.1093/pcp/pci022; Johnson X, 2006, PLANT PHYSIOL, V142, P1014, DOI 10.1104/pp.106.087676; Kenrick P, 1997, NATURE, V389, P33, DOI 10.1038/37918; Li CJ, 1999, PHYSIOL PLANTARUM, V106, P415, DOI 10.1034/j.1399-3054.1999.106409.x; Lopez-Raez JA, 2008, NEW PHYTOL, V178, P863, DOI 10.1111/j.1469-8137.2008.02406.x; Matusova R, 2005, PLANT PHYSIOL, V139, P920, DOI 10.1104/pp.105.061382; Miyawaki K, 2006, P NATL ACAD SCI USA, V103, P16598, DOI 10.1073/pnas.0603522103; Morris SE, 2001, PLANT PHYSIOL, V126, P1205, DOI 10.1104/pp.126.3.1205; Mouchel CF, 2007, CURR OPIN PLANT BIOL, V10, P473, DOI 10.1016/j.pbi.2007.08.005; Napoli C, 1996, PLANT PHYSIOL, V111, P27, DOI 10.1104/pp.111.1.27; NEHAUSER JL, 2004, PLOS BIOL, V2, pE258; REMY W, 1994, P NATL ACAD SCI USA, V91, P11841, DOI 10.1073/pnas.91.25.11841; Schwartz SH, 2004, J BIOL CHEM, V279, P46940, DOI 10.1074/jbc.M409004200; Smith S., 1997, MYCORRHIZAL SYMBIOSI, V2nd Edn; Sorefan K, 2003, GENE DEV, V17, P1469, DOI 10.1101/gad.256603; Stirnberg P, 2002, DEVELOPMENT, V129, P1131; Stirnberg P, 2007, PLANT J, V50, P80, DOI 10.1111/j.1365-313X.2007.03032.x; Strader LC, 2008, NAT CHEM BIOL, V4, P337, DOI 10.1038/nchembio0608-337; Symons G. M., 1997, Pisum Genetics, V29, P1; Turnbull CGN, 2002, PLANT J, V32, P255, DOI 10.1046/j.1365-313X.2002.01419.x; Vierheilig H, 1998, APPL ENVIRON MICROB, V64, P5004; Xie X, 2008, PHYTOCHEMISTRY, V69, P427, DOI 10.1016/j.phytochem.2007.07.017; Xie X, 2007, J AGR FOOD CHEM, V55, P8067, DOI 10.1021/jf0715121; Yoneyama K, 2008, NEW PHYTOL, V179, P484, DOI 10.1111/j.1469-8137.2008.02462.x; Yoneyama K, 2007, PLANTA, V227, P125, DOI 10.1007/s00425-007-0600-5; Yoneyama K, 2007, PLANTA, V225, P1031, DOI 10.1007/s00425-006-0410-1	51	1398	1531	37	697	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 11	2008	455	7210					189	U22		10.1038/nature07271	http://dx.doi.org/10.1038/nature07271			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	346SZ	18690209				2022-12-28	WOS:000259090800039
J	Brooks, BA; Foster, J; Sandwell, D; Wolfe, CJ; Okubo, P; Poland, M; Myer, D				Brooks, Benjamin A.; Foster, James; Sandwell, David; Wolfe, Cecily J.; Okubo, Paul; Poland, Michael; Myer, David			Magmatically triggered slow slip at Kilauea volcano, Hawaii	SCIENCE			English	Article							EARTHQUAKES		[Brooks, Benjamin A.; Foster, James; Wolfe, Cecily J.] Univ Hawaii, Sch Ocean & Earth Sci & Technol, Honolulu, HI 96822 USA; [Sandwell, David; Myer, David] Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; [Okubo, Paul; Poland, Michael] US Geol Survey, Hawaiian Volcano Observ, Hawaii Natl Pk, HI 96718 USA	University of Hawaii System; University of California System; University of California San Diego; Scripps Institution of Oceanography; United States Department of the Interior; United States Geological Survey	Brooks, BA (corresponding author), Univ Hawaii, Sch Ocean & Earth Sci & Technol, 1680 East West Rd, Honolulu, HI 96822 USA.		Foster, James/G-7942-2012; Myer, David G/E-1425-2011; Wolfe, Cecily/E-7874-2011	Foster, James/0000-0003-2052-5798; Myer, David G/0000-0001-8599-3694; Wolfe, Cecily/0000-0003-3144-5697; Poland, Michael/0000-0001-5240-6123	NSF's Geophysics program	NSF's Geophysics program(National Science Foundation (NSF))	We thank A. Miklius, K. Kamibayashi, M. Sako, and P. Segall for their collaboration on operation of the Kilauea GPS network. This work was supported by NSF's Geophysics program.	Brooks BA, 2006, EARTH PLANET SC LETT, V246, P207, DOI 10.1016/j.epsl.2006.03.035; Cayol V, 2000, SCIENCE, V288, P2343, DOI 10.1126/science.288.5475.2343; Owen SE, 2006, J VOLCANOL GEOTH RES, V150, P163, DOI 10.1016/j.jvolgeores.2005.07.012; Poland M.P., 2008, EOS T AGU, V89, P37, DOI DOI 10.1029/2008EO050001; SCHWARTZ SY, 2007, REV GEOPHYS, V45; Segall P, 2006, NATURE, V442, P71, DOI 10.1038/nature04938	6	50	51	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 29	2008	321	5893					1177	1177		10.1126/science.1159007	http://dx.doi.org/10.1126/science.1159007			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341ZM	18755967				2022-12-28	WOS:000258754400033
J	Danovaro, R; Dell'Anno, A; Corinaldesi, C; Magagnini, M; Noble, R; Tamburini, C; Weinbauer, M				Danovaro, Roberto; Dell'Anno, Antonio; Corinaldesi, Cinzia; Magagnini, Mirko; Noble, Rachel; Tamburini, Christian; Weinbauer, Markus			Major viral impact on the functioning of benthic deep-sea ecosystems	NATURE			English	Article							MARINE VIRUSES; HYDROSTATIC-PRESSURE; ORGANIC-MATTER; KEY ROLE; MORTALITY; SEDIMENTS; BACTERIOPLANKTON; WATERS; DNA; INFECTION	Viruses are the most abundant biological organisms of the world's oceans. Viral infections are a substantial source of mortality in a range of organisms - including autotrophic and heterotrophic plankton - but their impact on the deep ocean and benthic biosphere is completely unknown. Here we report that viral production in deep- sea benthic ecosystems worldwide is extremely high, and that viral infections are responsible for the abatement of 80% of prokaryotic heterotrophic production. Virus- induced prokaryotic mortality increases with increasing water depth, and beneath a depth of 1,000 m nearly all of the prokaryotic heterotrophic production is transformed into organic detritus. The viral shunt, releasing on a global scale similar to 0.37 - 0.63 gigatonnes of carbon per year, is an essential source of labile organic detritus in the deep- sea ecosystems. This process sustains a high prokaryotic biomass and provides an important contribution to prokaryotic metabolism, allowing the system to cope with the severe organic resource limitation of deep- sea ecosystems. Our results indicate that viruses have an important role in global biogeochemical cycles, in deep- sea metabolism and the overall functioning of the largest ecosystem of our biosphere.	[Danovaro, Roberto; Dell'Anno, Antonio; Corinaldesi, Cinzia; Magagnini, Mirko] Polytech Univ Marche, Dept Marine Sci, Fac Sci, I-60131 Ancona, Italy; [Noble, Rachel] Univ N Carolina, Inst Marine Sci, Morehead City, NC 28557 USA; [Tamburini, Christian] Univ Aix Marseille 2, Ctr Oceanol Marseille, CNRS, UMR 6117, F-13288 Marseille 9, France; [Weinbauer, Markus] CNRS, F-06234 Villefranche Sur Mer, France; [Weinbauer, Markus] Lab Oceanog Villefranche, Microbial Ecol & Biogeochem Grp, F-06234 Villefranche Sur Mer, France; [Weinbauer, Markus] Univ Paris 06, Lab Oceanog Villefranche, F-06234 Villefranche Sur Mer, France	Marche Polytechnic University; University of North Carolina; University of North Carolina Chapel Hill; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite	Danovaro, R (corresponding author), Polytech Univ Marche, Dept Marine Sci, Fac Sci, Via Brecce Bianche, I-60131 Ancona, Italy.	r.danovaro@univpm.it	Tamburini, Christian/AAO-8577-2020; Weinbauer, Markus/ABC-7017-2020; Weinbauer, Markus/G-8038-2011; Tamburini, Christian/I-7821-2012; Dell'Anno, Antonio AD/G-9468-2012	Tamburini, Christian/0000-0003-3752-7423; Weinbauer, Markus/0000-0002-7697-5571; Tamburini, Christian/0000-0003-3752-7423; Dell'Anno, Antonio AD/0000-0002-4324-7834; Noble, Rachel/0000-0001-9071-8312	project HERMES; ANR POTES	project HERMES(European Commission); ANR POTES(French National Research Agency (ANR))	This work was financially supported by the EU within the framework of the project HERMES. C. T. was supported by the ANR POTES.	Anderson MJ, 2004, DISTLM V 5 FORTRAN C; Bartlett DH, 2002, BBA-PROTEIN STRUCT M, V1595, P367, DOI 10.1016/S0167-4838(01)00357-0; Corinaldesi C, 2007, LIMNOL OCEANOGR, V52, P508, DOI 10.4319/lo.2007.52.2.0508; Danovaro R, 2003, DEEP-SEA RES PT I, V50, P1411, DOI 10.1016/j.dsr.2003.07.001; Danovaro R, 2001, APPL ENVIRON MICROB, V67, P1384, DOI 10.1128/AEM.67.3.1384-1387.2001; Danovaro R, 2008, FRESHWATER BIOL, V53, P1186, DOI 10.1111/j.1365-2427.2008.01961.x; Dell'Anno A, 2005, SCIENCE, V309, P2179, DOI 10.1126/science.1117475; Deming J. W., 1993, ORGANIC GEOCHEMISTRY, P119; Druffel ERM, 1999, SCIENCE, V284, P1139, DOI 10.1126/science.284.5417.1139; Fry J. C., 1990, METHODS AQUATIC BACT, P27; FUHRMAN JA, 1982, MAR BIOL, V66, P109, DOI 10.1007/BF00397184; Fuhrman JA, 1995, LIMNOL OCEANOGR, V40, P1236, DOI 10.4319/lo.1995.40.7.1236; Fuhrman JA, 1999, NATURE, V399, P541, DOI 10.1038/21119; Gage J. D., 1991, DEEP SEA BIOL NATURA; Helton RR, 2006, APPL ENVIRON MICROB, V72, P4767, DOI 10.1128/AEM.00297-06; Jahnke RA, 1996, GLOBAL BIOGEOCHEM CY, V10, P71, DOI 10.1029/95GB03525; Mari X, 2007, APPL ENVIRON MICROB, V73, P5245, DOI 10.1128/AEM.00762-07; Mei ML, 2004, LIMNOL OCEANOGR, V49, P459, DOI 10.4319/lo.2004.49.2.0459; Noble RT, 1999, AQUAT MICROB ECOL, V20, P1, DOI 10.3354/ame020001; PROCTOR LM, 1990, NATURE, V343, P60, DOI 10.1038/343060a0; Rex MA, 2006, MAR ECOL PROG SER, V317, P1, DOI 10.3354/meps317001; Siem-Jorgensen M, 2008, MAR BIOL RES, V4, P165, DOI 10.1080/17451000801888718; Steward Grieg F., 1992, Marine Microbial Food Webs, V6, P57; SUTTLE CA, 1990, NATURE, V347, P467, DOI 10.1038/347467a0; Suttle CA, 2005, NATURE, V437, P356, DOI 10.1038/nature04160; Suttle CA, 2007, NAT REV MICROBIOL, V5, P801, DOI 10.1038/nrmicro1750; Tamburini C, 2003, AQUAT MICROB ECOL, V32, P209, DOI 10.3354/ame032209; Tamburini C, 2002, DEEP-SEA RES PT II, V49, P2109, DOI 10.1016/S0967-0645(02)00030-9; Weinbauer MG, 2004, FEMS MICROBIOL REV, V28, P127, DOI 10.1016/j.femsre.2003.08.001; Weinbauer MG, 2003, LIMNOL OCEANOGR, V48, P1457, DOI 10.4319/lo.2003.48.4.1457; Weinbauer MG, 1998, AQUAT MICROB ECOL, V15, P103, DOI 10.3354/ame015103; WEINBAUER MG, 1993, APPL ENVIRON MICROB, V59, P4074, DOI 10.1128/AEM.59.12.4074-4082.1993; Wen K, 2004, APPL ENVIRON MICROB, V70, P3862, DOI 10.1128/AEM.70.7.3862-3867.2004; Whitman WB, 1998, P NATL ACAD SCI USA, V95, P6578, DOI 10.1073/pnas.95.12.6578; Wilhelm SW, 2002, MICROBIAL ECOL, V43, P168, DOI 10.1007/s00248-001-1021-9; Wilhelm SW, 1999, BIOSCIENCE, V49, P781, DOI 10.2307/1313569; Witte U, 2003, NATURE, V424, P763, DOI 10.1038/nature01799; Wommack KE, 2000, MICROBIOL MOL BIOL R, V64, P69, DOI 10.1128/MMBR.64.1.69-114.2000; YAYANOS AA, 1995, ANNU REV MICROBIOL, V49, P777, DOI 10.1146/annurev.mi.49.100195.004021	39	259	292	3	128	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 28	2008	454	7208					1084	U27		10.1038/nature07268	http://dx.doi.org/10.1038/nature07268			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341MW	18756250				2022-12-28	WOS:000258719600030
J	Lantieri, L; Meningaud, JP; Grimbert, P; Bellivier, F; Lefaucheur, JP; Ortonne, N; Benjoar, MD; Lang, P; Wolkenstein, P				Lantieri, Laurent; Meningaud, Jean-Paul; Grimbert, Philippe; Bellivier, Frank; Lefaucheur, Jean-Pascal; Ortonne, Nicolas; Benjoar, Marc-David; Lang, Philippe; Wolkenstein, Pierre			Repair of the lower and middle parts of the face by composite tissue allotransplantation in a patient with massive plexiform neurofibroma: a 1-year follow-up study	LANCET			English	Article							HUMAN HAND TRANSPLANTATION; ALLOGRAFT; TYPE-1; REJECTION; TOLERANCE; TUMORS	Background The risk to benefit ratio of face transplantation with a composite tissue allograft remains debatable, although this procedure is technically feasible. We report here a 1-year follow-up of a patient who underwent face transplantation with a composite tissue allograft. Methods On Jan 21, 2007, a 29-year-old man with neurofibromatosis type 1 underwent resection of a massive plexiform neurofibroma diffusely infiltrating the middle and lower part of his face. The main goal was to restore both the cutaneous appearance and function of the face, including, in particular, control of orbicularis oculi and oris muscle contraction. The issues of immunosuppressive therapy, psychological outcome, and social reintergration were addressed, together with the monitoring of graft rejection by biopsies of the skin and mucosa. Findings The initial postoperative course was uncomplicated. Two episodes of clinical rejection occurred on days 28 and 64. The second episode was associated with cytomegalovirus infection. Both episodes resolved favourably, with no further clinical signs of rejection, making the reduction of immunosuppressive treatment possible. A year after surgery, the functional outcome was very good, with successful sensory and motor reinnervation in the transplanted territory. Psychological recovery was excellent, with complete social reintegration. Interpretation This case demonstrates the feasibility of surgically removing a large part of the face and replacing it with a composite tissue allograft. This facial repair procedure, which seems to have a satisfactory risk to benefit ratio, could be offered in rare and selected cases.	[Lantieri, Laurent; Meningaud, Jean-Paul; Grimbert, Philippe; Bellivier, Frank; Lefaucheur, Jean-Pascal; Ortonne, Nicolas; Benjoar, Marc-David; Lang, Philippe; Wolkenstein, Pierre] Univ Paris 12, Fac Med, IFR10, INSERM U 841, Creteil, France; [Lantieri, Laurent; Meningaud, Jean-Paul; Benjoar, Marc-David] Serv Chirurg Plast Reconstruct & Esthet, AP HP, Grp Henri Mondor Albert Chenevier, Creteil, France; [Grimbert, Philippe; Lang, Philippe] Serv Nephrol & Transplantat, AP HP, Grp Henri Mondor Albert Chenevier, Creteil, France; [Bellivier, Frank] Psychiat Serv, AP HP, Grp Henri Mondor Albert Chenevier, Creteil, France; [Lefaucheur, Jean-Pascal] Serv Physiol Explorat Fonctionnelles, AP HP, Grp Henri Mondor Albert Chenevier, Creteil, France; [Ortonne, Nicolas] Serv Anat, AP HP, Grp Henri Mondor Albert Chenevier, Creteil, France; [Wolkenstein, Pierre] Serv Dermatol, AP HP, Grp Henri Mondor Albert Chenevier, Creteil, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Lantieri, L (corresponding author), CHU Henri Mondor, Dept Plast & Reconstruct Surg, F-94010 Creteil, France.	laurent.lantieri@hmn.aphp.fr	grimbert, philippe/Q-5337-2018; BELLIVIER, FRANK/H-5197-2012; Lantieri, Laurent/AAD-2025-2019	BELLIVIER, FRANK/0000-0002-3660-6640				Barr ML, 1998, NEW ENGL J MED, V339, P1744, DOI 10.1056/NEJM199812103392404; BOUHANNA E, 2004, ALLOTRANSPLANTATION; Devauchelle B, 2006, LANCET, V368, P203, DOI 10.1016/S0140-6736(06)68935-6; Dubernard JM, 2007, NEW ENGL J MED, V357, P2451, DOI 10.1056/NEJMoa072828; Evans DGR, 2002, J MED GENET, V39, P311, DOI 10.1136/jmg.39.5.311; Gutmann DH, 1997, JAMA-J AM MED ASSOC, V278, P51, DOI 10.1001/jama.278.1.51; JACKSON IT, 1995, CLIN PLAST SURG, V22, P513; Kanitakis J, 2006, TRANSPLANTATION, V82, P1610, DOI 10.1097/01.tp.0000248780.55263.33; Kasiske BL, 2005, AM J TRANSPLANT, V5, P1405, DOI 10.1111/j.1600-6143.2005.00853.x; Lantieri LA, 2006, SOUTH MED J, V99, P421, DOI 10.1097/01.smj.0000210143.28625.21; Lanzetta M, 2004, TRANSPL P, V36, P664, DOI 10.1016/j.transproceed.2004.03.006; Merlo CA, 2004, J HEART LUNG TRANSPL, V23, P774, DOI 10.1016/S1053-2498(03)00265-1; Nett PC, 2004, TRANSPLANTATION, V78, P1036, DOI 10.1097/01.TP.0000137105.92464.F3; Nopajaroonsri C, 1996, HUM PATHOL, V27, P982, DOI 10.1016/S0046-8177(96)90229-4; Paraskevas A, 2007, ANN CHIR PLAST ESTH, V52, P485, DOI 10.1016/j.anplas.2007.06.003; Petit F, 2004, AM J BIOETHICS, V4, P14, DOI 10.1080/15265160490496868; Petit F, 2004, PLAST RECONSTR SURG, V113, P1429, DOI 10.1097/01.PRS.0000112747.85388.39; Prabhune KA, 2003, TRANSPLANTATION, V76, P1548, DOI 10.1097/01.TP.0000085288.12571.65; Schneeberger S, 2005, TRANSPLANTATION, V80, P441, DOI 10.1097/01.tp.0000168454.68139.0a; Starzl TE, 2008, NEW ENGL J MED, V358, P407, DOI 10.1056/NEJMe0707578; Taure G, 2006, J ORAL MAXIL SURG, V64, P789, DOI 10.1016/j.joms.2006.01.010; Wolkenstein P, 2001, ARCH DERMATOL, V137, P1421, DOI 10.1001/archderm.137.11.1421; Wolkenstein P, 2001, ARCH DERMATOL, V137, P233	23	235	242	2	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	2008	372	9639					639	645		10.1016/S0140-6736(08)61277-5	http://dx.doi.org/10.1016/S0140-6736(08)61277-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	340BX	18722868				2022-12-28	WOS:000258622200027
J	Rauch, SD				Rauch, Steven D.			Idiopathic sudden sensorineural hearing loss	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BLIND CLINICAL-TRIAL; INTRATYMPANIC DEXAMETHASONE; STEROID PERFUSION; INNER-EAR; THERAPY; DEAFNESS; CARBOGEN; FAILURE; JAPAN		[Rauch, Steven D.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Rauch, SD (corresponding author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA.	steven_rauch@meei.harvard.edu			Best Doctors; IMEDECS; Partners Online Specialty Consultations	Best Doctors; IMEDECS; Partners Online Specialty Consultations	Dr. Rauch reports receiving consulting fees from Best Doctors, IMEDECS, and Partners Online Specialty Consultations. No other potential conflict of interest relevant to this article was reported.	Alexiou C, 2001, ARCH OTOLARYNGOL, V127, P253, DOI 10.1001/archotol.127.3.253; Aoki D, 2006, OTOLARYNG HEAD NECK, V134, P783, DOI 10.1016/j.otohns.2005.12.029; Banerjee A, 2005, OTOL NEUROTOL, V26, P878, DOI 10.1097/01.mao.0000185052.07513.5a; BYL FM, 1984, LARYNGOSCOPE, V94, P647; Choung YH, 2006, LARYNGOSCOPE, V116, P747, DOI 10.1097/01.mlg.0000205183.29986.f6; Cinamon U, 2001, EUR ARCH OTO-RHINO-L, V258, P477, DOI 10.1007/s004050100366; Conlin AE, 2007, ARCH OTOLARYNGOL, V133, P582, DOI 10.1001/archotol.133.6.582; Conlin AE, 2007, ARCH OTOLARYNGOL, V133, P573, DOI 10.1001/archotol.133.6.573; Fetterman BL, 1996, AM J OTOL, V17, P529; Fitzgerald DC, 2007, ANN OTO RHINOL LARYN, V116, P253, DOI 10.1177/000348940711600405; Gianoli GJ, 2001, OTOLARYNG HEAD NECK, V125, P142, DOI 10.1067/mhn.2001.117162; HALLBERG O E, 1956, Laryngoscope, V66, P1237; Haynes DS, 2007, LARYNGOSCOPE, V117, P3, DOI 10.1097/01.mlg.0000245058.11866.15; Herr BD, 2005, OTOLARYNG HEAD NECK, V132, P527, DOI 10.1016/j.otohns.2004.09.138; Ho GM, 2004, LARYNGOSCOPE, V114, P1184; Hughes GB, 1996, OTOLARYNG CLIN N AM, V29, P393; JAFFE BF, 1967, ARCHIV OTOLARYNGOL, V86, P55; Kallinen J, 1997, ANN OTO RHINOL LARYN, V106, P22, DOI 10.1177/000348949710600104; Kopke RD, 2001, OTOL NEUROTOL, V22, P475, DOI 10.1097/00129492-200107000-00011; Lefebvre PP, 2002, ACTA OTO-LARYNGOL, V122, P698, DOI 10.1080/003655402/000028037; LIN HC, IN PRESS STROKE; MATTOX DE, 1977, ANN OTO RHINOL LARYN, V86, P463, DOI 10.1177/000348947708600406; MEGIGHIAN D, 1986, ARCH OTO-RHINO-LARYN, V243, P250, DOI 10.1007/BF00464440; Minoda R, 2000, AM J OTOL, V21, P819; Nakashima T, 2000, OTOLARYNG HEAD NECK, V123, P593, DOI 10.1067/mhn.2000.109486; Parnes LS, 1999, LARYNGOSCOPE, V109, P1, DOI 10.1097/00005537-199907001-00001; SHAIA FT, 1976, LARYNGOSCOPE, V86, P389, DOI 10.1288/00005537-197603000-00008; SIMMONS FB, 1973, LARYNGOSCOPE, V83, P1221, DOI 10.1288/00005537-197308000-00005; Stokroos RJ, 1998, ACTA OTO-LARYNGOL, V118, P488, DOI 10.1080/00016489850154603; Taylor DM, 2003, WILD ENVIRON MED, V14, P83, DOI 10.1580/1080-6032(2003)014[0083:ESDIAA]2.0.CO;2; Tucci DL, 2002, OTOL NEUROTOL, V23, P301, DOI 10.1097/00129492-200205000-00012; Wei BPC, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003998.pub2; Westerlaken BO, 2003, ANN OTO RHINOL LARYN, V112, P993, DOI 10.1177/000348940311201113; Westerlaken BO, 2007, LARYNGOSCOPE, V117, P684, DOI 10.1097/mlg.0b013e3180316d3b; WILSON WR, 1980, ARCH OTOLARYNGOL, V106, P772; YANAGITA N, 1994, ACTA OTO-LARYNGOL, P9	36	226	261	2	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 21	2008	359	8					833	840		10.1056/NEJMcp0802129	http://dx.doi.org/10.1056/NEJMcp0802129			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339HL	18716300				2022-12-28	WOS:000258568600008
J	LeGrand, SB; Leskuski, D; Zama, I				LeGrand, Susan B.; Leskuski, Dona; Zama, Ivan			Narrative review: Furosemide for hypercalcemia: An unproven yet common practice	ANNALS OF INTERNAL MEDICINE			English	Review							IMMOBILIZATION HYPERCALCEMIA; RENAL-FAILURE; DISSEMINATED COCCIDIOIDOMYCOSIS; MALIGNANT HYPERCALCEMIA; ZOLEDRONIC ACID; PAMIDRONATE; ETIDRONATE; CALCITONIN; COMBINATION; DISODIUM	Although primary hyperparathyroidism is the most common cause of hypercalcemia, cancer is the most common cause requiring inpatient intervention. An estimated 10% to 20% of all patients with cancer have hypercalcemia at some point in their disease trajectory, particularly in advanced disease. Aggressive saline hydration and varying doses of furosemide continue to be the standard of care for emergency management. However, a review of the evidence for the use of furosemide in the medical management of hypercalcemia yields only case reports published before the introduction of bisphosphonates, in contrast to multiple randomized, controlled trials supporting the use of bisphosphonates. The use of furosemide in the management of hypercalcemia should no longer be recommended.	[LeGrand, Susan B.] Cleveland Clin, Harry R Horvitz Ctr Palliat Med, Taussig Ctr Inst, WHO Demostrat Project, Cleveland, OH 44195 USA; Capital Hospice & Capital Palliat Care Consultant, Falls Church, VA USA	Cleveland Clinic Foundation	LeGrand, SB (corresponding author), Cleveland Clin, Harry R Horvitz Ctr Palliat Med, Taussig Ctr Inst, WHO Demostrat Project, 9500 Euclid Ave R35, Cleveland, OH 44195 USA.	legrans@ccf.org						AGUS ZS, 2008, TREATMENT HYPERCALCE; Alborzi F, 2002, OBES SURG, V12, P871, DOI 10.1381/096089202320995736; BAGUET JC, 1972, REV RHUM MAL OSTEO-M, V39, P531; Body Jean-Jacques, 2000, Cancer, V88, P3054, DOI 10.1002/1097-0142(20000615)88:12+<3054::AID-CNCR23>3.0.CO;2-Z; Caldwell JW, 2004, AM J MED SCI, V327, P15, DOI 10.1097/00000441-200401000-00004; CARLSON RW, 2008, ACP MED, P2425; CARON C, 1975, UNION MED CAN, V104, P272; Chang JT, 2003, NEW ENGL J MED, V349, P1676; CLINE DM, 2004, EMERGENCY MED MANUAL, P659; FILLASTRE JP, 1973, CURR THER RES CLIN E, V15, P641; FUKAGAWA M, 2008, CURRENT MED DIAGNOSI; GARDNER DG, 2007, GREENSPANS BASIC CLI, P281; Gomella L.G., 2007, CLIN POCKET REFERENC, V11th; Helzberg J, 1983, J Kans Med Soc, V84, P16; Henrich D, 2006, ACTA HAEMATOL-BASEL, V116, P165, DOI 10.1159/000094676; HOLT EH, 2008, ACP MED, P698; HUMBERT G, 1972, NOUV PRESSE MED, V1, P2025; Kedlaya D, 1998, ARCH PHYS MED REHAB, V79, P222, DOI 10.1016/S0003-9993(98)90304-5; KHOSLA S, 2008, HARRISONS PRINCIPLES, P285; Latos D L, 1973, W V Med J, V69, P52; Le Gall J R, 1971, Ann Med Interne (Paris), V122, P613; Lee DC, 1998, J TOXICOL-CLIN TOXIC, V36, P719, DOI 10.3109/15563659809162621; LONDNER M, 2004, TINTANALLIS EMERGENC, P106; LUCE JA, 2005, HOSP MED; Machado CE, 1996, CLIN NEPHROL, V45, P175; Major P, 2001, J CLIN ONCOL, V19, P558, DOI 10.1200/JCO.2001.19.2.558; Markowitz GS, 2003, KIDNEY INT, V64, P281, DOI 10.1046/j.1523-1755.2003.00071.x; Massagli TL, 1999, ARCH PHYS MED REHAB, V80, P998, DOI 10.1016/S0003-9993(99)90050-3; Morgan JGE, 2021, CLIN ANAESTHESIOL, V6th, P582; MORTON RA, 2004, CLIN ONCOLOGY, P957; Mundy GR, 1997, AM J MED, V103, P134, DOI 10.1016/S0002-9343(97)80047-2; NAJJAR SS, 1972, J PEDIATR-US, V81, P1171, DOI 10.1016/S0022-3476(72)80257-9; Pecherstorfer Martin, 2003, Treat Endocrinol, V2, P273, DOI 10.2165/00024677-200302040-00005; Peralta Maylene Claire I, 2002, Endocr Pract, V8, P213; POLLACK MR, 2008, BRENNER RECTORS KIDN, P588; SAMBANDAM K, 2007, WASHINGTON MANUAL ME; Saunders Y, 2004, PALLIATIVE MED, V18, P418, DOI 10.1191/0269216304pm914ra; Sekine M, 1998, ONCOL REP, V5, P197; SINGER FR, 1991, ARCH INTERN MED, V151, P471, DOI 10.1001/archinte.151.3.471; Stewart AF, 2005, NEW ENGL J MED, V352, P373, DOI 10.1056/NEJMcp042806; SUKI WN, 1970, NEW ENGL J MED, V283, P836, DOI 10.1056/NEJM197010152831603; Tal A, 1996, SOUTHERN MED J, V89, P637, DOI 10.1097/00007611-199606000-00020; THIEBAUD D, 1990, ARCH INTERN MED, V150, P2125, DOI 10.1001/archinte.150.10.2125; TOPF JM, 2005, PRINCIPLES CRITICAL, P1161; WARRELL RP, 1991, J CLIN ONCOL, V9, P1467, DOI 10.1200/JCO.1991.9.8.1467; Westphal SA, 1998, MAYO CLIN PROC, V73, P893, DOI 10.4065/73.9.893; WISNESKI LA, 1990, CALCIFIED TISSUE INT, V46, pS26, DOI 10.1007/BF02553290; WYSOLMERSKI JJ, 2007, CECIL MED, P1897; ZWEIG JI, 1980, JAMA-J AM MED ASSOC, V244, P437, DOI 10.1001/jama.1980.03310050015011	49	99	101	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 19	2008	149	4					259	+		10.7326/0003-4819-149-4-200808190-00007	http://dx.doi.org/10.7326/0003-4819-149-4-200808190-00007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	338RQ	18711156				2022-12-28	WOS:000258526700005
J	Branscomb, LM				Branscomb, Lewis M.			Science and industry - Research alone is not enough	SCIENCE			English	Editorial Material									[Branscomb, Lewis M.] Univ Calif San Diego, Scripps Inst Oceanog, Sch Int Relat & Pacific Studies, San Diego, CA 92093 USA; [Branscomb, Lewis M.] Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography; Harvard University	Branscomb, LM (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, Sch Int Relat & Pacific Studies, San Diego, CA 92093 USA.	lbranscomb@ucsd.edu						ACHTMEYER WF, 2003, E BUSINESS INNOVATIO; *AM ASS ADV SCI, 2007, R D BUDG POL PROGR G; Atkinson R., 2008, BOOSTING PRODUCTIVIT, P8; Auerswald PE., 2003, J TECHNOLOGY TRANSFE, V28, P227, DOI DOI 10.1023/A:1024980525678; Auerswald P, 2008, TECHNOL SOC, V30, P339, DOI 10.1016/j.techsoc.2008.04.021; BRITAN G, 2007, MIT SLOAN MANAGE REV, V48, P30; Committee on Prospering in the Global Economy of the 21st Century, 2007, RIS GATH STORM; *COUNC COMP, 2007, COMP IND AM STANDS, P74; HAGEL J, 2005, ONLY SUSTAINABLE EDG, P87; Hagel J, 2006, WORKSH HIGH TECH REG; Hill CT, 2007, ISSUES SCI TECHNOL, V24, P78; IBM, 2007, IBM ANN REP 2007; Palmisano SJ, 2006, FOREIGN AFF, V85, P127, DOI 10.2307/20031973; *US NAT SCI BOARD, 2006, SCI ENG IND 2006, P6; 2008, W CAREY LECT AAAS FO	15	5	5	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2008	321	5891					915	916		10.1126/science.1160496	http://dx.doi.org/10.1126/science.1160496			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	337LD	18703726				2022-12-28	WOS:000258436700020
J	Lamb, HR; Weinberger, LE				Lamb, H. Richard; Weinberger, Linda E.			Mental health courts as a way to provide treatment to violent persons with severe mental illness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CRIMINAL-JUSTICE SYSTEM; RISK; ILL; SCHIZOPHRENIA; DISORDERS; OFFENDERS		[Lamb, H. Richard; Weinberger, Linda E.] Univ So Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA; [Weinberger, Linda E.] Univ So Calif, Keck Sch Med, Inst Psychiat Law & Behav Sci, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Lamb, HR (corresponding author), 1861 Lombardy Rd, San Marino, CA 91108 USA.	hlamb@usc.edu						Elbogen EB, 2007, CRIM JUSTICE BEHAV, V34, P197, DOI 10.1177/0093854806290326; Fisler C, 2005, PSYCHOL PUBLIC POL L, V11, P587, DOI 10.1037/1076-8971.11.4.587; Hiday VA, 2006, INT J LAW PSYCHIAT, V29, P316, DOI 10.1016/j.ijlp.2004.08.010; Hodgins S, 2001, INT J LAW PSYCHIAT, V24, P427, DOI 10.1016/S0160-2527(01)00077-2; Lamb HR, 2007, PSYCHIAT SERV, V58, P782, DOI 10.1176/appi.ps.58.6.782; Lamb HR, 1999, PSYCHIATR SERV, V50, P907, DOI 10.1176/ps.50.7.907; Lamb HR, 2004, PSYCHIAT QUART, V75, P107, DOI 10.1023/B:PSAQ.0000019753.63627.2c; Minkoff K, 2004, PSYCHIAT CLIN N AM, V27, P727, DOI 10.1016/j.psc.2004.07.003; *NAT COMM CORR HLT, 2002, HLTH STAT SOON TO BE; Pia L, 2006, PSYCHIAT CLIN NEUROS, V60, P531, DOI 10.1111/j.1440-1819.2006.01576.x; SLATE RN, 2008, CRIMINZALIZATION MEN; Swanson JW, 2006, ARCH GEN PSYCHIAT, V63, P490, DOI 10.1001/archpsyc.63.5.490; Trestman RL, 2007, J AM ACAD PSYCHIATRY, V35, P490; *US BUR JUST STAT, PRIS STAT; WILSON D, 1995, INT J LAW PSYCHIAT, V18, P61, DOI 10.1016/0160-2527(94)00027-1	15	8	8	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	2008	300	6					722	724		10.1001/jama.300.6.722	http://dx.doi.org/10.1001/jama.300.6.722			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336OM	18698071				2022-12-28	WOS:000258374500025
J	Silverman, JG; Decker, MR; Saggurti, N; Balaiah, D; Raj, A				Silverman, Jay G.; Decker, Michele R.; Saggurti, Niranjan; Balaiah, Donta; Raj, Anita			Intimate partner violence and HIV infection among married Indian women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GENDER-BASED VIOLENCE; SEXUALLY-TRANSMITTED INFECTION; RURAL EASTERN CAPE; DOMESTIC VIOLENCE; RISK BEHAVIOR; PHYSICAL VIOLENCE; HIV/AIDS EPIDEMIC; DATING VIOLENCE; SOUTH-AFRICA; MEN	Context Despite reductions in prevalence of human immunodeficiency virus (HIV) infection among the general population of India, women account for a rising percentage of all HIV cases with husbands' risk behavior described as the major source of women's infection. Intimate partner violence (IPV) has been described as being associated with heterosexual transmission of HIV to women in India and elsewhere. Objective To assess the relationship between experiencing IPV and the occurrence of HIV infection in a nationally representative sample of married Indian women tested for HIV. Design, Setting, and Participants The Indian National Family Health Survey 3 was conducted across all Indian states in 2005 through 2006. The nationally representative sample included 124 385 married women; analyses conducted in 2007 and 2008 were limited to 28 139 married women who provided IPV data and HIV test results via systematic selection into respective subsamples. Main Outcome Measures Prevalence estimates of lifetime IPV and HIV infection were calculated and demographic differences assessed. Intimate partner violence was conceptualized as physical violence with or without sexual violence and then was further categorized as physical violence only vs physical and sexual violence. Regression models were used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) for HIV infection among Indian women based on experiences of IPV after adjusting for demographics and women's HIV risk behaviors. Results One-third of married Indian women (35.49%) reported experiencing physical IPV with or without sexual violence from their husbands; 7.68% reported both physical and sexual IPV, and 27.80% reported experiencing physical IPV in the absence of sexual violence. Approximately 1 in 450 women (0.22%) tested positive for HIV. In adjusted models, married Indian women experiencing both physical and sexual violence from husbands demonstrated elevated HIV infection prevalence vs those not experiencing IPV (0.73% vs 0.19%; adjusted OR, 3.92; 95% CI, 1.41-10.94; P = .01). Physical IPV alone was not associated with risk of HIV infection. Women's personal sexual risk behaviors were not associated with HIV infection. Conclusions Among married Indian women, physical violence combined with sexual violence from husbands was associated with an increased prevalence of HIV infection. Prevention of IPV may augment efforts to reduce the spread of HIV/AIDS.	[Silverman, Jay G.; Decker, Michele R.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA; [Saggurti, Niranjan] Populat Council, New Delhi, India; [Balaiah, Donta] Indian Council Med Res, Inst Res Reprod, Bombay 400012, Maharashtra, India; [Raj, Anita] Boston Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Indian Council of Medical Research (ICMR); ICMR - National Institute for Research in Reproductive Health (NIRRH); Boston University	Silverman, JG (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, 667 Huntington Ave, Boston, MA 02115 USA.	jsilverm@hsph.harvard.edu		Saggurti, Niranjan/0000-0002-5267-8425; Decker, Michele/0000-0002-7085-7080	NICHD NIH HHS [R03HD055120] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD055120] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		[Anonymous], HIV AIDS IND; Bates LM, 2004, INT FAM PLAN PERSPEC, V30, P190, DOI 10.1363/3019004; Bhuiya A, 2003, J HEALTH POPUL NUTR, V21, P48; Chandrasekaran Varalakshmi, 2007, Indian J Med Sci, V61, P253; Chatterjee N, 2006, J HEALTH POPUL NUTR, V24, P81; Decker MR, 2008, INT J GYNECOL OBSTET, V100, P18, DOI 10.1016/j.ijgo.2007.06.045; Decker MR, 2005, PEDIATRICS, V116, pE272, DOI 10.1542/peds.2005-0194; Dunkle KL, 2004, LANCET, V363, P1415, DOI 10.1016/S0140-6736(04)16098-4; Dunkle KL, 2007, SOC SCI MED, V65, P1235, DOI 10.1016/j.socscimed.2007.04.029; Dunkle KL, 2007, SEX TRANSM INFECT, V83, P173, DOI 10.1136/sti.2007.024950; Dunkle KL, 2006, AIDS, V20, P2107, DOI 10.1097/01.aids.0000247582.00826.52; Dworkin SL, 2007, AM J PUBLIC HEALTH, V97, P13, DOI 10.2105/AJPH.2005.074591; El-Bassel N, 2001, J SUBST ABUSE, V13, P29, DOI 10.1016/S0899-3289(01)00068-2; Fonck K, 2005, AIDS BEHAV, V9, P335, DOI 10.1007/s10461-005-9007-0; Gangakhedkar RR, 1997, JAMA-J AM MED ASSOC, V278, P2090, DOI 10.1001/jama.278.23.2090; Garcia-Moreno C, 2006, LANCET, V368, P1260, DOI 10.1016/S0140-6736(06)69523-8; Gilbert L, 2007, J URBAN HEALTH, V84, P667, DOI 10.1007/s11524-007-9214-2; Go VF, 2003, AIDS BEHAV, V7, P263, DOI 10.1023/A:1025443719490; Godbole S, 2005, INDIAN J MED RES, V121, P356; *INT I POP SCI MAC, IND NAT FAM HLTH SUR; Jewkes R, 2006, INT J EPIDEMIOL, V35, P1461, DOI 10.1093/ije/dyl218; Jewkes R, 2006, SOC SCI MED, V63, P2949, DOI 10.1016/j.socscimed.2006.07.027; *JOINT UN PROGR HI, 2007 AIDS EP UPD; *JOINT UN PROGR HI, IND COUNTR PROF; *JOINT UN PROGR HI, NEP COUNTR PROF; Joint United Nations Programme on HIV/AIDS, REP GLOB AIDS EP; Koenig MA, 2006, AM J PUBLIC HEALTH, V96, P132, DOI 10.2105/AJPH.2004.050872; Koenig MA, 2003, DEMOGRAPHY, V40, P269, DOI 10.1353/dem.2003.0014; Krishnan Suneeta, 2005, Health Care Women Int, V26, P87, DOI 10.1080/07399330490493368; Kumar S, 2005, BRIT J PSYCHIAT, V187, P62, DOI 10.1192/bjp.187.1.62; Martin SL, 2004, LANCET, V363, P1410, DOI 10.1016/S0140-6736(04)16133-3; Martin SL, 1999, JAMA-J AM MED ASSOC, V282, P1967, DOI 10.1001/jama.282.20.1967; Mehta SH, 2006, JAIDS-J ACQ IMM DEF, V41, P75, DOI 10.1097/01.qai.0000174653.17911.4a; Mercer A, 2007, SEX TRANSM DIS, V34, P265, DOI 10.1097/01.olq.0000240384.61924.65; Naved RT, 2006, SOC SCI MED, V62, P2917, DOI 10.1016/j.socscimed.2005.12.001; Newmann S, 2000, INT J STD AIDS, V11, P250, DOI 10.1258/0956462001915796; Patel V, 2006, SEX TRANSM INFECT, V82, P243, DOI 10.1136/sti.2005.016451; Peedicayil A, 2004, BJOG-INT J OBSTET GY, V111, P682, DOI 10.1111/j.1471-0528.2004.00151.x; Purwar M B, 1999, J Obstet Gynaecol Res, V25, P165; Quinn TC, 2005, SCIENCE, V308, P1582, DOI 10.1126/science.1112489; Raj A, 2007, AIDS CARE, V19, P970, DOI 10.1080/09540120701335246; Raj A, 2006, AM J PUBLIC HEALTH, V96, P1873, DOI 10.2105/AJPH.2005.081554; Schensul SL, 2006, J URBAN HEALTH, V83, P614, DOI 10.1007/s11524-006-9076-z; Silverman JG, 2007, SEX TRANSM INFECT, V83, P211, DOI 10.1136/sti.2006.023366; Sivaram S, 2005, HEALTH PROMOT INT, V20, P327, DOI 10.1093/heapro/dai012; Slaughter L, 1997, AM J OBSTET GYNECOL, V176, P609, DOI 10.1016/S0002-9378(97)70556-8; StataCorp, 2005, STAT STAT SOFTW REL; Stephenson Rob, 2007, Indian J Med Sci, V61, P251; Straus MA, 1996, J FAM ISSUES, V17, P283, DOI 10.1177/019251396017003001; WHO, PUTT WOM 1 ETH SAF R; *WHO JOINT UN PROG, GUID MEAS NAT HIV PR; Wingood GM, 2003, J URBAN HEALTH, V80, P67; Wingood GM, 2000, AM J PREV MED, V19, P270, DOI 10.1016/S0749-3797(00)00228-2; World Health Organization (WHO), VIOL WOM HIV AIDS CR; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	55	191	194	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	2008	300	6					703	710		10.1001/jama.300.6.703	http://dx.doi.org/10.1001/jama.300.6.703			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	336OM	18698068	Bronze			2022-12-28	WOS:000258374500022
J	Yang, YD; Cho, HW; Koo, JY; Tak, MH; Cho, YY; Shim, WS; Park, SP; Lee, J; Lee, B; Kim, BM; Raouf, R; Shin, YK; Oh, U				Yang, Young Duk; Cho, Hawon; Koo, Jae Yeon; Tak, Min Ho; Cho, Yeongyo; Shim, Won-Sik; Park, Seung Pyo; Lee, Jesun; Lee, Byeongjun; Kim, Byung-Moon; Raouf, Ramin; Shin, Young Ki; Oh, Uhtaek			TMEM16A confers receptor-activated calcium-dependent chloride conductance	NATURE			English	Article							CA2+-ACTIVATED CL-CHANNELS; RAT SUBMANDIBULAR-GLAND; PAROTID ACINAR-CELLS; CYSTIC-FIBROSIS; PROTEIN-KINASE; TRANSCRIPTOME ANALYSIS; ENDOTHELIAL-CELLS; AIRWAY EPITHELIA; SMOOTH-MUSCLE; MEMBRANE	Calcium (Ca2+)-activated chloride channels are fundamental mediators in numerous physiological processes including transepithelial secretion, cardiac and neuronal excitation, sensory transduction, smooth muscle contraction and fertilization. Despite their physiological importance, their molecular identity has remained largely unknown. Here we show that transmembrane protein 16A(TMEM16A, which we also call anoctamin 1 (ANO1)) is a bona fide Ca2+-activated chloride channel that is activated by intracellular Ca2+ and Ca2+- mobilizing stimuli. With eight putative transmembrane domains and no apparent similarity to previously characterized channels, ANO1 defines a new family of ionic channels. The biophysical properties as well as the pharmacological profile of ANO1 are in full agreement with native Ca2+- activated chloride currents. ANO1 is expressed in various secretory epithelia, the retina and sensory neurons. Furthermore, knockdown of mouse Ano1 markedly reduced native Ca2+-activated chloride currents as well as saliva production in mice. We conclude that ANO1 is a candidate Ca2+-activated chloride channel that mediates receptor- activated chloride currents in diverse physiological processes.	[Yang, Young Duk; Cho, Hawon; Koo, Jae Yeon; Tak, Min Ho; Cho, Yeongyo; Shim, Won-Sik; Park, Seung Pyo; Lee, Jesun; Lee, Byeongjun; Kim, Byung-Moon; Shin, Young Ki; Oh, Uhtaek] Seoul Natl Univ, Sensory Res Ctr, CRI, Coll Pharm, Seoul 151742, South Korea; [Raouf, Ramin] UCL, Mol Nocicept Grp, London WC1E 6BT, England	Seoul National University (SNU); University of London; University College London	Oh, U (corresponding author), Seoul Natl Univ, Sensory Res Ctr, CRI, Coll Pharm, Seoul 151742, South Korea.	utoh@snu.ac.kr	Shim, Won-Sik/HGU-0398-2022; yang, xiao-jun/B-1927-2009; Shin, Young Kee/C-8929-2011	Shin, Young Kee/0000-0003-0896-718X; Raouf, Ramin/0000-0002-5890-2221	Acceleration Research of MOEST/KOSEF of Korea; Brain Korea 21 Project; Wellcome Trust Foundation, UK	Acceleration Research of MOEST/KOSEF of Korea(Korea Science and Engineering Foundation); Brain Korea 21 Project(Ministry of Education & Human Resources Development (MOEHRD), Republic of Korea); Wellcome Trust Foundation, UK(Wellcome Trust)	We thank R. MacKinnon and J. Wood for a review of the manuscript. We also thank B. Hille for his technical comment on ion permeability. This work was supported by Acceleration Research of MOEST/ KOSEF of Korea. This work was also supported by the Brain Korea 21 Project and by the Wellcome Trust Foundation, UK (R.R.).	ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; Arreola J, 2003, J PHYSIOL-LONDON, V547, P197, DOI 10.1113/jphysiol.2002.028373; Arreola J, 2002, J PHYSIOL-LONDON, V545, P207, DOI 10.1113/jphysiol.2002.021980; Arreola J, 1996, J GEN PHYSIOL, V108, P35, DOI 10.1085/jgp.108.1.35; BOUCHER RC, 1989, J CLIN INVEST, V84, P1424, DOI 10.1172/JCI114316; Carles A, 2006, ONCOGENE, V25, P1821, DOI 10.1038/sj.onc.1209203; Cunningham SA, 1995, J BIOL CHEM, V270, P31016, DOI 10.1074/jbc.270.52.31016; Eggermont Jan, 2004, Proc Am Thorac Soc, V1, P22, DOI 10.1513/pats.2306010; Elble RC, 2001, J BIOL CHEM, V276, P40510, DOI 10.1074/jbc.M104821200; Espinosa I, 2008, AM J SURG PATHOL, V32, P210, DOI 10.1097/PAS.0b013e3181238cec; EVANS MG, 1986, J PHYSIOL-LONDON, V378, P437, DOI 10.1113/jphysiol.1986.sp016229; Frings S, 2000, PROG NEUROBIOL, V60, P247, DOI 10.1016/S0301-0082(99)00027-1; FULLER CM, 1994, J BIOL CHEM, V269, P26642; Greenwood IA, 2002, J BIOL CHEM, V277, P22119, DOI 10.1074/jbc.C200215200; GRUBB BR, 1994, AM J PHYSIOL, V266, pC1478, DOI 10.1152/ajpcell.1994.266.5.C1478; Gruber AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1261; Gruber AD, 1998, GENOMICS, V54, P200, DOI 10.1006/geno.1998.5562; Guibert C, 1997, CELL CALCIUM, V21, P421, DOI 10.1016/S0143-4160(97)90053-1; Hartzell C, 2005, PHYSIOLOGY, V20, P292, DOI 10.1152/physiol.00021.2005; Hartzell C, 2005, ANNU REV PHYSIOL, V67, P719, DOI 10.1146/annurev.physiol.67.032003.154341; Hartzell HC, 2008, PHYSIOL REV, V88, P639, DOI 10.1152/physrev.00022.2007; He XJ, 1997, PFLUG ARCH EUR J PHY, V433, P260; Huang P, 2001, J BIOL CHEM, V276, P20093, DOI 10.1074/jbc.M009376200; Huang X, 2006, GENE CHROMOSOME CANC, V45, P1058, DOI 10.1002/gcc.20371; Kenyon JL, 2002, CURR TOP MEMBR, V53, P135; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; Kuruma A, 2000, J GEN PHYSIOL, V115, P59, DOI 10.1085/jgp.115.1.59; Large WA, 1996, AM J PHYSIOL-CELL PH, V271, pC435; Lee MG, 1997, J BIOL CHEM, V272, P32951, DOI 10.1074/jbc.272.52.32951; Liu XB, 2007, P NATL ACAD SCI USA, V104, P17542, DOI 10.1073/pnas.0701254104; MARICQ AV, 1988, NEURON, V1, P503, DOI 10.1016/0896-6273(88)90181-X; Nilius B, 2002, CURR TOP MEMBR, V53, P327; Nilius B, 2003, ACTA PHYSIOL SCAND, V177, P119, DOI 10.1046/j.1365-201X.2003.01060.x; Nilius B, 1997, J PHYSIOL-LONDON, V498, P381, DOI 10.1113/jphysiol.1997.sp021865; Nilius B, 1997, CELL CALCIUM, V22, P53, DOI 10.1016/S0143-4160(97)90089-0; Piper AS, 2003, J PHYSIOL-LONDON, V547, P181, DOI 10.1113/jphysiol.2002.033688; Qu ZQ, 2004, J GEN PHYSIOL, V123, P327, DOI 10.1085/jgp.200409031; Rosenfeld MA, 1996, CHEST, V109, P241, DOI 10.1378/chest.109.1.241; Schwiebert Erik M., 1999, Physiological Reviews, V79, pS145; Sun H, 2002, P NATL ACAD SCI USA, V99, P4008, DOI 10.1073/pnas.052692999; Willis W.D., 2004, SENSORY MECH SPINAL, V207, P1067, DOI [10.1126/science.207.4435.1067.b, DOI 10.1126/SCIENCE.207.4435.1067.B]; Zholos A, 2005, J GEN PHYSIOL, V125, P197, DOI 10.1085/jgp.200409161	42	970	1036	3	94	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 30	2008	455	7217					1210	U36		10.1038/nature07313	http://dx.doi.org/10.1038/nature07313			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	366DZ	18724360				2022-12-28	WOS:000260462100037
J	Duke, T; Wandi, F; Jonathan, M; Matai, S; Kaupa, M; Saavu, M; Subhi, R; Peel, D				Duke, Trevor; Wandi, Francis; Jonathan, Merilyn; Matai, Sens; Kaupa, Magdalene; Saavu, Martin; Subhi, Rami; Peel, David			Improved oxygen systems for childhood pneumonia: a multihospital effectiveness study in Papua New Guinea	LANCET			English	Article							COST-EFFECTIVENESS; HYPOXEMIA; CHILDREN; MORTALITY; HOSPITALS	Background In rural hospitals of developing countries, oxygen supplies are poor and detection of hypoxaemia is difficult. Oxygen concentrators and pulse oximeters might help to manage the disease; however, use of such technology in developing countries needs comprehensive assessment. We studied the effect of an improved oxygen system on death rate in children with pneumonia in Papua New Guinea. Methods We installed an improved oxygen system in five hospitals in Papua New Guinea, and assessed its use in more than 11000 children with pneumonia (2001-07) and compared case-fatality rates. Admissions between January, 2001, and December, 2004, formed the pre-intervention group, and those between July, 2005, and October, 2007, formed the post-intervention group. Oxygen concentrators and pulse oximeters were introduced in the five hospitals, and a protocol for detection of hypoxaemia and clinical use of oxygen was supplied. All children admitted had their oxygen saturation measured; if it was less than 90%, oxygen was delivered via nasal prongs at a starting flow rate of 0.5-1 L/min. We recorded all costs associated with the establishment and maintenance of this system. The study was approved by the Medical Research Advisory Committee of Papua New Guinea, number MRAC 04.02. Findings Before the use of this system, 356 of 7161 children admitted in the five hospitals for pneumonia died (case-fatality rate 4.97% [95% CI 4.5-5.5]), whereas 133 of 4130 children died in the 27 months after the introduction of the system (3.22% [2.7-3.8]). After the improved system was introduced, the risk of death for a child with pneumonia was 35% lower than was that before the project began (risk ratio 0.65 [0.52-0.78], p<0.0001). Mortality rates varied between hospitals. The estimated costs of this system were US$51 per patient treated, US$1673 per life saved, and US$50 per disability-adjusted life-year (DALY) averted. Interpretation Pulse oximetry and oxygen concentrators can alleviate oxygen shortages, reduce mortality, and improve quality of care for children with pneumonia in developing countries. The cost-effectiveness of this system compared favourably with that of other public-health interventions. Funding The Papua New Guinea National Department of Health; WHO, Papua New Guinea and Western Pacific Regional Office; AirSep corporation, Buffalo, NY, USA; the Ross Trust, VIC, Australia; AusAID; Jacques Gostelli, Switzerland; and a grant from the University of Melbourne.	[Duke, Trevor; Subhi, Rami] Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Ctr Int Child Hlth,Dept Paed, Melbourne, Vic, Australia; [Duke, Trevor] Univ Papua New Guinea, Discipline Child Hlth, Sch Med & Hlth Sci, Waigani, Papua N Guinea; [Wandi, Francis] Kundiawa Hosp, Kundiawa, Papua N Guinea; [Jonathan, Merilyn] Papua New Guinea Natl Dept Hlth, Family Hlth Serv, Waigani, NCD, Papua N Guinea; [Matai, Sens] Papua New Guinea Natl Dept Hlth, Hlth Facil Branch, Waigani, NCD, Papua N Guinea; [Kaupa, Magdalene] Mt Hagen Hosp, Mt Hagen, Papua N Guinea; [Saavu, Martin] Mendi Hosp, Mendi, Papua N Guinea; [Peel, David] Ashdown Consultants, Hartfield, E Sussex, England	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; University of Papua New Guinea	Duke, T (corresponding author), Royal Childrens Hosp, Ctr Int Child Hlth, Dept Paediat, Royal Childrens Hosp, Flemington Rd, Parkville, Vic 3052, Australia.	trevor.duke@rch.org.au			WHO; R E Ross Trust (VIC, Australia); WHO (Papua New Guinea); University of Melbourne	WHO(World Health Organization); R E Ross Trust (VIC, Australia); WHO (Papua New Guinea)(World Health Organization); University of Melbourne(University of Melbourne)	We thank the nurses, doctors, and administrators of the five hospitals for their enthusiasm and commitment to this project during the 6 years since its inception; the members of the Paediatric Society who encouraged and supported this study; Enoch Posanai, job Hawap, Hilda Polume, William Lagani from Family Health Services for their support during the years; Eigil Sorensen, Reynaldo Pangan and Norbert Rehlis from WHO for their support, funding, and assistance with procurement of equipment; and AirSep for their generous donation of oxygen concentrators, CCyS for their donation of pulse oximetry sensor probes, and Salter laboratories for their donation of tubing and prongs. The study was supported by the R E Ross Trust (VIC, Australia), Jacques Gosteli, the WHO (Papua New Guinea), and a grant from the University of Melbourne (Early Career Research Development Grant, 2004).	Dobson M, 1996, LANCET, V347, P1597, DOI 10.1016/S0140-6736(96)91080-6; DOBSON MB, 1991, ANAESTHESIA, V46, P217, DOI 10.1111/j.1365-2044.1991.tb09413.x; Duke T, 2001, INT J TUBERC LUNG D, V5, P511; Duke T, 2002, ARCH DIS CHILD, V86, P108, DOI 10.1136/adc.86.2.108; DYKE T, 1994, BRIT MED J, V308, P119, DOI 10.1136/bmj.308.6921.119; Edejer TTT, 2005, BMJ-BRIT MED J, V331, P1177, DOI 10.1136/bmj.38652.550278.7C; Junge S, 2006, TROP MED INT HEALTH, V11, P367, DOI 10.1111/j.1365-3156.2006.01570.x; Laman M, 2005, ANN TROP PAEDIATR, V25, P23, DOI 10.1179/146532805X23317; Matai S, 2008, ANN TROP PAEDIATR, V28, P71, DOI 10.1179/146532808X270716; Mulholland K, 2007, LANCET, V370, P285, DOI 10.1016/S0140-6736(07)61130-1; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Paediatric Society of Papua New Guinea, 2005, STAND TREATM COMM IL; PEDERSEN J, 1991, BRIT J ANAESTH, V66, P264, DOI 10.1093/bja/66.2.264; Sinha A, 2007, LANCET, V369, P389, DOI 10.1016/S0140-6736(07)60195-0; Steinhoff M, 2007, LANCET, V369, P1409, DOI 10.1016/S0140-6736(07)60644-8; Wandi F, 2006, ANN TROP PAEDIATR, V26, P277, DOI 10.1179/146532806X152791; WEBER MW, 1995, J PEDIATR-US, V127, P378, DOI 10.1016/S0022-3476(95)70067-6; Weber MW, 1996, PEDIATR PULM, V22, P125, DOI 10.1002/(SICI)1099-0496(199608)22:2<125::AID-PPUL8>3.0.CO;2-P; Weber MW, 1998, LANCET, V351, P1589, DOI 10.1016/S0140-6736(05)61160-9; *WHO, 2005, COUGH DIFF BREATH HO; World Health Organization, DIS ADJ LIF YEARS DA	21	181	183	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 11	2008	372	9646					1328	1333		10.1016/S0140-6736(08)61164-2	http://dx.doi.org/10.1016/S0140-6736(08)61164-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	360MB	18708248				2022-12-28	WOS:000260060500031
J	Nott, A; Watson, PM; Robinson, JD; Crepaldi, L; Riccio, A				Nott, Alexi; Watson, P. Marc; Robinson, James D.; Crepaldi, Luca; Riccio, Antonella			S-nitrosylation of histone deacetylase 2 induces chromatin remodelling in neurons	NATURE			English	Article							NITRIC-OXIDE; SIGNALING PATHWAY; EXPRESSION; ROLES	Brain- derived neurotrophic factor ( BDNF) and other neurotrophins have a vital role in the development of the rat and mouse nervous system by influencing the expression of many specific genes that promote differentiation, cell survival, synapse formation and, later, synaptic plasticity(1). Although nitric oxide ( NO) is known to be an important mediator of BDNF signalling in neurons(2), the mechanisms by which neurotrophins influence gene expression during development and plasticity remain largely unknown. Here we show that BDNF triggers NO synthesis and S- nitrosylation of histone deacetylase 2 ( HDAC2) in neurons, resulting in changes to histone modifications and gene activation. S- nitrosylation of HDAC2 occurs at Cys 262 and Cys 274 and does not affect deacetylase activity. In contrast, nitrosylation of HDAC2 induces its release from chromatin, which increases acetylation of histones surrounding neurotrophin- dependent gene promoters and promotes transcription. Notably, nitrosylation of HDAC2 in embryonic cortical neurons regulates dendritic growth and branching, possibly by the activation of CREB ( cyclic- AMP-responsive-element- binding protein)- dependent genes. Thus, by stimulating NO production and S- nitrosylation of HDAC2, neurotrophic factors promote chromatin remodelling and the activation of genes that are associated with neuronal development.	[Nott, Alexi; Watson, P. Marc; Robinson, James D.; Crepaldi, Luca; Riccio, Antonella] UCL, MRC, Lab Mol & Cell Biol, London WC1E 6BT, England; [Nott, Alexi; Watson, P. Marc; Robinson, James D.; Crepaldi, Luca; Riccio, Antonella] UCL, Dept Neurosci Physiol & Pharmacol, London WC1E 6BT, England	University of London; University College London; University of London; University College London	Riccio, A (corresponding author), UCL, MRC, Lab Mol & Cell Biol, Mortimer St, London WC1E 6BT, England.	a.riccio@ucl.ac.uk	Nott, Alexi/K-6103-2019	Nott, Alexi/0000-0002-2029-7193	Medical Research Council [G0500792]; European Research Council [MIRG-CT-2005-016501]; MRC Career Development Fellowship [G117/533]; MRC Career Development Award; Medical Research Council [MC_U122663296, G120/934] Funding Source: researchfish; MRC [G0500792, G120/934, MC_U122663296] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Research Council(European Research Council (ERC)European Commission); MRC Career Development Fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC Career Development Award(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We are grateful to D. D. Ginty, A. Lloyd, M. Raff and A. Saiardi for comments and to all members of the Riccio laboratory for discussion. Wethank E. Seto for providing HDAC plasmids and A. Chittka for help with the purification of recombinant HDAC2. We also thank C. Andreassi for help with cell lines and molecular biology techniques. This work was supported by the Medical Research Council (MRC; grant G0500792), and the European Research Council (Marie Curie International Reintegration grant MIRG-CT-2005-016501). A. R. is a recipient of an MRC Career Development Fellowship (G117/533) and P. M. W. of an MRC Career Development Award.	Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Boehning D, 2003, ANNU REV NEUROSCI, V26, P105, DOI 10.1146/annurev.neuro.26.041002.131047; BREDT DS, 1994, NEURON, V13, P301, DOI 10.1016/0896-6273(94)90348-4; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Fischer A, 2007, NATURE, V447, P178, DOI 10.1038/nature05772; Forrester MT, 2007, J BIOL CHEM, V282, P13977, DOI 10.1074/jbc.M609684200; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Haendeler J, 2002, NAT CELL BIOL, V4, P743, DOI 10.1038/ncb851; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; Huang Y, 2005, NEURON, V46, P533, DOI 10.1016/j.neuron.2005.03.028; Jaffrey S R, 2001, Sci STKE, V2001, ppl1, DOI 10.1126/stke.2001.86.pl1; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Mallis RJ, 2001, BIOCHEM J, V355, P145, DOI 10.1042/bj3550145; Marshall HE, 2004, P NATL ACAD SCI USA, V101, P8841, DOI 10.1073/pnas.0403034101; Mustafa AK, 2007, P NATL ACAD SCI USA, V104, P2950, DOI 10.1073/pnas.0611620104; Redmond L, 2002, NEURON, V34, P999, DOI 10.1016/S0896-6273(02)00737-7; Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918; Riccio A, 2006, MOL CELL, V21, P283, DOI 10.1016/j.molcel.2005.12.006; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Stroissnigg H, 2007, NAT CELL BIOL, V9, P1035, DOI 10.1038/ncb1625; Uehara T, 2006, NATURE, V441, P513, DOI 10.1038/nature04782; Wegener D, 2003, CHEM BIOL, V10, P61, DOI 10.1016/S1074-5521(02)00305-8; Whalen EJ, 2007, CELL, V129, P511, DOI 10.1016/j.cell.2007.02.046; Wink DA, 1999, METHOD ENZYMOL, V301, P201; ZHANG J, 1995, ANNU REV PHARMACOL, V35, P213; Zweifel LS, 2005, NAT REV NEUROSCI, V6, P615, DOI 10.1038/nrn1727	33	327	334	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	2008	455	7211					411	U67		10.1038/nature07238	http://dx.doi.org/10.1038/nature07238			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349EX	18754010				2022-12-28	WOS:000259265200049
J	Zubkov, MV; Tarran, GA				Zubkov, Mikhail V.; Tarran, Glen A.			High bacterivory by the smallest phytoplankton in the North Atlantic Ocean	NATURE			English	Article							AMINO-ACID-UPTAKE; PLANKTONIC PROTISTS; SURFACE WATERS; FLOW-CYTOMETRY; FOOD WEBS; MIXOTROPHY; BACTERIOPLANKTON; CYANOBACTERIA; ASSIMILATION; ENUMERATION	Planktonic algae, <5 mu m in size are major fixers of inorganic carbon in the ocean(1). They dominate phytoplankton biomass in post-bloom, stratified oceanic temperate waters(2). Traditionally, large and small algae are viewed as having a critical growth dependence on inorganic nutrients, which the latter can better acquire at lower ambient concentrations owing to their higher surface area to volume ratios(3,4). Nonetheless, recent phosphate tracer experiments in the oligotrophic ocean(5) have suggested that small algae obtain inorganic phosphate indirectly, possibly through feeding on bacterioplankton. There have been numerous microscopy- based studies of algae feeding mixotrophically(6,7) in the laboratory(8-10) and field(11-14), as well as mathematical modelling of the ecological importance of mixotrophy(15). However, because of methodological limitations(16) there has not been a direct comparison of obligate heterotrophic and mixotrophic bacterivory. Here we present direct evidence that small algae carry out 40 - 95% of the bacterivory in the euphotic layer of the temperate North Atlantic Ocean in summer. A similar range of 37 - 70% was determined in the surface waters of the tropical North- East Atlantic Ocean, suggesting the global significance of mixotrophy. This finding reveals that even the smallest algae have less dependence on dissolved inorganic nutrients than previously thought, obtaining a quarter of their biomass from bacterivory. This has important implications for how we perceive nutrient acquisition and limitation of carbon- fixing protists as well as control of bacterioplankton in the ocean.	[Zubkov, Mikhail V.] Natl Ocean Ctr, Southampton SO14 3ZH, Hants, England; [Tarran, Glen A.] Plymouth Marine Lab, Plymouth PL1 3DH, Devon, England	NERC National Oceanography Centre; Plymouth Marine Laboratory	Zubkov, MV (corresponding author), Natl Ocean Ctr, Southampton SO14 3ZH, Hants, England.	mvz@noc.soton.ac.uk	Zubkov, Mikhail/AAW-9674-2020	Zubkov, Mikhail/0000-0001-7723-6810	UK Natural Environment Research Council (NERC); Oceans 2025 core programmes of the National Oceanography Centre; Southampton and Plymouth Marine Laboratory; NERC thematic programme Surface Ocean Low Atmosphere Study (SOLAS); NERC [soc010012, soc010008, NE/E016138/1, pml010002] Funding Source: UKRI; Natural Environment Research Council [soc010012, pml010002, NE/C001931/1, NE/E016138/1, soc010008] Funding Source: researchfish	UK Natural Environment Research Council (NERC)(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Oceans 2025 core programmes of the National Oceanography Centre; Southampton and Plymouth Marine Laboratory; NERC thematic programme Surface Ocean Low Atmosphere Study (SOLAS)(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	We gratefully acknowledge the captain, officers and crew aboard the RRS Discovery for their help during the cruises, M. Moore for sharing chlorophyll concentration measurements, P. Hill for helping with setting up experiments on the second cruise, and P. Warwick for his help with radiotracer measurements ashore. We thank M. Sleigh, A. Martin and R. Leakey for their critical comments on the earlier drafts of the paper. We thank H. Ducklow for constructive criticism of the earlier version of this paper. This study was supported by the UK Natural Environment Research Council (NERC) through the Oceans 2025 core programmes of the National Oceanography Centre, Southampton and Plymouth Marine Laboratory. The second cruise was supported by the NERC thematic programme Surface Ocean Low Atmosphere Study (SOLAS).	ARENOVSKI AL, 1995, J PLANKTON RES, V17, P801, DOI 10.1093/plankt/17.4.801; BIRD DF, 1986, SCIENCE, V231, P493, DOI 10.1126/science.231.4737.493; CARON DA, 2000, MICROBIAL ECOLOGY OC, P495, DOI DOI 10.1175/1520-0493(2000)1281993:SOOTWJ2.0.CO;2; CHISHOLM SW, 1992, ENVIR SCI R, V43, P213; Fagerbakke KM, 1996, AQUAT MICROB ECOL, V10, P15, DOI 10.3354/ame010015; Hansen PJ, 2002, MAR BIOL, V141, P975, DOI 10.1007/s00227-002-0879-5; Jones RI, 2000, FRESHWATER BIOL, V45, P219, DOI 10.1046/j.1365-2427.2000.00672.x; LI WKW, 1994, LIMNOL OCEANOGR, V39, P169, DOI 10.4319/lo.1994.39.1.0169; MALONE TC, 1980, PHYSL ECOLOGY PHYTOP, P433; Marie D, 1997, APPL ENVIRON MICROB, V63, P186, DOI 10.1128/AEM.63.1.186-193.1997; Mary I, 2008, FEMS MICROBIOL ECOL, V63, P36, DOI 10.1111/j.1574-6941.2007.00414.x; Olson R.J., 2018, HDB METHODS AQUATIC, P175, DOI DOI 10.1201/9780203752746; Rothhaupt KO, 1996, ECOLOGY, V77, P716, DOI 10.2307/2265496; SHERR BF, 1987, APPL ENVIRON MICROB, V53, P958, DOI 10.1128/AEM.53.5.958-965.1987; Sherr EB, 2002, ANTON LEEUW INT J G, V81, P293, DOI 10.1023/A:1020591307260; Stibor H, 2003, PROTIST, V154, P91, DOI 10.1078/143446103764928512; Tarran GA, 2001, DEEP-SEA RES PT II, V48, P963, DOI 10.1016/S0967-0645(00)00104-1; Thingstad TF, 1996, ECOLOGY, V77, P2108, DOI 10.2307/2265705; Tittel J, 2003, P NATL ACAD SCI USA, V100, P12776, DOI 10.1073/pnas.2130696100; Unrein F, 2007, LIMNOL OCEANOGR, V52, P456, DOI 10.4319/lo.2007.52.1.0456; VAQUE D, 1994, MAR ECOL PROG SER, V109, P263, DOI 10.3354/meps109263; Zubkov MV, 2007, ENVIRON MICROBIOL, V9, P2079, DOI 10.1111/j.1462-2920.2007.01324.x; Zubkov MV, 2006, CYTOM PART A, V69A, P1010, DOI 10.1002/cyto.a.20332; Zubkov M, 2007, J PLANKTON RES, V29, P79; Zubkov MV, 2004, FEMS MICROBIOL ECOL, V50, P153, DOI 10.1016/j.femsec.2004.06.009; Zubkov MV, 2005, FEMS MICROBIOL ECOL, V54, P281, DOI 10.1016/j.femsec.2005.04.001; Zubkov MV, 1998, FEMS MICROBIOL ECOL, V27, P85, DOI 10.1111/j.1574-6941.1998.tb00527.x; ZUBKOV MV, 1995, MICROBIAL ECOL, V30, P157, DOI 10.1007/BF00172571	28	254	258	3	108	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 11	2008	455	7210					224	U48		10.1038/nature07236	http://dx.doi.org/10.1038/nature07236			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	346SZ	18690208				2022-12-28	WOS:000259090800047
J	Funatogawa, I; Funatogawa, T; Yano, E				Funatogawa, Ikuko; Funatogawa, Takashi; Yano, Eiji			Do overweight children necessarily make overweight adults? Repeated cross sectional annual nationwide survey of Japanese girls and women over nearly six decades	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BRITISH CHILDREN; OBESITY; TRENDS; BIRTH; BMI; PREVALENCE; ADOLESCENTS; STANDARDS; WORLDWIDE; THINNESS	Objective To compare growth curves of body mass index from children to adolescents, and then to young adults, in Japanese girls and women in birth cohorts born from 1930 to 1999. Design Retrospective repeated cross sectional annual nationwide surveys (national nutrition survey, Japan) carried out from 1948 to 2005. Setting Japan. Participants 76 635 females from 1 to 25 years of age. Main outcome measure Body mass index. Results Generally, body mass index decreased in preschool children (2-5 years), increased in children (6-12 years) and adolescents (13-18 years), and slightly decreased in youngadults (19-25 years) in theseJapanese females. However, the curves differed among birth cohorts. More recent cohorts were more overweight as children but thinner as young women. The increments in body mass index in early childhood were larger in more recent cohorts than in older cohorts. However, the increments in body mass index in adolescents were smaller and the decrease in body mass index in young adults started earlier, with lower peak values in more recent cohorts than in older cohorts. The decrements in body mass index in young adults were similar in all birth cohorts. Conclusions An overweight birth cohort in childhood does not necessarily continue to be overweight in young adulthood. Not only seculartrends in body mass index at fixed ages but also growth curves for wide age ranges by birth cohorts should be considered to study obesity and thinness. Growth curves by birth cohorts were produced bya repeated cross sectional annual survey over nearly six decades.	[Funatogawa, Ikuko; Yano, Eiji] Teikyo Univ, Sch Med, Dept Hyg & Publ Hlth, Tokyo 1738605, Japan; [Funatogawa, Takashi] Chugai Pharmaceut Co Ltd, Clin Res Planning Dept, Tokyo 1038324, Japan	Teikyo University; Chugai Pharmaceutical Co., Ltd.; Roche Holding	Funatogawa, I (corresponding author), Teikyo Univ, Sch Med, Dept Hyg & Publ Hlth, Tokyo 1738605, Japan.	ifunatogawa-tky@umin.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology [(B) 20700255]	Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	IF's research was supported by grant-in-aid for young scientists (B) 20700255 from the Ministry of Education, Culture, Sports, Science, and Technology.	Balding DJ, 2004, APPL LONGITUDINAL AN; Chinn S, 2001, BRIT MED J, V322, P24, DOI 10.1136/bmj.322.7277.24; Cole TJ, 2007, BMJ-BRIT MED J, V335, P194, DOI 10.1136/bmj.39238.399444.55; Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240; Hermanussen M, 2007, ANTHROPOL ANZ, V65, P275, DOI 10.1127/anthranz/65/2007/275; Inokuchi M, 2007, ANN HUM BIOL, V34, P354, DOI 10.1080/03014460701300109; Kaneda F., 2004, Japanese Journal of Nutrition and Dietetics, V62, P347; Kiriike N, 1998, PSYCHIAT CLIN NEUROS, V52, P279, DOI 10.1046/j.1440-1819.1998.00387.x; Kwon JW, 2007, OBESITY, V15, P277, DOI 10.1038/oby.2007.539; Matsushita Y, 2004, OBES RES, V12, P205, DOI 10.1038/oby.2004.27; *MIN HLTH LAB WELF, 2008, NAT HLTH NUTR SURV A; *MIN HLTH LAB WELF, 2004, NAT NUTR SURV ANN RE; Murata M, 2000, AM J CLIN NUTR, V72, p1379S, DOI 10.1093/ajcn/72.5.1379s; MUST A, 1991, AM J CLIN NUTR, V53, P839, DOI 10.1093/ajcn/53.4.839; Olsen LW, 2006, EPIDEMIOLOGY, V17, P292, DOI 10.1097/01.ede.0000208349.16893.e0; Organization WH, 2000, WHO TECHN REP SER, DOI DOI 10.1016/J.BBI.2016.02.019; Prentice AM, 1998, BRIT MED J, V317, P1401, DOI 10.1136/bmj.317.7170.1401; ROLLANDCACHERA MF, 1991, EUR J CLIN NUTR, V45, P13; Szklo M., 2019, EPIDEMIOLOGY BASICS, V4; Takimoto H, 2004, AM J PUBLIC HEALTH, V94, P1592, DOI 10.2105/AJPH.94.9.1592; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613; Troiano RP, 1998, PEDIATRICS, V101, P497; Twisk JWR, 2003, APPL LONGITUDINAL DA; Wang Y, 2006, INT J PEDIATR OBES, V1, P11, DOI 10.1080/17477160600586747; Yoshiike N, 1996, J Epidemiol, V6, pS189; Yoshiike N, 2002, Obes Rev, V3, P183, DOI 10.1046/j.1467-789X.2002.00070.x	26	12	13	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 30	2008	337	7668							a802	10.1136/bmj.a802	http://dx.doi.org/10.1136/bmj.a802			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350OM	18719011	Green Published, hybrid			2022-12-28	WOS:000259362100028
J	Brody, DL; Magnoni, S; Schwetye, KE; Spinner, ML; Esparza, TJ; Stocchetti, N; Zipfel, GJ; Holtzman, DM				Brody, David L.; Magnoni, Sandra; Schwetye, Kate E.; Spinner, Michael L.; Esparza, Thomas J.; Stocchetti, Nino; Zipfel, Gregory J.; Holtzman, David M.			Amyloid-beta dynamics correlate with neurological status in the injured human brain	SCIENCE			English	Article							IN-VIVO; INTRACEREBRAL MICRODIALYSIS; CEREBRAL MICRODIALYSIS; SYNAPTIC PLASTICITY; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; HEAD-INJURY; OLIGOMERS; MEMORY; DEPOSITION	The amyloid-beta peptide (A beta) plays a central pathophysiological role in Alzheimer's disease, but little is known about the concentration and dynamics of this secreted peptide in the extracellular space of the human brain. We used intracerebral microdialysis to obtain serial brain interstitial fluid (ISF) samples in 18 patients who were undergoing invasive intracranial monitoring after acute brain injury. We found a strong positive correlation between changes in brain ISF A beta concentrations and neurological status, with A beta concentrations increasing as neurological status improved and falling when neurological status declined. Brain ISF A beta concentrations were also lower when other cerebral physiological and metabolic abnormalities reflected depressed neuronal function. Such dynamics fit well with the hypothesis that neuronal activity regulates extracellular A beta concentration.	[Brody, David L.; Schwetye, Kate E.; Spinner, Michael L.; Esparza, Thomas J.; Holtzman, David M.] Washington Univ, Dept Neurol, St Louis, MO 63110 USA; [Brody, David L.; Schwetye, Kate E.; Spinner, Michael L.; Esparza, Thomas J.; Holtzman, David M.] Washington Univ, Hope Ctr Neurol Disorders, St Louis, MO 63110 USA; [Magnoni, Sandra; Stocchetti, Nino] Osped Maggiore, Policlin Mangiagalli & Regina Elena, Dept Anesthesia & Intens Care, Fdn Ist Ricovero & Cura Carattere Sci, I-20100 Milan, Italy; [Stocchetti, Nino] Univ Milan, Milan, Italy; [Zipfel, Gregory J.] Washington Univ, Dept Neurol Surg, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); University of Milan; Washington University (WUSTL)	Brody, DL (corresponding author), Washington Univ, Dept Neurol, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu	Stocchetti, Nino/O-7444-2017; Magnoni, Sandra/AAC-7479-2022	Stocchetti, Nino/0000-0003-3250-6834; Magnoni, Sandra/0000-0002-1723-0844	NIH [NS049237, AG13956]; Burroughs Wellcome Career Award in the Biomedical Sciences; Cure Alzheimer's Fund; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS049237] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Career Award in the Biomedical Sciences(Burroughs Wellcome Fund); Cure Alzheimer's Fund; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank the participants and their families for their invaluable contributions. We appreciate the assistance of our neurosurgical colleagues for referring patients; M. Pluderi for placing several microdialysis catheters; and P. Bianchi, G. Brandi, M. Carbonara, U. Deledda, B. Hall, L. Magni, E. Milner, J. Sagar, and T. Zoerle for help collecting samples. Valuable discussions with R. Bateman, R. Bullock, J. Cirrito, R. Dacey, M. Diringer, L. Hillered, P. Hutchinson, J. Ladensen, N. Temkin, and W. Powers are acknowledged. We are grateful to Eli Lilly and Co. for providing the antibodies used in the Ab ELISAs. This work was supported by NIH grant NS049237 (D.L.B.), a Burroughs Wellcome Career Award in the Biomedical Sciences (D.L.B.), NIH grant AG13956 ( D.M.H.), and Cure Alzheimer's Fund (D.M.H.).	Abrahamson EE, 2006, EXP NEUROL, V197, P437, DOI 10.1016/j.expneurol.2005.10.011; Bateman RJ, 2007, NEUROLOGY, V68, P666, DOI 10.1212/01.wnl.0000256043.50901.e3; Buckner RL, 2005, J NEUROSCI, V25, P7709, DOI 10.1523/JNEUROSCI.2177-05.2005; Cirrito JR, 2008, NEURON, V58, P42, DOI 10.1016/j.neuron.2008.02.003; Cirrito JR, 2005, NEURON, V48, P913, DOI 10.1016/j.neuron.2005.10.028; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Corbett R, 1997, J CEREBR BLOOD F MET, V17, P363, DOI 10.1097/00004647-199704000-00001; Games D, 2006, J ALZHEIMERS DIS, V9, P133; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Kamenetz F, 2003, NEURON, V37, P925, DOI 10.1016/S0896-6273(03)00124-7; Klyubin I, 2005, NAT MED, V11, P556, DOI 10.1038/nm1234; Lazarov O, 2002, J NEUROSCI, V22, P9785; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Ronne-Engstrom E, 2001, J NEUROSURG, V94, P397, DOI 10.3171/jns.2001.94.3.0397; Selkoe DJ, 2002, J CLIN INVEST, V110, P1375, DOI 10.1172/JCI200216783; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; TEASDALE G, 1974, LANCET, V2, P81; Tesco G, 2007, NEURON, V54, P721, DOI 10.1016/j.neuron.2007.05.012; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a	28	250	260	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 29	2008	321	5893					1221	1224		10.1126/science.1161591	http://dx.doi.org/10.1126/science.1161591			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341ZM	18755980	Green Accepted			2022-12-28	WOS:000258754400048
J	Froguel, P; Blakemore, AIF				Froguel, Philippe; Blakemore, Alexandra I. F.			Focus on research: The power of the extreme in elucidating obesity	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Froguel, Philippe; Blakemore, Alexandra I. F.] Univ London Imperial Coll Sci Technol & Med, Dept Genom Med, Hammersmith Hosp, London, England	Imperial College London	Froguel, P (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Genom Med, Hammersmith Hosp, London, England.		FROGUEL, Philippe/O-6799-2017; Blakemore, Alexandra I F/D-2253-2009	FROGUEL, Philippe/0000-0003-2972-0784; Blakemore, Alexandra I F/0000-0003-0661-564X	MRC [G0600331] Funding Source: UKRI; Medical Research Council [G0600331] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Benzinou M, 2008, NAT GENET, V40, P943, DOI 10.1038/ng.177; Chambers JC, 2008, NAT GENET, V40, P716, DOI 10.1038/ng.156; Levin BE, 2007, AM J PHYSIOL-REG I, V293, pR988, DOI 10.1152/ajpregu.00434.2007; Stranger BE, 2007, SCIENCE, V315, P848, DOI 10.1126/science.1136678; Wardle J, 2008, AM J CLIN NUTR, V87, P398, DOI 10.1093/ajcn/87.2.398	5	23	24	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 28	2008	359	9					891	893		10.1056/NEJMp0805396	http://dx.doi.org/10.1056/NEJMp0805396			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	341IU	18753645				2022-12-28	WOS:000258708300003
J	San Miguel, JF; Schlag, R; Khuageva, NK; Dimopoulos, MA; Shpilberg, O; Kropff, M; Spicka, I; Petrucci, MT; Palumbo, A; Samoilova, OS; Dmoszynska, A; Abdulkadyrov, KM; Schots, R; Jiang, B; Mateos, M; Anderson, KC; Esseltine, DL; Liu, K; Cakana, A; van de Velde, H; Richardson, PG				San Miguel, Jesus F.; Schlag, Rudolf; Khuageva, Nuriet K.; Dimopoulos, Meletios A.; Shpilberg, Ofer; Kropff, Martin; Spicka, Ivan; Petrucci, Maria T.; Palumbo, Antonio; Samoilova, Olga S.; Dmoszynska, Anna; Abdulkadyrov, Kudrat M.; Schots, Rik; Jiang, Bin; Mateos, Maria-Victoria; Anderson, Kenneth C.; Esseltine, Dixie L.; Liu, Kevin; Cakana, Andrew; van de Velde, Helgi; Richardson, Paul G.		VISTA Trial Investigators	Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	49th Annual Meeting of the American-Society-of-Hematology	DEC 08-11, 2007	Atlanta, GA	Amer Soc Hematol			ELDERLY UNTREATED PATIENTS; COMBINATION CHEMOTHERAPY; PERIPHERAL NEUROPATHY; ASSESSMENT SCHEDULE; PROGNOSTIC-FACTORS; TRANSPLANTATION; DEXAMETHASONE; REVERSIBILITY; SENSITIVITY; THALIDOMIDE	Background: The standard treatment for patients with multiple myeloma who are not candidates for high-dose therapy is melphalan and prednisone. This phase 3 study compared the use of melphalan and prednisone with or without bortezomib in previously untreated patients with multiple myeloma who were ineligible for high-dose therapy. Methods: We randomly assigned 682 patients to receive nine 6-week cycles of melphalan (at a dose of 9 mg per square meter of body-surface area) and prednisone (at a dose of 60 mg per square meter) on days 1 to 4, either alone or with bortezomib (at a dose of 1.3 mg per square meter) on days 1, 4, 8, 11, 22, 25, 29, and 32 during cycles 1 to 4 and on days 1, 8, 22, and 29 during cycles 5 to 9. The primary end point was the time to disease progression. Results: The time to progression among patients receiving bortezomib plus melphalan-prednisone (bortezomib group) was 24.0 months, as compared with 16.6 months among those receiving melphalan-prednisone alone (control group) (hazard ratio for the bortezomib group, 0.48; P<0.001). The proportions of patients with a partial response or better were 71% in the bortezomib group and 35% in the control group; complete-response rates were 30% and 4%, respectively (P<0.001). The median duration of the response was 19.9 months in the bortezomib group and 13.1 months in the control group. The hazard ratio for overall survival was 0.61 for the bortezomib group (P=0.008). Adverse events were consistent with established profiles of toxic events associated with bortezomib and melphalan-prednisone. Grade 3 events occurred in a higher proportion of patients in the bortezomib group than in the control group (53% vs. 44%, P=0.02), but there were no significant differences in grade 4 events (28% and 27%, respectively) or treatment-related deaths (1% and 2%). Conclusions: Bortezomib plus melphalan-prednisone was superior to melphalan-prednisone alone in patients with newly diagnosed myeloma who were ineligible for high-dose therapy. (ClinicalTrials.gov number, NCT00111319.).	[San Miguel, Jesus F.; Mateos, Maria-Victoria] Hosp Univ Salamanca, CIC, IBMCC USAL CSIC, Salamanca, Spain; [Schlag, Rudolf] Praxisklin Dr Schlag, Wurzburg, Germany; [Khuageva, Nuriet K.] SP Botkin Moscow City Clin Hosp, Moscow, Russia; [Dimopoulos, Meletios A.] Univ Athens, Sch Med, GR-11527 Athens, Greece; [Shpilberg, Ofer] Rabin Med Ctr, Petah Tiqwa, Israel; [Kropff, Martin] Univ Munster, Munster, Germany; [Spicka, Ivan] Univ Hosp Prague, Prague, Czech Republic; [Petrucci, Maria T.] Univ Roma La Sapienza, Rome, Italy; [Palumbo, Antonio] Univ Turin, Turin, Italy; [Samoilova, Olga S.] Nizhnii Novgorod Reg Clin Hosp, Nizhnii Novgorod, Russia; [Dmoszynska, Anna] Med Univ Lublin, Lublin, Poland; [Abdulkadyrov, Kudrat M.] St Petersburg Clin Res Inst Hematol & Transfus, St Petersburg, Russia; [Schots, Rik] Belgian Hematol Soc, Myeloma Study Grp, Brussels, Belgium; [Jiang, Bin] Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China; [Anderson, Kenneth C.; Richardson, Paul G.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Esseltine, Dixie L.] Millennium Pharmaceut Inc, Cambridge, MA USA; [Liu, Kevin] Johnson & Johnson, Raritan, NJ USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Athens Medical School; National & Kapodistrian University of Athens; Rabin Medical Center; University of Munster; General University Hospital Prague; Sapienza University Rome; University of Turin; Medical University of Lublin; Russian Research Institute of Hematology & Transfusiology; Peking University; Harvard University; Dana-Farber Cancer Institute; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Johnson & Johnson; Johnson & Johnson USA	San Miguel, JF (corresponding author), Hosp Univ Salamanca, CIC, IBMCC USAL CSIC, Paseo San Vicente 58-182, Salamanca, Spain.	sanmigiz@usal.es	Dimopoulos, Meletios Athanasios/AAD-4130-2019; Zachee, Pierre/B-5391-2018; ALEGRE, ADRIAN/AAE-4268-2021; Greil, Richard F/C-7673-2017; San-Miguel, Jesús F./V-8977-2018; Hajek, Roman/I-6639-2017	Zachee, Pierre/0000-0002-2275-5143; ALEGRE, ADRIAN/0000-0002-2423-822X; Greil, Richard F/0000-0002-4462-3694; San-Miguel, Jesús F./0000-0002-9183-4857; Hajek, Roman/0000-0001-6955-6267; Spicka, Ivan/0000-0002-5451-5283; Dimopoulos, Meletios/0000-0001-8990-3254; o'dwyer, michael/0000-0002-6173-7140; Kuliczkowski, Kazimierz/0000-0001-6812-1421; abdulkadyrov, kudrat/0000-0002-3771-909X; gunsilius, eberhard/0000-0003-1327-2921; Masszi, Tamas/0000-0002-9038-302X; CAVO, MICHELE/0000-0003-4514-3227				ALEXANIAN R, 1969, J AMER MED ASSOC, V208, P1680, DOI 10.1001/jama.208.9.1680; Anagnostopoulos A, 2005, EUR J HAEMATOL, V75, P370, DOI 10.1111/j.1600-0609.2005.00532.x; Anderson KC, 2008, LEUKEMIA, V22, P231, DOI 10.1038/sj.leu.2405016; [Anonymous], 1998, J Clin Oncol, V16, P3832; Attal M, 1996, NEW ENGL J MED, V335, P91, DOI 10.1056/NEJM199607113350204; Augustson BM, 2005, J CLIN ONCOL, V23, P9219, DOI 10.1200/JCO.2005.03.2086; Barlogie B, 1997, BLOOD, V89, P789, DOI 10.1182/blood.V89.3.789; Berenson JR, 2006, J CLIN ONCOL, V24, P937, DOI 10.1200/JCO.2005.03.2383; Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x; BOCCADORO M, 1991, J CLIN ONCOL, V9, P444, DOI 10.1200/JCO.1991.9.3.444; Child JA, 2003, NEW ENGL J MED, V348, P1875, DOI 10.1056/NEJMoa022340; Durie BGM, 2007, LEUKEMIA, V21, P1134, DOI 10.1038/sj.leu.2404582; Durie BGM, 2006, LEUKEMIA, V20, P2220, DOI 10.1038/sj.leu.2404428; Durie BGM, 2006, LEUKEMIA, V20, P1467, DOI 10.1038/sj.leu.2404284; Facon T, 2006, BLOOD, V107, P1292, DOI 10.1182/blood-2005-04-1588; Facon T, 2007, LANCET, V370, P1209, DOI 10.1016/S0140-6736(07)61537-2; Greipp PR, 2005, J CLIN ONCOL, V23, P6281, DOI 10.1200/JCO.2005.07.904; Greipp PR, 2005, J CLIN ONCOL, V23, P3412, DOI 10.1200/JCO.2005.04.242; Hernandez JM, 2004, BRIT J HAEMATOL, V127, P159, DOI 10.1111/j.1365-2141.2004.05186.x; Jagannath S, 2004, BRIT J HAEMATOL, V127, P165, DOI 10.1111/j.1365-2141.2004.05188.x; Kyle RA, 2005, NEW ENGL J MED, V352, P841; Kyle RA, 2007, J CLIN ONCOL, V25, P2464, DOI 10.1200/JCO.2007.12.1269; Ma MH, 2003, CLIN CANCER RES, V9, P1136; Mateos MV, 2008, HAEMATOLOGICA, V93, P560, DOI 10.3324/haematol.12106; Mateos MV, 2006, BLOOD, V108, P2165, DOI 10.1182/blood-2006-04-019778; Mitsiades N, 2003, BLOOD, V101, P2377, DOI 10.1182/blood-2002-06-1768; Moreau P, 2007, BLOOD, V110, p353A; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Palumbo A, 2006, LANCET, V367, P825, DOI 10.1016/S0140-6736(06)68338-4; Palumbo A, 2007, J CLIN ONCOL, V25, P4459, DOI 10.1200/JCO.2007.12.3463; Panageas KS, 2007, J NATL CANCER I, V99, P428, DOI 10.1093/jnci/djk091; Richardson PG, 2008, J NATL CANCER I, V100, P373, DOI 10.1093/jnci/djn012; Richardson PG, 2007, BLOOD, V110, P3557, DOI 10.1182/blood-2006-08-036947; Richardson PG, 2006, J CLIN ONCOL, V24, P3113, DOI 10.1200/JCO.2005.04.7779; Richardson PG, 2005, NEW ENGL J MED, V352, P2487, DOI 10.1056/NEJMoa043445; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Ries L., 2005, SEER CANC STAT REV 1; San Miguel JF, 2005, BLOOD, V106, p111A	38	1468	1501	0	91	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 28	2008	359	9					906	917		10.1056/NEJMoa0801479	http://dx.doi.org/10.1056/NEJMoa0801479			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	341IU	18753647	Green Published, Bronze			2022-12-28	WOS:000258708300005
J	Speranza, G; Javaheri, S				Speranza, Giovanna; Javaheri, Sepehr			Flu-like illness - and a rash	LANCET			English	Editorial Material							CHRONIC MENINGOCOCCEMIA; DEFICIENCY; COMPLEMENT		[Speranza, Giovanna] McGill Univ, Jewish Gen Hosp, Dept Med Oncol, Montreal, PQ H3T 1E2, Canada; [Javaheri, Sepehr] Ctr Sante & Serv Sociaux Eskers Labitibi, Amos, PQ, Canada	McGill University	Speranza, G (corresponding author), Sir Mortimer B Davis Jewish Hosp, Dept Med Oncol, 3755 Cote St Catherine Rd, Montreal, PQ H3T 1E2, Canada.	giovanna.speranza@mail.mcgill.ca						BENOIT FL, 1963, AM J MED, V35, P103, DOI 10.1016/0002-9343(63)90167-0; GREGORY B, 1992, ARCH DERMATOL, V128, P1643, DOI 10.1001/archderm.1992.04530010149016; Harwood CA, 2005, BRIT J DERMATOL, V153, P669, DOI 10.1111/j.1365-2133.2005.06771.x; MORRIS JT, 1992, SOUTHERN MED J, V85, P1030, DOI 10.1097/00007611-199210000-00027; NIELSEN HE, 1990, SCAND J INFECT DIS, V22, P31, DOI 10.3109/00365549009023116	5	1	1	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 23	2008	372	9639					688	688		10.1016/S0140-6736(08)61281-7	http://dx.doi.org/10.1016/S0140-6736(08)61281-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	340BX	18722873				2022-12-28	WOS:000258622200033
J	Koren, I; Martins, JV; Remer, LA; Afargan, H				Koren, Ilan; Martins, J. Vanderlei; Remer, Lorraine A.; Afargan, Hila			Smoke invigoration versus inhibition of clouds over the Amazon	SCIENCE			English	Article							POLLUTION AEROSOL; MODIS; MICROPHYSICS; ALBEDO; IMPACT; RAIN; AIR	The effect of anthropogenic aerosols on clouds is one of the most important and least understood aspects of human- induced climate change. Small changes in the amount of cloud coverage can produce a climate forcing equivalent in magnitude and opposite in sign to that caused by anthropogenic greenhouse gases, and changes in cloud height can shift the effect of clouds from cooling to warming. Focusing on the Amazon, we show a smooth transition between two opposing effects of aerosols on clouds: the microphysical and the radiative. We show how a feedback between the optical properties of aerosols and the cloud fraction can modify the aerosol forcing, changing the total radiative energy and redistributing it over the atmospheric column.	[Koren, Ilan; Afargan, Hila] Weizmann Inst Sci, Dept Environm Sci, IL-76100 Rehovot, Israel; [Martins, J. Vanderlei] Univ Maryland Baltimore Cty, Dept Phys, Baltimore, MD 21250 USA; [Martins, J. Vanderlei] Univ Maryland Baltimore Cty, Joint Ctr Earth Syst Technol, Baltimore, MD 21250 USA; [Martins, J. Vanderlei; Remer, Lorraine A.] NASA, Atmospheres Lab, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA	Weizmann Institute of Science; University System of Maryland; University of Maryland Baltimore County; University System of Maryland; University of Maryland Baltimore County; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Koren, I (corresponding author), Weizmann Inst Sci, Dept Environm Sci, IL-76100 Rehovot, Israel.		Koren, Ilan/K-1417-2012	Koren, Ilan/0000-0001-6759-6265				Ackerman AS, 2000, SCIENCE, V288, P1042, DOI 10.1126/science.288.5468.1042; Andreae MO, 2004, SCIENCE, V303, P1337, DOI 10.1126/science.1092779; Brennan JI, 2005, IEEE T GEOSCI REMOTE, V43, P911, DOI 10.1109/TGRS.2005.844662; Charlson RJ, 2007, TELLUS B, V59, P715, DOI [10.1111/j.1600-0889.2007.00297.x, 10.1111/J.1600-0889.2007.00297.x]; Feingold G, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021369; Feingold G, 2001, J GEOPHYS RES-ATMOS, V106, P22907, DOI 10.1029/2001JD000732; Graf HF, 2004, SCIENCE, V303, P1309, DOI 10.1126/science.1094411; Jiang HL, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2005JD006138; Kaufman YJ, 2005, P NATL ACAD SCI USA, V102, P11207, DOI 10.1073/pnas.0505191102; KAUFMAN YJ, 1993, J APPL METEOROL, V32, P729, DOI [10.1175/1520-0450(1993)032<0729:EOASOC>2.0.CO;2, 10.1175/1520-0450(1993)032&lt;0729:EOASOC&gt;2.0.CO;2]; Kaufman YJ, 2006, SCIENCE, V313, P655, DOI 10.1126/science.1126232; Khain A, 2005, Q J ROY METEOR SOC, V131, P2639, DOI 10.1256/qj.04.62; King MD, 2003, IEEE T GEOSCI REMOTE, V41, P442, DOI 10.1109/TGRS.2002.808226; Koren I, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023187; Koren I, 2004, SCIENCE, V303, P1342, DOI 10.1126/science.1089424; Koren I, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL031530; Koren I, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL029253; Levy RC, 2007, J GEOPHYS RES-ATMOS, V112, DOI 10.1029/2006JD007815; Myhre G, 2007, ATMOS CHEM PHYS, V7, P3081, DOI 10.5194/acp-7-3081-2007; Nobre CA, 1998, J GEOPHYS RES-ATMOS, V103, P31809, DOI 10.1029/98JD00992; Platnick S, 2003, IEEE T GEOSCI REMOTE, V41, P459, DOI 10.1109/TGRS.2002.808301; Rosenfeld D, 2000, SCIENCE, V287, P1793, DOI 10.1126/science.287.5459.1793; TWOMEY S, 1977, J ATMOS SCI, V34, P1149, DOI 10.1175/1520-0469(1977)034<1149:TIOPOT>2.0.CO;2; Wetzel MA, 1999, J GEOPHYS RES-ATMOS, V104, P31287, DOI 10.1029/1999JD900922	24	298	305	5	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 15	2008	321	5891					946	949		10.1126/science.1159185	http://dx.doi.org/10.1126/science.1159185			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	337LD	18703738				2022-12-28	WOS:000258436700034
J	Veatch, RM				Veatch, Robert M.			Donating hearts after cardiac death - Reversing the irreversible	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DONOR RULE		Georgetown Univ, Kennedy Inst Eth, Washington, DC 20057 USA	Georgetown University	Veatch, RM (corresponding author), Georgetown Univ, Kennedy Inst Eth, Washington, DC 20057 USA.							[Anonymous], 1993, Kennedy Inst Ethics J, V3, pA1; Koppelman ER, 2003, AM J BIOETHICS, V3, P1, DOI 10.1162/152651603321611782; Truog RD, 2003, CRIT CARE MED, V31, P2391, DOI 10.1097/01.CCM.0000090869.19410.3C; Youngner SJ, 1999, DEFINITION OF DEATH, pXIII; 1997, NONHEART BEATING ORG	5	83	85	1	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 14	2008	359	7					672	673		10.1056/NEJMp0805451	http://dx.doi.org/10.1056/NEJMp0805451			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336XE	18703468				2022-12-28	WOS:000258397900002
J	Mullan, Z				Mullan, Zoe			Profile - Lola Dare: creating African solutions for better health	LANCET			English	Biographical-Item												zoe.mullan@lancet.com						DARE L, PUBLICATION LIST	1	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 9	2008	372	9637					439	439		10.1016/S0140-6736(08)61182-4	http://dx.doi.org/10.1016/S0140-6736(08)61182-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	335OD	18692701				2022-12-28	WOS:000258299000012
J	Bonneau, R				Bonneau, Richard			Dissecting the quorum-sensing receptor LuxNe	CELL			English	Editorial Material									[Bonneau, Richard] NYU, Ctr Comparat Funct Genom, New York, NY 10003 USA; [Bonneau, Richard] Courant Inst Math Sci, New York, NY 10012 USA; [Bonneau, Richard] Inst Syst Biol, Seattle, WA 98103 USA	New York University; Institute for Systems Biology (ISB)	Bonneau, R (corresponding author), NYU, Ctr Comparat Funct Genom, 100 Washington Sq E, New York, NY 10003 USA.	bonneau@cs.nyu.edu	Bonneau, Richard/ABD-6737-2021; Bonneau, Richard/GZL-2900-2022					Waters CM, 2005, ANNU REV CELL DEV BI, V21, P319, DOI 10.1146/annurev.cellbio.21.012704.131001	1	2	3	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 8	2008	134	3					390	391		10.1016/j.cell.2008.07.028	http://dx.doi.org/10.1016/j.cell.2008.07.028			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SO	18692463	Bronze			2022-12-28	WOS:000258665500012
J	Walsh, S; Koehler, CM				Walsh, Susan; Koehler, Carla M.			Gazing at translocation in the mitochondrion	CELL			English	Editorial Material							PROTEIN TRANSLOCATION; ENDOPLASMIC-RETICULUM; MEMBRANES; TIM23; MECHANISMS; INNER; LINKS; OUTER		[Walsh, Susan; Koehler, Carla M.] Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Koehler, CM (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.	koehler@chem.ucla.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061721] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alder NN, 2008, MOL BIOL CELL, V19, P159, DOI 10.1091/mbc.E07-07-0669; Alder NN, 2005, J CELL BIOL, V168, P389, DOI 10.1083/jcb.200409174; Donzeau M, 2000, CELL, V101, P401, DOI 10.1016/S0092-8674(00)80850-8; Johnson AE, 2005, TRAFFIC, V6, P1078, DOI 10.1111/j.1600-0854.2005.00340.x; Kutik S, 2007, J CELL BIOL, V179, P585, DOI 10.1083/jcb.200708199; Neupert W, 2007, ANNU REV BIOCHEM, V76, P723, DOI 10.1146/annurev.biochem.76.052705.163409; Rapoport TA, 2007, NATURE, V450, P663, DOI 10.1038/nature06384; Truscott KN, 2001, NAT STRUCT BIOL, V8, P1074, DOI 10.1038/nsb726; Yamamoto H, 2002, CELL, V111, P519, DOI 10.1016/S0092-8674(02)01053-X	9	0	1	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 8	2008	134	3					382	383		10.1016/j.cell.2008.07.024	http://dx.doi.org/10.1016/j.cell.2008.07.024			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SO	18692459	Bronze			2022-12-28	WOS:000258665500008
J	Gelbard-Sagiv, H; Mukamel, R; Harel, M; Malach, R; Fried, I				Gelbard-Sagiv, Hagar; Mukamel, Roy; Harel, Michal; Malach, Rafael; Fried, Itzhak			Internally generated reactivation of single neurons in human hippocampus during free recall	SCIENCE			English	Article							MEDIAL TEMPORAL-LOBE; COGNITIVE NEUROSCIENCE; RECOGNITION MEMORY; RAT HIPPOCAMPUS; HUMAN BRAIN; SEQUENCES; RETRIEVAL; AMYGDALA; SLEEP; EXPERIENCE	The emergence of memory, a trace of things past, into human consciousness is one of the greatest mysteries of the human mind. Whereas the neuronal basis of recognition memory can be probed experimentally in human and nonhuman primates, the study of free recall requires that the mind declare the occurrence of a recalled memory ( an event intrinsic to the organism and invisible to an observer). Here, we report the activity of single neurons in the human hippocampus and surrounding areas when subjects first view cinematic episodes consisting of audiovisual sequences and again later when they freely recall these episodes. A subset of these neurons exhibited selective firing, which often persisted throughout and following specific episodes for as long as 12 seconds. Verbal reports of memories of these specific episodes at the time of free recall were preceded by selective reactivation of the same hippocampal and entorhinal cortex neurons. We suggest that this reactivation is an internally generated neuronal correlate for the subjective experience of spontaneous emergence of human recollection.	[Mukamel, Roy; Fried, Itzhak] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Mukamel, Roy; Fried, Itzhak] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA; [Gelbard-Sagiv, Hagar; Harel, Michal; Malach, Rafael] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; [Fried, Itzhak] Tel Aviv Univ, Funct Neurosurg Unit, Tel Aviv Med Ctr, IL-64239 Tel Aviv, Israel; [Fried, Itzhak] Tel Aviv Univ, Sackler Sch Med, IL-64239 Tel Aviv, Israel	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	Fried, I (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA.	ifried@mednet.ucla.edu	Mukamel, Roy/AAV-2900-2021; Galbard-Sagiv, Hagar/J-8482-2014	Mukamel, Roy/0000-0001-9359-8950; Galbard-Sagiv, Hagar/0000-0003-0379-3854	NINDS; Israel Science Foundation; Binational United States-Israel grant; Human Frontier Science Program Organization; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033221] Funding Source: NIH RePORTER	NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Israel Science Foundation(Israel Science Foundation); Binational United States-Israel grant; Human Frontier Science Program Organization(Human Frontier Science Program); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank the patients for their cooperation and participation in this study. We also thank E. Ho, B. Scott, E. Behnke, R. Kadivar, T. Fields, A. Postolova, K. Laird, C. Wilson, R. Quian-Quiroga, A. Kraskov, F. Mormann, and M. Cerf for assistance with data acquisition; B. Salaz and I. Wainwright for administrative help; and I. Kahn, Y. Nir, G. Buzsaki, E. Pastalkova, and S. Gilaie-Dotan for discussions and comments on this manuscript. This work was supported by NINDS (to I. Fried), Israel Science Foundation (to R. Malach), Binational United States-Israel grant (to I. Fried and R. Malach), and Human Frontier Science Program Organization (HFSPO) fellowship (to R. Mukamel).	Bird CM, 2008, NAT REV NEUROSCI, V9, P182, DOI 10.1038/nrn2335; Diba K, 2007, NAT NEUROSCI, V10, P1241, DOI 10.1038/nn1961; Eichenbaum H, 2004, NEURON, V44, P109, DOI 10.1016/j.neuron.2004.08.028; Fortin NJ, 2002, NAT NEUROSCI, V5, P458, DOI 10.1038/nn834; Foster DJ, 2006, NATURE, V440, P680, DOI 10.1038/nature04587; Fried I, 1999, J NEUROSURG, V91, P697, DOI 10.3171/jns.1999.91.4.0697; Fried I, 1997, NEURON, V18, P753, DOI 10.1016/S0896-6273(00)80315-3; HEIT G, 1988, NATURE, V333, P773, DOI 10.1038/333773a0; Henson RNA, 2000, J COGNITIVE NEUROSCI, V12, P913, DOI 10.1162/08989290051137468; Johnson A, 2007, J NEUROSCI, V27, P12176, DOI 10.1523/JNEUROSCI.3761-07.2007; Kahn I, 2004, J NEUROSCI, V24, P4172, DOI 10.1523/JNEUROSCI.0624-04.2004; Kreiman G, 2000, NATURE, V408, P357, DOI 10.1038/35042575; Kreiman G, 2000, NAT NEUROSCI, V3, P946, DOI 10.1038/78868; Lee AK, 2002, NEURON, V36, P1183, DOI 10.1016/S0896-6273(02)01096-6; Lisman JE, 1999, NEURON, V22, P233, DOI 10.1016/S0896-6273(00)81085-5; Miyashita Y, 2004, SCIENCE, V306, P435, DOI 10.1126/science.1101864; Moscovitch M, 2006, CURR OPIN NEUROBIOL, V16, P179, DOI 10.1016/j.conb.2006.03.013; Nyberg L, 2000, P NATL ACAD SCI USA, V97, P11120, DOI 10.1073/pnas.97.20.11120; Ojemann GA, 2002, NAT NEUROSCI, V5, P64, DOI 10.1038/nn785; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; OKEEFE J, 1978, HIPPOCAMPUS COGNITIV, P380; Pastalkova E, 2008, SCIENCE, V321, P1322, DOI 10.1126/science.1159775; Polyn SM, 2005, SCIENCE, V310, P1963, DOI 10.1126/science.1117645; Quiroga RQ, 2008, TRENDS COGN SCI, V12, P87, DOI 10.1016/j.tics.2007.12.003; Quiroga RQ, 2005, NATURE, V435, P1102, DOI 10.1038/nature03687; Rutishauser U, 2006, NEURON, V49, P805, DOI 10.1016/j.neuron.2006.02.015; Schacter DL, 1997, PHILOS T R SOC B, V352, P1689, DOI 10.1098/rstb.1997.0150; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Skaggs WE, 1996, SCIENCE, V271, P1870, DOI 10.1126/science.271.5257.1870; Squire LR, 2004, ANNU REV NEUROSCI, V27, P279, DOI 10.1146/annurev.neuro.27.070203.144130; Viskontas IV, 2006, J COGNITIVE NEUROSCI, V18, P1654, DOI 10.1162/jocn.2006.18.10.1654; Wheeler ME, 2000, P NATL ACAD SCI USA, V97, P11125, DOI 10.1073/pnas.97.20.11125; WILSON MA, 1994, SCIENCE, V265, P676, DOI 10.1126/science.8036517; Wood ER, 1999, NATURE, V397, P613, DOI 10.1038/17605	34	310	313	2	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 3	2008	322	5898					96	101		10.1126/science.1164685	http://dx.doi.org/10.1126/science.1164685			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	355AE	18772395	Green Accepted			2022-12-28	WOS:000259680200046
J	Thingstad, TF; Bellerby, RGJ; Bratbak, G; Borsheim, KY; Egge, JK; Heldal, M; Larsen, A; Neill, C; Nejstgaard, J; Norland, S; Sandaa, RA; Skjoldal, EF; Tanaka, T; Thyrhaug, R; Topper, B				Thingstad, T. F.; Bellerby, R. G. J.; Bratbak, G.; Borsheim, K. Y.; Egge, J. K.; Heldal, M.; Larsen, A.; Neill, C.; Nejstgaard, J.; Norland, S.; Sandaa, R. -A.; Skjoldal, E. F.; Tanaka, T.; Thyrhaug, R.; Topper, B.			Counterintuitive carbon-to-nutrient coupling in an Arctic pelagic ecosystem	NATURE			English	Article							ALGAL-BACTERIAL COMPETITION; ORGANIC-CARBON; SPRING BLOOM; RATES; PHOSPHORUS; LIMITATION; MARINE; GROWTH; ACCUMULATION; RESPIRATION	Predicting the ocean's role in the global carbon cycle requires an understanding of the stoichiometric coupling between carbon and growth- limiting elements in biogeochemical processes. A recent addition to such knowledge is that the carbon/nitrogen ratio of inorganic consumption and release of dissolved organic matter may increase in a high-CO2 world(1). This will, however, yield a negative feedback on atmospheric CO2 only if the extra organic material escapes mineralization within the photic zone. Here we show, in the context of an Arctic pelagic ecosystem, how the fate and effects of added degradable organic carbon depend critically on the state of the microbial food web. When bacterial growth rate was limited by mineral nutrients, extra organic carbon accumulated in the system. When bacteria were limited by organic carbon, however, addition of labile dissolved organic carbon reduced phytoplankton biomass and activity and also the rate at which total organic carbon accumulated, explained as the result of stimulated bacterial competition for mineral nutrients. This counterintuitive 'more organic carbon gives less organic carbon' effect was particularly pronounced in diatom- dominated systems where the carbon/ mineral nutrient ratio in phytoplankton production was high. Our results highlight how descriptions of present and future states of the oceanic carbon cycle require detailed understanding of the stoichiometric coupling between carbon and growth- limiting mineral nutrients in both autotrophic and heterotrophic processes.	[Thingstad, T. F.; Bratbak, G.; Egge, J. K.; Heldal, M.; Larsen, A.; Nejstgaard, J.; Norland, S.; Sandaa, R. -A.; Skjoldal, E. F.; Thyrhaug, R.; Topper, B.] Univ Bergen, Dept Biol, N-5020 Bergen, Norway; [Bellerby, R. G. J.; Neill, C.] Bjerknes Ctr Climate Res, N-5007 Bergen, Norway; [Bellerby, R. G. J.] Univ Bergen, Inst Geophys, N-5007 Bergen, Norway; [Borsheim, K. Y.] Inst Marine Res, N-5817 Bergen, Norway; [Tanaka, T.] CNRS, Lab Oceanog & Biogeochim, UMR6535, F-13288 Marseille 09, France	University of Bergen; Bjerknes Centre for Climate Research; University of Bergen; Institute of Marine Research - Norway; Centre National de la Recherche Scientifique (CNRS)	Thingstad, TF (corresponding author), Univ Bergen, Dept Biol, Jahnebakken 5,POB 7800, N-5020 Bergen, Norway.	frede.thingstad@bio.uib.no	Thingstad, Tron Frede/B-2254-2008; Bellerby, Richard/ABD-6590-2021; Bratbak, Gunnar/N-8786-2015; Tanaka, Tsuneo/G-3751-2011; Nejstgaard, Jens/ABB-8903-2020; Bellerby, Richard/B-5277-2012	Thingstad, Tron Frede/0000-0002-5593-819X; Bellerby, Richard/0000-0003-3598-4006; Bratbak, Gunnar/0000-0001-8388-4945; Nejstgaard, Jens/0000-0003-1236-0647; 	Research Council of Norway [175939/S30]; strategic institution project [158936/I10]; Bjerknes Centre of Climate Research Centre of Excellence [146003/V30, 178441/S40 Interact, 184860/S30 MERCLIM]; Norsk Hydro Produksjon AS [5404889]; Svalbard Science Forum as Arktisstipend	Research Council of Norway(Research Council of Norway); strategic institution project; Bjerknes Centre of Climate Research Centre of Excellence; Norsk Hydro Produksjon AS(Norsk Hydro ASA); Svalbard Science Forum as Arktisstipend	This work was financed by the Research Council of Norway through the International Polar Year project 175939/S30 'PAME-Nor' (IPY activity ID no. 71), with additional support from the strategic institution project 158936/I10 'Patterns in microbial diversity', Bjerknes Centre of Climate Research Centre of Excellence Project 146003/V30, project 178441/S40 'Interact' and project 184860/S30 'MERCLIM'. Support was received also from Norsk Hydro Produksjon AS project number 5404889, and from the Svalbard Science Forum as 'Arktisstipend'. We thank Kings Bay A/S and the staff at Ny Alesund for help with logistics.	Bellerby RGJ, 2005, GEOPH MONOG SERIES, V158, P189; Borsheim KY, 2005, J PLANKTON RES, V27, P743, DOI 10.1093/plankt/fbi047; Borsheim KY, 2000, AQUAT MICROB ECOL, V21, P115, DOI 10.3354/ame021115; Carmack E, 2006, PROG OCEANOGR, V71, P446, DOI 10.1016/j.pocean.2006.10.004; Church MJ, 2000, APPL ENVIRON MICROB, V66, P455, DOI 10.1128/AEM.66.2.455-466.2000; delGiorgio PA, 1997, NATURE, V385, P148, DOI 10.1038/385148a0; Ducklow HW, 2000, DEEP-SEA RES PT II, V47, P3227, DOI 10.1016/S0967-0645(00)00066-7; Eriksen NT, 2007, J APPL PHYCOL, V19, P161, DOI 10.1007/s10811-006-9122-y; Fagerbakke KM, 1996, AQUAT MICROB ECOL, V10, P15, DOI 10.3354/ame010015; Graneli W, 2004, DEEP-SEA RES PT II, V51, P2569, DOI 10.1016/j.dsr2.2001.01.003; Havskum H, 2003, LIMNOL OCEANOGR, V48, P129, DOI 10.4319/lo.2003.48.1.0129; HOBBIE JE, 1969, VERH INT VEREIN LIMN, V17, P725; Holmes RM, 1999, CAN J FISH AQUAT SCI, V56, P1801, DOI 10.1139/cjfas-56-10-1801; Holmes RM, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2007GL032837; Koroleff F., 1983, METHODS SEAWATER ANA, P125; Marie D, 1999, APPL ENVIRON MICROB, V65, P45; MARTINUSSEN I, 1987, MAR ECOL PROG SER, V37, P285, DOI 10.3354/meps037285; Parsons T. R., 1984, MANUAL CHEM BIOL MET, DOI [10.1016/B978-0-08-030287-4.50034-7, DOI 10.1016/B978-0-08-030287-4.50034-7, DOI 10.1016/C2009-0-07774-5]; POMEROY LR, 1986, SCIENCE, V233, P359, DOI 10.1126/science.233.4761.359; REY F, 1987, MAR ECOL PROG SER, V36, P307, DOI 10.3354/meps036307; Riebesell U, 2007, NATURE, V450, P545, DOI 10.1038/nature06267; Rivkin RB, 1997, LIMNOL OCEANOGR, V42, P730, DOI 10.4319/lo.1997.42.4.0730; Rose JM, 2007, LIMNOL OCEANOGR, V52, P886, DOI 10.4319/lo.2007.52.2.0886; SIMON M, 1989, MAR ECOL PROG SER, V51, P201, DOI 10.3354/meps051201; Smith David C., 1992, Marine Microbial Food Webs, V6, P107; Stets EG, 2008, LIMNOL OCEANOGR, V53, P137, DOI 10.4319/lo.2008.53.1.0137; Stroeve J, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL029703; THINGSTAD TF, 1993, MAR ECOL PROG SER, V99, P239, DOI 10.3354/meps099239; Thingstad TF, 2002, MAR ECOL PROG SER, V228, P15, DOI 10.3354/meps228015; Thingstad TF, 1997, LIMNOL OCEANOGR, V42, P398, DOI 10.4319/lo.1997.42.2.0398; VALDERRAMA JC, 1995, MANUAL HARMFUL MARIN, P262; Wassmann P, 1999, MAR ECOL-P S Z N I, V20, P321, DOI 10.1046/j.1439-0485.1999.2034081.x	32	134	135	3	138	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	2008	455	7211					387	U37		10.1038/nature07235	http://dx.doi.org/10.1038/nature07235			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349EX	18716617				2022-12-28	WOS:000259265200044
J	Wray, GA; Babbitt, CC				Wray, Gregory A.; Babbitt, Courtney C.			Genetics - Enhancing gene regulation	SCIENCE			English	Editorial Material							EVOLUTION; HUMANS; DROSOPHILA; SELECTION; GENOME		[Wray, Gregory A.; Babbitt, Courtney C.] Duke Univ, Dept Biol, Durham, NC 27708 USA; [Wray, Gregory A.; Babbitt, Courtney C.] Duke Univ, Inst Genome Sci & Policy, Durham, NC 27708 USA	Duke University; Duke University	Wray, GA (corresponding author), Duke Univ, Dept Biol, Box 90338, Durham, NC 27708 USA.	gwray@duke.edu	Visel, Axel/A-9398-2009	Visel, Axel/0000-0002-4130-7784				Boyle AP, 2008, CELL, V132, P311, DOI 10.1016/j.cell.2007.12.014; Enattah NS, 2002, NAT GENET, V30, P233, DOI 10.1038/ng826; Gompel N, 2005, NATURE, V433, P481, DOI 10.1038/nature03235; Hamblin MT, 2000, AM J HUM GENET, V66, P1669, DOI 10.1086/302879; Haygood R, 2007, NAT GENET, V39, P1140, DOI 10.1038/ng2104; Hong JW, 2008, SCIENCE, V321, P1314, DOI 10.1126/science.1160631; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; KING MC, 1975, SCIENCE, V188, P107, DOI 10.1126/science.1090005; Markstein M, 2002, P NATL ACAD SCI USA, V99, P763, DOI 10.1073/pnas.012591199; Prabhakar S, 2008, SCIENCE, V321, P1346, DOI 10.1126/science.1159974; Prabhakar S, 2006, SCIENCE, V314, P786, DOI 10.1126/science.1130738; Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434	12	12	12	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	2008	321	5894					1300	1301		10.1126/science.1163568	http://dx.doi.org/10.1126/science.1163568			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	344GG	18772422				2022-12-28	WOS:000258914300032
J	Nelson, S				Nelson, Sue			Big data: The Harvard computers	NATURE			English	Editorial Material												sue.nelson@zen.co.uk							0	12	13	0	98	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2008	455	7209					36	37		10.1038/455036a	http://dx.doi.org/10.1038/455036a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	343XS	18769425				2022-12-28	WOS:000258890200027
J	Singer, AJ; Dagum, AB				Singer, Adam J.; Dagum, Alexander B.			Current management of acute cutaneous wounds	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RANDOMIZED CONTROLLED TRIAL; HYDROFLUORIC-ACID BURNS; OF-THE-LITERATURE; THICKNESS BURNS; SUBUNGUAL HEMATOMAS; FROSTBITE INJURIES; NAIL TREPHINATION; SKIN TEARS; EFFICACY; CLOSURE		[Singer, Adam J.] SUNY Stony Brook, Dept Emergency Med, Stony Brook, NY 11794 USA; [Dagum, Alexander B.] SUNY Stony Brook, Div Plast & Reconstruct Surg, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Singer, AJ (corresponding author), SUNY Stony Brook, Dept Emergency Med, HSC L4-080, Stony Brook, NY 11794 USA.	adam.singer@stonybrook.edu	Singer, Adam/ABG-4506-2021		Closure Medical and Ethicon	Closure Medical and Ethicon	Dr. Singer reports receiving consulting and lecture fees and grant support from Closure Medical and Ethicon. No other potential conflict of interest relevant to this article was reported.	AFILALO M, 1992, BURNS, V18, P313, DOI 10.1016/0305-4179(92)90153-L; *AM BURN ASS, 2001, J BURN CARE REHABIL, V22, pS1; [Anonymous], 1990, J Burn Care Rehabil, V11, P98; Atiyeh BS, 2005, BURNS, V31, P944, DOI 10.1016/j.burns.2005.08.023; Biem J, 2003, CAN MED ASSOC J, V168, P305; BOHLER K, 1992, J AM ACAD DERMATOL, V26, P749, DOI 10.1016/0190-9622(92)70105-O; Bruen KJ, 2007, ARCH SURG-CHICAGO, V142, P546, DOI 10.1001/archsurg.142.6.546; Cassidy C, 2005, BURNS, V31, P890, DOI 10.1016/j.burns.2005.04.029; Cauchy E, 2000, J HAND SURG-AM, V25A, P969, DOI 10.1053/jhsu.2000.16357; Chachad S, 2004, CLIN PEDIATR, V43, P213, DOI 10.1177/000992280404300301; Chatterjee Justin S, 2005, Int Wound J, V2, P258; Chen E, 2000, ACAD EMERG MED, V7, P157, DOI 10.1111/j.1553-2712.2000.tb00519.x; *COMM TRAUM, 1998, RES OPT CAR INJ PAT; CUMMINGS P, 1995, AM J EMERG MED, V13, P396, DOI 10.1016/0735-6757(95)90122-1; Cuttle L, 2007, BURNS, V33, P701, DOI 10.1016/j.burns.2007.02.012; DIRE DJ, 1995, ACAD EMERG MED, V2, P4, DOI 10.1111/j.1553-2712.1995.tb03070.x; Dunser MW, 2004, BURNS, V30, P391, DOI 10.1016/j.burns.2004.01.005; EAGLSTEIN WH, 1985, J AM ACAD DERMATOL, V12, P434, DOI 10.1016/S0190-9622(85)80006-2; Eaglstein WH, 2002, DERMATOL SURG, V28, P263, DOI 10.1046/j.1524-4725.2002.01207.x; Edwards H, 1998, Int J Nurs Pract, V4, P25; Fessell DP, 1999, RADIOL CLIN N AM, V37, P831, DOI 10.1016/S0033-8389(05)70131-7; Field F K, 1994, Am J Surg, V167, p2S; Fraser JF, 2004, ANZ J SURG, V74, P139, DOI 10.1046/j.1445-2197.2004.02916.x; GIMBEL NS, 1957, ARCH SURG-CHICAGO, V74, P800; Gotschall CS, 1998, J BURN CARE REHABIL, V19, P279, DOI 10.1097/00004630-199807000-00002; HAMMOND JS, 1987, J TRAUMA, V27, P1161, DOI 10.1097/00005373-198710000-00011; HING E, 2006, ADV DATA VITAL HLTH, V374; HUTCHINSON JJ, 1989, WOUNDS, V1, P123; Jandera V, 2000, BURNS, V26, P265, DOI 10.1016/S0305-4179(99)00133-3; KIRKPATRICK JJR, 1995, BURNS, V21, P495, DOI 10.1016/0305-4179(95)00025-7; Kuo F, 2006, DERMATOL SURG, V32, P676, DOI 10.1111/j.1524-4725.2006.32140.x; Lund CC., SURG GYNECOL OBSTET, V79, P352; Maenthaisong R, 2007, BURNS, V33, P713, DOI 10.1016/j.burns.2006.10.384; Magnette J, 2004, EUR J DERMATOL, V14, P238; MAIMARIS C, 1988, ARCH EMERG MED, V5, P156; MALONE ML, 1991, J AM GERIATR SOC, V39, P591, DOI 10.1111/j.1532-5415.1991.tb03599.x; MCCAULEY RL, 1983, J TRAUMA, V23, P143, DOI 10.1097/00005373-198302000-00013; MEDEIROS I, 2001, COCHRANE DB SYST REV, V2; Meuleneire F, 2002, J Wound Care, V11, P365; Milne CT, 2005, GERIATR NURS, V26, P321, DOI 10.1016/j.gerinurse.2005.08.018; Mittra ES, 2003, ISRAELI J EMERG MED, V3, P9; Murphy JV, 2000, J TRAUMA, V48, P171, DOI 10.1097/00005373-200001000-00036; NAWAR EW, 2007, ADV DATA VITAL HLTH, V386; Nguyen NL, 2002, BURNS, V28, P173, DOI 10.1016/S0305-4179(01)00094-8; OFEIGSSON OJ, 1965, SURGERY, V57, P391; PATZAKIS MJ, 1989, WESTERN J MED, V150, P545; Pham C, 2007, BURNS, V33, P946, DOI 10.1016/j.burns.2007.03.020; PURDUE GF, 1985, J TRAUMA, V25, P167, DOI 10.1097/00005373-198502000-00017; ROBSON MC, 1981, J HAND SURG-AM, V6, P43, DOI 10.1016/S0363-5023(81)80010-X; Roser SE, 1999, J HAND SURG-AM, V24A, P1166; Sacks J J, 1996, Inj Prev, V2, P52, DOI 10.1136/ip.2.1.52; Schwab Robert A., 1995, Journal of Emergency Medicine, V13, P291, DOI 10.1016/0736-4679(95)00005-U; SEABERG DC, 1991, AM J EMERG MED, V9, P209, DOI 10.1016/0735-6757(91)90077-W; Sheridan R. L., 1995, Journal of Burn Care and Rehabilitation, V16, P605, DOI 10.1097/00004630-199511000-00008; Singer AJ, 2006, ACAD EMERG MED, V13, P686, DOI 10.1197/j.aem.2006.01.018; Singer AJ, 1997, NEW ENGL J MED, V337, P1142, DOI 10.1056/NEJM199710163371607; Singer AJ, 2006, AM J EMERG MED, V24, P183, DOI 10.1016/j.ajem.2005.08.021; Singer AJ, 2000, ACAD EMERG MED, V7, P114, DOI 10.1111/j.1553-2712.2000.tb00511.x; Singer AJ, 2002, SURGERY, V131, P270, DOI 10.1067/msy.2002.121377; Singh Aparajita, 2004, Asian J Surg, V27, P326, DOI 10.1016/S1015-9584(09)60061-0; Singh V, 2007, ANN PLAS SURG, V59, P109, DOI 10.1097/01.sap.0000252065.90759.e6; Smack DP, 1996, JAMA-J AM MED ASSOC, V276, P972, DOI 10.1001/jama.276.12.972; SWAIN AH, 1987, BRIT MED J, V295, P181, DOI 10.1136/bmj.295.6591.181; Talan DA, 1999, NEW ENGL J MED, V340, P85, DOI 10.1056/NEJM199901143400202; Tredget EE, 1998, J BURN CARE REHABIL, V19, P531, DOI 10.1097/00004630-199811000-00013; Twomey JA, 2005, J TRAUMA, V59, P1350, DOI 10.1097/01.ta.0000195517.50778.2e; Ugburo AO, 2004, BURNS, V30, P43, DOI 10.1016/j.burns.2003.09.016; Venter THJ, 2007, BURNS, V33, P917, DOI 10.1016/j.burns.2006.10.408; WINTER GD, 1962, NATURE, V193, P293, DOI 10.1038/193293a0; 1998, AUST NURS J, V5, P38	70	124	138	1	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2008	359	10					1037	1046		10.1056/NEJMra0707253	http://dx.doi.org/10.1056/NEJMra0707253			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	343KN	18768947				2022-12-28	WOS:000258852500008
J	Relman, AS				Relman, Arnold S.			Industry support of medical education	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Relman, AS (corresponding author), Channing Labs, 181 Longwood Ave,5th Floor,Room 571, Boston, MA 02115 USA.	arelman@rics.bwh.harvard.edu						*ACCR COUNC CONT M, 2006, ANN REP DAT; *ACCR COUNC CONT M, ACCME STAND COMM SUP; *AM MED ASS COUNC, IND SUPP PROF ED MED; Angell M., 2004, TRUTH DRUG CO THEY D; Association of American Medical Colleges, IND FUND MED ED REP; Brennan TA, 2006, JAMA-J AM MED ASSOC, V295, P429, DOI 10.1001/jama.295.4.429; Hager M., 2008, CONTINUING ED HLTH P; *KAIS FAM FDN, NEW PHRMA GUID BAN G; LAZAR K, 2008, BOSTON GLOBE    0711; Relman AS, 2003, JAMA-J AM MED ASSOC, V289, P2418, DOI 10.1001/jama.289.18.2418; Relman AS, 2001, JAMA-J AM MED ASSOC, V285, P2009, DOI 10.1001/jama.285.15.2009; Steinbrook R, 2008, JAMA-J AM MED ASSOC, V299, P1060, DOI 10.1001/jama.299.9.1060	12	43	43	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	2008	300	9					1071	1073		10.1001/jama.300.9.1071	http://dx.doi.org/10.1001/jama.300.9.1071			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	342YN	18768419				2022-12-28	WOS:000258819600025
J	Mochizuki, K; Yamada, T; Shinohara, M; Yamanaka, Y; Kanazawa, T				Mochizuki, Kimihiro; Yamada, Tomoaki; Shinohara, Masanao; Yamanaka, Yoshiko; Kanazawa, Toshihiko			Weak interplate coupling by seamounts and repeating M similar to 7 earthquakes	SCIENCE			English	Article							SUBDUCTION EROSION; NANKAI TROUGH; JAPAN TRENCH; RUPTURE; ZONE; DEFORMATION; MODEL	Subducting seamounts are thought to increase the normal stress between subducting and overriding plates. However, recent seismic surveys and laboratory experiments suggest that interplate coupling is weak. A seismic survey in the Japan Trench shows that a large seamount is being subducted near a region of repeating earthquakes of magnitude M similar to 7. Both observed seismicity and the pattern of rupture propagation during the 1982 M 7.0 event imply that interplate coupling was weak over the seamount. A large rupture area with small slip occurred in front of the seamount. Its northern bound could be determined by a trace of multiple subducted seamounts. Whereas a subducted seamount itself may not define the rupture area, its width may be influenced by that of the seamount.	[Mochizuki, Kimihiro; Yamada, Tomoaki; Shinohara, Masanao; Kanazawa, Toshihiko] Univ Tokyo, Earthquake Res Inst, Bunkyo Ku, Tokyo 1130032, Japan; [Yamanaka, Yoshiko] Nagoya Univ, Grad Sch Environm Studies, Chikusa Ku, Nagoya, Aichi 4648601, Japan	University of Tokyo; Nagoya University	Mochizuki, K (corresponding author), Univ Tokyo, Earthquake Res Inst, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	kimi@eri.u-tokyo.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank S. Hashimoto and T. Yagi for their assistance through preparation and operations of the OBSs; the captain and crew members of R/V Hakuho-Maru for their efforts to carry out the surveys and observation; T. Tsuru for discussion and providing us with published reflection sections; N. L. B. Bangs, N. Hirata, G. F. Moore, S. Okubo, and H. Sato for reviews; and Y. Fukao for discussion. Supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Bangs NLB, 2006, GEOLOGY, V34, P701, DOI 10.1130/G22451.1; Bilek SL, 2003, GEOLOGY, V31, P455, DOI 10.1130/0091-7613(2003)031<0455:COSROE>2.0.CO;2; CLOOS M, 1992, GEOLOGY, V20, P601, DOI 10.1130/0091-7613(1992)020<0601:TTSZEA>2.3.CO;2; Cummins PR, 2002, PHYS EARTH PLANET IN, V132, P75, DOI 10.1016/S0031-9201(02)00045-6; DEMETS C, 1994, GEOPHYS RES LETT, V21, P2191, DOI 10.1029/94GL02118; Dominguez S, 1998, TECTONOPHYSICS, V293, P207, DOI 10.1016/S0040-1951(98)00086-9; Dominguez S, 2000, TECTONICS, V19, P182, DOI 10.1029/1999TC900055; Hillier JK, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL029874; Husen S, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014045; KELLEHER J, 1976, J GEOPHYS RES, V81, P4885, DOI 10.1029/JB081i026p04885; Kodaira S, 2000, SCIENCE, V289, P104, DOI 10.1126/science.289.5476.104; LALLEMAND S, 1989, TECTONOPHYSICS, V160, P231, DOI 10.1016/0040-1951(89)90393-4; Miura S, 2003, TECTONOPHYSICS, V363, P79, DOI 10.1016/S0040-1951(02)00655-8; Ranero CR, 2000, NATURE, V404, P748, DOI 10.1038/35008046; Scholz CH, 1997, GEOLOGY, V25, P487, DOI 10.1130/0091-7613(1997)025<0487:TEOSSO>2.3.CO;2; TSURU T, 2002, J GEOPHYS RES, V107; von Huene R, 2004, GEOLOGY, V32, P913, DOI 10.1130/G20563.1	17	155	157	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2008	321	5893					1194	1197		10.1126/science.1160250	http://dx.doi.org/10.1126/science.1160250			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341ZM	18755973				2022-12-28	WOS:000258754400040
J	Feinerman, O; Veiga, J; Dorfman, JR; Germain, RN; Altan-Bonnet, G				Feinerman, Ofer; Veiga, Joel; Dorfman, Jeffrey R.; Germain, Ronald N.; Altan-Bonnet, Gregoire			Variability and robustness in T cell activation from regulated heterogeneity in protein levels	SCIENCE			English	Article							STOCHASTIC GENE-EXPRESSION; SINGLE-CELL; LIGAND DISCRIMINATION; NOISE; RESPONSES; SELECTION; DYNAMICS; MEMORY; NUMBER	In T cells, the stochasticity of protein expression could contribute to the useful diversification of biological functions within a clonal population or interfere with accurate antigen discrimination. Combining computer modeling and single- cell measurements, we examined how endogenous variation in the expression levels of signaling proteins might affect antigen responsiveness during T cell activation. We found that the CD8 co- receptor fine- tunes activation thresholds, whereas the soluble hematopoietic phosphatase 1 ( SHP- 1) digitally regulates cell responsiveness. Stochastic variation in the expression of these proteins generates substantial diversity of activation within a clonal population of T cells, but co- regulation of CD8 and SHP- 1 levels ultimately limits this very diversity. These findings reveal how eukaryotic cells can draw on regulated variation in gene expression to achieve phenotypic variability in a controlled manner.	[Feinerman, Ofer; Veiga, Joel; Dorfman, Jeffrey R.; Altan-Bonnet, Gregoire] Mem Sloan Kettering Canc Ctr, ImmunoDynam Grp, Program Computat Biol & Immunol, New York, NY 10065 USA; [Germain, Ronald N.] NIAID, Lymphocyte Biol Sect, Immunol Lab, Program Syst Immunol & Infect Dis Modeling,NIH,De, Bethesda, MD 20892 USA	Memorial Sloan Kettering Cancer Center; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Altan-Bonnet, G (corresponding author), Mem Sloan Kettering Canc Ctr, ImmunoDynam Grp, Program Computat Biol & Immunol, 1275 York Ave,Box 460, New York, NY 10065 USA.	altanbonnet@cbio.mskcc.org	Dorfman, Jeffrey R/M-4218-2017; Germain, Ronald N./Z-1945-2019; Dorfman, Jeffrey R/B-4854-2011; Germain, Ronald/ABE-7090-2020	Dorfman, Jeffrey R/0000-0001-9938-8911; Altan-Bonnet, Gregoire/0000-0002-7283-3162	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000403, ZIAAI000403, Z01AI000757] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 AI000403-24] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Altan-Bonnet G, 2005, PLOS BIOL, V3, P1925, DOI 10.1371/journal.pbio.0030356; Bar-Even A, 2006, NAT GENET, V38, P636, DOI 10.1038/ng1807; Becskei A, 2005, NAT GENET, V37, P937, DOI 10.1038/ng1616; Chang JT, 2007, SCIENCE, V315, P1687, DOI 10.1126/science.1139393; Davis MM, 2007, ANNU REV IMMUNOL, V25, P681, DOI 10.1146/annurev.immunol.24.021605.090600; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; Feinerman O, 2008, MOL IMMUNOL, V45, P619, DOI 10.1016/j.molimm.2007.03.028; Germain RN, 1999, ANNU REV IMMUNOL, V17, P467, DOI 10.1146/annurev.immunol.17.1.467; Germain RN, 2001, SCIENCE, V293, P240, DOI 10.1126/science.1062946; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Irish JM, 2004, CELL, V118, P217, DOI 10.1016/j.cell.2004.06.028; Kaern M, 2005, NAT REV GENET, V6, P451, DOI 10.1038/nrg1615; Kollmann M, 2005, NATURE, V438, P504, DOI 10.1038/nature04228; Korobkova E, 2004, NATURE, V428, P574, DOI 10.1038/nature02404; Li QJ, 2007, CELL, V129, P147, DOI 10.1016/j.cell.2007.03.008; Newman JRS, 2006, NATURE, V441, P840, DOI 10.1038/nature04785; Qi SY, 2001, P NATL ACAD SCI USA, V98, P6548, DOI 10.1073/pnas.111536798; Sigal A, 2006, NATURE, V444, P643, DOI 10.1038/nature05316; Stefanova I, 2003, NAT IMMUNOL, V4, P248, DOI 10.1038/ni895; Stemberger C, 2007, IMMUNITY, V27, P985, DOI 10.1016/j.immuni.2007.10.012; Suel GM, 2007, SCIENCE, V315, P1716, DOI 10.1126/science.1137455; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104	22	238	241	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	2008	321	5892					1081	1084		10.1126/science.1158013	http://dx.doi.org/10.1126/science.1158013			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339RL	18719282	Green Submitted, Green Accepted			2022-12-28	WOS:000258594900038
J	Lyon, BE; Chaine, AS; Winkler, DW				Lyon, Bruce E.; Chaine, Alexis S.; Winkler, David W.			Ecology - A matter of timing	SCIENCE			English	Editorial Material							WILD BIRD POPULATION; CLIMATE-CHANGE; PHENOTYPIC PLASTICITY; GONADAL CYCLES; EVOLUTION		[Lyon, Bruce E.] Univ Calif Santa Cruz, Dept Ecol & Evolutionary Biol, Santa Cruz, CA 95064 USA; [Chaine, Alexis S.] CNRS, Moulis USR 2936, Stn Ecol Expt, F-09200 Moulis, France; [Winkler, David W.] Cornell Univ, Museum Vertebrates, Ithaca, NY 14853 USA; [Winkler, David W.] Cornell Univ, Dept Ecol & Evolutionary Biol, Ithaca, NY 14853 USA	University of California System; University of California Santa Cruz; Centre National de la Recherche Scientifique (CNRS); Cornell University; Cornell University	Lyon, BE (corresponding author), Univ Calif Santa Cruz, Dept Ecol & Evolutionary Biol, Santa Cruz, CA 95064 USA.	lyon@biology.ucsc.edu	Lyon, Bruce E/E-8491-2011; Chaine, Alexis S/B-4062-2012					Both C, 2006, NATURE, V441, P81, DOI 10.1038/nature04539; Both C, 2004, P ROY SOC B-BIOL SCI, V271, P1657, DOI 10.1098/rspb.2004.2770; Charmantier A, 2008, SCIENCE, V320, P800, DOI 10.1126/science.1157174; Coppack T, 2007, J ORNITHOL, V148, pS459, DOI 10.1007/s10336-007-0158-9; Crick HQP, 1999, NATURE, V399, P423, DOI 10.1038/20839; Dawson A, 2008, PHILOS T R SOC B, V363, P1621, DOI 10.1098/rstb.2007.0004; Dunn P, 2004, ADV ECOL RES, V35, P69, DOI 10.1016/S0065-2504(04)35004-X; Gienapp P, 2008, MOL ECOL, V17, P167, DOI 10.1111/j.1365-294X.2007.03413.x; Lessells CM, 2008, PHILOS T R SOC B, V363, P1589, DOI 10.1098/rstb.2007.0008; Nussey DH, 2005, SCIENCE, V310, P304, DOI 10.1126/science.1117004; Rosenzweig C, 2008, NATURE, V453, P353, DOI 10.1038/nature06937; Silverin B, 2008, HORM BEHAV, V54, P60, DOI 10.1016/j.yhbeh.2008.01.015; Verhulst S, 2008, PHILOS T R SOC B, V363, P399, DOI 10.1098/rstb.2007.2146; Visser ME, 2008, P ROY SOC B-BIOL SCI, V275, P649, DOI 10.1098/rspb.2007.0997; WINGFIELD JC, 1992, J EXP ZOOL, V261, P214, DOI 10.1002/jez.1402610212	15	42	42	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	2008	321	5892					1051	1052		10.1126/science.1159822	http://dx.doi.org/10.1126/science.1159822			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339RL	18719273				2022-12-28	WOS:000258594900027
J	Scholes, RJ; Mace, GM; Turner, W; Geller, GN; Jurgens, N; Larigauderie, A; Muchoney, D; Walther, BA; Mooney, HA				Scholes, R. J.; Mace, G. M.; Turner, W.; Geller, G. N.; Juergens, N.; Larigauderie, A.; Muchoney, D.; Walther, B. A.; Mooney, H. A.			Ecology - Toward a global biodiversity observing system	SCIENCE			English	Editorial Material							INDICATORS		[Scholes, R. J.] CSIR, ZA-0001 Pretoria, South Africa; [Mace, G. M.] Univ London Imperial Coll Sci Technol & Med, Ctr Populat Biol, NERC, Ascot SL5 7PY, Berks, England; [Turner, W.] NASA Headquarters, Div Earth Sci, Washington, DC 20546 USA; [Geller, G. N.] CALTECH, Jet Prop Lab, NASA Ecol Forecasting Program, Pasadena, CA 91109 USA; [Juergens, N.] Univ Hamburg, Bioctr Klein Flottbek, D-22609 Hamburg, Germany; [Juergens, N.] Univ Hamburg, Bot Garden, D-22609 Hamburg, Germany; [Larigauderie, A.; Walther, B. A.] Museum Natl Hist Nat, DIVERSITAS, F-75231 Paris 05, France; [Muchoney, D.] GEO, CH-1211 Geneva 2, Switzerland; [Mooney, H. A.] Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Council for Scientific & Industrial Research (CSIR) - South Africa; Imperial College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); National Aeronautics & Space Administration (NASA); California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Hamburg; University of Hamburg; Museum National d'Histoire Naturelle (MNHN); Stanford University	Scholes, RJ (corresponding author), CSIR, POB 395, ZA-0001 Pretoria, South Africa.	bscholes@csir.co.za	Mace, Georgina M/I-3072-2016; Juergens, Norbert/K-4792-2013	Mace, Georgina M/0000-0001-8965-5211; Juergens, Norbert/0000-0003-3211-0549; Scholes, Robert/0000-0001-5537-6935; Geller, Gary/0000-0002-4490-6002	NERC [cpb010001] Funding Source: UKRI; Natural Environment Research Council [cpb010001] Funding Source: researchfish	NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Balmford A, 2005, SCIENCE, V307, P212, DOI 10.1126/science.1106281; *CBD, 2008, 9 C PART BONN GERM 1; Faith DP, 2002, CONSERV BIOL, V16, P248, DOI 10.1046/j.1523-1739.2002.00503.x; Hui DF, 2008, BIOL CONSERV, V141, P1091, DOI 10.1016/j.biocon.2008.02.001; Mace GM, 2007, CONSERV BIOL, V21, P1406, DOI 10.1111/j.1523-1739.2007.00830.x; NOSS RF, 1990, CONSERV BIOL, V4, P355, DOI 10.1111/j.1523-1739.1990.tb00309.x; Pereira HM, 2006, TRENDS ECOL EVOL, V21, P123, DOI 10.1016/j.tree.2005.10.015; *ROYAL SOC, 2003, 1103 ROYAL SOC; Scholes RJ, 2005, NATURE, V434, P45, DOI 10.1038/nature03289; *WORLD MET ORG, 2004, 1219 WORLD MET ORG	10	172	189	1	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	2008	321	5892					1044	1045		10.1126/science.1162055	http://dx.doi.org/10.1126/science.1162055			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339RL	18719268				2022-12-28	WOS:000258594900022
J	Criqui, MH; Golomb, BA				Criqui, Michael H.; Golomb, Beatrice A.			Lipid lowering: what and when to monitor	LANCET			English	Editorial Material							MAJOR CORONARY EVENTS; CHOLESTEROL; RISK; PREVENTION; IDENTIFY		[Criqui, Michael H.] Univ Calif San Diego, Dept Family & Prevent Med, Div Prevent Med, La Jolla, CA 92093 USA; [Golomb, Beatrice A.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Criqui, MH (corresponding author), Univ Calif San Diego, Dept Family & Prevent Med, Div Prevent Med, La Jolla, CA 92093 USA.	mcriqui@ucsd.edu						ALSHEIKHALI AA, 2004, CIRCULATION S3, V110, P813; Brown BG, 2001, NEW ENGL J MED, V345, P1583, DOI 10.1056/NEJMoa011090; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Criqui MH, 1998, AM J MED, V105, p48S, DOI DOI 10.1016/S0002-9343(98)00212-5; Glasziou PP, 2008, ANN INTERN MED, V148, P656, DOI 10.7326/0003-4819-148-9-200805060-00005; Gotto AM, 2000, CIRCULATION, V101, P477, DOI 10.1161/01.CIR.101.5.477; Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E; IRIBARREN C, 1995, CIRCULATION, V92, P2396, DOI 10.1161/01.CIR.92.9.2396; KINOSIAN B, 1995, J INVEST MED, V43, P443; Natarajan S, 2003, AM J PREV MED, V25, P50, DOI 10.1016/S0749-3797(03)00092-8; Robins SJ, 2001, JAMA-J AM MED ASSOC, V285, P1585, DOI 10.1001/jama.285.12.1585; Sniderman AD, 2006, J INTERN MED, V259, P455, DOI 10.1111/j.1365-2796.2006.01649.x; Superko HR, 2008, CIRCULATION, V117, P560, DOI 10.1161/CIRCULATIONAHA.106.667428; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	14	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 16	2008	372	9638					516	517		10.1016/S0140-6736(08)61213-1	http://dx.doi.org/10.1016/S0140-6736(08)61213-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339MS	18707970				2022-12-28	WOS:000258582300008
J	Navarro, L; Jay, F; Nomura, K; He, SY; Voinnet, O				Navarro, Lionel; Jay, Florence; Nomura, Kinya; He, Sheng Yang; Voinnet, Olivier			Suppression of the microRNA pathway by bacterial effector proteins	SCIENCE			English	Article							ARABIDOPSIS INNATE IMMUNITY; PSEUDOMONAS-SYRINGAE; PLANT IMMUNITY; SMALL RNAS; DEFENSE; BAK1; METHYLATION; RESISTANCE; INHIBITOR; SECRETION	Plants and animals sense pathogen- associated molecular patterns ( PAMPs) and in turn differentially regulate a subset of microRNAs ( miRNAs). However, the extent to which the miRNA pathway contributes to innate immunity remains unknown. Here, we show that miRNA- deficient mutants of Arabidopsis partly restore growth of a type III secretion- defective mutant of Pseudomonas syringae. These mutants also sustained growth of nonpathogenic Pseudomonas fluorescens and Escherichia coli strains, implicating miRNAs as key components of plant basal defense. Accordingly, we have identified P. syringae effectors that suppress transcriptional activation of some PAMP- responsive miRNAs or miRNA biogenesis, stability, or activity. These results provide evidence that, like viruses, bacteria have evolved to suppress RNA silencing to cause disease.	[Navarro, Lionel; Jay, Florence; Voinnet, Olivier] Univ Strasbourg 1, Inst Biol Mol Plantes, CNRS, UPR 2353, F-67084 Strasbourg, France; [Nomura, Kinya; He, Sheng Yang] Michigan State Univ, Dept Energy, Plant Res Lab, E Lansing, MI 48824 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Michigan State University	Voinnet, O (corresponding author), Univ Strasbourg 1, Inst Biol Mol Plantes, CNRS, UPR 2353, 12 Rue Gen Zimmer, F-67084 Strasbourg, France.	olivier.voinnet@ibmp-ulp.u-strasbg.fr	Bruening, Stefan/B-8505-2011	JAY, Florence/0000-0001-7353-8299; Voinnet, Olivier/0000-0001-6982-9544	NIAID NIH HHS [5R01AI060761, R01 AI060761-03, R01 AI060761] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060761] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agorio A, 2007, PLANT CELL, V19, P3778, DOI 10.1105/tpc.107.054494; Asai T, 2002, NATURE, V415, P977, DOI 10.1038/415977a; Baulcombe D, 2004, NATURE, V431, P356, DOI 10.1038/nature02874; Brodersen P, 2008, SCIENCE, V320, P1185, DOI 10.1126/science.1159151; Chinchilla D, 2007, NATURE, V448, P497, DOI 10.1038/nature05999; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; de Torres M, 2006, PLANT J, V47, P368, DOI 10.1111/j.1365-313X.2006.02798.x; Ding SW, 2007, CELL, V130, P413, DOI 10.1016/j.cell.2007.07.039; Dunoyer P, 2007, NAT GENET, V39, P848, DOI 10.1038/ng2081; Fahlgren N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000219; Hauck P, 2003, P NATL ACAD SCI USA, V100, P8577, DOI 10.1073/pnas.1431173100; He P, 2006, CELL, V125, P563, DOI 10.1016/j.cell.2006.02.047; Janjusevic R, 2006, SCIENCE, V311, P222, DOI 10.1126/science.1120131; Kasschau KD, 2003, DEV CELL, V4, P205, DOI 10.1016/S1534-5807(03)00025-X; Kasschau KD, 1998, CELL, V95, P461, DOI 10.1016/S0092-8674(00)81614-1; Katiyar-Agarwal S, 2007, GENE DEV, V21, P3123, DOI 10.1101/gad.1595107; Katiyar-Agarwal S, 2006, P NATL ACAD SCI USA, V103, P18002, DOI 10.1073/pnas.0608258103; Li J, 2002, CELL, V110, P213, DOI 10.1016/S0092-8674(02)00812-7; Li JJ, 2005, CURR BIOL, V15, P1501, DOI 10.1016/j.cub.2005.07.029; Li XY, 2005, P NATL ACAD SCI USA, V102, P12990, DOI 10.1073/pnas.0502425102; Mota LJ, 2005, ANN MED, V37, P234, DOI 10.1080/07853890510037329; Navarro L, 2006, SCIENCE, V312, P436, DOI 10.1126/science.1126088; Shan LB, 2000, PLANT CELL, V12, P2323, DOI 10.1105/tpc.12.12.2323; Shan LB, 2008, CELL HOST MICROBE, V4, P17, DOI 10.1016/j.chom.2008.05.017; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Xiang TT, 2008, CURR BIOL, V18, P74, DOI 10.1016/j.cub.2007.12.020; Yu B, 2005, SCIENCE, V307, P932, DOI 10.1126/science.1107130; Yuan J, 1996, J BACTERIOL, V178, P6399, DOI 10.1128/jb.178.21.6399-6402.1996; Zipfel C, 2006, CELL, V125, P749, DOI 10.1016/j.cell.2006.03.037	29	265	293	2	96	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2008	321	5891					964	967		10.1126/science.1159505	http://dx.doi.org/10.1126/science.1159505			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	337LD	18703740	Green Accepted			2022-12-28	WOS:000258436700039
J	Glass, DJ; Hall, N				Glass, David J.; Hall, Ned			A brief history of the hypothesis	CELL			English	Editorial Material									[Glass, David J.] Novartis Inst Biomed Res, Cambridge, MA 02139 USA; [Hall, Ned] Harvard Univ, Dept Philosophy, Cambridge, MA 02138 USA	Novartis; Harvard University	Glass, DJ (corresponding author), Novartis Inst Biomed Res, Cambridge, MA 02139 USA.	david.glass@novartis.com; ehall@fas.harvard.edu	Glass, David/AAI-3910-2021; Glass, David/C-4782-2012	Glass, David/0000-0001-6187-4164				ANDERSON C, 2008, WIRED           0716; BACON F, 2005, TRANSLATION USED NOV; Blake Ralph M., 1966, THEORIES SCI METHOD; Carnap Rudolf, 1980, STUDIES INDUCTIVE LO; Glass D. J, 2006, EXPT DESIGN BIOL; HALL AR, 1962, REVOLUTION SCI 1500; HALL N, 2001, BLACKWELLS COMPANION, P149; HUME D, 1999, TEXT USED ENQUIRY CO; Kuhn T., 1977, ESSENTIAL TENSION SE, DOI DOI 10.1086/AHR/83.5.1231; NEWTON I, 1999, TEXT USED PRINCIPIA; NEWTON I, 1979, TEXT USED OPTICKS TR; Nozick Robert., 2001, INVARIANCES STRUCTUR; POINCARE H, 1952, SCI HYPOTHESES; POPPER K, 2002, TEXT USED LOGIC SCI; RUSSELL B, 2007, TEXT USED PROBLEMS P	15	38	38	1	16	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 8	2008	134	3					378	381		10.1016/j.cell.2008.07.033	http://dx.doi.org/10.1016/j.cell.2008.07.033			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Biochemistry & Molecular Biology; Cell Biology	340SO	18692458	Bronze			2022-12-28	WOS:000258665500007
J	Hao, X				Hao, Xin			Science in China: 30 years on	CELL			English	Editorial Material																			0	6	6	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 8	2008	134	3					375	377		10.1016/j.cell.2008.07.035	http://dx.doi.org/10.1016/j.cell.2008.07.035			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SO	18692457	Bronze			2022-12-28	WOS:000258665500006
J	Cox, H; McDermid, C				Cox, Helen; McDermid, Cheryl			XDR tuberculosis can be cured with aggressive treatment	LANCET			English	Editorial Material							TB		[Cox, Helen] Macfarlane Burnet Inst Med Res & Publ Hlth, Melbourne, Vic 3004, Australia; [Cox, Helen; McDermid, Cheryl] Med Sans Frontieres, Cape Town, South Africa	Burnet Institute	Cox, H (corresponding author), Macfarlane Burnet Inst Med Res & Publ Hlth, Melbourne, Vic 3004, Australia.	hcox@burnet.edu.au		Cox, Helen/0000-0002-6538-7192				FEUER C, 2006, TUBERCULOSIS RES DEV; Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1; *GREEN LIGHT COMM, 2008, GLC PROGR APPL END G; KESHAVJEE S, 2008, LANCET          0825, DOI DOI 10.1016/S0140-6736(08)61204-0; Migliori GB, 2007, EUR RESPIR J, V30, P623, DOI 10.1183/09031936.00077307; Nathanson E, 2006, EMERG INFECT DIS, V12, P1389, DOI 10.3201/eid1209.051618; Raviglione M, 2006, INT J TUBERC LUNG D, V10, P1185; Ruddy M, 2005, THORAX, V60, P130, DOI 10.1136/thx.2004.026922; Singh JA, 2007, PLOS MED, V4, P19, DOI 10.1371/journal.pmed.0040050; *WHO IUATLD, 2008, 4 WHO IUATLD; *WHO STOP TB PARTN, 2007, GLOB MDR TB XDR TB R	11	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 18	2008	372	9647					1363	1365		10.1016/S0140-6736(08)61205-2	http://dx.doi.org/10.1016/S0140-6736(08)61205-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	362WP	18723217				2022-12-28	WOS:000260228200005
J	Zhou, Q; Brown, J; Kanarek, A; Rajagopal, J; Melton, DA				Zhou, Qiao; Brown, Juliana; Kanarek, Andrew; Rajagopal, Jayaraj; Melton, Douglas A.			In vivo reprogramming of adult pancreatic exocrine cells to beta-cells	NATURE			English	Article							TO-MESENCHYMAL TRANSITION; INSULIN-SECRETING CELLS; STEM-CELLS; B-CELLS; DIFFERENTIATION; FIBROBLASTS; TRANSDIFFERENTIATION; GENES; LIVER; GENERATION	One goal of regenerative medicine is to instructively convert adult cells into other cell types for tissue repair and regeneration. Although isolated examples of adult cell reprogramming are known, there is no general understanding of how to turn one cell type into another in a controlled manner. Here, using a strategy of re- expressing key developmental regulators in vivo, we identify a specific combination of three transcription factors (Ngn3 ( also known as Neurog3) Pdx1 and Mafa) that reprograms differentiated pancreatic exocrine cells in adult mice into cells that closely resemble beta-cells. The induced beta-cells are indistinguishable from endogenous islet beta-cells in size, shape and ultrastructure. They express genes essential for beta-cell function and can ameliorate hyperglycaemia by remodelling local vasculature and secreting insulin. This study provides an example of cellular reprogramming using defined factors in an adult organ and suggests a general paradigm for directing cell reprogramming without reversion to a pluripotent stem cell state.	[Zhou, Qiao; Kanarek, Andrew; Rajagopal, Jayaraj; Melton, Douglas A.] Harvard Univ, Howard Hughes Med Inst, Dept Stem Cell & Regenerat Biol, Harvard Stem Cell Inst, Cambridge, MA 02138 USA; [Brown, Juliana] Harvard Univ, Sch Med, Childrens Hosp, Dept Pathol,Harvard Stem Cell Inst, Boston, MA 02115 USA	Harvard University; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard Medical School	Melton, DA (corresponding author), Harvard Univ, Howard Hughes Med Inst, Dept Stem Cell & Regenerat Biol, Harvard Stem Cell Inst, 7 Divin Ave, Cambridge, MA 02138 USA.	dmelton@harvard.edu	Young, Richard A/F-6495-2012; Wilson, Matthew H/K-3193-2013	Young, Richard A/0000-0001-8855-8647; Zhou, Qiao/0000-0002-0099-3909	Damon-Runyon Cancer Research Foundation Postdoctoral Fellowship; Pathway to Independence (PI) Award; National Institute of Health; Harvard Stem Cell Institute; NIH	Damon-Runyon Cancer Research Foundation Postdoctoral Fellowship; Pathway to Independence (PI) Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harvard Stem Cell Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We are grateful to M. Ericsson for expert assistance on electron microscopy, R. Hellmiss-Peralta for advice on graphics, and B. Tilton and P. Rogers for FACS. We thank R. Martinez and G. Kenty for technical assistance; H. Edlund for the gift of Ptf1a antiserum; A. Kweudjeu for microarray analysis; members of the Melton laboratory for advice and feedback; and J. Sneddon, J. Annes and W. Anderson for critical reading of the manuscript. Q.Z. was supported by a Damon-Runyon Cancer Research Foundation Postdoctoral Fellowship and a Pathway to Independence (PI) Award from the National Institute of Health. D.A.M. is an HHMI investigator and this work was supported in part by the Harvard Stem Cell Institute and the NIH.	Baeyens L, 2005, DIABETOLOGIA, V48, P49, DOI 10.1007/s00125-004-1606-1; Brockes JR, 2002, NAT REV MOL CELL BIO, V3, P566, DOI 10.1038/nrm881; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; Cobaleda C, 2007, NATURE, V449, P473, DOI 10.1038/nature06159; DEROBERTIS EM, 1977, P NATL ACAD SCI USA, V74, P2470; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Ferber S, 2000, NAT MED, V6, P568, DOI 10.1038/75050; Gasa R, 2004, P NATL ACAD SCI USA, V101, P13245, DOI 10.1073/pnas.0405301101; Gershengorn MC, 2004, SCIENCE, V306, P2261, DOI 10.1126/science.1101968; Gu GQ, 2002, DEVELOPMENT, V129, P2447; Gurdon JB, 2006, ANNU REV CELL DEV BI, V22, P1, DOI 10.1146/annurev.cellbio.22.090805.140144; HADORN E, 1968, SCI AM, V219, P110, DOI 10.1038/scientificamerican1168-110; Heremans Y, 2002, J CELL BIOL, V159, P303, DOI 10.1083/jcb.200203074; Hochedlinger K, 2006, NATURE, V441, P1061, DOI 10.1038/nature04955; Jensen J, 2004, DEV DYNAM, V229, P176, DOI 10.1002/dvdy.10460; Kaneto H, 2005, DIABETES, V54, P1009, DOI 10.2337/diabetes.54.4.1009; Konstantinova I, 2007, CELL, V129, P359, DOI 10.1016/j.cell.2007.02.044; Lammert E, 2003, CURR BIOL, V13, P1070, DOI 10.1016/S0960-9822(03)00378-6; Meissner A, 2007, NAT BIOTECHNOL, V25, P1177, DOI 10.1038/nbt1335; Minami K, 2005, P NATL ACAD SCI USA, V102, P15116, DOI 10.1073/pnas.0507567102; Minami K, 2008, FRONT BIOSCI-LANDMRK, V13, P5824; Miyatsuka T, 2003, BIOCHEM BIOPH RES CO, V310, P1017, DOI 10.1016/j.bbrc.2003.09.108; Morton RA, 2007, MOL CELL ENDOCRINOL, V270, P87, DOI 10.1016/j.mce.2007.02.005; Murtaugh LC, 2003, ANNU REV CELL DEV BI, V19, P71, DOI 10.1146/annurev.cellbio.19.111301.144752; Okuno M, 2007, AM J PHYSIOL-ENDOC M, V292, pE158, DOI 10.1152/ajpendo.00180.2006; Orkin SH, 2008, CELL, V132, P631, DOI 10.1016/j.cell.2008.01.025; Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]; Sapir T, 2005, P NATL ACAD SCI USA, V102, P7964, DOI 10.1073/pnas.0405277102; Shen CN, 2000, NAT CELL BIOL, V2, P879, DOI 10.1038/35046522; Slack JMW, 2007, NAT REV MOL CELL BIO, V8, P369, DOI 10.1038/nrm2146; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tanaka EM, 2003, CURR OPIN GENET DEV, V13, P497, DOI 10.1016/j.gde.2003.08.003; Wang AY, 2007, MOL THER, V15, P255, DOI 10.1038/sj.mt.6300032; Wang AY, 2004, HUM GENE THER, V15, P405, DOI 10.1089/104303404322959551; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944; Whitehead GG, 2005, SCIENCE, V310, P1957, DOI 10.1126/science.1117637; Xie HF, 2004, CELL, V117, P663, DOI 10.1016/S0092-8674(04)00419-2; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zhou Q, 2007, DEV CELL, V13, P103, DOI 10.1016/j.devcel.2007.06.001	41	1497	1655	3	219	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 2	2008	455	7213					627	U30		10.1038/nature07314	http://dx.doi.org/10.1038/nature07314			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	354KY	18754011	Green Accepted			2022-12-28	WOS:000259639700038
J	Jones, S; Zhang, XS; Parsons, DW; Lin, JCH; Leary, RJ; Angenendt, P; Mankoo, P; Carter, H; Kamiyama, H; Jimeno, A; Hong, SM; Fu, BJ; Lin, MT; Calhoun, ES; Kamiyama, M; Walter, K; Nikolskaya, T; Nikolsky, Y; Hartigan, J; Smith, DR; Hidalgo, M; Leach, SD; Klein, AP; Jaffee, EM; Goggins, M; Maitra, A; Iacobuzio-Donahue, C; Eshleman, JR; Kern, SE; Hruban, RH; Karchin, R; Papadopoulos, N; Parmigiani, G; Vogelstein, B; Velculescu, VE; Kinzler, KW				Jones, Sian; Zhang, Xiaosong; Parsons, D. Williams; Lin, Jimmy Cheng-Ho; Leary, Rebecca J.; Angenendt, Philipp; Mankoo, Parminder; Carter, Hannah; Kamiyama, Hirohiko; Jimeno, Antonio; Hong, Seung-Mo; Fu, Baojin; Lin, Ming-Tseh; Calhoun, Eric S.; Kamiyama, Mihoko; Walter, Kimberly; Nikolskaya, Tatiana; Nikolsky, Yuri; Hartigan, James; Smith, Douglas R.; Hidalgo, Manuel; Leach, Steven D.; Klein, Alison P.; Jaffee, Elizabeth M.; Goggins, Michael; Maitra, Anirban; Iacobuzio-Donahue, Christine; Eshleman, James R.; Kern, Scott E.; Hruban, Ralph H.; Karchin, Rachel; Papadopoulos, Nickolas; Parmigiani, Giovanni; Vogelstein, Bert; Velculescu, Victor E.; Kinzler, Kenneth W.			Core signaling pathways in human pancreatic cancers revealed by global genomic analyses	SCIENCE			English	Article							COLORECTAL CANCERS; HUMAN BREAST; GENE; PROGRESSION; MUTATIONS	There are currently few therapeutic options for patients with pancreatic cancer, and new insights into the pathogenesis of this lethal disease are urgently needed. Toward this end, we performed a comprehensive genetic analysis of 24 pancreatic cancers. We first determined the sequences of 23,219 transcripts, representing 20,661 protein-coding genes, in these samples. Then, we searched for homozygous deletions and amplifications in the tumor DNA by using microarrays containing probes for similar to 10(6) single- nucleotide polymorphisms. We found that pancreatic cancers contain an average of 63 genetic alterations, the majority of which are point mutations. These alterations defined a core set of 12 cellular signaling pathways and processes that were each genetically altered in 67 to 100% of the tumors. Analysis of these tumors' transcriptomes with next- generation sequencing- by- synthesis technologies provided independent evidence for the importance of these pathways and processes. Our data indicate that genetically altered core pathways and regulatory processes only become evident once the coding regions of the genome are analyzed in depth. Dysregulation of these core pathways and processes through mutation can explain the major features of pancreatic tumorigenesis.	[Jones, Sian; Zhang, Xiaosong; Parsons, D. Williams; Lin, Jimmy Cheng-Ho; Leary, Rebecca J.; Angenendt, Philipp; Jimeno, Antonio; Calhoun, Eric S.; Hidalgo, Manuel; Leach, Steven D.; Klein, Alison P.; Jaffee, Elizabeth M.; Goggins, Michael; Maitra, Anirban; Iacobuzio-Donahue, Christine; Eshleman, James R.; Kern, Scott E.; Hruban, Ralph H.; Papadopoulos, Nickolas; Parmigiani, Giovanni; Vogelstein, Bert; Velculescu, Victor E.; Kinzler, Kenneth W.] Johns Hopkins Kimmel Canc Ctr, Sol Goldman Pancreat Canc Res Ctr, Ludwig Ctr, Baltimore, MD 21231 USA; [Jones, Sian; Zhang, Xiaosong; Parsons, D. Williams; Lin, Jimmy Cheng-Ho; Leary, Rebecca J.; Angenendt, Philipp; Jimeno, Antonio; Calhoun, Eric S.; Hidalgo, Manuel; Leach, Steven D.; Klein, Alison P.; Jaffee, Elizabeth M.; Goggins, Michael; Maitra, Anirban; Iacobuzio-Donahue, Christine; Eshleman, James R.; Kern, Scott E.; Hruban, Ralph H.; Papadopoulos, Nickolas; Parmigiani, Giovanni; Vogelstein, Bert; Velculescu, Victor E.; Kinzler, Kenneth W.] Johns Hopkins Kimmel Canc Ctr, Howard Hughes Med Inst, Baltimore, MD 21231 USA; [Parsons, D. Williams] Baylor Coll Med, Dept Pediat, Hematol Oncol Sect, Houston, TX 77030 USA; [Mankoo, Parminder; Carter, Hannah; Karchin, Rachel] Johns Hopkins Med Inst, Dept Biomed Engn, Inst Computat Med, Baltimore, MD 21218 USA; [Kamiyama, Hirohiko; Hong, Seung-Mo; Fu, Baojin; Lin, Ming-Tseh; Kamiyama, Mihoko; Walter, Kimberly; Klein, Alison P.; Jaffee, Elizabeth M.; Goggins, Michael; Maitra, Anirban; Iacobuzio-Donahue, Christine; Eshleman, James R.; Kern, Scott E.; Hruban, Ralph H.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21231 USA; [Nikolskaya, Tatiana] NI Vavilov Gen Genet Res Inst, Moscow 117809, Russia; [Nikolsky, Yuri] GeneGo Inc, St Joseph, MI 49085 USA; [Hartigan, James; Smith, Douglas R.] Agencourt Biosci Corp, Beverly, MA 01915 USA; [Leach, Steven D.] Johns Hopkins Med Inst, Dept Surg, Baltimore, MD 21231 USA; [Parmigiani, Giovanni] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; Baylor College of Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Russian Academy of Sciences; Vavilov Institute of General Genetics; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Vogelstein, B (corresponding author), Johns Hopkins Kimmel Canc Ctr, Sol Goldman Pancreat Canc Res Ctr, Ludwig Ctr, Baltimore, MD 21231 USA.	bertvog@gmail.com; velculescu@jhmi.edu; kinzlke@jhmi.edu	Velculescu, Victor/ABF-4846-2020; HIDALGO, MANUEL/I-4995-2015; Papadopoulos, Nickolas/K-7272-2012; Iacobuzio-Donahue, Christine/ABF-1295-2020; Nikolskaya, Tatiana/M-5008-2013; Karchin, Rachel/A-3385-2010; wang, edwin/G-5372-2010; Jones, Sian/A-5050-2012; Carter, Hannah/R-8425-2017	Velculescu, Victor/0000-0003-1195-438X; HIDALGO, MANUEL/0000-0002-3765-3318; Iacobuzio-Donahue, Christine/0000-0002-4672-3023; Jaffee, Elizabeth/0000-0003-3841-6549; Karchin, Rachel/0000-0002-5069-1239; Hong, Seung-Mo/0000-0002-8888-6007; Parsons, Donald/0000-0002-8775-3501; Carter, Hannah/0000-0002-1729-2463	Sol Goldman Charitable Trust; Lillian Goldman Charitable Trust; Lustgarten Foundation for Pancreatic Cancer Research; Virginia and D. K. Ludwig Fund for Cancer Research; Susan G. Komen Foundation; Michael Rolfe Pancreatic Cancer Foundation; Joseph C. Monastra Foundation for Pancreatic Cancer; Viragh Family Foundation; Broad Foundation; Emerald Foundation; NIH [CA62924, CA43460, CA57345, CA121113]; Beckman Coulter Corporation; NATIONAL CANCER INSTITUTE [R37CA057345, P50CA062924, R01CA121113, R01CA043460, R37CA043460, R01CA057345] Funding Source: NIH RePORTER	Sol Goldman Charitable Trust; Lillian Goldman Charitable Trust; Lustgarten Foundation for Pancreatic Cancer Research; Virginia and D. K. Ludwig Fund for Cancer Research; Susan G. Komen Foundation(Susan G. Komen Breast Cancer Foundation); Michael Rolfe Pancreatic Cancer Foundation; Joseph C. Monastra Foundation for Pancreatic Cancer; Viragh Family Foundation; Broad Foundation; Emerald Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Beckman Coulter Corporation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank J. Ptak, N. Silliman, L. Dobbyn, M. Whalen, M. Borges, G. Cusatis, M. Griffith, C. Henderson, C. Karikari, G. Mo, M. Mullendore, E. Palmisano, M. Raben, S. Solt, and D. Trusty for expert technical assistance; T. Sjoblom for help with database management for mutational analyses; Y. Ding for help with bioinformatic analyses; and J. Cameron, G. Feldmann, S. Salaria, L. Hua, and C. Yeo for helpful discussions. This project was performed under the auspices of the Goldman Pancreatic Cancer Genome Initiative and was funded by the Sol Goldman Charitable Trust; the Lillian Goldman Charitable Trust; the Lustgarten Foundation for Pancreatic Cancer Research; the Virginia and D. K. Ludwig Fund for Cancer Research; the Susan G. Komen Foundation; the Michael Rolfe Pancreatic Cancer Foundation; the Joseph C. Monastra Foundation for Pancreatic Cancer; the family and friends of George Rubis; the Viragh Family Foundation; the Broad Foundation; the Emerald Foundation; NIH grants CA62924, CA43460, CA57345, and CA121113; and Beckman Coulter Corporation. Under separate licensing agreements between the Johns Hopkins University and Genzyme, Beckman Coulter, and Exact Sciences Corporations, K. W. K., B. V., and V. E. V. are entitled to a share of royalties received by the university on sales of products related to research described in this paper. These authors and the university own Genzyme and Exact Sciences stock, which is subject to certain restrictions under university policy. The terms of these arrangements are managed by the Johns Hopkins University in accordance with its conflict-of- interest policies.	Chittenden TW, 2008, GENOMICS, V91, P508, DOI 10.1016/j.ygeno.2008.03.002; Edelman EJ, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.0040028; Efthimiou E, 2001, PANCREATOLOGY, V1, P571, DOI 10.1159/000055865; Ekins S, 2007, METH MOL B, V356, P319; Furukawa T, 1996, AM J PATHOL, V148, P1763; Greenman C, 2006, GENETICS, V173, P2187, DOI 10.1534/genetics.105.044677; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hartmann A, 1997, TRENDS GENET, V13, P27, DOI 10.1016/S0168-9525(96)10043-3; Hong OY, 2000, AM J PATHOL, V157, P1623, DOI 10.1016/S0002-9440(10)64800-6; Jaffee EM, 2002, CANCER CELL, V2, P25, DOI 10.1016/S1535-6108(02)00093-4; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Koorstra JBM, 2008, PANCREATOLOGY, V8, P110, DOI 10.1159/000123838; Lin J, 2007, GENOME RES, V17, P1304, DOI 10.1101/gr.6431107; Lister R, 2008, CELL, V133, P523, DOI 10.1016/j.cell.2008.03.029; Mimeault M, 2005, PANCREAS, V31, P301, DOI 10.1097/01.mpa.0000175893.04660.1b; Morin RD, 2008, BIOTECHNIQUES, V45, P81, DOI 10.2144/000112900; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Owens AH, 1982, TUMOR CELL HETEROGEN; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Sultan M, 2008, SCIENCE, V321, P956, DOI 10.1126/science.1160342; Tuveson DA, 2005, COLD SH Q B, V70, P65, DOI 10.1101/sqb.2005.70.040; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087	24	2844	2987	10	321	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	2008	321	5897					1801	1806		10.1126/science.1164368	http://dx.doi.org/10.1126/science.1164368			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	352MM	18772397	Green Accepted			2022-12-28	WOS:000259501300029
J	Chowdhury, EK; El Arifeen, S; Rahman, M; Hoque, DME; Hossain, MA; Begum, K; Siddik, A; Begum, N; Rahman, QSU; Akter, T; Haque, TM; Al-Helal, ZAM; Baqui, AH; Bryce, J; Black, RE				Chowdhury, Enayet K.; El Arifeen, Shams; Rahman, Muntasirur; Hoque, D. M. Emdadul; Hossain, M. Altaf; Begum, Khadija; Siddik, Ashraf; Begum, Nazma; Rahman, Qazi Sadeq-ur; Akter, Tasnima; Haque, Twaha M.; Al-Helal, Z. A. Motin; Baqui, Abdullah H.; Bryce, Jennifer; Black, Robert E.			Care at first-level facilities for children with severe pneumonia in Bangladesh: a cohort study	LANCET			English	Article							INTEGRATED MANAGEMENT; CHILDHOOD ILLNESS; ILL CHILDREN; HEALTH; STRATEGY	Background Guidelines on integrated management of childhood illness (IMCI) for severe pneumonia recommend referral to hospitals. However, in many settings, children who are referred do not actually attend hospital, which severely limits appropriate care. We aimed to assess the safety and effectiveness of modified guidelines that allowed most children with severe pneumonia to be treated locally in first-level facilities, with referral only for those with danger signs or other severe classifications. Methods We did an observational cohort study in ten first-level health facilities in Matlab, rural Bangladesh that had implemented IMCI guidelines. We assessed children with severe pneumonia who were aged between 2 and 59 months, and for whom we could obtain complete information, in two cohorts: 261 children who presented to these facilities between May, 2003, and April, 2004 (before implementation of the modified guidelines) and 1271 children between September, 2004, and August, 2005 (after full implementation). We obtained information about the characteristics and management of their illness, including referrals and admissions to hospital, from facility records. Staff visited households to obtain details of treatment, socioeconomic information, and final outcome, including mortality data. Findings 245 (94%) of 261 children who had severe pneumonia were referred to hospital before the guidelines were modified, compared with 1.07 (8%) of 1271 after implementation (p<0.0001). 94 (36%) children with severe pneumonia received correct management before the guidelines were modified, compared with 1145 (90%) children after implementation (p<0.0001). Before modification of the guidelines, three children with severe pneumonia who presented at first-level facilities died, with a case-fatality rate of 1. 1%; after modification, seven children died, with a case-fatality rate of 0 . 6% (p=0 . 39). Interpretation Local adaptation of the IMCI guidelines, with appropriate training and supervision, could allow safe and effective management of severe pneumonia, especially if compliance with referral is difficult because of geographic, financial, or cultural barriers. Funding Bill & Melinda Gates Foundation, WHO's Department of Child and Adolescent Health and Development, US Agency for International Development.	[Chowdhury, Enayet K.; El Arifeen, Shams; Rahman, Muntasirur; Hoque, D. M. Emdadul; Begum, Khadija; Siddik, Ashraf; Begum, Nazma; Rahman, Qazi Sadeq-ur; Akter, Tasnima; Haque, Twaha M.] Int Ctr Diarrhoeal Dis Res, Dhaka 1212, Bangladesh; [Hossain, M. Altaf; Al-Helal, Z. A. Motin] Govt Bangladesh, Directorate Gen Hlth Serv, Dhaka, Bangladesh; [Baqui, Abdullah H.; Bryce, Jennifer; Black, Robert E.] Johns Hopkins Bloomberg Sch Publ, Dept Int Hlth, Baltimore, MD USA	International Centre for Diarrhoeal Disease Research (ICDDR); Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	El Arifeen, S (corresponding author), Int Ctr Diarrhoeal Dis Res, 68 Shahid Tajuddin Ahmed Sharani, Dhaka 1212, Bangladesh.	shams@icddrb.org	Hoque, Dewan Md. Emdadul/J-1999-2019; Rahman, Muntasirur/U-8829-2017; Hoque, Dewan/O-3606-2015; Begum, Khadija/AAX-9372-2021; Akter, Tasnima/AAX-6255-2020; Chowdhury, Enayet/I-1267-2019	Hoque, Dewan Md. Emdadul/0000-0001-8219-9196; Rahman, Muntasirur/0000-0003-3800-7489; Hoque, Dewan/0000-0001-8219-9196; Begum, Khadija/0000-0001-7333-8596; Chowdhury, Enayet/0000-0002-9709-794X; Black, Robert/0000-0001-9926-7984; Arifeen, Shams/0000-0002-5372-5932	Bill and Melinda Gates Foundation; WHO's Department of Child and Adolescent Health and Development and of Cooperative Agreement [#388-A-00-97-00032-00]; US Agency for International Development; Department of Child and Adolescent Health and Development of WHO	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); WHO's Department of Child and Adolescent Health and Development and of Cooperative Agreement; US Agency for International Development(United States Agency for International Development (USAID)); Department of Child and Adolescent Health and Development of WHO	We thank the Government of Bangladesh for continued Support for the study and for the development and implementation of the modified guideline; the mothers and children who participated in the study; the MCE Technical Advisors and Robert Scherpbier of WHO, Child and Adolescent Health and Development (CAH), for providing important suggestions and guidance throughout the study: and Shamim Qazi of WHO, CAH, who reviewed air early draft. This study was done at the International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B) with support from the Bill and Melinda Gates Foundation through a grant to the WHO's Department of Child and Adolescent Health and Development and of Cooperative Agreement #388-A-00-97-00032-00 from the US Agency for International Development. This article is part of the Multi-Country Evaluation of IMCI Effectiveness, Cost and Impact (MCE), which is arranged, coordinated, and funded by the Department of Child and Adolescent Health and Development of WHO.	Al Fadil SM, 2003, B WORLD HEALTH ORGAN, V81, P708; ALDOYOBO E, 2004, LANCET, V364, P1141; Bryce J, 2004, AM J PUBLIC HEALTH, V94, P406, DOI 10.2105/AJPH.94.3.406; El Arifeen S, 2004, LANCET, V364, P1595, DOI 10.1016/S0140-6736(04)17312-1; Font Fidel, 2002, BMC Int Health Hum Rights, V2, P4, DOI 10.1186/1472-698X-2-4; Gove S, 1997, B WORLD HEALTH ORGAN, V75, P7; Hazir T, 2008, LANCET, V371, P49, DOI 10.1016/S0140-6736(08)60071-9; International Centre for Diarrhoeal Disease Research Bangladesh (ICDDR B), 2003, HLTH DEM SURV SYST M; Kalter HD, 2003, ACTA PAEDIATR, V92, P103; Kalter HD, 1997, B WORLD HEALTH ORGAN, V75, P65; Nolan T, 2001, LANCET, V357, P106, DOI 10.1016/S0140-6736(00)03542-X; Peterson S, 2004, LANCET, V363, P1955, DOI 10.1016/S0140-6736(04)16411-8; Rojas MX, 2006, COCHRANE DB SYST REV, V2; Rudan I, 2004, B WORLD HEALTH ORGAN, V82, P895; Simoes EAF, 2003, B WORLD HEALTH ORGAN, V81, P522; Tulloch J, 1999, LANCET, V354, pS16; *USAID, 2001, DEM HLTH SURV MEAS D; Victora CG, 2003, LANCET, V362, P233, DOI 10.1016/S0140-6736(03)13917-7; *WHO, 1998, WHOCHD98; *WHO DEP CHILD AD, 2000, WHOFCHCAH001; *WHO DEP CHILD AD, INT MAN CHILDH ILLN; *WHO UNICEF, 1997, WHOCHD973K; *WHO UNICEF, 2007, IMCI CHART BOOKL; *WHO UNICEF, 1997, INT MAN CHILDH ILLN; 1997, B WHO, V75, P122	25	40	41	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 6	2008	372	9641					822	830		10.1016/S0140-6736(08)61166-6	http://dx.doi.org/10.1016/S0140-6736(08)61166-6			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	347FB	18715634				2022-12-28	WOS:000259124900025
J	Goldston, D				Goldston, David			Big data: Data wrangling	NATURE			English	Editorial Material									[Goldston, David] House Comm Sci, Washington, DC 20515 USA			partyofone@gmail.com							0	18	25	3	110	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	2008	455	7209					15	15		10.1038/455015a	http://dx.doi.org/10.1038/455015a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	343XS	18769410	Bronze			2022-12-28	WOS:000258890200009
J	Wang, XM; Harris, RE; Bayston, LJ; Ashe, HL				Wang, Xiaomeng; Harris, Robin E.; Bayston, Laura J.; Ashe, Hilary L.			Type IV collagens regulate BMP signalling in Drosophila	NATURE			English	Article							BONE MORPHOGENETIC PROTEINS; GERMLINE STEM-CELLS; BASEMENT-MEMBRANE; DPP; GRADIENT; EMBRYO; SOG; DIFFERENTIATION; STIMULATION; BINDING	Dorsal-ventral patterning in vertebrate and invertebrate embryos is mediated by a conserved system of secreted proteins that establishes a bone morphogenetic protein (BMP) gradient. Although the Drosophila embryonic Decapentaplegic ( Dpp) gradient has served as a model to understand how morphogen gradients are established, no role for the extracellular matrix has been previously described. Here we show that type IV collagen extracellular matrix proteins bind Dpp and regulate its signalling in both the Drosophila embryo and ovary. We provide evidence that the interaction between Dpp and type IV collagen augments Dpp signalling in the embryo by promoting gradient formation, yet it restricts the signalling range in the ovary through sequestration of the Dpp ligand. Together, these results identify a critical function of type IV collagens in modulating Dpp in the extracellular space during Drosophila development. On the basis of our findings that human type IV collagen binds BMP4, we predict that this role of type IV collagens will be conserved.	[Wang, Xiaomeng; Harris, Robin E.; Bayston, Laura J.; Ashe, Hilary L.] Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Ashe, HL (corresponding author), Univ Manchester, Fac Life Sci, Oxford Rd, Manchester M13 9PT, Lancs, England.	hilary.ashe@manchester.ac.uk	Wang, Xiaomeng/F-9504-2015; Harris, Robin/ABA-6788-2020	Harris, Robin/0000-0001-6945-6741; Wang, Xiaomeng/0000-0002-1036-2764	BBSRC project grant; Biotechnology and Biological Sciences Research Council [BBS/B/11672] Funding Source: researchfish	BBSRC project grant(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	We thank M. O'Connor for plasmids, flies and advice on Dpp-HA staining; W. Chia, R. Ray and the Bloomington stock centre for fly stocks; E. Bier, P. ten Dijke, H. Bellen, L. Fessler and D. McKearin for antibodies; T. Jowitt for help with SPR; S. Lunj, M. Ronshaugen and W. Song for help; M. Ashe and W. Miles for reading the manuscript; and M. Levine whose laboratory this work was initiated in. This work was funded by a BBSRC project grant to H. L. A. and a BBSRC studentship to R. E. H.	Abe H, 2004, J BIOL CHEM, V279, P14201, DOI 10.1074/jbc.M310427200; Ashe HL, 2000, DEVELOPMENT, V127, P3305; Ashe HL, 2005, CURR BIOL, V15, pR375, DOI 10.1016/j.cub.2005.05.003; Ashe HL, 1999, NATURE, V398, P427, DOI 10.1038/18892; Belenkaya TY, 2004, CELL, V119, P231, DOI 10.1016/j.cell.2004.09.031; Bessa PC, 2008, J TISSUE ENG REGEN M, V2, P81, DOI 10.1002/term.74; Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; BLUMBERG B, 1988, J BIOL CHEM, V263, P18328; Bobik A, 2006, ARTERIOSCL THROM VAS, V26, P1712, DOI 10.1161/01.ATV.0000225287.20034.2c; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Eldar A, 2002, NATURE, V419, P304, DOI 10.1038/nature01061; Harradine KA, 2006, ANN MED, V38, P403, DOI 10.1080/07853890600919911; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Khoshnoodi J, 2006, J BIOL CHEM, V281, P38117, DOI 10.1074/jbc.R600025200; Kirilly D, 2007, CELL RES, V17, P15, DOI 10.1038/sj.cr.7310123; Kishigami S, 2005, CYTOKINE GROWTH F R, V16, P265, DOI 10.1016/j.cytogfr.2005.04.002; KNIBIEHLER B, 1990, CELL DIFFER DEV, V30, P147, DOI 10.1016/0922-3371(90)90082-8; Larrain J, 2000, DEVELOPMENT, V127, P821; LEE HS, 1988, MOL CELL BIOL, V8, P4727, DOI 10.1128/MCB.8.11.4727; LUNSTRUM GP, 1988, J BIOL CHEM, V263, P18318; Maduzia LL, 1997, BIOCHEM BIOPH RES CO, V238, P595, DOI 10.1006/bbrc.1997.7353; MCKEARIN D, 1995, DEVELOPMENT, V121, P2937; Medioni C, 2005, DEVELOPMENT, V132, P3069, DOI 10.1242/dev.01886; Morin X, 2001, P NATL ACAD SCI USA, V98, P15050, DOI 10.1073/pnas.261408198; PARALKAR VM, 1992, J CELL BIOL, V119, P1721, DOI 10.1083/jcb.119.6.1721; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; Podos SD, 1999, TRENDS GENET, V15, P396, DOI 10.1016/S0168-9525(99)01854-5; Reddi AH, 2005, CYTOKINE GROWTH F R, V16, P249, DOI 10.1016/j.cytogfr.2005.04.003; Reed BH, 2004, CURR BIOL, V14, P372, DOI 10.1016/j.cub.2004.02.029; Ross JJ, 2001, NATURE, V410, P479, DOI 10.1038/35068578; Schock F, 2003, GENE DEV, V17, P597, DOI 10.1101/gad.1068403; Shimmi O, 2005, CELL, V120, P873, DOI 10.1016/j.cell.2005.02.009; Srinivasan S, 2002, DEV CELL, V2, P91, DOI 10.1016/S1534-5807(01)00097-1; Wang YC, 2005, NATURE, V434, P229, DOI 10.1038/nature03318; Xie T, 1998, CELL, V94, P251, DOI 10.1016/S0092-8674(00)81424-5; Yasothornsrikul S, 1997, GENE, V198, P17, DOI 10.1016/S0378-1119(97)00274-6; Yu K, 2000, DEVELOPMENT, V127, P2143	37	241	243	1	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2008	455	7209					72	U49		10.1038/nature07214	http://dx.doi.org/10.1038/nature07214			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	343XS	18701888				2022-12-28	WOS:000258890200038
J	Angell, M				Angell, Marcia			Industry-sponsored clinical research - A broken system	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ROFECOXIB; DOCUMENTS; TRIALS		Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Cambridge, MA 02115 USA	Harvard University	Angell, M (corresponding author), Harvard Univ, Sch Med, Dept Global Hlth & Social Med, 651 Huntington Ave, Cambridge, MA 02115 USA.	marcia_angell@hms.harvard.edu						Angell M., 2004, TRUTH DRUG CO THEY D; Bekelman JE, 2003, JAMA-J AM MED ASSOC, V289, P454, DOI 10.1001/jama.289.4.454; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Campbell EG, 2007, JAMA-J AM MED ASSOC, V298, P1779, DOI 10.1001/jama.298.15.1779; Cosgrove L, 2006, PSYCHOTHER PSYCHOSOM, V75, P154, DOI 10.1159/000091772; DeAngelis CD, 2008, JAMA-J AM MED ASSOC, V299, P1833, DOI 10.1001/jama.299.15.1833; Kondro W, 2004, CAN MED ASSOC J, V170, P783, DOI 10.1503/cmaj.1040213; Psaty BM, 2008, JAMA-J AM MED ASSOC, V299, P1813, DOI 10.1001/jama.299.15.1813; Ross JS, 2008, JAMA-J AM MED ASSOC, V299, P1800, DOI 10.1001/jama.299.15.1800; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Steinbrook R, 2005, NEW ENGL J MED, V352, P2160, DOI 10.1056/NEJMp048353; Taylor R, 2005, NATURE, V437, P1070, DOI 10.1038/4371070a; TULLER D, 2004, NY TIMES        0720, pD5; Turner EH, 2008, NEW ENGL J MED, V358, P252, DOI 10.1056/NEJMsa065779	14	168	170	0	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	2008	300	9					1069	1071		10.1001/jama.300.9.1069	http://dx.doi.org/10.1001/jama.300.9.1069			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	342YN	18768418				2022-12-28	WOS:000258819600024
J	Waksman, R				Waksman, Ron			Drug-eluting stents: is new necessarily better?	LANCET			English	Editorial Material							CORONARY STENT; THROMBOSIS		[Waksman, Ron] Washington Hosp Ctr, Washington, DC 20010 USA	MedStar Washington Hospital Center	Waksman, R (corresponding author), Washington Hosp Ctr, Washington, DC 20010 USA.	ron.waksman@medstar.net						Beohar N, 2007, JAMA-J AM MED ASSOC, V297, P1992, DOI 10.1001/jama.297.18.1992; Camenzind E, 2007, CIRCULATION, V115, P1440, DOI 10.1161/CIRCULATIONAHA.106.666800; Daemen J, 2007, LANCET, V369, P667, DOI 10.1016/S0140-6736(07)60314-6; Grube E, 2006, EXPERT REV MED DEVIC, V3, P731, DOI 10.1586/17434440.3.6.731; Joner M, 2008, J AM COLL CARDIOL, V52, P333, DOI 10.1016/j.jacc.2008.04.030; McFadden EP, 2004, LANCET, V364, P1519, DOI 10.1016/S0140-6736(04)17275-9; Moses JW, 2003, NEW ENGL J MED, V349, P1315, DOI 10.1056/NEJMoa035071; Pfisterer M, 2006, J AM COLL CARDIOL, V48, P2584, DOI 10.1016/j.jacc.2006.10.026; PINTO TL, 2007, CIRCULATION, V117, P1603; Stone GW, 2008, JAMA-J AM MED ASSOC, V299, P1903, DOI 10.1001/jama.299.16.1903; Stone GW, 2004, NEW ENGL J MED, V350, P221, DOI 10.1056/NEJMoa032441; WINDECKER S, 2008, LANCET          0901, DOI DOI 10.1016/S0140-6736(08)61244-1	12	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP-OCT	2008	372	9644					1126	1128		10.1016/S0140-6736(08)61245-3	http://dx.doi.org/10.1016/S0140-6736(08)61245-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	355UN	18765163				2022-12-28	WOS:000259734700006
J	Johnston, MI; Fauci, AS				Johnston, Margaret I.; Fauci, Anthony S.			An HIV vaccine - Challenges and prospects	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Johnston, Margaret I.; Fauci, Anthony S.] NIAID, Vaccine Res Program, Div AIDS, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Johnston, MI (corresponding author), NIAID, Vaccine Res Program, Div AIDS, 9000 Rockville Pike, Bethesda, MD 20892 USA.		Franzeck, Fabian C/B-5055-2011					Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233; Chun TW, 1998, P NATL ACAD SCI USA, V95, P8869, DOI 10.1073/pnas.95.15.8869; Fauci AS, 2008, SCIENCE, V321, P530, DOI 10.1126/science.1161000; Goulder PJR, 2008, NAT REV IMMUNOL, V8, P619, DOI 10.1038/nri2357; Johnston MI, 2007, NEW ENGL J MED, V356, P2073, DOI 10.1056/NEJMra066267	5	88	94	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 28	2008	359	9					888	890		10.1056/NEJMp0806162	http://dx.doi.org/10.1056/NEJMp0806162			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	341IU	18753644				2022-12-28	WOS:000258708300002
J	Wiener, RS; Wiener, DC; Larson, RJ				Soylemez Wiener, Renda; Wiener, Daniel C.; Larson, Robin J.			Benefits and risks of tight glucose control in critically ill adults - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE INSULIN THERAPY; RANDOMIZED CONTROLLED-TRIAL; SURVIVING SEPSIS CAMPAIGN; GLYCEMIC CONTROL; BLOOD-GLUCOSE; MYOCARDIAL-INFARCTION; ISCHEMIC-STROKE; CARE PRACTICE; MANAGEMENT; HYPERGLYCEMIA	Context The American Diabetes Association and Surviving Sepsis Campaign recommend tight glucose control in critically ill patients based largely on 1 trial that shows decreased mortality in a surgical intensive care unit. Because similar studies report conflicting results and tight glucose control can cause dangerous hypoglycemia, the data underlying this recommendation should be critically evaluated. Objective To evaluate benefits and risks of tight glucose control vs usual care in critically ill adult patients. Data Sources MEDLINE ( 1950- 2008), the Cochrane Library, clinical trial registries, reference lists, and abstracts from conferences from both the American Thoracic Society ( 2001- 2008) and the Society of Critical Care Medicine ( 2004- 2008). Study Selection We searched for studies in any language in which adult intensive care patients were randomly assigned to tight vs usual glucose control. Of 1358 identified studies, 34 randomized trials ( 23 full publications, 9 abstracts, 2 unpublished studies) met inclusion criteria. Data Extraction and Analysis Two reviewers independently extracted information using a prespecified protocol and evaluated methodological quality with a standardized scale. Study investigators were contacted for missing details. We used both random- and fixed- effects models to estimate relative risks ( RRs). Results Twenty- nine randomized controlled trials totaling 8432 patients contributed data for this meta- analysis. Hospital mortality did not differ between tight glucose control and usual care overall ( 21.6% vs 23.3%; RR, 0.93; 95% confidence interval [ CI], 0.85- 1.03). There was also no significant difference in mortality when stratified by glucose goal ([ 1] very tight: <= 110 mg/ dL; 23% vs 25.2%; RR, 0.90; 95% CI, 0.77- 1.04; or [ 2] moderately tight: < 150 mg/ dL; 17.3% vs 18.0%; RR, 0.99; 95% CI, 0.83- 1.18) or intensive care unit setting ([ 1] surgical: 8.8% vs 10.8%; RR, 0.88; 95% CI, 0.63- 1.22; [ 2] medical: 26.9% vs 29.7%; RR, 0.92; 95% CI, 0.82- 1.04; or [ 3] medical- surgical: 26.1% vs 27.0%; RR, 0.95; 95% CI, 0.80- 1.13). Tight glucose control was not associated with significantly decreased risk for new need for dialysis ( 11.2% vs 12.1%; RR, 0.96; 95% CI, 0.76- 1.20), but was associated with significantly decreased risk of septicemia ( 10.9% vs 13.4%; RR, 0.76; 95% CI, 0.59- 0.97), and significantly increased risk of hypoglycemia ( glucose <= 40 mg/ dL; 13.7% vs 2.5%; RR, 5.13; 95% CI, 4.09- 6.43). Conclusion In critically ill adult patients, tight glucose control is not associated with significantly reduced hospital mortality but is associated with an increased risk of hypoglycemia.	[Soylemez Wiener, Renda; Larson, Robin J.] Dept Vet Affairs Med Ctr, VA Outcomes Grp, White River Jct, VT 05009 USA; [Soylemez Wiener, Renda; Larson, Robin J.] Dartmouth Med Sch, Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH USA; [Wiener, Daniel C.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA	VA Outcomes Group; Dartmouth College; Dartmouth College	Wiener, RS (corresponding author), Dept Vet Affairs Med Ctr, VA Outcomes Grp, 111 B, White River Jct, VT 05009 USA.	renda.s.wiener@dartmouth.edu	Wiener, Renda/AAO-1557-2020	Wiener, Renda/0000-0001-7712-2135				*AACE DIAB MELL CL, 2007, ENDOCR PRACT S1, V13, P1; Amer Diabet Assoc, 2008, DIABETES CARE, V31, pS12, DOI 10.2337/dc08-S012; Angus DC, 2005, AM J RESP CRIT CARE, V172, P1358, DOI 10.1164/rccm.2508009; Arabi Y, 2006, CRIT CARE MED, V34, pA65, DOI 10.1097/00003246-200612002-00227; Aragon D, 2006, AM J CRIT CARE, V15, P370, DOI 10.4037/ajcc2006.15.4.370; Bellomo R, 2005, MAYO CLIN PROC, V80, P1546, DOI 10.4065/80.12.1546; Benito B, 2008, MED CLIN-BARCELONA, V130, P601, DOI 10.1157/13120338; Bilotta F, 2008, NEUROCRIT CARE, V9, P159, DOI 10.1007/s12028-008-9084-9; Bilotta Federico, 2007, J Neurosurg Anesthesiol, V19, P156, DOI 10.1097/ANA.0b013e3180338e69; Bland DK, 2005, AM J CRIT CARE, V14, P370; Bruno A, 2008, STROKE, V39, P384, DOI 10.1161/STROKEAHA.107.493544; DAVIES RR, 1991, SCOT MED J, V36, P74, DOI 10.1177/003693309103600303; DELAROSA GD, 2006, INTENS CARE MED, pS237; Dellinger RP, 2008, INTENS CARE MED, V34, P17, DOI 10.1007/s00134-007-0934-2; Dellinger RP, 2004, INTENS CARE MED, V30, P536, DOI 10.1007/s00134-004-2210-z; Farah R, 2007, ISRAEL MED ASSOC J, V9, P140; FERNANDEZ R, 2005, P AM THORAC SOC, V2, pA37; Gandhi GY, 2007, ANN INTERN MED, V146, P233, DOI 10.7326/0003-4819-146-4-200702200-00002; Gray CS, 2007, LANCET NEUROL, V6, P397, DOI 10.1016/S1474-4422(07)70080-7; Grey Neil J, 2004, Endocr Pract, V10 Suppl 2, P46; He Wei, 2007, Zhonghua Wai Ke Za Zhi, V45, P1052; HENDERSON WR, 2005, P AM THORAC SOC, V2, pA37; Hirshberg E, 2008, CHEST, V133, P1328, DOI 10.1378/chest.07-2702; Hoedemaekers CW, 2005, CRIT CARE, V9, pR790, DOI 10.1186/cc3911; *I HEALTHC IMPR, IMPL EFF GLUC CONTR; Iapichino G, 2008, INTENS CARE MED, V34, P1843, DOI 10.1007/s00134-008-1158-9; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; KIA M, 2005, 91 ANN CLIN C AM COL; Mackenzie I, 2005, INTENS CARE MED, V31, P1136, DOI 10.1007/s00134-005-2677-2; MACKENZIE IM, 2005, P AM THORAC SOC, V2, pA295; Malesker MA, 2007, AM J CRIT CARE, V16, P589; Malhotra A, 2006, NEW ENGL J MED, V354, P516, DOI 10.1056/NEJMe058304; McMullin J, 2004, INTENS CARE MED, V30, P798, DOI 10.1007/s00134-004-2242-4; McMullin J, 2007, J CRIT CARE, V22, P112, DOI 10.1016/j.jcrc.2006.08.002; Mechanick JI, 2007, CURR OPIN CLIN NUTR, V10, P193, DOI 10.1097/MCO.0b013e32802b7016; *MICH HLTH SAF COA, TOOLK INT CAR UN IMP; Mitchell Imogen, 2006, Crit Care Resusc, V8, P289; Mitchell I, 2006, INTENS CARE MED, V32, P867, DOI 10.1007/s00134-006-0135-4; Oksanen T, 2007, INTENS CARE MED, V33, P2093, DOI 10.1007/s00134-007-0876-8; Preiser JC, 2007, INTENS CARE MED, V33, P570, DOI 10.1007/s00134-006-0485-y; Robinson KA, 2002, INT J EPIDEMIOL, V31, P150, DOI 10.1093/ije/31.1.150; SABERI AA, 2004, P AM THORAC SOC, V1, pA38; Schultz MJ, 2006, PLOS MED, V3, P2177, DOI 10.1371/journal.pmed.0030456; Schultz MJ, 2006, INTENS CARE MED, V32, P618, DOI 10.1007/s00134-006-0099-4; STECHER A, 2006, EUR TRAUM C MAY 24 2; Stefanidis A, 2002, ACTA CARDIOL, V57, P357, DOI 10.2143/AC.57.5.2005453; Treggiari MM, 2008, CRIT CARE, V12, DOI 10.1186/cc6807; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; van Wezel HB, 2006, J CLIN ENDOCR METAB, V91, P4144, DOI 10.1210/jc.2006-1199; Vriesendorp TM, 2006, CRIT CARE MED, V34, P2714, DOI 10.1097/01.CCM.0000241155.36689.91; Walters MR, 2006, CEREBROVASC DIS, V22, P116, DOI 10.1159/000093239; Wang Ling-cong, 2006, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V18, P748; Yu Wen-kui, 2005, Zhonghua Wai Ke Za Zhi, V43, P29	55	705	743	0	29	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2008	300	8					933	944		10.1001/jama.300.8.933	http://dx.doi.org/10.1001/jama.300.8.933			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	341AR	18728267	Bronze			2022-12-28	WOS:000258687100028
J	Barr, MS				Barr, Michael S.			The need to test the patient-centered medical home	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PRIMARY-CARE; HEALTH		Amer Coll Phys Inc, Washington, DC 20001 USA		Barr, MS (corresponding author), Amer Coll Phys Inc, 25 Massachusetts Ave NW,Suite 700, Washington, DC 20001 USA.	mbarr@acponline.org						*AM COLL PHYS, PAT CTR MED HOM OV; American College of Physicians, 2007, JOINT PRINC PAT CTR; [Anonymous], 2008, ANN INTERN MED, V148, P55, DOI 10.7326/0003-4819-148-1-200801010-00196; BARR MS, ADV MED HOME PATIENT; Collwill JM, 2008, HEALTH AFFAIR, V27, pW232, DOI 10.1377/hlthaff.27.3.w232; Davis K, 2007, MIRROR MIRROR WALL I; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; *FUT FAM MED PROJ, 2004, ANN FAM MED S, V1, pS3; Institute of Medicine , 2008, RETOOLING AGING AM B; Leatherman S., 2005, QUALITY HLTH CARE ME; Lipner RS, 2006, ANN INTERN MED, V144, P29, DOI 10.7326/0003-4819-144-1-200601030-00007; Nolte E, 2008, HEALTH AFFAIR, V27, P58, DOI 10.1377/hlthaff.27.1.58; Sepulveda MJ, 2008, HEALTH AFFAIR, V27, P151, DOI 10.1377/hlthaff.27.1.151; Starfield B, 2005, MILBANK Q, V83, P457, DOI 10.1111/j.1468-0009.2005.00409.x	14	78	78	1	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	2008	300	7					834	835		10.1001/jama.300.7.834	http://dx.doi.org/10.1001/jama.300.7.834			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	338VM	18714064				2022-12-28	WOS:000258537500024
J	Young, RF				Young, Ryland F., III			Molecular biology - Secret weapon	SCIENCE			English	Editorial Material							STREPTOCOCCUS-THERMOPHILUS; REPEATS; PROKARYOTES; RESISTANCE; ELEMENTS; GENES; DNA		Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Young, RF (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.	ryland@tamu.edu		Young, Ry/0000-0001-8001-2914	NIGMS NIH HHS [R01 GM027099] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersson AF, 2008, SCIENCE, V320, P1047, DOI 10.1126/science.1157358; Barrangou R, 2007, SCIENCE, V315, P1709, DOI 10.1126/science.1138140; Bolotin A, 2005, MICROBIOL-SGM, V151, P2551, DOI 10.1099/mic.0.28048-0; Brouns SJJ, 2008, SCIENCE, V321, P960, DOI 10.1126/science.1159689; Deveau H, 2008, J BACTERIOL, V190, P1390, DOI 10.1128/JB.01412-07; Haft DH, 2005, PLOS COMPUT BIOL, V1, P474, DOI 10.1371/journal.pcbi.0010060; Horvath P, 2008, J BACTERIOL, V190, P1401, DOI 10.1128/JB.01415-07; Jansen R, 2002, MOL MICROBIOL, V43, P1565, DOI 10.1046/j.1365-2958.2002.02839.x; Makarova KS, 2006, BIOL DIRECT, V1, DOI 10.1186/1745-6150-1-7; Mojica FJM, 2005, J MOL EVOL, V60, P174, DOI 10.1007/s00239-004-0046-3; Pourcel C, 2005, MICROBIOL-SGM, V151, P653, DOI 10.1099/mic.0.27437-0; Qimron U, 2006, P NATL ACAD SCI USA, V103, P19039, DOI 10.1073/pnas.0609428103	12	7	7	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2008	321	5891					922	923		10.1126/science.1162910	http://dx.doi.org/10.1126/science.1162910			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	337LD	18703730	Green Accepted			2022-12-28	WOS:000258436700025
J	Koglin, A; Lohr, F; Bernhard, F; Rogov, VV; Frueh, DP; Strieter, ER; Mofid, MR; Guntert, P; Wagner, G; Walsh, CT; Marahiel, MA; Dotsch, V				Koglin, Alexander; Loehr, Frank; Bernhard, Frank; Rogov, Vladimir V.; Frueh, Dominique P.; Strieter, Eric R.; Mofid, Mohammad R.; Guentert, Peter; Wagner, Gerhard; Walsh, Christopher T.; Marahiel, Mohamed A.; Doetsch, Volker			Structural basis for the selectivity of the external thioesterase of the surfactin synthetase	NATURE			English	Article							ACYL CARRIER PROTEIN; PEPTIDE SYNTHETASES; CHEMICAL-SHIFT; POLYKETIDE; BIOSYNTHESIS; MACROCYCLIZATION; RESTRAINTS; DYNAMICS; SYNTHASE; DATABASE	Non-ribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) found in bacteria, fungi and plants use two different types of thioesterases for the production of highly active biological compounds(1,2). Type I thioesterases (TEI) catalyse the release step from the assembly line(3) of the final product where it is transported from one reaction centre to the next as a thioester linked to a 4 '-phosphopantetheine (4 '-PP) cofactor that is covalently attached to thiolation (T) domains(4-9). The second enzyme involved in the synthesis of these secondary metabolites, the type II thioesterase (TEII), is a crucial repair enzyme for the regeneration of functional 4 '-PP cofactors of holo-T domains of NRPS and PKS systems(10-12). Mispriming of 4 '-PP cofactors by acetyl- and short-chain acyl-residues interrupts the biosynthetic system. This repair reaction is very important, because roughly 80% of CoA, the precursor of the 4 '-PP cofactor, is acetylated in bacteria(13). Here we report the three-dimensional structure of a type II thioesterase from Bacillus subtilis free and in complex with a T domain. Comparison with structures of TEI enzymes(3,14) shows the basis for substrate selectivity and the different modes of interaction of TEII and TEI enzymes with T domains. Furthermore, we show that the TEII enzyme exists in several conformations of which only one is selected on interaction with its native substrate, a modified holo-T domain.	[Koglin, Alexander; Loehr, Frank; Bernhard, Frank; Rogov, Vladimir V.; Guentert, Peter; Doetsch, Volker] Goethe Univ Frankfurt, Inst Biophys Chem, D-60438 Frankfurt, Germany; [Koglin, Alexander; Loehr, Frank; Bernhard, Frank; Rogov, Vladimir V.; Guentert, Peter; Doetsch, Volker] Goethe Univ Frankfurt, Ctr Biomol Magnet Resonance & Cluster Excellence, D-60438 Frankfurt, Germany; [Koglin, Alexander; Frueh, Dominique P.; Strieter, Eric R.; Wagner, Gerhard; Walsh, Christopher T.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Rogov, Vladimir V.] Russian Acad Sci, Inst Prot Res, Pushchino 142290, Russia; [Mofid, Mohammad R.; Marahiel, Mohamed A.] Univ Marburg, Dept Chem Biochem, D-35032 Marburg, Germany; [Guentert, Peter] Frankfurt Inst Adv Studies, D-60438 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt; Harvard University; Harvard Medical School; Russian Academy of Sciences; Philipps University Marburg	Dotsch, V (corresponding author), Goethe Univ Frankfurt, Inst Biophys Chem, D-60438 Frankfurt, Germany.	Christopher_Walsh@hms.harvard.edu; Marahiel@chemie.uni-marburg.de; VDoetsch@em.uni-frankfurt.de	Güntert, Peter/L-5577-2013; Doetsch, Volker/D-5697-2011; Frueh, Dominique P/A-6462-2008	Güntert, Peter/0000-0002-2911-7574; Frueh, Dominique P/0000-0003-4605-3776; Bernhard, Frank/0000-0002-4860-1783; mofid, mohammad reza/0000-0002-0347-8152; Dotsch, Volker/0000-0001-5720-212X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB002026] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM047467, R01GM049338, R01GM020011] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI042738-09, R01 AI042738] Funding Source: Medline; NIBIB NIH HHS [P41 EB002026-29, P41 EB002026-30, P41 EB002026-32, P41 EB002026-33, P41 EB002026-31, P41 EB002026] Funding Source: Medline; NIGMS NIH HHS [R01 GM020011-32, P01 GM047467, R01 GM020011, P01 GM047467-170012, R01 GM020011-30, P01 GM047467-15, P01 GM047467-17, P01 GM047467-14, R01 GM020011-37, R01 GM020011-31, P01 GM047467-12, R01 GM049338-17, R01 GM020011-28, R01 GM020011-29, P01 GM047467-16, R01 GM049338, P01 GM047467-160010, R01 GM020011-38, P01 GM047467-110009, P01 GM047467-13, P01 GM047467-160012] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; Belshaw PJ, 1999, SCIENCE, V284, P486, DOI 10.1126/science.284.5413.486; Bruner SD, 2002, STRUCTURE, V10, P301, DOI 10.1016/S0969-2126(02)00716-5; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cobas JC, 2003, CONCEPT MAGN RESON A, V19A, P80, DOI 10.1002/cmr.a.10089; Conti E, 1997, EMBO J, V16, P4174, DOI 10.1093/emboj/16.14.4174; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Dundas J, 2006, NUCLEIC ACIDS RES, V34, pW116, DOI 10.1093/nar/gkl282; Ferentz AE, 2000, Q REV BIOPHYS, V33, P29, DOI 10.1017/S0033583500003589; Findlow SC, 2003, BIOCHEMISTRY-US, V42, P8423, DOI 10.1021/bi0342259; Frueh DP, 2006, J BIOMOL NMR, V34, P31, DOI 10.1007/s10858-005-5338-4; Gardner KH, 1997, J AM CHEM SOC, V119, P7599, DOI 10.1021/ja9706514; Gehring AM, 1998, BIOCHEMISTRY-US, V37, P2648, DOI 10.1021/bi9726584; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Guntert Peter, 2004, Methods Mol Biol, V278, P353; IKURA M, 1991, Journal of Biomolecular NMR, V1, P299, DOI 10.1007/BF01875522; Jenni S, 2007, SCIENCE, V316, P254, DOI 10.1126/science.1138248; Johnson MA, 2006, PROTEIN SCI, V15, P1030, DOI 10.1110/ps.051964606; KIM Y, 1989, BIOCHEMISTRY-US, V28, P8792, DOI 10.1021/bi00448a017; Koglin A, 2006, SCIENCE, V312, P273, DOI 10.1126/science.1122928; Kopp F, 2007, NAT PROD REP, V24, P735, DOI 10.1039/b613652b; Lai JR, 2006, BIOCHEMISTRY-US, V45, P14869, DOI 10.1021/bi061979p; Leibundgut M, 2007, SCIENCE, V316, P288, DOI 10.1126/science.1138249; Liang J, 1998, PROTEIN SCI, V7, P1884, DOI 10.1002/pro.5560070905; Linne U, 2004, EUR J BIOCHEM, V271, P1536, DOI 10.1111/j.1432-1033.2004.04063.x; Meier JL, 2006, J AM CHEM SOC, V128, P12174, DOI 10.1021/ja063217n; Nederveen AJ, 2005, PROTEINS, V59, P662, DOI 10.1002/prot.20408; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Salzmann M, 1998, P NATL ACAD SCI USA, V95, P13585, DOI 10.1073/pnas.95.23.13585; Samel SA, 2007, STRUCTURE, V15, P781, DOI 10.1016/j.str.2007.05.008; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Schneider A, 1998, ARCH MICROBIOL, V169, P404, DOI 10.1007/s002030050590; Schwarzer D, 2002, P NATL ACAD SCI USA, V99, P14083, DOI 10.1073/pnas.212382199; Sieber SA, 2003, J AM CHEM SOC, V125, P10862, DOI 10.1021/ja0361852; Steller S, 2004, BIOCHEMISTRY-US, V43, P11331, DOI 10.1021/bi0493416; Walsh CT, 2004, SCIENCE, V303, P1805, DOI 10.1126/science.1094318; Yeh E, 2004, CHEMBIOCHEM, V5, P1290, DOI 10.1002/cbic.200400077; Zornetzer GA, 2006, BIOCHEMISTRY-US, V45, P5217, DOI 10.1021/bi052062d; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	40	101	111	1	71	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 14	2008	454	7206					907	U68		10.1038/nature07161	http://dx.doi.org/10.1038/nature07161			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	336XH	18704089	Green Accepted			2022-12-28	WOS:000258398600041
J	Hay, AD; Costelloe, C; Redmond, NM; Montgomery, AA; Fletcher, M; Hollinghurst, S; Peters, TJ				Hay, Alastair D.; Costelloe, Ceire; Redmond, Niamh M.; Montgomery, Alan A.; Fletcher, Margaret; Hollinghurst, Sandra; Peters, Tim J.			Paracetamol plus ibuprofen for the treatment of fever in children (PITCH): randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PRESCHOOL-CHILDREN; ACETAMINOPHEN; PLACEBO; PARENTS	Objective To investigate whether paracetamol ( acetaminophen) plus ibuprofen are superior to either drug alone for increasing time without fever and the relief of fever associated discomfort in febrile children managed at home. Design Individually randomised, blinded, three arm trial. Setting Primary care and households in England. Participants Children aged between 6 months and 6 years with axillary temperatures of at least 37.8 degrees C and up to 41.0 degrees C. Intervention Advice on physical measures to reduce temperature and the provision of, and advice to give, paracetamol plus ibuprofen, paracetamol alone, or ibuprofen alone. Main outcome measures Primary outcomes were the time without fever (<37.2 degrees C) in the first four hours after the first dose was given and the proportion of children reported as being normal on the discomfort scale at 48 hours. Secondary outcomes were time to first occurrence of normal temperature ( fever clearance), time without fever over 24 hours, fever associated symptoms, and adverse effects. Results On an intention to treat basis, paracetamol plus ibuprofen were superior to paracetamol for less time with fever in the first four hours ( adjusted difference 55 minutes, 95% confidence interval 33 to 77; P< 0.001) and may have been as good as ibuprofen ( 16 minutes, - 7 to 39; P= 0.2). For less time with fever over 24 hours, paracetamol plus ibuprofen were superior to paracetamol ( 4.4 hours, 2.4 to 6.3; P< 0.001) and to ibuprofen ( 2.5 hours, 0.6 to 4.4; P= 0.008). Combined therapy cleared fever 23 minutes ( 2 to 45; P= 0.025) faster than paracetamol alone but no faster than ibuprofen alone (- 3 minutes, 18 to - 24; P= 0.8). No benefit was found for discomfort or other symptoms, although power was low for these outcomes. Adverse effects did not differ between groups. Conclusion Parents, nurses, pharmacists, and doctors wanting to use medicines to supplement physical measures to maximise the time that children spend without fever should use ibuprofen first and consider the relative benefits and risks of using paracetamol plus ibuprofen over 24 hours. Trial registration Current Controlled Trials ISRCTN26362730.	[Hay, Alastair D.; Costelloe, Ceire; Redmond, Niamh M.; Montgomery, Alan A.; Hollinghurst, Sandra; Peters, Tim J.] Univ Bristol, Acad Unit Primary Hlth Care, NIHR Natl Sch Primary Care Res, Dept Community Based Med, Bristol BS8 2AA, Avon, England; [Fletcher, Margaret] Univ W England, Fac Hlth & Social Care, Bristol BS16 1QY, Avon, England	University of Bristol; University of West England	Hay, AD (corresponding author), Univ Bristol, Acad Unit Primary Hlth Care, NIHR Natl Sch Primary Care Res, Dept Community Based Med, Bristol BS8 2AA, Avon, England.	alastair.hay@bristol.ac.uk	Hay, Alastair/L-1818-2019	Redmond, Niamh M/0000-0001-8814-3396; Hay, Alastair/0000-0003-3012-375X; Montgomery, Alan/0000-0003-0450-1606; Peters, Tim/0000-0003-2881-4180	Department of Health [03/09/01] Funding Source: Medline; National Institute for Health Research [03/09/01, PC6/PDA04/10] Funding Source: researchfish	Department of Health; National Institute for Health Research(National Institute for Health Research (NIHR))		Aronoff DM, 2001, AM J MED, V111, P304, DOI 10.1016/S0002-9343(01)00834-8; BREWER EJ, 1968, ARTHRITIS RHEUM-US, V11, P645, DOI 10.1002/art.1780110506; *BRIT MED ASS ROYA, 2007, BNF CHILDR; Bua J, 2008, ARCH DIS CHILD, V93, P546, DOI 10.1136/adc.2008.139097; Craig JV, 2000, BRIT MED J, V320, P1174, DOI 10.1136/bmj.320.7243.1174; Erlewyn-Lajeunesse MDS, 2006, ARCH DIS CHILD, V91, P414, DOI 10.1136/adc.2005.087874; Hay AD, 2005, FAM PRACT, V22, P367, DOI 10.1093/fampra/cmi035; HOLLINGHURST S, 2008, BMJ IN PRESS; John CM, 2007, ARCH DIS CHILD, V92, P524, DOI 10.1136/adc.2006.103564; Kai J, 1996, BRIT MED J, V313, P983; KELLEY MT, 1992, CLIN PHARMACOL THER, V52, P181, DOI 10.1038/clpt.1992.128; KINMONTH AL, 1992, BRIT MED J, V305, P1134, DOI 10.1136/bmj.305.6862.1134; KRAMER LC, 2008, CLIN PEDIAT PHI 0616; Lal Avtar, 2000, Indian Journal of Pediatrics, V67, P865, DOI 10.1007/BF02723945; Lesko SM, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e20; MEREMIKWU M, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004264; MICHAEL MS, 2004, VACCINE, V22, P551; Moghal NE, 2004, ARCH DIS CHILD, V89, P276, DOI 10.1136/adc.2002.024141; Nabulsi MM, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-4; *NAT I HLTH CLIN E, 2007, FEV ILLN CHILDR ASS; Perrott DA, 2004, ARCH PEDIAT ADOL MED, V158, P521, DOI 10.1001/archpedi.158.6.521; Sarrell EM, 2006, ARCH PEDIAT ADOL MED, V160, P197, DOI 10.1001/archpedi.160.2.197; Sarrell M, 2002, PATIENT EDUC COUNS, V46, P61, DOI 10.1016/S0738-3991(01)00160-4; Treasure T, 1998, BRIT MED J, V317, P362; WALSON PD, 1989, CLIN PHARMACOL THER, V46, P9, DOI 10.1038/clpt.1989.100; Western Australia Commissioner for Children and Young People, 2020, NAT SERV FRAM CHILDR; WILSON JT, 1991, J PEDIATR-US, V119, P803, DOI 10.1016/S0022-3476(05)80307-5; Zar J., 1994, BIOSTATISTICAL ANAL; 1991, LANCET, V338, P1049	29	51	55	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 27	2008	337	7672							a1302	10.1136/bmj.a1302	http://dx.doi.org/10.1136/bmj.a1302			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	356SJ	18765450	Green Published, hybrid, Green Submitted			2022-12-28	WOS:000259797600037
J	Dietrich, LEP; Teal, TK; Price-Whelan, A; Newman, DK				Dietrich, Lars E. P.; Teal, Tracy K.; Price-Whelan, Alexa; Newman, Dianne K.			Redox-active antibiotics control gene expression and community behavior in divergent bacteria	SCIENCE			English	Article							PSEUDOMONAS-AERUGINOSA PA14; ESCHERICHIA-COLI; STREPTOMYCES-COELICOLOR; PHENAZINE ANTIBIOTICS; SUPEROXIDE STRESS; SOXR; BIOSYNTHESIS; PYOCYANIN; VIRULENCE; PARADIGM	It is thought that bacteria excrete redox- active pigments as antibiotics to inhibit competitors. In Pseudomonas aeruginosa, the endogenous antibiotic pyocyanin activates SoxR, a transcription factor conserved in Proteo- and Actinobacteria. In Escherichia coli, SoxR regulates the superoxide stress response. Bioinformatic analysis coupled with gene expression studies in P. aeruginosa and Streptomyces coelicolor revealed that the majority of SoxR regulons in bacteria lack the genes required for stress responses, despite the fact that many of these organisms still produce redox- active small molecules, which indicates that redox- active pigments play a role independent of oxidative stress. These compounds had profound effects on the structural organization of colony biofilms in both P. aeruginosa and S. coelicolor, which shows that "secondary metabolites" play important conserved roles in gene expression and development.	[Dietrich, Lars E. P.; Price-Whelan, Alexa; Newman, Dianne K.] MIT, Dept Biol, Cambridge, MA 01239 USA; [Newman, Dianne K.] MIT, Dept Earth & Planetary Sci, Cambridge, MA 01239 USA; [Dietrich, Lars E. P.; Newman, Dianne K.] MIT, Howard Hughes Med Inst, Cambridge, MA 01239 USA; [Teal, Tracy K.; Price-Whelan, Alexa] CALTECH, Div Biol, Pasadena, CA 91125 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); California Institute of Technology	Newman, DK (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 01239 USA.	dkn@mit.edu	Price-Whelan, Alexa/B-6045-2009	Price-Whelan, Alexa/0000-0001-7587-7534; Dietrich, Lars/0000-0003-2049-1137	EMBO Long Term Fellowship; Packard Foundation and Howard Hughes Medical Institute	EMBO Long Term Fellowship(European Molecular Biology Organization (EMBO)); Packard Foundation and Howard Hughes Medical Institute	We thank P. Straight (Harvard University); M. Bibb and A. Hesketh (John Innes Centre, UK) for providing S. coelicolor A3(2) strains M145 and M512; and N. C. Caiazza, C. T. Brown, and B. Wold for helpful discussions. This work was supported by an EMBO Long Term Fellowship (L.E.P.D.) and grants from the Packard Foundation and Howard Hughes Medical Institute (D.K.N.).	Aendekerk S, 2005, MICROBIOL-SGM, V151, P1113, DOI 10.1099/mic.0.27631-0; Chater KF, 2006, PHILOS T R SOC B, V361, P761, DOI 10.1098/rstb.2005.1758; CUNDLIFFE E, 1989, ANNU REV MICROBIOL, V43, P207, DOI 10.1146/annurev.micro.43.1.207; Davies DG, 1998, SCIENCE, V280, P295, DOI 10.1126/science.280.5361.295; Dietrich LEP, 2006, MOL MICROBIOL, V61, P1308, DOI 10.1111/j.1365-2958.2006.05306.x; Eiamphungporn W, 2006, J BACTERIOL, V188, P8669, DOI 10.1128/JB.00856-06; Floriano B, 1996, MOL MICROBIOL, V21, P385, DOI 10.1046/j.1365-2958.1996.6491364.x; Friedman L, 2004, MOL MICROBIOL, V51, P675, DOI 10.1046/j.1365-2958.2003.03877.x; Hernandez ME, 2004, APPL ENVIRON MICROB, V70, P921, DOI 10.1128/AEM.70.2.921-928.2004; Hernandez ME, 2001, CELL MOL LIFE SCI, V58, P1562, DOI 10.1007/PL00000796; Hopwood DA, 2007, STREPTOMYCES NATURE; Kobayashi K, 2004, J BIOCHEM, V136, P607, DOI 10.1093/jb/mvh168; Li XZ, 2000, J ANTIMICROB CHEMOTH, V46, P885, DOI 10.1093/jac/46.6.885; Liochev SI, 1999, J BIOL CHEM, V274, P9479, DOI 10.1074/jbc.274.14.9479; Maddula VSRK, 2006, MICROB ECOL, V52, P289, DOI 10.1007/s00248-006-9064-6; Mahajan-Miklos S, 1999, CELL, V96, P47, DOI 10.1016/S0092-8674(00)80958-7; Mavrodi DV, 2006, ANNU REV PHYTOPATHOL, V44, P417, DOI 10.1146/annurev.phyto.44.013106.145710; MAZZOLA M, 1992, APPL ENVIRON MICROB, V58, P2616, DOI 10.1128/AEM.58.8.2616-2624.1992; Palma M, 2005, INFECT IMMUN, V73, P2958, DOI 10.1128/IAI.73.5.2958-2966.2005; Park W, 2006, BIOCHEM BIOPH RES CO, V341, P51, DOI 10.1016/j.bbrc.2005.12.142; Pomposiello PJ, 2000, J BACTERIOL, V182, P23, DOI 10.1128/JB.182.1.23-29.2000; Price-Whelan A, 2006, NAT CHEM BIOL, V2, P71, DOI 10.1038/nchembio764; Price-Whelan A, 2007, J BACTERIOL, V189, P6372, DOI 10.1128/JB.00505-07; Tahlan K, 2007, MOL MICROBIOL, V63, P951, DOI 10.1111/j.1365-2958.2006.05559.x; TSANEVA IR, 1990, J BACTERIOL, V172, P4197, DOI 10.1128/jb.172.8.4197-4205.1990; TURNER JM, 1986, ADV MICROB PHYSIOL, V27, P211, DOI 10.1016/S0065-2911(08)60306-9; Wang Y, 2008, ENVIRON SCI TECHNOL, V42, P2380, DOI 10.1021/es702290a; WILLIAMS RP, 1956, BACTERIOL REV, V20, P282, DOI 10.1128/MMBR.20.4.282-284.1956; Yim G, 2007, PHILOS T R SOC B, V362, P1195, DOI 10.1098/rstb.2007.2044	29	300	312	7	117	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2008	321	5893					1203	1206		10.1126/science.1160619	http://dx.doi.org/10.1126/science.1160619			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341ZM	18755976	Green Accepted			2022-12-28	WOS:000258754400043
J	Hiller, S; Garces, RG; Malia, TJ; Orekhov, VY; Colombini, M; Wagner, G				Hiller, Sebastian; Garces, Robert G.; Malia, Thomas J.; Orekhov, Vladislav Y.; Colombini, Marco; Wagner, Gerhard			Solution structure of the integral human membrane protein VDAC-1 in detergent micelles	SCIENCE			English	Article							MITOCHONDRIAL OUTER-MEMBRANE; PEPTIDE-SPECIFIC ANTIBODIES; ANION-SELECTIVE CHANNEL; CYTOCHROME-C; TOPOLOGY; RELEASE; FAMILY; PROBES; SENSOR; SPERM	The voltage- dependent anion channel ( VDAC) mediates trafficking of small molecules and ions across the eukaryotic outer mitochondrial membrane. VDAC also interacts with antiapoptotic proteins from the Bcl- 2 family, and this interaction inhibits release of apoptogenic proteins from the mitochondrion. We present the nuclear magnetic resonance ( NMR) solution structure of recombinant human VDAC- 1 reconstituted in detergent micelles. It forms a 19- stranded beta barrel with the first and last strand parallel. The hydrophobic outside perimeter of the barrel is covered by detergent molecules in a beltlike fashion. In the presence of cholesterol, recombinant VDAC- 1 can form voltage- gated channels in phospholipid bilayers similar to those of the native protein. NMR measurements revealed the binding sites of VDAC- 1 for the Bcl- 2 protein Bcl-x(L), for reduced beta-nicotinamide adenine dinucleotide, and for cholesterol. Bcl-x(L) interacts with the VDAC barrel laterally at strands 17 and 18.	[Hiller, Sebastian; Garces, Robert G.; Malia, Thomas J.; Orekhov, Vladislav Y.; Wagner, Gerhard] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Colombini, Marco] Univ Maryland, Dept Biol, College Pk, MD 20742 USA; [Orekhov, Vladislav Y.] Univ Gothenburg, Swedish NMR Ctr, S-40530 Gothenburg, Sweden	Harvard University; Harvard Medical School; University System of Maryland; University of Maryland College Park; University of Gothenburg	Wagner, G (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	gerhard_wagner@hms.harvard.edu	Orekhov, Vladislav/AAC-8357-2022; Hiller, Sebastian/B-3573-2008; Colombini, Marco/A-1540-2014; Orekhov, Vladislav/AAD-8464-2019	Hiller, Sebastian/0000-0002-6709-4684; Orekhov, Vladislav/0000-0002-7892-6896	NIH roadmap grant [GM075879]; NIH [GM066360, GM47467, EB002026]; Swiss National Science Foundation; Wenner-Gren Foundation, Stockholm; Ludwig Foundation for Cancer Research; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB002026] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075879, P41GM066360, P01GM047467] Funding Source: NIH RePORTER	NIH roadmap grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Wenner-Gren Foundation, Stockholm; Ludwig Foundation for Cancer Research; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH roadmap grant GM075879. Purchase, operation, and maintenance of instruments used were supported by NIH grants GM066360, GM47467, and EB002026. S. H. was supported by the Swiss National Science Foundation. V.Y.O. was supported by the Wenner-Gren Foundation, Stockholm. Initial research on this project was supported by the Ludwig Foundation for Cancer Research. We thank V. Gelev from FBReagents.com, Cambridge, Massachusetts, for custom synthesis of the <SUP>2</SUP>H-LDAO; S. Samanta for help with the electrophysiological measurements; and D. Frueh, A. Koglin, Z.-Y.J. Sun, K. Oxenoid, and S. Jenni for technical help and valuable discussions. The atomic coordinates of VDAC-1 in LDAO micelles have been deposited at the Protein Data Bank with code 2k4t.	Brustovetsky N, 2003, J NEUROCHEM, V84, P196, DOI 10.1046/j.1471-4159.2003.01545.x; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; Colombini M, 2004, MOL CELL BIOCHEM, V256, P107, DOI 10.1023/B:MCBI.0000009862.17396.8d; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; De Pinto V, 2007, CHEMBIOCHEM, V8, P744, DOI 10.1002/cbic.200700009; DEPINTO V, 1989, EUR J BIOCHEM, V183, P179; DEPINTO V, 1991, BIOCHEMISTRY-US, V30, P10191, DOI 10.1021/bi00106a017; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; FORTE M, 1987, J BIOENERG BIOMEMBR, V19, P341, DOI 10.1007/BF00768537; GUO XW, 1995, J STRUCT BIOL, V114, P41, DOI 10.1006/jsbi.1995.1004; Heiden MGV, 2001, J BIOL CHEM, V276, P19414, DOI 10.1074/jbc.M101590200; Hilty C, 2004, CHEMBIOCHEM, V5, P467, DOI 10.1002/cbic.200300815; Hinsch KD, 2004, J BIOL CHEM, V279, P15281, DOI 10.1074/jbc.M313433200; Hodge T, 1997, J MEMBRANE BIOL, V157, P271, DOI 10.1007/s002329900235; Komarov AG, 2004, BIOPHYS J, V86, P152, DOI 10.1016/S0006-3495(04)74093-X; Koppel DA, 1998, J BIOL CHEM, V273, P13794, DOI 10.1074/jbc.273.22.13794; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; MANNELLA CA, 1982, J CELL BIOL, V94, P680, DOI 10.1083/jcb.94.3.680; MATIA TJ, 2007, BIOCHEMISTRY-US, V46, P514; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; Rosen MK, 1996, J MOL BIOL, V263, P627, DOI 10.1006/jmbi.1996.0603; Rostovtseva T, 1997, BIOPHYS J, V72, P1954, DOI 10.1016/S0006-3495(97)78841-6; Rostovtseva TK, 2004, J BIOL CHEM, V279, P13575, DOI 10.1074/jbc.M310593200; Sampson MJ, 2001, J BIOL CHEM, V276, P39206, DOI 10.1074/jbc.M104724200; SCHEIN SJ, 1976, J MEMBRANE BIOL, V30, P99, DOI 10.1007/BF01869662; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Song JM, 1998, J BIOL CHEM, V273, P24406, DOI 10.1074/jbc.273.38.24406; Song JM, 1998, BIOPHYS J, V74, P2926, DOI 10.1016/S0006-3495(98)78000-2; STANLEY S, 1995, J BIOL CHEM, V270, P16694, DOI 10.1074/jbc.270.28.16694; THOMAS L, 1993, P NATL ACAD SCI USA, V90, P5446, DOI 10.1073/pnas.90.12.5446; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; WHITE S, 2008, MEMBRANE PROTEINS KN; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZIZI M, 1994, J BIOL CHEM, V269, P1614	34	536	547	5	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2008	321	5893					1206	1210		10.1126/science.1161302	http://dx.doi.org/10.1126/science.1161302			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341ZM	18755977	Green Accepted			2022-12-28	WOS:000258754400044
J	Furie, B; Furie, BC				Furie, Bruce; Furie, Barbara C.			Mechanisms of disease: Mechanisms of thrombus formation	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PROTEIN-DISULFIDE-ISOMERASE; TISSUE FACTOR ACTIVITY; FACTOR-POSITIVE MICROPARTICLES; VON-WILLEBRAND-FACTOR; P-SELECTIN; FACTOR-XI; GLYCOPROTEIN-VI; PROCOAGULANT MICROPARTICLES; PLATELET-AGGREGATION; FIBRIN GENERATION		Beth Israel Deaconess Med Ctr, Div Hemostasis & Thrombosis, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Furie, B (corresponding author), Beth Israel Deaconess Med Ctr, Div Hemostasis & Thrombosis, Boston, MA 02215 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL087203] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL087203] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andre P, 2002, NAT MED, V8, P247, DOI 10.1038/nm0302-247; Angelillo-Scherrer A, 2001, NAT MED, V7, P215, DOI 10.1038/84667; [Anonymous], 1986, Lancet, V1, P397; BACH R, 1990, P NATL ACAD SCI USA, V87, P6995, DOI 10.1073/pnas.87.18.6995; Baugh RJ, 1998, J BIOL CHEM, V273, P4378, DOI 10.1074/jbc.273.8.4378; Bedard PW, 2008, J PHARMACOL EXP THER, V324, P497, DOI 10.1124/jpet.107.128124; Belting M, 2004, NAT MED, V10, P502, DOI 10.1038/nm1037; Bergmeier W, 2006, P NATL ACAD SCI USA, V103, P16900, DOI 10.1073/pnas.0608207103; BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; Boccaccio C, 2005, NATURE, V434, P396, DOI 10.1038/nature03357; Brass LF, 2005, J CLIN INVEST, V115, P3385, DOI 10.1172/JCI26869; Burgess JK, 2000, J BIOL CHEM, V275, P9758, DOI 10.1074/jbc.275.13.9758; Butenas S, 2005, BLOOD, V105, P2764, DOI 10.1182/blood-2004-09-3567; CALLANDER NS, 1992, CANCER-AM CANCER SOC, V70, P1194, DOI 10.1002/1097-0142(19920901)70:5<1194::AID-CNCR2820700528>3.0.CO;2-E; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Chen VM, 2006, J THROMB HAEMOST, V4, P2533, DOI 10.1111/j.1538-7836.2006.02236.x; Chen VM, 2006, BIOCHEMISTRY-US, V45, P12020, DOI 10.1021/bi061271a; Cho J, 2008, J CLIN INVEST, V118, P1123, DOI 10.1172/JCI34134; Chou J, 2004, BLOOD, V104, P3190, DOI 10.1182/blood-2004-03-0935; Davi G, 2007, NEW ENGL J MED, V357, P2482, DOI 10.1056/NEJMra071014; DAVIE EW, 1964, SCIENCE, V145, P1310, DOI 10.1126/science.145.3638.1310; Davies MJ, 1996, CIRCULATION, V94, P2013, DOI 10.1161/01.CIR.94.8.2013; Dietzen DJ, 2004, BLOOD, V103, P3038, DOI 10.1182/blood-2003-07-2399; Dorfleutner A, 2004, MOL BIOL CELL, V15, P4416, DOI 10.1091/mbc.E03-09-0640; Downing LJ, 1997, J VASC SURG, V25, P816, DOI 10.1016/S0741-5214(97)70211-8; DU XP, 1994, J BIOL CHEM, V269, P11673; DU XP, 1993, J BIOL CHEM, V268, P23087; Dubois C, 2007, J CLIN INVEST, V117, P953, DOI 10.1172/JCI30537; Dubois C, 2006, BLOOD, V107, P3902, DOI 10.1182/blood-2005-09-3687; Essex DW, 2001, BIOCHEMISTRY-US, V40, P6070, DOI 10.1021/bi002454e; Falati S, 2003, J EXP MED, V197, P1585, DOI 10.1084/jem.20021868; FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657; FURIE B, 1992, NEW ENGL J MED, V326, P800; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; Gailani D, 2007, ARTERIOSCL THROM VAS, V27, P2507, DOI 10.1161/ATVBAHA.107.155952; Giesen PLA, 1999, P NATL ACAD SCI USA, V96, P2311, DOI 10.1073/pnas.96.5.2311; GORDON SG, 1981, J CLIN INVEST, V67, P1665, DOI 10.1172/JCI110203; Goto S, 1998, J CLIN INVEST, V101, P479, DOI 10.1172/JCI973; Gross PL, 2005, J LEUKOCYTE BIOL, V78, P1318, DOI 10.1189/jlb.0405193; Hathcock JJ, 2004, BLOOD, V104, P123, DOI 10.1182/blood-2003-12-4352; Hirsh J, 2007, CIRCULATION, V116, P552, DOI 10.1161/CIRCULATIONAHA.106.685974; Holtkotter O, 2002, J BIOL CHEM, V277, P10789, DOI 10.1074/jbc.M112307200; Hron G, 2007, THROMB HAEMOSTASIS, V97, P119, DOI 10.1160/TH06-03-0141; Hugel B, 1999, BLOOD, V93, P3451, DOI 10.1182/blood.V93.10.3451.410k27_3451_3456; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Italiano JE, 2008, BLOOD, V111, P1227, DOI 10.1182/blood-2007-09-113837; Kleinschnitz C, 2006, J EXP MED, V203, P513, DOI 10.1084/jem.20052458; Liebman HA, 2003, THROMB RES, V111, P235, DOI 10.1016/j.thromres.2003.09.018; Lupu C, 2005, AM J PATHOL, V167, P1161, DOI 10.1016/S0002-9440(10)61204-7; MACFARLANE RG, 1964, NATURE, V202, P498, DOI 10.1038/202498a0; Mallat Z, 1999, CIRCULATION, V99, P348, DOI 10.1161/01.CIR.99.3.348; Mangin P, 2006, BLOOD, V107, P4346, DOI 10.1182/blood-2005-10-4244; Marcus AJ, 2005, SEMIN THROMB HEMOST, V31, P234, DOI 10.1055/s-2005-869528; Marcus AJ, 2002, NEW ENGL J MED, V347, P1025, DOI 10.1056/NEJMcibr021805; Marmur JD, 1996, CIRCULATION, V94, P1226, DOI 10.1161/01.CIR.94.6.1226; Massberg S, 2003, J EXP MED, V197, P41, DOI 10.1084/jem.20020945; MAYNARD JR, 1975, J CLIN INVEST, V55, P814, DOI 10.1172/JCI107992; Morel O, 2006, ARTERIOSCL THROM VAS, V26, P2594, DOI 10.1161/01.ATV.0000246775.14471.26; MORRISSEY JH, 1993, BLOOD, V81, P734; Myers DD, 2001, THROMB HAEMOSTASIS, V85, P423; Nanda N, 2005, BLOOD, V106, P3028, DOI 10.1182/blood-2005-01-0333; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; Ngo JCK, 2008, STRUCTURE, V16, P597, DOI 10.1016/j.str.2008.03.001; Ni HY, 2000, J CLIN INVEST, V106, P385, DOI 10.1172/JCI9896; Nieswandt B, 2001, EMBO J, V20, P2120, DOI 10.1093/emboj/20.9.2120; Orfeo T, 2005, J BIOL CHEM, V280, P42887, DOI 10.1074/jbc.M505506200; Orfeo T, 2004, J BIOL CHEM, V279, P19580, DOI 10.1074/jbc.M400727200; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; Osterud B, 2001, SEMIN HEMATOL, V38, P2, DOI 10.1016/S0037-1963(01)90139-8; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Panes O, 2007, BLOOD, V109, P5242, DOI 10.1182/blood-2006-06-030619; Pedicord DL, 2007, P NATL ACAD SCI USA, V104, P12855, DOI 10.1073/pnas.0705566104; Podrez EA, 2007, NAT MED, V13, P1086, DOI 10.1038/nm1626; Prevost N, 2005, P NATL ACAD SCI USA, V102, P9820, DOI 10.1073/pnas.0404065102; Rauch U, 2007, THROMB HAEMOSTASIS, V97, P9, DOI 10.1160/TH06-12-0687; Reinhardt C, 2008, J CLIN INVEST, V118, P1110, DOI 10.1172/JCI32376; Renne T, 2005, J EXP MED, V202, P271, DOI 10.1084/jem.20050664; Roque M, 2000, J AM COLL CARDIOL, V36, P2303, DOI 10.1016/S0735-1097(00)01018-4; Ruggeri ZM, 2000, J CLIN INVEST, V105, P699, DOI 10.1172/JCI9604; Salomon O, 2008, BLOOD, V111, P4113, DOI 10.1182/blood-2007-10-120139; Schmidt B, 2006, BIOCHEMISTRY-US, V45, P7429, DOI 10.1021/bi0603064; SEMERARO N, 1983, IMMUNOLOGY, V50, P529; Stone MD, 2005, BIOCHEMISTRY-US, V44, P6321, DOI 10.1021/bi050007z; Tesselaar MET, 2007, J THROMB HAEMOST, V5, P520, DOI 10.1111/j.1538-7836.2007.02369.x; Vandendries ER, 2007, P NATL ACAD SCI USA, V104, P288, DOI 10.1073/pnas.0610188104; Varki A, 2007, BLOOD, V110, P1723, DOI 10.1182/blood-2006-10-053736; Versteeg HH, 2007, J BIOL CHEM, V282, P25416, DOI 10.1074/jbc.M702410200; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Wang X, 2005, J THROMB HAEMOST, V3, P695, DOI 10.1111/j.1538-7836.2005.01236.x; Wouters MA, 2004, BIOESSAYS, V26, P73, DOI 10.1002/bies.10413	90	1134	1197	4	348	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 28	2008	359	9					938	949		10.1056/NEJMra0801082	http://dx.doi.org/10.1056/NEJMra0801082			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	341IU	18753650				2022-12-28	WOS:000258708300008
J	Rouse, DJ; Hirtz, DG; Thom, E; Varner, MW; Spong, CY; Mercer, BM; Iams, JD; Wapner, RJ; Sorokin, Y; Alexander, JM; Harper, M; Thorp, JM; Ramin, SM; Malone, FD; Carpenter, M; Miodovnik, M; Moawad, A; O'Sullivan, MJ; Peaceman, AM; Hankins, GDV; Langer, O; Caritis, SN; Roberts, JM				Rouse, Dwight J.; Hirtz, Deborah G.; Thom, Elizabeth; Varner, Michael W.; Spong, Catherine Y.; Mercer, Brian M.; Iams, Jay D.; Wapner, Ronald J.; Sorokin, Yoram; Alexander, James M.; Harper, Margaret; Thorp, John M., Jr.; Ramin, Susan M.; Malone, Fergal D.; Carpenter, Marshall; Miodovnik, Menachem; Moawad, Atef; O'Sullivan, Mary J.; Peaceman, Alan M.; Hankins, Gary D. V.; Langer, Oded; Caritis, Steve N.; Roberts, James M.		Eunice Kennedy Shriver NICHD Mater	A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	28th Annual Meeting of the Society-for-Maternal-Fetal-Medicine	JAN 28-FEB 02, 2008	Dallas, TX	Soc Maternal Fetal Med (SMFM)			BIRTH; PREVALENCE; CHILDREN; MORBIDITY	Background: Research suggests that fetal exposure to magnesium sulfate before preterm birth might reduce the risk of cerebral palsy. Methods: In this multicenter, placebo-controlled, double-blind trial, we randomly assigned women at imminent risk for delivery between 24 and 31 weeks of gestation to receive magnesium sulfate, administered intravenously as a 6-g bolus followed by a constant infusion of 2 g per hour, or matching placebo. The primary outcome was the composite of stillbirth or infant death by 1 year of corrected age or moderate or severe cerebral palsy at or beyond 2 years of corrected age. Results: A total of 2241 women underwent randomization. The baseline characteristics were similar in the two groups. Follow-up was achieved for 95.6% of the children. The rate of the primary outcome was not significantly different in the magnesium sulfate group and the placebo group (11.3% and 11.7%, respectively; relative risk, 0.97; 95% confidence interval [CI], 0.77 to 1.23). However, in a prespecified secondary analysis, moderate or severe cerebral palsy occurred significantly less frequently in the magnesium sulfate group (1.9% vs. 3.5%; relative risk, 0.55; 95% CI, 0.32 to 0.95). The risk of death did not differ significantly between the groups (9.5% vs. 8.5%; relative risk, 1.12; 95% CI, 0.85 to 1.47). No woman had a life-threatening event. Conclusions: Fetal exposure to magnesium sulfate before anticipated early preterm delivery did not reduce the combined risk of moderate or severe cerebral palsy or death, although the rate of cerebral palsy was reduced among survivors. (ClinicalTrials.gov number, NCT00014989.).	[Rouse, Dwight J.] Univ Alabama Birmingham, Birmingham, AL USA; [Hirtz, Deborah G.] Natl Inst Neurol Disorders & Stroke, Bethesda, MD USA; [Thom, Elizabeth] George Washington Univ, Ctr Biostat, Washington, DC USA; [Varner, Michael W.] Univ Utah, Salt Lake City, UT USA; [Spong, Catherine Y.] NICHHD, Bethesda, MD 20892 USA; [Mercer, Brian M.] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Mercer, Brian M.] Univ Tennessee, Memphis, TN USA; [Iams, Jay D.] Ohio State Univ, Columbus, OH 43210 USA; [Wapner, Ronald J.] Thomas Jefferson Univ, Philadelphia, PA 19107 USA; [Wapner, Ronald J.] Drexel Univ, Philadelphia, PA 19104 USA; [Sorokin, Yoram] Wayne State Univ, Detroit, MI USA; [Alexander, James M.] Univ Texas Dallas, SW Med Ctr, Dallas, TX 75230 USA; [Harper, Margaret] Wake Forest Univ, Winston Salem, NC 27109 USA; [Thorp, John M., Jr.] Univ N Carolina, Chapel Hill, NC USA; [Ramin, Susan M.] Univ Texas Houston, Houston, TX USA; [Malone, Fergal D.] Columbia Univ, New York, NY USA; [Carpenter, Marshall] Brown Univ, Providence, RI 02912 USA; [Miodovnik, Menachem] Univ Cincinnati, Cincinnati, OH USA; [Moawad, Atef] Univ Chicago, Chicago, IL 60637 USA; [O'Sullivan, Mary J.] Univ Miami, Miami, FL USA; [Peaceman, Alan M.] Northwestern Univ, Chicago, IL 60611 USA; [Hankins, Gary D. V.] Univ Texas Galveston, Med Branch, Galveston, TX 77550 USA; [Langer, Oded] Univ Texas San Antonio, San Antonio, TX USA; [Caritis, Steve N.; Roberts, James M.] Univ Pittsburgh, Pittsburgh, PA USA	University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); George Washington University; Utah System of Higher Education; University of Utah; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Case Western Reserve University; University of Tennessee System; University of Tennessee Health Science Center; University System of Ohio; Ohio State University; Jefferson University; Drexel University; Wayne State University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Wake Forest University; University of North Carolina; University of North Carolina Chapel Hill; University of Texas System; University of Texas Health Science Center Houston; Columbia University; Brown University; University System of Ohio; University of Cincinnati; University of Chicago; University of Miami; Northwestern University; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas at San Antonio (UTSA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Rouse, DJ (corresponding author), OHB 457,619 19th St S, Birmingham, AL 35249 USA.	drouse@uab.edu	Malone, Fergal/D-6233-2012; Roberts, James/AAI-3283-2020; Varner, Michael/K-9890-2013	Roberts, James/0000-0002-2671-3207; Varner, Michael/0000-0001-9455-3973; caritis, steve/0000-0002-2169-0712; Peaceman, Alan/0000-0002-4515-4850	NICHD NIH HHS [HD40544, U10 HD040545, U10 HD036801, U10 HD021410, HD27917, UG1 HD040500, HD27915, U10 HD027869-16, U10 HD027869-11, HD34208, U10 HD034208, HD40500, U10 HD027860, U10 HD027869-15, UG1 HD040485, UG1 HD040545, U10 HD027915, U10 HD027869-16S1, U10 HD034122, U10 HD027869-12, HD34116, U10 HD027917, U10 HD027869, HD21410, HD34210, HD53907, HD40485, U10 HD040500-09, U10 HD034116, HD40545, UG1 HD040512, UG1 HD034208, UG1 HD040544, HD40512, U10 HD027869-17, U10 HD027905, HD21414, UG1 HD027915, HD27860, U10 HD027869-13, UG1 HD040560, HD34136, HD27869, UG1 HD034116, U10 HD027869-18, U10 HD040544, HD27861, U10 HD027869-14, U10 HD040500, U01 HD036801, U10 HD040512, U01 HD019897, U10 HD040560, HD40560, U10 HD040485, U10 HD034136, UG1 HD027869, HD36801] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD040560, UG1HD034208, UG1HD040500, UG1HD027915, U10HD040500, UG1HD034116, U10HD040545, U10HD040512, U10HD034208, UG1HD027869, U10HD040485, UG1HD040545, U10HD034116, U10HD040544, U10HD027917, U10HD021410, U10HD027915, UG1HD040544, UG1HD040485, UG1HD040560, U10HD036801, UG1HD040512, U10HD027869] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U10HD027905, U01HD019897, U10HD034210, U01HD021414, U10HD034122, U10HD034136, U10HD027860, U10HD021414, U01HD036801, U01HD021410, U10HD027861] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bax M, 2005, DEV MED CHILD NEUROL, V47, P571, DOI 10.1017/S001216220500112X; Bayley N, 1993, BAYLEY SCALES INFANT; Benichou J, 1998, LANCET, V351, P290, DOI 10.1016/S0140-6736(05)78242-8; BLASCO PA, 1994, CLIN PEDIATR, V33, P388, DOI 10.1177/000992289403300703; CAPUTE AJ, 1985, AM J DIS CHILD, V139, P940, DOI 10.1001/archpedi.1985.02140110094038; Carey JC, 2000, NEW ENGL J MED, V342, P534, DOI 10.1056/NEJM200002243420802; Crowther C, 1998, LANCET, V351, P291, DOI 10.1016/S0140-6736(05)78241-6; Crowther CA, 2004, JAMA-J AM MED ASSOC, V291, P941, DOI 10.1001/jama.291.8.941-a; Crowther CA, 2003, JAMA-J AM MED ASSOC, V290, P2669, DOI 10.1001/jama.290.20.2669; CUMMINS SK, 1993, J PEDIATR-US, V123, P230, DOI 10.1016/S0022-3476(05)81693-2; Duley L, 2007, BJOG-INT J OBSTET GY, V114, P289, DOI 10.1111/j.1471-0528.2006.01165.x; Grether J, 1998, LANCET, V351, P292, DOI 10.1016/S0140-6736(05)78239-8; HALLAK M, 1993, OBSTET GYNECOL, V81, P185; Hirtz Deborah G., 1998, Current Opinion in Pediatrics, V10, P131, DOI 10.1097/00008480-199804000-00003; KUBAN KCK, 1994, NEW ENGL J MED, V330, P188, DOI 10.1056/NEJM199401203300308; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Leveno KJ, 1998, LANCET, V351, P291, DOI 10.1016/S0140-6736(05)78240-4; Marret S, 2008, GYNECOL OBSTET FERTI, V36, P278, DOI 10.1016/j.gyobfe.2008.01.012; Mercer BM, 1997, JAMA-J AM MED ASSOC, V278, P989, DOI 10.1001/jama.278.12.989; Mittendorf R, 2002, AM J OBSTET GYNECOL, V186, P1111, DOI 10.1067/mob.2002.123544; Mittendorf R, 1997, LANCET, V350, P1517, DOI 10.1016/S0140-6736(97)24047-X; Montori VM, 2005, BMJ-BRIT MED J, V330, P594, DOI 10.1136/bmj.330.7491.594; NELSON KB, 1982, PEDIATRICS, V69, P529; NELSON KB, 1995, PEDIATRICS, V95, P263; Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x; Pinto-Martin JA, 2001, PEDIATRICS, V108, P238; PINTOMARTIN JA, 1995, PEDIATRICS, V95, P249; Robertson CMT, 2007, JAMA-J AM MED ASSOC, V297, P2733, DOI 10.1001/jama.297.24.2733; Rouse DJ, 2003, AM J OBSTET GYNECOL, V188, P295, DOI 10.1067/mob.2003.130; STEVENSON RE, 1993, HUMAN MALFORMATION R, P21; Tommiska V, 2007, PEDIATRICS, V119, P29, DOI 10.1542/peds.2006-1472; Vincer MJ, 2006, PEDIATRICS, V118, pE1621, DOI 10.1542/peds.2006-1522; WEI LJ, 1988, CONTROL CLIN TRIALS, V9, P345, DOI 10.1016/0197-2456(88)90048-7; WEI LJ, 1989, CONTROL CLIN TRIALS, V10, P127; Winter S, 2002, PEDIATRICS, V110, P1220, DOI 10.1542/peds.110.6.1220	35	401	419	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 28	2008	359	9					895	905		10.1056/NEJMoa0801187	http://dx.doi.org/10.1056/NEJMoa0801187			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	341IU	18753646	Green Published, Green Accepted			2022-12-28	WOS:000258708300004
J	Grosshans, H; Filipowicz, W				Grosshans, Helge; Filipowicz, Witold			Proteomics joins the search for microRNA targets	CELL			English	Editorial Material							CELLS	Two recent studies published in Nature (Baek et al. 2008; Selbach et al., 2008) analyze changes in the proteome in response to individual microRNAs (miRNAs). This approach is a powerful means to identify miRNA targets and to quantify the contribution of translational repression to post-transcriptional gene silencing by miRNAs.	[Grosshans, Helge; Filipowicz, Witold] Friedrich Miescher Inst Biomed Res, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Grosshans, H (corresponding author), Friedrich Miescher Inst Biomed Res, CH-4002 Basel, Switzerland.	helge.grosshans@fmi.ch; witold.filipowicz@fmi.ch	Grosshans, Helge/W-8931-2019	Grosshans, Helge/0000-0002-8169-6905				BAEK D, 2008, NATURE IN PRESS, DOI DOI 10.1038/NATURE07242; Bellare P, 2007, NAT STRUCT MOL BIOL, V14, P684, DOI 10.1038/nsmb0807-684; Bhattacharyya SN, 2006, CELL, V125, P1111, DOI 10.1016/j.cell.2006.04.031; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Hobert O, 2007, CELL, V131, P22, DOI 10.1016/j.cell.2007.09.031; Kedde M, 2007, CELL, V131, P1273, DOI 10.1016/j.cell.2007.11.034; Kruger M, 2008, CELL, V134, P353, DOI 10.1016/j.cell.2008.05.033; Mishima Y, 2006, CURR BIOL, V16, P2135, DOI 10.1016/j.cub.2006.08.086; SELBACH M, 2008, NATURE IN PRESS, DOI DOI 10.1038/NATURE07228; Vinther J, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl590	10	37	43	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 22	2008	134	4					560	562		10.1016/j.cell.2008.08.008	http://dx.doi.org/10.1016/j.cell.2008.08.008			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SR	18724926	Bronze			2022-12-28	WOS:000258665800006
J	Pauluis, O; Czaja, A; Korty, R				Pauluis, Olivier; Czaja, Arnaud; Korty, Robert			The global atmospheric circulation on moist isentropes	SCIENCE			English	Article							STATIC STABILITY; TRANSPORT	The global atmospheric circulation transports energy from the equatorial regions to higher latitudes through a poleward flow of high- energy and - entropy parcels and an equatorward flow of air with lower energy and entropy content. Because of its turbulent nature, this circulation can only be described in some averaged sense. Here, we show that the total mass transport by the circulation is twice as large when averaged on moist isentropes than when averaged on dry isentropes. The additional mass transport on moist isentropes corresponds to a poleward flow of warm moist air near Earth's surface that rises into the upper troposphere within mid- latitudes and accounts for up to half of the air in the upper troposphere in polar regions.	[Pauluis, Olivier] NYU, Courant Inst Math Sci, New York, NY 10012 USA; [Czaja, Arnaud] Univ London Imperial Coll Sci Technol & Med, Space & Atmosphere Phys Grp, Dept Phys, London SW7 2AZ, England; [Korty, Robert] Texas A&M Univ, Dept Atmospher Sci, College Stn, TX 77843 USA	New York University; Imperial College London; Texas A&M University System; Texas A&M University College Station	Pauluis, O (corresponding author), NYU, Courant Inst Math Sci, 251 Mercer St, New York, NY 10012 USA.	pauluis@cims.nyu.edu	Korty, Robert L/E-2534-2012	Korty, Robert L/0000-0002-8743-5044; Czaja, Arnaud/0000-0003-3645-0284	NSF [ATM-0545047, PHY05-51164]; Natural Environment Research Council [NE/E001130/1] Funding Source: researchfish; NERC [NE/E001130/1] Funding Source: UKRI	NSF(National Science Foundation (NSF)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	This work was supported by NSF under grant no. ATM-0545047 and grant no. PHY05-51164.	ANDREWS DG, 1976, J ATMOS SCI, V33, P2031, DOI 10.1175/1520-0469(1976)033<2031:PWIHAV>2.0.CO;2; Czaja A, 2006, J ATMOS SCI, V63, P1498, DOI 10.1175/JAS3695.1; DUNKERTON T, 1978, J ATMOS SCI, V35, P2325, DOI 10.1175/1520-0469(1978)035<2325:OTMMMM>2.0.CO;2; EDMON HJ, 1980, J ATMOS SCI, V37, P2600, DOI 10.1175/1520-0469(1980)037<2600:EPCSFT>2.0.CO;2; EMANUEL KA, 1988, MON WEATHER REV, V116, P1805, DOI 10.1175/1520-0493(1988)116<1805:OEOSCA>2.0.CO;2; Frierson DMW, 2006, J ATMOS SCI, V63, P2548, DOI 10.1175/JAS3753.1; Held IM, 1999, J ATMOS SCI, V56, P1688, DOI 10.1175/1520-0469(1999)056<1688:TSBOTZ>2.0.CO;2; JOHNSON DR, 1989, ADV GEOPHYS, V31, P43, DOI 10.1016/S0065-2687(08)60053-9; Juckes MN, 2000, J ATMOS SCI, V57, P3050, DOI 10.1175/1520-0469(2000)057<3050:TSSOTM>2.0.CO;2; Kalnay E, 1996, B AM METEOROL SOC, V77, P437, DOI 10.1175/1520-0477(1996)077<0437:TNYRP>2.0.CO;2; Korty RL, 2007, J CLIMATE, V20, P5977, DOI 10.1175/2007JCLI1788.1; PALMEN E, 1951, Q J ROY METEOR SOC, V77, P337, DOI 10.1002/qj.49707733302; Palmen E.H., 1969, ATMOSPHERIC CIRCULAT; Peixoto J.P., 1992, PHYS CLIMATE, P520; Soden BJ, 2006, J CLIMATE, V19, P3354, DOI 10.1175/JCLI3799.1; STOKES G. G., 1847, MATH PHYS PAPERS, V8, P441, DOI DOI 10.1017/CBO9780511702242.013; TOWNSEND RD, 1985, J ATMOS SCI, V42, P1565, DOI 10.1175/1520-0469(1985)042<1565:ADSOTI>2.0.CO;2	18	105	107	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 22	2008	321	5892					1075	1078		10.1126/science.1159649	http://dx.doi.org/10.1126/science.1159649			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339RL	18719280				2022-12-28	WOS:000258594900036
J	Manyala, N; DiTusa, JF; Aeppli, G; Ramirez, AP				Manyala, N.; DiTusa, J. F.; Aeppli, G.; Ramirez, A. P.			Doping a semiconductor to create an unconventional metal	NATURE			English	Article							INSULATOR-TRANSITION; BEHAVIOR; SUPERCONDUCTIVITY; STATE	Landau - Fermi liquid theory, with its pivotal assertion that electrons in metals can be simply understood as independent particles with effective masses replacing the free electron mass, has been astonishingly successful. This is true despite the Coulomb interactions an electron experiences from the host crystal lattice, lattice defects and the other similar to 10(22) cm(-3) electrons. An important extension to the theory accounts for the behaviour of doped semiconductors(1,2). Because little in the vast literature on materials contradicts Fermi liquid theory and its extensions, exceptions have attracted great attention, and they include the high- temperature superconductors(3), silicon- based field- effect transistors that host two- dimensional metals(4), and certain rare- earth compounds at the threshold of magnetism(5-8). The origin of the non- Fermi liquid behaviour in all of these systems remains controversial. Here we report that an entirely different and exceedingly simple class of materials - doped small- bandgap semiconductors near a metal - insulator transition - can also display a non- Fermi liquid state. Remarkably, a modest magnetic field functions as a switch which restores the ordinary disordered Fermi liquid. Our data suggest that we have found a physical realization of the only mathematically rigorous route to a non- Fermi liquid, namely the 'undercompensated Kondo effect', where there are too few mobile electrons to compensate for the spins of unpaired electrons localized on impurity atoms(9-12).	[Manyala, N.; DiTusa, J. F.] Louisiana State Univ, Dept Phys & Astron, Baton Rouge, LA 70803 USA; [Aeppli, G.] UCL, London Ctr Nanotechnol, London WC1E 6BT, England; [Aeppli, G.] UCL, Dept Phys & Astron, London WC1E 6BT, England; [Manyala, N.] Natl Univ Lesotho, Dept Phys & Elect, Maseru 100, Lesotho; [Ramirez, A. P.] Alcatel Lucent, Bell Labs, Murray Hill, NJ 07974 USA	Louisiana State University System; Louisiana State University; University of London; University College London; University of London; University College London; Alcatel-Lucent; AT&T	DiTusa, JF (corresponding author), Louisiana State Univ, Dept Phys & Astron, Baton Rouge, LA 70803 USA.	ditusa@phys.lsu.edu	Manyala, Ncholu/F-1250-2011; Ramirez, Arthur/HGD-6619-2022	Manyala, Ncholu/0000-0003-2990-4284	National Science Foundation; Wolfson-Royal Society Research Merit Award; Basic Technologies Programme of the UK Research Councils	National Science Foundation(National Science Foundation (NSF)); Wolfson-Royal Society Research Merit Award(Royal Society of London); Basic Technologies Programme of the UK Research Councils	We thank Z. Fisk for discussions. J. F. D. acknowledges support from the National Science Foundation and G. A. acknowledges support from a Wolfson-Royal Society Research Merit Award and the Basic Technologies Programme of the UK Research Councils.	Aeppli G., 1992, COMMENTS COND MAT PH, V16, P155; Al'tshuler BL, 1987, SOV SCI REV A, V9, P223; Ashcroft N.W., 1976, SOLID STATE PHYS; BEILLE J, 1983, SOLID STATE COMMUN, V47, P399, DOI 10.1016/0038-1098(83)90928-6; BHATT RN, 1982, PHYS REV LETT, V48, P344, DOI 10.1103/PhysRevLett.48.344; CAVA RJ, 1987, PHYS REV LETT, V58, P1676, DOI 10.1103/PhysRevLett.58.1676; Chernikov MA, 1997, PHYS REV B, V56, P1366, DOI 10.1103/PhysRevB.56.1366; Coleman P, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.220405; Custers J, 2003, NATURE, V424, P524, DOI 10.1038/nature01774; DiTusa JF, 1998, PHYS REV B, V58, P10288, DOI 10.1103/PhysRevB.58.10288; DiTusa JF, 1997, PHYS REV LETT, V78, P2831, DOI 10.1103/PhysRevLett.78.2831; Ghosh S, 2003, NATURE, V425, P48, DOI 10.1038/nature01888; Husmann S, 1996, SCIENCE, V274, P1874, DOI 10.1126/science.274.5294.1874; Kravchenko SV, 1996, PHYS REV LETT, V77, P4938, DOI 10.1103/PhysRevLett.77.4938; LAKNER M, 1994, PHYS REV B, V50, P17064, DOI 10.1103/PhysRevB.50.17064; LEE PA, 1985, REV MOD PHYS, V57, P287, DOI 10.1103/RevModPhys.57.287; Manyala N, 2004, NAT MATER, V3, P255, DOI 10.1038/nmat1103; Manyala N, 2000, NATURE, V404, P581, DOI 10.1038/35007030; Mathur ND, 1998, NATURE, V394, P39, DOI 10.1038/27838; MATTHEISS LF, 1993, PHYS REV B, V47, P13114, DOI 10.1103/PhysRevB.47.13114; Mehta P, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.014430; PAALANEN MA, 1988, PHYS REV LETT, V61, P597, DOI 10.1103/PhysRevLett.61.597; Pfleiderer C, 2001, NATURE, V414, P427, DOI 10.1038/35106527; Posazhennikova A, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.036802; ROSENBAUM TF, 1983, PHYS REV B, V27, P7509, DOI 10.1103/PhysRevB.27.7509; SACRAMENTO PD, 1991, J PHYS-CONDENS MAT, V3, P9687, DOI 10.1088/0953-8984/3/48/010; SARACHIK MP, 1986, PHYS REV B, V34, P387, DOI 10.1103/PhysRevB.34.387; SCHLESINGER Z, 1993, PHYS REV LETT, V71, P1748, DOI 10.1103/PhysRevLett.71.1748; Schroder A, 2000, NATURE, V407, P351, DOI 10.1038/35030039; Si QM, 2001, NATURE, V413, P804, DOI 10.1038/35101507; VONMOLNAR S, 1983, PHYS REV LETT, V51, P706, DOI 10.1103/PhysRevLett.51.706; WERNICK JH, 1972, MATER RES BULL, V7, P1431, DOI 10.1016/0025-5408(72)90180-8	32	67	67	1	90	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 21	2008	454	7207					976	980		10.1038/nature07137	http://dx.doi.org/10.1038/nature07137			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339QB	18719585	Green Submitted			2022-12-28	WOS:000258591000034
J	Ruiz, R; Kang, HM; Detcheverry, FA; Dobisz, E; Kercher, DS; Albrecht, TR; de Pablo, JJ; Nealey, PF				Ruiz, Ricardo; Kang, Huiman; Detcheverry, Francois A.; Dobisz, Elizabeth; Kercher, Dan S.; Albrecht, Thomas R.; de Pablo, Juan J.; Nealey, Paul F.			Density multiplication and improved lithography by directed block copolymer assembly	SCIENCE			English	Article							ORDER-DISORDER TRANSITION; FILMS; SIMULATIONS; TEMPERATURE; DIMENSIONS; TEMPLATES; ARRAYS; MEDIA	Self-assembling materials spontaneously form structures at length scales of interest in nanotechnology. In the particular case of block copolymers, the thermodynamic driving forces for self- assembly are small, and low- energy defects can get easily trapped. We directed the assembly of defect- free arrays of isolated block copolymer domains at densities up to 1 terabit per square inch on chemically patterned surfaces. In comparing the assembled structures to the chemical pattern, the density is increased by a factor of four, the size is reduced by a factor of two, and the dimensional uniformity is vastly improved.	[Ruiz, Ricardo; Dobisz, Elizabeth; Kercher, Dan S.; Albrecht, Thomas R.] Hitachi Global Storage Technol, San Jose Res Ctr, San Jose, CA 95135 USA; [Kang, Huiman; Detcheverry, Francois A.; de Pablo, Juan J.; Nealey, Paul F.] Univ Wisconsin, Dept Biol & Chem Engn, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Ruiz, R (corresponding author), Hitachi Global Storage Technol, San Jose Res Ctr, 3403 Yerba Buena Rd, San Jose, CA 95135 USA.	Ricardo.Ruiz@hitachigst.com; nealey@engr.wisc.edu	Detcheverry, Francois/GWC-5306-2022; de Pablo, Juan/AAJ-9161-2021	Ruiz, Ricardo/0000-0002-1698-4281; Detcheverry, Francois/0000-0002-2987-9042				BATES FS, 1990, ANNU REV PHYS CHEM, V41, P525, DOI 10.1146/annurev.pc.41.100190.002521; Berry BC, 2007, NANO LETT, V7, P2789, DOI 10.1021/nl071354s; Black CT, 2007, IBM J RES DEV, V51, P605, DOI 10.1147/rd.515.0605; Black CT, 2007, ACS NANO, V1, P147, DOI 10.1021/nn7002663; Daoulas KC, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.036104; Daoulas KC, 2008, LANGMUIR, V24, P1284, DOI 10.1021/la702482z; Detcheverry FA, 2008, MACROMOLECULES, V41, P4989, DOI 10.1021/ma702514v; Edwards EW, 2007, MACROMOLECULES, V40, P90, DOI 10.1021/ma0607564; Edwards EW, 2004, ADV MATER, V16, P1315, DOI 10.1002/adma.200400763; HADZIIOANNOU G, 1979, COLLOID POLYM SCI, V257, P136, DOI 10.1007/BF01638138; Hashimoto T, 1999, MACROMOLECULES, V32, P952, DOI 10.1021/ma981249s; Hashimoto T, 1998, POLYMER, V39, P1573, DOI 10.1016/S0032-3861(97)00442-4; HERR DJC, 2006, FUTURE FAB INT, V20, P82; KELLER A, 1970, NATURE, V225, P538, DOI 10.1038/225538a0; Kim SH, 2006, MACROMOLECULES, V39, P8473, DOI 10.1021/ma061170k; Kim SH, 2004, ADV MATER, V16, P2119, DOI 10.1002/adma.200306577; Kim SO, 2003, NATURE, V424, P411, DOI 10.1038/nature01775; Park MJ, 2007, NANO LETT, V7, P3547, DOI 10.1021/nl072617l; Park SM, 2007, MACROMOLECULES, V40, P5084, DOI 10.1021/ma0702344; Ross C, 2001, ANNU REV MATER RES, V31, P203, DOI 10.1146/annurev.matsci.31.1.203; Segalman RA, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.196101; Segalman RA, 2001, ADV MATER, V13, P1152, DOI 10.1002/1521-4095(200108)13:15<1152::AID-ADMA1152>3.0.CO;2-5; Semiconductor industry association, 2005, INT TECHN ROADM SEM; Stoykovich MP, 2005, SCIENCE, V308, P1442, DOI 10.1126/science.1111041; Stuen KO, 2007, J VAC SCI TECHNOL B, V25, P1958, DOI 10.1116/1.2799970; Terris BD, 2005, J PHYS D APPL PHYS, V38, pR199, DOI 10.1088/0022-3727/38/12/R01; Thurn-Albrecht T, 2000, SCIENCE, V290, P2126, DOI 10.1126/science.290.5499.2126; Thurn-Albrecht T, 2000, ADV MATER, V12, P787, DOI 10.1002/(SICI)1521-4095(200006)12:11<787::AID-ADMA787>3.0.CO;2-1; Weller D, 1999, IEEE T MAGN, V35, P4423, DOI 10.1109/20.809134	29	1042	1128	8	471	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2008	321	5891					936	939		10.1126/science.1157626	http://dx.doi.org/10.1126/science.1157626			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	337LD	18703735				2022-12-28	WOS:000258436700031
J	Morton, MJ; Burnham, GM				Morton, Melinda J.; Burnham, Gilbert M.			Iraq's internally displaced persons - A hidden crisis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Morton, Melinda J.] Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD 21205 USA; [Morton, Melinda J.; Burnham, Gilbert M.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Morton, MJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Emergency Med, 600 N Wolfe St, Baltimore, MD 21205 USA.	melinda.morton@crisishealth.org		Hamer, Melinda/0000-0002-6736-1738				ALHASNAWI S, 2008, I MED NAT AC SCI IR; Alkhuzai AH, 2008, NEW ENGL J MED, V358, P484, DOI 10.1056/NEJMsa0707782; Ferris E, 2007, UPDATE HUMANITARIAN; Forced Migration Review, 2007, IR DISPL CRIS SEARCH; *IDP WORK GROUP, 2008, INT DISPL PERS IR UP; *INT ORG MIGR, BIW REP; *INT ORG MIGR, IR DISPL 2007 YEAR R; *INT ORG MIGR IR, IDP JUN 2008 IOM IR; *IR RED CRESC ORG, 2008, INT DISPL PEOPL IR U; *OXF INT, 105 OXF INT; *RELIEFWEB, INT DISPL UPD IR; *UN HIGH COMM REF, IR SIT; *UN OFF HIGH COMM, GUID PRINC INT DISPL; *UNICEF, IR STAT; *USAID, AUT COUNTR REP IR	15	19	21	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	2008	300	6					727	729		10.1001/jama.300.6.727	http://dx.doi.org/10.1001/jama.300.6.727			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336OM	18698073				2022-12-28	WOS:000258374500027
J	Tol, WA; Komproe, IH; Susanty, D; Jordans, MJD; Macy, RD; De Jong, JTVM				Tol, Wietse A.; Komproe, Ivan H.; Susanty, Dessy; Jordans, Mark J. D.; Macy, Robert D.; De Jong, Joop T. V. M.			School-based mental health intervention for children affected by political violence in Indonesia - A cluster randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-INCOME; SCALE; WAR; DISORDERS; COUNTRIES; VALIDITY	Context Little is known about the efficacy of mental health interventions for children exposed to armed conflicts in low- and middle-income settings. Childhood mental health problems are difficult to address in situations of ongoing poverty and political instability. Objective To assess the efficacy of a school-based intervention designed for conflict-exposed children, implemented in a low- income setting. Design, Setting, and Participants A cluster randomized trial involving 495 children (81.4% inclusion rate) who were a mean (SD) age of 9.9 (1.3) years, were attending randomly selected schools in political violence-affected communities in Poso, Indonesia, and were screened for exposure (>= 1 events), posttraumatic stress disorder, and anxiety symptoms compared with a wait-listed control group. Nonblinded assessment took place before, 1 week after, and 6 months after treatment between March and December 2006. Intervention Fifteen sessions, over 5 weeks, of a manualized, school-based group intervention, including trauma-processing activities, cooperative play, and creative-expressive elements, implemented by locally trained paraprofessionals. Main Outcome Measures We assessed psychiatric symptoms using the Child Posttraumatic Stress Scale, Depression Self-Rating Scale, the Self-Report for Anxiety Related Disorders 5-item version, and the Children's Hope Scale, and assessed function impairment as treatment outcomes using standardized symptom checklists and locally developed rating scales. Results Correcting for clustering of participants within schools, we found significantly more improvement in posttraumatic stress disorder symptoms (mean change difference, 2.78; 95% confidence interval [CI], 1.02 to 4.53) and maintained hope ( mean change difference, -2.21; 95% CI, -3.52 to -0.91) in the treatment group than in the wait-listed group. Changes in traumatic idioms (stress-related physical symptoms) (mean change difference, 0.50; 95% CI, -0.12 to 1.11), depressive symptoms (mean change difference, 0.70; 95% CI, -0.08 to 1.49), anxiety (mean change difference, 0.12; 95% CI, -0.31 to 0.56), and functioning (mean change difference, 0.52; 95% CI, -0.43 to 1.46) were not different between the treatment and wait-listed groups. Conclusions In this study of children in violence-affected communities, a school-based intervention reduced posttraumatic stress symptoms and helped maintain hope, but did not reduce traumatic-stress related symptoms, depressive symptoms, anxiety symptoms, or functional impairment. Trial Registration isrctn.org Identifier: ISRCTN25172408.	[Tol, Wietse A.; Komproe, Ivan H.; Jordans, Mark J. D.] Vrije Univ Amsterdam, HealthNet TPO, Dept Publ Hlth & Res, Med Ctr, NL-1074 VJ Amsterdam, Netherlands; [Tol, Wietse A.; Jordans, Mark J. D.] Vrije Univ Amsterdam, Sect Culture & Hlth, Med Ctr, NL-1074 VJ Amsterdam, Netherlands; [De Jong, Joop T. V. M.] Vrije Univ Amsterdam, Dept Psychiat, Med Ctr, NL-1074 VJ Amsterdam, Netherlands; [Susanty, Dessy] Church World Serv Indonesia, Sulawesi, Indonesia; [Macy, Robert D.] Harvard Univ, Sch Med, Ctr Trauma Psychol, Boston, MA USA; [De Jong, Joop T. V. M.] Boston Univ, Med Ctr, Dept Psychiat, Boston, MA USA	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Harvard University; Harvard Medical School; Boston University	Tol, WA (corresponding author), Vrije Univ Amsterdam, HealthNet TPO, Dept Publ Hlth & Res, Med Ctr, Tolstr 127, NL-1074 VJ Amsterdam, Netherlands.	wtol@healthnettpo.org	Komproe, Ivan/AAJ-8699-2021; Tol, Wietse A/G-8587-2013	Tol, Wietse A/0000-0003-2216-0526; Jordans, Mark/0000-0001-5925-8039				Aragon Lorraine, 2001, INDONESIA, V72, P45, DOI DOI 10.2307/3351481; Barenbaum J, 2004, J CHILD PSYCHOL PSYC, V45, P41, DOI 10.1046/j.0021-9630.2003.00304.x; BIRLESON P, 1981, J CHILD PSYCHOL PSYC, V22, P73, DOI 10.1111/j.1469-7610.1981.tb00533.x; Birmaher B, 1997, J AM ACAD CHILD PSY, V36, P545, DOI 10.1097/00004583-199704000-00018; Bolton P, 2002, SOC PSYCH PSYCH EPID, V37, P537, DOI 10.1007/s00127-002-0580-5; Bolton P, 2007, JAMA-J AM MED ASSOC, V298, P519, DOI 10.1001/jama.298.5.519; Boothby N, 2006, WORLD TURNED UPSIDE; BROWN G, 2005, PEACE DEV ANAL CENTR, V3; Campbell MK, 2004, BMJ-BRIT MED J, V328, P702, DOI 10.1136/bmj.328.7441.702; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; Cohen JA, 2004, J AM ACAD CHILD PSY, V43, P393, DOI 10.1097/00004583-200404000-00005; COHEN JA, 2000, TRAUMA VIOLENCE ABUS, V1, P29, DOI DOI 10.1177/1524838000001001003; De Jong JTVM, 2002, PL S STRESS, P1; Dybdahl R, 2001, CHILD DEV, V72, P1214, DOI 10.1111/1467-8624.00343; Foa EB, 2001, J CLIN CHILD PSYCHOL, V30, P376, DOI 10.1207/S15374424JCCP3003_9; Gordon JS, 2004, J TRAUMA STRESS, V17, P143, DOI 10.1023/B:JOTS.0000022620.13209.a0; Halperin JM, 2002, J AM ACAD CHILD PSY, V41, P245, DOI 10.1097/00004583-200203000-00003; *IASC, 2006, IASC GUID MENT HLTH; Jaycox L. H., 2006, SCH CAN HELP STUDENT; Khamis V., 2004, IMPACT CLASSROOM COM; Layne CM, 2001, GROUP DYN-THEOR RES, V5, P277, DOI 10.1037//1089-2699.5.4.277; Macy Robert D, 2003, New Dir Youth Dev, P51; Mollica RF, 2004, LANCET, V364, P2058, DOI 10.1016/S0140-6736(04)17519-3; Morris J, 2007, DISASTERS, V31, P71, DOI 10.1111/j.1467-7717.2007.00341.x; *MRC, 2002, CLUST RAND TRIALS ME; Patel V, 2007, LANCET, V370, P991, DOI 10.1016/S0140-6736(07)61240-9; Patel V, 2007, BRIT MED BULL, V81-82, P81, DOI 10.1093/bmb/ldm010; Rousseau C, 2005, J CHILD PSYCHOL PSYC, V46, P180, DOI 10.1111/j.1469-7610.2004.00344.x; Snyder CR, 1997, J PEDIATR PSYCHOL, V22, P399, DOI 10.1093/jpepsy/22.3.399; Stein BD, 2003, JAMA-J AM MED ASSOC, V290, P603, DOI 10.1001/jama.290.5.603; Stichick T, 2001, CHILD ADOL PSYCH CL, V10, P797, DOI 10.1016/S1056-4993(18)30031-2; Taylor TL, 2004, ARCH PEDIAT ADOL MED, V158, P786, DOI 10.1001/archpedi.158.8.786; Thabet AA, 2005, EUR CHILD ADOLES PSY, V14, P262, DOI 10.1007/s00787-005-0466-7; TOL WA, IN PRESS TREATING TR; van Ommeren M., 1999, TRANSCULT PSYCHIATRY, V36, P285, DOI [10.1177/136346159903600304, DOI 10.1177/136346159903600304]; Walker SP, 2007, LANCET, V369, P145, DOI 10.1016/S0140-6736(07)60076-2; Wiley-Exley E, 2007, SOC SCI MED, V64, P1231, DOI 10.1016/j.socscimed.2006.11.009; World Health Organization, 2005, ATL CHILD AD MENT HL	38	172	173	1	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	2008	300	6					655	662		10.1001/jama.300.6.655	http://dx.doi.org/10.1001/jama.300.6.655			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	336OM	18698064	Bronze			2022-12-28	WOS:000258374500018
J	van der Eijk, P				van der Eijk, Philip			The art of medicine - Nemesius of Emesa and early brain mapping	LANCET			English	Editorial Material									Univ Newcastle, No Ctr Hist Med, Sch Hist Studies, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Newcastle University - UK	van der Eijk, P (corresponding author), Univ Newcastle, No Ctr Hist Med, Sch Hist Studies, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	Philip.van-der-Eijk@newcastle.ac.uk						Harrington A., 1987, MED MIND DOUBLE BRAI; Rocca J, 2003, GALEN BRAIN ANATOMIC; SHARPLES RW, 2008, NEMESIUS EMESA NATUR; van der Eijk P.J., 2005, MED PHILOS CLASSICAL, P119; Von Staden H., 1989, HEROPHILUS ART MED E	5	8	8	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 9	2008	372	9637					440	441		10.1016/S0140-6736(08)61183-6	http://dx.doi.org/10.1016/S0140-6736(08)61183-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	335OD	18697251	Bronze			2022-12-28	WOS:000258299000013
J	Stagg, SM; LaPointe, P; Razvi, A; Gurkan, C; Potter, CS; Carragher, B; Balch, WE				Stagg, Scott M.; LaPointe, Paul; Razvi, Abbas; Gurkan, Cemal; Potter, Clinton S.; Carragher, Bridget; Balch, William E.			Structural basis for cargo regulation of COPII coat assembly	CELL			English	Article							ENDOPLASMIC-RETICULUM; VESICLE FORMATION; MEMBRANE CURVATURE; TRANSPORT; PROTEINS; GOLGI; CAGE; SELECTION; GTPASE; ER	Using cryo-electron microscopy, we have solved the structure of an icosidodecahedral COPII coat involved in cargo export from the endoplasmic reticulum ( ER) coassembled from purified cargo adaptor Sec23-24 and Sec13-31 lattice-forming complexes. The coat structure shows a tetrameric assembly of the Sec23-24 adaptor layer that is well positioned beneath the vertices and edges of the Sec13-31 lattice. Fitting the known crystal structures of the COPII proteins into the density map reveals a flexible hinge region stemming from interactions between WD40 beta-propeller domains present in Sec13 and Sec31 at the vertices. The structure shows that the hinge region can direct geometric cage expansion to accommodate a wide range of bulky cargo, including procollagen and chylomicrons, that is sensitive to adaptor function in inherited disease. The COPII coat structure leads us to propose a mechanism by which cargo drives cage assembly and membrane curvature for budding from the ER.	[Stagg, Scott M.; Potter, Clinton S.; Carragher, Bridget] Scripps Res Inst, Nat Resource Automated Mol Microscopy, La Jolla, CA 92037 USA; [Stagg, Scott M.; LaPointe, Paul; Razvi, Abbas; Gurkan, Cemal; Potter, Clinton S.; Carragher, Bridget; Balch, William E.] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; [Stagg, Scott M.; LaPointe, Paul; Razvi, Abbas; Gurkan, Cemal; Potter, Clinton S.; Carragher, Bridget; Balch, William E.] Scripps Res Inst, Dept Physiol Chem, La Jolla, CA 92037 USA; [Balch, William E.] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; [Balch, William E.] Scripps Res Inst, Inst Childhood & Neglected Dis, La Jolla, CA 92037 USA; [Gurkan, Cemal] Cyprus Inst Neurol & Genet, Dept Electron Microscopy & Mol Pathol, Nicosia, Cyprus; [Stagg, Scott M.] Florida State Univ, Inst Mol Biophys, Dept Chem & Biochem, Tallahassee, FL 32306 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; State University System of Florida; Florida State University	Carragher, B (corresponding author), Scripps Res Inst, Nat Resource Automated Mol Microscopy, La Jolla, CA 92037 USA.	bcarr@scripps.edu; webalch@scripps.edu	Gurkan, Cemal/S-5751-2016	Gurkan, Cemal/0000-0001-7379-4559; LaPointe, Paul/0000-0002-5465-1795; Carragher, Bridget/0000-0002-0624-5020	National Institutes of Health (NIH); National Center for Research Resources' P41 program [RR17573]; NIH [GM42336, GM073509]; Cystic Fibrosis Foundation Consortium [NIH R33EB00798, NSF EIA0121282]; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR017573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R33EB000798] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336, F32GM073509] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources' P41 program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cystic Fibrosis Foundation Consortium; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Work presented here was conducted at the National Resource for Automated Molecular Microscopy, which is supported by the National Institutes of Health (NIH) though the National Center for Research Resources' P41 program (RR17573) with additional NIH support to W. E. B. (GM42336) and S. S. (GM073509). P. L., A. R., and C. G. were supported by fellowships from the Cystic Fibrosis Foundation Consortium. We acknowledge Dr. Arthur J. Olson (NIH R33EB00798 and NSF EIA0121282 to A. Olson) for construction and use of tangible interface (3D) models for analysis of structural features of the COPII coat.	Antonny B, 2005, BIOCHEM SOC T, V33, P619, DOI 10.1042/BST0330619; Antonny B, 2003, EMBO REP, V4, P419, DOI 10.1038/sj.embor.embor812; Aridor M, 1999, J BIOL CHEM, V274, P4389, DOI 10.1074/jbc.274.7.4389; Aridor M, 2001, J CELL BIOL, V152, P213, DOI 10.1083/jcb.152.1.213; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; Bethune J, 2006, J MEMBRANE BIOL, V211, P65, DOI 10.1007/s00232-006-0859-7; Bi XP, 2007, DEV CELL, V13, P635, DOI 10.1016/j.devcel.2007.10.006; Bi XP, 2002, NATURE, V419, P271, DOI 10.1038/nature01040; Bielli A, 2005, J CELL BIOL, V171, P919, DOI 10.1083/jcb.200509095; Boyadjiev SA, 2006, NAT GENET, V38, P1192, DOI 10.1038/ng1876; Cai HQ, 2007, NATURE, V445, P941, DOI 10.1038/nature05527; Connerly PL, 2005, CURR BIOL, V15, P1439, DOI 10.1016/j.cub.2005.06.065; Fath S, 2007, CELL, V129, P1325, DOI 10.1016/j.cell.2007.05.036; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Fromme JC, 2007, DEV CELL, V13, P623, DOI 10.1016/j.devcel.2007.10.005; Gurkan C, 2006, NAT REV MOL CELL BIO, V7, P727, DOI 10.1038/nrm2025; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; LARKIN JM, 1986, J CELL BIOL, V103, P2619, DOI 10.1083/jcb.103.6.2619; Lee MCS, 2007, SEMIN CELL DEV BIOL, V18, P424, DOI 10.1016/j.semcdb.2007.06.007; Lee MCS, 2005, CELL, V122, P605, DOI 10.1016/j.cell.2005.07.025; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Mallick SP, 2005, ULTRAMICROSCOPY, V104, P8, DOI 10.1016/j.ultramic.2005.02.004; Matsuoka K, 2001, P NATL ACAD SCI USA, V98, P13705, DOI 10.1073/pnas.241522198; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Miller E, 2002, EMBO J, V21, P6105, DOI 10.1093/emboj/cdf605; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Shoulders CC, 2004, CURR OPIN LIPIDOL, V15, P191, DOI 10.1097/00041433-200404000-00012; Siddiqi SA, 2003, J CELL SCI, V116, P415, DOI 10.1242/jcs.00215; Stagg SM, 2007, CURR OPIN STRUC BIOL, V17, P221, DOI 10.1016/j.sbi.2007.03.010; Stagg SM, 2006, NATURE, V439, P234, DOI 10.1038/nature04339; Suloway C, 2005, J STRUCT BIOL, V151, P41, DOI 10.1016/j.jsb.2005.03.010; Supek F, 2002, J CELL BIOL, V158, P1029, DOI 10.1083/jcb.200207053; Tama F, 2004, J STRUCT BIOL, V147, P315, DOI 10.1016/j.jsb.2004.03.002; Ungewickell EJ, 2007, CURR OPIN CELL BIOL, V19, P417, DOI 10.1016/j.ceb.2007.05.003; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644; Young A, 2007, SEMIN CELL DEV BIOL, V18, P448, DOI 10.1016/j.semcdb.2007.07.006	37	197	203	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 8	2008	134	3					474	484		10.1016/j.cell.2008.06.024	http://dx.doi.org/10.1016/j.cell.2008.06.024			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SO	18692470	Green Accepted, Bronze			2022-12-28	WOS:000258665500020
J	Hyde, SC; Gill, DR				Hyde, Stephen C.; Gill, Deborah R.			Ignoring the nonsense: a phase II trial in cystic fibrosis	LANCET			English	Editorial Material							PREMATURE STOP MUTATIONS; CFTR FUNCTION; DISEASE; PTC124		[Hyde, Stephen C.; Gill, Deborah R.] John Radcliffe Hosp, UK Cyst Fibrosis Gene Therapy Consortium, Oxford OX3 9DU, England; [Hyde, Stephen C.; Gill, Deborah R.] John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Oxford OX3 9DU, England	University of Oxford; University of Oxford	Hyde, SC (corresponding author), John Radcliffe Hosp, UK Cyst Fibrosis Gene Therapy Consortium, Oxford OX3 9DU, England.	steve.hyde@ndcls.ox.ac.uk		Hyde, Stephen/0000-0002-8877-4005; Gill, Deborah/0000-0002-5264-054X				Boucher RC, 2007, J INTERN MED, V261, P5, DOI 10.1111/j.1365-2796.2006.01744.x; Clancy JP, 2001, AM J RESP CRIT CARE, V163, P1683, DOI 10.1164/ajrccm.163.7.2004001; Guan MX, 2000, HUM MOL GENET, V9, P1787, DOI 10.1093/hmg/9.12.1787; Hirawat S, 2007, J CLIN PHARMACOL, V47, P430, DOI 10.1177/0091270006297140; Holbrook JA, 2004, NAT GENET, V36, P801, DOI 10.1038/ng1403; Howard M, 1996, NAT MED, V2, P467, DOI 10.1038/nm0496-467; JOHNSON LG, 1992, NAT GENET, V2, P21, DOI 10.1038/ng0992-21; KAZAZIAN HH, 1994, HUM MUTAT, V4, P167; KEREM E, 2008, LANCET          0821; Mendell JT, 2001, CELL, V107, P411, DOI 10.1016/S0092-8674(01)00583-9; Mingeot-Leclercq MP, 1999, ANTIMICROB AGENTS CH, V43, P1003, DOI 10.1128/AAC.43.5.1003; Welch EM, 2007, NATURE, V447, P87, DOI 10.1038/nature05756; Wilschanski M, 2003, NEW ENGL J MED, V349, P1433, DOI 10.1056/NEJMoa022170	13	7	7	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG-SEP	2008	372	9640					691	692		10.1016/S0140-6736(08)61169-1	http://dx.doi.org/10.1016/S0140-6736(08)61169-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	344YZ	18722009				2022-12-28	WOS:000258964500004
J	Novembre, J; Johnson, T; Bryc, K; Kutalik, Z; Boyko, AR; Auton, A; Indap, A; King, KS; Bergmann, S; Nelson, MR; Stephens, M; Bustamante, CD				Novembre, John; Johnson, Toby; Bryc, Katarzyna; Kutalik, Zoltan; Boyko, Adam R.; Auton, Adam; Indap, Amit; King, Karen S.; Bergmann, Sven; Nelson, Matthew R.; Stephens, Matthew; Bustamante, Carlos D.			Genes mirror geography within Europe	NATURE			English	Article							GENOME-WIDE ASSOCIATION; STRATIFICATION; ANCESTRY; GENOTYPE; LOCI	Understanding the genetic structure of human populations is of fundamental interest to medical, forensic and anthropological sciences. Advances in high- throughput genotyping technology have markedly improved our understanding of global patterns of human genetic variation and suggest the potential to use large samples to uncover variation among closely spaced populations(1-5). Here we characterize genetic variation in a sample of 3,000 European individuals genotyped at over half a million variable DNA sites in the human genome. Despite low average levels of genetic differentiation among Europeans, we find a close correspondence between genetic and geographic distances; indeed, a geographical map of Europe arises naturally as an efficient two-dimensional summary of genetic variation in Europeans. The results emphasize that when mapping the genetic basis of a disease phenotype, spurious associations can arise if genetic structure is not properly accounted for. In addition, the results are relevant to the prospects of genetic ancestry testing(6); an individual's DNA can be used to infer their geographic origin with surprising accuracy often to within a few hundred kilometres.	[Novembre, John] Univ Calif Los Angeles, Dept Ecol & Evolutionary Biol, Interdept Program Bioinformat, Los Angeles, CA 90095 USA; [Novembre, John; Stephens, Matthew] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [Stephens, Matthew] Univ Chicago, Dept Stat, Chicago, IL 60637 USA; [Johnson, Toby; Kutalik, Zoltan; Bergmann, Sven] Univ Lausanne, CHUV, Dept Med Genet, CH-1005 Lausanne, Switzerland; [Johnson, Toby] Univ Lausanne, CHUV, Univ Inst Social & Preventat Med, CH-1005 Lausanne, Switzerland; [Johnson, Toby; Kutalik, Zoltan; Bergmann, Sven] Swiss Inst Bioinformat, Cent Adm, CH-1015 Lausanne, Switzerland; [Bryc, Katarzyna; Boyko, Adam R.; Auton, Adam; Indap, Amit; Bustamante, Carlos D.] Cornell Univ, Dept Biol Stat & Computat Biol, Ithaca, NY 14853 USA; [King, Karen S.; Nelson, Matthew R.] GlaxoSmithKline, Res Triangle Pk, NC 27709 USA	University of California System; University of California Los Angeles; University of Chicago; University of Chicago; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Swiss Institute of Bioinformatics; Cornell University; GlaxoSmithKline	Novembre, J (corresponding author), Univ Calif Los Angeles, Dept Ecol & Evolutionary Biol, Interdept Program Bioinformat, Los Angeles, CA 90095 USA.	jnovembre@ucla.edu	Auton, Adam J/B-1159-2009; Kutalik, Zoltan/HHZ-5697-2022; Novembre, John/G-1339-2011; Colaus, PsyColaus/K-6607-2013	Kutalik, Zoltan/0000-0001-8285-7523; Bergmann, Sven/0000-0002-6785-9034; Indap, Amit/0000-0002-3322-4735; Bustamante, Carlos D./0000-0002-4187-7920; Johnson, Toby/0000-0002-5998-3270	Giorgi-Cavaglieri Foundation; Swiss National Science Foundation; US National Science Foundation Postdoctoral Fellowship in Bioinformatics; US National Institutes of Health; GlaxoSmithKline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM083606] Funding Source: NIH RePORTER	Giorgi-Cavaglieri Foundation; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); US National Science Foundation Postdoctoral Fellowship in Bioinformatics(National Science Foundation (NSF)); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); GlaxoSmithKline(GlaxoSmithKline); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank J. Kooner and J. Chambers of the LOLIPOP study and G. Waeber, P. Vollenweider, D. Waterworth, J.S. Beckmann, M. Bochud and V. Mooser of the CoLaus study for providing access to their collections. Financial support was provided by the Giorgi-Cavaglieri Foundation (S.B.), the Swiss National Science Foundation (S.B.), US National Science Foundation Postdoctoral Fellowship in Bioinformatics (J.N.), US National Institutes of Health (M.S., C.D.B.) and GlaxoSmithKline (M.R.)	Bauchet M, 2007, AM J HUM GENET, V80, P948, DOI 10.1086/513477; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Campbell CD, 2005, NAT GENET, V37, P868, DOI 10.1038/ng1607; CAVALLISFORZA LL, 1994, HIST GEOGRAPHY HUMAN, V292; Clark AG, 2005, GENOME RES, V15, P1496, DOI 10.1101/gr.4107905; Eberle MA, 2000, GENET EPIDEMIOL, V19, pS29, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI5>3.0.CO;2-P; Falush D, 2003, GENETICS, V164, P1567; Firmann M, 2008, BMC CARDIOVASC DISOR, V8, DOI 10.1186/1471-2261-8-6; Hellenthal G, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000078; Jakobsson M, 2008, NATURE, V451, P998, DOI 10.1038/nature06742; Kooner JS, 2008, NAT GENET, V40, P149, DOI 10.1038/ng.2007.61; Lettre G, 2008, NAT GENET, V40, P584, DOI 10.1038/ng.125; Li JZ, 2008, SCIENCE, V319, P1100, DOI 10.1126/science.1153717; McCarthy MI, 2008, NAT REV GENET, V9, P356, DOI 10.1038/nrg2344; MENOZZI P, 1978, SCIENCE, V201, P786, DOI 10.1126/science.356262; NELSON MR, IN PRESS AM J HUM GE; Novembre J, 2008, NAT GENET, V40, P646, DOI 10.1038/ng.139; Patterson N, 2006, PLOS GENET, V2, P2074, DOI 10.1371/journal.pgen.0020190; Price AL, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0030236; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Shriver MD, 2004, NAT REV GENET, V5, P611, DOI 10.1038/nrg1405; SLATKIN M, 1985, EVOLUTION, V39, P53, DOI 10.2307/2408516; Tang H, 2006, AM J HUM GENET, V79, P1, DOI 10.1086/504302; Tian C, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040004; Weedon MN, 2008, NAT GENET, V40, P575, DOI 10.1038/ng.121; WEIR BS, 1984, EVOLUTION, V38, P1358, DOI [10.2307/2408641, 10.1111/j.1558-5646.1984.tb05657.x]; Zhu XF, 2002, GENET EPIDEMIOL, V23, P181, DOI 10.1002/gepi.210	28	873	893	11	192	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 6	2008	456	7218					98	U5		10.1038/nature07331	http://dx.doi.org/10.1038/nature07331			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369DH	18758442	Green Submitted, Green Accepted			2022-12-28	WOS:000260674000048
J	Ellison, JM; Libman				Ellison, James M.; Libman			A 60-year-old woman with mild memory impairment - Review of mild cognitive impairment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALZHEIMERS-DISEASE; DOUBLE-BLIND; OLDER-ADULTS; CONTROLLED-TRIAL; PRIMARY-CARE; VASCULAR DEMENTIA; MARITAL-STATUS; RISK-FACTOR; PERFORMANCE; DEPRESSION		[Ellison, James M.] McLean Hosp, Mem Diagnost Clin, Belmont, MA 02478 USA; [Ellison, James M.] Harvard Univ, Sch Med, Belmont, MA 02178 USA; [Ellison, James M.] McLean Hosp, Geriatr Psychiat Program, Belmont, MA 02478 USA	Harvard University; McLean Hospital; Harvard University; Harvard University; McLean Hospital	Ellison, JM (corresponding author), McLean Hosp, Mem Diagnost Clin, SB 322,115 Mill St, Belmont, MA 02478 USA.	ellisonj@mcleanpo.mclean.org	Ellison, James Michael/ABE-3629-2020		Sidney R. Rabb Charitable Trust; Sidney and Esther Rabb Charitable Foundation	Sidney R. Rabb Charitable Trust; Sidney and Esther Rabb Charitable Foundation	This Clinical Crossroads is made possible in part by a grant from the Sidney R. Rabb Charitable Trust and the Sidney and Esther Rabb Charitable Foundation.	Aggarwal NT, 2006, NEUROEPIDEMIOLOGY, V26, P140, DOI 10.1159/000091654; Alberts MJ, 2007, J NEUROL, V254, P1414, DOI 10.1007/s00415-007-0569-9; Alexopoulos GS, 2003, AM J GERIAT PSYCHIAT, V11, P46, DOI 10.1176/appi.ajgp.11.1.46; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; ASHFORD J, 2008, JAMA-J AM MED ASSOC, V299, P132; Ball KK, 2006, J AM GERIATR SOC, V54, P77, DOI 10.1111/j.1532-5415.2005.00568.x; BEARD CM, 1992, NEUROLOGY, V42, P2063, DOI 10.1212/WNL.42.11.2063; Belleville S, 2008, INT PSYCHOGERIATR, V20, P57, DOI 10.1017/S104161020700631X; Boustani M, 2003, ANN INTERN MED, V138, P927, DOI 10.7326/0003-4819-138-11-200306030-00015; Brayne C, 2007, JAMA-J AM MED ASSOC, V298, P2409, DOI 10.1001/jama.298.20.2409; Brodaty H, 2006, AM J GERIAT PSYCHIAT, V14, P391, DOI 10.1097/01.JGP.0000216181.20416.b2; Brodaty H, 1997, INT J GERIATR PSYCH, V12, P619, DOI 10.1002/(SICI)1099-1166(199706)12:6<619::AID-GPS554>3.0.CO;2-H; CHISTENSEN D, 2007, PRIM CARE COMPANION, V9, P32; Chodosh J, 2004, J AM GERIATR SOC, V52, P1051, DOI 10.1111/j.1532-5415.2004.52301.x; Cukierman T, 2005, DIABETOLOGIA, V48, P2460, DOI 10.1007/s00125-005-0023-4; DeCarli C, 2003, LANCET NEUROL, V2, P15, DOI 10.1016/S1474-4422(03)00262-X; deLeon MJ, 1997, NEUROBIOL AGING, V18, P1, DOI 10.1016/S0197-4580(96)00213-8; DINIZ BS, 2007, INT PSYCHOGERIATR, P1; Dunner DL, 1998, J CLIN PSYCHIAT, V59, P366, DOI 10.4088/JCP.v59n0705; Durga J, 2007, LANCET, V369, P208, DOI 10.1016/S0140-6736(07)60109-3; ELLISON J, 2003, DEPRESSION LATER LIF, P193; Farlow MR, 2004, NEUROLOGY, V63, P1898, DOI 10.1212/01.WNL.0000144279.21502.B7; FAZEKAS F, 1993, NEUROLOGY, V43, P1683, DOI 10.1212/WNL.43.9.1683; Feldman HH, 2007, LANCET NEUROL, V6, P501, DOI 10.1016/S1474-4422(07)70109-6; Ferris S, 2007, INT J GERIATR PSYCH, V22, P448, DOI 10.1002/gps.1711; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Freund-Levi Y, 2006, ARCH NEUROL-CHICAGO, V63, P1402, DOI 10.1001/archneur.63.10.1402; FRIEDLAND RP, 1988, ANN NEUROL, V24, P782, DOI 10.1002/ana.410240613; Graham JE, 1997, LANCET, V349, P1793, DOI 10.1016/S0140-6736(97)01007-6; Hartman-Stein Paula E, 2003, Online J Issues Nurs, V8, P6; Helmer C, 1999, NEUROLOGY, V53, P1953, DOI 10.1212/WNL.53.9.1953; Hentschel F, 2007, ACTA NEUROL SCAND, V115, P174, DOI 10.1111/j.1600-0404.2006.00762.x; Jessen F, 2007, PSYCHOL MED, V37, P1753, DOI 10.1017/S0033291707001122; Jonker C, 2000, INT J GERIATR PSYCH, V15, P983, DOI 10.1002/1099-1166(200011)15:11<983::AID-GPS238>3.0.CO;2-5; Jorm AF, 2001, AUST NZ J PSYCHIAT, V35, P776, DOI 10.1046/j.1440-1614.2001.00967.x; Knopman DS, 2001, NEUROLOGY, V56, P1143, DOI 10.1212/WNL.56.9.1143; KURZ A, 2008, INT J GERIATR P 0717; Larson EB, 2000, JAMA-J AM MED ASSOC, V283, P1046, DOI 10.1001/jama.283.8.1046; Larson EB, 2006, ANN INTERN MED, V144, P73, DOI 10.7326/0003-4819-144-2-200601170-00004; Lautenschlager NT, 2008, JAMA-J AM MED ASSOC, V300, P1027, DOI 10.1001/jama.300.9.1027; Logroscino G, 2004, BMJ-BRIT MED J, V328, P548, DOI 10.1136/bmj.37977.495729.EE; Lyketsos CG, 2002, JAMA-J AM MED ASSOC, V288, P1475, DOI 10.1001/jama.288.12.1475; McGuinness B, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004034.pub2; McMahon JA, 2006, NEW ENGL J MED, V354, P2764, DOI 10.1056/NEJMoa054025; Mittelman MS, 2003, INT PSYCHOGERIATR, V15, P247, DOI 10.1017/S104161020300927X; Modrego PJ, 2004, ARCH NEUROL-CHICAGO, V61, P1290, DOI 10.1001/archneur.61.8.1290; Molnar FJ, 2006, ALZ DIS ASSOC DIS, V20, P295, DOI 10.1097/01.wad.0000213843.43871.c7; Mowla A, 2007, J CLIN PSYCHOPHARM, V27, P67, DOI 10.1097/jcp.0b013e31802e0002; Mulsant BH, 2003, ARCH GEN PSYCHIAT, V60, P198, DOI 10.1001/archpsyc.60.2.198; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Nelson AP, 2008, CNS SPECTRUMS, V13, P56, DOI 10.1017/S1092852900016163; Nilsson LG, 2003, ACTA NEUROL SCAND, V107, P7, DOI 10.1034/j.1600-0404.107.s179.5.x; Okonkwo OC, 2006, J AM GERIATR SOC, V54, P1745, DOI 10.1111/j.1532-5415.2006.00916.x; Pappolla MA, 2003, NEUROLOGY, V61, P199, DOI 10.1212/01.WNL.0000070182.02537.84; PETERS O, 2006, ALZHEIMERS DEMENT, V2, pS509; Petersen RC, 2001, ARCH NEUROL-CHICAGO, V58, P1985, DOI 10.1001/archneur.58.12.1985; Petersen RC, 2005, NEW ENGL J MED, V352, P2379, DOI 10.1056/NEJMoa050151; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; Petersen RC, 2007, NAT CLIN PRACT NEURO, V3, P60, DOI 10.1038/ncpneuro0402; Petersen RC, 2006, ARCH NEUROL-CHICAGO, V63, P665, DOI 10.1001/archneur.63.5.665; *PHARM RES MAN AM, NEW MED DAT; QIZILBASH N, 2002, EVIDENCE BASED DEMEN, P357; RAFII M, 2008, JAMA-J AM MED ASSOC, V299, P132; Raiha I, 1998, J NEUROL NEUROSUR PS, V65, P785, DOI 10.1136/jnnp.65.5.785; Ramassamy C, 2006, EUR J PHARMACOL, V545, P51, DOI 10.1016/j.ejphar.2006.06.025; Ravaglia G, 2005, AGING CLIN EXP RES, V17, P374; Reid LM, 2006, DEMENT GERIATR COGN, V22, P471, DOI 10.1159/000096295; Reitz C, 2004, ARCH NEUROL-CHICAGO, V61, P705, DOI 10.1001/archneur.61.5.705; Resnick SM, 2006, J CLIN ENDOCR METAB, V91, P1802, DOI 10.1210/jc.2005-2097; Ries ML, 2008, J AM GERIATR SOC, V56, P920, DOI 10.1111/j.1532-5415.2008.01684.x; Rockwood K, 2006, ACTA NEUROL SCAND, V114, P71, DOI 10.1111/j.1600-0404.2006.00688.x; Scarmeas N, 2006, ARCH NEUROL-CHICAGO, V63, P1709, DOI 10.1001/archneur.63.12.noc60109; Schmitt JAJ, 2001, J PSYCHOPHARMACOL, V15, P173, DOI 10.1177/026988110101500304; Silverman DHS, 2001, JAMA-J AM MED ASSOC, V286, P2120, DOI 10.1001/jama.286.17.2120; Sobow T, 2007, NEUROL NEUROCHIR POL, V41, P13; Solfrizzi Vincenzo, 2008, Expert Rev Neurother, V8, P133, DOI 10.1586/14737175.8.1.133; Sparks DL, 2006, ACTA NEUROL SCAND, V114, P3, DOI 10.1111/j.1600-0404.2006.00690.x; Staekenborg SS, 2008, STROKE, V39, P317, DOI 10.1161/STROKEAHA.107.493353; Straus SE, 2005, EVIDENCE BASED MED P; Thal LJ, 2005, NEUROPSYCHOPHARMACOL, V30, P1204, DOI 10.1038/sj.npp.1300690; Trenkle DL, 2007, J ALZHEIMERS DIS, V11, P323; Tsai DH, 2006, J NEUROPSYCH CLIN N, V18, P384, DOI 10.1176/appi.neuropsych.18.3.384; Tsiakiri A., 2022, APPL NEUROPSYCH-ADUL, DOI [10.1080/23279095.2022.2074850, DOI 10.1080/23279095.2022.2074850]; TUOKKO H, 1995, J GERONTOL B-PSYCHOL, V50, pS173, DOI 10.1093/geronb/50B.3.S173; Visser PJ, 2006, NEUROLOGY, V67, P1201, DOI 10.1212/01.wnl.0000238517.59286.c5; Weiner DK, 2006, PAIN MED, V7, P60, DOI 10.1111/j.1526-4637.2006.00091.x; Williams PS., 2000, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001296, DOI 10.1002/14651858.CD001296]; [No title captured]; 2005, IMPORTANT PRESCRIBIN	89	18	19	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	2008	300	13					1566	1574		10.1001/jama.300.9.jrr80008	http://dx.doi.org/10.1001/jama.300.9.jrr80008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	354CY	18768403				2022-12-28	WOS:000259617700020
J	Hodnett, ED; Stremler, R; Willan, AR; Weston, JA; Lowe, NK; Simpson, KR; Fraser, WD; Gafni, A				Hodnett, Ellen D.; Stremler, Robyn; Willan, Andrew R.; Weston, Julie A.; Lowe, Nancy K.; Simpson, Kathleen R.; Fraser, William D.; Gafni, Amiram		SELAN Trial Grp	Effect on birth outcomes of a formalised approach to care in hospital labour assessment units: international, randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							OCCIPUT POSTERIOR POSITION; COMPLEX INTERVENTIONS; PAIN; PREGNANCY; ANXIETY; COMPLICATIONS; SATISFACTION; MANAGEMENT; DELIVERY; SUPPORT	Objective To determine if a complex nursing and midwifery intervention in hospital labour assessment units would increase the likelihood of spontaneous vaginal birth and improve other maternal and neonatal outcomes. Design Multicentre, randomised controlled trial with prognostic stratification by hospital. Setting 20 North American and UK hospitals. Participants 5002 nulliparous women experiencing contractions but not in active labour; 2501 were allocated to structured care and 2501 to usual care. Interventions Usual nursing or midwifery care or a minimum of one hour of care by a nurse or midwife trained in structured care, consisting of a formalised approach to assessment of and interventions for maternal emotional state, pain, and fetal position. Main outcome measures Primary outcome was spontaneous vaginal birth. Other outcomes included intrapartum interventions, women's views of their care, and indicators of maternal and fetal health during hospital stay and 6- 8 weeks after discharge. Results Outcome data were obtained for 4996 women. The rate of spontaneous vaginal birth was 64.0% ( n= 1597) in the structured care group and 61.3% ( n= 1533) in the usual care group ( odds ratio 1.12, 95% confidence interval 0.96 to 1.27). Fewer women allocated to structured care ( n= 403, 19.5%) rated staff helpfulness as less than very helpful than those allocated to usual care ( n= 544, 26.4%); odds ratio 0.67, 98.75% confidence interval 0.50 to 0.85. Fewer women allocated to structured care ( n= 233, 11.3%) were disappointed with the amount of attention received from staff than those allocated to usual care ( n= 407, 19.7%); odds ratio 0.51, 98.75% confidence interval 0.32 to 0.70. None of the other results met prespecified levels of statistical significance. Conclusion A structured approach to care in hospital labour assessment units increased satisfaction with care and was suggestive of a modest increase in the likelihood of spontaneous vaginal birth. Further study to strengthen the intervention is warranted. Trial registration Current Controlled Trials ISRCTN16315180.	[Hodnett, Ellen D.; Stremler, Robyn; Weston, Julie A.] Univ Toronto, Lawrence S Bloomberg Fac Nursing, Toronto, ON M5T 1P8, Canada; [Stremler, Robyn; Willan, Andrew R.] Hosp Sick Children, Program Child Hlth Evaluat Sci, Toronto, ON M5G 1X8, Canada; [Stremler, Robyn; Willan, Andrew R.] Univ Toronto, Res Inst, Toronto, ON M5T 1P8, Canada; [Willan, Andrew R.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON M5T 3M7, Canada; [Lowe, Nancy K.] Univ Colorado, Hlth Sci Ctr, Sch Nursing, Denver, CO 80262 USA; [Simpson, Kathleen R.] St Johns Mercy Med Ctr, St Louis, MO 63141 USA; [Fraser, William D.] Univ Montreal, Dept Obstet Gynecol, Montreal, PQ, Canada; [Gafni, Amiram] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Gafni, Amiram] McMaster Univ, Ctr Hlth Econ & Policy Evaluat, Hamilton, ON, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Saint Johns Mercy Medical Center; Universite de Montreal; McMaster University; McMaster University	Hodnett, ED (corresponding author), Univ Toronto, Lawrence S Bloomberg Fac Nursing, 155 Coll St, Toronto, ON M5T 1P8, Canada.	ellen.hodnett@utoronto.ca	Lee, Shoo K/P-3016-2015	Soltani, Hora/0000-0001-9611-6777	Canadian Institutes of Health Research [MCT59614]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	Canadian Institutes of Health Research (grant No MCT59614).	Astin JA, 2004, CLIN J PAIN, V20, P27, DOI 10.1097/00002508-200401000-00006; BECK NC, 1980, J PSYCHOSOM RES, V24, P343, DOI 10.1016/0022-3999(80)90026-4; BROWN S, 1994, BIRTH-ISS PERINAT C, V21, P4, DOI 10.1111/j.1523-536X.1994.tb00909.x; Campbell NC, 2007, BMJ-BRIT MED J, V334, P455, DOI 10.1136/bmj.39108.379965.BE; CHELMOW D, 1993, OBSTET GYNECOL, V81, P486; Cox J. L., 1994, PERINATAL PSYCHIAT U; CRAMOND W, 1962, LANCET, V2, P1241; CRANDON AJ, 1979, J PSYCHOSOM RES, V23, P109, DOI 10.1016/0022-3999(79)90014-X; ERICKSON MT, 1976, J PSYCHOSOM RES, V20, P207, DOI 10.1016/0022-3999(76)90022-2; Friedman EA, 1987, LABOR DELIVERY IMPAC; Gardberg M, 1998, OBSTET GYNECOL, V91, P746, DOI 10.1016/S0029-7844(98)00074-X; GARDBERG M, 1994, ACTA OBSTET GYN SCAN, V73, P45, DOI 10.3109/00016349409013392; Hawe P, 2004, BMJ-BRIT MED J, V328, P1561, DOI 10.1136/bmj.328.7455.1561; Hodnett ED, 2002, AM J OBSTET GYNECOL, V186, pS160, DOI 10.1067/mob.2002.121141; Hodnett ED, 2002, JAMA-J AM MED ASSOC, V288, P1373, DOI 10.1001/jama.288.11.1373; *I CLIN SYST IMPR, 2007, MAN LAB; Janssen PA, 2006, OBSTET GYNECOL, V108, P1463, DOI 10.1097/01.AOG.0000247644.64154.bb; KAPP TT, 1963, COMPR PSYCHIAT, V4, P9; LEDERMAN RP, 1979, NURS RES, V28, P94; McNiven PS, 1998, BIRTH-ISS PERINAT C, V25, P5, DOI 10.1046/j.1523-536x.1998.00005.x; *MEDSCINET, 2008, INT DAT SOL; Menacker Fay, 2005, Natl Vital Stat Rep, V54, P1; ODRISCOLL K, 1993, ACTIVE MANAGEMENT LA; OXOM H, 1986, OXOM FOOTE HUMAN LAB; PEARL ML, 1993, J REPROD MED, V38, P955; PORTER M, 1984, SOC SCI MED, V19, P1197, DOI 10.1016/0277-9536(84)90370-8; RUTHERFORD AM, 1981, NEW ZEAL MED J, V94, P419; SAUNDERS NJS, 1989, BRIT MED J, V299, P1423, DOI 10.1136/bmj.299.6713.1423; SIMKIN P, 1999, LABOR PROGR HDB EARL; Stephenson J, 1998, BMJ-BRIT MED J, V316, P611, DOI 10.1136/bmj.316.7131.611; Stremler R, 2005, BIRTH-ISS PERINAT C, V32, P243, DOI 10.1111/j.0730-7659.2005.00382.x; US Department of Health and Human Services, 2010, HLTH PEOPL 2010, V2; Watt Margo C., 2006, Cognitive Behaviour Therapy, V35, P248, DOI 10.1080/16506070600898553; WUITCHIK M, 1989, OBSTET GYNECOL, V73, P35	34	34	34	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2008	337	7670							a1021	10.1136/bmj.a1021	http://dx.doi.org/10.1136/bmj.a1021			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354DT	18755762	hybrid, Green Published			2022-12-28	WOS:000259619800039
J	Umehara, M; Hanada, A; Yoshida, S; Akiyama, K; Arite, T; Takeda-Kamiya, N; Magome, H; Kamiya, Y; Shirasu, K; Yoneyama, K; Kyozuka, J; Yamaguchi, S				Umehara, Mikihisa; Hanada, Atsushi; Yoshida, Satoko; Akiyama, Kohki; Arite, Tomotsugu; Takeda-Kamiya, Noriko; Magome, Hiroshi; Kamiya, Yuji; Shirasu, Ken; Yoneyama, Koichi; Kyozuka, Junko; Yamaguchi, Shinjiro			Inhibition of shoot branching by new terpenoid plant hormones	NATURE			English	Article							ARBUSCULAR MYCORRHIZAL FUNGI; GERMINATION STIMULANTS; PHOSPHORUS DEFICIENCY; APICAL-DOMINANCE; GIBBERELLIC-ACID; PARASITIC PLANTS; ROOT PARASITES; ARABIDOPSIS; RICE; STRIGOL	Shoot branching is a major determinant of plant architecture and is highly regulated by endogenous and environmental cues. Two classes of hormones, auxin and cytokinin, have long been known to have an important involvement in controlling shoot branching. Previous studies using a series of mutants with enhanced shoot branching suggested the existence of a third class of hormone( s) that is derived from carotenoids, but its chemical identity has been unknown. Here we show that levels of strigolactones, a group of terpenoid lactones, are significantly reduced in some of the branching mutants. Furthermore, application of strigolactones inhibits shoot branching in these mutants. Strigolactones were previously found in root exudates acting as communication chemicals with parasitic weeds and symbiotic arbuscular mycorrhizal fungi. Thus, we propose that strigolactones act as a new hormone class - or their biosynthetic precursors - in regulating above- ground plant architecture, and also have a function in underground communication with other neighbouring organisms.	[Umehara, Mikihisa; Hanada, Atsushi; Yoshida, Satoko; Takeda-Kamiya, Noriko; Magome, Hiroshi; Kamiya, Yuji; Shirasu, Ken; Yamaguchi, Shinjiro] RIKEN, Plant Sci Ctr, Yokohama, Kanagawa 2300045, Japan; [Akiyama, Kohki] Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Naka Ku, Osaka 5998531, Japan; [Arite, Tomotsugu; Kyozuka, Junko] Univ Tokyo, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 1138652, Japan; [Yoneyama, Koichi] Utsunomiya Univ, Weed Sci Ctr, Utsunomiya, Tochigi 3218505, Japan	RIKEN; University of Tokyo; Utsunomiya University	Yamaguchi, S (corresponding author), RIKEN, Plant Sci Ctr, Yokohama, Kanagawa 2300045, Japan.	shinjiro@postman.riken.jp	Yoshida, Satoko/G-5003-2010; Umehara, M/D-2416-2011; Akiyama, Kohki/B-4668-2012; yoshida, satoko/AAO-4892-2020; Shirasu, Ken/ABF-5306-2020; Shirasu, Ken/A-4455-2010; Kamiya, Yuji/F-9420-2010; Yamaguchi, Shinjiro/F-9684-2010; Yoneyama, Koichi/A-9819-2012; Kyozuka, Junko/E-7844-2012; Yoshida, Satoko/AAZ-4757-2021	Yoshida, Satoko/0000-0002-9999-7861; yoshida, satoko/0000-0002-9999-7861; Shirasu, Ken/0000-0002-0349-3870; Shirasu, Ken/0000-0002-0349-3870; Kamiya, Yuji/0000-0003-4415-520X; Yoneyama, Koichi/0000-0002-4930-035X; Akiyama, Kohki/0000-0002-9171-9058; Kyozuka, Junko/0000-0003-2242-7171	MEXT of Japan [1820810, 19678001, 19780040]; MAFF of Japan (Genomics for Agricultural Innovation) [IPG0001]; RIKEN Special Postdoctoral Researchers Program	MEXT of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); MAFF of Japan (Genomics for Agricultural Innovation); RIKEN Special Postdoctoral Researchers Program	We are grateful to S. Ishikawa for sequencing the d17-1 allele; K. Fujiwara for assistance in preparing plant materials; N. Makita and H. Sakakibara for their advice on rice hydroponic culture; and Y. Tsuchiya for advice on germination assays. We thank the Salk Institute and the Arabidopsis Biological Resource Center for providing Arabidopsis T-DNA insertion lines; T. Yokota, K. Yoneyama and X. Xie for sharing information on strigolactone analysis; M. Maekawa for propagating rice seeds; and K. Mori, P. McCourt and A. Gabar Babiker for providing (+)-strigol and 2 '-epi-orobanchol, (+)-GR24, and S. hermonthica seeds, respectively. This work was supported in part by grants from the MEXT of Japan ( 1820810 to K. Y., 19678001 to K. S. and 19780040 to Sa. Y.) and the MAFF of Japan (Genomics for Agricultural Innovation, IPG0001 to J.K.). M. U. is supported by the RIKEN Special Postdoctoral Researchers Program.	Akiyama K, 2005, NATURE, V435, P824, DOI 10.1038/nature03608; Arite T, 2007, PLANT J, V51, P1019, DOI 10.1111/j.1365-313X.2007.03210.x; Auldridge ME, 2006, PLANT J, V45, P982, DOI 10.1111/j.1365-313X.2006.02666.x; Beveridge CA, 1996, PLANT PHYSIOL, V110, P859, DOI 10.1104/pp.110.3.859; BEVERIDGE CA, 1994, PLANT PHYSIOL, V104, P953, DOI 10.1104/pp.104.3.953; Beveridge CA, 2000, PLANT PHYSIOL, V123, P689, DOI 10.1104/pp.123.2.689; Booker J, 2005, DEV CELL, V8, P443, DOI 10.1016/j.devcel.2005.01.009; Booker J, 2004, CURR BIOL, V14, P1232, DOI 10.1016/j.cub.2004.06.061; Bouwmeester HJ, 2007, TRENDS PLANT SCI, V12, P224, DOI 10.1016/j.tplants.2007.03.009; Bouwmeester HJ, 2003, CURR OPIN PLANT BIOL, V6, P358, DOI 10.1016/S1369-5266(03)00065-7; BRADOW JM, 1988, J PLANT GROWTH REGUL, V7, P227, DOI 10.1007/BF02025265; BRADOW JM, 1990, J PLANT GROWTH REGUL, V9, P35, DOI 10.1007/BF02041939; CLINE MG, 1991, BOT REV, V57, P318, DOI 10.1007/BF02858771; COOK CE, 1972, J AM CHEM SOC, V94, P6198, DOI 10.1021/ja00772a048; Goldstick D, 2008, RATIO, V21, P28, DOI 10.1111/j.1467-9329.2007.00382.x; Gressel J, 2004, CROP PROT, V23, P661, DOI 10.1016/j.cropro.2003.11.014; Gurney AL, 2006, NEW PHYTOL, V169, P199, DOI 10.1111/j.1469-8137.2005.01560.x; Humphrey AJ, 2006, PHYTOCHEMISTRY, V67, P636, DOI 10.1016/j.phytochem.2005.12.026; Ishikawa S, 2005, PLANT CELL PHYSIOL, V46, P79, DOI 10.1093/pcp/pci022; Joel DM, 2000, CROP PROT, V19, P753, DOI 10.1016/S0261-2194(00)00100-9; Johnson X, 2006, PLANT PHYSIOL, V142, P1014, DOI 10.1104/pp.106.087676; KAMACHI K, 1991, PLANT PHYSIOL, V96, P411, DOI 10.1104/pp.96.2.411; Lechner E, 2006, CURR OPIN PLANT BIOL, V9, P631, DOI 10.1016/j.pbi.2006.09.003; Lopez-Raez JA, 2008, NEW PHYTOL, V178, P863, DOI 10.1111/j.1469-8137.2008.02406.x; Magome H, 2004, PLANT J, V37, P720, DOI 10.1111/j.1365-313X.2003.01998.x; MANGNUS EM, 1992, J AGR FOOD CHEM, V40, P1230, DOI 10.1021/jf00019a031; Matusova R, 2005, PLANT PHYSIOL, V139, P920, DOI 10.1104/pp.105.061382; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Noren H, 2004, PHYSIOL PLANTARUM, V121, P343, DOI 10.1111/j.0031-9317.2004.00350.x; Ongaro V, 2008, J EXP BOT, V59, P67, DOI 10.1093/jxb/erm134; Schwartz SH, 2004, J BIOL CHEM, V279, P46940, DOI 10.1074/jbc.M409004200; Simons JL, 2007, PLANT PHYSIOL, V143, P697, DOI 10.1104/pp.106.087957; Snowden KC, 2005, PLANT CELL, V17, P746, DOI 10.1105/tpc.104.027714; Sorefan K, 2003, GENE DEV, V17, P1469, DOI 10.1101/gad.256603; Stirnberg P, 2002, DEVELOPMENT, V129, P1131; Sugimoto Y, 2008, PHYTOCHEMISTRY, V69, P212, DOI 10.1016/j.phytochem.2007.06.011; Turnbull CGN, 2002, PLANT J, V32, P255, DOI 10.1046/j.1365-313X.2002.01419.x; Varbanova M, 2007, PLANT CELL, V19, P32, DOI 10.1105/tpc.106.044602; Xie X, 2007, J AGR FOOD CHEM, V55, P8067, DOI 10.1021/jf0715121; Yoneyama K, 2008, NEW PHYTOL, V179, P484, DOI 10.1111/j.1469-8137.2008.02462.x; Yoneyama K, 2007, PLANTA, V227, P125, DOI 10.1007/s00425-007-0600-5; Yoneyama K, 2007, PLANTA, V225, P1031, DOI 10.1007/s00425-006-0410-1; Zou JH, 2005, PLANTA, V222, P604, DOI 10.1007/s00425-005-0007-0; Zou JH, 2006, PLANT J, V48, P687, DOI 10.1111/j.1365-313X.2006.02916.x	44	1310	1434	31	604	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 11	2008	455	7210					195	U29		10.1038/nature07272	http://dx.doi.org/10.1038/nature07272			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	346SZ	18690207				2022-12-28	WOS:000259090800040
J	Bohannon, J				Bohannon, John			The Gonzo scientist - Chasing the biggest shadow of all	SCIENCE			English	Editorial Material																		Stone R, 2008, SCIENCE, V321, P759, DOI 10.1126/science.321.5890.759	1	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	2008	321	5894					1297	1297		10.1126/science.1164877	http://dx.doi.org/10.1126/science.1164877			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	344GG	18772420				2022-12-28	WOS:000258914300030
J	Valle, L; Serena-Acedo, T; Liyanarachchi, S; Hampel, H; Comeras, I; Li, ZY; Zeng, QH; Zhang, HT; Pennison, MJ; Sadim, M; Pasche, B; Tanner, SM; de la Chapelle, A				Valle, Laura; Serena-Acedo, Tarsicio; Liyanarachchi, Sandya; Hampel, Heather; Comeras, Ilene; Li, Zhongyuan; Zeng, Qinghua; Zhang, Hong-Tao; Pennison, Michael J.; Sadim, Maureen; Pasche, Boris; Tanner, Stephan M.; de la Chapelle, Albert			Germline allele-specific expression of TGFBR1 confers an increased risk of colorectal cancer	SCIENCE			English	Article							HUMAN GENE-EXPRESSION; BETA RECEPTOR; TGFBR1-ASTERISK-6A; SMAD3; PREDISPOSITION; SUSCEPTIBILITY; TUMORIGENESIS; DEFICIENCY; KINDREDS; VARIANT	Much of the genetic predisposition to colorectal cancer (CRC) in humans is unexplained. Studying a Caucasian- dominated population in the United States, we showed that germline allele- specific expression ( ASE) of the gene encoding transforming growth factor-beta (TGF-beta) type I receptor, TGFBR1, is a quantitative trait that occurs in 10 to 20% of CRC patients and 1 to 3% of controls. ASE results in reduced expression of the gene, is dominantly inherited, segregates in families, and occurs in sporadic CRC cases. Although subtle, the reduction in constitutive TGFBR1 expression alters SMAD- mediated TGF-beta signaling. Two major TGFBR1 haplotypes are predominant among ASE cases, which suggests ancestral mutations, but causative germline changes have not been identified. Conservative estimates suggest that ASE confers a substantially increased risk of CRC ( odds ratio, 8.7; 95% confidence interval, 2.6 to 29.1), but these estimates require confirmation and will probably show ethnic differences.	[Zeng, Qinghua; Zhang, Hong-Tao; Pennison, Michael J.; Sadim, Maureen; Pasche, Boris] Northwestern Univ, Canc Genet Program, Div Hematol Oncol, Dept Med, Chicago, IL 60611 USA; [Zeng, Qinghua; Zhang, Hong-Tao; Pennison, Michael J.; Sadim, Maureen; Pasche, Boris] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA; [Valle, Laura; Serena-Acedo, Tarsicio; Liyanarachchi, Sandya; Hampel, Heather; Comeras, Ilene; Li, Zhongyuan; Tanner, Stephan M.; de la Chapelle, Albert] Ohio State Univ, Human Canc Genet Program, Ctr Comprehens Canc, Columbus, OH 43210 USA	Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Pasche, B (corresponding author), Northwestern Univ, Canc Genet Program, Div Hematol Oncol, Dept Med, Chicago, IL 60611 USA.	b-pasche@northwestern.edu; Stephan.Tanner@osumc.edu; Albert.delaChapelle@osumc.edu	Valle, Laura/H-8118-2012; Zhang, Hong-Tao/P-9661-2017; Hampel, Heather/AAV-4041-2020	Valle, Laura/0000-0003-0371-0844; Zhang, Hong-Tao/0000-0003-4182-421X; Hampel, Heather/0000-0001-7558-9794; Edsall, Lee Elizabeth/0000-0002-0326-2829	NIH [CA67941, CA16058, CA112520, CA108741]; Walter S. Mander Foundation; Jeannik M. Littlefield-American Association for Cancer Research Grant in Metastatic Colon Cancer Research; Fundacion Ramon Areces.; NATIONAL CANCER INSTITUTE [R01CA067941, P30CA016058, U01CA067941, R01CA112520, R01CA108741] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Walter S. Mander Foundation; Jeannik M. Littlefield-American Association for Cancer Research Grant in Metastatic Colon Cancer Research; Fundacion Ramon Areces.; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank H. He, K. Sotamaa, and W. Frankel for help. This work was supported by NIH grants CA67941, CA16058, CA112520, and CA108741; grants from the Walter S. Mander Foundation, Chicago, IL; and the Jeannik M. Littlefield-American Association for Cancer Research Grant in Metastatic Colon Cancer Research. L. V. was supported by a fellowship from the Fundacion Ramon Areces.	Bian Y, 2005, J CLIN ONCOL, V23, P3074, DOI 10.1200/JCO.2005.00.281; Bierie B, 2006, CYTOKINE GROWTH F R, V17, P29, DOI 10.1016/j.cytogfr.2005.09.006; de la Chapelle A, 2004, NAT REV CANCER, V4, P769, DOI 10.1038/nrc1453; Goring HHH, 2007, NAT GENET, V39, P1208, DOI 10.1038/ng2119; Kemp ZE, 2006, CANCER RES, V66, P5003, DOI 10.1158/0008-5472.CAN-05-4074; Lindor NM, 2005, JAMA-J AM MED ASSOC, V293, P1979, DOI 10.1001/jama.293.16.1979; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Massague J, 2008, MOL CELL, V29, P149, DOI 10.1016/j.molcel.2008.01.006; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Morley M, 2004, NATURE, V430, P743, DOI 10.1038/nature02797; Park SK, 2005, AGEING RES REV, V4, P55, DOI 10.1016/j.arr.2004.09.003; Pasche B, 1999, CANCER RES, V59, P5678; Pasche B, 2005, JAMA-J AM MED ASSOC, V294, P1634, DOI 10.1001/jama.294.13.1634; Pasche B, 1998, CANCER RES, V58, P2727; Pasche B, 2004, J CLIN ONCOL, V22, P756, DOI 10.1200/JCO.2004.99.271; Raval A, 2007, CELL, V129, P879, DOI 10.1016/j.cell.2007.03.043; Sekimoto G, 2007, CANCER RES, V67, P5090, DOI 10.1158/0008-5472.CAN-06-4629; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Skoglund J, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.033928; Skoglund J, 2007, CLIN CANCER RES, V13, P3748, DOI 10.1158/1078-0432.CCR-06-2865; Sodir NM, 2006, CANCER RES, V66, P8430, DOI 10.1158/0008-5472.CAN-06-1437; Stranger BE, 2007, NAT GENET, V39, P1217, DOI 10.1038/ng2142; Wiesner GL, 2003, P NATL ACAD SCI USA, V100, P12961, DOI 10.1073/pnas.2132286100; Xu YF, 2007, HUM MOL GENET, V16, pR14, DOI 10.1093/hmg/ddl486; Yan H, 2004, CURR OPIN ONCOL, V16, P39, DOI 10.1097/00001622-200401000-00008; Yan H, 2002, NAT GENET, V30, P25, DOI 10.1038/ng799; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	30	119	124	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	2008	321	5894					1361	1365		10.1126/science.1159397	http://dx.doi.org/10.1126/science.1159397			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	344GG	18703712	Green Accepted			2022-12-28	WOS:000258914300052
J	Poole, JE; Johnson, GW; Hellkamp, AS; Anderson, J; Callans, DJ; Raitt, MH; Reddy, RK; Marchlinski, FE; Yee, R; Guarnieri, T; Talajic, M; Wilber, DJ; Fishbein, DP; Packer, DL; Mark, DB; Lee, KL; Bardy, GH				Poole, Jeanne E.; Johnson, George W.; Hellkamp, Anne S.; Anderson, Jill; Callans, David J.; Raitt, Merritt H.; Reddy, Ramakota K.; Marchlinski, Francis E.; Yee, Raymond; Guarnieri, Thomas; Talajic, Mario; Wilber, David J.; Fishbein, Daniel P.; Packer, Douglas L.; Mark, Daniel B.; Lee, Kerry L.; Bardy, Gust H.			Prognostic importance of defibrillator shocks in patients with heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; PROPHYLACTIC IMPLANTATION; MYOCARDIAL DYSFUNCTION; ATRIAL-FIBRILLATION; TRIAL; TACHYARRHYTHMIA; THERAPY	Background: Patients with heart failure who receive an implantable cardioverter-defibrillator (ICD) for primary prevention (i.e., prevention of a first life-threatening arrhythmic event) may later receive therapeutic shocks from the ICD. Information about long-term prognosis after ICD therapy in such patients is limited. Methods: Of 829 patients with heart failure who were randomly assigned to ICD therapy, we implanted the ICD in 811. ICD shocks that followed the onset of ventricular tachycardia or ventricular fibrillation were considered to be appropriate. All other ICD shocks were considered to be inappropriate. Results: Over a median follow-up period of 45.5 months, 269 patients (33.2%) received at least one ICD shock, with 128 patients receiving only appropriate shocks, 87 receiving only inappropriate shocks, and 54 receiving both types of shock. In a Cox proportional-hazards model adjusted for baseline prognostic factors, an appropriate ICD shock, as compared with no appropriate shock, was associated with a significant increase in the subsequent risk of death from all causes (hazard ratio, 5.68; 95% confidence interval [CI], 3.97 to 8.12; P<0.001). An inappropriate ICD shock, as compared with no inappropriate shock, was also associated with a significant increase in the risk of death (hazard ratio, 1.98; 95% CI, 1.29 to 3.05; P=0.002). For patients who survived longer than 24 hours after an appropriate ICD shock, the risk of death remained elevated (hazard ratio, 2.99; 95% CI, 2.04 to 4.37; P<0.001). The most common cause of death among patients who received any ICD shock was progressive heart failure. Conclusions: Among patients with heart failure in whom an ICD is implanted for primary prevention, those who receive shocks for any arrhythmia have a substantially higher risk of death than similar patients who do not receive such shocks.	[Poole, Jeanne E.; Fishbein, Daniel P.; Bardy, Gust H.] Univ Washington, Sch Med, Div Cardiol, Seattle, WA 98195 USA; [Johnson, George W.; Anderson, Jill; Bardy, Gust H.] Seattle Inst Cardiac Res, Seattle, WA USA; [Hellkamp, Anne S.; Mark, Daniel B.; Lee, Kerry L.] Duke Clin Res Inst, Durham, NC USA; [Callans, David J.; Marchlinski, Francis E.] Univ Penn, Philadelphia, PA 19104 USA; [Raitt, Merritt H.] Portland VA Med Ctr, Portland, OR USA; [Raitt, Merritt H.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Reddy, Ramakota K.] Oregon Cardiol Assoc, Eugene, OR USA; [Yee, Raymond] Univ Western Ontario, Univ Hosp, London, ON N6A 5A5, Canada; [Guarnieri, Thomas] Johns Hopkins Univ, Baltimore, MD USA; [Talajic, Mario] Univ Montreal, Inst Cardiol Montreal, Montreal, PQ, Canada; [Wilber, David J.] Loyola Univ, Med Ctr, Maywood, IL 60153 USA; [Packer, Douglas L.] Mayo Clin, Rochester, MN USA	University of Washington; University of Washington Seattle; Duke University; University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; Oregon Health & Science University; Western University (University of Western Ontario); Johns Hopkins University; Universite de Montreal; Institut de Cardiologie de Montreal; Loyola University Chicago; Mayo Clinic	Poole, JE (corresponding author), Univ Washington, Sch Med, Div Cardiol, 1959 NE Pacific St,Box 356422, Seattle, WA 98195 USA.	jpoole@u.washington.edu	Callans, David/ABH-2176-2021; Yee, Raymond/H-1323-2011	Talajic, Mario/0000-0001-8469-4748; Marchlinski, Francis/0000-0001-7962-9423; Mark, Daniel/0000-0001-6340-8087; Raitt, Merritt/0000-0001-5638-7732	National Heart, Lung, and Blood Institute [UO1 HL55766, UO1 HL55297, UO1 HL55496]; Medtronic; Wyeth Pharmaceuticals; Boston Scientific/Guidant; Biotronik; Biosense Webster; Siemens Acuson; Boston Scientific; St. Jude Medical; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL055297, U01HL055766, U01HL055496] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Medtronic(Medtronic); Wyeth Pharmaceuticals(Wyeth); Boston Scientific/Guidant(Boston Scientific); Biotronik; Biosense Webster; Siemens Acuson; Boston Scientific(Boston Scientific); St. Jude Medical(St. Jude Medical); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by grants from the National Heart, Lung, and Blood Institute (UO1 HL55766, UO1 HL55297, and UO1 HL55496) and by Medtronic and Wyeth Pharmaceuticals. Dr. Poole reports receiving lecture fees from Medtronic and Boston Scientific/Guidant, grant support from Biotronik, and consulting fees from Philips; Ms. Anderson, receiving lecture fees from Boston Scientific/Guidant; Dr. Callans, receiving lecture fees from Biosense Webster, Siemens Acuson, Boston Scientific, and Medtronic and consulting fees from St. Jude Medical; Dr. Reddy, receiving consulting fees and lecture fees from Boston Scientific/Guidant, Medtronic, and St. Jude and holding stock options in Cambridge Heart; Dr. Marchlinski, receiving consulting fees, lecture fees, and grant support from Biosense Webster, lecture fees and grant support from Boston Scientific and St. Jude Medical, lecture fees from Medtronic, and consulting fees from GE Healthcare; Dr. Yee, receiving consulting fees from Medtronic; Dr. Talajic, receiving consulting fees and lecture fees from Medtronic and lecture fees from St. Jude Medical; Dr. Wilber, receiving consulting fees and lecture fees from Medtronic and lecture fees from Boston Scientific and St. Jude Medical; Dr. Fishbein, receiving lecture fees from Medtronic; Dr. Packer, receiving consulting fees from Medtronic and Boston Scientific/ Guidant, royalties from St. Jude Medical, and grant support from Boston Scientific; Dr. Mark, receiving consulting fees, lecture fees, and research grants from Medtronic and fees as editor of the American Heart Journal from Mosby; Dr. Lee, receiving grant support and consulting fees from Medtronic; and Dr. Bardy, receiving grant support from and having intellectual property rights with Medtronic, receiving consulting fees and grant support from Philips, receiving grant support from Laerdal and being a founder of and board member of and having equity and intellectual property rights with Cameron Health. No other potential conflict of interest relevant to this article was reported. We thank R. Conklin for help in the preparation of the manuscript.	Bardy G., 2000, ARRHYTHMIA TREATMENT, P323; Bardy GH, 2005, NEW ENGL J MED, V352, P2146; Bardy GH, 2005, NEW ENGL J MED, V352, P225, DOI 10.1056/NEJMoa043399; Benza RL, 2004, J CARD FAIL, V10, P279, DOI 10.1016/j.cardfail.2003.12.007; COX DR, 1972, J R STAT SOC B, V34, P187; Daubert JP, 2008, J AM COLL CARDIOL, V51, P1357, DOI 10.1016/j.jacc.2007.09.073; Goldenberg I, 2006, CIRCULATION, V113, P2810, DOI 10.1161/CIRCULATIONAHA.105.577262; Hasdemir C, 2002, J CARDIOVASC ELECTR, V13, P144, DOI 10.1046/j.1540-8167.2002.00144.x; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; Lewin JC, 2008, J AM COLL CARDIOL, V51, P2085; Moss AJ, 2004, CIRCULATION, V110, P3760, DOI 10.1161/01.CIR.0000150390.04704.B7; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; Olsson LG, 2006, J AM COLL CARDIOL, V47, P1997, DOI 10.1016/j.jacc.2006.01.060; Swedberg K, 2005, EUR HEART J, V26, P1303, DOI 10.1093/eurheartj/ehi166; Tang WC, 1999, J AM COLL CARDIOL, V34, P815, DOI 10.1016/S0735-1097(99)00270-3; Tokano T, 1998, J CARDIOVASC ELECTR, V9, P791, DOI 10.1111/j.1540-8167.1998.tb00118.x; Wathen MS, 2004, CIRCULATION, V110, P2591, DOI 10.1161/01.CIR.0000145610.64014.E4; WEAVER WD, 1982, NEW ENGL J MED, V307, P1101, DOI 10.1056/NEJM198210283071801; Wilkoff BL, 2004, J CARDIOVASC ELECTR, V15, P1002, DOI 10.1046/j.1540-8167.2004.03625.x; Xie JL, 1997, CIRCULATION, V96, P683; Yamaguchi H, 2002, RESUSCITATION, V54, P289, DOI 10.1016/S0300-9572(02)00149-1	21	1007	1036	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2008	359	10					1009	1017		10.1056/NEJMoa071098	http://dx.doi.org/10.1056/NEJMoa071098			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	343KN	18768944	Green Accepted, Bronze			2022-12-28	WOS:000258852500005
J	Lautenschlager, NT; Cox, KL; Flicker, L; Foster, JK; van Bockxmeer, FM; Xiao, JG; Greenop, KR; Almeida, OP				Lautenschlager, Nicola T.; Cox, Kay L.; Flicker, Leon; Foster, Jonathan K.; van Bockxmeer, Frank M.; Xiao, Jianguo; Greenop, Kathryn R.; Almeida, Osvaldo P.			Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; DOUBLE-BLIND; CLINICAL-TRIALS; PUBLIC-HEALTH; DENTATE GYRUS; EXERCISE; IMPAIRMENT; DEMENTIA; PREVENTION; INTERVENTIONS	Context Many observational studies have shown that physical activity reduces the risk of cognitive decline; however, evidence from randomized trials is lacking. Objective To determine whether physical activity reduces the rate of cognitive decline among older adults at risk. Design and Setting Randomized controlled trial of a 24- week physical activity intervention conducted between 2004 and 2007 in metropolitan Perth, Western Australia. Assessors of cognitive function were blinded to group membership. Participants We recruited volunteers who reported memory problems but did not meet criteria for dementia. Three hundred eleven individuals aged 50 years or older were screened for eligibility, 89 were not eligible, and 52 refused to participate. A total of 170 participants were randomized and 138 participants completed the 18- month assessment. Intervention Participants were randomly allocated to an education and usual care group or to a 24- week home- based program of physical activity. Main Outcome Measure Change in Alzheimer Disease Assessment Scale Cognitive Subscale ( ADAS- Cog) scores ( possible range, 0- 70) over 18 months. Results In an intent- to- treat analysis, participants in the intervention group improved 0.26 points ( 95% confidence interval, - 0.89 to 0.54) and those in the usual care group deteriorated 1.04 points ( 95% confidence interval, 0.32 to 1.82) on the ADAS- Cog at the end of the intervention. The absolute difference of the outcome measure between the intervention and control groups was - 1.3 points ( 95% confidence interval,- 2.38 to - 0.22) at the end of the intervention. At 18 months, participants in the intervention group improved 0.73 points( 95% confidence interval, - 1.27 to 0.03) on the ADAS- Cog, and those in the usual care group improved 0.04 points ( 95% confidence interval, - 0.46 to 0.88). Word list delayed recall and Clinical Dementia Rating sum of boxes improved modestly as well, whereas word list total immediate recall, digit symbol coding, verbal fluency, Beck depression score, and Medical Outcomes 36- Item Short- Form physical and mental component summaries did not change significantly. Conclusions In this study of adults with subjective memory impairment, a 6- month program of physical activity provided a modest improvement in cognition over an 18-month follow- up period. Trial Registration anzctr.org.au Identifier: ACTRN12605000136606.	[Lautenschlager, Nicola T.; Almeida, Osvaldo P.] Univ Western Australia, Sch Psychiat & Clin Neurosci, Perth, WA 6009, Australia; [Cox, Kay L.; Flicker, Leon] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia; [van Bockxmeer, Frank M.] Univ Western Australia, Sch Pathol & Lab Med, Perth, WA 6009, Australia; [Foster, Jonathan K.] Edith Cowan Univ, Sch Exercise Biomed & Hlth Sci, Perth, WA, Australia; [Foster, Jonathan K.] Hollywood Private Hosp, Neurosci Unit, Perth, WA, Australia; [Xiao, Jianguo] Hollywood Private Hosp, Epidemiol Branch, Perth, WA, Australia; [Foster, Jonathan K.] Hollywood Private Hosp, Dept Hlth Western Australia, Sir James McCusker Alzheimers Dis Res Unit, Perth, WA, Australia; [Lautenschlager, Nicola T.; Flicker, Leon; van Bockxmeer, Frank M.; Almeida, Osvaldo P.] Royal Perth Hosp, Perth, WA, Australia; [Lautenschlager, Nicola T.] Univ Melbourne, Acad Unit Psychiat Old Age, Dept Psychiat, Melbourne, Vic, Australia	University of Western Australia; University of Western Australia; University of Western Australia; Edith Cowan University; University of Western Australia; University of Western Australia; University of Western Australia; Royal Perth Hospital; University of Western Australia; University of Melbourne	Lautenschlager, NT (corresponding author), Univ Melbourne, Acad Unit Psychiat Old Age, St Vincents Aged Psychiat Serv, Normanby Unit,St Vincents Hosp, St Georges Campus,283 Cotham Rd, Kew, Vic 3101, Australia.	nicolatl@unimelb.edu.au	Xiao, Jian/GYU-4351-2022; Flicker, Leon/AAE-1530-2022; Flicker, Leon/A-9039-2008; Almeida, Osvaldo P./A-4925-2008; Greenop, Kathryn/D-9039-2011; Kennedy, Kristen M/B-4699-2008	Flicker, Leon/0000-0002-3650-0475; Almeida, Osvaldo P./0000-0002-8689-6199; Greenop, Kathryn/0000-0003-0325-1131; Kennedy, Kristen M/0000-0001-5373-9026; Lautenschlager, Nicola/0000-0003-4850-7794	National Health and Medical Research Council of Australia [303172]	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	This study was supported by grant 303172 from the National Health and Medical Research Council of Australia (Drs Lautenschlager, Almeida, Flicker, Cox and Foster).	Abbott RD, 2004, JAMA-J AM MED ASSOC, V292, P1447, DOI 10.1001/jama.292.12.1447; Almeida OP, 1999, INT J GERIATR PSYCH, V14, P858, DOI 10.1002/(SICI)1099-1166(199910)14:10<858::AID-GPS35>3.0.CO;2-8; Beardsall L, 1998, BRIT J CLIN PSYCHOL, V37, P229, DOI 10.1111/j.2044-8260.1998.tb01297.x; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Birks J, 2006, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001190.pub2, 10.1002/14651858.CD001190.pub3]; Bookheimer SY, 2000, NEW ENGL J MED, V343, P450, DOI 10.1056/NEJM200008173430701; Brookmeyer R, 2007, ALZHEIMERS DEMENT, V3, P186, DOI 10.1016/j.jalz.2007.04.381; *CERAD, 1996, DOC DAT ARCH REV 2 0; Chang JT, 2004, BRIT MED J, V328, P680, DOI 10.1136/bmj.328.7441.680; Colcombe SJ, 2004, P NATL ACAD SCI USA, V101, P3316, DOI 10.1073/pnas.0400266101; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Cox KL, 2003, PREV MED, V36, P17, DOI 10.1006/pmed.2002.1134; DELIS DC, 2001, DELISKAPLAN EXECUTIV, P871; Durga J, 2007, LANCET, V369, P208, DOI 10.1016/S0140-6736(07)60109-3; Feldman HH, 2007, LANCET NEUROL, V6, P501, DOI 10.1016/S1474-4422(07)70109-6; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Forette F, 2002, ARCH INTERN MED, V162, P2046, DOI 10.1001/archinte.162.18.2046; HIXSON JE, 1990, J LIPID RES, V31, P545; Jelic V, 2006, J NEUROL NEUROSUR PS, V77, P429, DOI 10.1136/jnnp.2005.072926; Kronenberg G, 2006, NEUROBIOL AGING, V27, P1505, DOI 10.1016/j.neurobiolaging.2005.09.016; Larson EB, 2006, ANN INTERN MED, V144, P73, DOI 10.7326/0003-4819-144-2-200601170-00004; Lines CR, 2003, NEUROLOGY, V60, P261, DOI 10.1212/01.WNL.0000042481.34899.13; Lithell H, 2003, J HYPERTENS, V21, P875, DOI 10.1097/00004872-200305000-00011; McMahon JA, 2006, NEW ENGL J MED, V354, P2764, DOI 10.1056/NEJMoa054025; Miller Ruth, 2006, J Phys Act Health, V3, P257, DOI 10.1123/jpah.3.3.257; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Netz Y, 2005, PSYCHOL AGING, V20, P272, DOI 10.1037/0882-7974.20.2.272; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Petersen RC, 2005, NEW ENGL J MED, V352, P2379, DOI 10.1056/NEJMoa050151; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; Podewils LJ, 2005, AM J EPIDEMIOL, V161, P639, DOI 10.1093/aje/kwi092; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; Spirduso WW, 2001, MED SCI SPORT EXER, V33, pS598, DOI 10.1097/00005768-200106001-00028; Stewart AL, 2001, MED SCI SPORT EXER, V33, P1126, DOI 10.1097/00005768-200107000-00010; Stranahan AM, 2006, NAT NEUROSCI, V9, P526, DOI 10.1038/nn1668; Swain RA, 2003, NEUROSCIENCE, V117, P1037, DOI 10.1016/S0306-4522(02)00664-4; Thal LJ, 2005, NEUROPSYCHOPHARMACOL, V30, P1204, DOI 10.1038/sj.npp.1300690; Thompson PD, 2003, CIRCULATION, V107, P3109, DOI 10.1161/01.CIR.0000075572.40158.77; Tudor-Locke C, 2004, SPORTS MED, V34, P1, DOI 10.2165/00007256-200434010-00001; Tudor-Locke C, 2002, SPORTS MED, V32, P795, DOI 10.2165/00007256-200232120-00004; Uda M, 2006, BRAIN RES, V1104, P64, DOI 10.1016/j.brainres.2006.05.066; van Gelder BM, 2004, NEUROLOGY, V63, P2316, DOI 10.1212/01.WNL.0000147474.29994.35; van Oijen M, 2007, ALZHEIMERS DEMENT, V3, P92, DOI 10.1016/j.jalz.2007.01.011; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Ware JE, 1998, J CLIN EPIDEMIOL, V51, P903, DOI 10.1016/S0895-4356(98)00081-X; Wechsler D, 1997, WECHSLER ADULT INTEL, VIII; WELSH KA, 1994, NEUROLOGY, V44, P609, DOI 10.1212/WNL.44.4.609; Weuve J, 2004, JAMA-J AM MED ASSOC, V292, P1454, DOI 10.1001/jama.292.12.1454; World Health Organization, 1992, INT STAT CLASS DIS	50	1058	1094	6	216	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	2008	300	9					1027	1037		10.1001/jama.300.9.1027	http://dx.doi.org/10.1001/jama.300.9.1027			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	342YN	18768414	Bronze			2022-12-28	WOS:000258819600019
J	Heckenberger, MJ; Russell, JC; Fausto, C; Toney, JR; Schmidt, MJ; Pereira, E; Franchetto, B; Kuikuro, A				Heckenberger, Michael J.; Russell, J. Christian; Fausto, Carlos; Toney, Joshua R.; Schmidt, Morgan J.; Pereira, Edithe; Franchetto, Bruna; Kuikuro, Afukaka			Pre-columbian urbanism, anthropogenic landscapes, and the future of the Amazon	SCIENCE			English	Article							FOREST; BIODIVERSITY	The archaeology of pre- Columbian polities in the Amazon River basin forces a reconsideration of early urbanism and long- term change in tropical forest landscapes. We describe settlement and land- use patterns of complex societies on the eve of European contact ( after 1492) in the Upper Xingu region of the Brazilian Amazon. These societies were organized in articulated clusters, representing small independent polities, within a regional peer polity. These patterns constitute a "galactic" form of prehistoric urbanism, sharing features with small- scale urban polities in other areas. Understanding long- term change in coupled human- environment systems relating to these societies has implications for conservation and sustainable development, notably to control ecological degradation and maintain regional biodiversity.	[Heckenberger, Michael J.; Toney, Joshua R.] Univ Florida, Dept Anthropol, Gainesville, FL 32611 USA; [Russell, J. Christian] Univ Florida, Land Use & Environm Change Inst, Gainesville, FL 32611 USA; [Fausto, Carlos; Franchetto, Bruna] Univ Fed Rio de Janeiro, Museu Nacl, BR-20940040 Rio De Janeiro, Brazil; [Schmidt, Morgan J.] Univ Florida, Dept Geog, Gainesville, FL 32611 USA; [Pereira, Edithe] Museu Paranese Emilio Goeldi, Coordenacao Ciencias Humanas, BR-66077830 Belem, Para, Brazil; [Kuikuro, Afukaka] PIX, Assoc Indigena Kuikuro Alto Xingu, Mato Grosso, Brazil	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Universidade Federal do Rio de Janeiro; State University System of Florida; University of Florida; Museu Paraense Emilio Goeldi	Heckenberger, MJ (corresponding author), Univ Florida, Dept Anthropol, Gainesville, FL 32611 USA.	mheck@ufl.edu	Fausto, Carlos/I-4550-2013	Fausto, Carlos/0000-0002-0617-6643	Museu Nacional, Universidade Federal do Rio de Janeiro; Museu Paraense Emilio Goeldi.; NSF Archaeology Program [BCS 0004487, BCS 0353129]; William T. Hillman Foundation; University of Florida	Museu Nacional, Universidade Federal do Rio de Janeiro; Museu Paraense Emilio Goeldi.; NSF Archaeology Program(National Science Foundation (NSF)); William T. Hillman Foundation; University of Florida(University of Florida)	Research was sponsored by the Museu Nacional, Universidade Federal do Rio de Janeiro, and Museu Paraense Emilio Goeldi. We acknowledge support by NSF Archaeology Program (grants BCS 0004487 and 0353129), the William T. Hillman Foundation, and the University of Florida.	ACKERLY DD, 1989, BRITTONIA, V41, P113, DOI 10.2307/2807515; Andersson E, 2006, ECOL SOC, V11; Balee W. L., 2006, TIME COMPLEXITY HIST; Carneiro R., 1984, ADAPTIVE RESPONSES N, P65, DOI [10.1016/B978-0-12-321250-4.50007-5, DOI 10.1016/B978-0-12-321250-4.50007-5]; CARNEIRO RL, 1970, SCIENCE, V169, P733, DOI 10.1126/science.169.3947.733; Cowgill GL, 2004, ANNU REV ANTHROPOL, V33, P525, DOI 10.1146/annurev.anthro.32.061002.093248; Cristiana Barreto, 2001, UNKNOWN AMAZON; Denevan William M., 2001, CULTIVATED LANDSCAPE; Erickson CL, 2000, NATURE, V408, P190, DOI 10.1038/35041555; Glaser B., 2004, AMAZONIAN DARK EARTH; Grunwald M, 2008, TIME            0407, P40; HANNERZ U, 1986, SOCIAL SCI ENCY, P86; Hecht S.B., 2008, FORTUNE MAGAZINE, P92; Heckenberger MJ, 2007, PHILOS T R SOC B, V362, P197, DOI 10.1098/rstb.2006.1979; Heckenberger MJ, 2003, SCIENCE, V301, P1710, DOI 10.1126/science.1086112; HECKENBERGER MJ, 2005, ECOLOGY POWER PERSON; Howard E., 2007, GARDEN CITIES TOMORR; Lamb D, 2005, SCIENCE, V310, P1628, DOI 10.1126/science.1111773; LAURENCE W, 2001, SCIENCE, V291, P348; LEGOFF J, 1964, CIVILIZATION OCCIDEN; LEHMANN J, 2003, AMAZONIAN DARK EARTH; Makowski K, 2008, HANDBOOK OF SOUTH AMERICAN ARCHAEOLOGY, P633, DOI 10.1007/978-0-387-74907-5_32; McIntosh R.J, 2005, ANCIENT MIDDLE NIGER; Nepstad D, 2006, CONSERV BIOL, V20, P65, DOI 10.1111/j.1523-1739.2006.00351.x; Neves EG, 2006, HIST ECOL SER, P279; NIMUENDAJU C, 1967, APINAYE; Renfrew Colin, 1986, PEER POLITY INTERACT; Righelato R, 2007, SCIENCE, V317, P902, DOI 10.1126/science.1141361; Roosevelt A.C., 1999, COMPLEX POLITIES ANC, P13; Tambiah StanleyJ., 1977, ANN NEW YORK ACAD SC, V193, P69, DOI DOI 10.1111/J.1749-6632.1977.TB41806.X; WALLACE S, 2007, NATL GEOGRAPHIC  JAN, P40; Willis KJ, 2007, PHILOS T R SOC B, V362, P169, DOI 10.1098/rstb.2006.1976; Yoffee Norman, 2005, MYTHS ARCHAIC STATE	33	164	178	3	95	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2008	321	5893					1214	1217		10.1126/science.1159769	http://dx.doi.org/10.1126/science.1159769			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341ZM	18755979				2022-12-28	WOS:000258754400046
J	Williams, TM; Selegue, JE; Werner, T; Gompel, N; Kopp, A; Carroll, SB				Williams, Thomas M.; Selegue, Jane E.; Werner, Thomas; Gompel, Nicolas; Kopp, Artyom; Carroll, Sean B.			The regulation and evolution of a genetic switch controlling sexually dimorphic traits in Drosophila	CELL			English	Article							DNA-BINDING; TRANSCRIPTIONAL REGULATION; SEX-DETERMINATION; DOUBLESEX; MELANOGASTER; PROTEINS; DIFFERENTIATION; RECOGNITION; MAB-3	Sexually dimorphic traits play key roles in animal evolution and behavior. Little is known, however, about the mechanisms governing their development and evolution. One recently evolved dimorphic trait is the male-specific abdominal pigmentation of Drosophila melanogaster, which is repressed in females by the Bric-a-brac (Bab) proteins. To understand the regulation and origin of this trait, we have identified and traced the evolution of the genetic switch controlling dimorphic bab expression. We show that the HOX protein Abdominal-B (ABD-B) and the sex-specific isoforms of Doublesex (DSX) directly regulate a bab cis-regulatory element (CRE). In females, ABD-B and DSX F activate bab expression whereas in males DSX M directly represses bab, which allows for pigmentation. A new domain of dimorphic bab expression evolved through multiple fine-scale changes within this CRE, whose ancestral role was to regulate other dimorphic features. These findings reveal how new dimorphic characters can emerge from genetic networks regulating pre-existing dimorphic traits.	[Williams, Thomas M.; Selegue, Jane E.; Werner, Thomas; Carroll, Sean B.] Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA; [Williams, Thomas M.; Selegue, Jane E.; Werner, Thomas; Carroll, Sean B.] Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA; [Gompel, Nicolas] CNRS, IBDML, UMR 6216, F-13288 Marseille 9, France; [Kopp, Artyom] Univ Calif Davis, Sect Evolut & Ecol, Davis, CA 95616 USA	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Centre National de la Recherche Scientifique (CNRS); University of California System; University of California Davis	Carroll, SB (corresponding author), Univ Wisconsin, Howard Hughes Med Inst, 1525 Linden Dr, Madison, WI 53706 USA.	sbcarrol@wisc.edu		Gompel, Nicolas/0000-0003-3358-7963	National Institutes of Health [GM076935]; Human Frontiers Science Program Fellowship [LT00640/2005-L]; Howard Hughes Medical Institute; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM076935] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Human Frontiers Science Program Fellowship(Human Frontier Science Program); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank V. Kassner, C. Walsh, M. Rebeiz, K. Vaccaro, and B. Prud'homme for technical assistance; J.-L. Couderc for technical advice; K. Venken for providing genomic attP docking site lines; F. Karch for providing germ-line-specific fC31 integrase lines, and T. Shirangi for comments on the manuscript. This work was supported by National Institutes of Health Postdoctoral fellowship (GM076935) to T. M. W., a Human Frontiers Science Program Fellowship (LT00640/2005- L) to T. W., and the Howard Hughes Medical Institute (S. B. C.).	AN WQ, 1995, EMBO J, V14, P1221, DOI 10.1002/j.1460-2075.1995.tb07105.x; Andersson Malte, 1994; Balhoff JP, 2005, P NATL ACAD SCI USA, V102, P8591, DOI 10.1073/pnas.0409638102; Bannina O, 2007, DEV BIOL, V311, P277, DOI 10.1016/j.ydbio.2007.07.030; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; Carroll SB, 2005, PLOS BIOL, V3, P1159, DOI 10.1371/journal.pbio.0030245; Carroll SB, 2008, CELL, V134, P25, DOI 10.1016/j.cell.2008.06.030; CELNIKER SE, 1987, GENE DEV, V1, P111, DOI 10.1101/gad.1.2.111; Cho S, 2007, GENETICS, V177, P1733, DOI 10.1534/genetics.107.078980; COSCHIGANO KT, 1993, GENE DEV, V7, P42, DOI 10.1101/gad.7.1.42; Couderc JL, 2002, DEVELOPMENT, V129, P2419; Coyne JA, 2008, EVOLUTION, V62, P214, DOI 10.1111/j.1558-5646.2007.00254.x; Darwin Charles, 1871, DESCENT MAN; DUNCAN I, 1987, ANNU REV GENET, V21, P285, DOI 10.1146/annurev.ge.21.120187.001441; DUNCAN IW, 1975, GENETICS, V80, P733; EKKER SC, 1994, EMBO J, V13, P3551, DOI 10.1002/j.1460-2075.1994.tb06662.x; Erdman SE, 1996, GENETICS, V144, P1639; Fisher R.A., 1930, GENETICAL THEORY NAT; Garrett-Engele CM, 2002, DEVELOPMENT, V129, P4661; Gompel N, 2003, NATURE, V424, P931, DOI 10.1038/nature01787; Hediger M, 2004, DEV GENES EVOL, V214, P29, DOI 10.1007/s00427-003-0372-2; Hittinger CT, 2007, NATURE, V449, P677, DOI 10.1038/nature06151; Jeong S, 2008, CELL, V132, P783, DOI 10.1016/j.cell.2008.01.014; Jeong S, 2006, CELL, V125, P1387, DOI 10.1016/j.cell.2006.04.043; JURSNICH VA, 1993, DEV BIOL, V155, P235, DOI 10.1006/dbio.1993.1021; Kopp A, 2000, NATURE, V408, P553, DOI 10.1038/35046017; Kopp A, 2002, DEV BIOL, V242, P15, DOI 10.1006/dbio.2001.0529; Lours C, 2003, NUCLEIC ACIDS RES, V31, P5389, DOI 10.1093/nar/gkg724; Robins Diane M, 2005, Novartis Found Symp, V268, P42; Verrijdt G, 2003, MOL GENET METAB, V78, P175, DOI 10.1016/S1096-7192(03)00003-9; Wilkins AS, 2004, BIOESSAYS, V26, P116, DOI 10.1002/bies.10414; Wittkopp PJ, 2003, TRENDS GENET, V19, P495, DOI 10.1016/S0168-9525(03)00194-X; Yi W, 2000, DEVELOPMENT, V127, P4469; Yi WS, 1999, DEVELOPMENT, V126, P873; Yoder JH, 2006, EVOL DEV, V8, P241, DOI 10.1111/j.1525-142X.2006.00095.x; Zauner H, 2003, EVOL DEV, V5, P466, DOI 10.1046/j.1525-142X.2003.03053.x	36	214	217	1	53	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	2008	134	4					610	623		10.1016/j.cell.2008.06.052	http://dx.doi.org/10.1016/j.cell.2008.06.052			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SR	18724934	Green Accepted, Bronze			2022-12-28	WOS:000258665800015
J	Navas-Acien, A; Silbergeld, EK; Pastor-Barriuso, R; Guallar, E				Navas-Acien, Ana; Silbergeld, Ellen K.; Pastor-Barriuso, Roberto; Guallar, Eliseo			Arsenic exposure and prevalence of type 2 diabetes in US adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PANCREATIC BETA-CELLS; DRINKING-WATER; EPIDEMIOLOGIC EVIDENCE; HUMAN URINE; MELLITUS; TRANSCRIPTION; GLUCOSE; DISEASES; TAIWAN; TRANSLOCATION	Context High chronic exposure to inorganic arsenic in drinking water has been related to diabetes development, but the effect of exposure to low to moderate levels of inorganic arsenic on diabetes risk is unknown. In contrast, arsenobetaine, an organic arsenic compound derived from seafood intake, is considered nontoxic. Objective To investigate the association of arsenic exposure, as measured in urine, with the prevalence of type 2 diabetes in a representative sample of US adults. Design, Setting, and Participants Cross-sectional study in 788 adults aged 20 years or older who participated in the 2003-2004 National Health and Nutrition Examination Survey (NHANES) and had urine arsenic determinations. Main Outcome Measure Prevalence of type 2 diabetes across intake of arsenic. Results The median urine levels of total arsenic, dimethylarsinate, and arsenobetaine were 7.1, 3.0, and 0.9 mu g/L, respectively. The prevalence of type 2 diabetes was 7.7%. After adjustment for diabetes risk factors and markers of seafood intake, participants with type 2 diabetes had a 26% higher level of total arsenic (95% confidence interval [Cl], 2.0%-56.0%) and a nonsignificant 10% higher level of dimethylarsinate (95% Cl, -8.0% to 33.0%) than participants without type 2 diabetes, and levels of arsenobetaine were similar to those of participants without type 2 diabetes. After similar adjustment, the odds ratios for type 2 diabetes comparing participants at the 80th vs the 20th percentiles were 3.58 for the level of total arsenic (95% Cl, 1.18-10.83), 1.57 for dimethylarsinate (95% Cl, 0.89-2.76), and 0.69 for arsenobetaine (95% Cl, 0.33-1.48). Conclusions After adjustment for biomarkers of seafood intake, total urine arsenic was associated with increased prevalence of type 2 diabetes. This finding supports the hypothesis that low levels of exposure to inorganic arsenic in drinking water, a widespread exposure worldwide, may play a role in diabetes prevalence. Prospective studies in populations exposed to a range of inorganic arsenic levels are needed to establish whether this association is causal.	[Navas-Acien, Ana; Silbergeld, Ellen K.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; [Navas-Acien, Ana; Guallar, Eliseo] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; [Navas-Acien, Ana; Guallar, Eliseo] Johns Hopkins Bloomberg Sch Publ Hlth, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21205 USA; [Pastor-Barriuso, Roberto] Inst Salud Carlos III, Natl Ctr Epidemiol, Madrid, Spain; [Pastor-Barriuso, Roberto] CIBER Epidemiol & Salud Publ, Madrid, Spain; [Guallar, Eliseo] Ctr Nacl Invest Cardiovasc, Dept Cardiovasc Epidemiol & Populat Genet, Madrid, Spain; [Guallar, Eliseo] Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Instituto de Salud Carlos III; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; Centro Nacional de Investigaciones Cardiovasculares (CNIC); Johns Hopkins University; Johns Hopkins Medicine	Navas-Acien, A (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, 615 N Wolfe St,Room W7033B, Baltimore, MD 21205 USA.	anavas@jhsph.edu	Guallar, Eliseo/D-3807-2014; Pastor-Barriuso, Roberto/AAA-6746-2019	Guallar, Eliseo/0000-0002-4471-9565; Pastor-Barriuso, Roberto/0000-0002-7325-3960	National Institute of Environmental Health Sciences Center in Urban Environmental Health [P30 ES 03819]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819] Funding Source: NIH RePORTER	National Institute of Environmental Health Sciences Center in Urban Environmental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by grant P30 ES 03819 from the National Institute of Environmental Health Sciences Center in Urban Environmental Health.	Aposhian HV, 2006, CHEM RES TOXICOL, V19, P1, DOI 10.1021/tx050106d; Bazuine M, 2003, EUR J BIOCHEM, V270, P3891, DOI 10.1046/j.1432-1033.2003.03771.x; Calderon RL, 1999, ENVIRON HEALTH PERSP, V107, P663, DOI 10.2307/3434459; CALDWELL KL, 2008, J EXPO SCI ENV EPID, P1, DOI DOI 10.1038/JES.2008.32; Chen CJ, 2007, TOXICOL APPL PHARM, V222, P298, DOI 10.1016/j.taap.2006.12.032; Coronado-Gonzalez JA, 2007, ENVIRON RES, V104, P383, DOI 10.1016/j.envres.2007.03.004; CULLEN WR, 1989, CHEM REV, V89, P713, DOI 10.1021/cr00094a002; Del Razo LM, 2002, FOOD CHEM TOXICOL, V40, P1423, DOI 10.1016/S0278-6915(02)00074-1; Diaz-Villasenor A, 2006, TOXICOL APPL PHARM, V214, P30, DOI 10.1016/j.taap.2005.11.015; Elrick LJ, 2001, DIABETES, V50, P2244, DOI 10.2337/diabetes.50.10.2244; Focazio M.J., 2000, RETROSPECTIVE ANAL O; Francesconi KA, 1997, ADV INORG CHEM, V44, P147; Francesconi KA, 2002, CLIN CHEM, V48, P92; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans World Health Organization & International Agency for Research on Cancer, 2004, SOM DRINK WAT DIS CO; Izquierdo-Vega JA, 2006, TOXICOL LETT, V160, P135, DOI 10.1016/j.toxlet.2005.06.018; Jensen GE, 1998, ANALYST, V123, P77, DOI 10.1039/a705699k; Karagas M R, 2001, Int J Occup Med Environ Health, V14, P171; LAI MS, 1994, AM J EPIDEMIOL, V139, P484, DOI 10.1093/oxfordjournals.aje.a117031; Lamm SH, 2006, J OCCUP ENVIRON MED, V48, P1001, DOI 10.1097/01.jom.0000237359.75757.25; Lewis DR, 1999, ENVIRON HEALTH PERSP, V107, P359, DOI 10.2307/3434539; Longnecker MP, 2001, ENVIRON HEALTH PERSP, V109, P871, DOI 10.2307/3454649; Macfarlane WM, 1999, J BIOL CHEM, V274, P1011, DOI 10.1074/jbc.274.2.1011; Macfarlane WM, 1997, J BIOL CHEM, V272, P20936, DOI 10.1074/jbc.272.33.20936; *NAT CTR ENV HLTH, LAB PROC MAN TOT ARS; *NAT CTR ENV HLTH, 2004, LAB PROC MAN ARS ARS; National Center for Health Statistics, DOC COD FREQ LAB COM; National Research Council, 1999, ARS DRINK WAT; Navas-Acien A, 2006, ENVIRON HEALTH PERSP, V114, P641, DOI 10.1289/ehp.8551; Navas-Acien A, 2005, AM J EPIDEMIOL, V162, P1037, DOI 10.1093/aje/kwi330; Paul DS, 2007, ENVIRON HEALTH PERSP, V115, P734, DOI 10.1289/ehp.9867; Rahman M, 1998, AM J EPIDEMIOL, V148, P198, DOI 10.1093/oxfordjournals.aje.a009624; Raml R, 2005, CHEM RES TOXICOL, V18, P1444, DOI 10.1021/tx050111h; Ruiz-Navarro ML, 1998, SCI TOTAL ENVIRON, V216, P55, DOI 10.1016/S0048-9697(98)00136-3; Ryan PB, 2000, ENVIRON HEALTH PERSP, V108, P731, DOI 10.2307/3434726; SABBIONI E, 1991, CARCINOGENESIS, V12, P1287, DOI 10.1093/carcin/12.7.1287; Salazard B, 2004, CELL BIOL TOXICOL, V20, P375, DOI 10.1007/s10565-004-1471-1; Schoof RA, 1999, FOOD CHEM TOXICOL, V37, P839, DOI 10.1016/S0278-6915(99)00073-3; Smedley PL, 2002, APPL GEOCHEM, V17, P517, DOI 10.1016/S0883-2927(02)00018-5; Steinmaus CM, 2005, ENVIRON RES, V99, P164, DOI 10.1016/j.envres.2004.10.003; Thomas DJ, 2001, TOXICOL APPL PHARM, V176, P127, DOI 10.1006/taap.2001.9258; Tseng CH, 2000, ENVIRON HEALTH PERSP, V108, P847, DOI 10.2307/3434992; US Environmental Protection Agency (EPA), 2001, FED REGISTER, V66, P6976; USDA, FOOD NUTR DAT DIET S; Walton FS, 2004, TOXICOL APPL PHARM, V198, P424, DOI 10.1016/j.taap.2003.10.026; Wang CH, 2007, TOXICOL APPL PHARM, V222, P315, DOI 10.1016/j.taap.2006.12.022; Wang SL, 2007, ENVIRON INT, V33, P805, DOI 10.1016/j.envint.2007.03.004; Wang SL, 2003, ENVIRON HEALTH PERSP, V111, P155, DOI 10.1289/ehp.5457; Wauson EM, 2002, TOXICOL SCI, V65, P211, DOI 10.1093/toxsci/65.2.211; Yost LJ, 1998, HUM ECOL RISK ASSESS, V4, P137, DOI 10.1080/1080703031877131; Zierold KM, 2004, AM J PUBLIC HEALTH, V94, P1936, DOI 10.2105/AJPH.94.11.1936	50	328	340	1	41	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	2008	300	7					814	822		10.1001/jama.300.7.814	http://dx.doi.org/10.1001/jama.300.7.814			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	338VM	18714061	Bronze			2022-12-28	WOS:000258537500021
J	Bernat, JL				Bernat, James L.			The boundaries of organ donation after circulatory death	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CARDIAC DEATH		Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA	Dartmouth College	Bernat, JL (corresponding author), Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA.							Bernat JL, 2006, J CLIN ETHIC, V17, P122; Bernat JL, 2006, AM J TRANSPLANT, V6, P281, DOI 10.1111/j.1600-6143.2005.01194.x; Magliocca JF, 2005, J TRAUMA, V58, P1095, DOI 10.1097/01.TA.0000169949.82778.DF; Mandell MS, 2006, CRIT CARE MED, V34, P2952, DOI 10.1097/01.CCM.0000247718.27324.65; Steinbrook R, 2007, NEW ENGL J MED, V357, P209, DOI 10.1056/NEJMp078066	5	97	98	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 14	2008	359	7					669	671		10.1056/NEJMp0804161	http://dx.doi.org/10.1056/NEJMp0804161			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336XE	18703467				2022-12-28	WOS:000258397900001
J	Stettler, C; Allemann, S; Wandel, S; Kastrati, A; Morice, MC; Schomig, A; Pfisterer, ME; Stone, GW; Leon, MB; de Lezo, JS; Goy, JJ; Park, SJ; Sabate, M; Suttorp, MJ; Kelbaek, H; Spaulding, C; Menichelli, M; Vermeersch, P; Dirksen, MT; Cervinka, P; De Carlo, M; Erglis, A; Chechi, T; Ortolani, P; Schalij, MJ; Diem, P; Meier, B; Windecker, S; Juni, P				Stettler, Christoph; Allemann, Sabin; Wandel, Simon; Kastrati, Adnan; Morice, Marie Claude; Schoemig, Albert; Pfisterer, Matthias E.; Stone, Gregg W.; Leon, Martin B.; Suarez de Lezo, Jose; Goy, Jean-Jacques; Park, Seung-Jung; Sabate, Manel; Suttorp, Maarten J.; Kelbaek, Henning; Spaulding, Christian; Menichelli, Maurizio; Vermeersch, Paul; Dirksen, Maurits T.; Cervinka, Pavel; De Carlo, Marco; Erglis, Andrejs; Chechi, Tania; Ortolani, Paolo; Schalij, Martin J.; Diem, Peter; Meier, Bernhard; Windecker, Stephan; Juni, Peter			Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-ARTERY-DISEASE; FOLLOW-UP; THROMBOSIS; OUTCOMES; IMPACT; TRIALS; RESTENOSIS; PREVENTION; MELLITUS; SAFETY		[Stettler, Christoph; Allemann, Sabin; Wandel, Simon; Juni, Peter] Univ Bern, Inst Social & Prevent Med, CH-3012 Bern, Switzerland; [Stettler, Christoph; Allemann, Sabin; Diem, Peter] Univ Hosp Bern, Div Endocrinol Diabet Clin Nutr, CH-3010 Bern, Switzerland; [Stettler, Christoph] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Int Ctr Circulatory Hlth, London, England; [Kastrati, Adnan; Schoemig, Albert] Tech Univ Munich, Deutsch Herzzentrum, Munich, Germany; [Morice, Marie Claude] Inst Hosp Jacques Cartier, Massy, France; [Pfisterer, Matthias E.] Univ Basel Hosp, Div Cardiol, CH-4031 Basel, Switzerland; [Stone, Gregg W.; Leon, Martin B.] Columbia Univ, Med Ctr, New York, NY USA; [Suarez de Lezo, Jose] Hosp Univ Reina Sofia, Serv Cardiol, Cordoba, Spain; [Goy, Jean-Jacques] Clin Cecil, Serv Cardiol, Lausanne, Switzerland; [Park, Seung-Jung] ASAN Med Ctr, Dept Med, Seoul, South Korea; [Sabate, Manel] Hosp San Pau, Dept Intervent Cardiol, Barcelona, Spain; [Suttorp, Maarten J.] St Antonius Hosp, Dept Intervent Cardiol, Nieuwegein, Netherlands; [Kelbaek, Henning] Rigshosp, Cardiac Catheterizat Lab, DK-2100 Copenhagen, Denmark; [Spaulding, Christian] Univ Paris 05, Cochin Hosp, Assistance Publ Hop Paris, Paris, France; [Spaulding, Christian] INSERM, U 780, Paris, France; [Menichelli, Maurizio] San Camillo Hosp, Rome, Italy; [Vermeersch, Paul] Antwerp Cardiovasc Inst Middelheim, Antwerp, Belgium; [Dirksen, Maurits T.] Onze Lieve Vrouw Hosp, Amsterdam Dept Intervent Cardiol, Amsterdam, Netherlands; [Cervinka, Pavel] Masaryk Hosp, Div Cardiol, Usti Nad Labem, Czech Republic; [De Carlo, Marco] Univ Pisa, Dept Cardiothorac & Vasc Dept, Pisa, Italy; [Erglis, Andrejs] Latvian State Univ, Inst Cardiol, LV-1063 Riga, Latvia; [Chechi, Tania] Cardiol & Cardiol Invasiva 2 AOU Careggi, Florence, Italy; [Ortolani, Paolo] Univ Bologna, S Orsola M Malpighi Hosp, Inst Cardiol, Bologna, Italy; [Schalij, Martin J.] Leiden Univ, Med Ctr, Dept Cardiol, Leiden, Netherlands; [Meier, Bernhard; Windecker, Stephan] Univ Hosp Bern, Dept Cardiol, CH-3010 Bern, Switzerland; [Windecker, Stephan; Juni, Peter] Univ Hosp Bern, CTU Bern, CH-3010 Bern, Switzerland	University of Bern; University of Bern; University Hospital of Bern; Imperial College London; German Heart Center Berlin; German Heart Centre Munich; Technical University of Munich; Jacques Cartier Private Hospital; University of Basel; Columbia University; Hospital Universitario Reina Sofia - Cordoba; University of Ulsan; Asan Medical Center; St. Antonius Hospital Utrecht; Rigshospitalet; University of Copenhagen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Onze Lieve Vrouwe Gasthuis Hospital; Masaryk Hospital; University of Pisa; University of Latvia; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern	Juni, P (corresponding author), Univ Bern, Inst Social & Prevent Med, CH-3012 Bern, Switzerland.	juni@ispm.unibe.ch	Menichelli, Maurizio/AAF-8525-2021; Diem, Peter/A-7650-2008; De Carlo, Marco/I-7973-2012; Sabate, Manel/AAX-7245-2021; Suárez de Lezo, José/AAX-9084-2021; , Kastrati/Y-2389-2019; Juni, Peter/Q-8700-2016	Diem, Peter/0000-0002-1190-9880; De Carlo, Marco/0000-0002-5763-9804; Suárez de Lezo, José/0000-0002-7621-3235; Juni, Peter/0000-0002-5985-0670; Sabate Tenas, Manel/0000-0002-2316-3705; Stettler, Christoph/0000-0003-1691-6059; , Simon/0000-0002-1442-597X; Erglis, Andrejs/0000-0002-3999-0182	Swiss National Science Foundation [3233BO-115212, 3233-066377, 3200-066378]; Swiss National Science Foundation's national research programme 53 [405340-104762]; Swiss National Science Foundation	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss National Science Foundation's national research programme 53(Swiss National Science Foundation (SNSF)); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	Swiss National Science Foundation (grant Nos 3233BO-115212, 3233-066377, and 3200-066378) to CSt and PJ. The implementation and validation of the statistical models used for this study were funded by the Swiss National Science Foundation's national research programme 53 (grant No 405340-104762) to PJ. CSt and PJ are PROSPER (program for social medicine, preventive and epidemiological research) fellows funded by the Swiss National Science Foundation. The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report.	Abizaid A, 2004, EUR HEART J, V25, P107, DOI 10.1016/j.ehj.2003.11.002; Caldwell DM, 2005, BMJ-BRIT MED J, V331, P897, DOI 10.1136/bmj.331.7521.897; Carter AJ, 2004, CATHETER CARDIO INTE, V61, P233, DOI 10.1002/ccd.10764; Cooper NJ, 2006, ARCH INTERN MED, V166, P1269, DOI 10.1001/archinte.166.12.1269; Cutlip DE, 2007, CIRCULATION, V115, P2344, DOI 10.1161/CIRCULATIONAHA.106.685313; Daemen J, 2007, LANCET, V369, P667, DOI 10.1016/S0140-6736(07)60314-6; Doyle B, 2007, CIRCULATION, V116, P2391, DOI 10.1161/CIRCULATIONAHA.107.707331; Evangelista V, 2005, THROMB HAEMOSTASIS, V93, P8, DOI 10.1160/TH04-07-0453; Finn AV, 2007, ARTERIOSCL THROM VAS, V27, P1500, DOI 10.1161/ATVBAHA.107.144220; Gingras AC, 2003, CURR TOP MICROBIOL, V279, P169; Hermiller JB, 2005, J AM COLL CARDIOL, V45, P1172, DOI 10.1016/j.jacc.2004.10.075; Joner M, 2006, J AM COLL CARDIOL, V48, P193, DOI 10.1016/j.jacc.2006.03.042; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Kastrati A, 2007, NEW ENGL J MED, V356, P1030, DOI 10.1056/NEJMoa067484; Lu G, 2004, STAT MED, V23, P3105, DOI 10.1002/sim.1875; Lumley T, 2002, STAT MED, V21, P2313, DOI 10.1002/sim.1201; Mauri L, 2007, NEW ENGL J MED, V356, P1020, DOI 10.1056/NEJMoa067731; Mehta RH, 2007, AM J CARDIOL, V100, p62M, DOI 10.1016/j.amjcard.2007.08.024; Moussa I, 2004, CIRCULATION, V109, P2273, DOI 10.1161/01.CIR.0000129767.45513.71; Ormiston JA, 2008, LANCET, V371, P899, DOI 10.1016/S0140-6736(08)60415-8; Pinto DS, 2006, J AM COLL CARDIOL, V48, P32, DOI 10.1016/j.jacc.2006.02.060; Pocock SJ, 2007, LANCET, V370, P2099, DOI 10.1016/S0140-6736(07)61898-4; Psaty BN, 2003, JAMA-J AM MED ASSOC, V289, P2534, DOI 10.1001/jama.289.19.2534; Serruys PW, 1998, LANCET, V352, P673, DOI 10.1016/S0140-6736(97)11128-X; Smith TC, 1995, STAT MED, V14, P2685, DOI 10.1002/sim.4780142408; Spaulding C, 2007, NEW ENGL J MED, V356, P989, DOI 10.1056/NEJMoa066633; Stettler C, 2007, LANCET, V370, P937, DOI 10.1016/S0140-6736(07)61444-5; Stettler C, 2006, AM HEART J, V152, P27, DOI 10.1016/j.ahj.2005.09.015; Stone GW, 2008, JAMA-J AM MED ASSOC, V299, P1903, DOI 10.1001/jama.299.16.1903; Stone GW, 2007, CIRCULATION, V115, P2842, DOI 10.1161/CIRCULATIONAHA.106.687186; THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351; Tu JV, 2007, NEW ENGL J MED, V357, P1393, DOI 10.1056/NEJMoa071076	32	217	232	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 20	2008	337	7671							a1331	10.1136/bmj.a1331	http://dx.doi.org/10.1136/bmj.a1331			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354EP	18757996	Green Published, hybrid			2022-12-28	WOS:000259622000030
J	Gaspard, N; Bouschet, T; Hourez, R; Dimidschstein, J; Naeije, G; van den Ameele, J; Espuny-Camacho, I; Herpoel, A; Passante, L; Schiffmann, SN; Gaillard, A; Vanderhaeghen, P				Gaspard, Nicolas; Bouschet, Tristan; Hourez, Raphael; Dimidschstein, Jordane; Naeije, Gilles; van den Ameele, Jelle; Espuny-Camacho, Ira; Herpoel, Adele; Passante, Lara; Schiffmann, Serge N.; Gaillard, Afsaneh; Vanderhaeghen, Pierre			An intrinsic mechanism of corticogenesis from embryonic stem cells	NATURE			English	Article							DEVELOPING CEREBRAL-CORTEX; DIRECTED DIFFERENTIATION; CORTICAL DEVELOPMENT; PROJECTION NEURON; RADIAL GLIA; SPECIFICATION; FATE; NEOCORTEX; TRANSPLANTATION; PRECURSORS	The cerebral cortex develops through the coordinated generation of dozens of neuronal subtypes, but the mechanisms involved remain unclear. Here we show that mouse embryonic stem cells, cultured without any morphogen but in the presence of a sonic hedgehog inhibitor, recapitulate in vitro the major milestones of cortical development, leading to the sequential generation of a diverse repertoire of neurons that display most salient features of genuine cortical pyramidal neurons. When grafted into the cerebral cortex, these neurons develop patterns of axonal projections corresponding to a wide range of cortical layers, but also to highly specific cortical areas, in particular visual and limbic areas, thereby demonstrating that the identity of a cortical area can be specified without any influence from the brain. The discovery of intrinsic corticogenesis sheds new light on the mechanisms of neuronal specification, and opens new avenues for the modelling and treatment of brain diseases.	[Gaspard, Nicolas; Bouschet, Tristan; Dimidschstein, Jordane; Naeije, Gilles; van den Ameele, Jelle; Espuny-Camacho, Ira; Herpoel, Adele; Passante, Lara; Vanderhaeghen, Pierre] Univ Libre Bruxelles, IRIBHN, Inst Interdisciplinary Res, B-1070 Brussels, Belgium; [Hourez, Raphael; Schiffmann, Serge N.] Univ Libre Bruxelles, Neurophysiol Lab, B-1070 Brussels, Belgium; [Gaillard, Afsaneh] Univ Poitiers, CNRS, Inst Physiol & Biol Cellulaires, F-86022 Poitiers, France	Universite Libre de Bruxelles; Universite Libre de Bruxelles; Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers	Vanderhaeghen, P (corresponding author), Univ Libre Bruxelles, IRIBHN, Inst Interdisciplinary Res, 808 Route Lennik, B-1070 Brussels, Belgium.	pierre.vanderhaeghen@ulb.ac.be	Bouschet, Tristan/C-8265-2019; Naeije, Gilles/AFT-2241-2022; Espuny, Ira/AAM-1991-2021	Bouschet, Tristan/0000-0002-7858-6115; Naeije, Gilles/0000-0003-1580-1970; Espuny, Ira/0000-0002-2356-2159; van den Ameele, Jelle/0000-0002-2744-0810; Vanderhaeghen, Pierre/0000-0001-7899-5720; Schiffmann, Serge/0000-0002-0118-9816; Dimidschstein, Jordane/0000-0001-6289-6891	Belgian FNRS, the Action de Recherches Concertees (ARC) Programs; Interuniversity Attraction Poles Program (IUAP); Belgian State; Federal Office; Walloon Region Excellence Program CIBLES; Belgian Queen Elizabeth Medical Foundation; UCB Neuroscience Award; Tournesol FNRS/CNRS Program; Televie; Marie Curie Grant; Research Fellows of the FNRS	Belgian FNRS, the Action de Recherches Concertees (ARC) Programs(Fonds de la Recherche Scientifique - FNRS); Interuniversity Attraction Poles Program (IUAP)(Belgian Federal Science Policy Office); Belgian State; Federal Office; Walloon Region Excellence Program CIBLES; Belgian Queen Elizabeth Medical Foundation; UCB Neuroscience Award; Tournesol FNRS/CNRS Program; Televie; Marie Curie Grant(European Commission); Research Fellows of the FNRS	We thank G. Vassart, M. Pandolfo and members of the laboratory and IRIBHM for support and discussions. We are indebted to A. Bilheu for technical assistance, J.-M. Vanderwinden for help with confocal microscopy, and V.De Maertelaer for statistical analyses. We thank F. Polleux, B. Hassan and C. Blanpain for comments on the manuscript. We are grateful to S. Arber, A. Goffinet, R. Hevner, R. di Lauro, Y. Sasai, S. Stifani, M. Studer and V. Tarabykin for providing us with antibodies, and to Y.-A. Barde for providing Tau-GFP ESC lines. This work was funded by the Belgian FNRS, the Action de Recherches Concertees (ARC) Programs (to P.V. and S.N.S.), the Interuniversity Attraction Poles Program (IUAP), Belgian State, Federal Office, the Walloon Region Excellence Program CIBLES, the Belgian Queen Elizabeth Medical Foundation and a UCB Neuroscience Award (to P.V.), the Tournesol FNRS/CNRS Program (to P.V. and A.G.), Televie (to S.N.S.), and a Marie Curie Grant (to T.B.). P.V. is a Senior Research Associate of the FNRS, and N.G., R.H., T.B., J.D. and L.P. were funded as Research Fellows of the FNRS.	Alcamo EA, 2008, NEURON, V57, P364, DOI 10.1016/j.neuron.2007.12.012; Andersson E, 2006, CELL, V124, P393, DOI [10.1016/j.cell.2005.10.037, 10.1016/J.CELL.2005.10.037]; Armentano M, 2007, NAT NEUROSCI, V10, P1277, DOI 10.1038/nn1958; BARBE MF, 1995, J NEUROSCI, V15, P1819, DOI 10.1523/JNEUROSCI.15-03-01819.1995; Bayer S.A., 1991, NEOCORTICAL DEV; Bibel M, 2004, NAT NEUROSCI, V7, P1003, DOI 10.1038/nn1301; Britanova O, 2008, NEURON, V57, P378, DOI 10.1016/j.neuron.2007.12.028; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Dehay C, 2007, NAT REV NEUROSCI, V8, P438, DOI 10.1038/nrn2097; EBRAHIMIGAILLARD A, 1994, DEV BRAIN RES, V77, P271, DOI 10.1016/0165-3806(94)90203-8; Frantz GD, 1996, NEURON, V17, P55, DOI 10.1016/S0896-6273(00)80280-9; Frost SB, 2000, J COMP NEUROL, V421, P29, DOI 10.1002/(SICI)1096-9861(20000522)421:1<29::AID-CNE3>3.0.CO;2-9; Gaillard A, 1998, ADV ANAT EMBRYOL CEL, V148, P1; Gaillard A, 2007, NAT NEUROSCI, V10, P1294, DOI 10.1038/nn1970; Glaser T, 2005, TRENDS NEUROSCI, V28, P397, DOI 10.1016/j.tins.2005.05.008; Gotz M, 2005, DEVELOPMENT, V132, P3327, DOI 10.1242/dev.01931; Gunhaga L, 2000, DEVELOPMENT, V127, P3283; Hand R, 2005, NEURON, V48, P45, DOI 10.1016/j.neuron.2005.08.032; Hevner RF, 2006, MOL NEUROBIOL, V33, P33, DOI 10.1385/MN:33:1:033; Hevner RF, 2003, DEV NEUROSCI-BASEL, V25, P139, DOI 10.1159/000072263; Inoue T, 2000, DEV BIOL, V219, P373, DOI 10.1006/dbio.2000.9616; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; Molyneaux BJ, 2007, NAT REV NEUROSCI, V8, P427, DOI 10.1038/nrn2151; Munoz-Sanjuan I, 2002, NAT REV NEUROSCI, V3, P271, DOI 10.1038/nrn786; Noctor SC, 2004, NAT NEUROSCI, V7, P136, DOI 10.1038/nn1172; O'Leary DDM, 2007, NEURON, V56, P252, DOI 10.1016/j.neuron.2007.10.010; Paxinos G, 1995, RAT NERVOUS SYSTEM, V2nd; Pinaudeau C, 2000, EUR J NEUROSCI, V12, P2486, DOI 10.1046/j.1460-9568.2000.00148.x; Polleux F, 2000, NATURE, V404, P567, DOI 10.1038/35007001; Puelles L, 2001, PHILOS T R SOC B, V356, P1583, DOI 10.1098/rstb.2001.0973; Qian XM, 2000, NEURON, V28, P69, DOI 10.1016/S0896-6273(00)00086-6; Rash BG, 2006, CURR OPIN NEUROBIOL, V16, P25, DOI 10.1016/j.conb.2006.01.004; Sansom SN, 2005, DEVELOPMENT, V132, P3947, DOI 10.1242/dev.01968; Schuurmans C, 2002, CURR OPIN NEUROBIOL, V12, P26, DOI 10.1016/S0959-4388(02)00286-6; Shen Q, 2006, NAT NEUROSCI, V9, P743, DOI 10.1038/nn1694; Smukler SR, 2006, J CELL BIOL, V172, P79, DOI 10.1083/jcb.200508085; Sur M, 2005, SCIENCE, V310, P805, DOI 10.1126/science.1112070; Vanderhaeghen P, 2004, TRENDS NEUROSCI, V27, P384, DOI 10.1016/j.tins.2004.05.009; Von Economo C.B., 1925, CYTOARCHITECTONICS A; Watanabe K, 2005, NAT NEUROSCI, V8, P288, DOI 10.1038/nn1402; Wernig M, 2002, J NEUROSCI RES, V69, P918, DOI 10.1002/jnr.10395; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8; Wilson SW, 2004, DEV CELL, V6, P167, DOI 10.1016/S1534-5807(04)00027-9; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780	45	445	456	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	2008	455	7211					351	U10		10.1038/nature07287	http://dx.doi.org/10.1038/nature07287			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349EX	18716623	Green Submitted			2022-12-28	WOS:000259265200036
J	Lynch, C				Lynch, Clifford			Big data: How do your data grow?	NATURE			English	Editorial Material									[Lynch, Clifford] Coalit Networked Informat, Washington, DC 20036 USA; [Lynch, Clifford] Univ Calif Berkeley, Sch Informat, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Lynch, C (corresponding author), Coalit Networked Informat, 21 Dupont Circle, Washington, DC 20036 USA.	cliff@cni.org		Lynch, Clifford/0000-0003-2803-4512				*ARL WORKSH NEW CO, 2006, STAND TEST TIM LONG	1	407	453	4	542	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2008	455	7209					28	29		10.1038/455028a	http://dx.doi.org/10.1038/455028a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	343XS	18769419				2022-12-28	WOS:000258890200019
J	Carrier, M; Le Gal, G; Wells, PS; Fergusson, D; Ramsay, T; Rodger, MA				Carrier, Marc; Le Gal, Gregoire; Wells, Philip S.; Fergusson, Dean; Ramsay, Tim; Rodger, Marc A.			Systematic review: The trousseau syndrome revisited: Should we screen extensively for cancer in patients with venous thromboembolism?	ANNALS OF INTERNAL MEDICINE			English	Review							DEEP-VEIN THROMBOSIS; MOLECULAR-WEIGHT HEPARIN; ACUTE PULMONARY-EMBOLISM; OCCULT CANCER; SUBSEQUENT MALIGNANCY; CLINICAL-TRIAL; DIAGNOSIS; RISK; COUMARIN; SURVIVAL	Background: Identifying previously undiagnosed cancer in patients with newly diagnosed venous thromboembolism (VTE) is important. Screening for malignant conditions can potentially diagnose more cases of cancer and at earlier stages, thereby preventing cancer-associated morbidity and perhaps mortality. Purpose: To summarize the period prevalence of previously undiagnosed cancer at baseline (within 1 month of VTE diagnosis), 6 months, and 12 months after VTE diagnosis and to quantify the additional value of an extensive cancer screening strategy (limited screening plus imaging techniques or tumor marker measurement) at baseline compared with more limited screening (history, physical examination, and simple widely available tests) at baseline. Data Sources: MEDLINE, EMBASE, the Cochrane Register of Controlled Trials, and Evidence-Based Medicine Reviews. Study Selection: A total of 36 studies that reported the prevalence of undiagnosed cancer at baseline, 6 months, and 12 months were selected. Fourteen articles and 1 abstract also met inclusion criteria for the assessment of extensive versus limited cancer screening. Data Extraction: Two reviewers independently extracted data onto standardized forms. Data Synthesis: The period prevalence of previously undiagnosed cancer in patients with unprovoked VTE was 6.1% (95% CI, 5.0% to 7.1%) at baseline and 10.0% (CI, 8.6% to 11.3%) from baseline to 12 months. An extensive screening strategy using computed tomography of the abdomen and pelvis statistically significantly increased the proportion of previously undiagnosed cancer detected from 49.4% (CI, 40.2% to 58.5%) (with limited screening alone) to 69.7% (CI, 61.1% to 77.8%) in patients with unprovoked VTE. Limitation: The investigators could not determine complication rates, cost-effectiveness, and difference in morbidity and mortality associated with extensive screening strategies. Conclusion: Previously undiagnosed cancer is frequent in patients with unprovoked VTE. Many cases of previously undiagnosed cancer are missed by screening. An extensive cancer screening strategy detects more malignant conditions than does a limited screening strategy.	[Rodger, Marc A.] Ottawa Hlth Res Inst, Clin Epidemiol Program, Inst Eye, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Ottawa, ON, Canada; Brest Univ Hosp, Brest, France	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; CHU Brest	Rodger, MA (corresponding author), Ottawa Hlth Res Inst, Clin Epidemiol Program, Inst Eye, 501 Smyth Rd,Room W6116, Ottawa, ON K1H 8L6, Canada.	mrodger@ohri.ca	LE GAL, Gregoire/K-1077-2012	Fergusson, Dean/0000-0002-3389-2485; Rodger, Marc/0000-0001-8166-3487; LE GAL, Gregoire/0000-0002-9253-248X; Ramsay, Tim/0000-0001-8478-8170	Canadian Institutes of Health Research; Heart and Stroke Foundation of Ontario	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Heart and Stroke Foundation of Ontario(Heart & Stroke Foundation of Ontario)	Dr. Carrier is a recipient of a Canadian Institutes of Health Research Fellowship. Dr. Fergusson is a recipient of a Canadian Institutes of Health Research New Investigator Research Award. Dr. Rodger is the recipient of a Career Scientist Award from the Heart and Stroke Foundation of Ontario. Dr. Wells is a recipient of a Canada Research Chair.	ADERKA D, 1986, CANCER, V57, P1846, DOI 10.1002/1097-0142(19860501)57:9<1846::AID-CNCR2820570925>3.0.CO;2-3; Ahmed Z, 1996, ANGIOLOGY, V47, P261, DOI 10.1177/000331979604700307; Baron JA, 1998, LANCET, V351, P1077, DOI 10.1016/S0140-6736(97)10018-6; BARRELLIER MT, 1992, J MAL VASCUL, V17, P277; Bastounis EA, 1996, J INTERN MED, V239, P153, DOI 10.1046/j.1365-2796.1996.426000.x; BILAND L, 1987, INTERNIST, V28, P285; Buller HR, 2007, J THROMB HAEMOST, V5, P246, DOI 10.1111/j.1538-7836.2007.02497.x; Bura A, 2004, J THROMB HAEMOST, V2, P441, DOI 10.1111/j.1538-7933.2004.00619.x; Cailleux N, 1997, J MAL VASCUL, V22, P322; Cornuz J, 1996, ANN INTERN MED, V125, P785, DOI 10.7326/0003-4819-125-10-199611150-00001; Enguidanos M J, 2002, An Med Interna, V19, P561; Fahrig, 1998, Int J Angiol, V7, P249, DOI 10.1007/BF01617404; Girolami A, 1999, BLOOD COAGUL FIBRIN, V10, P455, DOI 10.1097/00001721-199912000-00001; GOLDBERG RJ, 1987, ARCH INTERN MED, V147, P251, DOI 10.1001/archinte.147.2.251; GORE JM, 1982, ANN INTERN MED, V96, P556, DOI 10.7326/0003-4819-96-5-556; GRIFFIN MR, 1987, ARCH INTERN MED, V147, P1907, DOI 10.1001/archinte.147.11.1907; HALICI U, 2006, TRAKYA U FAK DERG, V23, P9; Hettiarachchi RJK, 1998, CANCER, V83, P180, DOI 10.1002/(SICI)1097-0142(19980701)83:1<180::AID-CNCR24>3.0.CO;2-S; KHAN KS, 2001, CRD REPORT 4 UNDERTA; Lazo-Langner A, 2007, J THROMB HAEMOST, V5, P729, DOI 10.1111/j.1538-7836.2007.02427.x; LEE AY, 2006, HEMATOLOGY AM SOC HE, V438, P43; Lee AYY, 2003, NEW ENGL J MED, V349, P146, DOI 10.1056/NEJMoa025313; Lee AYY, 2005, J CLIN ONCOL, V23, P2123, DOI 10.1200/JCO.2005.03.133; Lee AYY, 2003, J THROMB HAEMOST, V1, P2273, DOI 10.1046/j.1538-7836.2003.00490.x; Lee AYY, 2003, CIRCULATION, V107, pI17, DOI 10.1161/01.CIR.0000078466.72504.AC; Lyman GH, 2007, J CLIN ONCOL, V25, P5490, DOI 10.1200/JCO.2007.14.1283; MINAR E, 1982, DEUT MED WOCHENSCHR, V107, P1303, DOI 10.1055/s-2008-1070119; MONREAL M, 1991, CANCER, V67, P541, DOI 10.1002/1097-0142(19910115)67:2<541::AID-CNCR2820670237>3.0.CO;2-J; MONREAL M, 1988, ARCH INTERN MED, V148, P485, DOI 10.1001/archinte.148.2.485; Monreal M, 2004, J THROMB HAEMOST, V2, P876, DOI 10.1111/j.1538-7836.2004.00721.x; Monreal M, 1997, THROMB HAEMOSTASIS, V78, P1316; MONREAL M, 1993, CHEST, V103, P816, DOI 10.1378/chest.103.3.816; Netzer P, 1999, J CLIN ULTRASOUND, V27, P177, DOI 10.1002/(SICI)1097-0096(199905)27:4<177::AID-JCU2>3.0.CO;2-A; NORDSTROM M, 1994, BRIT MED J, V308, P891, DOI 10.1136/bmj.308.6933.891; OCONNOR NTJ, 1984, POSTGRAD MED J, V60, P275, DOI 10.1136/pgmj.60.702.275; Piccioli A, 2004, J THROMB HAEMOST, V2, P884, DOI 10.1111/j.1538-7836.2004.00720.x; Piccioli A, 2003, J THROMB HAEMOST, V1, P2271, DOI 10.1046/j.1538-7836.2003.00505.x; PISTORIUS MA, 1994, J MAL VASCUL, V19, P273; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; Prandoni P, 2002, BLOOD, V100, P3484, DOI 10.1182/blood-2002-01-0108; Rajan R, 1998, THROMB HAEMOSTASIS, V79, P19, DOI 10.1055/s-0037-1614211; Rance A, 1997, LANCET, V350, P1448, DOI 10.1016/S0140-6736(05)64210-9; RANFT J, 1991, INT ANGIOL, V10, P66; Ronsdorf A, 2003, SWISS MED WKLY, V133, P567; Saba HI, 2003, AM J HEMATOL, V72, P109, DOI 10.1002/ajh.10269; Sannella N A, 1991, Ann Vasc Surg, V5, P218, DOI 10.1007/BF02329376; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Snowdon C, 1999, CONTROL CLIN TRIALS, V20, P149, DOI 10.1016/S0197-2456(98)00049-X; Sorensen HT, 1998, NEW ENGL J MED, V338, P1169, DOI 10.1056/NEJM199804233381701; Subira M, 1999, AM J HEMATOL, V60, P181, DOI 10.1002/(SICI)1096-8652(199903)60:3<181::AID-AJH2>3.3.CO;2-W; TROUSSEAU A, 1963, CLIN MED HOTEL DIEU; VANDOORMAAL FF, 2007, J THROMB HAEMOST S2, V5; Wells G., NEWCASTLE OTTAWA SCA; White RH, 2005, ARCH INTERN MED, V165, P1782, DOI 10.1001/archinte.165.15.1782	54	206	217	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2008	149	5					323	W69		10.7326/0003-4819-149-5-200809020-00007	http://dx.doi.org/10.7326/0003-4819-149-5-200809020-00007			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	348SD	18765702				2022-12-28	WOS:000259229300005
J	Dyrbye, LN; Thomas, MR; Massie, FS; Power, DV; Eacker, A; Harper, W; Durning, S; Moutier, C; Szydlo, DW; Novotny, PJ; Sloan, JA; Shanafelt, TD				Dyrbye, Liselotte N.; Thomas, Matthew R.; Massie, F. Stanford; Power, David V.; Eacker, Anne; Harper, William; Durning, Steven; Moutier, Christine; Szydlo, Daniel W.; Novotny, Paul J.; Sloan, Jeff A.; Shanafelt, Tait D.			Burnout and suicidal ideation among US medical students	ANNALS OF INTERNAL MEDICINE			English	Article							UNITED-STATES; DEPRESSION; MULTICENTER; PREVALENCE; PHYSICIANS; DISTRESS; EMPATHY; STRESS; LIFE; CARE	Background: Little is known about the prevalence of suicidal ideation among U.S. medical students or how it relates to burnout. Objective: To assess the frequency of suicidal ideation among medical students and explore its relationship with burnout. Design: Cross-sectional 2007 and longitudinal 2006 to 2007 cohort study. Setting: 7 medical schools in the United States. Participants: 4287 medical students at 7 medical schools, with students at 5 institutions studied longitudinally. Measurements: Prevalence of suicidal ideation in the past year and its relationship to burnout, demographic characteristics, and quality of life. Results: Burnout was reported by 49.6% (95% CI, 47.5% to 51.8%) of students, and 11.2% (CI, 9.9% to 12.6%) reported suicidal ideation within the past year. In a sensitivity analysis that assumed all nonresponders did not have suicidal ideation, the prevalence of suicidal ideation in the past 12 months would be 5.8%. In the longitudinal cohort, burnout (P < 0.001 for all domains), quality of life (P < 0.002 for each domain), and depressive symptoms (P < 0.001) at baseline predicted suicidal ideation over the following year. In multivariable analysis, burnout and low mental quality of life at baseline were independent predictors of suicidal ideation over the following year. Of the 370 students who met criteria for burnout in 2006, 99 (26.8%) recovered. Recovery from burnout was associated with markedly less suicidal ideation, which suggests that recovery from burnout decreased suicide risk. Limitation: Although response rates (52% for the cross-sectional study and 65% for the longitudinal cohort study) are typical of physician surveys, nonresponse by some students reduces the precision of the estimated frequency of suicidal ideation and burnout. Conclusion: Approximately 50% of students experience burnout and 10% experience suicidal ideation during medical school. Burnout seems to be associated with increased likelihood of subsequent suicidal ideation, whereas recovery from burnout is associated with less suicidal ideation.	Mayo Clin, Rochester, MN USA; Univ Alabama Birmingham, Sch Med, Birmingham, AL USA; Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; Univ Washington, Sch Med, Seattle, WA USA; Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD USA; Univ Calif San Diego, San Diego, CA 92103 USA	Mayo Clinic; University of Alabama System; University of Alabama Birmingham; University of Minnesota System; University of Minnesota Twin Cities; University of Washington; University of Washington Seattle; University of Chicago; Uniformed Services University of the Health Sciences - USA; University of California System; University of California San Diego	Dyrbye, LN (corresponding author), 200 1st St SW, Rochester, MN 55905 USA.			Moutier, Christine/0000-0002-3826-7160	Mayo Clinic	Mayo Clinic	By an Education Innovation award from the Mayo Clinic.	[Anonymous], NATL COMORBIDITY SUR; ARTHUR NM, 1990, J COUNS DEV, V69, P186, DOI 10.1002/j.1556-6676.1990.tb01484.x; *ASS AM MED COLL, 2005, FACTS APPL MATR GRAD; *ASS AM MED COLL, 1995, MED SCH GRAD QUEST; Center C, 2003, JAMA-J AM MED ASSOC, V289, P3161, DOI 10.1001/jama.289.23.3161; CLARK DC, 1988, JAMA-J AM MED ASSOC, V260, P2521, DOI 10.1001/jama.260.17.2521; COOPERPATRICK L, 1994, JAMA-J AM MED ASSOC, V272, P1757, DOI 10.1001/jama.272.22.1757; Crosby AE, 1999, SUICIDE LIFE-THREAT, V29, P131; Dahlin M, 2005, MED EDUC, V39, P594, DOI 10.1111/j.1365-2929.2005.02176.x; Dahlin Marie E, 2007, BMC Med Educ, V7, P6, DOI 10.1186/1472-6920-7-6; Dyrbye LN, 2007, ARCH INTERN MED, V167, P2103, DOI 10.1001/archinte.167.19.2103; Dyrbye LN, 2006, MAYO CLIN PROC, V81, P1435, DOI 10.4065/81.11.1435; Dyrbye LN, 2006, ACAD MED, V81, P354, DOI 10.1097/00001888-200604000-00009; FLETCHER RH, 2005, LIPPINCOTT WILLIAMS, pCH11; Freund R.J., 2000, SAS SYSTEM REGRESSIO, DOI 10.1002/9780470057339.vas007; Givens JL, 2002, ACAD MED, V77, P918, DOI 10.1097/00001888-200209000-00024; Guthrie E, 1998, J ROY SOC MED, V91, P237, DOI 10.1177/014107689809100502; Hay LR, 1996, AM J PSYCHIAT, V153, P553; Kellerman SE, 2001, AM J PREV MED, V20, P61, DOI 10.1016/S0749-3797(00)00258-0; Kessler RC, 1999, ARCH GEN PSYCHIAT, V56, P617, DOI 10.1001/archpsyc.56.7.617; *LIAIS COMM MED ED, 2003, ACCR STAND; Mann JJ, 2005, JAMA-J AM MED ASSOC, V294, P2064, DOI 10.1001/jama.294.16.2064; MEEHAN PJ, 1992, AM J PSYCHIAT, V149, P41; *NAT CTR HLTH STAT, 2007, YOUTH RISK BEHAV SUR; PEPITONEARREOLAROCKWELL F, 1981, AM J PSYCHIAT, V138, P198; Schaufeli W.B., 1996, MASLACH BURNOUT INVE, V3rd, P22; Schernhammer E, 2005, NEW ENGL J MED, V352, P2473, DOI 10.1056/NEJMp058014; Schernhammer ES, 2004, AM J PSYCHIAT, V161, P2295, DOI 10.1176/appi.ajp.161.12.2295; Shanafelt TD, 2005, J GEN INTERN MED, V20, P559, DOI 10.1007/s11606-005-0102-8; Shanafelt TD, 2002, ANN INTERN MED, V136, P358, DOI 10.7326/0003-4819-136-5-200203050-00008; Soderfeldt M, 1996, SCAND J PSYCHOL, V37, P437, DOI 10.1111/j.1467-9450.1996.tb00675.x; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Thomas MR, 2007, J GEN INTERN MED, V22, P177, DOI 10.1007/s11606-006-0039-6; Thomas NK, 2004, JAMA-J AM MED ASSOC, V292, P2880, DOI 10.1001/jama.292.23.2880; Tjia J, 2005, J AM COLL HEALTH, V53, P219, DOI 10.3200/JACH.53.5.219-224; Toppinen-Tanner S, 2005, BEHAV MED, V31, P18, DOI 10.3200/BMED.31.1.18-32; Turner-Bowker DM, 2003, QUAL LIFE RES, V12, P1003, DOI 10.1023/A:1026179517081; Tyssen R, 2001, J AFFECT DISORDERS, V64, P69, DOI 10.1016/S0165-0327(00)00205-6; Ware JE Jr, 2001, SCORE INTERPRET SING; West CP, 2006, JAMA-J AM MED ASSOC, V296, P1071, DOI 10.1001/jama.296.9.1071; Whooley MA, 1997, J GEN INTERN MED, V12, P439, DOI 10.1046/j.1525-1497.1997.00076.x	41	820	847	12	111	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2008	149	5					334	W70		10.7326/0003-4819-149-5-200809020-00008	http://dx.doi.org/10.7326/0003-4819-149-5-200809020-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	348SD	18765703				2022-12-28	WOS:000259229300006
J	Gandhi, CS; Rees, DC				Gandhi, Chris S.; Rees, Douglas C.			Biochemistry - Opening the molecular floodgates	SCIENCE			English	Editorial Material							MECHANOSENSITIVE CHANNEL; ESCHERICHIA-COLI; GATING MECHANISM; ION-CHANNEL; K+ CHANNEL; MSCL; RESOLUTION		[Gandhi, Chris S.; Rees, Douglas C.] CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; [Rees, Douglas C.] CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute	Gandhi, CS (corresponding author), CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA.	dcrees@caltech.edu						Akitake B, 2007, NAT STRUCT MOL BIOL, V14, P1141, DOI 10.1038/nsmb1341; Bass RB, 2002, SCIENCE, V298, P1582, DOI 10.1126/science.1077945; Beckstein O, 2004, PHYS BIOL, V1, P42, DOI 10.1088/1478-3967/1/1/005; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Edwards MD, 2005, NAT STRUCT MOL BIOL, V12, P113, DOI 10.1038/nsmb895; Hamill OP, 2007, CURR TOP MEMBR, V58, P1; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Levina N, 1999, EMBO J, V18, P1730, DOI 10.1093/emboj/18.7.1730; Long SB, 2007, NATURE, V450, P376, DOI 10.1038/nature06265; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; Perozo E, 2002, NATURE, V418, P942, DOI 10.1038/nature00992; Steinbacher S, 2007, CURR TOP MEMBR, V58, P1, DOI 10.1016/S1063-5823(06)58001-9; Sukharev S, 2001, NATURE, V409, P720, DOI 10.1038/35055559; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; Vasquez V, 2008, SCIENCE, V321, P1210, DOI 10.1126/science.1159674; Wang WJ, 2008, SCIENCE, V321, P1179, DOI 10.1126/science.1159262; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	19	6	6	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2008	321	5893					1166	1167		10.1126/science.1162963	http://dx.doi.org/10.1126/science.1162963			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341ZM	18755963				2022-12-28	WOS:000258754400029
J	Perutz, RN				Perutz, Robin N.			Chemistry - A catalytic foothold for fluorocarbon reactions	SCIENCE			English	Editorial Material							HYDRODEFLUORINATION		[Perutz, Robin N.] Univ York, Dept Chem, York YO10 5DD, N Yorkshire, England	University of York - UK	Perutz, RN (corresponding author), Univ York, Dept Chem, York YO10 5DD, N Yorkshire, England.	rnp1@york.ac.uk						BRAUN T, 2006, COMPREHENSIVE ORGANO, V3; Douvris C, 2008, SCIENCE, V321, P1188, DOI 10.1126/science.1159979; Hong YC, 2003, PHYS PLASMAS, V10, P3410, DOI 10.1063/1.1587154; Huheey J.E., 1993, INORGANIC CHEM; Morawski AM, 2004, MAGN RESON MED, V52, P1255, DOI 10.1002/mrm.20287; Reed CA, 2005, CHEM COMMUN, P1669, DOI 10.1039/b415425h; REED CA, 1993, SCIENCE, V262, P402, DOI 10.1126/science.262.5132.402; Sandford G, 2000, PHILOS T R SOC A, V358, P455, DOI 10.1098/rsta.2000.0541; Sandford G, 2003, TETRAHEDRON, V59, P437, DOI 10.1016/S0040-4020(02)01568-5; Scott VJ, 2005, J AM CHEM SOC, V127, P2852, DOI 10.1021/ja0426138; So MK, 2004, ENVIRON SCI TECHNOL, V38, P4056, DOI 10.1021/es049441z; Vela J, 2005, J AM CHEM SOC, V127, P7857, DOI 10.1021/ja042672l; Wang T, 2007, ORG LETT, V9, P5629, DOI 10.1021/ol702591b	13	35	35	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2008	321	5893					1168	1169		10.1126/science.1161182	http://dx.doi.org/10.1126/science.1161182			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341ZM	18755964				2022-12-28	WOS:000258754400030
J	Staples, JE; Monath, TP				Staples, J. Erin; Monath, Thomas P.			Yellow fever: 100 years of discovery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Staples, J. Erin] Ctr Dis Control & Prevent, Arboviral Dis Branch, Div Vector Borne Infect Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, Ft Collins, CO 80521 USA; [Monath, Thomas P.] Kleiner Perkins Caufield & Byers, Menlo Pk, CA USA	Centers for Disease Control & Prevention - USA	Staples, JE (corresponding author), Ctr Dis Control & Prevent, Arboviral Dis Branch, Div Vector Borne Infect Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, 3150 Rampart Rd, Ft Collins, CO 80521 USA.	estaples@cdc.gov						[Anonymous], 1931, YELLOW FEVER EPIDEMI; [Anonymous], 2007, WKLY EPIDEMIOL REC; Bryan CS, 2004, INFECT DIS CLIN N AM, V18, P275, DOI 10.1016/j.idc.2004.01.007; Downs WG, 1973, ARTHROPOD BORNE VIRU; GERMAIN M, 1982, B I PASTEUR, V80, P315; Gubler DJ, 2004, COMP IMMUNOL MICROB, V27, P319, DOI 10.1016/j.cimid.2004.03.013; HADDOW AJ, 1965, T ROY SOC TROP MED H, V59, P436, DOI 10.1016/0035-9203(65)90062-3; LAI CJ, 2003, ADV VIRUS RES, V469, P509; Monath T. P., 2008, VACCINES, P959; MONATH TP, 1991, AM J TROP MED HYG, V45, P1; Reed W, 1901, J AMER MED ASSOC, V36, P431; RICE CM, 1985, SCIENCE, V229, P726, DOI 10.1126/science.4023707; Soper FL, 1937, AM J PUBLIC HEALTH N, V27, P1, DOI 10.2105/AJPH.27.1.1; Strode GK, 1951, YELLOW FEVER	14	80	83	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2008	300	8					960	962		10.1001/jama.300.8.960	http://dx.doi.org/10.1001/jama.300.8.960			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	341AR	18728272	Bronze			2022-12-28	WOS:000258687100033
J	Little, P; Lewith, G; Webley, F; Evans, M; Beattie, A; Middleton, K; Barnett, J; Ballard, K; Oxford, F; Smith, P; Yardley, L; Hollinghurst, S; Sharp, D				Little, Paul; Lewith, George; Webley, Fran; Evans, Maggie; Beattie, Angela; Middleton, Karen; Barnett, Jane; Ballard, Kathleen; Oxford, Frances; Smith, Peter; Yardley, Lucy; Hollinghurst, Sandra; Sharp, Debbie			Randomised controlled trial of Alexander technique lessons, exercise, and massage (ATEAM) for chronic and recurrent back pain	BMJ-BRITISH MEDICAL JOURNAL			English	Article							THERAPY; CARE; SEVERITY; QUALITY	Objective To determine the effectiveness of lessons in the Alexander technique, massage therapy, and advice from a doctor to take exercise (exercise prescription) along with nurse delivered behavioural counselling for patients with chronic or recurrent back pain. Design Factorial randomised trial. Setting 64 general practices in England. Participants 579 patients with chronic or recurrent low back pain; 144 were randomised to normal care, 147 to massage, 144 to six Alexander technique lessons, and 144 to 24 Alexander technique lessons; half of each of these groups were randomised to exercise prescription. Interventions Normal care (control), six sessions of massage, six or 24, lessons on the Alexander technique, and prescription for exercise from a doctor with nurse delivered behavioural counselling. Main outcome measures Roland Morris disability score (number of activities impaired by pain) and number of days in pain. Results Exercise and lessons in the Alexander technique, but not massage, remained effective atone year (compared with control Roland disability score 8.1: massage -0.58, 95% confidence interval -1.94 to 0.77, six lessons -1.40, -2.77 to -0.03, 24 lessons -3.4, -4.76 to -2.03, and exercise -1.29, -2.25 to -0.34). Exercise after six lessons achieved 72% of the effect of 24 lessons alone (Roland disability score -2.98 and -4.14, respectively). Number of days with back pain in the past four weeks were lower after lessons (compared with control median 21 days: 24 lessons -18, six lessons -10, massage -7) and quality of life improved significantly. No significant harms were reported. Conclusions One to one lessons in the Alexander technique from registered teachers have long term benefits for patients with chronic back pain. Six lessons followed by exercise prescription were nearly as effective as 24 lessons. Trial registration National Research Register N0028108728.	[Little, Paul; Lewith, George; Webley, Fran; Middleton, Karen; Barnett, Jane] Univ Southampton, Primary Care Grp, Community Clin Sci Div, Aldermoor Hlth Ctr, Southampton SO16 5ST, Hants, England; [Yardley, Lucy] Univ Southampton, Sch Psychol, Southampton SO16 5ST, Hants, England; [Smith, Peter] Univ Southampton, Dept Social Stat, Southampton SO9 5NH, Hants, England; [Evans, Maggie; Beattie, Angela; Hollinghurst, Sandra] Univ Bristol, Acad Unit Primary Hlth Care, Dept Community Based Med, Bristol BS8 1TH, Avon, England; [Ballard, Kathleen; Oxford, Frances] Soc Teachers Alexander Tech, London, England	University of Southampton; University of Southampton; University of Southampton; University of Bristol	Little, P (corresponding author), Univ Southampton, Primary Care Grp, Community Clin Sci Div, Aldermoor Hlth Ctr, Southampton SO16 5ST, Hants, England.	psl3@soton.ac.uk		Yardley, Lucy/0000-0002-3853-883X; Lewith, George/0000-0002-2364-3960; Little, Paul/0000-0003-3664-1873; sharp, deborah/0000-0003-3071-9860	MRC [G0001104] Funding Source: UKRI; Medical Research Council [G0001104] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Andersson GBJ, 1999, LANCET, V354, P581, DOI 10.1016/S0140-6736(99)01312-4; Assendelft W, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000447.PUB2; Beurskens AJHM, 1996, PAIN, V65, P71, DOI 10.1016/0304-3959(95)00149-2; BRERLEY S, 2003, BMC HLTH SERV R 0801, P3; BRERLEY S, 2003, BMC HLTH SERV R 0801, P16; CACCIATORE T, 2007, P INT SOC POST GAIT, P18; Cacciatore TW, 2005, PHYS THER, V85, P565; Cherkin DC, 2001, ARCH INTERN MED, V161, P1081, DOI 10.1001/archinte.161.8.1081; *CLIN STAND ADV GR, 1994, MAN GUID BACK PAIN; DAY SJ, 1989, BMJ-BRIT MED J, V299, P663, DOI 10.1136/bmj.299.6700.663; DEYO R, 1997, P 2 INT FOR PRIM CAR; Ernst E, 1999, J PAIN SYMPTOM MANAG, V17, P65, DOI 10.1016/S0885-3924(98)00129-8; Ernst E, 2003, FORSCH KOMP KLAS NAT, V10, P325, DOI 10.1159/000075886; FROST H, 1995, BRIT MED J, V310, P151, DOI 10.1136/bmj.310.6973.151; Furlan AD, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001351.pub2; FURLAN AD, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001929; Godin G, 1996, AM J HEALTH PROMOT, V11, P87, DOI 10.4278/0890-1171-11.2.87; Goldby LJ, 2006, SPINE, V31, P1083, DOI 10.1097/01.brs.0000216464.37504.64; Gurfinkel V, 2006, J NEUROPHYSIOL, V96, P2678, DOI 10.1152/jn.00406.2006; Hayden JA, 2005, ANN INTERN MED, V142, P765, DOI 10.7326/0003-4819-142-9-200505030-00013; Heymans MW., 2004, COCHRANE DATABASE SY, DOI [10.1002/14651858.CD000261.pub2, DOI 10.1002/14651858.CD000261.PUB2]; HILLSDON M, 1995, J EPIDEMIOL COMMUN H, V49, P448, DOI 10.1136/jech.49.5.448; Howie JGR, 1999, BMJ-BRIT MED J, V319, P738, DOI 10.1136/bmj.319.7212.738; Hsieh LLC, 2006, BMJ-BRIT MED J, V332, P696, DOI 10.1136/bmj.38744.672616.AE; KLABERMOFFATT J, 1994, UNPUB EXERCISE BASED; KLABERMOFFETT J, 1999, BRIT MED J, V319, P279; Little P, 2001, SPINE, V26, P2065, DOI 10.1097/00007632-200110010-00003; Little P, 1997, BMJ-BRIT MED J, V314, P722, DOI 10.1136/bmj.314.7082.722; MEADE TW, 1992, BRIT MED J, V304, P1310, DOI 10.1136/bmj.304.6837.1310; PATRICK DL, 1995, SPINE, V20, P1899, DOI 10.1097/00007632-199509000-00011; Preyde M, 2000, CAN MED ASSOC J, V162, P1815; Salovey P, 1992, VITAL HLTH STAT, V6; Sherman KJ, 2005, ANN INTERN MED, V143, P849, DOI 10.7326/0003-4819-143-12-200512200-00003; Stewart WF, 1999, PAIN, V79, P291, DOI 10.1016/S0304-3959(98)00181-X; THOMAS K, 2008, BMJ-BRIT MED J, V333, P611; Underwood M, 2004, BMJ-BRIT MED J, V329, P1377, DOI 10.1136/bmj.38282.669225AE; van Tulder MW, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000335; VANTULDER MW, 2005, COCHRANE DB SYST REV, P335; VONKORFF M, 1993, SPINE, V18, P855, DOI 10.1097/00007632-199306000-00008; VONKORFF M, 1992, PAIN, V50, P133, DOI 10.1016/0304-3959(92)90154-4; WADDELL G, 1993, PAIN, V52, P157, DOI 10.1016/0304-3959(93)90127-B; Waddell G, 2002, BACK PAIN INCAPACITY; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	43	96	98	2	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 23	2008	337	7667							a884	10.1136/bmj.a884	http://dx.doi.org/10.1136/bmj.a884			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	346FD	18713809	Green Published, Green Submitted, hybrid			2022-12-28	WOS:000259053100025
J	Steel, N; Bachmann, M; Maisey, S; Shekelle, P; Breeze, E; Marmot, M; Melzer, D				Steel, Nicholas; Bachmann, Max; Maisey, Susan; Shekelle, Paul; Breeze, Elizabeth; Marmot, Michael; Melzer, David			Self reported receipt of care consistent with 32 quality indicators: national population survey of adults aged 50 or more in England	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; HEALTH-CARE; OF-CARE; MEDICAL-CARE; MANAGEMENT; UK; PAY	Objective To assess the receipt of effective healthcare interventions in England by adults aged 50 or more with serious health conditions. Design National structured survey questionnaire with face to face interviews covering medical panel endorsed quality of care indicators for both publicly and privately provided care. Setting Private households across England. Participants 8688 participants in the English longitudinal study of ageing, of whorn 4417 reported diagnoses of one or more of 13 conditions. Main outcome measures Percentage of indicated interventions received by eligible participants for 32 clinical indicators and seven questions on patient centred care, and aggregate scores. Results Participants were eligible for 19082 items of indicated care. Receipt of indicated care varied substantially by condition. The percentage of indicated care received by eligible participants was highest for ischaemic heart disease (83%, 95% confidence interval 80% to 86%), followed by hearing problems (79%, 77% to 81%), pain management (78%, 73% to 83%), diabetes (74%, 72% to 76%), smoking cessation (74%, 71% to 76%), hypertension (72%, 69% to 76%), stroke (65%, 54% to 76%), depression (64%, 57% to 70%), patient centred care (58%, 57% to 60%), poor vision (58%, 54% to 63%), osteoporosis (53%, 49% to 57%), urinary incontinence (51%, 47% to 54%), fails management (44%, 37% to 51%), osteoarthritis (29%, 26% to 32%), and overall (62%, 62% to 63%). Substantially more indicated care was received for general medical (74%, 73% to 76%) than for geriatric conditions (57%, 55% to 58%), and for conditions included in the general practice pay for performance contract (75%, 73% to 76%) than excluded from it (58%, 56% to 59%). Conclusions Shortfalls in receipt of basic recommended care by adults aged 50 or more with common health conditions in England were most noticeable in areas associated with disability and frailty, but few areas were exempt. Efforts to improve care have substantial scope to achieve better health outcomes and particularly need to include chronic conditions that affect quality of life of older people.	[Steel, Nicholas; Bachmann, Max; Maisey, Susan] Univ E Anglia, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England; [Shekelle, Paul] RAND Corp, Santa Monica, CA USA; [Breeze, Elizabeth; Marmot, Michael] UCL, Dept Epidemiol & Publ Hlth, London, England; [Melzer, David] Peninsula Med Sch, Exeter, Devon, England	University of East Anglia; RAND Corporation; University of London; University College London; University of Exeter	Steel, N (corresponding author), Univ E Anglia, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England.	n.steel@uea.ac.uk	Steel, Nicholas/K-1592-2014; Breeze, Elizabeth/AAK-4927-2021; Marmot, M G/Y-3920-2019	Steel, Nicholas/0000-0003-1528-140X; Marmot, M G/0000-0002-2431-6419; Bachmann, Max Oscar/0000-0003-1770-3506; Melzer, David/0000-0002-0170-3838	UK National Coordinating Centre for Research Capacity Development, and the Commonwealth Fund; US National Institute on Aging; UK Department of Health; Department for Work and Pensions; Office for National Statistics; Department for Environment Food and Rural Affairs; Department for Transport; Department for Education and Skills; Department of Culture Media and Sport; HM Treasury; British Heart Foundation [RG/07/008/23674] Funding Source: researchfish; Medical Research Council [G8802774, G19/35, G0100222] Funding Source: researchfish	UK National Coordinating Centre for Research Capacity Development, and the Commonwealth Fund; US National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); UK Department of Health; Department for Work and Pensions; Office for National Statistics; Department for Environment Food and Rural Affairs(Department for Environment, Food & Rural Affairs (DEFRA)); Department for Transport; Department for Education and Skills; Department of Culture Media and Sport; HM Treasury; British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	NS was supported by the UK National Coordinating Centre for Research Capacity Development, and the Commonwealth Fund (a New York City based private independent foundation). The English longitudinal study of ageing was funded by the US National Institute on Aging, the UK Department of Health, Department for Work and Pensions, Office for National Statistics, Department for Environment Food and Rural Affairs, Department for Transport, Department for Education and Skills, Department of Culture Media and Sport, and HM Treasury. The funders had no influence over the analysis or presentation of results.	*AG HEALTHC RES QU, 2008, CONS ASS HEALTHC PRO; Asch SM, 2004, ANN INTERN MED, V141, P938, DOI 10.7326/0003-4819-141-12-200412210-00010; Banks J., 2006, RETIREMENT HLTH RELA; BETHELL C, 2001, PORTRAIT CHRONICALLY; Brook R H, 1986, Int J Technol Assess Health Care, V2, P53; Bunker JP, 2001, INT J EPIDEMIOL, V30, P1260, DOI 10.1093/ije/30.6.1260; Campbell S, 2007, NEW ENGL J MED, V357, P181, DOI 10.1056/NEJMsr065990; Chang JT, 2007, J GEN INTERN MED, V19, pS109; Counsell SR, 2007, JAMA-J AM MED ASSOC, V298, P2623, DOI 10.1001/jama.298.22.2623; *CTR MED MED SERV, 2005, MED CURR BEN SURV; Department of Health, 2001, NAT SERV FRAM OLD PE; Doran T, 2006, NEW ENGL J MED, V355, P375, DOI 10.1056/NEJMsa055505; Ganz DA, 2007, MED CARE, V45, P8, DOI 10.1097/01.mlr.0000241115.31531.15; Gemmell I, 2006, QUAL SAF HEALTH CARE, V15, P339, DOI 10.1136/qshc.2005.017061; *GEN PRACT COMM BM, 2003, INV GEN PRACT NEW GE; Grol R, 2001, MED CARE, V39, pII46; Hart JT, 2000, BRIT MED J, V320, P18; Higashi T, 2005, ANN INTERN MED, V143, P274, DOI 10.7326/0003-4819-143-4-200508160-00008; *I MED COMM HLTH C, 2001, CROSS QUAL CHASM NEW; Inouye SK, 2007, J AM GERIATR SOC, V55, P780, DOI 10.1111/j.1532-5415.2007.01156.x; Jha AK, 2003, NEW ENGL J MED, V348, P2218, DOI 10.1056/NEJMsa021899; LEATHERMAN S, 2005, QUEST QUALITY NHS CH; Lilford RJ, 2007, BMJ-BRIT MED J, V335, P648, DOI 10.1136/bmj.39317.641296.AD; Majeed A, 2005, PUBLIC HEALTH, V119, P105, DOI 10.1016/j.puhe.2004.06.006; MANT J, 1995, BMJ-BRIT MED J, V311, P793, DOI 10.1136/bmj.311.7008.793; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Millett C, 2006, J MED SCREEN, V13, P152, DOI 10.1258/096914106778440608; Reeves D, 2007, MED CARE, V45, P489, DOI 10.1097/MLR.0b013e31803bb479; Seddon ME, 2001, QUAL HEALTH CARE, V10, P152, DOI 10.1136/qhc.0100152..; Steel N, 2004, QUAL SAF HEALTH CARE, V13, P260, DOI 10.1136/qshc.2004.010280; Steel N, 2007, BRIT J GEN PRACT, V57, P449; Taylor R., 2007, HLTH WEALTH LIFESTYL; Tinetti ME, 2006, GERONTOLOGIST, V46, P717, DOI 10.1093/geront/46.6.717; Tisnado DM, 2006, MED CARE, V44, P132, DOI 10.1097/01.mlr.0000196952.15921.bf; Wenger NS, 2003, ANN INTERN MED, V139, P740, DOI 10.7326/0003-4819-139-9-200311040-00008; Wenger NS, 2001, ANN INTERN MED, V135, P642, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00002; WILKIN D, 2002, NATL TRACKER SURVEY	37	73	73	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 23	2008	337	7667							a957	10.1136/bmj.a957	http://dx.doi.org/10.1136/bmj.a957			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	346FD	18703659	hybrid, Green Published, Green Submitted			2022-12-28	WOS:000259053100026
J	Lefevre, F; Bertaux, JL; Clancy, RT; Encrenaz, T; Fast, K; Forget, F; Lebonnois, S; Montmessin, F; Perrier, S				Lefevre, Franck; Bertaux, Jean-Loup; Clancy, R. Todd; Encrenaz, Therese; Fast, Kelly; Forget, Francois; Lebonnois, Sebastien; Montmessin, Franck; Perrier, Severine			Heterogeneous chemistry in the atmosphere of Mars	NATURE			English	Article							MARTIAN ATMOSPHERE; WATER-VAPOR; INTERANNUAL VARIABILITY; OZONE; SPECTROSCOPY; STABILITY; APHELION; H2O2; PHOTOCHEMISTRY; ABUNDANCE	Hydrogen radicals are produced in the martian atmosphere by the photolysis of water vapour and subsequently initiate catalytic cycles that recycle carbon dioxide from its photolysis product carbon monoxide(1,2). These processes provide a qualitative explanation for the stability of the atmosphere of Mars, which contains 95 per cent carbon dioxide. Balancing carbon dioxide production and loss based on our current understanding of the gas-phase chemistry in the martian atmosphere has, however, proven to be difficult(3-5). Interactions between gaseous chemical species and ice cloud particles have been shown to be key factors in the loss of polar ozone observed in the Earth's stratosphere(6), and may significantly perturb the chemistry of the Earth's upper troposphere(7). Water-ice clouds are also commonly observed in the atmosphere of Mars(8-10) and it has been suggested previously that heterogeneous chemistry could have an important impact on the composition of the martian atmosphere(3-5,11). Here we use a state-of-the- art general circulation model together with new observations of the martian ozone layer(12-15) to show that model simulations to much improved quantitative agreement with observed martian ozone levels in comparison with model simulations based on gas-phase chemistry alone. Ozone is readily destroyed by hydrogen radicals and is therefore a sensitive tracer of the chemistry that regulates the atmosphere of Mars. Our results suggest that heterogeneous chemistry on ice clouds plays an important role in controlling the stability and composition of the martian atmosphere.	[Lefevre, Franck] Univ Paris 06, UPMC, Serv Aeron, F-75005 Paris, France; [Lefevre, Franck; Bertaux, Jean-Loup; Encrenaz, Therese; Forget, Francois; Lebonnois, Sebastien; Montmessin, Franck; Perrier, Severine] CNRS, INSU, F-75700 Paris, France; [Bertaux, Jean-Loup; Montmessin, Franck; Perrier, Severine] Univ Versailles St Quentin, Serv Aeron, F-91371 Verrieres Le Buisson, France; [Clancy, R. Todd] Space Sci Inst, Boulder, CO 80301 USA; [Encrenaz, Therese] Observ Paris, LESIA, F-92195 Meudon, France; [Fast, Kelly] NASA, Goddard Space Flight Ctr, Planetary Syst Lab, Greenbelt, MD 20771 USA; [Forget, Francois; Lebonnois, Sebastien] Univ Paris 06, UPMC, Meteorol Dynam Lab, F-75005 Paris, France	UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; UDICE-French Research Universities; Sorbonne Universite	Lefevre, F (corresponding author), Univ Paris 06, UPMC, Serv Aeron, F-75005 Paris, France.	franck.lefevre@aero.jussieu.fr		Montmessin, Franck/0000-0002-4187-1457; LEBONNOIS, SEBASTIEN/0000-0002-2390-8164				AKABANE T, 1993, ASTRON ASTROPHYS, V277, P302; ANBAR AD, 1993, J GEOPHYS RES-PLANET, V98, P10933, DOI 10.1029/93JE00132; ATREYA SK, 1994, J GEOPHYS RES-PLANET, V99, P13133, DOI 10.1029/94JE01085; ATREYA SK, 1990, GEOPHYS RES LETT, V17, P287, DOI 10.1029/GL017i003p00287; BARTH CA, 1973, SCIENCE, V179, P795, DOI 10.1126/science.179.4075.795; Clancy RT, 1999, ICARUS, V138, P49, DOI 10.1006/icar.1998.6059; Clancy RT, 1996, J GEOPHYS RES-PLANET, V101, P12777, DOI 10.1029/96JE00835; Clancy RT, 1996, J GEOPHYS RES-PLANET, V101, P12785, DOI 10.1029/96JE00836; Clancy RT, 2004, ICARUS, V168, P116, DOI 10.1016/j.icarus.2003.12.003; Clancy RT, 1996, ICARUS, V122, P36, DOI 10.1006/icar.1996.0108; Cooper PL, 1996, J PHYS CHEM-US, V100, P2249, DOI 10.1021/jp952142z; Encrenaz T, 2008, ICARUS, V195, P547, DOI 10.1016/j.icarus.2008.01.022; Encrenaz T, 2004, ICARUS, V170, P424, DOI 10.1016/j.icarus.2004.05.008; Encrenaz T, 2002, ASTRON ASTROPHYS, V396, P1037, DOI 10.1051/0004-6361:20021465; Fast K, 2006, ICARUS, V181, P419, DOI 10.1016/j.icarus.2005.12.001; Fouchet T, 2007, ICARUS, V190, P32, DOI 10.1016/j.icarus.2007.03.003; Jaegle L, 2000, J GEOPHYS RES-ATMOS, V105, P3877, DOI 10.1029/1999JD901016; Krasnopolsky VA, 2006, ICARUS, V185, P153, DOI 10.1016/j.icarus.2006.06.003; Lebonnois S, 2006, J GEOPHYS RES-PLANET, V111, DOI 10.1029/2005JE002643; Lefevre F, 2004, J GEOPHYS RES-PLANET, V109, DOI 10.1029/2004JE002268; Mateshvili N, 2007, J GEOPHYS RES-PLANET, V112, DOI 10.1029/2006JE002827; MCELROY MB, 1972, SCIENCE, V177, P986, DOI 10.1126/science.177.4053.986; Montabone L, 2005, ADV SPACE RES-SERIES, V36, P2146, DOI 10.1016/j.asr.2005.07.047; Montmessin F, 2004, J GEOPHYS RES-PLANET, V109, DOI 10.1029/2004JE002284; Moudden Y, 2007, ICARUS, V188, P18, DOI 10.1016/j.icarus.2006.11.005; PARKINSON TD, 1972, J ATMOS SCI, V29, P1380, DOI 10.1175/1520-0469(1972)029<1380:SAAOOO>2.0.CO;2; Perrier S, 2006, J GEOPHYS RES-PLANET, V111, DOI 10.1029/2006JE002681; SANDER SP, 2006, JPL PUBL, V62; Smith MD, 2004, ICARUS, V167, P148, DOI 10.1016/j.icarus.2003.09.010; Solomon S, 1999, REV GEOPHYS, V37, P275, DOI 10.1029/1999RG900008	30	94	95	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 21	2008	454	7207					971	975		10.1038/nature07116	http://dx.doi.org/10.1038/nature07116			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339QB	18719584				2022-12-28	WOS:000258591000033
J	Barrington, MJ; Scott, DA				Barrington, Michael J.; Scott, David A.			Do we need to justify epidural analgesia beyond pain relief?	LANCET			English	Editorial Material							ANESTHESIA; METAANALYSIS; MORBIDITY; TRIALS		[Barrington, Michael J.; Scott, David A.] St Vincents Hosp, Dept Anaesthesia, Fitzroy, Vic 3065, Australia	St Vincent's Hospital Melbourne	Barrington, MJ (corresponding author), St Vincents Hosp, Dept Anaesthesia, Fitzroy, Vic 3065, Australia.	michael.barrington@svhm.org.au						*AUSTR REG AN COLL, PROSP AUD PER NERV P; Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032; Beattie WS, 2001, ANESTH ANALG, V93, P853, DOI 10.1097/00000539-200110000-00010; Block BM, 2003, JAMA-J AM MED ASSOC, V290, P2455, DOI 10.1001/jama.290.18.2455; Brennan F, 2007, ANESTH ANALG, V105, P205, DOI 10.1213/01.ane.0000268145.52345.55; Cameron CM, 2007, ANESTHESIOLOGY, V106, P997, DOI 10.1097/01.anes.0000265160.32309.10; LIU S, 1995, ANESTHESIOLOGY, V82, P1474, DOI 10.1097/00000542-199506000-00019; Liu SS, 2006, REGION ANESTH PAIN M, V31, P291, DOI 10.1016/j.rapm.2006.05.006; Park WY, 2001, ANN SURG, V234, P560; Rigg JRA, 2002, LANCET, V359, P1276, DOI 10.1016/S0140-6736(02)08266-1; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; Shah BR, 2005, J CLIN EPIDEMIOL, V58, P550, DOI 10.1016/j.jclinepi.2004.10.016; WIJEYSUNDERA DN, 2008, LANCET          0811	13	16	16	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 16	2008	372	9638					514	516		10.1016/S0140-6736(08)61122-8	http://dx.doi.org/10.1016/S0140-6736(08)61122-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339MS	18692892				2022-12-28	WOS:000258582300007
J	Sawday, J				Sawday, Jonathan			Corpo-reality	LANCET			English	Editorial Material									Univ Strathclyde, Glasgow G1 1XH, Lanark, Scotland	University of Strathclyde	Sawday, J (corresponding author), Univ Strathclyde, Glasgow G1 1XH, Lanark, Scotland.	jonathan.sawday@strath.ac.uk						Brady A, 2006, EARLY MOD LIT HIST, P1, DOI 10.1057/9780230554870; Jupp Peter C, 1999, DEATH ENGLAND ILLUST; LLEWELYN N, 1992, ART DEATH VISUAL CUL; Sawday Jonathan, 2007, ENGINES IMAGINATION; Sawday Jonathan, 1995, BODY EMBLAZONED	5	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 16	2008	372	9638					528	529		10.1016/S0140-6736(08)61222-2	http://dx.doi.org/10.1016/S0140-6736(08)61222-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	339MS	18711801				2022-12-28	WOS:000258582300014
J	Arenz, A; Silver, RA; Schaefer, AT; Margrie, TW				Arenz, Alexander; Silver, R. Angus; Schaefer, Andreas T.; Margrie, Troy W.			The contribution of single synapses to sensory representation in vivo	SCIENCE			English	Article							RAPID BEHAVIORAL MODIFICATION; CEREBELLAR GRANULE CELLS; VESTIBULOOCULAR REFLEX; VESTIBULAR SYSTEM; PRIMATE FLOCCULUS; HEAD ROTATION; EYE-MOVEMENT; TRANSMISSION; MONKEY; NEURONS	The extent to which synaptic activity can signal a sensory stimulus limits the information available to a neuron. We determined the contribution of individual synapses to sensory representation by recording excitatory postsynaptic currents ( EPSCs) in cerebellar granule cells during a time- varying, quantifiable vestibular stimulus. Vestibular- sensitive synapses faithfully reported direction and velocity, rather than position or acceleration of whole- body motion, via bidirectional modulation of EPSC frequency. The lack of short- term synaptic dynamics ensured a highly linear relationship between velocity and charge transfer, and as few as 100 synapses provided resolution approaching psychophysical limits. This indicates that highly accurate stimulus representation can be achieved by small networks and even within single neurons.	[Arenz, Alexander; Silver, R. Angus; Schaefer, Andreas T.; Margrie, Troy W.] UCL, Dept Neurosci Physiol & Pharmacol, London WC1E 6JJ, England	University of London; University College London	Margrie, TW (corresponding author), UCL, Dept Neurosci Physiol & Pharmacol, Univ St, London WC1E 6JJ, England.	t.margrie@ucl.ac.uk		Schaefer, Andreas/0000-0002-4677-8788; Silver, Robin/0000-0002-5480-6638	BBSRC [BB/F005490/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/F005490/1] Funding Source: Medline; Medical Research Council [MC_U117597156] Funding Source: Medline; Wellcome Trust [072292, 064413] Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Angelaki DE, 2004, NATURE, V430, P560, DOI 10.1038/nature02754; BARBOUR B, 1993, NEURON, V11, P759, DOI 10.1016/0896-6273(93)90085-6; Barmack NH, 2008, J NEUROSCI, V28, P1140, DOI 10.1523/JNEUROSCI.3942-07.2008; CALVIN WH, 1967, SCIENCE, V155, P842, DOI 10.1126/science.155.3764.842; Cathala L, 2003, J NEUROSCI, V23, P6074, DOI 10.1523/JNEUROSCI.23-14-06074.2003; Chadderton P, 2004, NATURE, V428, P856, DOI 10.1038/nature02442; DiGregorio DA, 2002, NEURON, V35, P521, DOI 10.1016/S0896-6273(02)00787-0; Dino MR, 2001, EXP BRAIN RES, V140, P162, DOI 10.1007/s002210100790; Eccles J.C., 1967, CEREBELLUM NEURONAL, DOI [10.1016/0013-4694(69)90099-6, DOI 10.1016/0013-4694(69)90099-6]; FERNANDEZ C, 1971, J NEUROPHYSIOL, V34, P661, DOI 10.1152/jn.1971.34.4.661; Jorntell H, 2006, J NEUROSCI, V26, P11786, DOI 10.1523/JNEUROSCI.2939-06.2006; LISBERGER SG, 1978, J NEUROPHYSIOL, V41, P764, DOI 10.1152/jn.1978.41.3.764; LISBERGER SG, 1978, J NEUROPHYSIOL, V41, P733, DOI 10.1152/jn.1978.41.3.733; London M, 2005, ANNU REV NEUROSCI, V28, P503, DOI 10.1146/annurev.neuro.28.061604.135703; Ma WJ, 2006, NAT NEUROSCI, V9, P1432, DOI 10.1038/nn1790; Margrie TW, 2002, PFLUG ARCH EUR J PHY, V444, P491, DOI 10.1007/s00424-002-0831-z; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; Mergner T, 1993, J Vestib Res, V3, P41; NODA H, 1979, J PHYSIOL-LONDON, V294, P349, DOI 10.1113/jphysiol.1979.sp012934; NODA H, 1981, ANN NY ACAD SCI, V374, P465, DOI 10.1111/j.1749-6632.1981.tb30892.x; Rancz EA, 2007, NATURE, V450, P1245, DOI 10.1038/nature05995; Sadeghi SG, 2007, J NEUROSCI, V27, P771, DOI 10.1523/JNEUROSCI.4690-06.2007; Saviane C, 2006, NATURE, V439, P983, DOI 10.1038/nature04509; VANKAN PLE, 1993, J NEUROPHYSIOL, V69, P74, DOI 10.1152/jn.1993.69.1.74; Yang AZ, 2007, J NEUROPHYSIOL, V98, P3197, DOI 10.1152/jn.00798.2007	25	147	147	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2008	321	5891					977	980		10.1126/science.1158391	http://dx.doi.org/10.1126/science.1158391			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	337LD	18703744	Green Accepted			2022-12-28	WOS:000258436700043
J	Collins, FS				Collins, Francis S.			Retrospective - Victor A. McKusick (1921-2008)	SCIENCE			English	Biographical-Item									NHGRI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Collins, FS (corresponding author), NHGRI, NIH, Bethesda, MD 20892 USA.	4rancis@mail.nih.gov							0	6	6	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 15	2008	321	5891					925	925		10.1126/science.1163901	http://dx.doi.org/10.1126/science.1163901			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	337LD	18703732	Green Published			2022-12-28	WOS:000258436700027
J	Abreu, MT				Abreu, Maria T.			Harnessing the power of bacteria to protect the gut	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MOUSE; INTESTINE; CELLS; TOLL							Abreu, Maria T./0000-0002-7294-0574				ABRAMS GD, 1963, LAB INVEST, V12, P355; Burdelya LG, 2008, SCIENCE, V320, P226, DOI 10.1126/science.1154986; Chen R, 2008, ONCOGENE, V27, P225, DOI 10.1038/sj.onc.1210907; Fukata M, 2006, GASTROENTEROLOGY, V131, P862, DOI 10.1053/j.gastro.2006.06.017; Kaiser GC, 1999, EXP CELL RES, V249, P349, DOI 10.1006/excr.1999.4488; Riehl T, 2000, GASTROENTEROLOGY, V118, P1106, DOI 10.1016/S0016-5085(00)70363-5	6	4	4	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 14	2008	359	7					756	759		10.1056/NEJMcibr0804223	http://dx.doi.org/10.1056/NEJMcibr0804223			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336XE	18703481				2022-12-28	WOS:000258397900016
J	Wen, LP; Xu, TD; Yin, J				Wen, Liping; Xu, Tengda; Yin, Jia			Boils? Or coils?	LANCET			English	Editorial Material									[Wen, Liping; Yin, Jia] Peking Union Med Coll Hosp, Dept Allergy, Beijing 100730, Peoples R China; [Xu, Tengda] Peking Union Med Coll Hosp, Dept Emergency Med, Beijing 100730, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital	Yin, J (corresponding author), Peking Union Med Coll Hosp, Dept Allergy, Beijing 100730, Peoples R China.	doctoryinjia@163.com						DAmbrosio FP, 1996, ALLERGY, V51, P658, DOI 10.1111/j.1398-9995.1996.tb04688.x; HOSTYNEK JJ, 2004, DERMATOL THER, V12, P328; OKEREKE T, 1972, SCIENCE, V177, P358, DOI 10.1126/science.177.4046.358; Ros A, 1980, Contracept Fertil Sex (Paris), V8, P11; Yanagi T, 2005, LANCET, V366, P1050, DOI 10.1016/S0140-6736(05)67384-9	5	4	4	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 9	2008	372	9637					506	506		10.1016/S0140-6736(08)61201-5	http://dx.doi.org/10.1016/S0140-6736(08)61201-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	335OD	18692717				2022-12-28	WOS:000258299000034
J	Soroceanu, L; Akhavan, A; Cobbs, CS				Soroceanu, Liliana; Akhavan, Armin; Cobbs, Charles S.			Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection	NATURE			English	Article							NF-KAPPA-B; GLYCOPROTEIN-B; SOLUBLE FORM; NEUTRALIZING ANTIBODIES; SIGNAL-TRANSDUCTION; CELLULAR RECEPTOR; VIRAL REPLICATION; PERMISSIVE CELLS; UP-REGULATION; ENTRY	Human cytomegalovirus ( HCMV) is a ubiquitous human herpesvirus that can cause life- threatening disease in the fetus and the immunocompromised host(1). Upon attachment to the cell, the virus induces robust inflammatory, interferon- and growth- factor-like signalling(2-9). The mechanisms facilitating viral entry and gene expression are not clearly understood(4). Here we show that platelet- derived growth factor-alpha receptor (PDGFR-alpha) is specifically phosphorylated by both laboratory and clinical isolates of HCMV in various human cell types, resulting in activation of the phosphoinositide-3-kinase (PI(3)K) signalling pathway. Upon stimulation by HCMV, tyrosine- phosphorylated PDGFR-alpha associated with the p85 regulatory subunit of PI( 3) K and induced protein kinase B ( also known as Akt) phosphorylation, similar to the genuine ligand, PDGF-AA. Cells in which PDGFR-alpha was genetically deleted(10) or functionally blocked were non- permissive to HCMV entry, viral gene expression or infectious virus production. Re- introducing human PDGFRA gene into knockout cells restored susceptibility to viral entry and essential viral gene expression. Blockade of receptor function with a humanized PDGFR-alpha blocking antibody (IMC-3G3)(11) or targeted inhibition of its kinase activity with a small molecule (Gleevec)(12) completely inhibited HCMV viral internalization and gene expression in human epithelial, endothelial and fibroblast cells. Viral entry in cells harbouring endogenous PDGFR-alpha was competitively inhibited by pretreatment with PDGF-AA. We further demonstrate that HCMV glycoprotein B directly interacts with PDGFR-alpha, resulting in receptor tyrosine phosphorylation, and that glycoprotein B neutralizing antibodies(13) inhibit HCMV- induced PDGFR-alpha phosphorylation. Taken together, these data indicate that PDGFR-alpha is a critical receptor required for HCMV infection, and thus a target for novel anti- viral therapies.	[Soroceanu, Liliana; Akhavan, Armin; Cobbs, Charles S.] Calif Pacific Med Ctr, Res Inst, Dept Neurosci, San Francisco, CA 94107 USA; [Cobbs, Charles S.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA	California Pacific Medical Center; California Pacific Medical Center Research Institute; University of California System; University of California San Francisco	Cobbs, CS (corresponding author), Calif Pacific Med Ctr, Res Inst, Dept Neurosci, Suite 220,475 Brannan St, San Francisco, CA 94107 USA.	charles.cobbs@gmail.com			California Pacific Medical Center Research Institute; Arthur Flaming Foundation	California Pacific Medical Center Research Institute; Arthur Flaming Foundation	We thank M. Tallquist for the PDGFR-alpha knockout mouse fibroblasts, C. Heldin for the human PDGFR-alpha cDNA, D. Diamond for providing the soluble glycoprotein B, and N. Loizos (ImClone) for the IMC-3G3 antibody. We are grateful to W. Britt (University of Alabama at Birmingham) for viruses, glycoprotein B neutralizing antibodies and discussions. This study was supported by an institutional grant from California Pacific Medical Center Research Institute and by the Arthur Flaming Foundation.	Andreoni KA, 2002, J MED VIROL, V67, P33, DOI 10.1002/jmv.2189; Andrews A, 1999, INVEST OPHTH VIS SCI, V40, P2683; Boyle KA, 1998, J VIROL, V72, P1826, DOI 10.1128/JVI.72.3.1826-1833.1998; Boyle KA, 1999, MOL CELL BIOL, V19, P3607; Britt WJ, 2005, J VIROL, V79, P4066, DOI 10.1128/JVI.79.7.4066-4079.2005; BRITT WJ, 1984, VIROLOGY, V135, P369, DOI 10.1016/0042-6822(84)90193-4; BRITT WJ, 1996, FIELDS VIROLOGY; Carlson C, 1997, VIROLOGY, V239, P198, DOI 10.1006/viro.1997.8892; Chan G, 2004, BIOL REPROD, V71, P797, DOI 10.1095/biolreprod.104.028118; Cobbs CS, 2007, J NEURO-ONCOL, V85, P271, DOI 10.1007/s11060-007-9423-2; Compton T, 2004, TRENDS CELL BIOL, V14, P5, DOI 10.1016/j.tcb.2003.10.009; Cooray S, 2004, J GEN VIROL, V85, P1065, DOI 10.1099/vir.0.19771-0; English EP, 2006, J BIOL CHEM, V281, P2661, DOI 10.1074/jbc.M508485200; Feire AL, 2004, P NATL ACAD SCI USA, V101, P15470, DOI 10.1073/pnas.0406821101; Gredmark S, 2007, J VIROL, V81, P5112, DOI 10.1128/JVI.02197-06; HUANG ES, 1973, J VIROL, V12, P1473, DOI 10.1128/JVI.12.6.1473-1481.1973; Isaacson MK, 2007, J VIROL, V81, P6241, DOI 10.1128/JVI.00169-07; Isomura H, 2003, J VIROL, V77, P3602, DOI 10.1128/JVI.77.6.3602-3614.2003; Johnson RA, 2001, J VIROL, V75, P6022, DOI 10.1128/JVI.75.13.6022-6032.2001; LI L, 1995, J VIROL, V69, P6047, DOI 10.1128/JVI.69.10.6047-6053.1995; Loizos N, 2005, MOL CANCER THER, V4, P369; MAR EC, 1983, ANTIMICROB AGENTS CH, V24, P518, DOI 10.1128/AAC.24.4.518; Murphy E, 2003, P NATL ACAD SCI USA, V100, P14976, DOI 10.1073/pnas.2136652100; Murphy EA, 2000, J VIROL, V74, P7108, DOI 10.1128/JVI.74.15.7108-7118.2000; Netterwald JR, 2004, J VIROL, V78, P6688, DOI 10.1128/JVI.78.12.6688-6691.2004; Ozato K, 2007, J BIOL CHEM, V282, P20065, DOI 10.1074/jbc.R700003200; Sandler C, 2006, BIOCHEM BIOPH RES CO, V347, P31, DOI 10.1016/j.bbrc.2006.06.052; Shimamura M, 2006, J VIROL, V80, P4591, DOI 10.1128/JVI.80.9.4591-4600.2006; Simmen KA, 2001, P NATL ACAD SCI USA, V98, P7140, DOI 10.1073/pnas.121177598; THOMAS B, 1993, VIRUSES CELLULAR IMM; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang X, 2005, NAT MED, V11, P515, DOI 10.1038/nm1236; Wang X, 2003, NATURE, V424, P456, DOI 10.1038/nature01818; Wang ZD, 2004, J VIROL, V78, P3965, DOI 10.1128/JVI.78.8.3965-3976.2004; Yurochko AD, 1997, J VIROL, V71, P4638, DOI 10.1128/JVI.71.6.4638-4648.1997; Zhu H, 1997, P NATL ACAD SCI USA, V94, P13985, DOI 10.1073/pnas.94.25.13985	36	223	237	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	2008	455	7211					391	U43		10.1038/nature07209	http://dx.doi.org/10.1038/nature07209			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349EX	18701889				2022-12-28	WOS:000259265200045
J	Smith, JL; Sherman, DH				Smith, Janet L.; Sherman, David H.			Biochemistry - An enzyme assembly line	SCIENCE			English	Editorial Material							FATTY-ACID SYNTHASE; CRYSTAL-STRUCTURE; POLYKETIDE; ARCHITECTURE; RESOLUTION		[Smith, Janet L.; Sherman, David H.] Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; [Smith, Janet L.] Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; [Sherman, David H.] Univ Michigan, Dept Med Chem, Ann Arbor, MI 48109 USA; [Sherman, David H.] Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; [Sherman, David H.] Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Smith, JL (corresponding author), Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA.	janetsmith@umich.edu; davidhs@umich.edu			NIDDK NIH HHS [R01 DK042303, R01 DK042303-20] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042303] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chang ZX, 2004, J NAT PROD, V67, P1356, DOI 10.1021/np0499261; Fischbach MA, 2008, P NATL ACAD SCI USA, V105, P4601, DOI 10.1073/pnas.0709132105; Gokhale RS, 2007, NAT PROD REP, V24, P267, DOI 10.1039/b616817p; Gu LC, 2007, SCIENCE, V318, P970, DOI 10.1126/science.1148790; Jenni S, 2006, SCIENCE, V311, P1263, DOI 10.1126/science.1123251; Keatinge-Clay AT, 2006, STRUCTURE, V14, P737, DOI 10.1016/j.str.2006.01.009; Maier T, 2006, SCIENCE, V311, P1258, DOI 10.1126/science.1123248; Maier T, 2008, SCIENCE, V321, P1315, DOI 10.1126/science.1161269; Nougayrede JP, 2006, SCIENCE, V313, P848, DOI 10.1126/science.1127059; Tang YY, 2006, P NATL ACAD SCI USA, V103, P11124, DOI 10.1073/pnas.0601924103; Tanovic A, 2008, SCIENCE, V321, P659, DOI 10.1126/science.1159850; Thattai M, 2007, PLOS COMPUT BIOL, V3, P1827, DOI 10.1371/journal.pcbi.0030186	12	36	37	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	2008	321	5894					1304	1305		10.1126/science.1163785	http://dx.doi.org/10.1126/science.1163785			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	344GG	18772425	Green Accepted			2022-12-28	WOS:000258914300035
J	Stucki, A; Ludwig, R				Stucki, Armin; Ludwig, Roger			Bedbug bites	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Stucki, Armin; Ludwig, Roger] Univ Hosp Bern, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern	Stucki, A (corresponding author), Univ Hosp Bern, CH-3010 Bern, Switzerland.	armin.stucki@insel.ch							0	13	14	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2008	359	10					1047	1047		10.1056/NEJMicm060268	http://dx.doi.org/10.1056/NEJMicm060268			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	343KN	18768948				2022-12-28	WOS:000258852500009
J	Gralnek, IM; Barkun, AN; Bardou, M				Gralnek, Ian M.; Barkun, Alan N.; Bardou, Marc			Current concepts: Management of acute bleeding from a peptic ulcer	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PROTON-PUMP INHIBITION; UPPER GASTROINTESTINAL HEMORRHAGE; LOW-RISK PATIENTS; ENDOSCOPIC THERAPY; COST-EFFECTIVENESS; OUTPATIENT MANAGEMENT; ARTERIAL EMBOLIZATION; MEDICAL PROGRESS; ACID SUPPRESSION; EARLY DISCHARGE		[Gralnek, Ian M.] Technion Israel Inst Technol, Dept Gastroenterol, IL-31096 Haifa, Israel; [Gralnek, Ian M.] Technion Israel Inst Technol, Gastrointestinal Outcomes Unit, IL-31096 Haifa, Israel; [Gralnek, Ian M.] Technion Israel Inst Technol, Rappaport Fac Med, IL-31096 Haifa, Israel; [Barkun, Alan N.] McGill Univ, Div Gastroenterol, Montreal, PQ, Canada; [Barkun, Alan N.] McGill Univ, Div Clin Epidemiol, Montreal, PQ, Canada; [Bardou, Marc] Ctr Hosp Univ Bocage, INSERM Ctr Invest Clin Plurithemat, Dijon, France; [Bardou, Marc] Univ Bourgogne, Inst Fed Rech Sante Sci & Tech Informat & Commun, Dijon, France	Technion Israel Institute of Technology; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; McGill University; McGill University; CHU Dijon Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Gralnek, IM (corresponding author), Technion Israel Inst Technol, Dept Gastroenterol, Rambam Hlth Care Campus, IL-31096 Haifa, Israel.	i_gralnek@rambam.health.gov.il			Advanced Research Career Development Award; Department of Veterans Affairs [01-191-1]; Fonds de la Recherche en Sante, du Quebec; AstraZeneca; Abbott	Advanced Research Career Development Award; Department of Veterans Affairs(US Department of Veterans Affairs); Fonds de la Recherche en Sante, du Quebec(Fonds de la Recherche en Sante du Quebec); AstraZeneca(AstraZeneca); Abbott(Abbott Laboratories)	Supported by an Advanced Research Career Development Award and a grant (01-191-1) from the Department of Veterans Affairs (to Dr. Gralnek) and a research scholarship from Fonds de la Recherche en Sante, du Quebec (to Dr. Barkun).; Dr. Barkun reports receiving consulting fees from AstraZeneca and Abbott; and Dr. Bardou, lecture fees from AstraZeneca. No other potential conflict of interest relevant to this article was reported.	Adler DG, 2005, GASTROINTEST ENDOSC, V61, P356; Adler DG, 2004, GASTROINTEST ENDOSC, V60, P497; Al-Sabah S, 2008, CLIN GASTROENTEROL H, V6, P418, DOI 10.1016/j.cgh.2007.12.037; Aljebreen AM, 2004, GASTROINTEST ENDOSC, V59, P172, DOI 10.1016/S0016-5107(03)02543-4; Arabi Y, 2006, CRIT CARE, V10, DOI 10.1186/cc4958; Baradarian R, 2004, AM J GASTROENTEROL, V99, P619, DOI 10.1111/j.1572-0241.2004.04073.x; Bardou M, 2005, ALIMENT PHARM THER, V21, P677, DOI 10.1111/j.1365-2036.2005.02391.x; Barkun A, 2003, ANN INTERN MED, V139, P843, DOI 10.7326/0003-4819-139-10-200311180-00012; Barkun A, 2004, AM J GASTROENTEROL, V99, P1238, DOI 10.1111/j.1572-0241.2004.30272.x; Barkun AN, 1999, ALIMENT PHARM THER, V13, P1565; Barkun AN, 2004, ALIMENT PHARM THER, V19, P591, DOI 10.1046/j.1365-2036.2004.01808.x; Bjorkman DJ, 2004, GASTROINTEST ENDOSC, V60, P1, DOI 10.1016/S0016-5107(04)01287-8; Blatchford O, 2000, LANCET, V356, P1318, DOI 10.1016/S0140-6736(00)02816-6; Calvet X, 2004, GASTROENTEROLOGY, V126, P441, DOI 10.1053/j.gastro.2003.11.006; Carbonell N, 2006, AM J GASTROENTEROL, V101, P1211, DOI 10.1111/j.1572-0241.2006.00582.x; CHIU PWY, 2003, ANN COLL SURG HONG K, V7, P106; Chung IK, 2001, ENDOSCOPY, V33, P969, DOI 10.1055/s-2001-17951; Cipolletta L, 2002, GASTROINTEST ENDOSC, V55, P1, DOI 10.1067/mge.2002.119219; COOK DJ, 1992, GASTROENTEROLOGY, V102, P139, DOI 10.1016/0016-5085(92)91793-4; Corley DA, 1998, AM J GASTROENTEROL, V93, P336, DOI 10.1111/j.1572-0241.1998.00336.x; Das A, 2004, GASTROINTEST ENDOSC, V60, P85, DOI 10.1016/S0016-5107(04)01291-X; de la Fuente SG, 2006, J AM COLL SURGEONS, V202, P78, DOI 10.1016/j.jamcollsurg.2005.09.001; Dorward S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005415.pub2; Dulai GS, 2002, GASTROINTEST ENDOSC, V55, P321, DOI 10.1067/mge.2002.121880; FORREST JAH, 1974, LANCET, V2, P394; FREEMAN ML, 1993, GASTROINTEST ENDOSC, V39, P359, DOI 10.1016/S0016-5107(93)70106-6; HALL WH, 1989, JAMA-J AM MED ASSOC, V262, P1369; Hay JA, 1997, JAMA-J AM MED ASSOC, V278, P2151, DOI 10.1001/jama.278.24.2151; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hebert PC, 1999, NEW ENGL J MED, V340, P1056; Imhof M, 2003, LANGENBECK ARCH SURG, V387, P327, DOI 10.1007/s00423-002-0329-3; Jensen DM, 2006, AM J GASTROENTEROL, V101, P1991, DOI 10.1111/j.1572-0241.2006.00773.x; Jensen DM, 2002, GASTROENTEROLOGY, V123, P407, DOI 10.1053/gast.2002.34782; JENSEN DM, 2006, AM J GASTROENTEROL, V101, P2170; Kahi CJ, 2006, GASTROENTEROLOGY, V131, P980; Kahi CJ, 2005, GASTROENTEROLOGY, V129, P855, DOI 10.1053/j.gastro.2005.06.070; Kim SK, 2005, TECH GASTROINTEST EN, V7, P148, DOI 10.1016/j.tgie.2005.04.012; Lai KC, 1997, GASTROINTEST ENDOSC, V45, P26, DOI 10.1016/S0016-5107(97)70299-2; Laine L, 2005, GASTROENTEROLOGY, V129, P2127, DOI 10.1053/j.gastro.2005.10.039; LAINE L, 1994, NEW ENGL J MED, V331, P717, DOI 10.1056/NEJM199409153311107; Lanas A, 2006, ANN MED, V38, P415, DOI 10.1080/07853890600925843; Lassen A, 2006, AM J GASTROENTEROL, V101, P945, DOI 10.1111/j.1572-0241.2006.00518.x; Lau JY, 2007, NEW ENGL J MED, V356, P1631, DOI 10.1056/NEJMoa065703; Lau JYW, 2000, NEW ENGL J MED, V343, P310, DOI 10.1056/NEJM200008033430501; Lau JYW, 1999, NEW ENGL J MED, V340, P751, DOI 10.1056/NEJM199903113401002; Lau JYW, 1998, ENDOSCOPY, V30, P513, DOI 10.1055/s-2007-1001336; Lau JYW, 1997, GASTROINTEST ENDOSC, V46, P33, DOI 10.1016/S0016-5107(97)70206-2; Lee JG, 1999, GASTROINTEST ENDOSC, V50, P755, DOI 10.1016/S0016-5107(99)70154-9; Lee SD, 2004, J CLIN GASTROENTEROL, V38, P861, DOI 10.1097/00004836-200411000-00005; Leontiadis GI, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002094.pub3; Leontiadis GI, 2005, ALIMENT PHARM THER, V21, P1055, DOI 10.1111/j.1365-2036.2005.02441.x; Levine JE, 2002, ALIMENT PHARM THERAP, V16, P1137, DOI 10.1046/j.1365-2036.2002.01274.x; Lewis JD, 2002, AM J GASTROENTEROL, V97, P2540; Lim CH, 2006, ENDOSCOPY, V38, P581, DOI 10.1055/s-2006-925313; Ljungdahl M, 2002, EUR J SURG, V168, P384, DOI 10.1080/110241502320789050; Longstreth GF, 1998, GASTROINTEST ENDOSC, V47, P219, DOI 10.1016/S0016-5107(98)70316-5; Marmo R, 2003, GASTROINTEST ENDOSC, V57, P62, DOI 10.1067/mge.2003.48; Marmo R, 2007, AM J GASTROENTEROL, V102, P279, DOI 10.1111/j.1572-0241.2006.01023.x; Metz DC, 2006, ALIMENT PHARM THERAP, V23, P985, DOI 10.1111/j.1365-2036.2006.02850.x; MILLAT B, 1993, WORLD J SURG, V17, P568, DOI 10.1007/BF01659109; Moreno P, 1998, AM J MED, V105, P176, DOI 10.1016/S0002-9343(98)00243-5; Morgan D, 2002, CRIT CARE MED, V30, pS369, DOI 10.1097/00003246-200206001-00007; Ohmann C, 2005, SCAND J GASTROENTERO, V40, P914, DOI 10.1080/00365520510015809; Okazaki K, 2002, GUT, V51, P1, DOI 10.1136/gut.51.1.1; Paimela H, 2004, DIGEST SURG, V21, P185, DOI 10.1159/000079654; Park WG, 2007, GASTROINTEST ENDOSC, V66, P343, DOI 10.1016/j.gie.2006.11.019; POXON VA, 1991, BRIT J SURG, V78, P1344, DOI 10.1002/bjs.1800781124; Ripoll C, 2004, J VASC INTERV RADIOL, V15, P447; Rockall TA, 1996, LANCET, V347, P1138, DOI 10.1016/S0140-6736(96)90607-8; Rockall TA, 1996, GUT, V38, P316, DOI 10.1136/gut.38.3.316; Romagnuolo J, 2007, ARCH INTERN MED, V167, P265, DOI 10.1001/archinte.167.3.265; Spiegel BMR, 2003, AM J GASTROENTEROL, V98, P86; Spiegel BMR, 2001, ARCH INTERN MED, V161, P1393, DOI 10.1001/archinte.161.11.1393; Spiegel BMR, 2006, CLIN GASTROENTEROL H, V4, P988, DOI 10.1016/j.cgh.2006.05.019; Suerbaum S, 2002, NEW ENGL J MED, V347, P1175, DOI 10.1056/NEJMra020542; Sung JJY, 2003, ANN INTERN MED, V139, P237, DOI 10.7326/0003-4819-139-4-200308190-00005; Sung JJY, 2007, GUT, V56, P1364, DOI 10.1136/gut.2007.123976; Targownik LE, 2007, CLIN GASTROENTEROL H, V5, P403; Targownik LE, 2006, CLIN GASTROENTEROL H, V4, P1459, DOI 10.1016/j.cgh.2006.08.018; Thomopoulos KC, 2004, SCAND J GASTROENTERO, V39, P600, DOI 10.1080/00365520410004631; Tsoi KKF, 2008, GASTROINTEST ENDOSC, V67, P1056, DOI 10.1016/j.gie.2007.11.056; Viviane A, 2008, VALUE HEALTH, V11, P1, DOI 10.1111/j.1524-4733.2007.00208.x; Wong RCK, 2004, GASTROINTEST ENDOSC, V60, P804, DOI 10.1016/S0016-5107(04)02046-2	83	235	277	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 28	2008	359	9					928	937		10.1056/NEJMra0706113	http://dx.doi.org/10.1056/NEJMra0706113			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	341IU	18753649				2022-12-28	WOS:000258708300007
J	Steinman, TI; Samir, AE; Cornell, LD; Harris, NL; Schopick, EL; Tolkoff-Rubin, N; Banks, P				Steinman, Theodore I.; Samir, Anthony E.; Cornell, Lynn D.; Harris, Nancy Lee; Schopick, Emily L.; Tolkoff-Rubin, Nina; Banks, Peter			A man with abdominal pain, nausea, and an elevated level of serum creatinine - Acute phosphate nephropathy due to ingestion of oral sodium phosphate solution	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE-RENAL-FAILURE; ACUTE INTERSTITIAL NEPHRITIS; PROTON PUMP INHIBITORS; ACUTE-PANCREATITIS; BOWEL PREPARATION; DISEASE		[Steinman, Theodore I.] Beth Israel Deaconess Med Ctr, Div Renal, Boston, MA 02215 USA; [Samir, Anthony E.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Cornell, Lynn D.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Steinman, Theodore I.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Samir, Anthony E.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Cornell, Lynn D.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Steinman, TI (corresponding author), Beth Israel Deaconess Med Ctr, Div Renal, Boston, MA 02215 USA.			Samir, Anthony/0000-0002-7801-8724	American Renal Associates; Advance Medical; Advanced Magnetics; Otsuka Pharmaceutical; CardioKine Biopharma	American Renal Associates; Advance Medical; Advanced Magnetics; Otsuka Pharmaceutical(Otsuka Pharmaceutical); CardioKine Biopharma	Dr. Steinman reports receiving consulting fees from American Renal Associates, Advance Medical, and Advanced Magnetics; holding stock options and stock in Advanced Magnetics; and receiving research support from Otsuka Pharmaceutical and CardioKine Biopharma. No other potential conflict of interest relevant to this article was reported.	Aasebo W, 2007, NEPHROL DIAL TRANSPL, V22, P920, DOI 10.1093/ndt/gfl694; Ainley EJ, 2005, DIGEST DIS SCI, V50, P1319, DOI 10.1007/s10620-005-2780-9; Baker S, 2004, Crit Care Resusc, V6, P17; Brenner BM, 2004, BRENNER RECTORS KIDN; Carvounis CP, 2002, KIDNEY INT, V62, P2223, DOI 10.1046/j.1523-1755.2002.00683.x; Choudhury D, 2006, NAT CLIN PRACT NEPHR, V2, P80, DOI 10.1038/ncpneph0076; Geevasinga N, 2006, CLIN GASTROENTEROL H, V4, P597, DOI 10.1016/j.cgh.2005.11.004; Gonlusen G, 2006, ARCH PATHOL LAB MED, V130, P101; HEHER EC, 2007, NEPHROLOGY ROUNDS, V5; Kes P, 1996, RENAL FAILURE, V18, P621, DOI 10.3109/08860229609047686; Levey AS, 2003, ANN INTERN MED, V139, P605, DOI 10.7326/0003-4819-139-7-200310070-00029; Levey AS, 2003, ANN INTERN MED, V139, P137, DOI 10.7326/0003-4819-139-2-200307150-00013; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Ljutic D, 1996, RENAL FAILURE, V18, P629, DOI 10.3109/08860229609047687; Markowitz GS, 2005, J AM SOC NEPHROL, V16, P3389, DOI 10.1681/ASN.2005050496; Markowitz GS, 2004, HUM PATHOL, V35, P675, DOI 10.1016/j.humpath.2003.12.005; Mishra R, 2005, ENDOSCOPY, V37, P1259, DOI 10.1055/s-2005-921155; Myers RP, 2001, AM J GASTROENTEROL, V96, P3428; Rose M, 2005, NEPHROL DIAL TRANSPL, V20, P1518, DOI 10.1093/ndt/gfh908; Schrier RW, 2004, NEW ENGL J MED, V351, P159, DOI 10.1056/NEJMra032401; Simpson IJ, 2006, NEPHROLOGY, V11, P381, DOI 10.1111/j.1440-1797.2006.00651.x; Torpey N, 2004, NEPHROL DIAL TRANSPL, V19, P1441, DOI 10.1093/ndt/gfh137; TRAN DD, 1993, NEPHROL DIAL TRANSPL, V8, P1079	23	10	10	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 28	2008	359	9					951	960		10.1056/NEJMcpc0804600	http://dx.doi.org/10.1056/NEJMcpc0804600			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	341IU	18753652				2022-12-28	WOS:000258708300011
J	Gura, T				Gura, Trisha			Toxicity testing moves from the legislature to the Petri Dish - and back	CELL			English	Editorial Material								With the growing cost of using animals to test the safety of new chemicals and an increasing backlog of chemicals awaiting testing, the quest for cell-based in vitro alternatives for toxicity testing is gaining momentum.											0	16	17	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 22	2008	134	4					557	559		10.1016/j.cell.2008.08.011	http://dx.doi.org/10.1016/j.cell.2008.08.011			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SR	18724925	Bronze			2022-12-28	WOS:000258665800005
J	Ebbing, M; Bleie, O; Ueland, PM; Nordrehaug, JE; Nilsen, DW; Vollset, SE; Refsum, H; Pedersen, EKR; Nygard, O				Ebbing, Marta; Bleie, Oyvind; Ueland, Per Magne; Nordrehaug, Jan Erik; Nilsen, Dennis W.; Vollset, Stein Emil; Refsum, Helga; Pedersen, Eva Kristine Ringdal; Nygard, Ottar			Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography - A Randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOLIC-ACID SUPPLEMENTATION; EURO HEART SURVEY; VASCULAR-DISEASE; PLASMA HOMOCYSTEINE; ARTERY-DISEASE; MICROBIOLOGICAL ASSAY; INFLAMMATORY MARKERS; STROKE; RISK; PREVENTION	Context Observational studies have reported associations between circulating total homocysteine concentration and risk of cardiovascular disease. Oral administration of folic acid and vitamin B-12 can lower plasma total homocysteine levels. Objective To assess the effect of treatment with folic acid and vitamin B-12 and the effect of treatment with vitamin B-6 as secondary prevention in patients with coronary artery disease or aortic valve stenosis. Design, Setting, and Participants Randomized, double-blind controlled trial conducted in the 2 university hospitals in western Norway in 1999-2006. A total of 3096 adult participants undergoing coronary angiography (20.5% female; mean age, 61.7 years) were randomized. At baseline, 59.3 % had double- or triple-vessel disease, 83.7% had stable angina pectoris, and 14.9% had acute coronary syndromes. Interventions Using a 2 x 2 factorial design, participants were randomly assigned to 1 of 4 groups receiving daily oral treatment with folic acid, 0.8 mg, plus vitamin B-12, 0.4 mg, plus vitamin B-6, 40 mg (n = 772); folic acid plus vitamin B-12 (n = 772); vitamin B-6 alone (n = 772); or placebo (n = 780). Main Outcome Measures The primary end point was a composite of all-cause death, nonfatal acute myocardial infarction, acute hospitalization for unstable angina pectoris, and nonfatal thromboembolic stroke. Results Mean plasma total homocysteine concentration was reduced by 30% after 1 year of treatment in the groups receiving folic acid and vitamin B-12. The trial was terminated early because of concern among participants due to preliminary results from a contemporaneous Norwegian trial suggesting adverse effects from the intervention. During a median 38 months of follow-up, the primary end point was experienced by a total of 422 participants (13.7%): 219 participants (14.2%) receiving folic acid/vitamin B-12 vs 203 (13.1 %) not receiving such treatment (hazard ratio, 1.09; 95% confidence interval, 0.90-1.32; P=.36) and 200 participants (13.0%) receiving vitamin B-6 vs 222 (14.3%) not receiving vitamin B-6 (hazard ratio, 0.90; 95% confidence interval, 0.74-1.09; P=.28). Conclusions This trial did not find an effect of treatment with folic acid/vitamin B-12 or vitamin B-6 on total mortality or cardiovascular events. Our findings do not support the use of B vitamins as secondary prevention in patients with coronary artery disease. Trial Registration clinicaltrials.gov Identifier: NCT00354081.	[Ebbing, Marta; Bleie, Oyvind; Nordrehaug, Jan Erik; Nygard, Ottar] Haukeland Hosp, Dept Heart Dis, N-5021 Bergen, Norway; [Ueland, Per Magne] Univ Bergen, Inst Med, Pharmacol Sect, Bergen, Norway; [Nordrehaug, Jan Erik; Nilsen, Dennis W.; Pedersen, Eva Kristine Ringdal; Nygard, Ottar] Univ Bergen, Inst Med, Cardiol Sect, Bergen, Norway; [Vollset, Stein Emil] Univ Bergen, Dept Publ Hlth & Primary Hlth Care, Bergen, Norway; [Nilsen, Dennis W.] Stavanger Univ Hosp, Dept Cardiol, Stavanger, Norway; [Refsum, Helga] Univ Oslo, Inst Basic Med Sci, Dept Nutr, Oslo, Norway; [Refsum, Helga] Univ Oxford, Dept Physiol Anat & Genet, Oxford, England	University of Bergen; Haukeland University Hospital; University of Bergen; University of Bergen; University of Bergen; Stavanger University Hospital; University of Oslo; University of Oxford	Ebbing, M (corresponding author), Haukeland Hosp, Dept Heart Dis, Jonas Llesvel 65, N-5021 Bergen, Norway.	marta.ebbing@helse-bergen.no	Refsum, Helga/A-4073-2010; Nilsen, Dennis/AAM-4344-2020; Ueland, Per M/C-7340-2013	Ueland, Per Magne/0000-0002-1903-0571; Pedersen, Eva Ringdal/0000-0002-2545-1866	Advanced Research Program and Research Council of Norway; Norwegian Foundation for Health and Rehabilitation; Norwegian Heart and Lung Patient Organisation; Norwegian Ministry of Health and Care Services; Western Norway Regional Health Authority; Department of Heart Disease at Haukeland University Hospital; Locus for Homocysteine and Related Vitamins at the University of Bergen; Locus for Cardiac Research at the University of Bergen; Foundation to Promote Research Into Functional Vitamin B<INF>12</INF> Deficiency, Bergen, Norway; Alpharma Inc, Copenhagen, Denmark	Advanced Research Program and Research Council of Norway(Research Council of Norway); Norwegian Foundation for Health and Rehabilitation; Norwegian Heart and Lung Patient Organisation; Norwegian Ministry of Health and Care Services; Western Norway Regional Health Authority; Department of Heart Disease at Haukeland University Hospital; Locus for Homocysteine and Related Vitamins at the University of Bergen; Locus for Cardiac Research at the University of Bergen; Foundation to Promote Research Into Functional Vitamin B<INF>12</INF> Deficiency, Bergen, Norway; Alpharma Inc, Copenhagen, Denmark	This trial was funded by the Advanced Research Program and Research Council of Norway, the Norwegian Foundation for Health and Rehabilitation, the Norwegian Heart and Lung Patient Organisation, the Norwegian Ministry of Health and Care Services, the Western Norway Regional Health Authority, the Department of Heart Disease at Haukeland University Hospital, Locus for Homocysteine and Related Vitamins at the University of Bergen, Locus for Cardiac Research at the University of Bergen, the Foundation to Promote Research Into Functional Vitamin B<INF>12</INF> Deficiency, Bergen, Norway, and Alpharma Inc, Copenhagen, Denmark.	Albert CM, 2008, JAMA-J AM MED ASSOC, V299, P2027, DOI 10.1001/jama.299.17.2027; Alpert JS, 2000, EUR HEART J, V21, P1502, DOI 10.1053/euhj.2000.2305; Bazzano LA, 2006, JAMA-J AM MED ASSOC, V296, P2720, DOI 10.1001/jama.296.22.2720; Bleie O, 2007, J INTERN MED, V262, P244, DOI 10.1111/j.1365-2796.2007.01810.x; Bleie O, 2004, AM J CLIN NUTR, V80, P641; Bonaa KH, 2006, NEW ENGL J MED, V354, P1578, DOI 10.1056/NEJMoa055227; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Breeman A, 2006, J THORAC CARDIOV SUR, V132, P1001, DOI 10.1016/j.jtcvs.2006.05.051; Cannon CP, 2001, J AM COLL CARDIOL, V38, P2114, DOI 10.1016/S0735-1097(01)01702-8; Casas JP, 2005, LANCET, V365, P224, DOI 10.1016/S0140-6736(05)70152-5; Clarke R, 2007, CLIN CHEM LAB MED, V45, P1575, DOI 10.1515/CCLM.2007.346; Cole BF, 2007, JAMA-J AM MED ASSOC, V297, P2351, DOI 10.1001/jama.297.21.2351; Dierkes J, 2007, AM J CLIN NUTR, V86, P214; Durga J, 2005, ARCH INTERN MED, V165, P1388, DOI 10.1001/archinte.165.12.1388; Dusitanond P, 2005, STROKE, V36, P144, DOI 10.1161/01.STR.0000150494.91762.70; Eichholzer M, 2006, LANCET, V367, P1352, DOI 10.1016/S0140-6736(06)68582-6; Friso S, 2004, AM J CLIN NUTR, V79, P992; Friso S, 2001, CIRCULATION, V103, P2788; Hansma AHG, 2005, ANN ONCOL, V16, P1695, DOI 10.1093/annonc/mdi318; Jamison RL, 2007, JAMA-J AM MED ASSOC, V298, P1163, DOI 10.1001/jama.298.10.1163; KELLEHER BP, 1991, J CLIN PATHOL, V44, P592, DOI 10.1136/jcp.44.7.592; Lange H, 2004, NEW ENGL J MED, V350, P2673, DOI 10.1056/NEJMoa032845; Lenzen MJ, 2005, EUR HEART J, V26, P1169, DOI 10.1093/eurheartj/ehi238; Lewis SJ, 2005, BMJ-BRIT MED J, V331, P1053, DOI 10.1136/bmj.38611.658947.55; Logan RFA, 2008, GASTROENTEROLOGY, V134, P29, DOI 10.1053/j.gastro.2007.10.014; Lonn E, 2006, NEW ENGL J MED, V354, P1567, DOI 10.1056/NEJMoa060900; Loscalzo J, 2006, NEW ENGL J MED, V354, P1629, DOI 10.1056/NEJMe068060; Mason JB, 2007, CANCER EPIDEM BIOMAR, V16, P1325, DOI 10.1158/1055-9965.EPI-07-0329; Midttun O, 2005, CLIN CHEM, V51, P1206, DOI 10.1373/clinchem.2005.051169; *NAT KIDN DIS ED P, GFR CALC AD PAT 18 O; Nygard O., 1998, Netherlands Journal of Medicine, V52, pS29; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; OBROIN S, 1992, J CLIN PATHOL, V45, P344, DOI 10.1136/jcp.45.4.344; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Rimm EB, 1998, JAMA-J AM MED ASSOC, V279, P359, DOI 10.1001/jama.279.5.359; Robinson K, 1998, CIRCULATION, V97, P437; Schnyder G, 2002, JAMA-J AM MED ASSOC, V288, P973, DOI 10.1001/jama.288.8.973; Spence JD, 2007, LANCET NEUROL, V6, P830, DOI 10.1016/S1474-4422(07)70219-3; Ulrich CM, 2007, AM J CLIN NUTR, V86, P271, DOI 10.1093/ajcn/86.2.271; Wang XB, 2007, LANCET, V369, P1876, DOI 10.1016/S0140-6736(07)60854-X; Windelberg A, 2005, CLIN CHEM, V51, P2103, DOI 10.1373/clinchem.2005.053835; Yang QH, 2006, CIRCULATION, V113, P1335, DOI 10.1161/CIRCULATIONAHA.105.570846; Zee RYL, 2007, CLIN CHEM, V53, P845, DOI 10.1373/clinchem.2006.083881	43	322	336	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	2008	300	7					795	804		10.1001/jama.300.7.795	http://dx.doi.org/10.1001/jama.300.7.795			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	338VM	18714059	Bronze			2022-12-28	WOS:000258537500019
J	Richards, T				Richards, Tessa			Orphan diseases: which ones do we adopt?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												trichards@bmj.com							0	4	4	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 16	2008	337	7666							a1225	10.1136/bmj.a1225	http://dx.doi.org/10.1136/bmj.a1225			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	340TZ	18694885				2022-12-28	WOS:000258669200022
J	Brouns, SJJ; Jore, MM; Lundgren, M; Westra, ER; Slijkhuis, RJH; Snijders, APL; Dickman, MJ; Makarova, KS; Koonin, EV; van der Oost, J				Brouns, Stan J. J.; Jore, Matthijs M.; Lundgren, Magnus; Westra, Edze R.; Slijkhuis, Rik J. H.; Snijders, Ambrosius P. L.; Dickman, Mark J.; Makarova, Kira S.; Koonin, Eugene V.; van der Oost, John			Small CRISPR RNAs guide antiviral defense in prokaryotes	SCIENCE			English	Article							PROVIDES ACQUIRED-RESISTANCE; STREPTOCOCCUS-THERMOPHILUS; REPEATS; IDENTIFICATION; ELEMENTS; DNA; EVOLUTIONARY; SEQUENCE; VIRUSES; SYSTEM	Prokaryotes acquire virus resistance by integrating short fragments of viral nucleic acid into clusters of regularly interspaced short palindromic repeats ( CRISPRs). Here we show how virus- derived sequences contained in CRISPRs are used by CRISPR- associated ( Cas) proteins from the host to mediate an antiviral response that counteracts infection. After transcription of the CRISPR, a complex of Cas proteins termed Cascade cleaves a CRISPR RNA precursor in each repeat and retains the cleavage products containing the virus- derived sequence. Assisted by the helicase Cas3, these mature CRISPR RNAs then serve as small guide RNAs that enable Cascade to interfere with virus proliferation. Our results demonstrate that the formation of mature guide RNAs by the CRISPR RNA endonuclease subunit of Cascade is a mechanistic requirement for antiviral defense.	[Brouns, Stan J. J.; Jore, Matthijs M.; Lundgren, Magnus; Westra, Edze R.; Slijkhuis, Rik J. H.; van der Oost, John] Univ Wageningen & Res Ctr, Dept Agrotechnol & Food Sci, Microbiol Lab, NL-6703 HB Wageningen, Netherlands; [Snijders, Ambrosius P. L.; Dickman, Mark J.] Univ Sheffield, Dept Chem & Proc Engn, Sheffield S1 3JD, S Yorkshire, England; [Makarova, Kira S.; Koonin, Eugene V.] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA	Wageningen University & Research; University of Sheffield; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	van der Oost, J (corresponding author), Univ Wageningen & Res Ctr, Dept Agrotechnol & Food Sci, Microbiol Lab, Dreijenpl 10, NL-6703 HB Wageningen, Netherlands.	john.vanderoost@wur.nl	van+der+Oost, John/Y-2548-2019; Jore, Matthijs/F-7852-2018	Jore, Matthijs/0000-0002-0686-370X; Snijders, Bram/0000-0002-5416-8592; Brouns, Stan/0000-0002-9573-1724; Dickman, Mark/0000-0002-9236-0788	EPSRC [EP/D033713/1, EP/E036252/1] Funding Source: UKRI; Intramural NIH HHS [Z01 LM000061-14] Funding Source: Medline; Engineering and Physical Sciences Research Council [EP/D033713/1, EP/E036252/1] Funding Source: researchfish; NATIONAL LIBRARY OF MEDICINE [ZIALM000061] Funding Source: NIH RePORTER	EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Baba Tomoya, 2008, V416, P171, DOI 10.1007/978-1-59745-321-9_11; Barrangou R, 2007, SCIENCE, V315, P1709, DOI 10.1126/science.1138140; Beloglazova N, 2008, J BIOL CHEM, V283, P20361, DOI 10.1074/jbc.M803225200; Bolotin A, 2005, MICROBIOL-SGM, V151, P2551, DOI 10.1099/mic.0.28048-0; Deveau H, 2008, J BACTERIOL, V190, P1390, DOI 10.1128/JB.01412-07; Ebihara A, 2006, PROTEIN SCI, V15, P1494, DOI 10.1110/ps.062131106; Godde JS, 2006, J MOL EVOL, V62, P718, DOI 10.1007/s00239-005-0223-z; Haft DH, 2005, PLOS COMPUT BIOL, V1, P474, DOI 10.1371/journal.pcbi.0010060; Horvath P, 2008, J BACTERIOL, V190, P1401, DOI 10.1128/JB.01415-07; Jansen R, 2002, MOL MICROBIOL, V43, P1565, DOI 10.1046/j.1365-2958.2002.02839.x; Kim J., COMMUNICATION; Kunin V, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-4-r61; Lillestol Reidun K., 2006, Archaea, V2, P59, DOI 10.1155/2006/542818; Makarova KS, 2006, BIOL DIRECT, V1, DOI 10.1186/1745-6150-1-7; Mojica FJM, 2005, J MOL EVOL, V60, P174, DOI 10.1007/s00239-004-0046-3; Pourcel C, 2005, MICROBIOL-SGM, V151, P653, DOI 10.1099/mic.0.27437-0; Sorek R, 2008, NAT REV MICROBIOL, V6, P181, DOI 10.1038/nrmicro1793; Tang TH, 2005, MOL MICROBIOL, V55, P469, DOI 10.1111/j.1365-2958.2004.04428.x; Tang TH, 2002, P NATL ACAD SCI USA, V99, P7536, DOI 10.1073/pnas.112047299; Tyson GW, 2008, ENVIRON MICROBIOL, V10, P200, DOI 10.1111/j.1462-2920.2007.01444.x	20	1552	1800	34	652	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2008	321	5891					960	964		10.1126/science.1159689	http://dx.doi.org/10.1126/science.1159689			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	337LD	18703739	Green Accepted			2022-12-28	WOS:000258436700038
J	Kastrati, A; Neumann, FJ; Mehilli, J; Byrne, RA; Iijima, R; Buttner, HJ; Khattab, AA; Schulz, S; Blankenship, JC; Pache, J; Minners, J; Seyfarth, M; Graf, I; Skelding, KA; Dirschinger, J; Richardt, G; Berger, PB; Schomig, A				Kastrati, Adnan; Neumann, Franz-Josef; Mehilli, Julinda; Byrne, Robert A.; Iijima, Raisuke; Buettner, Heinz Joachim; Khattab, Ahmed A.; Schulz, Stefanie; Blankenship, James C.; Pache, Juergen; Minners, Jan; Seyfarth, Melchior; Graf, Isolde; Skelding, Kimberly A.; Dirschinger, Josef; Richardt, Gert; Berger, Peter B.; Schoemig, Albert		ISAR REACT 3 Trial Investigators	Bivalirudin versus unfractionated heparin during percutaneous coronary intervention	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLOPIDOGREL PRETREATMENT; CLINICAL-TRIAL; ABCIXIMAB; PCI; THERAPY; HIRULOG; EVENTS	Background: Whether bivalirudin is superior to unfractionated heparin in patients with stable or unstable angina who undergo percutaneous coronary intervention (PCI) after pretreatment with clopidogrel is unknown. Methods: We enrolled 4570 patients with stable or unstable angina (with normal levels of troponin T and creatine kinase MB) who were undergoing PCI after pretreatment with a 600-mg dose of clopidogrel at least 2 hours before the procedure; 2289 patients were randomly assigned in a double-blind manner to receive bivalirudin, and 2281 to receive unfractionated heparin. The primary end point was the composite of death, myocardial infarction, urgent target-vessel revascularization due to myocardial ischemia within 30 days after randomization, or major bleeding during the index hospitalization (with a net clinical benefit defined as a reduction in the incidence of the end point). The secondary end point was the composite of death, myocardial infarction, or urgent target-vessel revascularization. Results: The incidence of the primary end point was 8.3% (190 patients) in the bivalirudin group as compared with 8.7% (199 patients) in the unfractionated-heparin group (relative risk, 0.94; 95% confidence interval [CI], 0.77 to 1.15; P=0.57). The secondary end point occurred in 134 patients (5.9%) in the bivalirudin group and 115 patients (5.0%) in the unfractionated-heparin group (relative risk, 1.16; 95% CI, 0.91 to 1.49; P=0.23). The incidence of major bleeding was 3.1% (70 patients) in the bivalirudin group and 4.6% (104 patients) in the unfractionated-heparin group (relative risk, 0.66; 95% CI, 0.49 to 0.90; P=0.008). Conclusions: In patients with stable and unstable angina who underwent PCI after pretreatment with clopidogrel, bivalirudin did not provide a net clinical benefit (i.e., it did not reduce the incidence of the composite end point of death, myocardial infarction, urgent target-vessel revascularization, or major bleeding) as compared with unfractionated heparin, but it did significantly reduce the incidence of major bleeding. (ClinicalTrials.gov number, NCT00262054.).	[Kastrati, Adnan; Mehilli, Julinda; Byrne, Robert A.; Iijima, Raisuke; Schulz, Stefanie; Pache, Juergen; Seyfarth, Melchior; Graf, Isolde; Schoemig, Albert] Tech Univ Munich, Deutsch Herzzentrum, D-80636 Munich, Germany; [Neumann, Franz-Josef; Buettner, Heinz Joachim; Minners, Jan] Herz Zentrum, Bad Krozingen, Germany; [Khattab, Ahmed A.; Richardt, Gert] Segeberger Kliniken, Herzzentrum, Bad Segeberg, Germany; [Dirschinger, Josef; Schoemig, Albert] Tech Univ Munich, Med Klin Rechts Isar 1, Munich, Germany; [Blankenship, James C.; Skelding, Kimberly A.; Berger, Peter B.] Geisinger Med Ctr, Danville, PA 17822 USA	German Heart Center Berlin; German Heart Centre Munich; Technical University of Munich; Segeberger Kliniken Group; Technical University of Munich; Geisinger Medical Center	Kastrati, A (corresponding author), Tech Univ Munich, Deutsch Herzzentrum, Lazarettstr 36, D-80636 Munich, Germany.	kastrati@dhm.mhn.de	Blankenship, James/AAX-4084-2020; , Kastrati/Y-2389-2019; Mehilli, Julinda/F-2629-2016; Byrne, Robert/C-3902-2016; Schupke, Stefanie/G-8382-2016	Blankenship, James/0000-0003-4966-533X; Byrne, Robert/0000-0001-5224-6393; Schupke, Stefanie/0000-0002-0294-2283; Kufner, Sebastian/0000-0002-8091-4552				American College of Cardiology, 2006, J Am Coll Cardiol, V48, pe1, DOI 10.1016/j.jacc.2006.05.021; BITTL JA, 1995, NEW ENGL J MED, V333, P764, DOI 10.1056/NEJM199509213331204; Chew DP, 2001, CIRCULATION, V103, P961; Eikelboom J, 2003, J AM COLL CARDIOL, V41, p70S, DOI 10.1016/S0735-1097(02)02687-6; Feit F, 2007, AM J CARDIOL, V100, P1364, DOI 10.1016/j.amjcard.2007.06.026; Kastrati A, 2006, JAMA-J AM MED ASSOC, V295, P1531, DOI 10.1001/jama.295.13.joc60034; Kastrati A, 2004, NEW ENGL J MED, V350, P232, DOI 10.1056/NEJMoa031859; Kong DF, 1999, CIRCULATION, V100, P2049, DOI 10.1161/01.CIR.100.20.2049; Lincoff AM, 2004, AM J CARDIOL, V93, P1092, DOI 10.1016/j.amjcard.2004.01.033; Lincoff AM, 2003, JAMA-J AM MED ASSOC, V289, P853, DOI 10.1001/jama.289.7.853; Lincoff AM, 2002, AM HEART J, V143, P847, DOI 10.1067/mhj.2002.122173; LINCOFF AM, 2003, JAMA-J AM MED ASSOC, V289, P1638; Mauri L, 2007, NEW ENGL J MED, V356, P1020, DOI 10.1056/NEJMoa067731; Mehilli J, 2004, CIRCULATION, V110, P3627, DOI 10.1161/01.CIR.0000148956.93631.4D; Mehta SR, 2001, LANCET, V358, P527, DOI 10.1016/S0140-6736(01)05701-4; Montalescot G, 2006, J AM COLL CARDIOL, V48, P931, DOI 10.1016/j.jacc.2006.04.090; Montalescot G, 2006, NEW ENGL J MED, V355, P1006, DOI 10.1056/NEJMoa052711; Ndrepepa G, 2008, J AM COLL CARDIOL, V51, P690, DOI 10.1016/j.jacc.2007.10.040; Price MJ, 2006, AM J CARDIOL, V98, P681, DOI 10.1016/j.amjcard.2006.03.054; Sabatine MS, 2005, JAMA-J AM MED ASSOC, V294, P1224, DOI 10.1001/jama.294.10.1224; Steinhubl SR, 2002, JAMA-J AM MED ASSOC, V288, P2411, DOI 10.1001/jama.288.19.2411; Steinhubl SR, 2003, JAMA-J AM MED ASSOC, V289, P987; Stone GW, 2008, NEW ENGL J MED, V358, P2218, DOI 10.1056/NEJMoa0708191; Stone GW, 2007, JAMA-J AM MED ASSOC, V298, P2497, DOI 10.1001/jama.298.21.2497; Stone GW, 2007, LANCET, V369, P907, DOI 10.1016/S0140-6736(07)60450-4; Stone GW, 2006, NEW ENGL J MED, V355, P2203, DOI 10.1056/NEJMoa062437; *TIMI STUD GROUP, DEF US TIMI TRIALS; von Beckerath N, 2005, CIRCULATION, V112, P2946, DOI 10.1161/CIRCULATIONAHA.105.559088; Wang R, 2007, NEW ENGL J MED, V357, P2189, DOI 10.1056/NEJMsr077003	29	278	295	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 14	2008	359	7					688	696		10.1056/NEJMoa0802944	http://dx.doi.org/10.1056/NEJMoa0802944			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336XE	18703471				2022-12-28	WOS:000258397900005
J	Johnson, K; Asher, J; Rosborough, S; Raja, A; Panjabi, R; Beadling, C; Lawry, L				Johnson, Kirsten; Asher, Jana; Rosborough, Stephanie; Raja, Amisha; Panjabi, Rajesh; Beadling, Charles; Lawry, Lynn			Association of combatant status and sexual violence with health and mental health outcomes in postconflict Liberia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTTRAUMATIC-STRESS-DISORDER; INTERNALLY DISPLACED PERSONS; NORTHERN UGANDA; WAR; SYMPTOMS; CONFLICT; TRAUMA	Context Liberia's wars since 1989 have cost tens of thousands of lives and left many people mentally and physically traumatized. Objectives To assess the prevalence and impact of war-related psychosocial trauma, including information on participation in the Liberian civil wars, exposure to sexual violence, social functioning, and mental health. Design, Setting, and Participants A cross-sectional, population-based, multi-stage random cluster survey of 1666 adults aged 18 years or older using structured interviews and questionnaires, conducted during a 3-week period in May 2008 in Liberia. Main Outcome Measures Symptoms of major depressive disorder (MDD) and post-traumatic stress disorder (PTSD), social functioning, exposure to sexual violence, and health and mental health needs among Liberian adults who witnessed or participated in the conflicts during the last 2 decades. Results In the Liberian adult household-based population, 40% (95% confidence interval [CI], 36%-45%; n = 672/1659) met symptom criteria for MDD, 44% (95% CI, 38%-49%; n = 718/1661) met symptom criteria for PTSD, and 8% (95% CI, 5%-10%; n = 133/1666) met criteria for social dysfunction. Thirty-three percent of respondents (549/1666) reported having served time with fighting forces, and 33.2% of former combatant respondents (182/549) were female. Former combatants experienced higher rates of exposure to sexual violence than noncombatants: among females, 42.3% (95% CI, 35.4%-49.1%) vs 9.2% (95% CI, 6.7%-11.7%), respectively; among males, 32.6% (95% CI, 27.6%-37.6%) vs 7.4% (95% CI, 4.5%-10.4%). The rates of symptoms of PTSD, MDD, and suicidal ideation were higher among former combatants than noncombatants and among those who experienced sexual violence vs those who did not. The prevalence of PTSD symptoms among female former combatants who experienced sexual violence (74%; 95% CI, 63%-84%) was higher than among those who did not experience sexual violence (44%; 95% CI, 33%-53%). The prevalence of PTSD symptoms among male former combatants who experienced sexual violence was higher (81%; 95% CI, 74%-87%) than among male former combatants who did not experience sexual violence (46%; 95% CI, 39%-52%). Male former combatants who experienced sexual violence also reported higher rates of symptoms of depression and suicidal ideation. Both former combatants and noncombatants experienced inadequate access to health care (33.0% [95% CI, 22.6%-43.4%] and 30.1% [95% CI, 18.7%-41.6%], respectively). Conclusions Former combatants in Liberia were not exclusively male. Both female and male former combatants who experienced sexual violence had worse mental health outcomes than noncombatants and other former combatants who did not experience exposure to sexual violence.	[Beadling, Charles; Lawry, Lynn] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Ctr Disaster & Humanitarian Assistance Med, Bethesda, MD 20814 USA; [Lawry, Lynn] Johns Hopkins Univ, Dept Int Hlth, Bloomberg Sch Publ Hlth, Bethesda, MD USA; [Johnson, Kirsten; Rosborough, Stephanie] Harvard Univ, Harvard Humanitarian Initiat, Cambridge, MA 02138 USA; [Johnson, Kirsten] McGill Univ, Inst Hlth & Social Policy, Montreal, PQ, Canada; [Asher, Jana] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA; [Rosborough, Stephanie] Brigham & Womens Hosp, Div Int Hlth, Humanitarian Program, Boston, MA 02115 USA; [Lawry, Lynn] Brigham & Womens Hosp, Div Womens Hlth, Humanitarian Program, Boston, MA 02115 USA; [Raja, Amisha] Univ Connecticut, Greater Hartford Consortium, VA Med Ctr, Newington, CT USA; [Raja, Amisha; Panjabi, Rajesh] HIV Equ Initiat Tiyatien Hlth, Zwedru, Liberia; [Panjabi, Rajesh] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Panjabi, Rajesh] Harvard Univ, Sch Med, Boston, MA USA	Uniformed Services University of the Health Sciences - USA; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Harvard University; McGill University; Carnegie Mellon University; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; University of Connecticut; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Lawry, L (corresponding author), Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Ctr Disaster & Humanitarian Assistance Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	llawry@cdham.org	Lawry, Lynn/ABE-8391-2021; Asher, Jana Lynn/AAB-1393-2021; Johnson, Kirsten/AAF-7009-2020	Lawry, Lynn/0000-0001-8229-8768; Asher, Jana Lynn/0000-0003-0559-0372; 				Ai AL, 2002, J TRAUMA STRESS, V15, P157, DOI 10.1023/A:1014864225889; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; *AMN INT, DEM REP CONG CHILDR; Amowitz LL, 2002, JAMA-J AM MED ASSOC, V287, P513, DOI 10.1001/jama.287.4.513; [Anonymous], SAMPL SIZ CALC; Askin Kelly Dawn, 1997, WAR CRIMES WOMEN PRO; Betancourt TS, 2008, PSYCHOSOCIAL ADJUSTM; Bolton P, 2002, SOC PSYCH PSYCH EPID, V37, P537, DOI 10.1007/s00127-002-0580-5; Bolton P, 2007, JAMA-J AM MED ASSOC, V298, P519, DOI 10.1001/jama.298.5.519; Burt CDB, 2001, MEM COGNITION, V29, P127, DOI 10.3758/BF03195747; Cardozo BL, 2004, JAMA-J AM MED ASSOC, V292, P575, DOI 10.1001/jama.292.5.575; *CDCP, SUIC ID; Foa EB, 2000, J TRAUMA STRESS, V13, P181, DOI 10.1023/A:1007781909213; *HUM RIGHTS WATCH, YOUTH POV BLOO LETH; Human Rights Watch, FIGHT KILL CHILD SOL; Inter-Agency Standing Committee, IASC GUID MENT HLTH; Jennings PJ, 2001, LANCET, V357, P302, DOI 10.1016/S0140-6736(00)03625-4; Kim G, 2007, AM J PUBLIC HEALTH, V97, P353, DOI 10.2105/AJPH.2005.073635; Kothari CL, 2006, ANN EMERG MED, V47, P190, DOI 10.1016/j.annemergmed.2005.10.016; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; LEHTONEN R, 1994, PRACTICAL METHODS DE; LUMLEY T, 2008, SURVEY ANAL R; MCDOUGALL GJ, UN CONT FORMS SLAVER; *NAT COMM DIS DEM, DDRR CONS REP PHAS 1; *NIH, SUIC SUIC BEH; Odenwald M, 2007, PLOS MED, V4, P1959, DOI 10.1371/journal.pmed.0040341; Omanyondo M., 2004, SEXUAL GENDER BASED; Pham PN, 2004, JAMA-J AM MED ASSOC, V292, P602, DOI 10.1001/jama.292.5.602; REIS C, 2002, PREVALENCE SEXUAL VI; Resnick HS, 1997, BEHAV MED, V23, P65, DOI 10.1080/08964289709596730; Saltzman LE, 2002, INTIMATE PARTNER VIO; Schafer I, 2007, CURR OPIN PSYCHIATR, V20, P614, DOI 10.1097/YCO.0b013e3282f0ffd9; Schafran LH, 1996, AM J PUBLIC HEALTH, V86, P15, DOI 10.2105/AJPH.86.1.15; SHACKMAN G, 2003, SAMPLE SIZE DESIGN E, P8; Swiss S, 1998, JAMA-J AM MED ASSOC, V279, P625, DOI 10.1001/jama.279.8.625; Thompson J, 1997, MEMORY, V5, P615, DOI 10.1080/741941482; *UN HIGH COMM REF, PSYCH MENT HLTH PROG; *UN POP FUND, GEND BAS VIOL PRIC T; United Nations, UN MISS LIB; Verma V, 1996, INT STAT REV, V64, P265, DOI 10.2307/1403786; Vinck P, 2007, JAMA-J AM MED ASSOC, V298, P543, DOI 10.1001/jama.298.5.543; World Health Organization, FAC GUID EPI COV SUR	42	143	144	2	31	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	2008	300	6					676	690		10.1001/jama.300.6.676	http://dx.doi.org/10.1001/jama.300.6.676			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	336OM	18698066	Bronze			2022-12-28	WOS:000258374500020
J	Mazumdar, M				Mazumdar, Maitreyi			Febrile seizures and risk of death	LANCET			English	Editorial Material							CHILDREN; CONVULSIONS		Childrens Hosp, Dept Neurol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital	Mazumdar, M (corresponding author), Childrens Hosp, Dept Neurol, 300 Longwood Ave, Boston, MA 02115 USA.	maitreyi.mazumdar@childrens.harvard.edu						Hoyert D L, 2001, Natl Vital Stat Rep, V49, P1; Kinney HC, 2007, PEDIATR DEVEL PATHOL, V10, P208, DOI 10.2350/06-08-0144.1; LENNOX MA, 1954, J PEDIATR-US, V45, P179, DOI 10.1016/S0022-3476(54)80140-5; Mathews T J, 2004, Natl Vital Stat Rep, V53, P1; Moon RY, 2007, LANCET, V370, P1578, DOI 10.1016/S0140-6736(07)61662-6; NELSON KB, 1978, PEDIATRICS, V61, P720; NELSON KB, 1976, NEW ENGL J MED, V295, P1029, DOI 10.1056/NEJM197611042951901; *NIH, 1981, EPILEPSIA, V22, P377; OFFRINGA M, 1994, J PEDIATR-US, V124, P574, DOI 10.1016/S0022-3476(05)83136-1; SUNDERLAND R, 1981, LANCET, V2, P176; Vestergaard M, 2002, ARCH DIS CHILD, V86, P125, DOI 10.1136/adc.86.2.125; Vestergaard M, 2008, LANCET, V372, P457, DOI 10.1016/S0140-6736(08)61198-8	12	1	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 9	2008	372	9637					429	430		10.1016/S0140-6736(08)61176-9	http://dx.doi.org/10.1016/S0140-6736(08)61176-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	335OD	18692699				2022-12-28	WOS:000258299000007
J	Mark, DB; Anstrom, KJ; Sun, JL; Clapp-Channing, NE; Tsiatis, AA; Davidson-Ray, L; Lee, KL; Bardy, GH				Mark, Daniel B.; Anstrom, Kevin J.; Sun, Jie L.; Clapp-Channing, Nancy E.; Tsiatis, Anastasios A.; Davidson-Ray, Linda; Lee, Kerry L.; Bardy, Gust H.		Sudden Cardiac Death Heart Failure	Quality of life with defibrillator therapy or amiodarone in heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMPLANTABLE DEFIBRILLATORS; VENTRICULAR ARRHYTHMIAS; HIGH-RISK; SURGERY; TRIAL	Background: Implantable cardioverter-defibrillator (ICD) therapy significantly prolongs life in patients at increased risk for sudden death from depressed left ventricular function. However, whether this increased longevity is accompanied by deterioration in the quality of life is unclear. Methods: In a randomized trial, we compared ICD therapy or amiodarone with state-of-the-art medical therapy alone in 2521 patients who had stable heart failure with depressed left ventricular function. We prospectively measured quality of life at baseline and at months 3, 12, and 30; data collection was 93 to 98% complete. The Duke Activity Status Index (which measures cardiac physical functioning) and the Medical Outcomes Study 36-Item Short-Form Mental Health Inventory 5 (which measures psychological well-being) were prespecified primary outcomes. Multiple additional quality-of-life outcomes were also examined. Results: Psychological well-being in the ICD group, as compared with medical therapy alone, was significantly improved at 3 months (P=0.01) and at 12 months (P=0.003) but not at 30 months. No clinically or statistically significant differences in physical functioning among the study groups were observed. Additional quality-of-life measures were improved in the ICD group at 3 months, 12 months, or both, but there was no significant difference at 30 months. ICD shocks in the month preceding a scheduled assessment were associated with a decreased quality of life in multiple domains. The use of amiodarone had no significant effects on the primary quality-of-life outcomes. Conclusions: In a large primary-prevention population with moderately symptomatic heart failure, single-lead ICD therapy was not associated with any detectable adverse quality-of-life effects during 30 months of follow-up.	[Mark, Daniel B.; Anstrom, Kevin J.; Clapp-Channing, Nancy E.; Davidson-Ray, Linda] Duke Univ, Med Ctr, Outcomes Res Grp, Durham, NC 27710 USA; [Sun, Jie L.; Lee, Kerry L.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA; [Mark, Daniel B.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Anstrom, Kevin J.; Lee, Kerry L.] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC 27710 USA; [Tsiatis, Anastasios A.] N Carolina State Univ, Dept Stat, Raleigh, NC 27695 USA; [Bardy, Gust H.] Univ Washington, Seattle Inst Cardiac Res, Seattle, WA 98195 USA	Duke University; Duke University; Duke University; Duke University; University of North Carolina; North Carolina State University; University of Washington; University of Washington Seattle	Mark, DB (corresponding author), Duke Univ, Med Ctr, Outcomes Res Grp, Durham, NC 27710 USA.			Mark, Daniel/0000-0001-6340-8087	National Heart, Lung, and Blood Institute [UO1-HL55496, UO1-HL55766, UO1-HL55297]; Medtronic, Wyeth-Ayerst Laboratories; Knoll Pharmaceuticals; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL055496, U01HL055766, U01HL055297] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Medtronic, Wyeth-Ayerst Laboratories(Medtronic); Knoll Pharmaceuticals(Abbott Laboratories); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by grants (UO1-HL55496, UO1-HL55766, and UO1-HL55297) from the National Heart, Lung, and Blood Institute, and by Medtronic, Wyeth-Ayerst Laboratories, and Knoll Pharmaceuticals. Dr. Mark reports receiving grant support and lecture fees from Medtronic; Dr. Anstrom, grant support from Medtronic Vascular; and Dr. Lee, grant support and consulting fees from Medtronic; Dr. Bardy reports receiving grant support from and having intellectual property rights with Medtronic, receiving consulting fees and grant support from Philips Medical, receiving grant support from Laerdal, and being a founder of and board member of and having equity and intellectual property rights with Cameron Health. No other potential conflict of interest relevant to this article was reported. We thank Melanie R. Daniels for her editorial support, Judy Stafford for her assistance in data analysis, the site coordinators who collected the data for the study, and the patients who volunteered to participate in the study.	Bardy GH, 2005, NEW ENGL J MED, V352, P2146; Bardy GH, 2005, NEW ENGL J MED, V352, P225, DOI 10.1056/NEJMoa043399; Bigger JT, 1997, NEW ENGL J MED, V337, P1569, DOI 10.1056/NEJM199711273372201; Dawid AP, 2000, J AM STAT ASSOC, V95, P407, DOI 10.2307/2669377; DOVAL HC, 1994, LANCET, V344, P493, DOI 10.1016/S0140-6736(94)91895-3; Efron Bradley., 1993, INTRO BOOTSTRAP, DOI 10.1007/978-1-4899-4541-9; Hayden D, 2005, BIOMETRICS, V61, P305, DOI 10.1111/j.0006-341X.2005.030227.x; Hlatky MA, 1997, NEW ENGL J MED, V336, P92, DOI 10.1056/NEJM199701093360203; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; Irvine J, 2002, AM HEART J, V144, P282, DOI 10.1067/mhj.2002.124049; KOLATA G, 2002, NY TIMES        0325; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; Namerow PB, 1999, PACE, V22, P1305, DOI 10.1111/j.1540-8159.1999.tb00623.x; Rector TS, 2005, OVERVIEW MINNESOTA L; Rector TS, 1987, HEART FAIL, V3, P198; Schron EB, 2002, CIRCULATION, V105, P589, DOI 10.1161/hc0502.103330; SINGH SN, 1995, NEW ENGL J MED, V333, P77, DOI 10.1056/NEJM199507133330201; Torrance G W, 1989, Int J Technol Assess Health Care, V5, P559; Ware JE, 1993, SF36 HLTH SURVEY MAN	20	170	170	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2008	359	10					999	1008		10.1056/NEJMoa0706719	http://dx.doi.org/10.1056/NEJMoa0706719			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	343KN	18768943	Green Accepted			2022-12-28	WOS:000258852500004
J	von Huene, R				von Huene, Roland			Geophysics - When seamounts subduct	SCIENCE			English	Editorial Material							SEA-FLOOR ROUGHNESS		Univ Calif Davis, Dept Geol, Diamond Springs, CA 95619 USA		von Huene, R (corresponding author), Univ Calif Davis, Dept Geol, Diamond Springs, CA 95619 USA.	rhuene@mindspring.com						Bilek SL, 2003, GEOLOGY, V31, P455, DOI 10.1130/0091-7613(2003)031<0455:COSROE>2.0.CO;2; Booth-Rea G, 2007, GEOCHEM GEOPHY GEOSY, V8, DOI 10.1029/2007GC001639; CLOOS M, 1992, GEOLOGY, V20, P601, DOI 10.1130/0091-7613(1992)020<0601:TTSZEA>2.3.CO;2; DeShon HR, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB002294; Fisher DM, 1998, GEOLOGY, V26, P467, DOI 10.1130/0091-7613(1998)026<0467:EOSSFR>2.3.CO;2; Husen S, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014045; Mochizuki K, 2008, SCIENCE, V321, P1194, DOI 10.1126/science.1160250; Sahling H, 2008, GEOCHEM GEOPHY GEOSY, V9, DOI 10.1029/2008GC001978; von Huene R, 2008, GEOCHEM GEOPHY GEOSY, V9, DOI 10.1029/2008GC002013	9	37	37	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2008	321	5893					1165	1166		10.1126/science.1162868	http://dx.doi.org/10.1126/science.1162868			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341ZM	18755962				2022-12-28	WOS:000258754400028
J	Kageyama, A; Miyagoshi, T; Sato, T				Kageyama, Akira; Miyagoshi, Takehiro; Sato, Tetsuya			Formation of current coils in geodynamo simulations	NATURE			English	Article							ROTATING SPHERICAL-SHELL; MAGNETOHYDRODYNAMIC DYNAMO; GEOMAGNETIC-FIELD; COMPUTER-SIMULATION; POLARITY REVERSALS; DIPOLE FIELD; CONVECTION; VISUALIZATION; EQUATIONS	Computer simulations have been playing an important role in the development of our understanding of the geodynamo(1-3), but direct numerical simulation of the geodynamo with a realistic parameter regime is still beyond the power of today's supercomputers. Difficulties in simulating the geodynamo arise from the extreme conditions of the core, which are characterized by very large or very small values of the non- dimensional parameters of the system. Among them, the Ekman number, E, has been adopted as a barometer of the distance of simulations from real core conditions, in which E is of the order of 10(-15). Following the initial computer simulations of the geodynamo(4,5), the Ekman number achieved has been steadily decreasing, with recent geodynamo simulations(6-8) performed with E of the order of 10(-6). Here we present a geodynamo simulation with an Ekman number of the order of 10(-7)-the highest-resolution simulation yet achieved, making use of 4,096 processors of the Earth Simulator. We have found that both the convection flow and magnetic field structures are qualitatively different from those found in larger- Ekman- number dynamos. The convection takes the form of sheet plumes or radial sheet jets(9), rather than the columnar cell structures(10) that are usually found. We have found that this sheet plume convection is an effective dynamo and the generated current is organized as a set of coils in the shape of helical springs or at times as a torus.	[Kageyama, Akira; Miyagoshi, Takehiro; Sato, Tetsuya] Japan Agcy Marine Earth Sci & Technol, Earth Simulator Ctr, Yokohama, Kanagawa 2360001, Japan	Japan Agency for Marine-Earth Science & Technology (JAMSTEC)	Kageyama, A (corresponding author), Japan Agcy Marine Earth Sci & Technol, Earth Simulator Ctr, Yokohama, Kanagawa 2360001, Japan.	kage@jamstec.go.jp	Kageyama, Akira/H-4537-2013	Kageyama, Akira/0000-0003-0433-668X; Miyagoshi, Takehiro/0000-0002-8908-9990	KAKENHI [17540404]; The Mitsubishi Foundation	KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); The Mitsubishi Foundation	We thank P. Olson and J. Aurnou for pointing out the close connection between the sheet plume structure observed in this simulation and the experiments of ref. 9. We thank I. Sumita for a detailed explanation of his laboratory experiments and comments, and for providing Fig. 2a. We thank N. Ohno for helping with the visualization. This work was supported by KAKENHI ( 17540404) and The Mitsubishi Foundation.	Aubert J, 2001, PHYS EARTH PLANET IN, V128, P51, DOI 10.1016/S0031-9201(01)00277-1; Aubert J, 2008, GEOPHYS J INT, V172, P945, DOI 10.1111/j.1365-246X.2007.03693.x; BUSSE FH, 1975, GEOPHYS J ROY ASTR S, V42, P437, DOI 10.1111/j.1365-246X.1975.tb05871.x; Busse FH, 2002, PHYS FLUIDS, V14, P1301, DOI 10.1063/1.1455626; CHESSHIRE G, 1990, J COMPUT PHYS, V90, P1, DOI 10.1016/0021-9991(90)90196-8; Christensen UR, 2006, GEOPHYS J INT, V166, P97, DOI 10.1111/j.1365-246X.2006.03009.x; Davidson PA., 2001, INTRO MAGNETOHYDRODY; GILMAN PA, 1981, ASTROPHYS J SUPPL S, V45, P335, DOI 10.1086/190714; GLATZMAIER GA, 1995, NATURE, V377, P203, DOI 10.1038/377203a0; Jones CA, 2000, PHILOS T R SOC A, V358, P873, DOI 10.1098/rsta.2000.0565; Kageyama A, 1999, PHYS REV LETT, V82, P5409, DOI 10.1103/PhysRevLett.82.5409; Kageyama A, 1997, PHYS REV E, V55, P4617, DOI 10.1103/PhysRevE.55.4617; Kageyama A, 2000, PROG THEOR PHYS SUPP, P665, DOI 10.1143/PTPS.138.665; KAGEYAMA A, 1995, PHYS PLASMAS, V2, P1421, DOI 10.1063/1.871485; KAGEYAMA A, 2004, P ACM IEEE SC2004 C, P35, DOI DOI 10.1109/SC.2004.1; KAGEYAMA A, 2004, GEOCHEM GEOPHYS GEOS, V5; Kono M, 2002, REV GEOPHYS, V40, DOI 10.1029/2000RG000102; Li JH, 2002, SCIENCE, V295, P1887, DOI 10.1126/science.1066959; Ochi MM, 1999, PHYS PLASMAS, V6, P777, DOI 10.1063/1.873317; Ohno N, 2007, PHYS EARTH PLANET IN, V163, P305, DOI 10.1016/j.pepi.2007.02.013; Olson P, 2006, EARTH PLANET SC LETT, V250, P561, DOI 10.1016/j.epsl.2006.08.008; Plaut E, 2005, J FLUID MECH, V528, P119, DOI 10.1017/S0022112004003180; Roberts PH, 2000, REV MOD PHYS, V72, P1081, DOI 10.1103/RevModPhys.72.1081; Sakuraba A, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL029898; Stellmach S, 2004, PHYS REV E, V70, DOI 10.1103/PhysRevE.70.056312; Sumita I, 2000, PHYS EARTH PLANET IN, V117, P153, DOI 10.1016/S0031-9201(99)00094-1; Takahashi F, 2005, SCIENCE, V309, P459, DOI 10.1126/science.1111831; Zhang K, 2006, REP PROG PHYS, V69, P1581, DOI 10.1088/0034-4885/69/5/R06; [No title captured]	29	75	76	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	2008	454	7208					1106	1109		10.1038/nature07227	http://dx.doi.org/10.1038/nature07227			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341MW	18756255				2022-12-28	WOS:000258719600035
J	Strigari, LE; Bullock, JS; Kaplinghat, M; Simon, JD; Geha, M; Willman, B; Walker, MG				Strigari, Louis E.; Bullock, James S.; Kaplinghat, Manoj; Simon, Joshua D.; Geha, Marla; Willman, Beth; Walker, Matthew G.			A common mass scale for satellite galaxies of the Milky Way	NATURE			English	Article							DARK-MATTER SUBSTRUCTURE; DWARF GALAXIES; EVOLUTION; PROFILES; ORIGIN; HALOES	The Milky Way has at least twenty- three known satellite galaxies that shine with luminosities ranging from about a thousand to a billion times that of the Sun. Half of these galaxies were discovered(1,2) in the past few years in the Sloan Digital Sky Survey, and they are among the least luminous galaxies in the known Universe. A determination of the mass of these galaxies provides a test of galaxy formation at the smallest scales(3,4) and probes the nature of the dark matter that dominates the mass density of the Universe(5). Here we use new measurements of the velocities of the stars in these galaxies(6,7) to show that they are consistent with them having a common mass of about 10(7) M. within their central 300 parsecs. This result demonstrates that the faintest of the Milky Way satellites are the most dark- matter- dominated galaxies known, and could be a hint of a new scale in galaxy formation or a characteristic scale for the clustering of dark matter.	[Strigari, Louis E.; Bullock, James S.; Kaplinghat, Manoj] Univ Calif Irvine, Ctr Cosmol, Dept Phys & Astron, Irvine, CA 92697 USA; [Bullock, James S.] CALTECH, Dept Astron, Pasadena, CA 91125 USA; [Geha, Marla] Yale Univ, Dept Astron, New Haven, CT 06520 USA; [Willman, Beth] Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA; [Walker, Matthew G.] Univ Cambridge, Inst Astron, Cambridge CB3 0HA, England	University of California System; University of California Irvine; California Institute of Technology; Yale University; Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; University of Cambridge	Strigari, LE (corresponding author), Univ Calif Irvine, Ctr Cosmol, Dept Phys & Astron, Irvine, CA 92697 USA.	lstrigar@uci.edu	Bullock, James/K-1928-2015; Simon, Joshua D/AAX-7117-2021; Walker, Matthew G/P-1777-2014	Bullock, James/0000-0003-4298-5082; Walker, Matthew G/0000-0003-2496-1925; Strigari, Louis/0000-0001-5672-6079; Kaplinghat, Manoj/0000-0001-8555-0164	Science and Technology Facilities Council [ST/F001967/1, PP/E00105X/1] Funding Source: researchfish; STFC [PP/E00105X/1, ST/F001967/1] Funding Source: UKRI	Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))		Belokurov V, 2007, ASTROPHYS J, V654, P897, DOI 10.1086/509718; BLUMENTHAL GR, 1984, NATURE, V311, P517, DOI 10.1038/311517a0; Bode P, 2001, ASTROPHYS J, V556, P93, DOI 10.1086/321541; Bullock JS, 2000, ASTROPHYS J, V539, P517, DOI 10.1086/309279; Bullock JS, 2001, MON NOT R ASTRON SOC, V321, P559, DOI 10.1046/j.1365-8711.2001.04068.x; Diemand J, 2005, NATURE, V433, P389, DOI 10.1038/nature03270; Diemand J, 2007, ASTROPHYS J, V657, P262, DOI 10.1086/510736; DUNKLEY J, 2008, 5 YEAR WILKINSON MIC; EFSTATHIOU G, 1992, MNRAS, V256, P43; Fellhauer M, 2007, MON NOT R ASTRON SOC, V375, P1171, DOI 10.1111/j.1365-2966.2006.11404.x; Gilmore G, 2007, ASTROPHYS J, V663, P948, DOI 10.1086/518025; KAUFFMANN G, 1993, MON NOT R ASTRON SOC, V264, P201, DOI 10.1093/mnras/264.1.201; Klypin A, 1999, ASTROPHYS J, V522, P82, DOI 10.1086/307643; Kravtsov AV, 2004, ASTROPHYS J, V609, P482, DOI 10.1086/421322; Martin NF, 2007, MON NOT R ASTRON SOC, V380, P281, DOI 10.1111/j.1365-2966.2007.12055.x; MARTIN NF, 2008, COMPREHENSIVE MAXIMU; Mateo M, 1998, ANNU REV ASTRON ASTR, V36, P435, DOI 10.1146/annurev.astro.36.1.435; MATEO M, 1993, ASTRON J, V105, P510, DOI 10.1086/116449; Mayer L, 2007, NATURE, V445, P738, DOI 10.1038/nature05552; Moore B, 1999, ASTROPHYS J, V524, pL19, DOI 10.1086/312287; Munoz RR, 2006, ASTROPHYS J, V650, pL51, DOI 10.1086/508685; PEEBLES PJE, 1982, ASTROPHYS J, V263, pL1, DOI 10.1086/183911; PIATEK S, 1995, ASTRON J, V109, P1071, DOI 10.1086/117342; Spergel DN, 2007, ASTROPHYS J SUPPL S, V170, P377, DOI 10.1086/513700; Strigari LE, 2007, ASTROPHYS J, V669, P676, DOI 10.1086/521914; Walker MG, 2007, ASTROPHYS J, V667, pL53, DOI 10.1086/521998; WHITE SDM, 1983, ASTROPHYS J, V274, pL1, DOI 10.1086/184139; Willman B, 2005, ASTRON J, V129, P2692, DOI 10.1086/430214; Wyithe JSB, 2006, NATURE, V441, P322, DOI 10.1038/nature04748	31	413	414	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	2008	454	7208					1096	1097		10.1038/nature07222	http://dx.doi.org/10.1038/nature07222			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341MW	18756252	Green Submitted			2022-12-28	WOS:000258719600032
J	Vano-Galvan, S; Sanchez-Olaso, A				Vano-Galvan, Sergio; Sanchez-Olaso, Alberto			Squamous-cell carcinoma manifesting as a cutaneous horn	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Vano-Galvan, Sergio; Sanchez-Olaso, Alberto] Hosp Ramon & Cajal, E-28034 Madrid, Spain	Hospital Universitario Ramon y Cajal	Vano-Galvan, S (corresponding author), Hosp Ramon & Cajal, E-28034 Madrid, Spain.	sergiovano@yahoo.es		Vano-Galvan, Sergio/0000-0003-2773-7494					0	6	6	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 28	2008	359	9					E10	E10		10.1056/NEJMicm075948	http://dx.doi.org/10.1056/NEJMicm075948			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	341IU	18753642				2022-12-28	WOS:000258708300010
J	Alekseyenko, AA; Peng, SY; Larschan, E; Gorchakov, AA; Lee, OK; Kharchenko, P; McGrath, SD; Wang, CI; Mardis, ER; Park, PJ; Kuroda, MI				Alekseyenko, Artyom A.; Peng, Shouyong; Larschan, Erica; Gorchakov, Andrey A.; Lee, Ok-Kyung; Kharchenko, Peter; McGrath, Sean D.; Wang, Charlotte I.; Mardis, Elaine R.; Park, Peter J.; Kuroda, Mitzi I.			A sequence motif within chromatin entry sites directs MSL establishment on the Drosophila X chromosome	CELL			English	Article							DOSAGE COMPENSATION COMPLEX; ROX RNA GENES; BINDING-SITES; DNA-BINDING; INACTIVATION CENTER; TARGET GENES; PROTEIN; TRANSCRIPTION; REVEALS; GENOME	The Drosophila MSL complex associates with active genes specifically on the male X chromosome to acetylate histone H4 at lysine 16 and increase expression approximately 2-fold. To date, no DNA sequence has been discovered to explain the specificity of MSL binding. We hypothesized that sequence-specific targeting occurs at "chromatin entry sites,'' but the majority of sites are sequence independent. Here we characterize 150 potential entry sites by ChIP-chip and ChIP-seq and discover a GA-rich MSL recognition element (MRE). The motif is only slightly enriched on the X chromosome (similar to 2fold), but this is doubled when considering its preferential location within or 30 to active genes (> 4-fold enrichment). When inserted on an autosome, a newly identified site can direct local MSL spreading to flanking active genes. These results provide strong evidence for both sequence-dependent and -independent steps in MSL targeting of dosage compensation to the male X chromosome.	[Alekseyenko, Artyom A.; Peng, Shouyong; Larschan, Erica; Gorchakov, Andrey A.; Lee, Ok-Kyung; Park, Peter J.; Kuroda, Mitzi I.] Brigham & Womens Hosp, Dept Med, Div Genet, Harvard Partners Ctr Genet & Genom, Boston, MA 02115 USA; [Alekseyenko, Artyom A.; Larschan, Erica; Gorchakov, Andrey A.; Wang, Charlotte I.; Kuroda, Mitzi I.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; [Peng, Shouyong; Kharchenko, Peter; Park, Peter J.] Childrens Hosp, Childrens Hosp Informat Program, Boston, MA 02115 USA; [McGrath, Sean D.; Mardis, Elaine R.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63108 USA; [McGrath, Sean D.; Mardis, Elaine R.] Washington Univ, Sch Med, Genome Sequencing Ctr, St Louis, MO 63108 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Washington University (WUSTL); Washington University (WUSTL)	Park, PJ (corresponding author), Brigham & Womens Hosp, Dept Med, Div Genet, Harvard Partners Ctr Genet & Genom, 75 Francis St, Boston, MA 02115 USA.	peter_park@harvard.edu; mkuroda@genetics.med.harvard.edu	Mardis, Elaine/W-2202-2019; Gorchakov, Andrey A/N-5840-2015; McGrath, Sean David/AAT-3540-2020	Gorchakov, Andrey A/0000-0003-2830-4236; McGrath, Sean David/0000-0001-9064-8449; Park, Peter/0000-0001-9378-960X	National Institutes of Health [GM45744, GM67825, HG003079]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG003079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045744, K25GM067825, R37GM045744] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Many thanks to M. Gelbart, T. Sural, P. Yang, and M. Tolstorukov for critical comments on the manuscript; H. Oh, J. Bateman, T. Wu, J. Bischof, F. Karch, and K. Basler for key fly stocks; S. Elgin for important discussions; Y. Schwartz and T. Kahn for sharing protocols; and J. Racine and A. Sarovschii for technical assistance. This work was supported by the National Institutes of Health: GM45744 to M. I. K., GM67825 to P. J. P., and HG003079 to E. R. M. (co-PI).	Alekseyenko AA, 2006, GENE DEV, V20, P848, DOI 10.1101/gad.1400206; Amrein H, 1997, CELL, V88, P459, DOI 10.1016/S0092-8674(00)81886-3; Bai XY, 2004, EMBO J, V23, P2853, DOI 10.1038/sj.emboj.7600299; Bailey TL, 2006, NUCLEIC ACIDS RES, V34, pW369, DOI 10.1093/nar/gkl198; Bateman JR, 2006, GENETICS, V173, P769, DOI 10.1534/genetics.106.056945; Bischof J, 2007, P NATL ACAD SCI USA, V104, P3312, DOI 10.1073/pnas.0611511104; Boyle AP, 2008, CELL, V132, P311, DOI 10.1016/j.cell.2007.12.014; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; Csankovszki G, 2004, SCIENCE, V303, P1182, DOI 10.1126/science.1092938; Dahlsveen IK, 2006, PLOS GENET, V2, P104, DOI 10.1371/journal.pgen.0020005; Demakova OV, 2003, CHROMOSOMA, V112, P103, DOI 10.1007/s00412-003-0249-1; Ercan S, 2007, NAT GENET, V39, P403, DOI 10.1038/ng1983; Euskirchen GM, 2007, GENOME RES, V17, P898, DOI 10.1101/gr.5583007; Fagegaltier D, 2004, PLOS BIOL, V2, P1854, DOI 10.1371/journal.pbio.0020341; Gallach M, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-408; Gilfillan GD, 2006, GENE DEV, V20, P858, DOI 10.1101/gad.1399406; Gilfillan GD, 2007, NUCLEIC ACIDS RES, V35, P3561, DOI 10.1093/nar/gkm282; Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; Holohan EE, 2007, PLOS GENET, V3, P1211, DOI 10.1371/journal.pgen.0030112; Kageyama Y, 2001, EMBO J, V20, P2236, DOI 10.1093/emboj/20.9.2236; Kelley RL, 1999, CELL, V98, P513, DOI 10.1016/S0092-8674(00)81979-0; KELLEY RL, 1995, CELL, V81, P867, DOI 10.1016/0092-8674(95)90007-1; Kind J, 2007, GENE DEV, V21, P2030, DOI 10.1101/gad.430807; Larschan E, 2007, MOL CELL, V28, P121, DOI 10.1016/j.molcel.2007.08.011; Lee JT, 1997, NATURE, V386, P275, DOI 10.1038/386275a0; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; Legube G, 2006, GENE DEV, V20, P871, DOI 10.1101/gad.377506; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Liu XS, 2002, NAT BIOTECHNOL, V20, P835, DOI 10.1038/nbt717; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; Lucchesi JC, 2005, ANNU REV GENET, V39, P615, DOI 10.1146/annurev.genet.39.073003.094210; Lyman LM, 1997, GENETICS, V147, P1743; Lyon MF, 2003, SEMIN CELL DEV BIOL, V14, P313, DOI 10.1016/j.semcdb.2003.09.015; McDonel P, 2006, NATURE, V444, P614, DOI 10.1038/nature05338; Meller VH, 1997, CELL, V88, P445, DOI 10.1016/S0092-8674(00)81885-1; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Oh H, 2004, CURR BIOL, V14, P481, DOI 10.1016/j.cub.2004.03.004; Okamoto I, 2004, SCIENCE, V303, P644, DOI 10.1126/science.1092727; PALMER MJ, 1994, GENE DEV, V8, P698, DOI 10.1101/gad.8.6.698; Park Y, 2003, MOL CELL, V11, P977, DOI 10.1016/S1097-2765(03)00147-3; Park Y, 2002, SCIENCE, V298, P1620, DOI 10.1126/science.1076686; Pavesi G, 2004, NUCLEIC ACIDS RES, V32, pW199, DOI 10.1093/nar/gkh465; Schneider R, 2007, GENE DEV, V21, P3027, DOI 10.1101/gad.1604607; Sekinger EA, 2005, MOL CELL, V18, P735, DOI 10.1016/j.molcel.2005.05.003; Stenberg P, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-158; Sun LV, 2003, P NATL ACAD SCI USA, V100, P9428, DOI 10.1073/pnas.1533393100; van Steensel B, 2003, P NATL ACAD SCI USA, V100, P2580, DOI 10.1073/pnas.0438000100; Wade JT, 2005, GENE DEV, V19, P2619, DOI 10.1101/gad.1355605; Wutz A, 2000, MOL CELL, V5, P695, DOI 10.1016/S1097-2765(00)80248-8	51	199	201	0	10	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 22	2008	134	4					599	609		10.1016/j.cell.2008.06.033	http://dx.doi.org/10.1016/j.cell.2008.06.033			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SR	18724933	Bronze, Green Accepted			2022-12-28	WOS:000258665800014
J	Chen, KC; Wu, WW; Liao, CN; Chen, LJ; Tu, KN				Chen, Kuan-Chia; Wu, Wen-Wei; Liao, Chien-Neng; Chen, Lih-Juann; Tu, K. N.			Observation of atomic diffusion at twin-modified grain boundaries in copper	SCIENCE			English	Article							CU LINES; ELECTROMIGRATION; INTERCONNECTS	Grain boundaries affect the migration of atoms and electrons in polycrystalline solids, thus influencing many of the mechanical and electrical properties. By introducing nanometer- scale twin defects into copper grains, we show that we can change the grain- boundary structure and atomic- diffusion behavior along the boundary. Using in situ ultrahigh- vacuum and high- resolution transmission electron microscopy, we observed electromigration- induced atomic diffusion in the twin- modified grain boundaries. The triple point where a twin boundary meets a grain boundary was found to slow down grain- boundary and surface electromigration by one order of magnitude. We propose that this occurs because of the incubation time of nucleation of a new step at the triple points. The long incubation time slows down the overall rate of atomic transport.	[Chen, Kuan-Chia; Liao, Chien-Neng; Chen, Lih-Juann] Natl Tsing Hua Univ, Dept Mat Sci & Engn, Hsinchu 30013, Taiwan; [Wu, Wen-Wei] Natl Chiao Tung Univ, Dept Mat Sci & Engn, Hsinchu 30010, Taiwan; [Tu, K. N.] Univ Calif Los Angeles, Dept Mat Sci & Engn, Los Angeles, CA 90095 USA	National Tsing Hua University; National Yang Ming Chiao Tung University; University of California System; University of California Los Angeles	Liao, CN (corresponding author), Natl Tsing Hua Univ, Dept Mat Sci & Engn, Hsinchu 30013, Taiwan.	cnliao@mx.nthu.edu.tw	Chen, L.J./F-1669-2010	Liao, Chien-Neng/0000-0003-2513-1085; Wu, Wen-Wei/0000-0002-8388-8417	National Science Council [NSC 96-2120-M-007-006, NSC 96-2628-E-007-018-MY3]; NSF-Nanoscale Interdisciplinary Research Team [CMS-0506841]	National Science Council(Ministry of Science and Technology, Taiwan); NSF-Nanoscale Interdisciplinary Research Team(National Science Foundation (NSF))	The work was supported by the National Science Council through grants NSC 96-2120-M-007-006 and 96- 2628- E- 007- 018- MY3. K. N. T. acknowledges the support of NSF- Nanoscale Interdisciplinary Research Team contract CMS-0506841.	BALLUFFI RW, 1982, METALL TRANS A, V13, P2069, DOI 10.1007/BF02648378; BORGESEN P, 1992, APPL PHYS LETT, V60, P1706, DOI 10.1063/1.107192; CHAN SW, 1985, ACTA METALL MATER, V33, P1113, DOI 10.1016/0001-6160(85)90205-6; Chen KC, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2740109; Frankovic R, 1996, IEEE T ELECTRON DEV, V43, P2233, DOI 10.1109/16.544396; HALL EO, 1951, P PHYS SOC LOND B, V64, P747, DOI 10.1088/0370-1301/64/9/303; Hau-Riege CS, 2004, MICROELECTRON RELIAB, V44, P195, DOI 10.1016/j.microrel.2003.10.020; Hu CK, 1998, MATER CHEM PHYS, V52, P5, DOI 10.1016/S0254-0584(98)80000-X; Hu CK, 1999, APPL PHYS LETT, V74, P2945, DOI 10.1063/1.123974; Hu CK, 1997, THIN SOLID FILMS, V308, P443, DOI 10.1016/S0040-6090(97)00487-2; Huang JS, 2001, J APPL PHYS, V89, P2130, DOI 10.1063/1.1340004; KARIMI M, 1995, PHYS REV B, V52, P5364, DOI 10.1103/PhysRevB.52.5364; Liao CN, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2081138; Liniger E, 2002, J APPL PHYS, V92, P1803, DOI 10.1063/1.1492871; Lu L, 2004, SCIENCE, V304, P422, DOI 10.1126/science.1092905; PETCH NJ, 1953, J IRON STEEL I, V174, P25; SUTTON AP, 1995, INTERFACES CRYSTALLI, P598; Tu KN, 2003, J APPL PHYS, V94, P5451, DOI 10.1063/1.1611263	18	305	311	21	308	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	2008	321	5892					1066	1069		10.1126/science.1160777	http://dx.doi.org/10.1126/science.1160777			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339RL	18719278				2022-12-28	WOS:000258594900033
J	Dyker, CA; Bertrand, G				Dyker, C. Adam; Bertrand, Guy			Chemistry - Soluble allotropes of main-group elements	SCIENCE			English	Editorial Material							DIVALENT CARBON(0) COMPOUNDS; CARBENE; CARBODICARBENE; BENT; P-4		[Dyker, C. Adam; Bertrand, Guy] Univ Calif Riverside, UCR CNRS Joint Res Chem Lab UMI 2957, Dept Chem, Riverside, CA 92521 USA	University of California System; University of California Riverside	Bertrand, G (corresponding author), Univ Calif Riverside, UCR CNRS Joint Res Chem Lab UMI 2957, Dept Chem, Riverside, CA 92521 USA.	cadamd@ucr.edu; gbertran@mail.ucr.edu	Dyker, C. Adam/C-4450-2008	Dyker, C. Adam/0000-0002-0149-0166				ARDUENGO AJ, 1991, J AM CHEM SOC, V113, P361, DOI 10.1021/ja00001a054; Dyker CA, 2008, ANGEW CHEM INT EDIT, V47, P3206, DOI 10.1002/anie.200705620; Furstner A, 2008, ANGEW CHEM INT EDIT, V47, P3210, DOI 10.1002/anie.200705798; IGAU A, 1989, ANGEW CHEM INT EDIT, V28, P621, DOI 10.1002/anie.198906211; Kaufhold O, 2008, ANGEW CHEM INT EDIT, V47, P4057, DOI 10.1002/anie.200800846; Masuda JD, 2007, J AM CHEM SOC, V129, P14180, DOI 10.1021/ja077296u; Masuda JD, 2007, ANGEW CHEM INT EDIT, V46, P7052, DOI 10.1002/anie.200703055; Tonner R, 2008, CHEM-EUR J, V14, P3260, DOI 10.1002/chem.200701390; Tonner R, 2007, ANGEW CHEM INT EDIT, V46, P8695, DOI 10.1002/anie.200701632; Wang YZ, 2008, SCIENCE, V321, P1069, DOI 10.1126/science.1160768; Wang YZ, 2008, J AM CHEM SOC, V130, P3298, DOI 10.1021/ja800257j; Wang Y, 2007, J AM CHEM SOC, V129, P12412, DOI 10.1021/ja075932i	12	105	106	0	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 22	2008	321	5892					1050	1051		10.1126/science.1162926	http://dx.doi.org/10.1126/science.1162926			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339RL	18719272				2022-12-28	WOS:000258594900026
J	Kim, JJ; Goldie, SJ				Kim, Jane J.; Goldie, Sue J.			Health and economic implications of HPV vaccination in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-PAPILLOMAVIRUS VACCINATION; COST-EFFECTIVENESS ANALYSIS; CANCER-SOCIETY GUIDELINE; CERVICAL-CANCER; CONSENSUS GUIDELINES; PARTICLE VACCINE; INFECTION; IMPACT; WOMEN; PREVALENCE	Background: The cost-effectiveness of prophylactic vaccination against human papillomavirus types 16 (HPV-16) and 18 (HPV-18) is an important consideration for guidelines for immunization in the United States. Methods: We synthesized epidemiologic and demographic data using models of HPV-16 and HPV-18 transmission and cervical carcinogenesis to compare the health and economic outcomes of vaccinating preadolescent girls (at 12 years of age) and vaccinating older girls and women in catch-up programs (to 18, 21, or 26 years of age). We examined the health benefits of averting other HPV-16-related and HPV-18-related cancers, the prevention of HPV-6-related and HPV-11-related genital warts and juvenile-onset recurrent respiratory papillomatosis by means of the quadrivalent vaccine, the duration of immunity, and future screening practices. Results: On the assumption that the vaccine provided lifelong immunity, the cost-effectiveness ratio of vaccination of 12-year-old girls was $43,600 per quality-adjusted life-year (QALY) gained, as compared with the current screening practice. Under baseline assumptions, the cost-effectiveness ratio for extending a temporary catch-up program for girls to 18 years of age was $97,300 per QALY; the cost of extending vaccination of girls and women to the age of 21 years was $120,400 per QALY, and the cost for extension to the age of 26 years was $152,700 per QALY. The results were sensitive to the duration of vaccine-induced immunity; if immunity waned after 10 years, the cost of vaccination of preadolescent girls exceeded $140,000 per QALY, and catch-up strategies were less cost-effective than screening alone. The cost-effectiveness ratios for vaccination strategies were more favorable if the benefits of averting other health conditions were included or if screening was delayed and performed at less frequent intervals and with more sensitive tests; they were less favorable if vaccinated girls were preferentially screened more frequently in adulthood. Conclusions: The cost-effectiveness of HPV vaccination will depend on the duration of vaccine immunity and will be optimized by achieving high coverage in preadolescent girls, targeting initial catch-up efforts to women up to 18 or 21 years of age, and revising screening policies.	[Kim, Jane J.; Goldie, Sue J.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Program Hlth Decis Sci, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Kim, JJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Program Hlth Decis Sci, 718 Huntington Ave,2nd Fl, Boston, MA 02115 USA.	jkim@hsph.harvard.edu			National Cancer Institute [R01 CA93435]; Centers for Disease Control and Prevention; American Cancer Society; Bill and Melinda Gates Foundation [30505]; NATIONAL CANCER INSTITUTE [R01CA093435] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); American Cancer Society(American Cancer Society); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by grants from the National Cancer Institute (R01 CA93435), the Centers for Disease Control and Prevention, and the American Cancer Society, and by the Bill and Melinda Gates Foundation ( 30505) for related work in developing countries.; No potential conflict of interest relevant to this article was reported.; We thank the entire cervical- cancer prevention team at the Program in Health Decision Science, Harvard School of Public Health, including Jeremy Goldhaber-Fiebert, Jesse Ortendahl, Meredith O'Shea, Katie Kobus, Steven Sweet, Nicole Gastineau Campos, and Bethany Andres-Beck, for their contributions.	*AM CANC SOC, CANC FACTS FIG 2007; American College of Obstetricians and Gynecologists, 2003, Int J Gynaecol Obstet, V83, P237; Centers of Disease Control and Prevention, 2001, MMWR Recomm Rep, V50, P1, DOI 10.1103/PhysRevE.106.055304; [Anonymous], [No title captured]; Barnabas RV, 2006, PLOS MED, V3, P624, DOI 10.1371/journal.pmed.0030138; BARNABAS RV, 2007, OUTCOMES RES, V7, P1; Bishai D, 2000, ARCH OTOLARYNGOL, V126, P935, DOI 10.1001/archotol.126.8.935; Boot HJ, 2007, VACCINE, V25, P6245, DOI 10.1016/j.vaccine.2007.05.061; Brisson M, 2007, VACCINE, V25, P5399, DOI 10.1016/j.vaccine.2007.04.086; *CDCP, 2006, HPV VACC QUEST ANSW; Clifford G, 2006, VACCINE, V24, P26, DOI 10.1016/j.vaccine.2006.05.026; Clifford GM, 2003, BRIT J CANCER, V89, P101, DOI 10.1038/sj.bjc.6601024; Clifford GM, 2003, BRIT J CANCER, V88, P63, DOI 10.1038/sj.bjc.6600688; Clifford GM, 2005, LANCET, V366, P991, DOI 10.1016/S0140-6736(05)67069-9; Dasbach EJ, 2006, EPIDEMIOL REV, V28, P88, DOI 10.1093/epirev/mxj006; DERKAY CS, 1995, ARCH OTOLARYNGOL, V121, P1386; Dunne EF, 2007, JAMA-J AM MED ASSOC, V297, P813, DOI 10.1001/jama.297.8.813; Eichler HG, 2004, VALUE HEALTH, V7, P518, DOI 10.1111/j.1524-4733.2004.75003.x; Elbasha EH, 2007, EMERG INFECT DIS, V13, P28, DOI 10.3201/eid1301.060438; Eltoum IA, 2007, CANCER CYTOPATHOL, V111, P34, DOI 10.1002/cncr.22487; Fiore Anthony E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Franceschi S, 2002, BRIT J CANCER, V86, P705, DOI 10.1038/sj.bjc.6600194; Franco EL, 2006, VACCINE, V24, P171, DOI 10.1016/j.vaccine.2006.05.061; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; Garland SM, 2007, NEW ENGL J MED, V356, P1928, DOI 10.1056/NEJMoa061760; Gold MR, 1998, MED CARE, V36, P778, DOI 10.1097/00005650-199806000-00002; Goldhaber-Fiebert JD, 2008, JNCI-J NATL CANCER I, V100, P308, DOI 10.1093/jnci/djn019; Goldie SJ, 2004, OBSTET GYNECOL, V103, P619, DOI 10.1097/01.AOG.0000120143.50098.c7; Goldie SJ, 2004, JNCI-J NATL CANCER I, V96, P604, DOI 10.1093/jnci/djh104; Goldie SJ, 2007, VACCINE, V25, P6257, DOI 10.1016/j.vaccine.2007.05.058; Hamilton Brady E, 2006, Natl Vital Stat Rep, V55, P1; Harper DM, 2006, LANCET, V367, P1247, DOI 10.1016/S0140-6736(06)68439-0; Hu D, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2008.03.064; Hughes JP, 2002, EPIDEMIOLOGY, V13, P631, DOI 10.1097/00001648-200211000-00006; Insinga RP, 2005, PHARMACOECONOMICS, V23, P1107, DOI 10.2165/00019053-200523110-00004; Insinga RP, 2004, CANCER EPIDEM BIOMAR, V13, P355; Insinga RP, 2003, CLIN INFECT DIS, V36, P1397, DOI 10.1086/375074; *INT UN CANC, 1966, CANC INC 5 CONT; Iskedjian M, 2004, VACCINE, V22, P4215, DOI 10.1016/j.vaccine.2004.04.025; Jain N., 2007, Morbidity and Mortality Weekly Report, V56, P885; Kim JJ, 2007, BRIT J CANCER, V97, P1322, DOI 10.1038/sj.bjc.6604023; Kim JJ, 2007, AM J EPIDEMIOL, V166, P137, DOI 10.1093/aje/kwm086; Kulasingam SL, 2003, JAMA-J AM MED ASSOC, V290, P781, DOI 10.1001/jama.290.6.781; Lacey CJN, 2006, VACCINE, V24, P35, DOI 10.1016/j.vaccine.2006.06.015; Mao C, 2006, OBSTET GYNECOL, V107, P1425; Mao C, 2006, OBSTET GYNECOL, V107, P18, DOI 10.1097/01.AOG.0000192397.41191.fb; Mosher William D, 2005, Adv Data, P1; *NCI, 2005, SURV EP END RES SEER; Newall AT, 2007, LANCET INFECT DIS, V7, P289, DOI 10.1016/S1473-3099(07)70083-X; Paavonen J, 2007, LANCET, V370, P1414; Paavonen J, 2007, LANCET, V369, P2161, DOI 10.1016/S0140-6736(07)60946-5; Parkin DM, 2006, VACCINE, V24, P11, DOI 10.1016/j.vaccine.2006.05.111; Sanders GD, 2003, EMERG INFECT DIS, V9, P37; Saslow D, 2002, CA-CANCER J CLIN, V52, P342, DOI 10.3322/canjclin.52.6.342; Saslow D, 2007, CA-CANCER J CLIN, V57, P7, DOI 10.3322/canjclin.57.1.7; SONI A, 2007, 173 AG HEALTHC RES Q; Stanley M, 2006, VACCINE, V24, P106, DOI 10.1016/j.vaccine.2006.05.110; Taira AV, 2004, EMERG INFECT DIS, V10, P1915, DOI 10.3201/eid1011.040222; Villa L, 2007, LANCET, V369, P1861, DOI 10.1016/S0140-6736(07)60852-6; Villa LL, 2007, NEW ENGL J MED, V356, P1915, DOI 10.1056/NEJMoa061741; Wallace LA, 2005, VACCINE, V23, P5624, DOI 10.1016/j.vaccine.2005.06.034; Winer RL, 2003, AM J EPIDEMIOL, V157, P218, DOI 10.1093/aje/kwf180; Winer RL, 2003, AM J EPIDEMIOL, V157, P859; Wright TC, 2002, JAMA-J AM MED ASSOC, V287, P2120, DOI 10.1001/jama.287.16.2120; Wright TC, 2004, OBSTET GYNECOL, V103, P304, DOI 10.1097/01.AOG.0000109426.82624.f8; Wright TC, 2007, AM J OBSTET GYNECOL, V197, P346, DOI 10.1016/j.ajog.2007.07.047	66	266	278	0	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 21	2008	359	8					821	832		10.1056/NEJMsa0707052	http://dx.doi.org/10.1056/NEJMsa0707052			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339HL	18716299	Green Accepted, Bronze			2022-12-28	WOS:000258568600007
J	Sobel, HW; Suzuki, Y				Sobel, Henry W.; Suzuki, Yoichiro			Yoji Totsuka (1942-2008) - Obituary	NATURE			English	Biographical-Item									[Sobel, Henry W.] Univ Calif Irvine, Sch Phys Sci, Irvine, CA 92697 USA; [Suzuki, Yoichiro] Univ Tokyo, Kamioka Observ, Inst Cosm Ray Res, Gifu 5061205, Japan	University of California System; University of California Irvine; University of Tokyo	Sobel, HW (corresponding author), Univ Calif Irvine, Sch Phys Sci, Irvine, CA 92697 USA.	hsobel@uci.edu; suzuki@suketto.icrr.u-tokyo.ac.jp	Suzuki, Yoichiro/F-7542-2010; Sobel, Henry/A-4369-2011	Suzuki, Yoichiro/0000-0001-7340-6675; 					0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 21	2008	454	7207					954	954		10.1038/454954a	http://dx.doi.org/10.1038/454954a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339QB	18719580				2022-12-28	WOS:000258591000029
J	Tseng, YH; Kokkotou, E; Schulz, TJ; Huang, TL; Winnay, JN; Taniguchi, CM; Tran, TT; Suzuki, R; Espinoza, DO; Yamamoto, Y; Ahrens, MJ; Dudley, AT; Norris, AW; Kulkarni, RN; Kahn, CR				Tseng, Yu-Hua; Kokkotou, Efi; Schulz, Tim J.; Huang, Tian Lian; Winnay, Jonathon N.; Taniguchi, Cullen M.; Tran, Thien T.; Suzuki, Ryo; Espinoza, Daniel O.; Yamamoto, Yuji; Ahrens, Molly J.; Dudley, Andrew T.; Norris, Andrew W.; Kulkarni, Rohit N.; Kahn, C. Ronald			New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure	NATURE			English	Article							ADIPOCYTE DIFFERENTIATION; TRANSCRIPTIONAL CONTROL; GLUCOSE-UPTAKE; INSULIN; FAT; STIMULATION; CELLS; COMMITMENT; EXPRESSION; C3H10T1/2	Adipose tissue is central to the regulation of energy balance. Two functionally different types of fat are present in mammals: white adipose tissue, the primary site of triglyceride storage, and brown adipose tissue, which is specialized in energy expenditure and can counteract obesity61. Factors that specify the developmental fate and function of white and brown adipose tissue remain poorly understood(2,3). Here we demonstrate that whereas some members of the family of bone morphogenetic proteins ( BMPs) support white adipocyte differentiation, BMP7 singularly promotes differentiation of brown preadipocytes even in the absence of the normally required hormonal induction cocktail. BMP7 activates a full program of brown adipogenesis including induction of early regulators of brown fat fate PRDM16 ( PR- domain- containing 16; ref. 4) and PGC-1 alpha ( peroxisome proliferator- activated receptor-gamma ( PPAR gamma) coactivator-1 alpha; ref. 5), increased expression of the brown- fat- defining marker uncoupling protein 1 ( UCP1) and adipogenic transcription factors PPAR gamma and CCAAT/ enhancer- binding proteins ( C/ EBPs), and induction of mitochondrial biogenesis via p38 mitogen- activated protein ( MAP) kinase-( also known as Mapk14) and PGC- 1- dependent pathways. Moreover, BMP7 triggers commitment of mesenchymal progenitor cells to a brown adipocyte lineage, and implantation of these cells into nude mice results in development of adipose tissue containing mostly brown adipocytes. Bmp7 knockout embryos show a marked paucity of brown fat and an almost complete absence of UCP1. Adenoviral-ediated expression of BMP7 in mice results in a significant increase in brown, but not white, fat mass and leads to an increase in energy expenditure and a reduction in weight gain. These data reveal an important role of BMP7 in promoting brown adipocyte differentiation and thermogenesis in vivo and in vitro, and provide a potential new therapeutic approach for the treatment of obesity.	[Tseng, Yu-Hua; Schulz, Tim J.; Huang, Tian Lian; Winnay, Jonathon N.; Taniguchi, Cullen M.; Tran, Thien T.; Suzuki, Ryo; Espinoza, Daniel O.; Yamamoto, Yuji; Kahn, C. Ronald] Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Obes & Hormone Act, Boston, MA 02215 USA; [Kulkarni, Rohit N.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Cell & Mol Physiol, Boston, MA 02215 USA; [Kokkotou, Efi] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA; [Ahrens, Molly J.; Dudley, Andrew T.] Northwestern Univ, Dept Biochem, Evanston, IL 60208 USA; [Norris, Andrew W.] Univ Iowa, Childrens Hosp, Div Pediat Endocrinol, Iowa City, IA 52242 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Northwestern University; University of Iowa	Tseng, YH (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Obes & Hormone Act, Boston, MA 02215 USA.	yu-hua.tseng@joslin.harvard.edu	Suzuki, Ryo/AAA-2736-2019; Tseng, Yu-Hua/AAE-6471-2021; Norris, Andrew W/O-5499-2018; Kahn, Ronald/AAY-2435-2021; Schulz, Tim/F-4842-2013	Suzuki, Ryo/0000-0002-2965-6906; Tseng, Yu-Hua/0000-0003-2053-9559; Norris, Andrew W/0000-0001-8396-9543; Kahn, Ronald/0000-0002-7583-9228; Schulz, Tim/0000-0002-8413-3972; Taniguchi, Cullen/0000-0002-8052-3316	National Institutes of Health [R01 DK077097, R21 DK070722, P30 DK46200, P30 DK040561, R01 DK67536, K08 DK64906, R01 DK 060837]; Tanita Healthy Weight Community; Eleanor and Miles Shore 50th Anniversary Scholar Program; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK077097, K08DK064906, R01DK060837, R01DK067536, P30DK046200, R21DK070722, P30DK040561] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Tanita Healthy Weight Community; Eleanor and Miles Shore 50th Anniversary Scholar Program; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We acknowledge T.-C. He for providing adenoviruses expressing BMPs. We thank M. Rourk and L. Mazzola for help with the animal experiments, J. Hu, C. Cahill, A. McSweeney, L. Polivy and R. Bronson for technical assistance, and P. Zhang for statistical consultation. We thank A. Butte and P. Laustsen for inputs on initiation of this project. We thank M. Uldry and B. Spiegelman for providing the PGC- 1 null cells. This work was supported in part by the National Institutes of Health grants R01 DK077097, R21 DK070722, P30 DK46200 and P30 DK040561 ( to Y.- H. T.), R01 DK67536 ( to R. N. K.), K08 DK64906 ( to A. W. N.) and R01 DK 060837 ( to C. R. K), the Tanita Healthy Weight Community, and the Eleanor and Miles Shore 50th Anniversary Scholar Program from Harvard Medical School ( to Y.- H. T.).	Bandyopadhyay A, 2006, PLOS GENET, V2, P2116, DOI 10.1371/journal.pgen.0020216; Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023; Cao WH, 2004, MOL CELL BIOL, V24, P3057, DOI 10.1128/MCB.24.7.3057-3067.2004; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623-200308000-00017; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; Farmer SR, 2006, CELL METAB, V4, P263, DOI 10.1016/j.cmet.2006.07.001; Fasshauer M, 2000, J BIOL CHEM, V275, P25494, DOI 10.1074/jbc.M004046200; Fasshauer M, 2001, MOL CELL BIOL, V21, P319, DOI 10.1128/MCB.21.1.319-329.2001; Gesta S, 2007, CELL, V131, P242, DOI 10.1016/j.cell.2007.10.004; Godin RE, 1998, DEVELOPMENT, V125, P3473; HAUNER H, 1989, J CLIN INVEST, V84, P1663, DOI 10.1172/JCI114345; Jin WZ, 2006, DEV CELL, V10, P461, DOI 10.1016/j.devcel.2006.02.016; Klein J, 1999, J BIOL CHEM, V274, P34795, DOI 10.1074/jbc.274.49.34795; Laustsen PG, 2002, GENE DEV, V16, P3213, DOI 10.1101/gad.1034802; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; Nedergaard J., 1986, BROWN ADIPOSE TISSUE, P152; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066; Seale P, 2007, CELL METAB, V6, P38, DOI 10.1016/j.cmet.2007.06.001; Tang QQ, 2004, P NATL ACAD SCI USA, V101, P9607, DOI 10.1073/pnas.0403100101; Tobin JF, 2006, DRUG DISCOV TODAY, V11, P405, DOI 10.1016/j.drudis.2006.03.016; Tseng YH, 2002, J BIOL CHEM, V277, P31601, DOI 10.1074/jbc.M202932200; Tseng YH, 2005, NAT CELL BIOL, V7, P601, DOI 10.1038/ncb1259; Tseng YH, 2004, MOL CELL BIOL, V24, P1918, DOI 10.1128/MCB.24.5.1918-1929.2004; Tseng YH, 2007, CELL SCI REV, V3, P342; Ueki K, 2004, P NATL ACAD SCI USA, V101, P10422, DOI 10.1073/pnas.0402511101; Uldry M, 2006, CELL METAB, V3, P333, DOI 10.1016/j.cmet.2006.04.002; Varga AC, 2005, ONCOGENE, V24, P5713, DOI 10.1038/sj.onc.1208919; WANG EA, 1993, GROWTH FACTORS, V9, P57, DOI 10.3109/08977199308991582; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Zeisberg M, 2003, NAT MED, V9, P964, DOI 10.1038/nm888	36	790	878	1	112	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 21	2008	454	7207					1000	U44		10.1038/nature07221	http://dx.doi.org/10.1038/nature07221			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339QB	18719589	Green Accepted			2022-12-28	WOS:000258591000040
J	Cossaro, A; Mazzarello, R; Rousseau, R; Casalis, L; Verdini, A; Kohlmeyer, A; Floreano, L; Scandolo, S; Morgante, A; Klein, ML; Scoles, G				Cossaro, A.; Mazzarello, R.; Rousseau, R.; Casalis, L.; Verdini, A.; Kohlmeyer, A.; Floreano, L.; Scandolo, S.; Morgante, A.; Klein, M. L.; Scoles, G.			X-ray diffraction and computation yield the structure of alkanethiols on gold(111)	SCIENCE			English	Article							SELF-ASSEMBLED MONOLAYERS; SUPERLATTICE STRUCTURE; AU(111); GOLD; DECANETHIOL; ADSORPTION; INTERFACE; DENSITY; SURFACE; GROWTH	The structure of self- assembled monolayers ( SAMs) of long- chain alkyl sulfides on gold( 111) has been resolved by density functional theory- based molecular dynamics simulations and grazing incidence x- ray diffraction for hexanethiol and methylthiol. The analysis of molecular dynamics trajectories and the relative energies of possible SAM structures suggest a competition between SAM ordering, driven by the lateral van der Waals interaction between alkyl chains, and disordering of interfacial Au atoms, driven by the sulfur- gold interaction. We found that the sulfur atoms of the molecules bind at two distinct surface sites, and that the first gold surface layer contains gold atom vacancies ( which are partially redistributed over different sites) as well as gold adatoms that are laterally bound to two sulfur atoms.	[Cossaro, A.; Verdini, A.; Floreano, L.; Morgante, A.] CNR, Ist Nazl Fis Mat, Lab TASC, I-34012 Trieste, Italy; [Mazzarello, R.; Rousseau, R.; Scoles, G.] Scuola Int Super Studi Avanzati, I-34014 Trieste, Italy; [Casalis, L.; Scoles, G.] Sincrotrone Trieste SCpA, I-34012 Trieste, Italy; [Kohlmeyer, A.; Klein, M. L.] Univ Penn, Ctr Mol Modeling, Philadelphia, PA 19104 USA; [Kohlmeyer, A.; Klein, M. L.] Univ Penn, Dept Chem, Philadelphia, PA 19104 USA; [Scandolo, S.] Abdus Salam Int Ctr Theoret Phys, I-34014 Trieste, Italy; [Scandolo, S.] INFM Democritos Natl Simulat Ctr, I-34014 Trieste, Italy; [Morgante, A.] Univ Trieste, Dept Phys, I-34127 Trieste, Italy; [Scoles, G.] Princeton Univ, Dept Chem, Princeton, NJ 08544 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Padua; International School for Advanced Studies (SISSA); Elettra Sincrotrone Trieste; University of Pennsylvania; University of Pennsylvania; Abdus Salam International Centre for Theoretical Physics (ICTP); University of Trieste; Princeton University	Morgante, A (corresponding author), CNR, Ist Nazl Fis Mat, Lab TASC, I-34012 Trieste, Italy.	morgante@tasc.infm.it	Scandolo, Sandro/AAC-9081-2019; Mazzarello, Riccardo/G-4502-2014; Morgante, Alberto/C-5199-2010; VERDINI, ALBERTO/H-6516-2013; Rousseau, Roger/C-3703-2014; Morgante, Alberto/ABF-5813-2020	Scandolo, Sandro/0000-0003-3826-4813; Mazzarello, Riccardo/0000-0003-2319-375X; Morgante, Alberto/0000-0001-9021-2944; VERDINI, ALBERTO/0000-0001-8880-2080; Morgante, Alberto/0000-0001-9021-2944; Kohlmeyer, Axel/0000-0001-6204-6475; Cossaro, Albano/0000-0002-8429-1727				ANSELMETTI D, 1994, EUROPHYS LETT, V27, P365, DOI 10.1209/0295-5075/27/5/006; CAMILLONE N, 1993, J CHEM PHYS, V98, P3503, DOI 10.1063/1.464071; Fenter P, 1998, SURF SCI, V412-13, P213, DOI 10.1016/S0039-6028(98)00428-2; FENTER P, 1994, SCIENCE, V266, P1216, DOI 10.1126/science.266.5188.1216; Gerstenberg MC, 2000, PHYS REV B, V61, P7678, DOI 10.1103/PhysRevB.61.7678; Gronbeck H, 2007, J PHYS CHEM B, V111, P3325, DOI 10.1021/jp0700128; Hakkinen H, 2006, J PHYS CHEM B, V110, P9927, DOI 10.1021/jp0619787; Jadzinsky PD, 2007, SCIENCE, V318, P430, DOI 10.1126/science.1148624; Lavrich DJ, 1998, J PHYS CHEM B, V102, P3456, DOI 10.1021/jp980047v; Love JC, 2005, CHEM REV, V105, P1103, DOI 10.1021/cr0300789; Maksymovych P, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.146103; Mazzarello R, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.016102; Nagoya A, 2007, J PHYS-CONDENS MAT, V19, DOI 10.1088/0953-8984/19/36/365245; NUZZO RG, 1990, J CHEM PHYS, V93, P767, DOI 10.1063/1.459528; Poirier GE, 1999, LANGMUIR, V15, P1167, DOI 10.1021/la981374x; Prato M, 2008, J PHYS CHEM C, V112, P3899, DOI 10.1021/jp711194s; Riposan A, 2006, J PHYS CHEM B, V110, P23926, DOI 10.1021/jp063774w; Schreiber F, 2000, PROG SURF SCI, V65, P151, DOI 10.1016/S0079-6816(00)00024-1; Torrelles X, 2006, J PHYS CHEM B, V110, P5586, DOI 10.1021/jp054879m; Torrelles X, 2004, LANGMUIR, V20, P9396, DOI 10.1021/la048979f; Ulman A, 1996, CHEM REV, V96, P1533, DOI 10.1021/cr9502357; Ulrich J, 2006, J PHYS CHEM B, V110, P2462, DOI 10.1021/jp056455y; Vargas MC, 2001, J PHYS CHEM B, V105, P9509, DOI [10.1021/jp012241e, 10.1021/jp01224le]; Vericat C, 2006, J PHYS-CONDENS MAT, V18, pR867, DOI 10.1088/0953-8984/18/48/R01; Wang JG, 2007, J PHYS CHEM C, V111, P12149, DOI 10.1021/jp0745891; Whetten RL, 2007, SCIENCE, V318, P407, DOI 10.1126/science.1150176; Yu M, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.166102	27	270	272	5	144	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2008	321	5891					943	946		10.1126/science.1158532	http://dx.doi.org/10.1126/science.1158532			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	337LD	18703737				2022-12-28	WOS:000258436700033
J	King, AA; Ionides, EL; Pascual, M; Bouma, MJ				King, Aaron A.; Ionides, Edward L.; Pascual, Mercedes; Bouma, Menno J.			Inapparent infections and cholera dynamics	NATURE			English	Article							VIBRIO-CHOLERAE; ENDEMIC CHOLERA; CLIMATE; ENVIRONMENT; BANGLADESH; EPIDEMICS; DISEASE	In many infectious diseases, an unknown fraction of infections produce symptoms mild enough to go unrecorded, a fact that can seriously compromise the interpretation of epidemiological records. This is true for cholera, a pandemic bacterial disease, where estimates of the ratio of asymptomatic to symptomatic infections have ranged from 3 to 100 (refs 1-5). In the absence of direct evidence, understanding of fundamental aspects of cholera transmission, immunology and control has been based on assumptions about this ratio and about the immunological consequences of inapparent infections. Here we show that a model incorporating high asymptomatic ratio and rapidly waning immunity, with infection both from human and environmental sources, explains 50 yr of mortality data from 26 districts of Bengal, the pathogen's endemic home. We find that the asymptomatic ratio in cholera is far higher than had been previously supposed and that the immunity derived from mild infections wanes much more rapidly than earlier analyses have indicated. We find, too, that the environmental reservoir(5,6) (free-living pathogen) is directly responsible for relatively few infections but that it may be critical to the disease's endemicity. Our results demonstrate that inapparent infections can hold the key to interpreting the patterns of disease outbreaks. New statistical methods(7), which allow rigorous maximum likelihood inference based on dynamical models incorporating multiple sources and outcomes of infection, seasonality, process noise, hidden variables and measurement error, make it possible to test more precise hypotheses and obtain unexpected results. Our experience suggests that the confrontation of time-series data with mechanistic models is likely to revise our understanding of the ecology of many infectious diseases.	[King, Aaron A.; Pascual, Mercedes] Univ Michigan, Dept Ecol & Evolutionary Biol, Ann Arbor, MI 48109 USA; [King, Aaron A.] Univ Michigan, Dept Math, Ann Arbor, MI 48109 USA; [Ionides, Edward L.] Univ Michigan, Dept Stat, Ann Arbor, MI 48109 USA; [Pascual, Mercedes] Santa Fe Inst, Santa Fe, NM 87501 USA; [Bouma, Menno J.] Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; The Santa Fe Institute; University of London; London School of Hygiene & Tropical Medicine	King, AA (corresponding author), Univ Michigan, Dept Ecol & Evolutionary Biol, Ann Arbor, MI 48109 USA.	kingaa@umich.edu	King, Aaron A/B-8092-2012; Ibrahim, Essam Hassan/G-1960-2018	King, Aaron A/0000-0001-6159-3207; Ibrahim, Essam Hassan/0000-0003-0130-2257				AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Anisimova M, 2001, MOL BIOL EVOL, V18, P1585, DOI 10.1093/oxfordjournals.molbev.a003945; Barndorff-Nielsen O. E., 1994, INFERENCE ASYMPTOTIC; Bouma MJ, 2001, HYDROBIOLOGIA, V460, P147, DOI 10.1023/A:1013165215074; Burnham K.P., 2002, MODEL SELECTION MULT, V2nd, DOI [10.1007/b97636, DOI 10.1007/B97636]; Casella G., 2021, STAT INFERENCE; CASH RA, 1974, J INFECT DIS, V129, P45, DOI 10.1093/infdis/129.1.45; CASH RA, 1974, J INFECT DIS, V130, P325, DOI 10.1093/infdis/130.4.325; Faruque SM, 2005, P NATL ACAD SCI USA, V102, P1702, DOI 10.1073/pnas.0408992102; Faruque SM, 2005, P NATL ACAD SCI USA, V102, P6119, DOI 10.1073/pnas.0502069102; Feachem R G, 1982, Trop Dis Bull, V79, P1; GLASS RI, 1983, J INFECT DIS, V148, P998, DOI 10.1093/infdis/148.6.998; GLASS RI, 1982, AM J EPIDEMIOL, V116, P959, DOI 10.1093/oxfordjournals.aje.a113498; Glass Roger I., 1992, P129; Hartley DM, 2006, PLOS MED, V3, P63, DOI 10.1371/journal.pmed.0030007; Hilborn Ray, 1997, V28; Huq A, 2005, APPL ENVIRON MICROB, V71, P4645, DOI 10.1128/AEM.71.8.4645-4654.2005; Ionides EL, 2006, P NATL ACAD SCI USA, V103, P18438, DOI 10.1073/pnas.0603181103; ISLAM MS, 1993, J DIARRHOEAL DIS RES, V11, P197; Jensen MA, 2006, P NATL ACAD SCI USA, V103, P4652, DOI 10.1073/pnas.0600166103; KAPER JB, 1995, CLIN MICROBIOL REV, V8, P48, DOI 10.1128/CMR.8.1.48; Kloeden P.E., 1999, NUMERICAL SOLUTION S; Koelle K, 2004, AM NAT, V163, P901, DOI 10.1086/420798; Koelle K, 2005, NATURE, V436, P696, DOI 10.1038/nature03820; Le vine MM, 1981, ACUTE ENTERIC INFECT, P443; MCCORMACK WM, 1969, AM J EPIDEMIOL, V89, P658, DOI 10.1093/oxfordjournals.aje.a120979; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; R Development Core Team, 2007, R LANG ENV STAT COMP; Rice JA, 1988, MATH STAT DATA ANAL; Rodo X, 2002, P NATL ACAD SCI USA, V99, P12901, DOI 10.1073/pnas.182203999; Sack DA, 2004, LANCET, V363, P223, DOI 10.1016/S0140-6736(03)15328-7; Sack RB, 2003, J INFECT DIS, V187, P96, DOI 10.1086/345865; SELF SG, 1987, J AM STAT ASSOC, V82, P605, DOI 10.2307/2289471; SIDDIQUE AK, 1991, LANCET, V337, P1125, DOI 10.1016/0140-6736(91)92789-5; VANDELINDE PA, 1965, B WORLD HEALTH ORGAN, V32, P515; *WHO, 1950, WKL EP REC	36	289	293	2	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 14	2008	454	7206					877	U29		10.1038/nature07084	http://dx.doi.org/10.1038/nature07084			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	336XH	18704085	Green Published			2022-12-28	WOS:000258398600034
J	Huertas, P; Cortes-Ledesma, F; Sartori, AA; Aguilera, A; Jackson, SP				Huertas, Pablo; Cortes-Ledesma, Felipe; Sartori, Alessandro A.; Aguilera, Andres; Jackson, Stephen P.			CDK targets Sae2 to control DNA-end resection and homologous recombination	NATURE			English	Article							DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; REPAIR PATHWAYS; DAMAGE RESPONSE; KINASE-ACTIVITY; PROTEIN-KINASE; MRE11 COMPLEX; HUMAN CTIP; GENE	DNA double- strand breaks ( DSBs) are repaired by two principal mechanisms: non- homologous end- joining ( NHEJ) and homologous recombination ( HR)(1). HR is the most accurate DSB repair mechanism but is generally restricted to the S and G2 phases of the cell cycle, when DNA has been replicated and a sister chromatid is available as a repair template(2-5). By contrast, NHEJ operates throughout the cell cycle but assumes most importance in G1 ( refs 4, 6). The choice between repair pathways is governed by cyclindependent protein kinases (CDKs)(2,3,5,7), with a major site of control being at the level of DSB resection, an event that is necessary for HR but not NHEJ, and which takes place most effectively in S and G2 ( refs 2, 5). Here we establish that cell- cycle control of DSB resection in Saccharomyces cerevisiae results from the phosphorylation by CDK of an evolutionarily conserved motif in the Sae2 protein. We show that mutating Ser 267 of Sae2 to a non- phosphorylatable residue causes phenotypes comparable to those of a sae2 Delta null mutant, including hypersensitivity to camptothecin, defective sporulation, reduced hairpin- induced recombination, severely impaired DNA- end processing and faulty assembly and disassembly of HR factors. Furthermore, a Sae2 mutation that mimics constitutive Ser 267 phosphorylation complements these phenotypes and overcomes the necessity of CDK activity for DSB resection. The Sae2 mutations also cause cell- cycle- stage specific hypersensitivity to DNA damage and affect the balance between HR and NHEJ. These findings therefore provide amechanistic basis for cell- cycle control of DSB repair and highlight the importance of regulating DSB resection.	[Huertas, Pablo; Sartori, Alessandro A.; Jackson, Stephen P.] Univ Cambridge, Wellcome Trust & Canc Res UK Gurdon Inst, Cambridge CB2 1QN, England; [Huertas, Pablo; Sartori, Alessandro A.; Jackson, Stephen P.] Univ Cambridge, Dept Zool, Cambridge CB2 1QN, England; [Cortes-Ledesma, Felipe; Aguilera, Andres] Univ Seville, CSIC, Ctr Andaluz Biol Mol & Med Regenerat, CABIMER, Seville 41092, Spain	University of Cambridge; University of Cambridge; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; University of Sevilla; CSIC - Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER)	Jackson, SP (corresponding author), Univ Cambridge, Wellcome Trust & Canc Res UK Gurdon Inst, Tennis Court Rd, Cambridge CB2 1QN, England.	s.jackson@gurdon.cam.ac.uk	Ledesma, Felipe Cortés/F-4803-2014; Jackson, Stephen Philip/R-4548-2019; Sartori, Alessandro/AAK-7840-2021; Aguilera, Andres/L-1825-2014; Huertas, Pablo/N-2245-2016; Dry, Kate/I-2328-2014	Ledesma, Felipe Cortés/0000-0002-0440-6783; Jackson, Stephen Philip/0000-0001-9317-7937; Sartori, Alessandro/0000-0003-2770-0333; Aguilera, Andres/0000-0003-4782-1714; Huertas, Pablo/0000-0002-1756-4449; 	Long- Term EMBO Fellowship; Swiss National Foundation Grant; Cancer Research UK; European Community [LSHG-CT-2005-512113)]; Spanish Ministry of Science and Education [BFU2006-05, CDS2007-0015260]; Junta de Andalucia [CVI624]	Long- Term EMBO Fellowship(European Molecular Biology Organization (EMBO)); Swiss National Foundation Grant(Swiss National Science Foundation (SNSF)); Cancer Research UK(Cancer Research UK); European Community(European Commission); Spanish Ministry of Science and Education(Spanish Government); Junta de Andalucia(Junta de Andalucia)	We thank M. P. Longhese, R. Rothstein, K. Lobachev, M. Lichten and M. Foiani for providing strains, and R. Driscoll, S. Gravel, K. Dry and K. Miller for helpful discussions and comments on the manuscript. P. H. is the recipient of a Long- Term EMBO Fellowship. A. A. S. is supported by a Swiss National Foundation Grant. The S. P. J. laboratory is supported by grants from Cancer Research UK and the European Community ( Integrated Project DNA repair, grant LSHG-CT-2005-512113). The A. A. laboratory is supported by grants from the Spanish Ministry of Science and Education (BFU2006-05260 and CDS2007-0015) and Junta de Andalucia (CVI624).	Aylon Y, 2004, EMBO J, V23, P4868, DOI 10.1038/sj.emboj.7600469; Aylon Y, 2004, DNA REPAIR, V3, P797, DOI 10.1016/j.dnarep.2004.04.013; Baroni E, 2004, MOL CELL BIOL, V24, P4151, DOI 10.1128/MCB.24.10.4151-4165.2004; Bishop AC, 2000, NATURE, V407, P395, DOI 10.1038/35030148; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Caspari T, 2002, GENE DEV, V16, P1195, DOI 10.1101/gad.221402; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Clerici M, 2005, J BIOL CHEM, V280, P38631, DOI 10.1074/jbc.M508339200; Cortes-Ledesma F, 2006, EMBO REP, V7, P919, DOI 10.1038/sj.embor.7400774; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; Hinz JM, 2005, DNA REPAIR, V4, P782, DOI 10.1016/j.dnarep.2005.03.005; Ira G, 2004, NATURE, V431, P1011, DOI 10.1038/nature02964; Karathanasis E, 2002, GENETICS, V161, P1015; Lazzaro F, 2008, EMBO J, V27, P1502, DOI 10.1038/emboj.2008.81; Lee K, 2007, GENETICS, V176, P2003, DOI 10.1534/genetics.107.076539; Lengsfeld BM, 2007, MOL CELL, V28, P638, DOI 10.1016/j.molcel.2007.11.001; Limbo O, 2007, MOL CELL, V28, P134, DOI 10.1016/j.molcel.2007.09.009; Lisby M, 2004, CELL, V118, P699, DOI 10.1016/j.cell.2004.08.015; Lobachev KS, 2002, CELL, V108, P183, DOI 10.1016/S0092-8674(02)00614-1; McKee AHZ, 1997, GENETICS, V146, P797; Mendenhall MD, 1998, MICROBIOL MOL BIOL R, V62, P1191, DOI 10.1128/MMBR.62.4.1191-1243.1998; Neale MJ, 2005, NATURE, V436, P1053, DOI 10.1038/nature03872; Penkner A, 2007, EMBO J, V26, P5071, DOI 10.1038/sj.emboj.7601916; Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977; Prinz S, 1997, GENETICS, V146, P781; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rattray AJ, 2001, GENETICS, V158, P109; Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337; Shrivastav M, 2008, CELL RES, V18, P134, DOI 10.1038/cr.2007.111; Sugawara N, 2006, METHOD ENZYMOL, V408, P416, DOI 10.1016/S0076-6879(06)08026-8; Uanschou C, 2007, EMBO J, V26, P5061, DOI 10.1038/sj.emboj.7601913	31	347	355	2	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 2	2008	455	7213					689	U86		10.1038/nature07215	http://dx.doi.org/10.1038/nature07215			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	354KY	18716619	Green Accepted			2022-12-28	WOS:000259639700052
J	Yang, ZL; Stratton, C; Francis, PJ; Kleinman, ME; Tan, PL; Gibbs, D; Tong, ZZ; Chen, HY; Constantine, R; Yang, X; Chen, YH; Zeng, JX; Davey, L; Ma, XN; Hau, VS; Wang, C; Harmon, J; Buehler, J; Pearson, E; Patel, S; Kaminoh, Y; Watkins, S; Luo, L; Zabriskie, NA; Bernstein, PS; Cho, WG; Schwager, A; Hinton, DR; Klein, ML; Hamon, SC; Simmons, E; Yu, BF; Campochiaro, B; Sunness, JS; Campochiaro, P; Jorde, L; Parmigiani, G; Zack, DJ; Katsanis, N; Ambati, J; Zhang, K				Yang, Zhenglin; Stratton, Charity; Francis, Peter J.; Kleinman, Mark E.; Tan, Perciliz L.; Gibbs, Daniel; Tong, Zongzhong; Chen, Haoyu; Constantine, Ryan; Yang, Xian; Chen, Yuhong; Zeng, Jiexi; Davey, Lisa; Ma, Xiang; Hau, Vincent S.; Wang, Chi; Harmon, Jennifer; Buehler, Jeanette; Pearson, Erik; Patel, Shrena; Kaminoh, Yuuki; Watkins, Scott; Luo, Ling; Zabriskie, Norman A.; Bernstein, Paul S.; Cho, Wongil; Schwager, Andrea; Hinton, David R.; Klein, Michael L.; Hamon, Sara C.; Simmons, Emily; Yu, Beifeng; Campochiaro, Betsy; Sunness, Janet S.; Campochiaro, Peter; Jorde, Lynn; Parmigiani, Giovanni; Zack, Donald J.; Katsanis, Nicholas; Ambati, Jayakrishna; Zhang, Kang			Toll-like receptor 3 and geographic atrophy in age-related macular degeneration	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMPLEMENT FACTOR-H; DOUBLE-STRANDED-RNA; UTAH MORMONS; GENETIC-STRUCTURE; BLOOD-GROUPS; RISK; VARIANT; SUSCEPTIBILITY; HAPLOTYPE; DNA	BACKGROUND Age- related macular degeneration is the most common cause of irreversible visual impairment in the developed world. Advanced age- related macular degeneration consists of geographic atrophy and choroidal neovascularization. The specific genetic variants that predispose patients to geographic atrophy are largely unknown. METHODS We tested for an association between the functional toll- like receptor 3 gene ( TLR3) variant rs3775291 ( involving the substitution of phenylalanine for leucine at amino acid 412) and age- related macular degeneration in Americans of European descent. We also tested for the effect of TLR3 Leu and Phe variants on the viability of human retinal pigment epithelial cells in vitro and on apoptosis of retinal pigment epithelial cells from wild- type mice and Tlr3- knockout ( Tlr3(-/-)) mice. RESULTS The Phe variant ( encoded by the T allele at rs3775291) was associated with protection against geographic atrophy ( P = 0.005). This association was replicated in two independent case - control series of geographic atrophy ( P = 5.43 x 10(-4) and P = 0.002). No association was found between TLR3 variants and choroidal neovascularization. A prototypic TLR3 ligand induced apoptosis in a greater fraction of human retinal pigment epithelial cells with the Leu - Leu genotype than those with the Leu - Phe genotype and in a greater fraction of wild- type mice than Tlr3(-/-) mice. CONCLUSIONS The TLR3 412Phe variant confers protection against geographic atrophy, probably by suppressing the death of retinal pigment epithelial cells. Since double- stranded RNA ( dsRNA) can activate TLR3- mediated apoptosis, our results suggest a role of viral dsRNA in the development of geographic atrophy and point to the potential toxic effects of short- interfering- RNA therapies in the eye.	[Yang, Zhenglin; Chen, Haoyu; Yang, Xian; Chen, Yuhong; Zeng, Jiexi; Zhang, Kang] Univ Calif San Diego, Shiley Eye Ctr, San Diego, CA 92037 USA; [Tan, Perciliz L.; Davey, Lisa; Wang, Chi; Campochiaro, Betsy; Sunness, Janet S.; Campochiaro, Peter; Parmigiani, Giovanni; Zack, Donald J.; Katsanis, Nicholas] Johns Hopkins Univ, Inst Med Genet, Baltimore, MD 21205 USA; [Yang, Zhenglin] Sichuan Acad Med Sci, Chengdu, Peoples R China; [Yang, Zhenglin] Sichuan Prov Peoples Hosp, Chengdu, Peoples R China; [Yang, Zhenglin; Stratton, Charity; Gibbs, Daniel; Tong, Zongzhong; Chen, Haoyu; Constantine, Ryan; Yang, Xian; Chen, Yuhong; Zeng, Jiexi; Ma, Xiang; Hau, Vincent S.; Harmon, Jennifer; Buehler, Jeanette; Pearson, Erik; Patel, Shrena; Kaminoh, Yuuki; Watkins, Scott; Luo, Ling; Zabriskie, Norman A.; Bernstein, Paul S.; Schwager, Andrea; Yu, Beifeng; Jorde, Lynn; Zhang, Kang] Univ Utah, Sch Med, Salt Lake City, UT USA; [Francis, Peter J.; Klein, Michael L.; Simmons, Emily] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Kleinman, Mark E.; Cho, Wongil; Ambati, Jayakrishna] Univ Kentucky, Lexington, KY USA; [Sunness, Janet S.] Greater Baltimore Med Ctr, Baltimore, MD USA; [Hinton, David R.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA; [Hamon, Sara C.] Rockefeller Univ, New York, NY 10021 USA; [Zhang, Kang] Peking Univ, Inst Mol Med, Beijing 100871, Peoples R China	University of California System; University of California San Diego; Johns Hopkins University; Sichuan Provincial People's Hospital; Sichuan Provincial People's Hospital; Utah System of Higher Education; University of Utah; Oregon Health & Science University; University of Kentucky; Greater Baltimore Medical Center; University of Southern California; Rockefeller University; Peking University	Zhang, K (corresponding author), Univ Calif San Diego, Shiley Eye Ctr, San Diego, CA 92037 USA.	nkatsan1@jhmi.edu; kangzhang@ucsd.edu	Zhang, Kang/Y-2740-2019; Chen, Haoyu/A-7432-2013; Katsanis, Nicholas/E-1837-2012; Mitchell, Paul/P-1498-2014; Chu, Kai On/E-2325-2016; Ma, Xiang/E-4173-2013	Zhang, Kang/0000-0002-4549-1697; Chen, Haoyu/0000-0003-0676-4610; Ma, Xiang/0000-0001-9427-8385; Katsanis, Nicholas/0000-0002-2480-0171; Sunness, Janet/0000-0001-8823-0780; Zack, Don/0000-0002-7966-1973; Blum, Emily/0000-0002-3110-9944	National Institutes of Health; Veterans Affairs Merit Award; Foundation Fighting Blindness; Macula Vision Research Foundation; Ruth and Milton Steinbach Fund; Research to Prevent Blindness; Burroughs Wellcome Fund Clinical Scientist Award in Translational Research; American Health Assistance Foundation; Dr. E. Vernon & Eloise C. Smith Endowment Fund; Arnold and Mabel Beckman Foundation; Alcon; GlaxoSmithKline; Alimera; Genentech; CoMentis; Quark Pharmaceuticals; Allergan; Acucela; Oxigene; NATIONAL EYE INSTITUTE [R01EY014428, R01EY014448] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veterans Affairs Merit Award(US Department of Veterans Affairs); Foundation Fighting Blindness(European Commission); Macula Vision Research Foundation; Ruth and Milton Steinbach Fund; Research to Prevent Blindness(Research to Prevent Blindness (RPB)); Burroughs Wellcome Fund Clinical Scientist Award in Translational Research(Burroughs Wellcome Fund); American Health Assistance Foundation; Dr. E. Vernon & Eloise C. Smith Endowment Fund; Arnold and Mabel Beckman Foundation; Alcon(Novartis); GlaxoSmithKline(GlaxoSmithKline); Alimera; Genentech(Roche HoldingGenentech); CoMentis; Quark Pharmaceuticals; Allergan(AbbVieAllergan); Acucela; Oxigene; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	Supported by grants from the National Institutes of Health (to Drs. Klein, Campochiaro, Zack, Katsanis, Ambati, and Zhang); a Veterans Affairs Merit Award (to Dr. Zhang); grants from the Foundation Fighting Blindness (to Drs. Francis, Campochiaro, Zack, Katsanis, and Zhang), the Macula Vision Research Foundation (to Drs. Katsanis, Ambati, and Zhang), the Ruth and Milton Steinbach Fund (to Drs. Campochiaro, Zack, and Zhang), and Research to Prevent Blindness ( to Drs. Francis, Campochiaro, Zack, Ambati, and Zhang); a Burroughs Wellcome Fund Clinical Scientist Award in Translational Research ( to Drs. Ambati and Zhang); grants from the American Health Assistance Foundation ( to Drs. Z. Yang, Ambati, and Zhang), the Dr. E. Vernon & Eloise C. Smith Endowment Fund ( to Dr. Ambati), and the Arnold and Mabel Beckman Foundation ( to Dr. Hinton); and generous gifts from the Guerrieri Family Foundation and from Robert and Clarice Smith ( to Dr. Zack).; Dr. Campochiaro reports receiving grant support from Alcon, GlaxoSmithKline, Alimera, Genentech, and CoMentis. Dr. Zack reports receiving consulting fees from Alcon, Fovea, and Novartis, receiving lecture fees from Alcon, owning equity in Merck and Pfizer, and receiving grant support from Alcon and Fovea. Dr. Ambati reports receiving consulting fees from Quark Pharmaceuticals and Allergan and being listed on a patent on TLR3 that has been applied for by the University of Kentucky. Dr. Zhang reports having an equity interest in Navigen, receiving grant support and lecture fees from Genentech, and receiving consulting fees from Acucela and Oxigene. No other potential conflict of interest relevant to this article was reported.; We thank the participants and their families; the staff of the Ambati, Katsanis, and Zhang laboratories; Jonathan Stoddard, Bradley Katz, Robert Kwan, Gregory Brinton, John Carver, John Brand, Lisa Schneider, Adam Jorgenson, Neil Bressler, Mary Gail Engle, and Christine Spee for assistance in obtaining blood samples and technical assistance; and Dr. Guy Zimmerman for critical reading of a draft of the manuscript.	ABRAMSON HJ, 2001, COMPUTER PROGRAMS EP; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157; Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807; Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; Enari M, 1998, NATURE, V393, P396, DOI 10.1038/30782; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gitlin L, 2006, P NATL ACAD SCI USA, V103, P8459, DOI 10.1073/pnas.0603082103; Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750; Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180; Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; Hughes AE, 2007, NAT GENET, V39, P567, DOI 10.1038/ng0407-567c; Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890; Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437; Kariko K, 2004, J IMMUNOL, V172, P6545, DOI 10.4049/jimmunol.172.11.6545; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005; Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873; Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131; Marchini J, 2004, NAT GENET, V36, P512, DOI 10.1038/ng1337; MCLELLAN T, 1984, AM J HUM GENET, V36, P836; OBRIEN E, 1994, HUM BIOL, V66, P743; OBrien E, 1996, AM J HUM BIOL, V8, P609, DOI 10.1002/(SICI)1520-6300(1996)8:5<609::AID-AJHB6>3.0.CO;2-Q; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106; Schroder M, 2005, TRENDS IMMUNOL, V26, P462, DOI 10.1016/j.it.2005.07.002; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811; Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154; 1999, 1 AREDS, V20, P573	42	171	187	1	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 2	2008	359	14					1456	U57		10.1056/NEJMoa0802437	http://dx.doi.org/10.1056/NEJMoa0802437			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354ID	18753640	Green Accepted			2022-12-28	WOS:000259631700006
J	Parsons, DW; Jones, S; Zhang, XS; Lin, JCH; Leary, RJ; Angenendt, P; Mankoo, P; Carter, H; Siu, IM; Gallia, GL; Olivi, A; McLendon, R; Rasheed, BA; Keir, S; Nikolskaya, T; Nikolsky, Y; Busam, DA; Tekleab, H; Diaz, LA; Hartigan, J; Smith, DR; Strausberg, RL; Marie, SKN; Shinjo, SMO; Yan, H; Riggins, GJ; Bigner, DD; Karchin, R; Papadopoulos, N; Parmigiani, G; Vogelstein, B; Velculescu, VE; Kinzler, KW				Parsons, D. Williams; Jones, Sian; Zhang, Xiaosong; Lin, Jimmy Cheng-Ho; Leary, Rebecca J.; Angenendt, Philipp; Mankoo, Parminder; Carter, Hannah; Siu, I-Mei; Gallia, Gary L.; Olivi, Alessandro; McLendon, Roger; Rasheed, B. Ahmed; Keir, Stephen; Nikolskaya, Tatiana; Nikolsky, Yuri; Busam, Dana A.; Tekleab, Hanna; Diaz, Luis A., Jr.; Hartigan, James; Smith, Doug R.; Strausberg, Robert L.; Marie, Suely Kazue Nagahashi; Shinjo, Sueli Mieko Oba; Yan, Hai; Riggins, Gregory J.; Bigner, Darell D.; Karchin, Rachel; Papadopoulos, Nick; Parmigiani, Giovanni; Vogelstein, Bert; Velculescu, Victor E.; Kinzler, Kenneth W.			An integrated genomic analysis of human glioblastoma Multiforme	SCIENCE			English	Article							NADP(+)-DEPENDENT ISOCITRATE DEHYDROGENASE; SECONDARY GLIOBLASTOMA; COLORECTAL CANCERS; MALIGNANT GLIOMAS; GENETIC PATHWAYS; HUMAN BREAST; PIK3CA GENE; MUTATIONS; EXPRESSION; FREQUENCY	Glioblastoma multiforme ( GBM) is the most common and lethal type of brain cancer. To identify the genetic alterations in GBMs, we sequenced 20,661 protein coding genes, determined the presence of amplifications and deletions using high- density oligonucleotide arrays, and performed gene expression analyses using next- generation sequencing technologies in 22 human tumor samples. This comprehensive analysis led to the discovery of a variety of genes that were not known to be altered in GBMs. Most notably, we found recurrent mutations in the active site of isocitrate dehydrogenase 1 ( IDH1) in 12% of GBM patients. Mutations in IDH1 occurred in a large fraction of young patients and in most patients with secondary GBMs and were associated with an increase in overall survival. These studies demonstrate the value of unbiased genomic analyses in the characterization of human brain cancer and identify a potentially useful genetic alteration for the classification and targeted therapy of GBMs.	[Parsons, D. Williams; Jones, Sian; Zhang, Xiaosong; Lin, Jimmy Cheng-Ho; Leary, Rebecca J.; Angenendt, Philipp; Diaz, Luis A., Jr.; Papadopoulos, Nick; Parmigiani, Giovanni; Vogelstein, Bert; Velculescu, Victor E.; Kinzler, Kenneth W.] Johns Hopkins Kimmel Canc Ctr, Ludwig Ctr Canc Genet & Therapeut, Baltimore, MD 21231 USA; [Parsons, D. Williams; Jones, Sian; Zhang, Xiaosong; Lin, Jimmy Cheng-Ho; Leary, Rebecca J.; Angenendt, Philipp; Diaz, Luis A., Jr.; Papadopoulos, Nick; Parmigiani, Giovanni; Vogelstein, Bert; Velculescu, Victor E.; Kinzler, Kenneth W.] Johns Hopkins Kimmel Canc Ctr, Howard Hughes Med Inst, Baltimore, MD 21231 USA; [Parsons, D. Williams] Baylor Coll Med, Dept Pediat, Hematol Oncol Sect, Houston, TX 77030 USA; [Mankoo, Parminder; Carter, Hannah; Karchin, Rachel] Johns Hopkins Med Inst, Dept Biomed Engn, Inst Computat Med, Baltimore, MD 21218 USA; [Siu, I-Mei; Gallia, Gary L.; Olivi, Alessandro; Riggins, Gregory J.] Johns Hopkins Med Inst, Dept Neurosurg, Baltimore, MD 21231 USA; [McLendon, Roger; Rasheed, B. Ahmed; Keir, Stephen; Yan, Hai; Bigner, Darell D.] Duke Univ, Med Ctr, Dept Pathol, Pediat Brain Tumor Fdn, Durham, NC 27710 USA; [McLendon, Roger; Rasheed, B. Ahmed; Keir, Stephen; Yan, Hai; Bigner, Darell D.] Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr, Durham, NC 27710 USA; [Nikolskaya, Tatiana] Vavilov Inst Gen Genet, Moscow 117809, Russia; [Nikolsky, Yuri] GeneGo Inc, St Joseph, MI 49085 USA; [Busam, Dana A.; Tekleab, Hanna; Strausberg, Robert L.] J Craig Venter Inst, Rockville, MD 20850 USA; [Hartigan, James; Smith, Doug R.] Agencourt Biosci Corp, Beverly, MA 01915 USA; [Marie, Suely Kazue Nagahashi; Shinjo, Sueli Mieko Oba] Univ Sao Paulo, Sch Med, Dept Neurol, Sao Paulo, Brazil	Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; Baylor College of Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Duke University; Duke University; Russian Academy of Sciences; Vavilov Institute of General Genetics; J. Craig Venter Institute; Universidade de Sao Paulo	Vogelstein, B (corresponding author), Johns Hopkins Kimmel Canc Ctr, Ludwig Ctr Canc Genet & Therapeut, Baltimore, MD 21231 USA.	bertvog@gmail.com; velculescu@jhmi.edu; kinzlke@jhmi.edu	Nikolskaya, Tatiana/M-5008-2013; wang, edwin/G-5372-2010; Karchin, Rachel/A-3385-2010; Olivi, Alessandro/K-6531-2016; Oba-Shinjo, Sueli M./C-4017-2012; Velculescu, Victor/ABF-4846-2020; Jones, Sian/A-5050-2012; Papadopoulos, Nickolas/K-7272-2012; Marie, Suely Kazue Nagahashi/D-1870-2012; Carter, Hannah/R-8425-2017	Olivi, Alessandro/0000-0002-4489-7564; Oba-Shinjo, Sueli M./0000-0002-1650-5973; Velculescu, Victor/0000-0003-1195-438X; Marie, Suely Kazue Nagahashi/0000-0003-4419-7928; Parsons, Donald/0000-0002-8775-3501; Karchin, Rachel/0000-0002-5069-1239; Carter, Hannah/0000-0002-1729-2463; Diaz, Luis/0000-0002-7079-8914; Edsall, Lee Elizabeth/0000-0002-0326-2829	Ludwig Fund for Cancer Research; NIH [CA121113, NS052507, CA43460, CA57345, CA62924, CA09547, 5P50-NS-20023, CA108786, CA11898]; Pew Charitable Trusts; Pediatric Brain Tumor Foundation Institute; Hirschhorn Foundation; Alex's Lemonade Stand Foundation; American Brain Tumor Association; American Society of Clinical Oncology; Brain Tumor Research Fund; Beckman Coulter Corporation; NATIONAL CANCER INSTITUTE [R01CA140316, R01CA011898, R37CA057345, P50CA108786, T32CA009547, R37CA011898, R01CA043460, P50CA062924, R37CA043460, R01CA121113, R01CA057345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS052507, P50NS020023] Funding Source: NIH RePORTER	Ludwig Fund for Cancer Research; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pew Charitable Trusts; Pediatric Brain Tumor Foundation Institute; Hirschhorn Foundation; Alex's Lemonade Stand Foundation; American Brain Tumor Association; American Society of Clinical Oncology; Brain Tumor Research Fund; Beckman Coulter Corporation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank N. Silliman, J. Ptak, L. Dobbyn, and M. Whalen for assistance with PCR amplification; D. Lister, L. J. Ehinger, D. L. Satterfield, J. D. Funkhouser, and P. Killela for assistance with DNA purification; T. Sjoblom for assistance with database management; the Agencourt sequencing team for assistance with automated sequencing; and C.-S. Liu and the SoftGenetics team for their assistance with mutation detection analyses. This project was carried out under the auspices of the Ludwig Brain Tumor Initiative and was supported by the Virginia and D. K. Ludwig Fund for Cancer Research, NIH grants CA121113, NS052507, CA43460, CA57345, CA62924, CA09547, 5P50-NS-20023, CA108786, and CA11898, the Pew Charitable Trusts, the Pediatric Brain Tumor Foundation Institute, the Hirschhorn Foundation, Alex's Lemonade Stand Foundation, the American Brain Tumor Association, the American Society of Clinical Oncology, the Brain Tumor Research Fund and Beckman Coulter Corporation. Under separate licensing agreements between the Johns Hopkins University and Genzyme, Beckman Coulter, and Exact Sciences Corporations, B. V., V. E. V., and K.W. K. are entitled to a share of royalties received by the university on sales of products related to research described in this paper. These authors and the university own Genzyme and Exact Sciences stock, which is subject to certain restrictions under university policy. The terms of these arrangements are managed by the Johns Hopkins University in accordance with its conflict-of-interest policies.	Broderick DK, 2004, CANCER RES, V64, P5048, DOI 10.1158/0008-5472.CAN-04-1170; Cahill DP, 2007, CLIN CANCER RES, V13, P2038, DOI 10.1158/1078-0432.CCR-06-2149; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Ekins S, 2007, METH MOL B, V356, P319; Frederick L, 2000, CANCER RES, V60, P1383; Gallia GL, 2006, MOL CANCER RES, V4, P709, DOI 10.1158/1541-7786.MCR-06-0172; Geisbrecht BV, 1999, J BIOL CHEM, V274, P30527, DOI 10.1074/jbc.274.43.30527; Hunter C, 2006, CANCER RES, V66, P3987, DOI 10.1158/0008-5472.CAN-06-0127; Jennings GT, 1997, BIOCHEMISTRY-US, V36, P13743, DOI 10.1021/bi970916r; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105; KARCHIN R, 2008, STRUCTURAL MODELS MU; Kil IS, 2007, FREE RADICAL BIO MED, V43, P1197, DOI 10.1016/j.freeradbiomed.2007.07.009; Kim SY, 2007, MOL CELL BIOCHEM, V302, P27, DOI 10.1007/s11010-007-9421-x; Kleihues P, 1999, Neuro Oncol, V1, P44, DOI 10.1093/neuonc/1.1.44; KRAUSRUP.R, 1973, J COMP NEUROL, V148, P211, DOI 10.1002/cne.901480206; LEARY RJ, IN PRESS P NATL ACAD; Lee SM, 2002, FREE RADICAL BIO MED, V32, P1185, DOI 10.1016/S0891-5849(02)00815-8; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lin J, 2007, GENOME RES, V17, P1304, DOI 10.1101/gr.6431107; Lister R, 2008, CELL, V133, P523, DOI 10.1016/j.cell.2008.03.029; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Maher EA, 2006, CANCER RES, V66, P11502, DOI 10.1158/0008-5472.CAN-06-2072; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Mizoguchi M, 2004, BRAIN PATHOL, V14, P372, DOI 10.1111/j.1750-3639.2004.tb00080.x; Morin RD, 2008, BIOTECHNIQUES, V45, P81, DOI 10.2144/000112900; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Nekrutenko A, 1998, MOL BIOL EVOL, V15, P1674, DOI 10.1093/oxfordjournals.molbev.a025894; Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011; Saha S, 2002, NAT BIOTECHNOL, V20, P508, DOI 10.1038/nbt0502-508; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; SCHERER JH, 1940, AM J CANCER, V40, P159; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Steemers FJ, 2006, NAT METHODS, V3, P31, DOI 10.1038/NMETH842; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Sultan M, 2008, SCIENCE, V321, P956, DOI 10.1126/science.1160342; Thiel G, 1995, ANTICANCER RES, V15, P2495; Tso CL, 2006, CANCER RES, V66, P159, DOI 10.1158/0008-5472.CAN-05-0077; Ueki K, 1996, CANCER RES, V56, P150; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Winter JM, 2006, CANCER BIOL THER, V5, P360, DOI 10.4161/cbt.5.4.2552; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Xu X, 2004, J BIOL CHEM, V279, P33946, DOI 10.1074/jbc.M404298200	47	4195	4441	9	399	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 26	2008	321	5897					1807	1812		10.1126/science.1164382	http://dx.doi.org/10.1126/science.1164382			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	352MM	18772396	Green Accepted			2022-12-28	WOS:000259501300030
J	Yamagishi, Y; Sakuno, T; Shimura, M; Watanabe, Y				Yamagishi, Yuya; Sakuno, Takeshi; Shimura, Mari; Watanabe, Yoshinori			Heterochromatin links to centromeric protection by recruiting shugoshin	NATURE			English	Article							PROTEIN PHOSPHATASE 2A; FISSION YEAST; CELL-CYCLE; MEIOSIS-I; COHESION; HP1; PHOSPHORYLATION; LOCALIZATION; CHROMOSOME; METHYLATION	The centromere of a chromosome is composed mainly of two domains, a kinetochore assembling core centromere and pericentromeric heterochromatin regions(1,2). The crucial role of centromeric heterochromatin is still unknown, because even in simpler unicellular organisms such as the fission yeast Schizosaccharomyces pombe, the heterochromatin protein Swi6 ( HP1 homologue) has several functions at centromeres, including silencing gene expression and recombination, enriching cohesin, promoting kinetochore assembly, and, ultimately, preventing erroneous microtubule attachment to the kinetochores(1,3-6). Here we show that the requirement of heterochromatin for mitotic chromosome segregation is largely replaced by forcibly enriching cohesin at centromeres in fission yeast. However, this enrichment of cohesin is not sufficient to replace the meiotic requirement for heterochromatin. We find that the heterochromatin protein Swi6 associates directly with meiosis- specific shugoshin Sgo1, a protector of cohesin at centromeres. A point mutation of Sgo1 (V242E), which abolishes the interaction with Swi6, impairs the centromeric localization and function of Sgo1. The forced centromeric localization of Sgo1 restores proper meiotic chromosome segregation in swi6 Delta cells. We also show that the direct link between HP1 and shugoshin is conserved in human cells. Taken together, our findings suggest that the recruitment of shugoshin is the important primary role for centromeric heterochromatin in ensuring eukaryotic chromosome segregation.	[Yamagishi, Yuya; Sakuno, Takeshi; Watanabe, Yoshinori] Univ Tokyo, Lab Chromosome Dynam, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan; [Yamagishi, Yuya; Sakuno, Takeshi; Watanabe, Yoshinori] Univ Tokyo, Grad Program Biophys & Biochem, Grad Sch Sci, Tokyo 1130032, Japan; [Shimura, Mari] Int Med Ctr Japan, Dept Intractable Dis, Tokyo 1628655, Japan	University of Tokyo; University of Tokyo; National Center for Global Health & Medicine - Japan	Watanabe, Y (corresponding author), Univ Tokyo, Lab Chromosome Dynam, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan.	ywatanab@iam.u-tokyo.ac.jp	Sakuno, Takeshi/Y-9478-2019	Watanabe, Yoshinori/0000-0002-5488-4812	Global COE programme (Integrative life Science Based on the Study of Biosignaling Mechanisms); MEXT, Japan; Toray Science Foundation; Grants-in-Aid for Research on Advanced Medical Technology; Ministry of Health, Labour and Welfare	Global COE programme (Integrative life Science Based on the Study of Biosignaling Mechanisms)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); MEXT, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Toray Science Foundation(Toray Industries, Inc.); Grants-in-Aid for Research on Advanced Medical Technology(Ministry of Health, Labour and Welfare, Japan); Ministry of Health, Labour and Welfare(Ministry of Health, Labour and Welfare, Japan)	We thank S. Hauf for reading the manuscript critically; R. Allshire, S. Grewal and the Yeast Genetic Resource Center (YGRC) for yeast strains; J.-i. Nakayama for Swi6 antibody; and all the members of our laboratory for their valuable support and discussion. This work was supported in part by the Global COE programme (Integrative life Science Based on the Study of Biosignaling Mechanisms), MEXT, Japan, the Toray Science Foundation (to Y.W.), Special Coordination Funds for Promoting Science and Technology (to T. S.) and Grants-in-Aid for Research on Advanced Medical Technology, Ministry of Health, Labour and Welfare (to M. S.) and for Specially Promoted Research, MEXT, Japan ( to Y.W.).	Amor DJ, 2004, TRENDS CELL BIOL, V14, P359, DOI 10.1016/j.tcb.2004.05.009; Bernard P, 2001, SCIENCE, V294, P2539, DOI 10.1126/science.1064027; Fischle W, 2005, NATURE, V438, P1116, DOI 10.1038/nature04219; Folco HD, 2008, SCIENCE, V319, P94, DOI 10.1126/science.1150944; Fukagawa T, 2004, NAT CELL BIOL, V6, P784, DOI 10.1038/ncb1155; Grewal SIS, 2007, NAT REV GENET, V8, P35, DOI 10.1038/nrg2008; Guenatri M, 2004, J CELL BIOL, V166, P493, DOI 10.1083/jcb.200403109; Hayakawa T, 2003, J CELL SCI, V116, P3327, DOI 10.1242/jcs.00635; Hirota T, 2005, NATURE, V438, P1176, DOI 10.1038/nature04254; Kawashima SA, 2007, GENE DEV, V21, P420, DOI 10.1101/gad.1497307; Kitajima TS, 2006, NATURE, V441, P46, DOI 10.1038/nature04663; Kitajima TS, 2005, CURR BIOL, V15, P353, DOI 10.1016/j.cub.2004.12.044; Kitajima TS, 2003, SCIENCE, V300, P1152, DOI 10.1126/science.1083634; Kitajima TS, 2004, NATURE, V427, P510, DOI 10.1038/nature02312; Koch T, 2008, PHARMACOL THERAPEUT, V117, P199, DOI 10.1016/j.pharmthera.2007.10.003; Lee J, 2008, NAT CELL BIOL, V10, P42, DOI 10.1038/ncb1667; McGuinness BE, 2005, PLOS BIOL, V3, P433, DOI 10.1371/journal.pbio.0030086; Minc E, 1999, CHROMOSOMA, V108, P220, DOI 10.1007/s004120050372; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nonaka N, 2002, NAT CELL BIOL, V4, P89, DOI 10.1038/ncb739; Obuse C, 2004, NAT CELL BIOL, V6, P1135, DOI 10.1038/ncb1187; Okada T, 2007, CELL, V131, P1287, DOI 10.1016/j.cell.2007.10.045; Pidoux AL, 2005, PHILOS T R SOC B, V360, P569, DOI 10.1098/rstb.2004.1611; Rabitsch KP, 2004, CURR BIOL, V14, P287, DOI 10.1016/j.cub.2004.01.051; Riedel CG, 2006, NATURE, V441, P53, DOI 10.1038/nature04664; Salic A, 2004, CELL, V118, P567, DOI 10.1016/j.cell.2004.08.016; Smothers JF, 2000, CURR BIOL, V10, P27, DOI 10.1016/S0960-9822(99)00260-2; Sugimoto K, 2001, CELL STRUCT FUNCT, V26, P705, DOI 10.1247/csf.26.705; Toyoda Y, 2006, MOL BIOL CELL, V17, P2287, DOI 10.1091/mbc.E05-11-1089	29	142	144	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 11	2008	455	7210					251	U79		10.1038/nature07217	http://dx.doi.org/10.1038/nature07217			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	346SZ	18716626				2022-12-28	WOS:000259090800053
J	Lopez, S				Lopez, Sebastian			Astronomy - The universe measured with a comb	SCIENCE			English	Editorial Material							DECELERATION; PRECISION		[Lopez, Sebastian] Univ Chile, Dept Astron, Santiago, Chile	Universidad de Chile	Lopez, S (corresponding author), Univ Chile, Dept Astron, Casilla 36-D, Santiago, Chile.	slopez@das.uchile.cl	Lopez, Sebastián/I-5657-2016	Lopez, Sebastián/0000-0003-0389-0902				Araujo-Hauck C., 2007, MESSENGER, V129, P24; Li CH, 2008, NATURE, V452, P610, DOI 10.1038/nature06854; Liske J, 2008, MON NOT R ASTRON SOC, V386, P1192, DOI 10.1111/j.1365-2966.2008.13090.x; Loeb A, 1998, ASTROPHYS J, V499, pL111, DOI 10.1086/311375; Murphy MT, 2007, MON NOT R ASTRON SOC, V380, P839, DOI 10.1111/j.1365-2966.2007.12147.x; SANDAGE A, 1962, ASTROPHYS J, V136, P319, DOI 10.1086/147385; Steinmetz T, 2008, SCIENCE, V321, P1335, DOI 10.1126/science.1161030; Udem T, 2002, NATURE, V416, P233, DOI 10.1038/416233a	8	4	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	2008	321	5894					1301	1302		10.1126/science.1163194	http://dx.doi.org/10.1126/science.1163194			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	344GG	18772423				2022-12-28	WOS:000258914300033
J	Wofford, B				Wofford, Ben			One hundred thousand cows - A fable	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												jbenwofford@charter.net							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	2008	300	9					1005	1005		10.1001/jama.300.9.1005	http://dx.doi.org/10.1001/jama.300.9.1005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	342YN	18768405				2022-12-28	WOS:000258819600001
J	El-Sadr, WM; Grund, B; Neuhaus, J; Babiker, A; Cohen, CJ; Darbyshire, J; Emery, S; Lundgren, JD; Phillips, A; Neaton, JD				El-Sadr, W. M.; Grund, B.; Neuhaus, J.; Babiker, A.; Cohen, C. J.; Darbyshire, J.; Emery, S.; Lundgren, J. D.; Phillips, A.; Neaton, J. D.		SMART Study Grp	Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy - a randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article							CD4 CELL COUNT; VIROLOGICAL SUPPRESSION; TREATMENT INTERRUPTION; NAIVE INDIVIDUALS; AIDS DISEASES; INFECTION; SMART; LOAD	Background: Episodic use of antiretroviral therapy guided by CD4(+) cell counts is inferior to continuous antiretroviral therapy. Objective: To determine whether reinitiating continuous antiretroviral therapy in patients who received episodic treatment reduces excess risk for opportunistic disease or death. Design: Randomized, controlled trial. Patients: 5472 HIV-infected individuals with CD4(+) cell counts greater than 0.350 x 10(9) cells/L enrolled from January 2002 to January 2006. Intervention: Episodic or continuous antiretroviral therapy initially, followed by continuous therapy in participants previously assigned to episodic treatment. Results: Eighteen months after the recommendation to reinitiate continuous therapy, mean CD4(+) cell counts were 0.152 x 10(9) cells/L (95% CI, 0.136 to 0.167 x 10(9) cells/ L) less in participants previously assigned to episodic treatment (P < 0.001). The proportion of follow-up time spent with CD4(+) cell counts of 0.500 x 10(9) cells/L or more and HIV RNA levels of 400 copies/mL or less was 29% for participants initially assigned to episodic therapy and 66% for those assigned to continuous therapy. Participants who reinitiated continuous therapy experienced rapid suppression of HIV RNA levels (89.7% with HIV RNA levels <= 400 copies/mL after 6 months), but CD4(+) cell counts after 6 months remained 0.140 x 10(9) cells/L below baseline. The hazard ratio (episodic versus continuous treatment) for opportunistic disease or death decreased after the recommendation to reinitiate continuous therapy (from 2.5 [CI, 1.8 to 3.5] to 1.4 [CI, 1.0 to 2.0]; P = 0.033 for difference). The residual excess risk was attributable to failure to reinitiate therapy by some participants and slow recovery of CD4(+) cell counts for those who reinitiated therapy. Limitation: Follow-up was too short to assess the full effect of switching from episodic to continuous antiretroviral therapy. Conclusion: Reinitiating continuous antiretroviral therapy in patients previously assigned to episodic treatment reduced excess risk for opportunistic disease or death, but excess risk remained. Episodic antiretroviral therapy, as used in the SMART study, should be avoided.	Columbia Univ, Harlem Hosp Ctr, New York, NY USA; Community Res Initiat New England, Boston, MA USA; MRC, Clin Trials Unit, London, England; Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia; Univ Copenhagen, Copenhagen, Denmark; Rigshosp, DK-2100 Copenhagen, Denmark	Columbia University; Medical Research Council Clinical Trials Unit; University of New South Wales Sydney; Kirby Institute; University of Copenhagen; Rigshospitalet; University of Copenhagen	Neaton, JD (corresponding author), Univ Minnesota, Sch Publ Hlth, Div Biostat, 2221 Univ Ave SE,Room 200, Minneapolis, MN 55414 USA.	jim@ccbr.umn.edu	Emery, Sean/O-9122-2019; Ostergaard, Lars/AAA-3020-2020; Grund, Birgit/G-7054-2016; Phillips, Andrew N/B-4427-2008; Lundgren, Jens/AAE-6876-2019; Emery, Sean/J-3825-2017; Brites, Carlos/D-1353-2013; Pulido, Federico/B-8417-2009	Emery, Sean/0000-0001-6072-8309; Ostergaard, Lars/0000-0003-2459-0511; Grund, Birgit/0000-0003-4275-7880; Phillips, Andrew N/0000-0003-2384-4807; Emery, Sean/0000-0001-6072-8309; Koirala, Janak/0000-0002-3608-474X; Tambussi, Giuseppe/0000-0002-0604-2960; Kinghorn, George/0000-0001-6608-5076; Krolewiecki, Alejandro/0000-0001-9054-1211; Leen, Clifford/0000-0001-8439-7719; Lundgren, Jens/0000-0001-8901-7850; Okhuysen, Pablo/0000-0002-1596-3411; Brites, Carlos/0000-0002-4673-6991; OBRIEN, STEPHEN/0000-0001-7857-0757; Cabie, Andre/0000-0003-0117-3061; Goetz, Matthew/0000-0003-4542-992X; Guaragna, Graciela/0000-0002-9649-664X; Rubio Garcia, Rafael/0000-0001-8132-4303; Walmsley, Sharon/0000-0002-3959-5692; McGee, Blake/0000-0002-5286-7963; Ristola, Matti/0000-0001-5115-2811; Pulido, Federico/0000-0002-7414-8812; Ostergaard, Lars/0000-0002-7619-605X; Kozal, Michael/0000-0002-3100-8254; Gayet-Ageron, Angele/0000-0002-6164-9693; Easterbrook, Philippa/0000-0002-2603-5418; Medland, Nicholas Andrew/0000-0003-0403-8930; Magenta, Lorenzo/0000-0002-7644-3647; Young, Barnaby/0000-0003-1010-2230; ABEL, Sylvie/0000-0002-3351-0547; Kumar, Professor Amit/0000-0002-5913-4308	National Institute of Allergy and Infectious Disease, National Institutes of Health [U01AI042170, U01AI46362, U01AI068641]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI046362, U01AI042170, U01AI068641] Funding Source: NIH RePORTER; MRC [MC_U122886352] Funding Source: UKRI; Medical Research Council [MC_U122886352] Funding Source: researchfish	National Institute of Allergy and Infectious Disease, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	By the National Institute of Allergy and Infectious Disease, National Institutes of Health (grants U01AI042170, U01AI46362, and U01AI068641).	Ananworanich J, 2005, JAIDS-J ACQ IMM DEF, V39, P523; Baker JV, 2008, AIDS, V22, P841, DOI 10.1097/QAD.0b013e3282f7cb76; Beral V, 2004, AIDS, V18, P51, DOI [10.1097/00002030-200401020-00006, 10.1097/01.aids.0000096908.73209.5d]; Bogaards JA, 2003, ANTIVIR THER, V8, P43; Boschi A, 2006, J ANTIMICROB CHEMOTH, V57, P520, DOI 10.1093/jac/dki472; Burman WJ, 2008, JAIDS-J ACQ IMM DEF, V47, P185, DOI 10.1097/QAI.0b013e31815acaa4; Chen RY, 2002, AIDS RES HUM RETROV, V18, P909, DOI 10.1089/088922202760265588; El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360; Emery S, 2008, J INFECT DIS, V197, P1133, DOI 10.1086/586713; Gras L, 2007, JAIDS-J ACQ IMM DEF, V45, P183, DOI 10.1097/QAI.0b013e31804d685b; Hennessey KA, 2000, AIDS RES HUM RETROV, V16, P103, DOI 10.1089/088922200309449; Hunt PW, 2003, AIDS, V17, P1907, DOI 10.1097/00002030-200309050-00009; KULLER LH, 2008, P 15 ANN C RETR OPP; Lifson AR, 2008, HIV CLIN TRIALS, V9, P177, DOI 10.1310/hct0903-177; Lundgren JD, 2008, J INFECT DIS, V197, P1145, DOI 10.1086/529523; May MT, 2006, LANCET, V368, P451, DOI 10.1016/S0140-6736(06)69152-6; Mocroft A, 2007, LANCET, V370, P407, DOI 10.1016/S0140-6736(07)60948-9; Phillips AN, 2008, ANTIVIR THER, V13, P177; Phillips AN, 2007, AIDS, V21, P1717; Silverberg MJ, 2007, AIDS, V21, P1957, DOI 10.1097/QAD.0b013e3282ed6338; Smit C, 2006, AIDS, V20, P741, DOI 10.1097/01.aids.0000216375.99560.a2; Weber R, 2006, ARCH INTERN MED, V166, P1632, DOI 10.1001/archinte.166.15.1632	22	106	108	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2008	149	5					289	W62		10.7326/0003-4819-149-5-200809020-00003	http://dx.doi.org/10.7326/0003-4819-149-5-200809020-00003			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	348SD	18765698				2022-12-28	WOS:000259229300001
J	Gould, M				Gould, Mark			End of the free lunch?	BRITISH MEDICAL JOURNAL			English	Editorial Material												mark@hickorywind.demon.co.uk						*J MAC FDN, 2008, CONT ED HLTH PROF; Pharmaceutical Research and Manufacturers of America, 2008, COD INT HLTH PROF	2	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 30	2008	337	7668							a1399	10.1136/bmj.a1399	http://dx.doi.org/10.1136/bmj.a1399			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350OM	18728077				2022-12-28	WOS:000259362100023
J	Kippenberg, TJ; Vahala, KJ				Kippenberg, T. J.; Vahala, K. J.			Cavity optomechanics: Back-action at the mesoscale	SCIENCE			English	Review							QUANTUM-NOISE; MIRROR; OSCILLATOR; PARTICLES; POSITION	The coupling of optical and mechanical degrees of freedom is the underlying principle of many techniques to measure mechanical displacement, from macroscale gravitational wave detectors to microscale cantilevers used in scanning probe microscopy. Recent experiments have reached a regime where the back- action of photons caused by radiation pressure can influence the optomechanical dynamics, giving rise to a host of long- anticipated phenomena. Here we review these developments and discuss the opportunities for innovative technology as well as for fundamental science.	[Kippenberg, T. J.] Max Planck Inst Quantum Opt, D-85748 Garching, Germany; [Vahala, K. J.] CALTECH, Dept Appl Phys, Pasadena, CA 91125 USA	Max Planck Society; California Institute of Technology	Kippenberg, TJ (corresponding author), Swiss Fed Inst Technol, EPFL, CH-1015 Lausanne, Switzerland.	tjk@mpq.mpg.de; vahala@caltech.edu	Kippenberg, T. J./B-3133-2013	Kippenberg, T. J./0000-0002-3408-886X	Alexander von Humboldt Foundation; Max Planck Independent Junior Research Group; Marie Curie Excellence Grant; Deutsche Forschungsgemeinschaft (DFG project Ground State Cooling); Nanosystems Initiative Munich	Alexander von Humboldt Foundation(Alexander von Humboldt Foundation); Max Planck Independent Junior Research Group; Marie Curie Excellence Grant(European Commission); Deutsche Forschungsgemeinschaft (DFG project Ground State Cooling)(German Research Foundation (DFG)); Nanosystems Initiative Munich	K.J.V. acknowledges support from the Alexander von Humboldt Foundation. T.J.K. gratefully acknowledges support via a Max Planck Independent Junior Research Group, a Marie Curie Excellence Grant, the Deutsche Forschungsgemeinschaft (DFG project Ground State Cooling), and Nanosystems Initiative Munich. The authors thank T. W. Hansch for discussions.	ALSING P, 1988, PHYS REV A, V37, P2970, DOI 10.1103/PhysRevA.37.2970; ANETSBERGER G, 2008, IN PRESS NAT PHOTONI; Arcizet O, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.133601; Arcizet O, 2006, PHYS REV A, V73, DOI 10.1103/PhysRevA.73.033819; Arcizet O, 2006, NATURE, V444, P71, DOI 10.1038/nature05244; Ashkin A, 1997, P NATL ACAD SCI USA, V94, P4853, DOI 10.1073/pnas.94.10.4853; ASHKIN A, 1970, PHYS REV LETT, V24, P156, DOI 10.1103/PhysRevLett.24.156; Braginsky V. B., 1977, MEASUREMENT WEAK FOR; Braginsky V. B., 1992, QUANTUM MEASUREMENT; Braginsky VB, 2002, PHYS LETT A, V293, P228, DOI 10.1016/S0375-9601(02)00020-8; Brown KR, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.137205; Carmon T, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.123901; CAVES CM, 1981, PHYS REV D, V23, P1693, DOI 10.1103/PhysRevD.23.1693; Cohadon PF, 1999, PHYS REV LETT, V83, P3174, DOI 10.1103/PhysRevLett.83.3174; Corbitt T, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.150802; Craighead HG, 2000, SCIENCE, V290, P1532, DOI 10.1126/science.290.5496.1532; DORSEL A, 1983, PHYS REV LETT, V51, P1550, DOI 10.1103/PhysRevLett.51.1550; Dykman M. I., 1978, Soviet Physics - Solid State, V20, P1306; Eichenfield M, 2007, NAT PHOTONICS, V1, P416, DOI 10.1038/nphoton.2007.96; FABRE C, 1994, PHYS REV A, V49, P1337, DOI 10.1103/PhysRevA.49.1337; Gigan S, 2006, NATURE, V444, P67, DOI 10.1038/nature05273; HANSCH TW, 1975, OPT COMMUN, V13, P68, DOI 10.1016/0030-4018(75)90159-5; Heidmann A, 1997, APPL PHYS B-LASERS O, V64, P173, DOI 10.1007/s003400050162; Hood CJ, 2000, SCIENCE, V287, P1447, DOI 10.1126/science.287.5457.1447; Hossein-Zadeh M, 2006, PHYS REV A, V74, DOI 10.1103/PhysRevA.74.023813; HOSSEINZADEH M, 2007, PHOTONICS TECHNOL LE, V20, P4; Jacobs K, 1999, PHYS REV A, V60, P538, DOI 10.1103/PhysRevA.60.538; Kimble HJ, 2002, PHYS REV D, V65, DOI 10.1103/PhysRevD.65.022002; Kippenberg TJ, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.033901; Kippenberg TJ, 2007, OPT EXPRESS, V15, P17172, DOI 10.1364/OE.15.017172; Kleckner D, 2006, NATURE, V444, P75, DOI 10.1038/nature05231; Knobel RG, 2003, NATURE, V424, P291, DOI 10.1038/nature01773; LaHaye MD, 2004, SCIENCE, V304, P74, DOI 10.1126/science.1094419; Leibfried D, 2003, REV MOD PHYS, V75, P281, DOI 10.1103/RevModPhys.75.281; Mancini S, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.120401; Mancini S, 1998, PHYS REV LETT, V80, P688, DOI 10.1103/PhysRevLett.80.688; Marquardt F, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.093902; MARSHALL W, 2003, PHYS REV LETT, V91; Maunz P, 2004, NATURE, V428, P50, DOI 10.1038/nature02387; Metzger CH, 2004, NATURE, V432, P1002, DOI 10.1038/nature03118; Murch KW, 2008, NAT PHYS, V4, P561, DOI 10.1038/nphys965; Naik A, 2006, NATURE, V443, P193, DOI 10.1038/nature05027; Pinard M, 1999, EUR PHYS J D, V7, P107; Poggio M, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.017201; Povinelli ML, 2005, OPT EXPRESS, V13, P8286, DOI 10.1364/OPEX.13.008286; Rakich PT, 2007, NAT PHOTONICS, V1, P658, DOI 10.1038/nphoton.2007.203; Rokhsari H, 2005, OPT EXPRESS, V13, P5293, DOI 10.1364/OPEX.13.005293; Rugar D, 2004, NATURE, V430, P329, DOI 10.1038/nature02658; SANDBERG VD, 1980, REV MOD PHYS, V52, P341; Schliesser A, 2008, NAT PHYS, V4, P415, DOI 10.1038/nphys939; Schliesser A, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.243905; Schwab KC, 2005, PHYS TODAY, V58, P36, DOI 10.1063/1.2012461; Sheard BS, 2004, PHYS REV A, V69, DOI 10.1103/PhysRevA.69.051801; STENHOLM S, 1986, REV MOD PHYS, V58, P699, DOI 10.1103/RevModPhys.58.699; Thompson JD, 2008, NATURE, V452, P72, DOI 10.1038/nature06715; Tian L, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.266403; Tittonen I, 1999, PHYS REV A, V59, P1038, DOI 10.1103/PhysRevA.59.1038; Vahala KJ, 2008, PHYS REV A, V78, DOI 10.1103/PhysRevA.78.023832; Wilson-Rae I, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.093901; Wilson-Rae I, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.075507; WINELAND D, 1975, B AM PHYS SOC, V20, P637	62	1434	1463	12	415	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2008	321	5893					1172	1176		10.1126/science.1156032	http://dx.doi.org/10.1126/science.1156032			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341ZM	18755966				2022-12-28	WOS:000258754400032
J	Silver, L; Bassett, MT				Silver, Lynn; Bassett, Mary T.			Food safety for the 21st century	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							TRANS-FATTY-ACIDS; UNITED-STATES; CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; PUBLIC-HEALTH; SODIUM-INTAKE; BURDEN; OVERWEIGHT; OBESITY; ADULTS		[Silver, Lynn; Bassett, Mary T.] New York City Dept Hlth & Mental Hyg, New York, NY 10013 USA	New York City Department of Health & Mental Hygiene	Bassett, MT (corresponding author), New York City Dept Hlth & Mental Hyg, 125 Worth St,Room 345, New York, NY 10013 USA.	mbassett@health.nyc.gov		Silver, Lynn/0000-0002-2680-7393				Ascherio A, 1999, NEW ENGL J MED, V340, P1994, DOI 10.1056/NEJM199906243402511; Briefel RR, 2004, ANNU REV NUTR, V24, P401, DOI 10.1146/annurev.nutr.23.011702.073349; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Dickinson BD, 2007, ARCH INTERN MED, V167, P1460, DOI 10.1001/archinte.167.14.1460; Havas S, 2004, AM J PUBLIC HEALTH, V94, P19, DOI 10.2105/AJPH.94.1.19; Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847; Karppanen H, 2006, PROG CARDIOVASC DIS, V49, P59, DOI 10.1016/j.pcad.2006.07.001; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; LEVY AS, 1996, IMPACT NLEA CONSUMER; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Mead PS, 1999, EMERG INFECT DIS, V5, P607, DOI 10.3201/eid0505.990502; Mokdad AH, 2004, JAMA-J AM MED ASSOC, V291, P1238, DOI 10.1001/jama.291.10.1238; Mozaffarian D, 2006, NEW ENGL J MED, V354, P1601, DOI 10.1056/NEJMra054035; *UK FOOD STAND AG, 2007, DIET SOD LEV SURV	14	21	22	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2008	300	8					957	959		10.1001/jama.300.8.957	http://dx.doi.org/10.1001/jama.300.8.957			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	341AR	18728271				2022-12-28	WOS:000258687100032
J	Guo, SZ; Han, Y; Zhang, XD; Lu, BL; Yi, CG; Zhang, H; Ma, XJ; Wang, DT; Yang, L; Fan, X; Liu, YJ; Lu, KH; Li, HY				Guo, Shuzhong; Han, Yon; Zhang, Xudong; Lu, Binglun; Yi, Chenggang; Zhang, Hui; Ma, Xianjie; Wang, Datai; Yang, Li; Fan, Xing; Liu, Yunjing; Lu, Kaihua; Li, Huiyuan			Human facial allotransplantation: a 2-year follow-up study	LANCET			English	Article							ALLOGRAFT TRANSPLANTATION; FACE TRANSPLANTATION; KIDNEY-TRANSPLANTATION; SCALP TRANSPLANTATION; TOLERANCE INDUCTION; DIABETES-MELLITUS; RAT MODEL; REJECTION; TACROLIMUS; REPLANTATION	Background Progress in composite tissue allotransplantation could provide a new treatment for patients with severe facial disfigurements. We did a partial facial allotransplantation in 2006, and report here the 2 year follow-up of the patient. Methods The recipient, a 30-year-old man from China, had his face severely injured by a bear in October, 2004. Allograft composite tissue transplantation was done in April, 2006, after careful systemic preparation. The surgery included anastomosis of the right mandibular artery and anterior facial vein, whole repair of total nose, upper lip, parotid gland, front wall of the maxillary sinus, part of the infraorbital wall, and zygomatic bone. Facial nerve anastomosis was done during the surgery. Quadruple inummomodulatory therapy was used, containing tacrolimus, mycophenolate mofetil, corticosteroids, and humanised IL-2 receptor monoclonal antibody. Follow-up included T lymphocyte subgroups in peripheral blood, pathological and immunohistochemical examinations, functional progress, and psychological support. Findings Composite tissue flap survived well. There were three acute rejection episodes at 3, 5, and 17 months after transplantation, but these were controlled by adjustment of the tacrolimus dose or the application of methylprednisolone pulse therapy. Hepatic and renal functions were normal, and there was no infection. The patient developed hyperglycaemia on day 3 after transplantation, which was controlled by medication. Interpretation Facial transplantation could be successful in the short term, but the procedure was not without complications. However, promising results could mean that this procedure might be an option for long-term restoration of severe facial disfigurement. Funding New Clinical Technique Foundation of Xijing Hospital.	[Guo, Shuzhong; Han, Yon; Zhang, Xudong; Lu, Binglun; Yi, Chenggang; Zhang, Hui; Ma, Xianjie; Wang, Datai; Yang, Li; Fan, Xing; Liu, Yunjing; Lu, Kaihua; Li, Huiyuan] Fourth Mil Med Univ, Inst Plast Surg, Xijing Hosp, Xian 710032, Peoples R China	Air Force Military Medical University	Guo, SZ (corresponding author), Fourth Mil Med Univ, Inst Plast Surg, Xijing Hosp, Xian 710032, Peoples R China.	mzf0709@fmmu.edu.cn			New Clinical Technique Foundation of Xjjing Hospital [XJGX0605M02]; National Nature Science Foundation of China [30672189]	New Clinical Technique Foundation of Xjjing Hospital; National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was completely funded by the New Clinical Technique Foundation of Xjjing Hospital (grant number XJGX0605M02). The animal studies were funded by the National Nature Science Foundation of China (number 30672189). We thank the following specialists or teams for their close cooperation in this facial transplantation: Zhang Yongsheng, Zhang Yingzhi, Li Xiangdong, Li Xiaokang, Guo Minghua, and Fan Daiming; Xiong Lize, Chen Shaoyang, and their team; Wang He, Don Kefeng, Yi Dinghua, Zhao Qingquan, Tao Kaishan, and their teams; Wen Aidong, and his team; Ji Qiuhe and his team; Liu Baolin; Lin Maochang; Hao Xiaoke, Ding Zhenruo, and their team; Shi Mei and her team; Fu Jufang, Bian Dongmei, and their teams; Xu Fuming. And we especially thank the people who have worked on this study, but are not mentioned here.	Ahsan N, 2002, AM J TRANSPLANT, V2, P568, DOI 10.1034/j.1600-6143.2002.20612.x; Bhorade SM, 2003, AM J TRANSPLANT, V3, P1570, DOI 10.1046/j.1600-6135.2003.00260.x; Brown Charles S, 2007, Int J Surg, V5, P353, DOI 10.1016/j.ijsu.2006.06.019; Copstein LA, 2004, TRANSPL P, V36, P882, DOI 10.1016/j.transproceed.2004.04.008; Demir Y, 2004, PLAST RECONSTR SURG, V114, P1790, DOI 10.1097/01.PRS.0000142414.92308.AB; Devauchelle B, 2006, LANCET, V368, P203, DOI 10.1016/S0140-6736(06)68935-6; DEZ LEB, 2002, PLAST RECONSTR SURG, V110, P1374; Dubernard J M, 1999, Chirurgie, V124, P358, DOI 10.1016/S0001-4001(00)80007-0; Dubernard JM, 2007, NEW ENGL J MED, V357, P2451, DOI 10.1056/NEJMoa072828; Hettiaratchy S, 2006, PLAST RECONSTR SURG, V117, P1043, DOI 10.1097/01.prs.0000201204.57587.e8; Hettiaratchy S, 2002, LANCET, V360, P5, DOI 10.1016/S0140-6736(02)09361-3; ISHIDA H, 2004, TRANSPLANTATION, V78, P54; Kanitakis J, 2005, EUR J DERMATOL, V15, P235; Kaplan B, 2008, CLIN TRANSPLANT, V22, P250, DOI 10.1111/j.1399-0012.2007.00757.x; Kerman RH, 1996, TRANSPLANTATION, V62, P201, DOI 10.1097/00007890-199607270-00009; Kvernmo HD, 2005, ACTA ORTHOP, V76, P14, DOI 10.1080/00016470510030283; Lee KW, 2004, TRANSPL P, V36, P2009, DOI 10.1016/j.transproceed.2004.08.137; Light JA, 2002, CLIN TRANSPLANT, V16, P30, DOI 10.1034/j.1399-0012.16.s7.4.x; Ma Zhong-Li, 2002, Di Yi Jun Yi Da Xue Xue Bao, V22, P509; Moore R, 2006, CLIN TRANSPLANT, V20, P755, DOI 10.1111/j.1399-0012.2006.00565.x; Morris P, 2007, TRANSPLANTATION, V83, P109, DOI 10.1097/01.tp.0000254201.89012.ae; Mottershead M, 2007, EXPERT OPIN BIOL TH, V7, P1583, DOI 10.1517/14712598.7.10.1583; Okie S, 2006, NEW ENGL J MED, V354, P889, DOI 10.1056/NEJMp068005; Pei G, 2000, Zhonghua Yi Xue Za Zhi, V80, P417; Siemionow M, 2006, PLAST RECONSTR SURG, V117, P876, DOI 10.1097/01.prs.0000204876.27481.fc; Siemionow M, 2005, TRANSPLANTATION, V79, P558, DOI 10.1097/01.TP.0000152799.16035.B7; Siemionow M, 2004, PLAST RECONSTR SURG, V113, P1421, DOI 10.1097/01.PRS.0000112792.44312.A5; Siemionow M, 2006, J RECONSTR MICROSURG, V22, P329, DOI 10.1055/s-2006-946709; Siemionow MZ, 2005, TRANSPL P, V37, P201, DOI 10.1016/j.transproceed.2004.12.055; Singh D, 2003, TRANSPL P, V35, P2395, DOI 10.1016/j.transproceed.2003.08.007; Tanaka Y, 2005, TRANSPLANTATION, V79, P1262, DOI 10.1097/01.TP.0000161667.99145.20; Thomas A, 1998, PLAST RECONSTR SURG, V102, P2085, DOI 10.1097/00006534-199811000-00041; Ulusal AE, 2005, PLAST RECONSTR SURG, V116, P811, DOI 10.1097/01.prs.0000176249.27930.38; Ulusal BG, 2003, PLAST RECONSTR SURG, V112, P1302, DOI 10.1097/01.PRS.0000079823.84984.BB; Wilhelmi BJ, 2003, ANN PLAS SURG, V50, P535, DOI 10.1097/01.SAP.0000037875.69379.56; Yagmurdur MC, 2004, TRANSPL P, V36, P144, DOI 10.1016/j.transproceed.2003.11.044; Zhou Y C, 1991, Clin Transpl, P313	37	205	222	0	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	2008	372	9639					631	638		10.1016/S0140-6736(08)61276-3	http://dx.doi.org/10.1016/S0140-6736(08)61276-3			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	340BX	18722867				2022-12-28	WOS:000258622200026
J	Watts, G; Greenwood, B				Watts, Geoff; Greenwood, Brian			Tightening the net around malaria	BRITISH MEDICAL JOURNAL			English	Editorial Material												geoff@scileg.freeserve.co.uk							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 23	2008	337	7667							a1267	10.1136/bmj.a1267	http://dx.doi.org/10.1136/bmj.a1267			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	346FD	18713800				2022-12-28	WOS:000259053100022
J	Kumar, P; Ban, HS; Kim, SS; Wu, HQ; Pearson, T; Greiner, DL; Laouar, A; Yao, JH; Haridas, V; Habiro, K; Yang, YG; Jeong, JH; Lee, KY; Kim, YH; Kim, SW; Peipp, M; Fey, GH; Manjunath, N; Shultz, LD; Lee, SK; Shankar, P				Kumar, Priti; Ban, Hong-Seok; Kim, Sang-Soo; Wu, Haoquan; Pearson, Todd; Greiner, Dale L.; Laouar, Amale; Yao, Jiahong; Haridas, Viraga; Habiro, Katsuyoshi; Yang, Yong-Guang; Jeong, Ji-Hoon; Lee, Kuen-Yong; Kim, Yong-Hee; Kim, Sung Wan; Peipp, Matthias; Fey, Georg H.; Manjunath, N.; Shultz, Leonard D.; Lee, Sang-Kyung; Shankar, Premlata			T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice	CELL			English	Article							SMALL INTERFERING RNA; LENTIVIRAL VECTOR; CHAIN IMMUNOTOXIN; MOUSE MODEL; HU MICE; IN-VIVO; C-MYB; ANTIBODY; INHIBITION; THERAPY	Evaluation of the therapeutic potential of RNAi for HIV infection has been hampered by the challenges of siRNA delivery and lack of suitable animal models. Using a delivery method for T cells, we show that siRNA treatment can dramatically suppress HIV infection. A CD7-specific single-chain antibody was conjugated to oligo-9-arginine peptide (scFvCD79R) for T cell-specific siRNA delivery in NOD/SCIDIL2r gamma(-/-) mice reconstituted with human lymphocytes (Hu-PBL) or CD34(+) hematopoietic stem cells (Hu-HSC). In HIV-infected Hu-PBL mice, treatment with anti-CCR5 (viral coreceptor) and antiviral siRNAs complexed to scFvCD7-9R controlled viral replication and prevented the disease-associated CD4 T cell loss. This treatment also suppressed endogenous virus and restored CD4 T cell counts in mice reconstituted with HIV+ peripheral blood mononuclear cells. Moreover, scFvCD7-9R could deliver antiviral siRNAs to naive T cells in Hu-HSC mice and effectively suppress viremia in infected mice. Thus, siRNA therapy for HIV infection appears to be feasible in a preclinical animal model.	[Ban, Hong-Seok; Lee, Kuen-Yong; Kim, Yong-Hee; Lee, Sang-Kyung] Hanyang Univ, Dept Bioengn, Seoul 133791, South Korea; [Ban, Hong-Seok; Lee, Kuen-Yong; Kim, Yong-Hee; Lee, Sang-Kyung] Hanyang Univ, Hanyang Fus Mat Program, Seoul 133791, South Korea; [Kumar, Priti; Kim, Sang-Soo; Wu, Haoquan; Laouar, Amale; Yao, Jiahong; Haridas, Viraga; Manjunath, N.; Shankar, Premlata] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA; [Kumar, Priti; Kim, Sang-Soo; Wu, Haoquan; Laouar, Amale; Yao, Jiahong; Haridas, Viraga; Manjunath, N.; Shankar, Premlata] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Pearson, Todd; Greiner, Dale L.] Univ Massachusetts, Sch Med, Dept Med, Div Diabet, Worcester, MA 01605 USA; [Habiro, Katsuyoshi; Yang, Yong-Guang] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02129 USA; [Jeong, Ji-Hoon; Kim, Sung Wan] Univ Utah, Ctr Controlled Chem Delivery, Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT 84112 USA; [Peipp, Matthias] Univ Kiel, Div Stem Cell Transplantat & Immunotherapy, D-24105 Kiel, Germany; [Fey, Georg H.] Univ Erlangen Nurnberg, D-91058 Erlangen, Germany; [Shultz, Leonard D.] Jackson Lab, Bar Harbor, ME 04609 USA	Hanyang University; Hanyang University; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Harvard Medical School; Massachusetts General Hospital; Utah System of Higher Education; University of Utah; University of Kiel; University of Erlangen Nuremberg; Jackson Laboratory	Lee, SK (corresponding author), Hanyang Univ, Dept Bioengn, Seoul 133791, South Korea.	sangkyunglee@hanyang.ac.kr; premlata.shankar@ttuhsc.edu	Kumar, Priti/C-5699-2009; Laouar, Amale/AAO-2903-2020; Peipp, Matthias/A-8775-2013; Ban, Hyun Seung/F-9526-2014; kim, sang-soo/C-6573-2009	Ban, Hyun Seung/0000-0002-2698-6037; Kim, Sang-Soo/0000-0002-9135-380X; Yang, Yong-Guang/0000-0003-4985-1247; Lee, Kuen Yong/0000-0002-5759-5952; Peipp, Matthias/0000-0002-5088-3804; Wu, Haoquan/0000-0001-9386-3187	NIH/National Institute of Allergy and Infectious Diseases [RO1 A1071882, R21 AI06532, AI075419]; Korea Ministry of Education and Science Technology [R01-2006-000-10506-0, F104AA010005-07A0101-00510]; Seoul RBD [CR070027]; CFAR [P30 A060354]; NIH [CA34196]; Juvenile Diabetes Research Foundation; MOEHRD [KRF-2006-352-D00070]; Wilhelm Sander Foundation; NATIONAL CANCER INSTITUTE [P30CA034196] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI075419, R01AI071882, P30AI060354] Funding Source: NIH RePORTER	NIH/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Korea Ministry of Education and Science Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Seoul RBD(Seoul RBD program); CFAR; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation); MOEHRD(Ministry of Education & Human Resources Development (MOEHRD), Republic of Korea); Wilhelm Sander Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Changseon Choi and Nahyun Kim for technical assistance and Luke Jasenosky for editing the manuscript. This work was supported by the following grants: NIH/National Institute of Allergy and Infectious Diseases RO1 A1071882 and R21 AI06532 to P. S., Korea Ministry of Education and Science Technology R01-2006-000-10506-0 and F104AA010005-07A0101-00510 and Seoul R&BD CR070027 to S. K. L., CFAR fellowship P30 A060354 to P. K., NIH/NIAID Autoimmunity Prevention Center grant to D. L. G., NIH CA34196 to L. D. S., Juvenile Diabetes Research Foundation to D. L. G., L. D. S., and T. P., MOEHRD KRF-2006-352-D00070 to S. S. K., NIH/NIAID UO1 AI075419 to M. N., a Wilhelm Sander Foundation research grant to G. H. F, and the Seoul Fellowship to H. S. B.	Anderson J, 2007, MOL THER, V15, P1182, DOI 10.1038/sj.mt.6300157; Banerjea A, 2003, MOL THER, V8, P62, DOI 10.1016/S1525-0016(03)00140-0; Berges BK, 2008, VIROLOGY, V373, P342, DOI 10.1016/j.virol.2007.11.020; Berges BK, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-76; Bonilla FA, 1997, INT IMMUNOL, V9, P1875, DOI 10.1093/intimm/9.12.1875; Bremer E, 2005, CANCER RES, V65, P3380, DOI 10.1158/0008-5472.CAN-04-2756; Caron G, 2005, J IMMUNOL, V175, P1551, DOI 10.4049/jimmunol.175.3.1551; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Fais S, 1999, J VIROL, V73, P6453, DOI 10.1128/JVI.73.8.6453-6459.1999; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Frankel AE, 1997, LEUKEMIA LYMPHOMA, V26, P287, DOI 10.3109/10428199709051778; Goffinet C, 2006, FASEB J, V20, P500, DOI 10.1096/fj.05-4651fje; Gorantla S, 2007, J VIROL, V81, P2700, DOI 10.1128/JVI.02010-06; Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791; Hamamoto K, 2002, MICROBIOL IMMUNOL, V46, P741, DOI 10.1111/j.1348-0421.2002.tb02759.x; Hogrefe RI, 2006, NUCLEOS NUCLEOT NUCL, V25, P889, DOI 10.1080/15257770600793885; Ishikawa F, 2005, BLOOD, V106, P1565, DOI 10.1182/blood-2005-02-0516; John M, 2007, NATURE, V449, P745, DOI 10.1038/nature06179; Kim WL, 2006, MOL THER, V14, P343, DOI 10.1016/j.ymthe.2006.03.022; Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901; LAZAROVITS AI, 1993, J IMMUNOL, V150, P5163; Lee SK, 2005, BLOOD, V106, P818, DOI 10.1182/blood-2004-10-3959; Levine BL, 2006, P NATL ACAD SCI USA, V103, P17372, DOI 10.1073/pnas.0608138103; LIPSICK JS, 1987, MOL CELL BIOL, V7, P3358, DOI 10.1128/MCB.7.9.3358; Manjunath N, 2006, TRENDS IMMUNOL, V27, P328, DOI 10.1016/j.it.2006.05.006; Marasco WA, 2007, NAT BIOTECHNOL, V25, DOI 10.1038/nbt1363; Nakata H, 2005, J VIROL, V79, P2087, DOI 10.1128/JVI.79.4.2087-2096.2005; Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725; Peer D, 2007, P NATL ACAD SCI USA, V104, P4095, DOI 10.1073/pnas.0608491104; Peipp M, 2002, CANCER RES, V62, P2848; Rossi JJ, 2007, NAT BIOTECHNOL, V25, P1444, DOI 10.1038/nbt1367; Scherer L, 2007, GENE THER, V14, P1057, DOI 10.1038/sj.gt.3302977; Shacklett BL, 2008, PLOS MED, V5, P16, DOI 10.1371/journal.pmed.0050013; Shankar P, 2005, JAMA-J AM MED ASSOC, V293, P1367, DOI 10.1001/jama.293.11.1367; Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101; Song EW, 2003, J VIROL, V77, P7174, DOI 10.1128/JVI.77.13.7174-7181.2003; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Surabhi RM, 2002, J VIROL, V76, P12963, DOI 10.1128/JVI.76.24.12963-12973.2002; Svoboda P, 2007, CURR OPIN MOL THER, V9, P248; ter Brake O, 2008, MOL THER, V16, P557, DOI 10.1038/sj.mt.6300382; ter Brake O, 2006, MOL THER, V14, P883, DOI 10.1016/j.ymthe.2006.07.007; von Eije KJ, 2008, J VIROL, V82, P2895, DOI 10.1128/JVI.02035-07; Wan L, 2006, PROTEIN EXPRES PURIF, V48, P307, DOI 10.1016/j.pep.2006.02.005; Watanabe S, 2007, J VIROL, V81, P13259, DOI 10.1128/JVI.01353-07; Wu HQ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001020; Xiao CC, 2007, CELL, V131, P146, DOI 10.1016/j.cell.2007.07.021; Zeng F, 2006, NAT PROTOC, V1, P920, DOI 10.1038/nprot.2006.81	47	467	507	2	83	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	2008	134	4					577	586		10.1016/j.cell.2008.06.034	http://dx.doi.org/10.1016/j.cell.2008.06.034			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SR	18691745	Green Accepted, Bronze			2022-12-28	WOS:000258665800012
J	Pevzner, PA; Kim, S; Ng, J				Pevzner, Pavel A.; Kim, Sangtae; Ng, Julio			Comment on "protein sequences from mastodon and Tyrannosaurus rex revealed by mass spectrometry"	SCIENCE			English	Editorial Material									[Pevzner, Pavel A.; Kim, Sangtae; Ng, Julio] Univ Calif San Diego, Dept Comp Sci & Engn, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Pevzner, PA (corresponding author), Univ Calif San Diego, Dept Comp Sci & Engn, 9500 Gilman Dr,Mail Code 0404, La Jolla, CA 92093 USA.	ppevzner@cs.ucsd.edu		Collins, Matthew/0000-0003-4226-5501				Asara JM, 2008, SCIENCE, V319, DOI 10.1126/science.1147364; Asara JM, 2007, SCIENCE, V317, P1324, DOI 10.1126/science.317.5843.1324; Asara JM, 2007, SCIENCE, V316, P280, DOI 10.1126/science.1137614; Buckley M, 2008, SCIENCE, V319, DOI 10.1126/science.1147046; Frank AM, 2007, J PROTEOME RES, V6, P114, DOI 10.1021/pr060271u; Kim S, 2008, J PROTEOME RES, V7, P3354, DOI 10.1021/pr8001244; WOODWARD SR, 1994, SCIENCE, V266, P1229	7	49	51	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 22	2008	321	5892								10.1126/science.1155006	http://dx.doi.org/10.1126/science.1155006			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339RL	18719266				2022-12-28	WOS:000258594900018
J	Ackermann, M; Stecher, B; Freed, NE; Songhet, P; Hardt, WD; Doebeli, M				Ackermann, Martin; Stecher, Baerbel; Freed, Nikki E.; Songhet, Pascal; Hardt, Wolf-Dietrich; Doebeli, Michael			Self-destructive cooperation mediated by phenotypic noise	NATURE			English	Article							GENE-EXPRESSION; IN-VIVO; EVOLUTION; INFECTION	In many biological examples of cooperation, individuals that cooperate cannot benefit from the resulting public good. This is especially clear in cases of self- destructive cooperation, where individuals die when helping others. If self- destructive cooperation is genetically encoded, these genes can only be maintained if they are expressed by just a fraction of their carriers, whereas the other fraction benefits from the public good. One mechanism that can mediate this differentiation into two phenotypically different sub- populations is phenotypic noise(1,2). Here we show that noisy expression of self- destructive cooperation can evolve if individuals that have a higher probability for self- destruction have, on average, access to larger public goods. This situation, which we refer to as assortment, can arise if the environment is spatially structured. These results provide a new perspective on the significance of phenotypic noise in bacterial pathogenesis: it might promote the formation of cooperative sub- populations that die while preparing the ground for a successful infection. We show experimentally that this model captures essential features of Salmonella typhimurium pathogenesis. We conclude that noisily expressed self- destructive cooperative actions can evolve under conditions of assortment, that self- destructive cooperation is a plausible biological function of phenotypic noise, and that self- destructive cooperation mediated by phenotypic noise could be important in bacterial pathogenesis.	[Ackermann, Martin; Freed, Nikki E.] ETH, Inst Integrat Biol, CH-8092 Zurich, Switzerland; [Stecher, Baerbel; Songhet, Pascal; Hardt, Wolf-Dietrich] ETH, Inst Microbiol, CH-8092 Zurich, Switzerland; [Doebeli, Michael] Univ British Columbia, Dept Zool, Vancouver, BC V6T 1Z4, Canada; [Doebeli, Michael] Univ British Columbia, Dept Math, Vancouver, BC V6T 1Z4, Canada	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of British Columbia; University of British Columbia	Ackermann, M (corresponding author), ETH, Inst Integrat Biol, CH-8092 Zurich, Switzerland.	martin.ackermann@env.ethz.ch; hardt@micro.biol.ethz.ch; doebeli@zoology.ubc.ca	Stecher, Bärbel/A-2911-2015; Ackermann, Martin/V-4554-2017; Stecher, Barbel/B-9940-2019; Doebeli, Michael/D-5391-2012	Stecher, Bärbel/0000-0002-7445-5193; Ackermann, Martin/0000-0003-0087-4819; Hardt, Wolf-Dietrich/0000-0002-9892-6420	Roche Research Foundation; Novartis Foundation; NSERC ( Canada); UBS foundation; ETH research foundation [TH-10 06-1]; Swiss National Science Foundation [310000-113623/1]; European Union [SavinMucoPath number 032296]	Roche Research Foundation; Novartis Foundation(Novartis); NSERC ( Canada)(Natural Sciences and Engineering Research Council of Canada (NSERC)); UBS foundation; ETH research foundation; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); European Union(European Commission)	We are grateful to Markus Schlumberger, K. Aktories, I. Just, S. Hammerschmidt and J. Fletcher for discussions, and M. Barthel and the RCHCI team for professional help with the animal experiments. M. A. and N. E. F. were supported by the Swiss National Science Foundation, and M. A. was also supported by the Roche Research Foundation and the Novartis Foundation. M. D. is supported by NSERC ( Canada). B. S. and W.- D. H. were supported by the UBS foundation. Salmonella work in the Hardt laboratory is supported by grants from the ETH research foundation (TH- 10 06- 1), the Swiss National Science Foundation (310000-113623/1) and the European Union ( SavinMucoPath number 032296).	Avery SV, 2006, NAT REV MICROBIOL, V4, P577, DOI 10.1038/nrmicro1460; Brown SP, 2008, ECOL LETT, V11, P44, DOI 10.1111/j.1461-0248.2007.01125.x; BULL JJ, 1987, EVOLUTION, V41, P303, DOI 10.1111/j.1558-5646.1987.tb05799.x; CHARLESWORTH B, 1978, J THEOR BIOL, V72, P297, DOI 10.1016/0022-5193(78)90095-4; Cummings LA, 2006, MOL MICROBIOL, V61, P795, DOI 10.1111/j.1365-2958.2006.05271.x; Dieckmann U, 1996, J MATH BIOL, V34, P579, DOI 10.1007/BF02409751; Dubnau D, 2006, MOL MICROBIOL, V61, P564, DOI 10.1111/j.1365-2958.2006.05249.x; Hauert C, 2004, NATURE, V428, P643, DOI 10.1038/nature02360; Hautefort I, 2003, APPL ENVIRON MICROB, V69, P7480, DOI 10.1128/AEM.69.12.7480-7491.2003; Kaern M, 2005, NAT REV GENET, V6, P451, DOI 10.1038/nrg1615; Kothary MH, 2001, J FOOD SAFETY, V21, P49, DOI 10.1111/j.1745-4565.2001.tb00307.x; Kussell E, 2005, GENETICS, V169, P1807, DOI 10.1534/genetics.104.035352; LIMA AAM, 1988, INFECT IMMUN, V56, P582, DOI 10.1128/IAI.56.3.582-588.1988; Lysenko ES, 2005, PLOS PATHOG, V1, P3, DOI 10.1371/journal.ppat.0010001; MAY RM, 1995, P ROY SOC B-BIOL SCI, V261, P209, DOI 10.1098/rspb.1995.0138; Metz J. A. J., 1996, STOCHASTIC SPATIAL S, P183; NOWAK M, 1990, ACTA APPL MATH, V20, P247, DOI 10.1007/BF00049570; Nowak MA, 2006, SCIENCE, V314, P1560, DOI 10.1126/science.1133755; Ogunniyi AD, 2007, INFECT IMMUN, V75, P350, DOI 10.1128/IAI.01103-06; Paton JC, 1996, TRENDS MICROBIOL, V4, P103, DOI 10.1016/0966-842X(96)81526-5; Raberg L, 2006, AM NAT, V168, P41, DOI 10.1086/505160; Raser JM, 2005, SCIENCE, V309, P2010, DOI 10.1126/science.1105891; Rodemann JF, 2007, CLIN GASTROENTEROL H, V5, P339, DOI 10.1016/j.cgh.2006.12.027; Schlumberger MC, 2005, P NATL ACAD SCI USA, V102, P12548, DOI 10.1073/pnas.0503407102; Stecher B, 2008, TRENDS MICROBIOL, V16, P107, DOI 10.1016/j.tim.2007.12.008; Stecher B, 2007, PLOS BIOL, V5, P2177, DOI 10.1371/journal.pbio.0050244; Voth DE, 2005, CLIN MICROBIOL REV, V18, P247, DOI 10.1128/CMR.18.2.247-263.2005; Wagner PL, 2002, MOL MICROBIOL, V44, P957, DOI 10.1046/j.1365-2958.2002.02950.x; Wolf DM, 2005, J THEOR BIOL, V234, P255, DOI 10.1016/j.jtbi.2004.11.021	29	282	283	0	33	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 21	2008	454	7207					987	990		10.1038/nature07067	http://dx.doi.org/10.1038/nature07067			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339QB	18719588				2022-12-28	WOS:000258591000037
J	Rubin, EM				Rubin, Edward M.			Genomics of cellulosic biofuels	NATURE			English	Review							ETHANOL TOLERANCE; ESCHERICHIA-COLI; DRAFT SEQUENCE; ENZYMES; GENES; FUEL; WOOD	The development of alternatives to fossil fuels as an energy source is an urgent global priority. Cellulosic biomass has the potential to contribute to meeting the demand for liquid fuel, but land-use requirements and process inefficiencies represent hurdles for large-scale deployment of biomass-to-biofuel technologies. Genomic information gathered from across the biosphere, including potential energy crops and microorganisms able to break down biomass, will be vital for improving the prospects of significant cellulosic biofuel production.	DOE Joint Genome Inst, Walnut Creek, CA 94598 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	United States Department of Energy (DOE); United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Rubin, EM (corresponding author), DOE Joint Genome Inst, 2800 Mitchell Dr, Walnut Creek, CA 94598 USA.	emrubin@lbl.gov						Atsumi S, 2008, NATURE, V451, P86, DOI 10.1038/nature06450; Bao QY, 2002, GENOME RES, V12, P689, DOI 10.1101/gr.219302; Busov VB, 2008, NEW PHYTOL, V177, P589, DOI 10.1111/j.1469-8137.2007.02324.x; Del Rio JC, 2007, J AGR FOOD CHEM, V55, P5461, DOI 10.1021/jf0705264; Dinus RJ, 2001, CRIT REV PLANT SCI, V20, P51, DOI 10.1016/S0735-2689(01)80012-5; Doebley JF, 2006, CELL, V127, P1309, DOI 10.1016/j.cell.2006.12.006; Duerre Peter, 2007, Biotechnology Journal, V2, P1525, DOI 10.1002/biot.200700168; Filichkin SA, 2007, PLANT BIOTECHNOL J, V5, P615, DOI 10.1111/j.1467-7652.2007.00267.x; Georgieva TI, 2007, CENT EUR J BIOL, V2, P364, DOI 10.2478/s11535-007-0026-x; Gilbert HJ, 2007, MOL MICROBIOL, V63, P1568, DOI 10.1111/j.1365-2958.2007.05640.x; Gioia J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000928; Goff SA, 2002, SCIENCE, V296, P92, DOI 10.1126/science.1068275; Hill J, 2006, P NATL ACAD SCI USA, V103, P11206, DOI 10.1073/pnas.0604600103; Himmel ME, 2007, SCIENCE, V315, P804, DOI 10.1126/science.1137016; Hugenholtz P, 2002, GENOME BIOL, V3; Jarboe LR, 2007, ADV BIOCHEM ENG BIOT, V108, P237, DOI 10.1007/10_2007_068; Jeffries TW, 2007, NAT BIOTECHNOL, V25, P319, DOI 10.1038/nbt1290; Kalluri UC, 2007, BMC PLANT BIOL, V7, DOI 10.1186/1471-2229-7-59; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; LAFORGE FB, 1918, J IND ENG CHEM, V10, P925; Lartigue C, 2007, SCIENCE, V317, P632, DOI 10.1126/science.1144622; Lykidis A, 2007, J BACTERIOL, V189, P2477, DOI 10.1128/JB.01899-06; Merchant SS, 2007, SCIENCE, V318, P245, DOI 10.1126/science.1143609; Mosier N, 2005, BIORESOURCE TECHNOL, V96, P673, DOI 10.1016/j.biortech.2004.06.025; Nolling J, 2001, J BACTERIOL, V183, P4823, DOI 10.1128/JB.183.16.4823-4838.2001; OHTA K, 1991, APPL ENVIRON MICROB, V57, P893, DOI 10.1128/AEM.57.4.893-900.1991; Ragauskas AJ, 2006, SCIENCE, V311, P484, DOI 10.1126/science.1114736; Reddy N, 2005, TRENDS BIOTECHNOL, V23, P22, DOI 10.1016/j.tibtech.2004.11.002; Sanderson K, 2006, NATURE, V444, P673, DOI 10.1038/444673a; Seo JS, 2005, NAT BIOTECHNOL, V23, P63, DOI 10.1038/nbt1045; Taylor LE, 2006, J BACTERIOL, V188, P3849, DOI 10.1128/JB.01348-05; Tilman D, 2006, SCIENCE, V314, P1598, DOI 10.1126/science.1133306; Tuskan GA, 2006, SCIENCE, V313, P1596, DOI 10.1126/science.1128691; van Maris AJA, 2006, ANTON LEEUW INT J G, V90, P391, DOI 10.1007/s10482-006-9085-7; van Wyk JPH, 2001, TRENDS BIOTECHNOL, V19, P172, DOI 10.1016/S0167-7799(01)01601-8; Viikari L, 2007, ADV BIOCHEM ENG BIOT, V108, P121, DOI 10.1007/10_2007_065; Wang M, 2007, BIOELECTROCHEMISTRY, V71, P107, DOI 10.1016/j.bioelechem.2007.04.003; Warnecke F, 2007, NATURE, V450, P560, DOI 10.1038/nature06269; Yomano LP, 1998, J IND MICROBIOL BIOT, V20, P132, DOI 10.1038/sj.jim.2900496; Yu J, 2002, SCIENCE, V296, P79, DOI 10.1126/science.1068037	40	762	810	17	413	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 14	2008	454	7206					841	845		10.1038/nature07190	http://dx.doi.org/10.1038/nature07190			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	336XH	18704079				2022-12-28	WOS:000258398600026
J	Yusuf, S; Diener, H; Sacco, RL; Cotton, D; Ounpuu, S; Lawton, WA; Palesch, Y; Martin, RH; Albers, GW; Bath, P; Bornstein, N; Chan, BPL; Chen, S; Cunha, L; Dahlof, B; De Keyser, J; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lu, CZ; Machnig, T; Pais, P; Roberts, R; Skvortsova, V; Teal, P; Toni, D; VanderMaelen, C; Voigt, T; Weber, M; Yoon, B				Yusuf, Salim; Diener, Hans-Christoph; Sacco, Ralph L.; Cotton, Daniel; Ounpuu, Stephanie; Lawton, William A.; Palesch, Yuko; Martin, Renee H.; Albers, Gregory W.; Bath, Philip; Bornstein, Natan; Chan, Bernard P. L.; Chen, Sien-Tsong; Cunha, Luis; Dahlof, Bjorn; De Keyser, Jacques; Donnan, Geoffrey A.; Estol, Conrado; Gorelick, Philip; Gu, Vivian; Hermansson, Karin; Hilbrich, Lutz; Kaste, Markku; Lu, Chuanzhen; Machnig, Thomas; Pais, Prem; Roberts, Robin; Skvortsova, Veronika; Teal, Philip; Toni, Danilo; VanderMaelen, Cam; Voigt, Thor; Weber, Michael; Yoon, Byung-Woo		PRoFESS Study Grp	Telmisartan to prevent recurrent stroke and cardiovascular events	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BLOOD-PRESSURE; DOUBLE-BLIND; MORTALITY; RAMIPRIL; COMBINATION; RATIONALE; MORBIDITY; DESIGN; TRIAL	Background: Prolonged lowering of blood pressure after a stroke reduces the risk of recurrent stroke. In addition, inhibition of the renin-angiotensin system in high-risk patients reduces the rate of subsequent cardiovascular events, including stroke. However, the effect of lowering of blood pressure with a renin-angiotensin system inhibitor soon after a stroke has not been clearly established. We evaluated the effects of therapy with an angiotensin-receptor blocker, telmisartan, initiated early after a stroke. Methods: In a multicenter trial involving 20,332 patients who recently had an ischemic stroke, we randomly assigned 10,146 to receive telmisartan (80 mg daily) and 10,186 to receive placebo. The primary outcome was recurrent stroke. Secondary outcomes were major cardiovascular events (death from cardiovascular causes, recurrent stroke, myocardial infarction, or new or worsening heart failure) and new-onset diabetes. Results: The median interval from stroke to randomization was 15 days. During a mean follow-up of 2.5 years, the mean blood pressure was 3.8/2.0 mm Hg lower in the telmisartan group than in the placebo group. A total of 880 patients (8.7%) in the telmisartan group and 934 patients (9.2%) in the placebo group had a subsequent stroke (hazard ratio in the telmisartan group, 0.95; 95% confidence interval [CI], 0.86 to 1.04; P=0.23). Major cardiovascular events occurred in 1367 patients (13.5%) in the telmisartan group and 1463 patients (14.4%) in the placebo group (hazard ratio, 0.94; 95% CI, 0.87 to 1.01; P=0.11). New-onset diabetes occurred in 1.7% of the telmisartan group and 2.1% of the placebo group (hazard ratio, 0.82; 95% CI, 0.65 to 1.04; P=0.10). Conclusions: Therapy with telmisartan initiated soon after an ischemic stroke and continued for 2.5 years did not significantly lower the rate of recurrent stroke, major cardiovascular events, or diabetes. (ClinicalTrials.gov number, NCT00153062.).	[Yusuf, Salim] Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON L8L 2X2, Canada; [Roberts, Robin] McMaster Univ, Clin Trial Methodol Grp, Hamilton, ON, Canada; [Diener, Hans-Christoph] Univ Duisburg Essen, Essen, Germany; [Sacco, Ralph L.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA; [Cotton, Daniel; Hilbrich, Lutz; VanderMaelen, Cam; Voigt, Thor] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA; [Palesch, Yuko; Martin, Renee H.] Med Univ S Carolina, Charleston, SC 29425 USA; [Albers, Gregory W.] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA; [Bath, Philip] Univ Nottingham, Nottingham NG7 2RD, England; [Bornstein, Natan] Ichilov Hosp, Tel Aviv, Israel; [Chan, Bernard P. L.] Natl Univ Singapore Hosp, Singapore 117548, Singapore; [Chen, Sien-Tsong] Chang Gung Mem Hosp, Taipei 10591, Taiwan; [Cunha, Luis] Hosp Univ Coimbra, Coimbra, Portugal; [Dahlof, Bjorn] Sahlgrens Univ Hosp, S-41345 Gothenburg, Sweden; [De Keyser, Jacques] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands; [Donnan, Geoffrey A.] Univ Melbourne, Melbourne, Vic 3010, Australia; [Estol, Conrado] Neurol Ctr Treatment & Res, Buenos Aires, DF, Argentina; [Gorelick, Philip] Univ Illinois, Chicago, IL USA; [Kaste, Markku] Univ Helsinki, Cent Hosp, Helsinki, Finland; [Lu, Chuanzhen] Huashan Hosp, Shanghai, Peoples R China; [Pais, Prem] St Johns Med Coll, Bangalore, Karnataka, India; [Skvortsova, Veronika] Russian State Med Univ, Moscow 117437, Russia; [Teal, Philip] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Toni, Danilo] Univ Roma La Sapienza, Rome, Italy; [Weber, Michael] SUNY Downstate Coll Med, New York, NY USA; [Yoon, Byung-Woo] Seoul Natl Univ Hosp, Seoul 110744, South Korea	McMaster University; Population Health Research Institute; McMaster University; University of Duisburg Essen; University of Miami; Boehringer Ingelheim; Medical University of South Carolina; Stanford University; University of Nottingham; Tel Aviv University; National University of Singapore; Chang Gung Memorial Hospital; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); Sahlgrenska University Hospital; University of Groningen; University of Melbourne; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Helsinki; Helsinki University Central Hospital; Fudan University; St. John's National Academy of Health Sciences; St. John's Medical College; Pirogov Russian National Research Medical University; University of British Columbia; Sapienza University Rome; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Seoul National University (SNU); Seoul National University Hospital	Yusuf, S (corresponding author), Hamilton Hlth Sci, Populat Hlth Res Inst, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.	yusufs@mcmaster.ca	Varakin, Yuriy Ya/C-8634-2012; Timerbaeva, Sofia L/C-9051-2012; Kasner, Scott/C-6109-2011; Witte, Otto/P-4127-2018; Sacco, Ralph/Y-9278-2019; Moskovko, Gennadii/AAE-8505-2019; Iversen, Helle Klingenberg/B-9154-2009; Parfenov, Vladimir/AAG-7021-2019; amintaeva, asya/B-4416-2012; Kotov, Sergey V./E-4451-2017; bladin, chris/B-9136-2013; Tanne, David/F-2560-2010; Vanhooren, Geert/H-4433-2011; De Keyser, Jacques/D-3725-2013; Forsting, Michael/C-6925-2013; passmore, anthony/C-9824-2009; Parsons, Mark W./G-3750-2014; Kovrazhkina, Elena/AAR-2425-2021; Toni, Danilo/K-3151-2016; De Keyser, Jacques/AAA-8721-2021; Egido, Jose A/E-3837-2015; Luisa, Sacchetti/F-2644-2011; Hamann, Gerhard F./J-6300-2014; Chen, Christopher/E-7023-2013; LEYS, Didier/G-2955-2016; Bath, Philip/F-9020-2011; Skogar, Orjan/A-4084-2013	Witte, Otto/0000-0003-2101-4105; Moskovko, Gennadii/0000-0002-8349-8865; Parfenov, Vladimir/0000-0002-1992-7960; Kotov, Sergey V./0000-0002-8706-7317; Tanne, David/0000-0002-6699-2220; Vanhooren, Geert/0000-0001-6818-9346; De Keyser, Jacques/0000-0002-3394-7757; Toni, Danilo/0000-0003-2735-8427; De Keyser, Jacques/0000-0002-3394-7757; Egido, Jose A/0000-0003-1698-9127; Luisa, Sacchetti/0000-0002-2318-9868; Chen, Christopher/0000-0002-1047-9225; LEYS, Didier/0000-0003-4408-4392; Albers, Gregory/0000-0003-0263-4632; Papamitsakis, Nikolaos/0000-0001-9003-3399; Wieneke, Heinrich/0000-0002-6709-0982; Bath, Philip/0000-0003-2734-5132; De Falco, Fabrizio/0000-0001-5065-1678; Iversen, Helle Klingenberg/0000-0002-5880-6352; Wuttig, Helge/0000-0003-1877-8905; Teitelbaum, Jeanne/0000-0002-9834-3882; Poppert, Holger/0000-0003-2189-7681; Yusuf, Salim/0000-0003-4776-5601; Milo, Ron/0000-0001-8556-2579; Donnan, Geoffrey/0000-0001-6324-3403; Kaste, Markku/0000-0001-6557-6412; Cunha, Luis/0000-0002-0828-3485; corea, francesco/0000-0002-5864-9991; Skogar, Orjan/0000-0002-7527-7229; Molto Jorda, Jose Manuel/0000-0002-3861-6295; Dichgans, Martin/0000-0002-0654-387X; Consoli, Domenico/0000-0002-2050-5538; Fiebach, Jochen B./0000-0002-7936-6958; Dalkara, Turgay/0000-0003-3943-7819	Boehringer Ingelheim; Bayer Schering Pharma; GlaxoSmithKline; Sanofi-Aventis; Bristol-Myers Squibb; AstraZeneca; Abbott; Bayer Vital; D-Pharm; Fresenius; Janssen Cilag; Merck; Novartis; Novo Nordisk; Paion; Parke-Davis; Pfizer; Sankyo; Servier; Solvay; Thrombogenics; Wyeth; Yamaguchi; NMT Medical, Parexel International; Forest Research Institute; Daiichi Sankyo; Bayer; TAP Pharmaceutical Products; Myriad,; Takeda; Brainsgate; diaDexus; Forest Laboratories; Gilead; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K23NS054084] Funding Source: NIH RePORTER	Boehringer Ingelheim(Boehringer Ingelheim); Bayer Schering Pharma(Bayer AG); GlaxoSmithKline(GlaxoSmithKline); Sanofi-Aventis(Sanofi-Aventis); Bristol-Myers Squibb(Bristol-Myers Squibb); AstraZeneca(AstraZeneca); Abbott(Abbott Laboratories); Bayer Vital(Bayer AG); D-Pharm; Fresenius; Janssen Cilag(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Merck(Merck & Company); Novartis(Novartis); Novo Nordisk(Novo Nordisk); Paion; Parke-Davis; Pfizer(Pfizer); Sankyo; Servier(Servier); Solvay(Solvay SA); Thrombogenics; Wyeth(Wyeth); Yamaguchi; NMT Medical, Parexel International; Forest Research Institute; Daiichi Sankyo(Daiichi Sankyo Company Limited); Bayer(Bayer AG); TAP Pharmaceutical Products; Myriad,; Takeda(Takeda Pharmaceutical Company Ltd); Brainsgate; diaDexus; Forest Laboratories; Gilead(Gilead Sciences); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported by Boehringer Ingelheim. In selected countries, the telmisartan comparison was supported by Bayer Schering Pharma and GlaxoSmithKline.; Dr. Yusuf reports receiving consulting and lecture fees from Boehringer Ingelheim, Sanofi-Aventis, Bristol-Myers Squibb, AstraZeneca, and GlaxoSmithKline and grant support from Sanofi-Aventis, Bristol-Myers Squibb, and GlaxoSmithKline; Dr. Diener, receiving honoraria, consulting, and lecture fees from Abbott, AstraZeneca, Bayer Vital, Bristol-Myers Squibb, Boehringer Ingelheim, D-Pharm, Fresenius, GlaxoSmithKline, Janssen Cilag, Merck, Novartis, Novo Nordisk, Paion, Parke-Davis, Pfizer, Sanofi-Aventis, Sankyo, Servier, Solvay, Thrombogenics, Wyeth, and Yamaguchi and grant support from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Novartis, Janssen-Cilag, and Sanofi-Aventis; Dr. Sacco, receiving consulting fees from Boehringer Ingelheim, GlaxoSmithKline, and Sanofi-Aventis and lecture fees from Boehringer Ingelheim; Mr. Cotton, Mr. Lawton, and Drs. Ounpuu, Gu, Hermansson, Hilbrich, Machnig, VanderMaelen, and Voigt, being employees of Boehringer Ingelheim; Drs. Palesch and Martin, receiving consulting fees from Boehringer Ingelheim; Dr. Albers, receiving consulting and lecture fees from Boehringer Ingelheim and grant support from Boehringer Ingelheim, NMT Medical, Parexel International, AstraZeneca, and Forest Research Institute; Drs. Bath, Chen, De Keyser, and Estol, receiving consulting fees from Boehringer Ingelheim; Dr. Dahlof, receiving consulting fees from Boehringer Ingelheim, Daiichi Sankyo, and Novartis and lecture fees from Boehringer Ingelheim, Novartis, and Pfizer; Drs. Donnan and Kaste and Mr. Roberts, receiving consulting and lecture fees from Boehringer Ingelheim; Dr. Gorelick, receiving consulting fees from Boehringer Ingelheim, Bayer, TAP Pharmaceutical Products, Myriad, Pfizer, Takeda, Daiichi Sankyo, Novartis, Merck, Brainsgate, and D-Pharm and lecture fees from Boehringer Ingelheim and diaDexus; Dr. Pais, receiving consulting fees and grant support from Boehringer Ingelheim; Dr. Teal, receiving consulting and lecture fees from Sanofi-Aventis, Bristol-Myers Squibb, and Boehringer Ingelheim and consulting fees from Bayer; Dr. Toni, receiving consulting fees from Boehringer Ingelheim and lecture fees from Boehringer Ingelheim, Sanofi-Aventis, and Novo Nordisk; and Dr. Weber, receiving consulting and lecture fees or honoraria from Novartis, Bristol-Myers Squibb, Daiichi Sankyo, Boehringer Ingelheim, GlaxoSmithKline, and Forest Laboratories, consulting fees from Gilead and Takeda, and lecture fees or honoraria from Sanofi-Aventis. No other potential conflict of interest relevant to this article was reported.; We thank Colette Easton, Judy Lindeman, and Vicky Hinstridge for their technical assistance and Karuna Bellamkonda and Michael Pannucci for their programming support.	Bosch J, 2002, BMJ-BRIT MED J, V324, P699, DOI 10.1136/bmj.324.7339.699; Bosch J, 2006, NEW ENGL J MED, V355, P1551; Connolly S, 2006, AM HEART J, V151, P1187, DOI 10.1016/j.ahj.2005.06.026; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; De Giorgio L, 2000, NEW ENGL J MED, V342, P1376; Diener HC, 2007, CEREBROVASC DIS, V23, P368, DOI 10.1159/000100105; Elliott WJ, 2007, LANCET, V369, P1518; Leonardi-Bee J, 2002, STROKE, V33, P1315, DOI 10.1161/01.STR.0000014509.11540.66; LONN EM, 1994, CIRCULATION, V90, P2056, DOI 10.1161/01.CIR.90.4.2056; MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; PROGRESS Collaborat Grp, 2001, LANCET, V358, P1556; PROGRESS Collaborative Grp, 2002, LANCET, V359, P2120; Sacco R, 2008, CEREBROVASC DIS, V25, P192, DOI 10.1159/000113740; Schrader J, 2005, STROKE, V36, P1218, DOI 10.1161/01.STR.0000166048.35740.a9; Schrader J, 2003, STROKE, V34, P1699, DOI 10.1161/01.STR.0000075777.18006.89; Teo KK, 2004, AM HEART J, V148, P52, DOI 10.1016/j.ahj.2004.03.020; Turnbull F, 2003, LANCET, V362, P1527; Yong M, 2005, STROKE, V36, P2619, DOI 10.1161/01.STR.0000189998.74892.24; Yusuf S, 2001, JAMA-J AM MED ASSOC, V286, P1882, DOI 10.1001/jama.286.15.1882; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Yusuf S, 2008, NEW ENGL J MED, V358, P1547, DOI 10.1056/NEJMoa0801317	22	557	582	1	65	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 18	2008	359	12					1225	1237		10.1056/NEJMoa0804593	http://dx.doi.org/10.1056/NEJMoa0804593			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	349DV	18753639	Green Accepted, Green Published			2022-12-28	WOS:000259259900006
J	Brar, SS; Shen, AYJ; Jorgensen, MB; Kotlewski, A; Aharonian, VJ; Desai, N; Ree, M; Shah, AI; Burchette, RJ				Brar, Somjot S.; Shen, Albert Yuh-Jer; Jorgensen, Michael B.; Kotlewski, Adam; Aharonian, Vicken J.; Desai, Natasha; Ree, Michael; Shah, Ahmed Ijaz; Burchette, Raoul J.			Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE-RENAL-FAILURE; CHRONIC KIDNEY-DISEASE; FENOLDOPAM MESYLATE; DIABETES-MELLITUS; PREDICTION; NEPHROTOXICITY; INSUFFICIENCY; INTERVENTION; REDUCTIONS	Context Sodium bicarbonate has been suggested as a possible strategy for prevention of contrast medium - induced nephropathy, a common cause of renal failure associated with prolonged hospitalization, increased health care costs, and substantial morbidity and mortality. Objective To determine if sodium bicarbonate is superior to sodium chloride for preventing contrast medium - induced nephropathy in patients with moderate to severe chronic kidney dysfunction who are undergoing coronary angiography. Design, Setting, and Patients Randomized, controlled, single- blind study conducted between January 2, 2006, and January 31, 2007, and enrolling 353 patients with stable renal disease who were undergoing coronary angiography at a single US center. Included patients were 18 years or older and had an estimated glomerular filtration rate of 60 mL/ min per 1.73 m(2) or less and 1 or more of diabetes mellitus, history of congestive heart failure, hypertension, or age older than 75 years. Interventions Patients were randomized to receive either sodium chloride ( n= 178) or sodium bicarbonate ( n= 175) administered at the same rate ( 3 mL/ kg for 1 hour before coronary angiography, decreased to 1.5 mL/ kg per hour during the procedure and for 4 hours after the completion of the procedure). Main Outcome Measure The primary end point was a 25% or greater decrease in the estimated glomerular filtration rate on days 1 through 4 after contrast exposure. Results Median patient age was 71 ( interquartile range, 65- 76) years, and 45% had diabetes mellitus. The groups were well matched for baseline characteristics. The primary end point was met in 13.3% of the sodium bicarbonate group and 14.6% of the sodium chloride group ( relative risk, 0.94; 95% confidence interval, 0.55- 1.60; P=. 82). In patients randomized to receive sodium bicarbonate vs sodium chloride, the rates of death, dialysis, myocardial infarction, and cerebrovascular events did not differ significantly at 30 days ( 1.7% vs 1.7%, 0.6% vs 1.1%, 0.6% vs 0%, and 0% vs 2.2%, respectively) or at 30 days to 6 months ( 0.6% vs 2.3%, 0.6% vs 1.1%, 0.6% vs 2.3%, and 0.6% vs 1.7%, respectively) ( P >.10 for all). Conclusion The results of this study do not suggest that hydration with sodium bicarbonate is superior to hydration with sodium chloride for the prevention of contrast medium - induced nephropathy in patients with moderate to severe chronic kidney disease who are undergoing coronary angiography. Trial Registration clinicaltrials. gov Identifier: NCT00312117.	[Brar, Somjot S.] Columbia Univ, Med Ctr, Ctr Intervent Vasc Therapy, New York, NY 10032 USA; [Shen, Albert Yuh-Jer; Jorgensen, Michael B.; Kotlewski, Adam; Aharonian, Vicken J.; Desai, Natasha; Ree, Michael; Shah, Ahmed Ijaz] Kaiser Permanente, Los Angeles, CA USA; [Shen, Albert Yuh-Jer; Jorgensen, Michael B.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA	Columbia University; Kaiser Permanente	Brar, SS (corresponding author), Columbia Univ, Med Ctr, Ctr Intervent Vasc Therapy, 161 Ft Washington Ave,5th Floor, New York, NY 10032 USA.	sbrar@cvri.org	Shah, Ahmed/GRX-6522-2022		Kaiser Permanente Southern California	Kaiser Permanente Southern California	This study was supported by Kaiser Permanente Southern California.	Aspelin P, 2003, NEW ENGL J MED, V348, P491, DOI 10.1056/NEJMoa021833; ATKINS JL, 1986, NEPHRON, V44, P70, DOI 10.1159/000183915; Barrett BJ, 2006, NEW ENGL J MED, V354, P379, DOI 10.1056/NEJMcp050801; Briguori C, 2007, CIRCULATION, V115, P1211, DOI 10.1161/CIRCULATIONAHA.106.687152; CAMPBELL DR, 1990, J CAN ASSOC RADIOL, V41, P133; Caulfield JL, 1996, J BIOL CHEM, V271, P25859, DOI 10.1074/jbc.271.42.25859; Dangas G, 2005, AM J CARDIOL, V95, P13, DOI 10.1016/j.amjcard.2004.08.056; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; Iakovou Ioannis, 2003, J Invasive Cardiol, V15, P18; Katholi RE, 1998, AM J KIDNEY DIS, V32, P64, DOI 10.1053/ajkd.1998.v32.pm9669426; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Levy EM, 1996, JAMA-J AM MED ASSOC, V275, P1489, DOI 10.1001/jama.275.19.1489; MANSKE CL, 1990, AM J MED, V89, P615, DOI 10.1016/0002-9343(90)90180-L; McCullough PA, 1997, AM J MED, V103, P368, DOI 10.1016/S0002-9343(97)00150-2; McCullough PA, 2006, AM J CARDIOL, V98, p27K, DOI 10.1016/amjcard.2006.01.022; Mehran R, 2004, J AM COLL CARDIOL, V44, P1393, DOI 10.1016/j.jacc.2004.06.068; Merten GJ, 2004, JAMA-J AM MED ASSOC, V291, P2328, DOI 10.1001/jama.291.19.2328; MOORE RD, 1992, RADIOLOGY, V182, P649, DOI 10.1148/radiology.182.3.1535876; Nikolsky E, 2005, KIDNEY INT, V67, P706, DOI 10.1111/j.1523-1755.2005.67131.x; Nikolsky E, 2004, AM J CARDIOL, V94, P300, DOI 10.1016/j.amjcard.2004.04.023; Nikolsky Eugenia, 2003, Rev Cardiovasc Med, V4 Suppl 1, pS7; PARFREY PS, 1989, NEW ENGL J MED, V320, P143, DOI 10.1056/NEJM198901193200303; RUDNICK MR, 1995, KIDNEY INT, V47, P254, DOI 10.1038/ki.1995.32; RUSSO D, 1995, J AM SOC NEPHROL, V6, P1451; Solomon RJ, 2007, CIRCULATION, V115, P3189, DOI 10.1161/CIRCULATIONAHA.106.671644; Spargias K, 2004, CIRCULATION, V110, P2837, DOI 10.1161/01.CIR.0000146396.19081.73; SPARGIAS K, 2005, CIRCULATION, V111, P379; SPORER H, 1981, EUR J CLIN INVEST, V11, P311, DOI 10.1111/j.1365-2362.1981.tb02122.x; Stone GW, 2003, JAMA-J AM MED ASSOC, V290, P2284, DOI 10.1001/jama.290.17.2284; Tepel M, 2000, NEW ENGL J MED, V343, P180, DOI 10.1056/NEJM200007203430304; Thygesen K, 2007, J AM COLL CARDIOL, V50, P2173, DOI 10.1016/j.jacc.2007.09.011; Tumlin JA, 2002, AM HEART J, V143, P894, DOI 10.1067/mhj.2002.122118	32	265	286	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	2008	300	9					1038	1046		10.1001/jama.300.9.1038	http://dx.doi.org/10.1001/jama.300.9.1038			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	342YN	18768415				2022-12-28	WOS:000258819600020
J	Heidemann, C; Sun, Q; van Dam, RM; Meigs, JB; Zhang, CL; Tworoger, SS; Mantzoros, CS; Hu, FB				Heidemann, Christin; Sun, Qi; van Dam, Rob M.; Meigs, James B.; Zhang, Cuilin; Tworoger, Shelley S.; Mantzoros, Christos S.; Hu, Frank B.			Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-ARTERY-DISEASE; INSULIN-RESISTANCE; METABOLIC SYNDROME; SERUM RESISTIN; PLASMA RESISTIN; ADIPOSE-TISSUE; OLDER MEN; MELLITUS; OBESITY; HUMANS	Background: Adiponectin and resistin are recently discovered adipokines that may provide a molecular link between adiposity and type 2 diabetes. Objective: To evaluate whether total and high-molecular-weight adiponectin and resistin are associated with future risk for type 2 diabetes, independent of obesity and other known diabetes risk factors. Design: Prospective, nested, case - control study. Setting: United States. Participants: 1038 initially healthy women of the Nurses' Health Study who developed type 2 diabetes after blood sampling (1989 to 1990) through 2002 and 1136 matched control participants. Measurements: Plasma concentrations of total and high-molecular-weight adiponectin and resistin. Results: In multivariate models including body mass index, higher total and high-molecular-weight adiponectin levels were associated with a substantially lower risk for type 2 diabetes (odds ratio [OR] comparing the highest with the lowest quintiles, 0.17 [95% CI, 0.12 to 0.25] for total adiponectin and 0.10 [CI, 0.06 to 0.15] for high-molecular-weight adiponectin). A higher ratio of high-molecular-weight to total adiponectin was associated with a statistically significantly lower risk even after adjustment for total adiponectin (OR, 0.45 [CI, 0.31 to 0.65]). In the multivariate model without body mass index, higher resistin levels were associated with a higher risk for diabetes (OR, 1.68 [CI, 1.25 to 2.25]), but the association was no longer statistically significant after adjustment for body mass index (OR, 1.28 [CI, 0.93 to 1.76]). Limitation: The findings apply mainly to white women and could be partly explained by residual confounding from imperfectly measured or unmeasured variables. Conclusion: Adiponectin is strongly and inversely associated with risk for diabetes, independent of body mass index, whereas resistin is not. The ratio of high-molecular-weight to total adiponectin is related to risk for diabetes independent of total adiponectin, suggesting an important role of the relative proportion of high-molecular-weight adiponectin in diabetes pathogenesis.	Harvard Univ, Sch Publ Hlth, Massachusetts Gen Hosp, Brigham & Womens Hosp, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; NIH, Bethesda, MD 20892 USA	Harvard University; Brigham & Women's Hospital; Harvard T.H. Chan School of Public Health; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; National Institutes of Health (NIH) - USA	Hu, FB (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02215 USA.	frank.hu@channing.harvard.edu	Hu, Frank/C-1919-2013; van Dam, Rob M/F-9674-2010; Mantzoros, Christos/Y-2902-2019; Meigs, James/P-3927-2019	van Dam, Rob M/0000-0002-7354-8734; Meigs, James/0000-0002-2439-2657; Tworoger, Shelley/0000-0002-6986-7046; Zhang, Cuilin/0000-0002-8014-2708	National Institute of Child Health & Human Development [CA87969, DK58845, DK58785]; German Academic Exchange Service; Hans & Eugenia Juetting Foundation; American Diabetes; Tanita Corporation; Beth Israel Deaconess Medical Center; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008888] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA087969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058845, R56DK058785, R01DK058785, K24DK080140] Funding Source: NIH RePORTER	National Institute of Child Health & Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); German Academic Exchange Service(Deutscher Akademischer Austausch Dienst (DAAD)); Hans & Eugenia Juetting Foundation; American Diabetes(American Diabetes Association); Tanita Corporation; Beth Israel Deaconess Medical Center; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	By the National Institutes of Health and the Intramural Research Program of the National Institute of Child Health & Human Development (grants CA87969, DK58845 and DK58785). Dr. Heidemann was supported by fellowships of the German Academic Exchange Service and the Hans & Eugenia Juetting Foundation. Dr. Meigs received a Career Development Award from the American Diabetes. Dr. Mantzoros was supported by discretionary grants from the Tanita Corporation and Beth Israel Deaconess Medical Center.	Ahima RS, 2006, OBESITY, V14, P242, DOI 10.1038/oby.2006.317; AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Al-Harithy RN, 2005, ANN SAUDI MED, V25, P283, DOI 10.5144/0256-4947.2005.283; Bayes B, 2007, AM J TRANSPLANT, V7, P416, DOI 10.1111/j.1600-6143.2006.01646.x; Bluher M, 2007, DIABETES CARE, V30, P280, DOI 10.2337/dc06-1362; Bruun JM, 2003, AM J PHYSIOL-ENDOC M, V285, pE527, DOI 10.1152/ajpendo.00110.2003; Chanchay S, 2006, INT J VITAM NUTR RES, V76, P125, DOI 10.1024/0300-9831.76.3.125; Chandran M, 2003, DIABETES CARE, V26, P2442, DOI 10.2337/diacare.26.8.2442; Choi KM, 2004, CLIN ENDOCRINOL, V61, P75, DOI 10.1111/j.1365-2265.2004.02063.x; Colditz GA, 2005, NAT REV CANCER, V5, P388, DOI 10.1038/nrc1608; Daimon M, 2003, DIABETES CARE, V26, P2015, DOI 10.2337/diacare.26.7.2015; de Courten BV, 2004, DIABETES, V53, P1279, DOI 10.2337/diabetes.53.5.1279; Degawa-Yamauchi M, 2003, J CLIN ENDOCR METAB, V88, P5452, DOI 10.1210/jc.2002-021808; Field AE, 2001, ARCH INTERN MED, V161, P1581, DOI 10.1001/archinte.161.13.1581; Fisher FM, 2005, DIABETOLOGIA, V48, P1084, DOI 10.1007/s00125-005-1758-7; GREENLAND S, 1995, EPIDEMIOLOGY, V6, P356, DOI 10.1097/00001648-199507000-00005; GREENLAND S, 1998, MODERN EPIDEMIOLOGY, P201; Hara K, 2006, DIABETES CARE, V29, P1357, DOI 10.2337/dc05-1801; Heilbronn LK, 2004, J CLIN ENDOCR METAB, V89, P1844, DOI 10.1210/jc.2003-031410; Hu FB, 2004, DIABETES, V53, P693, DOI 10.2337/diabetes.53.3.693; Hu FB, 1999, JAMA-J AM MED ASSOC, V282, P1433, DOI 10.1001/jama.282.15.1433; Kaplan RC, 2007, CANCER EPIDEM BIOMAR, V16, P1291, DOI 10.1158/1055-9965.EPI-06-1089; Knobler H, 2006, EUR J ENDOCRINOL, V154, P87, DOI 10.1530/eje.1.02054; Koenig W, 2006, J AM COLL CARDIOL, V48, P1369, DOI 10.1016/j.jacc.2006.06.053; Lara-Castro C, 2006, DIABETES, V55, P249, DOI 10.2337/diabetes.55.1.249; Lee JH, 2003, J CLIN ENDOCR METAB, V88, P4848, DOI 10.1210/jc.2003-030519; Lindsay RS, 2002, LANCET, V360, P57, DOI 10.1016/S0140-6736(02)09335-2; Lu HL, 2006, WORLD J GASTROENTERO, V12, P1747, DOI 10.3748/wjg.v12.i11.1747; McTernan PG, 2006, CURR OPIN LIPIDOL, V17, P170, DOI 10.1097/01.mol.0000217899.59820.9a; Mitchell M, 2005, REPRODUCTION, V130, P583, DOI 10.1530/rep.1.00521; Nakashima R, 2006, J CLIN ENDOCR METAB, V91, P3873, DOI 10.1210/jc.2006-1158; Norata GD, 2007, EUR J ENDOCRINOL, V156, P279, DOI 10.1530/eje.1.02338; Oh DK, 2007, DIABETES OBES METAB, V9, P282, DOI 10.1111/j.1463-1326.2006.00610.x; Pang SS, 2006, CELL MOL IMMUNOL, V3, P29; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Schulze MB, 2005, ANNU REV PUBL HEALTH, V26, P445, DOI 10.1146/annurev.publhealth.26.021304.144532; Schulze MB, 2005, DIABETIC MED, V22, P1178, DOI 10.1111/j.1464-5491.2005.01585.x; Silha JV, 2003, EUR J ENDOCRINOL, V149, P331, DOI 10.1530/eje.0.1490331; Snehalatha C, 2003, DIABETES CARE, V26, P3226, DOI 10.2337/diacare.26.12.3226; Snijder MB, 2006, DIABETES CARE, V29, P2498, DOI 10.2337/dc06-0952; Spranger J, 2003, LANCET, V361, P226, DOI 10.1016/S0140-6736(03)12255-6; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Tokuyama Y, 2007, METABOLISM, V56, P693, DOI 10.1016/j.metabol.2006.12.019; Utzschneider KM, 2005, DIABETOLOGIA, V48, P2330, DOI 10.1007/s00125-005-1932-y; Wannamethee SG, 2007, DIABETES CARE, V30, P1200, DOI 10.2337/dc06-2416; Willett W.C., 1998, SAUPTIKAPARVAN MAHAB, DOI [10.1093/acprof:oso/9780195122978.001.0001, DOI 10.1093/ACPROF:OSO/9780195122978.001.0001, DOI 10.1093/ACPROF:OSO/9780195122978.003.11]; Yaturu S, 2006, CYTOKINE, V34, P219, DOI 10.1016/j.cyto.2006.05.005; Youn BS, 2004, J CLIN ENDOCR METAB, V89, P150, DOI 10.1210/jc.2003-031121	48	163	174	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2008	149	5					307	W66		10.7326/0003-4819-149-5-200809020-00005	http://dx.doi.org/10.7326/0003-4819-149-5-200809020-00005			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	348SD	18765700	Green Accepted			2022-12-28	WOS:000259229300003
J	Bambra, CI				Bambra, Clare I.			Incapacity benefit reform and the politics of ill health	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Bambra, Clare I.] Wolfson Res Inst, Stockton On Tees, England	Durham University	Bambra, CI (corresponding author), Wolfson Res Inst, Stockton On Tees, England.	clare.bambra@durham.ac.uk	Bambra, Clare l/C-1392-2010	Bambra, Clare l/0000-0002-1294-6851					0	16	16	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 30	2008	337	7668							a1452	10.1136/bmj.a1452	http://dx.doi.org/10.1136/bmj.a1452			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	350OM	18753173				2022-12-28	WOS:000259362100034
J	Dean, AJ; Clark, DJ; Stephen, JB; McBride, VA; Bassani, L; Bazzano, A; Bird, AJ; Hill, AB; Shaw, SE; Ubertini, P				Dean, A. J.; Clark, D. J.; Stephen, J. B.; McBride, V. A.; Bassani, L.; Bazzano, A.; Bird, A. J.; Hill, A. B.; Shaw, S. E.; Ubertini, P.			Polarized gamma-ray emission from the crab	SCIENCE			English	Article							PULSAR WIND NEBULA; SYNCHROTRON NEBULA; VELA PULSAR; CHANDRA; POLARIMETRY; SPECTRUM; JET	Pulsar systems accelerate particles to immense energies. The detailed functioning of these engines is still poorly understood, but polarization measurements of high- energy radiation may allow us to locate where the particles are accelerated. We have detected polarized gamma rays from the vicinity of the Crab pulsar using data from the spectrometer on the International Gamma- Ray Astrophysics Laboratory satellite. Our results show polarization with an electric vector aligned with the spin axis of the neutron star, demonstrating that a substantial fraction of the high- energy electrons responsible for the polarized photons are produced in a highly ordered structure close to the pulsar.	[Dean, A. J.; Clark, D. J.; McBride, V. A.; Bird, A. J.; Hill, A. B.; Shaw, S. E.] Univ Southampton, Sch Phys & Astron, Southampton SO17 1BJ, Hants, England; [Stephen, J. B.; Bassani, L.] INAF IASF, I-40129 Bologna, Italy; [Bazzano, A.; Ubertini, P.] INAF IASF, I-00133 Rome, Italy	University of Southampton; Istituto Nazionale Astrofisica (INAF); Istituto Nazionale Astrofisica (INAF)	Dean, AJ (corresponding author), Univ Southampton, Sch Phys & Astron, Southampton SO17 1BJ, Hants, England.			Hill, Adam/0000-0003-3470-4834; Bassani, Loredana/0000-0003-4858-6963; Bazzano, Angela/0000-0002-2017-4396	ESA project; Italian Space Agency [I/R/008/07/0]; United Kingdom by Science and Technology Funding Council [PP/C000714/1]; STFC [PP/D001013/1] Funding Source: UKRI; Science and Technology Facilities Council [PP/D001013/1] Funding Source: researchfish	ESA project; Italian Space Agency(Agenzia Spaziale Italiana (ASI)); United Kingdom by Science and Technology Funding Council; STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))	The authors thank C. Jordain and P. Dubath for supplying Crab ephemeris data and the University of Southampton for the use of their Iridis 2 Beowulf Cluster. This paper is based on observations with INTEGRAL, an ESA project with instruments and science data center funded by ESA member states (especially the principal investigator countries: Denmark, France, Germany, Italy, Switzerland, and Spain), the Czech Republic, and Poland, and with the participation of Russia and the United States. This work was supported by the Italian Space Agency with contract I/R/008/07/0 and in the United Kingdom by Science and Technology Funding Council grant PP/C000714/1.	Agostinelli S, 2003, NUCL INSTRUM METH A, V506, P250, DOI 10.1016/S0168-9002(03)01368-8; Aharonian F, 2006, ASTRON ASTROPHYS, V457, P899, DOI 10.1051/0004-6361:20065351; Aharonian F, 2005, SCIENCE, V307, P1938, DOI 10.1126/science.1108643; Bird AJ, 2007, ASTROPHYS J SUPPL S, V170, P175, DOI 10.1086/513148; Gaensler BM, 2002, ASTROPHYS J, V569, P878, DOI 10.1086/339354; Gaensler BM, 2001, ASTROPHYS J, V556, pL107, DOI 10.1086/322982; Gotthelf EV, 2000, ASTROPHYS J, V532, pL117, DOI 10.1086/312568; Helfand DJ, 2001, ASTROPHYS J, V556, P380, DOI 10.1086/321533; HESTER JJ, 1995, ASTROPHYS J, V448, P240, DOI 10.1086/175956; Hester JJ, 2002, ASTROPHYS J, V577, pL49, DOI 10.1086/344132; Kanbach G, 2005, AIP CONF PROC, V801, P306, DOI 10.1063/1.2141887; Kirsch MGF, 2006, ASTRON ASTROPHYS, V453, P173, DOI 10.1051/0004-6361:20054783; Kuiper L, 2001, ASTRON ASTROPHYS, V378, P918, DOI 10.1051/0004-6361:20011256; Laing RA, 2002, MON NOT R ASTRON SOC, V336, P328, DOI 10.1046/j.1365-8711.2002.05756.x; Lei F, 1997, SPACE SCI REV, V82, P309, DOI 10.1023/A:1005027107614; Massaro E, 2006, ASTRON ASTROPHYS, V459, P859, DOI 10.1051/0004-6361:20065118; Mizuno T, 2005, NUCL INSTRUM METH A, V540, P158, DOI 10.1016/j.nima.2004.11.009; Mori K, 2004, ASTROPHYS J, V609, P186, DOI 10.1086/421011; Ng CY, 2004, ASTROPHYS J, V601, P479, DOI 10.1086/380486; Pavlov GG, 2003, ASTROPHYS J, V591, P1157, DOI 10.1086/375531; Pavlov GG, 2001, ASTROPHYS J, V554, pL189, DOI 10.1086/321721; Perlman ES, 2006, ASTROPHYS J, V651, P735, DOI 10.1086/506587; Roberts MSE, 2003, ASTROPHYS J, V588, P992, DOI 10.1086/374266; Takata J, 2007, ASTROPHYS J, V656, P1044, DOI 10.1086/510190; Weisskopf MC, 2000, ASTROPHYS J, V536, pL81, DOI 10.1086/312733; WEISSKOPF MC, 1978, ASTROPHYS J, V220, pL117, DOI 10.1086/182648; Willingale R, 2001, ASTRON ASTROPHYS, V365, pL212, DOI 10.1051/0004-6361:20000114; Winkler C, 2003, ASTRON ASTROPHYS, V411, pL1, DOI 10.1051/0004-6361:20031288	28	170	170	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 29	2008	321	5893					1183	1185		10.1126/science.1149056	http://dx.doi.org/10.1126/science.1149056			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341ZM	18755970				2022-12-28	WOS:000258754400036
J	Melhuish, EC; Sylva, K; Sammons, P; Siraj-Blatchford, I; Taggart, B; Phan, MB; Malin, A				Melhuish, Edward C.; Sylva, Kathy; Sammons, Pam; Siraj-Blatchford, Iram; Taggart, Brenda; Phan, Mai B.; Malin, Antero			The early years - Preschool influences on mathematics achievement	SCIENCE			English	Editorial Material							COGNITIVE-DEVELOPMENT; HEAD-START; CHILDHOOD; CHILDREN; INEQUALITY; EXPERIENCE; PROGRAM; CENTERS; SCHOOL		[Melhuish, Edward C.; Malin, Antero] Univ London Birkbeck Coll, Inst Study Children Families & Social Issues, London WC1B 3RA, England; [Sylva, Kathy] Univ Oxford, Oxford OX2 6PY, England; [Sammons, Pam] Univ Nottingham, Nottingham NG8 1BB, England; [Siraj-Blatchford, Iram; Taggart, Brenda] Univ London, Inst Educ, London WC1H 0AL, England; [Phan, Mai B.] Univ Kent, Canterbury CT2 7NZ, Kent, England	University of London; Birkbeck University London; University of Oxford; University of Nottingham; University of London; University College London; UCL Institute of Education; University of Kent	Melhuish, EC (corresponding author), Univ London Birkbeck Coll, Inst Study Children Families & Social Issues, 7 Bedford Sq, London WC1B 3RA, England.	e.melhuish@bbk.ac.uk	Sammons, Pamela/AAF-7210-2021	Sammons, Pamela/0000-0001-6988-6784				Aboud FE, 2006, EARLY CHILD RES Q, V21, P46, DOI 10.1016/j.ecresq.2006.01.008; Berlinski S., 2006, EFFECT PREPRIMARY ED; Berlinski S., 2007, GIVING CHILDREN BETT; Currie J, 2000, J HUM RESOUR, V35, P755, DOI 10.2307/146372; Diamond A, 2007, SCIENCE, V318, P1387, DOI 10.1126/science.1151148; Feinstein L, 2003, ECONOMICA, V70, P73, DOI 10.1111/1468-0335.t01-1-00272; Goldstein H, 1995, MULTILEVEL STAT MODE, V2nd; Heckman JJ, 2006, SCIENCE, V312, P1900, DOI 10.1126/science.1128898; Karoly LA., 2005, EARLY CHILDHOOD INTE; Loeb S, 2007, ECON EDUC REV, V26, P52, DOI 10.1016/j.econedurev.2005.11.005; Love JM, 2005, DEV PSYCHOL, V41, P885, DOI 10.1037/0012-1649.41.6.885; McCain M., 1999, EARLY YEARS STUDY RE; Melhuish EC, 2008, J SOC ISSUES, V64, P95, DOI 10.1111/j.1540-4560.2008.00550.x; Montie JE, 2006, EARLY CHILD RES Q, V21, P313, DOI 10.1016/j.ecresq.2006.07.007; Organization for Economic Co-operation and Development, 2004, LEARN TOM WORLD 1 RE; Reynolds AJ, 2004, CHILD DEV, V75, P1299, DOI 10.1111/j.1467-8624.2004.00742.x; Sacker A, 2002, SOC SCI MED, V55, P863, DOI 10.1016/S0277-9536(01)00228-3; SAMMONS P, 2002, 8A U LOND I ED; Sammons P., 1999, SCH EFFECTIVENESS CO; SYLVA K, 2004, 12 DFES DEP ED SKILL; Sylva K, 2007, INT J EARLY YEARS ED, V15, P49, DOI 10.1080/09669760601106968; United Nations Educational Scientific and Cultural Organization, 2021, EARL CHILDH CAR ED; Zigler E, 2006, VISION FOR UNIVERSAL PRESCHOOL EDUCATION, P1, DOI 10.2277/ 0521612993	23	122	125	3	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 29	2008	321	5893					1161	1162		10.1126/science.1158808	http://dx.doi.org/10.1126/science.1158808			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	341ZM	18755959				2022-12-28	WOS:000258754400025
J	Morgan, JV				Morgan, Joanna V.			Comment on determining chondritic impactor size from the marine osmium isotope record	SCIENCE			English	Editorial Material							PROJECTILE		Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England	Imperial College London	Morgan, JV (corresponding author), Univ London Imperial Coll Sci Technol & Med, S Kensington Campus, London SW7 2AZ, England.	j.morgan@imperial.ac.uk						ALVAREZ LW, 1980, SCIENCE, V208, P1095, DOI 10.1126/science.208.4448.1095; Baldwin EC, 2007, METEORIT PLANET SCI, V42, P1905, DOI 10.1111/j.1945-5100.2007.tb00549.x; Ivanov BA, 2005, SOLAR SYST RES+, V39, P381, DOI 10.1007/s11208-005-0051-0; Morgan J, 1997, NATURE, V390, P472, DOI 10.1038/37291; MORGAN J, 2008, LARGE METEORITE IMPA, V4, P3016; Paquay FS, 2008, SCIENCE, V320, P214, DOI 10.1126/science.1152860; Pierazzo E, 2000, METEORIT PLANET SCI, V35, P117, DOI 10.1111/j.1945-5100.2000.tb01979.x; Vickery A.M., 1990, GEOL SOC AM SPEC PAP, V247, P289, DOI DOI 10.1130/SPE247-P289); Wilson L, 1999, METEORIT PLANET SCI, V34, P479, DOI 10.1111/j.1945-5100.1999.tb01355.x	9	5	5	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 29	2008	321	5893								10.1126/science.1159174	http://dx.doi.org/10.1126/science.1159174			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341ZM	18755958				2022-12-28	WOS:000258754400021
J	Kumle, M				Kumle, Merethe			Declining breast cancer incidence and decreased HRT use	LANCET			English	Editorial Material							THERAPY		Univ Tromso, Inst Community Med, Fac Med, N-9037 Tromso, Norway	UiT The Arctic University of Tromso	Kumle, M (corresponding author), Univ Tromso, Inst Community Med, Fac Med, N-9037 Tromso, Norway.	Merethe.Kumle@ism.uit.no						Allemand H, 2008, B CANCER, V95, P11, DOI 10.1684/bdc.2008.0556; Beral V, 2006, J MED SCREEN, V13, P59, DOI 10.1258/096914106777589678; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Canfell K, 2008, MED J AUSTRALIA, V188, P1; Eggen AE, 2005, J CLIN ONCOL, V23, P3636, DOI 10.1200/JCO.2005.05.378; Hofvind S, 2008, ACTA ONCOL, V47, P225, DOI 10.1080/02841860701518041; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; JOHNSTON M, 2006, NZ HERALD       1220; Katalinic A, 2008, BREAST CANCER RES TR, V107, P427, DOI 10.1007/s10549-007-9566-z; Kerlikowske K, 2007, JNCI-J NATL CANCER I, V99, P1335, DOI 10.1093/jnci/djm111; Kliewer EV, 2007, NEW ENGL J MED, V357, P509; *NORW I PUBL HLTH, DRUG CONS NORW; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Ravdin PM, 2007, NEW ENGL J MED, V356, P1670, DOI 10.1056/NEJMsr070105; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Soerjomataram I, 2007, J CLIN ONCOL, V25, P5038, DOI 10.1200/JCO.2007.13.7281; The Norwegian Cancer Registry, 2008, INC DAT BREAST CANC; Zahl PH, 2007, NEW ENGL J MED, V357, P510	18	95	97	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	2008	372	9639					608	610		10.1016/S0140-6736(08)61255-6	http://dx.doi.org/10.1016/S0140-6736(08)61255-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	340BX	18722851				2022-12-28	WOS:000258622200007
J	Ferrari, R; Pellegrini, M; Horwitz, GA; Xie, W; Berk, AJ; Kurdistani, SK				Ferrari, Roberto; Pellegrini, Matteo; Horwitz, Gregory A.; Xie, Wei; Berk, Arnold J.; Kurdistani, Siavash K.			Epigenetic reprogramming by adenovirus e1a	SCIENCE			English	Article							VIRAL MECHANISM; REVEALS; CELLS	Adenovirus e1a induces quiescent human cells to replicate. We found that e1a causes global relocalization of the RB ( retinoblastoma) proteins ( RB, p130, and p107) and p300/ CBP histone acetyltransferases on promoters, the effect of which is to restrict the acetylation of histone 3 lysine- 18 ( H3K18ac) to a limited set of genes, thereby stimulating cell cycling and inhibiting antiviral responses and cellular differentiation. Soon after expression, e1a binds transiently to promoters of cell cycle and growth genes, causing enrichment of p300/ CBP, PCAF ( p300/ CBP- associated factor), and H3K18ac; depletion of RB proteins; and transcriptional activation. e1a also associates transiently with promoters of antiviral genes, causing enrichment for RB, p130, and H4K16ac; increased nucleosome density; and transcriptional repression. At later times, e1a and p107 bind mainly to promoters of development and differentiation genes, repressing transcription. The temporal order of e1a binding requires its interactions with p300/ CBP and RB proteins. Our data uncover a defined epigenetic reprogramming leading to cellular transformation.	[Ferrari, Roberto; Xie, Wei; Kurdistani, Siavash K.] Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; [Pellegrini, Matteo] Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA; [Horwitz, Gregory A.; Berk, Arnold J.] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; [Berk, Arnold J.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; [Kurdistani, Siavash K.] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; [Kurdistani, Siavash K.] Univ Calif Los Angeles, David Geffen Sch Med, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Kurdistani, SK (corresponding author), Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA.	skurdistani@mednet.ucla.edu	Ferrari, Roberto/O-8143-2015; BERK, ARNOLD/AAF-7052-2020; Xie, Wei/J-1380-2017	Ferrari, Roberto/0000-0002-0453-0899; Xie, Wei/0000-0003-2126-3849; Kurdistani, Siavash/0000-0003-3295-3511; Pellegrini, Matteo/0000-0001-9355-9564	U. S. Public Health Service [CA25235]; HHMI Early Career Award; UCLA Specialized Program of Research Excellence in Prostate Cancer; American Society Cancer grant; NATIONAL CANCER INSTITUTE [R01CA025235, R37CA025235] Funding Source: NIH RePORTER	U. S. Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); HHMI Early Career Award(Howard Hughes Medical Institute); UCLA Specialized Program of Research Excellence in Prostate Cancer; American Society Cancer grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank M. Carey for critical comments, M. Grunstein for providing the histone acetylation antibodies, and C. Millar and A. Sperling and for help with microarrays. Supported by U. S. Public Health Service grant CA25235 (A. J. B.), an HHMI Early Career Award, a UCLA Specialized Program of Research Excellence in Prostate Cancer grant, and an Society American Cancer grant ( S. K. K.). Microarray data have been deposited in the Gene Expression Omnibus under accession numbers GSE12045, GSE12046, and GSE12047.	Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Elemento O, 2007, MOL CELL, V28, P337, DOI 10.1016/j.molcel.2007.09.027; Ghosh MK, 2003, MOL CELL, V12, P255, DOI 10.1016/S1097-2765(03)00225-9; Horwitz GA, 2008, SCIENCE, V321, P1084, DOI 10.1126/science.1155544; Liu X, 2007, GENE DEV, V21, P2711, DOI 10.1101/gad.1590607; Miller DL, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-4-r58; MONTELL C, 1984, CELL, V36, P951, DOI 10.1016/0092-8674(84)90045-X; Mujtaba S, 2007, ONCOGENE, V26, P5521, DOI 10.1038/sj.onc.1210618; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Xu XQ, 2007, GENOME RES, V17, P1550, DOI 10.1101/gr.6783507	12	173	176	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	2008	321	5892					1086	1088		10.1126/science.1155546	http://dx.doi.org/10.1126/science.1155546			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339RL	18719284	Green Accepted			2022-12-28	WOS:000258594900040
J	Green, MR				Green, Michael R.			Senescence: Not just for tumor suppression	CELL			English	Editorial Material							LIVER FIBROSIS; APOPTOSIS; CANCER	Cellular senescence provides an intrinsic barrier to tumor development by preventing the proliferation of cells that are at risk for malignant transformation. In this issue, Krizhanovsky et al. (2008) report that senescence is an important player not only in tumor suppression but also in the response of liver tissue to injury.	[Green, Michael R.] Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Program Gene Funct & Express, Worcester, MA 01605 USA; [Green, Michael R.] Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Program Mol Med, Worcester, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Green, MR (corresponding author), Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Program Gene Funct & Express, Worcester, MA 01605 USA.	michael.green@umassmed.edu						Campisi J, 2005, SCIENCE, V309, P886, DOI 10.1126/science.1116801; Elsharkawy AM, 2005, APOPTOSIS, V10, P927, DOI 10.1007/s10495-005-1055-4; Friedman SL, 2008, GASTROENTEROLOGY, V134, P1655, DOI 10.1053/j.gastro.2008.03.003; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Radaeva S, 2006, GASTROENTEROLOGY, V130, P435, DOI 10.1053/j.gastro.2005.10.055; Sharpless NE, 2005, NATURE, V436, P636, DOI 10.1038/436636a; Wiemann SU, 2002, FASEB J, V16, P935, DOI 10.1096/fj.01-0977com; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529	8	17	18	0	10	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 22	2008	134	4					562	564		10.1016/j.cell.2008.08.003	http://dx.doi.org/10.1016/j.cell.2008.08.003			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SR	18724927	Bronze			2022-12-28	WOS:000258665800007
J	Kutay, U; Panse, VG				Kutay, Ulrike; Panse, Vikram Govind			Gle1 does double duty	CELL			English	Editorial Material							MESSENGER-RNA EXPORT; BOX PROTEIN DBP5	During nuclear export, Gle1 (the nuclear-pore- associated mRNA export factor) activates the DEAD-box protein Dbp5 to remodel exported mRNA-protein complexes on the cytoplasmic face of the nuclear pore complex. In this issue, Bolger et al. (2008) now report additional roles for Gle1 in translation initiation and termination.	[Kutay, Ulrike; Panse, Vikram Govind] ETH, Inst Biochem, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Kutay, U (corresponding author), ETH, Inst Biochem, Schafmattstr 18, CH-8093 Zurich, Switzerland.	ulrike.kutay@bc.biol.ethz.ch; vikram.panse@bc.biol.ethz.ch		Panse, Vikram/0000-0001-7950-5746				Alcazar-Roman AR, 2006, NAT CELL BIOL, V8, P711, DOI 10.1038/ncb1427; Cole CN, 2006, CURR OPIN CELL BIOL, V18, P299, DOI 10.1016/j.ceb.2006.04.006; Gross T, 2007, SCIENCE, V315, P646, DOI 10.1126/science.1134641; Lund MK, 2005, MOL CELL, V20, P645, DOI 10.1016/j.molcel.2005.10.005; Nousiainen HO, 2008, NAT GENET, V40, P155, DOI 10.1038/ng.2007.65; Pisarev AV, 2007, CELL, V131, P286, DOI 10.1016/j.cell.2007.08.041; Tran EJ, 2007, MOL CELL, V28, P850, DOI 10.1016/j.molcel.2007.09.019; Weirich CS, 2006, NAT CELL BIOL, V8, P668, DOI 10.1038/ncb1424	8	7	9	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 22	2008	134	4					564	566		10.1016/j.cell.2008.08.009	http://dx.doi.org/10.1016/j.cell.2008.08.009			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SR	18724928	Bronze			2022-12-28	WOS:000258665800008
J	Fosarelli, P				Fosarelli, Pat			Medicine, spirituality, and patient care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Ecumen Inst Theol, Baltimore, MD 21210 USA		Fosarelli, P (corresponding author), Ecumen Inst Theol, 5400 Roland Ave, Baltimore, MD 21210 USA.	pfosarelli@stmarys.edu						Curlin FA, 2007, ARCH INTERN MED, V167, P649, DOI 10.1001/archinte.167.7.649; *JOINT COMM, 2004, SPIR ASS; KOENIG H, 2007, SPIRITUALITY PATIENT, pCH1; Koenig HG, 2002, JAMA-J AM MED ASSOC, V288, P487, DOI 10.1001/jama.288.4.487; Mueller PS, 2001, MAYO CLIN PROC, V76, P1225, DOI 10.4065/76.12.1225; Puchalski C, 2000, J Palliat Med, V3, P129, DOI 10.1089/jpm.2000.3.129; Silverman M. E., 2003, THE QUOTABLE OSLER	7	16	18	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	2008	300	7					836	838		10.1001/jama.300.7.836	http://dx.doi.org/10.1001/jama.300.7.836			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	338VM	18714065				2022-12-28	WOS:000258537500025
J	Kollef, MH; Afessa, B; Anzueto, A; Veremakis, C; Kerr, KM; Margolis, BD; Craven, DE; Roberts, PR; Arroliga, AC; Hubmayr, RD; Restrepo, MI; Auger, WR; Schinner, R				Kollef, Marin H.; Afessa, Bekele; Anzueto, Antonio; Veremakis, Christopher; Kerr, Kim M.; Margolis, Benjamin D.; Craven, Donald E.; Roberts, Pamela R.; Arroliga, Alejandro C.; Hubmayr, Rolf D.; Restrepo, Marcos I.; Auger, William R.; Schinner, Regina		NASCENT Invest Grp	Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia - The NASCENT Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	20th Annual Congress of the European-Society-of-Intensive-Care-Medicine	OCT 07-10, 2007	Berlin, GERMANY	European Soc Intens Care Med			INTENSIVE-CARE-UNIT; DOUBLE-BLIND; MECHANICAL VENTILATION; AIRWAY COLONIZATION; DECONTAMINATION; PREVENTION; CATHETERS; OUTCOMES; BURDEN; EPIDEMIOLOGY	Context Ventilator-associated pneumonia (VAP) causes substantial morbidity. A silver-coated endotracheal tube has been designed to reduce VAP incidence by preventing bacterial colonization and biofilm formation. Objective To determine whether a silver-coated endotracheal tube would reduce the incidence of microbiologically confirmed VAP. Design, Setting, and Participants Prospective, randomized, single-blind, controlled study conducted in 54 centers in North America. A total of 9417 adult patients (>= 18 years) were screened between 2002 and 2006. A total of 2003 patients expected to require mechanical ventilation for 24 hours or longer were randomized. Intervention Patients were assigned to undergo intubation with 1 of 2 high-volume, low-pressure endotracheal tubes, similar except for a silver coating on the experimental tube. Main Outcome Measures Primary outcome was VAP incidence based on quantitative bronchoalveolar lavage fluid culture with 10(4) colony-forming units/mL or greater in patients intubated for 24 hours or longer. Other outcomes were VAP incidence in all intubated patients, time to VAP onset, length of intubation and duration of intensive care unit and hospital stay, mortality, and adverse events. Results Among patients intubated for 24 hours or longer, rates of microbiologically confirmed VAP were 4.8% (37/766 patients; 95% confidence interval [Cl], 3.4%-6.6%) in the group receiving the silver-coated tube and 7.5% (56/743; 95% Cl, 5.7%-9.7%) (P=.03) in the group receiving the uncoated tube (all intubated patients, 3.8% [37/968; 95% Cl, 2.7%-5.2%] and 5.8% [56/964; 95% Cl, 4.4%-7.5%] [P=.04]), with a relative risk reduction of 35.9% (95% Cl, 3.6%-69.0%; all intubated patients, 34.2% [95% Cl, 1.2%-67.9%]). The silver-coated endotracheal tube was associated with delayed occurrence of VAP (P=.005). No statistically significant between-group differences were observed in durations of intubation, intensive care unit stay, and hospital stay; mortality; and frequency and severity of adverse events. Conclusion Patients receiving a silver-coated endotracheal tube had a statistically significant reduction in the incidence of VAP and delayed time to VAP occurrence compared with those receiving a similar, uncoated tube. Trial Registration clinicaltrials.gov Identifier: NCT00148642.	[Kollef, Marin H.] Washington Univ, Sch Med, St Louis, MO 63110 USA; [Afessa, Bekele; Hubmayr, Rolf D.] Mayo Clin, Coll Med, Rochester, MN USA; [Anzueto, Antonio; Restrepo, Marcos I.] S Texas Vet Hlth Care Syst Audie L Murphy Div, San Antonio, TX USA; [Anzueto, Antonio] Univ Hosp, San Antonio, TX USA; [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA; [Veremakis, Christopher] St Johns Mercy Med Ctr, St Louis, MO 63141 USA; [Kerr, Kim M.; Auger, William R.] Univ Calif San Diego, La Jolla, CA 92093 USA; [Margolis, Benjamin D.] W Suburban Hosp, Oak Pk, IL USA; [Craven, Donald E.] Lahey Clin Med Ctr, Burlington, MA 01803 USA; [Craven, Donald E.] Tufts Univ, Sch Med, Boston, MA 02111 USA; [Roberts, Pamela R.] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA; [Arroliga, Alejandro C.] Cleveland Clin, Cleveland, OH 44106 USA; [Restrepo, Marcos I.] VERDICT, San Antonio, TX USA; [Schinner, Regina] FGK Clin Res GmbH, Munich, Germany	Washington University (WUSTL); Mayo Clinic; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Health San Antonio; Saint Johns Mercy Medical Center; University of California System; University of California San Diego; Lahey Hospital & Medical Center; Tufts University; Wake Forest University; Wake Forest Baptist Medical Center; Cleveland Clinic Foundation	Kollef, MH (corresponding author), Washington Univ, Sch Med, 660 S Euclid Ave, St Louis, MO 63110 USA.	mkollef@im.wustl.edu	Restrepo, Marcos I/H-4442-2014; Arroliga, Alejandro/AAX-3933-2021					Ahearn DG, 2000, CURR MICROBIOL, V41, P120, DOI 10.1007/s002840010105; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Babcock HM, 2004, CHEST, V125, P2224, DOI 10.1378/chest.125.6.2224; Berra L, 2004, ANESTHESIOLOGY, V100, P1446, DOI 10.1097/00000542-200406000-00017; Berra L, 2008, INTENS CARE MED, V34, P1020, DOI 10.1007/s00134-008-1099-3; BRUNIER H, 1996, PEST PLANNING EVALUA; Chandra J, 2005, APPL ENVIRON MICROB, V71, P8795, DOI 10.1128/AEM.71.12.8795-8801.2005; Cook D, 2000, CRIT CARE MED, V28, P3547, DOI 10.1097/00003246-200010000-00034; Cook D, 1998, NEW ENGL J MED, V338, P791, DOI 10.1056/NEJM199803193381203; Cook D, 2000, INTENS CARE MED, V26, pS31, DOI 10.1007/s001340051116; Cook DJ, 1998, ANN INTERN MED, V129, P433, DOI 10.7326/0003-4819-129-6-199809150-00002; Craven DE, 2006, CHEST, V130, P251, DOI 10.1378/chest.130.1.251; Cunliffe D, 1999, APPL ENVIRON MICROB, V65, P4995; Dezfulian C, 2005, AM J MED, V118, P11, DOI 10.1016/j.amjmed.2004.07.051; Dodek P, 2004, ANN INTERN MED, V141, P305, DOI 10.7326/0003-4819-141-4-200408170-00011; Dunn K, 2004, BURNS, V30, pS1, DOI 10.1016/S0305-4179(04)90000-9; Eggimann P, 2003, INTENS CARE MED, V29, P2086, DOI 10.1007/s00134-003-1991-9; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Esteban A, 2000, AM J RESP CRIT CARE, V161, P1450, DOI 10.1164/ajrccm.161.5.9902018; Fourrier F, 2005, CRIT CARE MED, V33, P1728, DOI 10.1097/01.CCM.0000171537.03493.B0; Freeman BD, 2005, CRIT CARE MED, V33, P2513, DOI 10.1097/01.CCM.0000186369.91799.44; GABRIEL MM, 1995, CURR MICROBIOL, V30, P17, DOI 10.1007/BF00294518; Garcia MS, 1998, AM J RESP CRIT CARE, V158, P908, DOI 10.1164/ajrccm.158.3.9712079; Girou E, 2004, INTENS CARE MED, V30, P225, DOI 10.1007/s00134-003-2077-4; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; HOSMER DW, 1989, APPL LOGISTIC REGRES; Koeman M, 2006, AM J RESP CRIT CARE, V173, P1348, DOI 10.1164/rccm.200505-820OC; Kollef M, 2006, AM J RESP CRIT CARE, V173, P91, DOI 10.1164/rccm.200504-656OC; KOLLEF M, IN PRESS CHEST; Kollef Marin H, 2005, Respir Care, V50, P714; Kollef MH, 2004, CRIT CARE MED, V32, P1396, DOI 10.1097/01.CCM.0000128569.09113.FB; Kollef MH, 2005, CHEST, V128, P3854, DOI 10.1378/chest.128.6.3854; Lansdown Alan B G, 2006, Curr Probl Dermatol, V33, P17; Olson ME, 2002, CHEST, V121, P863, DOI 10.1378/chest.121.3.863; Patel JD, 2007, J BIOMED MATER RES A, V80A, P742, DOI 10.1002/jbm.a.31103; PETERING HG, 1976, PHARMACOL THER PT A, V1, P127, DOI 10.1016/0362-5478(76)90002-4; PINGLETON SK, 1992, CHEST, V102, pS553, DOI 10.1378/chest.102.5_Supplement_1.553S; Pittet D, 1999, ANN INTERN MED, V130, P126, DOI 10.7326/0003-4819-130-2-199901190-00006; PUGIN J, 1991, JAMA-J AM MED ASSOC, V265, P2704, DOI 10.1001/jama.265.20.2704; Rello J, 2002, CHEST, V122, P2115, DOI 10.1378/chest.122.6.2115; Rello J, 2002, CHEST, V122, P656, DOI 10.1378/chest.122.2.656; Rello J, 2006, CRIT CARE MED, V34, P2766, DOI 10.1097/01.CCM.0000242154.49632.B0; Roe D, 2008, J ANTIMICROB CHEMOTH, V61, P869, DOI 10.1093/jac/dkn034; American Medical Association, 2004, MMWR Recomm Rep, V53, P1; TEBBS SE, 1994, EUR J CLIN MICROBIOL, V13, P111, DOI 10.1007/BF01982182; Whitehead J, 1997, DESIGN ANAL SEQUENTI; Zack JE, 2002, CRIT CARE MED, V30, P2407, DOI 10.1097/00003246-200211000-00001	47	328	359	1	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	2008	300	7					805	813		10.1001/jama.300.7.805	http://dx.doi.org/10.1001/jama.300.7.805			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	338VM	18714060				2022-12-28	WOS:000258537500020
J	Wijeysundera, DN; Beattie, WS; Austin, PC; Hux, JE; Laupacis, A				Wijeysundera, Duminda N.; Beattie, W. Scott; Austin, Peter C.; Hux, Janet E.; Laupacis, Andreas			Epidural anaesthesia and survival after intermediate-to-high risk non-cardiac surgery: a population-based cohort study	LANCET			English	Article							PROPENSITY-SCORE METHODS; ADMINISTRATIVE DATA; RANDOMIZED-TRIALS; ANALGESIA; OUTCOMES; MORTALITY; COMORBIDITIES; COMPLICATIONS; METAANALYSIS; MORBIDITY	Background Although epidural anaesthesia and analgesia have numerous benefits, their effects on postoperative survival are unclear. We therefore undertook a population-based cohort study to determine whether perioperative epidural anaesthesia or analgesia is associated with improved 30-day survival. Methods We used population-based linked administrative 6latabases to do a retrospective cohort study of 259037 patients, aged 40 years or older, who underwent selected elective intermediate-to-high risk non-cardiac surgical procedures between April 1, 1994, and March 31, 2004, in Ontario, Canada. Propensity-score methods were used to construct a matched-pairs cohort that reduced important baseline differences between patients who received epidural anaesthesia or analgesia as opposed to those that did not. We then determined the association of epidural anaesthesia with 30-day mortality within these matched-pairs. Findings Of the 259037 patients, 56556 (22%) received epidural anaesthesia. Within the matched-pairs cohort (n=88 188), epidural anaesthesia was associated with a small reduction in 30-day mortality (1 . 7% vs 2. 0%; relative risk 0 . 89, 95% Cl 0 . 81-0. 98, p=0. 02). Interpretation Epidural anaesthesia and analgesia were associated with a small improvement in 30-day survival, but this effect should be interpreted cautiously. The estimate had borderline significance, despite a large sample size. Its absolute magnitude was also small, corresponding to a number needed to treat of 477. Our study, therefore, does not provide compelling evidence that epidural anaesthesia improves postoperative survival. Nonetheless, our results support the safety of perioperative epidural anaesthesia when used for indications other than improving survival (eg, improving postoperative pain relief, preventing postoperative pulmonary complications). Funding Institute for Clinical Evaluative Sciences.	[Wijeysundera, Duminda N.; Beattie, W. Scott] Toronto Gen Hosp, Dept Anesthesia, Toronto, ON M5G 2C4, Canada; [Wijeysundera, Duminda N.; Austin, Peter C.; Hux, Janet E.; Laupacis, Andreas] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Wijeysundera, Duminda N.; Austin, Peter C.; Hux, Janet E.; Laupacis, Andreas] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Austin, Peter C.; Hux, Janet E.] Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; [Hux, Janet E.] Sunnybrook Hlth Sci Ctr, Dept Med, Toronto, ON M4N 3M5, Canada; [Laupacis, Andreas] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Laupacis, Andreas] St Michaels Hosp, Dept Med, Toronto, ON M5B 1W8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Wijeysundera, DN (corresponding author), Toronto Gen Hosp, Dept Anesthesia, Toronto, ON M5G 2C4, Canada.	duminda.wijeysundera@uhn.on.ca	Beattie, William Scott/A-4352-2008; Wijeysundera, Duminda/L-3350-2018	Wijeysundera, Duminda/0000-0002-5897-8605; Austin, Peter/0000-0003-3337-233X	Institute for Clinical Evaluative Sciences; Ontario Ministry of Health and Long-Term Care; Clinician-Scientist Award; Canadian Institutes of Health Research	Institute for Clinical Evaluative Sciences; Ontario Ministry of Health and Long-Term Care(Ministry of Health and Long-Term Care, Ontario); Clinician-Scientist Award; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This study was supported in part by the Institute for Clinical Evaluative Sciences, which is itself supported in part by a grant from the Ontario Ministry of Health and Long-Term Care. DNW is supported by a Clinician-Scientist Award, and PCA by a New Investigator Award from the Canadian Institutes of Health Research. WSB is the Fraser Elliot Chair of Cardiovascular Anaesthesiology at the University Health Network.	Agresti A, 2004, STAT MED, V23, P65, DOI 10.1002/sim.1589; [Anonymous], 2005, TECHN SUPPL HLTH CAR; Austin PC, 2006, STAT MED, V25, P2084, DOI 10.1002/sim.2328; Austin PC, 2002, AM HEART J, V144, P290, DOI 10.1067/mhj.2002.123839; Austin PC, 2008, J CLIN EPIDEMIOL, V61, P537, DOI 10.1016/j.jclinepi.2007.07.011; Austin PC, 2007, J THORAC CARDIOV SUR, V134, P1128, DOI 10.1016/j.jtcvs.2007.07.021; Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032; Basinski ASH, 1999, CARDIOVASCULAR HLTH, P31; Beattie WS, 2001, ANESTH ANALG, V93, P853, DOI 10.1097/00000539-200110000-00010; Beattie WS, 2003, ANESTH ANALG, V97, P919, DOI 10.1213/01.ANE.0000074660.05733.10; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; Block BM, 2003, JAMA-J AM MED ASSOC, V290, P2455, DOI 10.1001/jama.290.18.2455; BONDY SJ, 1999, CARDIOVASCULAR HLTH, P22; Bourne RB, 2005, ACCESS HLTH SERVICE, P114; Eagle KA, 2002, CIRCULATION, V105, P1257, DOI 10.1161/hc1002.104956; Gentleman JF, 1996, CAN J SURG, V39, P361; Hux JE, 2002, DIABETES CARE, V25, P512, DOI 10.2337/diacare.25.3.512; Juurlink D, 2006, CANADIAN I HLTH INFO; Koch CG, 2003, J THORAC CARDIOV SUR, V126, P2032, DOI 10.1016/S0022-5223(03)00950-4; Lee DS, 2005, MED CARE, V43, P182, DOI 10.1097/00005650-200502000-00012; LIU S, 1995, ANESTHESIOLOGY, V82, P1474, DOI 10.1097/00000542-199506000-00019; Liu SS, 2007, ANESTH ANALG, V105, P789, DOI 10.1213/01.ane.0000278089.16848.1e; Moen V, 2004, ANESTHESIOLOGY, V101, P950, DOI 10.1097/00000542-200410000-00021; Ochroch EA, 2007, ANESTH ANALG, V105, P1787, DOI 10.1213/01.ane.0000290339.76513.e3; Oldman M, 2004, ANESTH ANALG, V98, P1486, DOI 10.1213/01.ANE.0000113549.98873.B1; Park WY, 2001, ANN SURG, V234, P560; Quan HD, 2002, MED CARE, V40, P675, DOI 10.1097/00005650-200208000-00007; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; R Development Core Team, 2007, R LANG ENV STAT COMP; Rigg JRA, 2002, LANCET, V359, P1276, DOI 10.1016/S0140-6736(02)08266-1; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; Romano PS, 2002, AM J MED QUAL, V17, P145, DOI 10.1177/106286060201700404; ROSENBAUM PR, 1985, AM STAT, V39, P33, DOI 10.2307/2683903; Rubin DB, 2007, STAT MED, V26, P20, DOI 10.1002/sim.2739; Shah BR, 2005, J CLIN EPIDEMIOL, V58, P550, DOI 10.1016/j.jclinepi.2004.10.016; TU K, 2007, OPEN MED, V1, pE3; Williams J. I., 1996, PATTERNS HLTH CARE O, P339; Wu CL, 2004, REGION ANESTH PAIN M, V29, P525, DOI 10.1016/j.rapm.2004.07.002; Yeager MP, 2004, REGION ANESTH PAIN M, V29, P515, DOI 10.1016/j.rapm.2004.08.024; YEAGER MP, 1987, ANESTHESIOLOGY, V66, P729, DOI 10.1097/00000542-198706000-00004; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421	41	161	166	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 16	2008	372	9638					562	569		10.1016/S0140-6736(08)61121-6	http://dx.doi.org/10.1016/S0140-6736(08)61121-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339MS	18692893				2022-12-28	WOS:000258582300030
J	Diaz, RJ; Rosenberg, R				Diaz, Robert J.; Rosenberg, Rutger			Spreading dead zones and consequences for marine ecosystems	SCIENCE			English	Review							GULF-OF-MEXICO; HISTORICAL-PERSPECTIVE; OXYGEN DEPLETION; COASTAL WATERS; ENERGY-FLOW; HYPOXIA; EUTROPHICATION; TRENDS; SEA; ENRICHMENT	Dead zones in the coastal oceans have spread exponentially since the 1960s and have serious consequences for ecosystem functioning. The formation of dead zones has been exacerbated by the increase in primary production and consequent worldwide coastal eutrophication fueled by riverine runoff of fertilizers and the burning of fossil fuels. Enhanced primary production results in an accumulation of particulate organic matter, which encourages microbial activity and the consumption of dissolved oxygen in bottom waters. Dead zones have now been reported from more than 400 systems, affecting a total area of more than 245,000 square kilometers, and are probably a key stressor on marine ecosystems.	[Diaz, Robert J.] Coll William & Mary, Virginia Inst Marine Sci, Gloucester Point, VA 23062 USA; [Rosenberg, Rutger] Univ Gothenburg, Dept Marine Ecol, S-45034 Fiskebackskil, Sweden	William & Mary; Virginia Institute of Marine Science; University of Gothenburg	Diaz, RJ (corresponding author), Coll William & Mary, Virginia Inst Marine Sci, Gloucester Point, VA 23062 USA.	diaz@vims.edu						ALLER RC, 1994, CHEM GEOL, V114, P331, DOI 10.1016/0009-2541(94)90062-0; Baird D, 2004, ECOL APPL, V14, P805, DOI 10.1890/02-5094; Breitburg D, 2002, ESTUARIES, V25, P767, DOI 10.1007/BF02804904; Cardinale M, 1999, FISH RES, V41, P285, DOI 10.1016/S0165-7836(99)00021-1; Chan F, 2008, SCIENCE, V319, P920, DOI 10.1126/science.1149016; Conley DJ, 2007, ECOL APPL, V17, pS165, DOI 10.1890/05-0766.1; Diaz, 1990, PERSPECTIVES CHESAPE, V1990, P25; Diaz RJ, 1995, OCEANOGR MAR BIOL, V33, P245; Dortch Q., 2001, COASTAL HYPOXIA CONS, DOI [10.1029/CE058p0038, DOI 10.1029/CE058P0038]; Duce RA, 2008, SCIENCE, V320, P893, DOI 10.1126/science.1150369; ELMGREN R, 1989, AMBIO, V18, P326; Galloway JN, 2008, SCIENCE, V320, P889, DOI 10.1126/science.1136674; GARLO EV, 1979, ESTUAR COAST MAR SCI, V8, P421, DOI 10.1016/0302-3524(79)90059-8; GRAF G, 1992, OCEANOGR MAR BIOL, V30, P149; Helly JJ, 2004, DEEP-SEA RES PT I, V51, P1159, DOI 10.1016/j.dsr.2004.03.009; *INT PAN CLIM CHAN, 2007, CLIM CHANG 2007 PHYS; Jones PD, 2006, MAR POLLUT BULL, V53, P144, DOI 10.1016/j.marpolbul.2005.11.025; Justic D, 1996, LIMNOL OCEANOGR, V41, P992, DOI 10.4319/lo.1996.41.5.0992; JUSTIC D, 1987, ESTUAR COAST SHELF S, V25, P435, DOI 10.1016/0272-7714(87)90035-7; Karlson K, 2002, OCEANOGR MAR BIOL, V40, P427; Kemp WM, 2005, MAR ECOL PROG SER, V303, P1, DOI 10.3354/meps303001; Mee L, 2006, SCI AM, V295, P78, DOI 10.1038/scientificamerican1106-78; Mee Laurence D., 2005, Oceanography, V18, P100; MEE LD, 1992, AMBIO, V21, P278; MOLLER P, 1985, MAR ECOL PROG SER, V27, P109, DOI 10.3354/meps027109; Naqvi SWA, 2000, NATURE, V408, P346, DOI 10.1038/35042551; Nixon SW, 2002, ESTUARIES, V25, P782, DOI 10.1007/BF02804905; PARKER CA, 1991, ESTUARIES, V14, P248, DOI 10.2307/1351660; Pearson T.H., 1978, Oceanography and Marine Biology an Annual Review, V16, P229; PEARSON TH, 1992, NETH J SEA RES, V28, P317, DOI 10.1016/0077-7579(92)90034-C; Rabalais NN, 2007, ESTUAR COAST, V30, P753, DOI 10.1007/BF02841332; Rabalais NN, 2002, ANNU REV ECOL SYST, V33, P235, DOI 10.1146/annurev.ecolsys.33.010802.150513; ROSENBERG R, 1976, OIKOS, V27, P414, DOI 10.2307/3543460; ROSENBERG R, 1985, MAR POLLUT BULL, V16, P227, DOI 10.1016/0025-326X(85)90505-3; Rosenberg R, 2002, MAR ECOL PROG SER, V234, P43, DOI 10.3354/meps234043; Sanderson EW, 2002, BIOSCIENCE, V52, P891, DOI 10.1641/0006-3568(2002)052[0891:THFATL]2.0.CO;2; SenGupta BK, 1996, GEOLOGY, V24, P227, DOI 10.1130/0091-7613(1996)024<0227:SODICS>2.3.CO;2; Tilman D, 2001, SCIENCE, V292, P281, DOI 10.1126/science.1057544; Turner RE, 2008, ENVIRON SCI TECHNOL, V42, P2323, DOI 10.1021/es071617k; Tyler RM, 2007, MAR ECOL PROG SER, V333, P257, DOI 10.3354/meps333257	40	3896	4060	84	2432	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2008	321	5891					926	929		10.1126/science.1156401	http://dx.doi.org/10.1126/science.1156401			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	337LD	18703733				2022-12-28	WOS:000258436700028
J	Metrangolo, P; Resnati, G				Metrangolo, P.; Resnati, G.			Chemistry - Halogen versus hydrogen	SCIENCE			English	Editorial Material							BONDS; CONFORMATION		[Metrangolo, P.; Resnati, G.] Politecn Milan, Dept Chem Mat & Chem Engn Giulio Natta, I-20131 Milan, Italy	Polytechnic University of Milan	Metrangolo, P (corresponding author), Politecn Milan, Dept Chem Mat & Chem Engn Giulio Natta, I-20131 Milan, Italy.	pierangelo.metrangolo@polimi.it; giuseppe.resnati@polimi.it	Metrangolo, Pierangelo/D-4106-2011; Resnati, Giuseppe/C-8650-2011	Resnati, Giuseppe/0000-0002-0797-9296; METRANGOLO, PIERANGELO/0000-0002-7945-099X				Aakeroy CB, 2007, J AM CHEM SOC, V129, P13772, DOI 10.1021/ja073201c; Aakeroy CB, 2007, CHEM COMMUN, P4236, DOI 10.1039/b707458a; Auffinger P, 2004, P NATL ACAD SCI USA, V101, P16789, DOI 10.1073/pnas.0407607101; Corradi E, 2000, ANGEW CHEM INT EDIT, V39, P1782, DOI 10.1002/(SICI)1521-3773(20000515)39:10<1782::AID-ANIE1782>3.0.CO;2-5; HASSEL O, 1970, SCIENCE, V170, P497, DOI 10.1126/science.170.3957.497; Hays FA, 2003, BIOCHEMISTRY-US, V42, P9586, DOI 10.1021/bi0346603; Legon AC, 2008, STRUCT BOND, V126, P17, DOI 10.1007/430_2007_063; Lim CW, 2007, P NATL ACAD SCI USA, V104, P6986, DOI 10.1073/pnas.0611123104; Metrangolo P, 2008, ANGEW CHEM INT EDIT, V47, P6114, DOI 10.1002/anie.200800128; Saha BK, 2005, CRYSTENGCOMM, V7, P355, DOI 10.1039/b501693b; Sun AW, 2006, SCIENCE, V312, P1030, DOI 10.1126/science.1124621; Voth AR, 2007, P NATL ACAD SCI USA, V104, P6188, DOI 10.1073/pnas.0610531104; VOTH AR, THESIS OREGON STATE	13	390	393	1	109	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2008	321	5891					918	919		10.1126/science.1162215	http://dx.doi.org/10.1126/science.1162215			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	337LD	18703728				2022-12-28	WOS:000258436700022
J	Otero, G; Biddau, G; Sanchez-Sanchez, C; Caillard, R; Lopez, MF; Rogero, C; Palomares, FJ; Cabello, N; Basanta, MA; Ortega, J; Mendez, J; Echavarren, AM; Perez, R; Gomez-Lor, B; Martin-Gago, JA				Otero, Gonzalo; Biddau, Giulio; Sanchez-Sanchez, Carlos; Caillard, Renaud; Lopez, Maria F.; Rogero, Celia; Palomares, F. Javier; Cabello, Noemi; Basanta, Miguel A.; Ortega, Jose; Mendez, Javier; Echavarren, Antonio M.; Perez, Ruben; Gomez-Lor, Berta; Martin-Gago, Jose A.			Fullerenes from aromatic precursors by surface-catalysed cyclodehydrogenation	NATURE			English	Article							CRUSHED-FULLERENE; C-60 ADSORPTION; C60H30; FILMS	Graphite vaporization provides an uncontrolled yet efficient means of producing fullerene molecules. However, some fullerene derivatives or unusual fullerene species might only be accessible through rational and controlled synthesis methods. Recently, such an approach has been used(1) to produce isolable amounts of the fullerene C-60 from commercially available starting materials. But the overall process required 11 steps to generate a suitable polycyclic aromatic precursor molecule, which was then dehydrogenated in the gas phase with a yield of only about one per cent. Here we report the formation of C-60 and the triazafullerene C57N3 from aromatic precursors using a highly efficient surface-catalysed cyclodehydrogenation process. We find that after deposition onto a platinum (111) surface and heating to 750 K, the precursors are transformed into the corresponding fullerene and triazafullerene molecules with about 100 per cent yield. We expect that this approach will allow the production of a range of other fullerenes and heterofullerenes(2,3), once suitable precursors are available. Also, if the process is carried out in an atmosphere containing guest species, it might even allow the encapsulation of atoms or small molecules to form endohedral fullerenes(4,5).	[Otero, Gonzalo; Sanchez-Sanchez, Carlos; Caillard, Renaud; Lopez, Maria F.; Palomares, F. Javier; Mendez, Javier; Gomez-Lor, Berta; Martin-Gago, Jose A.] CSIC, Inst Ciencia Mat, Madrid 28049, Spain; [Biddau, Giulio; Basanta, Miguel A.; Ortega, Jose; Perez, Ruben] Univ Autonoma Madrid, Dept Fis Teor Mat Condensada, E-28049 Madrid, Spain; [Rogero, Celia; Martin-Gago, Jose A.] CSIC INTA, Ctr Astrobiol, Madrid 28850, Spain; [Cabello, Noemi; Echavarren, Antonio M.] Inst Chem Res Catalonia ICIQ, Tarragona 43007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Ciencia de Materiales de Madrid (ICMM); CSIC - Instituto de Ciencias Matematicas (ICMAT); Instituto de Ciencia de Materiales de Sevilla (ICMS-CSIC); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Astrobiologia (INTA); Barcelona Institute of Science & Technology; Universitat Rovira i Virgili; Institute of Chemical Research of Catalonia	Gomez-Lor, B (corresponding author), CSIC, Inst Ciencia Mat, Madrid 28049, Spain.	bgl@icmm.csic.es; gago@icmm.csic.es	Palomares, Francisco Javier/C-4605-2011; Mateo, Jose Ortega/I-4358-2014; Perez, Ruben/F-1849-2010; Méndez, Javier/E-4682-2010; Lopez, Maria/HHC-3659-2022; GOMEZ-LOR, BERTA/T-1273-2019; Echavarren, Antonio M/A-2116-2010; Lopez, Maria Francisca/C-4571-2011; Méndez, Javier/ABG-1362-2020; Otero-Irurueta, Gonzalo/ABI-6311-2020; SANCHEZ, CARLOS SANCHEZ/M-2767-2014; sanchez, carlos/HDO-1962-2022; Martin-Gago, Jose Angel J. A./B-2237-2010; Berta, Gomez-Lor/A-5708-2011; Rogero, Celia/Q-1907-2017; ortega, enrique/I-4445-2012	Palomares, Francisco Javier/0000-0002-4768-2219; Mateo, Jose Ortega/0000-0001-9156-1038; Perez, Ruben/0000-0001-5896-541X; Méndez, Javier/0000-0002-6882-1775; GOMEZ-LOR, BERTA/0000-0002-2995-9624; Echavarren, Antonio M/0000-0001-6808-3007; Lopez, Maria Francisca/0000-0001-7894-566X; Méndez, Javier/0000-0002-6882-1775; Otero-Irurueta, Gonzalo/0000-0003-3214-8002; SANCHEZ, CARLOS SANCHEZ/0000-0001-8644-3766; Martin-Gago, Jose Angel J. A./0000-0003-2663-491X; Berta, Gomez-Lor/0000-0002-2995-9624; Rogero, Celia/0000-0002-2812-8853; Biddau, Giulio/0000-0003-1170-919X; Cabello, Noemi/0000-0002-3861-4003				Felici R, 2005, NAT MATER, V4, P688, DOI 10.1038/nmat1456; GALE RJ, 1977, PHYS REV LETT, V38, P1027, DOI 10.1103/PhysRevLett.38.1027; Gomez-Lor B, 2004, ORG LETT, V6, P2993, DOI 10.1021/ol048760s; Gomez-Lor B, 2002, CHEM COMMUN, P370, DOI 10.1039/b110587f; Gomez-Lor B, 1999, CHEM COMMUN, P2431, DOI 10.1039/a906990i; Hellgren N, 2005, THIN SOLID FILMS, V471, P19, DOI 10.1016/j.tsf.2004.03.027; HUMMELEN JC, 1995, SCIENCE, V269, P1554, DOI 10.1126/science.269.5230.1554; Iwamatsu S, 2006, ANGEW CHEM INT EDIT, V45, P5337, DOI 10.1002/anie.200601241; Jelinek P, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.235101; Komatsu K, 2005, SCIENCE, V307, P238, DOI 10.1126/science.1106185; Lesnard H, 2007, J AM CHEM SOC, V129, P4298, DOI 10.1021/ja067442g; Murata Y, 2003, CHEM-EUR J, V9, P1600, DOI 10.1002/chem.200390184; Orzali T, 2008, J PHYS CHEM C, V112, P378, DOI 10.1021/jp076024a; Orzali T, 2006, APPL SURF SCI, V252, P5534, DOI 10.1016/j.apsusc.2005.12.149; Pascual JI, 2000, CHEM PHYS LETT, V321, P78, DOI 10.1016/S0009-2614(00)00337-7; Rubin Y, 1999, TOP CURR CHEM, V199, P67; Schull G, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.226105; Scott LT, 2002, SCIENCE, V295, P1500, DOI 10.1126/science.1068427; Segall MD, 2002, J PHYS-CONDENS MAT, V14, P2717, DOI 10.1088/0953-8984/14/11/301; Soto G, 2004, MATER LETT, V58, P2178, DOI 10.1016/j.matlet.2004.01.019; Vostrowsky O, 2006, CHEM REV, V106, P5191, DOI 10.1021/cr050561e; Weckesser J, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.161403	22	237	240	6	130	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 14	2008	454	7206					865	U19		10.1038/nature07193	http://dx.doi.org/10.1038/nature07193			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	336XH	18704082				2022-12-28	WOS:000258398600031
J	Wakabi, W				Wakabi, Wairagala			Profile - Eric Laroche: expert on health needs in humanitarian crises	LANCET			English	Biographical-Item												w_wakabi@yahoo.com							0	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG-SEP	2008	372	9640					709	709		10.1016/S0140-6736(08)61292-1	http://dx.doi.org/10.1016/S0140-6736(08)61292-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	344YZ	18761211				2022-12-28	WOS:000258964500013
J	Qi, HH; Ongusaha, PP; Myllyharju, J; Cheng, DM; Pakkanen, O; Shi, YJ; Lee, SW; Peng, JM; Shi, Y				Qi, Hank H.; Ongusaha, Pat P.; Myllyharju, Johanna; Cheng, Dongmei; Pakkanen, Outi; Shi, Yujiang; Lee, Sam W.; Peng, Junmin; Shi, Yang			Prolyl 4-hydroxylation regulates Argonaute 2 stability	NATURE			English	Article							MICRORNA-DEPENDENT LOCALIZATION; P-BODIES; PROTEIN; EXPRESSION; COLLAGEN; HYDROXYLASES; PROCOLLAGEN; DOMAIN; RISC; FORM	Human Argonaute ( Ago) proteins are essential components of the RNA- induced silencing complexes ( RISCs). Argonaute 2 ( Ago2) has a P-element- induced wimpy testis ( PIWI) domain, which folds like RNase H and is responsible for target RNA cleavage in RNA interference(1). Proteins such as Dicer, TRBP, MOV10, RHA, RCK/p54 and KIAA1093 associate with Ago proteins and participate in small RNA processing, RISC loading and localization of Ago proteins in the cytoplasmic messenger RNA processing bodies(1,2). However, mechanisms that regulate RNA interference remain obscure. Here we report physical interactions between Ago2 and the alpha-(P4H-alpha(I)) and beta-(P4H-beta) subunits of the type I collagen prolyl- 4- hydroxylase (C-P4H( I)). Mass spectrometric analysis identified hydroxylation of the endogenous Ago2 at proline 700. In vitro, both Ago2 and Ago4 seem to be more efficiently hydroxylated than Ago1 and Ago3 by recombinant human C-P4H( I). Importantly, human cells depleted of P4H-alpha(I) or P4H-beta by short hairpin RNA and P4H-alpha(I) null mouse embryonic fibroblast cells showed reduced stability of Ago2 and impaired short interfering RNA programmed RISC activity. Furthermore, mutation of proline 700 to alanine also resulted in destabilization of Ago2, thus linking Ago2 P700 and hydroxylation at this residue to its stability regulation. These findings identify hydroxylation as a post- translational modification important for Ago2 stability and effective RNA interference.	[Qi, Hank H.; Ongusaha, Pat P.; Shi, Yujiang; Lee, Sam W.; Shi, Yang] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Ongusaha, Pat P.; Lee, Sam W.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Boston, MA 02129 USA; [Myllyharju, Johanna; Pakkanen, Outi] Univ Oulu, Oulu Ctr Cell Matrix Res, Bioctr Oulu, FIN-90014 Oulu, Finland; [Myllyharju, Johanna; Pakkanen, Outi] Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland; [Cheng, Dongmei; Peng, Junmin] Emory Univ, Dept Human Genet, Ctr Neurodegenerat Dis, Sch Med, Atlanta, GA 30322 USA; [Shi, Yujiang] Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Dept Med, Boston, MA 02115 USA; [Shi, Yujiang] Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, BCMP, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; University of Oulu; University of Oulu; Emory University; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Shi, Y (corresponding author), Harvard Univ, Sch Med, Dept Pathol, New Res Bldg 854,77 Ave Louis Pasteur, Boston, MA 02115 USA.	yang_shi@hms.harvard.edu	Hu, Ruogu/B-2203-2008; Peng, Junmin/N-2614-2018	Peng, Junmin/0000-0003-0472-7648; Qi, Hank/0000-0002-3401-4940	Canadian Institute of Health Research; Health Science Council of the Academy of Finland [202469]; S. Juselius foundation; National Institutes of Health [AG025688, GM53874]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053874] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG025688] Funding Source: NIH RePORTER	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Health Science Council of the Academy of Finland(Academy of Finland); S. Juselius foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank C. C. Mello, A. Grishok and P. A. Sharp for reading this manuscript and discussion. We thank E. Lehtimaki and R. Juntunen for in vitro hydroxylation assays, J. Lykke-Andersen and N. Kedersha for polyclonal anti-Dcp1a antibody and anti-Tia1 antibody, and the personnel of the Biocenter Oulu Transgenic Animal Core Facility and the University of Oulu Laboratory Animal Centre for technical assistance. We also thank the Kazusa DNA Research Institute (Japan) for providing the KIAA clones with numbers 1567, 1093, 1582 and 1460 and N. R. Wall for pOZ-FH-Ago1 plasmid. H. H. Q. was supported by a Canadian Institute of Health Research postdoctoral fellowship. This work was supported by grants from the Health Science Council of the Academy of Finland (202469) and the S. Juselius foundation to J. M. and National Institutes of Health grants to J. P. (AG025688) and Y.S. (GM53874).	BERG RA, 1982, METHOD ENZYMOL, V82, P372; Chen L, 2006, J BIOL CHEM, V281, P10849, DOI 10.1074/jbc.M511237200; Chu CY, 2006, PLOS BIOL, V4, P1122, DOI 10.1371/journal.pbio.0040210; Cikaluk DE, 1999, MOL BIOL CELL, V10, P3357, DOI 10.1091/mbc.10.10.3357; Fahling M, 2006, J BIOL CHEM, V281, P26089, DOI 10.1074/jbc.M604939200; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hieta R, 2003, J BIOL CHEM, V278, P34966, DOI 10.1074/jbc.M303624200; Hirsila M, 2005, FASEB J, V19, P1308, DOI 10.1096/fj.04-3399fje; Hofbauer KH, 2003, EUR J BIOCHEM, V270, P4515, DOI 10.1046/j.1432-1033.2003.03846.x; Holster T, 2007, J BIOL CHEM, V282, P2512, DOI 10.1074/jbc.M606608200; John DCA, 1999, NAT BIOTECHNOL, V17, P385, DOI 10.1038/7945; Kaelin WG, 2005, BIOCHEM BIOPH RES CO, V338, P627, DOI 10.1016/j.bbrc.2005.08.165; Kivirikko K. I., 1992, POSTTRANSLATIONAL MO, P1; Leung AKL, 2006, P NATL ACAD SCI USA, V103, P18125, DOI 10.1073/pnas.0608845103; Liu G, 2003, J BIOL CHEM, V278, P17557, DOI 10.1074/jbc.M210696200; Liu JD, 2005, NAT CELL BIOL, V7, P719, DOI 10.1038/ncb1274; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Nakatani Y, 2003, METHOD ENZYMOL, V370, P430; Parker R, 2007, MOL CELL, V25, P635, DOI 10.1016/j.molcel.2007.02.011; Peng JM, 2001, J MASS SPECTROM, V36, P1083, DOI 10.1002/jms.229; Peters L, 2007, MOL CELL, V26, P611, DOI 10.1016/j.molcel.2007.05.001; Rivas FV, 2005, NAT STRUCT MOL BIOL, V12, P340, DOI 10.1038/nsmb918; Robb GB, 2007, MOL CELL, V26, P523, DOI 10.1016/j.molcel.2007.04.016; Rocnik EF, 1998, J CLIN INVEST, V101, P1889, DOI 10.1172/JCI1025; Sen GL, 2005, NAT CELL BIOL, V7, P633, DOI 10.1038/ncb1265; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467	26	167	173	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	2008	455	7211					421	U78		10.1038/nature07186	http://dx.doi.org/10.1038/nature07186			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349EX	18690212	Green Accepted			2022-12-28	WOS:000259265200051
J	Collin, S; Reeves, BC; Hendy, J; Fulop, N; Hutchings, A; Priedane, E				Collin, Simon; Reeves, Barnaby C.; Hendy, Jane; Fulop, Naomi; Hutchings, Andrew; Priedane, Eugenia			Implementation of computerised physician order entry (CPOE) and picture archiving and communication systems (PACS) in the NHS: quantitative before and after study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFORMATION-TECHNOLOGY; LABORATORY TESTS; DIAGNOSTIC-TESTS; IMPACT; CARE; INTERVENTION; CHALLENGES; EFFICIENCY; REDUNDANT; PROGRAM	Objective To assess the impact of components of the national programme for information technology (NPfIT) on measures of clinical and operational efficiency. Design Quasi- experimental controlled before and after study using routinely collected patient level data. Setting Four NHS acute hospital trusts in England. Data sources Inpatient admissions and outpatient appointments, 2000- 5. Interventions A system for ordering pathology tests and browsing results ( computerised physician order entry, CPOE) and a system for requesting radiological examinations and displaying images ( picture archiving and communications system, PACS). Main outcome measures Requests per inpatient, outpatient, or day case patient for full blood count, urine culture and urea and electrolytes tests, and plain x ray film, computed tomography, and ultrasonography examinations. Results CPOE was associated with a reduction in the proportion of outpatient appointments at which full blood count ( odds ratio 0.25, 95% confidence interval 0.16 to 0.40), urea and electrolytes ( 0.55, 0.39 to 0.77), and urine culture ( 0.30, 0.17 to 0.51) tests were ordered, and at which full blood count tests were repeated ( 0.73, 0.53 to 0.99). Conversely, the same system was associated with an almost fourfold increase in the use of urea and electrolytes tests among day case patients ( 3.63, 1.66 to 7.94). PACS was associated with a reduction in repeat plain x ray films at outpatient appointments ( 0.62, 0.44 to 0.88) and a reduction in inpatient computed tomography ( 0.83, 0.70 to 0.98). Conversely, it was associated with increases in computed tomography requested at outpatient appointments ( 1.89, 1.26 to 2.84) and computed tomography repeated within 48 hours during an inpatient stay ( 2.18, 1.52 to 3.14). Conclusions CPOE and PACS were associated with both increases and reductions in tests and examinations. The magnitude of the changes is potentially important with respect to the efficiency of provision of health care. Better information about the impact of modern IT is required to enable healthcare organisations to manage implementation optimally.	[Collin, Simon] Univ Bristol, Dept Social Med, Bristol BS8 1TH, Avon, England; [Reeves, Barnaby C.] Univ Bristol, Dept Clin Sci SBristol, Bristol BS8 1TH, Avon, England; [Hendy, Jane] Hlth & Care Infrastruct Res & Innovat Ctr, London, England; [Fulop, Naomi] Kings Coll London, Hlth & Hlth Policy NIHR Kings Patient Safety, London WC2R 2LS, England; [Fulop, Naomi] Kings Coll London, Serv Qual Res Ctr, London WC2R 2LS, England; [Hutchings, Andrew; Priedane, Eugenia] London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1, England	University of Bristol; University of Bristol; University of London; King's College London; University of London; King's College London; University of London; London School of Hygiene & Tropical Medicine	Reeves, BC (corresponding author), Univ Bristol, Bristol Royal Infirm, Clin Trials & Evaluat Unit, Level 7, Bristol BS2 8HW, Avon, England.	barney.reeves@bristol.ac.uk	Collin, S M/AAK-6789-2020	Collin, S M/0000-0002-1239-1681; Hutchings, Andrew/0000-0003-0215-9923; Fulop, Naomi/0000-0001-5306-6140	NHS service and delivery organisation research and delivery programme [SDO/44/2003]	NHS service and delivery organisation research and delivery programme	NHS service and delivery organisation research and delivery programme (SDO/44/2003).	Aarts J, 2006, METHOD INFORM MED, V45, P53; Aarts J, 2004, J AM MED INFORM ASSN, V11, P207, DOI 10.1197/jamia.M1372; Aarts Jos, 2007, Int J Med Inform, V76 Suppl 1, pS4, DOI 10.1016/j.ijmedinf.2006.05.009; Bates DW, 1999, AM J MED, V106, P144, DOI 10.1016/S0002-9343(98)00410-0; Bates DW, 1998, AM J MED, V104, P361, DOI 10.1016/S0002-9343(98)00063-1; Berg M, 2001, INT J MED INFORM, V64, P143, DOI 10.1016/S1386-5056(01)00200-3; Bryan S, 1999, J Health Serv Res Policy, V4, P204; Callen JL, 2006, J AM MED INFORM ASSN, V13, P643, DOI 10.1197/jamia.M2152; Chang BH, 2000, J CLIN EPIDEMIOL, V53, P1036, DOI 10.1016/S0895-4356(00)00223-7; Chaudhry B, 2006, ANN INTERN MED, V144, P742, DOI 10.7326/0003-4819-144-10-200605160-00125; Cook TD, 2002, EXPT QUASIEXPERIMENT, P1, DOI 10.1198/jasa.2005.s22; Cox Benita, 2002, J Manag Med, V16, P199, DOI 10.1108/02689230210434934; Crowe B, 2004, J TELEMED TELECARE, V10, pS25, DOI 10.1258/1357633042614339; *DEP HLTH, 2005, EFF MAP; *DEP HLTH, 2008, CONN HLTH; Fridell K, 2007, J DIGIT IMAGING, V20, P411, DOI 10.1007/s10278-006-1054-1; Georgiou A, 2007, INT J MED INFORM, V76, P583, DOI 10.1016/j.ijmedinf.2006.04.002; Georgiou A, 2007, INT J MED INFORM, V76, P514, DOI 10.1016/j.ijmedinf.2006.02.004; Hendy J, 2005, BMJ-BRIT MED J, V331, P331, DOI 10.1136/bmj.331.7512.331; Hendy J, 2007, BRIT MED J, V334, P1360, DOI 10.1136/bmj.39195.598461.551; *INF CTR, OUTP DAT QUAL REP 20; Keen J, 1995, HEALTH POLICY, V34, P153, DOI 10.1016/0168-8510(95)00767-9; Nitrosi A, 2007, J DIGIT IMAGING, V20, P140, DOI 10.1007/s10278-007-9006-y; Pare G, 2005, INT J TECHNOL ASSESS, V21, P471, DOI 10.1017/S0266462305050658; REEVES BC, 2008, EVALUATION IT MODERN; Snyder R, 2006, INT J MED INFORM, V75, P730, DOI 10.1016/j.ijmedinf.2005.10.002; TIERNEY WM, 1987, ANN INTERN MED, V107, P569, DOI 10.7326/0003-4819-107-4-569; TIERNEY WM, 1990, NEW ENGL J MED, V322, P1499, DOI 10.1056/NEJM199005243222105; van den Bosch AE, 2006, J AM SOC ECHOCARDIOG, V19, P7, DOI 10.1016/j.echo.2005.07.009; Wang TJ, 2002, ARCH INTERN MED, V162, P1885, DOI 10.1001/archinte.162.16.1885; Watkins JR, 1999, INT J TECHNOL ASSESS, V15, P497, DOI 10.1017/S0266462399015354; Weatherburn GC, 1999, BRIT J RADIOL, V72, P653, DOI 10.1259/bjr.72.859.10624322; Westbrook JI, 2006, J CLIN PATHOL, V59, P533, DOI 10.1136/jcp.2005.029983; Weydert JA, 2005, ARCH PATHOL LAB MED, V129, P1141	34	25	25	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 13	2008	337	7670							a939	10.1136/bmj.a939	http://dx.doi.org/10.1136/bmj.a939			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354DT	18703655	Green Submitted, Green Published, Green Accepted, hybrid			2022-12-28	WOS:000259619800040
J	Aziz, EF; Ottosson, N; Faubel, M; Hertel, IV; Winter, B				Aziz, Emad F.; Ottosson, Niklas; Faubel, Manfred; Hertel, Ingolf V.; Winter, Bernd			Interaction between liquid water and hydroxide revealed by core-hole de-excitation	NATURE			English	Article							CHEM.-CHEM.-PHYS.; NEAT WATER; ULTRAFAST DYNAMICS; AUTOIONIZATION; SURFACE; HYDRATION; MECHANISM; IONS	The hydroxide ion plays an important role in many chemical and biochemical processes in aqueous solution(1). But ourmolecular- level understanding of its unusual and fast transport in water, and of the solvation patterns that allow fast transport, is far from complete. One proposal seeks to explain the properties and behaviour of the hydroxide ion by essentially regarding it as a water molecule that is missing a proton(2), and by inferring transport mechanisms and hydration structures from those of the excess proton. A competing proposal invokes instead unique and interchanging hydroxide hydration complexes, particularly the hypercoordinated OH-(H2O)(4) species and tri- coordinated OH-(H2O)(3) that can form a transient hydrogen bond between the H atom of the OH- and a neighbouring water molecule(3-5). Here we report measurements of core- level photoelectron emission and intermolecular Coulombic decay(6-8) for an aqueous hydroxide solution, which show that the hydrated hydroxide ion is capable of transiently donating a hydrogen bond to surrounding watermolecules. In agreement with recent experimental studies of hydroxide solutions(9-12), our finding thus supports the notion that the hydration structure of the hydroxide ion cannot be inferred from that of the hydrated excess proton.	[Aziz, Emad F.; Ottosson, Niklas; Winter, Bernd] BESSY, D-12489 Berlin, Germany; [Ottosson, Niklas] Uppsala Univ, Dept Phys, SE-75121 Uppsala, Sweden; [Faubel, Manfred] Max Planck Inst Dynam & Selbstorg, D-37073 Gottingen, Germany; [Hertel, Ingolf V.; Winter, Bernd] Max Born Inst Nichtlineare Opt & Kurzzeitspekt, D-12489 Berlin, Germany; [Hertel, Ingolf V.] Free Univ Berlin, Inst Expt Phys, D-14195 Berlin, Germany	Helmholtz Association; Helmholtz-Zentrum fuer Materialien und Energie GmbH (HZB); Uppsala University; Max Planck Society; Max Born Institute for Nonlinear Optics & Short Term Spectroscopy; Free University of Berlin	Winter, B (corresponding author), BESSY, Albert Einstein Str 15, D-12489 Berlin, Germany.	bernd.winter@bessy.de	Aziz, Emad/A-4463-2017; Winter, Bernd/D-4657-2011; Winter, Bernd/W-9956-2019	Aziz, Emad/0000-0003-1794-4350; Winter, Bernd/0000-0002-5597-8888				Agmon N, 2000, CHEM PHYS LETT, V319, P247, DOI 10.1016/S0009-2614(00)00136-6; Asthagiri D, 2004, P NATL ACAD SCI USA, V101, P7229, DOI 10.1073/pnas.0401696101; Averbukh V, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.263002; Barth S, 2006, PHYS CHEM CHEM PHYS, V8, P3218, DOI 10.1039/b602019d; Beattie JK, 2008, PHYS CHEM CHEM PHYS, V10, P330, DOI 10.1039/b713702h; BLANDAMER MJ, 1970, CHEM REV, V70, P59, DOI 10.1021/cr60263a002; Botti A, 2004, J CHEM PHYS, V120, P10154, DOI 10.1063/1.1705572; Cappa CD, 2005, J PHYS CHEM B, V109, P7046, DOI 10.1021/jp0445324; Cappa CD, 2007, J PHYS CHEM A, V111, P4776, DOI 10.1021/jp070551c; Cederbaum LS, 1997, PHYS REV LETT, V79, P4778, DOI 10.1103/PhysRevLett.79.4778; Chandra A, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.145901; Chen XY, 2008, ANNU REV PHYS CHEM, V59, P203, DOI 10.1146/annurev.physchem.58.032806.104702; Crowell RA, 2004, J CHEM PHYS, V120, P11712, DOI 10.1063/1.1739213; FOX M, 1977, FARADAY DISCUSS, V64, P167, DOI 10.1039/dc9776400167; HYNES JT, 2007, HYDROGEN TRANSFER RE, pCH21; Imberti S, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1899147; Megyes T, 2008, J CHEM PHYS, V128, DOI 10.1063/1.2821956; Muller IB, 2006, J CHEM PHYS, V125, DOI 10.1063/1.2357921; Petersen PB, 2005, J PHYS CHEM B, V109, P7976, DOI 10.1021/jp044479j; Robertson WH, 2003, SCIENCE, V299, P1367, DOI 10.1126/science.1080695; Smiechowski M, 2007, J PHYS CHEM A, V111, P2889, DOI 10.1021/jp0659397; Tuckerman ME, 2006, ACCOUNTS CHEM RES, V39, P151, DOI 10.1021/ar040207n; Tuckerman ME, 2002, NATURE, V417, P925, DOI 10.1038/nature00797; Vacha R, 2008, PHYS CHEM CHEM PHYS, V10, P332, DOI 10.1039/b713702h; Vacha R, 2007, PHYS CHEM CHEM PHYS, V9, P4736, DOI 10.1039/b704491g; Winter B, 2006, CHEM REV, V106, P1176, DOI 10.1021/cr040381p; Winter B, 2007, J CHEM PHYS, V127, DOI 10.1063/1.2770457; Winter B, 2008, J AM CHEM SOC, V130, P7130, DOI 10.1021/ja8009742	28	162	164	1	95	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	2008	455	7209					89	91		10.1038/nature07252	http://dx.doi.org/10.1038/nature07252			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	343XS	18769437				2022-12-28	WOS:000258890200042
J	Doeleman, SS; Weintroub, J; Rogers, AEE; Plambeck, R; Freund, R; Tilanus, RPJ; Friberg, P; Ziurys, LM; Moran, JM; Corey, B; Young, KH; Smythe, DL; Titus, M; Marrone, DP; Cappallo, RJ; Bock, DCJ; Bower, GC; Chamberlin, R; Davis, GR; Krichbaum, TP; Lamb, J; Maness, H; Niell, AE; Roy, A; Strittmatter, P; Werthimer, D; Whitney, AR; Woody, D				Doeleman, Sheperd S.; Weintroub, Jonathan; Rogers, Alan E. E.; Plambeck, Richard; Freund, Robert; Tilanus, Remo P. J.; Friberg, Per; Ziurys, Lucy M.; Moran, James M.; Corey, Brian; Young, Ken H.; Smythe, Daniel L.; Titus, Michael; Marrone, Daniel P.; Cappallo, Roger J.; Bock, Douglas C. -J.; Bower, Geoffrey C.; Chamberlin, Richard; Davis, Gary R.; Krichbaum, Thomas P.; Lamb, James; Maness, Holly; Niell, Arthur E.; Roy, Alan; Strittmatter, Peter; Werthimer, Daniel; Whitney, Alan R.; Woody, David			Event-horizon-scale structure in the supermassive black hole candidate at the Galactic Centre	NATURE			English	Article							SAGITTARIUS-A-ASTERISK; X-RAY; INTRINSIC SIZE; PROPER MOTION; RADIO-SOURCE; MILKY-WAY; 86 GHZ; VLBI; EMISSION; COMPACT	The cores of most galaxies are thought to harbour supermassive black holes, which power galactic nuclei by converting the gravitational energy of accreting matter into radiation(1). Sagittarius A* ( Sgr A*), the compact source of radio, infrared and X- ray emission at the centre of the Milky Way, is the closest example of this phenomenon, with an estimated black hole mass that is 4,000,000 times that of the Sun(2,3). A long- standing astronomical goal is to resolve structures in the innermost accretion flow surrounding Sgr A*, where strong gravitational fields will distort the appearance of radiation emitted near the black hole. Radio observations at wavelengths of 3.5 mm and 7 mm have detected intrinsic structure in Sgr A*, but the spatial resolution of observations at these wavelengths is limited by interstellar scattering(4-7). Here we report observations at a wavelength of 1.3 mm that set a size of 37(-10)(+16) microarcseconds on the intrinsic diameter of Sgr A*. This is less than the expected apparent size of the event horizon of the presumed black hole, suggesting that the bulk of Sgr A* emission may not be centred on the black hole, but arises in the surrounding accretion flow.	[Doeleman, Sheperd S.; Rogers, Alan E. E.; Corey, Brian; Smythe, Daniel L.; Titus, Michael; Cappallo, Roger J.; Niell, Arthur E.; Whitney, Alan R.] MIT, Haystack Observ, Westford, MA 01886 USA; [Weintroub, Jonathan; Moran, James M.; Young, Ken H.] Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA; [Plambeck, Richard; Bower, Geoffrey C.; Maness, Holly] Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA; [Freund, Robert; Ziurys, Lucy M.; Strittmatter, Peter] Univ Arizona, Steward Observ, Arizona Radio Observ, Tucson, AZ 85721 USA; [Tilanus, Remo P. J.; Friberg, Per; Davis, Gary R.] Joint Astron Ctr, Hilo, HI 96720 USA; [Tilanus, Remo P. J.] Netherlands Org Sci Res, NL-2509 AC The Hague, Netherlands; [Marrone, Daniel P.] Natl Radio Astron Observ, Charlottesville, VA 22903 USA; [Marrone, Daniel P.] Univ Chicago, Kavli Inst Cosmol Phys, Chicago, IL 60637 USA; [Bock, Douglas C. -J.] CARMA, Big Pine, CA 93513 USA; [Chamberlin, Richard] Caltech Submillimeter Observ, Hilo, HI 96720 USA; [Krichbaum, Thomas P.; Roy, Alan] Max Planck Inst Radioastron, D-53121 Bonn, Germany; [Lamb, James; Woody, David] CALTECH, OVRO, Big Pine, CA 93513 USA; [Werthimer, Daniel] Univ Calif Berkeley, Space Sci Lab, Berkeley, CA 94720 USA	Massachusetts Institute of Technology (MIT); Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; University of California System; University of California Berkeley; National Radio Astronomy Observatory (NRAO); University of Arizona; National Radio Astronomy Observatory (NRAO); University of Chicago; California Institute of Technology; Max Planck Society; California Institute of Technology; University of California System; University of California Berkeley	Doeleman, SS (corresponding author), MIT, Haystack Observ, Route 40, Westford, MA 01886 USA.	sdoeleman@haystack.mit.edu	Bower, Geoffrey/ABC-8386-2020; Lamb, James/AAY-1701-2021	Bower, Geoffrey/0000-0003-4056-9982; Niell, Arthur/0000-0001-5267-4005; Marrone, Daniel/0000-0002-2367-1080; Roy, Alan/0000-0002-1931-0135; Krichbaum, T. P./0000-0002-4892-9586; Rogers, Alan/0000-0003-1941-7458; Moran, James/0000-0002-3882-4414	National Science Foundation	National Science Foundation(National Science Foundation (NSF))	High-frequency VLBI work at MIT Haystack Observatory is supported by grants from the National Science Foundation. The Submillimeter Array is a joint project between the Smithsonian Astrophysical Observatory and the Academia Sinica Institute of Astronomy and Astrophysics. We thank G. Weaver for the loan of a frequency reference from Johns Hopkins University Applied Physics Labs; J. Davis for use of GPS equipment; I. Diegel, R. Vessot, D. Phillips and E. Mattison for assistance with hydrogen masers; the NASA Geodesy Program for loan of the CARMA Hydrogen Maser; D. Kubo, J. Test, P. Yamaguchi, G. Reiland, J. Hoge and M. Hodges for technical assistance; M. Gurwell for SMAcalibration data; A. Kerr and A. Lichtenberger for contributions at ARO/SMT; A. Broderick, V. Fish, A. Loeb and I. Shapiro for discussions; and the staff at all participating facilities.	Backer DC, 1999, ASTROPHYS J, V524, P805, DOI 10.1086/307857; Bower GC, 2004, SCIENCE, V304, P704, DOI 10.1126/science.1094023; Bower GC, 2006, ASTROPHYS J, V648, pL127, DOI 10.1086/508019; Broderick AE, 2006, MON NOT R ASTRON SOC, V367, P905, DOI 10.1111/j.1365-2966.2006.10152.x; Broderick AE, 2006, ASTROPHYS J, V638, pL21, DOI 10.1086/500930; Doeleman SS, 2001, ASTRON J, V121, P2610, DOI 10.1086/320376; Eckart A, 2006, ASTRON ASTROPHYS, V450, P535, DOI 10.1051/0004-6361:20054418; Falcke H, 2000, ASTRON ASTROPHYS, V362, P113; Falcke H, 2000, ASTROPHYS J, V528, pL13, DOI 10.1086/312423; Frolov V. P., 1998, BLACK HOLE PHYS BASI, DOI 10.1007/978-94-011-5139-9#about-this-book; KORMENDY J, 1995, ANNU REV ASTRON ASTR, V33, P581, DOI 10.1146/annurev.aa.33.090195.003053; Krichbaum TP, 1998, ASTRON ASTROPHYS, V335, pL106; Maoz E, 1998, ASTROPHYS J, V494, pL181, DOI 10.1086/311194; Marrone DP, 2008, ASTROPHYS J, V682, P373, DOI 10.1086/588806; Noble SC, 2007, CLASSICAL QUANT GRAV, V24, pS259, DOI 10.1088/0264-9381/24/12/S17; Reid MJ, 2004, ASTROPHYS J, V616, P872, DOI 10.1086/424960; REID MJ, 1993, ANNU REV ASTRON ASTR, V31, P345; ROGERS AEE, 1994, ASTROPHYS J, V434, pL59, DOI 10.1086/187574; ROGERS AEE, 1995, ASTRON J, V109, P1391, DOI 10.1086/117371; Schodel R, 2002, NATURE, V419, P694, DOI 10.1038/nature01121; Shen ZQ, 2005, NATURE, V438, P62, DOI 10.1038/nature04205; Yusef-Zadeh F, 2006, ASTROPHYS J, V644, P198, DOI 10.1086/503287	23	556	560	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2008	455	7209					78	80		10.1038/nature07245	http://dx.doi.org/10.1038/nature07245			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	343XS	18769434	Green Submitted			2022-12-28	WOS:000258890200039
J	Nahler, NH; White, JD; Larue, J; Auerbach, DJ; Wodtke, AM				Nahler, N. H.; White, J. D.; LaRue, J.; Auerbach, D. J.; Wodtke, A. M.			Inverse velocity dependence of vibrationally promoted electron emission from a metal surface	SCIENCE			English	Article							EXCITATION; MOLECULES; SCATTERING; CATALYSIS; NO	All previous experimental and theoretical studies of molecular interactions at metal surfaces show that electronically nonadiabatic influences increase with molecular velocity. We report the observation of a nonadiabatic electronic effect that follows the opposite trend: The probability of electron emission from a low- work function surface-Au(111) capped by half a monolayer of Cs- increases as the velocity of the incident NO molecule decreases during collisions with highly vibrationally excited NO(X-2 Pi(1/2), V = 18; V is the vibrational quantum number of NO), reaching 0.1 at the lowest velocity studied. We show that these results are consistent with a vibrational autodetachment mechanism, whereby electron emission is possible only beyond a certain critical distance from the surface. This outcome implies that important energy- dissipation pathways involving nonadiabatic electronic excitations and, furthermore, not captured by present theoretical methods may influence reaction rates at surfaces.	[Nahler, N. H.; White, J. D.; LaRue, J.; Wodtke, A. M.] Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA; [Auerbach, D. J.] GRT Inc, Santa Barbara, CA 93111 USA	University of California System; University of California Santa Barbara	Wodtke, AM (corresponding author), Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA.	wodtke@chem.ucsb.edu	LaRue, Jerry/N-9047-2017; Nahler, N Hendrik/H-9223-2012; Wodtke, Alec M/I-4848-2012; Auerbach, Daniel J/J-7109-2014	LaRue, Jerry/0000-0002-8081-5335; Nahler, N Hendrik/0000-0002-7932-431X; Auerbach, Daniel J/0000-0001-9494-3066; Wodtke, Alec/0000-0002-6509-2183	NSF [CHE-0454806, OISE-0530268]; Partnership for International Research and Education-for Electron Chemistry and Catalysis at Interfaces; Feodor-Lynen fellowship; Alexander von Humboldt Foundation	NSF(National Science Foundation (NSF)); Partnership for International Research and Education-for Electron Chemistry and Catalysis at Interfaces; Feodor-Lynen fellowship; Alexander von Humboldt Foundation(Alexander von Humboldt Foundation)	We gratefully acknowledge financial support from the NSF (grant CHE-0454806) and the Partnership for International Research and Education-for Electron Chemistry and Catalysis at Interfaces (NSF grant OISE-0530268). N.H.N. acknowledges financial support through a Feodor-Lynen fellowship provided by the Alexander von Humboldt Foundation. We thank D. Matsiev for many useful discussions and suggestions and a critical reading of this manuscript.	Auerbach DJ, 2001, SCIENCE, V294, P2488, DOI 10.1126/science.1067543; Born M, 1927, ANN PHYS-BERLIN, V84, P0457; BRAKO R, 1989, REP PROG PHYS, V52, P655, DOI 10.1088/0034-4885/52/6/001; Gergen B, 2001, SCIENCE, V294, P2521, DOI 10.1126/science.1066134; Greber T., 1997, Surface Science Reports, V28, P1, DOI 10.1016/S0167-5729(97)00005-8; GREBER T, 1994, PHYS REV B, V50, P8755, DOI 10.1103/PhysRevB.50.8755; Greeley J, 2002, ANNU REV PHYS CHEM, V53, P319, DOI 10.1146/annurev.physchem.53.100301.131630; Hasselbrink E, 2006, CURR OPIN SOLID ST M, V10, P192, DOI 10.1016/j.cossms.2007.04.003; HELLBERG L, 1995, PHYS REV LETT, V74, P4742, DOI 10.1103/PhysRevLett.74.4742; Huang Y, 2000, PHYS REV LETT, V84, P2985, DOI 10.1103/PhysRevLett.84.2985; Huang YH, 2000, SCIENCE, V290, P111, DOI 10.1126/science.290.5489.111; Ji XZ, 2005, J AM CHEM SOC, V127, P5792, DOI 10.1021/ja050945m; JONGMA RT, 1995, J CHEM PHYS, V102, P1925, DOI 10.1063/1.468758; Katz G, 2005, J PHYS CHEM B, V109, P18876, DOI 10.1021/jp052107k; KOHN W, 1965, PHYS REV, V140, P1133, DOI 10.1103/PhysRev.140.A1133; Larue JL, 2008, J CHEM PHYS, V129, DOI 10.1063/1.2953712; Neyman KM, 2005, CATAL TODAY, V105, P2, DOI 10.1016/j.cattod.2005.04.006; Nienhaus H, 2002, SURF SCI REP, V45, P3, DOI 10.1016/S0167-5729(01)00019-X; Nikitin EE, 1999, ANNU REV PHYS CHEM, V50, P1, DOI 10.1146/annurev.physchem.50.1.1; Ran Q, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.237601; RETTNER CT, 1985, PHYS REV LETT, V55, P1904, DOI 10.1103/PhysRevLett.55.1904; Shenvi N, 2006, J CHEM PHYS, V125, DOI 10.1063/1.2357740; White JD, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2166360; White JD, 2005, NATURE, V433, P503, DOI 10.1038/nature03213; Wodtke AM, 2004, INT REV PHYS CHEM, V23, P513, DOI 10.1080/01442350500037521	25	57	57	3	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2008	321	5893					1191	1194		10.1126/science.1160040	http://dx.doi.org/10.1126/science.1160040			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341ZM	18755972	Green Submitted			2022-12-28	WOS:000258754400039
J	Vasquez, V; Sotomayor, M; Cordero-Morales, J; Schulten, K; Perozo, E				Vasquez, Valeria; Sotomayor, Marcos; Cordero-Morales, Julio; Schulten, Klaus; Perozo, Eduardo			A structural mechanism for MscS gating in lipid bilayers	SCIENCE			English	Article							MECHANOSENSITIVE CHANNEL; MOLECULAR-DYNAMICS; ION-CHANNEL; PORE; CONDUCTION; PRESSURE	The mechanosensitive channel of small conductance (MscS) is a key determinant in the prokaryotic response to osmotic challenges. We determined the structural rearrangements associated with MscS activation in membranes, using functorial measurements, electron paramagnetic resonance spectroscopy, and computational analyses. MscS was trapped in its open conformation after the transbilayer pressure profile was modified through the asymmetric incorporation of lysophospholipids. The transition from the closed to the open state is accompanied by the downward tilting of the transmembrane TM1-TM2 hairpin and by the expansion, tilt, and rotation of the TM3 helices. These movements expand the permeation pathway, leading to an increase in accessibility to water around TM3. Our open MscS model is compatible with single- channel conductance measurements and supports the notion that helix tilting is associated with efficient pore widening in mechanosensitive channels.	[Vasquez, Valeria; Cordero-Morales, Julio; Perozo, Eduardo] Univ Chicago, Dept Biochem & Mol Biol, Inst Biophys Dynam, Chicago, IL 60637 USA; [Vasquez, Valeria; Cordero-Morales, Julio] Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; [Sotomayor, Marcos] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; [Sotomayor, Marcos] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; [Schulten, Klaus] Univ Illinois, Dept Phys, Urbana, IL 61801 USA; [Schulten, Klaus] Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA	University of Chicago; University of Virginia; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; University of Illinois System; University of Illinois Urbana-Champaign	Perozo, E (corresponding author), Univ Chicago, Dept Biochem & Mol Biol, Inst Biophys Dynam, 920 E 58Th St, Chicago, IL 60637 USA.	eperozo@uchicago.edu	Schulten, Klaus/D-5561-2009; Sotomayor, Marcos/T-2411-2019; Sotomayor, Marcos/J-4898-2012	Sotomayor, Marcos/0000-0002-3333-1805; Sotomayor, Marcos/0000-0002-3333-1805; Cordero Morales, Julio/0000-0002-6505-5403; Vasquez, Valeria/0000-0001-8494-1534	NIH grants [GM063617, P41-RR05969, 1 R01 GM067887]; NSF grant [LRAC MCA93S028]; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR005969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063617, R01GM067887] Funding Source: NIH RePORTER	NIH grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF grant(National Science Foundation (NSF)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank V. Jogini, S. Chakrapani, H. Raghuraman, and D. M. Cortes for providing comments and experimental advice and G. R. Meyer for EPR data analysis script. M. S. is an associate of the Howard Hughes Medical Institute in the laboratory of David Corey. This work was supported by NIH grants GM063617 (E. P.), P41-RR05969 (K.S.), and 1 R01 GM067887 (K.S.). Supercomputer time was provided through NSF grant LRAC MCA93S028.	Akitake B, 2005, J GEN PHYSIOL, V125, P143, DOI 10.1085/jgp.200409198; Akitake B, 2007, NAT STRUCT MOL BIOL, V14, P1141, DOI 10.1038/nsmb1341; Anishkin A, 2004, BIOPHYS J, V86, P2883, DOI 10.1016/S0006-3495(04)74340-4; Anishkin A, 2008, J GEN PHYSIOL, V132, P67, DOI 10.1085/jgp.200810000; Bass RB, 2002, SCIENCE, V298, P1582, DOI 10.1126/science.1077945; Betanzos M, 2002, NAT STRUCT BIOL, V9, P704, DOI 10.1038/nsb828; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Christensen AP, 2007, NAT REV NEUROSCI, V8, P510, DOI 10.1038/nrn2149; Edwards MD, 2005, NAT STRUCT MOL BIOL, V12, P113, DOI 10.1038/nsmb895; FARAHBAKHSH ZT, 1992, PHOTOCHEM PHOTOBIOL, V56, P1019, DOI 10.1111/j.1751-1097.1992.tb09725.x; Gottlieb P, 2008, PFLUG ARCH EUR J PHY, V455, P1097, DOI 10.1007/s00424-007-0359-3; Gullingsrud J, 2001, BIOPHYS J, V80, P2074, DOI 10.1016/S0006-3495(01)76181-4; Gullingsrud J, 2003, BIOPHYS J, V85, P2087, DOI 10.1016/S0006-3495(03)74637-2; Hayakawa K, 2008, J CELL SCI, V121, P496, DOI 10.1242/jcs.022053; Koprowski P, 1998, J MEMBRANE BIOL, V164, P253, DOI 10.1007/s002329900410; Kwan KY, 2006, NEURON, V50, P277, DOI 10.1016/j.neuron.2006.03.042; Levina N, 1999, EMBO J, V18, P1730, DOI 10.1093/emboj/18.7.1730; Maingret F, 2000, J BIOL CHEM, V275, P10128, DOI 10.1074/jbc.275.14.10128; Markin VS, 2007, CURR TOP MEMBR, V58, P87, DOI 10.1016/S1063-5823(06)58004-4; MARTINAC B, 1990, NATURE, V348, P261, DOI 10.1038/348261a0; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; Martinac B, 2001, CELL PHYSIOL BIOCHEM, V11, P61, DOI 10.1159/000047793; Miller S, 2003, EMBO J, V22, P36, DOI 10.1093/emboj/cdg011; Moe P, 2005, BIOCHEMISTRY-US, V44, P12239, DOI 10.1021/bi0509649; Nomura T, 2006, BIOPHYS J, V91, P2874, DOI 10.1529/biophysj.106.084541; Okada K, 2002, J BIOL CHEM, V277, P27682, DOI 10.1074/jbc.M202497200; Perozo E, 2002, NAT STRUCT BIOL, V9, P696, DOI 10.1038/nsb827; Perozo E, 2001, J GEN PHYSIOL, V118, P193, DOI 10.1085/jgp.118.2.193; Perozo E, 2002, NATURE, V418, P942, DOI 10.1038/nature00992; Pivetti CD, 2003, MICROBIOL MOL BIOL R, V67, P66, DOI 10.1128/MMBR.67.1.66-85.2003; Smart OS, 1996, J MOL GRAPH MODEL, V14, P354, DOI 10.1016/S0263-7855(97)00009-X; Sompornpisut P, 2008, BIOPHYS J, V95, P5349, DOI 10.1529/biophysj.108.142984; Sotomayor M, 2006, BIOPHYS J, V90, P3496, DOI 10.1529/biophysj.105.080069; Sotomayor M, 2004, BIOPHYS J, V87, P3050, DOI 10.1529/biophysj.104.046045; Sotomayor M, 2007, BIOPHYS J, V92, P886, DOI 10.1529/biophysj.106.095232; Spronk SA, 2006, BIOPHYS J, V90, P3555, DOI 10.1529/biophysj.105.080432; Steinbacher S, 2007, CURR TOP MEMBR, V58, P1, DOI 10.1016/S1063-5823(06)58001-9; Sukharev S, 2001, NATURE, V409, P720, DOI 10.1038/35055559; Vasquez V, 2008, J MOL BIOL, V378, P55, DOI 10.1016/j.jmb.2007.10.086; Vasquez V, 2007, BIOCHEMISTRY-US, V46, P6766, DOI 10.1021/bi700322k; Yoshimura K, 2004, BIOPHYS J, V86, P2113, DOI 10.1016/S0006-3495(04)74270-8	41	136	139	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2008	321	5893					1210	1214		10.1126/science.1159674	http://dx.doi.org/10.1126/science.1159674			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341ZM	18755978	Green Accepted			2022-12-28	WOS:000258754400045
J	Saper, RB; Phillips, RS; Sehgal, A; Khouri, N; Davis, RB; Paquin, J; Thuppil, V; Kales, SN				Saper, Robert B.; Phillips, Russell S.; Sehgal, Anusha; Khouri, Nadia; Davis, Roger B.; Paquin, Janet; Thuppil, Venkatesh; Kales, Stefanos N.			Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUPPLEMENTS; METAL; PRODUCTS; REMEDIES	Context Lead, mercury, and arsenic have been detected in a substantial proportion of Indian- manufactured traditional Ayurvedic medicines. Metals may be present due to the practice of rasa shastra ( combining herbs with metals, minerals, and gems). Whether toxic metals are present in both US- and Indian- manufactured Ayurvedic medicines is unknown. Objectives To determine the prevalence of Ayurvedic medicines available via the Internet containing detectable lead, mercury, or arsenic and to compare the prevalence of toxic metals in US- vs Indian- manufactured medicines and between rasa shastra and non - rasa shastra medicines. Design A search using 5 Internet search engines and the search terms Ayurveda and Ayurvedic medicine identified 25 Web sites offering traditional Ayurvedic herbs, formulas, or ingredients commonly used in Ayurveda, indicated for oral use, and available for sale. From 673 identified products, 230 Ayurvedic medicines were randomly selected for purchase in August- October 2005. Country of manufacturer/ Web site supplier, rasa shastra status, and claims of Good Manufacturing Practices were recorded. Metal concentrations were measured using x- ray fluorescence spectroscopy. Main Outcome Measures Prevalence of medicines with detectable toxic metals in the entire sample and stratified by country of manufacture and rasa shastra status. Results One hundred ninety- three of the 230 requested medicines were received and analyzed. The prevalence of metal- containing products was 20.7% ( 95% confidence interval [ CI], 15.2%- 27.1%). The prevalence of metals in US- manufactured products was 21.7% ( 95% CI, 14.6%- 30.4%) compared with 19.5% ( 95% CI, 11.3%-30.1%) in Indian products ( P=. 86). Rasa shastra compared with non - rasa shastra medicines had a greater prevalence of metals ( 40.6% vs 17.1%; P=. 007) and higher median concentrations of lead ( 11.5 mu g/g vs 7.0 mu g/ g; P=. 03) and mercury ( 20 800 mu g/ g vs 34.5 mu g/ g; P=. 04). Among the metal- containing products, 95% were sold by US Web sites and 75% claimed Good Manufacturing Practices. All metal-containing products exceeded 1 or more standards for acceptable daily intake of toxic metals. Conclusion One- fifth of both US- manufactured and Indian- manufactured Ayurvedic medicines purchased via the Internet contain detectable lead, mercury, or arsenic.	[Saper, Robert B.; Sehgal, Anusha; Khouri, Nadia] Boston Med Ctr, Dept Family Med, Boston, MA 02118 USA; [Saper, Robert B.; Sehgal, Anusha; Khouri, Nadia] Boston Univ, Sch Med, Dept Family Med, Boston, MA 02118 USA; [Phillips, Russell S.; Davis, Roger B.] Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med & Primary Care, Boston, MA 02215 USA; [Phillips, Russell S.; Davis, Roger B.] Harvard Univ, Sch Med, Div Res & Educ Complementary & Integrat Med Thera, Osher Res Ctr, Boston, MA USA; [Kales, Stefanos N.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; [Paquin, Janet] US EPA, New England Reg Lab, N Chelmsford, MA USA; [Thuppil, Venkatesh] St Johns Med Coll, Natl Referral Ctr Lead Poisoning India, Bangalore, Karnataka, India; [Thuppil, Venkatesh] St Johns Med Coll, Dept Biochem & Biophys, Bangalore, Karnataka, India; [Kales, Stefanos N.] Harvard Univ, Sch Med, Cambridge Hlth Alliance, Cambridge, MA 02138 USA	Boston Medical Center; Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; United States Environmental Protection Agency; St. John's National Academy of Health Sciences; St. John's Medical College; St. John's National Academy of Health Sciences; St. John's Medical College; Harvard University; Cambridge Health Alliance	Saper, RB (corresponding author), Boston Med Ctr, Dept Family Med, 1 Boston Med Ctr Pl,Dowling 5 S, Boston, MA 02118 USA.	robert.saper@bmc.org	Saper, Robert B/Y-4598-2018	Saper, Robert B/0000-0002-0992-6198	Career Development Award [K07 AT002915-03]; National Center for Complementary and Alternative Medicine (NCCAM); National Institutes of Health; Mid-Career Investigator Award [5K24AT000589-07]; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [K24AT000589, K07AT002915] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [T32AT000051] Funding Source: NIH RePORTER	Career Development Award; National Center for Complementary and Alternative Medicine (NCCAM)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mid-Career Investigator Award; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Dr Saper is supported by a Career Development Award (K07 AT002915-03) from the National Center for Complementary and Alternative Medicine (NCCAM), National Institutes of Health. Dr Phillips is supported by a Mid-Career Investigator Award (5K24AT000589-07) from NCCAM.	*AM HERB PROD ASS, AHPA COD ETH BUS CON; BAER RD, 1988, J ETHNOPHARMACOL, V24, P31, DOI 10.1016/0378-8741(88)90137-7; *CAL ENV PROT AG, 2008, PROP 65 SAF HARB LEV; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P582; Dolan SP, 2003, J AGR FOOD CHEM, V51, P1307, DOI 10.1021/jf026055x; Dwivedi SK, 2002, ARCH ENVIRON HEALTH, V57, P229, DOI 10.1080/00039890209602941; Ernst E, 2002, EUR J CLIN PHARMACOL, V57, P891, DOI 10.1007/s00228-001-0400-y; Gogtay NJ, 2002, DRUG SAFETY, V25, P1005, DOI 10.2165/00002018-200225140-00003; Institute of Medicine and National Research Council, 2005, DIET SUPPL FRAM EV S; Kales SN, 2007, MED SCI MONITOR, V13, pCR295; Ko RJ, 1998, NEW ENGL J MED, V339, P847, DOI 10.1056/NEJM199809173391214; McGinnis JM, 2006, ANN INTERN MED, V145, P364, DOI 10.7326/0003-4819-145-5-200609050-00136; Morris CA, 2003, JAMA-J AM MED ASSOC, V290, P1505, DOI 10.1001/jama.290.11.1505; Ramachandran R., 2006, FRONTLINE, V23; Raman P, 2004, J AGR FOOD CHEM, V52, P7822, DOI 10.1021/jf049150+; RIOUX J, 2005, LIGHT AYURVEDA J HLT, V3, P24; Saper RB, 2004, JAMA-J AM MED ASSOC, V292, P2868, DOI 10.1001/jama.292.23.2868; Satpute AD, 2003, RASA RATNA SAMUCHAYA; SHASTRI K, 1979, RASA TARANGINI SADAN; *US EPA, INT RISK INF SYST IR; 2007, FED REG         0625, P34838	21	292	301	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2008	300	8					915	923		10.1001/jama.300.8.915	http://dx.doi.org/10.1001/jama.300.8.915			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	341AR	18728265	Bronze, Green Accepted			2022-12-28	WOS:000258687100026
J	Strate, LL; Liu, YL; Syngal, S; Aldoori, WH; Giovannucci, EL				Strate, Lisa L.; Liu, Yan L.; Syngal, Sapna; Aldoori, Walid H.; Giovannucci, Edward L.			Nut, corn, and popcorn consumption and the incidence of diverticular disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COLORECTAL-CANCER RISK; NATURAL-HISTORY; PROSTATE-CANCER; ANTIINFLAMMATORY DRUGS; MAGNESIUM INTAKE; HEART-DISEASE; COLON; EPIDEMIOLOGY; PATHOGENESIS; REAPPRAISAL	Context Patients with diverticular disease are frequently advised to avoid eating nuts, corn, popcorn, and seeds to reduce the risk of complications. However, there is little evidence to support this recommendation. Objective To determine whether nut, corn, or popcorn consumption is associated with diverticulitis and diverticular bleeding. Design and Setting The Health Professionals Follow- up Study is a cohort of US men followed up prospectively from 1986 to 2004 via self- administered questionnaires about medical ( biennial) and dietary ( every 4 years) information. Men reporting newly diagnosed diverticulosis or diverticulitis were mailed supplemental questionnaires. Participants The study included 47 228 men aged 40 to 75 years who at baseline were free of diverticulosis or its complications, cancer, and inflammatory bowel disease and returned a food- frequency questionnaire. Main Outcome Measures Incident diverticulitis and diverticular bleeding. Results During 18 years of follow- up, there were 801 incident cases of diverticulitis and 383 incident cases of diverticular bleeding. We found inverse associations between nut and popcorn consumption and the risk of diverticulitis. The multivariate hazard ratios for men with the highest intake of each food ( at least twice per week) compared with men with the lowest intake ( less than once per month) were 0.80 ( 95% confidence interval, 0.63- 1.01; P for trend=. 04) for nuts and 0.72 ( 95% confidence interval, 0.56- 0.92; P for trend=. 007) for popcorn. No associations were seen between corn consumption and diverticulitis or between nut, corn, or popcorn consumption and diverticular bleeding or uncomplicated diverticulosis. Conclusions In this large, prospective study of men without known diverticular disease, nut, corn, and popcorn consumption did not increase the risk of diverticulosis or diverticular complications. The recommendation to avoid these foods to prevent diverticular complications should be reconsidered.	[Strate, Lisa L.] Harborview Med Ctr, Div Gastroenterol, Dept Med, Seattle, WA 98104 USA; [Strate, Lisa L.] Univ Washington, Sch Med, Seattle, WA USA; [Liu, Yan L.; Giovannucci, Edward L.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; [Giovannucci, Edward L.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Syngal, Sapna; Giovannucci, Edward L.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Syngal, Sapna] Brigham & Womens Hosp, Dept Med, Div Gastroenterol, Boston, MA 02115 USA; [Giovannucci, Edward L.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; [Syngal, Sapna] Dana Farber Canc Inst, Div Populat Sci, Boston, MA 02115 USA; [Aldoori, Walid H.] Wyeth Consumer Healthcare Inc, Mississauga, ON, Canada	Harborview Medical Center; University of Washington; University of Washington Seattle; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Pfizer	Strate, LL (corresponding author), Harborview Med Ctr, Div Gastroenterol, Dept Med, 325 9th Ave,Box 359773, Seattle, WA 98104 USA.	lstrate@u.washington.edu			Agency for Healthcare Research and Quality [K08 HS14062]; National Cancer Institute [P01 CA055075, K24CA113433]; National Heart, Lung, and Blood Institute [R01HL035464]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS014062] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K24CA113433, P01CA055075] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was funded by grant K08 HS14062 from the Agency for Healthcare Research and Quality (Dr Strate); grants P01 CA055075 (Dr Giovannucci) and K24CA113433(Dr Syngal) from the National Cancer Institute; and grant R01HL035464 from the National Heart, Lung, and Blood Institute (Dr Giovannucci).	Albert CM, 2002, ARCH INTERN MED, V162, P1382, DOI 10.1001/archinte.162.12.1382; Aldoori WH, 1998, J NUTR, V128, P714, DOI 10.1093/jn/128.4.714; Aldoori WH, 1998, ARCH FAM MED, V7, P255, DOI 10.1001/archfami.7.3.255; ALDOORI WH, 1994, AM J CLIN NUTR, V60, P757, DOI 10.1093/ajcn/60.5.757; ALDOORI WH, 1995, GUT, V36, P276, DOI 10.1136/gut.36.2.276; ALMY TP, 1980, NEW ENGL J MED, V302, P324, DOI 10.1056/NEJM198002073020605; BERMAN LG, 1968, SURG GYNECOL OBSTETR, V127, P481; Bogardus ST, 2006, J CLIN GASTROENTEROL, V40, pS108, DOI 10.1097/01.mcg.0000212603.28595.5c; COX DR, 1972, J R STAT SOC B, V34, P187; Dobbins C, 2006, COLORECTAL DIS, V8, P37, DOI 10.1111/j.1463-1318.2005.00847.x; FLEISCHN.FG, 1965, RADIOLOGY, V84, P599, DOI 10.1148/84.4.599; Floch MH, 2004, J CLIN GASTROENTEROL, V38, pS2, DOI 10.1097/01.mcg.0000124003.07433.ee; Folsom AR, 2006, AM J EPIDEMIOL, V163, P232, DOI 10.1093/aje/kwj037; Hebert JR, 1998, JNCI-J NATL CANCER I, V90, P1637, DOI 10.1093/jnci/90.21.1637; HORNER JL, 1958, AM J DIG DIS, V3, P343, DOI 10.1007/BF02232401; Hu F B, 1999, Curr Atheroscler Rep, V1, P204, DOI 10.1007/s11883-999-0033-7; Hu FB, 1998, BMJ-BRIT MED J, V317, P1341, DOI 10.1136/bmj.317.7169.1341; HUGHES LE, 1969, GUT, V10, P344, DOI 10.1136/gut.10.5.344; Jacobs DO, 2007, NEW ENGL J MED, V357, P2057, DOI 10.1056/NEJMcp073228; Jain MG, 1999, NUTR CANCER, V34, P173, DOI 10.1207/S15327914NC3402_8; Jenab M, 2004, CANCER EPIDEM BIOMAR, V13, P1595; Jiang R, 2006, AM J EPIDEMIOL, V163, P222, DOI 10.1093/aje/kwj033; Jiang R, 2002, JAMA-J AM MED ASSOC, V288, P2554, DOI 10.1001/jama.288.20.2554; Korzenik JR, 2006, J CLIN GASTROENTEROL, V40, pS112, DOI 10.1097/01.mcg.0000225503.59923.6c; Laine L, 2006, ALIMENT PHARM THER, V24, P751, DOI 10.1111/j.1365-2036.2006.03043.x; Laine L, 2003, GASTROENTEROLOGY, V124, P288, DOI 10.1053/gast.2003.50054; MCGUIRE HH, 1994, ANN SURG, V220, P653, DOI 10.1097/00000658-199411000-00008; MEYERS MA, 1976, GASTROENTEROLOGY, V71, P577; MEYERS MA, 1976, AM J ROENTGENOL, V127, P901, DOI 10.2214/ajr.127.6.901; MILLS PK, 1989, CANCER, V64, P598, DOI 10.1002/1097-0142(19890801)64:3&lt;598::AID-CNCR2820640306&gt;3.0.CO;2-6; Mimura T, 2004, DIS COLON RECTUM, V47, P371, DOI 10.1007/s10350-003-0050-5; Morris CR, 2003, GUT, V52, P1734, DOI 10.1136/gut.52.12.1734; Morris CR, 2003, BRIT J SURG, V90, P1267, DOI 10.1002/bjs.4221; Morris CR, 2002, POSTGRAD MED J, V78, P654, DOI 10.1136/pmj.78.925.654; MORSON BC, 1963, P ROY SOC MED, V56, P798, DOI 10.1177/003591576305600916; PARKS TG, 1968, P ROY SOC MED, V61, P932, DOI 10.1177/003591576806100931; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; Rosemar A, 2008, DIS COLON RECTUM, V51, P450, DOI 10.1007/s10350-007-9172-5; Sabate J, 1999, AM J CLIN NUTR, V70, p500S, DOI 10.1093/ajcn/70.3.500s; Sandler RS, 2002, GASTROENTEROLOGY, V122, P1500, DOI 10.1053/gast.2002.32978; Schechter S, 1999, DIS COLON RECTUM, V42, P470, DOI 10.1007/BF02234169; Shaheen NJ, 2006, AM J GASTROENTEROL, V101, P2128, DOI 10.1111/j.1572-0241.2006.00723.x; Stollman NH, 1999, AM J GASTROENTEROL, V94, P3110, DOI 10.1111/j.1572-0241.1999.01501.x; Stumpf M, 2001, INT J COLORECTAL DIS, V16, P271, DOI 10.1007/s003840100310; Tsai CJ, 2004, AM J EPIDEMIOL, V160, P961, DOI 10.1093/aje/kwh302; *US FDA, QUAL HLTH CLAIMS LET; van den Brandt PA, 2007, BRIT J CANCER, V96, P510, DOI 10.1038/sj.bjc.6603577; WELCH CE, 1953, ANN SURG, V138, P332, DOI 10.1097/00000658-195313830-00005	48	144	149	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2008	300	8					907	914		10.1001/jama.300.8.907	http://dx.doi.org/10.1001/jama.300.8.907			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	341AR	18728264	Green Accepted, Bronze			2022-12-28	WOS:000258687100025
J	Mendelow, AD; Timothy, J; Steers, JW; Lecky, F; Yates, D; Bouamra, O; Woodford, M; Hutchinson, PJ				Mendelow, A. David; Timothy, Jake; Steers, James W.; Lecky, Fiona; Yates, David; Bouamra, Omar; Woodford, Maralyn; Hutchinson, Peter J.			Management of patients with head injury	LANCET			English	Editorial Material							GUIDELINES; REHABILITATION; ADULTS; IMPACT; AUDIT; RULE		[Mendelow, A. David; Timothy, Jake; Steers, James W.; Hutchinson, Peter J.] Royal Coll Surgeons England, Soc British Neurol Surg, London WC2A 3PN, England; [Lecky, Fiona; Yates, David; Bouamra, Omar; Woodford, Maralyn] Univ Manchester, Trauma Audit & Res Network, Manchester, Lancs, England	Royal College of Surgeons of England; University of Manchester	Mendelow, AD (corresponding author), Newcastle Gen Hosp, Ward 31,North Wing,Westgate Rd, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.	A.D.Mendelow@ncl.ac.uk	Mendelow, Alexander/AAW-2878-2021		MRC [G0600986, G0601025, G9439390, G0001237] Funding Source: UKRI; Medical Research Council [G0001237, G0600986, G0601025, G9439390] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		*AM COLL SURG, 2005, ADV TRAUM LIF SUPP D; Bradley LJ, 2006, BRIT J NEUROSURG, V20, P36, DOI 10.1080/02688690600600855; Brain Trauma Foundation, GUID MAN SEV TRAUM B; Hassan Z, 2005, EMERG MED J, V22, P845, DOI 10.1136/emj.2004.021717; Hutchinson PJ, 2006, BMJ-BRIT MED J, V332, P118, DOI 10.1136/bmj.332.7533.118-a; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Leaman AM, 2004, EMERG MED J, V21, P400, DOI 10.1136/emj.2004.015024; Lee JB, 2004, EMERG MED J, V21, P125; Lloyd DA, 2005, ANN ROY COLL SURG, V87, P323, DOI 10.1308/003588405X51191; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Miller L, 2004, BMC HEALTH SERV RES, V4, DOI 10.1186/1472-6963-4-7; National Institute for Clinical Excellence, 2007, HEAD INJ TRIAG ASS I; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; *ROYAL AUSTR COLL, MAN AC NEUR RUR REM; *ROYAL COLL PAED C, EARL MAN PAT HEAD IN; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P23, DOI 10.1007/s00508-006-0760-5; Shravat BP, 2006, EMERG MED J, V23, P109, DOI 10.1136/emj.2004.022327; *SIGN, 2000, EARL MAN PAT HEAD IN; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Study Group on Head Injury of the Italian Society for Neurosurgery, 1996, J NEUROSURG SCI, V40, P11; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; *TRAUM AUD RES NET, TARN DAT	24	16	16	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	2008	372	9639					685	687		10.1016/S0140-6736(08)61280-5	http://dx.doi.org/10.1016/S0140-6736(08)61280-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	340BX	18722872				2022-12-28	WOS:000258622200032
J	Danzl, JG; Haller, E; Gustavsson, M; Mark, MJ; Hart, R; Bouloufa, N; Dulieu, O; Ritsch, H; Nagerl, HC				Danzl, Johann G.; Haller, Elmar; Gustavsson, Mattias; Mark, Manfred J.; Hart, Russell; Bouloufa, Nadia; Dulieu, Olivier; Ritsch, Helmut; Naegerl, Hanns-Christoph			Quantum gas of deeply bound ground state molecules	SCIENCE			English	Article							COLD MOLECULES; CESIUM; SPECTROSCOPY; ATOMS; CS-2	Molecular cooling techniques face the hurdle of dissipating translational as well as internal energy in the presence of a rich electronic, vibrational, and rotational energy spectrum. In our experiment, we create a translationally ultracold, dense quantum gas of molecules bound by more than 1000 wave numbers in the electronic ground state. Specifically, we stimulate with 80% efficiency, a two- photon transfer of molecules associated on a Feshbach resonance from a Bose- Einstein condensate of cesium atoms. In the process, the initial loose, long- range electrostatic bond of the Feshbach molecule is coherently transformed into a tight chemical bond. We demonstrate coherence of the transfer in a Ramsey- type experiment and show that the molecular sample is not heated during the transfer. Our results show that the preparation of a quantum gas of molecules in specific rovibrational states is possible and that the creation of a Bose- Einstein condensate of molecules in their rovibronic ground state is within reach.	[Danzl, Johann G.; Haller, Elmar; Gustavsson, Mattias; Mark, Manfred J.; Hart, Russell; Naegerl, Hanns-Christoph] Univ Innsbruck, Inst Phys Expt, A-6020 Innsbruck, Austria; [Bouloufa, Nadia; Dulieu, Olivier] Univ Paris 11, Aime Cotton Lab, CNRS, F-91405 Orsay, France; [Danzl, Johann G.; Haller, Elmar; Gustavsson, Mattias; Mark, Manfred J.; Hart, Russell; Ritsch, Helmut; Naegerl, Hanns-Christoph] Univ Innsbruck, Zentrum Quantenphys, A-6020 Innsbruck, Austria; [Ritsch, Helmut] Univ Innsbruck, Inst Theoret Phys, A-6020 Innsbruck, Austria	University of Innsbruck; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Innsbruck; University of Innsbruck	Danzl, JG (corresponding author), Univ Innsbruck, Inst Phys Expt, Technikerstr 25, A-6020 Innsbruck, Austria.	johann.danzl@uibk.ac.at	Gustavsson, Mattias/A-3397-2009; Mark, Manfred J/E-4286-2010; Naegerl, Hanns-Christoph/E-7329-2010; Danzl, Johann Georg/AGX-2475-2022; Ritsch, Helmut/L-4704-2016; Danzl, Johann/N-9987-2015; Haller, Elmar/E-8916-2010	Mark, Manfred J/0000-0001-8157-4716; Naegerl, Hanns-Christoph/0000-0002-7789-4431; Danzl, Johann Georg/0000-0001-8559-3973; Ritsch, Helmut/0000-0001-7013-5208; Danzl, Johann/0000-0001-8559-3973; Haller, Elmar/0000-0002-7951-1721	Austrian Ministry of Science and Research (Bundesministerium fur Wissenschaft und Forschung; Austrian Science Fund (Fonds zur Forderung der wissenschaftlichen Forschung); START prize grant; European Science Foundation; EuroQUAM collective research project QuDipMol	Austrian Ministry of Science and Research (Bundesministerium fur Wissenschaft und Forschung; Austrian Science Fund (Fonds zur Forderung der wissenschaftlichen Forschung)(Austrian Science Fund (FWF)); START prize grant(Austrian Science Fund (FWF)); European Science Foundation(European Science Foundation (ESF)European Commission); EuroQUAM collective research project QuDipMol	We thank the team of J. Hecker Denschlag, the LevT team in our group, and T. Bergeman for very helpful discussions and M. Prevedelli for technical assistance. We are indebted to R. Grimm for generous support and gratefully acknowledge funding by the Austrian Ministry of Science and Research (Bundesministerium fur Wissenschaft und Forschung) and the Austrian Science Fund (Fonds zur Forderung der wissenschaftlichen Forschung) in the form of a START prize grant and by the European Science Foundation in the framework of the EuroQUAM collective research project QuDipMol.	Amiot C, 2002, J CHEM PHYS, V117, P5155, DOI 10.1063/1.1499122; Bergmann K, 1998, REV MOD PHYS, V70, P1003, DOI 10.1103/RevModPhys.70.1003; Chin C, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.123201; DeMille D, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.067901; DeMille D, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.043202; Doyle J, 2004, EUR PHYS J D, V31, P149, DOI 10.1140/epjd/e2004-00151-x; Goral K, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.170406; Herbordt W, 2003, EURASIP J APPL SIG P, V2003, P21, DOI 10.1155/S1110865703211094; Jaksch D, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.040402; Jones KM, 2006, REV MOD PHYS, V78, P483, DOI 10.1103/RevModPhys.78.483; Kohler T, 2006, REV MOD PHYS, V78, P1311, DOI 10.1103/RevModPhys.78.1311; Kraemer T, 2006, NATURE, V440, P315, DOI 10.1038/nature04626; Kraemer T, 2004, APPL PHYS B-LASERS O, V79, P1013, DOI 10.1007/s00340-004-1657-5; Krems RV, 2005, INT REV PHYS CHEM, V24, P99, DOI 10.1080/01442350500167161; NIGUSCIO M, 2008, ULTRACOLD FERMI GASE; Sage JM, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.203001; Staanum P, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.023201; Stwalley WC, 2004, EUR PHYS J D, V31, P221, DOI 10.1140/epjd/e2004-00147-6; Volz T, 2006, NAT PHYS, V2, P692, DOI 10.1038/nphys415; Weber T, 2003, SCIENCE, V299, P232, DOI 10.1126/science.1079699; WEICKENMEIER W, 1985, J CHEM PHYS, V82, P5354, DOI 10.1063/1.448618; Winkler K, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.043201; Zahzam N, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.023202; Zelevinsky T, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.043201	24	298	298	2	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	2008	321	5892					1062	1066		10.1126/science.1159909	http://dx.doi.org/10.1126/science.1159909			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339RL	18719277	Green Submitted			2022-12-28	WOS:000258594900032
J	Sabin, TD; Jednacz, JA; Staats, PN; Cummings, TJ; Harris, NL; Sims, JR; Kolp, R; Scott, BJ				Sabin, Thomas D.; Jednacz, Jeffrey A.; Staats, Paul N.; Cummings, Thomas J., Jr.; Harris, Nancy Lee; Sims, John R., II; Kolp, Rebecca; Scott, Brian J.			A woman with headache and behavioral changes - Probable paraneoplastic limbic encephalitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OVARIAN TERATOMA; RECEPTOR ENCEPHALITIS		[Sabin, Thomas D.] Massachusetts Gen Hosp, Tufts Med Ctr, Dept Neurol, Boston, MA 02114 USA; [Jednacz, Jeffrey A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Staats, Paul N.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Sabin, Thomas D.] Tufts Univ, Sch Med, Dept Neurol, Boston, MA 02111 USA; [Jednacz, Jeffrey A.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Staats, Paul N.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Tufts Medical Center; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Tufts University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Sabin, TD (corresponding author), Massachusetts Gen Hosp, Tufts Med Ctr, Dept Neurol, Boston, MA 02114 USA.							Dalmau J, 2008, LANCET NEUROL, V7, P327, DOI 10.1016/S1474-4422(08)70060-7; Dalmau J, 2007, ANN NEUROL, V61, P25, DOI 10.1002/ana.21050; Darnell RB, 2003, NEW ENGL J MED, V349, P1543, DOI 10.1056/NEJMra023009; Di Stefano F, 2003, RHEUMATOLOGY, V42, P1418, DOI 10.1093/rheumatology/keg346; Iizuka T, 2008, NEUROLOGY, V70, P504, DOI 10.1212/01.wnl.0000278388.90370.c3; PAYNE D, 1981, CANCER, V48, P721, DOI 10.1002/1097-0142(19810801)48:3<721::AID-CNCR2820480311>3.0.CO;2-U; Suhler EB, 2003, ARCH OPHTHALMOL-CHIC, V121, P133; Tavassoli F A, 2003, WHO CLASSIFICATION T, V5; Vitaliani R, 2005, ANN NEUROL, V58, P594, DOI 10.1002/ana.20614; Wiese W, 2004, J RHEUMATOL, V31, P1854	10	33	37	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 21	2008	359	8					842	853		10.1056/NEJMcpc0804644	http://dx.doi.org/10.1056/NEJMcpc0804644			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339HL	18716302				2022-12-28	WOS:000258568600011
J	Soucek, L; Whitfield, J; Martins, CP; Finch, AJ; Murphy, DJ; Sodir, NM; Karnezis, AN; Swigart, LB; Nasi, S; Evan, GI				Soucek, Laura; Whitfield, Jonathan; Martins, Carla P.; Finch, Andrew J.; Murphy, Daniel J.; Sodir, Nicole M.; Karnezis, Anthony N.; Swigart, Lamorna Brown; Nasi, Sergio; Evan, Gerard I.			Modelling Myc inhibition as a cancer therapy	NATURE			English	Article							C-MYC; NEOPLASTIC PHENOTYPE; EXPRESSION; PROLIFERATION; PROGRESSION; ONCOGENE; PROMOTER; GENE; SKIN; DIMERIZATION	Myc is a pleiotropic basic helix - loop - helix leucine zipper transcription factor that coordinates expression of the diverse intracellular and extracellular programs that together are necessary for growth and expansion of somatic cells(1). In principle, this makes inhibition of Myc an attractive pharmacological approach for treating diverse types of cancer. However, enthusiasm has been muted by lack of direct evidence that Myc inhibition would be therapeutically efficacious, concerns that it would induce serious side effects by inhibiting proliferation of normal tissues, and practical difficulties in designing Myc inhibitory drugs. We have modelled genetically both the therapeutic impact and the side effects of systemic Myc inhibition in a preclinical mouse model of Ras- induced lung adenocarcinoma by reversible, systemic expression of a dominant- interfering Myc mutant. We show that Myc inhibition triggers rapid regression of incipient and established lung tumours, defining an unexpected role for endogenous Myc function in the maintenance of Ras- dependent tumours in vivo. Systemic Myc inhibition also exerts profound effects on normal regenerating tissues. However, these effects are well tolerated over extended periods and rapidly and completely reversible. Our data demonstrate the feasibility of targeting Myc, a common downstream conduit for many oncogenic signals, as an effective, efficient and tumour- specific cancer therapy.	[Soucek, Laura; Whitfield, Jonathan; Martins, Carla P.; Finch, Andrew J.; Murphy, Daniel J.; Sodir, Nicole M.; Karnezis, Anthony N.; Nasi, Sergio; Evan, Gerard I.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; [Soucek, Laura; Whitfield, Jonathan; Martins, Carla P.; Finch, Andrew J.; Murphy, Daniel J.; Sodir, Nicole M.; Karnezis, Anthony N.; Swigart, Lamorna Brown; Evan, Gerard I.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Nasi, Sergio] Univ Roma La Sapienza, CNR, Ist Biol & Patol Mol, I-00185 Rome, Italy	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome	Evan, GI (corresponding author), Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA.	gevan@cc.ucsf.edu	Whitfield, Jonathan/N-6690-2014; Soucek, Laura/AAG-7393-2019; Soucek, Laura/AAG-8377-2019; Murphy, Daniel/V-1079-2019	Whitfield, Jonathan/0000-0002-4925-7283; Soucek, Laura/0000-0002-4750-7971; Murphy, Daniel/0000-0002-5538-5468; Finch, Andrew/0000-0002-8065-4623	National Cancer Institute [2R01 CA98018]; AIRC; ASI; CNR; MIUR FIRB; FIRS; Human Frontier Science Program; NATIONAL CANCER INSTITUTE [T32CA108462, R01CA098018] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); AIRC(Fondazione AIRC per la ricerca sul cancro); ASI(Agenzia Spaziale Italiana (ASI)); CNR(Consiglio Nazionale delle Ricerche (CNR)); MIUR FIRB(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); FIRS; Human Frontier Science Program(Human Frontier Science Program); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank T. Jacks and S. Artandi for their gifts of LSL-Kras<SUP>G12D</SUP> and beta-actin-rtTA+ mice, respectively. We thank F. Rostker for technical assistance and Y. Yaron and L. Johnson for advice on the LSL-Kras<SUP>G12D</SUP> model and adenovirus inhalation. We thank our laboratory colleagues for their comments and feedback. This study was supported by grant 2R01 CA98018 from the National Cancer Institute (to G.I.E.). S.N. acknowledges support from AIRC, ASI, CNR, MIUR FIRB and FIRS. C.P.M. is a Leukemia and Lymphoma Society Fellow. J.W. acknowledges support from Human Frontier Science Program. This paper is dedicated to the memory of Judah Folkman.	AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; Arvanitis C, 2005, CANCER LETT, V226, P95, DOI 10.1016/j.canlet.2004.10.043; Baskar JF, 1996, J VIROL, V70, P3207, DOI 10.1128/JVI.70.5.3207-3214.1996; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; Evan GI, 2006, CANCER CELL, V10, P345, DOI 10.1016/j.ccr.2006.10.013; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; Flores I, 2004, ONCOGENE, V23, P5923, DOI 10.1038/sj.onc.1207796; FURTH PA, 1991, NUCLEIC ACIDS RES, V19, P6205, DOI 10.1093/nar/19.22.6205; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; KOTHARY R, 1991, MECH DEVELOP, V35, P25, DOI 10.1016/0925-4773(91)90038-8; Murphy MJ, 2005, TRENDS CELL BIOL, V15, P128, DOI 10.1016/j.tcb.2005.01.008; Nair SK, 2006, CURR TOP MICROBIOL, V302, P123; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Prochownik Edward V, 2004, Expert Rev Anticancer Ther, V4, P289, DOI 10.1586/14737140.4.2.289; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; Sawamura D, 1999, J INVEST DERMATOL, V112, P828, DOI 10.1046/j.1523-1747.1999.00583.x; Soucek L, 2004, CELL DEATH DIFFER, V11, P1038, DOI 10.1038/sj.cdd.4401443; Soucek L, 2002, CANCER RES, V62, P3507; Soucek L, 1998, ONCOGENE, V17, P2463, DOI 10.1038/sj.onc.1202199; Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490; Wright DE, 2001, BLOOD, V97, P2278, DOI 10.1182/blood.V97.8.2278; Zhan Y, 2000, DNA CELL BIOL, V19, P639, DOI 10.1089/10445490050199045	30	585	624	4	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 2	2008	455	7213					679	683		10.1038/nature07260	http://dx.doi.org/10.1038/nature07260			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	354KY	18716624	Green Accepted			2022-12-28	WOS:000259639700050
J	Schmitt, F; Kirchmann, PS; Bovensiepen, U; Moore, RG; Rettig, L; Krenz, M; Chu, JH; Ru, N; Perfetti, L; Lu, DH; Wolf, M; Fisher, IR; Shen, ZX				Schmitt, F.; Kirchmann, P. S.; Bovensiepen, U.; Moore, R. G.; Rettig, L.; Krenz, M.; Chu, J. -H.; Ru, N.; Perfetti, L.; Lu, D. H.; Wolf, M.; Fisher, I. R.; Shen, Z. -X.			Transient electronic structure and melting of a charge density wave in TbTe3	SCIENCE			English	Article							RAMAN-SCATTERING; SUPERCONDUCTORS; THERMALIZATION; EXCITATIONS; K0.3MOO3	Obtaining insight into microscopic cooperative effects is a fascinating topic in condensed matter research because, through self- coordination and collectivity, they can lead to instabilities with macroscopic impacts like phase transitions. We used femtosecond time- and angle- resolved photoelectron spectroscopy (trARPES) to optically pump and probe TbTe3, an excellent model system with which to study these effects. We drove a transient charge density wave melting, excited collective vibrations in TbTe3, and observed them through their time-, frequency-, and momentum- dependent influence on the electronic structure. We were able to identify the role of the observed collective vibration in the transition and to document the transition in real time. The information that we demonstrate as being accessible with trARPES will greatly enhance the understanding of all materials exhibiting collective phenomena.	[Kirchmann, P. S.; Bovensiepen, U.; Rettig, L.; Krenz, M.; Perfetti, L.; Wolf, M.] Free Univ Berlin, Fachbereich Phys, D-14195 Berlin, Germany; [Schmitt, F.; Moore, R. G.; Chu, J. -H.; Ru, N.; Fisher, I. R.; Shen, Z. -X.] Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA; [Moore, R. G.; Lu, D. H.; Shen, Z. -X.] Stanford Synchrotron Radiat Lab, Menlo Pk, CA 94025 USA; [Wolf, M.] Fritz Haber Inst, Dept Phys Chem, D-14195 Berlin, Germany; [Fisher, I. R.; Shen, Z. -X.] Stanford Univ, Geballe Lab Adv Mat, Stanford, CA 94305 USA	Free University of Berlin; Stanford University; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; Max Planck Society; Fritz Haber Institute of the Max Planck Society; Stanford University	Bovensiepen, U (corresponding author), Free Univ Berlin, Fachbereich Phys, Arnimallee 14, D-14195 Berlin, Germany.	uwe.bovensiepen@physik.fu-berlin.de; zxshen@stanford.edu	Wolf, Martin/Q-3548-2016; Bovensiepen, Uwe/AGE-9200-2022; Krenz, Marcel/J-8949-2014; Moore, Rob/CAG-8039-2022; Rettig, Laurenz/H-6462-2016; Kirchmann, Patrick S/C-1195-2008; Bovensiepen, Uwe/E-7435-2017; Chu, Jiun-Haw/B-1613-2012	Bovensiepen, Uwe/0000-0002-1506-4491; Moore, Rob/0000-0002-1608-5411; Rettig, Laurenz/0000-0002-0725-6696; Kirchmann, Patrick S/0000-0002-4835-0654; Bovensiepen, Uwe/0000-0002-1506-4491; Fisher, Ian/0000-0002-1278-7862; Chu, Jiun-Haw/0000-0001-6222-1210	Max-Planck-Gesellschaft; International Max Planck Research School; Deutsche Forschungsgemeinschaft [BO 1823/2, Sfb 450]; Heisenberg program; U. S. Department of Energy Office of Basic Energy Science, Division of Materials Science and Engineering	Max-Planck-Gesellschaft(Max Planck Society); International Max Planck Research School; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Heisenberg program(German Research Foundation (DFG)); U. S. Department of Energy Office of Basic Energy Science, Division of Materials Science and Engineering(United States Department of Energy (DOE))	We thank L. DeGiorgi et al. and D. Mihailovic et al. for fruitful discussions. We acknowledge funding from the Max-Planck-Gesellschaft through the International Max Planck Research School and by the Deutsche Forschungsgemeinschaft through BO 1823/2, Sfb 450, and the Heisenberg program. This work is supported by the U. S. Department of Energy Office of Basic Energy Science, Division of Materials Science and Engineering.	Baum P, 2007, SCIENCE, V318, P788, DOI 10.1126/science.1147724; Bovensiepen U, 2007, J PHYS-CONDENS MAT, V19, DOI 10.1088/0953-8984/19/8/083201; Brouet V, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.235104; BROUET V, 2004, PHYS REV LETT, V93; Cavalleri A, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.161102; Chollet M, 2005, SCIENCE, V307, P86, DOI 10.1126/science.1105067; Damascelli A, 2003, REV MOD PHYS, V75, P473, DOI 10.1103/RevModPhys.75.473; Dekorsy T, 2000, TOP APPL PHYS, V76, P169; Demsar J, 1999, PHYS REV LETT, V83, P800, DOI 10.1103/PhysRevLett.83.800; DIMASI E, 1995, PHYS REV B, V52, P14516, DOI 10.1103/PhysRevB.52.14516; Fang A, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.046401; FANN WS, 1992, PHYS REV B, V46, P13592, DOI 10.1103/PhysRevB.46.13592; Fritz DM, 2007, SCIENCE, V315, P633, DOI 10.1126/science.1135009; Gruner G., 1994, FRONTIERS PHYS, V89; Gweon GH, 1998, PHYS REV LETT, V81, P886, DOI 10.1103/PhysRevLett.81.886; Laverock J, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.085114; Lisowski M, 2004, APPL PHYS A-MATER, V78, P165, DOI 10.1007/s00339-003-2301-7; LITTLEWOOD PB, 1982, PHYS REV B, V26, P4883, DOI 10.1103/PhysRevB.26.4883; Loukakos PA, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.097401; Malliakas C, 2005, J AM CHEM SOC, V127, P6510, DOI 10.1021/ja0505292; Perfetti L, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.067402; Rethfeld B, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.214303; Ru N, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.035114; Schmising CVK, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.257601; SOORYAKUMAR R, 1981, PHYS REV B, V23, P3213, DOI 10.1103/PhysRevB.23.3213; TRAVAGLINI G, 1983, SOLID STATE COMMUN, V45, P289, DOI 10.1016/0038-1098(83)90483-0	26	355	359	2	162	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 19	2008	321	5896					1649	1652		10.1126/science.1160778	http://dx.doi.org/10.1126/science.1160778			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349RG	18703710				2022-12-28	WOS:000259300400026
J	Ogata, H; Claverie, JM				Ogata, Hiroyuki; Claverie, Jean-Michel			Microbiology - How to infect a mimivirus	SCIENCE			English	Editorial Material							VIRUSES; PATTERN		[Ogata, Hiroyuki; Claverie, Jean-Michel] Univ Aix Marseille 2, Struct & Genom Informat Lab, CNRS, UPR 2589,IFR 88, FR-13288 Marseille, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Ogata, H (corresponding author), Univ Aix Marseille 2, Struct & Genom Informat Lab, CNRS, UPR 2589,IFR 88, Parc Sci Luminy, FR-13288 Marseille, France.	ogata@igs.cnrs-mrs.fr; jean-michel.claverie@univmed.fr	Claverie, Jean Michel/Z-2183-2019; Claverie, Jean-Michel/AAG-4889-2019	Claverie, Jean-Michel/0000-0003-1424-0315				Abergel C, 2007, J VIROL, V81, P12406, DOI 10.1128/JVI.01107-07; Allen MJ, 2006, J VIROL, V80, P7699, DOI 10.1128/JVI.00491-06; Brussaard CPD, 2004, VIROLOGY, V319, P280, DOI 10.1016/j.virol.2003.10.033; Claverie JM, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-6-110; Koonin EV, 2005, TRENDS GENET, V21, P647, DOI 10.1016/j.tig.2005.09.006; La Scola B, 2003, SCIENCE, V299, P2033; LASCOLA B, 2008, NATURE; Monier A, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-7-r106; Nagasaki K, 2005, APPL ENVIRON MICROB, V71, P3599, DOI 10.1128/AEM.71.7.3599-3607.2005; Nagasaki K, 2008, J MICROBIOL, V46, P235, DOI 10.1007/s12275-008-0098-y; Ogata H, 2007, GENOME RES, V17, P1353, DOI 10.1101/gr.6358607; Raoult D, 2004, SCIENCE, V306, P1344, DOI 10.1126/science.1101485; Renesto P, 2006, J VIROL, V80, P11678, DOI 10.1128/JVI.00940-06; Zauberman N, 2008, PLOS BIOL, V6, P1104, DOI 10.1371/journal.pbio.0060114	14	11	11	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	2008	321	5894					1305	1306		10.1126/science.1164839	http://dx.doi.org/10.1126/science.1164839			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	344GG	18772426				2022-12-28	WOS:000258914300036
J	Sloane, PD; Cohen, LW; Konrad, TR; Williams, CS; Schumacher, JG; Zimmerman, S				Sloane, Philip D.; Cohen, Lauren W.; Konrad, Thomas R.; Williams, Christianna S.; Schumacher, John G.; Zimmerman, Sheryl			Brief communication: Physician interest in volunteer service during retirement	ANNALS OF INTERNAL MEDICINE			English	Article							BABY-BOOMERS; SHORTAGE; TRENDS; WORK; AGE	Background: Baby boomers approaching retirement will include unprecedented numbers of physicians, many of whom want to remain productive. Objective: To determine interest in health care - related volunteering during retirement among physicians trained to provide general medical care to adults. Design: Cross-sectional mailed survey conducted May through July 2006. Setting: North Carolina. Participants: 910 physicians, 55 years of age or older, whose primary specialty involved direct, nonsurgical care of adults. Measurements: Current volunteerism and future interest in selected activities. Results: Of the respondents, 89.8% were male and 87.4% were white; 57.4% worked full-time, 21.7% worked part-time, and 21.0% were retired. Of current retirees, 37.1% expressed interest in volunteering. Areas of greatest interest were medical teaching, working in free medical clinics, and international care. Strong incentives included staying mentally active (67.3%) or involved in medicine (61.2%) and contributing to society (60.5%). Substantial barriers included concerns about malpractice (61.5%) and paperwork or bureaucracy (46.0%). The majority of respondents (66.7%) felt that lack of payment would not influence volunteering. Limitations: The 59% overall response rate and exclusion of unlicensed retired physicians limit study generalizability. The data were provided by self-response and could not be independently validated. Conclusion: Retired physicians are a potential source of manpower that could contribute to provision of health care, particularly in medical teaching and clinical care of underserved persons.	Univ N Carolina, Sch Social Work, Chapel Hill, NC 27599 USA; Univ Maryland Baltimore Cty, Ctr Aging Studies, Baltimore, MD 21228 USA	University of North Carolina; University of North Carolina Chapel Hill; University System of Maryland; University of Maryland Baltimore County	Sloane, PD (corresponding author), Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Dept Family Med, 725 Martin Luther King Jr Blvd,CB 7590, Chapel Hill, NC 27599 USA.	psloane@med.unc.edu	Konrad, Thomas R./AAT-9276-2020	Konrad, Thomas R/0000-0002-5269-0440	Alzheimer's Association [PIO-04-1004]	Alzheimer's Association(Alzheimer's Association)	By Pioneer Award PIO-04-1004 from the Alzheimer's Association.	*AM COLL PHYS, INT VOL PHYS GUID GE; BAHRAMI B, 2001, J APPL BUSINESS RES, V17, P55; Blumenthal D, 2004, NEW ENGL J MED, V350, P1780, DOI 10.1056/NEJMhpr033066; *BUR HLTH PROF, 2006, PHYS SUPPL DEM; Choi LH, 2003, J APPL GERONTOL, V22, P179, DOI 10.1177/0733464803022002001; Cooper RA, 2002, HEALTH AFFAIR, V21, P140, DOI 10.1377/hlthaff.21.1.140; De Ville K, 2007, J PUBLIC HEALTH MAN, V13, P530; DEITCH CH, 1995, RADIOLOGY, V194, P33, DOI 10.1148/radiology.194.1.7997578; Dohm A, 2000, MON LABOR REV, V123, P17; Frank E, 2003, J WOMEN HEALTH GEN-B, V12, P589, DOI 10.1089/154099903768248294; Gendell M, 1998, MON LABOR REV, V121, P20; HATTIS PA, 2004, OVERCOMING BARRIERS, P1033; Holoweiko M, 1996, Med Econ, V73, P176; HOLOWEIKO M, 1996, MED ECON, V73, P181; KLETKE P, 1998, ABSTR BOOK ASS HLTH, V15, P91; Libow LS, 2005, NEW ENGL J MED, V352, P750, DOI 10.1056/NEJMp048140; Scott HD, 2000, JAMA-J AM MED ASSOC, V283, P99, DOI 10.1001/jama.283.1.99; Shapiro Howard B, 2003, Fam Pract Manag, V10, P52; STAUB W, 2006, MEDGENMED, V8, P16; Travis KW, 1999, J CLIN ANESTH, V11, P175, DOI 10.1016/S0952-8180(99)00023-9; *VOL MED, HIST; WAN H, 2005, 65 US 2005 US CENS B, P6; Weiner JP, 2002, HEALTH AFFAIR, V21, P160, DOI 10.1377/hlthaff.21.1.160; Wilson LB, 2000, NURS OUTLOOK, V48, P34, DOI 10.1067/mno.2000.98119; 2005, ANN LONG TERM CARE, V13, P18	25	9	9	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2008	149	5					317	W67		10.7326/0003-4819-149-5-200809020-00006	http://dx.doi.org/10.7326/0003-4819-149-5-200809020-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	348SD	18765701				2022-12-28	WOS:000259229300004
J	Wald, D				Wald, David			Commentary: Controversies in NICE guidance on familial hypercholesterolaemia	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Wald, David] Univ London St Bartholomews Hosp Med Coll, Sch Med, Wolfson Inst Prevent Med, London EC1M 6BQ, England	University of London; Queen Mary University London	Wald, D (corresponding author), Univ London St Bartholomews Hosp Med Coll, Sch Med, Wolfson Inst Prevent Med, London EC1M 6BQ, England.	d.s.wald@qmul.ac.uk						Daniels SR, 2008, PEDIATRICS, V122, P198, DOI 10.1542/peds.2008-1349; Gaede P, 2003, NEW ENGL J MED, V348, P383, DOI 10.1056/NEJMoa021778; *NAT I HLTH CLIN E, 2008, CLIN GUID, V71; Starr B, 2008, CLIN CHEM LAB MED, V46, P791, DOI 10.1515/CCLM.2008.135; Tanne JH, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a813; WALD DS, 2007, BRIT MED J, V335, P573	6	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 30	2008	337	7668								10.1136/bmj.a1304	http://dx.doi.org/10.1136/bmj.a1304			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350OM	18753175				2022-12-28	WOS:000259362100031
J	Vijg, J; Campisi, J				Vijg, Jan; Campisi, Judith			Puzzles, promises and a cure for ageing	NATURE			English	Review							LIFE-SPAN; CAENORHABDITIS-ELEGANS; CALORIE RESTRICTION; DIETARY RESTRICTION; MICE LACKING; STEM-CELLS; LONGEVITY; DROSOPHILA; GENE; GROWTH	Recent discoveries in the science of ageing indicate that lifespan in model organisms such as yeast, nematodes, flies and mice is plastic and can be manipulated by genetic, nutritional or pharmacological intervention. A better understanding of the targets of such interventions, as well as the proximate causes of ageing-related degeneration and disease, is essential before we can evaluate if abrogation of human senescence is a realistic prospect.	[Vijg, Jan; Campisi, Judith] Buck Inst Age Res, Novato, CA 94945 USA; [Campisi, Judith] Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	Buck Institute for Research on Aging; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Campisi, J (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	jvijg@aecom.yu.edu; JCampisi@lbl.gov			US National Institutes of Health; Ellison Medical Foundation; NATIONAL INSTITUTE ON AGING [P30AG025708, P01AG017242] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ellison Medical Foundation(Lawrence Ellison Foundation); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank N. Barzilai, A. de Grey, G. Lithgow and M. Gough for comments on the manuscript and P. Kapahi, R. Shmookler Reis, L. Balducci and Y. Suh for discussions. The authors' work is supported by the US National Institutes of Health and Ellison Medical Foundation.	Ayyadevara S, 2008, AGING CELL, V7, P13, DOI 10.1111/j.1474-9726.2007.00348.x; Bahar R, 2006, NATURE, V441, P1011, DOI 10.1038/nature04844; Bartke A, 2005, ENDOCRINOLOGY, V146, P3718, DOI 10.1210/en.2005-0411; Barzilai N, 2003, JAMA-J AM MED ASSOC, V290, P2030, DOI 10.1001/jama.290.15.2030; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Beekman M, 2006, J GERONTOL A-BIOL, V61, P355, DOI 10.1093/gerona/61.4.355; Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Botstein D, 1997, SCIENCE, V277, P1259, DOI 10.1126/science.277.5330.1259; Broughton SJ, 2005, P NATL ACAD SCI USA, V102, P3105, DOI 10.1073/pnas.0405775102; Bruder CEG, 2008, AM J HUM GENET, V82, P763, DOI 10.1016/j.ajhg.2007.12.011; Calder RB, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-183; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Capri M, 2006, ANN NY ACAD SCI, V1067, P252, DOI 10.1196/annals.1354.033; Chen D, 2007, TRENDS MOL MED, V13, P64, DOI 10.1016/j.molmed.2006.12.004; Clancy DJ, 2002, SCIENCE, V296, P319, DOI 10.1126/science.1069366; De Grey ADNJ, 2002, ANN NY ACAD SCI, V959, P452, DOI 10.1111/j.1749-6632.2002.tb02115.x; DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567; Dirks AJ, 2006, MECH AGEING DEV, V127, P1, DOI 10.1016/j.mad.2005.09.001; DOBZHANSKY T, 1973, AM BIOL TEACH, V35, P125, DOI 10.2307/4444260; Finch CE, 2004, SCIENCE, V305, P1736, DOI 10.1126/science.1092556; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Floyd RA, 2006, AGING CELL, V5, P51, DOI 10.1111/j.1474-9726.2006.00189.x; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Frei B, 2004, J NUTR, V134, p3196S, DOI 10.1093/jn/134.11.3196S; FRIEDMAN DB, 1988, GENETICS, V118, P75; Furber JD, 2006, REJUV RES, V9, P274, DOI 10.1089/rej.2006.9.274; Gems D, 2002, AGING CELL, V1, P1, DOI 10.1046/j.1474-9728.2002.00003.x; Giannakou ME, 2004, TRENDS CELL BIOL, V14, P408, DOI 10.1016/j.tcb.2004.07.006; Grotewiel MS, 2005, AGEING RES REV, V4, P372, DOI 10.1016/j.arr.2005.04.001; Harding C, 2008, CANCER RES, V68, P4465, DOI 10.1158/0008-5472.CAN-07-1670; Harper JM, 2006, AGING CELL, V5, P441, DOI 10.1111/j.1474-9726.2006.00236.x; Herndon LA, 2002, NATURE, V419, P808, DOI 10.1038/nature01135; Ingram DK, 2006, AGING CELL, V5, P97, DOI 10.1111/j.1474-9726.2006.00202.x; Jenkins NL, 2004, P ROY SOC B-BIOL SCI, V271, P2523, DOI 10.1098/rspb.2004.2897; Kapahi P, 1999, FREE RADICAL BIO MED, V26, P495, DOI 10.1016/S0891-5849(98)00323-2; Keaney M, 2003, FREE RADICAL BIO MED, V34, P277, DOI 10.1016/S0891-5849(02)01290-X; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; Kinsella KG, 2005, J AM GERIATR SOC, V53, pS299, DOI 10.1111/j.1532-5415.2005.53494.x; Kirkwood TBL, 2005, CELL, V120, P437, DOI 10.1016/j.cell.2005.01.027; KIRKWOOD TBL, 1977, NATURE, V270, P301, DOI 10.1038/270301a0; KIRKWOOD TBL, 1986, ACCURACY MOL PROCESS; Kirkwood TBL, 2008, NATURE, V451, P644, DOI 10.1038/451644a; KLASS MR, 1983, MECH AGEING DEV, V22, P279, DOI 10.1016/0047-6374(83)90082-9; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Kuningas M, 2007, EUR J HUM GENET, V15, P294, DOI 10.1038/sj.ejhg.5201766; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Masoro EJ, 2005, MECH AGEING DEV, V126, P913, DOI 10.1016/j.mad.2005.03.012; Mattison JA, 2003, EXP GERONTOL, V38, P35, DOI 10.1016/S0531-5565(02)00146-8; McCarty MF, 2004, MED HYPOTHESES, V63, P334, DOI 10.1016/j.mehy.2004.01.043; Medawar P., 1952, UNSOLVED PROBLEM BIO; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; Meydani M, 1998, ANN NY ACAD SCI, V854, P352, DOI 10.1111/j.1749-6632.1998.tb09915.x; Miller RA, 2007, AGING CELL, V6, P565, DOI 10.1111/j.1474-9726.2007.00311.x; Morten KJ, 2006, J BIOL CHEM, V281, P3354, DOI 10.1074/jbc.M509261200; Muller FL, 2007, FREE RADICAL BIO MED, V43, P477, DOI 10.1016/j.freeradbiomed.2007.03.034; OLSHANSKY SJ, 1990, SCIENCE, V250, P634, DOI 10.1126/science.2237414; Pelosi L, 2007, FASEB J, V21, P1393, DOI 10.1096/fj.06-7690com; Perls T, 2007, J GERONTOL A-BIOL, V62, P1028, DOI 10.1093/gerona/62.9.1028; Rando TA, 2006, NATURE, V441, P1080, DOI 10.1038/nature04958; Santini MP, 2007, CIRC RES, V100, P1732, DOI 10.1161/CIRCRESAHA.107.148791; Selman C, 2008, FASEB J, V22, P807, DOI 10.1096/fj.07-9261com; Sharpless NE, 2007, NAT REV MOL CELL BIO, V8, P703, DOI 10.1038/nrm2241; Smith JS, 2002, TRENDS CELL BIOL, V12, P404, DOI 10.1016/S0962-8924(02)02342-5; Spencer CC, 2003, AGING CELL, V2, P123, DOI 10.1046/j.1474-9728.2003.00044.x; Suckling K, 2007, EXPERT OPIN THER TAR, V11, P1133, DOI 10.1517/14728222.11.9.1133; Suh Y, 2008, P NATL ACAD SCI USA, V105, P3438, DOI 10.1073/pnas.0705467105; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Ulrich P, 2001, RECENT PROG HORM RES, V56, P1, DOI 10.1210/rp.56.1.1; Vaitkevicius PV, 2001, P NATL ACAD SCI USA, V98, P1171, DOI 10.1073/pnas.98.3.1171; Vaupel JW, 1998, SCIENCE, V280, P855, DOI 10.1126/science.280.5365.855; Vijg J., 2007, AGING GENOME; Wang C, 2007, J NEUROSCI, V27, P8563, DOI 10.1523/JNEUROSCI.0218-07.2007; Weindruch R, 2006, BIOGERONTOLOGY, V7, P169, DOI 10.1007/s10522-006-9007-0; Yang J, 2005, EXP GERONTOL, V40, P867, DOI 10.1016/j.exger.2005.08.001	75	272	280	0	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	2008	454	7208					1065	1071		10.1038/nature07216	http://dx.doi.org/10.1038/nature07216			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341MW	18756247	Green Accepted			2022-12-28	WOS:000258719600027
J	Holtzer, R; Verghese, J; Wang, CL; Hall, CB; Lipton, RB				Holtzer, Roee; Verghese, Joe; Wang, Cuiling; Hall, Charles B.; Lipton, Richard B.			Within-person across-neuropsychological test variability and incident dementia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MILD COGNITIVE IMPAIRMENT; INTRAINDIVIDUAL VARIABILITY; ALZHEIMERS-DISEASE; MEMORY IMPAIRMENT; PERFORMANCE; DIAGNOSIS; GAIT; PREVALENCE; PREDICTION; INCREASES	Context Neuropsychological tests are used to predict and diagnose dementia. However, to our knowledge, no studies to date have examined whether within-person across-neuropsychological test variability predicts dementia. Objective To examine whether within-person across-neuropsychological test variability predicts future dementia. Design The Einstein Aging Study (EAS) is a population-based longitudinal study of aging and dementia located in Bronx County, New York. We used Cox proportional hazards models using age as the time scale to estimate hazard ratios (HRs) for performance on individual neuropsychological tests (Free and Cued Selective Reminding Test, Digit Symbol Substitution subtest of the Wechsler Adult Intelligence Scale Revised, and the Vocabulary subtest of the Wechsler Adult Intelligence Scale Revised) and for within-person across-neuropsychological test variability as predictors of incident dementia. Analyses were stratified by sex, and controlled for education and medical illness. Setting and Participants A total of 1797 participants (age >= 70 years) enrolled in the EAS between October 1993 and December 2007. Participants seen for the baseline visit only (n = 750), prevalent dementia cases (n = 72), and those with missing follow-up information (n = 78) were excluded. A total of 897 individuals were included in this investigation. Participants had follow-up visits every 12 to 18 months. Main Outcome Measure Incident dementia. Results Sixty-one cases of incident dementia were identified during follow-up (mean [SD], 3.3 [2.4] years), of which 26 were in the highest quartile of within-person across-neuropsychological test variability. Adjusting for sex, education, and medical illness, variability was associated with incident dementia (HR for 1-point difference in variability, 3.93 [95% confidence interval {Cl}, 2.04-7.56]). The association persisted even after adjusting for level of performance on individual neuropsychological tests (HR for 1-point difference in variability, 2.10 [95% Cl, 1.04-4.23]). Comparing Cox models using neuropsychological tests with and without within-person across-neuropsychological test variablity showed that the former improved the prediction of dementia. Sensitivity in a model predicting dementia at 1 year also improved when neuropsychological test variability was included. Conclusions In this population, within-person across-neuropsychological test variability was associated with development of incident dementia independent of neuropsychological test performance. This finding needs to be confirmed in future studies.	[Holtzer, Roee; Verghese, Joe; Lipton, Richard B.] Yeshiva Univ Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10461 USA; [Wang, Cuiling; Hall, Charles B.; Lipton, Richard B.] Yeshiva Univ Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10461 USA; [Holtzer, Roee] Yeshiva Univ Albert Einstein Coll Med, Ferkauf Grad Sch Psychol, Bronx, NY 10461 USA; [Lipton, Richard B.] Yeshiva Univ Albert Einstein Coll Med, Inst Aging Res, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Holtzer, R (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Neurol, Rousso Bldg,Room 306,1165 Morris Pk Ave, Bronx, NY 10461 USA.	rholtzer@aecom.yu.edu	Lipton, Richard Bruce/AAY-2818-2021; Lipton, Richard B/B-5060-2011; Hall, Charles B./AAX-8216-2020	Hall, Charles/0000-0001-9982-8120; Holtzer, Roee/0000-0001-6639-0724	National Institute on Aging [AGO3949, K23 AG030857, AG025119]; NATIONAL INSTITUTE ON AGING [K23AG030857, P01AG003949, R01AG025119] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The Einstein Aging Study is supported by the National Institute on Aging program project grant AGO3949. Dr Holtzer is supported by the National Institute on Aging Paul B. Beeson Award K23 AG030857. Dr Verghese is supported by the National Institute on Aging grant AG025119.	Albert MS, 2001, J INT NEUROPSYCH SOC, V7, P631, DOI 10.1017/S1355617701755105; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Backman L, 2005, NEUROPSYCHOLOGY, V19, P520, DOI 10.1037/0894-4105.19.4.520; Bellgrove MA, 2004, NEUROPSYCHOLOGIA, V42, P1910, DOI 10.1016/j.neuropsychologia.2004.05.007; Bischkopf J, 2002, ACTA PSYCHIAT SCAND, V106, P403, DOI 10.1034/j.1600-0447.2002.01417.x; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; Christensen H, 2005, NEUROPSYCHOLOGY, V19, P309, DOI 10.1037/0894-4105.19.3.309; CHUI HC, 1992, NEUROLOGY, V42, P473, DOI 10.1212/WNL.42.3.473; Collie A, 2002, J CLIN EXP NEUROPSYC, V24, P720, DOI 10.1076/jcen.24.6.720.8397; Crystal HA, 2000, ARCH NEUROL-CHICAGO, V57, P713, DOI 10.1001/archneur.57.5.713; DeCarli C, 2003, LANCET NEUROL, V2, P15, DOI 10.1016/S1474-4422(03)00262-X; Dixon RA, 2007, NEUROPSYCHOLOGY, V21, P381, DOI 10.1037/0894-4105.21.3.381; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fuld PA., 1978, ALZHEIMERS DIS SENIL, V7, P185; Grober E, 1999, NEUROBIOL AGING, V20, P573, DOI 10.1016/S0197-4580(99)00063-9; Grober E, 2000, NEUROLOGY, V54, P827, DOI 10.1212/WNL.54.4.827; GROBER E, 1988, NEUROLOGY, V38, P900, DOI 10.1212/WNL.38.6.900; Hall CB, 2001, STAT MED, V20, P3695, DOI 10.1002/sim.1113; Hall CB, 2003, COMPUT STAT DATA AN, V42, P91, DOI 10.1016/S0167-9473(02)00148-2; Holtzer R, 2006, NEUROPSYCHOLOGY, V20, P215, DOI 10.1037/0894-4105.20.2.215; Holtzer R, 2007, NEUROPSYCHOLOGY, V21, P540, DOI 10.1037/0894-4105.21.5.540; Hultsch DF, 2000, NEUROPSYCHOLOGY, V14, P588, DOI 10.1037/0894-4105.14.4.588; Jokinen H, 2006, J NEUROL NEUROSUR PS, V77, P28, DOI 10.1136/jnnp.2005.069120; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; Kliegel M, 2004, GERONTOLOGY, V50, P39, DOI 10.1159/000074388; KNOTEK PC, 1990, BRAIN LANG, V38, P465, DOI 10.1016/0093-934X(90)90131-Y; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Lezak M.D., 1995, NEUROPSYCHOLOGICAL A; Li SC, 2004, GERONTOLOGY, V50, P28, DOI 10.1159/000074386; Lipton RB, 2003, J AM GERIATR SOC, V51, P1382, DOI 10.1046/j.1532-5415.2003.51455.x; MASUR DM, 1994, NEUROLOGY, V44, P1427, DOI 10.1212/WNL.44.8.1427; MATARAZZO JD, 1988, J CLIN PSYCHOL, V44, P940, DOI 10.1002/1097-4679(198811)44:6<940::AID-JCLP2270440615>3.0.CO;2-A; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; McPherson SE, 1996, BRAIN COGNITION, V31, P269, DOI 10.1006/brcg.1996.0045; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Petersen RC, 2001, ARCH NEUROL-CHICAGO, V58, P1985, DOI 10.1001/archneur.58.12.1985; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Potter G.G., 2006, GERIATRIC NEUROPSYCH, P5; Prifitera A., 1989, PSYCHOL ASSESSMENT J, V1, P186, DOI [https://doi.org/10.1037/1040-3590.1.3.186, DOI 10.1037/1040-3590.1.3.186]; Salthouse TA, 2007, NEUROPSYCHOLOGY, V21, P401, DOI 10.1037/0894-4105.21.4.401; Sarazin M, 2007, NEUROLOGY, V69, P1859, DOI 10.1212/01.wnl.0000279336.36610.f7; Schretlen DJ, 2003, J INT NEUROPSYCH SOC, V9, P864, DOI 10.1017/S1355617703960061; Silvey S.D., 1975, REPRINTING MONOGRAPH; Sliwinski M, 1997, J Int Neuropsychol Soc, V3, P317; Stuss DT, 2003, BRAIN, V126, P2363, DOI 10.1093/brain/awg237; Stuss DT, 1999, NEUROPSYCHOLOGIA, V37, P1005, DOI 10.1016/S0028-3932(98)00158-4; Thiebaut ACM, 2004, STAT MED, V23, P3803, DOI 10.1002/sim.2098; Verghese J, 1999, NEUROLOGY, V53, P1974, DOI 10.1212/WNL.53.9.1974; Verghese J, 2004, AGE AGEING, V33, P628, DOI 10.1093/ageing/afh210; Verghese J, 2002, NEW ENGL J MED, V347, P1761, DOI 10.1056/NEJMoa020441; Verghese J, 2007, J NEUROL NEUROSUR PS, V78, P929, DOI 10.1136/jnnp.2006.106914; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; West R, 2002, BRAIN COGNITION, V49, P402, DOI 10.1006/brcg.2001.1507; West R, 2001, EUR J COGN PSYCHOL, V13, P91, DOI 10.1080/09541440042000232	56	155	154	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	2008	300	7					823	830		10.1001/jama.300.7.823	http://dx.doi.org/10.1001/jama.300.7.823			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	338VM	18714062	Bronze, Green Accepted			2022-12-28	WOS:000258537500022
J	Doran, T; Fullwood, C; Kontopantelis, E; Reeves, D				Doran, Tim; Fullwood, Catherine; Kontopantelis, Evangelos; Reeves, David			Effect of financial incentives on inequalities in the delivery of primary clinical care in England: analysis of clinical activity indicators for the quality and outcomes framework	LANCET			English	Article							HEALTH-CARE; UNITED-KINGDOM; EQUITY; PAY; PERFORMANCE	Background The quality and outcomes framework is a financial incentive scheme that remunerates general practices in the UK for their performance against a set of quality indicators. Incentive schemes can increase inequalities in the delivery of care if practices in affluent areas are more able to respond to the incentives than are those in deprived areas. We examined the relation between socioeconomic inequalities and delivered quality of clinical care in the first 3 years of this scheme. Methods We analysed data extracted automatically from clinical computing systems for 7637 general practices in England, data from the UK census, and data for characteristics of practices and patients from the 2006 general medical statistics database. Practices were grouped into equal-sized quintiles on the basis of area deprivation in their locality. We calculated overall levels of achievement, defined as the proportion of patients who were deemed eligible by the practices for whom the targets were achieved, for 48 clinical activity indicators during the first 3 years of the incentive scheme (from 2004-05 to 2006-07). Findings Median overall reported achievement was 85.1% (IQR 79.0-89.1) in year 1, 89.3% (86.0-91.5) in year 2, and 90.8% (88.5-92.6) in year 3. In year 1, area deprivation was associated with lower levels of achievement, with median achievement ranging from 86.8% (82.2-89.6) for quintile 1 (least deprived) to 82.8% (75.2-87.8) for quintile 5 (most deprived). Between years 1 and 3, median achievement increased by 4.4% for quintile 1 and by 7.6% for quintile 5, and the gap in median achievement narrowed from 4.0% to 0.8% during this period. Increase in achievement during this time was inversely associated with practice performance in previous years (p<0.0001), but was not associated with area deprivation (p=0.062). Interpretation Our results suggest that financial incentive schemes have the potential to make a substantial contribution to the reduction of inequalities in the delivery of clinical care related to area deprivation. Funding None.	[Doran, Tim; Fullwood, Catherine; Kontopantelis, Evangelos; Reeves, David] Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England	University of Manchester	Doran, T (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Williamson Bldg, Manchester M13 9PL, Lancs, England.	tim.doran@manchester.ac.uk	Sandall, Jane/D-4146-2009; Kontopantelis, Evangelos/H-2966-2019; Reeves, David/H-6203-2014	Sandall, Jane/0000-0003-2000-743X; Kontopantelis, Evangelos/0000-0001-6450-5815; Reeves, David/0000-0001-6377-6859; Fullwood, Catherine/0000-0003-4136-2027	UK Government Department of Health	UK Government Department of Health	The National Primary Care Research and Development Centre receives core funding from the UK Government Department of Health. The views expressed are those of the authors and not necessarily those of the Department of Health.	Adams J, 2004, BRIT MED J, V329, P142, DOI 10.1136/bmj.38114.679387.AE; Ashworth M, 2007, BRIT J GEN PRACT, V57, P441; Campbell S, 2007, NEW ENGL J MED, V357, P181, DOI 10.1056/NEJMsr065990; *DEP HLTH, 1998, 1 CLASS SERV QUAL NE; Department of Health, 2004, QOF GUID; Department of Health, 2003, TACKL HLTH IN PROGR; Department of Health, 2002, TACKL HLTH IN; Department of Health, 1999, SAV LIV OUR HLTH NAT; Department of Health, 2007, TACKL HLTH IN 2004 0; Doran T, 2006, NEW ENGL J MED, V355, P375, DOI 10.1056/NEJMsa055505; Evans T, 2001, CHALLENGING INEQUITI; Exworthy M, 2006, MILBANK Q, V84, P75, DOI 10.1111/j.1468-0009.2006.00439.x; GRAVELLE H, 2008, 34 CHE U YORK; Guthrie B, 2006, BRIT J GEN PRACT, V56, P836; *INF CTR, 2008, GEN PERS MED SERV EN; *INF CTR, 2007, QUAL OUTC FRAM 2006; *INF CTR, QUAL OUTC FRAM DAT 2; Lumley T, 2002, ANNU REV PUBL HEALTH, V23, P151, DOI 10.1146/annurev.publhealth.23.100901.140546; Mackenbach JP, 2003, INT J HEALTH SERV, V33, P523, DOI 10.2190/C12H-NBA4-7QWE-6K3T; Marmot M, 2007, LANCET, V370, P1153, DOI 10.1016/S0140-6736(07)61385-3; National Audit Office, 2008, NHS PAY MOD NEW CONT; *OFF DEP PRIM MIN, 2004, IND DEPR; READING R, 2004, BMJ-BRIT MED J, V308, P1142; Reeves D, 2007, MED CARE, V45, P489, DOI 10.1097/MLR.0b013e31803bb479; Roland M, 2004, NEW ENGL J MED, V351, P1448, DOI 10.1056/NEJMhpr041294; Schou L, 1994, Community Dent Health, V11, P97; Sigfrid LA, 2006, J PUBLIC HEALTH-UK, V28, P221, DOI 10.1093/pubmed/fdl028; TOWNSEND J, 1994, BMJ-BRIT MED J, V309, P923, DOI 10.1136/bmj.309.6959.923; Tugwell P, 2006, BMJ-BRIT MED J, V332, P358, DOI 10.1136/bmj.332.7537.358; van der Meer JBW, 1998, J CLIN EPIDEMIOL, V51, P171, DOI 10.1016/S0895-4356(97)00267-9; Victora CG, 2000, LANCET, V356, P1093, DOI 10.1016/S0140-6736(00)02741-0; Weinehall L, 1999, J EPIDEMIOL COMMUN H, V53, P243, DOI 10.1136/jech.53.4.243; Weinehall L, 2001, SCAND J PUBLIC HEALT, P59; WHO Europe, 1978, DECL ALM AT	34	180	180	1	27	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG-SEP	2008	372	9640					728	736		10.1016/S0140-6736(08)61123-X	http://dx.doi.org/10.1016/S0140-6736(08)61123-X			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	344YZ	18701159				2022-12-28	WOS:000258964500029
J	Mahrus, S; Trinidad, JC; Barkan, DT; Sali, A; Burlingame, AL; Wells, JA				Mahrus, Sami; Trinidad, Jonathan C.; Barkan, David T.; Sali, Andrej; Burlingame, Alma L.; Wells, James A.			Global Sequencing of proteolytic cleavage sites in apoptosis by specific Labeling of protein N termini	CELL			English	Article							MASS-SPECTROMETRY; DATABASE; PROTEOMICS; INHIBITORS; RECEPTOR; MODELS; PHOSPHORYLATION; CHEMOTHERAPY; SUBTILIGASE; RECOGNITION	The nearly 600 proteases in the human genome regulate a diversity of biological processes, including programmed cell death. Comprehensive characterization of protease signaling in complex biological samples is limited by available proteomic methods. We have developed a general approach for global identification of proteolytic cleavage sites using an engineered enzyme to selectively biotinylate free protein N termini for positive enrichment of corresponding N-terminal peptides. Using this method to study apoptosis, we have sequenced 333 caspase-like cleavage sites distributed among 292 protein substrates. These sites are generally not predicted by in vitro caspase substrate specificity but can be used to predict other physiological caspase cleavage sites. Structural bioinformatic studies show that caspase cleavage sites often appear in surface-accessible loops and even occasionally in helical regions. Strikingly, we also find that a disproportionate number of caspase substrates physically interact, suggesting that these dimeric proteases target protein complexes and networks to elicit apoptosis.	[Mahrus, Sami; Trinidad, Jonathan C.; Sali, Andrej; Burlingame, Alma L.; Wells, James A.] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA; [Mahrus, Sami; Wells, James A.] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA; [Barkan, David T.] Univ Calif San Francisco, Grad Grp Bioinformat, San Francisco, CA 94158 USA; [Barkan, David T.; Sali, Andrej] Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Wells, JA (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA.	jim.wells@ucsf.edu	Trinidad, Jonathan/GWR-2077-2022; Wells, Jim A/O-9854-2016		National Institutes of Health (NIH) [F32 GM074458, R01 GM081051, R01, P01 GM71790, U54 GM074945]; Hartwell Foundation; NIH NCRR [01614]; Adelson Medical Research Foundation; Sandler Family Supporting Foundation; Hewlett-Packard; NetApps; IBM; Intel; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054762, P01GM071790, U54GM074945, R01GM081051, F32GM074458] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Hartwell Foundation; NIH NCRR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Adelson Medical Research Foundation; Sandler Family Supporting Foundation; Hewlett-Packard; NetApps; IBM(International Business Machines (IBM)); Intel(Intel Corporation); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to members of the Wells, Burlingame, and Sali labs for useful discussions. This work was supported by National Institutes of Health (NIH) F32 GM074458 (S. M.), NIH R01 GM081051 (J. A. W.), the Hartwell Foundation (J. A. W.), NIH NCRR 01614 (A. L. B.), the Adelson Medical Research Foundation (A. L. B.), NIH R01 GM54762 (A. S.), NIH P01 GM71790 (A. S.), NIH U54 GM074945 (A. S.), the Sandler Family Supporting Foundation (A. S.), Hewlett-Packard (A. S.), NetApps (A. S.), IBM (A. S.), and Intel (A. S.).	ABRAHMSEN L, 1991, BIOCHEMISTRY-US, V30, P4151, DOI 10.1021/bi00231a007; Berman HM, 2002, ACTA CRYSTALLOGR D, V58, P899, DOI 10.1107/S0907444902003451; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Braisted AC, 1997, METHOD ENZYMOL, V289, P298; BROWN JL, 1976, J BIOL CHEM, V251, P1009; CHANG TK, 1994, P NATL ACAD SCI USA, V91, P12544, DOI 10.1073/pnas.91.26.12544; Chatr-Aryamontri A, 2007, NUCLEIC ACIDS RES, V35, pD572, DOI 10.1093/nar/gkl950; Collins MO, 2007, PROTEOMICS, V7, P2751, DOI 10.1002/pmic.200700145; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Eddy SR, 1998, BIOINFORMATICS, V14, P755, DOI 10.1093/bioinformatics/14.9.755; Elias JE, 2005, NAT METHODS, V2, P667, DOI 10.1038/NMETH785; Escaffit F, 2007, MOL CELL BIOL, V27, P554, DOI 10.1128/MCB.00869-06; Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149; Fischle W, 2001, J BIOL CHEM, V276, P35826, DOI 10.1074/jbc.M104935200; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Gevaert K, 2003, NAT BIOTECHNOL, V21, P566, DOI 10.1038/nbt810; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; HUBBARD SJ, 1991, J MOL BIOL, V220, P507, DOI 10.1016/0022-2836(91)90027-4; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Karagianni P, 2007, ONCOGENE, V26, P5439, DOI 10.1038/sj.onc.1210612; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kerrien S, 2007, NUCLEIC ACIDS RES, V35, pD561, DOI 10.1093/nar/gkl958; Lieberman J, 2003, CURR OPIN IMMUNOL, V15, P553, DOI 10.1016/S0952-7915(03)00108-0; Luthi AU, 2007, CELL DEATH DIFFER, V14, P641, DOI 10.1038/sj.cdd.4402103; Machuy N, 2005, MOL CELL PROTEOMICS, V4, P44, DOI 10.1074/mcp.M400089-MCP200; Maere S, 2005, BIOINFORMATICS, V21, P3448, DOI 10.1093/bioinformatics/bti551; McDonald L, 2005, NAT METHODS, V2, P955, DOI 10.1038/NMETH811; Mishra GR, 2006, NUCLEIC ACIDS RES, V34, pD411, DOI 10.1093/nar/gkj141; Olofsson MH, 2007, CLIN CANCER RES, V13, P3198, DOI 10.1158/1078-0432.CCR-07-0009; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Pieper U, 2006, NUCLEIC ACIDS RES, V34, pD291, DOI 10.1093/nar/gkj059; SCHECHTER I, 1968, BIOCHEM BIOPH RES CO, V32, P898, DOI 10.1016/0006-291X(68)90326-4; Schilling O, 2008, NAT BIOTECHNOL, V26, P685, DOI 10.1038/nbt1408; Scott FL, 2008, J BIOL CHEM, V283, P19499, DOI 10.1074/jbc.M800331200; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; Stennicke HR, 2000, BIOCHEM J, V350, P563, DOI 10.1042/0264-6021:3500563; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; Takezawa S, 2007, EMBO J, V26, P764, DOI 10.1038/sj.emboj.7601548; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Timmer JC, 2007, BIOCHEM J, V407, P41, DOI 10.1042/BJ20070775; Tozser J, 2003, BIOCHEM J, V372, P137, DOI 10.1042/BJ20021901; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; Vosseller K, 2006, MOL CELL PROTEOMICS, V5, P923, DOI 10.1074/mcp.T500040-MCP200; Wiegand UK, 2001, CELL DEATH DIFFER, V8, P734, DOI 10.1038/sj.cdd.4400867	46	337	346	1	55	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	SEP 5	2008	134	5					866	876		10.1016/j.cell.2008.08.012	http://dx.doi.org/10.1016/j.cell.2008.08.012			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	344SL	18722006	Green Accepted, Bronze			2022-12-28	WOS:000258947500025
J	Chambers, HF; Moellering, RC; Kamitsuka, P				Chambers, Henry F.; Moellering, Robert C., Jr.; Kamitsuka, Paul			Management of skin and soft-tissue infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RESISTANT STAPHYLOCOCCUS-AUREUS; UNCOMPLICATED SKIN; HOUSEHOLD CONTACTS; DOUBLE-BLIND; ABSCESSES; TRIAL; COLONIZATION; CEPHALEXIN; PENICILLIN; CHILDREN		[Chambers, Henry F.] Univ Calif San Francisco, Dept Med, Div Infect Dis, San Francisco, CA 94143 USA; [Moellering, Robert C., Jr.] Harvard Univ, Sch Med, Boston, MA 02215 USA; [Moellering, Robert C., Jr.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; [Kamitsuka, Paul] Wilmington Hlth Assoc, Wilmington, NC USA; [Kamitsuka, Paul] Univ N Carolina, Sch Med, Wilmington, NC 28401 USA	University of California System; University of California San Francisco; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; University of North Carolina; University of North Carolina Wilmington	Chambers, HF (corresponding author), Univ Calif San Francisco, Dept Med, Div Infect Dis, San Francisco, CA 94143 USA.							ANDERSON J, 1958, BMJ-BRIT MED J, V2, P1569, DOI 10.1136/bmj.2.5112.1569; BURN JI, 1957, BRIT MED J, V2, P193, DOI 10.1136/bmj.2.5038.193; Calfee DP, 2003, INFECT CONT HOSP EP, V24, P422, DOI 10.1086/502225; Daum RS, 2007, NEW ENGL J MED, V357, P1357; Ellis MW, 2004, CLIN INFECT DIS, V39, P971, DOI 10.1086/423965; Eron L J, 2006, Eur J Clin Microbiol Infect Dis, V25, P615, DOI 10.1007/s10096-006-0187-y; Fridkin SK, 2005, NEW ENGL J MED, V352, P2362; Fridkin SK, 2005, NEW ENGL J MED, V352, P1436, DOI 10.1056/NEJMoa043252; Giordano PA, 2006, CURR MED RES OPIN, V22, P2419, DOI 10.1185/030079906X148355; Kaplan SL, 2005, CLIN INFECT DIS, V40, P1785, DOI 10.1086/430312; King MD, 2006, ANN INTERN MED, V144, P309, DOI 10.7326/0003-4819-144-5-200603070-00005; Lee MC, 2004, PEDIATR INFECT DIS J, V23, P123, DOI 10.1097/01.inf.0000109288.06912.21; LLERA JL, 1985, ANN EMERG MED, V14, P15, DOI 10.1016/S0196-0644(85)80727-7; MACFIE J, 1977, BRIT J SURG, V64, P264, DOI 10.1002/bjs.1800640410; Moellering RC, 2006, ANN INTERN MED, V144, P368, DOI 10.7326/0003-4819-144-5-200603070-00014; Moellering RC, 2008, CLIN INFECT DIS, V46, P1032, DOI 10.1086/529445; Moran GJ, 2006, NEW ENGL J MED, V355, P666, DOI 10.1056/NEJMoa055356; Peralta G, 2006, Eur J Clin Microbiol Infect Dis, V25, P619, DOI 10.1007/s10096-006-0186-z; Rajendran PM, 2007, ANTIMICROB AGENTS CH, V51, P4044, DOI 10.1128/AAC.00377-07; Ruhe JJ, 2007, CLIN INFECT DIS, V44, P777, DOI 10.1086/511872; RUTHERFORD WH, 1970, LANCET, V1, P1077; Stevens DL, 2006, CLIN INFECT DIS, V42, P1219; Swartz MN, 2004, NEW ENGL J MED, V350, P904, DOI 10.1056/NEJMcp031807; Szumowski JD, 2007, ANTIMICROB AGENTS CH, V51, P423, DOI 10.1128/AAC.01244-06; York MK, 1999, J CLIN MICROBIOL, V37, P1727, DOI 10.1128/JCM.37.6.1727-1731.1999; Zafar U, 2007, INFECT CONT HOSP EP, V28, P966, DOI 10.1086/518965	26	26	27	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2008	359	10					1063	1067						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	343KN	18768953				2022-12-28	WOS:000258852500015
J	Weir, RAP; Dargie, HJ				Weir, Robin A. P.; Dargie, Henry J.			Austin flint murmur	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Weir, Robin A. P.; Dargie, Henry J.] Univ Glasgow, Western Infirm, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow	Weir, RAP (corresponding author), Univ Glasgow, Western Infirm, Glasgow G11 6NT, Lanark, Scotland.	robinweir75@hotmail.com							0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2008	359	10					E11	E11		10.1056/NEJMicm072437	http://dx.doi.org/10.1056/NEJMicm072437			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	343KN	18768939				2022-12-28	WOS:000258852500010
J	Brown, RH				Brown, Robert H., Jr.			Developmental biology - Neuron research leaps ahead	SCIENCE			English	Editorial Material							PLURIPOTENT STEM-CELLS; LATERAL-SCLEROSIS; MOTOR-NEURONS; ALS; FIBROBLASTS		[Brown, Robert H., Jr.] Massachusetts Gen Hosp, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Brown, RH (corresponding author), Massachusetts Gen Hosp, 16th St,Navy Yard, Charlestown, MA 02129 USA.	rhbrown@partners.org						Boillee S, 2006, NEURON, V52, P39, DOI 10.1016/j.neuron.2006.09.018; Di Giorgio FP, 2007, NAT NEUROSCI, V10, P608, DOI 10.1038/nn1885; Dimos JT, 2008, SCIENCE, V321, P1218, DOI 10.1126/science.1158799; Dunckley T, 2007, NEW ENGL J MED, V357, P775, DOI 10.1056/NEJMoa070174; Klein SM, 2005, HUM GENE THER, V16, P509, DOI 10.1089/hum.2005.16.509; Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374; Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]; Pasinelli P, 2006, NAT REV NEUROSCI, V7, P710, DOI 10.1038/nrn1971; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; van Es MA, 2007, LANCET NEUROL, V6, P869, DOI 10.1016/S1474-4422(07)70222-3; Wernig M, 2008, P NATL ACAD SCI USA, V105, P5856, DOI 10.1073/pnas.0801677105; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526	14	4	5	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2008	321	5893					1169	1170		10.1126/science.1163475	http://dx.doi.org/10.1126/science.1163475			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341ZM	18755965				2022-12-28	WOS:000258754400031
J	Wakabi, W				Wakabi, Wairagala			Lunch with the Lancet - Kgosi Letlape	LANCET			English	Editorial Material												w_wakabi@yahoo.com							0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 23	2008	372	9639					621	621		10.1016/S0140-6736(08)61263-5	http://dx.doi.org/10.1016/S0140-6736(08)61263-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	340BX	18722855	Bronze			2022-12-28	WOS:000258622200013
J	Fabian, AC; Johnstone, RM; Sanders, JS; Conselice, CJ; Crawford, CS; Gallagher, JS; Zweibel, E				Fabian, A. C.; Johnstone, R. M.; Sanders, J. S.; Conselice, C. J.; Crawford, C. S.; Gallagher, J. S., III; Zweibel, E.			Magnetic support of the optical emission line filaments in NGC 1275	NATURE			English	Article							PERSEUS CLUSTER; X-RAY; EXCITATION; CORE; DISCOVERY; SOFTWARE; FIELDS	The giant elliptical galaxy NGC 1275, at the centre of the Perseus cluster, is surrounded by a well- known giant nebulosity of emission-line filaments(1,2), which are plausibly in excess of 10(8) years old(3). The filaments are dragged out from the centre of the galaxy by radio-emitting 'bubbles' rising buoyantly in the hot intracluster gas(4), before later falling back. They act as markers of the feedback process by which energy is transferred from the central massive black hole to the surrounding gas. The mechanism by which the filaments are stabilized against tidal shear and dissipation into the surrounding extremely hot (4 x 10(7) K) gas has been unclear. Here we report observations that resolve thread- like structures in the filaments. Some threads extend over 6 kpc, yet are only 70 pc wide. We conclude that magnetic fields in the threads, in pressure balance with the surrounding gas, stabilize the filaments, so allowing a large mass of cold gas to accumulate and delay star formation.	[Fabian, A. C.; Johnstone, R. M.; Sanders, J. S.; Crawford, C. S.] Univ Cambridge, Inst Astron, Cambridge CB3 0HA, England; [Conselice, C. J.] Univ Nottingham, Sch Phys & Astron, Nottingham NG7 2RD, England; [Gallagher, J. S., III; Zweibel, E.] Univ Wisconsin, Dept Astron, Madison, WI 53706 USA; [Zweibel, E.] Univ Wisconsin, Dept Phys, Madison, WI 53706 USA	University of Cambridge; University of Nottingham; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Fabian, AC (corresponding author), Univ Cambridge, Inst Astron, Madingley Rd, Cambridge CB3 0HA, England.	acf@ast.cam.ac.uk	Conselice, Christopher J/B-4348-2013	Sanders, Jeremy/0000-0003-2189-4501; Conselice, Christopher/0000-0003-1949-7638; Zweibel, Ellen/0000-0003-4821-713X	Royal Society; NSF [AST 0507367];  [HST-GO-11207.07-A]; Science and Technology Facilities Council [ST/F00298X/1, ST/F001967/1] Funding Source: researchfish; STFC [ST/F001967/1, ST/F00298X/1] Funding Source: UKRI	Royal Society(Royal Society of London); NSF(National Science Foundation (NSF)); ; Science and Technology Facilities Council(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC)); STFC(UK Research & Innovation (UKRI)Science & Technology Facilities Council (STFC))	A. C. F. thanks the Royal Society for support. E. Z. acknowledges support from NSF AST 0507367 and J. S. G. from HST-GO-11207.07-A.	Bertin E, 1996, ASTRON ASTROPHYS SUP, V117, P393, DOI 10.1051/aas:1996164; Carlson MN, 1998, ASTRON J, V115, P1778, DOI 10.1086/300334; Fabian AC, 2006, MON NOT R ASTRON SOC, V366, P417, DOI 10.1111/j.1365-2966.2005.09896.x; Fabian AC, 2003, MON NOT R ASTRON SOC, V344, pL48, DOI 10.1046/j.1365-8711.2003.06856.x; Ferland GJ, 2008, MON NOT R ASTRON SOC, V386, pL72, DOI 10.1111/j.1745-3933.2008.00463.x; Hatch NA, 2006, MON NOT R ASTRON SOC, V367, P433, DOI 10.1111/j.1365-2966.2006.09970.x; Hatch NA, 2005, MON NOT R ASTRON SOC, V358, P765, DOI 10.1111/j.1365-2966.2005.08787.x; Heiles C, 2005, LECT NOTES PHYS, V664, P137, DOI 10.1007/3540313966_7; HOLTZMAN JA, 1992, ASTRON J, V103, P691, DOI 10.1086/116094; Johnstone RM, 2007, MON NOT R ASTRON SOC, V382, P1246, DOI 10.1111/j.1365-2966.2007.12460.x; Joye WA, 2005, ASTR SOC P, V347, P110; KENT SM, 1979, ASTROPHYS J, V230, P667, DOI 10.1086/157125; Koekemoer A. M., 2002, 2002 HST CAL WORKSH, P337; Low BC, 1996, SOL PHYS, V167, P217, DOI 10.1007/BF00146338; McKee C. F, 1993, PROTOSTARS PLANETS, P327; Reuland M, 2003, ASTROPHYS J, V592, P755, DOI 10.1086/375619; Salome P, 2008, ASTRON ASTROPHYS, V484, P317, DOI 10.1051/0004-6361:200809493; Sanders JS, 2007, MON NOT R ASTRON SOC, V381, P1381, DOI 10.1111/j.1365-2966.2007.12347.x; Taylor GB, 2006, MON NOT R ASTRON SOC, V368, P1500, DOI 10.1111/j.1365-2966.2006.10244.x	20	125	125	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 21	2008	454	7207					968	970		10.1038/nature07169	http://dx.doi.org/10.1038/nature07169			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339QB	18719583	Green Submitted			2022-12-28	WOS:000258591000032
J	Oberlander, J				Oberlander, Jonathan			The partisan divide - The McCain and Obama plans for US Health care reform	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ N Carolina, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Oberlander, J (corresponding author), Univ N Carolina, Chapel Hill, NC 27599 USA.							*C BUDG OFF, 2008, BUDG EC OUTL FISC YE; CHOLLET D, 2002, HLTH AFF MILLWOOD S, pW349, DOI DOI 10.1377/HLTHAFF.W2.349; Pollitz K, 2002, HEALTH AFFAIR, pW372; Reischauer RD, 2007, NEW ENGL J MED, V356, P1393, DOI 10.1056/NEJMp078034	4	15	15	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 21	2008	359	8					781	784		10.1056/NEJMp0804659	http://dx.doi.org/10.1056/NEJMp0804659			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	339HL	18716295				2022-12-28	WOS:000258568600002
J	Montalescot, G				Montalescot, Gilles			Mechanical reperfusion: treat well, treat on time too	LANCET			English	Editorial Material							PERCUTANEOUS CORONARY INTERVENTION; ELEVATION MYOCARDIAL-INFARCTION; GLYCOPROTEIN-IIB/IIIA INHIBITORS; ABCIXIMAB; TIROFIBAN; EPTIFIBATIDE; TRIAL; PCI		Univ Paris 06, CHU Pitie Salpetriere, INSERM, Inst Cardiol,U 856, F-75013 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Montalescot, G (corresponding author), Univ Paris 06, CHU Pitie Salpetriere, INSERM, Inst Cardiol,U 856, F-75013 Paris, France.	gilles.montalescot@psl.aphp.fr						DELUCA G, 2008, HEART           0605; Dudek D, 2007, EUR HEART J, V28, P384; Ellis SG, 2008, NEW ENGL J MED, V358, P2205, DOI 10.1056/NEJMoa0706816; Gilchrist IC, 2001, CIRCULATION, V104, P406, DOI 10.1161/hc2901.093504; Huber K, 2007, CIRCULATION, V116, P673; MEHILI J, 2008, AM COLL CARD ANN M C; Montalescot G, 2001, NEW ENGL J MED, V344, P1895, DOI 10.1056/NEJM200106213442503; Montalescot G, 2007, EUR HEART J, V28, P443, DOI 10.1093/eurheartj/ehl472; Mukherjee D, 2007, EXPERT OPIN DRUG MET, V3, P275, DOI 10.1517/17425255.3.2.275; Stone GW, 2008, NEW ENGL J MED, V358, P2218, DOI 10.1056/NEJMoa0708191; Tcheng JE, 1997, LANCET, V349, P1422; Topol EJ, 2001, NEW ENGL J MED, V344, P1888, DOI 10.1056/NEJM200106213442502; Valgimigli M, 2008, JAMA-J AM MED ASSOC, V299, P1788, DOI 10.1001/jama.299.15.joc80026; van't Hof AWJ, 2008, LANCET, V372, P537, DOI 10.1016/S0140-6736(08)61235-0; ZEYMER U, 2007, EPTIFIBATIDE VERSUS	15	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 16	2008	372	9638					509	510		10.1016/S0140-6736(08)61211-8	http://dx.doi.org/10.1016/S0140-6736(08)61211-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339MS	18707968				2022-12-28	WOS:000258582300004
J	Bargou, R; Leo, E; Zugmaier, G; Klinger, M; Goebeler, M; Knop, S; Noppeney, R; Viardot, A; Hess, G; Schuler, M; Einsele, H; Brandl, C; Wolf, A; Kirchinger, P; Klappers, P; Schmidt, M; Riethmuller, G; Reinhardt, C; Baeuerle, PA; Kufer, P				Bargou, Ralf; Leo, Eugen; Zugmaier, Gerhard; Klinger, Matthias; Goebeler, Mariele; Knop, Stefan; Noppeney, Richard; Viardot, Andreas; Hess, Georg; Schuler, Martin; Einsele, Hermann; Brandl, Christian; Wolf, Andreas; Kirchinger, Petra; Klappers, Petra; Schmidt, Margit; Riethmueller, Gert; Reinhardt, Carsten; Baeuerle, Patrick A.; Kufer, Peter			Tumor regression in cancer patients by very low doses of a T cell-engaging antibody	SCIENCE			English	Article							SINGLE-CHAIN ANTIBODY; CONSTRUCT; GROWTH; POTENT; INHIBITION; ACTIVATION; COLON; BITE; MICE	Previous attempts have shown the potential of T cells in immunotherapy of cancer. Here, we report on the clinical activity of a bispecific antibody construct called blinatumomab, which has the potential to engage all cytotoxic T cells in patients for lysis of cancer cells. Doses as low as 0.005 milligrams per square meter per day in non- Hodgkin's lymphoma patients led to an elimination of target cells in blood. Partial and complete tumor regressions were first observed at a dose level of 0.015 milligrams, and all seven patients treated at a dose level of 0.06 milligrams experienced a tumor regression. Blinatumomab also led to clearance of tumor cells from bone marrow and liver. T cell- engaging antibodies appear to have therapeutic potential for the treatment of malignant diseases.	[Leo, Eugen; Zugmaier, Gerhard; Klinger, Matthias; Brandl, Christian; Wolf, Andreas; Kirchinger, Petra; Klappers, Petra; Schmidt, Margit; Reinhardt, Carsten; Baeuerle, Patrick A.; Kufer, Peter] Micromet AG, D-81477 Munich, Germany; [Bargou, Ralf; Goebeler, Mariele] Univ Wurzburg, Interdisciplinary Phase 1 2 Unit, D-97070 Wurzburg, Germany; [Bargou, Ralf; Goebeler, Mariele; Knop, Stefan; Einsele, Hermann] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, D-97070 Wurzburg, Germany; [Leo, Eugen; Zugmaier, Gerhard; Klinger, Matthias; Brandl, Christian; Wolf, Andreas; Kirchinger, Petra; Klappers, Petra; Schmidt, Margit; Reinhardt, Carsten; Baeuerle, Patrick A.; Kufer, Peter] Micromet Inc, Bethesda, MD 20817 USA; [Noppeney, Richard] Univ Klinikum Essen, Klin Hamatol, Med Klin & Poliklin, D-45147 Essen, Germany; [Viardot, Andreas] Univ Ulm Klinikum, D-89081 Ulm, Germany; [Hess, Georg] Univ Mainz Klinikum, Med Klin & Poliklin 3, D-55131 Mainz, Germany; [Schuler, Martin] Univ Klinikum Essen, Innere Tumorforsch Klin, D-45122 Essen, Germany; [Riethmueller, Gert] Univ Munich, Inst Immunol, D-81333 Munich, Germany	Amgen; Amgen Research Munich GmbH; Micromet AG; University of Wurzburg; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Wurzburg; University of Duisburg Essen; Ulm University; Johannes Gutenberg University of Mainz; University of Duisburg Essen; University of Munich	Baeuerle, PA (corresponding author), Micromet AG, Staffelseestr 2, D-81477 Munich, Germany.	patrick.baeuerle@micromet-inc.com						Baeuerle PA, 2008, DRUG FUTURE, V33, P137, DOI 10.1358/dof.2008.033.02.1172578; Brandl C, 2007, CANCER IMMUNOL IMMUN, V56, P1551, DOI 10.1007/s00262-007-0298-z; Brischwein K, 2006, MOL IMMUNOL, V43, P1129, DOI 10.1016/j.molimm.2005.07.034; Brischwein K, 2007, J IMMUNOTHER, V30, P798, DOI 10.1097/CJI.0b013e318156750c; Cheson BD, 2007, HEMATOL ONCOL CLIN N, V21, P841, DOI 10.1016/j.hoc.2007.06.011; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Dreier T, 2003, J IMMUNOL, V170, P4397, DOI 10.4049/jimmunol.170.8.4397; Dreier T, 2002, INT J CANCER, V100, P690, DOI 10.1002/ijc.10557; Dudley ME, 2005, J CLIN ONCOL, V23, P2346, DOI 10.1200/JCO.2005.00.240; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gross S, 2008, IMMUNOL LETT, V116, P7, DOI 10.1016/j.imlet.2007.11.012; Hammond SA, 2007, CANCER RES, V67, P3927, DOI 10.1158/0008-5472.CAN-06-2760; Hoffmann P, 2005, INT J CANCER, V115, P98, DOI 10.1002/ijc.20908; Langer LF, 2007, EXPERT OPIN BIOL TH, V7, P1245, DOI 10.1517/14712598.7.8.1245; Loffler A, 2000, BLOOD, V95, P2098, DOI 10.1182/blood.V95.6.2098; Loffler A, 2003, LEUKEMIA, V17, P900, DOI 10.1038/sj.leu.2402890; MACK M, 1995, P NATL ACAD SCI USA, V92, P7021, DOI 10.1073/pnas.92.15.7021; Maloney DG, 1997, J CLIN ONCOL, V15, P3266, DOI 10.1200/JCO.1997.15.10.3266; Meidenbauer N, 2004, CANCER RES, V64, P6319, DOI 10.1158/0008-5472.CAN-04-1341; Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003; Muller D, 2007, CURR OPIN MOL THER, V9, P319; Offner S, 2006, MOL IMMUNOL, V43, P763, DOI 10.1016/j.molimm.2005.03.007; Rabinovich GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI 10.1146/annurev.immunol.25.022106.141609; Schlereth B, 2006, CANCER IMMUNOL IMMUN, V55, P503, DOI 10.1007/s00262-005-0001-1; Schlereth B, 2006, CANCER IMMUNOL IMMUN, V55, P785, DOI 10.1007/s00262-005-0082-x; Schlereth B, 2005, CANCER RES, V65, P2882, DOI 10.1158/0008-5472.CAN-04-2637; STAERZ UD, 1985, NATURE, V314, P628, DOI 10.1038/314628a0; Went P, 2006, BRIT J CANCER, V94, P128, DOI 10.1038/sj.bjc.6602924	28	773	953	7	115	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 15	2008	321	5891					974	977		10.1126/science.1158545	http://dx.doi.org/10.1126/science.1158545			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	337LD	18703743				2022-12-28	WOS:000258436700042
J	Kulp, TR; Hoeft, SE; Asao, M; Madigan, MT; Hollibaugh, JT; Fisher, JC; Stolz, JF; Culbertson, CW; Miller, LG; Oremland, RS				Kulp, T. R.; Hoeft, S. E.; Asao, M.; Madigan, M. T.; Hollibaugh, J. T.; Fisher, J. C.; Stolz, J. F.; Culbertson, C. W.; Miller, L. G.; Oremland, R. S.			Arsenic(III) fuels anoxygenic photosynthesis in hot spring biofilms from Mono Lake, California	SCIENCE			English	Article							ARSENITE OXIDASE GENES; MICROBIAL MATS; FERROUS IRON; ECTOTHIORHODOSPIRA; HYPERSALINE; METABOLISM; OXIDATION; BACTERIA	Phylogenetic analysis indicates that microbial arsenic metabolism is ancient and probably extends back to the primordial Earth. In microbial biofilms growing on the rock surfaces of anoxic brine pools fed by hot springs containing arsenite and sulfide at high concentrations, we discovered lightdependent oxidation of arsenite [ As( III)] to arsenate [ As( V)] occurring under anoxic conditions. The communities were composed primarily of Ectothiorhodospira- like purple bacteria or Oscillatoria- like cyanobacteria. A pure culture of a photosynthetic bacterium grew as a photoautotroph when As( III) was used as the sole photosynthetic electron donor. The strain contained genes encoding a putative As( V) reductase but no detectable homologs of the As( III) oxidase genes of aerobic chemolithotrophs, suggesting a reverse functionality for the reductase. Production of As( V) by anoxygenic photosynthesis probably opened niches for primordial Earth's first As( V)- respiring prokaryotes.	[Kulp, T. R.; Hoeft, S. E.; Miller, L. G.; Oremland, R. S.] US Geol Survey, Menlo Pk, CA 94025 USA; [Asao, M.; Madigan, M. T.] So Illinois Univ, Dept Microbiol, Carbondale, IL 62901 USA; [Hollibaugh, J. T.; Fisher, J. C.] Univ Georgia, Dept Marine Sci, Athens, GA 30602 USA; [Stolz, J. F.] Duquesne Univ, Dept Biol Sci, Pittsburgh, PA 15282 USA; [Culbertson, C. W.] US Geol Survey, Water Sci Ctr, Augusta, ME 04330 USA	United States Department of the Interior; United States Geological Survey; Southern Illinois University System; Southern Illinois University; University System of Georgia; University of Georgia; Duquesne University; United States Department of the Interior; United States Geological Survey	Oremland, RS (corresponding author), US Geol Survey, 345 Middlefield Rd, Menlo Pk, CA 94025 USA.	roremlan@usgs.gov	张, 楠/B-1010-2010	Miller, Laurence/0000-0002-7807-3475				Bosak T, 2007, GEOBIOLOGY, V5, P119, DOI 10.1111/j.1472-4669.2007.00104.x; Brocks JJ, 1999, SCIENCE, V285, P1033, DOI 10.1126/science.285.5430.1033; Budinoff CR, 2008, ISME J, V2, P340, DOI 10.1038/ismej.2007.115; CASTENHOLZ RW, 1990, FEMS MICROBIOL ECOL, V74, P325, DOI 10.1111/j.1574-6968.1990.tb04079.x; CLOERN JE, 1983, LIMNOL OCEANOGR, V28, P1049, DOI 10.4319/lo.1983.28.6.1049; COHEN Y, 1975, J BACTERIOL, V123, P855, DOI 10.1128/JB.123.3.855-861.1975; CULVER DA, 1969, LIMNOL OCEANOGR, V14, P862, DOI 10.4319/lo.1969.14.6.0862; D'Imperio S, 2007, APPL ENVIRON MICROB, V73, P7067, DOI 10.1128/AEM.01161-07; DesMarais DJ, 1995, ADV MICROB ECOL, V14, P251; EHRENREICH A, 1994, APPL ENVIRON MICROB, V60, P4517, DOI 10.1128/AEM.60.12.4517-4526.1994; Griffin BM, 2007, SCIENCE, V316, P1870, DOI 10.1126/science.1139478; Hoeft SE, 2007, INT J SYST EVOL MICR, V57, P504, DOI 10.1099/ijs.0.64576-0; Inskeep WP, 2007, ENVIRON MICROBIOL, V9, P934, DOI 10.1111/j.1462-2920.2006.01215.x; Jackson CR, 2001, ENVIRON MICROBIOL, V3, P532, DOI 10.1046/j.1462-2920.2001.00221.x; Kulp TR, 2006, APPL ENVIRON MICROB, V72, P6514, DOI 10.1128/AEM.01066-06; OREMLAND RS, 1987, GEOCHIM COSMOCHIM AC, V51, P2915, DOI 10.1016/0016-7037(87)90367-X; Oremland RS, 2005, SCIENCE, V308, P1305, DOI 10.1126/science.1110832; Oremland RS, 2003, SCIENCE, V300, P939, DOI 10.1126/science.1081903; Rashby SE, 2007, P NATL ACAD SCI USA, V104, P15099, DOI 10.1073/pnas.0704912104; RAYMOND JC, 1969, ARCH MIKROBIOL, V69, P121, DOI 10.1007/BF00409756; Rhine ED, 2007, BIOCHEM BIOPH RES CO, V354, P662, DOI 10.1016/j.bbrc.2007.01.004; Santini JM, 2000, APPL ENVIRON MICROB, V66, P92, DOI 10.1128/AEM.66.1.92-97.2000; Stolz JE, 2006, ANNU REV MICROBIOL, V60, P107, DOI 10.1146/annurev.micro.60.080805.142053; Summons RE, 1999, NATURE, V400, P554, DOI 10.1038/23005; Tice MM, 2004, NATURE, V431, P549, DOI 10.1038/nature02888; WIDDEL F, 1993, NATURE, V362, P834, DOI 10.1038/362834a0	26	157	169	3	126	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 15	2008	321	5891					967	970		10.1126/science.1160799	http://dx.doi.org/10.1126/science.1160799			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	337LD	18703741				2022-12-28	WOS:000258436700040
J	Frueh, DP; Arthanari, H; Koglin, A; Vosburg, DA; Bennett, AE; Walsh, CT; Wagner, G				Frueh, Dominique P.; Arthanari, Haribabu; Koglin, Alexander; Vosburg, David A.; Bennett, Andrew E.; Walsh, Christopher T.; Wagner, Gerhard			Dynamic thiolation-thioesterase structure of a non-ribosomal peptide synthetase	NATURE			English	Article							ACYL CARRIER PROTEIN; FATTY-ACID SYNTHASE; TRIPLE-RESONANCE EXPERIMENTS; ESCHERICHIA-COLI; MACROMOLECULAR STRUCTURE; C-13 MAGNETIZATION; NMR-SPECTROSCOPY; CHEMICAL-SHIFT; SWISS-MODEL; RESOLUTION	Non-ribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) produce numerous secondary metabolites with various therapeutic/antibiotic properties(1). Like fatty acid synthases (FAS), these enzymes are organized in modular assembly lines in which each module, made of conserved domains, incorporates a given monomer unit into the growing chain. Knowledge about domain or module interactions may enable reengineering of this assembly line enzymatic organization and open avenues for the design of new bioactive compounds with improved therapeutic properties. So far, little structural information has been available on how the domains interact and communicate. This may be because of inherent interdomain mobility hindering crystallization, or because crystallized molecules may not represent the active domain orientations(2). In solution, the large size and internal dynamics of multidomain fragments (> 35 kilodaltons) make structure determination by nuclear magnetic resonance a challenge and require advanced technologies. Here we present the solution structure of the apo-thiolation-thioesterase (T-TE) di-domain fragment of the Escherichia coli enterobactin synthetase EntF NRPS subunit. In the holoenzyme, the T domain carries the growing chain tethered to a 4 '-phosphopantetheine whereas the TE domain catalyses hydrolysis and cyclization of the iron chelator enterobactin. The T-TE di-domain forms a compact but dynamic structure with a well-defined domain interface; the two active sites are at a suitable distance for substrate transfer from T to TE. We observe extensive interdomain and intradomain motions forwell-defined regions and show that these are modulated by interactions with proteins that participate in the biosynthesis. The T-TE interaction described here provides a model for NRPS, PKS and FAS function in general as T-TE-like di-domains typically catalyse the last step in numerous assembly-line chain-termination machineries.	[Frueh, Dominique P.; Arthanari, Haribabu; Koglin, Alexander; Vosburg, David A.; Bennett, Andrew E.; Walsh, Christopher T.; Wagner, Gerhard] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Wagner, G (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	dominique_frueh@hms.harvard.edu; christopher_walsh@hms.harvard.edu; gerhard_wagner@hms.harvard.edu	Frueh, Dominique P/A-6462-2008; Vosburg, David/P-3944-2019	Frueh, Dominique P/0000-0003-4605-3776; Vosburg, David/0000-0003-3424-5471; Arthanari, Haribabu/0000-0002-7281-1289	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB002026] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P41GM066360, P01GM047467] Funding Source: NIH RePORTER; NIBIB NIH HHS [P41 EB002026-30, P41 EB002026-28, EB 002026, P41 EB002026, P41 EB002026-29, P41 EB002026-33, P41 EB002026-31, P41 EB002026-32] Funding Source: Medline; NIGMS NIH HHS [P41 GM066360, P41 GM066360-05, P01 GM047467-15, P01 GM047467, GM066360, P41 GM066360-04, P01 GM047467-110009, P01 GM047467-16, P01 GM047467-11, P01 GM047467-160012, P01 GM047467-13, P41 GM066360-01, P41 GM066360-02, P01 GM047467-12, P41 GM066360-03, GM47467, P01 GM047467-170012, P01 GM047467-14, P01 GM047467-17] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; Bruner SD, 2002, STRUCTURE, V10, P301, DOI 10.1016/S0969-2126(02)00716-5; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Ferentz AE, 2000, Q REV BIOPHYS, V33, P29, DOI 10.1017/S0033583500003589; Findlow SC, 2003, BIOCHEMISTRY-US, V42, P8423, DOI 10.1021/bi0342259; Frueh DP, 2006, J AM CHEM SOC, V128, P5757, DOI 10.1021/ja0584222; Frueh DP, 2006, J BIOMOL NMR, V34, P31, DOI 10.1007/s10858-005-5338-4; Gardner KH, 1997, J AM CHEM SOC, V119, P7599, DOI 10.1021/ja9706514; Gehring AM, 1997, BIOCHEMISTRY-US, V36, P8495, DOI 10.1021/bi970453p; Gehring AM, 1998, BIOCHEMISTRY-US, V37, P2648, DOI 10.1021/bi9726584; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hyberts SG, 2003, J BIOMOL NMR, V26, P335, DOI 10.1023/A:1024078926886; IKURA M, 1991, Journal of Biomolecular NMR, V1, P299, DOI 10.1007/BF01875522; Jenni S, 2006, SCIENCE, V311, P1263, DOI 10.1126/science.1123251; Jenni S, 2007, SCIENCE, V316, P254, DOI 10.1126/science.1138248; Johnson MA, 2006, PROTEIN SCI, V15, P1030, DOI 10.1110/ps.051964606; Keller R., 2004, COMPUTER AIDED RESON, V1; KIM Y, 1989, BIOCHEMISTRY-US, V28, P8792, DOI 10.1021/bi00448a017; Koglin A, 2006, SCIENCE, V312, P273, DOI 10.1126/science.1122928; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; LAMBALOT RH, 1995, J BIOL CHEM, V270, P24658, DOI 10.1074/jbc.270.42.24658; Leibundgut M, 2007, SCIENCE, V316, P288, DOI 10.1126/science.1138249; Lomakin IB, 2007, CELL, V129, P319, DOI 10.1016/j.cell.2007.03.013; Maier T, 2006, SCIENCE, V311, P1258, DOI 10.1126/science.1123248; Medek A, 2000, J BIOMOL NMR, V18, P229, DOI 10.1023/A:1026544801001; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; Nederveen AJ, 2005, PROTEINS, V59, P662, DOI 10.1002/prot.20408; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Pervushin K, 2003, J BIOMOL NMR, V25, P147, DOI 10.1023/A:1022225711122; Roche ED, 2003, BIOCHEMISTRY-US, V42, P1334, DOI 10.1021/BI026867m; Rovnyak D, 2004, J MAGN RESON, V170, P15, DOI 10.1016/j.jmr.2004.05.016; Salzmann M, 1998, P NATL ACAD SCI USA, V95, P13585, DOI 10.1073/pnas.95.23.13585; Samel SA, 2007, STRUCTURE, V15, P781, DOI 10.1016/j.str.2007.05.008; Samel SA, 2006, J MOL BIOL, V359, P876, DOI 10.1016/j.jmb.2006.03.062; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111; TOLMAN JR, 1995, P NATL ACAD SCI USA, V92, P9279, DOI 10.1073/pnas.92.20.9279; WAGNER G, 1995, NAT STRUCT BIOL, V2, P255, DOI 10.1038/nsb0495-255; Walsh CT, 2004, SCIENCE, V303, P1805, DOI 10.1126/science.1094318; Weber T, 2000, STRUCT FOLD DES, V8, P407, DOI 10.1016/S0969-2126(00)00120-9; Zornetzer GA, 2006, BIOCHEMISTRY-US, V45, P5217, DOI 10.1021/bi052062d	46	127	129	0	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 14	2008	454	7206					903	U62		10.1038/nature07162	http://dx.doi.org/10.1038/nature07162			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	336XH	18704088	Green Accepted			2022-12-28	WOS:000258398600040
J	Jacobson, IG; Ryan, MAK; Hooper, TI; Smith, TC; Amoroso, PJ; Boyko, EJ; Gackstetter, GD; Wells, TS; Bell, NS				Jacobson, Isabel G.; Ryan, Margaret A. K.; Hooper, Tomoko I.; Smith, Tyler C.; Amoroso, Paul J.; Boyko, Edward J.; Gackstetter, Gary D.; Wells, Timothy S.; Bell, Nicole S.			Alcohol use and alcohol-related problems before and after military combat deployment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; MILLENNIUM COHORT; PROBLEM DRINKING; BINGE DRINKING; UNITED-STATES; PRIME-MD; CONSUMPTION; DEPENDENCE; ABUSE	Context High rates of alcohol misuse after deployment have been reported among personnel returning from past conflicts, yet investigations of alcohol misuse after return from the current wars in Iraq and Afghanistan are lacking. Objectives To determine whether deployment with combat exposures was associated with new-onset or continued alcohol consumption, binge drinking, and alcoholrelated problems. Design, Setting, and Participants Data were from Millennium Cohort Study participants who completed both a baseline (July 2001 to June 2003; n = 77 047) and followup (June 2004 to February 2006; n = 55 021) questionnaire (follow-up response rate = 71.4%). After we applied exclusion criteria, our analyses included 48 481 participants (active duty, n = 26 613; Reserve or National Guard, n = 21 868). Of these, 5510 deployed with combat exposures, 5661 deployed without combat exposures, and 37 310 did not deploy. Main Outcome Measures New- onset and continued heavy weekly drinking, binge drinking, and alcohol-related problems at follow-up. Results Baseline prevalence of heavy weekly drinking, binge drinking, and alcoholrelated problems among Reserve or National Guard personnel who deployed with combat exposures was 9.0%, 53.6%, and 15.2%, respectively; follow-up prevalence was 12.5%, 53.0%, and 11.9%, respectively; and new-onset rates were 8.8%, 25.6%, and 7.1%, respectively. Among active-duty personnel, new-onset rates were 6.0%, 26.6%, and 4.8%, respectively. Reserve and National Guard personnel who deployed and reported combat exposures were significantly more likely to experience new-onset heavy weekly drinking (odds ratio [OR], 1.63; 95% confidence interval [CI], 1.36-1.96), binge drinking (OR, 1.46; 95% CI, 1.24-1.71), and alcohol-related problems (OR, 1.63; 95% CI, 1.33-2.01) compared with nondeployed personnel. The youngest members of the cohort were at highest risk for all alcohol-related outcomes. Conclusion Reserve and National Guard personnel and younger service members who deploy with reported combat exposures are at increased risk of new-onset heavy weekly drinking, binge drinking, and alcohol-related problems.	[Jacobson, Isabel G.; Ryan, Margaret A. K.; Smith, Tyler C.] US Dept Def, Ctr Deployment Hlth Res, Naval Hlth Res Ctr, San Diego, CA 92106 USA; [Hooper, Tomoko I.] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA; [Amoroso, Paul J.] Madigan Army Med Ctr, Ft Lewis, WA USA; [Boyko, Edward J.] Dept Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA; [Wells, Timothy S.] Wright Patterson Air Force Base, Air Force Res Lab, Dayton, OH USA; [Gackstetter, Gary D.] Analyt Serv Inc, Arlington, VA USA; [Bell, Nicole S.] Social Sectors Dev Strategies Inc, Tacoma, WA USA	United States Department of Defense; United States Navy; Naval Medical Research Center (NMRC); Naval Health Research Center (NHRC); Uniformed Services University of the Health Sciences - USA; Madigan Army Medical Center; United States Department of Defense; United States Air Force; US Air Force Research Laboratory	Jacobson, IG (corresponding author), US Dept Def, Ctr Deployment Hlth Res, Naval Hlth Res Ctr, 140 Sylvester Rd, San Diego, CA 92106 USA.	Isabel.Jacobson@med.navy.mil	Boyko, Edward J/G-2484-2017	Boyko, Edward J/0000-0002-3695-192X	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA013324] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Agrawal A, 2008, ADDICT BEHAV, V33, P1223, DOI 10.1016/j.addbeh.2008.04.003; Almeida-Filho N, 2004, REV SAUDE PUBL, V38, P45, DOI 10.1590/S0034-89102004000100007; American Association for Public Opinion Research, 2006, STAND DEF FIN DISP C, V4th; Ames GM, 2007, J STUD ALCOHOL DRUGS, V68, P336, DOI 10.15288/jsad.2007.68.336; Bell N S, 2001, Inj Prev, V7, P4, DOI 10.1136/ip.7.1.4; Bell NS, 2003, ALCOHOL CLIN EXP RES, V27, P826, DOI 10.1097/01.ALC.0000067978.27660.73; BRAY RM, 1991, AM J PUBLIC HEALTH, V81, P865, DOI 10.2105/AJPH.81.7.865; Bray RM, 2007, ADDICTION, V102, P1092, DOI 10.1111/j.1360-0443.2007.01841.x; Carlsson S, 2003, EUR J EPIDEMIOL, V18, P493, DOI 10.1023/A:1024694816036; Chilcoat HD, 1998, ADDICT BEHAV, V23, P827, DOI 10.1016/S0306-4603(98)00069-0; Coffman DL, 2007, PREV SCI, V8, P241, DOI 10.1007/s11121-007-0078-1; Costanzo PR, 2007, J STUD ALCOHOL DRUGS, V68, P727, DOI 10.15288/jsad.2007.68.727; Criqui MH, 1998, NOVART FDN SYMP, V216, P159; CRUM RM, 1992, AM J EPIDEMIOL, V135, P989, DOI 10.1093/oxfordjournals.aje.a116411; Crum Rosa M., 2000, Ethnicity and Disease, V10, P39; Cunradi CB, 2008, NICOTINE TOB RES, V10, P429, DOI 10.1080/14622200801889002; Dawson DA, 2006, J STUD ALCOHOL, V67, P195, DOI 10.15288/jsa.2006.67.195; Dawson DA, 2003, ALCOHOL RES HEALTH, V27, P18; Dawson DA, 2005, ALCOHOL CLIN EXP RES, V29, P902, DOI 10.1097/01.ALC.0000164544.45746.A7; Dawson DA, 1998, J SUBST ABUSE, V10, P321, DOI 10.1016/S0899-3289(99)00009-7; Dhalla S, 2007, CLIN INVEST MED, V30, P33, DOI 10.25011/cim.v30i1.447; DILLMAN DA, 1978, MAIL TELEPHONE SURVE, P325; Engel CC, 1999, J OCCUP ENVIRON MED, V41, P384, DOI 10.1097/00043764-199905000-00006; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fernandez WG, 2006, MIL MED, V171, P538, DOI 10.7205/MILMED.171.6.538; Gilman SE, 2008, J EPIDEMIOL COMMUN H, V62, P224, DOI 10.1136/jech.2006.059022; Goldberg IJ, 2001, CIRCULATION, V103, P472; GOLDBERG J, 1990, AM J PUBLIC HEALTH, V80, P570, DOI 10.2105/AJPH.80.5.570; Hasin DS, 2007, ARCH GEN PSYCHIAT, V64, P830, DOI 10.1001/archpsyc.64.7.830; Heeb JL, 2005, ADDICT BEHAV, V30, P403, DOI 10.1016/j.addbeh.2004.04.022; Hobson CJ, 1998, INT J STRESS MANAGE, V5, P1, DOI 10.1023/A:1022978019315; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; Hussong AM, 2007, ADDICT BEHAV, V32, P1054, DOI 10.1016/j.addbeh.2006.07.011; Killgore WDS, 2008, J PSYCHIATR RES, V42, P1112, DOI 10.1016/j.jpsychires.2008.01.001; Kozaric-Kovacic D, 2000, CROAT MED J, V41, P173; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lande RG, 2007, J AM OSTEOPATH ASSOC, V107, P401; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; MANN CAL, 2007, HUM VACCIN, V3, P245; McFarlane AC, 1998, ADDICT BEHAV, V23, P813, DOI 10.1016/S0306-4603(98)00098-7; McLeod DS, 2001, J TRAUMA STRESS, V14, P259, DOI 10.1023/A:1011157800050; Micklewright S, 1996, J R Nav Med Serv, V82, P34; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006; Naimi TS, 2003, JAMA-J AM MED ASSOC, V289, P70, DOI 10.1001/jama.289.1.70; RICHARDS MS, 1989, AM J PUBLIC HEALTH, V79, P1011, DOI 10.2105/AJPH.79.8.1011; Riddle JR, 2007, J CLIN EPIDEMIOL, V60, P192, DOI 10.1016/j.jclinepi.2006.04.008; Riper H, 2008, ADDICTION, V103, P218, DOI 10.1111/j.1360-0443.2007.02063.x; Rona RJ, 2007, BRIT MED J, V335, P603, DOI 10.1136/bmj.39274.585752.BE; ROSS HE, 1995, DRUG ALCOHOL DEPEN, V39, P111, DOI 10.1016/0376-8716(95)01150-W; Ryan MAK, 2007, J CLIN EPIDEMIOL, V60, P181, DOI 10.1016/j.jclinepi.2006.05.009; Schuckit MA, 2006, DRUG ALCOHOL DEPEN, V82, P194, DOI 10.1016/j.drugalcdep.2005.09.006; Schwartz DA, 1997, JAMA-J AM MED ASSOC, V277, P238, DOI 10.1001/jama.277.3.238; SHEPHERD J, 1989, BRIT J ADDICT, V84, P1045; Shipherd JC, 2005, ADDICT BEHAV, V30, P595, DOI 10.1016/j.addbeh.2004.07.004; Smith B, 2007, AM J EPIDEMIOL, V166, P1345, DOI 10.1093/aje/kwm212; Smith B, 2007, AM J PREV MED, V32, P347, DOI 10.1016/j.amepre.2006.12.015; Smith TC, 2008, EPIDEMIOLOGY, V19, P505, DOI 10.1097/EDE.0b013e31816a9dff; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Smith TC, 2007, INT J ENVIRON HEAL R, V17, P271, DOI 10.1080/09603120701372243; Smith TC, 2007, ANN EPIDEMIOL, V17, P525, DOI 10.1016/j.annepidem.2006.12.002; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Spitzer RL, 2000, AM J OBSTET GYNECOL, V183, P759, DOI 10.1067/mob.2000.106580; Swendsen JD, 1998, COMPR PSYCHIAT, V39, P176, DOI 10.1016/S0010-440X(98)90058-X; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401; Ullman SE, 2006, ADDICT BEHAV, V31, P128, DOI 10.1016/j.addbeh.2005.04.002; Ullman SE, 2005, J STUD ALCOHOL, V66, P610, DOI 10.15288/jsa.2005.66.610; US Department of Health and Human Services and USDA, 2005, DIET GUID AM 2005; Vander Weg MW, 2006, MIL MED, V171, P177, DOI 10.7205/MILMED.171.2.177; Weathers F.W., 1993, PTSD CHECKLIST PCL R; Werner MJ, 1996, J ADOLESCENT HEALTH, V18, P276, DOI 10.1016/1054-139X(95)00207-9; White AM, 2006, ALCOHOL CLIN EXP RES, V30, P1006, DOI 10.1111/j.1530-0277.2006.00122.x; WILLIAMS GD, 1985, J STUD ALCOHOL, V46, P223, DOI 10.15288/jsa.1985.46.223; Williams Jeffrey O, 2002, Work, V18, P141; Wynd CA, 1998, MIL MED, V163, P283, DOI 10.1093/milmed/163.5.283	79	473	476	0	36	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	2008	300	6					663	675		10.1001/jama.300.6.663	http://dx.doi.org/10.1001/jama.300.6.663			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	336OM	18698065	Green Accepted			2022-12-28	WOS:000258374500019
J	Smith, G; Yard, J				Smith, Graeme; Yard, Jon			Quantum communication with zero-capacity channels	SCIENCE			English	Article							BOUND ENTANGLEMENT; SEPARABILITY	Communication over a noisy quantum channel introduces errors in the transmission that must be corrected. A fundamental bound on quantum error correction is the quantum capacity, which quantifies the amount of quantum data that can be protected. We show theoretically that two quantum channels, each with a transmission capacity of zero, can have a nonzero capacity when used together. This unveils a rich structure in the theory of quantum communications, implying that the quantum capacity does not completely specify a channel's ability to transmit quantum information.	[Smith, Graeme] IBM Corp, Thomas J Watson Res Ctr, Yorktown Hts, NY 10598 USA; [Yard, Jon] Los Alamos Natl Lab, Quantum Inst, Ctr Nonlinear Studies, Los Alamos, NM 87545 USA	International Business Machines (IBM); United States Department of Energy (DOE); Los Alamos National Laboratory	Smith, G (corresponding author), IBM Corp, Thomas J Watson Res Ctr, 1101 Kitchawan Rd, Yorktown Hts, NY 10598 USA.	gsbsmith@gmail.com			CNLS; Quantum Institute; Laboratory Directed Research and Development; U. S. Department of Energy	CNLS; Quantum Institute; Laboratory Directed Research and Development; U. S. Department of Energy(United States Department of Energy (DOE))	We are indebted to C. Bennett, C. Callaway, E. Timmermans, B. Toner, and A. Winter for encouragement and comments on an earlier draft. J. Y. is supported by the CNLS and the Quantum Institute through grants provided by the Laboratory Directed Research and Development program of the U. S. Department of Energy.	Bennett CH, 2004, SCIENCE, V303, P1784, DOI 10.1126/science.1092381; Bennett CH, 1997, PHYS REV LETT, V78, P3217, DOI 10.1103/PhysRevLett.78.3217; Bennett CH., 1984, P IEEE INT C COMP SY, P175; CZEKAJ L, PREPRINT; DiVincenzo DP, 1998, PHYS REV A, V57, P830, DOI 10.1103/PhysRevA.57.830; Duan R, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.020501; Dur W, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.020503; Horodecki K, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.160502; Horodecki K, 2008, IEEE T INFORM THEORY, V54, P2621, DOI 10.1109/TIT.2008.921709; Horodecki M, 1996, PHYS LETT A, V223, P1, DOI 10.1016/S0375-9601(96)00706-2; Horodecki P, 1997, PHYS LETT A, V232, P333, DOI 10.1016/S0375-9601(97)00416-7; Horodecki P, 1999, PHYS REV LETT, V82, P1056, DOI 10.1103/PhysRevLett.82.1056; Peres A, 1996, PHYS REV LETT, V77, P1413, DOI 10.1103/PhysRevLett.77.1413; Richardson T, 2003, IEEE COMMUN MAG, V41, P126, DOI 10.1109/MCOM.2003.1222728; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x; Shor PW, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.107901; SHOR PW, 1994, AN S FDN CO, P124; Shor PW, 2001, PHYS REV LETT, V86, P2681, DOI 10.1103/PhysRevLett.86.2681; Smith G, 2008, IEEE T INFORM THEORY, V54, P4208, DOI 10.1109/TIT.2008.928269; Smith G, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.030501; WOOTTERS WK, 1982, NATURE, V299, P802, DOI 10.1038/299802a0	24	211	217	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 26	2008	321	5897					1812	1815		10.1126/science.1162242	http://dx.doi.org/10.1126/science.1162242			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	352MM	18719249	Green Submitted			2022-12-28	WOS:000259501300031
J	Rudan, I; Campbell, H				Rudan, Igor; Campbell, Harry			Childhood pneumonia deaths: a new role for health workers?	LANCET			English	Editorial Material							ORAL AMOXICILLIN; CHILDREN; MORTALITY		[Rudan, Igor] Univ Spit Med Sch, Croatian Ctr Global Hlth, Split 21000, Croatia; [Rudan, Igor; Campbell, Harry] Univ Edinburgh, Sch Med, Edinburgh, Midlothian, Scotland	University of Split; University of Edinburgh	Rudan, I (corresponding author), Univ Spit Med Sch, Croatian Ctr Global Hlth, Split 21000, Croatia.	irudan@hotmail.com	Rudan, Igor/I-1467-2012; Campbell, Harry/E-2959-2010	Rudan, Igor/0000-0001-6993-6884; Campbell, Harry/0000-0002-6169-6262				Addo-Yobo E, 2004, LANCET, V364, P1141, DOI 10.1016/S0140-6736(04)17100-6; Bryce J, 2003, LANCET, V362, P159, DOI 10.1016/S0140-6736(03)13870-6; Bryce J, 2006, LANCET, V368, P1067, DOI 10.1016/S0140-6736(06)69339-2; CHOWDHURY EK, 2008, LANCET          0819, DOI DOI 10.1016/S0140-6736(08)61166-6; Gove S, 1997, B WORLD HEALTH ORGAN, V75, P119; Greenwood BM, 2007, B WORLD HEALTH ORGAN, V85, P502, DOI 10.2471/BLT.07.044032; Hazir T, 2008, LANCET, V371, P49, DOI 10.1016/S0140-6736(08)60071-9; Mulholland K, 2007, LANCET, V370, P285, DOI 10.1016/S0140-6736(07)61130-1; Rudan I, 2005, LANCET, V365, P2031, DOI 10.1016/S0140-6736(05)66697-4; Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769; Rudan I, 2007, LANCET INFECT DIS, V7, P56, DOI 10.1016/S1473-3099(06)70687-9; Tulloch J., 1999, Lancet (British edition), V354, P16, DOI 10.1016/S0140-6736(99)90252-0	12	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 6	2008	372	9641					781	782		10.1016/S0140-6736(08)61167-8	http://dx.doi.org/10.1016/S0140-6736(08)61167-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	347FB	18715635				2022-12-28	WOS:000259124900005
J	Contopoulos-Ioannidis, DG; Alexiou, GA; Gouvias, TC; Ioannidis, JPA				Contopoulos-Ioannidis, Despina G.; Alexiou, George A.; Gouvias, Theodore C.; Ioannidis, John P. A.			Medicine - Life cycle of translational research for medical interventions	SCIENCE			English	Editorial Material									[Alexiou, George A.; Gouvias, Theodore C.; Ioannidis, John P. A.] Univ Ioannina, Clin Trials & Evidence Based Med Unit, Dept Hyg & Epidemiol, Sch Med, GR-45110 Ioannina, Greece; [Contopoulos-Ioannidis, Despina G.] Univ Ioannina, Sch Med, Dept Pediat, GR-45110 Ioannina, Greece; [Contopoulos-Ioannidis, Despina G.] George Washington Univ, Sch Med, Dept Pediat, Washington, DC 20037 USA; [Ioannidis, John P. A.] Tufts Med Ctr, Dept Med, Boston, MA 02111 USA; [Ioannidis, John P. A.] Tufts Univ, Sch Med, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA; [Ioannidis, John P. A.] Fdn Res & Technol Hellas, Inst Biomed Res, Ioannina, Greece	University of Ioannina; University of Ioannina; George Washington University; Tufts Medical Center; Tufts University; Foundation for Research & Technology - Hellas (FORTH)	Ioannidis, JPA (corresponding author), Univ Ioannina, Clin Trials & Evidence Based Med Unit, Dept Hyg & Epidemiol, Sch Med, GR-45110 Ioannina, Greece.	jioannid@cc.uoi.gr	Ioannidis, John P. A./G-9836-2011; Alexiou, George A/B-3995-2012	Alexiou, George A/0000-0003-0257-4481				Booth B, 2004, NAT REV DRUG DISCOV, V3, P451, DOI 10.1038/nrd1384; Chong CR, 2007, NATURE, V448, P645, DOI 10.1038/448645a; Contopoulos-Ioannidis DG, 2003, AM J MED, V114, P477, DOI 10.1016/S0002-9343(03)00013-5; Cuatrecasas P, 2006, J CLIN INVEST, V116, P2837, DOI 10.1172/JCI29999; Duyk G, 2003, SCIENCE, V302, P603, DOI 10.1126/science.1090521; Hackam DG, 2006, JAMA-J AM MED ASSOC, V296, P1731, DOI 10.1001/jama.296.14.1731; Ioannidis JP, 2004, J TRANSL MED, V2, P5, DOI DOI 10.1186/1479-5876-2-5; Ioannidis JPA, 2005, JAMA-J AM MED ASSOC, V294, P218, DOI 10.1001/jama.294.2.218; Marincola Francesco M, 2003, J Transl Med, V1, P1, DOI 10.1186/1479-5876-1-1; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Zerhouni EA, 2005, JAMA-J AM MED ASSOC, V294, P1352, DOI 10.1001/jama.294.11.1352; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	12	133	140	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	2008	321	5894					1298	1299		10.1126/science.1160622	http://dx.doi.org/10.1126/science.1160622			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	344GG	18772421				2022-12-28	WOS:000258914300031
J	Elsner, JB; Kossin, JP; Jagger, TH				Elsner, James B.; Kossin, James P.; Jagger, Thomas H.			The increasing intensity of the strongest tropical cyclones	NATURE			English	Article							HURRICANE INTENSITY; POTENTIAL INTENSITY; SENSITIVITY; ENVIRONMENT; SATELLITE; CLIMATE; MODEL	Atlantic tropical cyclones are getting stronger on average, with a 30- year trend that has been related to an increase in ocean temperatures over the Atlantic Ocean and elsewhere(1-4). Over the rest of the tropics, however, possible trends in tropical cyclone intensity are less obvious, owing to the unreliability and incompleteness of the observational record and to a restricted focus, in previous trend analyses, on changes in average intensity. Here we overcome these two limitations by examining trends in the upper quantiles of per- cyclone maximum wind speeds ( that is, the maximum intensities that cyclones achieve during their lifetimes), estimated from homogeneous data derived from an archive of satellite records. We find significant upward trends for wind speed quantiles above the 70th percentile, with trends as high as 0.3 +/- 0.09 m s(-1) yr(-1) (s.e.) for the strongest cyclones. We note separate upward trends in the estimated lifetime-maximum wind speeds of the very strongest tropical cyclones ( 99th percentile) over each ocean basin, with the largest increase at this quantile occurring over the North Atlantic, although not all basins show statistically significant increases. Our results are qualitatively consistent with the hypothesis that as the seas warm, the ocean has more energy to convert to tropical cyclone wind.	[Elsner, James B.; Jagger, Thomas H.] Florida State Univ, Dept Geog, Tallahassee, FL 32306 USA; [Kossin, James P.] Univ Wisconsin, Cooperat Inst Meteorol Satellite Studies, Madison, WI 53706 USA	State University System of Florida; Florida State University; University of Wisconsin System; University of Wisconsin Madison	Elsner, JB (corresponding author), Florida State Univ, Dept Geog, Tallahassee, FL 32306 USA.	jelsner@fsu.edu	Jagger, Thomas/B-1713-2008; Kossin, James/C-2022-2016; Kossin, James/D-3929-2011	Jagger, Thomas/0000-0001-7823-3750; Kossin, James/0000-0003-0461-9794; Elsner, James/0000-0001-6805-7431	US National Science Foundation [ATM-0738172, ATM-0614812]; Risk Prediction Initiative of the Bermuda Institute for Ocean Studies [RPI06-3-001]; Div Atmospheric & Geospace Sciences [0738172] Funding Source: National Science Foundation	US National Science Foundation(National Science Foundation (NSF)); Risk Prediction Initiative of the Bermuda Institute for Ocean Studies; Div Atmospheric & Geospace Sciences(National Science Foundation (NSF)NSF - Directorate for Geosciences (GEO))	The work was supported by the US National Science Foundation (ATM-0738172 and ATM-0614812) and by the Risk Prediction Initiative of the Bermuda Institute for Ocean Studies (RPI06-3-001).	Bengtsson L, 2007, TELLUS A, V59, P539, DOI 10.1111/j.1600-0870.2007.00251.x; Bister M, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000776; Chan JCL, 2006, SCIENCE, V311, DOI 10.1126/science.1121522; Elsner JB, 2007, TELLUS A, V59, P476, DOI 10.1111/J.1600-0870.2007.00244.X; Emanuel K, 2005, NATURE, V436, P686, DOI 10.1038/nature03906; EMANUEL KA, 1991, ANNU REV FLUID MECH, V23, P179, DOI 10.1146/annurev.fluid.23.1.179; Franklin JL, 2003, WEATHER FORECAST, V18, P32, DOI 10.1175/1520-0434(2003)018<0032:GDWPIH>2.0.CO;2; Gunshor MM, 2004, J ATMOS OCEAN TECH, V21, P61, DOI 10.1175/1520-0426(2004)021<0061:IOTIWA>2.0.CO;2; Holland GJ, 1997, J ATMOS SCI, V54, P2519, DOI 10.1175/1520-0469(1997)054<2519:TMPIOT>2.0.CO;2; Klotzbach PJ, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL025881; Knapp KR, 2007, J APPL REMOTE SENS, V1, DOI 10.1117/1.2712816; Knapp KR, 2008, J ATMOS OCEAN TECH, V25, P183, DOI 10.1175/2007JTECHA910.1; Knapp KR, 2007, B AM METEOROL SOC, V88, P1359, DOI 10.1175/BAMS-88-9-1359; Knutson TR, 2004, J CLIMATE, V17, P3477, DOI [10.1175/1520-0442(2004)017<3477:IOCWOS>2.0.CO;2, 10.1175/1520-0442(2004)017&lt;3477:IOCWOS&gt;2.0.CO;2]; Kossin JP, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2006GL028836; Landsea CW, 2006, SCIENCE, V313, P452, DOI 10.1126/science.1128448; Landsea CW, 2005, NATURE, V438, pE11, DOI 10.1038/nature04477; Pielke RA, 2005, B AM METEOROL SOC, V86, P1571, DOI 10.1175/BAMS-86-11-1571; Rayner NA, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002670; Shen WX, 2000, J CLIMATE, V13, P109, DOI 10.1175/1520-0442(2000)013<0109:ASSOTT>2.0.CO;2; Swanson KL, 2008, GEOCHEM GEOPHY GEOSY, V9, DOI 10.1029/2007GC001844; Trenberth K, 2005, SCIENCE, V308, P1753, DOI 10.1126/science.1112551; Vecchi GA, 2007, NATURE, V450, P1066, DOI 10.1038/nature06423; YU K, 2003, STATISTICIAN, V52, P331, DOI DOI 10.1111/1467-9984.00363	25	701	721	9	200	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	2008	455	7209					92	95		10.1038/nature07234	http://dx.doi.org/10.1038/nature07234			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	343XS	18769438				2022-12-28	WOS:000258890200043
J	Howe, D; Costanzo, M; Fey, P; Gojobori, T; Hannick, L; Hide, W; Hill, DP; Kania, R; Schaeffer, M; St Pierre, S; Twigger, S; White, O; Rhee, SY				Howe, Doug; Costanzo, Maria; Fey, Petra; Gojobori, Takashi; Hannick, Linda; Hide, Winston; Hill, David P.; Kania, Renate; Schaeffer, Mary; St Pierre, Susan; Twigger, Simon; White, Owen; Rhee, Seung Yon			Big data: The future of biocuration	NATURE			English	Editorial Material							MINIMUM INFORMATION		[Howe, Doug] Univ Oregon 5291, Zebrafish Informat Network, Eugene, OR 97403 USA; [Costanzo, Maria] Stanford Univ, Stanford, CA 94305 USA; [Fey, Petra] Northwestern Univ, Biomed Informat Ctr, Chicago, IL 60611 USA; [Gojobori, Takashi] Res Org Informat & Syst, Ctr Informat Biol, Natl Inst Genet, Mishima, Shizuoka 4118540, Japan; [Gojobori, Takashi] Res Org Informat & Syst, DNA Data Bank Japan, Natl Inst Genet, Mishima, Shizuoka 4118540, Japan; [Hannick, Linda] J Craig Venter Inst, Rockville, MD 20850 USA; [Hide, Winston] Univ Western Cape, S African Natl Bioinformat Inst, ZA-7535 Bellville, South Africa; [Hide, Winston] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Hill, David P.] Jackson Lab, Bar Harbor, ME 04609 USA; [Kania, Renate] EML Res GmbH, Sci Databases & Visualizat, D-69118 Heidelberg, Germany; [Schaeffer, Mary] Univ Missouri, Div Plant Sci, Columbia, MO USA; [Schaeffer, Mary] USDA, Plant Genet Res Unit, Cultural Res Serv, Columbia, MO 65211 USA; [St Pierre, Susan] Harvard Univ, Cambridge, MA 02138 USA; [Twigger, Simon] Med Coll Wisconsin, Bioinformat Res Ctr, Milwaukee, WI 53226 USA; [White, Owen] Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Inst Genome Sci, Baltimore, MD 21201 USA; [Rhee, Seung Yon] Carnegie Inst Sci, Dept Plant Biol, Stanford, CA 94305 USA	University of Oregon; Stanford University; Northwestern University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; J. Craig Venter Institute; South African National Biodiversity Institute; University of the Western Cape; Harvard University; Harvard T.H. Chan School of Public Health; Jackson Laboratory; University of Missouri System; University of Missouri Columbia; United States Department of Agriculture (USDA); Harvard University; Medical College of Wisconsin; University System of Maryland; University of Maryland Baltimore; Carnegie Institution for Science	Howe, D (corresponding author), Univ Oregon 5291, Zebrafish Informat Network, Eugene, OR 97403 USA.	dhowe@cs.uoregon.edu; rhee@acoma.stanford.edu	Fey, Petra/O-5977-2015; Hide, Winston Hide/C-7217-2009; Hide, Winston/R-3815-2019; Hide, Winston A/V-2727-2017	Fey, Petra/0000-0002-4532-2703; Hide, Winston Hide/0000-0002-8621-3271; Hide, Winston/0000-0002-8621-3271; Hide, Winston A/0000-0002-8621-3271; Twigger, Simon/0000-0001-5659-3632; Hannick, Linda/0000-0002-8018-8466; Howe, Douglas/0000-0001-5831-7439	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P41HG002659] Funding Source: NIH RePORTER; NHGRI NIH HHS [P41 HG002659, P41 HG002659-07] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Benson DA, 2014, NUCLEIC ACIDS RES, V42, pD32, DOI [10.1093/nar/gkp1024, 10.1093/nar/gkt1030, 10.1093/nar/gks1195, 10.1093/nar/gkw1070, 10.1093/nar/gkq1079, 10.1093/nar/gkn723, 10.1093/nar/gkr1202, 10.1093/nar/gkx1094]; Bourne P, 2005, PLOS COMPUT BIOL, V1, P179, DOI 10.1371/journal.pcbi.0010034; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Burkhardt K, 2006, PLOS COMPUT BIOL, V2, P1186, DOI 10.1371/journal.pcbi.0020099; Deutsch EW, 2008, NAT BIOTECHNOL, V26, P305, DOI 10.1038/nbt1391; Field D, 2008, NAT BIOTECHNOL, V26, P541, DOI 10.1038/nbt1360; Huss JW, 2008, PLOS BIOL, V6, P1398, DOI 10.1371/journal.pbio.0060175; Jenkins H, 2004, NAT BIOTECHNOL, V22, P1601, DOI 10.1038/nbt1041; Mons B, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-5-r89; Orchard S, 2007, NAT BIOTECHNOL, V25, P894, DOI 10.1038/nbt1324; Ort DR, 2008, PLANT PHYSIOL, V146, P1022, DOI 10.1104/pp.104.900252; PALMER C, 2007, INT J DIGITAL CURATI, V2, P31; Rhee SY, 2004, PLANT PHYSIOL, V134, P543, DOI 10.1104/pp.103.035907; Salimi N, 2006, PLOS COMPUT BIOL, V2, P1190, DOI 10.1371/journal.pcbi.0020125; Seringhaus M, 2008, FEBS LETT, V582, P1170, DOI 10.1016/j.febslet.2008.02.073; Seringhaus MR, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-17; Taylor CF, 2007, NAT BIOTECHNOL, V25, P887, DOI 10.1038/nbt1329; Wheeler DL, 2008, NUCLEIC ACIDS RES, V36, pD13, DOI 10.1093/nar/gkm1000	18	486	523	4	713	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 4	2008	455	7209					47	50		10.1038/455047a	http://dx.doi.org/10.1038/455047a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	343XS	18769432	Green Accepted, Bronze			2022-12-28	WOS:000258890200034
J	Rothman, DJ; Chimonas, S				Rothman, David J.; Chimonas, Susan			New developments in managing physician-industry relationships	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Rothman, David J.; Chimonas, Susan] Columbia Univ Coll Phys & Surg, Ctr Med Profess, New York, NY 10032 USA; [Rothman, David J.] Inst Med Profess, New York, NY USA; [Rothman, David J.; Chimonas, Susan] Prescript Project, Boston, MA USA	Columbia University	Rothman, DJ (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Med Profess, 630 W 168th St, New York, NY 10032 USA.	djr5@columbia.edu		Chimonas, Susan/0000-0002-7742-5950				American Medical Association, 1998, ETH GUID GIFTS PHYS; Blumenthal D, 2004, NEW ENGL J MED, V351, P1885, DOI 10.1056/NEJMhpr042734; Brennan TA, 2006, JAMA-J AM MED ASSOC, V295, P429, DOI 10.1001/jama.295.4.429; Coyle SL, 2002, ANN INTERN MED, V136, P396, DOI 10.7326/0003-4819-136-5-200203050-00014; Dana J, 2003, JAMA-J AM MED ASSOC, V290, P252, DOI 10.1001/jama.290.2.252; PETERSEN M, 2001, NY TIMES        0821, pC1; *PHARM RES MAN AM, 2002, PHRMA COD INT HEALTH; *US DEP HHS, 2003, FED REGISTER, V68, P23731; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373	9	37	38	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	2008	300	9					1067	1069		10.1001/jama.300.9.1067	http://dx.doi.org/10.1001/jama.300.9.1067			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	342YN	18768417				2022-12-28	WOS:000258819600023
J	Aiello, LP				Aiello, Lloyd Paul			Targeting intraocular neovascularization and edema - One drop at a time	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							VASCULAR-PERMEABILITY; KINASE INHIBITOR		[Aiello, Lloyd Paul] Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA; [Aiello, Lloyd Paul] Joslin Diabet Ctr, Sect Eye Res, Boston, MA 02215 USA; [Aiello, Lloyd Paul] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Aiello, LP (corresponding author), Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA.							Doukas J, 2008, J CELL PHYSIOL, V216, P29, DOI 10.1002/jcp.21426; Gao BB, 2007, NAT MED, V13, P181, DOI 10.1038/nm1534; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; Scheppke L, 2008, J CLIN INVEST, V118, P2337, DOI [10.1172/JC133361, 10.1172/JCI33361]; Watanabe D, 2005, NEW ENGL J MED, V353, P782, DOI 10.1056/NEJMoa041773	5	31	34	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 28	2008	359	9					967	969		10.1056/NEJMcibr0804551	http://dx.doi.org/10.1056/NEJMcibr0804551			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	341IU	18753655				2022-12-28	WOS:000258708300014
J	Badcock, C; Crespi, B				Badcock, Christopher; Crespi, Bernard			Battle of the sexes may set the brain	NATURE			English	Editorial Material									[Badcock, Christopher] London Sch Econ, London WC2A 2AE, England; [Crespi, Bernard] Simon Fraser Univ, Burnaby, BC V5A 1S6, Canada	University of London; London School Economics & Political Science; Simon Fraser University	Badcock, C (corresponding author), London Sch Econ, Houghton St, London WC2A 2AE, England.	crespi@sfu.ca						Badcock C, 2006, J EVOLUTION BIOL, V19, P1007, DOI 10.1111/j.1420-9101.2006.01091.x; Crespi B, 2008, BEHAV BRAIN SCI, V31, P241, DOI 10.1017/S0140525X08004214; HAMILTON WD, 2005, NARROW ROADS GENE LA, V3, P206	3	42	42	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 28	2008	454	7208					1054	1055		10.1038/4541054a	http://dx.doi.org/10.1038/4541054a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341MW	18756240	Bronze			2022-12-28	WOS:000258719600021
J	Seale, P; Bjork, B; Yang, WL; Kajimura, S; Chin, S; Kuang, SH; Scime, A; Devarakonda, S; Conroe, HM; Erdjument-Bromage, H; Tempst, P; Rudnicki, MA; Beier, DR; Spiegelman, BM				Seale, Patrick; Bjork, Bryan; Yang, Wenli; Kajimura, Shingo; Chin, Sherry; Kuang, Shihuan; Scime, Anthony; Devarakonda, Srikripa; Conroe, Heather M.; Erdjument-Bromage, Hediye; Tempst, Paul; Rudnicki, Michael A.; Beier, David R.; Spiegelman, Bruce M.			PRDM16 controls a brown fat/skeletal muscle switch	NATURE			English	Article							ADIPOSE-TISSUE; PPAR-GAMMA; ADIPOCYTE DIFFERENTIATION; WHITE FAT; UNCOUPLING PROTEIN; SKELETAL-MUSCLE; GENE-EXPRESSION; SATELLITE CELLS; ADULT HUMANS; STEM-CELLS	Brown fat can increase energy expenditure and protect against obesity through a specialized program of uncoupled respiration. Here we show by in vivo fate mapping that brown, but not white, fat cells arise from precursors that express Myf5, a gene previously thought to be expressed only in the myogenic lineage. We also demonstrate that the transcriptional regulator PRDM16 ( PRD1- BF1- RIZ1 homologous domain containing 16) controls a bidirectional cell fate switch between skeletal myoblasts and brown fat cells. Loss of PRDM16 from brown fat precursors causes a loss of brown fat characteristics and promotes muscle differentiation. Conversely, ectopic expression of PRDM16 in myoblasts induces their differentiation into brown fat cells. PRDM16 stimulates brown adipogenesis by binding to PPAR-gamma (peroxisome-proliferator-activated receptor-gamma) and activating its transcriptional function. Finally, Prdm16-deficient brown fat displays an abnormal morphology, reduced thermogenic gene expression and elevated expression of muscle-specific genes. Taken together, these data indicate that PRDM16 specifies the brown fat lineage from a progenitor that expresses myoblast markers and is not involved in white adipogenesis.	[Seale, Patrick; Yang, Wenli; Kajimura, Shingo; Chin, Sherry; Devarakonda, Srikripa; Conroe, Heather M.; Spiegelman, Bruce M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; [Seale, Patrick; Yang, Wenli; Kajimura, Shingo; Chin, Sherry; Devarakonda, Srikripa; Conroe, Heather M.; Spiegelman, Bruce M.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; [Bjork, Bryan; Beier, David R.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA; [Kuang, Shihuan; Scime, Anthony; Rudnicki, Michael A.] Ottawa Hlth Res Inst, Program Mol Med, Sprott Ctr Stem Cell Res, Ottawa, ON K1H 8L6, Canada; [Erdjument-Bromage, Hediye; Tempst, Paul] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Ottawa; Ottawa Hospital Research Institute; Memorial Sloan Kettering Cancer Center	Spiegelman, BM (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 1 Jimmy Fund Way, Boston, MA 02115 USA.	bruce_spiegelman@dfci.harvard.edu	Kajimura, Shingo/AAC-5090-2019	Kajimura, Shingo/0000-0003-0672-5910; Erdjument-Bromage, Hediye/0000-0003-0224-3594; Kuang, Shihuan/0000-0001-9180-3180; Rudnicki, Michael/0000-0002-3866-5249; Tempst, Paul/0000-0002-6680-3987	American Heart Association; Japan Society for the Promotion of Science; Susan Komen Breast Cancer Foundation; Picower Foundation; National Institutes of Health; National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031405] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Susan Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); Picower Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank V. Seale and F. LeGrand for help with the lineage tracing studies and R. Gupta for discussions. We are grateful to P. Soriano for the Myf5-Cre mice and F. Constantini for the R26R3-YFP reporter mice. P. S. is supported by a fellowship from the American Heart Association. S. Kajimura is supported by a fellowship from the Japan Society for the Promotion of Science. S. D. is supported by the Susan Komen Breast Cancer Foundation. This work is funded by the Picower Foundation and a National Institutes of Health grant to B. M. S. and an National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases grant to M. A. R.	Almind K, 2007, P NATL ACAD SCI USA, V104, P2366, DOI 10.1073/pnas.0610416104; Asakura A, 2001, DIFFERENTIATION, V68, P245, DOI 10.1046/j.1432-0436.2001.680412.x; Atit R, 2006, DEV BIOL, V296, P164, DOI 10.1016/j.ydbio.2006.04.449; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Barbera MJ, 2001, J BIOL CHEM, V276, P1486, DOI 10.1074/jbc.M006246200; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Cederberg A, 2001, CELL, V106, P563, DOI 10.1016/S0092-8674(01)00474-3; Christian M, 2005, MOL CELL BIOL, V25, P9383, DOI 10.1128/MCB.25.21.9383-9391.2005; COUSIN B, 1992, J CELL SCI, V103, P931; Dong FY, 2006, DEVELOPMENT, V133, P4891, DOI 10.1242/dev.02693; Drori S, 2005, GENE DEV, V19, P362, DOI 10.1101/gad.1240705; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GARRUTI G, 1992, INT J OBESITY, V16, P383; Gesta S, 2007, CELL, V131, P242, DOI 10.1016/j.cell.2007.10.004; Ghorbani M, 1997, BIOCHEM PHARMACOL, V54, P121, DOI 10.1016/S0006-2952(97)00162-7; Guerra C, 1998, J CLIN INVEST, V102, P412, DOI 10.1172/JCI3155; Hansen JB, 2006, BIOCHEM J, V398, P153, DOI 10.1042/BJ20060402; Hansen JB, 2004, P NATL ACAD SCI USA, V101, P4112, DOI 10.1073/pnas.0301964101; Himms-Hagen J, 2000, AM J PHYSIOL-CELL PH, V279, pC670, DOI 10.1152/ajpcell.2000.279.3.C670; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; Hub MS, 2004, J CELL BIOL, V166, P865, DOI 10.1083/jcb.200403004; HUTTUNEN P, 1981, EUR J APPL PHYSIOL O, V46, P339, DOI 10.1007/BF00422121; Kajimura S, 2008, GENE DEV, V22, P1397, DOI 10.1101/gad.1666108; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; Kuang SH, 2007, CELL, V129, P999, DOI 10.1016/j.cell.2007.03.044; Lin JD, 2002, J BIOL CHEM, V277, P1645, DOI 10.1074/jbc.C100631200; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; Megeney LA, 1996, GENE DEV, V10, P1173, DOI 10.1101/gad.10.10.1173; Mueller E, 2002, J BIOL CHEM, V277, P41925, DOI 10.1074/jbc.M206950200; Nedergaard J, 2007, AM J PHYSIOL-ENDOC M, V293, pE444, DOI 10.1152/ajpendo.00691.2006; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Scime A, 2005, CELL METAB, V2, P283, DOI 10.1016/j.cmet.2005.10.002; Seale P, 2007, CELL METAB, V6, P38, DOI 10.1016/j.cmet.2007.06.001; Shefer G, 2004, J CELL SCI, V117, P5393, DOI 10.1242/jcs.01419; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Tallquist MD, 2000, DEVELOPMENT, V127, P5059; Timmons JA, 2007, P NATL ACAD SCI USA, V104, P4401, DOI 10.1073/pnas.0610615104; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tseng YH, 2004, MOL CELL BIOL, V24, P1918, DOI 10.1128/MCB.24.5.1918-1929.2004; Uldry M, 2006, CELL METAB, V3, P333, DOI 10.1016/j.cmet.2006.04.002; Xue BZ, 2007, J LIPID RES, V48, P41, DOI 10.1194/jlr.M600287-JLR200	44	1616	1747	6	238	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 21	2008	454	7207					961	U27		10.1038/nature07182	http://dx.doi.org/10.1038/nature07182			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339QB	18719582	Green Accepted			2022-12-28	WOS:000258591000031
J	Grimes, DA				Grimes, David A.			The nomogram epidemic: Resurgence of a medical relic	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PROSTATE-CANCER; RECURRENCE; MEN	The obsolete calculators known as nomograms have become epidemic in recent medical literature. The frequency of articles in PubMed retrieved with this search term nearly doubled between 1990 to 1999 and 2000 to 2007. Popular in medicine from about 1925 to 1975, a nomogram is a crude graphical means for solving an equation by placing a straightedge across several scales. Today, most reported nomograms are inconsistent with both established definitions and half a century of clinical use. The need for nomograms disappeared with the advent of personal computing. Instead of constructing nomograms, authors should develop software, such as prediction models, that can either be downloaded to personal digital assistants or be used on the Internet. Modern computing features both accuracy and speed; nomograms offer only the latter.	Family Hlth Int, Res Triangle Pk, NC 27709 USA		Grimes, DA (corresponding author), Family Hlth Int, POB 13950, Res Triangle Pk, NC 27709 USA.	dgrimes@fhi.org			U.S. Agency	U.S. Agency	By Family Health International, with funds from the U. S. Agency for International Development.	ALTMAN DG, 1980, BRIT MED J, V281, P1336, DOI 10.1136/bmj.281.6251.1336; ANDERSON DM, 2003, DORLANDS ILLUSTRATED; DEAN AG, 1991, AM J PREV MED, V7, P178, DOI 10.1016/S0749-3797(18)30936-X; Ellett Marsha L Cirgin, 2005, Clin Nurs Res, V14, P11, DOI 10.1177/1054773804270919; ELLETT ML, 2005, CLIN NURS RES, V14, P28; FAGAN TJ, 1975, NEW ENGL J MED, V293, P257; GANDON F, HIST COMPUTER SCI; Gold JS, 2007, ANN SURG ONCOL, V14, P3159, DOI 10.1245/s10434-007-9542-1; Grobman WA, 2007, OBSTET GYNECOL, V109, P806, DOI 10.1097/01.AOG.0000259312.36053.02; Hankins TL, 1999, ISIS, V90, P50, DOI 10.1086/384241; Kattan MW, 2003, STAT MED, V22, P3515, DOI 10.1002/sim.1574; Kattan MW, 1998, JNCI-J NATL CANCER I, V90, P766, DOI 10.1093/jnci/90.10.766; Lang T., 1997, REPORT STAT MED ANNO, DOI 10.1097/00006205-199705000-00022; Last JM., 2001, DICT EPIDEMIOLOGY, V4th; Mondaini N, 2002, INT J IMPOT RES, V14, P283, DOI 10.1038/sj.ijir.3900887; Nguyen ND, 2007, OSTEOPOROSIS INT, V18, P1109, DOI 10.1007/s00198-007-0362-8; Ota H, 2000, FERTIL STERIL, V74, P313, DOI 10.1016/S0015-0282(00)00638-5; Pugh MB, 2000, STEDMANS MED DICT; Rujiwetpongstorn Jittima, 2007, Archives of Gynecology and Obstetrics, V276, P351, DOI 10.1007/s00404-007-0352-2; Stephenson AJ, 2006, BJU INT, V98, P39, DOI 10.1111/j.1464-410X.2006.06173.x; TUFTE E, NOMOGRAMS; Veerkamp MJ, 2004, CIRCULATION, V109, P2980, DOI 10.1161/01.CIR.0000130646.93255.86; Wikipedia, NOM; DEFINITION NOMOGRAM	24	67	69	2	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 19	2008	149	4					273	275		10.7326/0003-4819-149-4-200808190-00010	http://dx.doi.org/10.7326/0003-4819-149-4-200808190-00010			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	338RQ	18711159				2022-12-28	WOS:000258526700008
J	Loeb, M; Hanna, S; Nicolle, L; Eyles, J; Elliott, S; Rathbone, M; Drebot, M; Neupane, B; Fearon, M; Mahony, J				Loeb, Mark; Hanna, Steven; Nicolle, Lindsay; Eyles, John; Elliott, Susan; Rathbone, Michel; Drebot, Michael; Neupane, Binod; Fearon, Margaret; Mahony, James			Prognosis after west nile virus infection	ANNALS OF INTERNAL MEDICINE			English	Article							FATIGUE SEVERITY SCALE; PSYCHOMETRIC PROPERTIES; UNITED-STATES; FOLLOW-UP; NEW-YORK; DEPRESSION; ENCEPHALITIS; EPIDEMIC; OUTCOMES; FEVER	Background: The long-term prognosis of patients infected with West Nile virus is not well understood. Objective: To describe the patterns of physical and mental function after infection with West Nile virus and to determine factors associated with recovery. Design: Longitudinal cohort study. Setting: Data were collected during home visits and from ambulatory clinics in 4 Canadian provinces. Participants: 156 persons with West Nile virus infection. Measurements: Scores on the Physical Component Summary and Mental Component Summary of the Short Form-36, Depression Anxiety Stress Scale, and Fatigue Severity Scale. Results: Physical and mental function, as well as mood and fatigue, seemed to return to normal within 1 year of symptom onset. Participants with neuroinvasive disease took slightly longer to recover. Maximum predicted recovery or rate of recovery in any domain did not differ between participants with meningoencephalitis and those with encephalitis. Lack of preexisting comorbid conditions was associated with faster recovery of physical function, whereas lack of comorbid conditions and male sex were associated with faster recovery of mental function. Limitations: The analysis excluded 7 patients who died shortly after diagnosis, so the study's estimates of prognosis may be over-optimistic. The authors did not formally assess neuropsychological difficulties. The estimates of recovery are relative to the U. S. population, not to participants' function levels before West Nile virus infection. Conclusion: Physical and mental outcome measures seem to normalize within approximately 1 year in patients with West Nile virus. The presence of preexisting comorbid conditions is associated with longer recovery.	[Loeb, Mark] McMaster Univ, Hamilton, ON L8N 3Z5, Canada	McMaster University	Loeb, M (corresponding author), McMaster Univ, MDCL 3200,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	loebm@mcmaster.ca		Hanna, Steven/0000-0003-3120-9600	Canadian Institutes of Health Research [69010]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	Funded by the Canadian Institutes of Health Research (grant no. 69010).	[Anonymous], 1988, NONLINEAR REGRESSION, DOI DOI 10.1002/9780470316757; Beaty BJ, 1989, DIAGNOSTIC PROCEDURE, P797; Berner YN, 2002, J AM GERIATR SOC, V50, P1844, DOI 10.1046/j.1532-5415.2002.505402.x; Brown TA, 1997, BEHAV RES THER, V35, P79, DOI 10.1016/S0005-7967(96)00068-X; Carson PJ, 2006, CLIN INFECT DIS, V43, P723, DOI 10.1086/506939; Crawford JR, 2003, BRIT J CLIN PSYCHOL, V42, P111, DOI 10.1348/014466503321903544; Gottfried K, 2005, SOUTH MED J, V98, P603, DOI 10.1097/01.SMJ.0000155633.43244.AC; Haaland KY, 2006, EMERG INFECT DIS, V12, P1260, DOI 10.3201/eid1708.060097; Hayes EB, 2006, ANNU REV MED, V57, P181, DOI 10.1146/annurev.med.57.121304.131418; Hayes EB, 2006, PEDIATR INFECT DIS J, V25, P1065, DOI 10.1097/01.inf.0000243324.14658.58; Klee AL, 2004, EMERG INFECT DIS, V10, P1405, DOI 10.3201/eid1008.030879; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Lerdal A, 2005, SCAND J PUBLIC HEALT, V33, P123, DOI 10.1080/14034940410028406; Martin DA, 2002, CLIN DIAGN LAB IMMUN, V9, P544, DOI 10.1128/CDLI.9.3.544-549.2002; Mostashari F, 2001, LANCET, V358, P261, DOI 10.1016/S0140-6736(01)05480-0; Murray KO, 2007, EMERG INFECT DIS, V13, P479, DOI 10.3201/eid1303.060602; Nash D, 2001, NEW ENGL J MED, V344, P1807, DOI 10.1056/NEJM200106143442401; Ou Alan C, 2005, J La State Med Soc, V157, P42; Patnaik JL, 2006, EMERG INFECT DIS, V12, P1129, DOI 10.3201/eid1207.051399; Pinheiro J, 2001, MIXED EFFECTS MODELS; Sejvar JJ, 2006, EMERG INFECT DIS, V12, P514, DOI 10.3201/eid1203.050643; Sejvar JJ, 2003, JAMA-J AM MED ASSOC, V290, P511, DOI 10.1001/jama.290.4.511; Voelker R, 2008, JAMA-J AM MED ASSOC, V299, P2135, DOI 10.1001/jama.299.18.2135; Ware J., 2001, SF 36 PHYS MENTAL HL, P1994; Ware JE, 1993, SF36 HLTH SURVEY MAN; Watson JT, 2004, ANN INTERN MED, V141, P360, DOI 10.7326/0003-4819-141-5-200409070-00010	26	41	41	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 19	2008	149	4					232	+		10.7326/0003-4819-149-4-200808190-00004	http://dx.doi.org/10.7326/0003-4819-149-4-200808190-00004			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	338RQ	18711153				2022-12-28	WOS:000258526700002
J	Bita, I; Yang, JKW; Jung, YS; Ross, CA; Thomas, EL; Berggren, KK				Bita, Ion; Yang, Joel K. W.; Jung, Yeon Sik; Ross, Caroline A.; Thomas, Edwin L.; Berggren, Karl K.			Graphoepitaxy of self-assembled block copolymers on two-dimensional periodic patterned templates	SCIENCE			English	Article							THIN-FILMS; DIBLOCK COPOLYMERS; MONOLAYER FILMS; LITHOGRAPHY; POLYMERS; DOMAINS; ARRAYS; ENERGY	Self- assembling materials are the building blocks of bottom- up nanofabrication processes, but they need to be templated to impose long- range order and eliminate defects. In this work, the self- assembly of a thin film of a spherical- morphology block copolymer is templated using an array of nanoscale topographical elements that act as surrogates for the minority domains of the block copolymer. The orientation and periodicity of the resulting array of spherical microdomains are governed by the commensurability between the block copolymer period and the template period and is accurately described by a free- energy model. This method, which forms high- spatial-frequency arrays using a lower- spatial- frequency template, will be useful in nanolithography applications such as the formation of high- density microelectronic structures.	[Bita, Ion; Jung, Yeon Sik; Ross, Caroline A.; Thomas, Edwin L.] MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA; [Yang, Joel K. W.; Berggren, Karl K.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Ross, CA (corresponding author), MIT, Dept Mat Sci & Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	caross@mit.edu; elt@mit.edu; berggren@mit.edu	JUNG, YEON SIK/C-1798-2011; Tuluc, Petronel/C-2527-2011; Yang, Joel K.W./L-7892-2016	JUNG, YEON SIK/0000-0002-7709-8347; Yang, Joel K.W./0000-0003-3301-1040; Thomas, Edwin/0000-0001-5911-6524				BAIN CD, 1989, J AM CHEM SOC, V111, P321, DOI 10.1021/ja00183a049; Cheng JY, 2002, APPL PHYS LETT, V81, P3657, DOI 10.1063/1.1519356; Cheng JY, 2001, ADV MATER, V13, P1174, DOI 10.1002/1521-4095(200108)13:15<1174::AID-ADMA1174>3.0.CO;2-Q; Cheng JY, 2004, NAT MATER, V3, P823, DOI 10.1038/nmat1211; CHENG JY, 2008, ADV MAT         0707; DABBOUSI BO, 1994, CHEM MATER, V6, P216, DOI 10.1021/cm00038a020; Darling SB, 2007, PROG POLYM SCI, V32, P1152, DOI 10.1016/j.progpolymsci.2007.05.004; DEGENNES PG, 1980, MACROMOLECULES, V13, P1069, DOI 10.1021/ma60077a009; Edwards EW, 2004, ADV MATER, V16, P1315, DOI 10.1002/adma.200400763; Fasolka MJ, 2001, ANN REV MATER RES, V31, P323, DOI 10.1146/annurev.matsci.31.1.323; HELFAND E, 1975, ACCOUNTS CHEM RES, V8, P295, DOI 10.1021/ar50093a002; Jung YS, 2007, NANO LETT, V7, P2046, DOI 10.1021/nl070924l; Kellogg GJ, 1996, PHYS REV LETT, V76, P2503, DOI 10.1103/PhysRevLett.76.2503; Kim SO, 2003, NATURE, V424, P411, DOI 10.1038/nature01775; KINNING DJ, 1984, MACROMOLECULES, V17, P1712, DOI 10.1021/ma00139a013; Lammertink RGH, 2000, ADV MATER, V12, P98, DOI 10.1002/(SICI)1521-4095(200001)12:2<98::AID-ADMA98>3.0.CO;2-5; MANSKY P, 1995, J MATER SCI, V30, P1987, DOI 10.1007/BF00353023; Park C, 2003, POLYMER, V44, P6725, DOI 10.1016/j.polymer.2003.08.011; Park M, 1997, SCIENCE, V276, P1401, DOI 10.1126/science.276.5317.1401; Rockford L, 1999, PHYS REV LETT, V82, P2602, DOI 10.1103/PhysRevLett.82.2602; Ruiz R, 2008, SCIENCE, V321, P936, DOI 10.1126/science.1157626; Segalman RA, 2005, MAT SCI ENG R, V48, P191, DOI 10.1016/j.mser.2004.12.003; Segalman RA, 2001, ADV MATER, V13, P1152, DOI 10.1002/1521-4095(200108)13:15<1152::AID-ADMA1152>3.0.CO;2-5; Stoykovich MP, 2005, SCIENCE, V308, P1442, DOI 10.1126/science.1111041; Thurn-Albrecht T, 2000, SCIENCE, V290, P2126, DOI 10.1126/science.290.5499.2126; Yang JKW, 2007, J VAC SCI TECHNOL B, V25, P2025, DOI 10.1116/1.2801881	26	708	726	9	335	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 15	2008	321	5891					939	943		10.1126/science.1159352	http://dx.doi.org/10.1126/science.1159352			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	337LD	18703736				2022-12-28	WOS:000258436700032
J	Segalman, RA				Segalman, Rachel A.			Materials science - Directing self-assembly toward perfection	SCIENCE			English	Editorial Material							BLOCK-COPOLYMER LITHOGRAPHY		[Segalman, Rachel A.] Univ Calif Berkeley, Dept Chem Engn, Berkeley, CA 94720 USA; [Segalman, Rachel A.] Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Segalman, RA (corresponding author), Univ Calif Berkeley, Dept Chem Engn, Berkeley, CA 94720 USA.	segalman@berkeley.edu						Angelescu DE, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.025702; [Anonymous], 2007, INT TECHNOLOGY ROADM; BATES FS, 1990, ANNU REV PHYS CHEM, V41, P525, DOI 10.1146/annurev.pc.41.100190.002521; Bita I, 2008, SCIENCE, V321, P939, DOI 10.1126/science.1159352; Cheng JY, 2002, APPL PHYS LETT, V81, P3657, DOI 10.1063/1.1519356; Kim SO, 2003, NATURE, V424, P411, DOI 10.1038/nature01775; Park M, 1997, SCIENCE, V276, P1401, DOI 10.1126/science.276.5317.1401; Rockford L, 1999, PHYS REV LETT, V82, P2602, DOI 10.1103/PhysRevLett.82.2602; Ruiz R, 2008, SCIENCE, V321, P936, DOI 10.1126/science.1157626; Segalman RA, 2005, MAT SCI ENG R, V48, P191, DOI 10.1016/j.mser.2004.12.003; Segalman RA, 2001, ADV MATER, V13, P1152, DOI 10.1002/1521-4095(200108)13:15<1152::AID-ADMA1152>3.0.CO;2-5; Stoykovich MP, 2005, SCIENCE, V308, P1442, DOI 10.1126/science.1111041	12	47	47	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2008	321	5891					919	920		10.1126/science.1162907	http://dx.doi.org/10.1126/science.1162907			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	337LD	18703729				2022-12-28	WOS:000258436700023
J	Altschuler, SJ; Angenent, SB; Wang, YQ; Wu, LF				Altschuler, Steven J.; Angenent, Sigurd B.; Wang, Yanqin; Wu, Lani F.			On the spontaneous emergence of cell polarity	NATURE			English	Article							EXCHANGE FACTOR CDC24P; POSITIVE FEEDBACK; SYMMETRY-BREAKING; PLASMA-MEMBRANE; POLARIZATION; GTPASE; CDC42P; PROTEINS; SYSTEM; MODEL	Diverse cell polarity networks require positive feedback for locally amplifying distributions of signalling molecules at the plasma membrane(1). Additional mechanisms, such as directed transport(2) or coupled inhibitors(3,4), have been proposed to be required for reinforcing a unique axis of polarity. Here we analyse a simple model of positive feedback, with strong analogy to the 'stepping stone' model of population genetics(5), in which a single species of diffusible, membrane-bound signalling molecules can self-recruit from a cytoplasmic pool. We identify an intrinsic stochastic mechanism through which positive feedback alone is sufficient to account for the spontaneous establishment of a single site of polarity. We find that the polarization frequency has an inverse dependence on the number of signalling molecules: the frequency of polarization decreases as the number of molecules becomes large. Experimental observation of polarizing Cdc42 in budding yeast is consistent with this prediction. Our work suggests that positive feedback can work alone or with additional mechanisms to create robust cell polarity.	[Altschuler, Steven J.; Wang, Yanqin; Wu, Lani F.] Univ Texas SW Med Ctr Dallas, Green Ctr Syst Biol, Dept Pharmacol, Dallas, TX 75390 USA; [Altschuler, Steven J.; Wang, Yanqin; Wu, Lani F.] Univ Texas SW Med Ctr Dallas, Simmons Canc Ctr, Dallas, TX 75390 USA; [Angenent, Sigurd B.] Univ Wisconsin, Dept Math, Madison, WI 53706 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Wisconsin System; University of Wisconsin Madison	Altschuler, SJ (corresponding author), Univ Texas SW Med Ctr Dallas, Green Ctr Syst Biol, Dept Pharmacol, Dallas, TX 75390 USA.	steven.altschuler@utsouthwestern.edu; lani.wu@utsouthwestern.edu			NIGMS NIH HHS [R01 GM071794-05, R01 GM071794] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071794] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Bose I, 2001, J BIOL CHEM, V276, P7176, DOI 10.1074/jbc.M010546200; Brandman O, 2005, SCIENCE, V310, P496, DOI 10.1126/science.1113834; Bustelo XR, 2007, BIOESSAYS, V29, P356, DOI 10.1002/bies.20558; Butty AC, 2002, EMBO J, V21, P1565, DOI 10.1093/emboj/21.7.1565; Chisari M, 2007, J BIOL CHEM, V282, P24092, DOI 10.1074/jbc.M704246200; DerMardirossian C, 2005, TRENDS CELL BIOL, V15, P356, DOI 10.1016/j.tcb.2005.05.001; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Ebersbach G, 2007, TRENDS MICROBIOL, V15, P101, DOI 10.1016/j.tim.2007.01.004; Elf J., 2004, Systems Biology, V1, P230, DOI 10.1049/sb:20045021; Fivaz M, 2008, CURR BIOL, V18, P44, DOI 10.1016/j.cub.2007.11.051; Gassama-Diagne A, 2006, NAT CELL BIOL, V8, P963, DOI 10.1038/ncb1461; GIERER A, 1972, KYBERNETIK, V12, P30, DOI 10.1007/BF00289234; Irazoqui JE, 2003, NAT CELL BIOL, V5, P1062, DOI 10.1038/ncb1068; KIMURA M, 1964, GENETICS, V49, P561; Kozlov MM, 2007, BIOPHYS J, V93, P3811, DOI 10.1529/biophysj.107.110411; Krishnan J, 2007, BIOPHYS J, V92, P816, DOI 10.1529/biophysj.106.087353; Levin SA., 1979, PATTERN FORMATION DY, P210; Marco E, 2007, CELL, V129, P411, DOI 10.1016/j.cell.2007.02.043; Ozbudak EM, 2005, DEV CELL, V9, P565, DOI 10.1016/j.devcel.2005.08.014; Qian H, 2002, P NATL ACAD SCI USA, V99, P10376, DOI 10.1073/pnas.152007599; Samoilov MS., 2006, NAT REV GENET, V2006, pr, DOI [DOI 10.1126/STKE.3662006RE17, 10.1126/stke.3662006re17]; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Shimada Y, 2004, EMBO J, V23, P1051, DOI 10.1038/sj.emboj.7600124; Sohrmann M, 2003, TRENDS CELL BIOL, V13, P526, DOI 10.1016/j.tcb.2003.08.006; Suel GM, 2007, SCIENCE, V315, P1716, DOI 10.1126/science.1137455; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; Wedlich-Soldner R, 2003, SCIENCE, V299, P1231, DOI 10.1126/science.1080944; Wedlich-Soldner R, 2004, J CELL BIOL, V166, P889, DOI 10.1083/jcb.200405061; Weiner OD, 2002, NAT CELL BIOL, V4, P509, DOI 10.1038/ncb811	30	175	175	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 14	2008	454	7206					886	U41		10.1038/nature07119	http://dx.doi.org/10.1038/nature07119			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	336XH	18704086	Green Accepted			2022-12-28	WOS:000258398600036
J	Vestergaard, M; Pedersen, MG; Ostergaard, JR; Pedersen, CB; Olsen, J; Christensen, J				Vestergaard, Mogens; Pedersen, Marianne Giortz; Ostergaard, John R.; Pedersen, Carsten Bocker; Olsen, Jorn; Christensen, Jakob			Death in children with febrile seizures: a population-based cohort study	LANCET			English	Article							EPILEPSY; CONVULSIONS; MORTALITY; RISK; PROGNOSIS	Background No studies have had sufficient size to estimate mortality in children with febrile seizures. We studied mortality after febrile seizures in a large population-based cohort of children in Denmark with up to 28 years of follow-up. Methods We identified 1675 643 children born in Denmark between Jan 1, 1977, and Dec 31, 2004, by linking information from nationwide registers for civil service, health, and cause of death. Children were followed up from 3 months of age, until death, emigration, or Aug 31, 2005. We estimated overall and cause-specific mortality after first febrile seizures with survival analyses. Furthermore, we undertook a case-control study nested within the cohort and retrieved information from medical records about febrile seizure and neurological abnormalities for children who died (N=8172) and individually-matched controls (N=40 860). Findings We identified 8172 children who died, including 232 deaths in 55 215 children with a history of febrile seizures. The mortality rate ratio was 80% higher during the first year (adjusted mortality rate ratio 1.80 [95% CI 1.31-2.40]) and 90% higher during the second year (1.89 [1.27-2.70]) after the first febrile seizure; thereafter it was close to that noted for the general population. 132 of 100 000 children (95% CI 102-163) died within 2 years of a febrile seizure compared with 67 (57-76) deaths per 100 000 children without a history of this disorder. In the nested case-control study, children with simple (<= 15 min and no recurrence within 24 h) febrile seizure had a mortality rate similar to that of the background population (adjusted mortality rate ratio 1.09 [95% CI 0.72-1.64]), whereas mortality was increased for those with complex (> 15 min or recurrence within 24 h) febrile seizures (1.99 [1.24-3.21]). This finding was partly explained by pre-existing neurological abnormalities and subsequent epilepsy. Interpretation Long-term mortality is not increased in children with febrile seizures, but there seems to be a small excess mortality during the 2 years after complex febrile seizures. Parents should be reassured that death after febrile seizures is very rare, even in high-risk children. Funding The Danish Research Agency, Lennart Gram Memorial Trust (Denmark), P A Messerschmidt and Wife's Foundation (Denmark), Managing Director Kurt Bonnelycke and Mrs Grethe Bonnelyckes Foundation (Denmark).	[Vestergaard, Mogens] Aarhus Univ, Dept Gen Practice, Inst Publ Hlth, DK-8000 Aarhus C, Denmark; [Pedersen, Marianne Giortz; Pedersen, Carsten Bocker] Aarhus Univ, Natl Ctr Register Based Res, DK-8000 Aarhus C, Denmark; [Ostergaard, John R.] Aarhus Univ Hosp, Dept Pediat, DK-8000 Aarhus, Denmark; [Christensen, Jakob] Aarhus Univ Hosp, Dept Neurol, DK-8000 Aarhus, Denmark; [Christensen, Jakob] Aarhus Univ Hosp, Dept Pharmacol, DK-8000 Aarhus, Denmark; [Olsen, Jorn] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA	Aarhus University; Aarhus University; Aarhus University; Aarhus University; Aarhus University; University of California System; University of California Los Angeles	Vestergaard, M (corresponding author), Aarhus Univ, Dept Gen Practice, Inst Publ Hlth, Vennelyst Blvd 6, DK-8000 Aarhus C, Denmark.	mogens.vestergaard@alm.au.dk	Pedersen, Carsten Bøcker/B-8441-2013; Vestergaard, Mogens/M-9333-2014; Olsen, Jørn/F-8801-2015	Pedersen, Carsten Bøcker/0000-0003-2077-8533; Vestergaard, Mogens/0000-0001-8830-2174; Olsen, Jørn/0000-0001-7462-5140; Christensen, Jakob/0000-0002-9385-6435				Andersen P. K., 2012, STAT MODELS BASED CO; Andersen TF, 1999, DAN MED BULL, V46, P263; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; BALSLEV T, 1991, ACTA PAEDIATR SCAND, V80, P466, DOI 10.1111/j.1651-2227.1991.tb11883.x; BAUMER JH, 1981, DEV MED CHILD NEUROL, V23, P462; BERG AT, 1992, NEW ENGL J MED, V327, P1122, DOI 10.1056/NEJM199210153271603; Breslow N E, 1987, IARC Sci Publ, P1; BRESLOW NE, 1996, STAT APPL, V8, P23; Camfield CS, 2002, LANCET, V359, P1891, DOI 10.1016/S0140-6736(02)08779-2; Camfield Peter, 2005, Semin Pediatr Neurol, V12, P10, DOI 10.1016/j.spen.2004.11.005; COCKERELL OC, 1994, LANCET, V344, P918, DOI 10.1016/S0140-6736(94)92270-5; Donner EJ, 2001, NEUROLOGY, V57, P430, DOI 10.1212/WNL.57.3.430; EKHOLM E, 1950, ACTA PAEDIATR, V39, P481, DOI 10.1111/j.1651-2227.1950.tb08545.x; FORSGREN L, 1990, ACTA PAEDIATR SCAND, V79, P550, DOI 10.1111/j.1651-2227.1990.tb11510.x; HAUSER WA, 1980, EPILEPSIA, V21, P399, DOI 10.1111/j.1528-1157.1980.tb04088.x; Hills, 1993, STAT MODELS EPIDEMIO; Juel K, 1999, DAN MED BULL, V46, P354; Kinney HC, 2007, PEDIATR DEVEL PATHOL, V10, P208, DOI 10.2350/06-08-0144.1; Knudsen LB, 1998, DAN MED BULL, V45, P320; NELSON KB, 1978, PEDIATRICS, V61, P720; *NIH, 1981, EPILEPSIA, V22, P377; Nilsson L, 1999, LANCET, V353, P888, DOI 10.1016/S0140-6736(98)05114-9; Pedersen CB, 2006, DAN MED BULL, V53, P441; PIERCE DA, 1993, RADIAT RES, V134, P134, DOI 10.2307/3578452; Rosthoj S, 2004, COMPUT METH PROG BIO, V74, P69, DOI 10.1016/S0169-2607(03)00069-5; Rothman K., 1998, MODERN EPIDEMIOLOGY; SENANAYAKE N, 1995, SEIZURE, V4, P273, DOI 10.1016/S1059-1311(95)80004-2; Shinnar S, 2001, EPILEPSIA, V42, P47, DOI 10.1046/j.1528-1157.2001.10000.x; Shinnar S, 1999, PEDIAT NEUROLOGY PRI, P676; Sillanpaa M, 1998, NEW ENGL J MED, V338, P1715, DOI 10.1056/NEJM199806113382402; SUNDERLAND R, 1981, LANCET, V2, P176; van Stuijvenberg M, 1999, ACTA PAEDIATR, V88, P618, DOI 10.1080/08035259950169260; VERITY CM, 1991, BMJ-BRIT MED J, V303, P1373, DOI 10.1136/bmj.303.6814.1373; Vestergaard M, 2006, J CLIN EPIDEMIOL, V59, P61, DOI 10.1016/j.jclinepi.2005.05.008; Vestergaard M, 2002, ARCH DIS CHILD, V86, P125, DOI 10.1136/adc.86.2.125; Vestergaard M, 2007, AM J EPIDEMIOL, V165, P911, DOI 10.1093/aje/kwk086	36	45	47	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 9	2008	372	9637					457	463		10.1016/S0140-6736(08)61198-8	http://dx.doi.org/10.1016/S0140-6736(08)61198-8			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	335OD	18692714				2022-12-28	WOS:000258299000029
J	Boxem, M; Maliga, Z; Klitgord, N; Li, N; Lemmens, I; Mana, M; de Lichtervelde, L; Mul, JD; van de Peut, D; Devos, M; Simonis, N; Yildirim, MA; Cokol, M; Kao, HL; de Smet, AS; Wang, HD; Schlaitz, AL; Hao, T; Milstein, S; Fan, CY; Tipsword, M; Drew, K; Galli, M; Rhrissorrakrai, K; Drechsel, D; Koller, D; Roth, FP; Iakoucheva, LM; Dunker, AK; Bonneau, R; Gunsalus, KC; Hill, DE; Piano, F; Tavernier, J; van den Heuvel, S; Hyman, AA; Vidal, M				Boxem, Mike; Maliga, Zoltan; Klitgord, Niels; Li, Na; Lemmens, Irma; Mana, Miyeko; de Lichtervelde, Lorenzo; Mul, Joram D.; van de Peut, Diederik; Devos, Maxime; Simonis, Nicolas; Yildirim, Muhammed A.; Cokol, Murat; Kao, Huey-Ling; de Smet, Anne-Sophie; Wang, Haidong; Schlaitz, Anne-Lore; Hao, Tong; Milstein, Stuart; Fan, Changyu; Tipsword, Mike; Drew, Kevin; Galli, Matilde; Rhrissorrakrai, Kahn; Drechsel, David; Koller, Daphne; Roth, Frederick P.; Iakoucheva, Lilia M.; Dunker, A. Keith; Bonneau, Richard; Gunsalus, Kristin C.; Hill, David E.; Piano, Fabio; Tavernier, Jan; van den Heuvel, Sander; Hyman, Anthony A.; Vidal, Marc			A protein domain-based interactome network for C-elegans early embryogenesis	CELL			English	Article							NUCLEAR-PORE COMPLEX; CENTROSOME MATURATION; INTERACTION MAP; GENOME; RESOURCE; IDENTIFICATION; ARCHITECTURE; CENTRIOLAR; REQUIRE; MODELS	Many protein-protein interactions are mediated through independently folding modular domains. Proteome-wide efforts to model protein-protein interaction or "interactome'' networks have largely ignored this modular organization of proteins. We developed an experimental strategy to efficiently identify interaction domains and generated a domain-based interactome network for proteins involved in C. elegans early-embryonic cell divisions. Minimal interacting regions were identified for over 200 proteins, providing important information on their domain organization. Furthermore, our approach increased the sensitivity of the two-hybrid system, resulting in amore complete interactome network. This interactome modeling strategy revealed insights into C. elegans centrosome function and is applicable to other biological processes in this and other organisms.	[Boxem, Mike; Klitgord, Niels; Li, Na; de Lichtervelde, Lorenzo; Mul, Joram D.; van de Peut, Diederik; Devos, Maxime; Simonis, Nicolas; Yildirim, Muhammed A.; Hao, Tong; Milstein, Stuart; Fan, Changyu; Hill, David E.; Vidal, Marc] Harvard Univ, Sch Med, CCSB, Boston, MA 02115 USA; [Boxem, Mike; Klitgord, Niels; Li, Na; de Lichtervelde, Lorenzo; Mul, Joram D.; van de Peut, Diederik; Devos, Maxime; Simonis, Nicolas; Yildirim, Muhammed A.; Hao, Tong; Milstein, Stuart; Fan, Changyu; Hill, David E.; Vidal, Marc] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Boxem, Mike; Klitgord, Niels; Li, Na; de Lichtervelde, Lorenzo; Mul, Joram D.; van de Peut, Diederik; Devos, Maxime; Simonis, Nicolas; Yildirim, Muhammed A.; Hao, Tong; Milstein, Stuart; Fan, Changyu; Hill, David E.; Vidal, Marc] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; [Boxem, Mike] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; [Maliga, Zoltan; de Smet, Anne-Sophie; Tipsword, Mike; Drechsel, David; Hyman, Anthony A.] Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; [Lemmens, Irma; de Smet, Anne-Sophie; Tavernier, Jan] Univ Ghent VIB, Dept Med Prot Res, B-9000 Ghent, Belgium; [Lemmens, Irma; de Smet, Anne-Sophie; Tavernier, Jan] Univ Ghent, Fac Med & Hlth Sci, Dept Biochem, B-9000 Ghent, Belgium; [Cokol, Murat; Roth, Frederick P.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Mana, Miyeko; Kao, Huey-Ling; Drew, Kevin; Rhrissorrakrai, Kahn; Bonneau, Richard; Gunsalus, Kristin C.; Piano, Fabio] NYU, Ctr Genom & Syst Biol, Dept Biol, New York, NY 10003 USA; [Wang, Haidong; Koller, Daphne] Stanford Univ, Dept Comp Sci, Stanford, CA 94305 USA; [Galli, Matilde; van den Heuvel, Sander] Univ Utrecht, Fac Sci, Div Dev Biol, NL-3584 CH Utrecht, Netherlands; [Iakoucheva, Lilia M.] Rockefeller Univ, Lab Stat Genet, New York, NY 10065 USA; [Dunker, A. Keith] Indiana Univ, Sch Med & Informat, Ctr Computat Biol & Bioinformat, Indianapolis, IN 46202 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Max Planck Society; Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University; Harvard University; Harvard Medical School; New York University; Stanford University; Utrecht University; Rockefeller University; Indiana University System; Indiana University-Purdue University Indianapolis	Boxem, M (corresponding author), Harvard Univ, Sch Med, CCSB, Boston, MA 02115 USA.	mboxem@partners.org; hyman@mpi-cbg.de; marc_vidal@dfci.harvard.edu	Bonneau, Richard/ABD-6737-2021; Klitgord, Niels/B-5121-2009; Tavernier, Jan/AAG-3636-2019; Boxem, Mike/B-8857-2011; Simonis, Nicolas/E-5124-2010; Bonneau, Richard/GZL-2900-2022; Hyman, Tony/F-1923-2011; Hill, David E/B-6617-2011; Hyman, Anthony A/B-3917-2017; Yildirim, Muhammed/J-3695-2014; van den Heuvel, Sander J.L./B-8892-2011; Roth, Frederick P/H-6308-2011; Mul, Joram/C-3125-2011	Hyman, Anthony A/0000-0003-3664-154X; Yildirim, Muhammed/0000-0003-2826-1766; van den Heuvel, Sander J.L./0000-0001-9015-7463; Roth, Frederick/0000-0002-6628-649X; Drew, Kevin/0000-0002-1260-4413; Galli, Matilde/0000-0002-2861-7032; Iakoucheva, Lilia/0000-0002-4542-5219; Mana, Miyeko/0000-0002-5516-4008; Mul, Joram/0000-0003-0453-2568	Leukemia Research Foundation; W. M. Keck foundation; National Institutes of Health [R21RR023114, R01HG001715, R33CA105405, R33CA81658, R21CA113711, U54 CA011295, CA95281]; United States Army Medical Research Acquisition Activity [W23RYX-3275-N605]; New York State Foundation of Science, Technology; Academic Research [C040066]; National Science Foundation [MCB 0444818, BDI-0345474, IUAP-P6:28, UG-GOA12051401, FWO-G.0031.06]; NATIONAL CANCER INSTITUTE [R33CA081658, R33CA105405, P01CA095281, U54CA112952, R21CA113711] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R21RR023114] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001715] Funding Source: NIH RePORTER	Leukemia Research Foundation; W. M. Keck foundation(W.M. Keck Foundation); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); United States Army Medical Research Acquisition Activity; New York State Foundation of Science, Technology; Academic Research; National Science Foundation(National Science Foundation (NSF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We are grateful to X. Xin and C. Boone for sharing of the cDNA library and yeast strains, to Joe Hargitai for unparalleled parallel computing support, to IBM's World Community Grid (http://www.wcgrid.org), and to M. Cusick for critical reading of the manuscript. Support was provided by the Leukemia Research Foundation to M. B., the W. M. Keck foundation to M. V., the FWO-V to I.L., National Institutes of Health grants R21RR023114 (M.B. P.I.), R01HG001715 ( M.V. P.I.), R33CA105405 (M.V. P.I.), R33CA81658 (M.V. P.I.), R21CA113711 (L.M.I. P.I.), U54 CA011295 (J. Nevins, PI; M.V. subcontract), and CA95281 (S.v.d.H.), United States Army Medical Research Acquisition Activity grant W23RYX-3275-N605 (K.C.G.), New York State Foundation of Science, Technology, and Academic Research grant C040066 (K.C.G.), National Science Foundation grants MCB 0444818 to L. M. I. and BDI-0345474 to D. K. and grants IUAP-P6:28, UG-GOA12051401, and FWO-G.0031.06 to J. T. M. V. is a "Chercheur Qualifie Honoraire'' from the Fonds de la Recherche Scientifique (FRS-FNRS, French Community of Belgium).	Alber F, 2007, NATURE, V450, P695, DOI 10.1038/nature06405; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Bornberg-Bauer E, 2005, CELL MOL LIFE SCI, V62, P435, DOI 10.1007/s00018-004-4416-1; Chivian D, 2003, PROTEINS, V53, P524, DOI 10.1002/prot.10529; Dammermann A, 2004, DEV CELL, V7, P815, DOI 10.1016/j.devcel.2004.10.015; Dammermann A, 2008, J CELL BIOL, V180, P771, DOI 10.1083/jcb.200709102; Davey NE, 2006, NUCLEIC ACIDS RES, V34, P3546, DOI 10.1093/nar/gkl486; Delattre M, 2006, CURR BIOL, V16, P1844, DOI 10.1016/j.cub.2006.07.059; Eyckerman S, 2001, NAT CELL BIOL, V3, P1114, DOI 10.1038/ncb1201-1114; Formstecher E, 2005, GENOME RES, V15, P376, DOI 10.1101/gr.2659105; Fromont-Racine M, 2002, METHOD ENZYMOL, V350, P513, DOI 10.1016/S0076-6879(02)50982-4; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Fuxreiter M, 2007, BIOINFORMATICS, V23, P950, DOI 10.1093/bioinformatics/btm035; Galy V, 2003, MOL BIOL CELL, V14, P5104, DOI 10.1091/mbc.E03-04-0237; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Gough J, 2001, J MOL BIOL, V313, P903, DOI 10.1006/jmbi.2001.5080; Green RA, 2008, METHOD CELL BIOL, V85, P179, DOI 10.1016/S0091-679X(08)85009-1; Guglielmi B, 2004, NUCLEIC ACIDS RES, V32, P5379, DOI 10.1093/nar/gkh878; Gunsalus KC, 2005, NATURE, V436, P861, DOI 10.1038/nature03876; Hamill DR, 2002, DEV CELL, V3, P673, DOI 10.1016/S1534-5807(02)00327-1; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Kemp CA, 2004, DEV CELL, V6, P511, DOI 10.1016/S1534-5807(04)00066-8; Krogan NJ, 2006, NATURE, V440, P637, DOI 10.1038/nature04670; LaCount DJ, 2005, NATURE, V438, P103, DOI 10.1038/nature04104; Li, 1999, Genome Inform Ser Workshop Genome Inform, V10, P30; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Lim RYH, 2006, CURR OPIN CELL BIOL, V18, P342, DOI 10.1016/j.ceb.2006.03.006; Liu JF, 2004, PROTEINS, V55, P678, DOI 10.1002/prot.20095; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Matthews LR, 2001, GENOME RES, V11, P2120, DOI 10.1101/gr.205301; Mohan A, 2006, J MOL BIOL, V362, P1043, DOI 10.1016/j.jmb.2006.07.087; Obradovic Z, 2005, PROTEINS, V61, P176, DOI 10.1002/prot.20735; Oegema Karen, 2006, WormBook, P1, DOI 10.1895/wormbook.1.72.1; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Pelletier L, 2006, NATURE, V444, P619, DOI 10.1038/nature05318; Peng K, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-208; Piano F, 2002, CURR BIOL, V12, P1959, DOI 10.1016/S0960-9822(02)01301-5; Praitis V, 2001, GENETICS, V157, P1217; Puntervoll P, 2003, NUCLEIC ACIDS RES, V31, P3625, DOI 10.1093/nar/gkg545; Reboul J, 2003, NAT GENET, V34, P35, DOI 10.1038/ng1140; Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Schlaitz AL, 2007, CELL, V128, P115, DOI 10.1016/j.cell.2006.10.050; Schwartz TU, 2005, CURR OPIN STRUC BIOL, V15, P221, DOI 10.1016/j.sbi.2005.03.003; Singh BB, 1999, J BIOL CHEM, V274, P37370, DOI 10.1074/jbc.274.52.37370; Sonnichsen B, 2005, NATURE, V434, P462, DOI 10.1038/nature03353; Stelzl U, 2005, CELL, V122, P957, DOI 10.1016/j.cell.2005.08.029; Trifonov EN, 2003, CURR OPIN STRUC BIOL, V13, P110, DOI 10.1016/S0959-440X(03)00005-8; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Vidalain PO, 2004, METHODS, V32, P363, DOI 10.1016/j.ymeth.2003.10.001; Walhout AJM, 1999, GENOME RES, V9, P1128, DOI 10.1101/gr.9.11.1128; Walhout AJM, 2000, SCIENCE, V287, P116, DOI 10.1126/science.287.5450.116; Walhout AJM, 2001, NAT REV MOL CELL BIO, V2, P55, DOI 10.1038/35048107; Walhout AJM, 2001, METHODS, V24, P297, DOI 10.1006/meth.2001.1190; Walhout AJM, 2000, METHOD ENZYMOL, V328, P575, DOI 10.1016/S0076-6879(00)28419-X; Wang HD, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r192; Zipperlen P, 2001, EMBO J, V20, P3984, DOI 10.1093/emboj/20.15.3984	59	156	163	2	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 8	2008	134	3					534	545		10.1016/j.cell.2008.07.009	http://dx.doi.org/10.1016/j.cell.2008.07.009			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SO	18692475	Green Accepted, Bronze			2022-12-28	WOS:000258665500025
J	Marson, A; Levine, SS; Cole, MF; Frampton, GM; Brambrink, T; Johnstone, S; Guenther, MG; Johnston, WK; Wernig, M; Newman, J; Calabrese, JM; Dennis, LM; Volkert, TL; Gupta, S; Love, J; Hannett, N; Sharp, PA; Bartel, DP; Jaenisch, R; Young, RA				Marson, Alexander; Levine, Stuart S.; Cole, Megan F.; Frampton, Garrett M.; Brambrink, Tobias; Johnstone, Sarah; Guenther, Matthew G.; Johnston, Wendy K.; Wernig, Marius; Newman, Jamie; Calabrese, J. Mauro; Dennis, Lucas M.; Volkert, Thomas L.; Gupta, Sumeet; Love, Jennifer; Hannett, Nancy; Sharp, Phillip A.; Bartel, David P.; Jaenisch, Rudolf; Young, Richard A.			Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells	CELL			English	Article							SELF-RENEWAL; DEVELOPMENTAL REGULATORS; EXPRESSION; PLURIPOTENCY; PROMOTERS; NETWORK; DICER; DIFFERENTIATION; BIOGENESIS; SIGNATURE	MicroRNAs (miRNAs) are crucial for normal embryonic stem (ES) cell self-renewal and cellular differentiation, but how miRNA gene expression is controlled by the key transcriptional regulators of ES cells has not been established. We describe here the transcriptional regulatory circuitry of ES cells that incorporates protein-coding and miRNA genes based on high-resolution ChIP-seq data, systematic identification of miRNA promoters, and quantitative sequencing of short transcripts in multiple cell types. We find that the key ES cell transcription factors are associated with promoters for miRNAs that are preferentially expressed in ES cells and with promoters for a set of silent miRNA genes. This silent set of miRNA genes is co-occupied by Polycomb group proteins in ES cells and shows tissue-specific expression in differentiated cells. These data reveal how key ES cell transcription factors promote the ES cell miRNA expression program and integrate miRNAs into the regulatory circuitry controlling ES cell identity.	[Marson, Alexander; Levine, Stuart S.; Cole, Megan F.; Frampton, Garrett M.; Brambrink, Tobias; Johnstone, Sarah; Guenther, Matthew G.; Johnston, Wendy K.; Wernig, Marius; Newman, Jamie; Dennis, Lucas M.; Volkert, Thomas L.; Gupta, Sumeet; Love, Jennifer; Hannett, Nancy; Bartel, David P.; Jaenisch, Rudolf; Young, Richard A.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Marson, Alexander; Cole, Megan F.; Frampton, Garrett M.; Johnstone, Sarah; Newman, Jamie; Calabrese, J. Mauro; Dennis, Lucas M.; Sharp, Phillip A.; Bartel, David P.; Jaenisch, Rudolf; Young, Richard A.] MIT, Dept Biol, Cambridge, MA 02139 USA; [Johnstone, Sarah; Bartel, David P.] MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; [Calabrese, J. Mauro; Sharp, Phillip A.] MIT, Koch Inst, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Young, RA (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	young@wi.mit.edu	Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Frampton, Garrett/0000-0002-2361-2750; Levine, Stuart/0000-0001-7363-562X	NIH [5-RO1-HDO45022, 5-R37-CA084198, 5-RO1-CA087869, HG002668]; Whitehead Institute; Cancer Center Support (Core); NCI [P30-CA14051]; NATIONAL CANCER INSTITUTE [R37CA084198, P30CA014051, R01CA087869] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002668] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067031] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Whitehead Institute; Cancer Center Support (Core); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank members of the Young, Jaenisch, and Bartel laboratories, especially T. Lee, for discussions and critical review of the manuscript. We also thank A. Ravi and A. Seila for their help and A. Smith for providing the ZHBTc4 cells. We are grateful to L. A. Boyer, B. Chevalier, R. Kumar, and T. Lee who were instrumental in performing location analysis in hES cells. We also thank Biology and Research Computing (BaRC), especially Tom DiCesare, for computational and technical support and graphic assistance. This work was supported in part by NIH grants 5-RO1-HDO45022, 5-R37-CA084198, and 5-RO1-CA087869 to R.J. and by NIH grant HG002668 and a grant from the Whitehead Institute to R.A.Y and partially by a Cancer Center Support (Core) grant P30-CA14051 from the NCI. R.A.Y. consults for Agilent Technologies.	Alon U, 2007, NAT REV GENET, V8, P450, DOI 10.1038/nrg2102; Barrera LO, 2008, GENOME RES, V18, P46, DOI 10.1101/gr.6654808; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Choi WY, 2007, SCIENCE, V318, P271, DOI 10.1126/science.1147535; Cole MF, 2008, GENE DEV, V22, P746, DOI 10.1101/gad.1642408; Farh KKH, 2005, SCIENCE, V310, P1817, DOI 10.1126/science.1121158; Fukao T, 2007, CELL, V129, P617, DOI 10.1016/j.cell.2007.02.048; Giraldez AJ, 2006, SCIENCE, V312, P75, DOI 10.1126/science.1122689; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Houbaviy HB, 2005, RNA, V11, P1245, DOI 10.1261/rna.2890305; Houbaviy HB, 2003, DEV CELL, V5, P351, DOI 10.1016/S1534-5807(03)00227-2; Jaenisch R, 2008, CELL, V132, P567, DOI 10.1016/j.cell.2008.01.015; Jiang JM, 2008, NAT CELL BIOL, V10, P353, DOI 10.1038/ncb1698; Johnson DS, 2007, SCIENCE, V316, P1497, DOI 10.1126/science.1141319; Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505; Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Krichevsky AM, 2006, STEM CELLS, V24, P857, DOI 10.1634/stemcells.2005-0441; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Laurent LC, 2008, STEM CELLS, V26, P1506, DOI 10.1634/stemcells.2007-1081; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Mineno J, 2006, NUCLEIC ACIDS RES, V34, P1765, DOI 10.1093/nar/gkl096; Morin RD, 2008, GENOME RES, V18, P610, DOI 10.1101/gr.7179508; Murchison EP, 2005, P NATL ACAD SCI USA, V102, P12135, DOI 10.1073/pnas.0505479102; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 2007, DEVELOPMENT, V134, P635, DOI 10.1242/dev.02787; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Robertson G, 2007, NAT METHODS, V4, P651, DOI 10.1038/NMETH1068; Sinkkonen L, 2008, NAT STRUCT MOL BIOL, V15, P259, DOI 10.1038/nsmb.1391; Stefani G, 2008, NAT REV MOL CELL BIO, V9, P219, DOI 10.1038/nrm2347; Suh MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019; Tam WL, 2008, STEM CELLS, V26, P2019, DOI 10.1634/stemcells.2007-1115; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Wang YM, 2007, NAT GENET, V39, P380, DOI 10.1038/ng1969; Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; YI F, 2008, STEM CELLS; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zhou XF, 2007, PLOS COMPUT BIOL, V3, P412, DOI 10.1371/journal.pcbi.0030037	58	1116	1191	2	119	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 8	2008	134	3					521	533		10.1016/j.cell.2008.07.020	http://dx.doi.org/10.1016/j.cell.2008.07.020			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SO	18692474	Bronze, Green Accepted			2022-12-28	WOS:000258665500024
J	Kerem, E; Hirawat, S; Armoni, S; Yaakov, Y; Shoseyov, D; Cohen, M; Nissim-Rafinia, M; Blau, H; Rivlin, J; Aviram, M; Elfring, GL; Northcutt, VJ; Miller, LL; Kerem, B; Wilschanski, M				Kerem, Eitan; Hirawat, Samit; Armoni, Shoshana; Yaakov, Yasmin; Shoseyov, David; Cohen, Michael; Nissim-Rafinia, Malka; Blau, Hannah; Rivlin, Joseph; Aviram, Micha; Elfring, Gary L.; Northcutt, Valerie J.; Miller, Langdon L.; Kerem, Batsheva; Wilschanski, Michael			Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial	LANCET			English	Article							NASAL POTENTIAL DIFFERENCE; MESSENGER-RNA DECAY; CHLORIDE TRANSPORT; STOP MUTATIONS; GENE-TRANSFER; CFTR FUNCTION; SUPPRESSION; GENTAMICIN; CELLS; MULTICENTER	Background In about 10% of patients worldwide and more than 50% of patients in Israel, cystic fibrosis results from nonsense mutations (premature stop codons) in the messenger RNA (mRNA) for the cystic fibrosis transmembrane conductance regulator (CFTR). PTC124 is an orally bioavailable small molecule that is designed to induce ribosomes to selectively read through premature stop codons during mRNA translation, to produce functional CFTR. Methods This phase II prospective trial recruited adults with cystic fibrosis who had at least one nonsense mutation in the CFTR gene. Patients were assessed in two 28-day cycles. During the first cycle, patients received PTC124 at 16 mg/kg per day in three doses every day for 14 days, followed by 14 days without treatment; in the second cycle, patients received 40 mg/kg of PTC124 in three doses every day for 14 days, followed by 14 days without treatment. The primary outcome had three components: change in CFTR-mediated total chloride transport; proportion of patients who responded to treatment; and normalisation of chloride transport, as assessed by transepithelial nasal potential difference (PD) at baseline, at the end of each 14-day treatment course, and after 14 days without treatment. The trial was registered with who.int/ictrp, and with clinicaltrials.gov, number NCT00237380. Findings Transepithelial nasal PD was evaluated in 23 patients in the first cycle and in 21 patients in the second cycle. Mean total chloride transport increased in the first treatment phase, with a change of -7. 1 (SD 7. 0) mV (p<0.0001), and in the second, with a change of -3.7 (SD 7.3) mV (p=0.032). We recorded a response in total chloride transport (defined as a change in nasal PD of -5 mV or more) in 16 of the 23 patients in the first cycle's treatment phase (p<0. 0001) and in eight of the 21 patients in the second cycle (p<0 . 0001). Total chloride transport entered the normal range for 13 of 23 patients in the first cycle's treatment phase (p=0.0003) and for nine of 21 in the second cycle (p=0 . 02). Two patients given PTC124 had constipation without intestinal obstruction, and four had mild dysuria. No drug-related serious adverse events were recorded. Interpretation In patients with cystic fibrosis who have a premature stop codon in the CFTR gene, oral administration of PTC124 to suppress nonsense mutations reduces the epithelial electrophysiological abnormalities caused by CFTR dysfunction. Funding PTC Therapeutics, Cystic Fibrosis Foundation Therapeutics.	[Kerem, Eitan; Armoni, Shoshana; Yaakov, Yasmin; Shoseyov, David; Cohen, Michael; Wilschanski, Michael] Hadassah Hebrew Univ Hosp, IL-91240 Jerusalem, Israel; [Hirawat, Samit; Elfring, Gary L.; Northcutt, Valerie J.; Miller, Langdon L.] PTC Therapeut, S Plainfield, NJ USA; [Nissim-Rafinia, Malka; Kerem, Batsheva] Hebrew Univ Jerusalem, Dept Genet, Inst Life Sci, IL-91904 Jerusalem, Israel; [Blau, Hannah] Schneider Childrens Hosp, Petah Tiqwa, Israel; [Rivlin, Joseph] Carmel Hosp, Haifa, Israel; [Aviram, Micha] Soroka Med Ctr, IL-84101 Beer Sheva, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Clalit Health Services; Carmel Medical Center; Ben Gurion University; Soroka Medical Center	Kerem, E (corresponding author), Hadassah Hebrew Univ Hosp, Mt Scopus, IL-91240 Jerusalem, Israel.	ek@cc.huji.ac.il			PTC Therapeutics; Cystic Fibrosis Foundation Therapeutics	PTC Therapeutics; Cystic Fibrosis Foundation Therapeutics(Italian Cystic Fibrosis Research Foundation)	This study was sponsored by PTC Therapeutics, and funded in part by a grant from the Cystic Fibrosis Foundation Therapeutics. We thank the patients who committed their time and effort despite the uncertainties of testing a new medication; Martin Sinaasappel for his expert review of the nasal potential difference tracings; Greg Elfring and James Dancy, Innovative Analytics, for their expertise in data management; Frella Kenoshi for capable monitoring of the conduct of this study; Elizabeth Colacino and Allen Reba for data review; and Peter Riebling for support with the submission process.	Bobadilla JL, 2002, HUM MUTAT, V19, P575, DOI 10.1002/humu.10041; Boyle MP, 2003, CHEST, V124, P482, DOI 10.1378/chest.124.2.482; Cancer Therapy Evaluation Program, 2003, COMM TERM CRIT ADV E; Clancy JP, 2001, AM J RESP CRIT CARE, V163, P1683, DOI 10.1164/ajrccm.163.7.2004001; Du M, 2002, J MOL MED, V80, P595, DOI 10.1007/s00109-002-0363-1; Du M, 2008, P NATL ACAD SCI USA, V105, P2064, DOI 10.1073/pnas.0711795105; Fajac I, 2004, THORAX, V59, P971, DOI 10.1136/thx.2003.020933; Graham SM, 2002, AM J RHINOL, V16, P145, DOI 10.1177/194589240201600304; HIGHSMITH WE, 1994, NEW ENGL J MED, V331, P974, DOI 10.1056/NEJM199410133311503; Hirawat S, 2007, J CLIN PHARMACOL, V47, P430, DOI 10.1177/0091270006297140; Isken O, 2007, GENE DEV, V21, P1833, DOI 10.1101/gad.1566807; Jain KK, 2006, CURR OPIN MOL THER, V8, P487; Jepsen M, 2000, AM J RHINOL, V14, P405, DOI 10.2500/105065800779954365; Kerem B, 1997, GENET TEST, V1, P35, DOI 10.1089/gte.1997.1.35; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; KNOWLES MR, 1995, NEW ENGL J MED, V333, P823, DOI 10.1056/NEJM199509283331302; KNOWLES MR, 1995, HUM GENE THER, V6, P445, DOI 10.1089/hum.1995.6.4-445; KNOWLES MR, 1995, AM J RESP CRIT CARE, V151, P65; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; Linde L, 2007, EUR J HUM GENET, V15, P1156, DOI 10.1038/sj.ejhg.5201889; Linde L, 2007, J CLIN INVEST, V117, P683, DOI 10.1172/JCI28523; McKone EF, 2006, CHEST, V130, P1441, DOI 10.1378/chest.130.5.1441; PECKHAM DG, 1995, CLIN SCI, V89, P277, DOI 10.1042/cs0890277; Schuler Daniel, 2004, J Cyst Fibros, V3 Suppl 2, P151, DOI 10.1016/j.jcf.2004.05.032; Sermet-Gaudelus I, 2005, AM J RESP CRIT CARE, V171, P1026, DOI 10.1164/rccm.200406-740OC; Standaert TA, 2004, PEDIATR PULM, V37, P385, DOI 10.1002/ppul.10448; Uwaifo C, 2006, PEDIATR PULM, V41, P151, DOI 10.1002/ppul.20328; Wagner JA, 2002, HUM GENE THER, V13, P1349, DOI 10.1089/104303402760128577; Welch EM, 2007, NATURE, V447, P87, DOI 10.1038/nature05756; Welsh MJ, 2001, METABOLIC MOL BASES, P5121; Weng YM, 1996, MOL CELL BIOL, V16, P5491, DOI 10.1128/mcb.16.10.5491; Wilschanski M, 2001, EUR RESPIR J, V17, P1208, DOI 10.1183/09031936.01.00092501; Wilschanski M, 2003, NEW ENGL J MED, V349, P1433, DOI 10.1056/NEJMoa022170; Wilschanski M, 2006, AM J RESP CRIT CARE, V174, P787, DOI 10.1164/rccm.200509-1377OC; Yaakov Y, 2007, CHEST, V132, P1219, DOI 10.1378/chest.06-2975; Zeitlin PL, 2002, MOL THER, V6, P119, DOI 10.1006/mthe.2002.0639	36	306	333	1	35	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG-SEP	2008	372	9640					719	727		10.1016/S0140-6736(08)61168-X	http://dx.doi.org/10.1016/S0140-6736(08)61168-X			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	344YZ	18722008				2022-12-28	WOS:000258964500028
J	Avorn, J				Avorn, Jerry			Drug warnings that can cause fits - Communicating risks in a data-poor environment	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Avorn, Jerry] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Avorn, Jerry] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA; [Avorn, Jerry] Harvard Interfac Initiat Medicat & Soc, Boston, MA USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University	Avorn, J (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.							2008, JOINT M PER CENTR NE	1	22	22	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2008	359	10					991	994		10.1056/NEJMp0805922	http://dx.doi.org/10.1056/NEJMp0805922			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	343KN	18768941				2022-12-28	WOS:000258852500002
J	Belcher, CM; McElwain, JC				Belcher, C. M.; McElwain, J. C.			Limits for combustion in low O-2 redefine paleoatmospheric predictions for the mesozoic	SCIENCE			English	Article							OXYGEN; FIRE; MODEL; EVOLUTION; RISE	Several studies have attempted to determine the lower limit of atmospheric oxygen under which combustion can occur; however, none have been conducted within a fully controlled and realistic atmospheric environment. We performed experimental burns ( using pine wood, moss, matches, paper, and a candle) at 20 degrees C in O-2 concentrations ranging from 9 to 21% and at ambient and high CO2 (2000 parts per million) in a controlled environment room, which was equipped with a thermal imaging system and full atmospheric, temperature, and humidity control. Our data reveal that the lower O-2 limit for combustion should be increased from 12 to 15%. These results, coupled with a record of Mesozoic paleowildfires, are incompatible with the prediction of prolonged intervals of low atmospheric O-2 levels (10 to 12%) in the Mesozoic.	[Belcher, C. M.; McElwain, J. C.] Univ Coll Dublin, Sch Biol & Environm Sci, Dublin 4, Ireland	University College Dublin	Belcher, CM (corresponding author), Univ Coll Dublin, Sch Biol & Environm Sci, Dublin 4, Ireland.	claire.belcher@ucd.ie	McElwain, Jennifer/AAX-1605-2020; McElwain, Jennifer/B-1735-2009	McElwain, Jennifer/0000-0002-1729-6755	European Union Marie Curie Excellence Grant [MEXT-CT-2006-042531]	European Union Marie Curie Excellence Grant(European Commission)	We acknowledge funding through a European Union Marie Curie Excellence Grant (MEXT-CT-2006-042531). We thank T. Gallagher for the use of the thermal imaging camera; M. Haworth, R. O'Hare, and D. Martin for much help and assistance in setting up the UCD Peac facility; J. Hunt and C. Hunt for supplying the moss; T. Lenton and two anonymous reviewers for improving the manuscript; L. Mander for insightful comments throughout; and M. Haworth, L. Mander, and M. Steinthorsdottir for safety supervision while working in subambient O<INF>2</INF> conditions.	Agee JK, 2002, FOREST ECOL MANAG, V167, P57, DOI 10.1016/S0378-1127(01)00690-9; ALBINI FA, 1976, INT30 USDA FOR SER; Bergman NM, 2004, AM J SCI, V304, P397, DOI 10.2475/ajs.304.5.397; Berner RA, 2001, AM J SCI, V301, P182, DOI 10.2475/ajs.301.2.182; Berner RA, 2003, ANNU REV EARTH PL SC, V31, P105, DOI 10.1146/annurev.earth.31.100901.141329; Berner RA, 2007, SCIENCE, V316, P557, DOI 10.1126/science.1140273; Berner RA, 2006, GEOCHIM COSMOCHIM AC, V70, P5653, DOI 10.1016/j.gca.2005.11.032; COPE MJ, 1980, NATURE, V283, P647, DOI 10.1038/283647a0; Falkowski PG, 2005, SCIENCE, V309, P2202, DOI 10.1126/science.1116047; Huey RB, 2005, SCIENCE, V308, P398, DOI 10.1126/science.1108019; Lenton TM, 2000, GLOBAL BIOGEOCHEM CY, V14, P249, DOI 10.1029/1999GB900076; Lenton TM, 2001, GLOBAL CHANGE BIOL, V7, P613, DOI 10.1046/j.1354-1013.2001.00429.x; LENTON TM, 2003, EVOLUTION PLANET EAR, P33; RASBASH DJ, 1968, COMBUST FLAME, V12, P33, DOI 10.1016/0010-2180(68)90006-0; Scott AC, 2000, PALAEOGEOGR PALAEOCL, V164, P281, DOI 10.1016/S0031-0182(00)00192-9; Scott AC, 2006, P NATL ACAD SCI USA, V103, P10861, DOI 10.1073/pnas.0604090103; UHL C, 1990, ECOLOGY, V71, P437, DOI 10.2307/1940299; WATSON A, 1978, BIOSYSTEMS, V10, P293, DOI 10.1016/0303-2647(78)90012-6; Watson A.J., 1978, THESIS U READING; Wildman RA, 2004, GEOLOGY, V32, P457, DOI 10.1130/G20255.1	20	128	139	2	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2008	321	5893					1197	1200		10.1126/science.1160978	http://dx.doi.org/10.1126/science.1160978			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341ZM	18755974				2022-12-28	WOS:000258754400041
J	Feig, DI; Soletsky, B; Johnson, RJ				Feig, Daniel I.; Soletsky, Beth; Johnson, Richard J.			Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SERUM URIC-ACID; ENDOTHELIAL FUNCTION; RISK-FACTORS; CARDIOVASCULAR-DISEASE; HYPERURICEMIA; ATHEROSCLEROSIS; DYSFUNCTION; PREVALENCE; CHILDREN	Context Hyperuricemia is a predictor for the development of hypertension and is commonly present in new- onset essential hypertension. Experimentally increasing uric acid levels using a uricase inhibitor causes systemic hypertension in animal models. Objective To determine whether lowering uric acid lowers blood pressure ( BP) in hyperuricemic adolescents with newly diagnosed hypertension. Design, Setting, and Patients Randomized, double- blind, placebo- controlled, crossover trial ( September 2004- March 2007) involving 30 adolescents ( aged 11- 17 years) who had newly diagnosed, never- treated stage 1 essential hypertension and serum uric acid levels >= 6 mg/ dL. Participants were treated at the Pediatric Hypertension Clinic at Texas Children's Hospital in Houston. Patients were excluded if they had stage 2 hypertension or known renal, cardiovascular, gastrointestinal tract, hepatic, or endocrine disease. Intervention Allopurinol, 200 mg twice daily for 4 weeks, and placebo, twice daily for 4 weeks, with a 2- week washout period between treatments. The order of the treatments was randomized. Main Outcome Measures Change in casual and ambulatory blood pressure. Results For casual BP, the mean change in systolic BP for allopurinol was -6.9 mm Hg ( 95% confidence interval [ CI], - 4.5 to - 9.3 mm Hg) vs - 2.0 mm Hg ( 95% CI, 0.3 to - 4.3 mm Hg; P=. 009) for placebo, and the mean change in diastolic BP for allopurinol was - 5.1 mm Hg ( 95% CI, - 2.5 to - 7.8 mm Hg) vs - 2.4 ( 95% CI, 0.2 to - 4.1; P=. 05) for placebo. Mean change in mean 24- hour ambulatory systolic BP for allopurinol was - 6.3 mm Hg ( 95% CI, - 3.8 to - 8.9 mm Hg) vs 0.8 mm Hg ( 95% CI, 3.4 to - 2.9 mm Hg; P=. 001) for placebo and mean 24- hour ambulatory diastolic BP for allopurinol was - 4.6 mm Hg (- 2.4 to - 6.8 mm Hg) vs - 0.3 mm Hg ( 95% CI, 2.3 to - 2.1 mm Hg; P=. 004) for placebo. Twenty of the 30 participants achieved normal BP by casual and ambulatory criteria while taking allopurinol vs 1 participant while taking placebo ( P <. 001). Conclusions In this short- term, crossover study of adolescents with newly diagnosed hypertension, treatment with allopurinol resulted in reduction of BP. The results represent a new potential therapeutic approach, although not a fully developed therapeutic strategy due to potential adverse effects. These preliminary findings require confirmation in larger clinical trials. Trial Registration clinicaltrials.gov Identifier: NCT00288184.	[Feig, Daniel I.; Soletsky, Beth] Baylor Coll Med, Dept Pediat, Renal Sect, Houston, TX 77030 USA; [Johnson, Richard J.] Univ Florida, Sch Med, Dept Med, Div Nephrol Hypertens & Transplantat, Gainesville, FL USA	Baylor College of Medicine; State University System of Florida; University of Florida	Feig, DI (corresponding author), Baylor Coll Med, Dept Pediat, Renal Sect, Houston, TX 77030 USA.	dfeig@bcm.tmc.edu		Johnson, Richard/0000-0003-3312-8193; Feig, Daniel/0000-0002-0017-6335	National Institutes of Health [5 K23 DK064587, HL-68607]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068607] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K23DK064587] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by National Institutes of Health grants 5 K23 DK064587 ( Dr Feig) and HL-68607 ( Dr Johnson).	Alper AB, 2005, HYPERTENSION, V45, P34, DOI 10.1161/01.HYP.0000150783.79172.bb; CANNON PJ, 1966, NEW ENGL J MED, V275, P457, DOI 10.1056/NEJM196609012750902; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; CROM WR, 1987, CLIN PHARMACOL THER, V41, P645, DOI 10.1038/clpt.1987.90; DAVIS N, 1897, JAMA-J AM MED ASSOC, V29, P267; Doehner W, 2002, CIRCULATION, V105, P2619, DOI 10.1161/01.CIR.0000017502.58595.ED; Erdogan D, 2005, INT J CLIN PRACT, V59, P1276, DOI 10.1111/j.1742-1241.2005.00621.x; Farquharson CA, 2002, CIRCULATION, V106, P221, DOI 10.1161/01.CIR.0000022140.61460.1D; Feig DI, 2003, HYPERTENSION, V42, P247, DOI 10.1161/01.HYP.0000085858.66548.59; Ferreira AP, 2007, J PEDIAT-BRAZIL, V83, P21, DOI [10.2223/JPED.1562, 10.1590/S0021-75572007000100005]; George J, 2006, CIRCULATION, V114, P2508, DOI 10.1161/CIRCULATIONAHA.106.651117; Greenberg B H, 2000, Congest Heart Fail, V6, P74, DOI 10.1111/j.1527-5299.2000.80140.x; GRUSKIN AB, 1985, AM J KIDNEY DIS, V6, P86, DOI 10.1016/S0272-6386(85)80146-3; Haig A, 1889, Br Med J, V1, P288; Isaacman DJ, 1996, PEDIATR EMERG CARE, V12, P340, DOI 10.1097/00006565-199610000-00004; Johnson RJ, 2004, NEW ENGL J MED, V350, P1071, DOI 10.1056/NEJMp048015; Johnson RJ, 2005, J AM SOC NEPHROL, V16, P1909, DOI 10.1681/ASN.2005010063; Kanellis J, 2003, HYPERTENSION, V41, P1287, DOI 10.1161/01.HYP.0000072820.07472.3B; Krishnan E, 2007, HYPERTENSION, V49, P298, DOI 10.1161/01.HYP.0000254480.64564.b6; Lasater M, 1998, Crit Care Nurs Q, V21, P97; Mazzali M, 2001, HYPERTENSION, V38, P1101, DOI 10.1161/hy1101.092839; Mazzali M, 2002, AM J PHYSIOL-RENAL, V282, pF991, DOI 10.1152/ajprenal.00283.2001; Mellen PB, 2006, HYPERTENSION, V48, P1037, DOI 10.1161/01.HYP.0000249768.26560.66; Mercuro G, 2004, AM J CARDIOL, V94, P932, DOI 10.1016/j.amjcard.2004.06.032; MESSERLI FH, 1980, ANN INTERN MED, V93, P817, DOI 10.7326/0003-4819-93-6-817; MOHAMED FA, 1879, LANCET, V1, P399; Natl High Blood Pressure Educ Prog, 2004, PEDIATRICS, V114, P555; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; Perlstein TS, 2006, HYPERTENSION, V48, P1031, DOI 10.1161/01.HYP.0000248752.08807.4c; Pianosi PT, 2004, EUR J APPL PHYSIOL, V92, P425, DOI 10.1007/s00421-004-1167-5; Pranulis M F, 2000, J Cardiovasc Manag, V11, P13; SAITO I, 1978, J AM GERIATR SOC, V26, P241, DOI 10.1111/j.1532-5415.1978.tb02396.x; Sanchez-Lozada LG, 2007, AM J PHYSIOL-RENAL, V292, pF1238, DOI 10.1152/ajprenal.00164.2006; Sarafidis PA, 2008, J CLIN HYPERTENS, V10, P130, DOI 10.1111/j.1751-7176.2008.07309.x; Sautin YY, 2007, AM J PHYSIOL-CELL PH, V293, pC584, DOI 10.1152/ajpcell.00600.2006; SELBY JV, 1990, AM J EPIDEMIOL, V131, P1017, DOI 10.1093/oxfordjournals.aje.a115593; Simonetti GD, 2007, J HYPERTENS, V25, P2370, DOI 10.1097/HJH.0b013e3282efeb7e; Smith RD, 2006, HYPERTENSION, V47, P771, DOI 10.1161/01.HYP.0000209642.11448.e0; Soergel M, 1997, J PEDIATR-US, V130, P178, DOI 10.1016/S0022-3476(97)70340-8; Sorof JM, 2004, PEDIATRICS, V113, P475, DOI 10.1542/peds.113.3.475; Staessen JA, 2001, LANCET, V358, P1305, DOI 10.1016/S0140-6736(01)06411-X; Sundstrom J, 2005, HYPERTENSION, V45, P28, DOI 10.1161/01.HYP.0000150784.92944.9a; TOMA I, 2007, AM SOC NEPHR ANN M N; Vaccarino V, 1999, ANN INTERN MED, V131, P62, DOI 10.7326/0003-4819-131-1-199907060-00012; Ventura H O, 2000, Congest Heart Fail, V6, P94, DOI 10.1111/j.1527-5299.2000.80147.x; WANG GT, 1993, ANAL BIOCHEM, V210, P351, DOI 10.1006/abio.1993.1207; Watanabe S, 2002, HYPERTENSION, V40, P355, DOI 10.1161/01.HYP.0000028589.66335.AA; Williams JL, 1921, ARCH INTERN MED, V27, P748, DOI 10.1001/archinte.1921.00100120119008; Zoccali C, 2006, J AM SOC NEPHROL, V17, P1466, DOI 10.1681/ASN.2005090949	49	627	678	3	38	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2008	300	8					924	932		10.1001/jama.300.8.924	http://dx.doi.org/10.1001/jama.300.8.924			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	341AR	18728266	Green Accepted			2022-12-28	WOS:000258687100027
J	Osika, W; Montgomery, SM				Osika, Walter; Montgomery, Scott M.			Physical control and coordination in childhood and adult obesity: longitudinal birth cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COGNITIVE-DEVELOPMENT; DEMENTIA; RISK; IQ; ENVIRONMENT; IMPAIRMENT; MECHANISMS; PREGNANCY; SMOKING; INSULIN	Objective To identify whether measures of childhood physical control and coordination as markers of neurological function are associated with obesity in adults. Design Longitudinal birth cohort study. Setting National child development study in Great Britain. Participants 11042 people born during one week in 1958. Main outcome measure Obesity at age 33 years deflned as body mass index >= 30. Results Among 7990 cohort members at age 7 years, teachers reported that poor hand control, poor coordination, and clumsiness "certainly applied" more often among those who would be obese adults, producing adjusted odds ratios of 1.57 (95% confidence interval 1.13 to 2.20; P=0.008) for poor hand control, 2.30 (1.52 to 3.46; P<0.001) for poor coordination, and 3.91 (2.61 to 5.87; P<0.001) for clumsiness. Among 6875 participants who had doctor administered assessments with continuous scores at age 11 years, poorer function was associated with later obesity, indicated by adjusted odds ratios (change in risk per unit increase in score) of 0.88 (0.81 to 0.96; P=0.003) for copying designs, 0.84 (0.78 to 0.91; P<0.001) for marking squares, and 1.14 (1.06 to 1.24; P<0.001) for picking up matches (a higher score indicates poor function in this test). Further adjustment for contemporaneous body mass index at age 7 or 11 years did not eliminate statistical significance for any of the associations. Conclusion Some aspects of poorer neurological function associated with adult obesity may have their origins in childhood.	[Osika, Walter] Orebro Univ Hosp, Dept Cardiol, SE-70185 Orebro, Sweden; [Montgomery, Scott M.] Orebro Univ Hosp, Clin Res Ctr, SE-70185 Orebro, Sweden; [Montgomery, Scott M.] Univ London Imperial Coll Sci Technol & Med, Charing Cross Hosp, Dept Primary Care & Social Med, London, England; [Montgomery, Scott M.] Karolinska Univ Hosp, Karolinska Inst, Clin Epidemiol Unit, Dept Med, Stockholm, Sweden	Orebro University; Orebro University; Imperial College London; Karolinska Institutet; Karolinska University Hospital	Osika, W (corresponding author), Orebro Univ Hosp, Dept Cardiol, SE-70185 Orebro, Sweden.	osika@hotmail.com	Montgomery, Scott/AAN-2546-2020	Montgomery, Scott/0000-0001-6328-5494; Osika, Walter/0000-0002-1583-7319	ESRC [ES/G002452/1] Funding Source: UKRI; Economic and Social Research Council [ES/G002452/1] Funding Source: researchfish	ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))		Breslau N, 2005, INT J EPIDEMIOL, V34, P1047, DOI 10.1093/ije/dyi163; Chandola T, 2006, INT J OBESITY, V30, P1422, DOI 10.1038/sj.ijo.0803279; Craft S, 2007, CURR ALZHEIMER RES, V4, P147, DOI 10.2174/156720507780362137; Douglas James W.B, 1964, HOME SCH; FERRI E, 1993, LIFE 33 5 FOLLOW UP; Graf C, 2004, INT J OBESITY, V28, P22, DOI 10.1038/sj.ijo.0802428; Gustafson D, 2006, LANCET NEUROL, V5, P713, DOI 10.1016/S1474-4422(06)70526-9; Hausman D B, 2001, Obes Rev, V2, P239, DOI 10.1046/j.1467-789X.2001.00042.x; Jefferis BJMH, 2002, BRIT MED J, V325, P305, DOI 10.1136/bmj.325.7359.305; Knecht S, 2008, PROG NEUROBIOL, V84, P85, DOI 10.1016/j.pneurobio.2007.09.003; Montgomery SM, 2002, BRIT MED J, V324, P26, DOI 10.1136/bmj.324.7328.26; Olsson GM, 2008, DIABETES CARE, V31, P514, DOI 10.2337/dc07-1399; Power C, 2006, INT J EPIDEMIOL, V35, P34, DOI 10.1093/ije/dyi183; Power C, 1997, INT J OBESITY, V21, P507, DOI 10.1038/sj.ijo.0800454; Reitz C, 2007, ARCH NEUROL-CHICAGO, V64, P1734, DOI 10.1001/archneur.64.12.1734; Rosengren A, 2005, ARCH INTERN MED, V165, P321, DOI 10.1001/archinte.165.3.321; Stott GH, 1987, SOCIAL ADJUSTMENT CH; Strachan MWJ, 2008, BRIT MED J, V336, P6, DOI 10.1136/bmj.39386.664016.BE; Tong S, 2007, J PEDIATR-US, V151, P284, DOI 10.1016/j.jpeds.2007.03.020; Toschke AM, 2003, AM J EPIDEMIOL, V158, P1068, DOI 10.1093/aje/kwg258; Viner RM, 2005, BRIT MED J, V330, P1354, DOI 10.1136/bmj.38453.422049.E0; Whitmer RA, 2005, BMJ-BRIT MED J, V330, P1360, DOI 10.1136/bmj.38446.466238.E0; Yaffe K, 2004, JAMA-J AM MED ASSOC, V292, P2237, DOI 10.1001/jama.292.18.2237; Yki-Jarvinen H, 2000, INT J OBESITY, V24, pS25, DOI 10.1038/sj.ijo.0801272	24	49	49	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 23	2008	337	7667							a699	10.1136/bmj.a699	http://dx.doi.org/10.1136/bmj.a699			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	346FD	18698093	Green Published, hybrid			2022-12-28	WOS:000259053100028
J	Mann, JFE; Schmieder, RE; McQueen, M; Dyal, L; Schumacher, H; Pogue, J; Wang, XY; Maggioni, A; Budaj, A; Chaithiraphan, S; Dickstein, K; Keltai, M; Metsarinne, K; Oto, A; Parkhomenko, A; Piegas, LS; Svendsen, TL; Teo, KK; Yusuf, S				Mann, Johannes F. E.; Schmieder, Roland E.; McQueen, Matthew; Dyal, Leanne; Schumacher, Helmut; Pogue, Janice; Wang, Xingyu; Maggioni, Aldo; Budaj, Andrzej; Chaithiraphan, Suphachai; Dickstein, Kenneth; Keltai, Matyas; Metsarinne, Kaj; Oto, Ali; Parkhomenko, Alexander; Piegas, Leopoldo S.; Svendsen, Tage L.; Teo, Koon K.; Yusuf, Salim		ONTARGET Investigators	Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial	LANCET			English	Article							CONVERTING ENZYME-INHIBITORS; RENIN-ANGIOTENSIN SYSTEM; II RECEPTOR BLOCKERS; DISEASE; COMBINATION; METAANALYSIS; PROGRESSION; NEPHROPATHY; PROTEINURIA; COOPERATE	Background Angiotensin receptor blockers (ARB) and angiotensin converting enzyme (ACE) inhibitors are known to reduce proteinuria. Their combination might be more effective than either treatment alone, but long-term data for comparative changes in renal function are not available. We investigated the renal effects of ramipril (an ACE inhibitor), telmisartan (an ARB), and their combination in patients aged 55 years or older with established atherosclerotic vascular disease or with diabetes with end-organ damage. Methods The trial ran from 2001 to 2007. After a 3-week run-in period, 25 620 participants were randomly assigned to ramipril 10 mg a day (n=8576), telmisartan 80 mg a day (n=8542), or to a combination of both drugs (n=8502; median follow-up was 56 months), and renal function and proteinuria were measured. The primary renal outcome was a composite of dialysis, doubling of serum creatinine, and death. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00153101. Findings 784 patients permanently discontinued randomised therapy during the trial because of hypotensive symptoms (406 on combination therapy, 149 on ramipril, and 229 on telmisartan). The number of events for the composite primary outcome was similar for telmisartan (n=1147 [13.4%]) and ramipril (1150 [13.5%]; hazard ratio [HR] 1.00, 95% Cl 0 . 92-1. 09), but was increased with combination therapy (1233 [14.5%]; HR 1. 09, 1.01-1.18, p=0.037). The secondary renal outcome, dialysis or doubling of serum creatinine, was similar with telmisartan (189 [2 . 21%]) and ramipril (174 [2.03%]; HR 1.09, 0.89-1.34) and more frequent with combination therapy (212 [2.49%]: HR 1.24, 1.01-1.51, p=0.038). Estimated glomerular filtration rate (eGFR) declined least with ramipril compared with telmisartan (-2-82 [SD 17.2] mL/min/1 . 73 m(2) vs -4.12 [17.4], p<0.0001) or combination therapy (-6.11 [17.9], p<0.0001). The increase in urinary albumin excretion was less with telmisartan (p=0.004) or with combination therapy (p=0.001) than with ramipril. Interpretation In people at high vascular risk, telmisartan's effects on major renal outcomes are similar to ramipril. Although combination therapy reduces proteinuria to a greater extent than monotherapy, overall it worsens major renal outcomes. Funding Boehringer-Ingelheim.	[Budaj, Andrzej] Grochowski Hosp, Postgrad Med Sch, Warsaw, Poland; [Chaithiraphan, Suphachai] Chaophya Hosp, Cardiac Ctr, Bangkok, Thailand; [Dickstein, Kenneth] Univ Bergen, Stavanger Hosp, Div Cardiol, Bergen, Norway; [McQueen, Matthew; Dyal, Leanne; Pogue, Janice; Teo, Koon K.; Yusuf, Salim] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada; [Keltai, Matyas] Semmelweis Univ, Gottsegen Gyorgy Hungarian Inst Cardiol, H-1085 Budapest, Hungary; [Maggioni, Aldo] ANMCO Res Ctr, Florence, Italy; [Mann, Johannes F. E.] Univ Munich, Schwabing Gen Hosp, Munich, Germany; [Mann, Johannes F. E.] Univ Munich, KfH Kidney Ctr, Munich, Germany; [Metsarinne, Kaj] Turku Univ, Cent Hosp, Kantasairaala, Finland; [Oto, Ali] Hacettepe Univ, Ankara, Turkey; [Parkhomenko, Alexander] Inst Cardiol, Kiev, Ukraine; [Piegas, Leopoldo S.] Inst Dante Pazzanese Cardiol, Sao Paulo, Brazil; [Schmieder, Roland E.] Univ Erlangen Nurnberg, Dept Hypertens & Nephrol, Erlangen, Germany; [Schumacher, Helmut] Boehringer Ingelheim KG, D-6507 Ingelheim, Germany; [Svendsen, Tage L.] Holbaek City Hosp, Holbaek, Denmark; [Wang, Xingyu] Fu Wai Hosp, Beijing Hypertens League Inst, Beijing, Peoples R China	Centre of Postgraduate Medical Education - Poland; University of Bergen; McMaster University; Population Health Research Institute; Semmelweis University; Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO); University of Munich; University of Munich; University of Turku; Hacettepe University; National Academy of Medical Sciences of Ukraine; National Scientific Center M.D. Strazhesko Institute of Cardiology of the National Academy of Medical Sciences of Ukraine; Instituto Dante Pazzanese de Cardiologia; University of Erlangen Nuremberg; Boehringer Ingelheim; Holbaek Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Chinese Hypertension League	Mann, JFE (corresponding author), McMaster Univ, ONTARGET Off, Hamilton Gen Hosp, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.	tbn02ab@mail.lrz-muenchen.de	Maggioni, Aldo Pietro/AAL-5334-2020; Hug, Balthasar L./G-1568-2010; Mann, Johannes/AAI-8803-2020	Maggioni, Aldo Pietro/0000-0003-2764-6779; Piegas, Leopoldo/0000-0003-1021-817X; da Silva Franco, Roberto Jorge/0000-0001-9787-4393; Budaj, Andrzej/0000-0002-6395-2098; Yusuf, Salim/0000-0003-4776-5601	Boehringer Ingelheim	Boehringer Ingelheim(Boehringer Ingelheim)	JM, RS, KT, SY, AB, MK, KM, and LP received consulting and lecture fees and research grants from Boehringer Ingelheim and from other companies manufacturing angiotensin receptor blockers. HS being an employee of Boehringer Ingelheim.	Bakris GL, 2000, ARCH INTERN MED, V160, P685, DOI 10.1001/archinte.160.5.685; Barnett AH, 2004, NEW ENGL J MED, V351, P1952, DOI 10.1056/NEJMoa042274; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Casas JP, 2005, LANCET, V366, P2026, DOI 10.1016/S0140-6736(05)67814-2; Gerstein HC, 2001, JAMA-J AM MED ASSOC, V286, P421, DOI 10.1001/jama.286.4.421; Hilgers KF, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341100; Jafar TH, 2003, ANN INTERN MED, V139, P244, DOI 10.7326/0003-4819-139-4-200308190-00006; Kunz R, 2008, LANCET, V371, P1575, DOI 10.1016/S0140-6736(08)60681-9; Kunz R, 2008, ANN INTERN MED, V148, P30, DOI 10.7326/0003-4819-148-1-200801010-00190; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; Mann JFE, 2003, AM J KIDNEY DIS, V42, P936, DOI 10.1016/j.ajkd.2003.07.015; Matchar DB, 2008, ANN INTERN MED, V148, P16, DOI 10.7326/0003-4819-148-1-200801010-00189; Nakao N, 2003, LANCET, V361, P117, DOI 10.1016/S0140-6736(03)12229-5; Phillips CO, 2007, ARCH INTERN MED, V167, P1930, DOI 10.1001/archinte.167.18.1930; Remuzzi G, 2006, J CLIN INVEST, V116, P288, DOI 10.1172/JCI27699; Stevens LA, 2006, NEW ENGL J MED, V354, P2473, DOI 10.1056/NEJMra054415; Teo KK, 2004, AM HEART J, V148, P52, DOI 10.1016/j.ahj.2004.03.020; Yusuf S, 2008, NEW ENGL J MED, V358, P1547, DOI 10.1056/NEJMoa0801317	18	1122	1176	0	43	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 16	2008	372	9638					547	553		10.1016/S0140-6736(08)61236-2	http://dx.doi.org/10.1016/S0140-6736(08)61236-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339MS	18707986				2022-12-28	WOS:000258582300028
J	Walley, T; Thakker, RV				Walley, T.; Thakker, R. V.			Developments for funding clinical research in the UK	LANCET			English	Editorial Material									[Walley, T.] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GF, Merseyside, England; [Thakker, R. V.] Univ Oxford, Nuffield Dept Clin Med, Oxford Ctr Diabet Endocrinol & Metab, Churchill Hosp, Oxford, England	University of Liverpool; University of Oxford	Walley, T (corresponding author), Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GF, Merseyside, England.	twalley@liv.ac.uk						*AC MED SCI, 2003, STRENGTH CLIN RES; [Anonymous], 2004, RES PATIENT BENEFIT; BIOSCIENCE INNOVATION AND GROWTH TEAM, 2004, BIOSC 2015 IMPR NAT; Cooksey D., 2006, REV UK HLTH RES FUND; DARLING A, 2007, PREBUDGET REPORT COM; Department of Health, 2006, BEST RES BEST HLTH N; *MRC, 2008, APPL GRANT DEV PATHW; *NAT I HLTH RES, 2008, NIHR HLTH TECHN ASS; *NAT I HLTH RES, 2008, NIHR PUBL HLTH RES P; *NAT I HLTH RES, EFF MECH EV EME PROG	10	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 16	2008	372	9638					518	519		10.1016/S0140-6736(08)61214-3	http://dx.doi.org/10.1016/S0140-6736(08)61214-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	339MS	18707971				2022-12-28	WOS:000258582300009
J	Anton, RF				Anton, Raymond F.			Naltrexone for the management of alcohol dependence	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; PRIMARY-CARE; COMBINED PHARMACOTHERAPIES; BEHAVIORAL INTERVENTIONS; NUCLEUS-ACCUMBENS; VENTRAL STRIATUM; SOCIAL DRINKERS; UNITED-STATES; ABUSE; METAANALYSIS	A 44- year-old businessman with a history of hypertension presents for evaluation with a report of being under stress at work and home, which has led to "unsatisfactory" sleep. Although there is some despondency, screening for depression is negative. His blood pressure is 158/ 98 mm Hg. Laboratory results include a mean corpuscular volume of 102 fl ( normal range, 80 to 100), an alanine aminotransferase level of 60 U per liter ( normal range, 7 to 41), an aspartate aminotransferase level of 45 U per liter ( normal range, 12 to 38), and a gamma-glutamyltransferase level of 110 U per liter ( normal range, 9 to 58). His physician asks about alcohol consumption, and the patient admits that perhaps he drinks "more than he should," since he often wakes up with a hangover and arrives late to work. After weekend golf outings, he comes home intoxicated, leading to arguments with his wife and embarrassment in front of his children. He has been quietly wondering about the need to cut down or stop drinking and wants some advice. His physician discusses medication or a referral to an alcohol clinic for further evaluation. Naltrexone is proposed as a treatment option.	[Anton, Raymond F.] Med Univ S Carolina, Charleston Alcohol Res Ctr, Charleston, SC 29425 USA; [Anton, Raymond F.] Med Univ S Carolina, Ctr Drug & Alcohol Programs, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Anton, RF (corresponding author), Med Univ S Carolina, Charleston Alcohol Res Ctr, 67 President St,POB MSC861 250861, Charleston, SC 29425 USA.	antonr@musc.edu			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [K05AA017435] Funding Source: NIH RePORTER; NIAAA NIH HHS [K05 AA017435, K05 AA017435-01] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Anton RF, 2006, JAMA-J AM MED ASSOC, V295, P2003, DOI 10.1001/jama.295.17.2003; Anton RF, 2004, PSYCHOPHARMACOLOGY, V173, P32, DOI 10.1007/s00213-003-1720-7; Anton RF, 2001, J CLIN PSYCHOPHARM, V21, P72, DOI 10.1097/00004714-200102000-00013; Anton RF, 1999, AM J PSYCHIAT, V156, P1758; BENJAMIN D, 1993, BRAIN RES, V621, P137, DOI 10.1016/0006-8993(93)90309-B; Berglund M, 2003, ALCOHOL CLIN EXP RES, V27, P1645, DOI 10.1097/01.ALC.0000090144.99832.19; Bouza C, 2005, ADDICTION, V100, P573; Carmen B, 2004, ADDICTION, V99, P811, DOI 10.1111/j.1360-0443.2004.00763.x; Carroll KM, 1997, ADDICT BEHAV, V22, P233, DOI 10.1016/S0306-4603(96)00038-X; Croop RS, 1997, ARCH GEN PSYCHIAT, V54, P1130; Donovan DM, 2008, J STUD ALCOHOL DRUGS, V69, P5, DOI 10.15288/jsad.2008.69.5; Drobes DJ, 2004, ALCOHOL CLIN EXP RES, V28, P1362, DOI 10.1097/01.ALC.0000139704.88862.01; Fiellin DA, 2000, AM J MED, V108, P227, DOI 10.1016/S0002-9343(99)00448-9; Fleming M, 2004, J AM BOARD FAM PRACT, V17, P247, DOI 10.3122/jabfm.17.4.247; Garbutt JC, 2005, JAMA-J AM MED ASSOC, V293, P1978; Garbutt JC, 2005, JAMA-J AM MED ASSOC, V293, P1617, DOI 10.1001/jama.293.13.1617; GARBUTT JC, 2005, JAMA-J AM MED ASSOC, V293, P2864; Gonzales RA, 1998, J NEUROSCI, V18, P10663; Grant BF, 2004, DRUG ALCOHOL DEPEN, V74, P223, DOI 10.1016/j.drugalcdep.2004.02.004; Hasin DS, 2007, ARCH GEN PSYCHIAT, V64, P830, DOI 10.1001/archpsyc.64.7.830; Heinz A, 2004, AM J PSYCHIAT, V161, P2344; Heinz A, 2004, AM J PSYCHIAT, V161, P1783, DOI 10.1176/appi.ajp.161.10.1783; Johnson BA, 2008, ARCH INTERN MED, V168, P1188, DOI 10.1001/archinte.168.11.1188; Johnson BA, 2007, JAMA-J AM MED ASSOC, V298, P1641, DOI 10.1001/jama.298.14.1641; Klatsky AL, 2004, HYPERTENSION, V44, P805, DOI 10.1161/01.HYP.0000146538.26193.60; Koob GF, 1998, ALCOHOL CLIN EXP RES, V22, P3, DOI 10.1097/00000374-199802000-00001; Kranzler HR, 2001, ALCOHOL CLIN EXP RES, V25, P1335, DOI 10.1097/00000374-200109000-00014; Krystal JH, 2001, NEW ENGL J MED, V345, P1734, DOI 10.1056/NEJMoa011127; LOWENFELS AB, 1984, ANN EMERG MED, V13, P1056, DOI 10.1016/S0196-0644(84)80070-0; Middaugh LD, 2003, ALCOHOL CLIN EXP RES, V27, P1892, DOI 10.1097/01.ALC.0000099264.36220.48; Miller PM, 2004, ADDICT BEHAV, V29, P1427, DOI 10.1016/j.addbeh.2004.06.013; Miller PM, 2004, ALCOHOL ALCOHOLISM, V39, P325, DOI 10.1093/alcalc/agh070; Miller WR, 2002, ADDICTION, V97, P265, DOI 10.1046/j.1360-0443.2002.00019.x; Myrick H, 2004, NEUROPSYCHOPHARMACOL, V29, P393, DOI 10.1038/sj.npp.1300295; Myrick H, 2008, ARCH GEN PSYCHIAT, V65, P466, DOI 10.1001/archpsyc.65.4.466; *NAT I ALC AB ALC, 2000, UPD EST EC COSTS ALC; *NAT I ALC AB ALC, 2004, COMBINE MON SER; National Institute on Alcohol Abuse and Alcoholism, 2007, HELP PAT WHO DRINK T; O'Malley SS, 2003, ARCH INTERN MED, V163, P1695, DOI 10.1001/archinte.163.14.1695; O'Malley SS, 2002, PSYCHOPHARMACOLOGY, V160, P19, DOI 10.1007/s002130100919; O'Malley SS, 2007, J CLIN PSYCHOPHARM, V27, P507, DOI 10.1097/jcp.0b013e31814ce50d; OMalley SS, 1996, ARCH GEN PSYCHIAT, V53, P217; Pettinati HM, 2005, J STUD ALCOHOL, P170, DOI 10.15288/jsas.2005.s15.170; Pettinati HM, 2000, J ADDICT DIS, V19, P71, DOI 10.1300/J069v19n01_06; Srisurapanont M, 2005, INT J NEUROPSYCHOPH, V8, P267, DOI 10.1017/S1461145704004997; Srisurapanont M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD1867.pub2; Streeton C, 2001, ALCOHOL ALCOHOLISM, V36, P544, DOI 10.1093/alcalc/36.6.544; *SUBST AB MENT HLT, 2007, NSDUH H, V32; *U UT HOSP DEP PHA, 2007, NEW DRUG B; *US DEP HHS, 1998, TREATM IMPR PROT TIP; Williams SH, 2005, AM FAM PHYSICIAN, V72, P1775; World Health Organization, 2004, GLOB STAT REP ALC PO; 2007, AM J PSYCHIAT, V164, pA5	53	102	102	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 14	2008	359	7					715	721		10.1056/NEJMct0801733	http://dx.doi.org/10.1056/NEJMct0801733			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336XE	18703474	Green Accepted			2022-12-28	WOS:000258397900008
J	Frohling, S; Dohner, H				Froehling, Stefan; Doehner, Hartmut			Chromosomal abnormalities in cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CHRONIC MYELOID-LEUKEMIA; TUMOR-SUPPRESSOR GENES; COMPARATIVE GENOMIC HYBRIDIZATION; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; PROSTATE-CANCER; BCR-ABL; TRANSCRIPTION FACTOR; BREAST-CANCER; LUNG-CANCER		[Doehner, Hartmut] Univ Hosp Ulm, Dept Internal Med 3, D-89081 Ulm, Germany; [Froehling, Stefan] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Hematol, Boston, MA USA	Ulm University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Dohner, H (corresponding author), Univ Hosp Ulm, Dept Internal Med 3, Robert Koch Str 8, D-89081 Ulm, Germany.	hartmut.doehner@uniklinik-ulm.de	Döhner, Hartmut/C-8933-2016	Döhner, Hartmut/0000-0003-2116-5536				Albertson DG, 2008, NAT GENET, V40, P821, DOI 10.1038/ng0708-821; Alter Blanche P, 2007, Hematology Am Soc Hematol Educ Program, P29, DOI 10.1182/asheducation-2007.1.29; Apperley JF, 2002, NEW ENGL J MED, V347, P481, DOI 10.1056/NEJMoa020150; Baccarani M, 2007, HAEMATOLOGICA, V92, P1173, DOI 10.3324/haematol.11420; Boultwood J, 2002, BLOOD, V99, P4638, DOI 10.1182/blood.V99.12.4638; Cairncross G, 2006, J CLIN ONCOL, V24, P2707, DOI 10.1200/JCO.2005.04.3414; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Cimmino A, 2006, P NATL ACAD SCI USA, V103, P2464, DOI 10.1073/pnas.0510793103; Cloughesy TF, 2008, PLOS MED, V5, P139, DOI 10.1371/journal.pmed.0050008; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Curtiss NP, 2005, GENOMICS, V85, P600, DOI 10.1016/j.ygeno.2005.01.013; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; David M, 2007, BLOOD, V109, P61, DOI 10.1182/blood-2006-05-024828; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Demichelis F, 2007, ONCOGENE, V26, P5692, DOI 10.1038/sj.onc.1210630; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Dohner K, 1998, BLOOD, V92, P4031, DOI 10.1182/blood.V92.11.4031.423k55_4031_4035; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Dutt A, 2007, CURR OPIN ONCOL, V19, P43, DOI 10.1097/CCO.0b013e328011a8c1; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fodde R, 2002, SCIENCE, V298, P761, DOI 10.1126/science.1077707; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Goldman JM, 2003, NEW ENGL J MED, V349, P1451, DOI 10.1056/NEJMra020777; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Graux C, 2004, NAT GENET, V36, P1084, DOI 10.1038/ng1425; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; Helgeson BE, 2008, CANCER RES, V68, P73, DOI 10.1158/0008-5472.CAN-07-5352; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; Holst F, 2007, NAT GENET, V39, P655, DOI 10.1038/ng2006; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Hughes T, 2006, BLOOD, V108, P28, DOI 10.1182/blood-2006-01-0092; Kantarjian H, 2006, NEW ENGL J MED, V354, P2542, DOI 10.1056/NEJMoa055104; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Kim SY, 2007, CARCINOGENESIS, V28, P1387, DOI 10.1093/carcin/bgm086; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389; Kuppers R, 2005, NAT REV CANCER, V5, P251, DOI 10.1038/nrc1589; Laxman B, 2008, CANCER RES, V68, P645, DOI 10.1158/0008-5472.CAN-07-3224; Licht Jonathan D, 2005, Hematology Am Soc Hematol Educ Program, P137; LICHTER P, 1990, NATURE, V345, P93, DOI 10.1038/345093a0; List A, 2006, NEW ENGL J MED, V355, P1456, DOI 10.1056/NEJMoa061292; Liu WN, 2007, GENE CHROMOSOME CANC, V46, P972, DOI 10.1002/gcc.20482; Meyer S, 2007, GENE CHROMOSOME CANC, V46, P359, DOI 10.1002/gcc.20417; Meyerson M, 2007, NATURE, V448, P545, DOI 10.1038/448545a; Mitelman F, 2007, NAT REV CANCER, V7, P233, DOI 10.1038/nrc2091; Mrozek K, 2004, BLOOD REV, V18, P115, DOI 10.1016/S0268-960X(03)00040-7; Mullighan CG, 2008, NATURE, V453, P110, DOI 10.1038/nature06866; Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690; Nam RK, 2007, BRIT J CANCER, V97, P1690, DOI 10.1038/sj.bjc.6604054; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; O'Neil J, 2007, ONCOGENE, V26, P6838, DOI 10.1038/sj.onc.1210766; Okawa ER, 2008, ONCOGENE, V27, P803, DOI 10.1038/sj.onc.1210675; Owen LA, 2006, CELL CYCLE, V5, P2049, DOI 10.4161/cc.5.18.3213; Pedersen-Bjergaard Jens, 2007, Hematology Am Soc Hematol Educ Program, P392; Perner S, 2007, AM J SURG PATHOL, V31, P882, DOI 10.1097/01.pas.0000213424.38503.aa; Perner S, 2006, CANCER RES, V66, P8337, DOI 10.1158/0008-5472.CAN-06-1482; Pinkel D, 2005, NAT GENET, V37, pS11, DOI 10.1038/ng1569; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Riggi N, 2007, CANCER LETT, V254, P1, DOI 10.1016/j.canlet.2006.12.009; Rivera MN, 2007, SCIENCE, V315, P642, DOI 10.1126/science.1137509; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Sanz Miguel A, 2006, Hematology Am Soc Hematol Educ Program, P147; Scaglioni PP, 2007, CURR TOP MICROBIOL, V313, P85; Shaffer DR, 2006, NAT MED, V12, P14, DOI 10.1038/nm0106-14; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229; Taniguchi T, 2006, BLOOD, V107, P4223, DOI 10.1182/blood-2005-10-4240; Tomlins SA, 2006, CANCER RES, V66, P3396, DOI 10.1158/0008-5472.CAN-06-0168; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tomlins SA, 2007, NATURE, V448, P595, DOI 10.1038/nature06024; Wang ZY, 2008, BLOOD, V111, P2505, DOI 10.1182/blood-2007-07-102798; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Weisberg E, 2005, CANCER CELL, V7, P129, DOI 10.1016/j.ccr.2005.01.007; Weisberg E, 2005, CANCER CELL, V7, P399, DOI 10.1016/j.ccr.2005.03.026; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Yao J, 2006, CANCER RES, V66, P4065, DOI 10.1158/0008-5472.CAN-05-4083; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103	94	146	165	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 14	2008	359	7					722	734		10.1056/NEJMra0803109	http://dx.doi.org/10.1056/NEJMra0803109			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336XE	18703475				2022-12-28	WOS:000258397900009
J	Lenzer, J				Lenzer, Jeanne			Truly independent research?	BRITISH MEDICAL JOURNAL			English	Editorial Material							CLINICAL-TRIALS; CELECOXIB					jeanne.lenzer@gmail.com						*ASS CLIN RES ORG, 2008, CO PROF QUINT TRANSN; Bertagnolli MM, 2006, NEW ENGL J MED, V355, P873, DOI 10.1056/NEJMoa061355; BREITMEYER J, 2000, REPORTER, V9; *CENTERWATCH, 2008, STAT CLIN TRIALS IND; *CLINICALTRIALS GO, 2008, PROSP RAND EV CEL IN; *HARR INT, 2007, 9 ANN RQ INT SURV 60; Harrill SM, 1999, DRUG INF J, V33, P1033, DOI 10.1177/009286159903300408; LEFEVERS G, 2003, SCI REV MENTAL HLTH; Lenzer Jeanne, 2005, BMJ, V330, P691, DOI 10.1136/bmj.330.7493.691; LUSTGARTEN A, 2005, FORTUNE         0808; March J, 2004, JAMA-J AM MED ASSOC, V292, P807; Mirowski P, 2005, SOC STUD SCI, V35, P503, DOI 10.1177/0306312705052103; *MON, 2005, ADHD STD; Rettig RA, 2000, HEALTH AFFAIR, V19, P129, DOI 10.1377/hlthaff.19.2.129; Shuchman M, 2007, NEW ENGL J MED, V357, P1365, DOI 10.1056/NEJMp078176; Solomon SD, 2008, CIRCULATION, V117, P2104, DOI 10.1161/CIRCULATIONAHA.108.764530	16	6	6	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2008	337	7670							a1332	10.1136/bmj.a1332	http://dx.doi.org/10.1136/bmj.a1332			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354DT	18719008				2022-12-28	WOS:000259619800031
J	Grant, A; Gothard, P; Thwaites, G				Grant, Alison; Gothard, Philip; Thwaites, Guy			Managing drug resistant tuberculosis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							MYCOBACTERIUM-TUBERCULOSIS; DIAGNOSIS		[Grant, Alison; Gothard, Philip; Thwaites, Guy] UCL Hosp, NHS Fdn Trust, London WC1E 6JB, England; [Grant, Alison] Univ London London Sch Hyg & Trop Med, Clin Res Unit, London WC1E 7HT, England; [Thwaites, Guy] Univ London Imperial Coll Sci Technol & Med, Ctr Mol Microbiol & Infect, London SW7 2AZ, England	Oxford University Hospitals NHS Foundation Trust; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; London School of Hygiene & Tropical Medicine; Imperial College London	Grant, A (corresponding author), UCL Hosp, NHS Fdn Trust, London WC1E 6JB, England.	alison.grant@lshtm.ac.uk	Thwaites, Guy E/R-4993-2019	Thwaites, Guy E/0000-0002-2858-2087	UK Department of Health; Wellcome Trust; UCLH/UCL/LSHTM Comprehensive Biomedical Research Centre; National Institute for Health Research [PHCS/03/01] Funding Source: researchfish	UK Department of Health; Wellcome Trust(Wellcome TrustEuropean Commission); UCLH/UCL/LSHTM Comprehensive Biomedical Research Centre; National Institute for Health Research(National Institute for Health Research (NIHR))	We thank the World Heath Organization for providing figure 1. AG is supported by a public health career scientist award from the UK Department of Health and GT is funded by an intermediate fellowship from the Wellcome Trust. All authors receive support from the UCLH/UCL/LSHTM Comprehensive Biomedical Research Centre.	[Anonymous], 2003, AM J RESP CRIT CARE, V167, P603; Dale JW, 2005, J MED MICROBIOL, V54, P575, DOI 10.1099/jmm.0.45959-0; Escombe A Roderick, 2007, PLoS Med, V4, pe68, DOI 10.1371/journal.pmed.0040068; Espinal MA, 2001, INT J TUBERC LUNG D, V5, P887; FOX W, 1999, INT J TUBERC LUNG S2, V3, pS231; Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1; *HLTH PROT AG, 2007, TUB UK ANN REP TUB S; *HLTH PROT AG CTR, 2005, UK MYC SURV NETW REP; Kruijshaar ME, 2008, BRIT MED J, V336, P1231, DOI 10.1136/bmj.39546.573067.25; Leimane V, 2005, LANCET, V365, P318, DOI 10.1016/S0140-6736(05)17786-1; Maguire H, 2002, THORAX, V57, P617, DOI 10.1136/thorax.57.7.617; Mitchison DA, 2005, AM J RESP CRIT CARE, V171, P699, DOI 10.1164/rccm.200411-1603OE; Moore DAJ, 2006, NEW ENGL J MED, V355, P1539, DOI 10.1056/NEJMoa055524; Morrison J, 2008, LANCET INFECT DIS, V8, P359, DOI 10.1016/S1473-3099(08)70071-9; Mukherjee JS, 2004, LANCET, V363, P474, DOI 10.1016/S0140-6736(04)15496-2; Pillay M, 2007, CLIN INFECT DIS, V45, P1409, DOI 10.1086/522987; Sam IC, 2006, EMERG INFECT DIS, V12, P752, DOI 10.3201/eid1205.041339; Shin SS, 2006, EMERG INFECT DIS, V12, P687, DOI 10.3201/eid1204.041256; Taylor Zachary, 2005, Morbidity and Mortality Weekly Report, V54, P1; Tuberculosis Trials Committee iMRCS, 1948, BMJ, V2, P769; Volmink J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003510.pub2; WHO, 2004, INT POL COLL TB HIV; WHO, 2006, STOP TB STRAT; *WHO, 2008, GLOB TUB CONTR 2008; World Health Organization, 2006, GUID PROGR MAN DRUG; World Health Organization (WHO), 2008, ANT DRUG RES WORLD 4; [No title captured]	27	8	8	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 6	2008	337	7669							a1110	10.1136/bmj.a1110	http://dx.doi.org/10.1136/bmj.a1110			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	351JP	18755763	Green Accepted			2022-12-28	WOS:000259420900036
J	Kamerow, D				Kamerow, Douglas			Jabbering about jabs	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Kamerow, Douglas] RTI Int, Manchester, Lancs, England	Research Triangle Institute	Kamerow, D (corresponding author), RTI Int, Manchester, Lancs, England.	dkamerow@rti.org		Kamerow, Douglas/0000-0001-7000-9957				[Anonymous], 2008, MMWR-MORBID MORTAL W, V57, P893; 2008, BMJ, V337, pA1254	2	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 6	2008	337	7669							a1517	10.1136/bmj.a1517	http://dx.doi.org/10.1136/bmj.a1517			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	351JP	18768543				2022-12-28	WOS:000259420900029
J	Welton, AJ; Vickers, MR; Kim, J; Ford, D; Lawton, BA; MacLennan, AH; Meredith, SK; Martin, J; Meade, TW				Welton, Amanda J.; Vickers, Madge R.; Kim, Joseph; Ford, Deborah; Lawton, Beverley A.; MacLennan, Alastair H.; Meredith, Sarah K.; Martin, Jeannett; Meade, Tom W.		WISDOM Team	Health related quality of life after combined hormone replacement therapy: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							ESTROGEN PLUS PROGESTIN; CORONARY-HEART-DISEASE; POSTMENOPAUSAL WOMEN; OVARIECTOMIZED RATS; PHYSICAL HEALTH; SLEEP DURATION; DOUBLE-BLIND; OLDER WOMEN; ESTRADIOL; MENOPAUSE	Objective To assess the effect of combined hormone replacement therapy (HRT) on health related quality of life. Design Randomised placebo controlled double blind trial. Setting General practices in United Kingdom (384), Australia (94), and New Zealand (24). Participants Postmenopausal women aged 50-69 at randomisation; 3721 women with a uterus were randomised to combined oestrogen and progestogen (n=1862) or placebo (n=1859). Data on health related quality of life at one year were available from 1043 and 1087 women, respectively. Interventions Conjugated equine ciestrogen 0.625 mg plus mechroxyprogesterone acetate 2.5/5.0 mg or matched placebo orally daily for one year. Main outcome measures Health related quality of life and psychological wellbeing as measured by the women's health questionnaire. Changes in emotional and physical menopausal symptoms as measured by a symptoms questionnaire and depression by the Centre for Epidemiologic Studies depression scale (CES-D). Overall health related quality of life and overall quality of life as measured by the European quality of life instrument (EuroQol) and visual analogue scale, respectively. Results After one year small but significant improvements were observed in three of nine components of the women's health questionnaire for those taking combined HRT compared with those taking placebo: vasomotor symptoms (P<0.001), sexual functioning (P<0.001), and steep problems (P<0.001). Significantly fewer women in the combined HRT group reported hot flushes (P<0.001), night sweats (P<0.001), aching joints and muscles (P=0.001), insomnia (P<0.001), and vaginal dryness (P<0.0ol) than in the placebo group, but greater proportions reported breast tenderness (P<0.001) or vaginal discharge (P<0.001). Hot flushes were experienced in the combined HRT and placebo groups by. 30% and 29% at trial entry and 9% and 25% at one year, respectively. No significant differences in other menopausal symptoms, depression, or overall quality of life were observed at one year. Conclusions Combined HRT started many years after the menopause can improve health related quality of life. Trial registration ISRCTN 63718836.	[MacLennan, Alastair H.] Univ Adelaide, Womens & Childrens Hosp, Discipline Obstet & Gynaecol, Sch Paediat & Reprod Med, Adelaide, SA 5005, Australia; [Welton, Amanda J.; Vickers, Madge R.; Martin, Jeannett] MRC Gen Practice Res Framework, London NW1 2ND, England; [Kim, Joseph; Meade, Tom W.] London Sch Hyg & Trop Med, London WC1, England; [Ford, Deborah; Meredith, Sarah K.] MRC, Clin Trials Unit, London, England; [Lawton, Beverley A.] Wellington Sch Med & Hlth Sci, Womens Hlth Res Ctr, Dept Primary Hlth Care & Gen Practice, Wellington, New Zealand	University of Adelaide; Womens & Childrens Hospital Australia; University of London; London School of Hygiene & Tropical Medicine; Medical Research Council Clinical Trials Unit; University of Otago	MacLennan, AH (corresponding author), Univ Adelaide, Womens & Childrens Hosp, Discipline Obstet & Gynaecol, Sch Paediat & Reprod Med, Adelaide, SA 5005, Australia.	alastair.maclennan@adelaide.edu.au	Marley, John/F-1239-2010; Stocks, Nigel P/I-1083-2012	Stocks, Nigel/0000-0002-9018-0361; Lawton, Beverley/0000-0003-2447-8386	MRC [G0701113] Funding Source: UKRI; British Heart Foundation Funding Source: Medline; Medical Research Council [G0701113, MC_U122797165] Funding Source: Medline; Department of Health Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health		Almeida OP, 2006, NEUROBIOL AGING, V27, P141, DOI 10.1016/j.neurobiolaging.2004.12.012; Archer DF, 2001, FERTIL STERIL, V75, P1080, DOI 10.1016/S0015-0282(01)01792-7; Ayas NT, 2003, ARCH INTERN MED, V163, P205, DOI 10.1001/archinte.163.2.205; Basson R, 2006, NEW ENGL J MED, V354, P1497, DOI 10.1056/NEJMcp050154; Brunner RL, 2005, ARCH INTERN MED, V165, P1976, DOI 10.1001/archinte.165.17.1976; CELLA DF, 1995, SUPPORT CARE CANCER, V3, P11, DOI 10.1007/BF00343916; Christgau S, 2004, MENOPAUSE, V11, P508, DOI 10.1097/01.WCB.0000121484.18437.98; DALY E, 1993, BRIT MED J, V307, P836, DOI 10.1136/bmj.307.6908.836; de Boer AGEM, 2004, QUAL LIFE RES, V13, P311, DOI 10.1023/B:QURE.0000018499.64574.1f; Dolan P, 1995, SOCIAL TARIFF EUROQO; Dorman P, 1998, STROKE, V29, P63, DOI 10.1161/01.STR.29.1.63; Dorman PJ, 1997, STROKE, V28, P1876, DOI 10.1161/01.STR.28.10.1876; Gangwisch JE, 2006, HYPERTENSION, V47, P833, DOI 10.1161/01.HYP.0000217362.34748.e0; Gordon FT, 1996, HORM BEHAV, V30, P244, DOI 10.1006/hbeh.1996.0029; Gottlieb DJ, 2005, ARCH INTERN MED, V165, P863, DOI 10.1001/archinte.165.8.863; Hays J, 2003, NEW ENGL J MED, V348, P1839, DOI 10.1056/NEJMoa030311; Hlatky MA, 2002, JAMA-J AM MED ASSOC, V287, P591, DOI 10.1001/jama.287.5.591; HUNTER M, 1992, PSYCHOL HEALTH, V7, P45, DOI 10.1080/08870449208404294; Hunter M, 2000, QUAL LIFE RES, V9, P733, DOI 10.1023/A:1008973822876; Hyland ME, 1996, QUAL LIFE RES, V5, P469, DOI 10.1007/BF00540019; Hyland Michael E, 2003, Health Qual Life Outcomes, V1, P24, DOI 10.1186/1477-7525-1-24; Jenkinson C, 1997, MED CARE, V35, P1109, DOI 10.1097/00005650-199711000-00003; Juniper EF, 1998, J ALLERGY CLIN IMMUN, V102, P16, DOI 10.1016/S0091-6749(98)70048-X; Kind P., 1996, QUALITY LIFE PHARMAC, V2nd; Kuba T, 2006, HORM BEHAV, V49, P441, DOI 10.1016/j.yhbeh.2005.09.007; LIAO KLM, 1995, PSYCHOL HEALTH, V10, P171, DOI 10.1080/08870449508401947; LIMOUZINLAMOTHE MA, 1994, AM J OBSTET GYNECOL, V170, P618, DOI 10.1016/S0002-9378(94)70239-X; Lopes AA, 2004, NEW ENGL J MED, V350, P622; Maki PM, 2007, NEUROLOGY, V69, P1322, DOI 10.1212/01.wnl.0000277275.42504.93; Minelli C, 2004, BMJ-BRIT MED J, V328, P371, DOI 10.1136/bmj.328.7436.371; Morrison MF, 2004, BIOL PSYCHIAT, V55, P406, DOI 10.1016/j.biopsych.2003.08.011; Mottola C A, 1993, Decubitus, V6, P56; Ockene JK, 2005, JAMA-J AM MED ASSOC, V294, P183, DOI 10.1001/jama.294.2.183; Phillips LS, 2005, FERTIL STERIL, V83, P558, DOI 10.1016/j.fertnstert.2004.11.012; Pines A, 2007, CLIMACTERIC, V10, P181, DOI 10.1080/13697130701361657; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROBERTS RE, 1983, AM J PSYCHIAT, V140, P41; Rosenthal MB, 2003, MENOPAUSE, V10, P4, DOI 10.1097/01.GME.0000043670.63447.A3; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Salpeter SR, 2006, J GEN INTERN MED, V21, P363, DOI 10.1111/j.1525-1497.2006.00389.x; Salpeter SR, 2004, J GEN INTERN MED, V19, P791, DOI 10.1111/j.1525-1497.2004.30281.x; Schmidt PJ, 2000, AM J OBSTET GYNECOL, V183, P414, DOI 10.1067/mob.2000.106004; Soares CD, 2001, ARCH GEN PSYCHIAT, V58, P529; Szoeke CEI, 2005, CLIMACTERIC, V8, P49, DOI 10.1080/13697130400012296; TESTA MA, 1994, ANNU REV PUBL HEALTH, V15, P535; VANAGT HME, 1994, SOC SCI MED, V39, P1537, DOI 10.1016/0277-9536(94)90005-1; Vickers M, 2002, CLIMACTERIC, V5, P317, DOI 10.1080/713605309; Vickers Madge R, 2007, BMC Womens Health, V7, P2, DOI 10.1186/1472-6874-7-2; Vickers MR, 2007, BMJ-BRIT MED J, V335, P239, DOI 10.1136/bmj.39266.425069.AD; Zethraeus N, 1997, BRIT J OBSTET GYNAEC, V104, P1191, DOI 10.1111/j.1471-0528.1997.tb10945.x	50	110	114	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 6	2008	337	7669							a1190	10.1136/bmj.a1190	http://dx.doi.org/10.1136/bmj.a1190			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	351JP	18719013	Green Accepted, Green Published, hybrid			2022-12-28	WOS:000259420900032
J	Rowley, JD; Blumenthal, T				Rowley, Janet D.; Blumenthal, Thomas			Medicine - The cart before the horse	SCIENCE			English	Editorial Material							CHROMOSOMAL TRANSLOCATIONS; LEUKEMIA; TRANSCRIPTION		[Rowley, Janet D.] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Blumenthal, Thomas] Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	University of Chicago; University of Colorado System; University of Colorado Boulder	Rowley, JD (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave,MC 2115, Chicago, IL 60637 USA.	jrowley@medicine.bsd.uchicago.edu; tom.blumenthal@colorado.edu						BLUMENTHAL T, WORMBOOK; Dorn R, 2001, P NATL ACAD SCI USA, V98, P9724, DOI 10.1073/pnas.151268698; Hochhaus A, 2008, BLOOD, V111, P1039, DOI 10.1182/blood-2007-07-103523; Janz S, 2003, GENE CHROMOSOME CANC, V36, P211, DOI 10.1002/gcc.10178; Li H, 2008, SCIENCE, V321, P1357, DOI 10.1126/science.1156725; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; MCKEITHAN TW, 1990, SEMIN ONCOL, V17, P30; Mitchell JA, 2008, GENE DEV, V22, P20, DOI 10.1101/gad.454008; Mitelman F, 2004, NAT GENET, V36, P331, DOI 10.1038/ng1335; Nowacki M, 2008, NATURE, V451, P153, DOI 10.1038/nature06452; Osborne CS, 2007, PLOS BIOL, V5, P1763, DOI 10.1371/journal.pbio.0050192; Rowley JD, 2001, NAT REV CANCER, V1, P245, DOI 10.1038/35106108; Takahara T, 2005, MOL CELL, V18, P245, DOI 10.1016/j.molcel.2005.03.018; Zhang YM, 2006, DNA REPAIR, V5, P1282, DOI 10.1016/j.dnarep.2006.05.020	14	16	16	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	2008	321	5894					1302	1304		10.1126/science.1163791	http://dx.doi.org/10.1126/science.1163791			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	344GG	18772424				2022-12-28	WOS:000258914300034
J	Gallego, PH; Craig, ME; Hing, S; Donaghue, KC				Gallego, Patricia Herold; Craig, Maria E.; Hing, Stephen; Donaghue, Kim C.			Role of blood pressure in development of early retinopathy in adolescents with, type 1 diabetes: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INCIDENT COHORT; YOUNG-PATIENTS; MELLITUS; PROGRESSION; PREVALENCE; RISK; COMPLICATIONS; HYPERTENSION; POPULATION; ALBUMINURIA	Objective To examine the relation between blood pressure and the development of early retinopathy in adolescents with childhood onset type 1 diabetes. Design Prospective cohort study. Setting Diabetes Complications Assessment Service at the Children's Hospital at Westmead, Sydney, Australia. Participants 1869 patients with type 1 diabetes (54% female) screened for retinopathy with baseline median age 13.4 (interquartile range 12.0-15.2) years, duration 4.9 (3.1-7.0) years, and albumin excretion rate of 4.4 (3.16.8) mu g/min plus a subgroup of 1093 patients retinopathy-free at baseline and followed for a median 4.1 (2.4-6.6) years. Main outcome measures Early background retinopathy; blood pressure. Results Overall, retinopathy developed in 673 (36%) participants at anytime point. In the retinopathy-free group, higher systolic blood pressure (odds ratio 1.01, 95% confidence interval 1.003 to 1.02) and diastolic blood pressure (1.01, 1.002 to 1.03) were predictors of retinopathy, after adjustment for albumin excretion rate (1.27,1.13 to 1.42), haemoglobin A(1c) (1.08,1.02 to 1.15), duration of diabetes (1.16, 1.13 to 1.19), age (1.13, 1.08 to 1.17), and height (0.98, 0.97 to 0.99). In a subgroup of 1025 patients with albumin excretion rate below 7.5 mu g/ min, the cumulative risk of retinopathy at 10 years' duration of diabetes was higher for those with systolic blood pressure on or above the 90th centile compared with those below the 90th centile (58% v 35%, P=0.03). The risk was also higher for patients with diastolic blood pressure on or above the 90th centile compared with those below the 90th centile (57% v 35%, P=0.005). Conclusions Both systolic and diastolic blood pressure are predictors of retinopathy and increase the probability of early retinopathy independently of incipient nephropathy in young patients with type 1 diabetes.	[Gallego, Patricia Herold; Craig, Maria E.; Hing, Stephen; Donaghue, Kim C.] Childrens Hosp Westmead, Inst Endocrinol & Diabet, Westmead, NSW 2145, Australia; [Craig, Maria E.; Donaghue, Kim C.] Univ Sydney, Discipline Paediat & Child Hlth, Sydney, NSW 2006, Australia; [Craig, Maria E.] Univ New S Wales, Sch Womens & Childrens Hlth, Sydney, NSW 2052, Australia	University of Sydney; University of Sydney; University of New South Wales Sydney	Donaghue, KC (corresponding author), Childrens Hosp Westmead, Inst Endocrinol & Diabet, Locked Bag 4001, Westmead, NSW 2145, Australia.	KimD@chw.edu.au		Craig, Maria E/0000-0001-6004-576X				Agardh CD, 1997, DIABETES RES CLIN PR, V35, P113, DOI 10.1016/S0168-8227(97)01386-7; Alibrahim E, 2006, OPHTHALMOLOGY, V113, P1499, DOI 10.1016/j.ophtha.2006.05.009; Amer Diabet Assoc, 2002, DIABETES CARE, V25, P199; [Anonymous], 1991, Ophthalmology, V98, P786; CDC, 2022, ANN REP EM INF PROGR; Chaturvedi N, 1998, LANCET, V351, P28, DOI 10.1016/S0140-6736(97)06209-0; CIGNARELLI M, 1992, DIABETES CARE, V15, P1002, DOI 10.2337/diacare.15.8.1002; Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240; DANSER AHJ, 1994, INVEST OPHTH VIS SCI, V35, P1008; Donaghue KC, 2005, DIABETIC MED, V22, P711, DOI 10.1111/j.1464-5491.2005.01527.x; EROSS J, 1984, ANN CLIN BIOCHEM, V21, P477, DOI 10.1177/000456328402100606; Estacio RO, 1998, AM J KIDNEY DIS, V31, P947, DOI 10.1053/ajkd.1998.v31.pm9631838; Falkner B, 1996, PEDIATRICS, V98, P649; Fleiss J. L., 1981, STAT METHODS RATES P, V2; Guillausseau PJ, 1998, DIABETIC MED, V15, P151, DOI 10.1002/(SICI)1096-9136(199802)15:2<151::AID-DIA527>3.3.CO;2-9; Guillausseau PJ, 1998, DIABETIC MED, V15, P709; *INT SOC PED AD DI, 2000, ISPAD CONS GUID MAN, P95; Kernell A, 1997, DIABETOLOGIA, V40, P307, DOI 10.1007/s001250050679; KLEIN BEK, 1995, ARCH OPHTHALMOL-CHIC, V113, P601, DOI 10.1001/archopht.1995.01100050069033; Klein BEK, 1996, ARCH OPHTHALMOL-CHIC, V114, P109; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; Klein R, 1998, OPHTHALMOLOGY, V105, P1801, DOI 10.1016/S0161-6420(98)91020-X; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; Larsson LI, 1999, ACTA OPHTHALMOL SCAN, V77, P430, DOI 10.1034/j.1600-0420.1999.770415.x; LeCaire T, 2006, AM J EPIDEMIOL, V164, P143, DOI 10.1093/aje/kwj166; MARSHALL G, 1993, OPHTHALMOLOGY, V100, P1133; Matthews DR, 2004, ARCH OPHTHALMOL-CHIC, V122, P1631; Mohsin F, 2005, DIABETES CARE, V28, P1974, DOI 10.2337/diacare.28.8.1974; Nazaimoon EMW, 1999, DIABETES RES CLIN PR, V46, P213; Nordwall M, 2006, J PEDIATR ENDOCR MET, V19, P45; Nordwall M, 2004, DIABETOLOGIA, V47, P1266, DOI 10.1007/s00125-004-1431-6; NORGAARD K, 1991, DIABETIC MED, V8, P334, DOI 10.1111/j.1464-5491.1991.tb01606.x; Patel A, 2007, LANCET, V370, P829, DOI 10.1016/S0140-6736(07)61303-8; PATEL V, 1992, BMJ-BRIT MED J, V305, P678, DOI 10.1136/bmj.305.6855.678; RASSAM SMB, 1995, EXP PHYSIOL, V80, P53, DOI 10.1113/expphysiol.1995.sp003834; Roy MS, 2000, ARCH OPHTHALMOL-CHIC, V118, P105; Schrier RW, 2002, KIDNEY INT, V61, P1086, DOI 10.1046/j.1523-1755.2002.00213.x; Skrivarhaug T, 2006, DIABETOLOGIA, V49, P2281, DOI 10.1007/s00125-006-0364-7; Strippoli GFM, 2005, J AM SOC NEPHROL, V16, P3081, DOI 10.1681/ASN.2004080634; Taplin CE, 2005, MED J AUSTRALIA, V183, P243, DOI 10.5694/j.1326-5377.2005.tb07028.x; Taylor RH, 1997, EYE, V11, P547, DOI 10.1038/eye.1997.141; ZEGER SL, 1989, BIOMETRICS, V45, P347	42	73	75	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 30	2008	337	7668							a918	10.1136/bmj.a918	http://dx.doi.org/10.1136/bmj.a918			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350OM	18728082	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000259362100027
J	Detsky, ME; Etchells, E				Detsky, Michael E.; Etchells, Edward			Single-patient rooms for safe patient-centered hospitals	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RESISTANT STAPHYLOCOCCUS-AUREUS; CARE		[Etchells, Edward] Sunnybrook Hlth Sci Ctr, Div Gen Internal Med, Patient Safety Serv, Toronto, ON M4N 3M5, Canada; [Etchells, Edward] Sunnybrook Hlth Sci Ctr, Ctr Hlth Serv Sci, Toronto, ON M4N 3M5, Canada; [Detsky, Michael E.; Etchells, Edward] Univ Toronto, Dept Med, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Etchells, E (corresponding author), Sunnybrook Hlth Sci Ctr, Div Gen Internal Med, Patient Safety Serv, 2075 Bayview Ave,Room C410, Toronto, ON M4N 3M5, Canada.	edward.etchells@sunnybrook.ca						Bacon A, 1920, JAMA-J AM MED ASSOC, V74, P123; Barlas D, 2001, ANN EMERG MED, V38, P135, DOI 10.1067/mem.2001.115441; Cepeda JA, 2005, LANCET, V365, P295, DOI 10.1016/S0140-6736(05)17783-6; Cooper BS, 2004, BMJ-BRIT MED J, V329, P533, DOI 10.1136/bmj.329.7465.533; Hendrich AL, 2004, AM J CRIT CARE, V13, P35, DOI 10.4037/ajcc2004.13.1.35; Janssen PA, 2000, BIRTH-ISS PERINAT C, V27, P235, DOI 10.1046/j.1523-536x.2000.00235.x; Stelfox HT, 2003, JAMA-J AM MED ASSOC, V290, P1899, DOI 10.1001/jama.290.14.1899; ULRICH R, 2004, ROLE PHYS ENV 21 CEN, P10; Ulrich RS, 2006, LANCET, V368, pS38, DOI 10.1016/S0140-6736(06)69921-2; *US DEP HHS, 2006, 2006 GUID DES CONSTR; Vietri NJ, 2004, AM J INFECT CONTROL, V32, P262, DOI 10.1016/j.ajic.2003.12.006; 2003, USE SINLE PATIENT RO	12	35	36	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2008	300	8					954	956		10.1001/jama.300.8.954	http://dx.doi.org/10.1001/jama.300.8.954			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	341AR	18728270				2022-12-28	WOS:000258687100031
J	Armitage, PJ				Armitage, Philip J.			Astronomy - Stars in the making	SCIENCE			English	Editorial Material							SUPERMASSIVE BLACK-HOLE; GALACTIC-CENTER; CENTRAL PARSEC; GALAXY; DISKS; DYNAMICS; YOUTH		Univ Colorado, Joint Inst Lab Astrophys, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Armitage, PJ (corresponding author), Univ Colorado, Joint Inst Lab Astrophys, Boulder, CO 80309 USA.	pja@jilau1.colorado.edu						Alexander RD, 2008, ASTROPHYS J, V674, P927, DOI 10.1086/525519; Bender R, 2005, ASTROPHYS J, V631, P280, DOI 10.1086/432434; Bonnell IA, 2008, SCIENCE, V321, P1060, DOI 10.1126/science.1160653; Brown WR, 2006, ASTROPHYS J, V647, P303, DOI 10.1086/505165; Genzel R, 2000, MON NOT R ASTRON SOC, V317, P348, DOI 10.1046/j.1365-8711.2000.03582.x; Gerhard O, 2001, ASTROPHYS J, V546, pL39, DOI 10.1086/318054; Ghez AM, 2003, ASTROPHYS J, V586, pL127, DOI 10.1086/374804; HILLS JG, 1988, NATURE, V331, P687, DOI 10.1038/331687a0; Kolykhalov P.I., 1980, SOV ASTRON LETT+, V6, P357; Lu JR, 2006, J PHYS CONF SER, V54, P279, DOI 10.1088/1742-6596/54/1/044; Morris M, 1996, ANNU REV ASTRON ASTR, V34, P645, DOI 10.1146/annurev.astro.34.1.645; Nayakshin S, 2005, MON NOT R ASTRON SOC, V364, pL23, DOI 10.1111/j.1745-3933.2005.00097.x; Paumard T, 2006, ASTROPHYS J, V643, P1011, DOI 10.1086/503273; Schodel R, 2002, NATURE, V419, P694, DOI 10.1038/nature01121	15	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 22	2008	321	5892					1047	1048		10.1126/science.1162876	http://dx.doi.org/10.1126/science.1162876			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339RL	18719270				2022-12-28	WOS:000258594900024
J	Schenker, Y; Lo, B; Ettinger, KM; Fernandez, A				Schenker, Yael; Lo, Bernard; Ettinger, Katharine M.; Fernandez, Alicia			Navigating language barriers under difficult circumstances	ANNALS OF INTERNAL MEDICINE			English	Article							LIMITED ENGLISH PROFICIENCY; SPANISH-SPEAKING PATIENTS; HEALTH-CARE; EMERGENCY-DEPARTMENT; INTERPRETER SERVICES; PHYSICIAN LANGUAGE; SATISFACTION; QUALITY; ACCESS; IMPACT	The proportion of the U. S. population with limited English proficiency is growing. Physicians often find themselves caring for patients with limited English proficiency in settings with limited language services. There has been little exploration of the decisions physicians face when providing care across language barriers. The authors offer a conceptual framework to aid physicians in thinking through difficult choices about language services and provide responses to common questions encountered in the care of patients with limited English proficiency. Specifically, they describe 4 factors that should inform the decision to call an interpreter (the clinical situation, degree of language gap, available resources, and patient preference), discuss who may be an appropriate interpreter, and offer strategies for when a professional interpreter is not available. The authors use a hypothetical case to illustrate how decisions about language services may evolve over the course of an interaction. This conceptual and practical approach can help clinicians to improve the quality of care provided to patients with limited English proficiency.	[Fernandez, Alicia] Univ Calif San Francisco, San Francisco, CA 94143 USA; Calif Pacific Med Ctr, San Francisco, CA USA	University of California System; University of California San Francisco; California Pacific Medical Center	Fernandez, A (corresponding author), Univ Calif San Francisco, Box 1364, San Francisco, CA 94143 USA.	afernandez@medsfgh.ucsf.edu			National Institutes of Health (NIH) [MH062246]; Career Development Award [K23-RR018324-01]; NIH Roadmap Clinical and Translational Sciences Award [U01 AI46749]; Greenwall Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES [K23RR018342, G20RR018324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI046749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH062246] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Career Development Award; NIH Roadmap Clinical and Translational Sciences Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Greenwall Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	The authors thank Leila Alpers, Robert Brody, Leah Karliner, and Jeff Kohlwes for their comments on an earlier draft of this manuscript.; Grant Support: By the National Institutes of Health (NIH) Career Development Award K23-RR018324-01 (Dr. Fernandez) and NIH Center Grant MH062246 (Dr. Lo), NIH Roadmap Clinical and Translational Sciences Award U01 AI46749 (Dr. Lo), and the Greenwall Foundation (Dr. Lo).	Abbe M, 2006, PEDIATR BLOOD CANCER, V47, P819, DOI 10.1002/pbc.20841; [Anonymous], 2006, HOSP LANGUAGE SERVIC; Apter AJ, 1998, AM J RESP CRIT CARE, V157, P1810, DOI 10.1164/ajrccm.157.6.9712007; Baker DW, 1998, MED CARE, V36, P1461, DOI 10.1097/00005650-199810000-00004; *CAL AC FAM PHYS, 2007, ADDR LANG CULT PRACT; Carrasquillo O, 1999, J GEN INTERN MED, V14, P82, DOI 10.1046/j.1525-1497.1999.00293.x; Chen A. H., 2007, Medical management of vulnerable and underserved patients: principles, practice, and populations, P265; Chen AH, 2007, J GEN INTERN MED, V22, P362, DOI 10.1007/s11606-007-0366-2; Cohen AL, 2005, PEDIATRICS, V116, P575, DOI 10.1542/peds.2005-0521; DIAMOND L, 2008, GETTING USE INTERPRE; Divi C, 2007, INT J QUAL HEALTH C, V19, P60, DOI 10.1093/intqhc/mzl069; DOWER C, 2007, IMPROVING LANGUAGE A; Elderkin-Thompson V, 2001, SOC SCI MED, V52, P1343, DOI 10.1016/S0277-9536(00)00234-3; Fernandez A, 2004, J GEN INTERN MED, V19, P167, DOI 10.1111/j.1525-1497.2004.30266.x; Flores G, 2005, MED CARE RES REV, V62, P255, DOI 10.1177/1077558705275416; Flores G, 2003, PEDIATRICS, V111, P6, DOI 10.1542/peds.111.1.6; Flores G, 2006, NEW ENGL J MED, V355, P229, DOI 10.1056/NEJMp058316; Gadon M, 2007, J GEN INTERN MED, V22, P341, DOI 10.1007/s11606-007-0311-4; Garcia EA, 2004, PEDIATR EMERG CARE, V20, P373, DOI 10.1097/01.pec.0000133611.42699.08; Grubbs V, 2006, J GEN INTERN MED, V21, P683, DOI 10.1111/j.1525-1497.2006.00492.x; JACOBS B, 1995, J ROY SOC MED, V88, pP474; Joint Commission, 2008, JOINT COMM 2008 REQ; Karliner LS, 2007, HEALTH SERV RES, V42, P727, DOI 10.1111/j.1475-6773.2006.00629.x; Karliner LS, 2004, J GEN INTERN MED, V19, P175, DOI 10.1111/j.1525-1497.2004.30268.x; Kuo D, 1999, J GEN INTERN MED, V14, P547, DOI 10.1046/j.1525-1497.1999.07258.x; Kuo DZ, 2007, PEDIATRICS, V119, pE920, DOI 10.1542/peds.2006-1508; Lee KC, 2006, JAMA-J AM MED ASSOC, V296, P1050, DOI 10.1001/jama.296.9.1050; Moreno MR, 2007, J GEN INTERN MED, V22, P331, DOI 10.1007/s11606-007-0344-8; O'Leary SCB, 2003, PEDIATRICS, V111, pE569, DOI 10.1542/peds.111.5.e569; Perkins J, 2003, ENSURING LINGUISTIC; Regenstein M, 2007, J GEN INTERN MED, V22, P356, DOI 10.1007/s11606-007-0358-2; Schenker Y, 2007, J GEN INTERN MED, V22, P294, DOI 10.1007/s11606-007-0359-1; Schyve PM, 2007, J GEN INTERN MED, V22, P360, DOI 10.1007/s11606-007-0365-3; U. S. Department of Health and Human Services Office of Minority Health, NAT STAND CULT LING; Wilson E, 2005, J GEN INTERN MED, V20, P800, DOI 10.1111/j.1525-1497.2005.0174.x; WILSONSTRONKS A, 2007, HOSP LANGUAGE CULTUR; Youdelman MK, 2008, HEALTH AFFAIR, V27, P424, DOI 10.1377/hlthaff.27.2.424	37	44	44	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 19	2008	149	4					264	+		10.7326/0003-4819-149-4-200808190-00008	http://dx.doi.org/10.7326/0003-4819-149-4-200808190-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	338RQ	18711157	Green Accepted			2022-12-28	WOS:000258526700006
J	Peake, STC; Mason, JC; Mittal, T; Amrani, M; Mohiaddin, R; Bell, A; Grocott-Mason, R; Dubrey, SW				Peake, Simon T. C.; Mason, Justin C.; Mittal, Tarun; Amrani, Mohamed; Mohiaddin, Raad; Bell, Alex; Grocott-Mason, Richard; Dubrey, Simon W.			Growing pains - and a heart attack	LANCET			English	Editorial Material							TAKAYASU-ARTERITIS		[Peake, Simon T. C.; Grocott-Mason, Richard; Dubrey, Simon W.] Hillingdon Hosp, Dept Cardiol, Uxbridge UB8 3NN, Middx, England; [Mason, Justin C.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Rheumatol Unit, London, England; [Mittal, Tarun] Harefield Hosp, Dept Radiol, Harefield UB9 6JH, Middx, England; [Amrani, Mohamed] Harefield Hosp, Dept Cardiothorac Surg, Harefield UB9 6JH, Middx, England; [Mohiaddin, Raad] Royal Brompton Hosp, Dept Radiol, London SW3 6LY, England; [Bell, Alex] Royal Brompton Hosp, Dept Pathol, London SW3 6LY, England; [Bell, Alex] Harefield Hosp, Dept Pathol, Harefield UB9 6JH, Middx, England	Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; Royal Brompton Hospital; Royal Brompton Hospital; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital	Dubrey, SW (corresponding author), Hillingdon Hosp, Dept Cardiol, Pield Hlth Rd, Uxbridge UB8 3NN, Middx, England.	simon.dubrey@thh.nhs.uk		Mason, Justin/0000-0001-7783-1660				Cakar N, 2008, J RHEUMATOL, V35, P913; KERR GS, 1994, ANN INTERN MED, V120, P919, DOI 10.7326/0003-4819-120-11-199406010-00004; LUPIHERRERA E, 1977, AM HEART J, V93, P94, DOI 10.1016/S0002-8703(77)80178-6; NAKAO K, 1967, CIRCULATION, V35, P1141, DOI 10.1161/01.CIR.35.6.1141; Steeds RP, 2006, INT J CARDIOL, V109, P1, DOI 10.1016/j.ijcard.2004.09.023	5	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 16	2008	372	9638					600	600		10.1016/S0140-6736(08)61238-6	http://dx.doi.org/10.1016/S0140-6736(08)61238-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339MS	18707988				2022-12-28	WOS:000258582300033
J	Nampiaparampil, DE				Nampiaparampil, Devi E.			Prevalence of chronic pain after traumatic brain injury - A systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							POSTTRAUMATIC-STRESS-DISORDER; SHELL SHOCK; HEAD-INJURY; MINOR HEAD; SYMPTOMS; DISABILITY; SEVERITY; VETERANS	Context The Centers for Disease Control and Prevention estimates that approximately 1.4 million US individuals sustain traumatic brain injuries (TBIs) per year. Previous reports suggest an association between TBI and chronic pain syndromes (eg, headache) thought to be more common in patients with mild TBI and in those who have sustained brain injury from violent rather than unintentional trauma. Comorbid psychiatric disorders such as posttraumatic stress disorder (PTSD) may also mediate chronic pain symptoms. Objectives To determine the prevalence of chronic pain as an underdiagnosed consequence of TBI and to review the interaction between chronic pain and severity of TBI as well as the characteristics of pain after TBI among civilians and combatants. Evidence Acquisition The Ovid/MEDLINE database was searched for articles published between 1951 and February 2008 using any combination of the terms brain injury, pain, headache, blast injury, and combat (combat disorders, war, military medicine, wounds and injuries, military personnel, veterans). The PubMed and MD Consult databases were searched in a similar fashion. The Cochrane Collaboration, National Institutes of Health Clinical Trials Database, Meta-Register of Current Controlled Trials, and CRISP databases were searched using the keyword brain injury. All articles in peer-reviewed journals reporting original data on pain syndromes in adult patients with TBI with regard to pain prevalence, pain category, risk factors, pathogenesis, and clinical course were selected, and manual searches were performed of their reference lists. The data were pooled and prevalence rates calculated. Evidence Synthesis Twenty-three studies (15 cross-sectional, 5 prospective, and 3 retrospective) including 4206 patients were identified. Twelve studies assessed headache pain in 1670 patients. Of these, 966 complained of chronic headache, yielding a prevalence of 57.8% (95% confidence interval [CI], 55.5%-60.2%). Among civilians, the prevalence of chronic pain was greater in patients with mild TBI (75.3% [95% CI, 72.7%-77.9%]) compared with moderate or severe TBI (32.1% [95% CI, 29.3%34.9%]). Twenty studies including 3289 civilian patients with TBI yielded a chronic pain prevalence of 51.5% (95% CI, 49.8%-53.2%). Three studies assessed TBI among 917 veterans and yielded a pain prevalence of 43.1% (95% CI, 39.9%-46.3%). PTSD may mediate chronic pain, but brain injury appears to have an independent correlation with chronic pain. Conclusions Chronic pain is a common complication of TBI. It is independent of psychologic disorders such as PTSD and depression and is common even among patients with apparently minor injuries to the brain.	[Nampiaparampil, Devi E.] Vet Affairs Cent Calif Healthcare Syst, Dept Neurol & Rehabil, Fresno, CA 93703 USA; [Nampiaparampil, Devi E.] Vet Affairs Cent Calif Healthcare Syst, Dept Internal Med, Fresno, CA 93703 USA		Nampiaparampil, DE (corresponding author), Vet Affairs Cent Calif Healthcare Syst, Dept Neurol & Rehabil, 2615 E Clinton Ave, Fresno, CA 93703 USA.	devichechi@gmail.com						Alfano DP, 2000, ARCH CLIN NEUROPSYCH, V15, P831, DOI 10.1016/S0887-6177(00)80329-7; Allerdings MD, 2006, BRAIN COGNITION, V60, P193, DOI 10.1016/j.bandc.2004.09.018; ANDERSEN G, 1995, PAIN, V61, P187, DOI 10.1016/0304-3959(94)00144-4; Asmundson GJG, 2004, EUR J PAIN, V8, P345, DOI 10.1016/j.ejpain.2003.10.008; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; Bombardier CH, 2002, ARCH PHYS MED REHAB, V83, P1765, DOI 10.1053/apmr.2002.36085; Bryant RA, 1999, J HEAD TRAUMA REHAB, V14, P588, DOI 10.1097/00001199-199912000-00007; *CDCP, 1999, FACTS CONC BRAIN INJ; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; COSGROVE JL, 1989, AM J PHYS MED REHAB, V68, P15, DOI 10.1097/00002060-198902000-00005; De Benedittis G, 1983, J Neurosurg Sci, V27, P177; FIORAVANTI M, 1983, CEPHALALGIA, V3, P221, DOI 10.1177/03331024830030S137; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; Geisser ME, 1996, PAIN, V66, P207, DOI 10.1016/0304-3959(96)03038-2; GELLMAN H, 1992, PAIN, V51, P307, DOI 10.1016/0304-3959(92)90214-V; Geuze E, 2007, ARCH GEN PSYCHIAT, V64, P76, DOI 10.1001/archpsyc.64.1.76; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; *HEAD INJ INT SPEC, 1993, J HEAD TRAUMA REHAB, V8, P86; Hoffman JM, 2007, AM J PHYS MED REHAB, V86, P962, DOI 10.1097/PHM.0b013e31815b5ee5; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; JENSEN OK, 1990, CEPHALALGIA, V10, P285, DOI 10.1046/j.1468-2982.1990.1006285.x; KIRSCHBLUM S, 2001, SPINAL CORD INJURY M; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Landy PJB, 1998, INJURY, V29, P199, DOI 10.1016/S0020-1383(97)00178-2; Langlois JA, 2004, TRAUMATIC BRAIN INJU; Leung J, 2007, CLIN REHABIL, V21, P171, DOI 10.1177/0269215506070254; Meltzer-Brody S, 2007, OBSTET GYNECOL, V109, P902, DOI 10.1097/01.AOG.0000258296.35538.88; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Murray CK, 2005, MIL MED, V170, P516, DOI 10.7205/MILMED.170.6.516; Myers CS, 1915, LANCET, V1, P316; *OFF COMM PUBL LAI, 2003, NIH PUBL; *OFF COMM PUBL LIA, 2002, NIH PUBL; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Schaller WF, 1939, J AMER MED ASSOC, V113, P1779; Shaffer RA, 1999, MIL MED, V164, P17, DOI 10.1093/milmed/164.1.17; Sherman Kristen Brewer, 2006, Phys Med Rehabil Clin N Am, V17, P473, DOI 10.1016/j.pmr.2005.11.007; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; TANELIAN T, 2008, RAND MONOGRAPHS; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Warden DL, 2005, J NEUROTRAUM, V22, P1178; WARDEN DL, 2005, WAR NEUROTRAUMA DEFE, P60; Whalley MG, 2007, PAIN, V132, P332, DOI 10.1016/j.pain.2007.08.011; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x; Zafonte R, 2004, J HEAD TRAUMA REHAB, V19, P89, DOI 10.1097/00001199-200403000-00002	50	392	398	2	42	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	2008	300	6					711	719		10.1001/jama.300.6.711	http://dx.doi.org/10.1001/jama.300.6.711			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336OM	18698069				2022-12-28	WOS:000258374500023
J	Stover, E; Vinck, P				Stover, Eric; Vinck, Patrick			Cyclone Nargis and the politics of relief and reconstruction aid in Burma (Myanmar)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Stover, Eric; Vinck, Patrick] Univ Calif Berkeley, Human Rights Ctr, Berkeley, CA 94720 USA; [Stover, Eric] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; [Stover, Eric] Univ Calif Berkeley, Boalt Hall Sch Law, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Stover, E (corresponding author), Univ Calif Berkeley, Human Rights Ctr, 460 Stephens Hall 2300, Berkeley, CA 94720 USA.	stovere@berkeley.edu						CUNY F, 1983, DISASTERS DEV, P94; Human Rights Center, 2005, TSUN HUM RIGHTS VULN; *INT REG INF NETW, 2008, MYANM FOOD ASS LIK U; Pearce L, 2003, NAT HAZARDS, V28, P211, DOI 10.1023/A:1022917721797; PETRIE C, END MISSION REPORT; SIDDIQUE AK, 1987, TROP GEOGR MED, V26, P3; STOVER E, 2007, GATHERING STORM INFE, P53; *UN OFF HIGH COMM, GUID PRINC INT DISPL; *UNICEF, GLANC MYANM; VanRooyen M, 2005, NEW ENGL J MED, V352, P435, DOI 10.1056/NEJMp058013; WHO, 2007, COUNTR HLTH SYST PRO; *WHO, STAT ANN WORLD HLTH	13	18	18	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	2008	300	6					729	731		10.1001/jama.300.6.729	http://dx.doi.org/10.1001/jama.300.6.729			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336OM	18698074				2022-12-28	WOS:000258374500028
J	Ishikawa, H; Barber, GN				Ishikawa, Hiroki; Barber, Glen N.			STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling	NATURE			English	Article							RIG-I; ANTIVIRAL RESPONSES; PROTEIN-SYNTHESIS; RNA VIRUSES; KAPPA-B; RECOGNITION; ACTIVATION; MECHANISM; HELICASES; PATHWAY	The cellular innate immune system is essential for recognizing pathogen infection and for establishing effective host defence. But critical molecular determinants responsible for facilitating an appropriate immune response - following infection with DNA and RNA viruses, for example - remain to be identified. Here we report the identification, following expression cloning, of a molecule ( STING; stimulator of interferon genes) that appears essential for effective innate immune signalling processes. It comprises five putative transmembrane regions, predominantly resides in the endoplasmic reticulum and is able to activate both NF-kappa B and IRF3 transcription pathways to induce expression of type I interferon (IFN-alpha and IFN-beta) and exert a potent anti- viral state following expression. In contrast, loss of STING rendered murine embryonic fibroblasts extremely susceptible to negative-stranded virus infection, including vesicular stomatitis virus. Further, STING ablation abrogated the ability of intracellular B-form DNA, as well as members of the herpesvirus family, to induce IFN-beta, but did not significantly affect the Toll- like receptor ( TLR) pathway. Yeast two- hybrid and co- immunoprecipitation studies indicated that STING interacts with RIG- I and with SSR2 ( also known as TRAP beta), which is a member of the translocon-associated protein ( TRAP) complex required for protein translocation across the endoplasmic reticulum membrane following translation(1,2.) Ablation by RNA interference of both TRAPb and translocon adaptor SEC61 beta was subsequently found to inhibit STING's ability to stimulate expression of IFN-beta. Thus, as well as identifying a regulator of innate immune signalling, our results imply a potential role for the translocon in innate signalling pathways activated by select viruses as well as intracellular DNA.	[Ishikawa, Hiroki; Barber, Glen N.] Univ Miami, Sch Med, Dept Med, Miami, FL 33136 USA; [Ishikawa, Hiroki; Barber, Glen N.] Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA	University of Miami; University of Miami	Barber, GN (corresponding author), Univ Miami, Sch Med, Dept Med, Miami, FL 33136 USA.	gbarber@med.miami.edu			NIAID NIH HHS [R01 AI079336-01, R01 AI079336] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI079336] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Balachandran S, 2004, NATURE, V432, P401, DOI 10.1038/nature03124; Balachandran S, 2007, J IMMUNOL, V178, P2429, DOI 10.4049/jimmunol.178.4.2429; Beutler B, 2007, NAT REV IMMUNOL, V7, P753, DOI 10.1038/nri2174; Chien YC, 2006, CELL, V127, P157, DOI 10.1016/j.cell.2006.08.034; Faria PA, 2005, MOL CELL, V17, P93, DOI 10.1016/j.molcel.2004.11.023; Guo W, 2004, TRENDS CELL BIOL, V14, P61, DOI 10.1016/j.tcb.2003.12.008; HARTMANN E, 1993, EUR J BIOCHEM, V214, P375, DOI 10.1111/j.1432-1033.1993.tb17933.x; Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505; Ishii KJ, 2006, NAT IMMUNOL, V7, P40, DOI 10.1038/ni1282; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Lipschutz JH, 2003, J BIOL CHEM, V278, P20954, DOI 10.1074/jbc.M213210200; Loo YM, 2008, J VIROL, V82, P335, DOI 10.1128/JVI.01080-07; Mavinakere MS, 2006, J VIROL, V80, P6771, DOI 10.1128/JVI.00492-06; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Menetret JF, 2005, J MOL BIOL, V348, P445, DOI 10.1016/j.jmb.2005.02.053; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Onomoto K, 2007, CURR TOP MICROBIOL, V316, P193; Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Stetson DB, 2006, IMMUNITY, V24, P93, DOI 10.1016/j.immuni.2005.12.003; Takahasi K, 2008, MOL CELL, V29, P428, DOI 10.1016/j.molcel.2007.11.028; Takeuchi O, 2007, IMMUNOL REV, V220, P214, DOI 10.1111/j.1600-065X.2007.00562.x; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087	25	1854	1981	24	323	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 2	2008	455	7213					674	U74		10.1038/nature07317	http://dx.doi.org/10.1038/nature07317			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	354KY	18724357	Green Accepted			2022-12-28	WOS:000259639700049
J	Kenzelmann, M; Strassle, T; Niedermayer, C; Sigrist, M; Padmanabhan, B; Zolliker, M; Bianchi, AD; Movshovich, R; Bauer, ED; Sarrao, JL; Thompson, JD				Kenzelmann, M.; Straessle, Th.; Niedermayer, C.; Sigrist, M.; Padmanabhan, B.; Zolliker, M.; Bianchi, A. D.; Movshovich, R.; Bauer, E. D.; Sarrao, J. L.; Thompson, J. D.			Coupled superconducting and magnetic order in CeCoIn5	SCIENCE			English	Article								Strong magnetic fluctuations can provide a coupling mechanism for electrons that leads to unconventional superconductivity. Magnetic order and superconductivity have been found to coexist in a number of magnetically mediated superconductors, but these order parameters generally compete. We report that close to the upper critical field, CeCoIn5 adopts a multicomponent ground state that simultaneously carries cooperating magnetic and superconducting orders. Suppressing superconductivity in a first- order transition at the upper critical field leads to the simultaneous collapse of the magnetic order, showing that superconductivity is necessary for the magnetic order. A symmetry analysis of the coupling between the magnetic order and the superconducting gap function suggests a form of superconductivity that is associated with a nonvanishing momentum.	[Kenzelmann, M.; Straessle, Th.; Niedermayer, C.; Padmanabhan, B.; Zolliker, M.] Paul Scherrer Inst, Lab Dev & Methods, CH-5232 Villigen, Switzerland; [Kenzelmann, M.] ETH, Solid State Phys Lab, CH-8093 Zurich, Switzerland; [Straessle, Th.; Niedermayer, C.; Padmanabhan, B.] ETH, Neutron Scattering Lab, CH-5232 Villigen, Switzerland; [Sigrist, M.] ETH, Inst Theoret Phys, CH-8093 Zurich, Switzerland; [Bianchi, A. D.] Univ Montreal, Dept Phys, Montreal, PQ H3C 3J7, Canada; [Bianchi, A. D.] Univ Montreal, Regroupement Quebecois Mat Pointe, Montreal, PQ H3C 3J7, Canada; [Movshovich, R.; Bauer, E. D.; Sarrao, J. L.; Thompson, J. D.] Los Alamos Natl Lab, Los Alamos, NM 87545 USA	Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; Universite de Montreal; Universite de Montreal; United States Department of Energy (DOE); Los Alamos National Laboratory	Kenzelmann, M (corresponding author), Paul Scherrer Inst, Lab Dev & Methods, CH-5232 Villigen, Switzerland.		Bianchi, Andrea/AAZ-8661-2021; Bianchi, Andrea D/E-9779-2010; Kenzelmann, Michel/ABE-1645-2020; Sigrist, Manfred/C-4570-2008; Niedermayer, Christof/K-4436-2014; Bauer, Eric D/D-7212-2011; Kenzelmann, Michel/A-8438-2008	Bianchi, Andrea/0000-0001-9340-6971; Bianchi, Andrea D/0000-0001-9340-6971; Sigrist, Manfred/0000-0002-8627-5093; Niedermayer, Christof/0000-0001-6508-8988; Kenzelmann, Michel/0000-0001-7913-4826; Movshovich, Roman/0000-0002-3667-634X; Bauer, Eric/0000-0003-0017-1937	Swiss National Science Foundation [PP002-102831]; Swiss National Center of Competence in Research program Materials with Novel Electronic Properties; Los Alamos Laboratory Directed Research and Development program; Natural Sciences and Engineering Research Council of Canada (Canada); Fonds Quebecois de la Recherche sur la Nature et les Technologies (Quebec); Canada Research Chair Foundation	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss National Center of Competence in Research program Materials with Novel Electronic Properties(Swiss National Science Foundation (SNSF)); Los Alamos Laboratory Directed Research and Development program(United States Department of Energy (DOE)Los Alamos National Laboratory); Natural Sciences and Engineering Research Council of Canada (Canada)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Fonds Quebecois de la Recherche sur la Nature et les Technologies (Quebec)(FQRNT); Canada Research Chair Foundation(Canada Research Chairs)	Work at ETH was supported by the Swiss National Science Foundation under contract PP002-102831. This work is based on experiments performed at the Swiss spallation neutron source SINQ, Paul Scherrer Institute, Villigen, Switzerland, and was supported by the Swiss National Center of Competence in Research program Materials with Novel Electronic Properties. Work at Los Alamos was performed under the auspices of the U. S. Department of Energy and supported in part by the Los Alamos Laboratory Directed Research and Development program. A. D. B. received support from the Natural Sciences and Engineering Research Council of Canada (Canada), Fonds Quebecois de la Recherche sur la Nature et les Technologies (Quebec), and the Canada Research Chair Foundation.	APERIS A, IN PRESS J PHYS COND; Bianchi A, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.257001; Bianchi A, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.187004; Bianchi A, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.137002; Bianchi AD, 2008, SCIENCE, V319, P177, DOI 10.1126/science.1150600; Curro NJ, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.180514; Flouquet J, 2006, CR PHYS, V7, P22, DOI 10.1016/j.crhy.2005.11.008; FULDE P, 1964, PHYS REV, V135, pA550, DOI 10.1103/PhysRev.135.A550; Hall D, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.212508; Izawa K, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.057002; KAKUYANAGL K, 2005, PHYS REV, V94; LARKIN AI, 1965, SOV PHYS JETP-USSR, V20, P762; Monthoux P, 2007, NATURE, V450, P1177, DOI 10.1038/nature06480; Movshovich R, 2001, PHYS REV LETT, V86, P5152, DOI 10.1103/PhysRevLett.86.5152; Paglione J, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.246405; Petrovic C, 2001, J PHYS-CONDENS MAT, V13, pL337, DOI 10.1088/0953-8984/13/17/103; Radovan HA, 2003, NATURE, V425, P51, DOI 10.1038/nature01842; Settai R, 2001, J PHYS-CONDENS MAT, V13, pL627, DOI 10.1088/0953-8984/13/27/103; SIGRIST M, 1991, REV MOD PHYS, V63, P239, DOI 10.1103/RevModPhys.63.239; Stock C, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.087001; Vorontsov A, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.237001; Watanabe T, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.020506; Young BL, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.036402	23	273	273	5	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2008	321	5896					1652	1654		10.1126/science.1161818	http://dx.doi.org/10.1126/science.1161818			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349RG	18719250	Green Submitted			2022-12-28	WOS:000259300400027
J	Krishnan, MN; Ng, A; Sukumaran, B; Gilfoy, FD; Uchil, PD; Sultana, H; Brass, AL; Adametz, R; Tsui, M; Qian, F; Montgomery, RR; Lev, S; Mason, PW; Koski, RA; Elledge, SJ; Xavier, RJ; Agaisse, H; Fikrig, E				Krishnan, Manoj N.; Ng, Aylwin; Sukumaran, Bindu; Gilfoy, Felicia D.; Uchil, Pradeep D.; Sultana, Hameeda; Brass, Abraham L.; Adametz, Rachel; Tsui, Melody; Qian, Feng; Montgomery, Ruth R.; Lev, Sima; Mason, Peter W.; Koski, Raymond A.; Elledge, Stephen J.; Xavier, Ramnik J.; Agaisse, Herve; Fikrig, Erol			RNA interference screen for human genes associated with West Nile virus infection	NATURE			English	Article							DENGUE-VIRUS; INTERACTION NETWORK; VIRAL SPREAD; HOST-CELLS; PROTEIN; ENTRY; REPLICATION; DATABASE; IDENTIFICATION; ENDOCYTOSIS	West Nile virus ( WNV), and related flaviviruses such as tick- borne encephalitis, Japanese encephalitis, yellow fever and dengue viruses, constitute a significant global human health problem(1). However, our understanding of the molecular interaction of such flaviviruses with mammalian host cells is limited(1). WNV encodes only 10 proteins, implying that it may use many cellular proteins for infection(1). WNV enters the cytoplasm through pH- dependent endocytosis, undergoes cycles of translation and replication, assembles progeny virions in association with endoplasmic reticulum, and exits along the secretory pathway(1-3). RNA interference ( RNAi) presents a powerful forward genetics approach to dissect virus - host cell interactions(4-6). Here we report the identification of 305 host proteins that affect WNV infection, using a human- genome-wide RNAi screen. Functional clustering of the genes revealed a complex dependence of this virus on host cell physiology, requiring a wide variety of molecules and cellular pathways for successful infection. We further demonstrate a requirement for the ubiquitin ligase CBLL1 in WNV internalization, a post- entry role for the endoplasmic- reticulum- associated degradation pathway in viral infection, and the monocarboxylic acid transporter MCT4 as a viral replication resistance factor. By extending this study to dengue virus, we show that flaviviruses have both overlapping and unique interaction strategies with host cells. This study provides a comprehensive molecular portrait of WNV - human cell interactions that forms a model for understanding single plus- stranded RNA virus infection, and reveals potential antiviral targets.	[Krishnan, Manoj N.; Sukumaran, Bindu; Sultana, Hameeda; Fikrig, Erol] Yale Univ, Sch Med, Infect Dis Sect, Dept Internal Med, New Haven, CT 06520 USA; [Qian, Feng; Montgomery, Ruth R.] Yale Univ, Sch Med, Rheumatol Sect, Dept Internal Med, New Haven, CT 06520 USA; [Uchil, Pradeep D.; Adametz, Rachel; Agaisse, Herve] Yale Univ, Sch Med, Sect Microbial Pathogenesis, New Haven, CT 06520 USA; [Ng, Aylwin; Xavier, Ramnik J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA; [Ng, Aylwin; Xavier, Ramnik J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA; [Gilfoy, Felicia D.; Mason, Peter W.] Univ Texas Galveston, Med Branch, Dept Pathol, Galveston, TX 77555 USA; [Tsui, Melody] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Syst Biol, Boston, MA 02115 USA; [Brass, Abraham L.; Elledge, Stephen J.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Genet,Ctr Genet & Genom, Boston, MA 02115 USA; [Lev, Sima] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; [Koski, Raymond A.] L2 Diagnost, New Haven, CT 06511 USA; [Elledge, Stephen J.; Fikrig, Erol] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	Yale University; Yale University; Yale University; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Texas System; University of Texas Medical Branch Galveston; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Weizmann Institute of Science; Howard Hughes Medical Institute	Fikrig, E (corresponding author), Yale Univ, Sch Med, Infect Dis Sect, Dept Internal Med, 333 Cedar St, New Haven, CT 06520 USA.	erol.fikrig@yale.edu	Ng, Aylwin/AAQ-6478-2020; Qian, Feng/F-8186-2010; Lev, Sima/AAP-7880-2020	Lev, Sima/0000-0002-2108-3330; Montgomery, Ruth/0000-0002-8661-4454; Uchil, Pradeep/0000-0002-7236-858X	New England Regional Center of Excellence in Biodefense and Emerging Infectious Disease [U54AI057159]; NIH [AI062773, U54 AI057156]; Crohn's and Colitis Foundation of America; CCIB development funds; Emerging and Tropical Infectious Diseases [AI07526]; NIAID; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI070343, R01AI032947, U54AI057156, R01AI041440, R01AI062773, T32AI007526, U54AI057159] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561] Funding Source: NIH RePORTER	New England Regional Center of Excellence in Biodefense and Emerging Infectious Disease(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Crohn's and Colitis Foundation of America; CCIB development funds; Emerging and Tropical Infectious Diseases; NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The human genome RNAi library wasmade available through the support of the New England Regional Center of Excellence in Biodefense and Emerging Infectious Disease (U54AI057159). The screening was performed at the ICCB-Longwood screening facility (Harvard Medical School). We thank B. Lindenbach for suggestions and Y. Benita for illustrations. We thank L2 Diagnostics for providing the anti-WNV antibody. This work was supported by the NIH. A.N. is supported by a fellowship award from the Crohn's and Colitis Foundation of America. R.J.X. is supported by the NIH (AI062773) and by CCIB development funds. F.D.G was supported by an NIH training grant in Emerging and Tropical Infectious Diseases (AI07526); portions of this work were supported by a grant from NIAID to P.W.M. through the WRCE ( NIH U54 AI057156). E. F. and S.J.E. are Investigators of the Howard Hughes Medical Institute.	Bader GD, 2003, NUCLEIC ACIDS RES, V31, P248, DOI 10.1093/nar/gkg056; Brass AL, 2008, SCIENCE, V319, P921, DOI 10.1126/science.1152725; Brinton MA, 2002, ANNU REV MICROBIOL, V56, P371, DOI 10.1146/annurev.micro.56.012302.160654; Chiu MW, 2007, J BIOMED SCI, V14, P429, DOI 10.1007/s11373-007-9151-9; Chu JJH, 2004, J VIROL, V78, P10543, DOI 10.1128/JVI.78.19.10543-10555.2004; Davis WG, 2007, J VIROL, V81, P10172, DOI 10.1128/JVI.00531-07; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Emara MM, 2007, P NATL ACAD SCI USA, V104, P9041, DOI 10.1073/pnas.0703348104; Fredericksen BL, 2004, J VIROL, V78, P7737, DOI 10.1128/JVI.78.14.7737-7747.2004; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Hanks SK, 2003, FRONT BIOSCI-LANDMRK, V8, pD982, DOI 10.2741/1114; HELENIUS A, 1980, J CELL BIOL, V84, P404, DOI 10.1083/jcb.84.2.404; Hirsch AJ, 2005, J VIROL, V79, P11943, DOI 10.1128/JVI.79.18.11943-11951.2005; Khor R, 2003, TRAFFIC, V4, P857, DOI 10.1046/j.1398-9219.2003.0140.x; Krishnan MN, 2007, J VIROL, V81, P4881, DOI 10.1128/JVI.02210-06; Lim J, 2006, CELL, V125, P801, DOI 10.1016/j.cell.2006.03.032; Mackenzie JM, 2007, CELL HOST MICROBE, V2, P229, DOI 10.1016/j.chom.2007.09.003; Mashimo T, 2002, P NATL ACAD SCI USA, V99, P11311, DOI 10.1073/pnas.172195399; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Mi HY, 2005, NUCLEIC ACIDS RES, V33, pD284, DOI 10.1093/nar/gki078; Mishra GR, 2006, NUCLEIC ACIDS RES, V34, pD411, DOI 10.1093/nar/gkj141; Ng TI, 2007, HEPATOLOGY, V45, P1413, DOI 10.1002/hep.21608; Pelkmans L, 2005, NATURE, V436, P78, DOI 10.1038/nature03571; Rossi SL, 2005, VIROLOGY, V331, P457, DOI 10.1016/j.virol.2004.10.046; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Samuel MA, 2006, J VIROL, V80, P7009, DOI 10.1128/JVI.00489-06; Schelhaas M, 2007, CELL, V131, P516, DOI 10.1016/j.cell.2007.09.038; Scherbik SV, 2006, J VIROL, V80, P2987, DOI 10.1128/JVI.80.6.2987-2999.2006; Scholle F, 2005, VIROLOGY, V342, P77, DOI 10.1016/j.virol.2005.07.021; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Tecle T, 2007, J IMMUNOL, V178, P8046, DOI 10.4049/jimmunol.178.12.8046; Wakana Y, 2008, MOL BIOL CELL, V19, P1825, DOI 10.1091/mbc.E07-08-0781	34	404	420	1	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 11	2008	455	7210					242	U67		10.1038/nature07207	http://dx.doi.org/10.1038/nature07207			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	346SZ	18690214	Green Accepted			2022-12-28	WOS:000259090800051
J	Pesu, M; Watford, WT; Wei, L; Xu, LL; Fuss, I; Strober, W; Andersson, J; Shevach, EM; Quezado, M; Bouladoux, N; Roebroek, A; Belkaid, Y; Creemers, J; O'Shea, JJ				Pesu, Marko; Watford, Wendy T.; Wei, Lai; Xu, Lili; Fuss, Ivan; Strober, Warren; Andersson, John; Shevach, Ethan M.; Quezado, Martha; Bouladoux, Nicolas; Roebroek, Anton; Belkaid, Yasmine; Creemers, John; O'Shea, John J.			T-cell-expressed proprotein convertase furin is essential for maintenance of peripheral immune tolerance	NATURE			English	Article							ACTIVATION; BETA; GROWTH; MICE; CONVERSION; INDUCTION; COLITIS; MASTER; FOXP3	Furin is one of seven proprotein convertase family members that promote proteolytic maturation of proproteins(1). It is induced in activated T cells and is reported to process a variety of substrates including the anti- inflammatory cytokine transforming growth factor (TGF)-beta 1 ( refs 2 - 4), but the non- redundant functions of furin versus other proprotein convertases in T cells are unclear. Here we show that conditional deletion of furin in T cells allowed for normal T- cell development but impaired the function of regulatory and effector T cells, which produced less TGF-beta 1. Furin-deficient T regulatory (T-reg) cells were less protective in a T- cell transfer colitis model and failed to induce Foxp3 in normal T cells. Additionally, furin- deficient effector cells were inherently over-active and were resistant to suppressive activity of wild- type T-reg cells. Thus, our results indicate that furin is indispensable in maintaining peripheral tolerance, which is due, at least in part, to its non- redundant, essential function in regulating TGF-beta 1 production. Targeting furin has emerged as a strategy in malignant and infectious disease(5,6). Our results suggest that inhibiting furin might activate immune responses, but may result in a breakdown in peripheral tolerance.	[Pesu, Marko; Watford, Wendy T.; Wei, Lai; O'Shea, John J.] NIAMSD, Mol Immunol & Inflammat Branch, NIH, Bethesda, MD 20892 USA; [Xu, Lili; Fuss, Ivan; Strober, Warren] NIAID, Mucosal Immun Sect, Host Def Lab, NIH, Bethesda, MD 20892 USA; [Andersson, John; Shevach, Ethan M.] NIAID, Cellular Immunol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA; [Bouladoux, Nicolas; Belkaid, Yasmine] NIAID, Mucosal Immunol Unit, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; [Quezado, Martha] NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; [Roebroek, Anton; Creemers, John] Katholieke Univ Leuven, Biochem Neuroendocrinol Lab, B-3000 Louvain, Belgium; [Roebroek, Anton; Creemers, John] VIB, B-3000 Louvain, Belgium	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); KU Leuven; Flanders Institute for Biotechnology (VIB)	Pesu, M (corresponding author), NIAMSD, Mol Immunol & Inflammat Branch, NIH, Bethesda, MD 20892 USA.	pesum@mail.nih.gov	Wei, Lai/D-1088-2014; Andersson, John/A-4436-2009; Pesu, Marko/L-6344-2013	Pesu, Marko/0000-0002-7541-3921; Belkaid, Yasmine/0000-0001-9962-3571; Andersson, John/0000-0003-2799-6349; Watford, Wendy/0000-0003-4261-5399; Bouladoux, Nicolas/0000-0003-1593-671X	Intramural Research Program of NIAMS; Academy of Finland; Finnish Medical Foundation; Maud Kuistila Memorial Foundation; Fonds voor Wetenschappelijk Onderzoek Vlaanderen; Geconcerteerde Onderzoeksactie van de Vlaamse Gemeenschap; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000959, ZIAAI000354, Z01AI001061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041160, ZIAAR041159] Funding Source: NIH RePORTER	Intramural Research Program of NIAMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Academy of Finland(Academy of Finland); Finnish Medical Foundation; Maud Kuistila Memorial Foundation; Fonds voor Wetenschappelijk Onderzoek Vlaanderen(FWO); Geconcerteerde Onderzoeksactie van de Vlaamse Gemeenschap; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank J. Bonifacino (National Institute of Child Health and Human Development) and S. Wahl (National Institute of Dental and Craniofacial Research) for providing comments and reading the manuscript, A. Singer (National Cancer Institute) and L. Pobenzinsky (NCI) for providing suggestions, and M. Oukka (HarvardMedical School) for providing Foxp3- GFP mice. This work was supported by the Intramural Research Program of NIAMS, Academy of Finland, the Finnish Medical Foundation, the Maud Kuistila Memorial Foundation, the 'Fonds voor Wetenschappelijk Onderzoek Vlaanderen' and 'Geconcerteerde Onderzoeksactie van de Vlaamse Gemeenschap'.	ANDERSSON J, IN PRESS J EXP MED; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Bassi DE, 2005, MOL CARCINOGEN, V44, P151, DOI 10.1002/mc.20134; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Dubois CM, 2001, AM J PATHOL, V158, P305, DOI 10.1016/S0002-9440(10)63970-3; FINK PJ, 1994, J IMMUNOL, V152, P4270; Kretschmer K, 2005, NAT IMMUNOL, V6, P1219, DOI 10.1038/ni1265; Li MO, 2007, IMMUNITY, V26, P579, DOI 10.1016/j.immuni.2007.03.014; Liang S, 2005, J EXP MED, V201, P127, DOI 10.1084/jem.20041201; Nakamura K, 2004, J IMMUNOL, V172, P834, DOI 10.4049/jimmunol.172.2.834; Ornatowski W, 2007, J CLIN INVEST, V117, P3489, DOI 10.1172/JCI31499; Pesu M, 2006, BLOOD, V108, P983, DOI 10.1182/blood-2005-09-3824; Powrie F, 1996, J EXP MED, V183, P2669, DOI 10.1084/jem.183.6.2669; Roebroek AJM, 2004, J BIOL CHEM, V279, P53442, DOI 10.1074/jbc.M407152200; Roebroek AJM, 1998, DEVELOPMENT, V125, P4863; Rubtsov YP, 2007, NAT REV IMMUNOL, V7, P443, DOI 10.1038/nri2095; Scamuffa N, 2008, J CLIN INVEST, V118, P352, DOI 10.1172/JCI32040; Schon MP, 1999, J IMMUNOL, V162, P6641; Shiryaev SA, 2007, J BIOL CHEM, V282, P20847, DOI 10.1074/jbc.M703847200; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; Tang QZ, 2008, NAT IMMUNOL, V9, P239, DOI 10.1038/ni1572; Taylor NA, 2003, FASEB J, V17, P1215, DOI 10.1096/fj.02-0831rev; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; Travis MA, 2007, NATURE, V449, P361, DOI 10.1038/nature06110	25	150	159	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 11	2008	455	7210					246	U73		10.1038/nature07210	http://dx.doi.org/10.1038/nature07210			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	346SZ	18701887	Green Accepted			2022-12-28	WOS:000259090800052
J	Lehmann, J; Sohi, S				Lehmann, Johannes; Sohi, Saran			Comment on "fire-derived charcoal causes loss of forest humus"	SCIENCE			English	Editorial Material							BLACK CARBON		[Lehmann, Johannes] Cornell Univ, Dept Crop & Soil Sci, Ithaca, NY 14853 USA; [Sohi, Saran] Rothamsted Res, Harpenden AL5 2JQ, Herts, England	Cornell University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	Lehmann, J (corresponding author), Cornell Univ, Dept Crop & Soil Sci, 909 Bradfield Hall, Ithaca, NY 14853 USA.	CL273@cornell.edu	Sohi, Saran/K-1220-2019; Lehmann, Johannes/H-2682-2014	Sohi, Saran/0000-0003-3207-8665; Lehmann, Johannes/0000-0002-4701-2936				Cheng CH, 2006, ORG GEOCHEM, V37, P1477, DOI 10.1016/j.orggeochem.2006.06.022; CRONAN CS, 1985, GEOCHIM COSMOCHIM AC, V49, P1697, DOI 10.1016/0016-7037(85)90140-1; Czimczik CI, 2002, ORG GEOCHEM, V33, P1207, DOI 10.1016/S0146-6380(02)00137-7; Freitas JCC, 2001, CARBON, V39, P535, DOI 10.1016/S0008-6223(00)00169-X; Hamer U, 2004, ORG GEOCHEM, V35, P823, DOI 10.1016/j.orggeochem.2004.03.003; Kaiser K, 2000, ORG GEOCHEM, V31, P711, DOI 10.1016/S0146-6380(00)00046-2; Lehmann J, 2007, NATURE, V447, P143, DOI 10.1038/447143a; Preston CM, 2006, BIOGEOSCIENCES, V3, P397, DOI 10.5194/bg-3-397-2006; Tom MS, 1997, NATURE, V389, P170, DOI DOI 10.1038/38260; Wardle DA, 2008, SCIENCE, V320, P629, DOI 10.1126/science.1154960	10	51	61	2	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	2008	321	5894								10.1126/science.1160005	http://dx.doi.org/10.1126/science.1160005			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	344GG	18772418	Green Submitted			2022-12-28	WOS:000258914300027
J	La Scola, B; Desnues, C; Pagnier, I; Robert, C; Barrassi, L; Fournous, G; Merchat, M; Suzan-Monti, M; Forterre, P; Koonin, E; Raoult, D				La Scola, Bernard; Desnues, Christelle; Pagnier, Isabelle; Robert, Catherine; Barrassi, Lina; Fournous, Ghislain; Merchat, Michele; Suzan-Monti, Marie; Forterre, Patrick; Koonin, Eugene; Raoult, Didier			The virophage as a unique parasite of the giant mimivirus	NATURE			English	Article							MULTIPLE SEQUENCE ALIGNMENT; OCEAN SAMPLING EXPEDITION; BACTERIAL; VIRUSES	Viruses are obligate parasites of Eukarya, Archaea and Bacteria. Acanthamoeba polyphaga mimivirus ( APMV) is the largest known virus; it grows only in amoeba and is visible under the optical microscope. Mimivirus possesses a 1,185- kilobase double- stranded linear chromosome whose coding capacity is greater than that of numerous bacteria and archaea(1-3). Here we describe an icosahedral small virus, Sputnik, 50 nm in size, found associated with a new strain of APMV. Sputnik cannot multiply in Acanthamoeba castellanii but grows rapidly, after an eclipse phase, in the giant virus factory found in amoebae co- infected with APMV(4). Sputnik growth is deleterious to APMV and results in the production of abortive forms and abnormal capsid assembly of the host virus. The Sputnik genome is an 18.343- kilobase circular double- stranded DNA and contains genes that are linked to viruses infecting each of the three domains of life Eukarya, Archaea and Bacteria. Of the 21 predicted protein- coding genes, eight encode proteins with detectable homologues, including three proteins apparently derived from APMV, a homologue of an archaeal virus integrase, a predicted primase helicase, a packaging ATPase with homologues in bacteriophages and eukaryotic viruses, a distant homologue of bacterial insertion sequence transposase DNA- binding subunit, and a Zn- ribbon protein. The closest homologues of the last four of these proteins were detected in the Global Ocean Survey environmental data set(5), suggesting that Sputnik represents a currently unknown family of viruses. Considering its functional analogy with bacteriophages, we classify this virus as a virophage. The virophage could be a vehicle mediating lateral gene transfer between giant viruses.	[La Scola, Bernard; Desnues, Christelle; Pagnier, Isabelle; Robert, Catherine; Barrassi, Lina; Fournous, Ghislain; Suzan-Monti, Marie; Raoult, Didier] Univ Mediterranee, URMITE, Ctr Natl Rech Sci, Fac Med,UMR IRD 6236, F-13385 Marseille 5, France; [Merchat, Michele] Climespace, F-75012 Paris, France; [Forterre, Patrick] Univ Paris 11, Ctr Orsay, Inst Microbiol & Genet, F-91405 Orsay, France; [Forterre, Patrick] Inst Pasteur, Dept Microbiol, F-75724 Paris 15, France; [Koonin, Eugene] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; GDF Suez; UDICE-French Research Universities; Universite Paris Saclay; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Raoult, D (corresponding author), Univ Mediterranee, URMITE, Ctr Natl Rech Sci, Fac Med,UMR IRD 6236, 27 Blvd Jean Moulin, F-13385 Marseille 5, France.	didier.raoult@gmail.com	Desnues, Christelle/B-1383-2010; Desnues, Christelle/ABG-2910-2021; LA SCOLA, Bernard/P-6477-2016; RAOULT, Didier/A-8434-2008	Desnues, Christelle/0000-0002-2178-0355; Desnues, Christelle/0000-0002-2178-0355; LA SCOLA, Bernard/0000-0001-8006-7704; RAOULT, Didier/0000-0002-0633-5974; Pagnier, Isabelle/0000-0002-1724-3450	Centre National de la Recherche Scientifique; CIFFRE fellowship; Intramural Research Program of the National Institutes of Health; National Library of Medicine; Institut Universitaire de France	Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); CIFFRE fellowship; Intramural Research Program of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Library of Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); Institut Universitaire de France	We thank X. de Lamballerie, S. Azza, P. de Clocquement, L. Espinosa, B. Campagna, N. Aldrovandi, V. Brice, A. Bernard, C. Ivars, B. Giumelli and Y. Wolf for expert assistance. This work was funded by the Centre National de la Recherche Scientifique (CNRS, credits recurrents). I. P. is funded by a CIFFRE fellowship, E. K. is supported by the Intramural Research Program of the National Institutes of Health, National Library of Medicine, and P. F. is funded by the Institut Universitaire de France.	Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; De Silva FS, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-23; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; FAUQUET CM, 2005, VIRUS TAXONOMY, P1163; Filee J, 2007, TRENDS GENET, V23, P10, DOI 10.1016/j.tig.2006.11.002; Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149; Ghai R, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-198; Iyer LM, 2004, NUCLEIC ACIDS RES, V32, P5260, DOI 10.1093/nar/gkh828; Jobb G, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-18; Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436; Koonin EV, 2006, BIOL DIRECT, V1, DOI 10.1186/1745-6150-1-1; Koonin EV, 2005, CURR BIOL, V15, pR167, DOI 10.1016/j.cub.2005.02.042; Kowalczewska M, 2007, FUTURE MICROBIOL, V2, P631, DOI 10.2217/17460913.2.6.631; La Scola B, 2000, FEMS MICROBIOL ECOL, V34, P129, DOI 10.1016/S0168-6496(00)00084-2; La Scola B, 2003, SCIENCE, V299, P2033; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Lukashin AV, 1998, NUCLEIC ACIDS RES, V26, P1107, DOI 10.1093/nar/26.4.1107; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; Moreira D, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-12; OLIVEIRA S, 1995, VIROLOGY, V207, P392, DOI 10.1006/viro.1995.1098; Raoult D, 2004, SCIENCE, V306, P1344, DOI 10.1126/science.1101485; Raoult D, 2008, NAT REV MICROBIOL, V6, P315, DOI 10.1038/nrmicro1858; Rasmussen M, 2003, J BIOL CHEM, V278, P32313, DOI 10.1074/jbc.M304709200; Rusch DB, 2007, PLOS BIOL, V5, P398, DOI 10.1371/journal.pbio.0050077; Suzan-Monti M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000328; Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092; Williamson SJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001456	27	374	413	7	162	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 4	2008	455	7209					100	U65		10.1038/nature07218	http://dx.doi.org/10.1038/nature07218			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	343XS	18690211				2022-12-28	WOS:000258890200045
J	Chin-Hong, PV; Berry, JM; Cheng, SC; Catania, JA; Da Costa, M; Darragh, TM; Fishman, F; Jay, N; Pollack, LM; Palefsky, JM				Chin-Hong, Peter V.; Berry, J. Michael; Cheng, Su-Chun; Catania, Joseph A.; Da Costa, Maria; Darragh, Teresa M.; Fishman, Fred; Jay, Naomi; Pollack, Lance M.; Palefsky, Joel M.			Comparison of patient- and clinician-collected anal cytology samples to screen for human papillomavirus - Associated anal Intraepithelial neoplasia in men who have sex with men	ANNALS OF INTERNAL MEDICINE			English	Article							HIV-POSITIVE MEN; HOMOSEXUAL-MEN; BISEXUAL MEN; LESIONS; PREVALENCE; CANCER; INFECTION; POPULATION; SPECTRUM; EXPLORE	Background: Human papillomavirus (HPV)-associated anal cancer is increasing in prevalence and is more common among men who have sex with men and HIV-positive individuals than cervical cancer is among women in the United States. Cytology screening can detect the anal cancer precursor, anal intraepithelial neoplasia (AIN). Little is known about self-collected samples for AIN screening, and few community-based AIN estimates exist. Objective: To compare the sensitivity of self-collected versus cliniciancollected anal cytology specimens to detect biopsy-confirmed AIN and the prevalence estimate of AIN in a community sample. Design: Cross-sectional study. Participants were mailed anal cytology self-collection kits with instructions. Clinicians repeated anal cytology and performed high-resolution anoscopy with biopsies as the diagnostic reference standard. Setting: San Francisco, California. Patients: Community-based sample of men who have sex with men. Measurements: Prevalence of anal HPV and AIN. Sensitivity and specificity of self-collected and clinician-collected anal cytology specimens to diagnose AIN were calculated. Results: Biopsy-proven AIN was diagnosed in 57% of HIV-positive and 35% of HIV-negative participants (P = 0.04), and 80% provided adequate self-collected specimens for interpretation. The sensitivity of cytology to detect AIN in HIV-positive men was 75% (95% CI, 51% to 93%) when self-collected and 90% (CI, 68% to 99%) when clinician-collected; respective values in HIV-negative men were 48% (CI, 26% to 70%) and 62% (CI, 38% to 82%). The specificity of cytology to detect AIN in HIV-positive men was 50% (CI, 22% to 78%) when self-collected and 64% (CI, 36% to 86%) when clinician-collected; respective values in HIV-negative men were 86% (CI, 71% to 94%) and 85% (CI, 72% to 93%). Limitations: The study sample was from a narrowly defined geographical area. Participants self-reported HIV status. Conclusion: In a community-based sample, a high proportion of HIV-positive and HIV-negative men who have sex with men have AIN. The sensitivity of cytology to detect AIN is higher for clinician-collected versus self-collected specimens and for HIV-positive versus HIV-negative men. The specificity of cytology to detect AIN is higher in HIV-negative versus HIV-positive men. However, the probability of AIN in a patient with a negative cytology result may not be low enough (23% for HIV-negative men and 45% for HIV-positive men with a patient-collected specimen) for clinicians to be comfortable recommending no anoscopy for those with a negative cytology result if done as a one-time test. These data raise the question of whether the optimal population screening strategy is cytology screening with anoscopy only for those who test positive or whether anoscopy should be recommended for everyone in these risk groups. Given limited resources and the limited number of clinicians trained in anoscopy, cytology screening may be the best current approach to identifying disease in the at-risk population.	[Chin-Hong, Peter V.] Univ Calif San Francisco, San Francisco, CA 94143 USA; Oregon State Univ, Corvallis, OR 97331 USA	University of California System; University of California San Francisco; Oregon State University	Chin-Hong, PV (corresponding author), Univ Calif San Francisco, Box 0654,513 Parnassus Ave,Room S 380, San Francisco, CA 94143 USA.	phong@php.ucsf.edu			American Cancer Society Institutional Research; National Institutes of Health [K23 AI054157, R01 CA54053, R01 CA/AI 88739, R01 MH54320]; California Universitywide AIDS Research Program [ID04-SF-008]; General Clinical Research Center [5 M01-RR-00079]; CYTYC Corporation; NATIONAL CANCER INSTITUTE [R01CA054053] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI054157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH054320] Funding Source: NIH RePORTER	American Cancer Society Institutional Research(American Cancer Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); California Universitywide AIDS Research Program; General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); CYTYC Corporation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	By an American Cancer Society Institutional Research Award (Dr. Chin-Hong); grants K23 AI054157 (Dr. Chin-Hong), R01 CA54053 (Dr. Palefsky), R01 CA/AI 88739 (Dr. Palefsky), and R01 MH54320 (Dr. Catania) from the National Institutes of Health; the California Universitywide AIDS Research Program (ID04-SF-008, Dr. Catania); the General Clinical Research Center, with funds provided by the Division of Research Resources (5 M01-RR-00079, Dr. Palefsky); and CYTYC Corporation.	Allison JE, 1996, NEW ENGL J MED, V334, P155, DOI 10.1056/NEJM199601183340304; BINSON D, 1996, AM STAT ASS 1996 P S; Catania JA, 2001, AM J PUBLIC HEALTH, V91, P907, DOI 10.2105/AJPH.91.6.907; Chin-Hong PV, 2005, JNCI-J NATL CANCER I, V97, P896, DOI 10.1093/jnci/dji163; Chin-Hong PV, 2004, J INFECT DIS, V190, P2070, DOI 10.1086/425906; Chin-Hong PV, 2002, CLIN INFECT DIS, V35, P1127, DOI 10.1086/344057; Cranston RD, 2004, JAIDS-J ACQ IMM DEF, V36, P915, DOI 10.1097/00126334-200408010-00004; CRITCHLOW CW, 1995, AIDS, V9, P1255, DOI 10.1097/00002030-199511000-00007; DALING JR, 1987, NEW ENGL J MED, V317, P973, DOI 10.1056/NEJM198710153171601; Fox PA, 2005, SEX TRANSM INFECT, V81, P142, DOI 10.1136/sti.2003.008318; Goedert JJ, 1998, LANCET, V351, P1833, DOI 10.1016/S0140-6736(97)09028-4; Hall MC, 2004, PEDIATRICS, V114, P182, DOI 10.1542/peds.114.1.182; Jay N, 1997, DIS COLON RECTUM, V40, P919, DOI 10.1007/BF02051199; Johnson LG, 2004, CANCER-AM CANCER SOC, V101, P281, DOI 10.1002/cncr.20364; Lampinen Thomas M, 2006, Cytojournal, V3, P4, DOI 10.1186/1742-6413-3-4; Lytwyn A, 2005, CANCER-AM CANCER SOC, V103, P1447, DOI 10.1002/cncr.20927; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Nanda K, 2000, ANN INTERN MED, V132, P810, DOI 10.7326/0003-4819-132-10-200005160-00009; Osmond DH, 2007, AM J PUBLIC HEALTH, V97, P1677, DOI 10.2105/AJPH.2005.062851; Osmond DH, 2000, J ACQ IMMUN DEF SYND, V24, P363; Palefsky JM, 2005, AIDS, V19, P1407, DOI 10.1097/01.aids.0000181012.62385.4a; Palefsky JM, 1997, J ACQ IMMUN DEF SYND, V14, P415, DOI 10.1097/00042560-199704150-00004; Palefsky JM, 1998, J ACQ IMMUN DEF SYND, V17, P314, DOI 10.1097/00042560-199804010-00004; Palefsky JM, 1998, AIDS, V12, P495, DOI 10.1097/00002030-199805000-00011; Palefsky JM, 1998, J ACQ IMMUN DEF SYND, V17, P320, DOI 10.1097/00042560-199804010-00005; Sellors JW, 2000, CAN MED ASSOC J, V163, P513; SOOST HJ, 1991, ACTA CYTOL, V35, P8; SURAWICZ CM, 1995, AM J GASTROENTEROL, V90, P1776; Van der Snoek EM, 2005, ACTA DERM-VENEREOL, V85, P437, DOI 10.1080/00015550510032850; Xia Q, 2006, JAIDS-J ACQ IMM DEF, V41, P238, DOI 10.1097/01.qai.0000185574.98472.36	30	115	116	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2008	149	5					300	W63		10.7326/0003-4819-149-5-200809020-00004	http://dx.doi.org/10.7326/0003-4819-149-5-200809020-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	348SD	18765699				2022-12-28	WOS:000259229300002
J	Rasko, DA; Moreira, CG; Li, DR; Reading, NC; Ritchie, JM; Waldor, MK; Williams, N; Taussig, R; Wei, SG; Roth, M; Hughes, DT; Huntley, JF; Fina, MW; Falck, JR; Sperandio, V				Rasko, David A.; Moreira, Cristiano G.; Li, De Run; Reading, Nicola C.; Ritchie, Jennifer M.; Waldor, Matthew K.; Williams, Noelle; Taussig, Ron; Wei, Shuguang; Roth, Michael; Hughes, David T.; Huntley, Jason F.; Fina, Maggy W.; Falck, John R.; Sperandio, Vanessa			Targeting QseC signaling and virulence for antibiotic development	SCIENCE			English	Article							BACTERIA; COMMUNICATION; INHIBITION; SENSOR	Many bacterial pathogens rely on a conserved membrane histidine sensor kinase, QseC, to respond to host adrenergic signaling molecules and bacterial signals in order to promote the expression of virulence factors. Using a high- throughput screen, we identified a small molecule, LED209, that inhibits the binding of signals to QseC, preventing its autophosphorylation and consequently inhibiting QseC- mediated activation of virulence gene expression. LED209 is not toxic and does not inhibit pathogen growth; however, this compound markedly inhibits the virulence of several pathogens in vitro and in vivo in animals. Inhibition of signaling offers a strategy for the development of broad- spectrum antimicrobial drugs.	[Rasko, David A.; Moreira, Cristiano G.; Reading, Nicola C.; Hughes, David T.; Huntley, Jason F.; Sperandio, Vanessa] Univ Texas SW Med Ctr Dallas, Dept Microbiol, Dallas, TX 75390 USA; [Li, De Run; Williams, Noelle; Wei, Shuguang; Roth, Michael; Falck, John R.; Sperandio, Vanessa] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA; [Ritchie, Jennifer M.; Waldor, Matthew K.] Harvard Univ, Sch Med, Channing Lab, Brigham & Womens Hosp, Boston, MA 02115 USA; [Taussig, Ron; Fina, Maggy W.; Falck, John R.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Texas System; University of Texas Southwestern Medical Center Dallas	Sperandio, V (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Microbiol, Dallas, TX 75390 USA.	vanessa.sperandio@utsouthwestern.edu	Falck, John R/B-3030-2011; Huntley, Jason F/N-3848-2015; Moreira, Cristiano/D-8694-2014; Moreira, Cristiano Gallina/AHB-1469-2022	Falck, John R/0000-0002-9219-7845; Huntley, Jason F/0000-0002-0501-6103; Moreira, Cristiano/0000-0002-0689-4119; Moreira, Cristiano Gallina/0000-0002-0689-4119; Waldor, Matthew/0000-0003-1843-7000; Roth, Michael/0000-0002-9056-332X; Ritchie, Jennifer/0000-0002-1244-3082; David, Rasko/0000-0002-7337-7154	NIH [RO3 NS053582, RO1 AI053067, RO1 GM31278, PO1-AI055637-03, UO1-AI77853, R21 AI067827]; Ellison Medical Foundation; Burroughs Wellcome Fund; Robert A. Welch Foundation; UT Southwestern Medical Center; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI055637, R21AI067827, R01AI053067, U01AI077853] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R03NS053582] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ellison Medical Foundation(Lawrence Ellison Foundation); Burroughs Wellcome Fund(Burroughs Wellcome Fund); Robert A. Welch Foundation(The Welch Foundation); UT Southwestern Medical Center; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank M. V. Norgard, E. Vitetta, V. Miller, and S. L. McKnight for comments and J. Richardson for pathological review of tissues from LED209- treated mice. This work was supported by NIH grants RO3 NS053582, RO1 AI053067, RO1 GM31278, PO1- AI055637- 03, UO1- AI77853, and R21 AI067827; the Ellison Medical Foundation; the Burroughs Wellcome Fund; the Robert A. Welch Foundation; and a High Impact High Risk grant from UT Southwestern Medical Center. M. K. W. is a Howard Hughes Medical Institute investigator. This work yielded the provisional patent application UTSD: 1854USP1.	Bearson BL, 2008, MICROB PATHOGENESIS, V44, P271, DOI 10.1016/j.micpath.2007.10.001; Beuzon CR, 2000, EMBO J, V19, P3235, DOI 10.1093/emboj/19.13.3235; Cegelski L, 2008, NAT REV MICROBIOL, V6, P17, DOI 10.1038/nrmicro1818; Clarke MB, 2006, P NATL ACAD SCI USA, V103, P10420, DOI 10.1073/pnas.0604343103; Hughes DT, 2008, NAT REV MICROBIOL, V6, P111, DOI 10.1038/nrmicro1836; Hung DT, 2005, SCIENCE, V310, P670, DOI 10.1126/science.1116739; Jiang LI, 2007, J BIOL CHEM, V282, P10576, DOI 10.1074/jbc.M609695200; Levy SB, 2004, NAT MED, V10, pS122, DOI 10.1038/nm1145; Lyon GJ, 2003, CHEM BIOL, V10, P1007, DOI 10.1016/j.chembiol.2003.11.003; Merighi M, 2006, J BACTERIOL, V188, P141, DOI 10.1128/JB.188.1.141-149.2006; Palumbi SR, 2001, SCIENCE, V293, P1786, DOI 10.1126/science.293.5536.1786; ROYCHOUDHURY S, 1993, P NATL ACAD SCI USA, V90, P965, DOI 10.1073/pnas.90.3.965; Sperandio V, 2003, P NATL ACAD SCI USA, V100, P8951, DOI 10.1073/pnas.1537100100; Tarr PI, 2002, NEW ENGL J MED, V347, P2171; Wagner PL, 2001, J BACTERIOL, V183, P2081, DOI 10.1128/JB.183.6.2081-2085.2001; Weiss DS, 2007, P NATL ACAD SCI USA, V104, P6037, DOI 10.1073/pnas.0609675104; Zhang XP, 2000, J INFECT DIS, V181, P664, DOI 10.1086/315239	17	371	387	2	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	2008	321	5892					1078	1080		10.1126/science.1160354	http://dx.doi.org/10.1126/science.1160354			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	339RL	18719281	Green Accepted			2022-12-28	WOS:000258594900037
J	Singhal, S; Khoury, S				Singhal, Shalabh; Khoury, Saeb			Imaging of thebesian venous system	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Singhal, Shalabh; Khoury, Saeb] Univ Cincinnati, Coll Med, Cincinnati, OH 45267 USA	University of Cincinnati	Singhal, S (corresponding author), Univ Cincinnati, Coll Med, Cincinnati, OH 45267 USA.	singhash@ucmail.uc.edu							0	7	7	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 14	2008	359	7					E8	E8		10.1056/NEJMicm072885	http://dx.doi.org/10.1056/NEJMicm072885			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336XE	18703466				2022-12-28	WOS:000258397900011
J	Loevinsohn, B; Sayed, GD				Loevinsohn, Benjamin; Sayed, Ghulam Dastagir			Lessons from the health sector in Afghanistan - How progress can be made in challenging circumstances	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MATERNAL MORTALITY; SERVICES		[Loevinsohn, Benjamin; Sayed, Ghulam Dastagir] World Bank, Washington, DC 20433 USA	The World Bank	Loevinsohn, B (corresponding author), World Bank, 1818 H St NW, Washington, DC 20433 USA.	bloevinsohn@worldbank.org						Amowitz LL, 2002, JAMA-J AM MED ASSOC, V288, P1284, DOI 10.1001/jama.288.10.1284; Bartlett LA, 2005, LANCET, V365, P864, DOI 10.1016/S0140-6736(05)71044-8; *EC INT UN, 2007, COUNTR REP AFGH; *ISL REP AFGH MIN, BAS PACK HLTH SERV A; Loevinsohn B, 2005, LANCET, V366, P676, DOI 10.1016/S0140-6736(05)67140-1; *MIN PUBL HLTH, 2007, AFGH HLTH SECT BAL S; Palmer N, 2006, BMJ-BRIT MED J, V332, P718, DOI 10.1136/bmj.332.7543.718; Peters DH, 2007, B WORLD HEALTH ORGAN, V85, P146, DOI 10.2471/BLT.06.033746; Richards T, 2007, BRIT MED J, V334, P925, DOI 10.1136/bmj.39201.772083.BE; *UNICEF, STAT WORLDS CHILDR 2; *UNICEF CENTR STAT, MULT IND CLUST SURV; Waldman R, 2006, AFGHANISTANS HLTH SY; *WHO E MED REG OFF, EM PREP HUM ACT HLTH	13	34	34	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	2008	300	6					724	726		10.1001/jama.300.6.724	http://dx.doi.org/10.1001/jama.300.6.724			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336OM	18698072				2022-12-28	WOS:000258374500026
J	Park, MA; Li, JT; Hagan, JB; Maddox, DE; Abraham, RS				Park, Miguel A.; Li, James T.; Hagan, John B.; Maddox, Daniel E.; Abraham, Roshini S.			Common variable immunodeficiency: a new look at an old disease	LANCET			English	Review							MEMORY B-CELLS; SUBCUTANEOUS IMMUNOGLOBULIN REPLACEMENT; DOSE INTRAVENOUS IMMUNOGLOBULIN; MONOCLONAL-ANTIBODY TREATMENT; SELECTIVE IGA DEFICIENCY; GRANULOMATOUS-DISEASE; T-CELLS; THROMBOCYTOPENIC PURPURA; CLINICAL-FEATURES; IMMUNE-DEFICIENCY	Primary immunodeficiencies comprise many diseases caused by genetic defects primarily affecting the immune system. About 150 such diseases have been identified with more than 120 associated genetic defects. Although primary immunodeficiencies are quite rare in incidence, the prevalence can range from one in 500 to one in 500 000 in the general population, depending on the diagnostic skills and medical resources available in different countries. Common variable immunodeficiency (CVID) is the primary immunodeficiency most commonly encountered in clinical practice, and appropriate diagnosis and management of patients will have a significant effect on morbidity and mortality as well as financial aspects of health care. Advances in diagnostic laboratory methods, including B-cell subset analysis and genetic testing, coupled with new insights into the molecular basis of immune dysfunction in some patients with CVID, have enabled advances in the clinical classification of this heterogeneous disease.	[Abraham, Roshini S.] Mayo Clin, Coll Med, Dept Lab Med & Pathol, Div Clin Biochem & Immunol, Rochester, MN 55905 USA; [Park, Miguel A.; Li, James T.; Hagan, John B.; Maddox, Daniel E.] Mayo Clin, Div Allerg Dis, Dept Internal Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Abraham, RS (corresponding author), Mayo Clin, Coll Med, Dept Lab Med & Pathol, Div Clin Biochem & Immunol, Hilton 210E,200 1st St SW, Rochester, MN 55905 USA.	abraham.roshini@mayo.edu		Maddox, Daniel/0000-0001-8097-8794				Agematsu K, 1997, EUR J IMMUNOL, V27, P2073, DOI 10.1002/eji.1830270835; Alachkar H, 2006, CLIN IMMUNOL, V120, P310, DOI 10.1016/j.clim.2006.05.003; Alliot C, 2001, J ROY SOC MED, V94, P187, DOI 10.1177/014107680109400412; Aspalter RM, 2000, CLIN EXP IMMUNOL, V121, P506, DOI 10.1046/j.1365-2249.2000.01317.x; Bates CA, 2004, J ALLERGY CLIN IMMUN, V114, P415, DOI 10.1016/j.jaci.2004.05.057; BAUMERT E, 1992, CLIN EXP IMMUNOL, V90, P25; Bayry J, 2005, TRENDS MOL MED, V11, P370, DOI 10.1016/j.molmed.2005.06.005; Boncristiano M, 2000, EUR J IMMUNOL, V30, P2632, DOI 10.1002/1521-4141(200009)30:9<2632::AID-IMMU2632>3.0.CO;2-C; Bonilla FA, 2005, ANN ALLERG ASTHMA IM, V94, pS1, DOI 10.1016/S1081-1206(10)61142-8; Bossuyt X, 2007, CLIN CHEM, V53, P124, DOI 10.1373/clinchem.2007.075861; Brandt D, 2006, AUTOIMMUN REV, V5, P465, DOI 10.1016/j.autrev.2006.03.010; Brennan VM, 2003, CLIN EXP IMMUNOL, V133, P247, DOI 10.1046/j.1365-2249.2003.02199.x; Broides A, 2004, CLIN IMMUNOL, V113, P221, DOI 10.1016/j.clim.2004.07.008; Brouet JC, 2000, EUR J IMMUNOL, V30, P2516, DOI 10.1002/1521-4141(200009)30:9<2516::AID-IMMU2516>3.0.CO;2-Z; Buckley RH, 2006, J ALLERGY CLIN IMMUN, V117, P756, DOI 10.1016/j.jaci.2006.01.008; BURKS AW, 1986, NEW ENGL J MED, V314, P560, DOI 10.1056/NEJM198602273140907; Busse PJ, 2002, J ALLERGY CLIN IMMUN, V109, P1001, DOI 10.1067/mai.2002.124999; Campos RD, 2000, J CLIN IMMUNOL, V20, P77; Carbone J, 2005, ANN NY ACAD SCI, V1051, P666, DOI 10.1196/annals.1361.111; Caress JB, 2003, NEUROLOGY, V60, P1822, DOI 10.1212/01.WNL.0000068335.01620.9D; Carsetti R, 2005, J ALLERGY CLIN IMMUN, V115, P412, DOI 10.1016/j.jaci.2004.10.048; CARTER RH, 1992, SCIENCE, V256, P105, DOI 10.1126/science.1373518; Castigli E, 2006, J ALLERGY CLIN IMMUN, V117, P740, DOI 10.1016/j.jaci.2006.01.038; Castigli E, 2005, NAT GENET, V37, P829, DOI 10.1038/ng1601; Castigli E, 2007, NAT GENET, V39, P430, DOI 10.1038/ng0407-430; Cataldo F, 1998, GUT, V42, P362, DOI 10.1136/gut.42.3.362; Chanock SJ, 2007, NATURE, V447, P655, DOI 10.1038/447655a; Chapel HM, 2000, J CLIN IMMUNOL, V20, P94, DOI 10.1023/A:1006678312925; Conley ME, 1999, CLIN IMMUNOL, V93, P190, DOI 10.1006/clim.1999.4799; Conley ME, 2002, J PEDIATR-US, V141, P566, DOI 10.1067/mpd.2002.127711; Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725; Cunningham-Rundles C, 2003, ALLERGY ASTHMA PROC, V24, P409; Cunningham-Rundles C, 2001, Curr Allergy Asthma Rep, V1, P421, DOI 10.1007/s11882-001-0027-1; Cunningham-Rundles C, 2002, BLOOD REV, V16, P61, DOI 10.1054/blre.2001.0185; Cunningham-Rundles C, 2001, CLIN IMMUNOL, V100, P181, DOI 10.1006/clim.2001.5052; CUNNINGHAMRUNDLES C, 1989, J CLIN IMMUNOL, V9, P22, DOI 10.1007/BF00917124; CUNNINGHAMRUNDLES C, 1984, ANN INTERN MED, V101, P435, DOI 10.7326/0003-4819-101-4-435; CURTIN JJ, 1991, CLIN RADIOL, V44, P82, DOI 10.1016/S0009-9260(05)80501-X; Di Renzo M, 2004, CLIN EXP MED, V3, P211, DOI 10.1007/s10238-004-0027-2; Durandy A, 2006, CURR OPIN RHEUMATOL, V18, P369, DOI 10.1097/01.bor.0000231905.12172.b5; Eades-Perner AM, 2007, CLIN EXP IMMUNOL, V147, P306, DOI 10.1111/j.1365-2249.2006.03292.x; Eastwood D, 2004, CLIN EXP IMMUNOL, V137, P584, DOI 10.1111/j.1365-2249.2004.02581.x; Eibl MM, 1995, FOLIA MICROBIOL, V40, P360, DOI 10.1007/BF02814744; EISENSTEIN EM, 1993, J CLIN IMMUNOL, V13, P247, DOI 10.1007/BF00919383; FARRINGTON M, 1994, P NATL ACAD SCI USA, V91, P1099, DOI 10.1073/pnas.91.3.1099; Fasano MB, 1996, MEDICINE, V75, P251, DOI 10.1097/00005792-199609000-00002; FASTH A, 1982, J CLIN IMMUNOL, V2, P86, DOI 10.1007/BF00916891; Fecteau JF, 2006, J IMMUNOL, V177, P3728, DOI 10.4049/jimmunol.177.6.3728; Ferry BL, 2005, CLIN EXP IMMUNOL, V140, P532, DOI 10.1111/j.1365-2249.2005.02793.x; Garcia MAM, 2001, RESP MED, V95, P191, DOI 10.1053/rmed.2000.1020; GARDULF A, 1995, LANCET, V345, P365; Gardulf A, 2006, J CLIN IMMUNOL, V26, P177, DOI 10.1007/s10875-006-9002-x; Go RS, 2000, MAYO CLIN PROC, V75, P83, DOI 10.4065/75.1.83; Goldacker S, 2005, CURR OPIN ALLERGY CL, V5, P504, DOI 10.1097/01.all.0000191888.97397.b3; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; Grimbacher B, 2003, NAT IMMUNOL, V4, P261, DOI 10.1038/ni902; HAMILOS DL, 1992, ANN ALLERGY, V68, P472; Hammarstrom L, 2000, CLIN EXP IMMUNOL, V120, P225, DOI 10.1046/j.1365-2249.2000.01131.x; Hatab AZ, 2005, J ALLERGY CLIN IMMUN, V116, P1161, DOI 10.1016/j.jaci.2005.08.041; HERMANS PE, 1976, AM J MED, V61, P221, DOI 10.1016/0002-9343(76)90173-X; HERMASZEWSKI RA, 1993, Q J MED, V86, P31; Holm AM, 2004, CLIN EXP IMMUNOL, V138, P278, DOI 10.1111/j.1365-2249.2004.02630.x; Horn J, 2007, CLIN IMMUNOL, V122, P156, DOI 10.1016/j.clim.2006.10.002; Jaffe EF, 2001, IMMUNOL ALLERGY CLIN, V21, P141, DOI 10.1016/S0889-8561(05)70197-1; JAFFE JS, 1993, BLOOD, V82, P192, DOI 10.1182/blood.V82.1.192.bloodjournal821192; JAFFE JS, 1993, PEDIATR RES, V33, pS24; JANEWAY CA, 1953, T ASSOC AM PHYSICIAN, V66, P200; Kainulainen L, 1999, J ALLERGY CLIN IMMUN, V104, P1031, DOI 10.1016/S0091-6749(99)70085-0; KATO E, 1988, JAMA-J AM MED ASSOC, V259, P3269, DOI 10.1001/jama.1988.03720220017011; KINLEN LJ, 1985, LANCET, V1, P263; KLEIN U, 1993, EUR J IMMUNOL, V23, P3272, DOI 10.1002/eji.1830231232; Klein U, 1997, BLOOD, V89, P1288, DOI 10.1182/blood.V89.4.1288; KLEMOLA T, 1987, ANN CLIN RES, V19, P248; Knight AK, 2006, AUTOIMMUN REV, V5, P156, DOI 10.1016/j.autrev.2005.10.002; Lack G, 1996, J PEDIATR-US, V129, P898, DOI 10.1016/S0022-3476(96)70035-5; Lee WI, 2005, BLOOD, V105, P1881, DOI 10.1182/blood-2003-12-4420; Lindberg K, 2001, SCAND J INFECT DIS, V33, P904, DOI 10.1080/00365540110076769; Mackay F, 2003, CYTOKINE GROWTH F R, V14, P311, DOI 10.1016/S1359-6101(03)00023-6; Mackay F, 2003, ANNU REV IMMUNOL, V21, P231, DOI 10.1146/annurev.immunol.21.120601.141152; Majolini MB, 1997, CLIN IMMUNOL IMMUNOP, V84, P98, DOI 10.1006/clin.1997.4372; McCluskey DR, 1989, P R COLL PHYSICIANS, V19, P191; Mechanic LJ, 1997, ANN INTERN MED, V127, P613, DOI 10.7326/0003-4819-127-8_Part_1-199710150-00005; Mellemkjaer L, 2002, CLIN EXP IMMUNOL, V130, P495, DOI 10.1046/j.1365-2249.2002.02004.x; Michel M, 2004, MEDICINE, V83, P254, DOI 10.1097/01.md.0000133624.65946.40; Moratto D, 2006, CLIN IMMUNOL, V121, P203, DOI 10.1016/j.clim.2006.07.003; Morimoto Y, 2005, CURR ALLERGY ASTHM R, V5, P370, DOI 10.1007/s11882-005-0008-x; NOLTE MT, 1979, CLIN EXP IMMUNOL, V36, P237; North ME, 1998, CLIN EXP IMMUNOL, V111, P70; Nos P, 2006, AM J GASTROENTEROL, V101, P2165, DOI 10.1111/j.1572-0241.2006.00763_5.x; OBREGON RG, 1994, CHEST, V106, P490, DOI 10.1378/chest.106.2.490; Ogershok PR, 2006, ANN ALLERG ASTHMA IM, V97, P653, DOI 10.1016/S1081-1206(10)61096-4; Pan-Hammarstrom Q, 2007, NAT GENET, V39, P429, DOI 10.1038/ng0407-429; Piqueras B, 2003, J CLIN IMMUNOL, V23, P385, DOI 10.1023/A:1025373601374; Punnonen J, 1997, SCAND J IMMUNOL, V45, P203, DOI 10.1046/j.1365-3083.1997.d01-381.x; Quartier P, 1999, J PEDIATR-US, V134, P589, DOI 10.1016/S0022-3476(99)70246-5; Rani S, 2022, SPAT INF RES, V30, P417, DOI 10.1007/s41324-022-00442-9; REINHERZ EL, 1981, NEW ENGL J MED, V304, P811, DOI 10.1056/NEJM198104023041403; ROIFMAN CM, 1985, AM J MED, V79, P171, DOI 10.1016/0002-9343(85)90006-3; ROIFMAN CM, 1987, LANCET, V1, P1075; Salzer U, 2005, CURR OPIN ALLERGY CL, V5, P496, DOI 10.1097/01.all.0000191887.89773.cc; Salzer U, 2005, NAT GENET, V37, P820, DOI 10.1038/ng1600; Salzer U, 2004, CLIN IMMUNOL, V113, P234, DOI 10.1016/j.clim.2004.07.002; SANDLER SG, 1995, TRANSFUS MED REV, V9, P1, DOI 10.1016/S0887-7963(05)80026-4; Sati HIA, 2001, BRIT J HAEMATOL, V113, P556, DOI 10.1046/j.1365-2141.2001.02742.x; SCHARENBERG AM, 2006, GENE REV; Schroeder HW, 2004, J INVEST MED, V52, P90, DOI 10.1136/jim-52-02-17; Schroeder HW, 2000, CLIN REV ALLERG IMMU, V19, P127, DOI 10.1385/CRIAI:19:2:127; Sewell WAC, 2003, DRUGS, V63, P1359; Smith KJ, 2001, BRIT J DERMATOL, V144, P597, DOI 10.1046/j.1365-2133.2001.04092.x; Stamboulis E, 2004, EUR NEUROL, V51, P51, DOI 10.1159/000075091; Tanaka N, 2006, J COMPUT ASSIST TOMO, V30, P828, DOI 10.1097/01.rct.0000228163.08968.26; Tangye SG, 1998, J EXP MED, V188, P1691, DOI 10.1084/jem.188.9.1691; Tangye SG, 2007, J IMMUNOL, V179, P13, DOI 10.4049/jimmunol.179.1.13; Taubenheim N, 2005, J IMMUNOL, V175, P5498, DOI 10.4049/jimmunol.175.8.5498; Thatayatikom A, 2005, ANN ALLERG ASTHMA IM, V95, P293, DOI 10.1016/S1081-1206(10)61228-8; Tsuiji M, 2006, J EXP MED, V203, P393, DOI 10.1084/jem.20052033; van Zelm MC, 2006, NEW ENGL J MED, V354, P1901, DOI 10.1056/NEJMoa051568; VORECHOVSKY I, 1995, CLIN IMMUNOL IMMUNOP, V77, P185, DOI 10.1006/clin.1995.1142; Vorechovsky I, 2000, J IMMUNOL, V164, P4408, DOI 10.4049/jimmunol.164.8.4408; VORECHOVSKY I, 1993, MUTAT RES, V290, P255, DOI 10.1016/0027-5107(93)90166-D; Wakim M, 2004, AM J HEMATOL, V76, P152, DOI 10.1002/ajh.20072; Warnatz K, 2006, BLOOD, V107, P3045, DOI 10.1182/blood-2005-07-2955; Warnatz K, 2005, CLIN IMMUNOL, V115, pS20; Warnatz K, 2002, BLOOD, V99, P1544, DOI 10.1182/blood.V99.5.1544; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Weiler CR, 2004, INT J DERMATOL, V43, P163, DOI 10.1111/j.1365-4632.2004.02236.x; Weller S, 2004, BLOOD, V104, P3647, DOI 10.1182/blood-2004-01-0346; Weller S, 2001, P NATL ACAD SCI USA, V98, P1166, DOI 10.1073/pnas.98.3.1166; Weston SA, 2001, CLIN EXP IMMUNOL, V124, P465, DOI 10.1046/j.1365-2249.2001.01556.x; Wheat WH, 2005, J EXP MED, V202, P479, DOI 10.1084/jem.20050381; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003; Zhang L, 2007, J ALLERGY CLIN IMMUN, V120, P1178, DOI 10.1016/j.jaci.2007.10.001	132	210	214	2	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 9	2008	372	9637					489	502		10.1016/S0140-6736(08)61199-X	http://dx.doi.org/10.1016/S0140-6736(08)61199-X			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	335OD	18692715				2022-12-28	WOS:000258299000032
J	Alder, NN; Jensen, RE; Johnson, AE				Alder, Nathan N.; Jensen, Robert E.; Johnson, Arthur E.			Fluorescence mapping of mitochondrial TM23 complex reveals a water-facing, substrate-interacting helix surface	CELL			English	Article							MULTIPLE CONDUCTANCE CHANNEL; TRANSLOCATION CONTACT SITES; TIME-RESOLVED FLUORESCENCE; PROTEIN IMPORT MOTOR; INNER MEMBRANE; PREPROTEIN TRANSLOCASE; ER MEMBRANE; PRESEQUENCE TRANSLOCASE; PERMEABILITY BARRIER; INTERMEMBRANE SPACE	Protein translocation across the mitochondrial inner membrane is mediated by the TIM23 complex. While its central component, Tim23, is believed to form a protein-conducting channel, the regions of this subunit that face the imported protein are unknown. To examine Tim23 structure and environment in intact membranes at high resolution, various derivatives, each with a single, environment-sensitive fluorescent probe positioned at a specific site, were assembled into functional TIM23 complexes in active mitochondria and analyzed by multiple spectral techniques. Probes placed sequentially throughout a transmembrane region that was identified by crosslinking as part of the protein-conducting channel revealed an a helix in an amphipathic environment. Probes on the aqueous-facing helical surface specifically underwent spectral changes during protein import, and their accessibility to hydrophilic quenching agents is considered in terms of channel gating. This approach has therefore provided an unprecedented view of a translocon channel structure in an intact, fully operational, membrane-embedded complex.	[Alder, Nathan N.; Johnson, Arthur E.] Texas A&M Hlth Sci Ctr, Dept Mol & Cellular Med, College Stn, TX 77843 USA; [Jensen, Robert E.] Johns Hopkins Sch Med, Dept Cell Biol & Anat, Baltimore, MD 21205 USA; [Johnson, Arthur E.] Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; [Johnson, Arthur E.] Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Johns Hopkins University; Johns Hopkins Medicine; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Johnson, AE (corresponding author), Texas A&M Hlth Sci Ctr, Dept Mol & Cellular Med, College Stn, TX 77843 USA.	ajohnson@medicine.tamhsc.edu	Johnson, Arthur E/G-3457-2012	Alder, Nathan/0000-0003-4474-7803	National Institutes of Health (NIH) [GM64580, GM26494, GM54021]; NIH National Research Service Award [GM70266]; Robert A. Welch Foundation [BE-0017]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064580, R01GM026494, F32GM070266] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Robert A. Welch Foundation(The Welch Foundation); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to Yiwei Miao and Yuanlong Shao for outstanding technical assistance, and to the members of the Johnson lab for helpful discussions. This work was supported by National Institutes of Health (NIH) grants GM64580 (to A.E.J. and R.E.J.), GM26494 (A.E.J.), and GM54021 (R.E.J.), NIH National Research Service Award grant GM70266 (N.N.A.), and by the Robert A. Welch Foundation (chair grant BE-0017).	Ackerman SH, 2005, PROG NUCLEIC ACID RE, V80, P95, DOI 10.1016/S0079-6603(05)80003-0; Alder NN, 2008, MOL BIOL CELL, V19, P159, DOI 10.1091/mbc.E07-07-0669; Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; Bol R, 2007, J BIOL CHEM, V282, P29785, DOI 10.1074/jbc.M702140200; Bolender N, 2008, EMBO REP, V9, P42, DOI 10.1038/sj.embor.7401126; Bomer U, 1997, EMBO J, V16, P2205, DOI 10.1093/emboj/16.9.2205; Chacinska A, 2003, EMBO J, V22, P5370, DOI 10.1093/emboj/cdg532; Chacinska A, 2005, CELL, V120, P817, DOI 10.1016/j.cell.2005.01.011; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; Dattelbaum JD, 2005, PROTEIN SCI, V14, P284, DOI 10.1110/ps.041146005; DAUM G, 1982, J BIOL CHEM, V257, P3028; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; Flanagan JJ, 2003, J BIOL CHEM, V278, P18628, DOI 10.1074/jbc.M300173200; Frazier AE, 2003, MOL CELL BIOL, V23, P7818, DOI 10.1128/MCB.23.21.7818-7828.2003; Futamura A, 2001, BIOCHEMISTRY-US, V40, P6680, DOI 10.1021/bi0029346; Geissler A, 2002, CELL, V111, P507, DOI 10.1016/S0092-8674(02)01073-5; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; Jittikoon J, 2007, BIOCHEMISTRY-US, V46, P10950, DOI 10.1021/bi7008213; Johnson AE, 2005, TRAFFIC, V6, P1078, DOI 10.1111/j.1600-0854.2005.00340.x; JOHNSON AE, 1976, BIOCHEMISTRY-US, V15, P569, DOI 10.1021/bi00648a018; Krayl M, 2007, MOL CELL BIOL, V27, P411, DOI 10.1128/MCB.01391-06; KUBRICH M, 1994, FEBS LETT, V349, P222, DOI 10.1016/0014-5793(94)00670-9; Kushnareva YE, 1999, ARCH BIOCHEM BIOPHYS, V366, P107, DOI 10.1006/abbi.1999.1190; LANCET D, 1977, BIOCHEMISTRY-US, V16, P5150, DOI 10.1021/bi00642a031; LIN S, 1991, PHOTOCHEM PHOTOBIOL, V54, P361, DOI 10.1111/j.1751-1097.1991.tb02028.x; Lohret TA, 1997, J CELL BIOL, V137, P377, DOI 10.1083/jcb.137.2.377; MARTIN J, 1991, J BIOL CHEM, V266, P18051; Martinez-Caballero S, 2007, J BIOL CHEM, V282, P3584, DOI 10.1074/jbc.M607551200; Meier S, 2005, J BIOL CHEM, V280, P7777, DOI 10.1074/jbc.M412158200; Meinecke M, 2006, SCIENCE, V312, P1523, DOI 10.1126/science.1127628; Mokranjac D, 2003, EMBO J, V22, P816, DOI 10.1093/emboj/cdg090; Mori H, 2003, J BIOL CHEM, V278, P14257, DOI 10.1074/jbc.M300230200; Moro F, 1999, EMBO J, V18, P3667, DOI 10.1093/emboj/18.13.3667; Musse AA, 2006, J BIOL CHEM, V281, P885, DOI 10.1074/jbc.M511140200; Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878; Neupert W, 2007, ANNU REV BIOCHEM, V76, P723, DOI 10.1146/annurev.biochem.76.052705.163409; O'Rourke B, 2007, ANNU REV PHYSIOL, V69, P19, DOI 10.1146/annurev.physiol.69.031905.163804; Okamoto K, 2002, EMBO J, V21, P3659, DOI 10.1093/emboj/cdf358; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; Reinhart G D, 1991, J Fluoresc, V1, P153, DOI 10.1007/BF00865362; Ryan KR, 1998, MOL CELL BIOL, V18, P178, DOI 10.1128/MCB.18.1.178; RYAN KR, 1993, J BIOL CHEM, V268, P23743; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Schwartz MP, 1999, P NATL ACAD SCI USA, V96, P13086, DOI 10.1073/pnas.96.23.13086; Shatursky O, 1999, CELL, V99, P293, DOI 10.1016/S0092-8674(00)81660-8; Shepard LA, 1998, BIOCHEMISTRY-US, V37, P14563, DOI 10.1021/bi981452f; Sirrenberg C, 1997, J BIOL CHEM, V272, P29963, DOI 10.1074/jbc.272.47.29963; Slotboom DJ, 1999, MICROBIOL MOL BIOL R, V63, P293, DOI 10.1128/MMBR.63.2.293-307.1999; Tamura Y, 2006, J CELL BIOL, V174, P631, DOI 10.1083/jcb.200603087; Truscott KN, 2001, NAT STRUCT BIOL, V8, P1074, DOI 10.1038/nsb726; Valdes R, 2004, BIOCHEMISTRY-US, V43, P6793, DOI 10.1021/bi049873m; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; van der Laan M, 2007, NAT CELL BIOL, V9, P1152, DOI 10.1038/ncb1635; Woolhead CA, 2004, CELL, V116, P725, DOI 10.1016/S0092-8674(04)00169-2; Yamamoto H, 2002, CELL, V111, P519, DOI 10.1016/S0092-8674(02)01053-X	59	80	80	0	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 8	2008	134	3					439	450		10.1016/j.cell.2008.06.007	http://dx.doi.org/10.1016/j.cell.2008.06.007			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SO	18692467	Bronze			2022-12-28	WOS:000258665500017
J	Starfield, B				Starfield, Barbara			Quality and outcomes framework: patient-centred?	LANCET			English	Editorial Material							HEALTH		[Starfield, Barbara] Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA	Johns Hopkins University	Starfield, B (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA.	bstarfie@jhsph.edu						Campbell SA, 2008, ANN FAM MED, V6, P228, DOI 10.1370/afm.844; DORAN T, 2008, LANCET          0812; Gandhi GY, 2008, JAMA-J AM MED ASSOC, V299, P2543, DOI 10.1001/jama.299.21.2543; GERVAS J, LANCET IN PRESS; Russell LB., 2007, PREVENTIONS POTENTIA; Starfield B, 2005, MILBANK Q, V83, P457, DOI 10.1111/j.1468-0009.2005.00409.x; Starfield B, 2007, SOC SCI MED, V64, P1355, DOI 10.1016/j.socscimed.2006.11.027; Woolf SH, 2008, JAMA-J AM MED ASSOC, V299, P2437, DOI 10.1001/jama.299.20.2437	8	8	8	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG-SEP	2008	372	9640					692	694		10.1016/S0140-6736(08)61124-1	http://dx.doi.org/10.1016/S0140-6736(08)61124-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	344YZ	18701158				2022-12-28	WOS:000258964500005
J	Fonarow, GC				Fonarow, Gregg C.			Statins and n-3 fatty acid supplementation in heart failure	LANCET			English	Editorial Material							TRIAL; ROSUVASTATIN; SURVIVAL; THERAPY; DEATH		[Fonarow, Gregg C.] Ahmanson UCLA Cardiomyopathy Ctr, Los Angeles, CA 90095 USA		Fonarow, GC (corresponding author), Ahmanson UCLA Cardiomyopathy Ctr, Los Angeles, CA 90095 USA.	gfonarow@mednet.ucla.edu	Fonarow, Gregg C/D-5988-2014	Fonarow, Gregg C/0000-0002-3192-8093				*GISSI HF INV, 2008, LANCET          0831; Go AS, 2006, JAMA-J AM MED ASSOC, V296, P2105, DOI 10.1001/jama.296.17.2105; Horwich TB, 2004, J AM COLL CARDIOL, V43, P642, DOI 10.1016/j.jacc.2003.07.049; Horwich TB, 2002, J CARD FAIL, V8, P216, DOI 10.1054/jcaf.2002.126519a; Hunt Sharon Ann, 2005, J Am Coll Cardiol, V46, pe1, DOI 10.1016/j.jacc.2005.08.022; Kjekshus J, 2007, NEW ENGL J MED, V357, P2248, DOI 10.1056/NEJMoa0706201; Krum H, 2002, J AM COLL CARDIOL, V39, P1567, DOI 10.1016/S0735-1097(02)01827-2; Masoudi FA, 2007, NEW ENGL J MED, V357, P2301, DOI 10.1056/NEJMe0707221; Ramasubbu K, 2008, J AM COLL CARDIOL, V51, P415, DOI 10.1016/j.jacc.2007.10.009; Rauchhaus M, 2000, LANCET, V356, P930, DOI 10.1016/S0140-6736(00)02690-8; Sola S, 2006, J AM COLL CARDIOL, V47, P332, DOI 10.1016/j.jacc.2005.06.088; Tavazzi L, 2004, EUR J HEART FAIL, V6, P635, DOI 10.1016/j.ejheart.2004.03.001; Uretsky BF, 2000, CIRCULATION, V102, P611, DOI 10.1161/01.CIR.102.6.611	13	14	15	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 4	2008	372	9645					1195	1196		10.1016/S0140-6736(08)61241-6	http://dx.doi.org/10.1016/S0140-6736(08)61241-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	357YB	18757087				2022-12-28	WOS:000259882000004
J	Valentine, J; Zhang, S; Zentgraf, T; Ulin-Avila, E; Genov, DA; Bartal, G; Zhang, X				Valentine, Jason; Zhang, Shuang; Zentgraf, Thomas; Ulin-Avila, Erick; Genov, Dentcho A.; Bartal, Guy; Zhang, Xiang			Three-dimensional optical metamaterial with a negative refractive index	NATURE			English	Article							TRANSMISSION; FREQUENCIES; TERAHERTZ; LIGHT	Metamaterials are artificially engineered structures that have properties, such as a negative refractive index(1-4), not attainable with naturally occurring materials. Negative- index metamaterials (NIMs) were first demonstrated for microwave frequencies(5,6), but it has been challenging to design NIMs for optical frequencies and they have so far been limited to optically thin samples because of significant fabrication challenges and strong energy dissipation in metals(7,8). Such thin structures are analogous to a monolayer of atoms, making it difficult to assign bulk properties such as the index of refraction. Negative refraction of surface plasmons was recently demonstrated but was confined to a two- dimensional waveguide(9). Three- dimensional ( 3D) optical metamaterials have come into focus recently, including the realization of negative refraction by using layered semiconductor metamaterials and a 3D magnetic metamaterial in the infrared frequencies; however, neither of these had a negative index of refraction(10,11). Here we report a 3D optical metamaterial having negative refractive index with a very high figure of merit of 3.5 ( that is, low loss). This metamaterial is made of cascaded 'fishnet' structures, with a negative index existing over a broad spectral range. Moreover, it can readily be probed from free space, making it functional for optical devices. We construct a prism made of this optical NIM to demonstrate negative refractive index at optical frequencies, resulting unambiguously from the negative phase evolution of the wave propagating inside the metamaterial. Bulk optical metamaterials open up prospects for studies of 3D optical effects and applications associated with NIMs and zero-index materials such as reversed Doppler effect, superlenses, optical tunnelling devices(12,13), compact resonators and highly directional sources(14).	[Valentine, Jason; Zhang, Shuang; Zentgraf, Thomas; Ulin-Avila, Erick; Genov, Dentcho A.; Bartal, Guy; Zhang, Xiang] Univ Calif Berkeley, NSF Nanoscale Sci & Engn Ctr NSEC, Berkeley, CA 94720 USA; [Zhang, Xiang] Univ Calif Berkeley, Lawrence Berkeley Lab, Div Sci Mat, Berkeley, CA 94720 USA	National Science Foundation (NSF); University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Zhang, X (corresponding author), Univ Calif Berkeley, NSF Nanoscale Sci & Engn Ctr NSEC, 3112 Etcheverry Hall, Berkeley, CA 94720 USA.	xiang@berkeley.edu	Valentine, Jason G/A-6121-2012; 1.4, ALS Beamline/I-1886-2014; Zhang, Xiang/F-6905-2011; ulin-avila, erick/M-3278-2014; Zentgraf, Thomas/G-8848-2013; zhang, shuang/G-5224-2011	Zentgraf, Thomas/0000-0002-8662-1101; Zhang, Shuang/0000-0003-4556-2333; Zhang, Xiang/0000-0002-3272-894X; Ulin-Avila, Erick/0000-0003-4098-529X	US Army Research Office (ARO) MURI programme [50432-PH-MUR]; NSF Nano-scale Science and Engineering Center [DMI-0327077]; Alexander von Humboldt Foundation; Office of Science; Office of Basic Energy Sciences; US Department of Energy [DE-AC02-05CH11231]	US Army Research Office (ARO) MURI programme; NSF Nano-scale Science and Engineering Center(National Science Foundation (NSF)); Alexander von Humboldt Foundation(Alexander von Humboldt Foundation); Office of Science(United States Department of Energy (DOE)); Office of Basic Energy Sciences(United States Department of Energy (DOE)); US Department of Energy(United States Department of Energy (DOE))	We acknowledge funding support from US Army Research Office (ARO) MURI programme 50432-PH-MUR and partly by the NSF Nano-scale Science and Engineering Center DMI-0327077. We thank H. Bechtel and M. C. Martin for assisting in measurements of near-infrared transmission and reflection, and S. R. J. Brueck for discussion. T.Z. acknowledges a fellowship from the Alexander von Humboldt Foundation. Multilayer deposition was performed at the Molecular Foundry, Lawrence Berkeley National Laboratory, which is supported by the Office of Science, Office of Basic Energy Sciences, of the US Department of Energy under contract no. DE-AC02-05CH11231.	Alu A, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.024304; Chen HT, 2006, NATURE, V444, P597, DOI 10.1038/nature05343; Dolling G, 2007, OPT LETT, V32, P551, DOI 10.1364/OL.32.000551; Edwards B, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.033903; Eleftheriades GV, 2007, IEEE MICROW WIREL CO, V17, P412, DOI 10.1109/LMWC.2007.897785; Enoch S, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.213902; Fan XB, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.073901; Grbic A, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.117403; Hoffman AJ, 2007, NAT MATER, V6, P946, DOI 10.1038/nmat2033; JOHNSON PB, 1972, PHYS REV B, V6, P4370, DOI 10.1103/PhysRevB.6.4370; Lai A, 2004, IEEE MICROW MAG, V5, P34, DOI 10.1109/MMW.2004.1337766; Lezec HJ, 2007, SCIENCE, V316, P430, DOI 10.1126/science.1139266; Li T, 2006, OPT EXPRESS, V14, P11155, DOI 10.1364/OE.14.011155; Linden S, 2004, SCIENCE, V306, P1351, DOI 10.1126/science.1105371; Liu N, 2008, NAT MATER, V7, P31, DOI 10.1038/nmat2072; Notomi M, 2000, PHYS REV B, V62, P10696, DOI 10.1103/PhysRevB.62.10696; Padilla WJ, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.107401; Panoiu NC, 2003, OPT COMMUN, V223, P331, DOI 10.1016/S0030-4018(03)01690-0; Parazzoli CG, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.107401; Pendry JB, 1998, J PHYS-CONDENS MAT, V10, P4785, DOI 10.1088/0953-8984/10/22/007; Pendry JB, 2000, PHYS REV LETT, V85, P3966, DOI 10.1103/PhysRevLett.85.3966; Shalaev VM, 2007, NAT PHOTONICS, V1, P41, DOI 10.1038/nphoton.2006.49; Shelby RA, 2001, SCIENCE, V292, P77, DOI 10.1126/science.1058847; Silveirinha M, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.157403; Smith DR, 2004, SCIENCE, V305, P788, DOI 10.1126/science.1096796; Soukoulis CM, 2007, SCIENCE, V315, P47, DOI 10.1126/science.1136481; Tsakmakidis KL, 2007, NATURE, V450, P397, DOI 10.1038/nature06285; VESELAGO VG, 1968, SOV PHYS USPEKHI, V10, P509, DOI 10.1070/PU1968v010n04ABEH003699; Yen TJ, 2004, SCIENCE, V303, P1494, DOI 10.1126/science.1094025; Zhang SA, 2006, OPT EXPRESS, V14, P6778, DOI 10.1364/OE.14.006778	30	1735	1804	69	1391	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 18	2008	455	7211					376	U32		10.1038/nature07247	http://dx.doi.org/10.1038/nature07247			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349EX	18690249				2022-12-28	WOS:000259265200041
J	Reil, JC; Bohm, M				Reil, Jan-Christian; Boehm, Michael			BEAUTIFUL results - the slower, the better?	LANCET			English	Editorial Material							RESTING HEART-RATE; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; TRIAL; CARVEDILOL; IVABRADINE; FAILURE		[Reil, Jan-Christian; Boehm, Michael] Univ Klinikum Saarlandes, Innere Med Klin 3, D-66421 Homburg, Germany	Universitatsklinikum des Saarlandes	Reil, JC (corresponding author), Univ Klinikum Saarlandes, Innere Med Klin 3, D-66421 Homburg, Germany.	reil@med-in.uni-saarland.de	Böhm, Michael/C-3638-2011					Bohm M, 2008, J HYPERTENS, V26, P18; Borer JS, 2004, NAT CLIN PRACT CARD, V1, P103, DOI 10.1038/ncpcardio0052; BROWN HF, 1979, NATURE, V280, P235, DOI 10.1038/280235a0; Custodis F, 2008, CIRCULATION, V117, P2377, DOI 10.1161/CIRCULATIONAHA.107.746537; Dargie HJ, 2001, LANCET, V357, P1385, DOI 10.1016/s0140-6736(00)04560-8; Diaz A, 2005, EUR HEART J, V26, P967, DOI 10.1093/eurheartj/ehi190; FOX K, 2008, LANCET          0831; Fox K, 2007, J AM COLL CARDIOL, V50, P823, DOI 10.1016/j.jacc.2007.04.079; HJALMARSON A, 1990, AM J CARDIOL, V65, P547, DOI 10.1016/0002-9149(90)91029-6; Kjekshus J, 1999, EUR HEART J SUPPL, V1, pH64; PALATINI P, 1994, CIRCULATION, V90, P2870, DOI 10.1161/01.CIR.90.6.2870; Poole-Wilson PA, 2003, LANCET, V362, P7, DOI 10.1016/S0140-6736(03)13800-7; Reil JC, 2007, CLIN RES CARDIOL, V96, P585, DOI 10.1007/s00392-007-0537-5; Tardif JC, 2005, EUR HEART J, V26, P2529, DOI 10.1093/eurheartj/ehi586; WILHELMSEN L, 1986, EUR HEART J, V7, P279, DOI 10.1093/oxfordjournals.eurheartj.a062065	15	33	36	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 6	2008	372	9641					779	780		10.1016/S0140-6736(08)61172-1	http://dx.doi.org/10.1016/S0140-6736(08)61172-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	347FB	18757092				2022-12-28	WOS:000259124900004
J	Keeney, G; Leslie, K				Keeney, Gary; Leslie, Kevin			Preparing fresh tissues for the microscope	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SURGICAL PATHOLOGY; EXPERIENCE		[Leslie, Kevin] Mayo Clin Arizona, Div Anat Pathol, Dept Lab Med & Pathol, Scottsdale, AZ 85259 USA; [Keeney, Gary] Mayo Clin Rochester, Div Anat Pathol, Dept Lab Med & Pathol, Rochester, MN USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic	Leslie, K (corresponding author), Mayo Clin, Dept Pathol, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	leslie.kevin@mayo.edu						BlackSchaffer WS, 1996, AM J CLIN PATHOL, V106, pS33; CULLEN TS, 1895, J HOPKINS HOSP B, V6, P67; DAHLIN DC, 1980, MAYO CLIN PROC, V55, P721; FERREIRO JA, 1995, MAYO CLIN PROC, V70, P1137, DOI 10.4065/70.12.1137; Gal AA, 2005, JAMA-J AM MED ASSOC, V294, P3135, DOI 10.1001/jama.294.24.3135; Pick L, 1897, Br Med J, V1, P140; ROSAI J, 1997, GUIDING SURG HAND HI, P295; Watts JC, 1996, AM J CLIN PATHOL, V106, pS74; Wilson LB, 1905, JAMA-J AM MED ASSOC, V45, P1737, DOI DOI 10.1001/JAMA.1905.52510230037003C	9	5	5	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	2008	300	9					1074	1076		10.1001/jama.300.9.1074	http://dx.doi.org/10.1001/jama.300.9.1074			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	342YN	18768420	Bronze			2022-12-28	WOS:000258819600026
J	Fehr, E; Bernhard, H; Rockenbach, B				Fehr, Ernst; Bernhard, Helen; Rockenbach, Bettina			Egalitarianism in young children	NATURE			English	Article							ALTRUISTIC PUNISHMENT; PAROCHIAL ALTRUISM; CHIMPANZEES; BEHAVIOR; PREFERENCES; HERITABILITY; ADVANTAGE; OUTCOMES; IMPACT; TRUST	Human social interaction is strongly shaped by other- regarding preferences, that is, a concern for the welfare of others. These preferences are important for a unique aspect of human sociality - large scale cooperation with genetic strangers but little is known about their developmental roots. Here we show that young children's other- regarding preferences assume a particular form, inequality aversion that develops strongly between the ages of 3 and 8. At age 3 - 4, the overwhelming majority of children behave selfishly, whereas most children at age 7 - 8 prefer resource allocations that remove advantageous or disadvantageous inequality. Moreover, inequality aversion is strongly shaped by parochialism, a preference for favouring the members of one's own social group. These results indicate that human egalitarianism and parochialism have deep developmental roots, and the simultaneous emergence of altruistic sharing and parochialism during childhood is intriguing in view of recent evolutionary theories which predict that the same evolutionary process jointly drives both human altruism and parochialism.	[Fehr, Ernst; Bernhard, Helen] Univ Zurich, Inst Empir Res Econ, CH-8006 Zurich, Switzerland; [Fehr, Ernst] Coll Helveticum, CH-8092 Zurich, Switzerland; [Rockenbach, Bettina] Univ Erfurt, D-99089 Erfurt, Germany	University of Zurich; University of Erfurt	Fehr, E (corresponding author), Univ Zurich, Inst Empir Res Econ, Blumlisalpstr 10, CH-8006 Zurich, Switzerland.	efehr@iew.uzh.ch; bettina.rockenbach@uni-erfurt.de	Rockenbach, Bettina/AAI-8072-2021; Rockenbach, Bettina/B-5447-2016	Rockenbach, Bettina/0000-0003-2624-1964; Rockenbach, Bettina/0000-0003-2624-1964	Foundations of Human Social Behaviour-Altruism versus Egoism' at the University of Zurich; Swiss National Science Foundation	Foundations of Human Social Behaviour-Altruism versus Egoism' at the University of Zurich; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	This paper is part of the Research Priority Program 'Foundations of Human Social Behaviour-Altruism versus Egoism' at the University of Zurich and of the Swiss National Competence Center in research on affective sciences, which is financed by the Swiss National Science Foundation. We also thank N. Kessler for her research assistance during the conduct of the experiments.	Benenson JF, 2007, EVOL HUM BEHAV, V28, P168, DOI 10.1016/j.evolhumbehav.2006.10.003; Bernhard H, 2006, NATURE, V442, P912, DOI 10.1038/nature04981; Boehm C, 1997, AM NAT, V150, pS100, DOI 10.1086/286052; BOEHM C, 1993, CURR ANTHROPOL, V34, P227, DOI 10.1086/204166; Bowles S, 2004, ROUNDTABLE SER BEHAV, P93; Boyd R, 2005, ORIGIN EVOLUTION CUL; Brown M, 2004, ECONOMETRICA, V72, P747, DOI 10.1111/j.1468-0262.2004.00511.x; Burkart JM, 2007, P NATL ACAD SCI USA, V104, P19762, DOI 10.1073/pnas.0710310104; Cesarini D, 2008, P NATL ACAD SCI USA, V105, P3721, DOI 10.1073/pnas.0710069105; CHAGNON NA, 1988, SCIENCE, V239, P985, DOI 10.1126/science.239.4843.985; Charness G, 2002, Q J ECON, V117, P817, DOI 10.1162/003355302760193904; Choi JK, 2007, SCIENCE, V318, P636, DOI 10.1126/science.1144237; Dana J, 2006, ORGAN BEHAV HUM DEC, V100, P193, DOI 10.1016/j.obhdp.2005.10.001; Dawes CT, 2007, NATURE, V446, P794, DOI 10.1038/nature05651; de Quervain DJF, 2004, SCIENCE, V305, P1254, DOI 10.1126/science.1100735; Eisenberg N., 1989, ROOTS PROSOCIAL BEHA; Eisenberg N., 2006, HDB CHILD PSYCHOL VO, V(6th ed., pp., P646, DOI 10.1002/9780470147658.chpsy0311; Ellingsen T, 2008, EVOL HUM BEHAV, V29, P100, DOI 10.1016/j.evolhumbehav.2007.11.001; Ellingsen T, 2007, J ECON PERSPECT, V21, P135, DOI 10.1257/jep.21.4.135; Falk A, 2006, GAME ECON BEHAV, V54, P293, DOI 10.1016/j.geb.2005.03.001; Falk A, 2005, ECONOMETRICA, V73, P2017, DOI 10.1111/j.1468-0262.2005.00644.x; Fehr E, 2002, NATURE, V415, P137, DOI 10.1038/415137a; Fehr E, 1999, Q J ECON, V114, P817, DOI 10.1162/003355399556151; Fliessbach K, 2007, SCIENCE, V318, P1305, DOI 10.1126/science.1145876; Fong C., 2006, HDB EC GIVING RECIPR; FOWLER JH, 2007, NATURE, V433, pE1; Goette L, 2006, AM ECON REV, V96, P212, DOI 10.1257/000282806777211658; Gurerk O, 2006, SCIENCE, V312, P108, DOI 10.1126/science.1123633; Harbaugh WT, 2000, ECON INQ, V38, P95, DOI 10.1093/ei/38.1.95; Hauert C, 2007, SCIENCE, V316, P1905, DOI 10.1126/science.1141588; Henrich J, 2005, BEHAV BRAIN SCI, V28, P795, DOI 10.1017/S0140525X05000142; Jensen K, 2006, P ROY SOC B-BIOL SCI, V273, P1013, DOI 10.1098/rspb.2005.3417; Jensen K, 2007, SCIENCE, V318, P107, DOI 10.1126/science.1145850; KNIGHT GP, 1977, CHILD DEV, V48, P1385, DOI 10.2307/1128497; Milinski M, 2002, NATURE, V415, P424, DOI 10.1038/415424a; Murnighan JK, 1998, J ECON PSYCHOL, V19, P415, DOI 10.1016/S0167-4870(98)00017-8; Nowak MA, 2005, NATURE, V437, P1291, DOI 10.1038/nature04131; Rockenbach B, 2006, NATURE, V444, P718, DOI 10.1038/nature05229; Shinada M, 2004, EVOL HUM BEHAV, V25, P379, DOI 10.1016/j.evolhumbehav.2004.08.001; Silk JB, 2005, NATURE, V437, P1357, DOI 10.1038/nature04243; Sutter M, 2007, GAME ECON BEHAV, V59, P364, DOI 10.1016/j.geb.2006.07.006; Sutter M, 2007, J ECON PSYCHOL, V28, P69, DOI 10.1016/j.joep.2006.09.001; Thompson C, 1997, COGNITIVE DEV, V12, P199, DOI 10.1016/S0885-2014(97)90013-7; Turiel E., 1998, HDB CHILD PSYCHOL, V3, P863, DOI DOI 10.1002/9780470147658.CHPSY0313; Van Lange PAM, 1999, J PERS SOC PSYCHOL, V77, P337, DOI 10.1037/0022-3514.77.2.337; Vonk J, 2008, ANIM BEHAV, V75, P1757, DOI 10.1016/j.anbehav.2007.09.036; Wallace B, 2007, P NATL ACAD SCI USA, V104, P15631, DOI 10.1073/pnas.0706642104; Warneken F, 2006, SCIENCE, V311, P1301, DOI 10.1126/science.1121448; Warneken F, 2007, PLOS BIOL, V5, P1414, DOI 10.1371/journal.pbio.0050184; Wellman HM, 2001, CHILD DEV, V72, P655, DOI 10.1111/1467-8624.00304	50	799	827	8	279	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	2008	454	7208					1079	U22		10.1038/nature07155	http://dx.doi.org/10.1038/nature07155			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	341MW	18756249	Green Accepted			2022-12-28	WOS:000258719600029
J	Ferner, RE				Ferner, Robin E.			Did the drug cause death? Codeine and breastfeeding	LANCET			English	Editorial Material							POSTMORTEM BLOOD-SAMPLES; MORPHINE CONCENTRATIONS; NEONATAL APNEA; REDISTRIBUTION; MILK; MORPHINE-6-GLUCURONIDE; MORPHINE-3-GLUCURONIDE; KINETICS; OPIOIDS; MOTHER		City Hosp, W Midlands Ctr Adverse Drug React, Birmingham B18 7QH, W Midlands, England; Univ Birmingham, Dept Clin Pharmacol, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham	Ferner, RE (corresponding author), City Hosp, W Midlands Ctr Adverse Drug React, Birmingham B18 7QH, W Midlands, England.	r.e.ferner@bham.ac.uk		Ferner, Robin/0000-0003-3769-1346				ADADI P, 2008, LANCET, V372, P626; Aronson JK, 2003, BRIT MED J, V327, P1222, DOI 10.1136/bmj.327.7425.1222; Baka NE, 2002, ANESTH ANALG, V94, P184, DOI 10.1097/00000539-200201000-00035; Barrett DA, 1996, BRIT J CLIN PHARMACO, V41, P531, DOI 10.1046/j.1365-2125.1996.03539.x; Bateman DN, 2008, LANCET, V372, P625, DOI 10.1016/S0140-6736(08)61266-0; Cook DS, 2000, J CLIN PATHOL, V53, P282, DOI 10.1136/jcp.53.4.282; Crandall CS, 2006, J FORENSIC SCI, V51, P413, DOI 10.1111/j.1556-4029.2006.00067.x; DAVIS JM, 1985, PEDIATR RES, V19, pA170, DOI 10.1203/00006450-198504000-00389; Dwyer P S, 1984, Hum Toxicol, V3 Suppl, p145S; FERNER RE, 2008, BR J CLIN PHARM 0529; Gerostamoulos J, 2000, J FORENSIC SCI, V45, P843; GOURLEY GR, 1986, LANCET, V1, P644; Koren G, 2006, LANCET, V368, P704, DOI 10.1016/S0140-6736(06)69255-6; Logan BK, 1996, J FORENSIC SCI, V41, P221; Madadi P, 2007, CAN FAM PHYSICIAN, V53, P33; MILLER RP, 1976, CLIN PHARMACOL THER, V19, P284; NAUMBURG EG, 1988, AM J DIS CHILD, V142, P11, DOI 10.1001/archpedi.1988.02150010017005; Pelissier-Alicot AL, 2003, J ANAL TOXICOL, V27, P533, DOI 10.1093/jat/27.8.533; POUNDER DJ, 1990, FORENSIC SCI INT, V45, P253, DOI 10.1016/0379-0738(90)90182-X; ROBIEUX I, 1990, J TOXICOL-CLIN TOXIC, V28, P365, DOI 10.3109/15563659008994437; Rouzioux J M, 1980, Acta Med Leg Soc (Liege), V30, P25; Skopp G, 2001, J ANAL TOXICOL, V25, P2, DOI 10.1093/jat/25.1.2; SMITH JW, 1982, CLIN RES, V30, pA259; WITTELS B, 1990, ANESTHESIOLOGY, V73, P864, DOI 10.1097/00000542-199011000-00012; YONEMITSU K, 1992, INT J LEGAL MED, V104, P347, DOI 10.1007/BF01369555; [No title captured]	26	14	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 23	2008	372	9639					606	608		10.1016/S0140-6736(08)61254-4	http://dx.doi.org/10.1016/S0140-6736(08)61254-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	340BX	18722850				2022-12-28	WOS:000258622200006
J	Ishii, K; Ogiyama, Y; Chikashige, Y; Soejima, S; Masuda, F; Kakuma, T; Hiraoka, Y; Takahashi, K				Ishii, Kojiro; Ogiyama, Yuki; Chikashige, Yuji; Soejima, Saeko; Masuda, Fumie; Kakuma, Tatsuyuki; Hiraoka, Yasushi; Takahashi, Kohta			Heterochromatin integrity affects chromosome reorganization after centromere dysfunction	SCIENCE			English	Article							FISSION YEAST; CHROMATIN; DISTINCT; REQUIRES; MEIOSIS; PROTEIN; GENOME; RNAI	The centromere is essential for the inheritance of genetic information on eukaryotic chromosomes. Epigenetic regulation of centromere identity has been implicated in genome stability, karyotype evolution, and speciation. However, little is known regarding the manner in which centromere dysfunction affects the chromosomal architectures. Here we show that in the fission yeast Schizosaccharomyces pombe, the conditional deletion of the centromere produces survivors that carry either a neocentromere- acquired chromosome at the subtelomeric region or an acentric chromosome rescued by intertelomere fusion with either of the remaining chromosomes. The ratio of neocentromere formation to telomere fusion is considerably decreased by the inactivation of genes involved in RNA interference- dependent heterochromatin formation. By affecting the modes of chromosomal reorganization, the genomic distribution of heterochromatin may influence the fate of karyotype evolution.	[Ishii, Kojiro; Ogiyama, Yuki; Soejima, Saeko; Masuda, Fumie; Takahashi, Kohta] Kurume Univ, Div Cell Biol, Inst Life Sci, Kurume, Fukuoka 830, Japan; [Chikashige, Yuji; Hiraoka, Yasushi] Natl Inst Informat & Commun Technol, Kobe Adv Informat & Commun Technol Res Ctr, Kobe, Hyogo, Japan; [Kakuma, Tatsuyuki] Kurume Univ, Ctr Biostat, Kurume, Fukuoka 830, Japan; [Hiraoka, Yasushi] Osaka Univ, Grad Sch Frontier Biosci, Osaka, Japan	Kurume University; National Institute of Information & Communications Technology (NICT) - Japan; Kurume University; Osaka University	Takahashi, K (corresponding author), Kurume Univ, Div Cell Biol, Inst Life Sci, Kurume, Fukuoka 830, Japan.	takahash@lsi.kurume-u.ac.jp	Ishii, Kojiro/L-5102-2017; Hiraoka, Yasushi/B-5111-2009	Hiraoka, Yasushi/0000-0001-9407-8228	Ministry of Education, Culture, Sports, Science, and Technology, Japan;; Time's Arrow and Biosignaling; Precursory Research for Embryonic Science and Technology; Japan Science and Technology Agency	Ministry of Education, Culture, Sports, Science, and Technology, Japan;(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Time's Arrow and Biosignaling; Precursory Research for Embryonic Science and Technology; Japan Science and Technology Agency(Japan Science & Technology Agency (JST))	We thank K. Nagao, S. Saitoh, and H. Kimura for their technical expertise and discussion and M. Yanagida, A. Carr, J. Nakayama, and K. Gull for providing experimental materials. This work was supported by Grants- in- Aid for Exploratory Research and Scientific Research on Priority Areas (Nuclear Dynamics, Chromosome Cycle, Decode Systems) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan; and a grant from Time's Arrow and Biosignaling, Precursory Research for Embryonic Science and Technology, Japan Science and Technology Agency.	Amor DJ, 2002, AM J HUM GENET, V71, P695, DOI 10.1086/342730; Cam HP, 2005, NAT GENET, V37, P809, DOI 10.1038/ng1602; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Craig JM, 2003, HUM MOL GENET, V12, P3109, DOI 10.1093/hmg/ddg330; Folco HD, 2008, SCIENCE, V319, P94, DOI 10.1126/science.1150944; Grewal SIS, 2007, NAT REV GENET, V8, P35, DOI 10.1038/nrg2008; Hall IM, 2003, P NATL ACAD SCI USA, V100, P193, DOI 10.1073/pnas.232688099; Hansen KR, 2005, MOL CELL BIOL, V25, P590, DOI 10.1128/MCB.25.2.590-601.2005; Henikoff S, 2001, SCIENCE, V293, P1098, DOI 10.1126/science.1062939; Karpen GH, 1997, TRENDS GENET, V13, P489, DOI 10.1016/S0168-9525(97)01298-5; Maggert KA, 2001, GENETICS, V158, P1615; Mata J, 2002, NAT GENET, V32, P143, DOI 10.1038/ng951; Murnane JP, 2004, BIOESSAYS, V26, P1164, DOI 10.1002/bies.20125; Partridge JF, 2000, GENE DEV, V14, P783; Saitoh S, 2005, MOL BIOL CELL, V16, P3666, DOI 10.1091/mbc.E05-01-0014; Sullivan BA, 2004, NAT STRUCT MOL BIOL, V11, P1076, DOI 10.1038/nsmb845; Takahashi K, 2000, SCIENCE, V288, P2215, DOI 10.1126/science.288.5474.2215; Villasante A, 2007, CELL CYCLE, V6, P2872, DOI 10.4161/cc.6.23.5047; Wiren M, 2005, EMBO J, V24, P2906, DOI 10.1038/sj.emboj.7600758	19	157	158	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	2008	321	5892					1088	1091		10.1126/science.1158699	http://dx.doi.org/10.1126/science.1158699			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339RL	18719285				2022-12-28	WOS:000258594900041
J	Royden, LH; Burchfiel, BC; van der Hilst, RD				Royden, Leigh H.; Burchfiel, B. Clark; van der Hilst, Robert D.			The geological evolution of the Tibetan plateau	SCIENCE			English	Review							AMBIENT SEISMIC NOISE; WAVE ARRAY TOMOGRAPHY; EASTERN MARGIN; CONTINENTAL DEFORMATION; 2-STATION ANALYSIS; COLLISION ZONE; SOUTHERN TIBET; CRUST BENEATH; SE TIBET; MANTLE		[Royden, Leigh H.; Burchfiel, B. Clark; van der Hilst, Robert D.] MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 01890 USA	Massachusetts Institute of Technology (MIT)	Royden, LH (corresponding author), MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 01890 USA.	lhroyden@mit.edu			NSF Earth Science, Continental Dynamics Program [EAR-0003571]	NSF Earth Science, Continental Dynamics Program(National Science Foundation (NSF))	This project has been supported by NSF Earth Science, Continental Dynamics Program since 1986, most recently by grant EAR-0003571. This work would not have been possible without the collaboration and support of our colleagues at the Chendu Institute of Geology and Mineral Resources over many years, especially Chen Zhiliang, and at the Geological Institute of Yunnan, in Kunming.	Akciz S, 2008, GEOSPHERE, V4, P292, DOI 10.1130/GES00111.1; Argand E, 1922, C GEOL INT, P171; Blisniuk PM, 2001, NATURE, V412, P628, DOI 10.1038/35088045; Burchfiel B.C., 1995, INT GEOL REV, V37, P661, DOI [10.1080/00206819509465424, DOI 10.1080/00206819509465424]; Burchfiel B.C., 2008, GSA TODAY GEOL SOC A, V18, P4, DOI [10.1130/GSATG18A.1, DOI 10.1130/GSATG18A.1]; Burchfiel B. C., 2004, GSA TODAY, V14, P4, DOI DOI 10.1130/1052-5173(2004)014<4:PANNGC>2.0.C0;2; BURCHFIEL BC, 1989, GEOLOGY, V17, P748, DOI 10.1130/0091-7613(1989)017<0448:IDWZOC>2.3.CO;2; Clark MK, 2000, GEOLOGY, V28, P703, DOI 10.1130/0091-7613(2000)28<703:TOBTEM>2.0.CO;2; Clark MK, 2005, GEOLOGY, V33, P525, DOI 10.1130/G21265.1; CLARK MK, 2006, J GEOPHYS RES, V111; COOK KL, 2008, J GEOPHYS RES; Cowgill E, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB002080; DeCelles PG, 2002, TECTONICS, V21, DOI 10.1029/2001TC001322; Engdahl ER, 1998, B SEISMOL SOC AM, V88, P722; ENGLAND P, 1989, J GEOPHYS RES-SOLID, V94, P17561, DOI 10.1029/JB094iB12p17561; Flesch LM, 2001, J GEOPHYS RES-SOL EA, V106, P16435, DOI 10.1029/2001JB000208; Hall R, 2004, GEOPHYS MONOGR SER, V149, P55, DOI 10.1029/149GM04; Holbig ES, 2008, J GEOPHYS RES-SOL EA, V113, DOI 10.1029/2007JB005149; Honza E, 2004, GEOPH MONOG SERIES, V149, P87, DOI 10.1029/149GM05; HOUSEMAN G, 1986, J GEOPHYS RES-SOLID, V91, P3651, DOI 10.1029/JB091iB03p03651; Kapp P, 2007, GEOL SOC AM BULL, V119, P917, DOI 10.1130/B26033.1; Kirby E, 2002, TECTONICS, V21, DOI 10.1029/2000TC001246; Li C., 2008, GEOCHEM GEOPHYS GEOS; LI C, 2008, EARTH PLANET SCI LET; Liu ZF, 2001, J SEDIMENT RES, V71, P971, DOI 10.1306/030901710971; Meade BJ, 2007, GEOLOGY, V35, P81, DOI 10.1130/G22924A.1; Meyer B, 1998, GEOPHYS J INT, V135, P1, DOI 10.1046/j.1365-246X.1998.00567.x; MOLNAR P, 1993, REV GEOPHYS, V31, P357, DOI 10.1029/93RG02030; Nelson KD, 1996, SCIENCE, V274, P1684, DOI 10.1126/science.274.5293.1684; OUIMET W, 2007, THESIS MIT; Rowley DB, 2006, NATURE, V439, P677, DOI 10.1038/nature04506; Rowley DB, 1998, J GEOL, V106, P229, DOI 10.1086/516018; Royden L, 1996, J GEOPHYS RES-SOL EA, V101, P17679, DOI 10.1029/96JB00951; Shen F, 2001, J GEOPHYS RES-SOL EA, V106, P6793, DOI 10.1029/2000JB900389; Shu LS, 2007, ACTA GEOL SIN-ENGL, V81, P573; Sibuet JC, 2004, GEOPHYS MONOGR SER, V149, P127; Tapponnier P, 2001, SCIENCE, V294, P1671, DOI 10.1126/science.105978; TAPPONNIER P, 1986, GEOL SOC LOND SPEC P, V19, P115, DOI DOI 10.1144/GSL.SP.1986.019.01.07; VANDERHILST R, 1993, EARTH PLANET SC LETT, V120, P395, DOI 10.1016/0012-821X(93)90253-6; Wang E., 1998, GEOLOGICAL SOC AM SP, V327, P108, DOI DOI 10.1130/0-8137-2327-2.1; Williams H, 2001, GEOLOGY, V29, P339, DOI 10.1130/0091-7613(2001)029<0339:AACODI>2.0.CO;2; Xu LL, 2007, PHYS EARTH PLANET IN, V165, P176, DOI 10.1016/j.pepi.2007.09.002; Yao HJ, 2008, GEOPHYS J INT, V173, P205, DOI 10.1111/j.1365-246X.2007.03696.x; Yao HJ, 2006, GEOPHYS J INT, V166, P732, DOI 10.1111/j.1365-246X.2006.03028.x; Zhang PZ, 2004, GEOLOGY, V32, P809, DOI 10.1130/G20554.1; Zhou RJ, 2007, ACTA GEOL SIN-ENGL, V81, P593	46	1145	1330	36	440	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	2008	321	5892					1054	1058		10.1126/science.1155371	http://dx.doi.org/10.1126/science.1155371			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339RL	18719275				2022-12-28	WOS:000258594900029
J	Lovell, DJ; Ruperto, N; Goodman, S; Reiff, A; Jung, L; Jarosova, K; Nemcova, D; Mouy, R; Sandborg, C; Bohnsack, J; Elewaut, D; Foeldvari, I; Gerloni, V; Rovensky, J; Minden, K; Vehe, RK; Weiner, LW; Horneff, G; Huppertz, HI; Olson, NY; Medich, JR; Carcereri-De-Prati, R; McIlraith, MJ; Giannini, EH; Martini, A				Lovell, Daniel J.; Ruperto, Nicolino; Goodman, Steven; Reiff, Andreas; Jung, Lawrence; Jarosova, Katerina; Nemcova, Dana; Mouy, Richard; Sandborg, Christy; Bohnsack, John; Elewaut, Dirk; Foeldvari, Ivan; Gerloni, Valeria; Rovensky, Jozef; Minden, Kirsten; Vehe, Richard K.; Weiner, L. Wagner; Horneff, Gerd; Huppertz, Hans-Iko; Olson, Nancy Y.; Medich, John R.; Carcereri-De-Prati, Roberto; McIlraith, Melissa J.; Giannini, Edward H.; Martini, Alberto		Pediat Rheumatology Collaborative; Pediat Rheumatology Int Trials Org	Adalimumab with or without methotrexate in juvenile rheumatoid arthritis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IDIOPATHIC ARTHRITIS; PLUS METHOTREXATE; DOUBLE-BLIND; TRIAL; IMPROVEMENT; ETANERCEPT; EFFICACY; CHILDREN; THERAPY; SAFETY	Background: Tumor necrosis factor (TNF) has a pathogenic role in juvenile rheumatoid arthritis. We evaluated the efficacy and safety of adalimumab, a fully human monoclonal anti-TNF antibody, in children with polyarticular-course juvenile rheumatoid arthritis. Methods: Patients 4 to 17 years of age with active juvenile rheumatoid arthritis who had previously received treatment with nonsteroidal antiinflammatory drugs underwent stratification according to methotrexate use and received 24 mg of adalimumab per square meter of body-surface area (maximum dose, 40 mg) subcutaneously every other week for 16 weeks. We randomly assigned patients with an American College of Rheumatology Pediatric 30% (ACR Pedi 30) response at week 16 to receive adalimumab or placebo in a double-blind fashion every other week for up to 32 weeks. Results: Seventy-four percent of patients not receiving methotrexate (64 of 86) and 94% of those receiving methotrexate (80 of 85) had an ACR Pedi 30 response at week 16 and were eligible for double-blind treatment. Among patients not receiving methotrexate, disease flares (the primary outcome) occurred in 43% of those receiving adalimumab and 71% of those receiving placebo (P=0.03). Among patients receiving methotrexate, flares occurred in 37% of those receiving adalimumab and 65% of those receiving placebo (P=0.02). At 48 weeks, the percentages of patients treated with methotrexate who had ACR Pedi 30, 50, 70, or 90 responses were significantly greater for those receiving adalimumab than for those receiving placebo; the differences between patients not treated with methotrexate who received adalimumab and those who received placebo were not significant. Response rates were sustained after 104 weeks of treatment. Serious adverse events possibly related to adalimumab occurred in 14 patients. Conclusions: Adalimumab therapy seems to be an efficacious option for the treatment of children with juvenile rheumatoid arthritis. (ClinicalTrials.gov number, NCT00048542.). .	[Lovell, Daniel J.; Giannini, Edward H.] Childrens Hosp, Med Ctr, Div Rheumatol, Cincinnati, OH 45229 USA; [Ruperto, Nicolino; Martini, Alberto] Pediat Rheumatol Int Trials Org, Ist Ricovero & Cura Carattere Sci G Gaslini, Genoa, Italy; [Goodman, Steven] Arthrit Associates S Florida, Delray Beach, FL USA; [Reiff, Andreas] Childrens Hosp, Los Angeles, CA 90027 USA; [Jung, Lawrence] Creighton Univ, Med Ctr, Omaha, NE USA; [Jung, Lawrence] Childrens Hosp, Omaha, NE USA; [Jarosova, Katerina] Revmatol Ustav, Prague, Czech Republic; [Nemcova, Dana] First Fac Med, Prague, Czech Republic; [Nemcova, Dana] Gen Fac Hosp, Prague, Czech Republic; [Mouy, Richard] Hop Necker Enfants Malad, Paris, France; [Sandborg, Christy] Stanford Univ, Med Ctr, Stanford, CA 94305 USA; [Bohnsack, John] Univ Utah, Hlth Sci Ctr, Salt Lake City, UT USA; [Elewaut, Dirk] Ghent Univ Hosp, B-9000 Ghent, Belgium; [Foeldvari, Ivan] Hamburger Zentrum Kinder & Jugendrheumatol, Hamburg, Germany; [Gerloni, Valeria] Ist Gaetano Pini, Milan, Italy; [Rovensky, Jozef] Natl Inst Rheumat Dis, Piestany, Slovakia; [Minden, Kirsten] Charite, Berlin, Germany; [Vehe, Richard K.] Univ Minnesota, Minneapolis, MN USA; [Weiner, L. Wagner] Univ Chicago, Larabida Hosp, Chicago, IL 60637 USA; [Horneff, Gerd] Zentrum Allgemeine Padiatrie & Neonatol, St Augustin, Germany; [Huppertz, Hans-Iko] Klinikum Bremen Mitte, Bremen, Germany; [Olson, Nancy Y.] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA; [Medich, John R.] Abbott Labs, Parsippany, NJ USA; [Carcereri-De-Prati, Roberto; McIlraith, Melissa J.] Abbott Labs, Ludwigshafen, Germany	Cincinnati Children's Hospital Medical Center; Children's Hospital Los Angeles; Creighton University; Charles University Prague; General University Hospital Prague; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Stanford University; Utah System of Higher Education; University of Utah; Ghent University; Ghent University Hospital; ASST Gaetano Pini CTO; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Minnesota System; University of Minnesota Twin Cities; University of Chicago; Klinikum Bremen-Mitte; University of Kansas; University of Kansas Medical Center; Abbott Laboratories	Lovell, DJ (corresponding author), Childrens Hosp, Med Ctr, Div Rheumatol, Locat E,Rm 2-129,MLC 4010,3333 Burnet Ave, Cincinnati, OH 45229 USA.	daniel.lovell@cchmc.org	Jarosova, Katerina/N-1353-2017; Elewaut, Dirk/K-6831-2014; Nemcova, Dana/J-7151-2017; Ruperto, Nicolino/K-3349-2018	Jarosova, Katerina/0000-0002-4975-6496; Nemcova, Dana/0000-0003-4983-4746; Ruperto, Nicolino/0000-0001-8407-7782; MARTINI, Alberto/0000-0001-7642-1459; Vehe, Richard/0000-0003-4679-8305	Abbott Laboratories; Genzyme; Regeneron; Bristol-Myers Squibb; Hoffmann-La Roche; Pfizer; Centocor; Amgen	Abbott Laboratories(Abbott Laboratories); Genzyme(Sanofi-AventisGenzyme Corporation); Regeneron(Regeneron); Bristol-Myers Squibb(Bristol-Myers Squibb); Hoffmann-La Roche(Hoffmann-La Roche); Pfizer(Pfizer); Centocor; Amgen(Amgen)	Abbott Laboratories. Dr. Giannini reports receiving consulting fees from Abbott Laboratories, Genzyme, Regeneron, Bristol-Myers Squibb, Hoffmann-La Roche, Pfizer, and Centocor; lecture fees from Genzyme; and grant support from Amgen, Abbott Laboratories, Bristol-Myers Squibb, Genzyme, and Pfizer. Drs. Medich, Carcereri-De-Prati, and McIlraith report being employed by Abbott Laboratories. No other potential conflict of interest relevant to this article was reported. We thank Carine Wouters, M. D. ( Belgium), Isabelle Kone-Paut, M. D., and Anne-Marie Prieur, M. D. ( France), Hartmut Michels, M. D. ( Germany), Richard Vesely, M. D. ( Slovak Republic), Maria Luz Gamir, M. D. ( Spain), and Thomas Atkinson, M. D., Elizabeth Chalom, M. D., Christos Gabriel, M. D., Gloria Higgins, Ph. D., M. D., Norman Ilowite, M. D., Olcay Jones, M. D., Ph. D., and Leonard Stein, M. D. ( United States) for their participation in the trial; Lori Lush, Pharm. D., at JK Associates and Michael A. Nissen, E. L. S., at Abbott Laboratories for their editorial support; and Kaushik Patra, Ph. D., and Ashish Kumar, Ph. D., both at Abbott Laboratories, for their help with data management and statistical analysis.	*ABB LAB, 2008, HUM AD; Breedveld FC, 2006, ARTHRITIS RHEUM-US, V54, P26, DOI 10.1002/art.21519; Genovese MC, 2005, J RHEUMATOL, V32, P1232; Giannini EH, 1997, ARTHRITIS RHEUM, V40, P1202; GIANNINI EH, 1992, NEW ENGL J MED, V326, P1043, DOI 10.1056/NEJM199204163261602; Keystone EC, 2004, ARTHRITIS RHEUM, V50, P1400, DOI 10.1002/art.20217; Lovell DJ, 2000, NEW ENGL J MED, V342, P763, DOI 10.1056/NEJM200003163421103; Maini RN, 2004, ARTHRITIS RHEUM-US, V50, P1051, DOI 10.1002/art.20159; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; Ravelli A, 2007, LANCET, V369, P767, DOI 10.1016/S0140-6736(07)60363-8; Ruperto N, 2004, ARTHRITIS RHEUM-US, V50, P2191, DOI 10.1002/art.20288; van de Putte BA, 2004, ANN RHEUM DIS, V63, P508, DOI 10.1136/ard.2003.013052; Weinblatt ME, 2006, ANN RHEUM DIS, V65, P753, DOI 10.1136/ard.2005.044404; Weinblatt ME, 2003, ARTHRITIS RHEUM, V48, P855, DOI 10.1002/art.546; Weinblatt ME, 2003, ARTHRITIS RHEUM-US, V48, P35, DOI 10.1002/art.10697	15	390	426	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 21	2008	359	8					810	820		10.1056/NEJMoa0706290	http://dx.doi.org/10.1056/NEJMoa0706290			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339HL	18716298				2022-12-28	WOS:000258568600006
J	Ruan, S				Ruan, Shuolun			About a boy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												shuolun.ruan@aya.yale.edu							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	2008	300	7					771	772		10.1001/jama.300.7.771	http://dx.doi.org/10.1001/jama.300.7.771			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	338VM	18714050				2022-12-28	WOS:000258537500001
J	Cauley, JA; LaCroix, AZ; Wu, L; Horwitz, M; Danielson, ME; Bauer, DC; Lee, JS; Jackson, RD; Robbins, JA; Wu, C; Stanczyk, FZ; LeBoff, MS; Wactawski-Wende, J; Sarto, G; Ockene, J; Cummings, SR				Cauley, Jane A.; LaCroix, Andrea Z.; Wu, LieLing; Horwitz, Mara; Danielson, Michelle E.; Bauer, Doug C.; Lee, Jennifer S.; Jackson, Rebecca D.; Robbins, John A.; Wu, Chunyuan; Stanczyk, Frank Z.; LeBoff, Meryl S.; Wactawski-Wende, Jean; Sarto, Gloria; Ockene, Judith; Cummings, Steven R.			Serum 25-hydroxyvitamin D concentrations and risk for hip fractures	ANNALS OF INTERNAL MEDICINE			English	Article							VITAMIN-D SUPPLEMENTATION; POSTMENOPAUSAL WOMEN; D DEFICIENCY; OLDER WOMEN; VERTEBRAL FRACTURES; FREE TESTOSTERONE; ELDERLY-WOMEN; BONE LOSS; HEALTH; PREVENTION	Background: The relationship between serum 25-hydroxyvitamin D [25(OH) vitamin D] concentration and hip fractures is unclear. Objective: To see whether low serum 25(OH) vitamin D concentrations are associated with hip fractures in community-dwelling women. Design: Nested case-control study. Setting: 40 clinical centers in the United States. Participants: 400 case-patients with incident hip fracture and 400 control participants matched on the basis of age, race or ethnicity, and date of blood draw. Both groups were selected from 39 795 postmenopausal women who were not using estrogens or other bone-active therapies and who had not had a previous hip fracture. Measurements: Serum 25(OH) vitamin D was measured and patients were followed for a median of 7.1 years (range, 0.7 to 9.3 years) to assess fractures. Results: Mean serum 25(OH) vitamin D concentrations were lower in case-patients than in control participants (55.95 nmol/L [SD, 20.28] vs. 59.60 nmol/L [SD, 18.05]; P = 0.007), and lower serum 25(OH) vitamin D concentrations increased hip fracture risk (adjusted odds ratio for each 25-nmol/L decrease, 1.33 [95% CI, 1.06 to 1.68]). Women with the lowest 25(OH) vitamin D concentrations (<= 47.5 nmol/L) had a higher fracture risk than did those with the highest concentrations (>= 70.7 nmol/L) (adjusted odds ratio, 1.71 [CI, 1.05 to 2.79]), and the risk increased statistically significantly across quartiles of serum 25(OH) vitamin D concentration (P for trend = 0.016). This association was independent of number of falls, physical function, frailty, renal function, and sex-steroid hormone levels and seemed to be partially mediated by bone resorption. Limitations: Few case-patients were nonwhite women. Bone mineral density and parathyroid hormone levels were not accounted for in the analysis. Conclusion: Low serum 25(OH) vitamin D concentrations are associated with a higher risk for hip fracture.	[Cauley, Jane A.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; Univ Washington, Seattle, WA 98195 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Calif Pacific Med Ctr, San Francisco Coordinating Ctr, Res Inst, San Francisco, CA USA; Univ Calif Davis, Davis, CA 95616 USA; Ohio State Univ, Columbus, OH 43210 USA; Univ So Calif, Los Angeles, CA USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA; SUNY Coll Buffalo, Buffalo, NY 14222 USA; Univ Wisconsin, Madison, WI USA; Univ Massachusetts, Amherst, MA 01003 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Washington; University of Washington Seattle; University of California System; University of California San Francisco; California Pacific Medical Center; California Pacific Medical Center Research Institute; University of California System; University of California Davis; University System of Ohio; Ohio State University; University of Southern California; Harvard University; Brigham & Women's Hospital; Harvard Medical School; State University of New York (SUNY) System; Buffalo State College; University of Wisconsin System; University of Wisconsin Madison; University of Massachusetts System; University of Massachusetts Amherst	Cauley, JA (corresponding author), Univ Pittsburgh, Dept Epidemiol, 130 DeSoto St,Crabtree A524, Pittsburgh, PA 15261 USA.	jcauley@edc.pitt.edu	Wactawski-Wende, Jean/AGH-5457-2022; Cauley, Jane A/N-4836-2015	Wactawski-Wende, Jean/0000-0003-3096-9595; Cauley, Jane A/0000-0003-0752-4408	National Heart, Lung and Blood Institute; National Institutes of Health; U. S. Department of Health and Human Services; U. S. Public Health Service Research [AR052105, AR048919]; National Center for Research Resources; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024160, UL1RR024146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048919, R01AR052105] Funding Source: NIH RePORTER	National Heart, Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U. S. Department of Health and Human Services; U. S. Public Health Service Research(United States Department of Health & Human ServicesUnited States Public Health Service); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank the WHI investigators. For a list of WHI investigators, see the Appendix, available at www.annals.org.; Grant Support: By the National Heart, Lung and Blood Institute, National Institutes of Health, U. S. Department of Health and Human Services. Additional support was provided by U. S. Public Health Service Research grants AR052105 and AR048919. Dr. Lee is supported by National Center for Research Resources grant UL 1 RR024146.	Anderson GL, 2003, ANN EPIDEMIOL, V13, pS5, DOI 10.1016/S1047-2797(03)00043-7; Binkley N, 2006, CLIN CHEM, V52, P2124, DOI 10.1373/clinchem.2006.074922; Bischoff-Ferrari HA, 2004, AM J MED, V116, P634, DOI 10.1016/j.amjmed.2003.12.029; Bischoff-Ferrari HA, 2004, JAMA-J AM MED ASSOC, V291, P1999, DOI 10.1001/jama.291.16.1999; Bischoff-Ferrari HA, 2005, JAMA-J AM MED ASSOC, V293, P2257, DOI 10.1001/jama.293.18.2257; Bischoff-Ferrari HA, 2007, J STEROID BIOCHEM, V103, P614, DOI 10.1016/j.jsbmb.2006.12.016; Colin EM, 2003, J CLIN ENDOCR METAB, V88, P3777, DOI 10.1210/jc.2002-021861; Cranney A., 2007, EFFECTIVENESS SAFETY; Cummings SR, 1998, NEW ENGL J MED, V339, P733, DOI 10.1056/NEJM199809103391104; Curb JD, 2003, ANN EPIDEMIOL, V13, pS122, DOI 10.1016/S1047-2797(03)00048-6; Dhesi JK, 2004, AGE AGEING, V33, P589, DOI 10.1093/ageing/afh209; Ensrud KE, 2007, ARCH INTERN MED, V167, P133, DOI 10.1001/archinte.167.2.133; FREEMAN RK, 1974, AM J OBSTET GYNECOL, V119, P239, DOI 10.1016/0002-9378(74)90040-4; Gerdhem P, 2005, OSTEOPOROSIS INT, V16, P1425, DOI 10.1007/s00198-005-1860-1; GOEBELSMANN U, 1974, AM J OBSTET GYNECOL, V119, P445, DOI 10.1016/0002-9378(74)90199-9; Grant AM, 2005, LANCET, V365, P1621, DOI 10.1016/S0140-6736(05)63013-9; Hays J, 2003, ANN EPIDEMIOL, V13, pS18, DOI 10.1016/S1047-2797(03)00042-5; Hays R D, 1993, Health Econ, V2, P217, DOI 10.1002/hec.4730020305; Heikkinen AM, 1998, CALCIFIED TISSUE INT, V62, P26, DOI 10.1007/s002239900389; Holick MF, 2005, J CLIN ENDOCR METAB, V90, P3215, DOI 10.1210/jc.2004-2364; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; Jackson RD, 2006, NEW ENGL J MED, V354, P669, DOI 10.1056/NEJMoa055218; Kestenbaum B, 2007, EUR J CLIN INVEST, V37, P607, DOI 10.1111/j.1365-2362.2007.01840.x; LeBoff MS, 1999, JAMA-J AM MED ASSOC, V281, P1505, DOI 10.1001/jama.281.16.1505; Lips P, 2001, ENDOCR REV, V22, P477, DOI 10.1210/er.22.4.477; Looker AC, 2002, BONE, V30, P771, DOI 10.1016/S8756-3282(02)00692-0; Looker AC, 2008, J BONE MINER RES, V23, P143, DOI 10.1359/JBMR.071003; Macdonald HM, 2008, BONE, V42, P996, DOI 10.1016/j.bone.2008.01.011; Manson JE, 2002, NEW ENGL J MED, V347, P716, DOI 10.1056/NEJMoa021067; Mezquita-Raya P, 2001, J BONE MINER RES, V16, P1408, DOI 10.1359/jbmr.2001.16.8.1408; OOMS ME, 1995, J CLIN ENDOCR METAB, V80, P1052, DOI 10.1210/jc.80.4.1052; Patterson RE, 1999, ANN EPIDEMIOL, V9, P178, DOI 10.1016/S1047-2797(98)00055-6; Probst-Hensch NM, 1999, ENDOCR-RELAT CANCER, V6, P165, DOI 10.1677/erc.0.0060165; Rinaldi S, 2002, CANCER EPIDEM BIOMAR, V11, P1065; Roddam AW, 2007, AM J EPIDEMIOL, V166, P1327, DOI 10.1093/aje/kwm210; Semba RD, 2000, AM J CLIN NUTR, V72, P1529; Snijder MB, 2005, J CLIN ENDOCR METAB, V90, P4119, DOI 10.1210/jc.2005-0216; SODERGARD R, 1982, J STEROID BIOCHEM, V16, P801, DOI 10.1016/0022-4731(82)90038-3; STANCZYK FZ, 1988, AM J OBSTET GYNECOL, V159, P1540, DOI 10.1016/0002-9378(88)90591-1; Vermeulen A, 1999, J CLIN ENDOCR METAB, V84, P3666, DOI 10.1210/jc.84.10.3666; WOO J, 1990, BONE MINER, V8, P31, DOI 10.1016/0169-6009(91)90138-P; Woods NF, 2005, J AM GERIATR SOC, V53, P1321, DOI 10.1111/j.1532-5415.2005.53405.x; Wortsman J, 2000, AM J CLIN NUTR, V72, P690, DOI 10.1093/ajcn/72.3.690	45	219	238	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 19	2008	149	4					242	+		10.7326/0003-4819-149-4-200808190-00005	http://dx.doi.org/10.7326/0003-4819-149-4-200808190-00005			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	338RQ	18711154	Green Published, Green Accepted			2022-12-28	WOS:000258526700003
J	Hirsch, AT; Miedema, MD				Hirsch, Alan T.; Miedema, Michael D.			Infrarenal aortic occlusion	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Hirsch, Alan T.; Miedema, Michael D.] Abbott NW Hosp, Minneapolis, MN 55407 USA		Hirsch, AT (corresponding author), Abbott NW Hosp, Minneapolis, MN 55407 USA.	hirsc005@umn.edu							0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 14	2008	359	7					735	735		10.1056/NEJMicm075250	http://dx.doi.org/10.1056/NEJMicm075250			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336XE	18703476				2022-12-28	WOS:000258397900010
J	Best, JA				Best, Jennifer A.			A stitch in time	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												jabest@u.washington.edu							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	2008	300	6					630	631		10.1001/jama.300.6.630	http://dx.doi.org/10.1001/jama.300.6.630			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336OM	18698054				2022-12-28	WOS:000258374500001
J	Kohrt, BA; Jordans, MJD; Tol, WA; Speckman, RA; Maharjan, SM; Worthman, CM; Komproe, IH				Kohrt, Brandon A.; Jordans, Mark J. D.; Tol, Wietse A.; Speckman, Rebecca A.; Maharjan, Sujen M.; Worthman, Carol M.; Komproe, Ivan H.			Comparison of mental health between former child soldiers and children never conscripted by armed groups in Nepal	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIFFICULTIES QUESTIONNAIRE SDQ; SELF-REPORT VERSION; PSYCHOMETRIC PROPERTIES; ADOLESCENT-PSYCHIATRY; GLOBAL ASSESSMENT; COMMUNITY SAMPLE; PTSD SYMPTOMS; STRENGTHS; DISORDERS; SCREEN	Context Former child soldiers are considered in need of special mental health interventions. However, there is a lack of studies investigating the mental health of child soldiers compared with civilian children in armed conflicts. Objective To compare the mental health status of former child soldiers with that of children who have never been conscripts of armed groups. Design, Setting, and Participants Cross-sectional cohort study conducted in March and April 2007 in Nepal comparing the mental health of 141 former child soldiers and 141 never-conscripted children matched on age, sex, education, and ethnicity. Main Outcome Measures Depression symptoms were assessed via the Depression Self Rating Scale, anxiety symptoms via the Screen for Child Anxiety Related Emotional Disorders, symptoms of posttraumatic stress disorder (PTSD) via the Child PTSD Symptom Scale, general psychological difficulties via the Strength and Difficulties Questionnaire, daily functioning via the Function Impairment tool, and exposure to traumatic events via the PTSD Traumatic Event Checklist of the Kiddie Schedule of Affective Disorders and Schizophrenia. Results Participants were amean of 15.75 years old at the time of this study, and former child soldiers ranged in age from 5 to 16 years at the time of conscription. All participants experienced at least 1 type of trauma. The numbers of former child soldiers meeting symptom cutoff scores were 75 (53.2%) for depression, 65 (46.1%) for anxiety, 78 (55.3%) for PTSD, 55 (39.0%) for psychological difficulties, and 88 (62.4%) for function impairment. After adjusting for traumatic exposures and other covariates, former soldier status was significantly associated with depression (odds ratio [OR], 2.41; 95% confidence interval [CI], 1.31-4.44) and PTSD among girls (OR, 6.80; 95% CI, 2.1621.58), and PTSD among boys (OR, 3.81; 95% CI, 1.06-13.73) but was not associated with general psychological difficulties (OR, 2.08; 95% CI, 0.86-5.02), anxiety (OR, 1.63; 95% CI, 0.77-3.45), or function impairment (OR, 1.34; 95% CI, 0.84-2.14). Conclusion In Nepal, former child soldiers display greater severity of mental health problems compared with children never conscripted by armed groups, and this difference remains for depression and PTSD (the latter especially among girls) even after controlling for trauma exposure.	[Kohrt, Brandon A.; Worthman, Carol M.] Emory Univ, Dept Anthropol, Atlanta, GA 30322 USA; [Speckman, Rebecca A.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; [Kohrt, Brandon A.; Jordans, Mark J. D.; Tol, Wietse A.; Maharjan, Sujen M.] Trichandra Coll, Transcultural Psychosocial Org Nepal, Kathmandu, Nepal; [Maharjan, Sujen M.] Trichandra Coll, Dept Psychol, Kathmandu, Nepal; [Jordans, Mark J. D.; Tol, Wietse A.] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands; [Jordans, Mark J. D.; Tol, Wietse A.; Komproe, Ivan H.] Healthnet TPO, Dept Publ Hlth & Res, Amsterdam, Netherlands	Emory University; Emory University; Rollins School Public Health; Vrije Universiteit Amsterdam	Kohrt, BA (corresponding author), Emory Univ, Dept Anthropol, 1557 Dickey Dr, Atlanta, GA 30322 USA.	brandonkohrt@gmail.com	Tol, Wietse A/G-8587-2013; Komproe, Ivan/AAJ-8699-2021	Tol, Wietse A/0000-0003-2216-0526; Jordans, Mark/0000-0001-5925-8039; Worthman, Carol M/0000-0002-5397-2298	NIMH NIH HHS [F31 MH075584] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH075584] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bayer CP, 2007, JAMA-J AM MED ASSOC, V298, P555, DOI 10.1001/jama.298.5.555; Beah Ishmael, 2007, LONG WAY GONE MEMOIR; Betancourt TS, 2008, PSYCHOSOCIAL ADJUSTM; BIRLESON P, 1980, DEV MED CHILD NEUROL, V22, P518; Birleson P, 2007, J PAEDIATR CHILD H, V43, P101, DOI 10.1111/j.1440-1754.2007.01025.x; Birmaher B, 1999, J AM ACAD CHILD PSY, V38, P1230, DOI 10.1097/00004583-199910000-00011; BLATTMAN C, 2006, CONSEQUENCES CHILD S; Bolton P, 2002, SOC PSYCH PSYCH EPID, V37, P537, DOI 10.1007/s00127-002-0580-5; *CENTR BUR STAT, 2003, CENS RES 2001; Child Soldiers International, 2015, RAD ONG RECR US CHIL; Cohen JA, 2004, J AM ACAD CHILD PSY, V43, P393, DOI 10.1097/00004583-200404000-00005; Demidenko E, 2007, STAT MED, V26, P3385, DOI 10.1002/sim.2771; Derluyn I, 2004, LANCET, V363, P861, DOI 10.1016/S0140-6736(04)15734-6; Dickson-Gomez J, 2002, ETHOS, V30, P327, DOI 10.1525/eth.2002.30.4.327; DOWDNEY L, TRAUMA RESILIENCE CU; Dyrborg J, 2000, EUR CHILD ADOLES PSY, V9, P195, DOI 10.1007/s007870070043; Foa EB, 2001, J CLIN CHILD PSYCHOL, V30, P376, DOI 10.1207/S15374424JCCP3003_9; Goodman R, 1998, EUR CHILD ADOLES PSY, V7, P125, DOI 10.1007/s007870050057; Goodman R, 2003, INT REV PSYCHIATR, V15, P166, DOI 10.1080/0954026021000046128; Goodman R, 2003, INT REV PSYCHIATR, V15, P173, DOI 10.1080/0954026021000046137; Goodman R, 2000, BRIT J PSYCHIAT, V177, P534, DOI 10.1192/bjp.177.6.534; Honwana A, 2006, ETHNOGR POLIT VIOLEN, P1; International Agency Standing Committee, 2007, IASC GUID MENT HLTH, P182; JORDANS MJD, 2007, VALIDATION STUDY MEN; Kaufman J., 1996, KIDDIE SADS PRESENT, DOI 10.1097/00004583-199707000-00021; Kohrt BA, 2005, ETHOS, V33, P125, DOI 10.1525/eth.2005.33.1.125; Kuruppuarachchi KALA, 2004, LANCET, V363, P1648, DOI 10.1016/S0140-6736(04)16214-4; Lamberg L, 2004, JAMA-J AM MED ASSOC, V292, P553, DOI 10.1001/jama.292.5.553; Lawoti Mahendra, 2003, STUDIES NEPALI HIST, V8, P67; LAYNE CMW, 2000, EVALUATION PROGRAM E; Machel G., 1996, IMPACT ARMED CONFLIC; Magambo C, 2004, LANCET, V363, P1647, DOI 10.1016/S0140-6736(04)16213-2; McDonnell FJ., 2007, GIRL SOLDIER STORY H; McKay Susan, 1998, PEACE CONFLICT J PEA, V4, P381, DOI DOI 10.1207/S15327949PAC0404_6; Miglioretti DL, 2007, AM J EPIDEMIOL, V165, P453, DOI 10.1093/aje/kwk020; Pearn J, 2003, J PAEDIATR CHILD H, V39, P166, DOI 10.1046/j.1440-1754.2003.00124.x; SAS Institute, 2008, SAS STAT US GUID; Schorre BEH, 2004, EUR CHILD ADOLES PSY, V13, P273, DOI 10.1007/s00787-004-0390-2; Sharma M, 2004, HIMALAYAN PEOPLES WA, P152; Specht I, 2006, INTERVENTION, V4, P219, DOI 10.1097/WTF.0b013e3280118167; SPSS Inc, 2006, SPSS COMP PROGR VERS; Thapa SB, 2005, SOC PSYCH PSYCH EPID, V40, P672, DOI 10.1007/s00127-005-0943-9; United Nations, 2006, REP SECR GEN CHILDR; United Nations Children's Fund, 2007, PAR PRINC PRINC GUID; van Ommeren M., 1999, TRANSCULT PSYCHIATRY, V36, P285, DOI [10.1177/136346159903600304, DOI 10.1177/136346159903600304]; WESSELLS MG, 2006, CHILD SOILDERS VIOLE	46	157	158	0	36	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	2008	300	6					691	702		10.1001/jama.300.6.691	http://dx.doi.org/10.1001/jama.300.6.691			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	336OM	18698067	Green Accepted, Bronze			2022-12-28	WOS:000258374500021
J	King, MC; Drivas, TG; Blobel, G				King, Megan C.; Drivas, Theodore G.; Blobel, Guenter			A network of nuclear envelope membrane proteins linking centromeres to microtubules	CELL			English	Article							SPINDLE-POLE BODY; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; MEIOTIC PROPHASE; DOMAIN PROTEINS; GENE; HETEROCHROMATIN; COMPLEX; CYTOSKELETON; ATTACHMENT	In the fission yeast S. pombe, nuclei are actively positioned at the cell center by microtubules. Here, we show that cytoplasmic microtubules are mechanically coupled to the nuclear heterochromatin through proteins embedded in the nuclear envelope. This includes an integral outer nuclear membrane protein of the KASH family ( Kms2) and two integral inner nuclear membrane proteins, the SUN-domain protein Sad1 and the previously uncharacterized protein Ima1. Ima1 specifically binds to heterochromatic regions and promotes the tethering of centromeric DNA to the SUN-KASH complex. In the absence of Ima1, or in cells harboring mutations in the centromeric Ndc80 complex, inefficient coupling of centromeric heterochromatin to Sad1 leads to striking defects in the ability of the nucleus to tolerate microtubule-dependent forces, leading to changes in nuclear shape, loss of spindle pole body components from the nuclear envelope, and partial dissociation of SUN-KASH complexes. This work highlights a framework for communication between cytoplasmic microtubules and chromatin.	[King, Megan C.; Drivas, Theodore G.; Blobel, Guenter] Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, New York, NY 10065 USA	Howard Hughes Medical Institute; Rockefeller University	King, MC (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, 1230 York Ave, New York, NY 10065 USA.	mking@rockefeller.edu		Drivas, Theodore/0000-0002-8717-0111	Kirschstein National Research Service; Howard Hughes Medical Institute; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM077919] Funding Source: NIH RePORTER	Kirschstein National Research Service(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the Nurse lab and the Yeast Genomic Resource Center for strains, K. Sawin for the mCherry tagging template pKS390, R. Tsien for permission to use the mCherry fusion, H. Shio for technical support, and M. P. Rout for the anti-GFP antibody. We also thank F. Neumann for technical help and suggesting the "nut and bolt'' analogy and C. P. Lusk for critical reading of the manuscript. This work was supported by a Kirschstein National Research Service Award Fellowship and a Charles H. Revson Senior Fellowship in Biomedical Science (to M.C.K.) and the Howard Hughes Medical Institute (to G. B.).	Akhtar A, 2007, NAT REV GENET, V8, P507, DOI 10.1038/nrg2122; Appelgren H, 2003, J CELL SCI, V116, P4035, DOI 10.1242/jcs.00707; Asakawa H, 2005, MOL BIOL CELL, V16, P2325, DOI 10.1091/mbc.e04-11-0996; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Bupp JM, 2007, J CELL BIOL, V179, P845, DOI 10.1083/jcb.200706040; Chikashige Y, 2006, CELL, V125, P59, DOI 10.1016/j.cell.2006.01.048; Crisp M, 2006, J CELL BIOL, V172, P41, DOI 10.1083/jcb.200509124; Ding R, 1997, MOL BIOL CELL, V8, P1461, DOI 10.1091/mbc.8.8.1461; Ekwall K, 1996, J CELL SCI, V109, P2637; Franco A, 2007, J CELL SCI, V120, P3345, DOI 10.1242/jcs.013698; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; Grewal SIS, 2007, NAT REV GENET, V8, P35, DOI 10.1038/nrg2008; Gruenbaum Y, 2005, NAT REV MOL CELL BIO, V6, P21, DOI 10.1038/nrm1550; HAGAN I, 1995, J CELL BIOL, V129, P1033, DOI 10.1083/jcb.129.4.1033; HAGAN IM, 1990, J CELL BIOL, V110, P1617, DOI 10.1083/jcb.110.5.1617; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Haque F, 2006, MOL CELL BIOL, V26, P3738, DOI 10.1128/MCB.26.10.3738-3751.2006; King MC, 2006, NATURE, V442, P1003, DOI 10.1038/nature05075; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LORENTZ A, 1994, GENE, V143, P139, DOI 10.1016/0378-1119(94)90619-X; Lusk CP, 2007, NAT REV MOL CELL BIO, V8, P414, DOI 10.1038/nrm2165; Malone CJ, 2003, CELL, V115, P825, DOI 10.1016/S0092-8674(03)00985-1; Miki F, 2004, MOL GENET GENOMICS, V270, P449, DOI 10.1007/s00438-003-0938-8; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Nabetani A, 2001, CHROMOSOMA, V110, P322, DOI 10.1007/s004120100153; Nakagawa H, 2002, GENE DEV, V16, P1766, DOI 10.1101/gad.997702; Niwa O, 2000, EMBO J, V19, P3831, DOI 10.1093/emboj/19.14.3831; Pajerowski JD, 2007, P NATL ACAD SCI USA, V104, P15619, DOI 10.1073/pnas.0702576104; Sawin KE, 2006, YEAST, V23, P1001, DOI 10.1002/yea.1404; Schirmer EC, 2003, SCIENCE, V301, P1380, DOI 10.1126/science.1088176; Shimanuki M, 1997, MOL GEN GENET, V254, P238, DOI 10.1007/s004380050412; Snaith HA, 2005, EMBO J, V24, P3690, DOI 10.1038/sj.emboj.7600838; Starr DA, 2005, BIOESSAYS, V27, P1136, DOI 10.1002/bies.20312; Szabo B, 2004, CELL MOTIL CYTOSKEL, V59, P38, DOI 10.1002/cm.20022; Tang X, 2006, J CELL BIOL, V173, P845, DOI 10.1083/jcb.200602152; Tomita K, 2007, CELL, V130, P113, DOI 10.1016/j.cell.2007.05.024; Tran PT, 2001, J CELL BIOL, V153, P397, DOI 10.1083/jcb.153.2.397; Tzur YB, 2006, NAT REV MOL CELL BIO, V7, P782, DOI 10.1038/nrm2003; West RR, 1998, MOL BIOL CELL, V9, P2839, DOI 10.1091/mbc.9.10.2839; Wilhelmsen K, 2006, J CELL SCI, V119, P5021, DOI 10.1242/jcs.03295; Yamamoto A, 2003, EMBO J, V22, P2284, DOI 10.1093/emboj/cdg222; Zhang QP, 2005, J CELL SCI, V118, P673, DOI 10.1242/jcs.01642	42	148	151	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 8	2008	134	3					427	438		10.1016/j.cell.2008.06.022	http://dx.doi.org/10.1016/j.cell.2008.06.022			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SO	18692466	Bronze, Green Accepted			2022-12-28	WOS:000258665500016
J	Sugiyama, S; Di Nardo, AA; Aizawa, S; Matsuo, I; Volovitch, M; Prochiantz, A; Hensch, TK				Sugiyama, Sayaka; Di Nardo, Ariel A.; Aizawa, Shinichi; Matsuo, Isao; Volovitch, Michel; Prochiantz, Alain; Hensch, Takao K.			Experience-dependent transfer of Otx2 homeoprotein into the visual cortex activates postnatal plasticity	CELL			English	Article							OCULAR DOMINANCE PLASTICITY; CRITICAL PERIOD PLASTICITY; FACTOR 4E EIF4E; CEREBRAL-CORTEX; TENASCIN-R; MONOCULAR DEPRIVATION; CORTICAL INTERNEURONS; HOMEODOMAIN PROTEIN; NEUROTROPHIC FACTOR; PERINEURONAL NETS	Neural circuits are shaped by experience in early postnatal life. Distinct GABAergic connections within visual cortex determine the timing of the critical period for rewiring ocular dominance to establish visual acuity. We find that maturation of the parvalbumin (PV)-cell network that controls plasticity onset is regulated by a selective re-expression of the embryonic Otx2 homeoprotein. Visual experience promoted the accumulation of non-cell-autonomous Otx2 in PV-cells, and cortical infusion of exogenous Otx2 accelerated both PV-cell development and critical period timing. Conversely, conditional removal of Otx2 from non-PV cells or from the visual pathway abolished plasticity. Thus, the experience-dependent transfer of a homeoprotein may establish the physiological milieu for postnatal plasticity of a neural circuit.	[Di Nardo, Ariel A.; Volovitch, Michel; Prochiantz, Alain] Ecole Normale Super, CNRS, UMR 8542, F-75230 Paris 05, France; [Sugiyama, Sayaka; Hensch, Takao K.] RIKEN Brain Sci Inst, Lab Neuronal Circuit Dev, Wako, Saitama 3510198, Japan; [Aizawa, Shinichi] RIKEN, Ctr Dev Biol, Chuo Ku, Kobe, Hyogo 6500047, Japan; [Matsuo, Isao] Osaka Med Ctr, Dept Mol Embryol, Osaka 5941101, Japan; [Matsuo, Isao] Res Inst Maternal & Child Hlth, Osaka 5941101, Japan; [Prochiantz, Alain] Coll France, F-75231 Paris, France; [Sugiyama, Sayaka; Hensch, Takao K.] Harvard Univ, Sch Med, Childrens Hosp, Dept Neurol, Boston, MA 02115 USA; [Hensch, Takao K.] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); RIKEN; RIKEN; Osaka Medical Center for Cancer & Cardiovascular Diseases; UDICE-French Research Universities; PSL Research University Paris; College de France; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University	Prochiantz, A (corresponding author), Ecole Normale Super, CNRS, UMR 8542, 46 Rue Ulm, F-75230 Paris 05, France.	prochian@biologie.ens.fr; hensch@mcb.harvard.edu	Sugiyama, Sayaka/AAQ-4489-2021; Di Nardo, Ariel A/P-4442-2017; Hensch, Takao/L-4182-2019	Sugiyama, Sayaka/0000-0002-2231-7880; Di Nardo, Ariel A/0000-0003-2944-488X; Matsuo, Isao/0000-0002-5916-6246; Volovitch, Michel/0000-0002-7488-764X	Human Frontiers Science Program HFSP [RGP0026/2002]; Fondation pour La Recherche Medicale (Longevite Cognitive et Sensorielle); Special Postdoctoral Research Program (RIKEN); Japanese Ministry of Science, Education and Technology MEXT [IBR 17021047]	Human Frontiers Science Program HFSP(Human Frontier Science Program); Fondation pour La Recherche Medicale (Longevite Cognitive et Sensorielle)(Fondation pour la Recherche Medicale); Special Postdoctoral Research Program (RIKEN); Japanese Ministry of Science, Education and Technology MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank D. Acampora and A. Simeone for graciously providing the Otx2-GFP mouse line and the original Otx2 plasmids; A. Ruiz i Altaba and M. Wassef for Otx2 antibody; S. Dupas for recombinant Otx2 protein; G. Corte for recombinant baculovirus; K. Moya, M. Beurdeley, and A. Scheuber for help in some experiments and discussion. Funded by the Human Frontiers Science Program (HFSP, RGP0026/2002), Fondation pour La Recherche Medicale (Longevite Cognitive et Sensorielle), and in part by the Special Postdoctoral Research Program (RIKEN) and Japanese Ministry of Science, Education and Technology (MEXT, IBR 17021047). S. S. is a Research Fellow of the Japan Society for the Promotion of Science (JSPS). A. A. D. is a fellow of the Canadian Institutes of Health Research (CIHR).	Acampora D, 2001, PROG NEUROBIOL, V64, P69, DOI 10.1016/S0301-0082(00)00042-3; Antonini A, 1999, J NEUROSCI, V19, P4388; Ba-Charvet KTN, 1998, DEVELOPMENT, V125, P4273; Baas D, 2000, MOL BRAIN RES, V78, P26, DOI 10.1016/S0169-328X(00)00060-7; Betts LR, 2005, NEURON, V45, P361, DOI 10.1016/j.neuron.2004.12.041; Bovolenta P, 1997, J NEUROSCI, V17, P4243; Briata P, 1999, FEBS LETT, V445, P160, DOI 10.1016/S0014-5793(99)00113-1; Bruckner G, 2000, J COMP NEUROL, V428, P616, DOI 10.1002/1096-9861(20001225)428:4<616::AID-CNE3>3.0.CO;2-K; Brunet I, 2005, NATURE, V438, P94, DOI 10.1038/nature04110; Brunet I, 2007, TRENDS NEUROSCI, V30, P260, DOI 10.1016/j.tins.2007.03.010; Brunet JF, 2002, CURR OPIN GENET DEV, V12, P435, DOI 10.1016/S0959-437X(02)00322-2; Butt SJB, 2007, J NEUROSCI, V27, P11847, DOI 10.1523/JNEUROSCI.3525-07.2007; Buzas P, 2001, J COMP NEUROL, V437, P259, DOI 10.1002/cne.1282; Cancedda L, 2004, J NEUROSCI, V24, P4840, DOI 10.1523/JNEUROSCI.0845-04.2004; Celio MR, 1998, TRENDS NEUROSCI, V21, P510, DOI 10.1016/S0166-2236(98)01298-3; Cruikshank SJ, 2007, NAT NEUROSCI, V10, P462, DOI 10.1038/nn1861; CYNADER M, 1980, J NEUROPHYSIOL, V43, P1026, DOI 10.1152/jn.1980.43.4.1026; DAW N, 1995, VISUAL DEV; DELRIO JA, 1994, DEV BRAIN RES, V81, P247, DOI 10.1016/0165-3806(94)90311-5; Di Cristo G, 2007, NAT NEUROSCI, V10, P1569, DOI 10.1038/nn2008; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; Erisir A, 2005, J COMP NEUROL, V485, P11, DOI 10.1002/cne.20507; Fagiolini M, 2004, SCIENCE, V303, P1681, DOI 10.1126/science.1091032; Fagiolini M, 2003, P NATL ACAD SCI USA, V100, P2854, DOI 10.1073/pnas.0536089100; FAGIOLINI M, 1994, VISION RES, V34, P709, DOI 10.1016/0042-6989(94)90210-0; Fagiolini M, 2000, NATURE, V404, P183, DOI 10.1038/35004582; FRANTZ GD, 1994, J NEUROSCI, V14, P5725; GAO B, 1994, EUR J NEUROSCI, V6, P837, DOI 10.1111/j.1460-9568.1994.tb00994.x; Gordon JA, 1996, J NEUROSCI, V16, P3274; Hanover JL, 1999, J NEUROSCI, V19, part. no.; Hensch TK, 2005, NAT REV NEUROSCI, V6, P877, DOI 10.1038/nrn1787; Hensch TK, 2004, SCIENCE, V303, P1678, DOI 10.1126/science.1091031; Hensch TK, 1998, SCIENCE, V282, P1504, DOI 10.1126/science.282.5393.1504; Holt CE, 2005, NEURON, V46, P169, DOI 10.1016/j.neuron.2005.03.021; Huang ZJ, 1999, CELL, V98, P739, DOI 10.1016/S0092-8674(00)81509-3; Iwai Y, 2003, J NEUROSCI, V23, P6695; Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189; Joliot A, 1997, DEVELOPMENT, V124, P1865; JOLIOT AH, 1991, NEW BIOL, V3, P1121; Katagiri H, 2007, NEURON, V53, P805, DOI 10.1016/j.neuron.2007.02.026; Klausberger T, 2002, J NEUROSCI, V22, P2513, DOI 10.1523/JNEUROSCI.22-07-02513.2002; Leventhal AG, 2003, SCIENCE, V300, P812, DOI 10.1126/science.1082874; Liu LO, 2000, MOL BRAIN RES, V82, P150, DOI 10.1016/S0169-328X(00)00203-5; Liu XB, 1996, P NATL ACAD SCI USA, V93, P7332, DOI 10.1073/pnas.93.14.7332; Majdan M, 2006, NAT NEUROSCI, V9, P650, DOI 10.1038/nn1674; Mandolesi G, 2005, CURR BIOL, V15, P2119, DOI 10.1016/j.cub.2005.10.045; Marshak S, 2007, J NEUROSCI, V27, P2444, DOI 10.1523/JNEUROSCI.4434-06.2007; Marty S, 1997, TRENDS NEUROSCI, V20, P198, DOI 10.1016/S0166-2236(96)01026-0; Mataga N, 2004, NEURON, V44, P1031, DOI 10.1016/j.neuron.2004.11.028; Minichiello L, 1999, NEURON, V24, P401, DOI 10.1016/S0896-6273(00)80853-3; Morales B, 2002, J NEUROSCI, V22, P8084; Morishita H, 2008, CURR OPIN NEUROBIOL, V18, P101, DOI 10.1016/j.conb.2008.05.009; MOWER GD, 1991, DEV BRAIN RES, V58, P151, DOI 10.1016/0165-3806(91)90001-Y; Muratovska A, 2004, FEBS LETT, V558, P63, DOI 10.1016/S0014-5793(03)01505-9; Nedelec S, 2004, P NATL ACAD SCI USA, V101, P10815, DOI 10.1073/pnas.0403824101; Nikonenko A, 2003, J COMP NEUROL, V456, P338, DOI 10.1002/cne.10537; Nothias F, 1998, CURR BIOL, V8, P459, DOI 10.1016/S0960-9822(98)70189-7; Packard M, 2003, NAT REV NEUROSCI, V4, P113, DOI 10.1038/nrn1036; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Prusky GT, 2003, EUR J NEUROSCI, V17, P167, DOI 10.1046/j.1460-9568.2003.02420.x; Rath MF, 2007, EXP EYE RES, V85, P65, DOI 10.1016/j.exer.2007.02.016; Rudy B, 2001, TRENDS NEUROSCI, V24, P517, DOI 10.1016/S0166-2236(00)01892-0; Saghatelyan AK, 2000, EUR J NEUROSCI, V12, P3331, DOI 10.1046/j.1460-9568.2000.00216.x; Salinas PC, 2005, J NEUROBIOL, V64, P435, DOI 10.1002/neu.20159; Sik A, 1998, P NATL ACAD SCI USA, V95, P3245, DOI 10.1073/pnas.95.6.3245; SOLTESZ I, 1995, NEURON, V14, P1273, DOI 10.1016/0896-6273(95)90274-0; Sugino K, 2006, NAT NEUROSCI, V9, P99, DOI 10.1038/nn1618; Sugiyama S, 2003, DEVELOPMENT, V130, P451, DOI 10.1242/dev.00232; Taha S, 2002, NEURON, V36, P483, DOI 10.1016/S0896-6273(02)00966-2; Tian E, 2002, DEV BIOL, V242, P204, DOI 10.1006/dbio.2001.0531; Tohmi M, 2006, J NEUROSCI, V26, P11775, DOI 10.1523/JNEUROSCI.1643-06.2006; Topisirovic I, 2005, HISTOL HISTOPATHOL, V20, P1275, DOI 10.14670/HH-20.1275; Tropea D, 2006, NAT NEUROSCI, V9, P660, DOI 10.1038/nn1689; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P1003, DOI 10.1152/jn.1963.26.6.1003; Wonders CP, 2006, NAT REV NEUROSCI, V7, P687, DOI 10.1038/nrn1954	75	336	343	1	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 8	2008	134	3					508	520		10.1016/j.cell.2008.05.054	http://dx.doi.org/10.1016/j.cell.2008.05.054			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SO	18692473	Bronze			2022-12-28	WOS:000258665500023
J	Doran, CM; Shakeshaft, AP				Doran, Christopher M.; Shakeshaft, Anthony P.			Using taxes to curb drinking in Australia	LANCET			English	Editorial Material									[Doran, Christopher M.; Shakeshaft, Anthony P.] Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Doran, CM (corresponding author), Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2052, Australia.	c.doran@unsw.edu.au	Shakeshaft, Anthony/U-4637-2017	Shakeshaft, Anthony/0000-0002-5472-0930				*AIHW, 2008, DRUG STAT, V20; Australian Institute of Health and Welfare (AIHW), 2002, 2001 NAT DRUG STRAT; Euromonitor International, 2008, ALC DRINKS AUSTR; WHTIE V, 2006, AUSTR SECONDARY SCH	4	24	24	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG-SEP	2008	372	9640					701	702		10.1016/S0140-6736(08)61287-8	http://dx.doi.org/10.1016/S0140-6736(08)61287-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	344YZ	18761210				2022-12-28	WOS:000258964500010
J	Brandl, K; Plitas, G; Mihu, CN; Ubeda, C; Jia, T; Fleisher, M; Schnabl, B; DeMatteo, RP; Pamer, EG				Brandl, Katharina; Plitas, George; Mihu, Coralia N.; Ubeda, Carles; Jia, Ting; Fleisher, Martin; Schnabl, Bernd; DeMatteo, Ronald P.; Pamer, Eric G.			Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits	NATURE			English	Article							TOLL-LIKE RECEPTOR-4; INTESTINAL COLONIZATION; BACTERICIDAL LECTIN; MICE; GUT; LIPOPOLYSACCHARIDE; TRANSLOCATION; RECOGNITION; INFECTIONS; THERAPY	Infection with antibiotic- resistant bacteria, such as vancomycin-resistant Enterococcus ( VRE), is a dangerous and costly complication of broad- spectrum antibiotic therapy(1,2). How antibiotic-mediated elimination of commensal bacteria promotes infection by antibiotic- resistant bacteria is a fertile area for speculation with few defined mechanisms. Here we demonstrate that antibiotic treatment of mice notably downregulates intestinal expression of RegIII gamma ( also known as Reg3g), a secreted C- type lectin that kills Gram- positive bacteria, including VRE. Downregulation of RegIII gamma markedly decreases in vivo killing of VRE in the intestine of antibiotic- treated mice. Stimulation of intestinal Toll- like receptor 4 by oral administration of lipopolysaccharide re-induces RegIII gamma, thereby boosting innate immune resistance of antibiotic-treated mice against VRE. Compromised mucosal innate immune defence, as induced by broad- spectrum antibiotic therapy, can be corrected by selectively stimulating mucosal epithelial Toll- like receptors, providing a potential therapeutic approach to reduce colonization and infection by antibiotic- resistant microbes.	[Brandl, Katharina; Mihu, Coralia N.; Ubeda, Carles; Jia, Ting; Pamer, Eric G.] Mem Sloan Kettering Canc Ctr, Infect Dis Serv, Dept Med, Program Immunol,Sloan Kettering Inst, New York, NY 10021 USA; [Plitas, George; DeMatteo, Ronald P.] Mem Sloan Kettering Canc Ctr, Hepatobiliary Serv, New York, NY 10021 USA; [Fleisher, Martin; Pamer, Eric G.] Mem Sloan Kettering Canc Ctr, Dept Clin Labs, New York, NY 10021 USA; [Schnabl, Bernd] Columbia Univ, Dept Med, New York, NY 10032 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Columbia University	Pamer, EG (corresponding author), Mem Sloan Kettering Canc Ctr, Infect Dis Serv, Dept Med, Program Immunol,Sloan Kettering Inst, 1275 York Ave, New York, NY 10021 USA.	pamere@mskcc.org	Ubeda, Carles/L-6815-2014	Ubeda, Carles/0000-0003-0560-4658; Brandl, Katharina/0000-0001-5485-9206	Alexander von Humboldt Foundation; NIH [AI39031, AI42135]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042135, R01AI039031, R37AI039031, R01AI080619] Funding Source: NIH RePORTER	Alexander von Humboldt Foundation(Alexander von Humboldt Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The authors thank L. V. Hooper for providing polyclonal RegIII gamma antiserum, I. Leiner for technical assistance, and W. Falk, B. Salzberger and all members of the Pamer laboratory for discussions. This research was supported by the Alexander von Humboldt Foundation through a Feodor Lynen postdoctoral fellowship to KB and NIH grant AI39031 and AI42135 to EGP.	Abreu MT, 2005, J IMMUNOL, V174, P4453, DOI 10.4049/jimmunol.174.8.4453; Brandl K, 2007, J EXP MED, V204, P1891, DOI 10.1084/jem.20070563; Cario E, 2000, J IMMUNOL, V164, P966, DOI 10.4049/jimmunol.164.2.966; Cash HL, 2006, PROTEIN EXPRES PURIF, V48, P151, DOI 10.1016/j.pep.2006.01.014; Cash HL, 2006, SCIENCE, V313, P1126, DOI 10.1126/science.1127119; Donskey CJ, 2004, CLIN INFECT DIS, V39, P219, DOI 10.1086/422002; Donskey CJ, 2000, NEW ENGL J MED, V343, P1925, DOI 10.1056/NEJM200012283432604; Hammett-Stabler CA, 1998, CLIN CHEM, V44, P1129; Hooper LV, 2003, NAT IMMUNOL, V4, P269, DOI 10.1038/ni888; Hornef MW, 2002, J EXP MED, V195, P559, DOI 10.1084/jem.20011788; Kanzler H, 2007, NAT MED, V13, P552, DOI 10.1038/nm1589; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; Lotz M, 2007, INT J MED MICROBIOL, V297, P379, DOI 10.1016/j.ijmm.2007.03.010; Miyazaki S, 2001, J MED MICROBIOL, V50, P695, DOI 10.1099/0022-1317-50-8-695; Murray BE, 2000, NEW ENGL J MED, V342, P710, DOI 10.1056/NEJM200003093421007; Nenci A, 2007, NATURE, V446, P557, DOI 10.1038/nature05698; Ortega-Cava CF, 2003, J IMMUNOL, V170, P3977, DOI 10.4049/jimmunol.170.8.3977; Pull SL, 2005, P NATL ACAD SCI USA, V102, P99, DOI 10.1073/pnas.0405979102; Pultz NJ, 2005, J INFECT DIS, V191, P949, DOI 10.1086/428090; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rice LB, 2001, EMERG INFECT DIS, V7, P183, DOI 10.3201/eid0702.010205; Rice LB, 2006, AM J INFECT CONTROL, V34, pS11, DOI 10.1016/j.ajic.2006.05.220; Richards MJ, 2000, INFECT CONT HOSP EP, V21, P510, DOI 10.1086/501795; Sonnenburg JL, 2006, PLOS BIOL, V4, P2213, DOI 10.1371/journal.pbio.0040413; Stiefel U, 2004, INFECT CONT HOSP EP, V25, P373, DOI 10.1086/502408; WELLS CL, 1990, J INFECT DIS, V162, P82, DOI 10.1093/infdis/162.1.82; WELLS CL, 1988, ANTIMICROB AGENTS CH, V32, P1769, DOI 10.1128/AAC.32.12.1769; Wenzel RP, 2000, NEW ENGL J MED, V343, P1961, DOI 10.1056/NEJM200012283432610	28	456	477	2	92	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 9	2008	455	7214					804	U8		10.1038/nature07250	http://dx.doi.org/10.1038/nature07250			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	357OB	18724361	Green Accepted			2022-12-28	WOS:000259854900048
J	Kim, WR; Biggins, SW; Kremers, WK; Wiesner, RH; Kamath, PS; Benson, JT; Edwards, E; Therneau, TM				Kim, W. Ray; Biggins, Scott W.; Kremers, Walter K.; Wiesner, Russell H.; Kamath, Patrick S.; Benson, Joanne T.; Edwards, Erick; Therneau, Terry M.			Hyponatremia and mortality among patients on the liver-transplant waiting list	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERNATIONAL NORMALIZED RATIO; SERUM SODIUM CONCENTRATION; VASOPRESSIN RECEPTOR ANTAGONIST; CIRRHOTIC-PATIENTS; PROGNOSTIC VALUE; DISEASE MELD; HEPATORENAL-SYNDROME; RENAL-FUNCTION; HEPATITIS-C; SURVIVAL	Background: Under the current liver-transplantation policy, donor organs are offered to patients with the highest risk of death. Methods: Using data derived from all adult candidates for primary liver transplantation who were registered with the Organ Procurement and Transplantation Network in 2005 and 2006, we developed and validated a multivariable survival model to predict mortality at 90 days after registration. The predictor variable was the Model for End-Stage Liver Disease (MELD) score with and without the addition of the serum sodium concentration. The MELD score (on a scale of 6 to 40, with higher values indicating more severe disease) is calculated on the basis of the serum bilirubin and creatinine concentrations and the international normalized ratio for the prothrombin time. Results: In 2005, there were 6769 registrants, including 1781 who underwent liver transplantation and 422 who died within 90 days after registration on the waiting list. Both the MELD score and the serum sodium concentration were significantly associated with mortality (hazard ratio for death, 1.21 per MELD point and 1.05 per 1-unit decrease in the serum sodium concentration for values between 125 and 140 mmol per liter; P<0.001 for both variables). Furthermore, a significant interaction was found between the MELD score and the serum sodium concentration, indicating that the effect of the serum sodium concentration was greater in patients with a low MELD score. When applied to the data from 2006, when 477 patients died within 3 months after registration on the waiting list, the combination of the MELD score and the serum sodium concentration was considerably higher than the MELD score alone in 32 patients who died (7%). Thus, assignment of priority according to the MELD score combined with the serum sodium concentration might have resulted in transplantation and prevented death. Conclusions: This population-wide study shows that the MELD score and the serum sodium concentration are important predictors of survival among candidates for liver transplantation.	[Kim, W. Ray; Wiesner, Russell H.; Kamath, Patrick S.] Mayo Clin, Coll Med, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA; [Kremers, Walter K.; Benson, Joanne T.; Therneau, Terry M.] Mayo Clin, Coll Med, Div Biostat, Rochester, MN 55905 USA; [Biggins, Scott W.] Univ Calif San Francisco, Div Gastroenterol & GI Hlth Outcomes, Policy & Econ Res Program, San Francisco, CA 94143 USA; [Edwards, Erick] United Network Organ Sharing, Richmond, VA USA	Mayo Clinic; Mayo Clinic; University of California System; University of California San Francisco; United Network for Organ Sharing	Kim, WR (corresponding author), Mayo Clin, Coll Med, Div Gastroenterol & Hepatol, 200 1st St, Rochester, MN 55905 USA.	kim.ray@mayo.edu	biggins, scott/AAQ-6532-2020	Kim, W. Ray/0000-0002-3030-860X	National Institute of Diabetes and Digestive and Kidney Diseases [DK-34238, DK-61617, DK-76565]; Palumbo Foundation; Jan Albrecht Commitment to Clinical Research in Liver Disease Award; American Liver Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K23DK061617, R01DK034238, K08DK076565] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Palumbo Foundation; Jan Albrecht Commitment to Clinical Research in Liver Disease Award; American Liver Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (DK-34238, DK-61617, and DK-76565) and the Palumbo Foundation and the Jan Albrecht Commitment to Clinical Research in Liver Disease Award from the American Liver Foundation.	Abbasoglu O, 1998, CLIN TRANSPLANT, V12, P263; ARROYO V, 1976, AM J DIG DIS, V21, P249, DOI 10.1007/BF01095898; Arroyo V, 2003, J HEPATOL, V38, pS69, DOI 10.1016/S0168-8278(03)00007-2; Bellest L, 2007, HEPATOLOGY, V46, P528, DOI 10.1002/hep.21680; Biggins SW, 2006, GASTROENTEROLOGY, V130, P1652, DOI 10.1053/j.gastro.2006.02.010; Biggins SW, 2005, HEPATOLOGY, V41, P32, DOI 10.1002/hep.20517; Borroni G, 2000, DIGEST LIVER DIS, V32, P605, DOI 10.1016/S1590-8658(00)80844-0; Bronster DJ, 2000, CLIN TRANSPLANT, V14, P1, DOI 10.1034/j.1399-0012.2000.140101.x; COSBY RL, 1989, MINER ELECTROL METAB, V15, P261; D'Agostino RB, 2001, JAMA-J AM MED ASSOC, V286, P180, DOI 10.1001/jama.286.2.180; D'Agostino RB, 2004, ADV SURVIVAL ANAL HD, P1; Dawwas MF, 2007, LIVER TRANSPLANT, V13, P1115, DOI 10.1002/lt.21154; EARLEY LE, 1959, J CLIN INVEST, V38, P545, DOI 10.1172/JCI103832; Fernandez-Esparrach G, 2001, J HEPATOL, V34, P46, DOI 10.1016/S0168-8278(00)00011-8; Freeman RB, 2002, LIVER TRANSPLANT, V8, P851, DOI 10.1053/jlts.2002.35927; Freeman RB, 2005, TRANSPLANT P, V37, P585, DOI 10.1016/j.transproceed.2004.12.099; Gerbes AL, 2003, GASTROENTEROLOGY, V124, P933, DOI 10.1053/gast.2003.50143; Ghobrial RM, 2001, ANN SURG, V234, P384, DOI 10.1097/00000658-200109000-00012; GINES A, 1993, GASTROENTEROLOGY, V105, P229, DOI 10.1016/0016-5085(93)90031-7; Heagerty PJ, 2005, BIOMETRICS, V61, P92, DOI 10.1111/j.0006-341X.2005.030814.x; Heuman DM, 2004, HEPATOLOGY, V40, P802, DOI 10.1002/hep.20405; Kamath PS, 2007, HEPATOLOGY, V45, P797, DOI 10.1002/hep.21563; Kamath PS, 2001, HEPATOLOGY, V33, P464, DOI 10.1053/jhep.2001.22172; LLACH J, 1988, GASTROENTEROLOGY, V94, P482, DOI 10.1016/0016-5085(88)90441-6; Londono MC, 2006, GASTROENTEROLOGY, V130, P1135, DOI 10.1053/j.gastro.2006.02.017; Malinchoc M, 2000, HEPATOLOGY, V31, P864, DOI 10.1053/he.2000.5852; Nair S, 2002, HEPATOLOGY, V35, P1179, DOI 10.1053/jhep.2002.33160; Onaca NN, 2003, AM J TRANSPLANT, V3, P626, DOI 10.1034/j.1600-6143.2003.00092.x; Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929; Porcel A, 2002, ARCH INTERN MED, V162, P323, DOI 10.1001/archinte.162.3.323; RIMOLA A, 1987, GASTROENTEROLOGY, V93, P148, DOI 10.1016/0016-5085(87)90327-1; Ruf AE, 2005, LIVER TRANSPLANT, V11, P336, DOI 10.1002/lt.20329; Saab S, 2003, LIVER TRANSPLANT, V9, P473, DOI 10.1053/jlts.2003.50090; SHEAR L, 1965, AM J MED, V39, P184, DOI 10.1016/0002-9343(65)90041-0; Tripodi A, 2007, HEPATOLOGY, V46, P520, DOI 10.1002/hep.21732; Trotter JF, 2007, AM J TRANSPLANT, V7, P1624, DOI 10.1111/j.1600-6143.2007.01822.x; Trotter JE, 2004, LIVER TRANSPLANT, V10, P995, DOI 10.1002/lt.20195; Wiesner RH, 2001, LIVER TRANSPLANT, V7, P567, DOI 10.1053/jlts.2001.25879; Wijdicks E F, 1996, Liver Transpl Surg, V2, P14, DOI 10.1002/lt.500020104; Wong F, 2003, HEPATOLOGY, V37, P182, DOI 10.1053/jhep.2003.50021	40	821	858	0	38	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2008	359	10					1018	1026		10.1056/NEJMoa0801209	http://dx.doi.org/10.1056/NEJMoa0801209			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	343KN	18768945	Green Accepted, Bronze			2022-12-28	WOS:000258852500006
J	Yuan, ZS; Chen, YA; Zhao, B; Chen, S; Schmiedmayer, J; Pan, JW				Yuan, Zhen-Sheng; Chen, Yu-Ao; Zhao, Bo; Chen, Shuai; Schmiedmayer, Joerg; Pan, Jian-Wei			Experimental demonstration of a BDCZ quantum repeater node	NATURE			English	Article							ATOMIC ENSEMBLES; ENTANGLEMENT; COMMUNICATION; DISTANCE	Quantum communication is a method that offers efficient and secure ways for the exchange of information in a network. Large- scale quantum communication(1-4) ( of the order of 100 km) has been achieved; however, serious problems occur beyond this distance scale, mainly due to inevitable photon loss in the transmission channel. Quantum communication eventually fails(5) when the probability of a dark count in the photon detectors becomes comparable to the probability that a photon is correctly detected. To overcome this problem, Briegel, Dur, Cirac and Zoller ( BDCZ) introduced the concept of quantum repeaters(6), combining entanglement swapping(7) and quantum memory to efficiently extend the achievable distances. Although entanglement swapping has been experimentally demonstrated(8), the implementation of BDCZ quantum repeaters has proved challenging owing to the difficulty of integrating a quantum memory. Here we realize entanglement swapping with storage and retrieval of light, a building block of the BDCZ quantum repeater. We follow a scheme(9,10) that incorporates the strategy of BDCZ with atomic quantum memories(11). Two atomic ensembles, each originally entangled with a single emitted photon, are projected into an entangled state by performing a joint Bell state measurement on the two single photons after they have passed through a 300- m fibre- based communication channel. The entanglement is stored in the atomic ensembles and later verified by converting the atomic excitations into photons. Our method is intrinsically phase insensitive and establishes the essential element needed to realize quantum repeaters with stationary atomic qubits as quantum memories and flying photonic qubits as quantum messengers.	[Yuan, Zhen-Sheng; Chen, Yu-Ao; Zhao, Bo; Chen, Shuai; Pan, Jian-Wei] Univ Heidelberg, Inst Phys, D-69120 Heidelberg, Germany; [Yuan, Zhen-Sheng; Chen, Yu-Ao; Pan, Jian-Wei] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Anhua 230026, Peoples R China; [Yuan, Zhen-Sheng; Chen, Yu-Ao; Pan, Jian-Wei] Univ Sci & Technol China, Dept Modern Phys, Anhua 230026, Peoples R China; [Schmiedmayer, Joerg] Vienna Univ Technol, Atominst Osterreichischen Univ, A-1020 Vienna, Austria	Ruprecht Karls University Heidelberg; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Technische Universitat Wien	Chen, YA (corresponding author), Univ Heidelberg, Inst Phys, Philosophenweg 12, D-69120 Heidelberg, Germany.	yuao@physi.uni-heidelberg.de; jian-wei.pan@physi.uni-heidelberg.de	Chen, Yu-Ao/B-2057-2013; Yuan, Zhen-Sheng/A-1061-2010; Pan, Jian-Wei/A-2332-2010; Schmiedmayer, Jörg/M-9669-2019; zhao, bo/M-8471-2017; zhao, bo/W-7599-2018; Schmiedmayer, Jörg/B-4717-2008	Chen, Yu-Ao/0000-0002-2309-2281; Yuan, Zhen-Sheng/0000-0003-4580-8225; Pan, Jian-Wei/0000-0002-6100-5142; Schmiedmayer, Jörg/0000-0001-7799-5614; zhao, bo/0000-0002-4950-1880; zhao, bo/0000-0002-4950-1880; Schmiedmayer, Jörg/0000-0001-7799-5614	Deutsche Forschungsgemeinschaft, the Alexander von Humboldt Foundation; Marie Curie Excellence Grant; ERC Grant; National Fundamental Research Program [2006CB921900]; CAS; NNSFC; Austrian Science Fund (FWF) [Z 118] Funding Source: researchfish	Deutsche Forschungsgemeinschaft, the Alexander von Humboldt Foundation(German Research Foundation (DFG)Alexander von Humboldt Foundation); Marie Curie Excellence Grant(European Commission); ERC Grant; National Fundamental Research Program; CAS(Chinese Academy of Sciences); NNSFC(National Natural Science Foundation of China (NSFC)); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	We thank W. Dur for discussions. This work was supported by the Deutsche Forschungsgemeinschaft, the Alexander von Humboldt Foundation, and the European Commission through the Marie Curie Excellence Grant and the ERC Grant. This work was also supported by the National Fundamental Research Program ( grant 2006CB921900), the CAS and the NNSFC.	Briegel HJ, 1998, PHYS REV LETT, V81, P5932, DOI 10.1103/PhysRevLett.81.5932; Chen S, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.180505; Chen YA, 2008, NAT PHYS, V4, P103, DOI 10.1038/nphys832; Chen ZB, 2007, PHYS REV A, V76, DOI 10.1103/PhysRevA.76.022329; Chou CW, 2007, SCIENCE, V316, P1316, DOI 10.1126/science.1140300; Duan LM, 2001, NATURE, V414, P413, DOI 10.1038/35106500; Foreman SM, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.153601; Gisin N, 2002, REV MOD PHYS, V74, P145, DOI 10.1103/RevModPhys.74.145; Harber DM, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.053616; Jiang L, 2007, PHYS REV A, V76, DOI 10.1103/PhysRevA.76.012301; Kuga T, 1997, PHYS REV LETT, V78, P4713, DOI 10.1103/PhysRevLett.78.4713; KWIAT PG, 1995, PHYS REV LETT, V75, P4337, DOI 10.1103/PhysRevLett.75.4337; Matsukevich DN, 2004, SCIENCE, V306, P663, DOI 10.1126/science.1103346; Moehring DL, 2007, NATURE, V449, P68, DOI 10.1038/nature06118; Pan JW, 1998, PHYS REV A, V57, P2208, DOI 10.1103/PhysRevA.57.2208; Pan JW, 1998, PHYS REV LETT, V80, P3891, DOI 10.1103/PhysRevLett.80.3891; Peng CZ, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.010505; Rosenberg D, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.010503; Sangouard N, 2008, PHYS REV A, V77, DOI 10.1103/PhysRevA.77.062301; Schmitt-Manderbach T, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.010504; Simon J, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.183601; Ursin R, 2007, NAT PHYS, V3, P481, DOI 10.1038/nphys629; Wilk T, 2007, SCIENCE, V317, P488, DOI 10.1126/science.1143835; Yuan ZS, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.180503; Zhao B, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.240502; ZUKOWSKI M, 1993, PHYS REV LETT, V71, P4287, DOI 10.1103/PhysRevLett.71.4287	27	328	338	4	104	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 28	2008	454	7208					1098	1101		10.1038/nature07241	http://dx.doi.org/10.1038/nature07241			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341MW	18756253	Green Submitted			2022-12-28	WOS:000258719600033
J	Leyland, E				Leyland, Elizabeth			Human papillomavirus vaccination: stabbing in the dark?	LANCET			English	Editorial Material									Univ Leeds, Sch Med, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Leyland, E (corresponding author), Univ Leeds, Sch Med, Leeds LS2 9JT, W Yorkshire, England.	lizleyland@hotmail.com						Bosch FX, 2008, ANN ONCOL, V19, P48, DOI 10.1093/annonc/mdn310; Brabin L, 2008, BRIT MED J, V336, P1056, DOI 10.1136/bmj.39541.534109.BE; *CANC RES UK, 2008, ENC UPT HPV VACC TRI; *DEP HLTH, 2008, INTRO HUM PAP VACC N; *DEP HLTH, 2008, INTRO HPV VACC NAT I; *DEP HLTH, 2008, IMM INF DIS GREEN BO, pCH18A; Di Giuseppe G, 2008, BRIT J CANCER, V99, P225, DOI 10.1038/sj.bjc.6604454; Kane MA, 2008, J FAM PLAN REPROD H, V34, P3, DOI 10.1783/147118908783332113; Kim J. J., 2008, BMJ-BRIT MED J, V337, P303	9	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	2008	372	9639					614	614		10.1016/S0140-6736(08)61258-1	http://dx.doi.org/10.1016/S0140-6736(08)61258-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	340BX	18722854				2022-12-28	WOS:000258622200010
J	Manning, AL; Compton, DA				Manning, Amity L.; Compton, Duane A.			SnapShot: Nonmotor proteins in spindle assembly	CELL			English	Editorial Material							MICROTUBULE; CELL		[Manning, Amity L.] Dartmouth Med Sch, Dept Biochem, Hanover, NH USA; Norris Cotton Canc Ctr, Lebanon, NH 03755 USA	Dartmouth College; Norris Cotton Cancer Center	Manning, AL (corresponding author), Dartmouth Med Sch, Dept Biochem, Hanover, NH USA.		Manning, Amity/AAC-8205-2019	Manning, Amity/0000-0003-1332-9086; Compton, Duane/0000-0002-4445-9118	NCI NIH HHS [P30 CA023108] Funding Source: Medline; NIGMS NIH HHS [R37 GM051542, GM51542, R01 GM051542] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051542, R37GM051542] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akhmanova A, 2008, NAT REV MOL CELL BIO, V9, P309, DOI 10.1038/nrm2369; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; Durcan TM, 2008, J CELL BIOL, V181, P595, DOI 10.1083/jcb.200711160; Goshima G, 2008, J CELL BIOL, V181, P421, DOI 10.1083/jcb.200711053; Jang CY, 2008, J CELL BIOL, V181, P255, DOI 10.1083/jcb.200711032; Johansen KM, 2007, INT REV CYTOL, V263, P155, DOI 10.1016/S0074-7696(07)63004-6; Manning AL, 2008, CURR OPIN CELL BIOL, V20, P101, DOI 10.1016/j.ceb.2007.11.004; Ruchaud S, 2007, NAT REV MOL CELL BIO, V8, P798, DOI 10.1038/nrm2257; Santamaria A, 2008, CURR BIOL, V18, P723, DOI 10.1016/j.cub.2008.04.041; Zhang D, 2007, J CELL BIOL, V177, P231, DOI 10.1083/jcb.200612011	10	10	10	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 22	2008	134	4					694	U18		10.1016/j.cell.2008.08.001	http://dx.doi.org/10.1016/j.cell.2008.08.001			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SR	18724941	Green Accepted, Bronze			2022-12-28	WOS:000258665800022
J	Barry, M; Hughes, JM				Barry, Michele; Hughes, James M.			Talking dirty - The politics of clean water and sanitation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Barry, Michele] Yale Univ, Sch Med, New Haven, CT 06520 USA; [Hughes, James M.] Emory Univ, Sch Med, Atlanta, GA USA; [Hughes, James M.] Emory Univ, Rollins Sch Publ Hlth, Ctr Global Safe Water, Atlanta, GA 30322 USA	Yale University; Emory University; Emory University; Rollins School Public Health	Barry, M (corresponding author), Yale Univ, Sch Med, New Haven, CT 06520 USA.							Ahmed MF, 2006, SCIENCE, V314, P1687, DOI 10.1126/science.1133146; Bartram J, 2005, LANCET, V365, P810, DOI 10.1016/S0140-6736(05)71007-2; Pruss-Ustun A., 2008, SAFER WATER BETTER H; *UN DEV PROGR, 2006, SUMM HUM DEV REP 200; White G., 1972, DRAWERS WATER	5	10	10	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 21	2008	359	8					784	787		10.1056/NEJMp0804650	http://dx.doi.org/10.1056/NEJMp0804650			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	339HL	18716296				2022-12-28	WOS:000258568600003
J	Vikse, BE; Irgens, LM; Leivestad, T; Skjaerven, R; Iversen, BM				Vikse, Bjorn Egil; Irgens, Lorentz M.; Leivestad, Torbjorn; Skjaerven, Rolv; Iversen, Bjarne M.			Preeclampsia and the risk of end-stage renal disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; MEDICAL BIRTH REGISTRY; PREGNANCY COMPLICATIONS; IMPAIRED ANGIOGENESIS; RETROSPECTIVE COHORT; BLOOD-PRESSURE; KIDNEY; WOMEN; HYPERTENSION; PARAMETERS	Background: It is unknown whether preeclampsia is a risk marker for subsequent end-stage renal disease (ESRD). Methods: We linked data from the Medical Birth Registry of Norway, which contains data on all births in Norway since 1967, with data from the Norwegian Renal Registry, which contains data on all patients receiving a diagnosis of end-stage renal disease (ESRD) since 1980, to assess the association between preeclampsia in one or more pregnancies and the subsequent development of ESRD. The study population consisted of women who had had a first singleton birth between 1967 and 1991; we included data from up to three pregnancies. Results: ESRD developed in 477 of 570,433 women a mean (+/-SD) of 17+/-9 years after the first pregnancy (overall rate, 3.7 per 100,000 women per year). Among women who had been pregnant one or more times, preeclampsia during the first pregnancy was associated with a relative risk of ESRD of 4.7 (95% confidence interval [CI], 3.6 to 6.1). Among women who had been pregnant two or more times, preeclampsia during the first pregnancy was associated with a relative risk of ESRD of 3.2 (95% CI, 2.2 to 4.9), preeclampsia during the second pregnancy with a relative risk of 6.7 (95% CI, 4.3 to 10.6), and preeclampsia during both pregnancies with a relative risk of 6.4 (95% CI, 3.0 to 13.5). Among women who had been pregnant three or more times, preeclampsia during one pregnancy was associated with a relative risk of ESRD of 6.3 (95% CI, 4.1 to 9.9), and preeclampsia during two or three pregnancies was associated with a relative risk of 15.5 (95% CI, 7.8 to 30.8). Having a low-birth-weight or preterm infant increased the relative risk of ESRD. The results were similar after adjustment for possible confounders and after exclusion of women who had kidney disease, rheumatic disease, essential hypertension, or diabetes mellitus before pregnancy. Conclusions: Although the absolute risk of ESRD in women who have had preeclampsia is low, preeclampsia is a marker for an increased risk of subsequent ESRD.	[Vikse, Bjorn Egil; Iversen, Bjarne M.] Haukeland Hosp, Inst Med, Dept Med, Renal Res Grp, N-5021 Bergen, Norway; [Vikse, Bjorn Egil; Iversen, Bjarne M.] Univ Bergen, Inst Med, Renal Res Grp, Bergen, Norway; [Irgens, Lorentz M.; Skjaerven, Rolv] Univ Bergen, Sect Epidemiol & Med Stat, Bergen, Norway; [Vikse, Bjorn Egil; Irgens, Lorentz M.; Skjaerven, Rolv; Iversen, Bjarne M.] Univ Bergen, Locus Registry Based Epidemiol, Bergen, Norway; [Irgens, Lorentz M.; Skjaerven, Rolv] Norwegian Inst Publ Hlth, Med Birth Registry Norway, Bergen, Norway; [Leivestad, Torbjorn] Univ Oslo, Rikshosp, Inst Immunol, Norwegian Renal Registry, N-0027 Oslo, Norway	University of Bergen; Haukeland University Hospital; University of Bergen; University of Bergen; University of Bergen; Norwegian Institute of Public Health (NIPH); University of Oslo; National Hospital Norway	Vikse, BE (corresponding author), Haukeland Hosp, Inst Med, Dept Med, Renal Res Grp, N-5021 Bergen, Norway.	bjorn.vikse@med.uib.no			Western Norway Regional Health Authority; Strategic Research Program of Haukeland University Hospital	Western Norway Regional Health Authority; Strategic Research Program of Haukeland University Hospital	Supported by grants from the Western Norway Regional Health Authority and the Strategic Research Program of Haukeland University Hospital.; No potential conflict of interest relevant to this article was reported.; We thank Stein Atle Lie for valuable statistical advice.	Agatisa PK, 2004, AM J PHYSIOL-HEART C, V286, pH1389, DOI 10.1152/ajpheart.00298.2003; ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; [Anonymous], 1990, AM J OBSTET GYNECOL, V163, P1691; Bar J, 1999, NEPHROL DIAL TRANSPL, V14, P1129, DOI 10.1093/ndt/14.5.1129; Chambers JC, 2001, JAMA-J AM MED ASSOC, V285, P1607, DOI 10.1001/jama.285.12.1607; Choi YJ, 2000, HUM PATHOL, V31, P1491, DOI 10.1053/hupa.2000.20373; Cotter AM, 2001, AM J OBSTET GYNECOL, V185, P781, DOI 10.1067/mob.2001.117304; Dahlstrom BL, 2006, ACTA OBSTET GYN SCAN, V85, P916, DOI 10.1080/00016340500442449; de Jong PE, 2004, KIDNEY INT, V66, P2109, DOI 10.1111/j.1523-1755.2004.66001.x; Hall JE, 2003, CURR OPIN NEPHROL HY, V12, P195, DOI 10.1097/00041552-200303000-00011; He S, 1999, THROMB HAEMOSTASIS, V81, P538; Hsu CY, 2006, ANN INTERN MED, V144, P21, DOI 10.7326/0003-4819-144-1-200601030-00006; Irgens HU, 2001, BRIT MED J, V323, P1213, DOI 10.1136/bmj.323.7323.1213; Irgens LM, 2000, ACTA OBSTET GYN SCAN, V79, P435, DOI 10.1034/j.1600-0412.2000.079006435.x; Joffe GM, 1998, AM J OBSTET GYNECOL, V179, P1032, DOI 10.1016/S0002-9378(98)70210-8; Kang DH, 2001, AM J KIDNEY DIS, V37, P601, DOI 10.1053/ajkd.2001.22087; Kang DH, 2001, J AM SOC NEPHROL, V12, P1448, DOI 10.1681/ASN.V1271448; Lawlor DA, 2002, BMJ-BRIT MED J, V325, P359, DOI 10.1136/bmj.325.7360.359; Levine RJ, 2004, NEW ENGL J MED, V350, P672, DOI 10.1056/NEJMoa031884; NISELL H, 1995, BRIT J OBSTET GYNAEC, V102, P876, DOI 10.1111/j.1471-0528.1995.tb10874.x; Orth SR, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000018401.82863.FD; Pell JP, 2004, AM J EPIDEMIOL, V159, P336, DOI 10.1093/aje/kwh064; Pouta A, 2004, HYPERTENSION, V43, P825, DOI 10.1161/01.HYP.0000120122.39231.88; Rasmussen S, 2007, HYPERTENSION, V49, P806, DOI 10.1161/01.HYP.0000259924.74947.aa; Sattar N, 2003, HYPERTENSION, V42, P39, DOI 10.1161/01.HYP.0000074428.11168.EE; Sibai BM, 1997, AM J OBSTET GYNECOL, V177, P1003, DOI 10.1016/S0002-9378(97)70004-8; SIBAI BM, 1995, AM J OBSTET GYNECOL, V172, P642, DOI 10.1016/0002-9378(95)90586-3; Skjaerven R, 2000, ACTA OBSTET GYN SCAN, V79, P440, DOI 10.1034/j.1600-0412.2000.079006440.x; Skjaerven R, 2002, NEW ENGL J MED, V346, P33, DOI 10.1056/NEJMoa011379; Skomsvoll JF, 2002, ACTA OBSTET GYN SCAN, V81, P831, DOI 10.1034/j.1600-0412.2002.810905.x; Smith GCS, 2001, LANCET, V357, P2002, DOI 10.1016/S0140-6736(00)05112-6; Smith GD, 2000, LANCET, V356, P2066, DOI 10.1016/S0140-6736(00)03406-1; Stene LC, 2007, NOR EPIDEMIOL, V17, P165; Vikse BE, 2006, J AM SOC NEPHROL, V17, P837, DOI 10.1681/ASN.2005050492; Wilson BJ, 2003, BRIT MED J, V326, P845, DOI 10.1136/bmj.326.7394.845	35	436	469	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 21	2008	359	8					800	809		10.1056/NEJMoa0706790	http://dx.doi.org/10.1056/NEJMoa0706790			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339HL	18716297				2022-12-28	WOS:000258568600005
J	van't Hof, AWJ; ten Berg, J; Heestermans, T; Dill, T; Funck, RC; van Werkum, W; Dambrink, JHE; Suryapranata, H; van Houwelingen, G; Ottervanger, JP; Stella, P; Giannitsis, E; Hamm, C				van't Hof, Arnoud W. J.; ten Berg, Jurrien; Heestermans, Ton; Dill, Thorsten; Funck, Reinhard C.; van Werkum, Wouter; Dambrink, Jan-Henk E.; Suryapranata, Harry; van Houwelingen, Gert; Ottervanger, Jan Paul; Stella, Pieter; Giannitsis, Evangelos; Hamm, Christian		Ongoing Tirofiban Myocardial Infar	Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial	LANCET			English	Article							PERCUTANEOUS CORONARY INTERVENTION; SEGMENT ELEVATION; PLATELET-AGGREGATION; TASK-FORCE; REPERFUSION; INHIBITION; METAANALYSIS; OUTCOMES; THERAPY; EVENTS	Background The most effective magnitude and timing of antiplatelet therapy is important in patients with acute ST-elevation myocardial infarction (STEMI). We investigated whether the results of primary coronary angioplasty (PCI) can be improved by the early administration of the glycoprotein IIb/IIIa blocker tirofiban at first medical contact in the ambulance or referral Centre. Methods We undertook a double-blind, randomised, placebo-controlled trial in 24 centres in the Netherlands, Germany, and Belgium. Between June 29, 2006, and Nov 13, 2007, 984 patients with STEMI who were candidates to undergo PCI were randomly assigned to either high-bolus dose tirofiban (n=491) or placebo (N=493) in addition to aspirin (500 mg), heparin (5000 IU), and clopidogrel (600 mg). Randomisation was by blinded sealed kits with study drug, in blocks of four. The primary endpoint was the extent of residual ST-segment deviation 1 h after PCI. Analysis was by intention to treat. The trial is registered, number ISRCTN06195297. Findings 936 (95%) patients were randomly assigned to treatment after a prehospital diagnosis of myocardial infarction in the ambulance. Median time from onset of symptoms to diagnosis was 76 min (IQR 35-150). Mean residual ST deviation before PCI (10 . 9 rum [SD 9.2] vs 12.1 mm [9.4], p=0 . 028) and 1 h after PCI (3-6 mm [4.6] vs 4.8 mm [6.3], p=0.003) was significantly lower in patients pretreated with high-bolus dose tirofiban than in those assigned to placebo. The rate of major bleeding did not differ significantly between the two groups (19 [4%] vs 14 [3%]; p=0 . 36). Interpretation Our finding that routine prehospital initiation of high-bolus dose tirofiban improved ST-segment resolution and clinical outcome after PCI, emphasises that further platelet aggregation inhibition besides high-dose clopidogrel is mandated in patients with STEMI undergoing PCL	[van't Hof, Arnoud W. J.; Heestermans, Ton; Dambrink, Jan-Henk E.; Suryapranata, Harry; Ottervanger, Jan Paul] Isala Klin, Dept Cardiol, NL-8011 JW Zwolle, Netherlands; [ten Berg, Jurrien; van Werkum, Wouter] St Antonius Hosp, Nieuwegein, Netherlands; [Dill, Thorsten; Hamm, Christian] Kerckhoff Klin GmbH, Bad Nauheim, Germany; [Suryapranata, Harry] Diagram BV, Zwolle, Netherlands; [van Houwelingen, Gert] Med Spectrum Twenet, Enschede, Netherlands; [Funck, Reinhard C.] Univ Marburg, Marburg, Germany; [Giannitsis, Evangelos] Universitatsklinikum Heidelberg, Heidelberg, Germany	Isala Clinics; St. Antonius Hospital Utrecht; Kerckhoff Clinic; Medical Spectrum Twente; Philipps University Marburg; Ruprecht Karls University Heidelberg	van't Hof, AWJ (corresponding author), Isala Klin, Dept Cardiol, Wezenland 20, NL-8011 JW Zwolle, Netherlands.	v.r.c.derks@isala.nl	Suryapranata, H./H-8095-2014; Hamm, Christian W./I-3155-2017	Hamm, Christian W./0000-0001-6763-4161	Merck and Co, Whitehouse Station, NJ, USA	Merck and Co, Whitehouse Station, NJ, USA(Merck & Company)	The study was partly funded by all unrestricted grant from Merck and Co, Whitehouse Station, NJ, USA. We thank all ambulance personnel who were involved in the trial for their cooperation and recruitment of patients.	Anderson JL, 1996, AM J CARDIOL, V78, P1, DOI 10.1016/S0002-9149(96)00217-2; Angeja BG, 2002, CIRCULATION, V105, P282, DOI 10.1161/hc0302.103588; Antman EM, 2008, CIRCULATION, V117, P296, DOI 10.1161/CIRCULATIONAHA.107.188209; Antman Elliott M., 2004, J Am Coll Cardiol, V44, pE1, DOI 10.1016/j.jacc.2004.07.014; Bassand JP, 2007, EUR HEART J, V28, P1598, DOI 10.1093/eurheartj/ehm161; BOVILL EG, 1991, ANN INTERN MED, V115, P256, DOI 10.7326/0003-4819-115-4-256; Budaj A, 2003, AM HEART J, V146, P999, DOI 10.1016/S0002-8703(03)00509-X; Carstensen S, 2007, EUR HEART J, V28, P2313, DOI 10.1093/eurheartj/ehm306; De Luca G, 2005, AM HEART J, V150, P1248, DOI 10.1016/j.ahj.2005.01.056; De Luca G, 2004, EUR HEART J, V25, P1009, DOI 10.1016/j.ehj.2004.03.021; De Luca G, 2007, INT J CARDIOL, V117, P232, DOI 10.1016/j.ijcard.2006.04.082; DELUCA G, 2008, HEART           0605, DOI DOI 10.1136/HRT.2008.141648; Ellis SG, 2008, NEW ENGL J MED, V358, P2205, DOI 10.1056/NEJMoa0706816; Ernst NMSKJ, 2004, J AM COLL CARDIOL, V44, P1187, DOI 10.1016/j.jacc.2004.06.050; Heestermans AACM, 2008, THROMB RES, V122, P776, DOI 10.1016/j.thromres.2008.01.021; Hochholzer W, 2005, CIRCULATION, V111, P2560, DOI 10.1161/01.CIR.0000160869.75810.98; Keeley EC, 2006, LANCET, V367, P579, DOI 10.1016/S0140-6736(06)68148-8; Kereiakes DJ, 1999, AM J CARDIOL, V84, P391, DOI 10.1016/S0002-9149(99)00321-5; Mandelzweig L, 2006, EUR HEART J, V27, P2285, DOI 10.1093/eurheartj/ehl196; Matetzky S, 2004, CIRCULATION, V109, P3171, DOI 10.1161/01.CIR.0000130846.46168.03; McDonald MA, 2008, EUR HEART J, V29, P871, DOI 10.1093/eurheartj/ehn078; MEHILI J, 2008, AM COLL CARD 2008 SC; Montalescot G, 2004, JAMA-J AM MED ASSOC, V292, P362, DOI 10.1001/jama.292.3.362; Montalescot G, 2001, NEW ENGL J MED, V344, P1895, DOI 10.1056/NEJM200106213442503; Montalescot G, 2007, EUR HEART J, V28, P443, DOI 10.1093/eurheartj/ehl472; Poli A, 2002, CIRCULATION, V106, P313, DOI 10.1161/01.CIR.0000022691.71708.94; Schneider DJ, 2002, AM J CARDIOL, V90, P1421, DOI 10.1016/S0002-9149(02)02892-8; SIMES RJ, 1995, CIRCULATION, V91, P1923, DOI 10.1161/01.CIR.91.7.1923; Stenestrand U, 2006, JAMA-J AM MED ASSOC, V296, P1749, DOI 10.1001/jama.296.14.1749; Stone GW, 2008, NEW ENGL J MED, V358, P2218, DOI 10.1056/NEJMoa0708191; Svilaas T, 2008, NEW ENGL J MED, V358, P557, DOI 10.1056/NEJMoa0706416; Topol EJ, 2003, J AM COLL CARDIOL, V42, P1886, DOI 10.1016/j.jacc.2003.09.010; Van de Werf F, 2003, EUR HEART J, V24, P28, DOI 10.1016/S0195-668X(02)00618-8; van 't Hof Arnoud W J, 2007, EuroIntervention, V3, P371, DOI 10.4244/EIJV3I3A67; van't Hof AWJ, 1998, CIRCULATION, V97, P2302, DOI 10.1161/01.CIR.97.23.2302; vantHof AWJ, 1997, LANCET, V350, P615, DOI 10.1016/S0140-6736(96)07120-6; vantHof AWJ, 2006, AM HEART J, V151, DOI DOI 10.1016/J.AHJ.2006.03.014; Zeymer U, 2003, AM HEART J, V146, P686, DOI 10.1016/S0002-8703(03)00326-0; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002	39	354	366	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 16	2008	372	9638					537	546		10.1016/S0140-6736(08)61235-0	http://dx.doi.org/10.1016/S0140-6736(08)61235-0			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339MS	18707985				2022-12-28	WOS:000258582300027
J	Truog, RD; Miller, FG				Truog, Robert D.; Miller, Franklin G.			The dead donor rule and organ transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							BRAIN-DEATH		[Truog, Robert D.] Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA; [Truog, Robert D.] Harvard Univ, Sch Med, Dept Social Med, Boston, MA 02115 USA; [Truog, Robert D.] Childrens Hosp, Div Crit Care Med, Boston, MA 02115 USA; [Miller, Franklin G.] NIH, Dept Bioeth, Bethesda, MD 20892 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; National Institutes of Health (NIH) - USA	Truog, RD (corresponding author), Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA.							[Anonymous], 1968, JAMA, V205, P337; BERNAT JL, 1981, ANN INTERN MED, V94, P389, DOI 10.1001/archinte.94.3.389; MILLER FG, IN PRESS HASTINGS CT; Shewmon DA, 1998, NEUROLOGY, V51, P1538, DOI 10.1212/WNL.51.6.1538; Truog RD, 1997, HASTINGS CENT REP, V27, P29, DOI 10.2307/3528024	5	128	130	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 14	2008	359	7					674	675		10.1056/NEJMp0804474	http://dx.doi.org/10.1056/NEJMp0804474			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336XE	18703469				2022-12-28	WOS:000258397900003
J	Loughlin, R; Riggs, B; Heald, R				Loughlin, Rose; Riggs, Blake; Heald, Rebecca			Snapshot: Motor proteins in spindle assembly	CELL			English	Editorial Material							DYNAMICS; LENGTH; ROLES		[Loughlin, Rose; Riggs, Blake; Heald, Rebecca] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Loughlin, R (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.			Heald, Rebecca/0000-0001-6671-6528				Brust-Mascher I, 2007, INT REV CYTOL, V259, P139, DOI 10.1016/S0074-7696(06)59004-7; Mitchison TJ, 2005, MOL BIOL CELL, V16, P3064, DOI 10.1091/mbc.E05-02-0174; Moores CA, 2006, J CELL SCI, V119, P3905, DOI 10.1242/jcs.03224; Tanaka TU, 2008, CURR OPIN CELL BIOL, V20, P53, DOI 10.1016/j.ceb.2007.11.005; Varga V, 2006, NAT CELL BIOL, V8, P957, DOI 10.1038/ncb1462; Walczak CE, 1998, CURR BIOL, V8, P903, DOI 10.1016/S0960-9822(07)00370-3; Walczak CE, 2008, INT REV CYTOL, V265, P111, DOI 10.1016/S0074-7696(07)65003-7; Yang ZY, 2007, CURR BIOL, V17, P973, DOI 10.1016/j.cub.2007.04.056	8	11	11	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 8	2008	134	3					548	U17		10.1016/j.cell.2008.07.038	http://dx.doi.org/10.1016/j.cell.2008.07.038			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SO	18692476	Bronze			2022-12-28	WOS:000258665500027
J	Rebsam, A; Mason, CA				Rebsam, Alexandra; Mason, Carol A.			Otx2's incredible journey	CELL			English	Editorial Material							VISUAL-CORTEX; PLASTICITY		[Rebsam, Alexandra; Mason, Carol A.] Columbia Univ, Coll Phys & Surg, Dept Pathol & Cell Biol, New York, NY 10032 USA; [Rebsam, Alexandra; Mason, Carol A.] Columbia Univ, Coll Phys & Surg, Dept Neurosci, New York, NY 10032 USA	Columbia University; Columbia University	Rebsam, A (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pathol & Cell Biol, 630 W 168th St,14-509 P&S Bldg, New York, NY 10032 USA.	adr2111@columbia.edu; cam4@columbia.edu	Rebsam, Alexandra/I-1977-2017	Rebsam, Alexandra/0000-0003-3964-2548				Brunet I, 2005, NATURE, V438, P94, DOI 10.1038/nature04110; Brunet I, 2007, TRENDS NEUROSCI, V30, P260, DOI 10.1016/j.tins.2007.03.010; Fagiolini M, 2000, NATURE, V404, P183, DOI 10.1038/35004582; Hensch TK, 2005, NAT REV NEUROSCI, V6, P877, DOI 10.1038/nrn1787; Hensch TK, 1998, SCIENCE, V282, P1504, DOI 10.1126/science.282.5393.1504; Huang ZJ, 2007, NAT REV NEUROSCI, V8, P673, DOI 10.1038/nrn2188; Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P1003, DOI 10.1152/jn.1963.26.6.1003	9	7	8	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 8	2008	134	3					386	387		10.1016/j.cell.2008.07.029	http://dx.doi.org/10.1016/j.cell.2008.07.029			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SO	18692461	Bronze			2022-12-28	WOS:000258665500010
J	Nicewicz, DA; MacMillan, DWC				Nicewicz, David A.; MacMillan, David W. C.			Merging photoredox catalysis with organocatalysis: The direct asymmetric alkylation of aldehydes	SCIENCE			English	Article							ELECTRON-TRANSFER; RADICALS; PHOTOCHEMISTRY; PHOTOPHYSICS; POTENTIALS; ACTIVATION; REDUCTION; ENAMINES	Photoredox catalysis and organocatalysis represent two powerful fields of molecule activation that have found widespread application in the areas of inorganic and organic chemistry, respectively. We merged these two catalysis fields to solve problems in asymmetric chemical synthesis. Specifically, the enantioselective intermolecular alpha-alkylation of aldehydes has been accomplished using an interwoven activation pathway that combines both the photoredox catalyst Ru(bpy)(3)Cl-2 (where bpy is 2,2 '-bipyridine) and an imidazolidinone organocatalyst. This broadly applicable, yet previously elusive, alkylation reaction is now highly enantioselective and operationally trivial.	[Nicewicz, David A.; MacMillan, David W. C.] Princeton Univ, Dept Chem, Merck Ctr Catalysis, Princeton, NJ 08544 USA	Princeton University	MacMillan, DWC (corresponding author), Princeton Univ, Dept Chem, Merck Ctr Catalysis, Princeton, NJ 08544 USA.	dmacmill@princeton.edu	昊翀, 谭/AAC-5077-2021		NIH General Medical Sciences [R01 GM078201-01-01]; Merck; Amgen; Bristol-Myers Squibb; NIH National Service Research Award [F32GM076816]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078201, F32GM076816] Funding Source: NIH RePORTER	NIH General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Merck(Merck & Company); Amgen(Amgen); Bristol-Myers Squibb(Bristol-Myers Squibb); NIH National Service Research Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank S. Bernhard for his assistance in performing quenching experiments, as well as many insightful discussions. Additionally, we thank T.J. Rainey for performing DFT calculations. Financial support was provided by the NIH General Medical Sciences (grant R01 GM078201-01-01) and gifts from Merck, Amgen, and Bristol-Myers Squibb. D.A.N. is grateful for a NIH National Service Research Award fellowship (F32GM076816).	Beeson TD, 2007, SCIENCE, V316, P582, DOI 10.1126/science. 1142696; Berkessel A, 2005, ASYMMETRIC ORGANOCATALYSIS: FROM BIOMIMETIC CONCEPTS TO APPLICATIONS IN ASYMMETRIC SYNTHESIS, P1, DOI 10.1002/3527604677; BOCK CR, 1979, J AM CHEM SOC, V101, P4815, DOI 10.1021/ja00511a007; Dai X, 2008, J AM CHEM SOC, V130, P3302, DOI 10.1021/ja8009428; Dalko P. I., 2007, ENANTIOSELECTIVE ORG; FUKUZUMI S, 1990, J PHYS CHEM-US, V94, P722, DOI 10.1021/j100365a039; Gray HB, 1996, ANNU REV BIOCHEM, V65, P537, DOI 10.1146/annurev.bi.65.070196.002541; Jang HY, 2007, J AM CHEM SOC, V129, P7004, DOI 10.1021/ja0719428; JURIS A, 1988, COORDIN CHEM REV, V84, P85, DOI 10.1016/0010-8545(88)80032-8; KALYANASUNDARAM K, 1982, COORDIN CHEM REV, V46, P159, DOI 10.1016/0010-8545(82)85003-0; Kim H, 2008, J AM CHEM SOC, V130, P398, DOI 10.1021/ja077212h; RENAUD P, 1990, SYNLETT, P624; Renaud P., 2001, RADICALS ORGANIC SYN; RUSSELL GA, 1991, J ORG CHEM, V56, P3475, DOI 10.1021/jo00011a007; Sibi MP, 2007, J AM CHEM SOC, V129, P4124, DOI 10.1021/ja069245n; TANNER DD, 1986, J ORG CHEM, V51, P5182, DOI 10.1021/jo00376a024; Vignola N, 2004, J AM CHEM SOC, V126, P450, DOI 10.1021/ja0392566; WAYNER DDM, 1986, CHEM PHYS LETT, V131, P189, DOI 10.1016/0009-2614(86)80542-5	18	1648	1658	47	1062	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	2008	322	5898					77	80		10.1126/science.1161976	http://dx.doi.org/10.1126/science.1161976			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	355AE	18772399	Green Accepted			2022-12-28	WOS:000259680200040
J	Fox, K; Ford, I; Steg, PG; Tendera, M; Robertson, M; Ferrari, R				Fox, Kim; Ford, Ian; Steg, P. Gabriel; Tendera, Michal; Robertson, Michele; Ferrari, Roberto		BEAUTIFUL Investigators	Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial	LANCET			English	Article							FAILURE; ATHEROSCLEROSIS; IVABRADINE; MORTALITY	Background The BEAUTIFUL study assessed the morbidity and mortality benefits of the heart rate-lowering agent ivabradine. The placebo arm of the BEAUTIFUL trial was a large cohort of patients with stable coronary artery disease and left-ventricular dysfunction. We did a subanalysis of this placebo group to test the hypothesis that elevated resting heart rate at baseline is a marker for subsequent cardiovascular death and morbidity. Methods The association of baseline resting heart rate with cardiovascular outcomes was analysed using Cox proportional hazard models for groups with a heart rate of 70 beats per min (bpm) or greater (2693 patients) versus less than 70 bpm (2745 patients). Additional analyses were done with finer categorisation of heart rate, and with heart rate as a continuous variable. Findings After adjustment for baseline characteristics, patients with heart rates of 70 bpm or greater had increased risk for cardiovascular death (34%, p=0.0041), admission to hospital for heart failure (53%, p<0.0001), admission to hospital for myocardial infarction (46%, p=0.0066), and coronary revascularisation. (38%, p=0.037). For every increase of 5 bpm, there were increases in cardiovascular death (8%, p=0.0005), admission to hospital for heart failure (16%, p<0.0001), admission to hospital for myocardial infarction (7%, p=0.052), and coronary revascularisation. (8%, p=0.034). The analysis of fine-groupings of heart rate suggests that the increase in mortality and heart failure outcomes rises continuously above 70 bpm, whereas the relation is less pronounced for coronary outcomes. For heart failure outcomes, the predictive value of resting heart rate was stronger for earlier events than for later events. Interpretation In patients with coronary artery disease and left-ventricular systolic dysfunction, elevated heart rate (70 bpm or greater) identifies those at increased risk of cardiovascular outcomes, with a differential effect on outcomes associated with heart failure and outcomes associated with coronary events. Funding Servier, France.	[Fox, Kim] Royal Brompton Hosp, London SW3 6NP, England; [Ford, Ian; Robertson, Michele] Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland; [Steg, P. Gabriel] Univ Paris 07, INSERM, Hop Bichat Claude Bernard, AP HP,U698, Paris, France; [Tendera, Michal] Med Univ Silesia, Katowice, Poland; [Ferrari, Roberto] Univ Ferrara, S Maugeri Fdn, I-44100 Ferrara, Italy	Royal Brompton Hospital; University of Glasgow; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Medical University Silesia; Istituti Clinici Scientifici Maugeri IRCCS; University of Ferrara	Fox, K (corresponding author), Royal Brompton Hosp, Sydney St, London SW3 6NP, England.	k.fox@rbht.nhs.uk	Arnolda, Leonard F/B-7986-2008; FERRARI, ROBERTO/ABD-5169-2020; Freedman, Saul B/C-1625-2013; Manolis, Antonis/F-5003-2014; STEG, Philippe Gabriel/Z-1567-2019; Tendera, Michal/AAA-1875-2022; Ford, Ian/ABE-6145-2020	Freedman, Saul B/0000-0002-3809-2911; Manolis, Antonis/0000-0002-0336-4745; Tendera, Michal/0000-0002-0812-6113; Ferrari, Roberto/0000-0003-2046-9175; STEG, Philippe Gabriel/0000-0001-6896-2941				Chatzizisis YS, 2007, J AM COLL CARDIOL, V49, P2379, DOI 10.1016/j.jacc.2007.02.059; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; Daly CA, 2005, EUR HEART J, V26, P996, DOI 10.1093/eurheartj/ehi171; Diaz A, 2005, EUR HEART J, V26, P967, DOI 10.1093/eurheartj/ehi190; Fox K, 2008, LANCET, V372, P807, DOI 10.1016/S0140-6736(08)61170-8; Fox K, 2008, CARDIOLOGY, V110, P271, DOI 10.1159/000112412; Fox K, 2006, AM HEART J, V152, P860, DOI 10.1016/j.ahj.2006.01.013; Giannoglou GD, 2008, INT J CARDIOL, V126, P302, DOI 10.1016/j.ijcard.2007.08.077; Gullestad L, 2005, J AM COLL CARDIOL, V45, P252, DOI 10.1016/j.jacc.2004.10.032; Heidland UE, 2001, CIRCULATION, V104, P1477, DOI 10.1161/hc3801.096325; Hjalmarson A, 2007, EUR HEART J SUPPL, V9, pF3, DOI 10.1093/eurheartj/sum030; Ingwall JS, 2004, CIRC RES, V95, P135, DOI 10.1161/01.RES.0000137170.41939.d9; KANNEL WB, 1987, AM HEART J, V113, P1489, DOI 10.1016/0002-8703(87)90666-1; Kjekshus J, 1999, EUR HEART J SUPPL, V1, pH64; Kolloch R, 2008, EUR HEART J, V29, P1327, DOI 10.1093/eurheartj/ehn123; Lechat P, 2001, CIRCULATION, V103, P1428, DOI 10.1161/01.CIR.103.10.1428; Mauss O, 2005, J ELECTROCARDIOL, V38, P106, DOI 10.1016/j.jelectrocard.2004.10.009; PANZA JA, 1992, J AM COLL CARDIOL, V20, P1092, DOI 10.1016/0735-1097(92)90363-R; PERSKI A, 1988, AM HEART J, V116, P1369, DOI 10.1016/0002-8703(88)90469-3; Poole-Wilson PA, 2003, HEART, V89, P42, DOI 10.1136/heart.89.1.42; SUTTONTYRRELL K, 1993, STROKE, V24, P355, DOI 10.1161/01.STR.24.3.355	21	634	685	0	28	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 6	2008	372	9641					817	821		10.1016/S0140-6736(08)61171-X	http://dx.doi.org/10.1016/S0140-6736(08)61171-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	347FB	18757091				2022-12-28	WOS:000259124900024
J	Law, MR; Majumdar, SR; Soumerai, SB				Law, Michael R.; Majumdar, Sumit R.; Soumerai, Stephen B.			Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: controlled longitudinal study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PROMOTION	Objective To assess the impact of direct to consumer advertising of prescription drugs in the United States on Canadian prescribing rates for three heavily marketed drugs-etanercept, mometasone, and tegaserod. Design Controlled quasi-experimental study using interrupted time series analysis. Population Representative sample of 2700 Canadian pharmacies and prescription data from 50 US Medicaid programmes. Main outcome measures Differences in number of filled prescriptions per 10000 population per month between English speaking and French speaking (control) Canadian provinces before and after the start of direct to consumer advertising in the United States. Results Spending on direct to consumer advertising for study drugs ranged from $194m to $314m (104m- pound 169m; pound ((euro)131m-(euro)212m) over the study period. Prescription rates for etanercept and mometasone did not increase in English speaking provinces relative to French speaking controls after the start of direct to consumer advertising. In contrast, tegaserod prescriptions increased 42% (0.56 prescriptions/ 10 000 residents, 95% confidence interval 0.37 to 0.76) in English speaking provinces immediately after the start of US direct to consumer advertising. Uncontrolled analysis of US Medicaid data showed a larger 56% increase in tegaserod prescriptions. However, this increase did not persist over time in either country, despite continued advertising. Conclusions Exposure to US direct to consumer advertising transiently influenced both Canadian and US prescribing rates for tegaserod, a drug later withdrawn owing to safety concerns. The impact of direct to consumer advertising on drug use seems to be highly variable and probably depends on the characteristics of the advertised drug, the level of exposure to direct to consumer advertising, and the cultural context.	[Law, Michael R.; Soumerai, Stephen B.] Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; [Law, Michael R.; Soumerai, Stephen B.] Harvard Pilgrim Hlth Care, Boston, MA 02215 USA; [Majumdar, Sumit R.] Univ Alberta Hosp, Div Gen Internal Med, Dept Med, Walter Mackenzie Hlth Sci Ctr 2E3 07, Edmonton, AB T6G 2B7, Canada	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; University of Alberta	Law, MR (corresponding author), Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, 133 Brookline Ave,6th Floor, Boston, MA 02215 USA.	mlaw@post.harvard.edu			Thomas 0 Pyle Fellowship; Fellowship in Pharmaceutical Policy at Harvard Medical School; Social Sciences and Humanities Research Council of Canada; Alberta Heritage Foundation for Medical Research (health scholar); Canadian Institutes of Health Research (new investigator); Agency for Healthcare Research and Quality [U18HS010391]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS010391] Funding Source: NIH RePORTER	Thomas 0 Pyle Fellowship; Fellowship in Pharmaceutical Policy at Harvard Medical School; Social Sciences and Humanities Research Council of Canada(Social Sciences and Humanities Research Council of Canada (SSHRC)); Alberta Heritage Foundation for Medical Research (health scholar)(Alberta Heritage Foundation for Medical Research); Canadian Institutes of Health Research (new investigator)(Canadian Institutes of Health Research (CIHR)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	MRL is supported by the Thomas 0 Pyle Fellowship and the Fellowship in Pharmaceutical Policy at Harvard Medical School and by a Social Sciences and Humanities Research Council of Canada doctoral fellowship. SRM receives salary support from the Alberta Heritage Foundation for Medical Research (health scholar) and the Canadian Institutes of Health Research (new investigator). SBS is an investigator in the HMO Research Network Centers for Education and Research on Therapeutics, supported by the Agency for Healthcare Research and Quality (grant No. U18HS010391). The funding and data sources for this study had no role in study design; in the collection, analysis, and interpretation of data: in the writing of the report: and in the decision to submit the article for publication.	*APPL MAN, 2000, CAN ACC INS PRESCR M; Bradford WD, 2006, HEALTH AFFAIR, V25, P1371, DOI 10.1377/hlthaff.25.5.1371; Calfee JE, 2002, J LAW ECON, V45, P673, DOI 10.1086/374704; Cassels A, 2006, BRIT MED J, V332, P1469, DOI 10.1136/bmj.332.7556.1469-a; *CTR MED MED SERV, 2005, MED MAN CAR ENR REP; *CTR MED MED SERV, 2007, STAT DRUG UT DAT; Donohue JM, 2004, MED CARE, V42, P1176, DOI 10.1097/00005650-200412000-00004; Donohue JM, 2007, NEW ENGL J MED, V357, P673, DOI 10.1056/NEJMsa070502; Evans BW, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003960.pub3; Gilbody S, 2005, QUAL SAF HEALTH CARE, V14, P246, DOI 10.1136/qshc.2004.012781; Hollon MF, 2005, JAMA-J AM MED ASSOC, V293, P2030, DOI 10.1001/jama.293.16.2030; HOMER A, 1999, JAMA-J AM MED ASSOC, V281, P380; *IAG RES, 2006, PRESCR DRUG ADV BREA; *IAG RES, 2005, ADV PRESCR DRUGS IS; Iizuka T, 2004, J IND ECON, V52, P349, DOI 10.1111/j.0022-1821.2004.00230.x; Lexchin J, 2006, HEALTH POLICY, V79, P214, DOI 10.1016/j.healthpol.2005.12.015; Majumdar SR, 2003, AM J MED, V115, P467, DOI 10.1016/S0002-9343(03)00422-4; Mansfield PR, 2008, MED J AUSTRALIA, V188, P13, DOI 10.5694/j.1326-5377.2008.tb01496.x; MacKinnon BJ, 2007, CAN MED ASSOC J, V176, P1405, DOI 10.1503/cmaj.070483; Mintzes B, 2003, CAN MED ASSOC J, V169, P405; *NEW YORK AM MARK, 2005, EFF AW BRIEF EFF ZEL; Roger E.M, 2003, DIFFUSION INNOVATION, V5th; Rosenthal MB, 2003, FRONTIERS HLTH POLIC, V6, P1; SCHOEN C, 2004, HEALTH AFFAIR, pW4, DOI DOI 10.1377/HLTHAFF.W4.487; Shuchman M, 2007, NEW ENGL J MED, V356, P2236, DOI 10.1056/NEJMp078080; *STAT CAN, 2007, MED TOT INC FAM TYP; *STAT CAN, 2007, Q DEM EST; *STAT CAN, 2007, POP SEX AG GROUP PRO; *STAT CAN, LANG COMP CAN HIGHL; *STAT CAN, 2006, TEL VIEW DAT TABL; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x; WEISSMAN JS, 2003, HLTH AFF MILLWOOD S, pW3	32	40	40	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 6	2008	337	7669							a1055	10.1136/bmj.a1055	http://dx.doi.org/10.1136/bmj.a1055			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	351JP	18765444	Green Submitted, Green Published			2022-12-28	WOS:000259420900034
J	Price, JF; Stewart, MC; Deary, IJ; Murray, GD; Sandercock, P; Butcher, I; Fowkes, FGR				Price, Jackie F.; Stewart, Marlene C.; Deary, Ian J.; Murray, Gordon D.; Sandercock, Peter; Butcher, Isabella; Fowkes, F. Gerald R.		AAA Trialists	Low dose aspirin and cognitive function in middle aged to elderly adults: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ANKLE-BRACHIAL INDEX; CARDIOVASCULAR-DISEASE; PRIMARY PREVENTION; DECLINE; RISK; POPULATION; IMPAIRMENT; MORTALITY; EVENTS	Objective To determine the effects of tow dose aspirin on cognitive function in middle aged to elderly men and women at moderately increased cardiovascular risk. Design Randomised double blind placebo controlled trial. Setting Central Scotland. Participants 3350 men and women aged over 50 participating in the aspirin for asymptomatic atherosclerosis trial. Intervention Low dose aspirin (100 mg daily) or placebo for five years. Main outcome measures Tests of memory, executive function, non-verbal reasoning, mental flexibility, and information processing five years after randomisation, with test scores used to create a summary cognitive score (general factor). Results At baseline, mean vocabulary scores (an indicator of previous cognitive ability) were similar in the aspirin (30.9, SD 4.7) and placebo (31.1, SD 4.7) groups. In the primary intention to treat analysis, there was no significant difference at follow-up between the groups in the proportion achieving over the median general factor cognitive score (32.7% and 34.8% respectively, odds ratio 0.91, 95% confidence interval 0.79 to 1.05, P=0.20) or in mean scores on the individual cognitive tests. There were also no significant differences in change in cognitive ability over the five years in a subset of 504 who underwent detailed cognitive testing at baseline. Conclusion Low dose aspirin does not affect cognitive function in middle aged to elderly people at moderately increased cardiovascular risk. Trial registration ISRCTN 66587262.	[Price, Jackie F.; Stewart, Marlene C.; Murray, Gordon D.; Butcher, Isabella; Fowkes, F. Gerald R.] Univ Edinburgh, Div Community Hlth Sci, Edinburgh, Midlothian, Scotland; [Deary, Ian J.] Univ Edinburgh, Sch Philosophy Psychol & Language, Edinburgh, Midlothian, Scotland; [Sandercock, Peter] Univ Edinburgh, Dept Clin Neurosci, Edinburgh, Midlothian, Scotland	University of Edinburgh; University of Edinburgh; University of Edinburgh	Price, JF (corresponding author), Univ Edinburgh, Div Community Hlth Sci, Edinburgh, Midlothian, Scotland.	Jackie.Price@ed.ac.uk	Deary, Ian J/C-6297-2009; Lindley, Richard/B-8148-2013	Deary, Ian J/0000-0002-1733-263X; Lindley, Richard/0000-0002-0104-5679; Fox, Keith/0000-0002-0140-2752; Stewart, Marlene/0000-0001-7939-7001; Price, Jackie/0000-0003-3251-3970; Murray, Gordon/0000-0001-9866-4734	British Heart Foundation; Chief Scientist Office of the Scottish Executive; Medical Research Council [G0700704B] Funding Source: researchfish	British Heart Foundation(British Heart Foundation); Chief Scientist Office of the Scottish Executive; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Wellcome Trust. Core funding for the AAA Trial was provided by the British Heart Foundation and the Chief Scientist Office of the Scottish Executive. Aspirin and placebo were provided by Bayer HealthCare.	Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Berger JS, 2006, JAMA-J AM MED ASSOC, V295, P306, DOI 10.1001/jama.295.3.306; BRETELER MMB, 1994, BRIT MED J, V308, P1604, DOI 10.1136/bmj.308.6944.1604; Carroll J. B., 1993, HUMAN COGNITIVE ABIL, DOI DOI 1017/CBO9780511571312; CARSTAIRS V, 1989, COMMUNITY MED, V11, P210, DOI 10.1093/oxfordjournals.pubmed.a042469; Cleland JGF, 2002, BMJ-BRIT MED J, V324, P103, DOI 10.1136/bmj.324.7329.103; Cleland JGF, 2002, PROG CARDIOVASC DIS, V44, P275, DOI 10.1053/pcad.2002.31597; COONEY TM, 1988, J GERONTOL, V43, pP12, DOI 10.1093/geronj/43.1.P12; Crawford JR, 2001, PSYCHOL MED, V31, P451, DOI 10.1017/S0033291701003634; Durga J, 2007, LANCET, V369, P208, DOI 10.1016/S0140-6736(07)60109-3; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fourrier A, 1996, J CLIN EPIDEMIOL, V49, P1201, DOI 10.1016/0895-4356(96)00202-8; Heald CL, 2006, ATHEROSCLEROSIS, V189, P61, DOI 10.1016/j.atherosclerosis.2006.03.011; Hedden T, 2004, NAT REV NEUROSCI, V5, P87, DOI 10.1038/nrn1323; Henderson AS, 1997, INT J GERIATR PSYCH, V12, P926, DOI 10.1002/(SICI)1099-1166(199709)12:9<926::AID-GPS665>3.3.CO;2-P; Johnston SC, 2004, ANN INTERN MED, V140, P237, DOI 10.7326/0003-4819-140-4-200402170-00005; Kang JH, 2007, BMJ-BRIT MED J, V334, P987, DOI 10.1136/bmj.39166.597836.BE; Kang JH, 2003, NEUROLOGY, V60, P1591; Kavanagh S, 1999, BRIT J PSYCHIAT, V174, P539, DOI 10.1192/bjp.174.6.539; Lezak M.D., 2012, NEUROPSYCHOLOGICAL A; McLoone P, 2000, CARSTAIRS SCORES SCO; Nelson H., 1991, NATL ADULT READING T; Price JF, 2006, J AM GERIATR SOC, V54, P763, DOI 10.1111/j.1532-5415.2006.00702.x; Prince M, 1998, NEUROLOGY, V50, P374, DOI 10.1212/WNL.50.2.374; Rabbitt P, 2001, NEUROPSYCHOLOGIA, V39, P532, DOI 10.1016/S0028-3932(00)00099-3; Raven J.C., 1998, ADV PROGR MATRICES; Richards M, 1997, J NEUROL NEUROSUR PS, V62, P269, DOI 10.1136/jnnp.62.3.269; Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613; Rozzini R, 1996, J AM GERIATR SOC, V44, P1025, DOI 10.1111/j.1532-5415.1996.tb02932.x; SAAG KG, 1995, J RHEUMATOL, V22, P2142; Salthouse T, 2005, INTELLIGENCE, V33, P551, DOI 10.1016/j.intell.2005.05.007; Salthouse TA, 2004, INTELLIGENCE, V32, P541, DOI 10.1016/j.intell.2004.07.003; Spreen O., 1991, PROFILE TEST RESULTS; Wardlaw JM, 2003, STROKE, V34, P806, DOI 10.1161/01.STR.0000058480.77236.B3; Wechsler D., 1998, WECHSLER ADULT INTEL; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	36	46	52	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 6	2008	337	7669							a1198	10.1136/bmj.a1198	http://dx.doi.org/10.1136/bmj.a1198			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	351JP	18762476	Green Published, hybrid, Green Submitted			2022-12-28	WOS:000259420900033
J	Berns, DM; Rudner, MS; Valenzuela, SO; Berggren, KK; Oliver, WD; Levitov, LS; Orlando, TP				Berns, David M.; Rudner, Mark S.; Valenzuela, Sergio O.; Berggren, Karl K.; Oliver, William D.; Levitov, Leonid S.; Orlando, Terry P.			Amplitude spectroscopy of a solid-state artificial atom	NATURE			English	Article							MACROSCOPIC QUANTUM STATES; SUPERCONDUCTING QUBIT; MAGNETIZATION; SUPERPOSITION; DYNAMICS	The energy- level structure of a quantum system, which has a fundamental role in its behaviour, can be observed as discrete lines and features in absorption and emission spectra. Conventionally, spectra are measured using frequency spectroscopy, whereby the frequency of a harmonic electromagnetic driving field is tuned into resonance with a particular separation between energy levels. Although this technique has been successfully employed in a variety of physical systems, including natural and artificial atoms and molecules, its application is not universally straightforward and becomes extremely challenging for frequencies in the range of tens to hundreds of gigahertz. Here we introduce a complementary approach, amplitude spectroscopy, whereby a harmonic driving field sweeps an artificial atom through the avoided crossings between energy levels at a fixed frequency. Spectroscopic information is obtained from the amplitude dependence of the system's response, thereby overcoming many of the limitations of a broadband- frequency- based approach. The resulting 'spectroscopy diamonds', the regions in parameter space where transitions between specific pairs of levels can occur, exhibit interference patterns and population inversion that serve to distinguish the atom's spectrum. Amplitude spectroscopy provides a means of manipulating and characterizing systems over an extremely broad bandwidth, using only a single driving frequency that may be orders of magnitude smaller than the energy scales being probed.	[Berns, David M.; Oliver, William D.; Orlando, Terry P.] MIT, Elect Res Lab, Cambridge, MA 02139 USA; [Berns, David M.; Rudner, Mark S.; Levitov, Leonid S.] MIT, Dept Phys, Cambridge, MA 02139 USA; [Valenzuela, Sergio O.] MIT, Francis Bitter Natl Magnet Lab, Cambridge, MA 02139 USA; [Berggren, Karl K.; Oliver, William D.] MIT, Lincoln Lab, Lexington, MA 02420 USA; [Orlando, Terry P.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Lincoln Laboratory; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Oliver, WD (corresponding author), MIT, Elect Res Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	oliver@ll.mit.edu	Valenzuela, Sergio/A-1169-2007; Rudner, Mark/C-9325-2015	Valenzuela, Sergio/0000-0002-4632-8891; Rudner, Mark/0000-0002-5150-6234; Levitov, Leonid/0000-0002-4268-731X	Air Force Office of Scientific Research and the Laboratory for Physical Sciences [F49620-01-1-0457]; Defense University Research Initiative in Nanotechnology; US government; US Department of Defence under Air Force Contract [FA8721-05-C-0002]	Air Force Office of Scientific Research and the Laboratory for Physical Sciences(United States Department of DefenseAir Force Office of Scientific Research (AFOSR)); Defense University Research Initiative in Nanotechnology; US government; US Department of Defence under Air Force Contract(United States Department of Defense)	We thank A. Shytov, J. Bylander, B. Turek, A. J. Kerman and J. Sage for discussions and D. Baker, V. Bolkhovsky, G. Fitch, E. Macedo, P. Murphy, K. Parrillo, R. Slattery and T. Weir at Lincoln Laboratory, MIT, for technical assistance. This work was supported by the Air Force Office of Scientific Research and the Laboratory for Physical Sciences (F49620-01-1-0457) under the Defense University Research Initiative in Nanotechnology programme, and by the US government. The work at Lincoln Laboratory was sponsored by the US Department of Defence under Air Force Contract No. FA8721-05-C-0002.	Ashhab S, 2007, PHYS REV A, V75, DOI 10.1103/PhysRevA.75.063414; Astafiev O, 2007, NATURE, V449, P588, DOI 10.1038/nature06141; Berkley AJ, 2003, SCIENCE, V300, P1548, DOI 10.1126/science.1084528; Berns DM, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.150502; Chiorescu I, 2004, NATURE, V431, P159, DOI 10.1038/nature02831; Chiorescu I, 2003, SCIENCE, V299, P1869, DOI 10.1126/science.1081045; CLARKE J, 1988, SCIENCE, V239, P992, DOI 10.1126/science.239.4843.992; Claudon J, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.187003; COHENTANNOUDJI C, 1992, ATOM PHOTON INTERACT, pCH6; Collin R.E., 2001, FDN MICROWAVE ENG; Friedman JR, 2000, NATURE, V406, P43, DOI 10.1038/35017505; Friedman JR, 1996, PHYS REV LETT, V76, P3830, DOI 10.1103/PhysRevLett.76.3830; Hanson R, 2007, REV MOD PHYS, V79, P1217, DOI 10.1103/RevModPhys.79.1217; Izmalkov A, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.037003; Izmalkov A, 2004, EUROPHYS LETT, V65, P844, DOI 10.1209/epl/i2003-10200-6; Johansson J, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.127006; Katz N, 2006, SCIENCE, V312, P1498, DOI 10.1126/science.1126475; Lang F, 2008, NAT PHYS, V4, P223, DOI 10.1038/nphys838; Lupascu A, 2007, NAT PHYS, V3, P119, DOI 10.1038/nphys509; Majer J, 2007, NATURE, V449, P443, DOI 10.1038/nature06184; Mark M, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.113201; Mark M, 2007, PHYS REV A, V76, DOI 10.1103/PhysRevA.76.042514; Mooij JE, 1999, SCIENCE, V285, P1036, DOI 10.1126/science.285.5430.1036; NAKAMURA H, 2001, NONADIABATIC TRANSIT, pCH12; Nakamura Y, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.246601; Nakamura Y, 1999, NATURE, V398, P786, DOI 10.1038/19718; Niskanen AO, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.174523; Oliver WD, 2005, SCIENCE, V310, P1653, DOI 10.1126/science.1119678; Orlando TP, 1999, PHYS REV B, V60, P15398, DOI 10.1103/PhysRevB.60.15398; Plourde BLT, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.060506; RUDNER MS, 2008, QUANTUM PHASE TOMOGR; Saito S, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.107001; SCHAWLOW AL, 1982, REV MOD PHYS, V54, P697, DOI 10.1103/RevModPhys.54.697; Siddiqi I, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.207002; Sillanpaa M, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.187002; Sillanpaa MA, 2007, NATURE, V449, P438, DOI 10.1038/nature06124; Stueckelberg E. C. G., 1932, HELV PHYS ACTA, V5, P369; Thomas L, 1996, NATURE, V383, P145, DOI 10.1038/383145a0; THOMPSON RC, 1985, REP PROG PHYS, V48, P531, DOI 10.1088/0034-4885/48/4/003; Valenzuela SO, 2006, SCIENCE, V314, P1589, DOI 10.1126/science.1134008; van der Wal CH, 2000, SCIENCE, V290, P773, DOI 10.1126/science.290.5492.773; van der Wiel WG, 2003, REV MOD PHYS, V75, P1, DOI 10.1103/RevModPhys.75.1; Vion D, 2002, SCIENCE, V296, P886, DOI 10.1126/science.1069372; Wallraff A, 2004, NATURE, V431, P162, DOI 10.1038/nature02851; Wernsdorfer W, 1999, SCIENCE, V284, P133, DOI 10.1126/science.284.5411.133; Wilson CM, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.257003; Wubs M, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.200404; You JQ, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.047001; Yu Y, 2002, SCIENCE, V296, P889, DOI 10.1126/science.1069452	50	120	123	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	2008	455	7209					51	U32		10.1038/nature07262	http://dx.doi.org/10.1038/nature07262			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	343XS	18769433	Green Submitted			2022-12-28	WOS:000258890200035
J	Chakravarti, A				Chakravarti, Aravinda			Victor Almon McKusick (1921-2008) - Obituary	NATURE			English	Biographical-Item									[Chakravarti, Aravinda] Johns Hopkins Univ, McKusick Nathans Inst Genet Med, Baltimore, MD 21093 USA	Johns Hopkins University	Chakravarti, A (corresponding author), Johns Hopkins Univ, McKusick Nathans Inst Genet Med, Baltimore, MD 21093 USA.	aravinda@jhmi.edu							0	3	3	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2008	455	7209					46	46		10.1038/455046a	http://dx.doi.org/10.1038/455046a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	343XS	18769431				2022-12-28	WOS:000258890200033
J	Windecker, S; Serruys, PW; Wandel, S; Buszman, P; Trznadel, S; Linke, A; Lenk, K; Ischinger, T; Klauss, V; Eberli, F; Corti, R; Wijns, W; Morice, MC; di Mario, C; Davies, S; van Geuns, RJ; Eerdmans, P; van Es, GA; Meier, B; Juni, P				Windecker, Stephan; Serruys, Patrick W.; Wandel, Simon; Buszman, Pawel; Trznadel, Stanislaw; Linke, Axel; Lenk, Karsten; Ischinger, Thomas; Klauss, Volker; Eberli, Franz; Corti, Roberto; Wijns, William; Morice, Marie Claude; di Mario, Carlo; Davies, Simon; van Geuns, Robert-Jan; Eerdmans, Pedro; van Es, Gerrit-Anne; Meier, Bernhard; Jueni, Peter			Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial	LANCET			English	Article							BARE-METAL STENTS; ARTERY-DISEASE; CLINICAL-TRIALS; UNCOATED STENTS; LATE THROMBOSIS; OFF-LABEL; METAANALYSIS; OUTCOMES	Background A novel stent platform eluting biolimus, a sirolimus analogue, from a biodegradable polymer showed promising results in preliminary studies. We compared the safety and efficacy of a biolimus-eluting stent (with biodegradable polymer) with a sirolimus-eluting stent (with durable polymer). Methods We undertook a multicentre, assessor-blind, non-inferiority study in ten European centres. 1707 patients aged 18 years or older with chronic stable coronary artery disease or acute coronary syndromes were centrally randomised by a computer-generated allocation sequence to treatment with either biolimus-eluting (n=857) or sirolimus-eluting (n=850) stents. The primary endpoint was a composite of cardiac death, myocardial infarction, or clinically-indicated target vessel revascularisation within 9 months. Analysis was by intention to treat. 427 patients were randomly allocated to angiographic follow-up, with in-stent percentage diameter stenosis as principal outcome measure at 9 months. The trial is registered with ClinicalTrials.gov, number NCT00389220. Findings We analysed all randomised patients. Biolimus-eluting stents were non-inferior to sirolimus-eluting stents for the primary endpoint at 9 months (79 [9%] patients vs 89 [11%], rate ratio 0 . 88 [95% Cl 0 . 64-1.19], p for non-inferiority=0.003, p for superiority=0 . 39). Frequency of cardiac death (14 [1.6%] vs 21 [2.5%], p for superiority=0.22), myocardial infarction (49 [5.7%] vs 39 [4.6%], p=0.30), and clinically-indicated target vessel revascularisation (38 [4.4%] vs 47 [5.5%], p= 0. 29) were similar for both stent types. 168 (79%) patients in the biolimus-eluting group and 167 (78%) in the sirolimus-eluting group had data for angiographic follow-up available. Biolimus-eluting stents were non-inferior to sirolimus-eluting stents in in-stent percentage diameter stenosis (20.9% vs 23.3%, difference -2.2% [95% Cl -6.0 to 1. 6], p for non-inferiority=0. 001, p for superiority=0.26). Interpretation Our results suggest that a stent eluting biolimus from a biodegradable polymer represents a safe and effective alternative to a stent eluting sirolimus from a durable polymer in patients with chronic stable coronary artery disease or acute coronary syndromes. Funding Biosensors Europe SA, Switzerland.	[Windecker, Stephan; Meier, Bernhard] Univ Hosp Bern, Dept Cardiol, CH-3010 Bern, Switzerland; [Windecker, Stephan; Wandel, Simon; Jueni, Peter] Univ Hosp Bern, CTU Bern, CH-3010 Bern, Switzerland; [Serruys, Patrick W.; van Geuns, Robert-Jan] Erasmus Univ, Thoraxctr, NL-3000 DR Rotterdam, Netherlands; [Wandel, Simon; Jueni, Peter] Univ Bern, Inst Social & Prevent Med, Bern, Switzerland; [Buszman, Pawel; Trznadel, Stanislaw] Med Univ Silesia, Katowice, Poland; [Linke, Axel; Lenk, Karsten] Herzzentrum Leipzig, Leipzig, Germany; [Ischinger, Thomas] Hosp Bogenhausen, Dept Cardiol, Munich, Germany; [Klauss, Volker] Univ Hosp Munich Innenstadt, Dept Cardiol, Munich, Germany; [Eberli, Franz] Triemli Spital Zurich, Dept Cardiol, Zurich, Switzerland; [Corti, Roberto] Univ Zurich Hosp, Dept Cardiol, CH-8091 Zurich, Switzerland; [Wijns, William] Onze Lieve Vrouwe Ziekenhuis, Dept Cardiol, Aalst, Belgium; [Morice, Marie Claude] Inst Cardiovasc, Paris, France; [di Mario, Carlo; Davies, Simon] Royal Brompton Hosp, Dept Cardiol, London SW3 6LY, England; [Eerdmans, Pedro] Biosensors Europe SA, Morges, Switzerland; [van Es, Gerrit-Anne] Cardialysis, Rotterdam, Netherlands	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; Erasmus University Rotterdam; Erasmus MC; University of Bern; Medical University Silesia; Heart Center Leipzig GMBH; Munchen Klinik; University of Munich; Triemli Hospital; University of Zurich; University Zurich Hospital; Royal Brompton Hospital; Cardialysis	Windecker, S (corresponding author), Univ Hosp Bern, Dept Cardiol, CH-3010 Bern, Switzerland.	stephan.windecker@insel.ch	Juni, Peter/Q-8700-2016; Di Mario, Carlo/K-5185-2018; van Geuns, Robert/AAR-6386-2021; van Geuns, Robert-Jan M/N-7976-2017; Buszman, Pawel/AAX-9336-2020	Juni, Peter/0000-0002-5985-0670; Di Mario, Carlo/0000-0002-4461-2055; van Geuns, Robert-Jan M/0000-0003-2943-5932; , Simon/0000-0002-1442-597X; Buszman, Pawel/0000-0002-2511-4077; Wijns, William/0000-0002-7267-4376	Biosensors Europe SA, Switzerland; CTU Bern; Bern University Hospital; Institute of Social and Preventive Medicine; University of Bern; Swiss National Science Foundation	Biosensors Europe SA, Switzerland; CTU Bern; Bern University Hospital; Institute of Social and Preventive Medicine; University of Bern; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	The LEADERS trial was funded by Biosensors Europe SA, Switzerland. The analysis was funded by intramural grants provided by CTU Bern, Bern University Hospital, the Institute of Social and Preventive Medicine, University of Bern, and the Swiss National Science Foundation to PJ. PJ is a PROSPER fellow funded by the Swiss National Science Foundation. CTU Bern is supported by the Swiss National Science Foundation. We thank Ton de Vries for confinuation of statistical analyses and Eveline Nuesch for additional analyses performed during revision of the report.	Bavry AA, 2006, AM J MED, V119, P1056, DOI 10.1016/j.amjmed.2006.01.023; Beohar N, 2007, JAMA-J AM MED ASSOC, V297, P1992, DOI 10.1001/jama.297.18.1992; Daemen J, 2007, LANCET, V369, P667, DOI 10.1016/S0140-6736(07)60314-6; Grube E, 2006, EXPERT REV MED DEVIC, V3, P731, DOI 10.1586/17434440.3.6.731; Grube Eberhard, 2005, EuroIntervention, V1, P53; Kaiser C, 2005, LANCET, V366, P921, DOI 10.1016/S0140-6736(05)67221-2; Kastrati A, 2005, JAMA-J AM MED ASSOC, V294, P819, DOI 10.1001/jama.294.7.819; Kastrati A, 2007, NEW ENGL J MED, V356, P1030, DOI 10.1056/NEJMoa067484; Kereiakes DJ, 2005, J AM COLL CARDIOL, V45, P1206, DOI 10.1016/j.jacc.2005.01.005; Kirkwood BR, 2003, ESSENTIAL MED STAT; Krucoff MW, 2008, J AM COLL CARDIOL, V51, P1543, DOI 10.1016/j.jacc.2008.01.020; Laarman GJ, 2006, NEW ENGL J MED, V355, P1105, DOI 10.1056/NEJMoa062598; Maisel WH, 2007, NEW ENGL J MED, V356, P981, DOI 10.1056/NEJMp068305; Moreno R, 2007, EUR HEART J, V28, P1583, DOI 10.1093/eurheartj/ehl423; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; Morice MC, 2006, JAMA-J AM MED ASSOC, V295, P895, DOI 10.1001/jama.295.8.895; Moses JW, 2003, NEW ENGL J MED, V349, P1315, DOI 10.1056/NEJMoa035071; Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I; Prineas R., 1982, MINNESOTA CODE MANUA; Schomig A, 2007, J AM COLL CARDIOL, V50, P1373, DOI 10.1016/j.jacc.2007.06.047; Serruys PW, 2006, NEW ENGL J MED, V354, P483, DOI 10.1056/NEJMra051091; Spaulding C, 2006, NEW ENGL J MED, V355, P1093, DOI 10.1056/NEJMoa062006; Stettler C, 2007, LANCET, V370, P937, DOI 10.1016/S0140-6736(07)61444-5; Stone GW, 2008, JAMA-J AM MED ASSOC, V299, P1903, DOI 10.1001/jama.299.16.1903; Stone GW, 2007, NEW ENGL J MED, V356, P998, DOI 10.1056/NEJMoa067193; Stone GW, 2004, NEW ENGL J MED, V350, P221, DOI 10.1056/NEJMoa032441; Win HK, 2007, JAMA-J AM MED ASSOC, V297, P2001, DOI 10.1001/jama.297.18.2001; Windecker S, 2005, NEW ENGL J MED, V353, P653, DOI 10.1056/NEJMoa051175; Wiviott SD, 2007, NEW ENGL J MED, V357, P2001, DOI 10.1056/NEJMoa0706482	30	503	530	1	46	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP-OCT	2008	372	9644					1163	1173		10.1016/S0140-6736(08)61244-1	http://dx.doi.org/10.1016/S0140-6736(08)61244-1			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	355UN	18765162				2022-12-28	WOS:000259734700031
J	Wang, WJ; Black, SS; Edwards, MD; Miller, S; Morrison, EL; Bartlett, W; Dong, CJ; Naismith, JH; Booth, IR				Wang, Wenjian; Black, Susan S.; Edwards, Michelle D.; Miller, Samantha; Morrison, Emma L.; Bartlett, Wendy; Dong, Changjiang; Naismith, James H.; Booth, Ian R.			The structure of an open form of an E. coli mechanosensitive channel at 3.45 angstrom resolution	SCIENCE			English	Article							CRYSTAL-STRUCTURE; ACETYLCHOLINE-RECEPTOR; ION-CHANNEL; K+ CHANNEL; MSCS; MECHANISM; COOPERATIVITY; DOMAIN; WATER; CYCLE	How ion channels are gated to regulate ion flux in and out of cells is the subject of intense interest. The Escherichia coli mechanosensitive channel, MscS, opens to allow rapid ion efflux, relieving the turgor pressure that would otherwise destroy the cell. We present a 3.45 angstrom-resolution structure for the MscS channel in an open conformation. This structure has a pore diameter of similar to 13 angstroms created by substantial rotational rearrangement of the three transmembrane helices. The structure suggests a molecular mechanism that underlies MscS gating and its decay of conductivity during prolonged activation. Support for this mechanism is provided by single-channel analysis of mutants with altered gating characteristics.	[Wang, Wenjian; Dong, Changjiang; Naismith, James H.] Univ St Andrews, Ctr Biomol Sci, St Andrews KY16 9ST, Fife, Scotland; [Black, Susan S.; Edwards, Michelle D.; Miller, Samantha; Morrison, Emma L.; Bartlett, Wendy; Booth, Ian R.] Univ Aberdeen, Sch Med Sci, Inst Med Sci, Aberdeen AB25 2ZD, Scotland	University of St Andrews; University of Aberdeen	Naismith, JH (corresponding author), Univ St Andrews, Ctr Biomol Sci, N Haugh, St Andrews KY16 9ST, Fife, Scotland.	naismith@st-and.ac.uk; i.r.booth@abdn.ac.uk	Miller, Samantha/A-4799-2010; Naismith, James Henderson/AAB-8614-2020; Naismith, James Henderson/H-3408-2012	Naismith, James Henderson/0000-0001-6744-5061; Naismith, James Henderson/0000-0001-6744-5061; Miller, Samantha/0000-0002-8223-9693	Wellcome Trust [GR077564MA, 040174]; Medical Research Council [G0400277]; Unilever (UK); Biotechnology Biological Sciences Research Council (BBSRC) [BB/F003455/1]; Scottish Funding Council; Biotechnology and Biological Sciences Research Council [BB/F003455/1] Funding Source: researchfish; BBSRC [BB/F003455/1] Funding Source: UKRI; MRC [G0400277] Funding Source: UKRI	Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Unilever (UK)(Unilever); Biotechnology Biological Sciences Research Council (BBSRC)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Scottish Funding Council; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Our research was supported by the Wellcome Trust ( grants GR077564MA and 040174), Medical Research Council ( G0400277), Unilever ( UK), and Biotechnology Biological Sciences Research Council (BBSRC) (BB/F003455/1). Structural biology used the facilities of the Scottish Structural Proteomics Facility funded by the Scottish Funding Council and BBSRC. We thank K. Johnson, T. Rasmussen, and F. Flett for their contributions to this work; D. Rees and R. Bass for advice on crystallization and for pre- release of x-ray intensities; and A. Leslie for a critical reading of the manuscript. Coordinates and data have been deposited in the Protein Data Bank (www. rcsb. org) with accession number 2vv5.	Aiyar J, 1996, J BIOL CHEM, V271, P31013, DOI 10.1074/jbc.271.49.31013; Akitake B, 2005, J GEN PHYSIOL, V125, P143, DOI 10.1085/jgp.200409198; Akitake B, 2007, NAT STRUCT MOL BIOL, V14, P1141, DOI 10.1038/nsmb1341; Anishkin A, 2004, BIOPHYS J, V86, P2883, DOI 10.1016/S0006-3495(04)74340-4; Bass RB, 2002, SCIENCE, V298, P1582, DOI 10.1126/science.1077945; Beckstein O, 2003, P NATL ACAD SCI USA, V100, P7063, DOI 10.1073/pnas.1136844100; Beckstein O, 2006, PHYS BIOL, V3, P147, DOI 10.1088/1478-3975/3/2/007; Booth IR, 2003, BIOCHEMISTRY-US, V42, P10045, DOI 10.1021/bi034953w; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Dong CJ, 2006, NATURE, V444, P226, DOI 10.1038/nature05267; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; Edwards MD, 2005, NAT STRUCT MOL BIOL, V12, P113, DOI 10.1038/nsmb895; Edwards MD, 2008, BIOPHYS J, V94, P3003, DOI 10.1529/biophysj.107.123448; FILATOV GN, 1995, MOL PHARMACOL, V48, P379; HOROVITZ A, 1990, J MOL BIOL, V214, P613, DOI 10.1016/0022-2836(90)90275-Q; HOROVITZ A, 1990, J MOL BIOL, V216, P1031, DOI 10.1016/S0022-2836(99)80018-7; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Koprowski P, 1998, J MEMBRANE BIOL, V164, P253, DOI 10.1007/s002329900410; Kung C, 2005, NATURE, V436, P647, DOI 10.1038/nature03896; Kurata HT, 2006, PROG BIOPHYS MOL BIO, V92, P185, DOI 10.1016/j.pbiomolbio.2005.10.001; Levina N, 1999, EMBO J, V18, P1730, DOI 10.1093/emboj/18.7.1730; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Long SB, 2005, SCIENCE, V309, P903, DOI 10.1126/science.1116270; Long SB, 2007, NATURE, V450, P376, DOI 10.1038/nature06265; Miller S, 2003, J BIOL CHEM, V278, P32246, DOI 10.1074/jbc.M303188200; Miller S, 2003, EMBO J, V22, P36, DOI 10.1093/emboj/cdg011; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Nomura T, 2008, BIOPHYS J, V94, P1638, DOI 10.1529/biophysj.107.114785; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; SERRANO L, 1990, BIOCHEMISTRY-US, V29, P9343, DOI 10.1021/bi00492a006; Smart OS, 1996, J MOL GRAPH MODEL, V14, P354, DOI 10.1016/S0263-7855(97)00009-X; Steinbacher S, 2007, CURR TOP MEMBR, V58, P1, DOI 10.1016/S1063-5823(06)58001-9; Sukharev S, 2002, BIOPHYS J, V83, P290, DOI 10.1016/S0006-3495(02)75169-2; Sukharev SI, 1999, J GEN PHYSIOL, V113, P525, DOI 10.1085/jgp.113.4.525	36	162	165	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2008	321	5893					1179	1183		10.1126/science.1159262	http://dx.doi.org/10.1126/science.1159262			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341ZM	18755969	Green Accepted			2022-12-28	WOS:000258754400035
J	Bhoj, VG; Chen, ZJ				Bhoj, Vijay G.; Chen, Zhijian J.			Linking retroelements to autoimmunity	CELL			English	Editorial Material							AICARDI-GOUTIERES-SYNDROME; DNA EXONUCLEASE TREX1; MUTATIONS	In this issue, Stetson et al. (2008) report a mechanism by which host cells avert an autoimmune response to self-nucleic acids. They show that the nuclease Trex1 prevents the accumulation of DNA derived from endogenous retroelements that, if left unchecked, trigger elevated production of type I interferons leading to autoimmunity.	[Bhoj, Vijay G.; Chen, Zhijian J.] Univ Texas SW Med Ctr Dallas, Dept Biol Mol, Dallas, TX 75390 USA; [Chen, Zhijian J.] Univ Texas SW Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas	Chen, ZJ (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Biol Mol, Dallas, TX 75390 USA.	zhijian.chen@utsouthwestern.edu	Chen, Zhijian/C-6039-2012	Chen, Zhijian/0000-0002-8475-8251	NIH; Welch Foundation	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Welch Foundation(The Welch Foundation)	We thank J. Cabrera for expert assistance in preparation of the figure. Research in the Chen laboratory is supported by grants from the NIH and the Welch Foundation. Z. J. C. is an HHMI investigator.	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Chowdhury D, 2006, MOL CELL, V23, P133, DOI 10.1016/j.molcel.2006.06.005; Crow YJ, 2006, NAT GENET, V38, P910, DOI 10.1038/ng1842; Crow YJ, 2006, NAT GENET, V38, P917, DOI 10.1038/ng1845; Lee-Kirsch MA, 2007, NAT GENET, V39, P1065, DOI 10.1038/ng2091; Mazur DJ, 1999, J BIOL CHEM, V274, P19655, DOI 10.1074/jbc.274.28.19655; Morita M, 2004, MOL CELL BIOL, V24, P6719, DOI 10.1128/MCB.24.15.6719-6727.2004; Richards A, 2007, NAT GENET, V39, P1068, DOI 10.1038/ng2082; Yang YG, 2007, CELL, V131, P873, DOI 10.1016/j.cell.2007.10.017	9	16	16	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 22	2008	134	4					569	571		10.1016/j.cell.2008.08.010	http://dx.doi.org/10.1016/j.cell.2008.08.010			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SR	18724930	Bronze			2022-12-28	WOS:000258665800010
J	Dix, MM; Simon, GM; Cravatt, BF				Dix, Melissa M.; Simon, Gabriel M.; Cravatt, Benjamin F.			Global mapping of the topography and magnitude of proteolytic events in apoptosis	CELL			English	Article							CASPASE-MEDIATED ACTIVATION; 2-DIMENSIONAL GEL-ELECTROPHORESIS; QUANTITATIVE PROTEOME ANALYSIS; AMINO-ACIDS; SUBSTRATE; IDENTIFICATION; PROTEASES; PROTEINS; CLEAVAGE; DISCOVERY	Proteolysis is a key regulatory process that promotes the (in) activation, translocation, and/or degradation of proteins. As such, there is considerable interest in methods to comprehensively characterize proteolytic pathways in biological systems. Here, we describe a robust and versatile proteomic platform that enables direct visualization of the topography and magnitude of proteolytic events on a global scale. We use this method to generate a proteome-wide map of proteolytic events induced by the intrinsic apoptotic pathway. This profile contained 91 characterized caspase substrates as well as 170 additional proteins not previously known to be cleaved during apoptosis. Surprisingly, the vast majority of proteolyzed proteins, regardless of the extent of cleavage, yielded persistent fragments that correspond to discrete protein domains, suggesting that the generation of active effector proteins may be a principal function of apoptotic proteolytic cascades.	[Dix, Melissa M.; Simon, Gabriel M.; Cravatt, Benjamin F.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; [Dix, Melissa M.; Simon, Gabriel M.; Cravatt, Benjamin F.] Scripps Res Inst, Dept Physiol Chem, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Cravatt, BF (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	cravatt@scripps.edu			National Institutes of Health [CA087660]; ARCS Foundation; Koshland Graduate Fellowship; Skaggs Institute for Chemical Biology; NATIONAL CANCER INSTITUTE [R01CA087660, R37CA087660] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ARCS Foundation; Koshland Graduate Fellowship; Skaggs Institute for Chemical Biology; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We gratefully acknowledge Andrew Su for programming assistance. This work was supported by National Institutes of Health (CA087660), the ARCS Foundation (G. M. S.), a Koshland Graduate Fellowship in Enzyme Biochemistry (G. M. S.), and the Skaggs Institute for Chemical Biology.	Abdel-Rahman HM, 2004, BIOL CHEM, V385, P1035, DOI 10.1515/BC.2004.134; Abud HE, 2004, CELL DEATH DIFFER, V11, P797, DOI 10.1038/sj.cdd.4401455; Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Bredemeyer AJ, 2004, P NATL ACAD SCI USA, V101, P11785, DOI 10.1073/pnas.0402353101; Brockstedt E, 1998, J BIOL CHEM, V273, P28057, DOI 10.1074/jbc.273.43.28057; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Correia JD, 2007, J BIOL CHEM, V282, P12557, DOI 10.1074/jbc.M609587200; Corthals GL, 2000, ELECTROPHORESIS, V21, P1104, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1104::AID-ELPS1104>3.3.CO;2-3; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; Craig R, 2005, RAPID COMMUN MASS SP, V19, P1844, DOI 10.1002/rcm.1992; Dean RA, 2007, MOL CELL PROTEOMICS, V6, P611, DOI 10.1074/mcp.M600341-MCP200; Dong MQ, 2007, SCIENCE, V317, P660, DOI 10.1126/science.1139952; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Enoksson M, 2007, J PROTEOME RES, V6, P2850, DOI 10.1021/pr0701052; Feng GP, 2002, AM J PHYSIOL-GASTR L, V282, pG825, DOI 10.1152/ajpgi.00467.2001; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Gerner C, 2000, J BIOL CHEM, V275, P39018, DOI 10.1074/jbc.M006495200; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Gygi SP, 2000, P NATL ACAD SCI USA, V97, P9390, DOI 10.1073/pnas.160270797; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; Jin ZY, 2005, CANCER BIOL THER, V4, P139, DOI 10.4161/cbt.4.2.1508; Ju WJ, 2007, P NATL ACAD SCI USA, V104, P14294, DOI 10.1073/pnas.0702251104; Keller UAD, 2007, BIOL CHEM, V388, P1159, DOI 10.1515/BC.2007.146; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; Kridel SJ, 2001, J BIOL CHEM, V276, P20572, DOI 10.1074/jbc.M100900200; Kuster B, 2005, NAT REV MOL CELL BIO, V6, P577, DOI 10.1038/nrm1683; Lee AY, 2004, PROTEOMICS, V4, P3429, DOI 10.1002/pmic.200400979; Li X, 2007, J PROTEOME RES, V6, P1190, DOI 10.1021/pr060559j; Liu HB, 2004, ANAL CHEM, V76, P4193, DOI 10.1021/ac0498563; Lohaus C, 2007, J PROTEOME RES, V6, P105, DOI 10.1021/pr060247g; Luthi AU, 2007, CELL DEATH DIFFER, V14, P641, DOI 10.1038/sj.cdd.4402103; Matrisian L.M., 1990, Current Topics in Developmental Biology, V24, P219, DOI 10.1016/S0070-2153(08)60089-7; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; McDonald L, 2005, NAT METHODS, V2, P955, DOI 10.1038/NMETH811; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Old WM, 2005, MOL CELL PROTEOMICS, V4, P1487, DOI 10.1074/mcp.M500084-MCP200; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; Riewald M, 2001, P NATL ACAD SCI USA, V98, P7742, DOI 10.1073/pnas.141126698; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Schilling O, 2007, CURR OPIN CHEM BIOL, V11, P36, DOI 10.1016/j.cbpa.2006.11.037; Schmidt F, 2007, ELECTROPHORESIS, V28, P4359, DOI 10.1002/elps.200700119; Shi R, 2007, J PROTEOME RES, V6, P2963, DOI 10.1021/pr0605668; Thiede B, 2006, PROTEOMICS, V6, P614, DOI 10.1002/pmic.200500120; Thiede B, 2005, PROTEOMICS, V5, P2123, DOI 10.1002/pmic.200401110; Timmer JC, 2007, CELL DEATH DIFFER, V14, P66, DOI 10.1038/sj.cdd.4402059; Timmer JC, 2007, BIOCHEM J, V407, P41, DOI 10.1042/BJ20070775; Turgeon VL, 1997, BRAIN RES REV, V25, P85, DOI 10.1016/S0165-0173(97)00015-5; Van Damme P, 2005, NAT METHODS, V2, P771, DOI 10.1038/NMETH792; van Kempen LCL, 2006, EUR J CANCER, V42, P728, DOI 10.1016/j.ejca.2006.01.004; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904	52	281	289	1	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	2008	134	4					679	691		10.1016/j.cell.2008.06.038	http://dx.doi.org/10.1016/j.cell.2008.06.038			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SR	18724940	Green Accepted, Bronze			2022-12-28	WOS:000258665800020
J	Schuldiner, M; Metz, J; Schmid, V; Denic, V; Rakwalska, M; Schmitt, HD; Schwappach, B; Weissman, JS				Schuldiner, Maya; Metz, Jutta; Schmid, Volker; Denic, Vladimir; Rakwalska, Magdalena; Schmitt, Hans Dieter; Schwappach, Blanche; Weissman, Jonathan S.			The GET complex mediates insertion of tail-anchored proteins into the ER membrane	CELL			English	Article							SIGNAL RECOGNITION PARTICLE; ENDOPLASMIC-RETICULUM MEMBRANE; SACCHAROMYCES-CEREVISIAE; NUCLEAR-ENVELOPE; GLOBAL ANALYSIS; YEAST; GOLGI; TRANSLOCATION; SED5; IDENTIFICATION	Tail-anchored (TA) proteins, defined by the presence of a single C-terminal transmembrane domain (TMD), play critical roles throughout the secretory pathway and in mitochondria, yet the machinery responsible for their proper membrane insertion remains poorly characterized. Here we show that Get3, the yeast homolog of the TA-interacting factor Asna1/Trc40, specifically recognizes TMDs of TA proteins destined for the secretory pathway. Get3 recognition represents a key decision step, whose loss can lead to misinsertion of TA proteins into mitochondria. Get3-TA protein complexes are recruited for endoplasmic reticulum (ER) membrane insertion by the Get1/Get2 receptor. In vivo, the absence of Get1/Get2 leads to cytosolic aggregation of Get3-TA complexes and broad defects in TA protein biogenesis. In vitro reconstitution demonstrates that the Get proteins directly mediate insertion of newly synthesized TA proteins into ER membranes. Thus, the GET complex represents a critical mechanism for ensuring efficient and accurate targeting of TA proteins.	[Schuldiner, Maya; Denic, Vladimir; Weissman, Jonathan S.] Univ Calif San Francisco, Howard Hughes Med Inst, Dept Cellular & Mol Pharmacol, San Francisco, CA 94158 USA; [Schuldiner, Maya; Denic, Vladimir; Weissman, Jonathan S.] Calif Inst Quantitat Biosci, San Francisco, CA 94158 USA; [Metz, Jutta; Schmid, Volker; Rakwalska, Magdalena; Schwappach, Blanche] Univ Heidelberg ZMBH, Zentrum Mol Biol, D-69120 Heidelberg, Germany; [Schmitt, Hans Dieter] Max Planck Inst Biophys Chem, Dept Mol Biol, D-37077 Gottingen, Germany	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Ruprecht Karls University Heidelberg; Max Planck Society	Schwappach, B (corresponding author), Univ Manchester, Fac Life Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	blanche.schwappach@manchester.ac.uk; weissman@cmp.ucsf.edu	Schuldiner, Maya/C-9488-2009	Schwappach, Blanche/0000-0003-0225-6432; Schuldiner, Maya/0000-0001-9947-115X; Weissman, Jonathan/0000-0003-2445-670X	International Human Frontier Science Program Organization; NIH [K99/R00]; DFG [SFB523, SCHW823/1-1, SFB638]; EMBO Young Investigator Programme; ZMBH; ZMBH, and a Wellcome Trust Senior Research Fellowship; HHMI	International Human Frontier Science Program Organization(Human Frontier Science Program); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DFG(German Research Foundation (DFG)); EMBO Young Investigator Programme(European Molecular Biology Organization (EMBO)); ZMBH; ZMBH, and a Wellcome Trust Senior Research Fellowship; HHMI(Howard Hughes Medical Institute)	We thank the following individuals: B. Toyama for graphical design; B. Farese and B. Dobberstein for sharing unpublished data and discussions; F. Hass, P. March (FLS Bioimaging Facility), and K. Thorn (UCSF Nikon Imaging Center) for help with microscopy; R. Hegde, J. Brodsky, P. Walter, J. Nunnari, D. Gallwitz, D. Gorlich, S. Schroder-Kohne, H. Riezman, A. Spang, R. Tsien, J. Audhya, D. Breslow, D. Cameron, and M. Seedorf for reagents and advice; O. Schuldiner, K. Filaski, D. Cameron, S. Collins, K. Tipton, M. Bassik, J. Weibe-zahn, M. Jonikas, N. Ignolia, and E. Rodriguez for discussions and comments on the manuscript. M. S. was supported by the International Human Frontier Science Program Organization, and is currently supported by an NIH K99/R00 award. H. D. S. was supported by DFG grant SFB523. B. S. was supported by an individual grant from the DFG (SCHW823/1-1), the SFB638, the EMBO Young Investigator Programme, the ZMBH, and a Wellcome Trust Senior Research Fellowship. J. S. W. is supported by HHMI. The authors declare that they have no competing financial interests.	Abell BM, 2007, J CELL SCI, V120, P1743, DOI 10.1242/jcs.002410; Abell BM, 2004, EMBO J, V23, P2755, DOI 10.1038/sj.emboj.7600281; Auld KL, 2006, GENETICS, V174, P215, DOI 10.1534/genetics.106.058362; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; Beilharz T, 2003, J BIOL CHEM, V278, P8219, DOI 10.1074/jbc.M212725200; Borgese N, 2001, MOL BIOL CELL, V12, P2482, DOI 10.1091/mbc.12.8.2482; Borgese N, 2007, CURR OPIN CELL BIOL, V19, P368, DOI 10.1016/j.ceb.2007.04.019; Brambillasca S, 2006, J CELL BIOL, V175, P767, DOI 10.1083/jcb.200608101; Brodsky JL, 2005, METHODS, V35, P354, DOI 10.1016/j.ymeth.2004.10.007; Bulbarelli A, 2002, J CELL SCI, V115, P1689; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Denic V, 2007, CELL, V130, P663, DOI 10.1016/j.cell.2007.06.031; Dimmer KS, 2002, MOL BIOL CELL, V13, P847, DOI 10.1091/mbc.01-12-0588; Egan B, 1999, FEBS LETT, V451, P243, DOI 10.1016/S0014-5793(99)00581-5; Egea PF, 2005, CURR OPIN STRUC BIOL, V15, P213, DOI 10.1016/j.sbi.2005.03.007; Elgersma Y, 1997, EMBO J, V16, P7326, DOI 10.1093/emboj/16.24.7326; Enyenihi AH, 2003, GENETICS, V163, P47; Favaloro V, 2008, J CELL SCI, V121, P1832, DOI 10.1242/jcs.020321; GARCIA PD, 1991, METHOD ENZYMOL, V194, P675; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; High S, 2004, BIOCHEM SOC T, V32, P659, DOI 10.1042/BST0320659; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hoepfner D, 2005, CELL, V122, P85, DOI 10.1016/j.cell.2005.04.025; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; James P, 1996, GENETICS, V144, P1425; Kao G, 2007, CELL, V128, P577, DOI 10.1016/j.cell.2006.12.031; KITADA K, 1995, GENE, V165, P203, DOI 10.1016/0378-1119(95)00552-H; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Labbe S, 1999, TRENDS MICROBIOL, V7, P500, DOI 10.1016/S0966-842X(99)01638-8; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Metz J, 2006, J BIOL CHEM, V281, P410, DOI 10.1074/jbc.M507481200; Mnaimneh S, 2004, CELL, V118, P31, DOI 10.1016/j.cell.2004.06.013; Mukhopadhyay R, 2006, FEBS LETT, V580, P3889, DOI 10.1016/j.febslet.2006.06.017; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; OGG SC, 1992, MOL BIOL CELL, V3, P895, DOI 10.1091/mbc.3.8.895; Pfanner N, 1997, CURR BIOL, V7, pR100, DOI 10.1016/S0960-9822(06)00048-0; Rabu C, 2007, CURR BIOL, V17, pR472, DOI 10.1016/j.cub.2007.04.031; RACHUBINSKI RA, 1980, J CELL BIOL, V84, P705, DOI 10.1083/jcb.84.3.705; Rapoport TA, 1999, BIOL CHEM, V380, P1143, DOI 10.1515/BC.1999.145; Roth AF, 2006, CELL, V125, P1003, DOI 10.1016/j.cell.2006.03.042; Sambade M, 2005, GENETICS, V170, P1539, DOI 10.1534/genetics.105.042812; Schuldiner M, 2005, CELL, V123, P507, DOI 10.1016/j.cell.2005.08.031; Shen J, 2003, BIOMETALS, V16, P369, DOI 10.1023/A:1022504311669; Stefanovic S, 2007, CELL, V128, P1147, DOI 10.1016/j.cell.2007.01.036; Tam YYC, 2005, J BIOL CHEM, V280, P34933, DOI 10.1074/jbc.M506208200; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Wattenberg B, 2001, TRAFFIC, V2, P66, DOI 10.1034/j.1600-0854.2001.20108.x; Weinberger A, 2005, MOL BIOL CELL, V16, P4918, DOI 10.1091/mbc.E05-02-0101; Wickner W, 2005, SCIENCE, V310, P1452, DOI 10.1126/science.1113752; WUESTEHUBE LJ, 1992, METHOD ENZYMOL, V219, P124; Yabal M, 2003, J BIOL CHEM, V278, P3489, DOI 10.1074/jbc.M210253200; Yamaguchi T, 2002, DEV CELL, V2, P295, DOI 10.1016/S1534-5807(02)00125-9; Zewail A, 2003, P NATL ACAD SCI USA, V100, P3345, DOI 10.1073/pnas.0530118100	55	351	357	1	32	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	2008	134	4					634	645		10.1016/j.cell.2008.06.025	http://dx.doi.org/10.1016/j.cell.2008.06.025			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SR	18724936	Green Published, Green Submitted, hybrid			2022-12-28	WOS:000258665800016
J	van der Wilt, GJ; Zielhuis, GA				van der Wilt, Gert Jan; Zielhuis, Gerhard A.			Merging evidence-based and mechanism-based medicine	LANCET			English	Editorial Material							PARKINSONS-DISEASE; HYPERVENTILATION; MANAGEMENT; REDUCTION; LOSARTAN; TARGET		[van der Wilt, Gert Jan; Zielhuis, Gerhard A.] Radboud Univ Nijmegen Med Ctr, Dept Epidemiol Biostat & Hlth Technol Assessment, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	van der Wilt, GJ (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Epidemiol Biostat & Hlth Technol Assessment, NL-6500 HB Nijmegen, Netherlands.	G.vanderwilt@mta.umcn.nl	van der Wilt, G.J./H-8120-2014; Zielhuis, Gerhard A./H-8123-2014	van der Wilt, G.J./0000-0002-5856-762X; 				Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; FEYERABEND PK, 1988, AGAINST METHOD; Furukawa T. A., 2007, COCHRANE DB SYST REV, V1; Goldstein DS, 2003, LANCET NEUROL, V2, P669, DOI 10.1016/S1474-4422(03)00555-6; HIBBERT G, 1989, BRIT J PSYCHIAT, V155, P805, DOI 10.1192/bjp.155.6.805; Kerr WJ, 1937, ANN INTERN MED, V11, P961, DOI 10.7326/0003-4819-11-6-961; *NAT I HLTH RES, EFF MECH EV EME PROG; Protogerou AD, 2007, J HYPERTENS, V25, P265, DOI 10.1097/HJH.0b013e3280114f23; Redon J, 2005, CURR OPIN NEPHROL HY, V14, P448, DOI 10.1097/01.mnh.0000168935.95527.0a; Senard JM, 2001, DRUG AGING, V18, P495, DOI 10.2165/00002512-200118070-00003	11	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 16	2008	372	9638					519	520		10.1016/S0140-6736(08)61215-5	http://dx.doi.org/10.1016/S0140-6736(08)61215-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339MS	18707972				2022-12-28	WOS:000258582300010
J	Wookey, J; Helffrich, G				Wookey, James; Helffrich, George			Inner-core shear-wave anisotropy and texture from an observation of PKJKP waves	NATURE			English	Article							ELASTIC-ANISOTROPY; TRAVEL-TIMES; MODEL; EARTH; IRON; HETEROGENEITY; CONSTRAINTS; ATTENUATION; NETWORK; PHASES	Since the discovery of the Earth's core a century ago(1), and the subsequent discovery(2) of a solid inner core (postulated to have formed by the freezing of iron(3)) seismologists have striven to understand this most remote part of the deep Earth. The most direct evidence for a solid inner core would be the observation of shear-mode body waves that traverse it, but these phases are extremely difficult to observe. Two reported observations in short-period data(4,5) have proved controversial(6). Arguably more successful have been studies of longer-period data(6,7), but such averaging limits the usefulness of the observations to reported sightings. We present two observations of an inner-core shear-wave phase at higher frequencies in stacked data from the Japanese High-Sensitivity Array, Hi-Net(8). From an analysis of timing, amplitude and waveform of the 'PKJKP' phase we derive constraints on inner-core compressional-wave velocity and shear attenuation at about 0.3 Hz which differ from standard isotropic core models(9). We can explain waveform features and can partially reconcile the otherwise large differences between core wavespeed and attenuation models that our observations apparently suggest if we invoke shear-wave anisotropy in the inner core. A simple model of an inner core composed of hexagonal close-packed iron with its c axis aligned perpendicular to the rotation axis(10) yields anisotropy that is compatible with both the shear-wave anisotropy that we observe and the well-established 3 per cent compressional-wave anisotropy.	[Wookey, James; Helffrich, George] Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England	University of Bristol	Wookey, J (corresponding author), Univ Bristol, Dept Earth Sci, Wills Mem Bldg,Queens Rd, Bristol BS8 1RJ, Avon, England.	j.wookey@bristol.ac.uk	Wookey, James/G-6113-2011	Wookey, James/0000-0002-7403-4380; Helffrich, George/0000-0002-7363-4552	Natural Environment Research Council [NE/C518030/1] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Barrett C.S., 1980, STRUCTURE METALS CRY; Beghein C, 2003, SCIENCE, V299, P552, DOI 10.1126/science.1078159; Bergman MI, 2005, PHYS EARTH PLANET IN, V153, P150, DOI 10.1016/j.pepi.2005.03.016; Birch F, 1940, AM J SCI, V238, P192; Buffett BA, 2001, NATURE, V413, P60, DOI 10.1038/35092543; Cao AM, 2005, SCIENCE, V308, P1453, DOI 10.1126/science.1109134; Cormier VF, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2002JB001796; CREAGER KC, 1992, NATURE, V356, P309, DOI 10.1038/356309a0; Deuss A, 2000, GEOPHYS J INT, V142, P67, DOI 10.1046/j.1365-246x.2000.00147.x; Helffrich GR, 1997, GEOPHYS J INT, V131, P741, DOI 10.1111/j.1365-246X.1997.tb06609.x; JULIAN BR, 1972, NATURE, V235, P317, DOI 10.1038/235317a0; Kaneshima S, 1996, GEOPHYS RES LETT, V23, P3075, DOI 10.1029/96GL03026; KENNETT BLN, 1995, GEOPHYS J INT, V122, P108, DOI 10.1111/j.1365-246X.1995.tb03540.x; Koper KD, 2005, EARTH PLANET SC LETT, V237, P680, DOI 10.1016/j.epsl.2005.07.013; Koper KD, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002750; Krasnoshchekov DN, 2005, NATURE, V435, P483, DOI 10.1038/nature03613; Lehmann I., 1936, BUR CENTR SEISMOL A, V14, P87; MUELLER G, 1985, J GEOPHYS, V58, P153; Obara K, 2005, REV SCI INSTRUM, V76, DOI 10.1063/1.1854197; Okal EA, 1998, EARTH PLANET SC LETT, V164, P23, DOI 10.1016/S0012-821X(98)00210-6; Oldham Richard Dixon, 1906, Q J GEOLOG SOC, V62, P456, DOI [10.1144/GSL.JGS.1906.062.01-04.21, DOI 10.1144/GSL.JGS.1906.062.01-04.21]; Rawlinson N, 2004, GEOPHYS J INT, V157, P332, DOI 10.1111/j.1365-246X.2004.02188.x; Romanowicz B, 2000, GEOPHYS MONOGR SER, V117, P161; Schimmel M, 1997, GEOPHYS J INT, V130, P497, DOI 10.1111/j.1365-246X.1997.tb05664.x; Song XD, 1997, REV GEOPHYS, V35, P297, DOI 10.1029/97RG01285; Steinle-Neumann G, 2001, NATURE, V413, P57, DOI 10.1038/35092536; STIXRUDE L, 1995, SCIENCE, V267, P1972, DOI 10.1126/science.267.5206.1972; Tanaka S, 1997, J GEOPHYS RES-SOL EA, V102, P2925, DOI 10.1029/96JB03187; THOMSEN L, 1986, GEOPHYSICS, V51, P1954, DOI 10.1190/1.1442051; TROMP J, 1993, NATURE, V366, P678, DOI 10.1038/366678a0; Vocadlo L, 2007, EARTH PLANET SC LETT, V254, P227, DOI 10.1016/j.epsl.2006.09.046; WIDMER R, 1991, GEOPHYS J INT, V104, P541, DOI 10.1111/j.1365-246X.1991.tb05700.x; Yoshida S, 1996, J GEOPHYS RES-SOL EA, V101, P28085, DOI 10.1029/96JB02700; Zhang KK, 1999, PHYS EARTH PLANET IN, V111, P93, DOI 10.1016/S0031-9201(98)00149-6	34	39	39	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 14	2008	454	7206					873	U24		10.1038/nature07131	http://dx.doi.org/10.1038/nature07131			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	336XH	18704084				2022-12-28	WOS:000258398600033
J	Suzuki, K; Verma, IM				Suzuki, Kotaro; Verma, Inder M.			Phosphorylation of SNAP-23 by I kappa B kinase 2 regulates mast cell degranulation	CELL			English	Article							MEMBRANE-FUSION; SIGNALING PATHWAYS; IMMUNE-RESPONSES; SNARE PROTEINS; LIPID RAFTS; PC12 CELLS; ACTIVATION; EXOCYTOSIS; COMPLEXES; MICE	Mast cells are known to play a pivotal role in allergic diseases. Cross-linking of the high-affinity receptor for IgE (Fc epsilon RI) leads to degranulation and allergic inflammation; however, the regulatory mechanisms of IgE-dependent exocytosis remain unknown. We show here that I kappa B kinase (IKK) 2 in mast cells plays critical roles in IgE-mediated anaphylaxis in vivo, and IgE-mediated degranulation in vitro, in an NF-kB-independent manner. Upon Fc epsilon RI stimulation, IKK2 phosphorylates SNAP-23, the target membrane soluble N-ethylmaleimide-sensitive fusion factor attachment protein receptor (SNARE), and ectopic expression of a phospho-mimetic mutant of SNAP-23 partially rescued the impaired IgE-mediated degranulation in IKK2-deficient mast cells. These results suggest that IKK2 phosphorylation of SNAP-23 leads to degranulation and anaphylactic reactions. While this reaction is NF-kB-independent, we additionally show that IKK2 also regulates late-phase allergic reactions promoted by the release of proinflammatory cytokines in an NF-kB-independent manner. The findings suggest that IKK2 is a central player in allergic reactions.	[Suzuki, Kotaro; Verma, Inder M.] Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA	Salk Institute	Verma, IM (corresponding author), Salk Inst Biol Studies, Genet Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	verma@salk.edu			NIH; Leducq Foundation; Lustgarten Foundation; Ellison Medical Foundation; Francis C. Berger Foundation; National Institute of Allergy And Infectious Diseases [AI048034]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048034, R37AI048034] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leducq Foundation(Leducq Foundation); Lustgarten Foundation; Ellison Medical Foundation(Lawrence Ellison Foundation); Francis C. Berger Foundation; National Institute of Allergy And Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We are very grateful to Dr. P. A. Roche for SNAP-23 phosphorylation site-specific antibodies, Drs. Y. Tamori and M. Kasuga for murine SNAP-23 cDNA, R. Jacobs for electron microscopy, Dr. Y. Soda for making shRNA plasmids, Drs. Q. Li, H. Matsuzaki, Y. Xia, F. Liu, and T. Marumoto for valuable discussion and help in the preparation of the manuscript, and G. Estepa and N. Hoong for technical help. K. S. is supported by grants from the NIH and the Leducq Foundation. I. M. V. is an American Cancer Society Professor of Molecular Biology, and supported in part by grants from NIH, Leducq Foundation, Lustgarten Foundation, Ellison Medical Foundation, and the H. N. and Francis C. Berger Foundation. The project described was supported by Grant Number AI048034 from the National Institute of Allergy And Infectious Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy And Infectious Diseases or the National Institutes of Health.	Bischoff SC, 2007, NAT REV IMMUNOL, V7, P93, DOI 10.1038/nri2018; Chamberlain LH, 2001, P NATL ACAD SCI USA, V98, P5619, DOI 10.1073/pnas.091502398; Correa RG, 2005, CURR BIOL, V15, P1291, DOI 10.1016/j.cub.2005.06.023; Demo SD, 1999, CYTOMETRY, V36, P340, DOI 10.1002/(SICI)1097-0320(19990801)36:4<340::AID-CYTO9>3.0.CO;2-C; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Gringhuis SI, 2005, MOL CELL BIOL, V25, P6454, DOI 10.1128/MCB.25.15.6454-6463.2005; Guo ZH, 1998, CELL, V94, P537, DOI 10.1016/S0092-8674(00)81594-9; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hepp G, 2005, J BIOL CHEM, V280, P6610, DOI 10.1074/jbc.M412126200; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kay JG, 2006, J BIOL CHEM, V281, P11949, DOI 10.1074/jbc.M600857200; Klemm S, 2006, J EXP MED, V203, P337, DOI 10.1084/jem.20051982; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Lee SH, 2004, P NATL ACAD SCI USA, V101, P17416, DOI 10.1073/pnas.0408061101; Li QT, 2000, GENE DEV, V14, P1729; Li QT, 2005, P NATL ACAD SCI USA, V102, P12425, DOI 10.1073/pnas.0505997102; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Lin RC, 2000, ANNU REV CELL DEV BI, V16, P19, DOI 10.1146/annurev.cellbio.16.1.19; Marash M, 2001, EMBO J, V20, P411, DOI 10.1093/emboj/20.3.411; Marti-Verdeaux S, 2003, J CELL SCI, V116, P325, DOI 10.1242/jcs.00216; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Paumet F, 2000, J IMMUNOL, V164, P5850, DOI 10.4049/jimmunol.164.11.5850; Peng YD, 2005, J LEUKOCYTE BIOL, V77, P975, DOI 10.1189/jlb.0204115; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Puri N, 2006, TRAFFIC, V7, P1482, DOI 10.1111/j.1600-0854.2006.00490.x; Salaun C, 2005, J BIOL CHEM, V280, P19449, DOI 10.1074/jbc.M501923200; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; Shambharkar PB, 2007, EMBO J, V26, P1794, DOI 10.1038/sj.emboj.7601622; Shen JS, 2007, CELL, V128, P183, DOI 10.1016/j.cell.2006.12.016; Thome M, 2004, NAT REV IMMUNOL, V4, P348, DOI 10.1038/nri1352; Thome M, 2003, TRENDS IMMUNOL, V24, P419, DOI 10.1016/S1471-4906(03)00177-7; Vicogne J, 2006, P NATL ACAD SCI USA, V103, P14761, DOI 10.1073/pnas.0606881103; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wegener E, 2006, MOL CELL, V23, P13, DOI 10.1016/j.molcel.2006.05.027	40	116	117	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 8	2008	134	3					485	495		10.1016/j.cell.2008.05.050	http://dx.doi.org/10.1016/j.cell.2008.05.050			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SO	18692471	Green Accepted, Bronze			2022-12-28	WOS:000258665500021
J	Song, MS; Salmena, L; Carracedo, A; Egia, A; Lo-Coco, F; Teruya-Feldstein, J; Pandolfi, PP				Song, Min Sup; Salmena, Leonardo; Carracedo, Arkaitz; Egia, Ainara; Lo-Coco, Francesco; Teruya-Feldstein, Julie; Pandolfi, Pier Paolo			The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network	NATURE			English	Article							NUCLEAR-BODY FORMATION; PROMYELOCYTIC LEUKEMIA; TUMOR SUPPRESSION; UBIQUITIN LIGASE; EXPRESSION; MDM2; DEGRADATION; PROTEIN; MONOUBIQUITYLATION; MUTATION	Nuclear exclusion of the PTEN ( phosphatase and tensin homologue deleted in chromosome 10) tumour suppressor has been associated with cancer progression(1-6). However, the mechanisms leading to this aberrant PTEN localization in human cancers are currently unknown. We have previously reported that ubiquitinylation of PTEN at specific lysine residues regulates its nuclear cytoplasmic partitioning(7). Here we show that functional promyelocytic leukaemia protein ( PML) nuclear bodies co- ordinate PTEN localization by opposing the action of a previously unknown PTEN- deubiquitinylating enzyme, herpesvirus- associated ubiquitin- specific protease ( HAUSP, also known as USP7), and that the integrity of this molecular framework is required for PTEN to be able to enter the nucleus. We find that PTEN is aberrantly localized in acute promyelocytic leukaemia, in which PML function is disrupted by the PML - RAR alpha fusion oncoprotein. Remarkably, treatment with drugs that trigger PML - RAR alpha degradation, such as all- trans retinoic acid or arsenic trioxide, restore nuclear PTEN. We demonstrate that PML opposes the activity of HAUSP towards PTEN through a mechanism involving the adaptor protein DAXX ( death domain- associated protein). In support of this paradigm, we show that HAUSP is overexpressed in human prostate cancer and is associated with PTEN nuclear exclusion. Thus, our results delineate a previously unknown PML DAXX - HAUSP molecular network controlling PTEN deubiquitinylation and trafficking, which is perturbed by oncogenic cues in human cancer, in turn defining a new deubiquitinylation- dependent model for PTEN subcellular compartmentalization.	[Song, Min Sup; Salmena, Leonardo; Carracedo, Arkaitz; Egia, Ainara; Pandolfi, Pier Paolo] Harvard Univ, Sch Med, Beth Israel Deaconess Canc Ctr, Canc Genet Program, Boston, MA 02215 USA; [Song, Min Sup; Salmena, Leonardo; Carracedo, Arkaitz; Egia, Ainara; Pandolfi, Pier Paolo] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; [Lo-Coco, Francesco] Univ Roma Tor Vergata, Dept Biopathol, I-00133 Rome, Italy; [Teruya-Feldstein, Julie] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Pathol, New York, NY 10021 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Rome Tor Vergata; Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Canc Ctr, Canc Genet Program, Boston, MA 02215 USA.	ppandolf@bidmc.harvard.edu	Carracedo, Arkaitz/F-7029-2011	Carracedo, Arkaitz/0000-0001-5957-1260; Salmena, Leonardo/0000-0003-4023-658X	NIH; International Human Frontier Science Program Organization; European Molecular Biology Organization; NATIONAL CANCER INSTITUTE [R01CA082328, P50CA092629] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); International Human Frontier Science Program Organization(Human Frontier Science Program); European Molecular Biology Organization(European Molecular Biology Organization (EMBO)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank B. Vogelstein, K.H. Baek, M. Lanotte and X. Jiang for sharing reagents and W. Gu for critical discussions. We thank all members of the Pandolfi laboratory, in particular K. Ito, S. Majid and L. Poliseno, for technical support, advice and discussion. This work was supported by NIH grants to P.P.P.L.S. is supported by the International Human Frontier Science Program Organization, and A.C. is supported by the European Molecular Biology Organization.	Baker SJ, 2007, CELL, V128, P25, DOI 10.1016/j.cell.2006.12.023; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bernardi R, 2007, NAT REV MOL CELL BIO, V8, P1006, DOI 10.1038/nrm2277; Carracedo A, 2008, CELL, V133, P550, DOI 10.1016/j.cell.2008.04.023; CUMMINS JM, 2004, NATURE, V428; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; Fridberg M, 2007, LEUKEMIA LYMPHOMA, V48, P2221, DOI 10.1080/10428190701636443; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Lin DY, 2006, MOL CELL, V24, P341, DOI 10.1016/j.molcel.2006.10.019; Liu JL, 2005, MOL CELL BIOL, V25, P6211, DOI 10.1128/MCB.25.14.6211-6224.2005; Marchenko ND, 2007, EMBO J, V26, P923, DOI 10.1038/sj.emboj.7601560; Perren A, 2000, AM J PATHOL, V157, P1097, DOI 10.1016/S0002-9440(10)64624-X; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Salmena L, 2007, NAT REV CANCER, V7, P409, DOI 10.1038/nrc2145; Scaglioni PP, 2006, CELL, V126, P269, DOI 10.1016/j.cell.2006.05.041; Shen TH, 2006, MOL CELL, V24, P331, DOI 10.1016/j.molcel.2006.09.013; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Song MS, 2008, EMBO J, V27, P1863, DOI 10.1038/emboj.2008.115; Tachibana M, 2002, CANCER-AM CANCER SOC, V94, P1955, DOI 10.1002/cncr.0678; Tallman MS, 2004, SEMIN HEMATOL, V41, P27, DOI 10.1053/j.seminhematol.2004.02.004; Tang J, 2006, NAT CELL BIOL, V8, P855, DOI 10.1038/ncb1442; Tatham MH, 2008, NAT CELL BIOL, V10, P538, DOI 10.1038/ncb1716; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; van der Horst A, 2006, NAT CELL BIOL, V8, P1064, DOI 10.1038/ncb1469; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Whiteman DC, 2002, INT J CANCER, V99, P63, DOI 10.1002/ijc.10294; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5; Zhou XP, 2002, AM J PATHOL, V161, P439, DOI 10.1016/S0002-9440(10)64200-9	30	377	415	2	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 9	2008	455	7214					813	U11		10.1038/nature07290	http://dx.doi.org/10.1038/nature07290			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	357OB	18716620	Green Accepted			2022-12-28	WOS:000259854900050
J	Tavazzi, L; Maggioni, AP; Marchioli, R; Barlera, S; Franzosi, MG; Latini, R; Lucci, D; Nicolosi, GL; Porcu, M; Tognoni, G				Tavazzi, Luigi; Maggioni, Aldo P.; Marchioli, Roberto; Barlera, Simona; Franzosi, Maria Grazia; Latini, Roberto; Lucci, Donata; Nicolosi, Gian Luigi; Porcu, Maurizio; Tognoni, Gianni		GISSI HF Investigators	Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial	LANCET			English	Article							IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS; FISH-OIL SUPPLEMENTATION; MYOCARDIAL-INFARCTION; DOCOSAHEXAENOIC ACID; PREVENZIONE TRIAL; SUDDEN-DEATH; METAANALYSIS; CONSUMPTION; HUMANS; MORTALITY	Background Several epidemiological and experimental studies suggest that n-3 polyunsaturated fatty acids (PUFA) can exert favourable effects on atherothrombotic cardiovascular disease, including arrhythmias. We investigated whether n-3 PUFA could improve morbidity and mortality in a large population of patients with symptomatic heart failure of any cause. Methods We undertook a randomised, double-blind, placebo-controlled trial in 326 cardiology and 31 internal medicine centres in Italy. We enrolled patients with chronic heart failure of New York Heart Association class II-IV, irrespective of cause and left ventricular ejection fraction, and randomly assigned them to n-3 PUFA 1 g daily (n=3494) or placebo (n=3481) by a concealed, computerised telephone randomisation system. Patients were followed up for a median of 3.9 years (IQR 3.0-4.5). Primary endpoints were time to death, and time to death or admission to hospital for cardiovascular reasons. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00336336. Findings We analysed all randomised patients. 955 (27%) patients died from any cause in the n-3 PUFA group and 1014 (29%) in the placebo group (adjusted hazard ratio [HR] 0 . 91 [95. 5% CI 0 . 833-0 . 998], p=0.041). 1981 (57%) patients in the n-3 PUFA group and 2053 (59%) in the placebo group died or were admitted to hospital for cardiovascular reasons (adjusted HR 0 . 92 [99% CI 0 . 849-0.999], p= 0. 009). In absolute terms, 56 patients needed to be treated for a median duration of 3.9 years -to avoid one death or 44 to avoid one event like death or admission to hospital for cardiovascular reasons. in both groups, gastrointestinal disorders were the most frequent adverse reaction (96 [3%] n-3 PUFA group vs 92 [3%] placebo group). Interpretation A simple and safe treatment with n-3 PUFA can provide a small beneficial advantage in terms of mortality and admission to hospital for cardiovascular reasons in patients with heart failure in a context of usual care. Funding Societa Prodotti Antibiotici (SPA; Italy), Pfizer, Sigma Tau, and AstraZeneca.	[Tavazzi, Luigi] GVM Hosp Care & Res, Cotignola, Italy; [Maggioni, Aldo P.; Lucci, Donata] ANMCO Res Ctr, Florence, Italy; [Marchioli, Roberto; Tognoni, Gianni] Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy; [Barlera, Simona; Franzosi, Maria Grazia; Latini, Roberto] Ist Ric Farmacol Mario Negri, Milan, Italy; [Nicolosi, Gian Luigi] AO S Maria Angeli, Pordenone, Italy; [Porcu, Maurizio] AO Brotzu S Michele, Cagliari, Italy	Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO); Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Tavazzi, L (corresponding author), GVM Hosp Care & Res, Cotignola, Italy.		sinagra, gianfranco gs/P-7643-2014; Milani, Valentina/AAB-5367-2019; Maggioni, Aldo Pietro/AAL-5334-2020; Latini, Roberto/AAB-1410-2020; Cosentino, Nicola/K-2853-2016; Tavazzi, Luigi/ABD-5119-2020; Turazza, Fabio/AAB-8736-2020; raimondo, rosa/N-5351-2019; Banzato, Alberto/AAF-2622-2021; De+Servi, Stefano/AAT-2631-2021; Nicolosi, Gian Luigi/AAT-9893-2020; Danzi, Gian Battista/P-2244-2016; Porcu, Maurizio/AAO-6175-2020	Milani, Valentina/0000-0002-2989-981X; Maggioni, Aldo Pietro/0000-0003-2764-6779; Latini, Roberto/0000-0002-3729-4650; Cosentino, Nicola/0000-0002-8628-3106; Tavazzi, Luigi/0000-0003-0336-8356; Turazza, Fabio/0000-0002-2348-5309; raimondo, rosa/0000-0002-7428-7564; Banzato, Alberto/0000-0001-5315-5135; Nicolosi, Gian Luigi/0000-0002-2218-2808; Danzi, Gian Battista/0000-0003-0897-8006; COLIZZI, CHRISTIAN/0000-0003-1378-3019; tarantini, luigi/0000-0003-2580-0963	Associazione Nazionale Medici Cardiologi Ospeclalieri (ANMCO), Florence, Italy; stituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy; SPA; Pfizer; Sigma Tau; AstraZeneca	Associazione Nazionale Medici Cardiologi Ospeclalieri (ANMCO), Florence, Italy; stituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy; SPA; Pfizer(Pfizer); Sigma Tau; AstraZeneca(AstraZeneca)	GISSI is endorsed by Associazione Nazionale Medici Cardiologi Ospeclalieri (ANMCO), Florence, Italy; by Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; and by Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy. SPA, Pfizer, Sigma Tau, and AstraZeneca concurred to fund the study SPA provided the experimental treatment. We thank the participants in the study, and the doctors, nurses, ethics committees, and administrative staffin hospitals who assisted with its conduct.	Arterburn LM, 2006, AM J CLIN NUTR, V83, p1467S, DOI 10.1093/ajcn/83.6.1467S; Bardy GH, 2005, NEW ENGL J MED, V352, P225, DOI 10.1056/NEJMoa043399; Braunwald E, 2001, EUR HEART J, V22, P825, DOI 10.1053/euhj.2001.2614; Brouwer IA, 2006, JAMA-J AM MED ASSOC, V295, P2613, DOI 10.1001/jama.295.22.2613; CHIN JPF, 1993, HYPERTENSION, V21, P22, DOI 10.1161/01.HYP.21.1.22; Di Stasi D, 2004, EUR J CLIN PHARMACOL, V60, P183, DOI 10.1007/s00228-004-0758-8; *GISSI HF INV, 2008, LANCET          0831; Grimsgaard S, 1998, AM J CLIN NUTR, V68, P52, DOI 10.1093/ajcn/68.1.52; He K, 2004, CIRCULATION, V109, P2705, DOI 10.1161/01.CIR.0000132503.19410.6B; He K, 2004, STROKE, V35, P1538, DOI 10.1161/01.STR.0000130856.31468.47; Hibbeln JR, 2006, AM J CLIN NUTR, V83, p1483S, DOI 10.1093/ajcn/83.6.1483S; Jenkins DJA, 2008, CAN MED ASSOC J, V178, P157, DOI 10.1503/cmaj.070261; Kjekshus J, 2007, NEW ENGL J MED, V357, P2248, DOI 10.1056/NEJMoa0706201; Leaf A, 2005, CIRCULATION, V112, P2762, DOI 10.1161/CIRCULATIONAHA.105.549527; Li QR, 2007, ARCH BIOCHEM BIOPHYS, V466, P250, DOI 10.1016/j.abb.2007.06.023; London B, 2007, CIRCULATION, V116, pE320, DOI 10.1161/CIRCULATIONAHA.107.712984; Macchia A, 2005, EUR J HEART FAIL, V7, P904, DOI 10.1016/j.ejheart.2005.04.008; Marchioli R, 2005, J MEMBRANE BIOL, V206, P117, DOI 10.1007/s00232-005-0788-x; Marchioli R, 2002, CIRCULATION, V105, P1897, DOI 10.1161/01.CIR.0000014682.14181.F2; Marchioli R, 2001, EUR HEART J SUPPL, V3, pD85, DOI 10.1016/S1520-765X(01)90126-9; Mozaffarian D, 2006, AM J CARDIOL, V97, P216, DOI 10.1016/j.amjcard.2005.08.025; Mozaffarian D, 2005, J AM COLL CARDIOL, V45, P2015, DOI 10.1016/j.jacc.2005.03.038; Mozaffarian D, 2005, CIRCULATION, V112, P1945, DOI 10.1161/CIRCULATIONAHA.105.556886; Mozaffarian D, 2008, CIRCULATION, V117, P1130, DOI 10.1161/CIRCULATIONAHA.107.732826; Mozaffarian D, 2006, JAMA-J AM MED ASSOC, V296, P1885, DOI 10.1001/jama.296.15.1885; Pepe S, 2002, CIRCULATION, V105, P2303, DOI 10.1161/01.CIR.0000015604.88808.74; Pfeffer MA, 2003, LANCET, V362, P759, DOI 10.1016/S0140-6736(03)14282-1; Raitt MH, 2005, JAMA-J AM MED ASSOC, V293, P2884, DOI 10.1001/jama.293.23.2884; Tavazzi L, 2004, AM HEART J, V148, P222, DOI 10.1016/j.ahj.2004.02.015; Tavazzi L, 2004, EUR J HEART FAIL, V6, P635, DOI 10.1016/j.ejheart.2004.03.001; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Wang CC, 2006, AM J CLIN NUTR, V84, P5, DOI 10.1093/ajcn/84.1.5	32	960	1029	3	68	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 4	2008	372	9645					1223	1230		10.1016/S0140-6736(08)61239-8	http://dx.doi.org/10.1016/S0140-6736(08)61239-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	357YB	18757090				2022-12-28	WOS:000259882000028
J	Yu, HY; Braun, P; Yildirim, MA; Lemmens, I; Venkatesan, K; Sahalie, J; Hirozane-Kishikawa, T; Gebreab, F; Li, N; Simonis, N; Hao, T; Rual, JF; Dricot, A; Vazquez, A; Murray, RR; Simon, C; Tardivo, L; Tam, S; Svrzikapa, N; Fan, CY; de Smet, AS; Motyl, A; Hudson, ME; Park, J; Xin, XF; Cusick, ME; Moore, T; Boone, C; Snyder, M; Roth, FP; Barabasi, AL; Tavernier, J; Hill, DE; Vidal, M				Yu, Haiyuan; Braun, Pascal; Yildirim, Muhammed A.; Lemmens, Irma; Venkatesan, Kavitha; Sahalie, Julie; Hirozane-Kishikawa, Tomoko; Gebreab, Fana; Li, Na; Simonis, Nicolas; Hao, Tong; Rual, Jean-Francois; Dricot, Amelie; Vazquez, Alexei; Murray, Ryan R.; Simon, Christophe; Tardivo, Leah; Tam, Stanley; Svrzikapa, Nenad; Fan, Changyu; de Smet, Anne-Sophie; Motyl, Adriana; Hudson, Michael E.; Park, Juyong; Xin, Xiaofeng; Cusick, Michael E.; Moore, Troy; Boone, Charlie; Snyder, Michael; Roth, Frederick P.; Barabasi, Albert-Laszlo; Tavernier, Jan; Hill, David E.; Vidal, Marc			High-quality binary protein interaction map of the yeast interactome network	SCIENCE			English	Article							GENOMIC ANALYSIS; SCALE; ANNOTATION; COMPLEXES; IDENTIFICATION; RESOURCE; ATLAS	Current yeast interactome network maps contain several hundred molecular complexes with limited and somewhat controversial representation of direct binary interactions. We carried out a comparative quality assessment of current yeast interactome data sets, demonstrating that high- throughput yeast two- hybrid ( Y2H) screening provides high- quality binary interaction information. Because a large fraction of the yeast binary interactome remains to be mapped, we developed an empirically controlled mapping framework to produce a "second- generation" high- quality, high- throughput Y2H data set covering similar to 20% of all yeast binary interactions. Both Y2H and affinity purification followed by mass spectrometry ( AP/ MS) data are of equally high quality but of a fundamentally different and complementary nature, resulting in networks with different topological and biological properties. Compared to co- complex interactome models, this binary map is enriched for transient signaling interactions and intercomplex connections with a highly significant clustering between essential proteins. Rather than correlating with essentiality, protein connectivity correlates with genetic pleiotropy.	[Yu, Haiyuan; Braun, Pascal; Yildirim, Muhammed A.; Venkatesan, Kavitha; Sahalie, Julie; Hirozane-Kishikawa, Tomoko; Gebreab, Fana; Li, Na; Simonis, Nicolas; Hao, Tong; Rual, Jean-Francois; Dricot, Amelie; Murray, Ryan R.; Simon, Christophe; Tardivo, Leah; Tam, Stanley; Svrzikapa, Nenad; Fan, Changyu; Park, Juyong; Cusick, Michael E.; Roth, Frederick P.; Barabasi, Albert-Laszlo; Hill, David E.; Vidal, Marc] Dana Farber Canc Inst, CCSB, Boston, MA 02115 USA; [Yu, Haiyuan; Braun, Pascal; Yildirim, Muhammed A.; Venkatesan, Kavitha; Sahalie, Julie; Hirozane-Kishikawa, Tomoko; Gebreab, Fana; Li, Na; Simonis, Nicolas; Hao, Tong; Rual, Jean-Francois; Dricot, Amelie; Murray, Ryan R.; Simon, Christophe; Tardivo, Leah; Tam, Stanley; Svrzikapa, Nenad; Fan, Changyu; Cusick, Michael E.; Hill, David E.; Vidal, Marc] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Yu, Haiyuan; Braun, Pascal; Yildirim, Muhammed A.; Venkatesan, Kavitha; Sahalie, Julie; Hirozane-Kishikawa, Tomoko; Gebreab, Fana; Li, Na; Simonis, Nicolas; Hao, Tong; Rual, Jean-Francois; Dricot, Amelie; Murray, Ryan R.; Simon, Christophe; Tardivo, Leah; Tam, Stanley; Svrzikapa, Nenad; Fan, Changyu; Cusick, Michael E.; Hill, David E.; Vidal, Marc] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; [Yildirim, Muhammed A.] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA; [Lemmens, Irma; de Smet, Anne-Sophie; Tavernier, Jan] Univ Ghent VIB, Dept Med Prot Res, Fac Med & Hlth Sci, B-9000 Ghent, Belgium; [Lemmens, Irma; de Smet, Anne-Sophie; Tavernier, Jan] Univ Ghent, Dept Biochem, Fac Med & Hlth Sci, B-9000 Ghent, Belgium; [Vazquez, Alexei] Inst Adv Study, Simons Ctr Syst Biol, Princeton, NJ 08540 USA; [Motyl, Adriana; Hudson, Michael E.; Snyder, Michael] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06620 USA; [Park, Juyong; Barabasi, Albert-Laszlo] Northeastern Univ, Ctr Complex Network Res, Boston, MA 02115 USA; [Park, Juyong; Barabasi, Albert-Laszlo] Northeastern Univ, Dept Phys, Boston, MA 02115 USA; [Park, Juyong; Barabasi, Albert-Laszlo] Northeastern Univ, Dept Biol, Boston, MA 02115 USA; [Park, Juyong; Barabasi, Albert-Laszlo] Northeastern Univ, Dept Comp Sci, Boston, MA 02115 USA; [Xin, Xiaofeng; Boone, Charlie] Univ Toronto, Banting & Best Dept Med Res, Terrence Donnelly Ctr Cellular & Biomol Res, Toronto, ON M5S 3E1, Canada; [Xin, Xiaofeng; Boone, Charlie] Univ Toronto, Dept Med Genet & Microbiol, Terrence Donnelly Ctr Cellular & Biomol Res, Toronto, ON M5S 3E1, Canada; [Moore, Troy] Open Biosyst, Huntsville, AL 35806 USA; [Roth, Frederick P.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University; Institute for Advanced Study - USA; Yale University; Northeastern University; Northeastern University; Northeastern University; Northeastern University; University of Toronto; University of Toronto; Harvard University; Harvard Medical School	Vidal, M (corresponding author), Dana Farber Canc Inst, CCSB, Boston, MA 02115 USA.	marc_vidal@dfci.harvard.edu	Braun, Pascal/B-9669-2013; Park, Juyong/I-2290-2012; Hill, David E/B-6617-2011; Simonis, Nicolas/E-5124-2010; Roth, Frederick P/H-6308-2011; Yildirim, Muhammed/J-3695-2014; Xin, Xiaofeng/G-7736-2016; Tavernier, Jan/AAG-3636-2019; Barabasi, Albert-Laszlo/S-6474-2017	Braun, Pascal/0000-0003-2012-6746; Yildirim, Muhammed/0000-0003-2826-1766; Xin, Xiaofeng/0000-0002-2439-7183; Roth, Frederick/0000-0002-6628-649X; Snyder, Michael/0000-0003-0784-7987; Barabasi, Albert/0000-0002-4028-3522; SVRZIKAPA, NENAD/0000-0003-2065-1794; Rual, Jean-Francois/0000-0003-4465-8819	W. M. Keck Foundation; Institute Sponsored Research funds from the Dana-Farber Cancer Institute Strategic Initiative; NIH [R01-HG001715, U01-A1070499-01, U56- CA113004, HG003224]; University of Ghent [GOA12051401]; Fund for Scientific Research Flanders [FWO-V G. 0031.06]; National Cancer Institute of Canada; NATIONAL CANCER INSTITUTE [U56CA113004] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG003224, R01HG001715] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI070499] Funding Source: NIH RePORTER	W. M. Keck Foundation(W.M. Keck Foundation); Institute Sponsored Research funds from the Dana-Farber Cancer Institute Strategic Initiative; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Ghent(Ghent University); Fund for Scientific Research Flanders(FWO); National Cancer Institute of Canada(Canadian Cancer Society (CCS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by funds from the W. M. Keck Foundation (M.V. and F. P. R.); by Institute Sponsored Research funds from the Dana-Farber Cancer Institute Strategic Initiative (M.V. and CCSB); by NIH grant R01- HG001715 (M.V. and F.P.R.); by NIH grants U01-A1070499- 01 and U56-CA113004 (A.-L.B.); by grant GOA12051401 from the University of Ghent and grant FWO-VG. 0031.06 from the Fund for Scientific Research Flanders (J.T.); by a grant from the National Cancer Institute of Canada (C.B.); and by NIH grant HG003224 (F.P.R.). I.L. is a postdoctoral fellow with the Fonds Wetenschappelijk Onderzoek-Vlanderen. M.V. is a "Chercheur Qualifi, Honoraire" from the Fonds de la Recherche Scientifique (FRS-FNRS, French Community of Belgium). We thank members of our laboratories for helpful discussions and Agencourt Biosciences for sequencing assistance. All data sets can be downloaded from our Web site (http://interactome.dfci.harvard.edu/S_cerevisiae).	Arifuzzaman M, 2006, GENOME RES, V16, P686, DOI 10.1101/gr.4527806; Bader JS, 2004, NAT BIOTECHNOL, V22, P78, DOI 10.1038/nbt924; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Butland G, 2005, NATURE, V433, P531, DOI 10.1038/nature03239; Colland F, 2004, GENOME RES, V14, P1324, DOI 10.1101/gr.2334104; Collins SR, 2007, MOL CELL PROTEOMICS, V6, P439, DOI 10.1074/mcp.M600381-MCP200; Dudley AM, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100004; Ewing RM, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100134; Eyckerman S, 2001, NAT CELL BIOL, V3, P1114, DOI 10.1038/ncb1201-1114; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Gavin AC, 2006, NATURE, V440, P631, DOI 10.1038/nature04532; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Gelperin DM, 2005, GENE DEV, V19, P2816, DOI 10.1101/gad.1362105; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Grigoriev A, 2003, NUCLEIC ACIDS RES, V31, P4157, DOI 10.1093/nar/gkg466; Han JDJ, 2005, NAT BIOTECHNOL, V23, P839, DOI 10.1038/nbt1116; Han JDJ, 2004, NATURE, V430, P88, DOI 10.1038/nature02555; Harris MA, 2008, NUCLEIC ACIDS RES, V36, pD440, DOI 10.1093/nar/gkm883; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jansen R, 2004, CURR OPIN MICROBIOL, V7, P535, DOI 10.1016/j.mib.2004.08.012; Jansen R, 2003, SCIENCE, V302, P449, DOI 10.1126/science.1087361; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; Krogan NJ, 2006, NATURE, V440, P637, DOI 10.1038/nature04670; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Luscombe NM, 2004, NATURE, V431, P308, DOI 10.1038/nature02782; Mewes HW, 2006, NUCLEIC ACIDS RES, V34, pD169, DOI 10.1093/nar/gkj148; Milo R, 2002, SCIENCE, V298, P824, DOI 10.1126/science.298.5594.824; Reboul J, 2003, NAT GENET, V34, P35, DOI 10.1038/ng1140; Reguly Teresa, 2006, J Biol, V5, P11, DOI 10.1186/jbiol36; Remy Ingrid, 2004, Methods Mol Biol, V261, P411; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Scholtens D, 2005, BIOINFORMATICS, V21, P3548, DOI 10.1093/bioinformatics/bti567; Stelzl U, 2005, CELL, V122, P957, DOI 10.1016/j.cell.2005.08.029; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Vidal M, 2001, CELL, V104, P333, DOI 10.1016/S0092-8674(01)00221-5; Vidalain PO, 2004, METHODS, V32, P363, DOI 10.1016/j.ymeth.2003.10.001; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750; Walhout AJM, 1999, GENOME RES, V9, P1128, DOI 10.1101/gr.9.11.1128; Walhout AJM, 2000, SCIENCE, V287, P116, DOI 10.1126/science.287.5450.116; Yu HY, 2007, PLOS COMPUT BIOL, V3, P713, DOI 10.1371/journal.pcbi.0030059; Yu HY, 2007, BIOINFORMATICS, V23, P2163, DOI 10.1093/bioinformatics/btm291; Yu HY, 2006, P NATL ACAD SCI USA, V103, P14724, DOI 10.1073/pnas.0508637103; Yu HY, 2004, GENOME RES, V14, P1107, DOI 10.1101/gr.1774904	45	1022	1059	7	190	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	2008	322	5898					104	110		10.1126/science.1158684	http://dx.doi.org/10.1126/science.1158684			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	355AE	18719252	Green Accepted			2022-12-28	WOS:000259680200048
J	Gillis, AJ; Schuller, AP; Skordalakes, E				Gillis, Andrew J.; Schuller, Anthony P.; Skordalakes, Emmanuel			Structure of the Tribolium castaneum telomerase catalytic subunit TERT	NATURE			English	Article							TEMPLATE BOUNDARY DEFINITION; HIV-1 REVERSE-TRANSCRIPTASE; RNA-BINDING DOMAIN; FUNCTIONAL MULTIMERIZATION; CELLULAR SENESCENCE; SECONDARY-STRUCTURE; CRYSTAL-STRUCTURE; IN-VIVO; YEAST; POLYMERASE	A common hallmark of human cancers is the overexpression of telomerase, a ribonucleoprotein complex that is responsible for maintaining the length and integrity of chromosome ends. Telomere length deregulation and telomerase activation is an early, and perhaps necessary, step in cancer cell evolution. Here we present the high- resolution structure of the Tribolium castaneum catalytic subunit of telomerase, TERT. The protein consists of three highly conserved domains, organized into a ring- like structure that shares common features with retroviral reverse transcriptases, viral RNA polymerases and B- family DNA polymerases. Domain organization places motifs implicated in substrate binding and catalysis in the interior of the ring, which can accommodate seven to eight bases of double- stranded nucleic acid. Modelling of an RNA - DNA heteroduplex in the interior of this ring demonstrates a perfect fit between the protein and the nucleic acid substrate, and positions the 39- end of the DNA primer at the active site of the enzyme, providing evidence for the formation of an active telomerase elongation complex.	[Gillis, Andrew J.; Schuller, Anthony P.; Skordalakes, Emmanuel] Wistar Inst Anat & Biol, Gene Express & Regulat Program, Philadelphia, PA 19104 USA	The Wistar Institute	Skordalakes, E (corresponding author), Wistar Inst Anat & Biol, Gene Express & Regulat Program, 3601 Spruce St, Philadelphia, PA 19104 USA.	skorda@wistar.org	Skordalakes, Emmanuel/H-7071-2019	Skordalakes, Emmanuel/0000-0002-7600-2833; Schuller, Anthony/0000-0003-3098-3055	Pennsylvania Department of Health; The Ellison Medical Foundation	Pennsylvania Department of Health; The Ellison Medical Foundation(Lawrence Ellison Foundation)	We thank R. Marmorstein for critical reading of this manuscript. This project was funded by the Pennsylvania Department of Health and The Ellison Medical Foundation.	Arai K, 2002, J BIOL CHEM, V277, P8538, DOI 10.1074/jbc.M111068200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Banik SSR, 2002, MOL CELL BIOL, V22, P6234, DOI 10.1128/MCB.22.17.6234-6246.2002; Beattie TL, 2001, MOL CELL BIOL, V21, P6151, DOI 10.1128/MCB.21.18.6151-6160.2001; BLACKBURN EH, 1994, CELL, V77, P621, DOI 10.1016/0092-8674(94)90046-9; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bosoy D, 2001, J BIOL CHEM, V276, P46305, DOI 10.1074/jbc.M108168200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bryan TM, 2003, MOL BIOL CELL, V14, P4794, DOI 10.1091/mbc.E03-07-0474; Campisi J, 2001, EXP GERONTOL, V36, P1619, DOI 10.1016/S0531-5565(01)00160-7; Chen JL, 2004, P NATL ACAD SCI USA, V101, P14683, DOI 10.1073/pnas.0406204101; Chen JL, 2003, GENE DEV, V17, P2747, DOI 10.1101/gad.1140303; Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202; Das K, 2007, J MOL BIOL, V365, P77, DOI 10.1016/j.jmb.2006.08.097; Di Marco S, 2005, J BIOL CHEM, V280, P29765, DOI 10.1074/jbc.M505423200; Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Ferrer-Orta C, 2004, J BIOL CHEM, V279, P47212, DOI 10.1074/jbc.M405465200; Finger SN, 2008, NUCLEIC ACIDS RES, V36, P1260, DOI 10.1093/nar/gkm866; Forstemann K, 2005, EMBO REP, V6, P361, DOI 10.1038/sj.embor.7400374; Friedman KL, 1999, GENE DEV, V13, P2863, DOI 10.1101/gad.13.21.2863; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Haering CH, 2000, P NATL ACAD SCI USA, V97, P6367, DOI 10.1073/pnas.130187397; Hammond PW, 1998, BIOCHEMISTRY-US, V37, P5162, DOI 10.1021/bi972988o; Hossain S, 2002, J BIOL CHEM, V277, P36174, DOI 10.1074/JBC.m201976200; Huard S, 2003, NUCLEIC ACIDS RES, V31, P4059, DOI 10.1093/nar/gkg437; Jacobs SA, 2006, NAT STRUCT MOL BIOL, V13, P218, DOI 10.1038/nsmb1054; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Lai CK, 2002, GENE DEV, V16, P415, DOI 10.1101/gad.962602; Lai CK, 2001, MOL CELL BIOL, V21, P990, DOI 10.1128/MCB.21.4.990-1000.2001; LEE MS, 1993, MOL CELL BIOL, V13, P6586, DOI 10.1128/MCB.13.10.6586; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Lue NF, 2005, J BIOL CHEM, V280, P26586, DOI 10.1074/jbc.M503028200; Lue NF, 2003, MOL CELL BIOL, V23, P8440, DOI 10.1128/MCB.23.23.8440-8449.2003; Ly H, 2003, MOL CELL BIOL, V23, P6849, DOI 10.1128/MCB.23.19.6849-6856.2003; Moriarty TJ, 2002, MOL CELL BIOL, V22, P1253, DOI 10.1128/MCB.22.4.1253-1265.2002; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; O'Connor CM, 2005, J BIOL CHEM, V280, P17533, DOI 10.1074/jbc.M501211200; Osanai M, 2006, GENE, V376, P281, DOI 10.1016/j.gene.2006.04.022; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; Prescott J, 1997, GENE DEV, V11, P2790, DOI 10.1101/gad.11.21.2790; Richards S, 2008, NATURE, V452, P949, DOI 10.1038/nature06784; Rouda S, 2007, STRUCTURE, V15, P1403, DOI 10.1016/j.str.2007.09.007; Sarafianos SG, 2002, EMBO J, V21, P6614, DOI 10.1093/emboj/cdf637; Seto AG, 2003, RNA, V9, P1323, DOI 10.1261/rna.5570803; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; Smith RA, 2006, J VIROL, V80, P7169, DOI 10.1128/JVI.00322-06; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Tzfati Y, 2000, SCIENCE, V288, P863, DOI 10.1126/science.288.5467.863; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; Wright WE, 2001, CURR OPIN GENET DEV, V11, P98, DOI 10.1016/S0959-437X(00)00163-5; WRIGHT WE, 1975, EXP CELL RES, V96, P113, DOI 10.1016/S0014-4827(75)80043-7	56	218	226	0	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 2	2008	455	7213					633	U36		10.1038/nature07283	http://dx.doi.org/10.1038/nature07283			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	354KY	18758444				2022-12-28	WOS:000259639700039
J	Podsypanina, K; Du, YCN; Jechlinger, M; Beverly, LJ; Hambardzumyan, D; Varmus, H				Podsypanina, Katrina; Du, Yi-Chieh Nancy; Jechlinger, Martin; Beverly, Levi J.; Hambardzumyan, Dolores; Varmus, Harold			Seeding and propagation of untransformed mouse mammary cells in the lung	SCIENCE			English	Article							BREAST-CANCER METASTASIS; TUMOR-METASTASIS; MICE	The acquisition of metastatic ability by tumor cells is considered a late event in the evolution of malignant tumors. We report that untransformed mouse mammary cells that have been engineered to express the inducible oncogenic transgenes MYC and Kras(D12), or polyoma middle T, and introduced into the systemic circulation of a mouse can bypass transformation at the primary site and develop into metastatic pulmonary lesions upon immediate or delayed oncogene induction. Therefore, previously untransformed mammary cells may establish residence in the lung once they have entered the bloodstream and may assume malignant growth upon oncogene activation. Mammary cells lacking oncogenic transgenes displayed a similar capacity for long- term residence in the lungs but did not form ectopic tumors.	[Podsypanina, Katrina; Du, Yi-Chieh Nancy; Jechlinger, Martin; Beverly, Levi J.; Hambardzumyan, Dolores; Varmus, Harold] Mem Sloan Kettering Canc Ctr, Program Canc Biol & Genet, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Podsypanina, K (corresponding author), Mem Sloan Kettering Canc Ctr, Program Canc Biol & Genet, 1275 York Ave, New York, NY 10021 USA.	podsypak@mskcc.org	Jechlinger, Martin/AAC-9442-2020	Jechlinger, Martin/0000-0002-3710-4466	NIH [K01 CA118731, P01 CA94060, R24 CA83084, P30-CA 08748]; Martell Foundation; U.S. Department of Defense [W81XWH-05-1-0220]; NATIONAL CANCER INSTITUTE [P01CA094060, P30CA008748, K01CA118731, R24CA083084] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Martell Foundation; U.S. Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank M. A. Melnick, G. Sanchez, A. Giannakou, and J. Demers for expert handling of the mouse colony; L. Chodosh for providing MMTV-rtTA transgenic mice; D. Felsher and J. M. Bishop for providing TetO-MYC transgenic mice; A. Olshen for assistance with statistical analysis; and L. K. Tan for assistance with histological analysis. Supported in part by awards from NIH (K01 CA118731 to K. P., P01 CA94060 to H. V., and R24 CA83084 and P30-CA 08748, which provides partial support for core facilities used in conducting this investigation), the Martell Foundation ( to H. V.), and the U.S. Department of Defense (W81XWH-05-1-0220 to M. J.).	Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Gunther EJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0551com; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hartwell KA, 2006, P NATL ACAD SCI USA, V103, P18969, DOI 10.1073/pnas.0608636103; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Podsypanina K, 2008, P NATL ACAD SCI USA, V105, P5242, DOI 10.1073/pnas.0801197105; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	17	214	220	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 26	2008	321	5897					1841	1844		10.1126/science.1161621	http://dx.doi.org/10.1126/science.1161621			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	352MM	18755941	Green Accepted			2022-12-28	WOS:000259501300040
J	Courbet, S; Gay, S; Arnoult, N; Wronka, G; Anglana, M; Brison, O; Debatisse, M				Courbet, Sylvain; Gay, Sophie; Arnoult, Nausica; Wronka, Gerd; Anglana, Mauro; Brison, Olivier; Debatisse, Michelle			Replication fork movement sets chromatin loop size and origin choice in mammalian cells	NATURE			English	Article							SITE-SPECIFIC INITIATION; COMMON FRAGILE SITES; DNA-REPLICATION; NUCLEAR-MATRIX; CHROMOSOMAL DNA; REPLICON; TRANSCRIPTION; ORIGNAI3; DYNAMICS; DOMAINS	Genome stability requires one, and only one, DNA duplication at each S phase. The mechanisms preventing origin firing on newly replicated DNA are well documented(1), but much less is known about the mechanisms controlling the spacing of initiation events 2,3, namely the completion of DNA replication. Here we show that origin use in Chinese hamster cells depends on both the movement of the replication forks and the organization of chromatin loops. We found that slowing the replication speed triggers the recruitment of latent origins within minutes, allowing the completion of S phase in a timely fashion. When slowly replicating cells are shifted to conditions of fast fork progression, although the decrease in the overall number of active origins occurs within 2 h, the cells still have to go through a complete cell cycle before the efficiency specific to each origin is restored. We observed a strict correlation between replication speed during a given S phase and the size of chromatin loops in the next G1 phase. Furthermore, we found that origins located at or near sites of anchorage of chromatin loops in G1 are activated preferentially in the following S phase. These data suggest a mechanism of origin programming in which replication speed determines the spacing of anchorage regions of chromatin loops, that, in turn, controls the choice of initiation sites.	[Courbet, Sylvain; Gay, Sophie; Arnoult, Nausica; Wronka, Gerd; Anglana, Mauro; Brison, Olivier; Debatisse, Michelle] Inst Curie, F-75248 Paris, France; [Courbet, Sylvain; Gay, Sophie; Arnoult, Nausica; Wronka, Gerd; Anglana, Mauro; Brison, Olivier; Debatisse, Michelle] Univ Paris 06, UPMC, F-75005 Paris, France; [Courbet, Sylvain; Gay, Sophie; Arnoult, Nausica; Wronka, Gerd; Anglana, Mauro; Brison, Olivier; Debatisse, Michelle] CNRS, UMR 7147, F-75700 Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS)	Debatisse, M (corresponding author), Inst Curie, 26 Rue Ulm, F-75248 Paris, France.	michelle.debatisse@curie.fr		Arnoult, Nausica/0000-0003-2633-0270	ARC; Ministere de la Recherche; La Ligue Nationale contre le Cancer; Agence Nationale de la Recherche	ARC(Australian Research Council); Ministere de la Recherche(Ministry of Science and Innovation, Spain (MICINN)Ministry of Research, France); La Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Agence Nationale de la Recherche(French National Research Agency (ANR))	We thank E. Blackburn, R. Rothstein and F. Toledo for discussions and critical reading of the manuscript, and Genomic Vision for making available the DNA combing technology. S.C. is supported by a grant from the ARC ( Association pour la Recherche sur le Cancer), and S.G. and N.A. are supported by a grant from the Ministere de la Recherche. The M.D. team is supported by La Ligue Nationale contre le Cancer and the Agence Nationale de la Recherche (ANR).	Anachkova B, 2005, J CELL BIOCHEM, V96, P951, DOI 10.1002/jcb.20610; Anglana M, 2003, CELL, V114, P385, DOI 10.1016/S0092-8674(03)00569-5; Berezney R, 2000, CHROMOSOMA, V108, P471, DOI 10.1007/s004120050399; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; BUONGIORNONARDELLI M, 1982, NATURE, V298, P100, DOI 10.1038/298100a0; DEBATISSE M, 1982, MOL CELL BIOL, V2, P1346, DOI 10.1128/MCB.2.11.1346; DePamphilis ML, 2006, CURR OPIN CELL BIOL, V18, P231, DOI 10.1016/j.ceb.2006.04.001; Dietzel S, 2001, NAT CELL BIOL, V3, P767, DOI 10.1038/35087089; El Achkar E, 2005, P NATL ACAD SCI USA, V102, P18069, DOI 10.1073/pnas.0506497102; Fernandez MA, 1997, J CELL BIOCHEM, V67, P541, DOI 10.1002/(SICI)1097-4644(19971215)67:4<541::AID-JCB11>3.0.CO;2-C; Gilbert DM, 2007, CHROMOSOMA, V116, P341, DOI 10.1007/s00412-007-0105-9; GILBERT DM, 1995, MOL CELL BIOL, V15, P2942; Hancock R, 2004, BIOL CELL, V96, P595, DOI 10.1016/j.biolcel.2004.05.003; Jenke ACW, 2004, P NATL ACAD SCI USA, V101, P11322, DOI 10.1073/pnas.0401355101; Kitamura E, 2006, CELL, V125, P1297, DOI 10.1016/j.cell.2006.04.041; Lawlis SJ, 1996, J CELL BIOL, V135, P1207, DOI 10.1083/jcb.135.5.1207; Lebofsky R, 2006, MOL BIOL CELL, V17, P5337, DOI 10.1091/mbc.E06-04-0298; Lemaitre JM, 2005, CELL, V123, P787, DOI 10.1016/j.cell.2005.08.045; Li F, 2003, J CELL BIOL, V161, P257, DOI 10.1083/jcb.200211127; Merrick CJ, 2004, J BIOL CHEM, V279, P20067, DOI 10.1074/jbc.M400022200; PARDOLL DM, 1980, CELL, V19, P527, DOI 10.1016/0092-8674(80)90527-9; Pasero P, 2002, GENE DEV, V16, P2479, DOI 10.1101/gad.232902; Razin SV, 2001, CELL MOL BIOL LETT, V6, P59; Svetlova EY, 2001, J CELL BIOCHEM, P170; Toledo F, 1999, NUCLEIC ACIDS RES, V27, P1600, DOI 10.1093/nar/27.7.1600; Toledo F, 1998, NUCLEIC ACIDS RES, V26, P2313, DOI 10.1093/nar/26.10.2313; Wu JR, 1996, SCIENCE, V271, P1270, DOI 10.1126/science.271.5253.1270	27	169	171	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 25	2008	455	7212					557	560		10.1038/nature07233	http://dx.doi.org/10.1038/nature07233			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	351TU	18716622				2022-12-28	WOS:000259449600051
J	Yu, XC; Tsibane, T; McGraw, PA; House, FS; Keefer, CJ; Hicar, MD; Tumpey, TM; Pappas, C; Perrone, LA; Martinez, O; Stevens, J; Wilson, IA; Aguilar, PV; Altschuler, EL; Basler, CF; Crowe, JE				Yu, Xiaocong; Tsibane, Tshidi; McGraw, Patricia A.; House, Frances S.; Keefer, Christopher J.; Hicar, Mark D.; Tumpey, Terrence M.; Pappas, Claudia; Perrone, Lucy A.; Martinez, Osvaldo; Stevens, James; Wilson, Ian A.; Aguilar, Patricia V.; Altschuler, Eric L.; Basler, Christopher F.; Crowe, James E., Jr.			Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors	NATURE			English	Article							HUMAN MONOCLONAL-ANTIBODIES; VIRUS-LIKE PARTICLES; SMALLPOX VACCINATION; HUMORAL IMMUNITY; PLASMA-CELLS; HEMAGGLUTININ; MEMORY; INFECTION; DURATION; ORIGIN	Investigation of the human antibody response to influenza virus infection has been largely limited to serology, with relatively little analysis at the molecular level. The 1918 H1N1 influenza virus pandemic was the most severe of the modern era(1). Recent work has recovered the gene sequences of this unusual strain(2), so that the 1918 pandemic virus could be reconstituted to display its unique virulence phenotypes(3,4). However, little is known about adaptive immunity to this virus. We took advantage of the 1918 virus sequencing and the resultant production of recombinant 1918 haemagglutinin ( HA) protein antigen to characterize at the clonal level neutralizing antibodies induced by natural exposure of survivors to the 1918 pandemic virus. Here we show that of the 32 individuals tested that were born in or before 1915, each showed seroreactivity with the 1918 virus, nearly 90 years after the pandemic. Seven of the eight donor samples tested had circulating B cells that secreted antibodies that bound the 1918 HA. We isolated B cells from subjects and generated five monoclonal antibodies that showed potent neutralizing activity against 1918 virus from three separate donors. These antibodies also cross- reacted with the genetically similar HA of a 1930 swine H1N1 influenza strain, but did not cross- react with HAs of more contemporary human influenza viruses. The antibody genes had an unusually high degree of somatic mutation. The antibodies bound to the 1918 HA protein with high affinity, had exceptional virus- neutralizing potency and protected mice from lethal infection. Isolation of viruses that escaped inhibition suggested that the antibodies recognize classical antigenic sites on the HA surface. Thus, these studies demonstrate that survivors of the 1918 influenza pandemic possess highly functional, virus- neutralizing antibodies to this uniquely virulent virus, and that humans can sustain circulating B memory cells to viruses for many decades after exposure - well into the tenth decade of life.	[Yu, Xiaocong; McGraw, Patricia A.; House, Frances S.; Keefer, Christopher J.; Hicar, Mark D.; Crowe, James E., Jr.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA; [Yu, Xiaocong; McGraw, Patricia A.; House, Frances S.; Keefer, Christopher J.; Hicar, Mark D.; Crowe, James E., Jr.] Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, Nashville, TN 37232 USA; [Tsibane, Tshidi; Pappas, Claudia; Martinez, Osvaldo; Aguilar, Patricia V.; Basler, Christopher F.] Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; [Tumpey, Terrence M.; Pappas, Claudia; Perrone, Lucy A.; Stevens, James] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA; [Stevens, James; Wilson, Ian A.] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; [Stevens, James; Wilson, Ian A.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; [Altschuler, Eric L.] Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA	Vanderbilt University; Vanderbilt University; Icahn School of Medicine at Mount Sinai; Centers for Disease Control & Prevention - USA; Scripps Research Institute; Scripps Research Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center	Crowe, JE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA.	altschel@umdnj.edu; Chris.Basler@mssm.edu; James.Crowe@vanderbilt.edu	Crowe, James/B-5549-2009; Basler, Christopher/AAG-8346-2019; Stevens, James/GQH-1081-2022	Crowe, James/0000-0002-0049-1079; Basler, Christopher/0000-0003-4195-425X; Martinez, Osvaldo/0000-0001-7335-4342; PERRONE. MSPH, PhD, LUCY A./0000-0003-2185-688X	University of Medicine and Dentistry of New Jersey; Institute for the Elimination of Health Disparities; National Institutes of Health [U54 AI057157, CA55896, AI42266]; Southeast Regional Center of Excellence for Emerging Infections and Biodefense [U19 AI057229]; Northeast Biodefense Center [U54 AI57158, U19 AI62623, AI057158]; Center for Investigating Viral Immunity and Antagonism [P01AI058113)]; NATIONAL CANCER INSTITUTE [R01CA055896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI042266, U19AI062623, U19AI057229, R01AI042266, R01AI048677, U54AI057158, P01AI058113, U54AI057157] Funding Source: NIH RePORTER	University of Medicine and Dentistry of New Jersey; Institute for the Elimination of Health Disparities; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Southeast Regional Center of Excellence for Emerging Infections and Biodefense(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Northeast Biodefense Center; Center for Investigating Viral Immunity and Antagonism; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank L. Schoenherr, K. Sharma, L. Adams (supported by the University of Medicine and Dentistry of New Jersey (UMDNJ) Institute for the Elimination of Health Disparities), C. Dokes, C. Gaines, B. Butter and S. Rivera for assistance with subjects, and S. Yoder and B. Briney for sample preparation. This work was supported by grants from the National Institutes of Health to J. E. C. (U54 AI057157, Southeast Regional Center of Excellence for Emerging Infections and Biodefense, and U19 AI057229), and C. F. B. (U54 AI57158, Northeast Biodefense Center, U19 AI62623, Center for Investigating Viral Immunity and Antagonism, and P01AI058113). I. A. W. and J. S. were supported in part by the National Institutes of Health (CA55896 and AI42266). P. V. A. was supported by a fellowship awarded by the Northeast Biodefense Center (AI057158). We thank P. Palese and A. Garcia- Sastre for advice and for providing H1N1 viruses, and M. Posner and L. Cavacini for the HMMA2.5 cell line.	Amanna IJ, 2007, NEW ENGL J MED, V357, P1903, DOI 10.1056/NEJMoa066092; Amanna IJ, 2006, IMMUNOL REV, V211, P320, DOI 10.1111/j.0105-2896.2006.00392.x; Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071; Brownlee GG, 2001, PHILOS T ROY SOC B, V356, P1871, DOI 10.1098/rstb.2001.1001; CATON AJ, 1982, CELL, V31, P417, DOI 10.1016/0092-8674(82)90135-0; Chen BJ, 2007, J VIROL, V81, P7111, DOI 10.1128/JVI.00361-07; Crotty S, 2003, J IMMUNOL, V171, P4969, DOI 10.4049/jimmunol.171.10.4969; Glaser L, 2005, J VIROL, V79, P11533, DOI 10.1128/JVI.79.17.11533-11536.2005; Hammarlund E, 2003, NAT MED, V9, P1131, DOI 10.1038/nm917; Johnson NPAS, 2002, B HIST MED, V76, P105, DOI 10.1353/bhm.2002.0022; Kash JC, 2006, NATURE, V443, P578, DOI 10.1038/nature05181; KENDAL AP, 1982, CONCEPTS PROCEDURES, pB17; Kobasa D, 2007, NATURE, V445, P319, DOI 10.1038/nature05495; Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139; Manz RA, 1997, NATURE, V388, P133, DOI 10.1038/40540; Mozdzanowska K, 1997, J VIROL, V71, P4347, DOI 10.1128/JVI.71.6.4347-4355.1997; NAKAJIMA K, 1978, NATURE, V274, P334, DOI 10.1038/274334a0; POSNER MR, 1987, HYBRIDOMA, V6, P611, DOI 10.1089/hyb.1987.6.611; REED L. J., 1938, AMER JOUR HYG, V27, P493; Ruiz M, 2000, NUCLEIC ACIDS RES, V28, P219, DOI 10.1093/nar/28.1.219; Slifka MK, 1998, IMMUNITY, V8, P363, DOI 10.1016/S1074-7613(00)80541-5; Stevens J, 2004, SCIENCE, V303, P1866, DOI 10.1126/science.1093373; Taubenberger JK, 2006, P AM PHILOS SOC, V150, P86; Taubenberger JK, 2005, NATURE, V437, P889, DOI 10.1038/nature04230; Tian CX, 2007, MOL IMMUNOL, V44, P2173, DOI 10.1016/j.molimm.2006.11.020; Tumpey TM, 2005, SCIENCE, V310, P77, DOI 10.1126/science.1119392; Tumpey TM, 2002, P NATL ACAD SCI USA, V99, P13849, DOI 10.1073/pnas.212519699; Weitkamp JH, 2003, J IMMUNOL METHODS, V275, P223, DOI 10.1016/S0022-1759(03)00013-9; YEWDELL JW, 1979, NATURE, V279, P246, DOI 10.1038/279246a0; Yu XC, 2008, J IMMUNOL METHODS, V336, P142, DOI 10.1016/j.jim.2008.04.008	30	304	319	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 25	2008	455	7212					532	U41		10.1038/nature07231	http://dx.doi.org/10.1038/nature07231			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	351TU	18716625	Green Accepted			2022-12-28	WOS:000259449600046
J	Paranjothy, S; Eisenhut, M; Lilley, M; Bracebridge, S; Abubakar, I; Mulla, R; Lack, K; Chalkley, D; Howard, J; Thomas, S; McEvoy, M				Paranjothy, S.; Eisenhut, M.; Lilley, M.; Bracebridge, S.; Abubakar, I.; Mulla, R.; Lack, K.; Chalkley, D.; Howard, J.; Thomas, S.; McEvoy, M.			Lesson of the week - Extensive transmission of Mycobacterium tuberculosis from 9 year old child with pulmonary tuberculosis and negative sputum smear	BMJ-BRITISH MEDICAL JOURNAL			English	Article									[Paranjothy, S.] Cardiff Univ, Sch Med, Clin Epidemiol Interdisciplinary Res Grp, Dept Primary Care & Publ Hlth, Cardiff CF14 4YS, Wales; [Eisenhut, M.; Mulla, R.] Luton & Dunstable Hosp NHS Fdn Trust, Luton LU4 0DZ, Beds, England; [Lilley, M.; Lack, K.; McEvoy, M.] Bedfordshire & Hertfordshire Hlth Protect Unit, Letchworth SG6 1BE, Herts, England; [Bracebridge, S.; Howard, J.; Thomas, S.] Inst Publ Hlth, Hlth Protect Agcy E England, Reg Epidemiol Unit, Cambridge CB2 2SR, England; [Abubakar, I.] Hlth Protect Agcy, Ctr Infect, Dept Resp Dis, London NW9 5EQ, England; [Abubakar, I.] Univ E Anglia, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England; [Chalkley, D.] Liverpool Chest Clin, Luton Training PCT, Luton LU1 1HH, Beds, England	Cardiff University; Health Protection Agency; University of Cambridge; Health Protection Agency; University of East Anglia	Paranjothy, S (corresponding author), Cardiff Univ, Sch Med, Clin Epidemiol Interdisciplinary Res Grp, Dept Primary Care & Publ Hlth, Cardiff CF14 4YS, Wales.	paranjothys@cf.ac.uk		Paranjothy, Shantini/0000-0002-0528-3121; Abubakar, Ibrahim/0000-0002-0370-1430; Howard, Julia/0000-0003-1612-2136				Behr MA, 1999, LANCET, V353, P444, DOI 10.1016/S0140-6736(98)03406-0; Bilukha Oleg O., 2005, Morbidity and Mortality Weekly Report, V54, P1; Curtis AB, 1999, NEW ENGL J MED, V341, P1491, DOI 10.1056/NEJM199911113412002; HERTZBERG GERH, 1957, AN EPIDEMIOLOGICAL INVESTIGATION ACTA TUBERC SCAND SUPPL, V38, P1; Lienhardt C, 2003, PEDIATRICS, V111, pE608, DOI 10.1542/peds.111.5.e608; LOUDON RG, 1969, AM REV RESPIR DIS, V99, P109; *NAT COLL CTR CHRO, 2006, TUB CLIN DIAGN MAN T; Singh M, 2005, ARCH DIS CHILD, V90, P624, DOI 10.1136/adc.2003.044255	8	14	15	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 6	2008	337	7669							a1184	10.1136/bmj.a1184	http://dx.doi.org/10.1136/bmj.a1184			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	351JP	18755765	Green Accepted			2022-12-28	WOS:000259420900038
J	Yusuf, S; Teo, K; Anderson, C; Pogue, J; Dyal, L; Copland, I; Schumacher, H; Dagenais, G; Sleight, P				Yusuf, S.; Teo, K.; Anderson, C.; Pogue, J.; Dyal, L.; Copland, I.; Schumacher, H.; Dagenais, G.; Sleight, P.		Telmisartan Randomised AssessmeNt	Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial	LANCET			English	Article							VENTRICULAR SYSTOLIC DYSFUNCTION; END-POINT REDUCTION; HEART-FAILURE; MYOCARDIAL-INFARCTION; LOSARTAN INTERVENTION; DIABETES-MELLITUS; CLINICAL-TRIALS; FOLLOW-UP; LIFE; CANDESARTAN	Background Angiotensin-converting enzyme (ACE) inhibitors reduce major cardiovascular events, but are not tolerated by about 20% of patients. We therefore assessed whether the angiotensin-receptor blocker telmisartan would be effective in patients intolerant to ACE inhibitors with cardiovascular disease or diabetes with end-organ damage. Methods After a 3-week run-in period, 5926 patients, many of whom were receiving concomitant proven therapies, were randomised to receive telmisartan 80 mg/day (n=2954) or placebo (n=2972) by use of a central automated randomisation system. Randomisation was stratified by hospital. The primary outcome was the composite of cardiovascular death, myocardial infarction, stroke, or hospitalisation for heart failure. Analyses were done by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00153101. Findings The median duration of follow-up was 56 (IQR 51-64) months. All randomised patients were included in the efficacy analyses. Mean blood pressure was lower in the telmisartan group than in the placebo group throughout the study (weighted mean difference between groups 4 .0/2.2 [SD 19.6/12. 0] mm Hg). 465 (15.7%) patients experienced the primary outcome in the telmisartan group compared with 504 (17 . 0%) in the placebo group (hazard ratio 0 . 92, 95% CI 0 . 81-1 . 05, p=0.216). One of the secondary outcomes-a composite of cardiovascular death, myocardial infarction, or stroke-occurred in 384 (13 . 0%) patients on telmisartan compared with 440 (14.8%) on placebo (0 . 87, 0 . 76-1 . 00, P=0. 048 unadjusted; p=0.068 after adjustment for multiplicity of comparisons and overlap with primary outcome). 894 (30.3%) patients receiving telmisartan were hospitalised for a cardiovascular reason, compared with 980 (33 .0%) on placebo (relative risk 0 . 92, 95% CI 0. 85-0. 99; p=0. 025). Fewer patients permanently discontinued study medication in the telmisartan group than in the placebo group (639 [21.6%] vs 705 [23.8%]; p=0.055); the most common reason for permanent discontinuation was hypotensive symptoms (29 [0.98%] in the telmisartan group vs 16 [0.54%] in the placebo group). Interpretation Telmisartan was well tolerated in patients unable to tolerate ACE inhibitors. Although the drug had no significant effect on the primary outcome of this study, which included hospitalisations for heart failure, it modestly reduced the risk of the composite outcome of cardiovascular death, myocardial infarction, or stroke. Funding Boehringer Ingelheim.	[Yusuf, S.] Hamilton Hlth Sci, Populat Hlth Res Inst, Hamilton, ON L8L 2X2, Canada; [Yusuf, S.] McMaster Univ, Hamilton, ON L8L 2X2, Canada	McMaster University; Population Health Research Institute; McMaster University	Yusuf, S (corresponding author), Hamilton Hlth Sci, Populat Hlth Res Inst, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.	yusufs@mcmaster.ca	Yusof, Zurkurnai/AAA-5893-2021; Force, Rex W/K-4094-2012; Davis, Stephen M/L-5260-2013; Vanhooren, Geert/H-4433-2011; Verheugt, F.W.A./H-8105-2014; Stanton, Alice V/F-4697-2012; bladin, chris/B-9136-2013; Munzel, Thomas/A-2912-2014; Böhm, Michael/C-3638-2011; Parsons, Mark W./G-3750-2014; Thompson, Peter L/P-1071-2014; Chen, Christopher/E-7023-2013; Arnold, Malcolm/G-2869-2011; Granger, Christopher B/D-3458-2014; Belenkov, Yury N/B-4159-2018; Jennings, Garry/B-3914-2009	Davis, Stephen M/0000-0003-0962-2300; Vanhooren, Geert/0000-0001-6818-9346; Munzel, Thomas/0000-0001-5503-4150; Chen, Christopher/0000-0002-1047-9225; Granger, Christopher B/0000-0002-0045-3291; Seo, Hong Seog/0000-0002-3228-7988; Liang, Chang-seng/0000-0002-0328-0277; McEneaney, David/0000-0002-1734-0736; Cunha, Luis/0000-0002-0828-3485; Held, Claes/0000-0001-9402-7404; da Silva Franco, Roberto Jorge/0000-0001-9787-4393; Ruilope, Luis M/0000-0001-6278-7951; ELISAF, MOSES/0000-0003-0505-078X; Yusuf, Salim/0000-0003-4776-5601; Stanton, Alice/0000-0002-4961-165X; Volpe, Massimo/0000-0002-9642-8380; Maher, Vincent/0000-0002-3592-4508	Boehringer Ingelheim; Heart and Stroke Foundation of Ontario; Senior Scientist Award; Canadian Institutes of Health Research	Boehringer Ingelheim(Boehringer Ingelheim); Heart and Stroke Foundation of Ontario(Heart & Stroke Foundation of Ontario); Senior Scientist Award; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	The study was supported by a grant from Boehringer Ingelheim. S Yusuf was supported by the Heart and Stroke Foundation of Ontario, and a Senior Scientist Award from the Canadian Institutes of Health Research. We thank Judy Lindeman for secretarial assistance.	Arnold JMO, 2003, CIRCULATION, V107, P1284, DOI 10.1161/01.CIR.0000054165.93055.42; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Bart BA, 1999, EUR HEART J, V20, P1182, DOI 10.1053/euhj.1998.1481; Bosch J, 2006, NEW ENGL J MED, V355, P1551; Braunwald E, 2004, NEW ENGL J MED, V351, P2058; COX DR, 1972, J R STAT SOC B, V34, P187; Dagenais GR, 2006, LANCET, V368, P581, DOI 10.1016/S0140-6736(06)69201-5; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Demers C, 2005, JAMA-J AM MED ASSOC, V294, P1794, DOI 10.1001/jama.294.14.1794; Elliott WJ, 2007, LANCET, V369, P201, DOI 10.1016/S0140-6736(07)60108-1; Ford I, 2007, NEW ENGL J MED, V357, P1477, DOI 10.1056/NEJMoa065994; Fox KM, 2003, LANCET, V362, P782; Furberg CD, 2000, JAMA-J AM MED ASSOC, V283, P1967; Gerstein HC, 2000, LANCET, V355, P253; Granger CB, 2003, LANCET, V362, P772, DOI 10.1016/S0140-6736(03)14284-5; Jong P, 2003, LANCET, V361, P1843, DOI 10.1016/S0140-6736(03)13501-5; Julius S, 2004, LANCET, V363, P2022, DOI 10.1016/S0140-6736(04)16451-9; Lindholm LH, 2002, LANCET, V359, P1004, DOI 10.1016/S0140-6736(02)08090-X; MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5; Maggioni AP, 2002, J AM COLL CARDIOL, V40, P1414, DOI 10.1016/S0735-1097(02)02304-5; McDowell SE, 2006, BMJ-BRIT MED J, V332, P1177, DOI 10.1136/bmj.38803.528113.55; Patel A, 2007, LANCET, V370, P829, DOI 10.1016/S0140-6736(07)61303-8; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Pfeffer MA, 2003, NEW ENGL J MED, V349, P1893, DOI 10.1056/NEJMoa032292; Teo KK, 2004, AM HEART J, V148, P52, DOI 10.1016/j.ahj.2004.03.020; Turnbull F, 2003, LANCET, V362, P1527; Verma S, 2004, BMJ-BRIT MED J, V329, P1248, DOI 10.1136/bmj.329.7477.1248; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; Yusuf S, 2005, CIRCULATION, V112, P48, DOI 10.1161/CIRCULATIONAHA.104.528166; Yusuf S, 2001, JAMA-J AM MED ASSOC, V286, P1882, DOI 10.1001/jama.286.15.1882; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Yusuf S, 2008, NEW ENGL J MED, V359, P1225, DOI 10.1056/NEJMoa0804593; Yusuf S, 2008, NEW ENGL J MED, V358, P1547, DOI 10.1056/NEJMoa0801317	33	771	799	0	33	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP-OCT	2008	372	9644					1174	1183		10.1016/S0140-6736(08)61242-8	http://dx.doi.org/10.1016/S0140-6736(08)61242-8			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	355UN	18757085				2022-12-28	WOS:000259734700032
J	Gerber, PA; Kukova, G; Meller, S; Neumann, NJ; Homey, B				Gerber, Peter A.; Kukova, Gabriela; Meller, Stephan; Neumann, Norbert J.; Homey, Bernhard			The dire consequences of doping	LANCET			English	Editorial Material									[Gerber, Peter A.; Kukova, Gabriela; Meller, Stephan; Neumann, Norbert J.; Homey, Bernhard] Univ Dusseldorf, Dept Dermatol, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Gerber, PA (corresponding author), Univ Dusseldorf, Dept Dermatol, Moorenstr 5, D-40225 Dusseldorf, Germany.	peterarne.gerber@uni-duesseldorf.de	Meller, Stephan/GYA-5568-2022; Gerber, Peter Arne/M-2746-2013; Gerber, Peter Arne/C-2000-2009	Gerber, Peter Arne/0000-0003-1657-1863; 					0	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 23	2008	372	9639					656	656		10.1016/S0140-6736(08)61278-7	http://dx.doi.org/10.1016/S0140-6736(08)61278-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	340BX	18722870	Bronze			2022-12-28	WOS:000258622200029
J	Horwitz, GA; Zhang, KL; McBrian, MA; Grunstein, M; Kurdistani, SK; Berk, AJ				Horwitz, Gregory A.; Zhang, Kangling; McBrian, Matthew A.; Grunstein, Michael; Kurdistani, Siavash K.; Berk, Arnold J.			Adenovirus small e1a alters global patterns of histone modification	SCIENCE			English	Article							CELL-CYCLE CONTROL; TRANSFORMATION; PROTEIN; E1A-PROTEINS; EXPRESSION; TARGETS; COMPLEX	Adenovirus small early region 1a ( e1a) protein drives cells into S phase by binding RB family proteins and the closely related histone acetyl transferases p300 and CBP. The interaction with RB proteins displaces them from DNA- bound E2F transcription factors, reversing their repression of cell cycle genes. However, it has been unclear how the e1a interaction with p300 and CBP promotes passage through the cell cycle. We show that this interaction causes a threefold reduction in total cellular histone H3 lysine 18 acetylation ( H3K18ac). CBP and p300 are required for acetylation at this site because their knockdown causes specific hypoacetylation at H3K18. SV40 T antigen also induces H3K18 hypoacetylation. Because global hypoacetylation at this site is observed in prostate carcinomas with poor prognosis, this suggests that processes resulting in global H3K18 hypoacetylation may be linked to oncogenic transformation.	[Horwitz, Gregory A.; Berk, Arnold J.] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; [Zhang, Kangling] Loma Linda Univ, Mass Spectrometry Facil, Dept Biochem, Sch Med, Loma Linda, CA 92350 USA; [McBrian, Matthew A.; Grunstein, Michael; Kurdistani, Siavash K.] Univ Calif Los Angeles, Dept Biol Chem, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Berk, Arnold J.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; Loma Linda University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Berk, AJ (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA.	berk@mbi.ucla.edu	BERK, ARNOLD/AAF-7052-2020	Kurdistani, Siavash/0000-0003-3295-3511	NIH [CA25235]; NATIONAL CANCER INSTITUTE [R01CA025235, R37CA025235] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by NIH grant CA25235 to A. J. B. and a Beckman Young Investigator Award to S. K. K. We thank C. Eng for technical assistance.	Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Blais A, 2007, CURR OPIN CELL BIOL, V19, P658, DOI 10.1016/j.ceb.2007.10.003; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Ferrari R, 2008, SCIENCE, V321, P1086, DOI 10.1126/science.1155546; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Liu X, 2007, GENE DEV, V21, P2711, DOI 10.1101/gad.1590607; MONTELL C, 1984, CELL, V36, P951, DOI 10.1016/0092-8674(84)90045-X; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; O'Hare MJ, 2001, P NATL ACAD SCI USA, V98, P646, DOI 10.1073/pnas.98.2.646; Rasti M, 2005, J VIROL, V79, P5594, DOI 10.1128/JVI.79.9.5594-5605.2005; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Wang G, 2002, J VIROL, V76, P9186, DOI 10.1128/JVI.76.18.9186-9193.2002; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	17	164	166	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	2008	321	5892					1084	1085		10.1126/science.1155544	http://dx.doi.org/10.1126/science.1155544			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339RL	18719283	Green Accepted			2022-12-28	WOS:000258594900039
J	Kirchhoff, F				Kirchhoff, Frank			Silencing HIV-1 in vivo	CELL			English	Editorial Material							RNA INTERFERENCE; DELIVERY	RNA interference holds great promise for antiviral therapy, but delivering effective quantities of small interfering RNAs (siRNAs) into the right target cells in vivo represents a major challenge. Kumar et al. (2008) now report a technique to target siRNAs specifically to T cells to suppress viral infection in a humanized mouse model of HIV/AIDS.	Univ Ulm, Inst Virol, D-89081 Ulm, Germany	Ulm University	Kirchhoff, F (corresponding author), Univ Ulm, Inst Virol, D-89081 Ulm, Germany.	frank.kirchhoff@uniklinik-ulm.de	Kirchhoff, Frank/O-8367-2018	Kirchhoff, Frank/0000-0002-7052-2360	German Research Foundation; Wilhelm-Sander Foundation; National Institutes of Health RO1 [AI067057]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI067057] Funding Source: NIH RePORTER	German Research Foundation(German Research Foundation (DFG)); Wilhelm-Sander Foundation; National Institutes of Health RO1(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The author thanks N. Arhel and G. Silvestri for helpful comments. F. K. is supported by the German Research Foundation, the Wilhelm-Sander Foundation, and National Institutes of Health RO1 grant AI067057.	Akhtar S, 2007, J CLIN INVEST, V117, P3623, DOI 10.1172/JCI33494; Berges BK, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-76; Corey DR, 2007, J CLIN INVEST, V117, P3615, DOI 10.1172/JCI33483; Dykxhoorn DM, 2006, PLOS MED, V3, P1000, DOI 10.1371/journal.pmed.0030242; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Grimm D, 2007, J CLIN INVEST, V117, P3633, DOI 10.1172/JCI34129; Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901; Shultz LD, 2007, NAT REV IMMUNOL, V7, P118, DOI 10.1038/nri2017; Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101	9	20	21	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 22	2008	134	4					566	568		10.1016/j.cell.2008.08.004	http://dx.doi.org/10.1016/j.cell.2008.08.004			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SR	18724929	Bronze			2022-12-28	WOS:000258665800009
J	Newton, K; Matsumoto, ML; Wertz, IE; Kirkpatrick, DS; Lill, JR; Tan, J; Dugger, D; Gordon, N; Sidhu, SS; Fellouse, FA; Komuves, L; French, DM; Ferrando, RE; Lam, C; Compaan, D; Yu, C; Bosanac, I; Hymowitz, SG; Kelley, RF; Dixit, VM				Newton, Kim; Matsumoto, Marissa L.; Wertz, Ingrid E.; Kirkpatrick, Donald S.; Lill, Jennie R.; Tan, Jenille; Dugger, Debra; Gordon, Nathaniel; Sidhu, Sachdev S.; Fellouse, Frederic A.; Komuves, Laszlo; French, Dorothy M.; Ferrando, Ronald E.; Lam, Cynthia; Compaan, Deanne; Yu, Christine; Bosanac, Ivan; Hymowitz, Sarah G.; Kelley, Robert F.; Dixit, Vishva M.			Ubiquitin chain editing revealed by polyubiquitin linkage-specific antibodies	CELL			English	Article							RECEPTOR-ASSOCIATED KINASE; KAPPA-B ACTIVATION; LYS63-LINKED POLYUBIQUITINATION; BINDING; MULTIUBIQUITINATION; LIBRARIES; RESPONSES; REQUIRES; COMPLEX; SYSTEM	Posttranslational modification of proteins with polyubiquitin occurs in diverse signaling pathways and is tightly regulated to ensure cellular homeostasis. Studies employing ubiquitin mutants suggest that the fate of polyubiquitinated proteins is determined by which lysine within ubiquitin is linked to the C terminus of an adjacent ubiquitin. We have developed linkage-specific antibodies that recognize polyubiquitin chains joined through lysine 63 (K63) or 48 (K48). A cocrystal structure of an anti-K63 linkage Fab bound to K63-linked diubiquitin provides insight into the molecular basis for specificity. We use these antibodies to demonstrate that RIP1, which is essential for tumor necrosis factor-induced NF-kappa B activation, and IRAK1, which participates in signaling by interleukin-1b and Toll-like receptors, both undergo polyubiquitin editing in stimulated cells. Both kinase adaptors initially acquire K63-linked polyubiquitin, while at later times K48-linked polyubiquitin targets them for proteasomal degradation. Polyubiquitin editing may therefore be a general mechanism for attenuating innate immune signaling.	[Newton, Kim; Tan, Jenille; Dugger, Debra; Dixit, Vishva M.] Genentech Inc, Dept Physiol Chem, San Francisco, CA 94080 USA; [Matsumoto, Marissa L.; Gordon, Nathaniel; Sidhu, Sachdev S.; Fellouse, Frederic A.; Kelley, Robert F.] Genentech Inc, Dept Antibody Engn, San Francisco, CA 94080 USA; [Wertz, Ingrid E.; Lam, Cynthia; Compaan, Deanne; Yu, Christine; Bosanac, Ivan; Hymowitz, Sarah G.] Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; [Kirkpatrick, Donald S.; Lill, Jennie R.] Genentech Inc, Dept Prot Chem, San Francisco, CA 94080 USA; [Komuves, Laszlo; French, Dorothy M.; Ferrando, Ronald E.] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Dixit, VM (corresponding author), Genentech Inc, Dept Physiol Chem, 1 DNA Way, San Francisco, CA 94080 USA.	dixit@gene.com	dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326; Matsumoto, Marissa/0000-0002-5353-1097; Kirkpatrick, Donald/0000-0003-3091-2804				Bennett EJ, 2007, NATURE, V448, P704, DOI 10.1038/nature06022; Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110; Conze DB, 2008, MOL CELL BIOL, V28, P3538, DOI 10.1128/MCB.02098-07; COOK WJ, 1992, J BIOL CHEM, V267, P16467; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Fellouse FA, 2007, J MOL BIOL, V373, P924, DOI 10.1016/j.jmb.2007.08.005; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Kanakaraj P, 1998, J EXP MED, V187, P2073, DOI 10.1084/jem.187.12.2073; Kim HT, 2007, J BIOL CHEM, V282, P17375, DOI 10.1074/jbc.M609659200; Kirkpatrick DS, 2006, NAT CELL BIOL, V8, P700, DOI 10.1038/ncb1436; Lee CV, 2004, J MOL BIOL, V340, P1073, DOI 10.1016/j.jmb.2004.05.051; Lee TH, 2004, J BIOL CHEM, V279, P33185, DOI 10.1074/jbc.M404206200; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Ordureau A, 2008, BIOCHEM J, V409, P43, DOI 10.1042/BJ20071365; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Pickart CM, 2005, METHOD ENZYMOL, V399, P21, DOI 10.1016/S0076-6879(05)99002-2; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Sidhu SS, 2000, METHOD ENZYMOL, V328, P333, DOI 10.1016/S0076-6879(00)28406-1; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Thomas JA, 1999, J IMMUNOL, V163, P978; Varadan R, 2002, J MOL BIOL, V324, P637, DOI 10.1016/S0022-2836(02)01198-1; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Windheim M, 2008, MOL CELL BIOL, V28, P1783, DOI 10.1128/MCB.02380-06; Xiao H, 2008, J BIOL CHEM, V283, P14654, DOI 10.1074/jbc.M706931200; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540	29	441	457	1	25	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 22	2008	134	4					668	678		10.1016/j.cell.2008.07.039	http://dx.doi.org/10.1016/j.cell.2008.07.039			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SR	18724939	Bronze			2022-12-28	WOS:000258665800019
J	Cummings, SR; Ettinger, B; Delmas, PD; Kenemans, P; Stathopoulos, V; Verweij, P; Mol-Arts, M; Kloosterboer, L; Mosca, L; Christiansen, C; Bilezikian, J; Kerzberg, EM; Johnson, S; Zanchetta, J; Grobbee, DE; Seifert, W; Eastell, R				Cummings, Steven R.; Ettinger, Bruce; Delmas, Pierre D.; Kenemans, Peter; Stathopoulos, Victoria; Verweij, Pierre; Mol-Arts, Mirjam; Kloosterboer, Lenus; Mosca, Lori; Christiansen, Claus; Bilezikian, John; Kerzberg, Eduardo Mario; Johnson, Susan; Zanchetta, Jose; Grobbee, Diederich E.; Seifert, Wilfried; Eastell, Richard		LIFT Trial Investigators	The effects of tibolone in older postmenopausal women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HORMONE-REPLACEMENT THERAPY; ESTROGEN PLUS PROGESTIN; BREAST-CANCER; BONE LOSS; IN-VITRO; PHYSICAL PERFORMANCE; DOUBLE-BLIND; ORG OD14; RISK; PREVENTION	Background: Tibolone has estrogenic, progestogenic, and androgenic effects. Although tibolone prevents bone loss, its effects on fractures, breast cancer, and cardiovascular disease are uncertain. Methods: In this randomized study, we assigned 4538 women, who were between the ages of 60 and 85 years and had a bone mineral density T score of -2.5 or less at the hip or spine or a T score of -2.0 or less and radiologic evidence of a vertebral fracture, to receive once-daily tibolone (at a dose of 1.25 mg) or placebo. Annual spine radiographs were used to assess for vertebral fracture. Rates of cardiovascular events and breast cancer were adjudicated by expert panels. Results: During a median of 34 months of treatment, the tibolone group, as compared with the placebo group, had a decreased risk of vertebral fracture, with 70 cases versus 126 cases per 1000 person-years (relative hazard, 0.55; 95% confidence interval [CI], 0.41 to 0.74; P<0.001), and a decreased risk of nonvertebral fracture, with 122 cases versus 166 cases per 1000 person-years (relative hazard, 0.74; 95% CI, 0.58 to 0.93; P=0.01). The tibolone group also had a decreased risk of invasive breast cancer (relative hazard, 0.32; 95% CI, 0.13 to 0.80; P=0.02) and colon cancer (relative hazard, 0.31; 95% CI, 0.10 to 0.96; P=0.04). However, the tibolone group had an increased risk of stroke (relative hazard, 2.19; 95% CI, 1.14 to 4.23; P=0.02), for which the study was stopped in February 2006 at the recommendation of the data and safety monitoring board. There were no significant differences in the risk of either coronary heart disease or venous thromboembolism between the two groups. Conclusions: Tibolone reduced the risk of fracture and breast cancer and possibly colon cancer but increased the risk of stroke in older women with osteoporosis. (ClinicalTrials.gov number, NCT00519857.).	[Cummings, Steven R.] San Francisco Coordinating Ctr, San Francisco, CA USA; [Cummings, Steven R.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA; [Cummings, Steven R.; Ettinger, Bruce] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Delmas, Pierre D.] Univ Lyon, Lyon, France; [Delmas, Pierre D.] INSERM, Res Unit 831, F-69008 Lyon, France; [Kenemans, Peter] Free Univ Amsterdam Hosp, Amsterdam, Netherlands; [Stathopoulos, Victoria] Organon, Roseland, NJ USA; [Verweij, Pierre; Mol-Arts, Mirjam; Kloosterboer, Lenus; Seifert, Wilfried] Organon, Oss, Netherlands; [Mosca, Lori] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; [Christiansen, Claus] Ctr Clin & Basic Res, Ballerup, Denmark; [Bilezikian, John] Columbia Univ, New York Presbyterian Hosp, New York, NY USA; [Bilezikian, John] Cornell Univ, New York, NY 10021 USA; [Kerzberg, Eduardo Mario] Hosp JM Ramos Mejia, Natl Reference Ctr Osteoporosis, Buenos Aires, DF, Argentina; [Johnson, Susan] Univ Iowa, Carver Coll Med, Iowa City, IA USA; [Zanchetta, Jose] Inst Invest Metab, Buenos Aires, DF, Argentina; [Grobbee, Diederich E.] Univ Utrecht Hosp, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Eastell, Richard] Univ Sheffield, Sheffield, S Yorkshire, England	California Pacific Medical Center; California Pacific Medical Center Research Institute; California Pacific Medical Center; California Pacific Medical Center Research Institute; University of California System; University of California San Francisco; Institut National de la Sante et de la Recherche Medicale (Inserm); Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Columbia University; Center Clinical & Basic Research; Columbia University; NewYork-Presbyterian Hospital; Cornell University; Hospital Ramos Mejia; University of Buenos Aires; University of Iowa; Utrecht University; Utrecht University Medical Center; University of Sheffield	Cummings, SR (corresponding author), San Francisco Coordinating Ctr, San Francisco, CA USA.		Verweij, P.E./H-8108-2014; Eastell, Richard/G-5851-2011; Grobbee, Diederick/C-7651-2014; Eisman, John A/C-2886-2014	Verweij, P.E./0000-0002-8600-9860; Eastell, Richard/0000-0002-0323-3366; Grobbee, Diederick/0000-0003-4472-4468; Erenus, Mithat/0000-0001-9385-7350; ORCEL, Philippe/0000-0001-7028-1133; Koranyi, Laszlo/0000-0002-5733-9350; Kerzberg, Eduardo/0000-0002-5704-6777; Diez-Perez, Adolfo/0000-0001-8162-0209	NHLBI NIH HHS [K24 HL076346] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL076346] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson GL, 2003, JAMA-J AM MED ASSOC, V290, P1739, DOI 10.1001/jama.290.13.1739; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; [Anonymous], 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Archer DF, 2007, J CLIN ENDOCR METAB, V92, P911, DOI 10.1210/jc.2006-2207; Barnes JF, 2005, MENOPAUSE, V12, P92, DOI 10.1097/00042192-200512010-00016; Barrett-Connor E, 2006, NEW ENGL J MED, V355, P125, DOI 10.1056/NEJMoa062462; Beral V, 2005, LANCET, V365, P1543, DOI 10.1016/S0140-6736(05)66455-0; Bjarnason NH, 1997, J CLIN ENDOCR METAB, V82, P1752, DOI 10.1210/jc.82.6.1752; Bjarnason NH, 1996, J CLIN ENDOCR METAB, V81, P2419, DOI 10.1210/jc.81.7.2419; Bots ML, 2006, EUR HEART J, V27, P746, DOI 10.1093/eurheartj/ehi695; Cauley, 2001, BREAST CANCER RES TR, V67, P191; Cauley JA, 2003, JAMA-J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729; Cauley JA, 2001, BREAST CANCER RES TR, V65, P125, DOI 10.1023/A:1006478317173; Chetrite G, 1997, ANTICANCER RES, V17, P135; Chetrite GS, 1999, ANTICANCER RES, V19, P269; Chlebowski RT, 2004, NEW ENGL J MED, V350, P991, DOI 10.1056/NEJMoa032071; Conner P, 2004, CLIMACTERIC, V7, P50, DOI 10.1080/13697130310001651472; Cummings SR, 2006, JAMA-J AM MED ASSOC, V296, P2601, DOI 10.1001/jama.296.21.2601; Cuzick J, 2003, LANCET, V361, P296, DOI 10.1016/S0140-6736(03)12342-2; Davison S, 2003, J CLIN ENDOCR METAB, V88, P2470, DOI 10.1210/jc.2002-021929; de Gooyer ME, 2003, STEROIDS, V68, P21, DOI 10.1016/S0039-128X(02)00112-5; Ederveen AGH, 2001, J BONE MINER RES, V16, P1651, DOI 10.1359/jbmr.2001.16.9.1651; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P2124; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; ETTINGER B, IN PRESS OBSTET GYNE; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Gallagher JC, 2001, J CLIN ENDOCR METAB, V86, P4717, DOI 10.1210/jc.86.10.4717; GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915; Genant HK, 1996, J BONE MINER RES, V11, P984; Gompel A, 2002, FERTIL STERIL, V78, P351, DOI 10.1016/S0015-0282(02)03203-X; Greenspan SL, 2005, AM J MED, V118, P1232, DOI 10.1016/j.amjmed.2005.03.004; Jacobsen DE, 2007, MATURITAS, V58, P7, DOI 10.1016/j.maturitas.2007.04.012; JELINEK J, 1984, J CLIN ENDOCR METAB, V59, P1224, DOI 10.1210/jcem-59-6-1224; KLOOSTERBOER HJ, 1994, J STEROID BIOCHEM, V49, P311, DOI 10.1016/0960-0760(94)90273-9; Kurman RJ, 1994, BLAUSTEINS PATHOLOGY, P411; Laan E, 2001, Climacteric, V4, P28, DOI 10.1080/713605033; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Landgren MB, 2005, MATURITAS, V50, P222, DOI 10.1016/j.maturitas.2004.06.001; Li CI, 2003, J CLIN ONCOL, V21, P28, DOI 10.1200/JCO.2003.03.088; Lippert C, 2002, EUR J GYNAECOL ONCOL, V23, P127; Martino S, 2004, J NATL CANCER I, V96, P1751, DOI 10.1093/jnci/djh319; Meeuwsen IB, 2002, MATURITAS, V41, P35, DOI 10.1016/S0378-5122(01)00251-1; Modelska K, 2003, AM J OBSTET GYNECOL, V188, P286, DOI 10.1067/mob.2003.117; Modelska K, 2002, J CLIN ENDOCR METAB, V87, P16, DOI 10.1210/jc.87.1.16; Mueck A. O., 2003, Archives of Gynecology and Obstetrics, V267, P139, DOI 10.1007/s00404-002-0291-x; Opatrny L, 2008, BJOG-INT J OBSTET GY, V115, P169, DOI 10.1111/j.1471-0528.2007.01520.x; Orwoll E, 2006, ARCH INTERN MED, V166, P2124, DOI 10.1001/archinte.166.19.2124; Raobaikady B, 2007, J STEROID BIOCHEM, V104, P154, DOI 10.1016/j.jsbmb.2007.03.027; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sawaya GF, 2000, ANN INTERN MED, V133, P942, DOI 10.7326/0003-4819-133-12-200012190-00009; Stone KL, 2003, J BONE MINER RES, V18, P1947, DOI 10.1359/jbmr.2003.18.11.1947; Stravitz R Todd, 2003, Clin Liver Dis, V7, P435, DOI 10.1016/S1089-3261(03)00027-8; Swanson SG, 2006, MENOPAUSE, V13, P917, DOI 10.1097/01.gme.0000247016.41007.c9; Tegos TJ, 2000, ANGIOLOGY, V51, P793, DOI 10.1177/000331970005101001; Werner HMJ, 2005, CLIMACTERIC, V8, P294, DOI 10.1080/13697130500197526	55	263	286	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 14	2008	359	7					697	708		10.1056/NEJMoa0800743	http://dx.doi.org/10.1056/NEJMoa0800743			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336XE	18703472	Green Accepted, Green Published			2022-12-28	WOS:000258397900006
J	Makker, HK; Brown, JP; Borgstein, R; Hayward, M; Griffith, JSG				Makker, Himender K.; Brown, James P.; Borgstein, Rudi; Hayward, Martin; Griffith, John S. G.			Under pressure	LANCET			English	Editorial Material							PERICARDIAL CYST		[Makker, Himender K.; Brown, James P.; Borgstein, Rudi; Griffith, John S. G.] N Middlesex Univ Hosp, London, England; [Hayward, Martin] UCL Hosp, London, England	University College London Hospitals NHS Foundation Trust; University of London; University College London	Makker, HK (corresponding author), N Middlesex Univ Hosp, London, England.	himender.makker@nmh.nhs.uk						Duwe BV, 2005, CHEST, V128, P2893, DOI 10.1378/chest.128.4.2893; FEIGIN DS, 1977, RADIOLOGY, V125, P15, DOI 10.1148/125.1.15; Ng AF, 1997, ANN THORAC SURG, V63, P1147, DOI 10.1016/S0003-4975(97)00066-0; Takeda S, 2003, CHEST, V124, P125, DOI 10.1378/chest.124.1.125; Tanoue Y, 2007, ANN THORAC SURG, V84, P282, DOI 10.1016/j.athoracsur.2007.01.058	5	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG-SEP	2008	372	9640					776	776		10.1016/S0140-6736(08)61308-2	http://dx.doi.org/10.1016/S0140-6736(08)61308-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	344YZ	18761223				2022-12-28	WOS:000258964500034
J	Atarashi, K; Nishimura, J; Shima, T; Umesaki, Y; Yamamoto, M; Onoue, M; Yagita, H; Ishii, N; Evans, R; Honda, K; Takeda, K				Atarashi, Koji; Nishimura, Junichi; Shima, Tatsuichiro; Umesaki, Yoshinori; Yamamoto, Masahiro; Onoue, Masaharu; Yagita, Hideo; Ishii, Naoto; Evans, Richard; Honda, Kenya; Takeda, Kiyoshi			ATP drives lamina propria T(H)17 cell differentiation	NATURE			English	Article							INFLAMMATORY-BOWEL-DISEASE; DENDRITIC CELLS; T-CELLS; TGF-BETA; P2X RECEPTORS; GENERATION; IMMUNITY; PATHWAY; IL-21; MICE	Interleukin ( IL)- 17- producing CD4 1 T lymphocytes ( T(H)17 cells) constitute a subset of T- helper cells involved in host defence and several immune disorders(1,2). An intriguing feature of T(H)17 cells is their selective and constitutive presence in the intestinal lamina propria(3). Here we show that adenosine 5 '- triphosphate ( ATP) that can be derived from commensal bacteria activates a unique subset of lamina propria cells, CD70(high) CD11c(low) cells, leading to the differentiation of T(H)17 cells. Germ- free mice exhibit much lower concentrations of luminal ATP, accompanied by fewer lamina propria T(H)17 cells, compared to specific- pathogen- free mice. Systemic or rectal administration of ATP into these germ- free mice results in a marked increase in the number of lamina propria T(H)17 cells. A CD70(high) CD11c(low) subset of the lamina propria cells expresses T(H)17- prone molecules, such as IL- 6, IL- 23p19 and trans-forming-growth- factor-beta-activating integrin-alpha V and -beta 8, in response to ATP stimulation, and preferentially induces T(H)17 differentiation of co- cultured naive CD4(+) T cells. The critical role of ATP is further underscored by the observation that administration of ATP exacerbates a T- cell- mediated colitis model with enhanced T(H)17 differentiation. These observations highlight the importance of commensal bacteria and ATP for T(H)17 differentiation in health and disease, and offer an explanation of why T(H)17 cells specifically present in the intestinal lamina propria.	[Atarashi, Koji; Nishimura, Junichi; Yamamoto, Masahiro; Honda, Kenya; Takeda, Kiyoshi] Osaka Univ, Lab Immune Regulat, Grad Sch Med, Suita, Osaka 5650871, Japan; [Shima, Tatsuichiro; Umesaki, Yoshinori; Onoue, Masaharu] Yakult Cent Inst Microbiol Res, Tokyo 1868650, Japan; [Yamamoto, Masahiro; Honda, Kenya; Takeda, Kiyoshi] Osaka Univ, WPI Immunol Frontier Res Ctr, Suita, Osaka 5650871, Japan; [Yagita, Hideo] Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1138421, Japan; [Ishii, Naoto] Tohoku Univ, Grad Sch Med, Dept Microbiol & Immunol, Aoba Ku, Sendai, Miyagi 9808575, Japan; [Evans, Richard] Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	Osaka University; Yakult Honsha Company, Limited; Osaka University; Juntendo University; Tohoku University; University of Leicester	Honda, K (corresponding author), Osaka Univ, Lab Immune Regulat, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	honda@ongene.med.osaka-u.ac.jp; ktakeda@ongene.med.osaka-u.ac.jp	Atarashi, Koji/I-5363-2014; Takeda, Kiyoshi/C-9331-2009; Honda, Kenya/N-5297-2015; Nishimura, Junichi/K-8390-2015	Atarashi, Koji/0000-0001-5422-0736; Nishimura, Junichi/0000-0001-8220-3423; Takeda, Kiyoshi/0000-0002-1778-6332; Ishii, Naoto/0000-0002-0549-8245	Ministry of Education, Culture, Sports, Science and Technology; Ministry of Health, Labour and Welfare; Osaka Foundation for the Promotion of Clinical Immunology; Ichiro Kanehara Foundation; Sumitomo Foundation; Senri Life Science Foundation; Naito Foundation	Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labour and Welfare(Ministry of Health, Labour and Welfare, Japan); Osaka Foundation for the Promotion of Clinical Immunology; Ichiro Kanehara Foundation; Sumitomo Foundation; Senri Life Science Foundation; Naito Foundation(Naito Memorial Foundation)	We thank A. Iwasaki and N. Tsuji for discussion, M. H. Jang, H. Ohno, H. Yamane, M. Yoshida and H. Shiomi for technical advice and reagents, and J. Borst for CD27-deficient mice. This work was supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology, the Ministry of Health, Labour and Welfare, the Osaka Foundation for the Promotion of Clinical Immunology, the Ichiro Kanehara Foundation, Sumitomo Foundation, Senri Life Science Foundation and the Naito Foundation.	Bettelli E, 2007, NAT IMMUNOL, V8, P345, DOI 10.1038/ni0407-345; Betti M, 2006, ANN ONCOL, V17, P235; Chang SY, 2008, J IMMUNOL, V180, P1609, DOI 10.4049/jimmunol.180.3.1609; Cho JH, 2007, GASTROENTEROLOGY, V133, P1327, DOI 10.1053/j.gastro.2007.08.032; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Cua DJ, 2006, NAT IMMUNOL, V7, P557, DOI 10.1038/ni0606-557; Denning TL, 2007, NAT IMMUNOL, V8, P1086, DOI 10.1038/ni1511; Fagarasan S, 2003, NAT REV IMMUNOL, V3, P63, DOI 10.1038/nri982; Hendriks J, 2000, NAT IMMUNOL, V1, P433, DOI 10.1038/80877; Idzko M, 2007, NAT MED, V13, P913, DOI 10.1038/nm1617; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Ivanova EP, 2006, INT MICROBIOL, V9, P37; Iwasaki A, 2007, ANNU REV IMMUNOL, V25, P381, DOI 10.1146/annurev.immunol.25.022106.141634; Khakh BS, 2006, NATURE, V442, P527, DOI 10.1038/nature04886; Korn T, 2007, NATURE, V448, P484, DOI 10.1038/nature05970; Leach MW, 1996, AM J PATHOL, V148, P1503; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Mazmanian SK, 2008, NATURE, V453, P620, DOI 10.1038/nature07008; Mizoguchi E, 2003, GASTROENTEROLOGY, V125, P148, DOI 10.1016/S0016-5085(03)00665-6; Niess JH, 2005, SCIENCE, V307, P254, DOI 10.1126/science.1102901; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Nurieva R, 2007, NATURE, V448, P480, DOI 10.1038/nature05969; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Schnurr M, 2005, BLOOD, V105, P1582, DOI 10.1182/blood-2004-05-1718; Takeda K, 1998, J IMMUNOL, V161, P4652; Travis MA, 2007, NATURE, V449, P361, DOI 10.1038/nature06110; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Zaba LC, 2007, J EXP MED, V204, P3183, DOI 10.1084/jem.20071094; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488	32	784	814	5	67	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 9	2008	455	7214					808	U10		10.1038/nature07240	http://dx.doi.org/10.1038/nature07240			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	357OB	18716618				2022-12-28	WOS:000259854900049
J	Nair, S; Schilling, TF				Nair, Sreelaja; Schilling, Thomas F.			Chemokine signaling controls endodermal migration during zebrafish gastrulation	SCIENCE			English	Article							CELL-MIGRATION; RECEPTOR CXCR4; GASTROINTESTINAL-TRACT; MYOCARDIAL MIGRATION; MESODERM MIGRATION; FIBRONECTIN; XENOPUS; EXPRESSION; ADHESION; SDF-1-ALPHA	Directed cell movements during gastrulation establish the germ layers of the vertebrate embryo and coordinate their contributions to different tissues and organs. Anterior migration of the mesoderm and endoderm has largely been interpreted to result from epiboly and convergent-extension movements that drive body elongation. We show that the chemokine Cxcl12b and its receptor Cxcr4a restrict anterior migration of the endoderm during zebrafish gastrulation, thereby coordinating its movements with those of the mesoderm. Depletion of either gene product causes disruption of integrin- dependent cell adhesion, resulting in separation of the endoderm from the mesoderm; the endoderm then migrates farther anteriorly than it normally would, resulting in bilateral duplication of endodermal organs. This process may have relevance to human gastrointestinal bifurcations and other organ defects.	[Nair, Sreelaja; Schilling, Thomas F.] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA	University of California System; University of California Irvine	Schilling, TF (corresponding author), Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA.	tschilli@uci.edu			NIH [R01NS41353, R01DE13828]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE013828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041353] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank E. Raz for cxcl12b and cxcr4a constructs; our laboratory colleagues, especially S. Piloto for help with qPCR and T. Hoffman for help with itgb1b constructs; and I. Blitz for reviewing the manuscript. Supported by NIH grants R01NS41353 and R01DE13828.	Alexander J, 1999, DEV BIOL, V215, P343, DOI 10.1006/dbio.1999.9441; Biemar F, 2001, DEV BIOL, V230, P189, DOI 10.1006/dbio.2000.0103; Chong SW, 2001, MECH DEVELOP, V109, P347, DOI 10.1016/S0925-4773(01)00520-2; David NB, 2002, P NATL ACAD SCI USA, V99, P16297, DOI 10.1073/pnas.252339399; Dickinson K, 2006, DEV DYNAM, V235, P368, DOI 10.1002/dvdy.20636; Field HA, 2003, DEV BIOL, V253, P279, DOI 10.1016/S0012-1606(02)00017-9; Fukui A, 2007, BIOCHEM BIOPH RES CO, V354, P472, DOI 10.1016/j.bbrc.2007.01.007; Hartmann TN, 2005, ONCOGENE, V24, P4462, DOI 10.1038/sj.onc.1208621; HOWARD JE, 1992, MECH DEVELOP, V38, P109, DOI 10.1016/0925-4773(92)90003-3; Jones J, 2007, EXP CELL RES, V313, P4051, DOI 10.1016/j.yexcr.2007.07.001; Juarez J, 2004, HISTOL HISTOPATHOL, V19, P299, DOI 10.14670/HH-19.299; Keller R, 2003, DIFFERENTIATION, V71, P171, DOI 10.1046/j.1432-0436.2003.710301.x; Keller R, 2002, SCIENCE, V298, P1950, DOI 10.1126/science.1079478; Knaut H, 2005, NEURON, V47, P653, DOI 10.1016/j.neuron.2005.07.014; Li Q, 2005, J NEUROSCI, V25, P1711, DOI 10.1523/JNEUROSCI.4393-04.2005; McGrath KE, 1999, DEV BIOL, V213, P442, DOI 10.1006/dbio.1999.9405; Montero JA, 2005, DEVELOPMENT, V132, P1187, DOI 10.1242/dev.01667; Mould AP, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-24; Ober EA, 2006, NATURE, V442, P688, DOI 10.1038/nature04888; Pelletier AJ, 2000, BLOOD, V96, P2682; Pezeron G, 2008, CURR BIOL, V18, P276, DOI 10.1016/j.cub.2008.01.028; Raz E, 2004, CURR OPIN CELL BIOL, V16, P169, DOI 10.1016/j.ceb.2004.01.004; Roberts DJ, 2000, DEV DYNAM, V219, P109, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1047>3.3.CO;2-Y; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Sakaguchi T, 2006, DEVELOPMENT, V133, P4063, DOI 10.1242/dev.02581; Schier AF, 2003, ANNU REV CELL DEV BI, V19, P589, DOI 10.1146/annurev.cellbio.19.041603.094522; Scott IC, 2007, DEV CELL, V12, P403, DOI 10.1016/j.devcel.2007.01.012; Solnica-Krezel L, 2005, CURR BIOL, V15, pR213, DOI 10.1016/j.cub.2005.03.016; Stevenson R.E., 1993, HUMAN MALFORMATIONS; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Trinh LA, 2004, DEV CELL, V6, P371; Warga RM, 1999, DEVELOPMENT, V126, P827; WATT FM, 1994, CURR BIOL, V4, P270, DOI 10.1016/S0960-9822(00)00063-4; Winklbauer R, 1996, DEV BIOL, V177, P413, DOI 10.1006/dbio.1996.0174; Winklbauer R, 1996, INT J DEV BIOL, V40, P305; Yusuf F, 2005, ANAT EMBRYOL, V210, P35, DOI 10.1007/s00429-005-0013-9; Zeng XXI, 2007, DEV CELL, V12, P391, DOI 10.1016/j.devcel.2007.01.011	37	96	97	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	2008	322	5898					89	92		10.1126/science.1160038	http://dx.doi.org/10.1126/science.1160038			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	355AE	18719251	Green Accepted			2022-12-28	WOS:000259680200044
J	Nedjic, J; Aichinger, M; Emmerich, J; Mizushima, N; Klein, L				Nedjic, Jelena; Aichinger, Martin; Emmerich, Jan; Mizushima, Noboru; Klein, Ludger			Autophagy in thymic epithelium shapes the T-cell repertoire and is essential for tolerance	NATURE			English	Article							GENOME-WIDE ASSOCIATION; CLASS-II PRESENTATION; CROHN-DISEASE; IN-VIVO; ANTIGEN; SELECTION; AIRE; MEDULLA; PROTEIN; VITRO	Recognition of self- antigen- derived epitopes presented by major histocompatibility complex class II ( MHC II) molecules on thymic epithelial cells ( TECs) is critical for the generation of a functional and self- tolerant CD4 T- cell repertoire. Whereas haematopoietic antigen- presenting cells generate MHC- II - peptide complexes predominantly through the processing of endocytosed polypeptides(1), it remains unknown if and how TECs use unconventional pathways of antigen presentation. Here we address the role of macroautophagy, a process that has recently been shown to allow for endogenous MHC II loading(2-6), in T- cell repertoire selection in the mouse thymus. In contrast to most other tissues, TECs had a high constitutive level of autophagy. Genetic interference with autophagy specifically in TECs led to altered selection of certain MHC-II-restricted T- cell specificities and resulted in severe colitis and multi- organ inflammation. Our findings indicate that autophagy focuses the MHC- II - peptide repertoire of TECs on their intracellular milieu, which notably comprises a wide array of otherwise strictly 'tissue-specific' self antigens(7,8). In doing so, it contributes to T- cell selection and is essential for the generation of a self- tolerant T- cell repertoire.	[Nedjic, Jelena; Aichinger, Martin; Emmerich, Jan; Klein, Ludger] Res Inst Mol Pathol, A-1030 Vienna, Austria; [Mizushima, Noboru] Tokyo Med & Dent Univ, Dept Physiol & Cell Biol, Bunkyo Ku, Tokyo 1138613, Japan; [Klein, Ludger] Univ Munich, Inst Immunol, D-80336 Munich, Germany	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Tokyo Medical & Dental University (TMDU); University of Munich	Klein, L (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	ludger.klein@med.lmu.de	Mizushima, Noboru/C-3635-2009; Klein, Ludger/G-8785-2011	Mizushima, Noboru/0000-0002-6258-6444; Klein, Ludger/0000-0003-2054-071X; Emmerich, Jan/0000-0002-7216-2231	Austrian National Science Fund [F023, Z58-B01]; European Union; FP6 Integrated Project Eurothymaide [LSHB-CT-2003-503410]; Boehringer Ingelheim	Austrian National Science Fund(Austrian Science Fund (FWF)); European Union(European Commission); FP6 Integrated Project Eurothymaide(European Commission); Boehringer Ingelheim(Boehringer Ingelheim)	We acknowledge support from the Austrian National Science Fund (Sonderforschungsbereich F023 and grant Z58-B01 'Wittgenstein Prize Meinrad Busslinger'; to J.N. and L. K.) and the European Union (FP6 Integrated Project 'Eurothymaide'; Contract LSHB-CT-2003-503410; to M.A., J.E. and L. K.). Research at the Research Institute of Molecular Pathology is funded by Boehringer Ingelheim. We thank C. Spona for technical assistance and M. Busslinger, M. S. Anderson, B. Kyewski and J. Derbinski for comments on the manuscript. We also thank H. Ploegh for discussions in the earliest phase of this project.	Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Aschenbrenner K, 2007, NAT IMMUNOL, V8, P351, DOI 10.1038/ni1444; Dengjel J, 2005, P NATL ACAD SCI USA, V102, P7922, DOI 10.1073/pnas.0501190102; Derbinski J, 2005, J EXP MED, V202, P33, DOI 10.1084/jem.20050471; Dorfel D, 2005, BLOOD, V105, P3199, DOI 10.1182/blood-2004-09-3556; Gallegos AM, 2004, J EXP MED, V200, P1039, DOI 10.1084/jem.20041457; Gray D, 2007, J EXP MED, V204, P2521, DOI 10.1084/jem.20070795; Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954; Huang J, 2007, CELL CYCLE, V6, P1837, DOI 10.4161/cc.6.15.4511; Ignatowicz L, 1996, CELL, V84, P521, DOI 10.1016/S0092-8674(00)81028-4; KIRBERG J, 1994, J EXP MED, V180, P25, DOI 10.1084/jem.180.1.25; Klein L, 1998, J EXP MED, V188, P5, DOI 10.1084/jem.188.1.5; Klein L, 2001, EUR J IMMUNOL, V31, P2476, DOI 10.1002/1521-4141(200108)31:8<2476::AID-IMMU2476>3.0.CO;2-T; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Kyewski B, 2006, ANNU REV IMMUNOL, V24, P571, DOI 10.1146/annurev.immunol.23.021704.115601; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Murata S, 2007, SCIENCE, V316, P1349, DOI 10.1126/science.1141915; MURPHY DB, 1989, NATURE, V338, P765, DOI 10.1038/338765a0; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; Nimmerjahn F, 2003, EUR J IMMUNOL, V33, P1250, DOI 10.1002/eji.200323730; Paludan C, 2005, SCIENCE, V307, P593, DOI 10.1126/science.1104904; Pua HH, 2007, J EXP MED, V204, P25, DOI 10.1084/jem.20061303; Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032; Rossi SW, 2007, J EXP MED, V204, P1267, DOI 10.1084/jem.20062497; Schmid D, 2007, IMMUNITY, V26, P79, DOI 10.1016/j.immuni.2006.10.018; Starr TK, 2003, ANNU REV IMMUNOL, V21, P139, DOI 10.1146/annurev.immunol.21.120601.141107; Tewari MK, 2005, NAT IMMUNOL, V6, P287, DOI 10.1038/ni1171; Tourne S, 1997, IMMUNITY, V7, P187, DOI 10.1016/S1074-7613(00)80522-1; Trombetta ES, 2005, ANNU REV IMMUNOL, V23, P975, DOI 10.1146/annurev.immunol.22.012703.104538; Zhou DL, 2005, IMMUNITY, V22, P571, DOI 10.1016/j.immuni.2005.03.009	32	373	394	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	2008	455	7211					396	U49		10.1038/nature07208	http://dx.doi.org/10.1038/nature07208			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	349EX	18701890				2022-12-28	WOS:000259265200046
J	Park, IH; Arora, N; Huo, H; Maherali, N; Ahfeldt, T; Shimamura, A; Lensch, MW; Cowan, C; Hochedlinger, K; Daley, GQ				Park, In-Hyun; Arora, Natasha; Huo, Hongguang; Maherali, Nimet; Ahfeldt, Tim; Shimamura, Akiko; Lensch, M. William; Cowan, Chad; Hochedlinger, Konrad; Daley, George Q.			Disease-specific induced pluripotent stem cells	CELL			English	Article							CRITICAL REGION; DOWN-SYNDROME; GENE; MUTATION; LOCUS; CHROMOSOME-21; GENERATION	Tissue culture of immortal cell strains from diseased patients is an invaluable resource for medical research but is largely limited to tumor cell lines or transformed derivatives of native tissues. Here we describe the generation of induced pluripotent stem (iPS) cells from patients with a variety of genetic diseases with either Mendelian or complex inheritance; these diseases include adenosine deaminase deficiency-related severe combined immunodeficiency (ADA-SCID), Shwachman-Bodian-Diamond syndrome (SBDS), Gaucher disease (GD) type III, Duchenne (DMD) and Becker muscular dystrophy (BMD), Parkinson disease (PD), Huntington disease (HD), juvenile-onset, type 1 diabetes mellitus (JDM), Down syndrome (DS)/trisomy 21, and the carrier state of Lesch-Nyhan syndrome. Such disease-specific stem cells offer an unprecedented opportunity to recapitulate both normal and pathologic human tissue formation in vitro, thereby enabling disease investigation and drug development.	[Park, In-Hyun; Arora, Natasha; Huo, Hongguang; Lensch, M. William; Daley, George Q.] Childrens Hosp, Dept Med, Div Pediat Hematol Oncol, Boston, MA 02115 USA; [Park, In-Hyun; Arora, Natasha; Huo, Hongguang; Lensch, M. William; Daley, George Q.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Park, In-Hyun; Arora, Natasha; Huo, Hongguang; Lensch, M. William; Daley, George Q.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Maherali, Nimet; Ahfeldt, Tim; Cowan, Chad; Hochedlinger, Konrad] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA; [Maherali, Nimet; Ahfeldt, Tim; Cowan, Chad; Hochedlinger, Konrad] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA; [Maherali, Nimet; Ahfeldt, Tim; Cowan, Chad; Hochedlinger, Konrad] Massachusetts Gen Hosp, Dept Stem Cell & Regenerat Biol, Boston, MA 02114 USA; [Maherali, Nimet] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; [Shimamura, Akiko] Univ Washington, Div Hematol Oncol, Dept Pediat, Seattle, WA 98109 USA; [Shimamura, Akiko] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; [Ahfeldt, Tim] Univ Med Ctr Hamburg Eppendorf, Dept Biochem & Mol Biol Mol Cell Biol 2, D-20246 Hamburg, Germany; [Cowan, Chad] Stowers Med Inst, Boston, MA 02115 USA; [Park, In-Hyun; Arora, Natasha; Huo, Hongguang; Maherali, Nimet; Ahfeldt, Tim; Lensch, M. William; Cowan, Chad; Hochedlinger, Konrad; Daley, George Q.] Harvard Stem Cell Inst, Boston, MA 02115 USA; [Daley, George Q.] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA; [Lensch, M. William; Daley, George Q.] Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Hamburg; University Medical Center Hamburg-Eppendorf; Stowers Institute for Medical Research; Harvard University; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute	Daley, GQ (corresponding author), Childrens Hosp, Dept Med, Div Pediat Hematol Oncol, Karp Family Res Bldg 7214,300 Longwood Ave, Boston, MA 02115 USA.	george.daley@childrens.harvard.edu	Ahfeldt, Tim/E-2935-2017	Ahfeldt, Tim/0000-0001-6377-7376	National Institutes of Health; Harvard Stem Cell Institute; Children's Hospital Stem Cell Program; John W. Henry Family Foundation; Burroughs Wellcome Fund; Leukemia and Lymphoma Society; Natural Sciences and Engineering Council of Canada; Sir James Lougheed Award; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059279] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD000256] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harvard Stem Cell Institute; Children's Hospital Stem Cell Program; John W. Henry Family Foundation; Burroughs Wellcome Fund(Burroughs Wellcome Fund); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Natural Sciences and Engineering Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)); Sir James Lougheed Award; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	G. Q. D. was supported by grants from the National Institutes of Health, the NIH Director's Pioneer Award of the NIH Roadmap for Medical Research, and private funds contributed to the Harvard Stem Cell Institute and the Children's Hospital Stem Cell Program. The work was made possible by the support and vision of Douglas and Diana Berthiaume, Jonathan and Patti Kraft, and the John W. Henry Family Foundation. G. Q. D. is a recipient of Clinical Scientist Awards in Translational Research from the Burroughs Wellcome Fund and the Leukemia and Lymphoma Society and is an Investigator of the Howard Hughes Medical Institute. K. H. was supported by the NIH Director's Innovator Award and the Harvard Stem Cell Institute. N. M. was supported by the Natural Sciences and Engineering Council of Canada and a Sir James Lougheed Award.	Antonarakis SE, 2004, NAT REV GENET, V5, P725, DOI 10.1038/nrg1448; Austin KM, 2005, BLOOD, V106, P1253, DOI 10.1182/blood-2005-02-0807; BEGGS AH, 1990, HUM GENET, V86, P45; BEUTLER E, 1991, P NATL ACAD SCI USA, V88, P10544, DOI 10.1073/pnas.88.23.10544; Bittles AH, 2007, EUR J PUBLIC HEALTH, V17, P221, DOI 10.1093/eurpub/ckl103; Brambrink T, 2008, CELL STEM CELL, V2, P151, DOI 10.1016/j.stem.2008.01.004; Calado RT, 2007, BLOOD, V110, P1141, DOI 10.1182/blood-2007-03-080044; CHAMBERLAIN JS, 1988, NUCLEIC ACIDS RES, V16, P11141, DOI 10.1093/nar/16.23.11141; Chen M, 1996, NAT GENET, V12, P448, DOI 10.1038/ng0496-448; Chong SS, 1997, HUM MOL GENET, V6, P301, DOI 10.1093/hmg/6.2.301; Di Giorgio FP, 2007, NAT NEUROSCI, V10, P608, DOI 10.1038/nn1885; DOETSCHMAN T, 1988, P NATL ACAD SCI USA, V85, P8583, DOI 10.1073/pnas.85.22.8583; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; Grimm S, 2004, NAT REV GENET, V5, P179, DOI 10.1038/nrg1291; HIRSCHHORN R, 1993, HUM MUTAT, V2, P320, DOI 10.1002/humu.1380020415; Lensch MW, 2007, CELL STEM CELL, V1, P253, DOI 10.1016/j.stem.2007.07.019; Lerou PH, 2008, NAT BIOTECHNOL, V26, P212, DOI 10.1038/nbt1378; Lowry WE, 2008, P NATL ACAD SCI USA, V105, P2883, DOI 10.1073/pnas.0711983105; Murry CE, 2008, CELL, V132, P661, DOI 10.1016/j.cell.2008.02.008; Nelson DL, 2004, SCIENCE, V306, P619, DOI 10.1126/science.1105226; NUSSBAUM RL, 1983, P NATL ACAD SCI-BIOL, V80, P4035, DOI 10.1073/pnas.80.13.4035; Olson LE, 2004, SCIENCE, V306, P687, DOI 10.1126/science.1098992; Park IH, 2008, NAT PROTOC, V3, P1180, DOI 10.1038/nprot.2008.92; Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]; Prior TW, 2005, J MOL DIAGN, V7, P317, DOI 10.1016/S1525-1578(10)60560-0; Rideout WM, 2002, CELL, V109, P17, DOI 10.1016/S0092-8674(02)00681-5; RIESS O, 1993, HUM MOL GENET, V2, P637, DOI 10.1093/hmg/2.6.637; Stadtfeld M, 2008, CELL STEM CELL, V2, P230, DOI 10.1016/j.stem.2008.02.001; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Verlinsky Y, 2005, REPROD BIOMED ONLINE, V10, P105, DOI 10.1016/S1472-6483(10)60810-3; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526	32	1636	1798	3	629	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 5	2008	134	5					877	886		10.1016/j.cell.2008.07.041	http://dx.doi.org/10.1016/j.cell.2008.07.041			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	344SL	18691744	Green Accepted, Bronze			2022-12-28	WOS:000258947500026
J	Clayburgh, DR; Yoon, JD; Cipriani, NA; Ricketts, PA; Arora, VM				Clayburgh, Daniel R.; Yoon, John D.; Cipriani, Nicole A.; Ricketts, Paul A.; Arora, Vineet M.			Collateral damage	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							INFERIOR VENA-CAVA; DEEP VENOUS THROMBOSIS; VEIN-THROMBOSIS; ACUTE APPENDICITIS; INTERRUPTION; MALFORMATIONS; HEMATURIA; ANOMALIES		[Clayburgh, Daniel R.; Cipriani, Nicole A.] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA; [Yoon, John D.; Ricketts, Paul A.; Arora, Vineet M.] Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Arora, VM (corresponding author), 5841 S Maryland Ave,MC 2007,AMB W216, Chicago, IL 60637 USA.	varora@medicine.bsd.uchicago.edu		Clayburgh, Daniel/0000-0002-3296-4926; Arora, Vineet/0000-0002-4745-7599				Abernethy J., 1783, PHILOS T R SOC LONDO, V83, P59; Adkins J, 1996, J ULTRAS MED, V15, P409; Bass YE, 2000, RADIOGRAPHICS, V20, P639, DOI 10.1148/radiographics.20.3.g00ma09639; Chee YL, 2001, BRIT J HAEMATOL, V114, P878, DOI 10.1046/j.1365-2141.2001.03025.x; Eifert S, 2000, J VASC SURG, V31, P462, DOI 10.1067/mva.2000.101464; Garcia-Fuster MJ, 2006, REV ESP CARDIOL, V59, P171, DOI 10.1157/13084646; GOLDENBERG SF, 1988, J UROLOGY, V139, P1296, DOI 10.1016/S0022-5347(17)42898-9; HAYASHI M, 1980, J UROLOGY, V124, P12, DOI 10.1016/S0022-5347(17)55268-4; Gil RJ, 2006, J VASC SURG, V44, P1114, DOI 10.1016/j.jvs.2006.06.021; Lane DA, 2005, MIL MED, V170, P739, DOI 10.7205/MILMED.170.9.739; Moulding FJ, 2005, AM J ROENTGENOL, V184, P703, DOI 10.2214/ajr.184.2.01840703; Obernosterer A, 2002, ANN INTERN MED, V136, P37, DOI 10.7326/0003-4819-136-1-200201010-00009; Takehara N, 2005, J THROMB THROMBOLYS, V19, P101, DOI 10.1007/s11239-005-1380-z; Timmers GJ, 1999, INT J CLIN PRACT, V53, P75; Tsuji Y, 2001, ANGIOLOGY, V52, P721, DOI 10.1177/000331970105201010	15	5	6	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2008	359	10					1048	1054		10.1056/NEJMcps0708994	http://dx.doi.org/10.1056/NEJMcps0708994			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	343KN	18768949				2022-12-28	WOS:000258852500011
J	Ratcliffe, JM; Nydam, ML				Ratcliffe, John M.; Nydam, Marie L.			Multimodal warning signals for a multiple predator world	NATURE			English	Article							ARCTIID MOTHS; EVOLUTION; LEPIDOPTERA; GENE; BATS; DISCRIMINATION; MITOCHONDRIAL; DEFENSES; UTILITY	Aposematism is an anti- predator defence, dependent on a predator's ability to associate unprofitable prey with a prey- borne signal(1). Multimodal signals should vary in efficacy according to the sensory systems of different predators; however, until now, the impact of multiple predator classes on the evolution of these signals had not been investigated(2,3). Here, using a community- level molecular phylogeny to generate phylogenetically independent contrasts, we show that warning signals of tiger moths vary according to the seasonal and daily activity patterns of birds and bats - predators with divergent sensory capacities. Many tiger moths advertise chemical defence(4,5) using conspicuous colouration and/ or ultrasonic clicks(3,6). During spring, when birds are active and bats less so, we found that tiger moths did not produce ultrasonic clicks. Throughout both spring and summer, tiger moths most active during the day were visually conspicuous. Those species emerging later in the season produced ultrasonic clicks; those that were most nocturnal were visually cryptic. Our results indicate that selective pressures from multiple predator classes have distinct roles in the evolution of multimodal warning displays now effective against a single predator class. We also suggest that the evolution of acoustic warning signals may lack the theoretical difficulties associated with the origination of conspicuous colouration.	[Nydam, Marie L.] Cornell Univ, Dept Ecol & Evolutionary Biol, Ithaca, NY 14853 USA; [Ratcliffe, John M.] Univ So Denmark, Ctr Sound Commun, Inst Biol, DK-5230 Odense M, Denmark	Cornell University; University of Southern Denmark	Nydam, ML (corresponding author), Cornell Univ, Dept Ecol & Evolutionary Biol, Ithaca, NY 14853 USA.	jmr@biology.sdu.dk; mln32@cornell.edu			NSERC; NIDCD; DNSRC	NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC)); NIDCD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); DNSRC(Danish Natural Science Research Council)	We thank R. Hoebeke for access to the Cornell University Insect Collection, T. Eisner for the loan of ultraviolet photography equipment, and the 15 people who scored the photographs. J. M. R. thanks M. Fitzpatrick for discussion. J. Barber, C. Beatty, I. Cuthill, T. Eisner and J. Fullard provided detailed comments that improved the manuscript. This study was funded by research grants to J. Fullard (NSERC), R. Hoy (NIDCD) and J. M. R. (NSERC and DNSRC). Molecular work was conducted at Cornell in the laboratory of R. Harrison and the Evolutionary Genetics Core Facility.	ACHARYA L, 1992, CAN J ZOOL, V70, P1292, DOI 10.1139/z92-180; Barber JR, 2006, J EXP BIOL, V209, P2637, DOI 10.1242/jeb.02295; Barber JR, 2007, P NATL ACAD SCI USA, V104, P9331, DOI 10.1073/pnas.0703627104; BARCLAY RMR, 1994, ANIM BEHAV, V48, P1013, DOI 10.1006/anbe.1994.1334; BENNETT ATD, 1994, VISION RES, V34, P1471, DOI 10.1016/0042-6989(94)90149-X; Brower AVZ, 1998, INSECT MOL BIOL, V7, P73, DOI 10.1046/j.1365-2583.1998.71052.x; Cadman M. D., 1987, ATLAS BREEDING BIRDS; CHO SW, 1995, MOL BIOL EVOL, V12, P650; Cott H.B., 1940, ADAPTIVE COLORATION; Dooling RJ, 2000, SPR HDB AUD, V13, P308; Dunn PO, 2001, EVOLUTION, V55, P161; FULLARD JH, 1977, NATURE, V267, P42, DOI 10.1038/267042a0; FULLARD JH, 1980, CAN J ZOOL, V58, P1745, DOI 10.1139/z80-241; Fullard JH, 2001, ANIM BEHAV, V62, P349, DOI 10.1006/anbe.2001.1753; FULLARD JH, 1977, CAN J ZOOL, V55, P1213, DOI 10.1139/z77-160; Godfrey WE, 1986, THE BIRDS OF CANADA; Gronquist M, 2001, P NATL ACAD SCI USA, V98, P13745, DOI 10.1073/pnas.231471698; Hristov N, 2005, CHEMOECOLOGY, V15, P105, DOI 10.1007/s00049-005-0301-0; Hristov NI, 2005, NATURWISSENSCHAFTEN, V92, P164, DOI 10.1007/s00114-005-0611-7; Lyytinen A, 2004, BEHAV ECOL, V15, P982, DOI 10.1093/beheco/arh102; Maddison D.R., 2007, MESQUITE 2 MODULAR S; Mappes J, 2005, TRENDS ECOL EVOL, V20, P598, DOI 10.1016/j.tree.2005.07.011; Mitchell A, 2006, SYST ENTOMOL, V31, P21, DOI 10.1111/j.1365-3113.2005.00306.x; Monteiro A, 2001, MOL PHYLOGENET EVOL, V18, P264, DOI 10.1006/mpev.2000.0872; NICOLAUS LK, 1983, SCIENCE, V220, P212, DOI 10.1126/science.220.4593.212; Nishida R, 2002, ANNU REV ENTOMOL, V47, P57, DOI 10.1146/annurev.ento.47.091201.145121; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; PURVIS A, 1995, COMPUT APPL BIOSCI, V11, P247; Ratcliffe JM, 2005, J EXP BIOL, V208, P4689, DOI 10.1242/jeb.01927; Ratcliffe JM, 2003, ANIM BEHAV, V65, P385, DOI 10.1006/anbe.2003.2059; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Rowe C, 2002, P ROY SOC B-BIOL SCI, V269, P1353, DOI 10.1098/rspb.2002.2012; Rowe C, 1999, EVOL ECOL, V13, P655, DOI 10.1023/A:1011021630244; Ruxton GD, 2004, AVOIDING ATTACK EVOL; SIMON C, 1994, ANN ENTOMOL SOC AM, V87, P651, DOI 10.1093/aesa/87.6.651; Stevens M, 2007, BIOL J LINN SOC, V90, P211, DOI 10.1111/j.1095-8312.2007.00725.x; Swofford D.L., 2003, PAUP VERSION 40 B10; WARD P S, 1974, Journal of Research on the Lepidoptera, V13, P23; Weller, 2002, CLADISTIC STUDY ARCT; YACK JE, 1988, CAN J ZOOL, V66, P753, DOI 10.1139/z88-111	40	81	81	2	92	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	2008	455	7209					96	U59		10.1038/nature07087	http://dx.doi.org/10.1038/nature07087			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	343XS	18769439				2022-12-28	WOS:000258890200044
J	Zuraw, BL				Zuraw, Bruce L.			Hereditary angioedema	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							C1 INHIBITOR CONCENTRATE; FRESH-FROZEN PLASMA; ANGIONEUROTIC-EDEMA; C1-INHIBITOR DEFICIENCY; CLINICAL SYNDROME; ACID THERAPY; PROPHYLAXIS; MANAGEMENT; DANAZOL; MUTATIONS		Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Zuraw, Bruce L.] Vet Affairs Med Ctr, San Diego, CA 92161 USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Zuraw, BL (corresponding author), Univ Calif San Diego, Dept Med, Mail Drop 0732,9500 Gilman Dr, La Jolla, CA 92093 USA.	bzuraw@ucsd.edu		Zuraw, Bruce/0000-0003-0640-6768	Lev Pharmaceuticals; CSL Behring; Dyax; Lev Pharmaceuticals and Pharming	Lev Pharmaceuticals; CSL Behring; Dyax; Lev Pharmaceuticals and Pharming	Dr. Zuraw reports receiving consulting fees from Lev Pharmaceuticals, Jerini, CSL Behring, and Dyax and grant support from Lev Pharmaceuticals and Pharming. No other potential conflict of interest relevant to this article was reported.	AGOSTONI A, 1992, MEDICINE, V71, P206, DOI 10.1097/00005792-199207000-00003; Agostoni A, 2004, J ALLERGY CLIN IMMUN, V114, pS51, DOI 10.1016/j.jaci.2004.06.047; Binkley KE, 2000, J ALLERGY CLIN IMMUN, V106, P546; Bissler JJ, 1997, P ASSOC AM PHYSICIAN, V109, P164; Bork K, 2006, AM J MED, V119, P267, DOI 10.1016/j.amjmed.2005.09.064; Bork K, 2000, LANCET, V356, P213, DOI 10.1016/S0140-6736(00)02483-1; Bork K, 2005, TRANSFUSION, V45, P1774, DOI 10.1111/j.1537-2995.2005.00602.x; Bork K, 1999, LANCET, V353, P1066, DOI 10.1016/S0140-6736(99)00110-5; Bork K, 2001, ARCH INTERN MED, V161, P714, DOI 10.1001/archinte.161.5.714; Bork K, 2008, ANN ALLERG ASTHMA IM, V100, P153, DOI 10.1016/S1081-1206(10)60424-3; Bork K, 2007, AM J MED, V120, P987, DOI 10.1016/j.amjmed.2007.08.021; BOUILLET L, 2008, AM J OBSTET GYN 0611; Bowen T, 2008, ANN ALLERG ASTHMA IM, V100, pS30, DOI 10.1016/S1081-1206(10)60584-4; BRICKMAN CM, 1986, J ALLERGY CLIN IMMUN, V77, P749, DOI 10.1016/0091-6749(86)90424-0; Byrd JB, 2006, IMMUNOL ALLERGY CLIN, V26, P725, DOI 10.1016/j.iac.2006.08.001; Church JA, 2004, ANN ALLERG ASTHMA IM, V92, P377, DOI 10.1016/S1081-1206(10)61578-5; Cicardi M, 1997, J ALLERGY CLIN IMMUN, V99, P194, DOI 10.1016/S0091-6749(97)70095-2; Cicardi M, 2003, TRANSFUS APHER SCI, V29, P221, DOI 10.1016/S1473-0502(03)00164-2; Cichon S, 2006, AM J HUM GENET, V79, P1098, DOI 10.1086/509899; DAVIS AE, 1988, ANNU REV IMMUNOL, V6, P595, DOI 10.1146/annurev.iy.06.040188.003115; Davis AE, 2006, IMMUNOL ALLERGY CLIN, V26, P633, DOI 10.1016/j.iac.2006.08.003; Dewald G, 2006, BIOCHEM BIOPH RES CO, V343, P1286, DOI 10.1016/j.bbrc.2006.03.092; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; Drouet C, 2008, J ALLERGY CLIN IMMUN, V121, P429, DOI 10.1016/j.jaci.2007.10.048; Farkas H, 2007, J ALLERGY CLIN IMMUN, V120, P941, DOI 10.1016/j.jaci.2007.06.026; Farkas H, 2007, PEDIATRICS, V120, pE713, DOI 10.1542/peds.2006-3303; Frank MM, 2006, IMMUNOL ALLERGY CLIN, V26, P653, DOI 10.1016/j.iac.2006.09.005; FRANK MM, 1976, ANN INTERN MED, V84, P580, DOI 10.7326/0003-4819-84-5-580; FRANK MM, 1972, NEW ENGL J MED, V286, P808, DOI 10.1056/NEJM197204132861503; FRANK MM, 1979, ARTHRITIS RHEUM, V22, P1295, DOI 10.1002/art.1780221118; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; Gompels MM, 2005, CLIN EXP IMMUNOL, V141, P189, DOI 10.1111/j.1365-2249.2005.02781.x; Gompels MM, 2005, CLIN EXP IMMUNOL, V139, P379, DOI 10.1111/j.1365-2249.2005.02726.x; Han ED, 2002, J CLIN INVEST, V109, P1057, DOI 10.1172/JCI200214211; JAFFE CJ, 1975, J ALLERGY CLIN IMMUN, V55, P386, DOI 10.1016/0091-6749(75)90077-9; Kunschak M, 1998, TRANSFUSION, V38, P540, DOI 10.1046/j.1537-2995.1998.38698326333.x; Levi M, 2006, J ALLERGY CLIN IMMUN, V117, P904, DOI 10.1016/j.jaci.2006.01.002; Lung CC, 1997, J ALLERGY CLIN IMMUN, V99, P134, DOI 10.1016/S0091-6749(97)81054-8; Monnier N, 2006, MOL IMMUNOL, V43, P2161, DOI 10.1016/j.molimm.2006.01.006; Nzeako UC, 2001, ARCH INTERN MED, V161, P2417, DOI 10.1001/archinte.161.20.2417; Pappalardo E, 2000, J ALLERGY CLIN IMMUN, V106, P1147, DOI 10.1067/mai.2000.110471; Prematta M, 2007, ANN ALLERG ASTHMA IM, V98, P383, DOI 10.1016/S1081-1206(10)60886-1; Roche O, 2005, ANN ALLERG ASTHMA IM, V94, P498, DOI 10.1016/S1081-1206(10)61121-0; ROSEN FS, 1965, SCIENCE, V148, P957, DOI 10.1126/science.148.3672.957; ROSEN FS, 1971, J CLIN INVEST, V50, P2143, DOI 10.1172/JCI106708; SHEFFER AL, 1972, NEW ENGL J MED, V287, P452, DOI 10.1056/NEJM197208312870907; Sloane DE, 2007, J ALLERGY CLIN IMMUN, V120, P654, DOI 10.1016/j.jaci.2007.06.037; Szeplaki G, 2005, J ALLERGY CLIN IMMUN, V115, P864, DOI 10.1016/j.jaci.2004.12.1130; Verpy E, 1996, AM J HUM GENET, V59, P308; Waytes AT, 1996, NEW ENGL J MED, V334, P1630, DOI 10.1056/NEJM199606203342503; Winnewisser J, 1997, J INTERN MED, V241, P39, DOI 10.1046/j.1365-2796.1997.76893000.x; Zuraw BL, 2000, J ALLERGY CLIN IMMUN, V105, P541, DOI 10.1067/mai.2000.104780; ZURAW BL, 1986, J ALLERGY CLIN IMMUN, V78, P1115, DOI 10.1016/0091-6749(86)90259-9; Zuraw BL, 2008, EXPERT OPIN INV DRUG, V17, P697, DOI [10.1517/13543784.17.5.697, 10.1517/13543784.17.5.697 ]	54	516	554	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2008	359	10					1027	1036		10.1056/NEJMcp0803977	http://dx.doi.org/10.1056/NEJMcp0803977			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	343KN	18768946				2022-12-28	WOS:000258852500007
J	Han, JC; Liu, QR; Jones, M; Levinn, RL; Menzie, CM; Jefferson-George, KS; Adler-Wailes, DC; Sanford, EL; Lacbawan, FL; Uhl, GR; Rennert, OM; Yanovski, JA				Han, Joan C.; Liu, Qing-Rong; Jones, MaryPat; Levinn, Rebecca L.; Menzie, Carolyn M.; Jefferson-George, Kyra S.; Adler-Wailes, Diane C.; Sanford, Ethan L.; Lacbawan, Felicitas L.; Uhl, George R.; Rennert, Owen M.; Yanovski, Jack A.			Brain-derived neurotrophic factor and obesity in the WAGR syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BODY-MASS INDEX; HUMAN PLATELETS; ENERGY-BALANCE; FACTOR BDNF; HYPERPHAGIA; DELETION; CHILDREN; PATIENT; HYPOTHALAMUS; ASSOCIATION	Background: Brain-derived neurotrophic factor (BDNF) has been found to be important in energy homeostasis in animal models, but little is known about its role in energy balance in humans. Heterozygous, variably sized, contiguous gene deletions causing haploinsufficiency of the WT1 and PAX6 genes on chromosome 11p13, approximately 4 Mb centromeric to BDNF (11p14.1), result in the Wilms' tumor, aniridia, genitourinary anomalies, and mental retardation (WAGR) syndrome. Hyperphagia and obesity were observed in a subgroup of patients with the WAGR syndrome. We hypothesized that the subphenotype of obesity in the WAGR syndrome is attributable to deletions that induce haploinsufficiency of BDNF. Methods: We studied the relationship between genotype and body-mass index (BMI) in 33 patients with the WAGR syndrome who were recruited through the International WAGR Syndrome Association. The extent of each deletion was determined with the use of oligonucleotide comparative genomic hybridization. Results: Deletions of chromosome 11p in the patients studied ranged from 1.0 to 26.5 Mb; 58% of the patients had heterozygous BDNF deletions. These patients had significantly higher BMI z scores throughout childhood than did patients with intact BDNF (mean [+/-SD] z score at 8 to 10 years of age, 2.08+/-0.45 in patients with heterozygous BDNF deletions vs. 0.88+/-1.28 in patients without BDNF deletions; P=0.03). By 10 years of age, 100% of the patients with heterozygous BDNF deletions (95% confidence interval [CI], 77 to 100) were obese (BMI greater/equal 95th percentile for age and sex) as compared with 20% of persons without BDNF deletions (95% CI, 3 to 56; P<0.001). The critical region for childhood-onset obesity in the WAGR syndrome was located within 80 kb of exon 1 of BDNF. Serum BDNF concentrations were approximately 50% lower among the patients with heterozygous BDNF deletions (P=0.001). Conclusions: Among persons with the WAGR syndrome, BDNF haploinsufficiency is associated with lower levels of serum BDNF and with childhood-onset obesity; thus, BDNF may be important for energy homeostasis in humans. (ClinicalTrials.gov number, NCT00006073.).	[Han, Joan C.; Levinn, Rebecca L.; Menzie, Carolyn M.; Jefferson-George, Kyra S.; Adler-Wailes, Diane C.; Sanford, Ethan L.; Yanovski, Jack A.] NIH, Unit Growth & Obes, Program Dev Endocrinol & Genet, Hatfield Clin Res Ctr, Bethesda, MD 20892 USA; [Rennert, Owen M.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Lab Clin Genom, Bethesda, MD USA; [Jones, MaryPat] NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA; [Lacbawan, Felicitas L.] NHGRI, Med Genet Branch, NIH, Bethesda, MD 20892 USA; [Liu, Qing-Rong; Uhl, George R.] NIDA, Mol Neurobiol Branch, Baltimore, MD USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	Yanovski, JA (corresponding author), NIH, Unit Growth & Obes, Program Dev Endocrinol & Genet, Hatfield Clin Res Ctr, 10 Ctr Dr,Rm 1E-3330,MSC 1103, Bethesda, MD 20892 USA.	jy15i@nih.gov	Liu, Qing-Rong/A-3059-2012; Rennert, owen/AAI-7374-2020	Liu, Qing-Rong/0000-0001-8477-6452; Yanovski, Jack/0000-0001-8542-1637; Han, Joan/0000-0003-4252-2678; Sanford, Ethan/0000-0002-7423-6521	Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health (NIH) [Z01-HD-00641]; NIH Office of Rare Diseases; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008822, ZIAHD000641] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000641] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [ZIADA000401, ZIADA000492] Funding Source: NIH RePORTER	Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIH Office of Rare Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	Supported by grants from the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health (NIH) (Z01-HD-00641) and from the NIH Office of Rare Diseases. Dr. Uhl reports holding patents for OPRM1 and DAT (SLC6A3), which might play roles in obesity, but having no patents or other financial interests that are related to brain-derived neurotrophic factor ( BDNF); and Dr. Yanovski, receiving research support for an obesity-related clinical trial from Obecure but having no financial interests that are related to BDNF. Drs. Han and Yanovski are commissioned officers in the U. S. Public Health Service. No other potential conflict of interest relevant to this article was reported. We thank the members of International WAGR Syndrome Association for assistance in identifying families who were willing to participate in this study, Dr. Jack W. Tsao for his assistance with evaluation of nociception in our patients and review of an earlier version of the manuscript, and Chanelle Wijensinghe for administrative assistance.	Allen SJ, 2006, CLIN SCI, V110, P175, DOI 10.1042/CS20050161; Amor DJ, 2002, CLIN DYSMORPHOL, V11, P73, DOI 10.1097/00019605-200201000-00016; Bell CG, 2005, NAT REV GENET, V6, P221, DOI 10.1038/nrg1556; Breau LM, 2002, PAIN, V99, P349, DOI 10.1016/S0304-3959(02)00179-3; Bremond-Gignac D, 2005, EUR J HUM GENET, V13, P409, DOI 10.1038/sj.ejhg.5201358; Breslow NE, 2003, J CLIN ONCOL, V21, P4579, DOI 10.1200/JCO.2003.06.096; Chaldakov GN, 2004, PROG BRAIN RES, V146, P279, DOI 10.1016/S0079-6123(03)46018-4; Chung WK, 2005, TRENDS ENDOCRIN MET, V16, P267, DOI 10.1016/j.tem.2005.06.009; COLE TJ, 1990, EUR J CLIN NUTR, V44, P45; DECASTRO JM, 1994, APPETITE, V23, P179, DOI 10.1006/appe.1994.1045; Dykens EM, 2007, OBESITY, V15, P1816, DOI 10.1038/oby.2007.216; El-Gharbawy AH, 2006, J CLIN ENDOCR METAB, V91, P3548, DOI 10.1210/jc.2006-0658; Farooqi IS, 2006, ENDOCR REV, V27, P710, DOI 10.1210/er.2006-0040; Fischbach BV, 2005, PEDIATRICS, V116, P984, DOI 10.1542/peds.2004-0467; Fox EA, 2004, AM J PHYSIOL-REG I, V286, pR994, DOI 10.1152/ajpregu.00727.2003; Friedel S, 2005, AM J MED GENET B, V132B, P96, DOI 10.1002/ajmg.b.30090; Fujimura H, 2002, THROMB HAEMOSTASIS, V87, P728; Gray J, 2006, DIABETES, V55, P3366, DOI 10.2337/db06-0550; Gul D, 2002, AM J MED GENET, V107, P70, DOI 10.1002/ajmg.10013; Gunstad J, 2006, NEUROPSYCHOBIOLOGY, V53, P153, DOI 10.1159/000093341; Jung R, 2006, MOL GENET METAB, V88, P256, DOI 10.1016/j.ymgme.2006.02.003; Kernie SG, 2000, EMBO J, V19, P1290, DOI 10.1093/emboj/19.6.1290; Krabbe KS, 2007, DIABETOLOGIA, V50, P431, DOI 10.1007/s00125-006-0537-4; Kuczmarski RJ, 2000, ADV DATA, V314, P1; Levin BE, 2007, AM J PHYSIOL-REG I, V293, pR988, DOI 10.1152/ajpregu.00434.2007; Lommatzsch M, 2005, NEUROBIOL AGING, V26, P115, DOI 10.1016/j.neurobiolaging.2004.03.002; Lyons WE, 1999, P NATL ACAD SCI USA, V96, P15239, DOI 10.1073/pnas.96.26.15239; Marlin S, 1994, Clin Dysmorphol, V3, P255; MCGAUGHRAN JM, 1995, J MED GENET, V32, P823, DOI 10.1136/jmg.32.10.823; Nakagawa T, 2000, DIABETES, V49, P436, DOI 10.2337/diabetes.49.3.436; Ogden CL, 2008, JAMA-J AM MED ASSOC, V299, P2401, DOI 10.1001/jama.299.20.2401; PELLEYMOUNTER MA, 1995, EXP NEUROL, V131, P229, DOI 10.1016/0014-4886(95)90045-4; Pruunsild P, 2007, GENOMICS, V90, P397, DOI 10.1016/j.ygeno.2007.05.004; Ribases M, 2005, EUR J HUM GENET, V13, P428, DOI 10.1038/sj.ejhg.5201351; Rios M, 2001, MOL ENDOCRINOL, V15, P1748, DOI 10.1210/me.15.10.1748; Tiberio G, 2000, CLIN DYSMORPHOL, V9, P63, DOI 10.1097/00019605-200009010-00014; Unger TJ, 2007, J NEUROSCI, V27, P14265, DOI 10.1523/JNEUROSCI.3308-07.2007; Wang CF, 2007, AM J PHYSIOL-REG I, V293, pR1037, DOI 10.1152/ajpregu.00125.2007; Xu BJ, 2003, NAT NEUROSCI, V6, P736, DOI 10.1038/nn1073; Yeo GSH, 2004, NAT NEUROSCI, V7, P1187, DOI 10.1038/nn1336; ZHANG YY, 1995, NATURE, V374, P479, DOI 10.1038/374479a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	42	208	217	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 28	2008	359	9					918	927		10.1056/NEJMoa0801119	http://dx.doi.org/10.1056/NEJMoa0801119			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	341IU	18753648	Green Accepted			2022-12-28	WOS:000258708300006
J	Pincus, LB; Fox, LP				Pincus, Laura B.; Fox, Lindy P.			The Stewart-Treves Syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Pincus, Laura B.; Fox, Lindy P.] Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Pincus, LB (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.	foxli@derm.ucsf.edu							0	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 28	2008	359	9					950	950		10.1056/NEJMicm071344	http://dx.doi.org/10.1056/NEJMicm071344			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	341IU	18753651				2022-12-28	WOS:000258708300009
J	Acilan, C; Saunders, WS				Acilan, Ceyda; Saunders, William S.			A tale of too many centrosomes	CELL			English	Review							SPINDLE POLES; NUMBERS	Having the correct number of centrosomes is crucial for proper chromosome segregation during cell division and for the prevention of aneuploidy, a hallmark of many cancer cells. Several recent studies (Basto et al., 2008; Kwon et al., 2008; Yang et al., 2008) reveal the importance of mechanisms that protect against the consequences of harboring too many centrosomes.	[Saunders, William S.] Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15235 USA; [Acilan, Ceyda] Istanbul Tech Univ, BioT Incorp, TR-34390 Istanbul, Turkey	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Istanbul Technical University	Saunders, WS (corresponding author), Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15235 USA.	wsaund@pitt.edu		Acilan, Ceyda/0000-0002-8936-3267				Basto R, 2008, CELL, V133, P1032, DOI 10.1016/j.cell.2008.05.039; Basto R, 2006, CELL, V125, P1375, DOI 10.1016/j.cell.2006.05.025; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Caussinus E, 2005, NAT GENET, V37, P1125, DOI 10.1038/ng1632; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; HATSUMI M, 1992, J CELL SCI, V101, P547; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; Huppertz B, 2006, MICRON, V37, P509, DOI 10.1016/j.micron.2005.12.011; Kwon M, 2008, GENE DEV, V22, P2189, DOI 10.1101/gad.1700908; Margall-Ducos G, 2007, J CELL SCI, V120, P3633, DOI 10.1242/jcs.016907; Merdes A, 2000, J CELL BIOL, V149, P851, DOI 10.1083/jcb.149.4.851; Pajcini KV, 2008, J CELL BIOL, V180, P1005, DOI 10.1083/jcb.200707191; Quintyne NJ, 2005, SCIENCE, V307, P127, DOI 10.1126/science.1104905; Saunders WS, 2000, P NATL ACAD SCI USA, V97, P303, DOI 10.1073/pnas.97.1.303; Sluder G, 1997, J CELL SCI, V110, P421; Srsen V, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-26; Wong RW, 2006, P NATL ACAD SCI USA, V103, P19783, DOI 10.1073/pnas.0609582104; Yamashita YM, 2008, J CELL BIOL, V180, P261, DOI 10.1083/jcb.200707083; Yang Z, 2008, NAT CELL BIOL, V10, P748, DOI 10.1038/ncb1738	19	30	30	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	2008	134	4					572	575		10.1016/j.cell.2008.08.007	http://dx.doi.org/10.1016/j.cell.2008.08.007			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SR	18724931	Bronze			2022-12-28	WOS:000258665800011
J	Stetson, DB; Ko, JS; Heidmann, T; Medzhitov, R				Stetson, Daniel B.; Ko, Joan S.; Heidmann, Thierry; Medzhitov, Ruslan			Trex1 prevents cell-intrinsic initiation of autoimmunity	CELL			English	Article							AICARDI-GOUTIERES-SYNDROME; SYSTEMIC-LUPUS-ERYTHEMATOSUS; TOLL-LIKE RECEPTORS; FAMILIAL CHILBLAIN LUPUS; INNATE IMMUNE-RESPONSES; DNA EXONUCLEASE TREX1; I INTERFERONS; ENDOGENOUS RETROVIRUSES; DENDRITIC CELLS; GENE INDUCTION	Detection of nucleic acids and induction of type I interferons (IFNs) are principal elements of antiviral defense but can cause autoimmunity if misregulated. Cytosolic DNA detection activates a potent, cell-intrinsic antiviral response through a poorly defined pathway. In a screen for proteins relevant to this IFN-stimulatory DNA (ISD) response, we identify 30 repair exonuclease 1 (Trex1). Mutations in the human trex1 gene cause Aicardi-Goutieres syndrome (AGS) and chilblain lupus, but the molecular basis of these diseases is unknown. We define Trex1 as an essential negative regulator of the ISD response and delineate the genetic pathway linking Trex1 deficiency to lethal autoimmunity. We show that single-stranded DNA derived fromendogenous retroelements accumulates in Trex1-deficient cells, and that Trex1 can metabolize reverse-transcribed DNA. These findings reveal a cell-intrinsic mechanism for initiation of autoimmunity, implicate the ISD pathway as the cause of AGS, and suggest an unanticipated contribution of endogenous retroelements to autoimmunity.	[Stetson, Daniel B.; Ko, Joan S.; Medzhitov, Ruslan] Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA; [Stetson, Daniel B.; Ko, Joan S.; Medzhitov, Ruslan] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA; [Heidmann, Thierry] Inst Gustave Roussy, CNRS, Unite Retrovirus Endogenes & Elements Retroides E, UMR8122, F-94805 Villejuif, France	Howard Hughes Medical Institute; Yale University; Yale University; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Stetson, DB (corresponding author), Univ Washington, Dept Immunol, Seattle, WA 98195 USA.	stetson@u.washington.edu; ruslan.medzhitov@yale.edu		Ko, Joan/0000-0002-5442-6416	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI084914, K99AI072945] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [K99 AI072945, R01 AI084914, K99 AI072945-01A1, 1K99AI072945-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alarcon-Riquelme ME, 2006, NAT GENET, V38, P866, DOI 10.1038/ng0806-866; Chowdhury D, 2006, MOL CELL, V23, P133, DOI 10.1016/j.molcel.2006.06.005; Christensen SR, 2006, IMMUNITY, V25, P417, DOI 10.1016/j.immuni.2006.07.013; Colmegna I, 2006, INFECT DIS CLIN N AM, V20, P913, DOI 10.1016/j.idc.2006.09.008; Crow YJ, 2006, NAT GENET, V38, P910, DOI 10.1038/ng1842; Crow YJ, 2006, NAT GENET, V38, P917, DOI 10.1038/ng1845; Crow YJ, 2003, J MED GENET, V40, P183, DOI 10.1136/jmg.40.3.183; Dewannieux M, 2004, NAT GENET, V36, P534, DOI 10.1038/ng1353; Esnault C, 2000, NAT GENET, V24, P363, DOI 10.1038/74184; Goodnow CC, 2007, CELL, V130, P25, DOI 10.1016/j.cell.2007.06.033; Gray DHD, 2007, P NATL ACAD SCI USA, V104, P18193, DOI 10.1073/pnas.0709160104; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Hoss M, 1999, EMBO J, V18, P3868, DOI 10.1093/emboj/18.13.3868; Ishii KJ, 2006, NAT IMMUNOL, V7, P40, DOI 10.1038/ni1282; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; Koyama S, 2007, J IMMUNOL, V179, P4711, DOI 10.4049/jimmunol.179.7.4711; Kumar H, 2006, J EXP MED, V203, P1795, DOI 10.1084/jem.20060792; Lande R, 2007, NATURE, V449, P564, DOI 10.1038/nature06116; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Lee-Kirsch MA, 2007, NAT GENET, V39, P1065, DOI 10.1038/ng2091; Lee-Kirsch MA, 2007, J MOL MED-JMM, V85, P531, DOI 10.1007/s00109-007-0199-9; LINDAHL T, 1969, J BIOL CHEM, V244, P5014; Liu CL, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-19; Lower R, 1999, TRENDS MICROBIOL, V7, P350, DOI 10.1016/S0966-842X(99)01565-6; Marshak-Rothstein A, 2007, ANNU REV IMMUNOL, V25, P419, DOI 10.1146/annurev.immunol.22.012703.104514; Martin DA, 2006, ARTHRITIS RHEUM-US, V54, P951, DOI 10.1002/art.21677; Mazur DJ, 1999, J BIOL CHEM, V274, P19655, DOI 10.1074/jbc.274.28.19655; Mazur DJ, 2001, J BIOL CHEM, V276, P17022, DOI 10.1074/jbc.M100623200; Morita M, 2004, MOL CELL BIOL, V24, P6719, DOI 10.1128/MCB.24.15.6719-6727.2004; Napirei M, 2000, NAT GENET, V25, P177, DOI 10.1038/76032; Nelson PN, 2003, J CLIN PATHOL-MOL PA, V56, P11, DOI 10.1136/mp.56.1.11; Okabe Y, 2005, J EXP MED, V202, P1333, DOI 10.1084/jem.20051654; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; Pascual V, 2006, CURR OPIN IMMUNOL, V18, P676, DOI 10.1016/j.coi.2006.09.014; Pichlmair A, 2007, IMMUNITY, V27, P370, DOI 10.1016/j.immuni.2007.08.012; Pisitkun P, 2006, SCIENCE, V312, P1669, DOI 10.1126/science.1124978; Rice G, 2007, AM J HUM GENET, V81, P713, DOI 10.1086/521373; Rice G, 2007, AM J HUM GENET, V80, P811, DOI 10.1086/513443; Richards A, 2007, NAT GENET, V39, P1068, DOI 10.1038/ng2082; Rudin CM, 2001, GENE CHROMOSOME CANC, V30, P64, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1066>3.0.CO;2-F; Sanchis A, 2005, J PEDIATR-US, V146, P701, DOI 10.1016/j.jpeds.2005.01.033; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Schulz O, 2005, NATURE, V433, P887, DOI 10.1038/nature03326; Shevelev IV, 2002, NAT REV MOL CELL BIO, V3, P364, DOI 10.1038/nrm804; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stetson DB, 2006, IMMUNITY, V25, P373, DOI 10.1016/j.immuni.2006.08.007; Stetson DB, 2006, IMMUNITY, V24, P93, DOI 10.1016/j.immuni.2005.12.003; Stoye JP, 1999, TRENDS MICROBIOL, V7, P430, DOI 10.1016/S0966-842X(99)01616-9; Subramanian S, 2006, P NATL ACAD SCI USA, V103, P9970, DOI 10.1073/pnas.0603912103; Sun QM, 2006, IMMUNITY, V24, P633, DOI 10.1016/j.immuni.2006.04.004; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; Takaoka A, 2007, NATURE, V448, P501, DOI 10.1038/nature06013; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Theofilopoulos AN, 2005, ANNU REV IMMUNOL, V23, P307, DOI 10.1146/annurev.immunol.23.021704.115843; Yang YG, 2007, CELL, V131, P873, DOI 10.1016/j.cell.2007.10.017; Yasutomo K, 2001, NAT GENET, V28, P313, DOI 10.1038/91070; Yoshida H, 2005, NAT IMMUNOL, V6, P49, DOI 10.1038/ni1146	57	872	900	2	39	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	2008	134	4					587	598		10.1016/j.cell.2008.06.032	http://dx.doi.org/10.1016/j.cell.2008.06.032			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SR	18724932	Bronze, Green Accepted			2022-12-28	WOS:000258665800013
J	Guston, DH				Guston, David H.			Innovation policy: not just a jumbo shrimp	NATURE			English	Editorial Material							SCIENCE		Arizona State Univ, Ctr Nanotechnol Soc, Tempe, AZ 85287 USA; Arizona State Univ, Consortium Sci Policy & Outcomes, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	Guston, DH (corresponding author), Arizona State Univ, Ctr Nanotechnol Soc, Tempe, AZ 85287 USA.	david.guston@asu.edu						Barben D, 2007, HANDBOOK OF SCIENCE AND TECHNOLOGY STUDIES, THIRD EDITION, P979; Bozeman B., 2007, PUBLIC VALUES PUBLIC; Fisher E., 2006, SCI PUBL POLICY, V33, P5; National Science and Technology Council Committee on Technology, 2000, NAT NAN IN LEAD NEXT; POLANYI M, 1962, MINERVA, V1, P54, DOI 10.1007/BF01101453; Roco MC, 2004, J NANOPART RES, V6, P1, DOI 10.1023/B:NANO.0000023243.25838.73; Sarewitz D, 2004, ENVIRON SCI POLICY, V7, P385, DOI 10.1016/j.envsci.2004.06.001	7	90	93	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 21	2008	454	7207					940	941		10.1038/454940a	http://dx.doi.org/10.1038/454940a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	339QB	18719568				2022-12-28	WOS:000258591000019
J	Srivastava, M; Begovic, E; Chapman, J; Putnam, NH; Hellsten, U; Kawashima, T; Kuo, A; Mitros, T; Salamov, A; Carpenter, ML; Signorovitch, AY; Moreno, MA; Kamm, K; Grimwood, J; Schmutz, J; Shapiro, H; Grigoriev, IV; Buss, LW; Schierwater, B; Dellaporta, SL; Rokhsar, DS				Srivastava, Mansi; Begovic, Emina; Chapman, Jarrod; Putnam, Nicholas H.; Hellsten, Uffe; Kawashima, Takeshi; Kuo, Alan; Mitros, Therese; Salamov, Asaf; Carpenter, Meredith L.; Signorovitch, Ana Y.; Moreno, Maria A.; Kamm, Kai; Grimwood, Jane; Schmutz, Jeremy; Shapiro, Harris; Grigoriev, Igor V.; Buss, Leo W.; Schierwater, Bernd; Dellaporta, Stephen L.; Rokhsar, Daniel S.			The Trichoplax genome and the nature of placozoans	NATURE			English	Article							ADHAERENS SCHULZE,F.E. PLACOZOA; MAXIMUM-LIKELIHOOD; PROTEIN FAMILIES; ORIGIN; GENES; EVOLUTION; PHYLUM; DIVERSITY; CNIDARIAN; POSITION	As arguably the simplest free- living animals, placozoans may represent a primitive metazoan form, yet their biology is poorly understood. Here we report the sequencing and analysis of the similar to 98 million base pair nuclear genome of the placozoan Trichoplax adhaerens. Whole- genome phylogenetic analysis suggests that placozoans belong to a 'eumetazoan' clade that includes cnidarians and bilaterians, with sponges as the earliest diverging animals. The compact genome shows conserved gene content, gene structure and synteny in relation to the human and other complex eumetazoan genomes. Despite the apparent cellular and organismal simplicity of Trichoplax, its genome encodes a rich array of transcription factor and signalling pathway genes that are typically associated with diverse cell types and developmental processes in eumetazoans, motivating further searches for cryptic cellular complexity and/ or as yet unobserved life history stages.	[Srivastava, Mansi; Begovic, Emina; Kawashima, Takeshi; Mitros, Therese; Carpenter, Meredith L.; Rokhsar, Daniel S.] Univ Calif Berkeley, Ctr Integrat Genom, Berkeley, CA 94720 USA; [Srivastava, Mansi; Begovic, Emina; Kawashima, Takeshi; Mitros, Therese; Carpenter, Meredith L.; Rokhsar, Daniel S.] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; [Begovic, Emina; Chapman, Jarrod; Putnam, Nicholas H.; Hellsten, Uffe; Kuo, Alan; Salamov, Asaf; Shapiro, Harris; Grigoriev, Igor V.; Rokhsar, Daniel S.] Dept Energy Joint Genome Inst, Walnut Creek, CA 94598 USA; [Kawashima, Takeshi] Okinawa Inst Sci & Technol, Okinawa 9042234, Japan; [Signorovitch, Ana Y.; Moreno, Maria A.; Schierwater, Bernd; Dellaporta, Stephen L.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; [Signorovitch, Ana Y.; Buss, Leo W.] Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06520 USA; [Buss, Leo W.] Yale Univ, Dept Geol & Geophys, New Haven, CT 06520 USA; [Kamm, Kai; Schierwater, Bernd] Stiftung Tieraerztliche Hochsch Hannover, Div Ecol & Evolut, Inst Tierokol & Zellbiol, D-30559 Hannover, Germany; [Grimwood, Jane; Schmutz, Jeremy] Stanford Univ, Stanford Human Genome Ctr, Palo Alto, CA 94304 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; Okinawa Institute of Science & Technology Graduate University; Yale University; Yale University; Yale University; Stanford University	Srivastava, M (corresponding author), Univ Calif Berkeley, Ctr Integrat Genom, Berkeley, CA 94720 USA.	msrivast@berkeley.edu; dsrokhsar@yahoo.com	Grimwood, Jane/ABD-5737-2021; Kawashima, Takeshi/M-4510-2015; Putnam, Nicholas/B-9968-2008; Carpenter, Meredith/B-4290-2011; Schmutz, Jeremy/N-3173-2013	Putnam, Nicholas/0000-0002-1315-782X; Schmutz, Jeremy/0000-0001-8062-9172; Kamm, Kai/0000-0001-8038-2843; Rokhsar, Daniel/0000-0002-8704-2224; Carpenter, Meredith/0000-0002-9798-9374; Grigoriev, Igor/0000-0002-3136-8903	USA Department of Energy's Office of Science, Biological and Environmental Research Program; Gordon and Betty Moore Foundation; National Science Foundation; German Science Foundation	USA Department of Energy's Office of Science, Biological and Environmental Research Program; Gordon and Betty Moore Foundation(Gordon and Betty Moore Foundation); National Science Foundation(National Science Foundation (NSF)); German Science Foundation(German Research Foundation (DFG))	This work was performed under the auspices of the USA Department of Energy's Office of Science, Biological and Environmental Research Program and by the University of California, Lawrence Livermore National Laboratory, Lawrence Berkeley National Laboratory and Los Alamos National Laboratory. The Center for Integrative Genomics is supported by a grant from the Gordon and Betty Moore Foundation. D. S. R. acknowledges support from R. A. Melmon. L. W. B., S. L. D. and M. A. M. were supported by the National Science Foundation. B. S. acknowledges support from the German Science Foundation.	Adamska M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001031; Adamska M, 2007, CURR BIOL, V17, pR836, DOI 10.1016/j.cub.2007.08.010; Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; BRIDGE D, 1995, MOL BIOL EVOL, V12, P679; Butschli O, 1884, MORPHOLOGISCHES JB, P415; Collins AG, 1998, P NATL ACAD SCI USA, V95, P15458, DOI 10.1073/pnas.95.26.15458; da Silva FB, 2007, GENET MOL BIOL, V30, P127, DOI 10.1590/S1415-47572007000100022; Dellaporta SL, 2006, P NATL ACAD SCI USA, V103, P8751, DOI 10.1073/pnas.0602076103; Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113; Ender A, 2003, MOL BIOL EVOL, V20, P130, DOI 10.1093/molbev/msg018; Erwin DH, 2002, DEVELOPMENT, V129, P3021; GRELL K G, 1971, Naturwissenschaftliche Rundschau, V24, P160; GRELL KG, 1981, ZOOMORPHOLOGY, V98, P47, DOI 10.1007/BF00310320; GRELL KG, 1972, Z MORPHOL TIERE, V73, P297, DOI 10.1007/BF00391925; GRELL KG, 1991, PLACOZOA PORIFERA CN, P13; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Hadrys T, 2005, MOL BIOL EVOL, V22, P1569, DOI 10.1093/molbev/msi150; Haen KM, 2007, MOL BIOL EVOL, V24, P1518, DOI 10.1093/molbev/msm070; Jakob W, 2004, DEV GENES EVOL, V214, P170, DOI 10.1007/s00427-004-0390-8; Lavrov DV, 2005, MOL BIOL EVOL, V22, P1231, DOI 10.1093/molbev/msi108; Lee PN, 2007, DEV BIOL, V310, P169, DOI 10.1016/j.ydbio.2007.05.040; Martinelli C, 2004, GENE EXPR PATTERNS, V4, P443, DOI 10.1016/j.modgep.2004.01.002; Martinelli C, 2003, DEV GENES EVOL, V213, P492, DOI 10.1007/s00427-003-0353-5; Maruyama YK, 2004, BIOL BULL-US, V206, P55, DOI 10.2307/1543198; Matus DQ, 2006, CURR BIOL, V16, P499, DOI 10.1016/j.cub.2006.01.052; Monteiro AS, 2006, EVOL DEV, V8, P174, DOI 10.1111/j.1525-142X.2006.00087.x; Muller W.E.G., 1996, Progress in Molecular and Subcellular Biology, V17, P183; Nichols SA, 2006, P NATL ACAD SCI USA, V103, P12451, DOI 10.1073/pnas.0604065103; PEARSE V B, 1989, Pacific Science, V43, P117; Pearse VB, 2007, INTEGR COMP BIOL, V47, P677, DOI 10.1093/icb/icm015; Putnam NH, 2008, NATURE, V453, P1064, DOI 10.1038/nature06967; Putnam NH, 2007, SCIENCE, V317, P86, DOI 10.1126/science.1139158; Ramesh MA, 2005, CURR BIOL, V15, P185, DOI 10.1016/j.cub.2005.01.003; RENWICK JH, 1971, ANNU REV GENET, V5, P81, DOI 10.1146/annurev.ge.05.120171.000501; RISINGER C, 1993, J BIOL CHEM, V268, P24408; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Ruiz-Trillo I, 2008, MOL BIOL EVOL, V25, P664, DOI 10.1093/molbev/msn006; RUTHMANN A, 1986, ZOOMORPHOLOGY, V106, P115, DOI 10.1007/BF00312113; Sakarya O, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000506; Schierwater B, 2005, BIOESSAYS, V27, P1294, DOI 10.1002/bies.20320; SCHIERWATER B, IN PRESS PLOS 1; Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502; SCHUCHERT P, 1993, ACTA ZOOL-STOCKHOLM, V74, P115, DOI 10.1111/j.1463-6395.1993.tb01227.x; Schulze FE, 1883, ZOOL ANZ, V6, P92; Shimodaira H, 2001, BIOINFORMATICS, V17, P1246, DOI 10.1093/bioinformatics/17.12.1246; Signorovitch AY, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030013; Signorovitch AY, 2006, BIOL BULL-US, V211, P149, DOI 10.2307/4134589; Signorovitch AY, 2005, P NATL ACAD SCI USA, V102, P15518, DOI 10.1073/pnas.0504031102; Swofford D.L., 1999, PAUP PHYLOGENETIC AN; SYED T, 2002, SENCKENBERG LETH, V82, P259; Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Voigt O, 2004, CURR BIOL, V14, pR944, DOI 10.1016/j.cub.2004.10.036; Weber JL, 1997, GENOME RES, V7, P401, DOI 10.1101/gr.7.5.401; WENDEROTH H, 1986, Z NATURFORSCH C, V41, P343	56	604	643	2	89	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 21	2008	454	7207					955	U19		10.1038/nature07191	http://dx.doi.org/10.1038/nature07191			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339QB	18719581	hybrid, Green Submitted			2022-12-28	WOS:000258591000030
J	Cochi, SL; Kew, O				Cochi, Stephen L.; Kew, Olen			Polio today - Are we on the verge of global eradication? Commentary	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							VACCINATION PROGRAM; POLIOMYELITIS		[Cochi, Stephen L.] Ctr Dis Control & Prevent, Global Immunizat Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA; [Kew, Olen] Ctr Dis Control & Prevent, Polio & Picomavirus Lab Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Cochi, SL (corresponding author), Ctr Dis Control & Prevent, Global Immunizat Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mailstop E-05, Atlanta, GA 30333 USA.	scochi@cdc.gov						Centers of Disease Control and Prevention, 2001, MMWR Recomm Rep, V50, P1, DOI 10.1103/PhysRevE.106.055304; [Anonymous], WHO VACC PREV DIS MO; Centers for Disease Control and Prevention (CDC), 2006, MMWR Morb Mortal Wkly Rep, V55, P145; Centers for Disease Control and Prevention (CDC), 2002, MMWR MORB MORTAL WKL, V51, P572; CRUZ RR, 1984, REV INFECT DIS, V6, pS408; DECASTRO JF, 1984, REV INFECT DIS, V6, pS397; DECOTO EML, 1984, REV INFECT DIS, V6, pS442; deQuadros CA, 1997, J INFECT DIS, V175, pS37, DOI 10.1093/infdis/175.Supplement_1.S37; FOEGE WH, 1993, JAMA-J AM MED ASSOC, V270, P1859, DOI 10.1001/jama.270.15.1859; RISI JB, 1984, REV INFECT DIS, V6, pS400; SABIN AB, 1980, B WORLD HEALTH ORGAN, V58, P141; SALK JE, 1953, JAMA-J AM MED ASSOC, V151, P1081, DOI 10.1001/jama.1953.13.1081; *WHO, GLOB POL ER IN WEB S; *WHO, WHOIVB0505 DEP IMM V; YANG BP, 1995, PEDIATR INFECT DIS J, V14, P308, DOI 10.1097/00006454-199504000-00011	15	15	15	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	2008	300	7					839	841		10.1001/jama.300.7.839	http://dx.doi.org/10.1001/jama.300.7.839			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	338VM	18714066	Bronze			2022-12-28	WOS:000258537500026
J	John, B; Hunter, CA				John, Beena; Hunter, Christopher A.			Immunology - Neutrophil soldiers or Trojan horses?	SCIENCE			English	Editorial Material							SAND FLY SALIVA; LEISHMANIA-MAJOR; DENDRITIC CELLS; GRANULOCYTES; MACROPHAGES		[John, Beena; Hunter, Christopher A.] Univ Penn, Sch Vet Med, Philadelphia, PA 19108 USA	University of Pennsylvania	John, B (corresponding author), Univ Penn, Sch Vet Med, Philadelphia, PA 19108 USA.	chunter@vet.upenn.edu	Hunter, Christopher/H-1970-2011					Kamhawi S, 2000, MICROBES INFECT, V2, P1765, DOI 10.1016/S1286-4579(00)01331-9; Laskay T, 2008, IMMUNOBIOLOGY, V213, P183, DOI 10.1016/j.imbio.2007.11.010; Laufs H, 2002, INFECT IMMUN, V70, P826, DOI 10.1128/IAI.70.2.826-835.2002; Lemos MP, 2004, J EXP MED, V199, P725, DOI 10.1084/jem.20030795; Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785; Peters NC, 2008, SCIENCE, V321, P970, DOI 10.1126/science.1159194; Udey MC, 2001, IMMUNOBIOLOGY, V204, P590, DOI 10.1078/0171-2985-00096; van Zandbergen G, 2004, J IMMUNOL, V173, P6521, DOI 10.4049/jimmunol.173.11.6521; van Zandbergen G, 2002, INFECT IMMUN, V70, P4177, DOI 10.1128/IAI.70.8.4177-4184.2002; Zer R, 2001, INT J PARASITOL, V31, P810, DOI 10.1016/S0020-7519(01)00190-4	10	25	27	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2008	321	5891					917	918		10.1126/science.1162914	http://dx.doi.org/10.1126/science.1162914			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	337LD	18703727				2022-12-28	WOS:000258436700021
J	Bintanja, R; van de Wal, RSW				Bintanja, R.; van de Wal, R. S. W.			North American ice-sheet dynamics and the onset of 100,000-year glacial cycles	NATURE			English	Article							MIDDLE PLEISTOCENE TRANSITION; HEMISPHERE GLACIATION; CLIMATE; VOLUME; TEMPERATURES; DEGLACIATION; EVOLUTION	The onset of major glaciations in the Northern Hemisphere about 2.7 million years ago(1) was most probably induced by climate cooling during the late Pliocene epoch(2,3). These glaciations, during which the Northern Hemisphere ice sheets successively expanded and retreated, are superimposed on this long-term climate trend, and have been linked to variations in the Earth's orbital parameters(4). One intriguing problem associated with orbitally driven glacial cycles is the transition from 41,000-year to 100,000-year climatic cycles that occurred without an apparent change in insolation forcing(5). Several hypotheses have been proposed to explain the transition, both including and excluding ice-sheet dynamics(6-10). Difficulties in finding a conclusive answer to this palaeoclimatic problem are related to the lack of sufficiently long records of ice-sheet volume or sea level. Here we use a comprehensive ice-sheet model and a simple ocean-temperature model(11) to extract three-million-year mutually consistent records of surface air temperature, ice volume and sea level from marine benthic oxygen isotopes(12). Although these records and their relative phasings are subject to considerable uncertainty owing to limited availability of palaeoclimate constraints, the results suggest that the gradual emergence of the 100,000-year cycles can be attributed to the increased ability of the merged North American ice sheets to survive insolation maxima and reach continental-scale size. The oversized, wet-based ice sheet probably responded to the subsequent insolation maximum by rapid thinning through increased basal-sliding(13,14), thereby initiating a glacial termination. Based on our assessment of the temporal changes in air temperature and ice volume during individual glacials, we demonstrate the importance of ice dynamics and ice-climate interactions in establishing the 100,000-year glacial cycles, with enhanced North American ice-sheet growth and the subsequent merging of the ice sheets being key elements.	[Bintanja, R.] Royal Netherlands Meteorol Inst, KNMI, NL-3732 GK De Bilt, Netherlands; [van de Wal, R. S. W.] Univ Utrecht, Inst Marine & Atmospher Res Utrecht IMAU, NL-3584 CC Utrecht, Netherlands	Royal Netherlands Meteorological Institute; Utrecht University	Bintanja, R (corresponding author), Royal Netherlands Meteorol Inst, KNMI, Wilhelminalaan 10, NL-3732 GK De Bilt, Netherlands.	bintanja@knmi.nl	van de wal, roderik/D-1705-2011	van de wal, roderik/0000-0003-2543-3892				Alley RB, 1999, ANNU REV EARTH PL SC, V27, P149, DOI 10.1146/annurev.earth.27.1.149; Berger A, 1999, QUATERNARY SCI REV, V18, P1, DOI 10.1016/S0277-3791(98)00033-X; Bintanja R, 2005, NATURE, V437, P125, DOI 10.1038/nature03975; Clark PU, 2006, QUATERNARY SCI REV, V25, P3150, DOI 10.1016/j.quascirev.2006.07.008; Clark PU, 1999, SCIENCE, V286, P1104, DOI 10.1126/science.286.5442.1104; Clark PU, 1998, PALEOCEANOGRAPHY, V13, P1, DOI 10.1029/97PA02660; HAYS JD, 1976, SCIENCE, V194, P1121, DOI 10.1126/science.194.4270.1121; Huybers P, 2007, QUATERNARY SCI REV, V26, P37, DOI 10.1016/j.quascirev.2006.07.013; IMBRIE J, 1984, MILANKOVITCH CLIMA 1, P269; Kawamura K, 2007, NATURE, V448, P912, DOI 10.1038/nature06015; Lawrence KT, 2006, SCIENCE, V312, P79, DOI 10.1126/science.1120395; Lear CH, 2000, SCIENCE, V287, P269, DOI 10.1126/science.287.5451.269; Lisiecki L.E., 2005, PALEOCEANOGRAPHY, V20; Lisiecki LE, 2007, QUATERNARY SCI REV, V26, P56, DOI 10.1016/j.quascirev.2006.09.005; MARSHALL SJ, 2002, GEOPHYS RES LETT, V29; Maslin MA, 1998, QUATERNARY SCI REV, V17, P411, DOI 10.1016/S0277-3791(97)00047-4; MASLIN MA, 2006, GSL SPECIAL PUBLICAT, V247, P19; MULLER RA, 1995, NATURE, V377, P107, DOI 10.1038/377107b0; Parrenin F, 2003, EARTH PLANET SC LETT, V214, P243, DOI 10.1016/S0012-821X(03)00363-7; Raymo ME, 2006, SCIENCE, V313, P492, DOI 10.1126/science.1123296; RAYMO ME, 1994, ANNU REV EARTH PL SC, V22, P353, DOI 10.1146/annurev.ea.22.050194.002033; Raymo ME, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000791; Raymo ME, 1997, PALEOCEANOGRAPHY, V12, P577, DOI 10.1029/97PA01169; Ruddiman WF, 2003, QUATERNARY SCI REV, V22, P1597, DOI 10.1016/S0277-3791(03)00087-8; SHACKLETON NJ, 1984, NATURE, V307, P620, DOI 10.1038/307620a0; Shackleton NJ, 2000, SCIENCE, V289, P1897, DOI 10.1126/science.289.5486.1897; Tziperman E, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2001PA000627; Valdes PJ, 1999, PHILOS T R SOC A, V357, P1873, DOI 10.1098/rsta.1999.0405; Weertman J., 1974, J GLACIOL, V13, P3, DOI [DOI 10.3189/S0022143000023327, 10.3189/S0022143000023327]	29	296	303	1	95	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 14	2008	454	7206					869	872		10.1038/nature07158	http://dx.doi.org/10.1038/nature07158			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	336XH	18704083				2022-12-28	WOS:000258398600032
J	Mills, JA; Gonzalez, RG; Jaffe, R; Castelino, FV; Harris, NL; Neal, J; Abraham, G				Mills, John A.; Gilberto Gonzalez, R.; Jaffe, Ronald; Castelino, Flavia V.; Harris, Nancy Lee; Neal, Joel; Abraham, George			A man with fatigue and lesions in the pituitary and cerebellum - Erdheim - Chester disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LANGERHANS-CELL HISTIOCYTOSIS; INTERFERON-ALPHA; INVOLVEMENT; SARCOIDOSIS		[Mills, John A.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; [Gilberto Gonzalez, R.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Mills, John A.] Harvard Univ, Sch Med, Dept Rheumatol, Boston, MA USA; [Gilberto Gonzalez, R.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Jaffe, Ronald] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA; [Neal, Joel] Dana Farber Canc Inst, Boston, MA 02115 USA; [Abraham, George] Univ Massachusetts, Sch Med, Worcester, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Dana-Farber Cancer Institute; University of Massachusetts System; University of Massachusetts Worcester	Mills, JA (corresponding author), Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA.							Bihan H, 2007, MEDICINE, V86, P259, DOI 10.1097/MD.0b013e31815585aa; Braiteh F, 2005, BLOOD, V106, P2992, DOI 10.1182/blood-2005-06-2238; Caturegli P, 2005, ENDOCR REV, V26, P599, DOI 10.1210/er.2004-0011; Chetritt J, 1999, HUM PATHOL, V30, P1093, DOI 10.1016/S0046-8177(99)90228-9; Dickson BC, 2008, VIRCHOWS ARCH, V452, P221, DOI 10.1007/s00428-007-0538-9; Dutta P, 2006, EXP CLIN ENDOCR DIAB, V114, P533, DOI 10.1055/s-2006-924122; Grois N, 2005, BRAIN, V128, P829, DOI 10.1093/brain/awh403; Haroche J, 2004, MEDICINE, V83, P371, DOI 10.1097/01.md.0000145368.17934.91; Haroche J, 2007, PRESSE MED, V36, P1663, DOI 10.1016/j.lpm.2007.04.032; Haroche J, 2006, ARTHRITIS RHEUM, V54, P3330, DOI 10.1002/art.22165; Jaffe R, 2004, PEDIATR DEVEL PATHOL, V7, P2, DOI 10.1007/s10024-003-1119-9; Panegyres PK, 2006, QJM-INT J MED, V99, P609, DOI 10.1093/qjmed/hcl081; PEEPLES DM, 1991, ARCH NEUROL-CHICAGO, V48, P554, DOI 10.1001/archneur.1991.00530170118031; Rosier RN, 2000, NEW ENGL J MED, V342, P875, DOI 10.1056/NEJM200003233421208; Scott TF, 2007, ARCH NEUROL-CHICAGO, V64, P691, DOI 10.1001/archneur.64.5.691; Vaglio A, 2006, LANCET, V367, P241, DOI 10.1016/S0140-6736(06)68035-5; Vencio EF, 2007, AM J SURG PATHOL, V31, P319, DOI 10.1097/01.pas.0000213366.33627.a0; VeyssierBelot C, 1996, MEDICINE, V75, P157, DOI 10.1097/00005792-199605000-00005; Weitzman S, 2005, PEDIATR BLOOD CANCER, V45, P256, DOI 10.1002/pbc.20246; 2000, N ENGL J MED, V342, P1620	20	22	22	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 14	2008	359	7					736	747		10.1056/NEJMcpc0804623	http://dx.doi.org/10.1056/NEJMcpc0804623			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336XE	18703477				2022-12-28	WOS:000258397900012
J	Corrigan, JD; Cole, TB				Corrigan, John D.; Cole, Thomas B.			Substance use disorders and clinical management of traumatic brain injury and posttraumatic stress disorder	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ALCOHOL; PTSD; IRAQ		[Cole, Thomas B.] JAMA, Chicago, IL 60654 USA; [Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Cole, TB (corresponding author), JAMA, 515 N State St, Chicago, IL 60654 USA.	tbcole@bellsouth.net	Corrigan, John D./E-2921-2011					Back SE, 2006, J NERV MENT DIS, V194, P690, DOI 10.1097/01.nmd.0000235794.12794.8a; Bradley R, 2005, AM J PSYCHIAT, V162, P214, DOI 10.1176/appi.ajp.162.2.214; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Corrigan JD, 2007, BRAIN INJURY, V21, P343, DOI 10.1080/02699050701253103; Drake RE, 2001, PSYCHIAT SERV, V52, P469, DOI 10.1176/appi.ps.52.4.469; Fear NT, 2007, ADDICTION, V102, P1749, DOI 10.1111/j.1360-0443.2007.01978.x; Ford Julian D, 2006, Am J Psychother, V60, P335; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Lux WE, 2007, J REHABIL RES DEV, V44, P951, DOI 10.1682/JRRD.2007.01.0009; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Ponsford J, 2007, BRAIN INJURY, V21, P1385, DOI 10.1080/02699050701796960; Soo C, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005239.pub2; Tanielian T, 2008, INVISIBLE WOUNDS WAR, P492	15	51	51	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 13	2008	300	6					720	721		10.1001/jama.300.6.720	http://dx.doi.org/10.1001/jama.300.6.720			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	336OM	18698070				2022-12-28	WOS:000258374500024
J	Green, RE; Malaspinas, AS; Krause, J; Briggs, AW; Johnson, PLF; Uhler, C; Meyer, M; Good, JM; Maricic, T; Stenzel, U; Prufer, K; Siebauer, M; Burbano, HA; Ronan, M; Rothberg, JM; Egholm, M; Rudan, P; Brajkovic, D; Kucan, Z; Gusic, I; Wikstrom, M; Laakkonen, L; Kelso, J; Slatkin, M; Paabo, S				Green, Richard E.; Malaspinas, Anna-Sapfo; Krause, Johannes; Briggs, Adrian W.; Johnson, Philip L. F.; Uhler, Caroline; Meyer, Matthias; Good, Jeffrey M.; Maricic, Tomislav; Stenzel, Udo; Pruefer, Kay; Siebauer, Michael; Burbano, Hernan A.; Ronan, Michael; Rothberg, Jonathan M.; Egholm, Michael; Rudan, Pavao; Brajkovic, Dejana; Kucan, Zeljko; Gusic, Ivan; Wikstrom, Marten; Laakkonen, Liisa; Kelso, Janet; Slatkin, Montgomery; Paeaebo, Svante			A complete neandertal mitochondrial genome sequence determined by high-throughput Sequencing	CELL			English	Article							CYTOCHROME-C-OXIDASE; ANCIENT DNA EXTRACTION; MODERN HUMANS; ANTHROPOID PRIMATES; EVOLUTION; PATTERNS; AMPLIFICATION; POLYMORPHISM; DROSOPHILA; ARTIFACTS	A complete mitochondrial (mt) genome sequence was reconstructed from a 38,000 year-old Neandertal individual with 8341 mtDNA sequences identified among 4.8 Gb of DNA generated from similar to 0.3 g of bone. Analysis of the assembled sequence unequivocally establishes that the Neandertal mtDNA falls outside the variation of extant human mtDNAs, and allows an estimate of the divergence date between the two mtDNA lineages of 660,000 +/- 140,000 years. Of the 13 proteins encoded in the mtDNA, subunit 2 of cytochrome c oxidase of the mitochondrial electron transport chain has experienced the largest number of amino acid substitutions in human ancestors since the separation from Neandertals. There is evidence that purifying selection in the Neandertal mtDNA was reduced compared with other primate lineages, suggesting that the effective population size of Neandertals was small.	[Green, Richard E.; Krause, Johannes; Briggs, Adrian W.; Meyer, Matthias; Good, Jeffrey M.; Maricic, Tomislav; Stenzel, Udo; Pruefer, Kay; Siebauer, Michael; Burbano, Hernan A.; Kelso, Janet; Paeaebo, Svante] Max Planck Inst Evolutionary Anthropol, D-04103 Leipzig, Germany; [Malaspinas, Anna-Sapfo; Slatkin, Montgomery] Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; [Johnson, Philip L. F.] Univ Calif Berkeley, Biophys Grad Grp, Berkeley, CA 94720 USA; [Uhler, Caroline] Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA; [Ronan, Michael; Egholm, Michael] 454 Life Sci, Branford, CT 06405 USA; [Rothberg, Jonathan M.] Rothberg Inst Childhood Dis, Guilford, CT 06437 USA; [Brajkovic, Dejana] Croatian Acad Sci & Arts, Inst Quaternary Paleontol & Geol, HR-10000 Zagreb, Croatia; [Wikstrom, Marten] Univ Helsinki, Inst Biotechnol, Program Struct Biol & Biophys, Helsinki Bioenergent Grp, FIN-00014 Helsinki, Finland; [Laakkonen, Liisa] Univ Helsinki, Fac Biosci, Dept Biol & Environm Sci, Div Biochem, FIN-00014 Helsinki, Finland	Max Planck Society; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Croatian Academy of Sciences & Arts; University of Helsinki; University of Helsinki	Green, RE (corresponding author), Max Planck Inst Evolutionary Anthropol, D-04103 Leipzig, Germany.	green@eva.mpg.de	Krause, Johannes/E-6640-2015; Krause, Johannes/AFP-2642-2022; Kelso, Janet/N-1812-2019; Burbano, Hernán/F-2952-2010	Krause, Johannes/0000-0001-5475-4690; Krause, Johannes/0000-0001-9144-3920; Kelso, Janet/0000-0002-3618-322X; Uhler, Caroline/0000-0002-7008-0216; Burbano, Hernan A./0000-0003-3433-719X; Wikstrom, Marten/0000-0002-7527-4415; Malaspinas, Anna-Sapfo/0000-0003-1001-7511; Green, Richard/0000-0003-0516-5827	Max Plank Society; NIH [R01-GM40282]; Roche company; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040282] Funding Source: NIH RePORTER	Max Plank Society(Max Planck Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Roche company; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the Croatian Academy of Sciences and Arts, the Berlin-Brandenburg Academy of Sciences, and the Presidential Innovation Fund of the Max Plank Society for making this work possible. We are indebted to Mark Stoneking, Weiwei Zhai, John Huelsenbeck, Jerome Fuchs, Mario Morl, Nick Patterson, David Reich, and Timothy White for helpful discussions. We also thank Bruce Rannala and Ziheng Yang for help with mcmctree, James Hudson Bullard for help with figures, and Christine Green for editing. A.-S.M., P.L.F.J., and M.S. are supported by NIH grant R01-GM40282. P.L.F.J. is also supported by a Chang-Lin Tien scholarship. M.E. is an employee of 454 Life Sciences, a Roche company.	Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779; Belevich I, 2006, NATURE, V440, P829, DOI 10.1038/nature04619; Briggs AW, 2007, P NATL ACAD SCI USA, V104, P14616, DOI 10.1073/pnas.0704665104; Brotherton P, 2007, NUCLEIC ACIDS RES, V35, P5717, DOI 10.1093/nar/gkm588; Brunet M, 2002, NATURE, V418, P145, DOI 10.1038/nature00879; Currat M, 2004, PLOS BIOL, V2, P2264, DOI 10.1371/journal.pbio.0020421; Doan JW, 2004, MOL PHYLOGENET EVOL, V33, P944, DOI 10.1016/j.ympev.2004.07.016; Elson JL, 2004, AM J HUM GENET, V74, P229, DOI 10.1086/381505; Galik K, 2004, SCIENCE, V305, P1450, DOI 10.1126/science.1098807; Gilbert MTP, 2007, SCIENCE, V317, P1927, DOI 10.1126/science.1146971; Gilbert MTP, 2003, AM J HUM GENET, V72, P32, DOI 10.1086/345378; Green RE, 2006, NATURE, V444, P330, DOI 10.1038/nature05336; Grossman LI, 2004, TRENDS GENET, V20, P578, DOI 10.1016/j.tig.2004.09.002; Harvati K, 2007, J HUM EVOL, V53, P732, DOI 10.1016/j.jhevol.2007.09.009; Hasegawa M, 1998, MOL BIOL EVOL, V15, P1499, DOI 10.1093/oxfordjournals.molbev.a025877; HIGUCHI R, 1984, NATURE, V312, P282, DOI 10.1038/312282a0; Hofreiter M, 2001, NUCLEIC ACIDS RES, V29, P4793, DOI 10.1093/nar/29.23.4793; Hublin JJ, 2006, CURR BIOL, V16, pR113, DOI 10.1016/j.cub.2006.02.009; Ingman M, 2000, NATURE, V408, P708, DOI 10.1038/35047064; Ingman M, 2006, NUCLEIC ACIDS RES, V34, pD749, DOI 10.1093/nar/gkj010; Kivisild T, 2006, GENETICS, V172, P373, DOI 10.1534/genetics.105.043901; Krause J, 2006, NATURE, V439, P724, DOI 10.1038/nature04432; Krause J, 2007, CURR BIOL, V17, P1908, DOI 10.1016/j.cub.2007.10.008; Krause J, 2007, NATURE, V449, P902, DOI 10.1038/nature06193; Krings M, 2000, NAT GENET, V26, P144, DOI 10.1038/79855; Krings M, 1997, CELL, V90, P19, DOI 10.1016/S0092-8674(00)80310-4; Krings M, 1999, P NATL ACAD SCI USA, V96, P5581, DOI 10.1073/pnas.96.10.5581; LANDER E S, 1988, Genomics, V2, P231; Lebatard AE, 2008, P NATL ACAD SCI USA, V105, P3226, DOI 10.1073/pnas.0708015105; Lohmueller KE, 2008, NATURE, V451, P994, DOI 10.1038/nature06611; Malez M., 1982, PALAEONTOLOGIA JUGOS, V29, P1; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; Meyer M, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkm1095; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; Muramoto K, 2007, P NATL ACAD SCI USA, V104, P7881, DOI 10.1073/pnas.0610031104; Nachman MW, 1996, GENETICS, V142, P953; Noonan JP, 2006, SCIENCE, V314, P1113, DOI 10.1126/science.1131412; Noonan JP, 2005, SCIENCE, V309, P597, DOI 10.1126/science.1113485; PAABO S, 1985, NATURE, V314, P644, DOI 10.1038/314644a0; Paabo S, 2004, ANNU REV GENET, V38, P645, DOI 10.1146/annurev.genet.37.110801.143214; PAABO S, 1988, NATURE, V334, P387, DOI 10.1038/334387b0; Paabo S, 1999, TRENDS CELL BIOL, V9, pM13, DOI 10.1016/S0968-0004(99)01497-8; Poinar HN, 2006, SCIENCE, V311, P392, DOI 10.1126/science.1123360; Rand DM, 1996, MOL BIOL EVOL, V13, P735, DOI 10.1093/oxfordjournals.molbev.a025634; REID RA, 1966, NATURE, V212, P257, DOI 10.1038/212257a0; Rohland N, 2007, NAT PROTOC, V2, P1756, DOI 10.1038/nprot.2007.247; Rohland N, 2007, BIOTECHNIQUES, V42, P343, DOI 10.2144/000112383; Ronaghi M, 1998, SCIENCE, V281, P363, DOI 10.1126/science.281.5375.363; Sampietro ML, 2006, MOL BIOL EVOL, V23, P1801, DOI 10.1093/molbev/msl047; Serre D, 2004, PLOS BIOL, V2, P313, DOI 10.1371/journal.pbio.0020057; Soficaru A, 2006, P NATL ACAD SCI USA, V103, P17196, DOI 10.1073/pnas.0608443103; Stiller M, 2006, P NATL ACAD SCI USA, V103, P13578, DOI 10.1073/pnas.0605327103; Templeton AR, 1996, GENETICS, V144, P1263; Uddin M, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-8; Wall JD, 2007, PLOS GENET, V3, P1862, DOI 10.1371/journal.pgen.0030175; Yang ZH, 2006, MOL BIOL EVOL, V23, P212, DOI 10.1093/molbev/msj024; Yang ZH, 2007, MOL BIOL EVOL, V24, P1586, DOI 10.1093/molbev/msm088; Zhang Z, 2000, J COMPUT BIOL, V7, P203, DOI 10.1089/10665270050081478	58	362	378	5	118	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 8	2008	134	3					416	426		10.1016/j.cell.2008.06.021	http://dx.doi.org/10.1016/j.cell.2008.06.021			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SO	18692465	Bronze, Green Accepted			2022-12-28	WOS:000258665500015
J	Bhatti, P; Sigurdson, AJ; Mabuchi, K				Bhatti, Parveen; Sigurdson, Alice J.; Mabuchi, Kiyohiko			Can low-dose radiation increase risk of cardiovascular disease?	LANCET			English	Editorial Material							INDUCED GENOMIC INSTABILITY; IONIZING-RADIATION; RADIOTHERAPY; MORTALITY; EXPOSURE; WORKERS		[Bhatti, Parveen; Sigurdson, Alice J.; Mabuchi, Kiyohiko] NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Mabuchi, K (corresponding author), NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.	mabuchik@mail.nih.gov		Bhatti, Parveen/0000-0003-1709-1781	NATIONAL CANCER INSTITUTE [Z01CP010133] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams MJ, 2003, CRIT REV ONCOL HEMAT, V45, P55, DOI 10.1016/S1040-8428(01)00227-X; Carr ZA, 2005, INT J RADIAT ONCOL, V61, P842, DOI 10.1016/j.ijrobp.2004.07.708; Hayashi T, 2003, INT J RADIAT BIOL, V79, P129, DOI 10.1080/0955300021000038662; Little MP, 2008, RADIAT RES, V169, P99, DOI 10.1667/RR1070.1; McGale P, 2005, RADIAT RES, V163, P247, DOI 10.1667/RR3314; McGeoghegan D, 2008, INT J EPIDEMIOL, V37, P506, DOI 10.1093/ije/dyn018; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Senkus-Konefka E, 2007, CANCER TREAT REV, V33, P578, DOI 10.1016/j.ctrv.2007.07.011; Vrijheid M, 2007, INT J EPIDEMIOL, V36, P1126, DOI 10.1093/ije/dym138	10	13	15	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG-SEP	2008	372	9640					697	699		10.1016/S0140-6736(08)61285-4	http://dx.doi.org/10.1016/S0140-6736(08)61285-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	344YZ	18761208				2022-12-28	WOS:000258964500008
J	Bird, SM; Farrar, J				Bird, Sheila M.; Farrar, Jeremy			Minimum dataset needed for confirmed human H5N1 cases	LANCET			English	Editorial Material							VIRUS		[Bird, Sheila M.] MRC, Biostat Unit, Cambridge CB2 0SR, England; [Farrar, Jeremy] Univ Oxford, Clin Res Unit, Hosp Trop Dis, Ho Chi Minh City, Vietnam	MRC Biostatistics Unit; University of Oxford	Bird, SM (corresponding author), MRC, Biostat Unit, Cambridge CB2 0SR, England.	sheila.bird@mrc-bsu.cam.ac.uk	Farrar, Jeremy J./HGA-7610-2022	Farrar, Jeremy/0000-0002-2700-623X	MRC [MC_U105260794] Funding Source: UKRI; Medical Research Council [MC_U105260794] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bird SM, 2003, STAT METHODS MED RES, V12, P261, DOI 10.1191/0962280203sm331ra; Box G.E.P., 1998, EVOLUTIONARY OPERATI; Hilton DA, 2004, J PATHOL, V203, P733, DOI 10.1002/path.1580; HUNTER WG, 1966, TECHNOMETRICS, V8, P389, DOI 10.2307/1266686; KANDUN IN, 2008, LANCET          0814, DOI DOI 10.1016/S0140-6736(08)61125-3; NICHOLL A, 2006, EUROSURVEILLANCE, V11, P74; Rosenberger WF, 1999, CONTROL CLIN TRIALS, V20, P328, DOI 10.1016/S0197-2456(99)00013-6; Vong S, 2006, EMERG INFECT DIS, V12, P1542, DOI 10.3201/eid1210.060424; *WHO, 2008, WELC INFL VIR TRACK; Zheng BJ, 2008, P NATL ACAD SCI USA, V105, P8091, DOI 10.1073/pnas.0711942105; 2007, LANCET, V369, P532; 2007, WHOS HSN1 CLIN CASE	12	9	9	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG-SEP	2008	372	9640					696	697		10.1016/S0140-6736(08)61126-5	http://dx.doi.org/10.1016/S0140-6736(08)61126-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	344YZ	18706687				2022-12-28	WOS:000258964500007
J	Ker, K; Perel, P; Blackhall, K; Roberts, I				Ker, Katharine; Perel, Pablo; Blackhall, Karen; Roberts, Ian			Uncertainties page - How effective are some common treatments for traumatic brain injury?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							SEVERE HEAD-INJURY; INTENSIVE-CARE; YOUNG-PEOPLE; MANNITOL; MANAGEMENT; DISABILITY; CENTERS; BURDEN; ADULTS; COMA		[Ker, Katharine; Perel, Pablo; Blackhall, Karen; Roberts, Ian] Univ London London Sch Hyg & Trop Med, Nutr & Publ Hlth Intervent Res Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Ker, K (corresponding author), Univ London London Sch Hyg & Trop Med, Nutr & Publ Hlth Intervent Res Unit, Keppel St, London WC1E 7HT, England.	Katharine.Ker@lshtm.ac.uk		/0000-0002-2342-301X; Ker, Katharine/0000-0002-1514-5005				BOHN DJ, 1989, CRIT CARE MED S, V118, P17; Cruz J, 2004, J NEUROSURG, V100, P376, DOI 10.3171/jns.2004.100.3.0376; Cruz J, 2002, NEUROSURGERY, V51, P628, DOI 10.1097/00006123-200209000-00006; Cruz J, 2001, NEUROSURGERY, V49, P864; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Enblad P, 2004, INTENS CARE MED, V30, P1058, DOI 10.1007/s00134-004-2206-8; Fraade-Blanar L, 2007, REV PANAM SALUD PUBL, V22, P254, DOI 10.1590/S1020-49892007000900005; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; McKeating EG, 1998, BRIT J NEUROSURG, V12, P7; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Roberts I, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000033; Roberts I, 2007, BRIT MED J, V334, P392, DOI 10.1136/bmj.39118.480023.BE; Sayre MR, 1996, ACAD EMERG MED, V3, P840, DOI 10.1111/j.1553-2712.1996.tb03528.x; Schierhout G, 2000, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD000566, 10.1002/14651858. CD000566]; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Wakai A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub4; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; *WHO AD HOC COMM H, 1996, INV HLTH RES DEV; Yamey G, 2007, BMJ-BRIT MED J, V335, P269, DOI 10.1136/bmj.39281.645035.80	24	9	10	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 27	2008	337	7672							a865	10.1136/bmj.a865	http://dx.doi.org/10.1136/bmj.a865			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	356SJ	18703657	Green Accepted			2022-12-28	WOS:000259797600044
J	Lee, PA				Lee, Patrick A.			Physics - An end to the drought of quantum spin liquids	SCIENCE			English	Editorial Material							STATE		[Lee, Patrick A.] MIT, Dept Phys, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Lee, PA (corresponding author), MIT, Dept Phys, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	palee@mit.edu						ANDERSON PW, 1987, SCIENCE, V235, P1196, DOI 10.1126/science.235.4793.1196; Friedel J, 2001, PHYS TODAY, V54, P88, DOI 10.1063/1.1420568; Helton JS, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.107204; Lee PA, 2006, REV MOD PHYS, V78, P17, DOI 10.1103/RevModPhys.78.17; Lee SS, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.036403; Motrunich OI, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.045105; Neel, 1936, ANN PHYS-PARIS, V5, P232; Okamoto Y, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.137207; Shimizu Y, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.107001; Yamashita S, 2008, NAT PHYS, V4, P459, DOI 10.1038/nphys942	11	340	343	0	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	2008	321	5894					1306	1307		10.1126/science.1163196	http://dx.doi.org/10.1126/science.1163196			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	344GG	18772427				2022-12-28	WOS:000258914300037
J	Maier, T; Leibundgut, M; Ban, N				Maier, Timm; Leibundgut, Marc; Ban, Nenad			The crystal structure of a mammalian fatty acid synthase	SCIENCE			English	Article							ACYL CARRIER PROTEIN; ACTIVE-SITE; DOMAIN; REDUCTASE; MECHANISM; CANCER; BIOSYNTHESIS; TRANSACYLASE; ORGANIZATION; ARCHITECTURE	Mammalian fatty acid synthase is a large multienzyme that catalyzes all steps of fatty acid synthesis. We have determined its crystal structure at 3.2 angstrom resolution covering five catalytic domains, whereas the flexibly tethered terminal acyl carrier protein and thioesterase domains remain unresolved. The structure reveals a complex architecture of alternating linkers and enzymatic domains. Substrate shuttling is facilitated by flexible tethering of the acyl carrier protein domain and by the limited contact between the condensing and modifying portions of the multienzyme, which are mainly connected by linkers rather than direct interaction. The structure identifies two additional nonenzymatic domains: ( i) a pseudo- ketoreductase and ( ii) a peripheral pseudo- methyltransferase that is probably a remnant of an ancestral methyltransferase domain maintained in some related polyketide synthases. The structural comparison of mammalian fatty acid synthase with modular polyketide synthases shows how their segmental construction allows the variation of domain composition to achieve diverse product synthesis.	[Maier, Timm; Leibundgut, Marc; Ban, Nenad] ETH, Inst Mol Biol & Biophys, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Ban, N (corresponding author), ETH, Inst Mol Biol & Biophys, CH-8092 Zurich, Switzerland.	ban@mol.biol.ethz.ch	Maier, Timm/A-8835-2016	Maier, Timm/0000-0002-7459-1363	Swiss National Science Foundation (SNSF); National Center of Excellence in Research Structural Biology program of the SNSF	Swiss National Science Foundation (SNSF)(Swiss National Science Foundation (SNSF)); National Center of Excellence in Research Structural Biology program of the SNSF(Swiss National Science Foundation (SNSF))	All data were collected at the Swiss Light Source (SLS, Paul Scherrer Institute, Villigen). We thank C. Schulze-Briese, S. Gutmann, R. Bingel-Erlenmeyer, S. Russo, A. Pauluhn, and T. Tomizaki for their outstanding support at the SLS; S. Jenni and M. Sutter for critically reading the manuscript and all members of the Ban laboratory for suggestions and discussions; R. Grosse-Kunstleve, P. Afonine, and P. Adams for support with the PHENIX software; and A. Jones for support with the program O. This work was supported by the Swiss National Science Foundation (SNSF) and the National Center of Excellence in Research Structural Biology program of the SNSF. Structure factors and atomic coordinates of the porcine FAS in the apo- and NADP<SUP>+</SUP>-bound form have been deposited in the Protein Data Bank with accession codes 2vz8 and 2vz9.	Airenne TT, 2003, J MOL BIOL, V327, P47, DOI 10.1016/S0022-2836(03)00038-X; Baldock C, 1998, J MOL BIOL, V284, P1529, DOI 10.1006/jmbi.1998.2271; Bunkoczi G, 2007, CHEM BIOL, V14, P1243, DOI 10.1016/j.chembiol.2007.10.013; Chakravarty B, 2004, P NATL ACAD SCI USA, V101, P15567, DOI 10.1073/pnas.0406901101; Edwards DJ, 2004, CHEM BIOL, V11, P817, DOI 10.1016/j.chembiol.2004.03.030; Fujii I, 2005, CHEM BIOL, V12, P1301, DOI 10.1016/j.chembiol.2005.09.015; Heath RJ, 2000, J BIOL CHEM, V275, P40128, DOI 10.1074/jbc.M005611200; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; Hori T, 2004, J BIOL CHEM, V279, P22615, DOI 10.1074/jbc.M312655200; Jenni S, 2006, SCIENCE, V311, P1263, DOI 10.1126/science.1123251; Jenni S, 2007, SCIENCE, V316, P254, DOI 10.1126/science.1138248; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Joshi AK, 2005, BIOCHEMISTRY-US, V44, P4100, DOI 10.1021/bi047856r; Joshi AK, 2003, CHEM BIOL, V10, P169, DOI 10.1016/S1074-5521(03)00023-1; JOSHI AK, 1993, J BIOL CHEM, V268, P22508; Keatinge-Clay AT, 2007, CHEM BIOL, V14, P898, DOI 10.1016/j.chembiol.2007.07.009; Keatinge-Clay AT, 2006, STRUCTURE, V14, P737, DOI 10.1016/j.str.2006.01.009; Khosla C, 2007, ANNU REV BIOCHEM, V76, P195, DOI 10.1146/annurev.biochem.76.053105.093515; Kimber MS, 2004, J BIOL CHEM, V279, P52593, DOI 10.1074/jbc.M408105200; Kuhajda FP, 2006, CANCER RES, V66, P5977, DOI 10.1158/0008-5472.CAN-05-4673; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Leesong M, 1996, STRUCTURE, V4, P253, DOI 10.1016/S0969-2126(96)00030-5; Leibundgut M, 2007, SCIENCE, V316, P288, DOI 10.1126/science.1138249; Lomakin IB, 2007, CELL, V129, P319, DOI 10.1016/j.cell.2007.03.013; LYNEN F, 1980, EUR J BIOCHEM, V112, P431; Maier T, 2006, SCIENCE, V311, P1258, DOI 10.1126/science.1123248; Martin JL, 2002, CURR OPIN STRUC BIOL, V12, P783, DOI 10.1016/S0959-440X(02)00391-3; Massengo-Tiasse RP, 2008, J BIOL CHEM, V283, P1308, DOI 10.1074/jbc.M708171200; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Molnar I, 2000, CHEM BIOL, V7, P97, DOI 10.1016/S1074-5521(00)00075-2; Nordling E, 2002, EUR J BIOCHEM, V269, P4267, DOI 10.1046/j.1432-1033.2002.03114.x; Oefner C, 2006, ACTA CRYSTALLOGR D, V62, P613, DOI 10.1107/S0907444906009474; Olsen JG, 2001, STRUCTURE, V9, P233, DOI 10.1016/S0969-2126(01)00583-4; Orita H, 2007, CLIN CANCER RES, V13, P7139, DOI 10.1158/1078-0432.CCR-07-1186; Pasta S, 2007, CHEM BIOL, V14, P1377, DOI 10.1016/j.chembiol.2007.11.007; Pemble CW, 2007, NAT STRUCT MOL BIOL, V14, P704, DOI 10.1038/nsmb1265; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; Persson B, 2003, CHEM-BIOL INTERACT, V143, P271, DOI 10.1016/S0009-2797(02)00223-5; Ploskon E, 2008, J BIOL CHEM, V283, P518, DOI 10.1074/jbc.M703454200; Price AC, 2004, STRUCTURE, V12, P417, DOI 10.1016/j.str.2004.02.008; Rangan VS, 2001, BIOCHEMISTRY-US, V40, P10792, DOI 10.1021/bi015535z; Rangan VS, 1997, J BIOL CHEM, V272, P11975, DOI 10.1074/jbc.272.18.11975; Richter CD, 2008, NAT CHEM BIOL, V4, P75, DOI 10.1038/nchembio.2007.61; Richter CD, 2007, FEBS J, V274, P2196, DOI 10.1111/j.1742-4658.2007.05757.x; Roujeinikova A, 2002, STRUCTURE, V10, P825, DOI 10.1016/S0969-2126(02)00775-X; Roujeinikova A, 2007, J MOL BIOL, V365, P135, DOI 10.1016/j.jmb.2006.09.049; Rozwarski DA, 1999, J BIOL CHEM, V274, P15582, DOI 10.1074/jbc.274.22.15582; Saito J, 2008, PROTEIN SCI, V17, P691, DOI 10.1110/ps.073288808; Schweizer E, 2004, MICROBIOL MOL BIOL R, V68, P501, DOI 10.1128/MMBR.68.3.501-517.2004; SERRE L, 1995, J BIOL CHEM, V270, P12961, DOI 10.1074/jbc.270.22.12961; Shimomura Y, 2003, J BACTERIOL, V185, P4211, DOI 10.1128/JB.185.14.4211-4218.2003; Smith S, 2003, PROG LIPID RES, V42, P289, DOI 10.1016/S0163-7827(02)00067-X; Smith S, 2007, NAT PROD REP, V24, P1041, DOI 10.1039/b603600g; Sullivan TJ, 2006, ACS CHEM BIOL, V1, P43, DOI 10.1021/cb0500042; Tang YY, 2006, P NATL ACAD SCI USA, V103, P11124, DOI 10.1073/pnas.0601924103; Tang YY, 2007, CHEM BIOL, V14, P931, DOI 10.1016/j.chembiol.2007.07.012; THOM JM, 1995, J MOL BIOL, V249, P785; Weissman KJ, 2006, CHEMBIOCHEM, V7, P485, DOI 10.1002/cbic.200500435; White SW, 2005, ANNU REV BIOCHEM, V74, P791, DOI 10.1146/annurev.biochem.74.082803.133524; Witkowski A, 1997, BIOCHEMISTRY-US, V36, P16338, DOI 10.1021/bi972242q; Zornetzer GA, 2006, BIOCHEMISTRY-US, V45, P5217, DOI 10.1021/bi052062d	61	332	345	2	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	2008	321	5894					1315	1322		10.1126/science.1161269	http://dx.doi.org/10.1126/science.1161269			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	344GG	18772430				2022-12-28	WOS:000258914300040
J	Rosenfeld, D; Lohmann, U; Raga, GB; O'Dowd, CD; Kulmala, M; Fuzzi, S; Reissell, A; Andreae, MO				Rosenfeld, Daniel; Lohmann, Ulrike; Raga, Graciela B.; O'Dowd, Colin D.; Kulmala, Markku; Fuzzi, Sandro; Reissell, Anni; Andreae, Meinrat O.			Flood or drought: How do aerosols affect precipitation?	SCIENCE			English	Review							DEEP CONVECTIVE CLOUDS; SUPERCOOLED LIQUID WATER; AIR-POLLUTION; HYDROLOGICAL CYCLE; PART I; MICROPHYSICS; RAIN; MODEL; SIMULATION; CLIMATE	Aerosols serve as cloud condensation nuclei (CCN) and thus have a substantial effect on cloud properties and the initiation of precipitation. Large concentrations of human- made aerosols have been reported to both decrease and increase rainfall as a result of their radiative and CCN activities. At one extreme, pristine tropical clouds with low CCN concentrations rain out too quickly to mature into long- lived clouds. On the other hand, heavily polluted clouds evaporate much of their water before precipitation can occur, if they can form at all given the reduced surface heating resulting from the aerosol haze layer. We propose a conceptual model that explains this apparent dichotomy.	[Rosenfeld, Daniel] Hebrew Univ Jerusalem, Inst Earth Sci, IL-91904 Jerusalem, Israel; [Lohmann, Ulrike] ETH, Inst Atmospher & Climate Sci, CH-8092 Zurich, Switzerland; [Raga, Graciela B.] Univ Nacl Autonoma Mexico, Mexico City 04510, DF, Mexico; [O'Dowd, Colin D.] Natl Univ Ireland Univ Coll Galway, Sch Phys, Environm Change Inst, Galway, Ireland; [O'Dowd, Colin D.] Natl Univ Ireland Univ Coll Galway, Ctr Climate & Air Pollut Studies, Environm Change Inst, Galway, Ireland; [Kulmala, Markku; Reissell, Anni] Univ Helsinki, Dept Phys, FIN-00014 Helsinki, Finland; [Fuzzi, Sandro] CNR, Ist Sci Atmosfera & Clima, I-40129 Bologna, Italy; [Andreae, Meinrat O.] Max Planck Inst Chem, Biogeochem Dept, D-55020 Mainz, Germany	Hebrew University of Jerusalem; Swiss Federal Institutes of Technology Domain; ETH Zurich; Universidad Nacional Autonoma de Mexico; Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway; University of Helsinki; Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze dell'Atmosfera e del Clima (ISAC-CNR); Max Planck Society	Rosenfeld, D (corresponding author), Hebrew Univ Jerusalem, Inst Earth Sci, IL-91904 Jerusalem, Israel.	daniel.rosenfeld@huji.ac.il	Andreae, Meinrat O./B-1068-2008; Lohmann, Ulrike/B-6153-2009; Rosenfeld, Daniel/AAJ-4617-2021; Raga, Graciela B/A-4340-2008; O'Dowd, Colin D/K-8904-2012; Rosenfeld, Daniel/F-6077-2016; Kulmala, Markku T/I-7671-2016; Fuzzi, Sandro/F-2675-2010	Andreae, Meinrat O./0000-0003-1968-7925; Lohmann, Ulrike/0000-0001-8885-3785; Rosenfeld, Daniel/0000-0002-0784-7656; Raga, Graciela B/0000-0002-4295-4991; O'Dowd, Colin D/0000-0002-3068-2212; Rosenfeld, Daniel/0000-0002-0784-7656; Kulmala, Markku T/0000-0003-3464-7825; Fuzzi, Sandro/0000-0002-5275-2381				Andreae M.O., 2008, ATMOS CHEM PHYS DISC, V8, P11293; Andreae MO, 2007, SCIENCE, V315, P50, DOI 10.1126/science.1136529; Andreae MO, 2004, SCIENCE, V303, P1337, DOI 10.1126/science.1092779; Bell TL, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2007GL033046; Bell TL, 2008, J GEOPHYS RES-ATMOS, V113, DOI 10.1029/2007JD008623; Cotton WR, 2007, HUMAN IMPACT ON WEATHER AND CLIMATE, 2ND EDITION, P1, DOI 10.2277/ 0521600561; Cui ZQ, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2005JD005981; DEMARIA M, 1985, J ATMOS SCI, V42, P1944, DOI 10.1175/1520-0469(1985)042<1944:LROAST>2.0.CO;2; Dusek U, 2006, SCIENCE, V312, P1375, DOI 10.1126/science.1125261; Freud E, 2008, ATMOS CHEM PHYS, V8, P1661, DOI 10.5194/acp-8-1661-2008; Graber ER, 2006, ATMOS CHEM PHYS, V6, P729, DOI 10.5194/acp-6-729-2006; GUNN R, 1957, J METEOROL, V14, P272, DOI 10.1175/1520-0469(1957)014<0272:AEIOTE>2.0.CO;2; Held IM, 2005, P NATL ACAD SCI USA, V102, P17891, DOI 10.1073/pnas.0509057102; JOHNSON DB, 1982, J ATMOS SCI, V39, P448, DOI 10.1175/1520-0469(1982)039<0448:TROGAU>2.0.CO;2; Khain A, 2005, Q J ROY METEOR SOC, V131, P2639, DOI 10.1256/qj.04.62; Khain A, 2004, J ATMOS SCI, V61, P2963, DOI 10.1175/JAS-3350.1; Khain AP, 2008, J ATMOS SCI, V65, P1721, DOI 10.1175/2007JAS2515.1; Khain AP, 2001, GEOPHYS RES LETT, V28, P3887, DOI 10.1029/2000GL012662; Koren I, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023187; Koren I, 2004, SCIENCE, V303, P1342, DOI 10.1126/science.1089424; Koren I, 2008, SCIENCE, V321, P946, DOI 10.1126/science.1159185; LEVIN Z, 2007, AER POLL IMP PREC SC; Lin JC, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2005JD006884; Lohmann U, 2008, ATMOS CHEM PHYS, V8, P2115, DOI 10.5194/acp-8-2115-2008; Lohmann U, 2005, ATMOS CHEM PHYS, V5, P715, DOI 10.5194/acp-5-715-2005; Lynn BH, 2005, MON WEATHER REV, V133, P59, DOI 10.1175/MWR-2841.1; Menon S, 2002, SCIENCE, V297, P2250, DOI 10.1126/science.1075159; Miller RL, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD004085; MOLINIE J, 1995, GEOPHYS RES LETT, V22, P1085, DOI 10.1029/95GL01036; National Research Council, 2003, CRIT ISS WEATH MOD R; National Research Council, 2005, RAD FORC CLIM CHANG; Phillips VTJ, 2007, J ATMOS SCI, V64, P338, DOI 10.1175/JAS3832.1; RADKE LF, 1989, SCIENCE, V246, P1146, DOI 10.1126/science.246.4934.1146; Ramanathan V, 2005, P NATL ACAD SCI USA, V102, P5326, DOI 10.1073/pnas.0500656102; Ramanathan V, 2001, SCIENCE, V294, P2119, DOI 10.1126/science.1064034; Rosenfeld D, 2006, ATMOS CHEM PHYS, V6, P2503, DOI 10.5194/acp-6-2503-2006; Rosenfeld D, 1999, GEOPHYS RES LETT, V26, P3105, DOI 10.1029/1999GL006066; Rosenfeld D, 2000, SCIENCE, V287, P1793, DOI 10.1126/science.287.5459.1793; Rosenfeld D, 2002, SCIENCE, V297, P1667, DOI 10.1126/science.1073869; Rosenfeld D, 2000, NATURE, V405, P440, DOI 10.1038/35013030; Rosenfeld D., 2003, METEOR MONOGR, V51, P59, DOI [DOI 10.1175/0065-9401(2003)029<0059:CSI0CM>2.0.C0;2, 10.1175/0065-9401(2003)0292.0.CO;2, DOI 10.1175/0065-9401(2003)0292.0.CO;2]; Rosenfeld D, 2008, J GEOPHYS RES-ATMOS, V113, DOI 10.1029/2007JD009544; Rotstayn LD, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2002JD002128; Rudich Y, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL016055; Rudich Y, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2003JD003472; Schultz DM, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2007GL031889; Seifert A, 2006, METEOROL ATMOS PHYS, V92, P67, DOI 10.1007/s00703-005-0113-3; SQUIRES P, 1958, TELLUS, V10, P256, DOI 10.1111/j.2153-3490.1958.tb02011.x; STEVENS B, 2008, ILEAPS NEWSLETTER, V5, P10; Streets DG, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL026471; Tao WK, 2007, J GEOPHYS RES-ATMOS, V112, DOI 10.1029/2007JD008728; Teller A, 2006, ATMOS CHEM PHYS, V6, P67, DOI 10.5194/acp-6-67-2006; van den Heever SC, 2006, J ATMOS SCI, V63, P1752, DOI 10.1175/JAS3713.1; vanZanten MC, 2005, J ATMOS SCI, V62, P88, DOI 10.1175/JAS-3355.1; Wang C, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD005720; Wang C, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD004084; Wild M, 2005, SCIENCE, V308, P847, DOI 10.1126/science.1103215; Williams E, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000380	58	1310	1368	31	626	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	2008	321	5894					1309	1313		10.1126/science.1160606	http://dx.doi.org/10.1126/science.1160606			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	344GG	18772428				2022-12-28	WOS:000258914300038
J	Hanson, JA; Chang, CB; Graves, SM; Li, ZB; Mason, TG; Deming, TJ				Hanson, Jarrod A.; Chang, Connie B.; Graves, Sara M.; Li, Zhibo; Mason, Thomas G.; Deming, Timothy J.			Nanoscale double emulsions stabilized by single-component block copolypeptides	NATURE			English	Article							MONODISPERSE DOUBLE EMULSIONS; MULTIPLE EMULSIONS; CURVATURE; DELIVERY; RELEASE	Water- in- oil- in- water emulsions are examples of double emulsions, in which dispersions of small water droplets within larger oil droplets are themselves dispersed in a continuous aqueous phase(1-3). Emulsions occur in many forms of processing and are used extensively by the foods, cosmetics and coatings industries. Because of their compartmentalized internal structure, double emulsions can provide advantages over simple oil- in- water emulsions for encapsulation, such as the ability to carry both polar and non- polar cargos, and improved control over release of therapeutic molecules(4-6). The preparation of double emulsions typically requires mixtures of surfactants for stability; the formation of double nanoemulsions, where both inner and outer droplets are under 100 nm, has not yet been achieved(7-9). Here we show that water- in- oil- in- water double emulsions can be prepared in a simple process and stabilized over many months using single- component, synthetic amphiphilic diblock copolypeptide surfactants. These surfactants even stabilize droplets subjected to extreme flow, leading to direct, mass production of robust double nanoemulsions that are amenable to nanostructured encapsulation applications in foods, cosmetics and drug delivery.	[Hanson, Jarrod A.; Li, Zhibo; Deming, Timothy J.] Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA 90095 USA; [Chang, Connie B.; Graves, Sara M.; Mason, Thomas G.; Deming, Timothy J.] Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; [Mason, Thomas G.] Univ Calif Los Angeles, Dept Phys & Astron, Los Angeles, CA 90095 USA; [Mason, Thomas G.; Deming, Timothy J.] Univ Calif Los Angeles, Calif Nanosyst Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Deming, TJ (corresponding author), Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA 90095 USA.	mason@chem.ucla.edu; demingt@seas.ucla.edu	Li, Zhibo/K-1614-2013; Deming, Timothy/I-5411-2013	Li, Zhibo/0000-0001-9512-1507; Deming, Timothy/0000-0002-0594-5025	National Science Foundation; Human Frontiers of Science Program; University of California; National Institutes of Health; National Center for Research Resources P41 programme	National Science Foundation(National Science Foundation (NSF)); Human Frontiers of Science Program(Human Frontier Science Program); University of California(University of California System); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources P41 programme(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work is supported by a grant from the National Science Foundation (T.J.D.), a grant from the Human Frontiers of Science Program (T.J.D.), and University of California start-up funds (T.J.D. and T.G.M.). Some of the work was conducted at the National Resource for Automated Molecular Microscopy (NRAMM) which is supported by the National Institutes of Health through the National Center for Research Resources P41 programme. We thank C. Potter and J. Quispe of NRAMMat the Scripps Research Institute, and S. Zhong and D. Pochan of the University of Delaware, for use of cryoelectron microscopy equipment.	Benichou A, 2004, ADV COLLOID INTERFAC, V108, P29, DOI 10.1016/j.cis.2003.10.013; Bibette J, 1999, REP PROG PHYS, V62, P969, DOI 10.1088/0034-4885/62/6/203; BREITENBACH JW, 1955, MONATSH, V86, P269; Carragher B, 2000, J STRUCT BIOL, V132, P33, DOI 10.1006/jsbi.2000.4314; Chang CB, 2008, ACS NANO, V2, P281, DOI 10.1021/nn700385z; Dalgleish DG, 1996, FOOD RES INT, V29, P541, DOI 10.1016/S0963-9969(96)00065-8; DAVIS SS, 1987, METHOD ENZYMOL, V149, P51; DICKINSON E, 1992, J CHEM SOC FARADAY T, V88, P2973, DOI 10.1039/ft9928802973; ENSER M, 1990, INT J BIOL MACROMOL, V12, P118, DOI 10.1016/0141-8130(90)90063-G; Ficheux MF, 1998, LANGMUIR, V14, P2702, DOI 10.1021/la971271z; Garti N, 1997, COLLOID SURFACE A, V123, P233, DOI 10.1016/S0927-7757(96)03809-5; Goubault C, 2001, LANGMUIR, V17, P5184, DOI 10.1021/la010407x; Holowka EP, 2005, J AM CHEM SOC, V127, P12423, DOI 10.1021/ja053557t; KATAOKA K, 1993, J CONTROL RELEASE, V24, P119; KATCHALSKI E, 1958, ADV PROTEIN CHEM, V13, P243, DOI 10.1016/S0065-3233(08)60600-2; KRICHELDORF HR, 1981, MAKROMOL CHEM, V182, P3077; LAPP C, 1963, J CHIM PHYS PCB, V60, P756, DOI 10.1051/jcp/1963600756; Loscertales IG, 2002, SCIENCE, V295, P1695, DOI 10.1126/science.1067595; Mason TG, 2006, J PHYS-CONDENS MAT, V18, pR635, DOI 10.1088/0953-8984/18/41/R01; Morais JM, 2008, J DISPER SCI TECHNOL, V29, P63, DOI 10.1080/01932690701688391; Niederhafner P, 2005, J PEPT SCI, V11, P757, DOI 10.1002/psc.721; Nowak AP, 2002, NATURE, V417, P424, DOI 10.1038/417424a; Okochi H, 2000, ADV DRUG DELIVER REV, V45, P5, DOI 10.1016/S0169-409X(00)00097-1; Okushima S, 2004, LANGMUIR, V20, P9905, DOI 10.1021/la0480336; Pays K, 2002, J CONTROL RELEASE, V79, P193, DOI 10.1016/S0168-3659(01)00535-1; SAITO M, 1995, BIOSCI BIOTECH BIOCH, V59, P388, DOI 10.1271/bbb.59.388; STREY R, 1994, COLLOID POLYM SCI, V272, P1005, DOI 10.1007/BF00658900; Utada AS, 2005, SCIENCE, V308, P537, DOI 10.1126/science.1109164; Wang YF, 2006, LANGMUIR, V22, P67, DOI 10.1021/la0523255; Zuidema HH, 1941, IND ENG CHEM, V13, P0312, DOI 10.1021/i560093a009	30	214	228	6	242	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2008	455	7209					85	U54		10.1038/nature07197	http://dx.doi.org/10.1038/nature07197			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	343XS	18769436				2022-12-28	WOS:000258890200041
J	Klass, P				Klass, Perri			Close calls	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NYU, New York, NY 10012 USA	New York University	Klass, P (corresponding author), NYU, 550 1St Ave, New York, NY 10012 USA.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2008	359	10					994	997		10.1056/NEJMp0804351	http://dx.doi.org/10.1056/NEJMp0804351			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	343KN	18768942				2022-12-28	WOS:000258852500003
J	Celotti, A				Celotti, Annalisa			Astronomy - Life after death	SCIENCE			English	Editorial Material							CRAB-NEBULA		SISSA, Int Sch Adv Studies, I-34014 Trieste, Italy	International School for Advanced Studies (SISSA)	Celotti, A (corresponding author), SISSA, Int Sch Adv Studies, Via Beirut 2-4, I-34014 Trieste, Italy.	celotti@sissa.it		Celotti, Anna Lisa/0000-0002-8106-2777				Baade W, 1942, ASTROPHYS J, V96, P188, DOI 10.1086/144446; BRECHER K, 1983, OBSERVATORY, V103, P106; Costa E, 2001, NATURE, V411, P662, DOI 10.1038/35079508; Dean AJ, 2008, SCIENCE, V321, P1183, DOI 10.1126/science.1149056; Duyvendak J. J. L., 1942, PASP, V54, P91, DOI DOI 10.1086/125409; Hillas AM, 1998, ASTROPHYS J, V503, P744, DOI 10.1086/306005; KENNEL CF, 1984, ASTROPHYS J, V283, P694, DOI 10.1086/162356; KENNEL CF, 1984, ASTROPHYS J, V283, P710, DOI 10.1086/162357; KNODLSEDER J, 2007, P SOC PHOTO-OPT INS, V6688, P5; Mayall N.U., 1942, PUBL ASTRON SOC PAC, V54, P95, DOI [10.1086/125410, DOI 10.1086/125410]; Minkowski R, 1942, ASTROPHYS J, V96, P199, DOI 10.1086/144447	11	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 29	2008	321	5893					1164	1165		10.1126/science.1163887	http://dx.doi.org/10.1126/science.1163887			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341ZM	18755961				2022-12-28	WOS:000258754400027
J	Martin, VM; Morgan, DJ; Jerram, DA; Caddick, MJ; Prior, DJ; Davidson, JP				Martin, Victoria M.; Morgan, Daniel J.; Jerram, Dougal A.; Caddick, Mark J.; Prior, David J.; Davidson, Jon P.			Bang! Month-scale eruption triggering at Santorini volcano	SCIENCE			English	Article							DIFFUSION		[Morgan, Daniel J.] Univ Leeds, Sch Earth & Environm, Leeds LS2 9JT, W Yorkshire, England; [Martin, Victoria M.; Jerram, Dougal A.; Davidson, Jon P.] Univ Durham, Dept Earth Sci, Durham DH1 3LE, England; [Caddick, Mark J.] ETH, Inst Mineral & Petrol, CH-8092 Zurich, Switzerland; [Prior, David J.] Univ Liverpool, Liverpool L69 3GP, Merseyside, England	University of Leeds; Durham University; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Liverpool	Morgan, DJ (corresponding author), Univ Leeds, Sch Earth & Environm, Leeds LS2 9JT, W Yorkshire, England.	d.j.morgan@leeds.ac.uk	Morgan, Daniel J/E-3881-2010; Jerram, Dougal/AAE-4371-2021; Caddick, Mark/AAF-3903-2019; Caddick, Mark J/R-3765-2016	Morgan, Daniel J/0000-0002-7292-2536; Caddick, Mark/0000-0001-8795-8438; Caddick, Mark J/0000-0001-8795-8438; Jerram, Dougal/0000-0003-0043-4426	Natural Environment Research Council of the UK [NE/C510316/1]; ETH Research Funds; Natural Environment Research Council [NE/C510316/1] Funding Source: researchfish	Natural Environment Research Council of the UK(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); ETH Research Funds; Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	This work was funded by grant NE/C510316/1 of the Natural Environment Research Council of the UK, and by ETH Research Funds (to M.J.C.). SEM imaging was assisted by E. Condliffe (Leeds). The authors thank two anonymous reviewers for input, which encouraged fO<INF>2</INF> variations to be considered and improved the manuscript. Editorial assistance from R. B. Hanson is warmly appreciated.	Coombs ML, 2000, CONTRIB MINERAL PETR, V140, P99, DOI 10.1007/s004100000166; Costa F, 2005, GEOLOGY, V33, P837, DOI 10.1130/G21675.1; Dohmen R, 2007, PHYS CHEM MINER, V34, P409, DOI 10.1007/s00269-007-0158-6; DRUITT TH, 1999, GEOL SOC LOND MEM, V19, P1; Martin VM, 2006, J VOLCANOL GEOTH RES, V154, P89, DOI 10.1016/j.jvolgeores.2005.09.021; Putirka KA, 2005, AM MINERAL, V90, P336, DOI 10.2138/am.2005.1449; Zellmer GF, 2005, J VOLCANOL GEOTH RES, V140, P171, DOI 10.1016/j.jvolgeores.2004.07.020	7	67	69	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2008	321	5893					1178	1178		10.1126/science.1159584	http://dx.doi.org/10.1126/science.1159584			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341ZM	18755968				2022-12-28	WOS:000258754400034
J	Kaganovich, D; Kopito, R; Frydman, J				Kaganovich, Daniel; Kopito, Ron; Frydman, Judith			Misfolded proteins partition between two distinct quality control compartments	NATURE			English	Article							TUMOR-SUPPRESSOR COMPLEX; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; FLUORESCENT PROTEIN; IN-VIVO; POLYGLUTAMINE EXPANSION; MOLECULAR CHAPERONES; ALPHA-SYNUCLEIN; YEAST; DEGRADATION	The accumulation of misfolded proteins in intracellular amyloid inclusions, typical of many neurodegenerative disorders including Huntington's and prion disease, is thought to occur after failure of the cellular protein quality control mechanisms. Here we examine the formation of misfolded protein inclusions in the eukaryotic cytosol of yeast and mammalian cell culture models. We identify two intracellular compartments for the sequestration of misfolded cytosolic proteins. Partition of quality control substrates to either compartment seems to depend on their ubiquitination status and aggregation state. Soluble ubiquitinated misfolded proteins accumulate in a juxtanuclear compartment where proteasomes are concentrated. In contrast, terminally aggregated proteins are sequestered in a perivacuolar inclusion. Notably, disease- associated Huntingtin and prion proteins are preferentially directed to the perivacuolar compartment. Enhancing ubiquitination of a prion protein suffices to promote its delivery to the juxtanuclear inclusion. Our findings provide a framework for understanding the preferential accumulation of amyloidogenic proteins in inclusions linked to human disease.	[Kaganovich, Daniel; Kopito, Ron; Frydman, Judith] Stanford Univ, Dept Biol, Stanford, CA 94305 USA; [Kaganovich, Daniel; Kopito, Ron; Frydman, Judith] Stanford Univ, BioX Program, Stanford, CA 94305 USA	Stanford University; Stanford University	Frydman, J (corresponding author), Stanford Univ, Dept Biol, Stanford, CA 94305 USA.	jfrydman@stanford.edu	Kaganovich, Daniel/K-2376-2012	Kaganovich, Daniel/0000-0003-2398-1596; , judith/0000-0003-2302-6943	NIH; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056433] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042842] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank R. Tsien, S. Michaelis, J. Glover, C. Enenkel and V. Albanese for reagents; J. Mulholland for electron microscopy and deconvolution microscopy help; S. Yamada and W. J. Nelson for help with the live cell microscopy. We thank R. Andino, W. Burkholder, J. England, R. Geller, M. Kaganovich, E. Bennett, J. Nelson and members of the Frydman laboratory for discussions and comments on the manuscript. This work was supported by grants from NIH to R. K. and J. F.	Adams A, 1997, METHODS YEAST GENETI; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Balch WE, 2008, SCIENCE, V319, P916, DOI 10.1126/science.1141448; Barral JM, 2004, SEMIN CELL DEV BIOL, V15, P17, DOI 10.1016/j.semcdb.2003.12.010; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Betting J, 1996, J BIOL CHEM, V271, P25790, DOI 10.1074/jbc.271.42.25790; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; Cohen E, 2006, SCIENCE, V313, P1604, DOI 10.1126/science.1124646; Duennwald ML, 2006, P NATL ACAD SCI USA, V103, P11051, DOI 10.1073/pnas.0604548103; Enenkel C, 1998, EMBO J, V17, P6144, DOI 10.1093/emboj/17.21.6144; Erjavec N, 2007, P NATL ACAD SCI USA, V104, P10877, DOI 10.1073/pnas.0701634104; Feldman DE, 1999, MOL CELL, V4, P1051, DOI 10.1016/S1097-2765(00)80233-6; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; Gidalevitz T, 2006, SCIENCE, V311, P1471, DOI 10.1126/science.1124514; Huyer G, 2004, MOL BIOL CELL, V15, P908, DOI 10.1091/mbc.E03-07-0546; Iwata A, 2005, P NATL ACAD SCI USA, V102, P13135, DOI 10.1073/pnas.0505801102; Kamhi-Nesher S, 2001, MOL BIOL CELL, V12, P1711, DOI 10.1091/mbc.12.6.1711; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Krobitsch S, 2000, P NATL ACAD SCI USA, V97, P1589, DOI 10.1073/pnas.97.4.1589; Kruse KB, 2006, MOL BIOL CELL, V17, P203, DOI 10.1091/mbc.e04-09-0779; Kruse KB, 2006, AUTOPHAGY, V2, P135, DOI 10.4161/auto.2.2.2388; Kuma A, 2007, AUTOPHAGY, V3, P323, DOI 10.4161/auto.4012; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Lippincott-Schwartz J, 2003, SCIENCE, V300, P87, DOI 10.1126/science.1082520; Mateus C, 2000, YEAST, V16, P1313, DOI 10.1002/1097-0061(200010)16:14<1313::AID-YEA626>3.0.CO;2-O; Matsumoto G, 2006, J BIOL CHEM, V281, P4477, DOI 10.1074/jbc.M509201200; Matsumoto G, 2005, J CELL BIOL, V171, P75, DOI 10.1083/jcb.200504050; McClellan AJ, 2005, CELL, V121, P739, DOI 10.1016/j.cell.2005.03.024; McClellan AJ, 2005, NAT CELL BIOL, V7, P736, DOI 10.1038/ncb0805-736; Melville MW, 2003, MOL CELL BIOL, V23, P3141, DOI 10.1128/MCB.23.9.3141-3151.2003; Muchowski PJ, 2005, NAT REV NEUROSCI, V6, P11, DOI 10.1038/nrn1587; MULHOLLAND J, 1994, J CELL BIOL, V125, P381, DOI 10.1083/jcb.125.2.381; Outeiro TF, 2003, SCIENCE, V302, P1772, DOI 10.1126/science.1090439; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Prinz A, 2000, BIOL CHEM, V381, P1025, DOI 10.1515/BC.2000.126; Rideout HJ, 2004, INT J BIOCHEM CELL B, V36, P2551, DOI 10.1016/j.biocel.2004.05.008; Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291; Rujano MA, 2006, PLOS BIOL, V4, P2325, DOI 10.1371/journal.pbio.0040417; Sarkar S, 2007, NAT CHEM BIOL, V3, P331, DOI 10.1038/nchembio883; Schaffar G, 2004, MOL CELL, V15, P95, DOI 10.1016/j.molcel.2004.06.029; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Siegel SJ, 2007, BIOCHEMISTRY-US, V46, P1503, DOI 10.1021/bi061853s; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Szeto J, 2006, AUTOPHAGY, V2, P189, DOI 10.4161/auto.2731; Tam S, 2006, NAT CELL BIOL, V8, P1155, DOI 10.1038/ncb1477; Taylor JP, 2003, HUM MOL GENET, V12, P749, DOI 10.1093/hmg/ddg074; Tkach JM, 2004, J BIOL CHEM, V279, P35692, DOI 10.1074/jbc.M400782200; Tongaonkar P, 1999, ANAL BIOCHEM, V272, P263, DOI 10.1006/abio.1999.4190; Vang S, 2005, FEBS J, V272, P2037, DOI 10.1111/j.1742-4658.2005.04630.x; Webb JL, 2003, J BIOL CHEM, V278, P25009, DOI 10.1074/jbc.M300227200; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; WRIGHT R, 1989, METHOD CELL BIOL, V31, P473; Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765	56	665	673	2	68	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	2008	454	7208					1088	U36		10.1038/nature07195	http://dx.doi.org/10.1038/nature07195			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	341MW	18756251	Green Accepted			2022-12-28	WOS:000258719600031
J	Galdi, S; Arcuri, L; Gawronski, B				Galdi, Silvia; Arcuri, Luciano; Gawronski, Bertram			Automatic mental associations predict future choices of undecided decision-makers	SCIENCE			English	Article							IMPLICIT ATTITUDES; SOCIAL COGNITION; BEHAVIOR	Common wisdom holds that choice decisions are based on conscious deliberations of the available information about choice options. On the basis of recent insights about unconscious influences on information processing, we tested whether automatic mental associations of undecided individuals bias future choices in a manner such that these choices reflect the evaluations implied by earlier automatic associations. With the use of a computer- based, speeded categorization task to assess automatic mental associations (i.e., associations that are activated unintentionally, difficult to control, and not necessarily endorsed at a conscious level) and self- report measures to assess consciously endorsed beliefs and choice preferences, automatic associations of undecided participants predicted changes in consciously reported beliefs and future choices over a period of 1 week. Conversely, for decided participants, consciously reported beliefs predicted changes in automatic associations and future choices over the same period. These results indicate that decision-makers sometimes have already made up their mind at an unconscious level, even when they consciously indicate that they are still undecided.	[Galdi, Silvia; Arcuri, Luciano] Univ Padua, Dept Dev Psychol & Socializat, I-35131 Padua, Italy; [Gawronski, Bertram] Univ Western Ontario, Dept Psychol, Soc Sci Ctr, London, ON N6A 5C2, Canada	University of Padua; Western University (University of Western Ontario)	Galdi, S (corresponding author), Univ Padua, Dept Dev Psychol & Socializat, Via Venezia 8, I-35131 Padua, Italy.	silvia.galdi@unipd.it	galdi, silvia/ABG-8837-2020; Galdi, Silvia/ABG-8411-2020	galdi, silvia/0000-0002-1343-9245; Gawronski, Bertram/0000-0001-7938-3339	Department of Developmental Psychology and Socialization of the University of Padova,; Canada Research Chairs Program [202555]; Social Sciences and Humanities Research Council of Canada [410-2005-1339]	Department of Developmental Psychology and Socialization of the University of Padova,; Canada Research Chairs Program(Canada Research Chairs); Social Sciences and Humanities Research Council of Canada(Social Sciences and Humanities Research Council of Canada (SSHRC))	This research was supported by grants from the Department of Developmental Psychology and Socialization of the University of Padova, the Canada Research Chairs Program (202555), and the Social Sciences and Humanities Research Council of Canada (410-2005-1339). We thank G. Bodenhausen and K. Trzesniewski for helpful comments on an earlier version of this article.	AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Arcuri L, 2008, POLIT PSYCHOL, V29, P369, DOI 10.1111/j.1467-9221.2008.00635.x; Bargh J.A., 1994, HDB SOCIAL COGNITION, V2nd ed., P1, DOI DOI 10.1007/S00572-005-0022-9; Fazio RH, 2003, ANNU REV PSYCHOL, V54, P297, DOI 10.1146/annurev.psych.54.101601.145225; FAZIO RH, 1995, J PERS SOC PSYCHOL, V69, P1013, DOI 10.1037/0022-3514.69.6.1013; Gawronski B, 2003, EUR J SOC PSYCHOL, V33, P573, DOI 10.1002/ejsp.166; Gawronski B, 2006, CONSCIOUS COGN, V15, P485, DOI 10.1016/j.concog.2005.11.007; Gawronski B, 2006, PSYCHOL BULL, V132, P692, DOI 10.1037/0033-2909.132.5.692; Gollwitzer PM, 1999, AM PSYCHOL, V54, P493, DOI 10.1037//0003-066X.54.7.493; Greenwald AG, 1998, J PERS SOC PSYCHOL, V74, P1464, DOI 10.1037/0022-3514.74.6.1464; Greenwald AG, 2003, J PERS SOC PSYCHOL, V85, P197, DOI 10.1037/0022-3514.85.2.197; Hofmann W, 2005, PERS SOC PSYCHOL B, V31, P1369, DOI 10.1177/0146167205275613; Hofmann Wilhelm, 2005, EUROPEAN REV SOCIAL, V16, P335, DOI [DOI 10.1080/10463280500443228, 10.1080/10463280500443228]; Hugenberg K, 2003, PSYCHOL SCI, V14, P640, DOI 10.1046/j.0956-7976.2003.psci_1478.x; Karpinski A, 2006, J PERS SOC PSYCHOL, V91, P16, DOI 10.1037/0022-3514.91.1.16; Payne BK, 2005, J PERS SOC PSYCHOL, V89, P277, DOI 10.1037/0022-3514.89.3.277; Strack F, 2004, PERS SOC PSYCHOL REV, V8, P220, DOI 10.1207/s15327957pspr0803_1; WITTENBRINK B, 2007, IMPLICIT MEASURES AT	18	169	172	1	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	2008	321	5892					1100	1102		10.1126/science.1160769	http://dx.doi.org/10.1126/science.1160769			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	339RL	18719288	Green Published			2022-12-28	WOS:000258594900044
J	Turner, M; Golovko, VB; Vaughan, OPH; Abdulkin, P; Berenguer-Murcia, A; Tikhov, MS; Johnson, BFG; Lambert, RM				Turner, Mark; Golovko, Vladimir B.; Vaughan, Owain P. H.; Abdulkin, Pavel; Berenguer-Murcia, Angel; Tikhov, Mintcho S.; Johnson, Brian F. G.; Lambert, Richard M.			Selective oxidation with dioxygen by gold nanoparticle catalysts derived from 55-atom clusters	NATURE			English	Article							SUPPORTED METAL-CLUSTERS; HETEROGENEOUS CATALYSTS; MOLECULAR-OXYGEN; EPOXIDATION; STYRENE; SIZE; HYDROGENATION; MECHANISM	Supported gold nanoparticles have excited much interest owing to their unusual and somewhat unexpected catalytic properties(1-7), but the origin of the catalytic activity is still not fully understood. Experimental work(4) on gold particles supported on a titanium dioxide ( 110) single- crystal surface has established a striking size threshold effect associated with a metal- to- insulator transition, with gold particles catalytically active only if their diameters fall below similar to 3.5 nm. However, the remarkable catalytic behaviour might also in part arise from strong electronic interaction between the gold and the titanium dioxide support(2,3,5). In the case of industrially important selective oxidation reactions, explanation of the effectiveness of gold nanoparticle catalysts is complicated by the need for additives to drive the reaction(5,7,8), and/or the presence of strong support interactions and incomplete understanding of their possible catalytic role(1-3,5). Here we show that very small gold entities (similar to 1.4 nm) derived from 55- atom gold clusters and supported on inert materials are efficient and robust catalysts for the selective oxidation of styrene by dioxygen. We find a sharp size threshold in catalytic activity, in that particles with diameters of similar to 2 nm and above are completely inactive. Our observations suggest that catalytic activity arises from the altered electronic structure intrinsic to small gold nanoparticles, and that the use of 55- atom gold clusters may prove a viable route to the synthesis of robust gold catalysts suited to practical application.	[Turner, Mark; Golovko, Vladimir B.; Vaughan, Owain P. H.; Abdulkin, Pavel; Berenguer-Murcia, Angel; Tikhov, Mintcho S.; Johnson, Brian F. G.; Lambert, Richard M.] Univ Cambridge, Chem Lab, Cambridge CB2 1EW, England	University of Cambridge	Lambert, RM (corresponding author), Univ Cambridge, Chem Lab, Cambridge CB2 1EW, England.	rml1@cam.ac.uk	Berenguer-Murcia, Ángel/D-1196-2014	Berenguer-Murcia, Ángel/0000-0003-3204-801X; Golovko, Vladimir/0000-0002-2679-8917	UK Engineering and Physical Sciences Research Council; King's College, Cambridge	UK Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); King's College, Cambridge	M. T. and O. P. H. V. acknowledge financial support from the UK Engineering and Physical Sciences Research Council and King's College, Cambridge, respectively.	Bowker M, 2007, CATAL TODAY, V122, P245, DOI 10.1016/j.cattod.2007.01.021; Boyen HG, 2002, SCIENCE, V297, P1533, DOI 10.1126/science.1076248; Chimentao RJ, 2005, APPL SURF SCI, V252, P793, DOI 10.1016/j.apsusc.2005.02.064; Deng XY, 2005, J AM CHEM SOC, V127, P17178, DOI 10.1021/ja0557031; HARUTA M, 1993, J CATAL, V144, P175, DOI 10.1006/jcat.1993.1322; HARUTA M, 1987, CHEM LETT, P405, DOI 10.1246/cl.1987.405; Haruta M, 2005, NATURE, V437, P1098, DOI 10.1038/4371098a; Haruta M, 2004, GOLD BULL, V37, P27, DOI 10.1007/BF03215514; Haruta M, 2002, CATTECH, V6, P102, DOI 10.1023/A:1020181423055; Haruta M, 1997, CATAL TODAY, V36, P153, DOI 10.1016/S0920-5861(96)00208-8; Hayashi T, 1998, J CATAL, V178, P566, DOI 10.1006/jcat.1998.2157; Hughes MD, 2005, NATURE, V437, P1132, DOI 10.1038/nature04190; Hutchison JE, 2004, INORG SYN, V34, P228; Lambert RM, 2005, J MOL CATAL A-CHEM, V228, P27, DOI 10.1016/j.molcata.2004.09.077; LOPEZQUINTELA MA, 1993, J COLLOID INTERF SCI, V158, P446, DOI 10.1006/jcis.1993.1277; Lu P, 1999, J PHYS CHEM B, V103, P9673, DOI 10.1021/jp992177p; Miller JT, 2006, J CATAL, V240, P222, DOI 10.1016/j.jcat.2006.04.004; Ono LK, 2006, SURF SCI, V600, P5041, DOI 10.1016/j.susc.2006.08.025; Raja R, 2005, CHEM COMMUN, P2026, DOI 10.1039/b418273a; Santra AK, 2003, J PHYS-CONDENS MAT, V15, pR31, DOI 10.1088/0953-8984/15/2/202; SAULT AG, 1986, SURF SCI, V169, P347, DOI 10.1016/0039-6028(86)90616-3; Sebastian J, 2006, J CATAL, V244, P208, DOI 10.1016/j.jcat.2006.09.005; Takahiro K, 2006, J APPL PHYS, V100, DOI 10.1063/1.2359688; Tang QH, 2004, CHEM COMMUN, P440, DOI 10.1039/b314864e; Valden M, 1998, SCIENCE, V281, P1647, DOI 10.1126/science.281.5383.1647; Vaughan OPH, 2005, J CATAL, V236, P401, DOI 10.1016/j.jcat.2005.10.019; WERTHEIM GK, 1988, PHYS REV B, V37, P844, DOI 10.1103/PhysRevB.37.844; Williams FJ, 2004, J AM CHEM SOC, V126, P8509, DOI 10.1021/ja039378y	29	1129	1141	27	918	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 21	2008	454	7207					981	U31		10.1038/nature07194	http://dx.doi.org/10.1038/nature07194			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	339QB	18719586				2022-12-28	WOS:000258591000035
J	Hemingway, H; Chen, R; Junghans, C; Timmis, A; Eldridge, S; Black, N; Shekelle, P; Feder, G				Hemingway, Harry; Chen, Ruoling; Junghans, Cornelia; Timmis, Adam; Eldridge, Sandra; Black, Nick; Shekelle, Paul; Feder, Gene			Appropriateness criteria for coronary angiography in angina: Reliability and validity	ANNALS OF INTERNAL MEDICINE			English	Article							AMERICAN-HEART-ASSOCIATION; STABLE ANGINA; COMPUTED-TOMOGRAPHY; MYOCARDIAL-INFARCTION; STRESS ECHOCARDIOGRAPHY; PRACTICE GUIDELINES; NUCLEAR-CARDIOLOGY; PROPENSITY SCORES; ARTERY-DISEASE; WORKING GROUP	Background: Evaluated criteria for tailoring the decision to perform coronary angiography in specific clinical scenarios are lacking. Objective: To determine the reliability and prognostic validity of patient-specific appropriateness criteria for coronary angiography among patients with suspected angina pectoris. Design: Prospective observational study. Two independent panels of clinicians scored 2400 patient-specific indications for coronary angiography as inappropriate, uncertain, or appropriate. Using a simple computer algorithm, patients were matched to 1 of these indications. Setting: 6 urban ambulatory care clinics in the United Kingdom. Patients: 9356 consecutive patients with recent-onset chest pain in whom stable angina was suspected. Measurements: Appropriateness ratings and clinical outcomes (coronary death and acute coronary syndrome events) over a median of 3 years of follow-up. Results: 660 coronary deaths or acute coronary syndrome events occurred. Agreement between the 2 panels (reliability) on appropriateness category was moderate (weighted kappa = 0.58; P < 0.001). Use of subsequent angiography was strongly related to appropriateness category ( P for linear trend < 0.001) according to scores from either panel. Among patients judged as appropriate candidates for angiography, underuse was common (57% according to panel A and 71.3% according to panel B), and not undergoing coronary angiography was associated with higher coronary event rates than was undergoing the procedure. The hazard ratio after adjustment for age, sex, exercise electrocardiography result, and secondary prevention medication was similar according to panel A (2.78 [95% CI, 1.77 to 4.37]) and panel B (2.47 [CI, 1.72 to 3.55]). Limitation: The study was too small to assess the relationship of angiography with coronary death and did not assess the reasons why patients did not receive angiography. Conclusion: Appropriateness scores offer prognostically valid criteria for judging which specific patients might benefit from coronary angiography. Patient-specific appropriateness scores help pinpoint areas where judgments diverge and are a promising tool for making guidelines more effective.	[Hemingway, Harry] UCL, Sch Med, London WC1E 6BT, England	University of London; University College London; UCL Medical School	Hemingway, H (corresponding author), UCL, Sch Med, 1-19 Torrington Pl, London WC1E 6BT, England.	h.hemingway@ucl.ac.uk	Junghans, Cornelia/ABG-4494-2020; Hemingway, Harry/C-1219-2009	Junghans, Cornelia/0000-0002-0663-3090; Hemingway, Harry/0000-0003-2279-0624; Chen, Ruoling/0000-0002-3033-8753; Feder, Gene/0000-0002-7890-3926	United Kingdom Department of Health's Policy Research Programme; NHS Research and Development Service Delivery and Organisation Programme; Department of Health	United Kingdom Department of Health's Policy Research Programme; NHS Research and Development Service Delivery and Organisation Programme; Department of Health	The authors thank the members of the 2 panels: specialists Khalid Barakat (Wexham Park), Alison Calver (Southampton), Kieron Daly (Galway), Mary Heber (Telford), Rob Henderson (Nottingham), Diana Holdright (London), Bruce Keogh (Birmingham), Patrick Magee (London), Stuart Pringle (Dundee), Jeremy Sayer (Harlow), Jane Skinner (Newcastle), and Adam Timmis (London) and family physicians Naureen Bhatti (London), Peter Brindle (Bristol), Nick Dunn (Southampton), Martin Eccles (Newcastle), Tom Fahey (Dundee), Gene Feder (London), Richard McManus (Birmingham), Andrew Murphy (Galway), Neville Purssell (London), and Judy Shakespeare (Oxford).; Grant Support: By the United Kingdom Department of Health's Policy Research Programme and the NHS Research and Development Service Delivery and Organisation Programme. Dr. Hemingway was supported by a Public Health Career Scientist Award from the Department of Health.	*ARIA INV, 2003, EV IND INSTR RAT APP, P1; ATWOOD JE, 1981, CIRCULATION, V64, P601, DOI 10.1161/01.CIR.64.3.601; Banerjee S, 2000, AM J CARDIOL, V85, P309, DOI 10.1016/S0002-9149(99)00738-9; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P766, DOI 10.1001/jama.269.6.766; Boden WE, 2007, NEW ENGL J MED, V356, P1503, DOI 10.1056/NEJMoa070829; Brindis RG, 2005, J AM COLL CARDIOL, V46, P1587, DOI 10.1016/j.jacc.2005.08.029; BROOK RH, 1988, LANCET, V1, P750; Carlisle DM, 1999, AM J MED, V106, P391, DOI 10.1016/S0002-9343(99)00051-0; CHASSIN M, 1989, APPROPRIATE INVESTIG, P21; Chertow GM, 2004, J AM SOC NEPHROL, V15, P2462, DOI 10.1097/01.ASN.0000135969.33773.0B; D'Agostino RB, 2007, CIRCULATION, V115, P2340, DOI 10.1161/CIRCULATIONAHA.105.594952; DEROUEN TA, 1977, CIRCULATION, V55, P324, DOI 10.1161/01.CIR.55.2.324; Douglas PS, 2008, CATHETER CARDIO INTE, V71, pE1, DOI [10.1002/ccd.21554, 10.1161/CIRCULATIONAHA.107.189097]; Douglas PS, 2008, J AM COLL CARDIOL, V51, P1127, DOI 10.1016/j.jacc.2007.12.005; ELMORE JG, 1994, NEW ENGL J MED, V331, P1493, DOI 10.1056/NEJM199412013312206; Fitch K., 2001, RAND UCLA APPROPRIAT; Fox K, 2006, EUR HEART J, V27, P1341, DOI 10.1093/eurheartj/ehl001; Garcia MJ, 2006, JAMA-J AM MED ASSOC, V296, P403, DOI 10.1001/jama.296.4.403; Gibbons RJ, 2008, J AM COLL CARDIOL, V51, P1283, DOI 10.1016/j.jacc.2007.10.064; Go AS, 2006, ANN INTERN MED, V144, P229, DOI 10.7326/0003-4819-144-4-200602210-00004; Griffin SC, 2007, BMJ-BRIT MED J, V334, P624, DOI 10.1136/bmj.39129.442164.55; Guadagnoli E, 2000, NEW ENGL J MED, V343, P1460, DOI 10.1056/NEJM200011163432006; Hemingway H, 2006, JAMA-J AM MED ASSOC, V295, P1404, DOI 10.1001/jama.295.12.1404; Hemingway H, 2003, BRIT MED J, V327, P895, DOI 10.1136/bmj.327.7420.895; Hemingway H, 2001, NEW ENGL J MED, V344, P645, DOI 10.1056/NEJM200103013440906; Hemingway H, 2008, CIRCULATION, V117, P1526, DOI 10.1161/CIRCULATIONAHA.107.720953; Hendel RC, 2006, J AM COLL CARDIOL, V48, P1475, DOI 10.1016/j.jacc.2006.07.003; Hepner KA, 2007, ANN INTERN MED, V147, P320, DOI 10.7326/0003-4819-147-5-200709040-00007; ISMAIL SM, 1989, BRIT MED J, V298, P707, DOI 10.1136/bmj.298.6675.707; Junghans C, 2007, ARCH INTERN MED, V167, P195, DOI 10.1001/archinte.167.2.195; KATO I, 1995, J CLIN EPIDEMIOL, V48, P1167, DOI 10.1016/0895-4356(94)00242-I; Kawamoto K, 2005, BMJ-BRIT MED J, V330, P765, DOI 10.1136/bmj.38398.500764.8F; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Laouri M, 1997, INT J QUAL HEALTH C, V9, P15, DOI 10.1093/intqhc/9.1.15; Mieres JH, 2005, CIRCULATION, V111, P682, DOI 10.1161/01.CIR.0000155233.67287.60; Normand SLT, 2001, J CLIN EPIDEMIOL, V54, P387, DOI 10.1016/S0895-4356(00)00321-8; Roger VL, 1998, J AM COLL CARDIOL, V32, P345, DOI 10.1016/S0735-1097(98)00229-0; Rosanio S, 1999, JAMA-J AM MED ASSOC, V282, P145, DOI 10.1001/jama.282.2.145; Roy PM, 2006, ANN INTERN MED, V144, P157, DOI 10.7326/0003-4819-144-3-200602070-00003; Scanlon PJ, 1999, CIRCULATION, V99, P2345, DOI 10.1161/01.CIR.99.17.2345; Sekhri N, 2007, HEART, V93, P458, DOI 10.1136/hrt.2006.090894; Sekhri N, 2008, BMJ-BRIT MED J, V336, P1058, DOI 10.1136/bmj.39534.571042.BE; Selby JV, 1996, NEW ENGL J MED, V335, P1888, DOI 10.1056/NEJM199612193352506; Shekelle PG, 1998, NEW ENGL J MED, V338, P1888, DOI 10.1056/NEJM199806253382607; Snow V, 2004, ANN INTERN MED, V141, P57, DOI 10.7326/0003-4819-141-1-200407060-00015; Stukel TA, 2007, JAMA-J AM MED ASSOC, V297, P278, DOI 10.1001/jama.297.3.278; Timmis AD, 2007, HEART, V93, P786, DOI 10.1136/hrt.2006.103119; Vader JP, 1997, INT J QUAL HEALTH C, V9, P87, DOI 10.1093/intqhc/9.2.87-a; WACKERS FJT, 1993, J AM COLL CARDIOL, V21, P1064, DOI 10.1016/0735-1097(93)90226-Q; ZAMAN J, 2008, CMAJ IN PRESS	50	35	35	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 19	2008	149	4					221	+		10.7326/0003-4819-149-4-200808190-00003	http://dx.doi.org/10.7326/0003-4819-149-4-200808190-00003			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	338RQ	18711152				2022-12-28	WOS:000258526700001
J	Hill, KP; Ross, JS; Egilman, DS; Krumholz, HM				Hill, Kevin P.; Ross, Joseph S.; Egilman, David S.; Krumholz, Harlan M.			The ADVANTAGE seeding trial: A review of internal documents	ANNALS OF INTERNAL MEDICINE			English	Article							CARDIOVASCULAR OUTCOMES; ROFECOXIB; PROMOTION; NAPROXEN	Background: Seeding trials, clinical studies conducted by pharmaceutical companies that are designed to seem as if they answer a scientific question but primarily fulfill marketing objectives, have not been described in detail. Purpose: To describe a known seeding trial, ADVANTAGE (Assessment of Differences between Vioxx and Naproxen To Ascertain Gastrointestinal Tolerability and Effectiveness), through documents of the trial sponsor, Merck & Co. (Whitehouse Station, New Jersey). Data Sources: Merck internal and external correspondence, reports, and presentations elicited to inform legal proceedings of Cona v Merck and Co., Inc., and McDarby v Merck and Co., Inc. The documents were created between 1998 and 2006. Data Extraction: An iterative case-study process of review, discussion, and re-review of documents to identify themes relevant to the design and conduct of ADVANTAGE. To supplement the case-study review, the authors did a systematic review of the literature to identify published manuscripts focused on seeding trials and their conduct. Data Synthesis: Review of the documents revealed 3 key themes: The trial was designed by Merck's marketing division to fulfill a marketing objective; Merck's marketing division handled both the scientific and the marketing data, including collection, analysis, and dissemination; and Merck hid the marketing nature of the trial from participants, physician investigators, and institutional review board members. Although the systematic review of the literature identified 6 articles that focused on the practice of seeding trials, none provided documentary evidence of their existence or conduct. Limitations: The legal documents in these cases provide useful, but limited, information about the practices of the pharmaceutical industry. This description of 1 company's actions is incomplete and may have limited generalizability. Conclusion: Documentary evidence shows that ADVANTAGE is an example of marketing framed as science. The documents indicate that ADVANTAGE was a seeding trial developed by Merck's marketing division to promote prescription of Vioxx (rofecoxib) when it became available on the market in 1999.	[Hill, Kevin P.] McLean Hosp, Belmont, MA 02478 USA; Mt Sinai Sch Med, New York, NY USA; Brown Univ, Providence, RI 02912 USA; Yale Univ, Sch Med, New Haven, CT USA; Yale New Haven Med Ctr, New Haven, CT 06504 USA	Harvard University; McLean Hospital; Icahn School of Medicine at Mount Sinai; Brown University; Yale University; Yale University	Hill, KP (corresponding author), McLean Hosp, 115 Mill St, Belmont, MA 02478 USA.	kphill@partners.org	Hill, Kevin/GLQ-8874-2022; , Harlan/AAI-2875-2020	Ross, Joseph/0000-0002-9218-3320	Hartford Foundation	Hartford Foundation	The authors thank Leslie Curry, PhD, for her advice on our methods for review of the litigation documents and Greg Mulvey for his help in organizing the documents.; Grant Support: Dr. Hill was a Scholar in the Robert Wood Johnson Clinical Scholars Program sponsored by the Robert Wood Johnson Foundation while working on this project. Dr. Ross is currently supported by the Hartford Foundation.	Andersen M, 2006, JAMA-J AM MED ASSOC, V295, P2759, DOI 10.1001/jama.295.23.2759; Anderson SJ, 2006, TOB CONTROL, V15, P254, DOI 10.1136/tc.2005.013854; AVORN J, 2005, POWERFUL MED BENEFIT, P480; Berenson Alex, 2005, N Y Times Web, pC13; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Braunstein N, 2005, ANN INTERN MED, V143, P158, DOI 10.7326/0003-4819-143-2-200507190-00118; Egilman DS, 2006, ANN INTERN MED, V144, P781, DOI 10.7326/0003-4819-144-10-200605160-00016; Fretheim A, 2005, BMC HEALTH SERV RES, V5, DOI 10.1186/1472-6963-5-21; GLADWELL M, 2000, TIPPING POINT LITTLE, P279; Glaser B.G., 1965, AWARENESS DYING; Greenland P, 2008, JAMA-J AM MED ASSOC, V299, P953, DOI 10.1001/jama.299.8.953; HIGBEE R, 2009, E COMMUNICATION 0319; Kesselheim AS, 2007, JAMA-J AM MED ASSOC, V297, P308, DOI 10.1001/jama.297.3.308; KESSLER DA, 1994, NEW ENGL J MED, V331, P1350, DOI 10.1056/NEJM199411173312007; Krumholz H, 2007, BMJ-BRIT MED J, V334, P120, DOI 10.1136/bmj.39024.487720.68; Lisse JR, 2003, ANN INTERN MED, V139, P539, DOI 10.7326/0003-4819-139-7-200310070-00005; MCKINES C, 1999, COMMUNICATION   0104; MILES MB, 1967, QUALITATIVE DATA ANA; POUCKET J, 1999, E COMMUNICATION 1130; Psaty BM, 2006, JAMA-J AM MED ASSOC, V295, P2787, DOI 10.1001/jama.295.23.2787; Ross JS, 2008, JAMA-J AM MED ASSOC, V299, P1800, DOI 10.1001/jama.299.15.1800; SCOLNICK E, 2001, E COMMUNICATION 0407; Steinman MA, 2006, ANN INTERN MED, V145, P284, DOI 10.7326/0003-4819-145-4-200608150-00008; STEPHENS MD, 2003, DRUG SAFETY, V8, P1; WAYNE GF, 2002, TOBACCO CONTROL S1, V11, P32, DOI DOI 10.1136/TC.11.SUPPL_1.I32; WEBB JK, COMMUNICATION; WEBER LJ, 2006, PROFITS PEOPLE ETHIC, P168; WEINER J, 1999, MERCK MARKETING POWE; WELLS F, 1988, BRIT MED J, V296, P399; YARBROUGH C, 1999, E COMMUNICATION 0714; 2001, ASSESSMENT DIFFERENC; 1999, P ADVANTAGE STUD INV	32	98	99	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 19	2008	149	4					251	+		10.7326/0003-4819-149-4-200808190-00006	http://dx.doi.org/10.7326/0003-4819-149-4-200808190-00006			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	338RQ	18711155				2022-12-28	WOS:000258526700004
J	Phatak, PD; Bonkovsky, HL; Kowdley, KV				Phatak, Pradyumna D.; Bonkovsky, Herbert L.; Kowdley, Kris V.			Hereditary hemochromatosis: Time for targeted screening	ANNALS OF INTERNAL MEDICINE			English	Article							GENE; POPULATION; MUTATION; PENETRANCE; PREVALENCE	The discovery of the HFE gene in 1996 heralded a decade of major advances in the understanding of the mechanisms that control iron absorption and body iron stores. A genetic definition of the common form of hereditary hemochromatosis became possible, and testing for the common causative HFE mutations is now widely available in clinical laboratories. Several population screening studies have confirmed that disease penetrance in HFE-related hereditary hemochromatosis is lower than previously believed, making universal population-based screening for this disorder unattractive. However, hereditary hemochromatosis may still cause morbidity and mortality because of iron overload. Early detection and use of appropriate therapy can prevent these manifestations and can only be achieved by targeted case finding. In this article, the authors draw attention again to hereditary hemochromatosis as a cause of preventable organ dysfunction and propose targeted case finding for Caucasian men of Northern European ancestry.	Virginia Mason Med Ctr, Seattle, WA 98101 USA; Rochester Gen Hosp, Rochester, NY 14621 USA; Carolinas Hlth Care Syst, Charlotte, NC USA; Univ Washington, Sch Med, Seattle, WA USA	Virginia Mason Medical Center; Rochester General Hospital; Carolinas HealthCare System; University of Washington; University of Washington Seattle	Kowdley, KV (corresponding author), Virginia Mason Med Ctr, 1201 9th Ave, Seattle, WA 98101 USA.		Bonkovsky, Herbert L./AAH-1892-2021; Kowdley, Kris/AAF-5202-2019	Bonkovsky, Herbert L./0000-0001-7387-3230; 	National Institutes of Health [K02957, RO1-DK-38825]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038825] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	In part by the National Institutes of Health (grants K02957 and RO1-DK-38825).	Adams PC, 2007, LANCET, V370, P1855, DOI 10.1016/S0140-6736(07)61782-6; Adams PC, 2005, NEW ENGL J MED, V352, P1769, DOI 10.1056/NEJMoa041534; Adams PC, 1999, AM J GASTROENTEROL, V94, P1593; Allen KJ, 2008, NEW ENGL J MED, V358, P221, DOI 10.1056/NEJMoa073286; Bacon Bruce R., 1999, Gastroenterology, V116, P193, DOI 10.1016/S0016-5085(99)70244-1; Beutler E, 2002, LANCET, V359, P211, DOI 10.1016/S0140-6736(02)07447-0; CADMAN D, 1984, JAMA-J AM MED ASSOC, V251, P1580, DOI 10.1001/jama.251.12.1580; Camaschella C, 2000, NAT GENET, V25, P14, DOI 10.1038/75534; Carella M, 1997, AM J HUM GENET, V60, P828; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Gagne G, 2007, CLIN GENET, V71, P46, DOI 10.1111/j.1399-0004.2006.00727.x; Hall MA, 2005, GENET MED, V7, P311, DOI 10.1097/01.GIM.0000162874.58370.C0; Jacobs EMC, 2007, NETH J MED, V65, P425; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; NIEDERAU C, 1994, BAILLIERE CLIN HAEM, V7, P881, DOI 10.1016/S0950-3536(05)80129-5; Phatak PD, 1998, ANN INTERN MED, V129, P954, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00006; Powell LW, 2000, J HEPATOL, V32, P48, DOI 10.1016/S0168-8278(00)80415-8; Qaseem A, 2005, ANN INTERN MED, V143, P517, DOI 10.7326/0003-4819-143-7-200510040-00010; Robson KJH, 2000, BRIT J HAEMATOL, V108, P31; Whitlock EP, 2006, ANN INTERN MED, V145, P209, DOI 10.7326/0003-4819-145-3-200608010-00009	20	40	41	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 19	2008	149	4					270	+		10.7326/0003-4819-149-4-200808190-00009	http://dx.doi.org/10.7326/0003-4819-149-4-200808190-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	338RQ	18711158				2022-12-28	WOS:000258526700007
J	Li, MO; Flavell, RA				Li, Ming O.; Flavell, Richard A.			TGF-beta: A master of all T cell trades	CELL			English	Review							GROWTH-FACTOR-BETA; RETINOIC-ACID; AUTOIMMUNE INFLAMMATION; FOXP3 EXPRESSION; DENDRITIC CELLS; CUTTING EDGE; IN-VIVO; GATA-3 EXPRESSION; LETHAL PHENOTYPE; HELPER TYPE-1		[Li, Ming O.] Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10021 USA; [Flavell, Richard A.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA; [Flavell, Richard A.] Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA	Memorial Sloan Kettering Cancer Center; Yale University; Howard Hughes Medical Institute; Yale University	Li, MO (corresponding author), Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10021 USA.	lim@mskcc.org; richard.flavell@yale.edu		li, ming/0000-0002-1383-0535	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR060723] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051665, R01DK051656, R29DK051656] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIAMS NIH HHS [R01 AR060723] Funding Source: Medline; NIDDK NIH HHS [DK51656, R01 DK051665] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; Benson MJ, 2007, J EXP MED, V204, P1765, DOI 10.1084/jem.20070719; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; Boivin GP, 1997, TRANSGENIC RES, V6, P197, DOI 10.1023/A:1018490007745; Bommireddy R, 2006, LAB INVEST, V86, P1008, DOI 10.1038/labinvest.3700460; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Burchill MA, 2007, J IMMUNOL, V178, P280, DOI 10.4049/jimmunol.178.1.280; Chen CH, 2003, J EXP MED, V197, P1689, DOI 10.1084/jem.20021170; Chen ML, 2005, P NATL ACAD SCI USA, V102, P419, DOI 10.1073/pnas.0408197102; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Danke NA, 2004, J IMMUNOL, V172, P5967, DOI 10.4049/jimmunol.172.10.5967; Davidson TS, 2007, J IMMUNOL, V178, P4022, DOI 10.4049/jimmunol.178.7.4022; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Fahlen L, 2005, J EXP MED, V201, P737, DOI 10.1084/jem.20040685; Fantini MC, 2004, J IMMUNOL, V172, P5149, DOI 10.4049/jimmunol.172.9.5149; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Fontenot JD, 2005, J EXP MED, V202, P901, DOI 10.1084/jem.20050784; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Gorelik L, 2000, IMMUNITY, V12, P171, DOI 10.1016/S1074-7613(00)80170-3; Gorelik L, 2002, J EXP MED, V195, P1499, DOI 10.1084/jem.20012076; Gorelik L, 2000, J IMMUNOL, V165, P4773, DOI 10.4049/jimmunol.165.9.4773; Green JC, 2003, WOMEN POLIT, V25, P1, DOI 10.1300/J014v25n04_01; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Heath VL, 2000, EUR J IMMUNOL, V30, P2639, DOI 10.1002/1521-4141(200009)30:9<2639::AID-IMMU2639>3.0.CO;2-7; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Iwata M, 2004, IMMUNITY, V21, P527, DOI 10.1016/j.immuni.2004.08.011; Jameson SC, 2005, SEMIN IMMUNOL, V17, P231, DOI 10.1016/j.smim.2005.02.003; Kaplan DH, 2007, J EXP MED, V204, P2545, DOI 10.1084/jem.20071401; Kobayashi S, 1999, J IMMUNOL, V163, P4013; Kretschmer K, 2005, NAT IMMUNOL, V6, P1219, DOI 10.1038/ni1265; Kronenberg M, 2005, NATURE, V435, P598, DOI 10.1038/nature03725; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Lacy-Hulbert A, 2007, P NATL ACAD SCI USA, V104, P15823, DOI 10.1073/pnas.0707421104; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Letterio JJ, 1996, J CLIN INVEST, V98, P2109, DOI 10.1172/JCI119017; Leveen P, 2005, BLOOD, V106, P4234, DOI 10.1182/blood-2005-05-1871; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; Li MO, 2007, IMMUNITY, V26, P579, DOI 10.1016/j.immuni.2007.03.014; Li MO, 2006, IMMUNITY, V25, P455, DOI 10.1016/j.immuni.2006.07.011; Liston A, 2007, CURR OPIN IMMUNOL, V19, P176, DOI 10.1016/j.coi.2007.02.005; Liu YZ, 2008, NAT IMMUNOL, V9, P632, DOI 10.1038/ni.1607; Lohr J, 2006, J EXP MED, V203, P2785, DOI 10.1084/jem.20061341; Longenecker G, 2002, CYTOKINE, V18, P43, DOI 10.1006/cyto.2002.1025; Lucas PJ, 2000, J EXP MED, V191, P1187, DOI 10.1084/jem.191.7.1187; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Marie JC, 2005, J EXP MED, V201, P1061, DOI 10.1084/jem.20042276; Marie JC, 2006, IMMUNITY, V25, P441, DOI 10.1016/j.immuni.2006.07.012; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Mathis D, 2004, IMMUNITY, V20, P509, DOI 10.1016/S1074-7613(04)00111-6; McGeachy MJ, 2008, IMMUNITY, V28, P445, DOI 10.1016/j.immuni.2008.03.001; McGeachy MJ, 2007, NAT IMMUNOL, V8, P1390, DOI 10.1038/ni1539; McKarns SC, 2004, J IMMUNOL, V172, P4275, DOI 10.4049/jimmunol.172.7.4275; Mempel TR, 2006, IMMUNITY, V25, P129, DOI 10.1016/j.immuni.2006.04.015; Mora JR, 2003, NATURE, V424, P88, DOI 10.1038/nature01726; Mu DZ, 2002, J CELL BIOL, V157, P493, DOI 10.1083/jcb.200109100; Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Murphy CA, 2003, J EXP MED, V198, P1951, DOI 10.1084/jem.20030896; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; Neurath MF, 2002, J EXP MED, V195, P1129, DOI 10.1084/jem.20011956; Newfeld SJ, 1999, GENETICS, V152, P783; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Peng YF, 2004, P NATL ACAD SCI USA, V101, P4572, DOI 10.1073/pnas.0400810101; Robinson RT, 2007, J IMMUNOL, V179, P71, DOI 10.4049/jimmunol.179.1.71; Robinson RT, 2006, LAB INVEST, V86, P815, DOI 10.1038/labinvest.3700439; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Starr TK, 2003, ANNU REV IMMUNOL, V21, P139, DOI 10.1146/annurev.immunol.21.120601.141107; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; Surh CD, 2005, SEMIN IMMUNOL, V17, P183, DOI 10.1016/j.smim.2005.02.007; Tang QZ, 2006, NAT IMMUNOL, V7, P83, DOI 10.1038/ni1289; Thomas DA, 2005, CANCER CELL, V8, P369, DOI 10.1016/j.ccr.2005.10.012; Tone Y, 2008, NAT IMMUNOL, V9, P194, DOI 10.1038/ni1549; Travis MA, 2007, NATURE, V449, P361, DOI 10.1038/nature06110; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Veldhoen M, 2006, NAT IMMUNOL, V7, P1151, DOI 10.1038/ni1391; Walker LSK, 2002, NAT REV IMMUNOL, V2, P11, DOI 10.1038/nri701; Wan YSY, 2005, P NATL ACAD SCI USA, V102, P5126, DOI 10.1073/pnas.0501701102; Yang XXO, 2007, J BIOL CHEM, V282, P9358, DOI 10.1074/jbc.C600321200; Yang ZW, 2007, J CELL BIOL, V176, P787, DOI 10.1083/jcb.200611044; Zheng SG, 2002, J IMMUNOL, V169, P4183, DOI 10.4049/jimmunol.169.8.4183; Zheng SG, 2007, J IMMUNOL, V178, P2018, DOI 10.4049/jimmunol.178.4.2018; Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878	90	631	672	0	46	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 8	2008	134	3					392	404		10.1016/j.cell.2008.07.025	http://dx.doi.org/10.1016/j.cell.2008.07.025			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	340SO	18692464	Green Accepted, Bronze			2022-12-28	WOS:000258665500013
